CZ297945B6 - Novel selective inhibitors of viral and bacterial neuraminidases, pharmaceutical compositions in which said inhibitors are comprised and the use of the inhibitors - Google Patents
Novel selective inhibitors of viral and bacterial neuraminidases, pharmaceutical compositions in which said inhibitors are comprised and the use of the inhibitors Download PDFInfo
- Publication number
- CZ297945B6 CZ297945B6 CZ0269097A CZ269097A CZ297945B6 CZ 297945 B6 CZ297945 B6 CZ 297945B6 CZ 0269097 A CZ0269097 A CZ 0269097A CZ 269097 A CZ269097 A CZ 269097A CZ 297945 B6 CZ297945 B6 CZ 297945B6
- Authority
- CZ
- Czechia
- Prior art keywords
- group
- independently
- groups
- alkyl
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Epoxy Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polyesters Or Polycarbonates (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
Nové selektivní inhibitory virových nebo bakteriálních neuraminidáz na bázi nových cyklických sloučenin obsahujících acidickou skupinu, bazickou skupinu, substituovanou amino nebo N-acylovou skupinu a skupinu mající volitelně hydroxylovanou alkanovou část a způsoby jejich přípravy. Použití inhibitorů podle vynálezu k přípravě farmaceutických přípravků pro prevenci a léčeni chřipkové infekce.Novel selective inhibitors of viral or bacterial neuraminidases based on novel cyclic compounds containing an acidic group, a basic group, a substituted amino or N-acyl group and a group having an optionally hydroxylated alkane moiety, and methods for their preparation. Use of the inhibitors of the invention for the preparation of pharmaceutical compositions for the prevention and treatment of influenza infection.
σ> CMσ> CM
N ON O
Nové selektivní inhibitory virových nebo bakteriálních neuraminidáz, farmaceutické prostředky tyto inhibitory obsahující a použití inhibitorůNovel selective inhibitors of viral or bacterial neuraminidases, pharmaceutical compositions containing them and the use of inhibitors
Oblast technikyTechnical field
Vynález se týká nových selektivních inhibitorů virových nebo bakteriálních neuraminidáz, farmaceutických prostředků obsahujících tyto inhibitoiy a použití inhibitorů pro přípravu farmaceutických přípravků pro léčení a prevenci chřipkové infekce.The invention relates to novel selective inhibitors of viral or bacterial neuraminidases, to pharmaceutical compositions containing these inhibitors, and to the use of inhibitors for the preparation of pharmaceutical compositions for the treatment and prevention of influenza infection.
Dosavadní stav technikyBACKGROUND OF THE INVENTION
Neuraminidáza, rovněž známá jako sialidáza, acylneuraminyl hydroláza, a EC 3.2.1.18) je enzym, který je běžný u zvířat a u řady mikroorganizmů. Je to glykolhydroláza, která odštěpuje koncové alfa-ketosidicky spojené kyseliny sialové od glykoproteinů, glykolipidů a oligosacharidů. Mnohé mikroorganismy, které obsahují neuraminidázu jsou patogenní pro člověka i jiné živočichy, včetně drůbeže, koní, prasat a tuleňů. Mezi tyto patogenní organizmy patří i chřipkový virus.Neuraminidase, also known as sialidase, acylneuraminyl hydrolase, and EC 3.2.1.18) is an enzyme that is common in animals and many microorganisms. It is a glycol hydrolase that cleaves terminal alpha-ketosidically linked sialic acids from glycoproteins, glycolipids and oligosaccharides. Many neuraminidase-containing microorganisms are pathogenic to humans and other animals, including poultry, horses, pigs and seals. Influenza virus is one of these pathogenic organisms.
Neuraminidáza se nepřímo považuje za jednu z příčin patogenity chřipkových virů. Existují domněnky, že pomáhá vývoji nově syntetizovaných vironů z nakažených buněk a pomáhá při pohybu viru (díky aktivitě své hydrolázy) přes tkáně dýchacího traktu.Neuraminidase is indirectly considered to be one of the causes of the pathogenicity of influenza viruses. It is believed that it helps the development of newly synthesized virons from infected cells and helps to move the virus (due to its hydrolase activity) through the tissues of the respiratory tract.
ItzsteinM. von aj.; „Nátuře“, 363(6428): 418—423 (1993), odhaluje racionální strukturu inhibitorů replikace chřipkového viru na bázi sialidázy.ItzsteinM. von aj .; "Nature", 363 (6428): 418-423 (1993), discloses the rational structure of sialidase-based influenza virus replication inhibitors.
Colman, P. M. a j.; Mezinárodní patentová přihláška WO 92/06691 PCT/AU90/00501, datum publikace 30. dubna 1992), Itzstein, L. M. von a j.; Evropská patentová přihláška 0 539 204 Al (EP 92309684.6, datum publikace 28. dubna 1993) a Itzstein, L. M. von aj.; Mezinárodní přihláška WO 91(16320 (PCT/AU91/00161, datum publikace 31. října 1991) uvádějí sloučeniny, které váží neuraminidázu a o kterých se tvrdí, že projevují antivirovou aktivitu in vivo.Colman, P. M. et al .; International Patent Application WO 92/06691 PCT / AU90 / 00501, published April 30, 1992), Itzstein, L. M. von et al .; European Patent Application 0 539 204 A1 (EP 92309684.6, published April 28, 1993) and Itzstein, L. M. von et al .; International Application WO 91 (16320 (PCT / AU91 / 00161, published October 31, 1991) discloses compounds that bind neuraminidase and which are said to exhibit antiviral activity in vivo.
Hlavním cílem předloženého vynálezu je inhibice virů, zvláště pak chřipkových virů. Konkrétně je cílem inhibice glykolytických enzymů, jako je neuraminidáza, zvláště pak selektivní inhibice virových nebo bakteriálních neuraminidáz.The main object of the present invention is to inhibit viruses, especially influenza viruses. Specifically, the goal is the inhibition of glycolytic enzymes such as neuraminidase, especially the selective inhibition of viral or bacterial neuraminidases.
Dalším cílem vynálezu je poskytnout inhibitory neuraminidázy, které se zpomaleně vylučují močí, které vstupují do nasálních nebo pulmonárních sekrecí ze systémového oběhu, které mají dostatečnou orální biopřístupnost ktomu, aby byly terapeuticky účinné, které mají zvýšenou potenci a vykazují klinicky přijatelný profil toxicity a mají další žádoucí farmakologické vlastnosti.It is a further object of the invention to provide neuraminidase inhibitors that are excreted in the urine that enter nasal or pulmonary secretions from the systemic circulation that have sufficient oral bioavailability to be therapeutically effective, have enhanced potency and exhibit a clinically acceptable toxicity profile and have additional desirable pharmacological properties.
Dále je cílem poskytnout zlepšené a méně nákladné metody syntézy inhibitorů neuraminidázy.It is further an object to provide improved and less expensive methods of synthesizing neuraminidase inhibitors.
Cílem předmětného vynálezu je také poskytnout zlepšené metody pro podávání známých a neobvyklých inhibitorů neuraminidázy.It is also an object of the present invention to provide improved methods for administering known and unusual neuraminidase inhibitors.
Dalším cílem je poskytnout složení užitečná při přípravě polymerů, surfaktantů anebo imunogenů a pro použití v dalších průmyslových pochodech a výrobcích.Another object is to provide compositions useful in the preparation of polymers, surfactants and / or immunogens and for use in other industrial processes and products.
Všechny tyto cíle a další předměty budou běžně zřejmé odborníkovi jakmile zváží vynález jako celek.All these objects and other objects will be readily apparent to one skilled in the art once the invention as a whole is considered.
-1 CZ 297945 B6-1 CZ 297945 B6
Podstata vynálezuSUMMARY OF THE INVENTION
Předmětem předloženého vynálezu jsou nové selektivní inhibitory virových nebo bakteriálních neuroaminidáz na bázi sloučenin obecného vzorce III nebo IVThe present invention provides novel selective inhibitors of viral or bacterial neuroaminidases based on compounds of formula III or IV
(III) (IV) , kde(III) (IV), where
E, je-(CRiRi)mlWb E, is - (CR 1 R 1) ml W b
Gi je N3, -CN, -OH, -OR6a, -NO2 nebo -{CR^^W,,G 1 is N 3 , -CN, -OH, -OR 6a , -NO 2 or -
Tj je -NR1W3, heterocyklická skupina zahrnující monocyklickou skupinu s 3 až 7 členným kruhem majícím 2 až 6 atomů uhlíku a 1 až 3 heteroatomy vybrané zN, O a S nebo bicyklickou skupinu se 7 až 10 členy v kruhu mající 4 až 9 atomů uhlíku a 1 až 3 heteroatomy vybrané z N, O a S, nebo tvořící spolu s Ui nebo Gi skupinu mající strukturuTj is -NR 1 W 3, a heterocyclic group comprising a monocyclic group having a 3 to 7 membered ring having 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O and S, or a 7 to 10 membered bicyclic group having 4 to 9 carbon atoms, and 1 to 3 heteroatoms selected from N, O and S, or forming together with a U 1 or G 1 group having the structure
U! je H nebo-XiW6,AT! is H or-XiW 6 ,
Ji a Jia jsou nezávisle Rb Br, Cl, F, I, CN, NO2 nebo N3,J 1 and J 1 are independently R b Br, Cl, F, I, CN, NO 2 or N 3 ,
Ri je nezávisle H nebo alkyl s 1 až 12 atomy uhlíku,R 1 is independently H or C 1 -C 12 alkyl,
R2 je nezávisle R3 nebo R4, kde každé R4 je nezávisle substituované 0 až 3 R3 skupinami,R 2 is independently R 3 or R 4, wherein each R 4 is independently substituted with 0 to 3 R 3 groups,
R3 je nezávisle F, Cl, Br, I, -CN, N3, -NO2, -ORóa, -ORb -N(Rj)2, -N(Ri)(R6b), -N(R6b)2, -SRb -SR.,,, -S(O)Rb -S(O)2Rb -S(O)ORb -S(O)OR6a, -S(O)2ORb -S(O)2OR6a, -C(O)ORb -C(O)R6c, -C(O)OR6a, -OC(O)Rb -NÍROÍQOjRO, -1^,)(0(0)^), -N^ )(0(0)0^), -N(Réb)(C(O)OR1), -C(O)N(R!)2, -C(O)N(R6b)(R1), -Ο^Ν^Χ, -Ο^ΧΝ^),), C(N(R,b))(N(R,)2), -CWROXNÍROÍRa,)), -C(N)(R6b))(N(R1)(R6b)), -C(N(R1))(N(R6b)2), -C(N(R6b))(N(R6b)2), -NÍROCÍNtROXNÍROz), -N(R1)C(N(R1))(N(R1)(R6b)), -N(R1)C(N(R6b))(N(R1)2), -NÍR^CWROXNÍRj),), -N(R6b)C(N(R6b))(N(R1)2), -N(R6b)C(N(R1))(N(R1)(R6b)), -N(R0C(N(RéOXNÍRjXRét,)), -Ν(^)0(Ν(^))(Ν^ι,)2), -Ν^ΟίΝ^))^)^)), -Ν^)0(Ν(^))(N(R6b)2), -N(R1)C(N(R6b))(N(R6b)2), -NÍRfibjC^bXCNÍRébh), =0, =S, =N(Rj) nebo =N(R6b),R 3 is independently F, Cl, Br, I, -CN, N 3 , -NO 2 , -OR 6a , -OR b -N (R 3) 2 , -N (R 1) (R 6 b ), -N (R 6) b ) 2 , -SR b -SR. ,,, -S (O) R b -S (O) 2 R b -S (O) OR b -S (O) OR 6 a , -S (O) 2 OR b -S (O) 2 OR 6, -C (O) OR b, -C (O) R 6c, -C (O) OR 6a, -OC (O) R b -NÍROÍQOjRO, -1 ^,) (0 (0) ^), -N ^) (0 (0) 0 ^), -N ( Rb ) (C (O) OR 1 ), -C (O) N (R 1) 2 , -C (O ) N (R 6b ) (R 1 ), -Ο ^ Ν ^ Χ, -Ο ^ ΧΝ ^),), C (N (R, b )) (N (R 1) 2 ), - , -C (N) (R 6b )) (N (R 1 ) (R 6b )), -C (N (R 1 )) (N (R 6b ) 2 ), -C (N (R 6b )) (N (R 6 b ) 2 ), -N-RACINTHROXO 2 , -N (R 1 ) C (N (R 1 )) (N (R 1 ) (R 6b )), -N (R 1 ) C (N (R 1 ) 6b )) (N (R 1 ) 2 ), -N (R 6 C) X),), -N (R 6b ) C (N (R 6 b )) (N (R 1 ) 2 ), -N (R 6b ) C (N (R 1 )) (N (R 1 ) (R 6b )), -N (R C (N (R 6 R 6 )), -Ν (^) 0 (Ν (^)) (Ν ^ ι,) 2 ) -Ν ΟίΝ ^ ^)) ^) ^)), -Ν ^) 0 (Ν (^)) (N (R6b) 2), -N (R 1) C (N (R 6b)) ( N (R 6b ) 2 ), -N (R 6b ) b = (R 6b ), = O, = S, = N (R 6) or = N (R 6 b ),
R4 je nezávisle alkyl s 1 až 12 atomy uhlíku, alkenyl se 2 až 12 atomy uhlíku nebo alkynyl se 2 až 12 atomy uhlíku,R 4 is independently C 1 -C 12 alkyl, C 2 -C 12 alkenyl or C 2 -C 12 alkynyl,
R5 je nezávisle R4, kde každé R4 je substituované 0 až 3 R3 skupinami,R 5 is independently R 4, wherein each R 4 is substituted with 0 to 3 R 3 groups,
R5a je nezávisle alky len s 1 až 12 atomy uhlíku, alkenylen se 2 až 12 atomy uhlíku nebo alkynylen se 2 až 12 atomy uhlíku, přičemž kterýkoliv alkylen, alkenylen nebo alkynylen je substituovaný 0 až 3 R3 skupinami,R 5a is independently C 1 -C 12 alkylene, C 2 -C 12 alkenylene or C 2 -C 12 alkynylene, wherein any alkylene, alkenylene or alkynylene is substituted with 0 to 3 R 3 groups,
Rga je nezávisle H, skupina mající vzorec í-VaTO, j_Va(V0(V2), í-Va(V3), f—Vb(V])2, J—Vb(V2), nebo í—Vc(Vi), kde Va je C, Vb je B, Al, N, Vc je O, S, Vj je W6, V2 je =C(Vj)2 a V3 je =C(Vj) nebo skupina vzorce í——va(V])(v4), I-vb(V4), f—vd(Vi)2(v4), f—Vd(V4)2, f-Ve(V1)3(V4), nebo J—V^KV,),, kde Va je P nebo N, Ve je S a V4 je =0, =S, =N-Vi nebo =C(Vi)2 za předpokladu, že alespoň jedno V4 je =0, =S nebo =N-Vi,RGA is independently H, a group having Formula I-wool, j_V and (V0 (V 2), the I-V a (V 3), F-V b (V]) 2, J-V b (V 2), or 1 - V c (Vi), where V a is C, V b is B, Al, N, V c is O, S, V j is W 6 , V 2 is = C (V j) 2 and V 3 is = C (V) or a group of the formula I - and (V]) (4), iV b (V 4), the f-d (Vi) 2 (4), F-V d (V 4) 2, fV e (V 1 ) 3 (V 4 ), or J 1 -V 1 H 2, where Va is P or N, V e is S and V 4 is = O, = S, = N-Vi or = C (Vi) 2 provided that at least one V 4 is = O, = S or = N-Vi,
R6b je nezávisle H, -C(O)R4, aminokyselina nebo polypeptid struktury Ri5NHCH(Ri6)C(O)~, kde R15 je H, aminokyselina nebo polypeptid, kde aminokyselina je vybraná ze skupiny zahrnující glycin, alanin, valin, leucin, izoleucin, serin, threonin, cystein, methionin, kyselinu glutamovou, aspartovou, lysin, hydroxylysin, arginin, histidin, fenylalanin, tyrosin, tryptofan, prolin, asparagin, glutamin a hydroxyprolin, polypeptid sestává ze zbytků těchto aminokyselin a R16 je alkyl s 1 až 6 atomy uhlíku,R 6b is independently H, -C (O) R 4 , an amino acid or polypeptide of R 15 NHCH (R 16 ) C (O) -, wherein R 15 is H, an amino acid or polypeptide, wherein the amino acid is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, tryptophan, proline, asparagine, glutamine and hydroxyproline, the polypeptide consisting of these amino acid residues and R 16 is alkyl of 1 to 6 carbon atoms,
R& je nezávisle H, -NHSO2R4, -NHC(O)R4, -N(R4)2, NH2 nebo -NH(R4) nebo aminokyselina nebo polypeptid struktury R]7C(O)CH(Ri6)NH-, kde Ri7 je OH, ORňa, OR5, zbytek aminokyseliny nebo polypeptidu kde aminokyselina je vybraná ze skupiny zahrnující glycin, alanin, valin, leucin, izoleucin, serin, threonin, cystein, methionin, kyselinu glutamovou, aspartovou, lysin, hydroxylysin, arginin, histidin, fenylalanin, tyrosin, tiyptofan, prolin, asparagin, glutamin a hydroxyprolin a polypeptid sestává ze zbytků těchto aminokyselin, & R is independently H, -NHSO 2 R 4, -NHC (O) R4, -N (R4) 2, NH2 or -NH (R4) or amino acid or polypeptide structure R] 7 C (O) CH (R 6 ) NH-, where R 7 is OH, oR NA, oR 5, an amino acid residue or polypeptide wherein the amino acid is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, thyptophan, proline, asparagine, glutamine and hydroxyproline, and the polypeptide consists of these amino acid residues,
Wi je -CO2H, -CO2Rda, -CO2R5, -CO2W5, -CO2R5aW5, -OSO3H, -SO3H, -SO2H, -OPO3H2, -PO3(R6a)2, ~PO3(H)(R6a), -OPO3(R6a)2, tetrazol nebo Rfic amid skupiny -CO2H, -OSO3H, -SO3H, -SO2H, -OPO3H2, -PO3(R6a)2, -PO3H2, nebo -PO3(H)(R6a),Wi is -CO 2 H, -CO 2 Rd a , -CO 2 R 5 , -CO 2 W 5 , -CO 2 R 5 and W 5 , -OSO 3 H, -SO 3 H, -SO 2 H, -OPO 3 H 2 , -PO 3 (R 6a ) 2, ~ PO 3 (H) (R 6a ), -OPO 3 (R 6a ) 2 , tetrazole or R ficamide of the group -CO 2 H, -OSO 3 H, - SO 3 H, -SO 2 H, -OPO 3 H 2, -PO 3 (R 6) 2, -PO 3 H 2 or -PO 3 (H) (R 6a)
W2 je (a) aminoalkylová, amidino, amidinoalkylová, guanidino nebo guanidinoalkylová skupina, kde alkylová skupina je nižší alkyl s 1 až 3 atomy uhlíku, přičemž v každém případě alkylová skupina slouží k připojení amino, aminoalkyl, amidino substituentu ke karbocyklickému kruhu, (b) N- nebo S- obsahující 5 nebo 6 členný kruh mající 1 nebo 2 heteroatomy nebo řečený kruh substituovaný 1 nebo 2 amino nebo guanidino skupinami, (c) alkyl s 2 až 3 atomy uhlíku substituovanými amino nebo guanidino skupinou nebo takový alkyl substituovaný amino skupinou a druhým substituentem vybraným ze skupiny sestávající z hydroxy a amino, (d) -NHRb -NÍRébXRO, -N(R6b)2, -NH(RS), -N(R6bXR5), -N(R5)2, -C(NH)(NH2), -NRi~C(NRjXNRjRj), -NH-C(NH)(NHR3), -NH-C(NH)NHRi), -NH-C(NH)NH2, -CH(CH2NHR|)(CH2OH), -CH(CH2NHRi)(CH2NHR1), -CH(NHRi)-(CRiRi)m2-CH(NHRi)Rb -CH(OH)(CRiRi)m2-CH(NHRi)Rb -CHÍNHR^CRjRO^-ÚHÍOHJRi, -(CR1R1)m2-S-C(NH)NH2, -N=C(NHRiXR3), -N=C(SR])N(Ri)2, -N(Ri)C(NH)N(R1)C=N nebo -N=C(NHRi)(Ri) a m2 je nezávisle celé číslo od 0 do 1,W 2 is (a) an aminoalkyl, amidino, amidinoalkyl, guanidino or guanidinoalkyl group wherein the alkyl group is lower alkyl of 1 to 3 carbon atoms, in each case the alkyl group serves to attach an amino, aminoalkyl, amidino substituent to the carbocyclic ring, ( b) an N- or S-containing 5 or 6 membered ring having 1 or 2 heteroatoms or said ring substituted with 1 or 2 amino or guanidino groups, (c) alkyl of 2 to 3 carbon atoms substituted by amino or guanidino group or such alkyl substituted amino group and a second substituent selected from the group consisting of hydroxy and amino, (d) -NHR b -NÍRébXRO, -N (R6b) 2, -NH (R S), -N (R 6 XR 5 b), -N (R 5 ) 2, -C (NH) (NH 2), -NR-C (NRjXNRjRj), -NH-C (NH) (NHR 3), -NH-C (NH) NHR), -NH-C (NH) NH 2, -CH (CH 2 NHR |) (CH 2 OH), -CH (CH 2 NHR i) (CH 2 NHR 1), -CH (NHR) - (Criro) m2 -CH (NHR) R b - CH (OH) (Criro) m2 -CH (NHR) R ^ b -CHÍNHR CRjRO -ÚHÍOHJRi ^ - (CR 1 R 1) m2 -SC (N H) NH 2 , -N = C (NHR 1 XR 3 ), -N = C (SR)) N (R 1) 2 , -N (R 1) C (NH) N (R 1 ) C = N or -N = C (NHR 1) (R 1) and m 2 is independently an integer from 0 to 1,
nebo (e) Růb amid kterékoliv z W2 skupin (a)-(d),or (e) R amide of any of the W 2 groups (a) - (d),
W3 je W4 nebo W5;W 3 is W 4 or W 5;
W4 je 5 nebo -C(O)R5, -C(O)W5, -SO2R5 nebo -SO2W5;W 4 is 5 or -C (O) R 5 , -C (O) W 5 , -SO 2 R 5 or -SO 2 W 5 ;
W5 je karbocyklická skupina, kde karbocyklická skupina je monocyklická skupina s 3 až 7 atomy uhlíku nebo bicyklická skupina se 7 až 12 atomy uhlíku, nebo heterocyklická skupina, kde heterocyklická skupina je monocyklická skupina s 3 až 7 členným kruhem majícím 2 až 6 atomů uhlíku a 1 až 3 heteroatomy vybrané z N, O, P a S nebo bicyklická skupina se 7 až 10 kruhových členů mající 4 až 9 atomů uhlíku a 1 až 3 heteroatomy vybrané zN, O, P a S, přičemž W5 je nezávisle substituované 0 až 3 R2 skupinami,W 5 is a carbocyclic group wherein the carbocyclic group is a monocyclic group of 3 to 7 carbon atoms or a bicyclic group of 7 to 12 carbon atoms, or a heterocyclic group wherein the heterocyclic group is a monocyclic group of 3 to 7 membered ring having 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P and S or a 7 to 10 ring member having 4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P and S, wherein W 5 is independently substituted with 0 up to 3 R 2 groups,
W6 je -R5, -W5, -R5aW5, -C(O)OR6a, -C(O)R6c, -C(O)N(R6b)2, -C(NR6b)(N(R6b)2), -C(S)N(Réb)2 nebo -C(O)R2,W 6 is -R 5, -W 5, -R 5a W 5, -C (O) OR6, -C (O) R 6c, -C (O) N (R6b) 2, -C (NR 6b ) (N (R 6b) 2), -C (S) N (R b) 2 or -C (O) R 2,
Xi je vazba, -O-, -N(H)-, -N(W6)-, -N(OH)-, -N(0W6)-, -N(NH2)-, -N(N(H))(W6))-, -N(N(Wó)2)-, -N(H)N(Wň))-, -S-, -SO- nebo -SO2_, a každé ηη je nezávisle celé číslo od 0 do 2 a jejich soli, solváty, resolvované enantiomery a čištěné diastereomery, s výjimkou sloučenin vzorce (IV), kde Ji a Ri jsou H a (a) Ej je -CO2H, Uj je -CH2OCH2C6H5, Ti je -NHCOCH3 a Gj je -N3, (b) Ei je -CO2H, Uj je -CH2OH, T, je -NHCOCH3 a Gj je -NH-C(=NH)NH2, -NH2 nebo -N3 a (c) Ei je CO2CH3, Ui je -CH2OH, Ti je -NHCOCH3 a Gj je -N3.X 1 is a bond, -O-, -N (H) -, -N (W 6 ) -, -N (OH) -, -N (O 6 ) -, -N (NH 2 ) -, -N (N (H)) (W 6 )) -, -N (N (W 6 ) 2 ) -, -N (H) N (W 6)) -, -S-, -SO- or -SO 2 - , and each ηη is independently an integer from 0 to 2 and salts, solvates, resolved enantiomers and purified diastereomers thereof, with the exception of compounds of formula (IV) wherein J 1 and R 1 are H and (a) E 1 is -CO 2 H, U 1 is -CH 2 OCH 2 C 6 H 5 , T 1 is -NHCOCH 3 and G 1 is -N 3 , (b) E 1 is -CO 2 H, U 1 is -CH 2 OH, T, is -NHCOCH 3 and G 1 is -NH-C ( = NH) NH 2 , -NH 2 or -N 3 and (c) E 1 is CO 2 CH 3 , U 1 is -CH 2 OH, Ti is -NHCOCH 3, and G 1 is -N 3 .
Předmětem vynálezu jsou dále selektivní inhibitory virových a bakteriálních neuroaminidáz, obecného vzorceThe invention further provides selective inhibitors of viral and bacterial neuroaminidases of the general formula
-4CZ 297945 B6 kde-4GB 297945 B6 where
G1 je-OH.-OR^nebo/CR^O^Wz,G 1 is -OH.-OR 2 or (CR 2 O) W 2,
T] je -NR1W3 nebo heterocyklická skupina, kde řečená heterocyklická skupina je monocyklická skupina s 3 až 7 členným kruhem majícím 2 až 6 atomů uhlíku a 1 až 3 heteroatomy vybrané z N, O a S nebo bicyklická skupina se 7 až 10 kruhovými členy mající 4 až 9 atomů uhlíku a 1 až 3 heteroatomy vybrané z N, O a S,T 1 is -NR 1 W 3 or a heterocyclic group, wherein said heterocyclic group is a monocyclic group of 3 to 7 membered rings having 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O and S or a bicyclic group of 7 to 10 ring members having 4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O and S,
RSa je nezávisle H, skupina obecného vzorce í—VaCVOs, J—Va(V1)(V2), J-Va(V3),R is independently H, a group of general formula I-VaCVOs, and N (V 1) (V 2) N and (V 3),
J—VbCVj),, J—Vb(V2), nebo J—V^VO, kde Va je C, Vb je N nebo P, Vc je O nebo S, Vi je W6, V2 je =C(Vi)2 a V3 je =C(V|) nebo skupina vzorceJ-VbCVj) ,, J-V b (V 2), or J-VO-V wherein V is C, V b is N or P, V c is O or S, W is the Vi 6, 2 = C (Vi) 2 and V 3 is = C (V 1) or a group of the formula
J-Va(V1)(V4), J-Vb(V4), J-Vd(V1)2(V4), f-Vd(v4)2, f—Ve(Vi)3(V4), nebo f—Ve(Vi)(V4)2, kde Vd je P nebo N, Ve je S a V4 je =0, =S, =N-Vj nebo =C(Vi)2 za předpokladu, že alespoň jedno V4 je =0, =S nebo =N-Vi,JV a (V 1 ) (V 4 ), JV b (V 4 ), JV d (V 1 ) 2 (V 4 ), fV d (v 4 ) 2 , f — V e (Vi) 3 (V 4 ) , or f - V e (Vi) (V 4 ) 2 , where V d is P or N, V e is S and V 4 is = O, = S, = N-V j or = C (Vi) 2 provided that at least one of V 4 is = O, = S or = N-Vi,
R6b je nezávisle H, -C(O)R4, aminokyselina nebo polypeptid struktury Ri5NHCH(Ri6)C(O)-, kde (Ri5) je H, aminokyselina nebo polypeptid.R 6b is independently H, -C (O) R 4 , an amino acid or polypeptide of R 15 NHCH (R 16 ) C (O) -, wherein (R 15 ) is H, an amino acid or polypeptide.
Dále jsou předmětem předloženého vynálezu selektivní inhibitory virových a bakteriálních neuroaminidáz vzorceFurther, the present invention provides selective inhibitors of viral and bacterial neuroaminidases of the formula
kdewhere
Ei je -COOH, -CO2R5, -CO2R5aW5 nebo -CO2W5,E 1 is -COOH, -CO 2 R 5, -CO 2 R 5 and W 5 or -CO 2 W 5 ,
G! je -N(R0R2, -N(R1)C(=NRi)(NR1)2 nebo -€(^)2-Ν(^)2,G! is -N (R0R 2, -N (R 1) C (= NR) (NR 1) 2, or - € (^) 2 -Ν (^) 2,
Ti je -NHC(O)CH3, -NHC(O)CH2F, -NHC(O)CHF2 nebo -NHC(O)CF3 aT 1 is -NHC (O) CH 3 , -NHC (O) CH 2 F, -NHC (O) CHF 2, or -NHC (O) CF 3, and
U] je -OR4, -SR4, NHR4 nebo Ν^)2.U 1 is -OR 4, -SR 4, NHR 4 or Ν (R) 2 .
Předmětem vynálezu jsou sloučeniny výše uvedeného vzorce kdeThe present invention provides compounds of the above formula wherein
R4 je alkyl s 1 až 12 atomy uhlíku, alkyl s 1 až 8 atomy uhlíku nebo alkenyl nebo alkynyl s 2 až 8 atomy, alkyl s 1 až 6 atomy uhlíku nebo alkenyl nebo alkynyl s 2 až 6 atomy,R 4 is alkyl of 1 to 12 carbon atoms, alkyl of 1 to 8 carbon atoms or alkenyl or alkynyl of 2 to 8 atoms, alkyl of 1 to 6 carbon atoms or alkenyl or alkynyl of 2 to 6 atoms,
-5CZ 297945 B6 alkyl s 1 až 6 atomy uhlíku, alkyl s 1 až 6 atomy uhlíku a každé Ri je vodík.C 1 -C 6 alkyl, C 1 -C 6 alkyl and each R 1 is hydrogen.
Význakem dalšího provedení inhibitorů podle vynálezu jsou sloučeniny výše uvedeného vzorce kde θι je -NH2, -N(H)C(N(H))(NH2), -NHCH3, -NHCH2CH3, -N(CH3)2, -N(CH2CH3)2, -N(CH3)(CH2CH3), -NHCH2CH2OH, -NHCH2CH2NH2 nebo -CH2NH2 aA feature of another embodiment of the inhibitors of the invention are compounds of the above formula wherein θι is -NH 2 , -N (H) C (N (H)) (NH 2 ), -NHCH 3 , -NHCH 2 CH 3 , -N (CH 3). 12 , -N (CH 2 CH 3 ) 2 , -N (CH 3 ) (CH 2 CH 3 ), -NHCH 2 CH 2 OH, -NHCH 2 CH 2 NH 2 or -CH 2 NH 2 and
Ti je -N(H)(C(O)CH3), -N(H)(C(O)CH2F), -N(H)(C(O)CHF2 nebo -N(H)(C(O)CF3).Ti is -N (H) (C (O) CH 3 ), -N (H) (C (O) CH 2 F), -N (H) (C (O) CHF 2, or -N (H) ( C (O) CF 3 ).
Dalším význakem vynálezu jsou inhibitory na bázi sloučenin podle výše uvedeného vzorce, kdeAnother aspect of the invention are inhibitors based on the compounds of the above formula wherein
E, je -C(O)OCH2CH3,E 1 is -C (O) OCH 2 CH 3 ,
Gi je -NH2, -NHCH3 nebo -NHCH2CH3 G 1 is -NH 2 , -NHCH 3, or -NHCH 2 CH 3
Ti je-NH(C(O)CH3) aTi is -NH (C (O) CH 3 ) a
Ui je -OCH(CH2CH3)2.U 1 is -OCH (CH 2 CH 3 ) 2 .
Předmětem předloženého vynálezu jsou nové selektivní inhibitory virových a bakteriálních neuroaminidáz vzorceThe present invention provides novel selective inhibitors of viral and bacterial neuroaminidases of the formula
//
Dále jsou předmětem předloženého vynálezu nové selektivní inhibitory virových a bakteriálních neuroaminidáz vzorceFurther, the present invention provides novel selective inhibitors of viral and bacterial neuroaminidases of the formula
ajejí soli a solváty.and salts and solvates thereof.
Předmětem předloženého vynálezu jsou rovněž selektivní inhibitory virových a bakteriálních neuroaminidáz vzorceThe present invention also provides selective inhibitors of viral and bacterial neuroaminidases of the formula
-6CZ 297945 B6-6GB 297945 B6
Vynález dále zahrnuje farmaceutické prostředky, které kromě účinné látky podle vynálezu dále obsahují i farmaceuticky přijatelný nosič.The invention further encompasses pharmaceutical compositions which, in addition to the active ingredient of the invention, further comprise a pharmaceutically acceptable carrier.
Dále vynález zahrnuje inhibici aktivity neuraminidázy způsobem spočívajícím v ošetření vzorku podezřelého z obsahu neuraminidázy sloučeninou nebo kompozicí, která je předmětem vynálezu.Further, the invention includes inhibiting neuraminidase activity by a method comprising treating a sample suspected of containing neuraminidase with a compound or composition of the invention.
Dále zahrnuje způsob inhibice aktivity neuraminidázy jež spočívá v tom, že se vzorek podezřelý z kontaminace neuraminidázou uvede do kontaktu s kompozicemi podle vynálezu.It further comprises a method of inhibiting neuraminidase activity by contacting a sample suspected of being contaminated with neuraminidase with the compositions of the invention.
Vynález dále zahrnuje metodu léčení nebo prevence virů, zvláště pak chřipkové virové infekce u nositele, která zahrnuje podávání terapeuticky účinné dávky antivirové aktivní sloučeniny popsané ve WO 91/16320, WO 92/06691 nebo US Patent 5 360 817 nositeli cestou jinou, než obvykle do dýchacího traktu.The invention further encompasses a method of treating or preventing a virus, particularly an influenza virus infection in a carrier, comprising administering to the carrier a therapeutically effective dose of the antiviral active compound described in WO 91/16320, WO 92/06691 or US Patent 5,360,817 by a route other than usual to respiratory tract.
Předmětem vynálezu jsou dále nové způsoby syntézy sloučenin podle předloženého vynálezu. Jedno takové provedení podle vynálezu je způsob použití sloučeniny o vzorci 281, přičemž způsob zahrnuje úpravu sloučeniny 281 sloučeninou o vzorci R5-X1-H, aby se tak vytvořila sloučenina se vzorcem 281.1.The invention further provides novel methods of synthesizing the compounds of the present invention. One such embodiment of the invention is a method of using a compound of formula 281, the method comprising treating compound 281 with a compound of formula R 5 -X 1 -H to form a compound of formula 281.1.
Předmětný způsob přípravy sloučeniny vzorceThe present method of preparing a compound of formula
kdewhere
Xi je -O-, —NR5 nebo -S-,X 1 is -O-, -NR 5 or -S-,
R5 je R4, kde každé R4 je substituované 0 až 3 R3 skupinami, přičemžR 5 is R 4, wherein each R 4 is substituted with 0 to 3 R 3 groups, wherein
R4 je alkyl s 1 až 12 atomy uhlíku, alkenyl s 2 až 12 atomy uhlíku nebo alkynyl s 2 až 12 atomy uhlíku, aR4 is alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, or alkynyl of 2 to 12 carbon atoms, and
R3 je nezávisle F, Cl, Br, I, -CN, N3, -NO2, -OR6a, -ORb -N(Ri)2,’-N(Ri)(R6b), -N(R6b)2, -SRb -SR6a, -SRb -SR&1, -S(O)Rb -S(O)2Rb -S(O)ORb -S(O)OR6a, -S(O)2ORb -S(O)2OR6a, -C(O)ORb -C(O)R6C, -C(O)OR6a, -OC(O)Rb -^^)^(0)^), -^)(0(0)^), -N(Rt)(C(O)ORO, -N(R6b)(C(O)OR1), -0(0)Ν(^)2, -C(O)N(R6b)(R1), -C(O)N(R6b)2, -C(NR3)(N(Rt)2), 0(Ν^))(Ν(^)2), -0(Ν(^))(Ν(^)Μ), -CÍNXRébBtNÍRjXReb)), -C(N(R0)(N(R6b)2), -CÍN^bjXNíRbbh), -Ν(^)0(Ν(^))(Ν^)2), -NÍROCÍNÍROXNtROÍRbb)), -N(R,)C^RbbjXNÍRjh), -N(R6b)C(N(R1))(N(R1)2), -N(R6b)C(N(R6b))(N(R1)2), -^)^(^))(N(R])(R6b)), -N(R1)C(N(R6b))(N(R1)(R6b)), -NÍROC^RO)^^), -Ν(Κ^)0(Ν(Κ^))(Ν(^) (Réb)), -N(R6b)C(N(R1))(N(R6b)2), -NCROC^RbOXNCRfibh), -N(R6b)C(N(R6b))(N(R6b)2), =O, =S, =N(Ri) nebo =N(R6b), kdeR 3 is independently F, Cl, Br, I, -CN, N 3, -NO 2, -OR 6a, -OR b -N (R) 2 '- N (Ri) (R6b), -N ( R6 b ) 2 , -SR b -SR 6a , -SR b -SR & 1 , -S (O) R b -S (O) 2 R b -S (O) OR b -S (O) OR 6 a , - S (O) 2 OR b -S (O) 2 OR 6a , -C (O) OR b -C (O) R 6 C , -C (O) OR 6a , -OC (O) R b - ^^) ^ (0) ^) - ^) (0 (0) ^), -N (R t) (C (O) ORO, -N (R 6b) (C (O) OR 1), -0 (0 ) Ν (^) 2, -C (O) N (R 6b) (R 1), -C (O) N (R6b) 2, -C (NR 3) (N (R t) 2), 0 (Ν ^)) (Ν (^) 2 ), -O (Ν (^)) (Ν (^) Μ), -CINXRbBtNR (XReb)), -C (N (R0) (N (R6b) 2), - TIN ^ bjXN (Rbbh), -Ν (^) 0 (Ν (^)) (Ν ^) 2 ), -NATIONAL (R) (N (R) b ), -N (R, C ^ RbbjX (R) b ), -N (R 6b ) C (N ( R 1 )) (N (R 1 ) 2 ), -N (R 6b ) C (N (R 6b )) (N (R 1 ) 2 ), - (R) 2 (R)) (N (R ) ) (R 6b )), -N (R 1 ) C (N (R 6b )) (N (R 1 ) (R 6b )), -OR (R 6 R) (^), -Ν (Κ ^) 0 (Ν) (Κ ^)) (Ν (^) (REB)), -N (R 6b) C (N (R1)) (N (R 6b) 2) ^ -NCROC RbOXNCRfibh), -N (R 6b) C (N (R 6b)) (N (R 6b) 2), = O, = S, = N (R) or = N (R6b), wherein
Ri je nezávisle H nebo alkyl s 1 až 12 atomy uhlíku,R 1 is independently H or C 1 -C 12 alkyl,
Réa je nezávisle H, skupina mající vzorec í-Va(V])3, J-VaíVjXVz), f-Va(V3),R 6a is independently H, a group having the formula 1-V and (V 1 ) 3 , J-V 1 (V 2 V 2 ), f V and (V 3 ),
I—VbCVO,, J—Vb(V2), nebo J—V^), kde Va je C, Vb je B, Al, N, Vc je O, S, V] je W6, V2 je =C(Vi)2 a V3 je =C(Vj) nebo skupina vzorce í—Va(V1)(V4), J-Vb(V4), f—νχνοχν,), j—Vd(V4)2, J—Ve(Vi)3(V4), nebo J—Ve(V0(V4)2, kde Vd je P nebo N, Veje SaV4je =0, =S, =N-V] nebo =C(Vj)2 za předpokladu, že alespoň jedno V4 je =0, =S nebo =N-Vi,I-VbCVO ,, J-V b (V 2), or V-J ^) wherein A is C, V b is B, Al, N, V c is O, S, V] W 6, 2 is = C (Vi) 2 and V 3 is = C (Vj) or a group of formula I-Va (V 1 ) (V 4 ), JV b (V 4 ), f-νχνοχν,), j-V d ( V 4 ) 2 , J-V e (Vi) 3 (V 4 ), or J-V e (V0 (V 4 ) 2 , where V d is P or N, V e is SaV 4 is = 0, = S , = NV] or = C (Vj) 2 , provided that at least one V 4 is = O, = S or = N-Vi,
Rňb je nezávisle H, -C(O)R4, aminokyselina nebo polypeptid struktury R15NHCH(R16)C(O)-, kde R15 je H, aminokyselina nebo polypeptid,R b is independently H, -C (O) R 4 , an amino acid or a polypeptide of structure R 15 NHCH (R 16) C (O) -, wherein R 15 is H, an amino acid or polypeptide,
Rbc je nezávisle H, -NHSO2R4, NHC(O)R4, -N(R4)2, NH2, ~NH(R4) nebo zbytek aminokyseliny nebo polypeptidu struktury Ri7C(O)CH(R]6)NH- kde R]7 je OH, OR, OR5, zbytek aminokyseliny nebo polypeptidu,R bc is independently H, -NHSO 2 R 4 , NHC (O) R 4 , -N (R 4 ) 2 , NH 2 ,-NH (R 4 ), or an amino acid or polypeptide residue of R 17 C (O) CH ( R 16 ) NH- wherein R 17 is OH, OR, OR 5 , an amino acid or polypeptide residue,
R5i je v kyselém prostředí stabilní chránící skupina pro karboxylovou kyselinu, spočívá v tom, že se sloučenina 281R 5 i is an acidic stable carboxylic acid protecting group, consisting of compound 281
(281) kde N3 a R5i mají výše vedený význam a(281) wherein N 3 and R 5 i are as defined above and
R54 je aziridinová aktivační skupina vybraná z CH3(CH2)2C(O)-, kde z je celé číslo od 0 do 10, substituovaná trifenylmetylem, BOC, Cbz a alkylsulfonátem, uvede do reakce se sloučeninou vzorceR 54 is an aziridine activating group selected from CH 3 (CH 2 ) 2 C (O) -, wherein z is an integer from 0 to 10, substituted with triphenylmethyl, BOC, Cbz and alkylsulfonate, reacted with a compound of formula
R5-X]-H, kde R5 a Xi mají výše uvedený význam.R 5 -X 1 -H, wherein R 5 and X 1 are as defined above.
-8CZ 297945 B6-8EN 297945 B6
Dalším příkladem provedení podle vynálezu je použití kyseliny chinové pro přípravu sloučeniny vzorce 272.Another embodiment of the invention is the use of quinic acid for the preparation of a compound of formula 272.
Předmětný způsob přípravy sloučeniny vzorce 272The present method of preparing the compound of Formula 272
/ (272) kde/ (272) where
R5i je chránící skupina karboxylové skupiny stabilní v kyselém prostředí, aR 5 i is an acid-stable carboxyl protecting group, and
R52 je hydroxy aktivační skupina, spočívá v tom, že se kyselina chinováR52 is a hydroxy activating group consisting of quinic acid
(kyselina chinová) uvede do reakce s geminálním dialkoxyalkanem nebo germinálním dialkoxycykloalkanem a kyselinou za vzniku sloučeniny vzorce 274(quinic acid) is reacted with geminal dialkoxyalkane or germinal dialkoxycycloalkane and an acid to form a compound of Formula 274
(274) kde(274) where
R5o je 1,2 diolová chránící skupina, která se dále podrobí reakci s metalickým oxidem a alkanolem za vzniku sloučeniny 275R 50 is a 1,2 diol protecting group which is further reacted with a metal oxide and an alkanol to form compound 275
(275)(275)
-9CZ 297945 B6 která se nechá reagovat s halogenidem sulfonové kyseliny a aminem za vzniku sloučeniny 276Which was reacted with a sulfonic acid halide and an amine to give compound 276
(276) která se nechá reagovat s dehydratačním činidlem a poté s kyselinou a alkanolem.(276) which is reacted with a dehydrating agent followed by an acid and an alkanol.
Vynález dále zahrnuje nové selektivní inhibitory virových a bakteriálních neuroaminidáz mající vzorec 271, 275, 276, 277, 278 nebo 279The invention further encompasses novel selective inhibitors of viral and bacterial neuroaminidases having the formula 271, 275, 276, 277, 278 or 279
(271)(271)
(275)(275)
(276)(276)
(277)(277)
(278)(278)
I (279) io kdeI (279) and where
R50 je ketal cyklohexanonu nebo acetonu,R50 is ketal of cyclohexanone or acetone,
R5i je lineární, větvený nebo cyklický alkyl, alkenyl nebo alkynyl s 1 až 12 atomy uhlíku,And R 5 is a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 12 carbon atoms;
R52 je vybraný ze skupiny metan, benzen nebo toluen sulfonyl ester,R 52 is selected from the group of methane, benzene or toluene sulfonyl ester,
R53 je metoxymetyl.R 53 is methoxymethyl.
-10CZ 297945 B6-10GB 297945 B6
Stručný popis výkresůBrief description of the drawings
Obrázky 1 a 2 znázorňují úrovně arteriální saturaci kyslíkem (SaO2) u myší nakažených chřipkou-A a léčených různými i.p. dávkami GG167 (-guanidino-2,4-dideoxy-2,3-dehydro-Nacetylneuraminové kyseliny), známou protichřipkovou sloučeninou (obrázek 1) a sloučeninou 203 podle předloženého vynálezu (obrázek 2). 50, 10, 2 a 0,5 mpk (mg/kg/den) zkušební sloučeniny a kontroly fyziologického roztoku, jsou označeny formou čtverečků, plných kruhů, trojúhelníčků, hvězdiček a prázdných kroužků. Ve všech obrázcích jsou * P<0,05, ** P<0,01 srovnávány s kontrolou ve fyziologickém roztoku.Figures 1 and 2 show levels of arterial oxygen saturation (SaO 2 ) in influenza-A infected mice and treated with various ip doses of GG167 (-guanidino-2,4-dideoxy-2,3-dehydro-Nacetylneuraminic acid), a known anti-influenza compound (Figure 1) and Compound 203 of the present invention (Figure 2). 50, 10, 2 and 0.5 mpk (mg / kg / day) of the test compound and saline control are indicated by squares, solid circles, triangles, asterisks and empty circles. In all figures, * P <0.05, ** P <0.01 are compared to saline control.
Obrázky 3-5 porovnávají úrovně SaO2 dosažené u myší nakažených chřipkou A léčených dávkami ribavirinu p.o. (trojúhelníčky), sloučeniny 203 (čtverečky) a GG167 (plné kroužky); kontroly fyziologického roztoku jsou prázdné kroužky: obrázek 3: 150 mpk každé sloučeniny 203 a GG167, 100 mpk ribavirinu; obrázek 4: 50 mpk sloučeniny 203 a GG167, 32 mpk ribavirinu; obrázek 5:10 mpk sloučeniny 203 a GG 167, 10 mpk ribavirinu.Figures 3-5 compare the levels of SaO 2 achieved in influenza A mice treated with doses of ribavirin po (triangles), compound 203 (squares), and GG167 (solid circles); saline controls are open circles: Figure 3: 150 mpk of each compound 203 and GG167, 100 mpk of ribavirin; Figure 4: 50 mpk of Compound 203 and GG167, 32 mpk of ribavirin; Figure 5:10 mpk of Compound 203 and GG 167, 10 mpk of ribavirin.
Obrázky 6-8 znázorňují úrovně saturace kyslíku u myší nakažených chřipkou A a léčených nízkými dávkami sloučeniny 262 (kroužky) a 260 (plné čtverečky) p.o. a GG167 (trojúhelníčky); fyziologické kontroly jsou prázdné kroužky a nenakažené kontrolní údaje jsou prázdné čtverečky: obrázek 6: mpk každé z testovacích sloučenin; obrázek 7: 1 mpk každé testovací sloučeniny; obrázek 8: 0,1 mpk každé testované sloučeniny.Figures 6-8 show oxygen saturation levels in mice infected with influenza A and treated with low doses of Compound 262 (circles) and 260 (solid squares) p.o. and GG167 (triangles); physiological controls are open circles and uninfected control data are open squares: Figure 6: mpk of each of the test compounds; Figure 7: 1 mpk of each test compound; Figure 8: 0.1 mpk of each test compound.
Sloučeniny podle předloženého vynálezu neobsahují sloučeniny dosud známé. Ovšem, jak dále bude zřejmé, v dalších částech, je možno v rámci vynálezu používat pro antivirové účely známé sloučeniny dosud vyráběné a používané jako meziprodukty při přípravě antivirových sloučenin. Pokud se týká Spojených států, sloučeniny nebo kompozice zde uváděné vylučují sloučeniny, které předpokládá 35 USC § 102 nebo 35 USC § 103. Konkrétně, nároky zde uváděné jsou formulované, aby byly vyloučené látky, jež jsou předpokládány nebo nejsou nové vzhledem kWO 91/16320, WO 92/06691, US patent 5 360 817 nebo Chandler, M.: a j.; J. Chem. Soc. Perkin Trans. 1, 1995, 1189-1197.The compounds of the present invention do not contain compounds known so far. However, as will become apparent in the following, the compounds of the present invention produced and used as intermediates in the preparation of antiviral compounds can be used for antiviral purposes. As far as the United States is concerned, the compounds or compositions disclosed herein exclude compounds that are contemplated by 35 USC § 102 or 35 USC § 103. Specifically, the claims herein are worded to exclude substances that are presumed or not new in view of kWO 91/16320 WO 92/06691, US Patent 5,360,817 or Chandler, M., et al .; J. Chem. Soc. Perkin Trans. 1, 1995, 1189-1197.
Bez ohledu na předcházející, v provedení vynálezu lze identifikovat sloučeniny, které mohou spadat do generického rozsahu WO 91/16320, WO 92/06691 nebo US patent 5,360,817, které však mají (a) vzorec la z '320 aplikace, (b) uhlík pro skupinu „A“ v '320 aplikaci a (c) R5 z aplikace '320 a '691, které jsou ,,-CH2 YR6, -CHYR5CH2YR6 nebo -CHYR6CHYR6CH2YR6“, kde YR6 nemůže být ani OH ani chráněnou OH, kde ochranná skupina je schopná hydrolýzy tak, aby poskytovala volné radikály OH v podmínkách humánního gastrointestinálního traktu, to znamená, že sloučeniny jsou stabilní vůči hydrolýze v gastrointestinálním traktu. V důsledku toho, typicky vyloučené z provedení podle předloženého vynálezu jsou sloučeniny u aplikací '320 nebo '691, kde R5 je acetyl nebo karbacyl mající 1-4 uhlíkové atomy.Notwithstanding the foregoing, in an embodiment of the invention, compounds may be identified that may fall within the generic range of WO 91/16320, WO 92/06691 or US Patent 5,360,817, but which have (a) formula 1a of the '320 application, (b) carbon for group "and" the '320 application, and (c) R5 of the application' 320 and '691 which are ,, - CH 2 YR 6, -CHYR 5 or 6 CH2YR -CHYR Chyra 6 6 CH 2 YR 6, "where YR 6 can be neither OH nor protected OH, where the protecting group is capable of hydrolysis to provide free OH radicals under conditions of the human gastrointestinal tract, i.e. the compounds are stable to hydrolysis in the gastrointestinal tract. As a result, typically excluded from embodiments of the present invention are compounds in applications of '320 or' 691, wherein R 5 is acetyl or carbacyl having 1-4 carbon atoms.
Předpisy a metody pro určování stability sloučenin v náhradní gastrointestinální sekreci jsou známé. Sloučeniny jsou zde definovány jako stabilní v gastrointestinálním traktu, kde méně než asi 50 molových procent chráněných skupin je zbaveno ochrany v náhradí intestinální anebo žaludeční šťávě po inkubaci 1 hodinu při 37 °C. Tyto sloučeniny se hodí pro předložené provedení podle vynálezu.Prescriptions and methods for determining the stability of compounds in surrogate gastrointestinal secretion are known. Compounds are defined herein as stable in the gastrointestinal tract wherein less than about 50 mole percent of the protected groups are deprived of protection in the intestinal and / or gastric juice after incubation for 1 hour at 37 ° C. These compounds are suitable for the present embodiment of the invention.
Je třeba si všimnout, že jen to, že sloučeniny jsou stabilní v gastrointestinálním traktu ještě neznamená, že nemohou být hydrolyzovány in vivo. Proléky budou obvykle stabilní v trávicím systému, avšak jsou podstatně hydrolyzovány na mateřské léky v trávicí šťávě, játrech nebo jiném metabolickém orgánu nebo uvnitř buněk obecně.It should be noted that just that the compounds are stable in the gastrointestinal tract does not mean that they cannot be hydrolyzed in vivo. Prodrugs will usually be stable in the digestive system, but are substantially hydrolyzed to maternal drugs in the digestive juice, liver or other metabolic organ, or within cells generally.
Ovšem, je třeba chápat, že jiná provedení předloženého vynálezu, která jsou úplněji popsána níže, zamýšlejí použití sloučenin, které jsou skutečně konkrétně uvedeny ve WO 91/16320,However, it is to be understood that other embodiments of the present invention, which are more fully described below, contemplate the use of compounds that are actually specifically disclosed in WO 91/16320,
- 11 CZ 297945 B6- 11 GB 297945 B6
WO 92/06691, nebo US patentu 5 360 817 včetně těch, ve kterých YR6 je volný hydroxyl nebo hydroxyl chráněný běžně hydrolyzovatelnou skupinou jako je acetyl. V takovém případě se ovšem sloučeniny poskytují novými cestami podávání.WO 92/06691, or US Patent 5,360,817 including those in which YR 6 is free hydroxyl or hydroxyl protected by a commonly hydrolyzable group such as acetyl. In such a case, however, the compounds are provided by new routes of administration.
V jiném provedení vynálezu uvedené sloučeniny neobsahují ty, ve kterých (a) E, je -CO2H, -P(O)OH)2, -NO2, -SO2H, -SO3H, tetrazolyl, -CH2CHO, -CHO, nebo -CH(CHO)2;In another embodiment of the invention said compounds do not contain those wherein (a) E is -CO 2 H, -P (O) OH) 2 , -NO 2 , -SO 2 H, -SO 3 H, tetrazolyl, -CH 2 CHO, -CHO, or -CH (CHO) 2 ;
(b) Gi je -CN, N3, -NHR20, NR20, -OR20, guanidino, SR2o -N(R20)--->0, -N(R20),(OR20),(b) G 1 is -CN, N 3 , -NHR 20 , NR 20 , -OR 20 , guanidino, SR 2 o -N (R 20 ) ---> 0, -N (R 20 ), (OR 20 ) ,
-N(H)(R2O)N(R2o)2, nesubstituovaný pyrimidinyl nebo nesubstituovaný (pyrimidinyl) metyl;-N (H) (R 20 ) N (R 20 ) 2 , unsubstituted pyrimidinyl or unsubstituted (pyrimidinyl) methyl;
(c) Ti je -NHR2o, -NO2; a R20 je H; acylová skupina mající 1-4 uhlíkové atomy; lineární nebo cyklická alkylová skupina mající 1-6 uhlíkových atomů nebo její analog substituovaný halogenem; allylová skupina nebo nesubstituovaná arylová skupina nebo aryl substituovaný halogenem, skupina OH, NO2, NH2 nebo COOH;(c) T 1 is -NHR 2 O, -NO 2 ; and R 20 is H; an acyl group having 1-4 carbon atoms; a linear or cyclic alkyl group having 1-6 carbon atoms or a halogen substituted analog thereof; allyl or unsubstituted aryl or halogen substituted aryl, OH, NO 2 , NH 2 or COOH;
(d) každý Ji je H; a (e) X] je vazba, -CH2-, nebo -CH2-CH2-;(d) each J 1 is H; and (e) X 1 is a bond, -CH 2 -, or -CH 2 -CH 2 -;
v takovém případě W6 není H, W7 nebo -CH2W7, kde W7 je H, -OR<)a, -ORj,-N(Ri)2, -N(Ri)(Rób)> _N(R6b)2, -SRí, nebo -SR6a.in which case W6 is not H, W 7 or -CH 2 W 7 wherein W 7 is H, -OR <) and, -OR J, -N (R) 2, -N (R) (ROB)> _ N (R 6) 2, -SR, or -SR 6a.
V dalším provedení vynálezu jsou sloučeniny podle předloženého vynálezu ty, ve kterých Ui není -CH2OH, -CH2OAc, nebo -CH2OCH2Ph.In another embodiment of the invention, the compounds of the present invention are those wherein U 1 is not -CH 2 OH, -CH 2 OAc, or -CH 2 OCH 2 Ph.
V dalším provedení podle vynálezu, jsou sloučeniny podle předloženého vynálezu ty, ve kterých Ui není přímo vázán na kruhu jádra atomem uhlíku nebo Uj není substituován hydroxylem nebo hydroxyesterem a zvláště Ui není polyhydroxyalkan, konkrétně -CH(OH)CH(OH)CH2OH.In another embodiment of the invention, the compounds of the present invention are those wherein U 1 is not directly bound to the ring by a carbon atom or U 1 is not substituted by hydroxyl or hydroxyester and particularly U 1 is not polyhydroxyalkane, in particular -CH (OH) CH (OH) CH 2 OH .
V dalším provedení podle vynálezu je Uj je rozvětvenou řetězovou skupinou R5 jak se popisuje níže nebo uhlíkovým cyklem, který je substituován minimálně jednou skupinou R5.In another embodiment of the invention, U 1 is a branched chain group R 5 as described below or a carbon cycle which is substituted with at least one R 5 group.
V dalších provedeních, vyloučených z vynálezu jsou sloučeniny s vzorcem:In other embodiments excluded from the invention, the compounds of formula:
-12CZ 297945 B6-12GB 297945 B6
OHOH
nebo /—- Sor / —- S
HOHIM
2. Ve vzorci V:2. In formula V:
A2 je -O- nebo -CH2-;A 2 is -O- or -CH 2 -;
fy je-CO2H;fy is -CO 2 H;
G] je-NH2;G 1 is -NH 2 ;
Tj je-N(H)(Ac); aTj is -N (H) (Ac); and
Ui je-CH2OH;U 1 is -CH 2 OH;
3. Ve vzorci V:3. In formula V:
A2 je-CH2Ei je -CH2OH nebo -CH2OTMS;A 2 is -CH 2 E 1 is -CH 2 OH or -CH 2 OTMS;
G] je-N3;G 1 is -N 3 ;
Tj je-N(H)(Ac); aTj is -N (H) (Ac); and
Ui je-CH2OCH2Ph;U 1 is -CH 2 OCH 2 Ph;
4. Ve vzorci V:4. In formula V:
A2 je-CH2Ei je-CO2H nebo-CO2CH3;A 2 is -CH 2 E 1 is -CO 2 H or -CO 2 CH 3 ;
G] je-N3;G 1 is -N 3 ;
Tj je-N(H)(Ac); aTj is -N (H) (Ac); and
Ui je-CH2OH;U 1 is -CH 2 OH;
5. Ve vzorci V:5. In formula V:
A2 je-CH2Ei je-CO2H nebo-CHO, nebo-CH2OH;A 2 is -CH 2 E 1 is -CO 2 H or -CHO, or -CH 2 OH;
Gi je-N3;G 1 is -N 3 ;
Ti je-N(H)(Ac); aTi is -N (H) (Ac); and
Ui je -CH2OCH2Ph;U 1 is -CH 2 OCH 2 Ph;
- 13CZ 297945 B6- 13GB 297945 B6
6. Ve vzorci VI:6. In formula VI:
A2 je -CH2-;A 2 is -CH 2 -;
Ej je-CO2H;Ej is -CO 2 H;
G, je-OCH3;G 1 is -OCH 3 ;
Tj je-NH2;aTj is -NH 2 ;
U, je-CH2OHaU 1 is -CH 2 OHa
7. Ve vzorci VI7. In formula VI
A2 je-CH2;Ei je-CO2H;A 2 is -CH 2 ; E 1 is -CO 2 H;
G] je-OCH3 G 1 is -OCH 3
Tj je-N(H) (Ac); aTj is -N (H) (Ac); and
Uj je-CH2OAc.U 1 is -CH 2 OAc.
Kdykoli je sloučenina zde popsaná substituována více než jednou ze stejně označených skupin, například „R, nebo „Róa“, pak je třeba rozumět, že skupiny mohou být stejné nebo různé, to znamená, že každá skupina se vybírá nezávisle.Whenever a compound described herein is substituted with more than one of the same labeled groups, for example, "R, or" R 6a ", it is to be understood that the groups may be the same or different, that is, each group is selected independently.
„Heterocykl“ jak je zde používán, zahrnuje jako příklad a nikoli jako omezení, tyto heterocykly popsané v Paquette, Leo A.; „Principles of Modem Heterocyclic Chemistry“ (W. A. Benjamin, New York, 1968), zvláště pak v kapitolách 1, 3, 4, 6, 7 a 9; „The Chemistry of Heterocyclic Compounds, A řada monografií (John Wiley & Sons, New York, 1950 až do současnosti), zvláště pak ve svazcích 13, 14, 16, 19 a 28; a„J. Am. Chem. Soc.“, 82:5566 (1960).The "heterocycle" as used herein includes, by way of example and not limitation, the heterocycles described in Paquette, Leo A .; "Principles of Modem Heterocyclic Chemistry" (W.A. Benjamin, New York, 1968), in particular Chapters 1, 3, 4, 6, 7 and 9; The Chemistry of Heterocyclic Compounds, A series of monographs (John Wiley & Sons, New York, 1950 to present), especially in volumes 13, 14, 16, 19 and 28; and "J. Am. Chem. Soc., 82: 5566 (1960).
Příklady heterocyklů zahrnují jako příklad a nikoli jako omezení pyridyl, thiazolyl, tetrahydrothiofenyl, sírou oxidizovaný tetrahydrothiofenyl, pyrimidinyl, furanyl, thienyl, pyrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianafitalenyl, indolyl, indolenyl, chinolinyl, izochinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydrochinolinyl, tetrahydroizochinolinyl, dekahydrochinolinyl, oktahydroizochinolinyl, azocinyl, triazinyl, 6H-l,2,5-tiadiazinyl, 2H, 6H-l,5,2-dithiazinyl, thienyl, thiantrenyl, izobenzofuranyl, chromenyl, xantenyl, fenoxantiinyl, 2H-pyrrolyl, izothiazolyl, izoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, izoindolyl, 3H-indolyl, lH-indazolyl, purinyl, 4H-chinalizinyl, ftalazinyl, nafityridinyl, chinoxalinyl, chinozolinyl, cinnolinyl, pteridinyl, 4aH-karbazolyl, karbazolyl, β-karbolinyl, fenantridinyl, akridinyl, pyrimidinyl, fenantrolinyl, fenazinyl, fenothiazinyl, furazanyl, fenoxazinyl, izochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, izoindolinyl, chinuklidinyl, morfolinyl, oxazolidinyl, benzotriazolyl, benzoizoxazolyl, oxindolyl, benzoxazolinyl, a izatinoyl.Examples of heterocycles include, by way of example and not limitation, pyridyl, thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphitalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, isoquinolinyl, isoquinolinyl, isoquinolinyl, isoquinolinyl, isoquinolinyl -piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H, 6H-1,5,2-dithiazinyl, thienyl, thienyl, thienyl, thienyl, thienyl, thienyl, thienyl, thienyl , isobenzofuranyl, chromenyl, xanthenyl, phenoxantiinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 1H-indazolyl, 1H-indazolyl, purinyl, 4H-quinalizinyl, phthalazinyl, naphthinyl, quinolinyl, quinoxalinyl , 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzoisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl.
Jako příklad, nikoli jako omezení, uhlíkem vázané heterocykly jsou vázány v polohách 2, 3, 4, 5 nebo 6 pyridinu, v polohách 3, 4, 5, nebo 6-pyridazinu, v polohách 2, 4, 5 nebo 6 pyrimidinu, v polohách 2, 3, 4 nebo 6 pyrazinu, v polohách 2, 3, 4 nebo 5 furanu, tetrahydrofuranu, thiofuranu, thiofenu, pyrrolu nebo tetrahydropyrrolu, v poloze 2, 4 nebo 5 oxazolu, imidazolu nebo thiazolu, v polohách 3, 4, nebo 5 izoxazolu, pyrazolu nebo izothiazolu, v poloze 2 nebo 3 aziridinu, v poloze 2, 3 nebo 4 azetidinu, v poloze 2, 3, 4, 5, 6, 7 nebo 8 chinolinu nebo v poloze 1, 3, 4, 5, 6, 7 nebo 8 izochinolinu. Přesto obvyklejší jsou uhlíkem vázané heterocykly, které zahrnují 2By way of example and not limitation, carbon-linked heterocycles are bonded at the 2, 3, 4, 5 or 6 positions of pyridine, at the 3, 4, 5, or 6-pyridazine positions, at the 2, 4, 5, or 6 positions of the pyrimidine. positions 2, 3, 4 or 6 of the pyrazine, at positions 2, 3, 4 or 5 of furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, at positions 2, 4 or 5 of oxazole, imidazole or thiazole, at positions 3, 4, or 5 isoxazole, pyrazole or isothiazole, at position 2 or 3 of aziridine, at position 2, 3 or 4 of azetidine, at position 2, 3, 4, 5, 6, 7 or 8 of quinoline or at position 1, 3, 4, 5 , 6, 7 or 8 isoquinoline. However, carbon-linked heterocycles, which include 2
- 14CZ 297945 B6 pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl,- 14CZ 297945 B6 pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl,
6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrímidinyl, 2-pyrazinyl, 3pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, nebo 5-thiazolyl.6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.
Jako příklad a nikoli jako omezení dusíkem vázané heterocyklyjsou vázány v poloze 1 aziridinu, azetidinu, pyrrolu, pyrrolidinu, 2-pyrrolinu, 3-pyrrolinu, imidazolu, imidazolidinu, 2-imidazolidinu, 3-imidazolidinu, pyrazolu, pyrazolinu, 2-pyrazolinu, 3-pyrazolinu, piperidinu, piperazinu, indolu, indolinu, ΙΗ-indazolu, v poloze 2 u izoindolu nebo izoindolinu, v poloze 4 morfolinu a poloze 9 karbazolu nebo β-karbolinu. Ještě obvykleji, dusíkem vázané heterocykly obsahují 1aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, a 1-piperidinyl.By way of example and not limitation, nitrogen-bonded heterocyclyls are attached at the 1-position of aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazolidine, 3-imidazolidine, pyrazole, pyrazoline, 2-pyrazoline, 3 -pyrazoline, piperidine, piperazine, indole, indoline, ind-indazole, at position 2 of isoindole or isoindoline, at position 4 of morpholine and position 9 of carbazole or β-carboline. More usually, nitrogen-bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
„Alkyl,“ ve smyslu jak se zde používá, pokud není uvedeno jinak, je uhlovodík Cj-Cu obsahující normální, sekundární, terciární nebo cyklické uhlíkové atomy. Příklady jsou metyl (Me, -CH3), etyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-metyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2, 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), 2-metyl-2-propyl (t-Bu, t-butyl, -C(CH3)3, 1-pentyl (n-pentyl, -CH2CH2CH2 CH2CH3), 2-pentyl (-CCH(CH3) CH2 CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-metyl-2-butyl (-C(CH3)2CH2CH3), 3-metyl-2-butyl (-CH(CH3)CH(CH3)2), 3-metyl-l-butyl (-CH2 CH2CH(CH3)2), 2-metyl-1-butyl (-CH2 CH(CH3) CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2 CH2CH3), 3-hexyl (-CH (CH2CH3)(CH2CH2 CH3)), 2-metyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-metyl-2-pentyl (-CH(CH3)CH(CH3CH2CH3), 4-metyl-2-pentyl (-CH(CH3)CH2 CH(CH3)2), 3-metyl-3-pentyl (-C(CH3)CH2CH3)2, 2-metyl-3-pentyl (-CH (CH2CH3)CH (CH3)2), 2,3-dimetyl-2-butyl (C(CH3)2CH(CH3)2, 3,3-dimetyl-2-butyl (-CH(CH3)C(CH3)3). Příklady alkylových skupin jsou uvedeny v tabulce 2 jako skupiny 2 - 5, 7, 9 a 100-399."Alkyl," as used herein, unless otherwise indicated, is a C 1 -C 10 hydrocarbon containing normal, secondary, tertiary, or cyclic carbon atoms. Examples are methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1-propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr i-propyl, -CH (CH 3 ) 2 ), 1-butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl (i-Bu, i -butyl, -CH 2 CH (CH 3 ) 2 , 2-butyl (s-Bu, s-butyl, -CH (CH 3 ) CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t -butyl, -C (CH 3 ) 3 , 1-pentyl (n-pentyl, -CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CCH (CH 3 ) CH 2 CH 2 CH 3 ), 3-pentyl (-CH (CH 2 CH 3 ) 2 ), 2-methyl-2-butyl (-C (CH 3 ) 2 CH 2 CH 3 ), 3-methyl-2-butyl (-CH (CH 3 ) CH (CH 3 ) 2 ), 3-methyl-1-butyl (-CH 2 CH 2 CH (CH 3 ) 2 ), 2-methyl-1-butyl (-CH 2 CH (CH 3 ) CH 2 CH 3 ) 1-hexyl (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-hexyl (-CH (CH 3 ) CH 2 CH 2 CH 2 CH 3 ), 3-hexyl (-CH (CH 2 CH 3 ) (CH 2 CH 2 CH 3 )), 2-methyl-2-pentyl (-C (CH 3 ) 2 CH 2 CH 2 CH 3 ), 3-methyl-2-pentyl (-CH (CH 3 ) CH (CH 3 CH 2 CH 3 ), 4-methyl-2-pentyl (-CH (CH 3 ) CH 2 CH (CH 3 ) 2 ), 3-methyl-3-pentyl (-C (CH 3 ) CH 2 CH 3 ) 2,2 -methyl-3-pentyl (-CH (CH 2 CH 3 ) CH (CH 3 ) 2 ), 2,3-dimethyl-2-butyl (-C (CH 3) 2 CH (CH 3) 2, 3,3-dimethyl-2-butyl (-CH (CH3) C (CH3) 3). Examples of alkyl groups are listed in Table 2 as groups 2-5, 7, 9 and 100-399.
V obvyklém provedení jsouIn a typical embodiment, they are
Ji a Jja nezávisle Rb Br, Cl, F, I, Cn, NO2 nebo N3, obvykle Ri nebo F, ještě obvyklejší pak je H nebo F, přesto však nej obvyklejší je H.J 1 and J 1 independently R b Br, Cl, F, I, C 11, NO 2 or N 3 , usually R 1 or F, more usually H or F, yet most common is H.
Ei je-(CRiRi)miWi.Ei is - (CR 1 R 1) m iWi.
Obvykle, Ri je H nebo alkyl s 1 - 12 uhlíkovými atomy, obvykle H nebo alkyl s jedním až 4 nebo 5-10 uhlíkovými atomy, nejčastěji H nebo alkyl s 1 - 12 uhlíkovými atomy, nejčastěji však H nebo alkyl s 1 - 3 uhlíkovými atomy vybraný z možností metyl, etyl, n-propyl a i-propyl. Nej častěji Ri je H.Typically, R 1 is H or alkyl of 1 to 12 carbon atoms, usually H or alkyl of 1 to 4 or 5-10 carbon atoms, most commonly H or alkyl of 1 to 12 carbon atoms, most commonly H or alkyl of 1 to 3 carbon atoms atoms selected from methyl, ethyl, n-propyl and i-propyl. Most often Ri is H.
mi je celé číslo od 0 do 2, obvykle 0 nebo 1, nejčastěji 0, m2 je celé číslo od 0 do 1, m3 je celé číslo od 0 do 3.m is an integer from 0 to 2, usually 0 or 1, most commonly 0, m 2 is an integer from 0 to 1, m 3 is an integer from 0 to 3.
Wi je skupina obsahující kyselý vodík, chráněná acidická skupina nebo RřJC amid skupiny obsahující kyselý vodík, což v kontextu vynálezu znamená skupinu, která má vodíkový atom, který možno odstranit zásadou a vzniká tak aniont nebo jeho odpovídající sůl nebo solvát. Obecné zásady kyselosti a zásaditosti organických materiálů jsou dobře chápány a je třeba je tak chápat při definování Wp Zde se jimi nezabýváme podrobně. Ovšem, popis je uveden v Streitwieser, A.“ a Heathcock, C. H.: „Introduction to Organic Chemistry, 2. vydání“ (Macmillan, New York, 1981), strana 60-64. Všeobecně, acidické skupiny podle vynálezu mají hodnota pK nižší než voda, obvykle nižší než pK=10, nejčastěji méně než pK=8, a často méně než pK=6. Patří sem tetrazoly a kyseliny uhlíku, síry, fosforu a dusíku, obvykle kyseliny karboxylové, sírová, sulfonová, sulfínová, fosforečná a fosfonová, společně s amidy R6c a R<,b esterů těchto kyselin (R6a a R6c jak jsou definovány níže). Například W] jsou -CO2H, -CO2R6a, -OSO3H-, -SO3H-, -SO2H,Wi is a group comprising an acidic hydrogen, a protected acidic group or RR JC amide group comprising an acidic hydrogen which, in the context of the invention means a group having a hydrogen atom that can be removed with a base and so formed anion or its corresponding salt or solvate thereof. The general principles of acidity and alkalinity of organic materials are well understood and should be understood when defining Wp. These are not discussed in detail here. However, the description is given in Streitwieser, A. "and Heathcock, CH:" Introduction to Organic Chemistry, 2nd Edition "(Macmillan, New York, 1981), pages 60-64. In general, the acidic groups of the invention have a pK value less than water, usually less than pK = 10, most often less than pK = 8, and often less than pK = 6. These include tetrazoles and carbon, sulfur, phosphorus and nitrogen acids, usually carboxylic, sulfuric, sulfonic, sulfic, phosphoric and phosphonic acids, together with the amides R 6c and R 6b of the esters of these acids (R 6a and R 6c as defined below) ). For example, W 1 are -CO 2 H, -CO 2 R 6a , -OSO 3 H-, -SO 3 H-, -SO 2 H,
-15CZ 297945 B6-15GB 297945 B6
-OPO3H2, -PO3(R6a)2, -PO3(H2), -PO3(H)(Rba) a ~OPO3(R6a)2- Wi je obvykle Ei a E] je obvykle -CO2H, -CO2Rea, -CO2R4 nebo CO2Ri a nejčastěji je CO2Ri4, kde R14 je normální nebo koncový sekundární alkyl Ci-C6.-OPO3H2, -PO 3 (R 6a) 2, -PO 3 (H 2), -PO 3 (H) (Rb) and ~ OPO 3 (R 6a) 2 Wi is usually Ei and E] is usually - CO 2 H, -CO 2 R a, -CO2R4, or CO 2 R, and CO 2 is the most commonly R 4, wherein R 14 is normal or secondary alkyl terminal C-C 6.
W] může rovněž být chráněna acidická skupina, která, v rámci vynálezu znamená acidickou skupinu, jak je popsaná výše, která byla chráněna jednou ze skupin běžně používaných jako takových skupin a které jsou popsány níže pod Rba- Mnohem obvykleji je chráněný W) -CO2Ri, -SO3Rb -SO3Rb -S(O)ORb -P(O)(ORi)2, -C(O)NHSO2R4, nebo -SO2NHC(O)-R4, přičemž Rj je definován výše.W 1 may also be protected by an acidic group which, within the scope of the invention, is an acidic group as described above, which has been protected by one of the groups commonly used as such and which are described below under Rba. 2 R 1, -SO 3 R b -SO 3 R b -S (O) OR b -P (O) (OR 1) 2 , -C (O) NHSO 2 R 4 , or -SO 2 NHC (O) -R 4 wherein R 1 is as defined above.
E] je nejčastěji vybráno z: -C(O)O(CH2)bCH((CH2)cCH3)2, kde malé b = 0 až 4, malé c = 0 až 4 a b + c = 1 až 4 nebo ze skupinyE] is most often selected from: -C (O) O (CH 2 ) b CH ((CH 2 ) c CH 3 ) 2 , where small b = 0 to 4, small c = 0 to 4 and b + c = 1 to 4 or from a group
Příklady skupin Ej jsou uvedeny v tabulkách 3a až 3b.Examples of groups Ej are given in Tables 3a to 3b.
G] je N3, -CN, -OH, ORba, -NO2 nebo -(CRiRi)mi W2, kde R] a m, jsou definovány výše. Běžně je Gi -(CRiRi)miW2.G 1 is N 3 , -CN, -OH, OR b and , -NO 2 or - (CR 1 R 1) m and W 2 , wherein R 1 and m are as defined above. Normally Gi - (CRiRi) m iW 2 .
W2 je skupina obsahující bazický heteroatom, chráněný bazický heteroatom nebo R<,b amid bazického heteroatomu. W2 obvykle obsahuje bazický heteroatom, který, v rámci vynálezu znamená atom jiný než je uhlík, který je schopný poskytovat proton, obvykle kyselý vodík, který má aciditu v rozsahu popsaném výše pro Wj. Základní zásady kyselosti jsou popsány v citovaném díle Streitwiesera a Heathcocka a umožňují pochopení významu termínů bazický heteroatom tak, jak jej chápou odborníci v tomto oboru. Všeobecně, bazické heteroatomy, použité ve sloučenině podle vynálezu, mají hodnoty pK pro odpovídající protonizovanou formu, které jsou v rozsahu hodnot popsaných výše pro W|. Bazické heteroatomy zahrnují heteroatomy běžné v organických sloučeninách, které mají nesdílený, nevazební, typu-n nebo podobný elektronový pár. Jako příklad, nikoliv však omezení, obvyklé bazické heteroatomy jsou kyslík, dusík a síra, tedy atomy ve skupinách jako jsou alkoholy, aminy, amidiny, quanidiny, sulfidy apod.., často aminy, amidiny a guanidiny. Běžně, W2 je amino nebo aminoalkyl (všeobecně nižší alkyl) skupina jako jeW 2 is a group containing a basic heteroatom, a protected basic heteroatom, or a R 1, b amide of a basic heteroatom. W 2 typically contains a basic heteroatom which, within the scope of the invention, is a non-carbon atom capable of providing a proton, usually acid hydrogen, having an acidity in the range described above for W 1. The basic principles of acidity are described in Streitwieser's and Heathcock's cited works and allow understanding of the terms "basic heteroatom" as understood by those skilled in the art. In general, the basic heteroatoms used in the compound of the invention have pK values for the corresponding protonated form which are in the range of values described above for W 1. Basic heteroatoms include heteroatoms common in organic compounds having a non-shared, non-bonding, type-n or similar electron pair. By way of example and not limitation, common basic heteroatoms are oxygen, nitrogen and sulfur, i.e. atoms in groups such as alcohols, amines, amidines, quanidines, sulfides and the like, often amines, amidines and guanidines. Typically, W 2 is an amino or aminoalkyl (generally lower alkyl) group such as
-16CZ 297945 B6 aminomefyl, aminoetyl nebo aminopropyl; amidinyl nebo amidinoalkylová skupina jako je amidinometyl, amidinoetyl nebo amidinopropyl; nebo quanidinyl nebo quanidinoalkylová skupina jako je quanidinometyl, quanidinoetyl nebo quanidinopropyl (v každém případě zde alkylová skupina slouží jako můstek bazického substituentu ke karbocyklovému kruhu). Častěji W2 je amino, amidino, guanidino, heterocykl, heterocykl substituovaný jednou nebo dvěma amino nebo guanidino skupinami (obvykle 1), nebo alkylem o 2 až 3 uhlíkových atomech substituovaných amino nebo guanidino skupinou nebo takovým alkylem substituovaným z aminem a druhou skupinou vybranou ze skupiny skládající se z hydroxy a amino. Heterocykly používané jako W2 jsou obvykle pěti až šestičlenné kruhy obsahující N nebo S, přičemž kruh obsahuje jeden nebo 2 heteroatomy. Tyto heterocykly jsou obvykle substituovány na uhlíkových atomech kruhu. Mohou být nasycené nebo nenasycené a mohou být spojeny k jádru cyklohexenu nižším alkylem (ml = 1 nebo 2) nebo přes -NRi- Přesto však obvyklejší je, že W2 je -NHRi, -C(NH)(NH2), -NR1-C(NR1)(NR1R3), -NH-C(NH)(NHR3), -NH-CÍNHXNHRO, -NH-C(NH)NH2, -CH(CH2NHRi)(C1-I2OH), -CH(CH2NHR])(CH2NHRi), -CH(NHR1)-(CRiR1)m2-CH(NHR1)R1, -CHtOHjíCRiRO^-CHÍNHRijRi nebo -CH(NHR1)-CRiRi)ni2-CH(OH)Ri, -(CR^O^SC(NH)NH2, -N=C(NHR!)(R3), -N=C(SRi)N(Ri)2, -N(R!)C(NH)N(Ri)C=N, nebo -N=C(NHR])(Ri); kde každé m2 je obvykle 0 a Ri je obvykle H a R3 je C(O)N(R])2).Aminomethyl, aminoethyl or aminopropyl; an amidinyl or amidinoalkyl group such as amidinomethyl, amidinoethyl or amidinopropyl; or a quanidinyl or quanidinoalkyl group such as quanidinomethyl, quanidinoethyl or quanidinopropyl (in each case the alkyl group serves here as a bridge of the basic substituent to the carbocycle ring). More often, W 2 is an amino, amidino, guanidino, heterocycle, heterocycle substituted with one or two amino or guanidino groups (usually 1), or an alkyl of 2 to 3 carbon atoms substituted with an amino or guanidino group or such alkyl substituted with an amine and a second group selected from a group consisting of hydroxy and amino. The heterocycles used as W 2 are usually five to six membered rings containing N or S, the ring containing one or 2 heteroatoms. These heterocycles are usually substituted on carbon ring atoms. They may be saturated or unsaturated and may be linked to the core cyclohexene by lower alkyl (ml = 1 or 2) or via -NRi- Still more typically, W 2 is -NHR, -C (NH) (NH 2), -NR 1 -C (NR 1 ) (NR 1 R 3 ), -NH-C (NH) (NHR 3 ), -NH-CINHXNHRO, -NH-C (NH) NH 2 , -CH (CH 2 NHR 1 ) (C1 -I 2 OH), -CH (CH 2 NHR 1), (CH 2 NHR 1 ), -CH (NHR 1 ) - (CR 1 R 1 ) m 2 -CH (NHR 1 ) R 1 , -CH 3 OH-CR 1 R 4 -CHINHR 1 R 1 or -CH ( NHR 1 ) -CR 1 R 11 N 2 -CH (OH) R 1, - (CR 4 O 4 SC (NH) NH 2 , -N = C (NHR 1) (R 3 ), -N = C (SR 1) N (R 1) 12 , -N (R 1) C (NH) N (R 1) C = N, or -N = C (NHR 1) (R 1), wherein each m 2 is usually 0 and R 1 is usually H and R 3 is C (O) N (R 12) 2 ).
W2 je možný jako chráněný bazický heteroatom, který v rámci předloženého vynálezu znamená bazický heteroatom jak je popsán výše, který byl chráněn R6b jako je jedna ze skupin běžných v tomto oboru. Takové skupiny jsou podrobně popsány v práci Greeneové (cit. dílo) jak je uvedeno níže. Tyto skupiny zahrnují jako příklad nikoliv však jako omezení amidy, karbamáty, aminoacetyl, iminy, enaminy, N-alkyl nebo N-aryl fosfinyly, N-alkyl nebo N-aryl sulfenyly nebo sulfonyly, N-alkyl nebo N-aryl silyly, thioetery, thioestery, disulfidy, sulfenyly a podobně. V některých provedeních ochranná skupina Rňb bude štěpitelná ve fyziologických podmínkách, obvykle bude štěpitelná in vivo kde, například základní heteroatom tvoří amid s organickou kyselinou nebo aminokyselinou, jako je v přírodě se vyskytující aminokyselina nebo polypeptid jak je popsáno níže u skupiny R6a.W 2 is possible as a protected basic heteroatom which within the context of the invention means a basic heteroatom as described above that has been protected R 6 b is one of the groups common in the art. Such groups are described in detail in Greene (cit. Work) as outlined below. These groups include, but are not limited to, amides, carbamates, aminoacetyl, imines, enamines, N-alkyl or N-aryl phosphinyls, N-alkyl or N-aryl sulfenyls or sulfonyls, N-alkyl or N-aryl silyls, thioethers, thioesters, disulfides, sulfenyls and the like. In some embodiments, the R 1b protecting group will be cleavable under physiological conditions, usually being cleavable in vivo where, for example, the basic heteroatom is an amide with an organic acid or amino acid, such as a naturally occurring amino acid or polypeptide as described below for R 6a .
Obvykle se Gj vybírá ze skupiny, která se skládá ze:Usually, Gj is selected from the group consisting of:
- 17CZ 297945 B6- 17GB 297945 B6
J $J $
N«5S^ nh2 wy%N 5 5S ^ nh 2 w y%
HNXn ch3 H N Xn ch 3
CHgCHg
OH ^CHg ^N^CHaOH ^ CH3 ^ N ^ CHa
Další příklady skupin Gi jsou uvedeny v tabulce 4.Further examples of Gi groups are given in Table 4.
Ti je -NR]W3 nebo heterocyklus nebo je brán společně s Uj nebo Gb aby vytvořil skupinu se strukturou:T 1 is -NR 1 W 3 or a heterocycle or is taken together with U 1 or G 2 to form a group having the structure:
kde Reb je definován níže a R] a W3 jsou definovány výše. Obvykle se Ij volí ze skupiny, která se io skládá z:wherein Reb is defined below and R 1 and W 3 are defined above. Usually, Ij is selected from the group consisting of:
-18CZ 297945 B6-18GB 297945 B6
W3 je W4 nebo W5, kde W4 je Ri nebo -C(O)R5, -C(O)W5, -SO2R5 nebo -SO2W5. Obvykle W3 je -C(O)R5 nebo W5.W 3 is W 4 or W 5 , wherein W 4 is R 1 or -C (O) R 5 , -C (O) W 5 , -SO 2 R 5 or -SO 2 W 5 . Typically W 3 is -C (O) R 5 or W 5 .
R2 je nezávisle R3 nebo R4 jak je definován níže s podmínkou, že každý R4 je nezávisle substituován s 0 až 3 skupinami R3;R 2 is independently R 3 or R 4 as defined below, with the proviso that each R 4 is independently substituted with 0 to 3 R 3 groups;
R3 je nezávisle F, Cl, Br, I, -CN, N3, -NO2, ~OR6a, -ORb -N(Ri)2, -N(Ri)(R6b), -N(Réb)2, -SRb -SR6a, -S(O)Rb -S(O)2Rb -S(O)ORi), -S(O)OR6a, -S(O)2ORb -S(O)2OR6a, -C(O)ORb -C(O)R6C, -C(O)OR6a, -OC(O)Rb -NCRjXCCOjR,), -^)(0(0)^), -^)(^0)0^), -N(RébXCÍOjORD, -C(O)N(R!)2, -C(O)N(R6b)(R]), -C(O)N(R6b)2, -CÍNRO^R]),), -C(N(R6b))(N(R02, -C^ROjíNÍROÍRet,)), -C(N(R6b))(N(R1)(R6b)), -C(N(R0)(N(R^b)2), -C(N(Rbb))(N(Rňb)2), -NKRijCÍNtROjtNÍRjE -NÍROCÍNtROXNÍRjXRa,)), -N(RI)C(N(R6b))(N(R1)2), -N(R6b)C(N(R1))(N(R1)2), -N(R6b)C(N(R6b))(N(R1)2), -N(R6b)C(N(R1))(N(R1)(R6b)), -N(Rj)C(N(R6b))(N(R1)(R6b)), -NÍRJCÍNÍRJjíNÍRbb),), -N(R6b)C(N(R6b))(N(R1)(R6b)), -N(R6b)C(N(R,))(N(R6b)2), -N(R1)C(N(R6b))(N(R6b)2), -N(R6b)C(N(R6b))(N(R6b)2), =0, =S, =N(RJ nebo =N(R6b). Obvykle R3 je F, Cl, CN, N3, NO2, -OR6a, ORb -N(R])2, -bXRjXRtf,), -N(R6b)2, -SRb -SRfe, -C(O)ORb -C(O)R6C, -C(O)OR6a, -OC(O)Rb -NRiC(O)Rb -N(R,b)C(O)Rb -C(O)N(R])2, -C(O)N(R6b)(R1), -C(O)N(R6b)2, nebo =0. Častěji skupiny R3 zahrnují R6b včetně -C(O)N(R6b)2, -CÍOjNÍRébXRO, -C(S)N(R6b)2 nebo -0(8^(^)(¾). Avšak obvykleji R3 je F, Cl, -CN, N3, -0Rb -N(Ri)2, -SRb -C(O)ORb -OC(O)Ri nebo =0. Mnohem obvykleji však R3 je F, -OR], -N(Ri)2, nebo =0. V rámci předloženého vynálezu „=O“ znamená dvojitou vazbou vázaný kyslíkový atom (oxo) a „=S“ =N(R6ba) a ,,N(Ri)“ znamenají sírové a dusíkové analogy.R 3 is independently F, Cl, Br, I, -CN, N 3 , -NO 2 , -OR 6a , -OR b -N (R 1) 2 , -N (R 1) (R 6 b ), -N (R 6) b ) 2 , -SR b -SR 6a , -S (O) R b -S (O) 2 R b -S (O) OR 1), -S (O) OR 6a , -S (O) 2 OR b -S (O) 2 OR 6, -C (O) OR b, -C (O) R6, -C (O) OR 6a, -OC (O) R b -NCRjXCCOjR,) - ^) (0 ( 0) ^) - ^) (^ 0) 0 ^), -N (RébXCÍOjORD, -C (O) N (R) 2, -C (O) N (R6b) (R]), -C (O) N (R6b) 2, R -CÍNRO ^])), -C (N (R6b)) (N (R 0 2, -C ^ ROjíNÍROÍRet,)), -C (N (R 6b) ) (N (R 1) (R 6b)), -C (N (R 0) (N (R b) 2), -C (N (R b b)) (N (R b) 2), -NKRijCÍNtROjtNÍRjE -NÍROCÍNtROXNÍRjXRa,)), -N (R ') C (N (R 6b)) (N (R 1) 2), -N (R 6b) C (N (R1)) (N (R 1) 2 ), -N (R 6b ) C (N (R 6b )) (N (R 1 ) 2 ), -N (R 6b ) C (N (R 1 )) (N (R 1 ) (R 6b )) , -N (R 6) C (N (R 6b )) (N (R 1 ) (R 6b )), -NR (R) b ), (N (R 6b )) (N (R 6b )) (N (R 6b )) 1 ) (R 6b )), -N (R 6b ) C (N (R 6)) (N (R 6b ) 2 ), -N (R 6 ) C (N (R 6b )) (N (R 6b) ) 2), -N (R 6b) C (N (R 6b)) (N (R 6b) 2), = 0, = S, = N (R or = N (R6b). Typically, R 3 is F , Cl, CN, N 3 , NO 2 , -OR 6a , OR b -N (R 1) 2 , -bXR 1 X R t (1), -N (R 6 b ) 2 , -SR b -SR b , -C (O) OR b -C (O) R 6 C , -C (O) OR 6a , -OC (O) R b -NR 1 C (O) R b -N (R, b ) C (O) R b -C (O) N (R 1) 2 , -C (O) N (R 6b ) (R 1 ), -C (O) N (R 6 b ) 2 , or = 0. More often, the groups R 3 include R 6b including -C (O) N (R6b) 2, -CÍOjNÍRébXRO, -C (S) N (R 6b) 2, or -0 (8 ^ (^) (¾). However, typically R 3 is F, Cl, -CN, N 3 , -OR b -N (R 1) 2 , -SR b -C (O) OR b -OC (O) R 1 or = O. More commonly, however, R 3 is F, -OR 1, -N (R 1) 2 , or = 0. In the present invention, "= O" means a double bonded oxygen atom (oxo) and "= S" = N (R 6ba ) and "N (R 1)""Means sulfur and nitrogen analogues.
R4 je alkyl s 1 až 12 uhlíkovými atomy a alkinyl nebo alkenyl se 2 až 12 uhlíkovými atomy. Alkyl 1¾ je obvykle 1 až 12 uhlíkový atom a alkenyl a alkinyly R4 jsou obvykle alkyly se 2 až 12 uhlíkovými atomy. R4 je obvykle alkyl (jak definován výše). Jestliže R4 je alkenyl pak to obvykle bývá etenyl (-CH=CH2), 1-prop-l-enyl (-CH=CHCH3), l-prop-2-enyl (-CH2CH=CH2), 2-prop-l-enyl (-C(=CH2)(CH3)), 1-but-l-enyl (-CH=CHCH2CH3), l-but-2-enyl (-CH2CH=CHCH3), l-but-3-enyl (CH2CH2CH=CH2), 2-metyl- 1-prop-l-enyl (-CH=C(CH3)2), 2-metyl-l-prop-2-enyl (CH2C(=CH2)(CH3)), 2-but-l-enyl (-C(=CH2)CH2CH3), 2-but-2-enyl (-C(CH3)=CHCH3), 2-but-3-enyl (-CH(CH3)CH=CH2), 1-pent-l-enyl (-C=CHCH2CH2CH3), l-pent-2-enyl (CHCH=CHCH2CH3), l-pent-3^nyl (-CHCH2CH=CHCH3, l-pent-4-enyl (CHCH2CH2CH=CH2), 2-pent-l-enyl (-C(=CH2)CH2CH2CH3), 2-pent-2-enyl (C(CH3)=CH2CH2CH3), 2-pent-3-enyl (-CH(CH3)CH=CHCH3), 2-pent-4-enyl (CH(CH3)CH2CH=CH2) nebo 3-metyl-l-but-2-enyl (-CH2CH=C(CH3)2) Obvykleji R4 alkenylové skupiny mají dva, tři nebo čtyři uhlíkové atomy. Je-li R4 alkinyl je to obvykle etinyl (-CCH), 1-prop-l-inyl (-CCCH3), l-prop-2-inyl (-CH2CCH), 1-but-l-inyl (-CCCH2CH3), l-but-2inyl (-CH2CCCH3), l-but-3-inyl (-CH2CH2CCH), 2-but-3-inyl (CH(CH3)CCH), 1-pent-linyl (-CCCH2CH2CH3), 1-pent-l-inyl (CH2CCCH2CH3), l-pent-3-inyl (-CH2CH2CCH3) nebo l-pent-4-inyl (CH2CH2CH2CCH). Obvykleji se alkinylové skupiny R4 skládají ze 2, 3 nebo 4 uhlíkových atomů.R 4 is alkyl of 1 to 12 carbon atoms and alkynyl or alkenyl of 2 to 12 carbon atoms. Alkyl 1 'is usually 1 to 12 carbon atoms, and alkenyl and alkynyl R 4 are typically alkyls of 2 to 12 carbon atoms. R 4 is usually alkyl (as defined above). If R 4 is alkenyl then it is usually ethenyl (-CH = CH 2 ), 1-prop-1-enyl (-CH = CHCH 3 ), 1-prop-2-enyl (-CH 2 CH = CH 2 ), 2 -prop-1-enyl (-C (= CH 2 ) (CH 3 )), 1-but-1-enyl (-CH = CHCH 2 CH 3 ), 1-but-2-enyl (-CH 2 CH = CHCH 3 ), 1-but-3-enyl (CH 2 CH 2 CH = CH 2 ), 2-methyl-1-prop-1-enyl (-CH = C (CH 3 ) 2 ), 2-methyl-1 -prop-2-enyl (CH 2 C (= CH 2 ) (CH 3 )), 2-but-1-enyl (-C (= CH 2 ) CH 2 CH 3 ), 2-but-2-enyl ( -C (CH 3 ) = CHCH 3 ), 2-but-3-enyl (-CH (CH 3 ) CH = CH 2 ), 1-pent-1-enyl (-C = CHCH 2 CH 2 CH 3 ), 1-pent-2-enyl (CHCH = CHCH 2 CH 3 ), 1-pent-3-yl (-CHCH 2 CH = CHCH 3 , 1-pent-4-enyl (CHCH 2 CH 2 CH = CH 2 ), 2-pent-1-enyl (-C (= CH 2 ) CH 2 CH 2 CH 3 ), 2-pent-2-enyl (C (CH 3 ) = CH 2 CH 2 CH 3 ), 2-pent-3 -enyl (-CH (CH 3 ) CH = CHCH 3 ), 2-pent-4-enyl (CH (CH 3 ) CH 2 CH = CH 2 ) or 3-methyl-1-but-2-enyl (-CH 2 CH = C (CH 3 ) 2 ) More typically, R 4 alkenyl groups have two, three or four carbon atoms. When R 4 is alkynyl it is usually ethynyl (-CCH), 1-prop-1-ynyl (-CCCH 3 ), 1-prop-2-ynyl (-CH 2 CCH), 1-but-1 -inyl (-CCCH 2 CH 3 ), 1-but- 2 -vinyl (-CH 2 CCCH 3 ), 1-but-3-ynyl (-CH 2 CH 2 CCH), 2-but-3-ynyl (CH (CH) 3 ) CCH), 1-pent-linyl (-CCH 2 CH 2 CH 3 ), 1-pent-1-ynyl (CH 2 CCCH 2 CH 3 ), 1-pent-3-ynyl (-CH 2 CH 2 CCH) 3) or L-pent-4-ynyl (-CH 2 CH 2 CH 2 CCH). More usually, the alkynyl groups R 4 consist of 2, 3 or 4 carbon atoms.
R5 je R4 jak je definováno výše nebo R4 substituovaný O až 3 skupinami R3. Obvykle R5 je alkylen, který se skládá z 1 nebo 4 uhlíkových atomů substituovaných O až 3 fluorovými atomy.R 5 is R 4 as defined above or R 4 substituted with 0 to 3 R 3 groups. Typically, R 5 is alkylene consisting of 1 or 4 carbon atoms substituted with 0 to 3 fluorine atoms.
Rsa je alky len s 1 až 12 uhlíkovými atomy, alkenylen s 2 až 12 uhlíkovými atomy nebo alkinylen s 2-12 uhlíkovými atomy, který je substituován O-R3 skupinami. Jak definováno výše pro R4, skupiny R5a obsahují 1 - 12 uhlíkových atomů, když alkylen má 2-12 uhlíkových atomů stejně tak jako alkinylen. Každá z obvyklých R4 skupin je obvyklá R3a skupina s podmínkou, že jeden z vodíkových atomů popisované skupiny R4 je odstraněn tak, aby vytvořil otevřenou vazbu na uhlíkový atom prostřednictvím druhé vazby na připojený R5a.R is alkylene having 1 to 12 carbon atoms, alkenylene having 2 to 12 carbon atoms, or alkynylene of 2-12 carbon atoms, which is substituted by OR 3 groups. As defined above for R 4, R 5a groups contain 1-12 carbon atoms when alkylene has 2-12 carbon atoms as well as alkynylene. Each of the usual R 4 groups is a conventional R 3a group, with the proviso that one of the hydrogen atoms of the described R 4 group is removed to form an open bond to the carbon atom through the other bond to the attached R 5a .
R10 je alkyl, alkenyl, alkinyl s 1 až 12 uhlíkovými atomy substituovanými O až 3 R2.R 10 is alkyl, alkenyl, alkynyl having 1 to 12 carbon atoms substituted with 0 to 3 R 2 .
-19CZ 297945 B6-19GB 297945 B6
Rh je nezávisle H nebo RioR12 je cykloalkyl se 3 až 10 uhlíkovými atomy, nebo cykloalkenyl se 4 až 10 uhlíkovými atomy.R h is independently H or R 10 R 12 is cycloalkyl of 3 to 10 carbon atoms, or cycloalkenyl of 4 to 10 carbon atoms.
Ri4 je normální a nebo koncový sekundární C]-C6 alkyl.R 14 is a normal or terminal terminal C 1 -C 6 alkyl.
W5 je karbocykl nebo heterocykl za předpokladu, že každé W5 je nezávisle substituován 0 až 3 skupinami R2. W5 karbocykly a T] a W5 heterocykly jsou stabilní chemické struktury. Tyto struktury se izolují s měřitelným výtěžkem, s měřitelnou čistotou z reakčních směsí za teplot od -78 do 200 °C. Každý W5 je nezávisle substituován 0 až 3 skupinami R2. Obvykle jsou Tj a W5 nasycené, nenasycené nebo aromatické kruhy, obsahující mono- nebo bicyklické karbocykly nebo heterocykly. Ještě běžnější je, že Ti nebo W5 má 3 - 10 kruhových atomů, nejčastěji 3-7 kruhových atomů a zcela běžně 3-6 kruhových atomů. T] a W5 kruhy jsou nasycené, jestliže obsahují 3 kruhové atomy, nasycené nebo mononenasycené, jestliže obsahují 4 kruhové atomy, nasycené nebo mono případně di-nenasycené, jestliže obsahují 5 kruhových atomů a nasycené mono nebo di nenasycené nebo aromatické, jestliže obsahují 6 kruhových atomů.W 5 is carbocycle or heterocycle provided that each W 5 is independently substituted with 0 to 3 R 2 groups. W 5 carbocycles and T 1 and W 5 heterocycles are stable chemical structures. These structures are isolated in measurable yield, with measurable purity from the reaction mixtures at temperatures from -78 to 200 ° C. Each W 5 is independently substituted with 0 to 3 R 2 groups. Typically, T 1 and W 5 are saturated, unsaturated or aromatic rings containing mono- or bicyclic carbocycles or heterocycles. Even more common is that Ti or W5 has 3-10 ring atoms, most often 3-7 ring atoms and quite commonly 3-6 ring atoms. T 1 and W 5 rings are saturated if they contain 3 ring atoms, saturated or monounsaturated if they contain 4 ring atoms, saturated or mono or di-unsaturated if they contain 5 ring atoms and saturated mono or di unsaturated or aromatic, if they contain 6 ring atoms of ring atoms.
Jestliže W5 je karbocyklem, je to obvyklý uhlíkový monocykl se 3 až 7 uhlíky nebo dvojitý kruh se 7 až 12 uhlíkovými atomy. Častěji W5 monocyklický karbocykl, má 3-6 kruhových atomů, ještě obvykle 5 nebo 6 kruhových atomů. W5 karbocykly o dvou kruzích, mají 7 až 12 kruhových atomů uspořádaných jako bicyklo (4, 5), (5,5), (5,6) nebo (6,6) systém, přesto však obvykleji to je 9 nebo 10 kruhových atomů, uspořádaných jako dvojitý kruh (5, 6) nebo (6,6). Příklady zahrnují cyklopropyl, cyklobutyl, cyklopentyl, 1-cyklopent-l-enyl, l-cyklopent-2-enyl, 1-cyklopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, fenyl, spiryl a naftyl.When W 5 is a carbocycle, it is a conventional carbon monocycle of 3 to 7 carbons or a double ring of 7 to 12 carbon atoms. More often, the W 5 monocyclic carbocycle has 3-6 ring atoms, still usually 5 or 6 ring atoms. W 5 dual-ring carbocycles, having 7 to 12 ring atoms arranged as a bicyclo (4, 5), (5,5), (5,6) or (6,6) system, but more usually 9 or 10 ring atoms atoms arranged as a double ring (5, 6) or (6,6). Examples include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl, spiryl and naphthyl.
Heterocyklus Ti nebo W5 je obvykle jeden kruh, který má 3 - 7 kruhových členů (2 až 6 uhlíkových atomů a 1 až 3 heteroatomy vybrané mezi N, O, P a S) nebo jde o dvojitý kruh, který má 7 až 10 kruhových členů (4 až 9 uhlíkových atomů a 1 až 3 heteroatomů z řady N, O, P a S). Obvyklejší je, že heterocyklické monocykly mají 3 až 6 kruhových atomů (2 až 5 uhlíkových atomů a 1 až 2 heteroatomy zvolené z řady N, O, S), přesto však ještě obvykleji to bývá 5 nebo 6 kruhových atomů (3 až 5 uhlíkových atomů a 1 až 2 heteroatomy buď N nebo S). Tj a W5 heterocyklické bicykly mají 7 až 10 kruhových atomů (6-9 uhlíkových atomů a 1 až 2 heteroatomy z řady N, O, S), uspořádané jako dvojitý kruh (4, 5), (5,5), (5,6) nebo (6,6), ještě obvykleji to bývá 9 až 10 kruhových atomů (8 až 9 uhlíkových atomů a 1 až 2 heteroatomy buď N nebo S), uspořádané jako dvojitý kruh (5,6) nebo (6,6).The heterocycle Ti or W5 is usually a single ring having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P and S) or a double ring having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms from the N, O, P and S series). More typically, heterocyclic monocycles have 3 to 6 ring atoms (2 to 5 carbon atoms and 1 to 2 heteroatoms selected from the series N, O, S), yet more usually 5 or 6 ring atoms (3 to 5 carbon atoms) and 1 to 2 heteroatoms of either N or S). Ti and W 5 heterocyclic bicycles have 7 to 10 ring atoms (6 to 9 carbon atoms and 1 to 2 heteroatoms from the series N, O and S) arranged as a double circle (4, 5), (5,5), (5 , 6) or (6,6), more usually 9 to 10 ring atoms (8 to 9 carbon atoms and 1 to 2 heteroatoms of either N or S), arranged as a double ring (5,6) or (6,6) ).
Obvykle se heterocykly Ti a W5 vybrané mezi pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, striazinyl, oxazolyl, imidazolyl, thiazolyl, izoxazolyl, pyrazolyl, izothiazolyl, furanyl, thiofuranyl, thienyl nebo pyrrolyl.Typically, the T 1 and W 5 heterocycles are selected from pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, striazinyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, furanyl, thiofuranyl, thienyl or pyrrolyl.
Obvyklejší je, že heterocyklus Ti a W5 je vázán prostřednictvím uhlíkového atomu nebo dusíkového atomu. Ještě obvyklejší je, že Ti heterocykly jsou vázány stabilní kovalentní vazbou prostřednictvím dusíkového atomu na cyklohexenový kruh sloučeniny podle vynálezu a W5 heterocykly jsou vázány stabilní kovalentní vazbou prostřednictvím uhlíkového nebo dusíkového atomu na cyklohexenový kruh sloučeniny podle vynálezu. Stabilní kovalentní vazby jsou chemicky stabilní struktury, jak již bylo uvedeno.Typically, the heterocycle of Ti and W 5 is bonded through a carbon or nitrogen atom. More typically, T 1 heterocycles are bonded by a stable covalent bond via a nitrogen atom to the cyclohexene ring of a compound of the invention and W 5 heterocycles are bonded by a stable covalent bond via a carbon or nitrogen atom to a cyclohexene ring of a compound of the invention. Stable covalent bonds are chemically stable structures as mentioned above.
-20CZ 297945 B6-20EN 297945 B6
Ui je H nebo -X]Wó, avšak častěji právě -XiW6.U 1 is H or -X 1 W 6, but more often -X 1 W 6 .
Xi je vazba, -CR5R5-, -(CRjRsjr-, -0-, -N(H)_, -N(W6)-, -N(OH)-, -N(0W6)-, -N(NH2)-, -N(N(H)(W6))-, -N(N(W6)2)-, -N(H)N(W6)-, -S-, -S0-, nebo -SO2_; obvykle je X, vazba, -CR5R5-, -(CR5R5)2-, -0-, -N(H)-, -N(R5)-, -N(OH)-, -N(OR5)-, -N(NH2)-, -N(N(H)(R5))-N(N(R5)2)~, -N(H)N(R5}-, -S-, -S0-, nebo -S02_, obvykleji X, je vazba. -CR1Ri-(CR]R1)2- -O- -NRj- -N(OR!)-, -N(NRiRj)-, -S-, -S0-, nebo -S02-; běžně Xj je -0-, 10 -ΝΗ-,-S-, -SO-nebo-S02W6 je -R5, -W5, -R5aW5, -C(O)OR6a, -0(0^, -0(Ο)Ν^)2, -C(NR6b)(N(R6b)2), -CCNR^)(N(H)(R6b)), -C(N(H)(N(R6b)2, -C(S)N(Réb)2, nebo -C(O)R2, obvykle je -R5, -W5, nebo -R5aW5; v někteiých provedeních W6 je Rb -C(0)-Ri, -CHRjW7, -CH(Ri) a W7, -CH(W7)2, (kde a je O 15 nebo 1, avšak je O, jestliže W7 je dvojmocný) nebo -C(O)W7. V některých provedeních W6 je -CHR!W7 nebo -C(0)W7, nebo W6 je -(CH2)mlCH((CH2)m3R3)2, -(CH2)mlC((CH2)m3R3)3; -(CH2)mlCH((CH2)m3R5aW5)2; -(CH2)mlCH((CH2)m3R3)((CH2)m3R5aR3)3; -(CH2)mlC((CH2)m3R3)2(CH2)m3R5aW5), (CH2)mlC((CH2)m3R5aW5/3 nebo -(CH2)mlC((CH2)m3R3)((CH2)m3R5aW5)2; a při tom m3 je celé číslo od 1 do 3.X 1 is a bond, -CR 5 R 5 -, - (CR 3 R 5 ) -, -O-, -N (H) -, -N (W 6 ) -, -N (OH) -, -N (OW 6 ) -, -N ( NH 2 ) -, -N (N (H) (W 6 )) -, -N (N (W 6 ) 2 ) -, -N (H) N (W 6 ) -, -S-, -SO- , or -SO 2 _ usually is X, a bond, -CR5R5-, - (CR 5 R 5) 2 -, -0-, -N (H) -, -N (R 5) -, -N (OH ) -, -N (OR 5 ) -, -N (NH 2 ) -, -N (N (H) (R 5 )) - N (N (R 5 ) 2 ) -, -N (H) N ( R 5 } -, -S-, -SO 2 -, or -SO 2 - , more usually X, is a bond -CR 1 R 1 - (CR 1 R 1 ) 2 - -O- -NR 3 -N- (OR 1) -, -N (NR 1 R 3) -, -S-, -SO 2 -, or -SO 2 -; commonly X 1 is -O-, 10 -ΝΗ-, -S-, -SO- or -SO 2 W 6 is - R 5, -W 5, -R 5a W 5, -C (O) OR 6a, -0 (0 ^, -0 (Ο) ^ Ν) 2, -C (NR 6) (N (R6b) 2 ) -CCNR ^) (N (H) (R6b)), -C (N (H) (N (R6b) 2, -C (S) N (R b) 2, or -C (O) R 2 , usually is -R 5 , -W 5 , or -R 5 and W 5 ; in some embodiments, W 6 is R b -C (O) -R 1 , -CHR 7 W 7 , -CH (R 1) and W 7 - CH (W 7 ) 2 , (where a is O 15 or 1, but is O when W 7 is divalent) or -C (O) W 7. In some embodiments, W 6 is -CHR 11 W 7 or -C ( 0) W 7 or W 6 is - (CH 2 ) ml CH ((CH 2 ) m 3 R 3 ) 2 , - (CH 2 ) ml C (( CH 2 ) m3 R 3 ) 3 ; - (CH 2 ) ml CH ((CH 2 ) m 3 R 5 and W 5 ) 2 ; - (CH 2 ) m 3 CH ((CH 2 ) m 3 R 3 ) ((CH 2 ) m 3 R 5 and R 3 ) 3 ; - (CH 2 ) ml C ((CH 2 ) m 3 R 3 ) 2 (CH 2 ) m 3 R 5a W 5 ), (CH 2 ) ml C ((CH 2 ) m 3 R 5a W 5/3 or - (CH 2 ) ml C ((CH 2 ) m 3 R 3 ) ((CH 2 ) m 3 R 5 and W 5 ) 2 , in which m 3 is an integer from 1 to 3.
W7 je R3 nebo R5, avšak obvykle je to alkyl s 1 až 12ti uhlíkovými atomy, substituovanými O až 3 skupinami R3, přičemž tyto jsou obvykle vybírány ze skupin obsahujících -NRi(Réb), -N(Réb)2, -ORéa, nebo SR6a. Ještě obvykle je W7 -ORi nebo alkyl se 3 až 12 uhlíkovými atomy substituovaný ORi.W 7 is R 3 or R 5 but usually it is alkyl of 1 to 12 carbon atoms substituted with O to 3 groups R 3, these are generally selected from a group containing -NR (Re b), -N (Re b) 2 , -ORea, or SR 6a . Still more typically, W 7 -OR 1 or alkyl of 3 to 12 carbon atoms is substituted with OR 1.
Obecně je Uj RjO-, -0CHR]W7.Generally Uj RjO-, -0CHR] W 7th
t 't '
ch3 ch 3
-21 CZ 297945 B6-21 GB 297945 B6
Příklady skupin Uj jsou uvedeny v tabulce 2.Examples of groups Uj are given in Table 2.
Provedení podle vynálezu zahrnuje sloučeninu vzorce:An embodiment of the invention comprises a compound of the formula:
kde E2 je Eb avšak obvykle je vybráno ze skupiny sestávající z:wherein E 2 is E b but is usually selected from the group consisting of:
OHOH
owo V-S'OH ,o w o V - S 'OH,
V™V ™
V^OH °\\ ,O-Rea > O-RSa V, OH, OR and OR Sa
a kde G2 je G;, avšak obvykle je vybráno ze skupiny sestávající z:and wherein G 2 is G 2 , but is typically selected from the group consisting of:
-22CZ 297945 B6 a kde T2 je R4 nebo R5. Obvykle T2 je alkyl o 1 až 2 uhlíkových atomech, substituovaných 0 až 3 atomy fluoru.And wherein T 2 is R 4 or R 5 . Typically, T 2 is alkyl of 1 to 2 carbon atoms, substituted with 0 to 3 fluorine atoms.
U2 jej edna ze skupin:In 2 of its groups:
R, ’ R?R, 'R?
kde R7 je H, -CH3, -CH2CH3, -CH2CH2CH3, -OCH3, -OAc (-O-C(O)CH3), -OH, -NH2 nebo -SH, obvykle H, -CH3 nebo -CH2CH3.wherein R 7 is H, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -OCH 3 , -OAc (-OC (O) CH 3 ), -OH, -NH 2, or -SH, usually H, -CH 3 or -CH 2 CH 3 .
Skupiny Réa a Rdb nejsou klíčové funkce a mohou se značně měnit. Pokud nejsou H, jejich funkcí je sloužit jako meziprodukt pro mateřský lék. To neznamená, že nejsou biologicky aktivní. Naopak, hlavní funkcí těchto skupin je konvertovat mateřský lék do proléku, přičemž mateřský lék je uvolňován po konverzi proléku in vivo. Protože aktivní proléky jsou absorbovány efektivněji než mateřské léky, mohou mít naopak často větší potenciál in vivo než mateřský lék. Rea aRéb se odstraňují buď in vitro, v případě chemických meziproduktů nebo in vivo v případě proléků. Pokud se týká chemických meziproduktů, není zvlášť důležité, že výsledné profunkční produkty, například alkoholy, budou fyziologicky přijatelné, třebaže obecně je více žádoucí, aby výrobky byly farmakologicky nezávadné.R e and R d and b are key features and may vary greatly. If they are not H, their function is to serve as an intermediate for the parent drug. This does not mean that they are not biologically active. Conversely, the main function of these groups is to convert the parent drug into a prodrug, wherein the parent drug is released upon conversion of the prodrug in vivo. Because active prodrugs are more efficiently absorbed than the parent drug, they can often have greater potential in vivo than the parent drug. Re and aReb are removed either in vitro, in the case of chemical intermediates, or in vivo in the case of prodrugs. With regard to chemical intermediates, it is not particularly important that the resulting pro-functional products, such as alcohols, will be physiologically acceptable, although in general it is more desirable that the products are pharmacologically sound.
Róa je H a nebo skupina tvořící eter nebo ester. „Éter tvořící skupina“ znamená skupinu, která je schopná vytvořit stabilní kovalentní vazbu mezi mateřskou molekulou a skupinou, která má vzorec:R 6a is H and or an ether or ester-forming group. "Ether forming group" means a group capable of forming a stable covalent bond between the parent molecule and a group having the formula:
J—O-Va(V!)3, f—O-Va(V0(V2), I—O-Va(V3) j—O-VbíVO,, J—O_Vb(V2), nebo J—O-VM kde Va je čtyřmocný atom obvykle vybraný mezi uhlíkem a křemíkem; Vb je trojmocný atom, obvykle vybraný ze skupiny B, Al, N a P, ještě obvykleji N a P; Vc je dvojmocný atom obvykle vybraný ze skupiny O, S a Se, nejčastěji S; V) je skupina navázaná na Va, Vb nebo Vc stabilní, jednoduchou kovalentní vazbou, obvykle V! je skupina W6, častěji pak Vj je H, R2, W5 nebo -R5aW5, a nejčastěji pak H nebo R2; V2 je skupina vázaná na Va nebo Vb stabilní dvojitou kovalentní vazbou za předpokladu, že V2 není = O, = S nebo =N- obvykle V2 je = C(Vi)2, kde V3 je jako popsáno výše; a V3 je skupina vázaná na Va stabilní trojnou kovalentní vazbou, obvykle to bývá, že V3 je = C(Vi), kde V3 je jako popsáno výše.J-OV and (V) 3-f and OC (V0 (V 2), and I-OV (V 3) j O VbíVO O_V ,, J-B (2), or J-O- VM wherein V a is a divalent atom usually selected from carbon and silicon, V b is a trivalent atom, usually selected from B, Al, N and P, more usually N and P; V c is a divalent atom usually selected from O, S and Se, most commonly S; V) is a group attached to V a , V b or V c by a stable, single covalent bond, usually V 1; is W 6 , more often V 1 is H, R 2 , W 5 or -R 5 and W 5 , and most often H or R 2 ; V 2 is a group bound to V a or V b by a stable double covalent bond, provided that V 2 is not = O, = S or = N- usually V 2 is = C (Vi) 2 , wherein V 3 is as described above; and V 3 is a group bonded to V and a stable triple covalent bond, typically it is that V 3 is = C (Vi), where V 3 is as described above.
„Skupina vytvářející ester“ znamená skupinu, která je schopná vytvářet stabilní, kovalentní vazbu mezi mateřskou molekulou a skupinou, která má vzorec:"Ester-forming group" means a group capable of forming a stable, covalent bond between the parent molecule and a group having the formula:
f—O-Va(V1)4, J—O-Vb(V4), J—o-vxv^cvaf — OV a (V 1 ) 4, J — OV b (V 4 ), J — o-vxv ^ cva
J—O-Vd(V4)2, J_o_Ve(V1)3(V4),neboJ—O-VeCVOÍV,), kde Va, Vb a Vi jsou jako popsány výše; Vd je pětimocný atom, obvykle vybrán z P nebo N; Ve je šestimocný atom obvykle S; a V4 je skupina vázaná na Va, Vb, Vd nebo Ve stabilní, dvojnou kovalentní vazbu, za předpokladu, že nejméně jedno V4 je =0, =S nebo =N-Vj, obvykle V4, jestliže je jiné než =0, =S, nebo =N-, je =C(Vi)2, kde V3 je jako popsáno výše.J - OV d (V 4 ) 2 , J o - V e (V 1 ) 3 (V 4 ), or J - O - V (V 4 ), wherein V a , V b and Vi are as described above; V d is a pentavalent atom, usually selected from P or N; V e is a hexavalent atom usually S; and V 4 is a group bonded to V a , V b , V d or V e by a stable, double covalent bond, provided that at least one V 4 is = O, = S or = N-Vj, usually V 4 if it is other than = O, = S, or = N-, is = C (Vi) 2 , wherein V 3 is as described above.
Ochranné skupiny pro funkce -OH (ať již hydroxy, kyselé nebo jiné funkce) jsou charakterizovány jako „skupiny tvořící etery nebo estery“.Protecting groups for -OH functions (whether hydroxy, acidic or other) are characterized as "ether-forming or ester-forming groups".
-23CZ 297945 B6-23EN 297945 B6
Zvláště významné jsou skupiny tvořící étery nebo estery, které jsou schopné fungovat jako ochranné skupiny ve zde uváděných syntetických schématech. Ovšem, některé hydroxylové athio ochranné skupiny nejsou skupinami, které by tvořily étery nebo estery, jak jistě pochopí odborník a jsou zahrnuty mezi amidy, o kterých se jedná pod R6c níže. Róc je schopný chránit hydroxylovou nebo thio skupinu, takže hydrolýzou z mateřské molekuly dostaneme hydroxyl nebo thio sloučeninu.Of particular interest are ether-forming or ester-forming groups which are capable of functioning as protecting groups in the synthetic schemes provided herein. However, some hydroxyl athio protecting groups are not ethers or esters groups, as will be understood by one of ordinary skill in the art, and are included among the amides discussed under R 6c below. Rho c is capable of protecting hydroxyl or thio groups such that hydrolysis from the parental molecule get hydroxy or thio compound.
Ve své úloze tvorby esteru R6a obvykle se váže na každou acidickou skupinu jaká je, například příkladně a ne omezujíce -CO2H nebo -C(S)OH skupina, resultující pak na -CO2R6a. R6a je například dedukováno z vypočítaných esterových skupin ve WO 95/07920.In its role of ester formation, R 6a typically is bound to any acidic group it is, e.g., exemplary and not restrictive -CO 2 H or -C (S) OH group, then the resultants -CO 2 R 6 and. For example, R 6a is deduced from the calculated ester groups in WO 95/07920.
Příklady Rea zahrnují:Examples of Re a include:
C3-Ci2 heterocykly (popsané výše) nebo aryl. Tyto aromatické skupiny mohou být polycyklické nebo monocyklické. Mezi příklady patří fenyl, spiryl, 2- a 3-pyrrolyl, 2- a 3-thienyl, 2- a 4imidazolyl, 2-, 4- a 5-oxazolyl, 3- a 4-izoxazolyl, 2-, 4- a 5-thiazolyl, 3-, 4- a 5-izothiazolyl, 3- a 4-pyrazolyl, 1-, 2-, 3- a 4-pyridinyl, a 1-, 2-, 4- a 5-pyrimidinyl.C 3 -C i2 heterocycle (described above) or aryl. These aromatic groups may be polycyclic or monocyclic. Examples include phenyl, spiryl, 2- and 3-pyrrolyl, 2- and 3-thienyl, 2- and 4-imidazolyl, 2-, 4- and 5-oxazolyl, 3- and 4-isoxazolyl, 2-, 4- and 5 -thiazolyl, 3-, 4- and 5-isothiazolyl, 3- and 4-pyrazolyl, 1-, 2-, 3- and 4-pyridinyl, and 1-, 2-, 4- and 5-pyrimidinyl.
C3-Ci2 heterocykl nebo aryl substituovaný halogenem, Rb Ri-O-C]-C12 alkylen, Ci-C12 alkoxy, CN, NO2, OH, karboxy, karboxyester, thiol, thioester, Ci-Ci2 halogenalkyl (1-6 halogenových atomů), C2-C!2 alkenyl nebo C2-Ci2 alkinyl. Tyto skupiny zahrnují 2-, 3- a 4-alkoxyfenyl (C]-Ci2 alkyl), 2-, 3- a 4-metoxyfenyl, 2-, 3- a 4-etoxyfenyl, 2,3-, 2,4-, 2,5-, 3,4- a 3,5dietoxyfenyl, 2- a 3-karboetoxy-4-hydroxyfenyl, 2- a 3-etoxy-4-hydroxyfenyl, 2- a 3-etoxy5-hydroxyfenyl, 2- a 3-etoxy-6-hydroxyfenyl, 2-, 3- a 4-O-acetylfenyl, 2-, 3- a 4dimetylaminofenyl, 2-, 3- a 4 metylmerkaptofenyl, 2-, 3- a 4-halogenfenyl (včetně 2-, 3- a 4fluorofenyl a 2-, 3- a 4-chlorofenyl), 2,3-, 2,4-, 2,5-, 2,6-, 3,4- a 3,5-dimetylfenyl, 2,3-, 2,4-,C 3 -C 12 heterocycle or aryl substituted with halogen, R b R 1 -OC 1 -C 12 alkylene, C 1 -C 12 alkoxy, CN, NO 2 , OH, carboxy, carboxyester, thiol, thioester, C 1 -C 12 haloalkyl (1 -6 halogen atoms), C 2 -C 12 alkenyl or C 2 -C 12 alkynyl. These groups include 2-, 3- and 4-alkoxyphenyl (C 1 -C 12 alkyl), 2-, 3- and 4-methoxyphenyl, 2-, 3- and 4-ethoxyphenyl, 2,3-, 2,4- 2,5-, 3,4- and 3,5-diethoxyphenyl, 2- and 3-carboethoxy-4-hydroxyphenyl, 2- and 3-ethoxy-4-hydroxyphenyl, 2- and 3-ethoxy-5-hydroxyphenyl, 2- and 3 -ethoxy-6-hydroxyphenyl, 2-, 3- and 4-O-acetylphenyl, 2-, 3- and 4-dimethylaminophenyl, 2-, 3- and 4-methylmercaptophenyl, 2-, 3- and 4-halophenyl 3- and 4-fluorophenyl and 2-, 3- and 4-chlorophenyl), 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dimethylphenyl, 2,3 -, 2,4-,
2,5-, 2,6-, 3,4- a 3,5-biskarboxyetylfenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- a 3,5-dimetoxyfenyl, 2,3, 2,4-, 2,5-, 2,6-, 3,4- a 3,5-dihalogenfenyl (včetně 2,4-difluorofenyl a 3,5-difluorfenyl), 2-, 3a 4-halogenalkylfenyl (1 až 5 halogenových atomů, alkyl C]-C]2 včetně 4-trifluorometylfenyl),2,5-, 2,6-, 3,4- and 3,5-biscarboxyethylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5- dimethoxyphenyl, 2,3, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dihalophenyl (including 2,4-difluorophenyl and 3,5-difluorophenyl), 2-, 3a 4-halogenalkylfenyl (1 to 5 halogen atoms, alkyl, C] -C] 2 including 4-trifluoromethylphenyl)
2- , 3- a 4-kyanofenyl, 2-, 3- a 4-nitrofenyl, 2-, 3- a 4-halogenalkylbenzyl (1 až 5 halogenových atomů, Ci-C]2 alkyl včetně 4-trifluorometylbenzyl a 2-, 3- a 4-trichlorometylfenyl a 2-,2-, 3- and 4-cyanophenyl, 2-, 3- and 4-nitrophenyl, 2-, 3- and 4-haloalkylbenzyl (1 to 5 halogen atoms, C 1 -C 12 alkyl including 4-trifluoromethylbenzyl and 2-, 3- and 4-trichloromethylphenyl and 2-,
3- a 4-trichlorometylfenyl), 4-N-metylpiperidinyl, 3-N-metylpiperidinyl, 1-etylpiperazinyl, benzyl, alkylsalicylfenyl (C1-C4 alkyl, včetně 2-, 3- a 4-etylsalicylfenyl), 2-, 3- a 4-acetylfenyl, 1,8-dihydroxynaftyl (-Ci0H6~OH) aaryloxy etyl (C6-C9 aryl (včetně fenoxy etyl)), 2,2'dihydroxybifenyl, 2-, 3- a 4-N,N-dialkylaminofenol, -C6H4CH2-N(CH3)2, trimetoxybenzyl, trietoxybenzyl, 2-alkyl pyridinyl (Ci_4 alkyl);3- and 4-trichloromethylphenyl), 4-N-methylpiperidinyl, 3-N-methylpiperidinyl, 1-ethylpiperazinyl, benzyl, alkylsalicylphenyl (C 1 -C 4 alkyl, including 2-, 3- and 4-ethylsalicylphenyl), 2-, 3- and 4-acetylphenyl, 1,8-dihydroxynaftyl (H6 0 -C ~ OH) aaryloxy ethyl (C6-C9 aryl (including phenoxy ethyl)) 2,2'dihydroxybifenyl, 2-, 3- and 4-N, N- dialkylaminophenol, -C 6 H 4 CH 2 -N (CH 3 ) 2 , trimethoxybenzyl, triethoxybenzyl, 2-alkyl pyridinyl (C 1-4 alkyl);
C4-Cs estery 2-karboxyfenyl; a Ci-C4 alkylen -C3-C6 aryl (včetně benzyl, -CH2-pyrrolyl, -CH2-thienyl, -CH2-imidazolyl, -CH2-oxazolyl, -CH2-izoxazolyl, -CH2-thiazolyl, -CH2-izothiazolyl, -CH2-pyrazolyl, -CH2-pyridinyl a -CH2-pyrimidinyl) substituované v části arylu 3 až 5 halogenovými atomy nebo 1 až 2 atomy nebo skupinami zvolenými mezi halogeny, C]-Ci2 alkoxy (včetně metoxy a etoxy), kyano, nitro, OH, Ci-C]2 halogenalkyl (1 až 6 halogenových atomů; včetně -CH2-CC13), Ci-Ci2 alkyl (včetně metyl a etyl), C2-Ci2 alkenyl nebo C2-Ci2 alkinyl;C 4 -C 8 esters of 2-carboxyphenyl; and C 1 -C 4 alkylene -C 3 -C 6 aryl (including benzyl, -CH 2 -pyrrolyl, -CH 2 -thienyl, -CH 2 -imidazolyl, -CH 2 -oxazolyl, -CH 2 -isoxazolyl, -CH 2 -thiazolyl, -CH 2 -isothiazolyl, -CH 2 -pyrazolyl, -CH 2 -pyridinyl and -CH 2 -pyrimidinyl) substituted in the aryl part with 3 to 5 halogen atoms or 1 to 2 atoms or groups selected among halogens, C 1 - C 12 alkoxy (including methoxy and ethoxy), cyano, nitro, OH, C 1 -C 12 haloalkyl (1 to 6 halogen atoms; including -CH 2 -CCl 3 ), C 1 -C 12 alkyl (including methyl and ethyl), C 2 -C 12 alkenyl or C 2 -C 12 alkynyl;
alkoxyetyl (Ci-C6 alkyl včetně -CH2-CH2-O-CH3 (metoxy etyl));alkoxyethyl (C 1 -C 6 alkyl including -CH 2 -CH 2 -O-CH 3 (methoxy ethyl));
-24CZ 297945 B6 alkyl substituovaný některou ze skupin uvedených výše pro aryl, zvláště OH nebo 1 až 3 halogenové atomy (včetně -CH3, -CH(CH3)2, -C(CH3)3, -CH2CH3, _(CH2)2CH3, -(CH2)3CH3, -(CH2)4CH3, -(CH2)5CH3, -CH2CH2F, -CH2CH2CI, -CH2CF3 a-CH2CCl3);-24CZ 297945 B6 alkyl substituted with any of the above groups for aryl, especially OH or 1 to 3 halogen atoms (including -CH 3 , -CH (CH 3 ) 2 , -C (CH 3 ) 3 , -CH 2 CH 3 , - (CH 2 ) 2 CH 3 , - (CH 2 ) 3 CH 3 , - (CH 2 ) 4 CH 3 , - (CH 2 ) 5 CH 3 , -CH 2 CH 2 F, -CH 2 CH 2 Cl, -CH 2 CF 3 and -CH 2 CCl 3 );
; -N-2-propylmorfolino,; -N-2-propylmorpholino,
2,3-dihydro-6-hydroxyinden, sesamol, katechol monoester, -CH^CÍOI-NÍRÝ, -CH2-S(O)(R1), -CH2-S(O)2(R1)-CH2(OC(O)CH2R1), cholesteryl, enolpyruvát (HOOC-C(=CH2)-), glyce rol; a nebo 6ti uhlíkový monosacharid, disacharid nebo oligosacharid (3 až 9 monosacharidových zbytků);2,3-dihydro-6-hydroxyindene, sesamol, catechol monoester, -CH 2 Cl 2 -NIOR, -CH 2 -S (O) (R 1 ), -CH 2 -S (O) 2 (R 1 ) -CH 2 ( OC (O) CH 2 R 1 ), cholesteryl, enolpyruvate (HOOC-C (= CH 2 ) -), glyce rol; or a 6 carbon monosaccharide, disaccharide or oligosaccharide (3 to 9 monosaccharide residues);
triglyceridy jako je a-D-p-diglyceridy (kde mastné kyseliny tvořící glyceridové lipidy obvykle jsou v případě se vyskytující nasycené nebo nenasycené mastné kyseliny C6_26, C6_i8 nebo Cé-io, jako jsou kyselina linolová, laurová, myristová, palmitová, stearová, olejová, palmitoolejová a linolenová a podobné matné kyseliny), vázané na acyl mateřské sloučeniny prostřednictvím glycerolového kyslíku triglyceridu;triglycerides such as ADP-diglycerides (wherein the fatty acids constituting the glyceride lipids generally are in the naturally occurring saturated or unsaturated fatty acids, C 6 _ 26 C 6 _i 8 or Ce-io, such as linoleic, lauric, myristic, palmitic, stearic , oleic, palmitoleic and linolenic acids and the like matic acids), bound to the acyl parent compound via glycerol oxygen triglyceride;
fosfolipidy spojené ke karboxylové skupině prostřednictvím fosfátu fosfolipidu;phospholipids linked to the carboxyl group via a phospholipid phosphate;
ftahalidyl (viz obrázek 1 Clayton a j., Antimicrob. Agents Chemo. 5(6):670-671 (1974);phthalidyl (see Figure 1 Clayton et al., Antimicrob. Agents Chemo. 5 (6): 670-671 (1974);
cyklické karbonáty jako (5-R<i-2-oxo-l,3-dioxolen-4-yl) metyl estery (Sakamoto a j., Chem. Pharm. Bull. 32(6)2241-2248 (1984) kde Ráje Rb R4 nebo aryl; acyclic carbonates such as (5-R, 1-2-oxo-1,3-dioxolen-4-yl) methyl esters (Sakamoto et al., Chem. Pharm. Bull. 32 (6) 2241-2248 (1984) wherein Ráje R b is R 4 or aryl;
Hydroxylové skupiny sloučenin tohoto vynálezu bývají podle možnosti substituovány jednou ze skupin III, IV nebo V uvedených ve WO94/21604 nebo izopropylem.The hydroxyl groups of the compounds of the invention are preferably substituted by one of the groups III, IV or V mentioned in WO94 / 21604 or by isopropyl.
Jako další provedení, tabulka A uvádí příklady esterových částí Rf,a, které například mohou být vázány přes kyslík na skupiny -C(O)O- a -P(O)(O-)2. Jsou rovněž uvedeny některé amidáty Růc, které se váží přímo na -C(O)- nebo -P(O)2. Estery struktur 1-5, 8-10 a 16, 17, 19-22 jsou syntetizovány reakcí sloučeniny, která má volný hydroxyl s odpovídajícím halogenidem (chloridem nebo acylchloridem a pod.) a N,N-dicyklohexyl-N-morfolin karboxamidin (nebo jinou bází jako je DBU, trietylamin, CsCO3, Ν,Ν-dimetylanilin apod.) v DMF (nebo jiném rozpouštědle jako je acetonitril nebo N-metylpyrrolidon). Jestliže W3 je fosfonát, pak estery struktur 5-7, 11, 12, 21 a 23-26 jsou syntetizovány reakcí alkoholu nebo alkoxidové soli (nebo odpovídajících aminů v případě sloučenin jako je 13, 14 a 15) s monochlorfosfonátem nebo dichlorofosfonátem (nebo jiným aktivovaným fosfonátem).As a further embodiment, Table A gives examples of ester moieties Rf, a , which, for example, may be bonded via oxygen to -C (O) O- and -P (O) (O-) 2 groups. There are also some amidates manually, which bind directly to -C (O) - or -P (O) second Esters of structures 1-5, 8-10 and 16, 17, 19-22 are synthesized by reacting a compound having free hydroxyl with the corresponding halide (chloride or acyl chloride and the like) and N, N-dicyclohexyl-N-morpholine carboxamidine (or another base such as DBU, triethylamine, CsCO 3 , Ν, dim-dimethylaniline and the like) in DMF (or another solvent such as acetonitrile or N-methylpyrrolidone). If W 3 is a phosphonate, then esters of structures 5-7, 11, 12, 21 and 23-26 are synthesized by reacting an alcohol or an alkoxide salt (or the corresponding amines for compounds such as 13, 14 and 15) with a monochlorophosphonate or dichlorophosphonate (or other activated phosphonate).
-25 CZ 297945 B6-25 GB 297945 B6
Tabulka ATable A
1. -CHrC(O)-N(Ri)3*1. -CH 2 C (O) -N (R 1) 3 *
2. -CHrSfOXRi)2. -CHrSfOXRi)
3. -CHrS(OMR0-CHrS (OMR0
4. -CHrO-C(O)-CH2-CeH9 Fourth -CHR-C (O) -CH 2 -C e H 9
5.3- cholesteryl5.3- cholesteryl
6.3- pyridyl6.3- pyridyl
7. N-ethylmorfolino7. N-ethylmorpholino
8. -CH2-O-C(O)-CeH5 8th -CH 2 -OC (O) -C e H 5
9. -CH2-O-C(O)-CH2CH3 9th -CH 2 -OC (O) -CH 2 CH 3
10. -CHrO-CCOHXCHah10. -CH 2 O-CCOHXCH 3
11. -CH2-CCI3 -CH 2 -CCl 3
12. -CeHs12. -CeHs
13. -NH-CHrC(0)OCH2CH3 13th -NH-CHR c (0) OCH 2 CH 3
14. -N(CH3)-CH2-C(O)O-CH2CH3 14. -N (CH 3 ) -CH 2 -C (O) O-CH 2 CH 3
15. -NHRi15. -NHR 1
16. -CR2-O-C(O)-CioH15 16th -CR 2 -OC (O) -CioH 15
IT.-CH^-CCOj-CHfCH^IT.-CH 2 -CCO 3 -CH 2 CH 2
18. -CH2-C#H(OC(O)CH2R,)-CH2-(OC(O)CH2R1)*18. -CH 2 -C # H (OC (O) CH 2 R 1) - CH 2 - (OC (O) CH 2 R 1 ) *
25.25.
o^cHjOíoic <H2C(O)NH 2 C (O) N
19. '19. '
-CH-,-O-C(O) 22.-CH-, -O-C (O) 22.
CH3O(O)CCH 3 O (O) C
# - středem chirality je (R), (S) nebo racemát.# - the center of chirality is the (R), (S) or racemate.
Jiné estery, které jsou vhodné pro použití v tomto případě, jsou popsány v EP 632,048.Other esters suitable for use in this case are described in EP 632,048.
R6a také zahrnuje „dvojitý ester“, který vytváří profunkěnost jako -CH2OC(O)OCH3,R 6a also includes a "double ester" which produces functionality like -CH 2 OC (O) OCH 3 ,
θ -CH2SCOCH3, -CEl2OCON(CH3)2, nebo alkyl- nebo aryl-acyloxyalkyl skupiny struktury -CH(Ri nebo W5)O((CO)R37) nebo -CH(Ri nebo W5)O((CO)OR38) (napojená na kyslík acidické skupiny), kde R37 a R38 jsou alkyl, aryl nebo alkylarylové skupiny (viz US patent 4,968,788). Často jsou R37 a R38 velké skupiny jako jsou rozvětvené alkyly, orto-substituovaný aryl, metasubstituovaný aryl nebo jejich kombinace včetně normálních, sekundárních izo- a terciárních alkylů s 1-6 uhlíkovými atomy. Příkladem je pivaloyloxymetyl. To jsou skupiny vhodnéθ -CH 2 SCOCH 3 , -CE 12 OCON (CH 3 ) 2 , or an alkyl- or aryl-acyloxyalkyl group of the structure -CH (R 1 or W 5 ) O ((CO) R 37 ) or -CH (R 1 or W 5) 10 (O) ((CO) OR 38 ) (linked to oxygen of an acidic group) wherein R 37 and R 38 are alkyl, aryl or alkylaryl groups (see US Patent 4,968,788). Often, R 37 and R 38 are large groups such as branched alkyls, ortho-substituted aryl, metasubstituted aryl or combinations thereof including normal, secondary iso- and tertiary alkyls of 1-6 carbon atoms. An example is pivaloyloxymethyl. These are suitable groups
-26CZ 297945 B6 pro konkrétní použití u proléků pro orální podávání. Například takové užitečné skupiny R6a jsou alkylacyloxymetyl estery ajejích deriváty včetně -CH(CH2CH2OCH3)OC(O)C(CH3)3,No. 297945 B6 for particular use in prodrugs for oral administration. For example, such useful R 6a groups are alkylacyloxymethyl esters and derivatives thereof including -CH (CH 2 CH 2 OCH 3 ) OC (O) C (CH 3 ) 3 ,
-CH2OC(O)Ci0H15, -CH2OC(O)C(CH3)3, -CH(CH2OCH3)OC(O)C(CH3)3, -CH(CH(CH3)2)OC(O)C(CH3)3, -CH2OC(O)CH2CH(CH3)2, -CH2OC(O)C6Hlb -CH 2 OC (O) C 10 H 15 , -CH 2 OC (O) C (CH 3 ) 3 , -CH (CH 2 OCH 3 ) OC (O) C (CH 3 ) 3 , -CH (CH (O) CH 3 ) 2 ) OC (O) C (CH 3 ) 3 , -CH 2 OC (O) CH 2 CH (CH 3 ) 2 , -CH 2 OC (O) C 6 H 1b
-CH2OC(O)C6H5, -CH2OC(0)CioH15, -CH2OC(O)CH2CH3, -CH2OC(O)CH(CH3)2, -ch2oc(O)C(CH3)3 a-CH2OC(O)CH2C6H5.-CH 2 OC (O) C 6 H 5 , -CH 2 OC (O) C 10 H 15 , -CH 2 OC (O) CH 2 CH 3 , -CH 2 OC (O) CH (CH 3 ) 2 , -ch 2 C (O) C (CH 3 ) 3 α-CH 2 OC (O) CH 2 C 6 H 5 .
Pro účely přípravy proléků, ester, který se obvykle volí je jeden z těch, které se zde používají jako antibiotické léky, zvláště pak cyklické karbonáty, dvojité estery nebo ftahalidyl, aryl nebo alkyl esteiy.For the purpose of preparing prodrugs, the ester that is usually selected is one of those used herein as antibiotic drugs, especially cyclic carbonates, double esters or phthalidyl, aryl or alkyl esters.
Jak bylo uvedeno, skupiny R6a, R^ a R6b se používají jako zábrana proti vedlejším reakcím s chráněnou skupinou během syntetických procesů, takže fungují během syntézy jako ochranné skupiny (PRT). Ve většině případů rozhodování, pokud se týká toho, jakou skupinu chránit, kdy to udělat a jaká má být povaha PRT, bude rozhodnutí záviset na chemii reakce, která se má chránit (tzn. kyselé, zásadité, oxidační, redukční nebo jiné podmínky) a zamýšlený směr syntézy. Skupiny PRT nemusí být a také obvykle nejsou stejné, jestliže je sloučenina substituována několika různými PRT. Obecně se PRT bude používat pro ochranu karboxylu, hydroxylových nebo aminových skupin. Aby bylo možno tuto ochranu zrušit a získat volné skupiny, to závisí na zamýšleném směru syntézy a reakčních podmínkách, se kterými se budeme setkávat a které se mohou objevit v jakémkoliv pořadí, které určí odborník.As noted, the groups R 6a , R 6 and R 6b are used to prevent side reactions with a protected group during synthetic processes, so that they function as a protecting group (PRT) during the synthesis. In most cases, the decision as to which group to protect, when to do it and the nature of the PRT will depend on the chemistry of the reaction to be protected (ie, acidic, alkaline, oxidative, reducing or other conditions) and the intended direction of synthesis. The PRT groups need not be and also are usually not the same when the compound is substituted with several different PRTs. Generally, PRT will be used to protect carboxyl, hydroxyl or amine groups. In order to remove this protection and to obtain free groups, this depends on the intended direction of the synthesis and the reaction conditions to be encountered and which may occur in any order determined by one skilled in the art.
Značně velký počet hydroxy ochranných skupin R6a a skupin R6c tvořících amidy a odpovídající chemické štěpící reakce je popsán v práci „Protective Groups in Organic Chemistry“, Theodory W. Greeneové (John Wiley # Sons, lne., New York, 1991, ISBN 0—471—62301—6) („Greene“). Viz rovněž Kocienski, Philip J.; „Protecting Groups“ (Georg Thieme Verlag Stuttgart, New York, 1994), která je uváděna v odkazech této části. Zvláště pak kapitola 1, Ochranné skupiny: Přehled, strany 1-20, Kapitola 2, Hydroxylové ochranné skupiny, strany 21-94, Kapitola 3, Diolové ochranné skupiny, strana 95-117, Kapitola 4, Karboxylové ochranné skupiny, strana 118-154, Kapitola 5, Karbonylové ochranné skupiny, strana 155-184. Pro R6a karboxylovou kyselinu, kyselinu fosfonovou (fosforitou), fosforitan, kyselinu sulfonovou a další ochranné skupiny pro kyseliny W) viz Greene tak, jak bude uvedeno dále. Tyto skupiny zahrnují estery, amidy, hydrazidy apod., které uvádíme jako příklad, nikoliv jako vymezení.A large number of hydroxy protecting groups R 6a and R 6c groups forming amides and the corresponding chemical cleavage reactions are described in "Protective Groups in Organic Chemistry" by Theodora W. Greene (John Wiley # Sons, Inc., New York, 1991, ISBN). 0—471—62301—6) (“Greene”). See also Kocienski, Philip J .; "Protecting Groups" (Georg Thieme Verlag Stuttgart, New York, 1994), which is incorporated herein by reference. In particular, Chapter 1, Protecting Groups: Overview, pages 1-20, Chapter 2, Hydroxyl protecting groups, pages 21-94, Chapter 3, Diol protecting groups, page 95-117, Chapter 4, Carboxyl protecting groups, page 118-154 , Chapter 5, Carbonyl Protective Groups, page 155-184. For R 6a carboxylic acid, phosphonic acid (phosphorous acid), phosphonite, sulfonic acid and other protecting groups for acids W) see Greene as described below. These groups include esters, amides, hydrazides and the like, which are given by way of example and not by way of limitation.
V některých provedeních je chráněná acidická skupina Rea esterem acidické skupiny a R<-,a je zbytkem funkce obsahující hydroxyl. V jiné části se aminosloučeniny R6c používá na ochranu funkce kyseliny. Zbytky funkcí obsahující vhodný hydroxyl nebo aminoskupinu jsou uvedeny výše anebo je nalezneme ve WO 95/07920. Zvlášť zajímavé jsou zbytky aminokyselin, esterů aminokyselin, polypeptidy nebo aryl alkoholy. Typické aminokyseliny, polypeptidy a karboxylesterifikované aminokyseliny a jejich zbytky jsou popsány na stranách 11-18 a na příbuzném textu WO 95/07920 jako skupiny L| nebo L2. WO 95/07920 výslovně uvádí amidáty kyselin fosfonových, avšak je třeba chápat, že tyto amidáty jsou tvořeny s kteroukoliv acidickou skupinou zde uváděnou a se zbytky aminokyselin, uváděných v WO 95/07920.In some embodiments, the protected acidic group R a is an ester of the acidic group R a -, and is a residue of a hydroxyl-containing function. In another aspect, the amino compound R6c is used to protect the acid function. Function residues containing a suitable hydroxyl or amino group are listed above or found in WO 95/07920. Of particular interest are amino acid residues, amino acid esters, polypeptides or aryl alcohols. Typical amino acids, polypeptides, and carboxylesterified amino acids and residues thereof are described on pages 11-18 and the related text of WO 95/07920 as L groups | or L 2 . WO 95/07920 explicitly mentions phosphonic acid amidates, but it is to be understood that these amidates are formed with any of the acidic groups disclosed herein and with the amino acid residues disclosed in WO 95/07920.
Typické estery Rea pro ochranu acidických funkcí W] jsou rovněž popsány ve WO 95/07920, přičemž opět je třeba to chápat tak, že stejné estery se mohou vytvářet s acidickými skupinami zde uvedenými, jako jsou fosfonáty v publikaci '920. Typické esterové skupiny jsou definovány minimálně v materiálu WO 95/07920 na stranách 89-93 (jako R31 nebo R35), v tabulce na straně 105 a na stranách 21-23 (jako R). Zvlášť zajímavé jsou estery nesubstituováných arylů jako je fenyl nebo aryl alkyl, jako benzyl nebo hydroxy-, halogen-, alkoxy-, karboxy- a/nebo alkylTypical esters R a and for protecting the acidic functions W 1 are also described in WO 95/07920, and again it is understood that the same esters can be formed with the acidic groups mentioned herein, such as the phosphonates in '920. Typical ester groups are defined at least in WO 95/07920 on pages 89-93 (as R 31 or R 35 ), in the table on page 105 and on pages 21-23 (as R). Of particular interest are esters of unsubstituted aryl such as phenyl or aryl alkyl such as benzyl or hydroxy-, halogen-, alkoxy-, carboxy- and / or alkyl
-27CZ 297945 B6 esterkarboxyl- substituovaný aiyl nebo alkyl-aryl, zvláště pak fenyl, orto-etoxyfenyl nebo C1-C4 alkylesterkarboxyfenyl (alkylesterylsalicilát C1-C12).Ester carboxyl-substituted aryl or alkyl-aryl, especially phenyl, ortho-ethoxyphenyl or C1-C4 alkyl ester carboxyphenyl (C1-C12 alkyl ester salicilate).
Chráněné acidické skupiny Wb zvláště při použití esteru nebo amidů podle WO 95/07920, se užívají jako proléky pro orální podávání. Ovšem, není podstatné to, že acidická skupina Wi má být chráněna, aby sloučeniny tohoto vynálezu mohly být efektivně podávány orální cestou. Jestliže sloučeniny vynálezu mají chráněné skupiny, konkrétně amidáty aminokyselin nebo substituované nebo nesubstituované arylestery, pak jsou podávány systematicky anebo orálně, a jsou schopné hydrolytického štěpení in vivo, aby se tak získaly volné kyseliny.The protected acidic groups W b especially when using the esters or amides of WO 95/07920, are used as prodrugs for oral administration. However, it is not essential that the acidic group Wi be protected so that the compounds of the invention can be effectively administered by the oral route. When the compounds of the invention have protected groups, in particular amino acid amidates or substituted or unsubstituted aryl esters, they are administered systemically or orally, and are capable of hydrolytic cleavage in vivo to obtain free acids.
Je chráněn jeden nebo více acidických hydroxylů. Jestliže jeden nebo více acidických hydroxylů je chráněn, pak se používá stejné nebo různé ochranné skupiny, např. estery mohou být různé nebo stejné nebo může jít o směsné amidáty a estery.One or more acidic hydroxyls are protected. When one or more acidic hydroxyls are protected, the same or different protecting groups are used, e.g. the esters may be different or the same or may be mixed amidates and esters.
Typické Róa hydroxy ochranné skupiny popsané u Greeneové (strany 14- 118) zahrnují etery (metyl), substituované metyl estery (metoxymetyl, metylthiometyl, Z-butylthiometyl, (fenyldimetylsilyl)metoxymetyl, benzyloxymetyl, p-metoxybenzyloxymetyl, (4-metoxyfenoxy)metyl, guaiakolmetyl, t-butoxymetyl, 4-pentenyloxymetyl, siloxymetyl, 2-metoxyetoxymetyl, 2,2,2trichloroetoxymetyl, bis(2-chloroetoxy)metyl, 2-(trimetylsilyl)etoxymetyl, tetrahydropyranyl, 3bromotetrahydropyranyl, 1-metoxycyclohexyl, 4-metoxytetrahydrothiopyranyl, 4-metoxytetrahydrothiopyranyl, 4-metoxytetrahydrothiopyranyl, 4-metoxytetrahydrothiopyranyl, .SýS-dioxido,Typical R 6a hydroxy protecting groups described by Greene (pages 14-118) include ethers (methyl), substituted methyl esters (methoxymethyl, methylthiomethyl, 2-butylthiomethyl, (phenyldimethylsilyl) methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, (4-methoxyphenoxy) methyl, guaiacolmethyl, t-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis (2-chloroethoxy) methyl, 2- (trimethylsilyl) ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl, 4-methoxycyclohexyl, 4-methoxycyclohexyl, 4-methoxycyclohexyl -methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, 5S-dioxido,
1- [(2-chloro-4-metyl)fenyl]^l-metoxypiperidin-4-yl, 35, l,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimetyl-4,7-metanobenzofuran-2yl)), substituované etyl etery (1-etoxyetyl, l-(2-chloretoxy)etyl 1-metyl-1-metoxyetyl, 1metyl-l-benzyloxyetyl, l-metyl-l-benzyloxy-2-fluoroetyl, 2,2,2-trichloroetyl, 2-trimetylsilyletyl, 2-(fenylselenyl)etyl, Z-butyl, allyl, p-chlorofenyl, p-etoxyfenyl, 2,4-dinitrofenyl, benzyl), substituované benzyl etery (p-metoxybenzyl, 3,4-dimetoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halogenbenzyl, 2,6-dichlorobenzyl, p-kyanobenzyl, p-fenylbenzyl, 2- a 4-pikolyl, 3-metyl-1 - [(2-chloro-4-methyl) phenyl] -4-methoxy-piperidin-4-yl, 35,1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a, 4,5,6 , 7,7a-octahydro-7,8,8-trimethyl-4,7-metanobenzofuran-2-yl), substituted ethyl ethers (1-ethoxyethyl, 1- (2-chloroethoxy) ethyl 1-methyl-1-methoxyethyl, 1-methyl -1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2- (phenylselenyl) ethyl, 2-butyl, allyl, p-chlorophenyl, p-ethoxyphenyl, 2,4-dinitrophenyl, benzyl), substituted benzyl ethers (p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2 - and 4-picolyl, 3-methyl-
2- pikolyl N-oxido, difenylmetyl, ρ,ρ-dinitrobenzhydryl, 5-dibenzosuberyl, trifenylmetyl, anaftyldifenylmetyl, p-metoxyfenyldifenylmetyl, di(p-etoxyfenyl)fenylmetyl, tri(p-metoxyfenyl)metyl, 4-(4—bromofenacyloxy)fenyldifenylmetyl, 4,4',4-tris(4,5-dichloroftalimidofenyl)metyl, 4,4',4-tris(levulinoyloxyfenyl)metyl, 4,4',4-tris(benzoyloxyfenyl)metyl, 3-(imidazol-2-picolyl N-oxido, diphenylmethyl, ρ, ρ-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, anaphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di (p-ethoxyphenyl) phenylmethyl, tri (p-methoxyphenyl) methyl, 4- (4-bromophenacyloxy) phenyldiphenylmethyl, 4,4 ', 4-tris (4,5-dichlorophthalimidophenyl) methyl, 4,4', 4-tris (levulinoyloxyphenyl) methyl, 4,4 ', 4-tris (benzoyloxyphenyl) methyl, 3- (imidazole-
1- ylmetyl)bis(4',4-dimetoxyfenyl)metyl, 1, l-bis(4-metoxyfenyl)-l-pyrenylmetyl, 9-anthryl, 9-(9-fenyl)xantenyl, 9-(9-fenyl-10-oxo)anthryl, l,3-benzodithiolan-2-yl, benzizothiazolyl1-ylmethyl) bis (4 ', 4-dimethoxyphenyl) methyl, 1,1-bis (4-methoxyphenyl) -1-pyrenylmethyl, 9-anthryl, 9- (9-phenyl) xanthenyl, 9- (9-phenyl- 10-oxo-anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl
S.S-dioxido; silyl etery (trimetylsilyl, trietylsilyl, triizopropylsilyl, dimetylizopropylsilyl, dietylizopropylsilyl, dimetylhexylsilyl, Z-butyldimetylsilyl, Z—butyldifenylsi lyl, tribenzylsilyl, tri— p—xylylsilyl, trifenylsilyl, difenylmetylsilyl, Z-butylmetoxyfenylsilyl; estery (mravenčan, benzoylmravenčan, acetát, chloroacetát, dichloroacetát, trichloroacetát, trifluoroacetát, metoxyacetát, trifenylmetoxyacetát, fenoxyacetát, p-chlorofenoxyacetát, p-poly-fenylacetát, 3-fenylpropionát, 4-oxopentanoát (levulinát), 4,4-(etylendithio)pentanát, pivaloát, adamantoát, krotonát, 4-metoxykrotonát, benzoát, p-fenylbenzoát, 2,4,6-trimetylbenzoát (mesitoát)); karbonáty (metyl, 9-fluorenylmetyl, etyl, 2,2,2-trichloroetyl, 2-(trimetylsilyl)etyl, 2-(fenylsulfonyl)etyl, 2(trifenylfosfonio)etyl, izobutyl, vinyl, allyl, p-nitrofenyl, benzyl, p-metoxybenzyl, 3,4dimetoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, S-benzyl thiokarbonát, 4-etoxy-l-naftyl, metyl dithiokarbonát); skupiny s kontrolovaným štěpením (2-jodobenzoát, 4-azidobutyrát, 4-nitro-4metylpentanoát, o-(dibromometyl)benzoát, 2-formylbenzensulfonát, 2-metylthiometoxy)etylkarbonát, 4-(metylthiometoxy)butyrát, 2-(metylthiometoxymetyl)benzoát); různé estery (2,6dichloro-4-metylfenoxyacetát, 2,6-dichloro-4-( 1,1,3,3-tetrametylbutyl)fenoxyacetát, 2,4-bis(l,l-dimetylpropyl)fenoxyacetát, chlorodifenylacetát, izobutyrát, monosukcinoát, (E)-2-metyl-S.S-dioxido; silyl ethers (trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsilyl, Z-butyldimethylsilyl, Z-butyldiphenylsilyl, tribenzylsilyl, diphenylmethylsilylsilyl, tri-p-xylylsilyl; dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, p-polyphenylacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4- (ethylenedithio) pentanoate, pivaloate, adamantoate, creme, creme Methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate)), carbonates (methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2- (trimethylsilyl) ethyl, 2- (phenylsulfonyl) ethyl, 2 (triphenylphosphonio) ethyl, isobutyl, vinyl, allyl, p-nitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl, methyl dithiocarbonate); by controlled cleavage of (2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o- (dibromomethyl) benzoate, 2-formylbenzenesulfonate, 2-methylthiomethoxy) ethyl carbonate, 4- (methylthiomethoxy) butyrate, 2- (methylthiomethoxymethyl) benzoate; various esters (2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4- (1,1,3,3-tetramethylbutyl) phenoxyacetate, 2,4-bis (1,1-dimethylpropyl) phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinate, (E) -2-methyl-
2- butenoát (tigloát), o-(metoxykarbonyl)benzoát, p-poly-benzoát, α-naftoát, nitrát, alkyl Ν,Ν,Ν',Ν'-tetrametylfosforodiamidát, N-fenylkarbamát, borát, dimetylfosfinothioyl, 2,4-dinitrofenylsulfenát); a sulfonáty (sulfát, etansulfonát (mesylát), benzylsulfonát, tosylát.)2-butenoate (tigloate), o- (methoxycarbonyl) benzoate, p-polybenzoate, α-naphthoate, nitrate, alkyl Ν, Ν, Ν ', Ν'-tetramethylphosphorodiamidate, N-phenylcarbamate, borate, dimethylphosphinothioyl, 2,4 -dinitrophenylsulfenate); and sulfonates (sulfate, ethanesulfonate (mesylate), benzylsulfonate, tosylate.)
-28CZ 297945 B6-28GB 297945 B6
Častěji obsahují Rea hydroxy ochranné skupiny substituované metyl etery, substituované benzyl etery, silyl etery a esteiy včetně esterů kyseliny sulfonové, ještě častěji trialkylsilyl etery, tosyláty a acetáty.More commonly, R e and hydroxy protecting groups contain substituted methyl ethers, substituted benzyl ethers, silyl ethers and esters including sulfonic esters, more often trialkylsilyl ethers, tosylates and acetates.
Typické 1,2—diol ochranné skupiny (jako je obecně tam, kde dvě OH skupiny se berou společně s ochrannou funkcí R6a) jsou popsány u Greeneové na stránkách 118-142 a zahrnují cyklické acetaly a ketaly (metylen, etyliden, 1-t-butyletyliden, 1-fenyletyliden, (4-metoxyfenyl)etyliden, 2,2,2-trichloroetyliden, acetonid (izopropyliden), cyklopentyliden, cyklohexyliden, cykloheptyliden, benzyliden, p-metoxybenzyliden, 2,4-dimetoxybenzyliden, 3,4-dimetoxybenzyliden, 2nitrobenzyliden); cyklické o-estery (metoxymetylen, etoxymetylen, dimetoxymetylen, 1metoxyetyliden, 1-etoxyetyliden, 1,2-dimetoxyetyliden, α-metoxybenzyliden, l-(N,N-dimetylamino)etyliden derivát, a-(N,N-dimetylamino)benzyliden derivát, 2-oxacyklopentylidene); silyl deriváty (di-L-butylsilylenová skupina, 1,3-(1,1,3,3-tetraizopropyldisiloxanyliden) a tetra-tbutoxydisiloxan-l,3-diyliden), cyklické karbonáty, cyklické boronáty, etyl boronát a fenyl boronát.Typical 1,2-diol protecting groups (such as generally where two OH groups are taken together with the protective function of R 6a ) are described by Greene at pages 118-142 and include cyclic acetals and ketals (methylene, ethylidene, 1-t). -butylethylidene, 1-phenylethylidene, (4-methoxyphenyl) ethylidene, 2,2,2-trichloroethylidene, acetonide (isopropylidene), cyclopentylidene, cyclohexylidene, cycloheptylidene, benzylidene, p-methoxybenzylidene, 2,4-dimethoxybenzylidene, 3,4-dimethoxybenzylidene 2-nitrobenzylidene); cyclic o-esters (methoxymethylene, ethoxymethylene, dimethoxymethylene, 1-methoxyethylidene, 1-ethoxyethylidene, 1,2-dimethoxyethylidene, α-methoxybenzylidene, 1- (N, N-dimethylamino) ethylidene derivative, α- (N, N-dimethylamino) benzylidene derivative 2-oxacyclopentylidene); silyl derivatives (di-L-butylsilylene group, 1,3- (1,1,3,3-tetraisopropyldisiloxanylidene) and tetra-butoxydisiloxane-1,3-diylidene), cyclic carbonates, cyclic boronates, ethyl boronate and phenyl boronate.
Obvykleji ochranná skupina 1,2—-diol zahrnuje ty, které jsou uvedené v tabulce B, a ještě obvykle pak epoxidy, acetonidy, cyklické ketaly a aryl acetaly.More commonly, the 1,2-diol protecting group includes those listed in Table B, and more usually epoxides, acetonides, cyclic ketals, and aryl acetals.
Tabulka B r sTable B r p
o. oo. o
T 1T 1
II oII o
T ' r9ozP,oT 'r 9 o zP, o
T r9on T r 9 o n
Y° oY ° o
T Λ r9o-ns zo o oTΛr 9 on sz ooo
kde R9 je Ci-C6 alkyl.wherein R 9 is C 1 -C 6 alkyl.
Réb je H, ochranná skupina pro amino nebo zbytek karboxyl obsahující sloučeniny, zvláště pak H, -C(O)R4, aminokyselina, polypeptid nebo ochranná skupina jiná než -C(O)R4, aminokyselina nebo polypeptid. Amidotvomý R6b, se nalezne například ve skupině G|. Když je R6t) aminokyselina nebo polypeptid, pak má strukturu Ri5NHCH(Ri6)C(O)-, kde Rí5 je H, aminokyselina nebo polypeptidový zbytek, nebo R5 a Ri6 jak je definováno níže.R e is H, an amino or carboxyl protecting group containing compounds, particularly H, -C (O) R 4, an amino acid, a polypeptide or a protecting group other than -C (O) R 4, an amino acid, or a polypeptide. The amide-forming R 6b is found, for example, in the group G 1. When R 6 t) an amino acid or polypeptide, it has the structure R 5 NHCH (R 6) C (O) -, wherein R i5 is H, an amino acid or polypeptide residue, or R5 and Ri6 as defined below.
Ri6 je nižší alkyl nebo nižší alkyl (C|-C6) substituovaný aminoskupinou, karboxylem, amidem, karboxylesterem, hydroxylem C6-C7 aryl, guanidinyl, imidazolyl, indolyl, sulfhydryl, sulfoxid a/nebo alkylfosfát. R10 se také bere společně s aminokyselinou α N, aby vytvářel prolinový zbytek (R10 = -CH2)3-). Ovšem Ri0 je všeobecně postranní skupinou v přírodě se vyskytujících aminokyselin, jako je H, -CH3, -CH(CH3)2, -CH2-CH(CH3)2, -CHCH3-CH2-CH3, -CH2-C6H5, -CH2CH2S-CH3, -CH2OH, -CH(OH)-CH3, -CH2-SH, -CH2-C6H4OH, -ch2-co-nh2, -CH2-CH2-CO-NH2, -CH2-COOH, -CH2-CH2-COOH, -(CH2)4-NH2 a-(CH2)3-NH-C(NH2)NH2. R10 rovněž zahrnuje l-guanidinoprop-3-yl, benzyl, 4-hydroxybenzyl, imidazol-4-yl, indol-3-yl, metoxyfenyl a etoxyfenyl.R 16 is lower alkyl or lower alkyl (C 1 -C 6 ) substituted with amino, carboxyl, amide, carboxylate, hydroxyl C 6 -C 7 aryl, guanidinyl, imidazolyl, indolyl, sulfhydryl, sulfoxide and / or alkyl phosphate. R10 is also taken together with the amino acid α N to form a proline residue (R10 = -CH 2 ) 3 -). However, R 10 is generally a side group of naturally occurring amino acids such as H, -CH 3 , -CH (CH 3 ) 2 , -CH 2 -CH (CH 3 ) 2 , -CHCH 3 -CH 2 -CH 3 , -CH 2 -C 6 H 5 , -CH 2 CH 2 S-CH 3 , -CH 2 OH, -CH (OH) -CH 3 , -CH 2 -SH, -CH 2 -C 6 H 4 OH, -ch 2 -co-nh 2 , -CH 2 -CH 2 -CO-NH 2 , -CH 2 -COOH, -CH 2 -CH 2 -COOH, - (CH 2 ) 4 -NH 2 and - (CH 2 ) 3 - NH-C (NH 2) NH second R 10 also includes 1-guanidinoprop-3-yl, benzyl, 4-hydroxybenzyl, imidazol-4-yl, indol-3-yl, methoxyphenyl and ethoxyphenyl.
-29CZ 297945 B6-29GB 297945 B6
Réb jsou obvykle zbytky karboxylových kyselin, avšak kterákoli z ochranných aminoskupin popisovaných Greenovou na stránkách 315-385 může být užitečná. Jedná se o karbamáty (metyl a etyl, 9-fluorenylmetyl, 9(2-sulfo)fluoroenylmetyl, 9-(2,7-dibromo)fluorenylmetyl, 2,7—di—t— butyl-(9-( 10,10-dioxo-l0,10,10,10-tetrahydrothioxanthyl))metyl, 4-metoxyfenacyl); substituovaný etyl (2,2,2-trichloroetyl, 2-trimetylsilyletyl, 2-fenyletyl, l-(l-adamantyl)-l-metyletyl, l,l-dimetyl-2-halogenetyl, l,l-dimetyl-2,2-dibromoetyl, l,l-dimetyl-2,2,2-trichloroetyl, 1metyl-l-(4-bifenylyl) etyl, l-(3,5-di-t-butylfenyl)-l-metyletyl, 2-(2- a 4'-pyridyl)etyl, 2(N,N-dicyklohexylkarboxamido)etyl, t-butyl, 1-adamantyl, vinyl, allyl, 1-izopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-chinolyl, N-hydroxypiperidinyl, alkyldithio, benzyl, p-metoxybenzyl, p-nitrobenzyl, p-bromobenzyl, p-chlorobenzyl, 2,4-dichlorobenzyl, 4-metylsulfínylbenzyl, 9-antrylmetyl, difenylmetyl); skupiny se řízeným štěpením (2-metylthioetyl, 2metylsulfonyletyl, 2-(p-toluensulfonyl)etyl, (2-(1,3-dithianyl)metyl, 4-metylthiofenyl, 2,4dimetylthiofenyl, 2-fosfonioetyl, 2-trifenylfosfonioizopropyl, l,l-dimetyl-2-kyanoetyl, mchloro-p-acyloxybenzyl, p-(dihydroxyboryl)benzyl, 5-benzizooxazolylmetyl, 2-(trifluorometyl)-6-chromonylmetyl); skupiny schopné fotolytického štěpení (m-nitrofenyl, 3,5-dimetoxybenzyl, o-nitrobenzyl, 3,4-dimetoxy-6-nitrobenzyl, fenyl(o-nitrofenyl)metyl); deriváty močovinového typu (fenothiazinyl-(10)-karbonyl, N'-p-toluensulfonylaminokarbonyl, N'-fenylaminothiokarbonyl); různé karbamáty (t-amyl, S-benzyl thiokarbamát, p-kyanobenzyl, cyklobutyl, cyklohexyl, cyklopentyl, cyklopropylmetyl, p-decyloxybenzyl, diizopropylmetyl, 2,2-dimetoxykarbonylvinyl, o-(N,N-dimetylkarboxamido)benzyl, 1,1 -dimetyl-3-(N,N-dimetylkarboxamido)propyl, 1,1-dimetylpropinyl, di(2-pyridyl)metyl, 2-furanylmetyl, 2-jodoetyl, Izobomyl, Izobutyl, Izonicotinyl, p-(p'-metoxyfenylazo)benzyl, 1-metylcyklobutyl, 1-metylcyklohexyl, 1metyl-1 -cyklopropylmetyl, 1 -metyl-1 -(3,5-dimetoxyfenyl)etyl, 1 -mety 1-1 -(p-fenylazofeny 1)etyl, 1-metyl-1-fenyletyl, l-metyl-l-(4-pyridyl)etyl, fenyl, p-(fenylazo)benzyl, 2,4,6-tri-tbutylfenyl, 4-(trimetylamonium)benzyl, 2,4,6-trimetylbenzyl); amidy (N-formyl, N-acetyl, Nchloroacetyl, N-trichloroacetyl, N-trifluoroacetyl, N-fenylacetyl, N-3-fenylpropionyl, Npicolinoyl, N-3-pyridylkarboxamid, N-benzoylfenylalanyl, N-benzoyl, N-p-fenylbenzoyl); amidy s regulovaným štěpením (N-o-nitrofenylacetyl, N-o-nitrofenoxyacetyl, N-acetoacetyl, (N'-dithiobenzyloxykarbonylamino)acetyl, N-3-(p-hydroxyfenyl)propionyl, N-3-(o-nitrofenyl)propionyl, N-2-metyl-2-(o-nitrofenoxy)propionyl, N-2-metyl-2-(o-fenylazofenoxy)propionyl, N-4-chlorobutyryl, N-3-metyl-3-nitrobutyryl, N-o-nitrocinnamoyl, N-acetylmethionin, N-o-nitrobenzoyl, N-o-(benzoyloxymetyl)benzoyl, 4,5-difenyl-3-oxazolin-2-on); cyklické imidy a deriváty (N-ftahalimid, N-dithiasuccinoyl, N-2,3-difenylmaleoyl, N-2,5dimetylpyrrolyl, N-l,l,4,4-tetrametyldisilylazacyklopentan a adiční produkt, 5-substituovaný, 1,3-dimetyl-l ,3,5-triazacyklohexan-2-on, 5-substituovaný 1,3-dibenzyl-l ,3-5-triazacyklohexan-2-on, 1-substituovaný 3,5-dinitro-4-pyridonyl); N-alkyl a N-aryl aminy (N-metyl, Nallyl, N-(2-(trimetylsilyl)etoxy)metyl, N-3-acetoxypropyl, N-(l-izopropyl-4-nitro-2-oxo-3pyrrolin-3-yl), quatemí amoniové soli, N-benzyl, N-di(4-metoxyfenyl)metyl, N-5-dibenzosuberyl, N-trifenylmetyl, N-(4-metoxyfenyl) difenylmetyl, N-9-fenylfluorenyl, N-2,7dichloro-9-flurenylmetylen, N-ferrocenylmetyl, N-2-pikolylamin Ν'-oxid), iminové deriváty (N-l,l-dimetylthiometylen, N-benzyliden, N-p-metoxybenzyliden, N-difenylmetylen, N-((2pyridyl)mesityl)metylen, N, (Ν',Ν'-dimetylaminometylen, Ν,Ν'-izopropyliden, N-p-nitrobenzyliden, N-salicyliden, N-5-chlorosalicyliden, N-(5-chloro-2-hydroxyfenyl)fenylmetylen, N-cyclohexyliden); enaminové deriváty (N-(5,5-dimetyl-3-oxo-l-cyklohexenyl)); N-metalické deriváty (deriváty N-boranu, deriváty kyseliny N-difenylborové kyseliny, N-(fenyl(pentakarbonylchrom - nebo tungsten))karbenyl, N-Cu nebo N-Zn chelát); N-N deriváty (N-nitro, N-nitroso, N-oxid); N-P deriváty (N-difenylfosfínyl, N-dimetylthiofosfinyl, N-dialkyl fosforyl, N-dibenzyl fosforyl, N-difenyl fosforyl); deriváty N-Si; deriváty N-S; deriváty N-sulfenyl (Nbenzensulfenyl, N-o-nitrobenzensulfenyl, N-2,4-dinitrobenzensulfenyl, N-pentachlorobenzensulfenyl, N-2-nitro-4-metoxybenzensulfenyl, N-trifenylmetylsulfenyl, N-3-nitropyridinsulfenyl); a deriváty N-sulfonyl (N-o-toluensulfonyl, N-benzensulfonyl, N-2,3,6-trimetyl-4metoxybenzensulfonyl, N-2,4,6-trimetoxybenzensulfonyl, N-2,6-dimetyM-metoxybenzensulfonyl, N-pentametylbenzensulfonyl, N-2,3,5,6-tetrametyl-4-metoxybenzensulfonyl, N-4metoxybenzensulfonyl, N-2,4,6-trimetylbenzensulfonyl, N-2,6-dimetoxy-4-metylbenzenRebs are usually carboxylic acid residues, but any of the amino protecting groups described by Green on pages 315-385 may be useful. These are carbamates (methyl and ethyl, 9-fluorenylmethyl, 9 (2-sulfo) fluoroenylmethyl, 9- (2,7-dibromo) fluorenylmethyl, 2,7-di-t-butyl- (9- (10,10- dioxo-10,10,10,10,10-tetrahydrothioxanthyl)) methyl, 4-methoxyphenacyl); substituted ethyl (2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-phenylethyl, 1- (1-adamantyl) -1-methylethyl, 1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2 -dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-1- (4-biphenylyl) ethyl, 1- (3,5-di-t-butylphenyl) -1-methylethyl, 2- (2) - and 4'-pyridyl) ethyl, 2 (N, N-dicyclohexylcarboxamido) ethyl, t-butyl, 1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl, N-hydroxypiperidinyl, alkyldithio , benzyl, p-methoxybenzyl, p-nitrobenzyl, p-bromobenzyl, p-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl, 9-anthylmethyl, diphenylmethyl); (2-methylthioethyl, 2-methylsulfonylethyl, 2- (p-toluenesulfonyl) ethyl, (2- (1,3-dithianyl) methyl, 4-methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2-triphenylphosphonioisopropyl), 1, 1-dimethyl-2-cyanoethyl, chloro-p-acyloxybenzyl, p- (dihydroxyboryl) benzyl, 5-benzisooxazolylmethyl, 2- (trifluoromethyl) -6-chromonylmethyl) groups capable of photolytic cleavage (m-nitrophenyl, 3,5-dimethoxybenzyl) , o-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, phenyl (o-nitrophenyl) methyl) urea-type derivatives (phenothiazinyl- (10) -carbonyl, N'-p-toluenesulfonylaminocarbonyl, N'-phenylaminothiocarbonyl); carbamates (t-amyl, S-benzyl thiocarbamate, p-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropylmethyl, p-decyloxybenzyl, diisopropylmethyl, 2,2-dimethoxycarbonylvinyl, o- (N, N-dimethylcarboxamido) benzyl, 1,1 - dimethyl-3- (N, N-dimethylcarboxamido) propyl, 1,1-dimethylpropinyl, di (2-pyridyl) methyl, 2-furanylmethyl, 2-iodoethyl, isobomyl, isobutyl, isonicotinyl, p- (p'-methoxyphenyls) lazo) benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1-methyl-1-cyclopropylmethyl, 1-methyl-1- (3,5-dimethoxyphenyl) ethyl, 1-methyl 1-1- (p-phenylazophenyl) ethyl, 1- methyl-1-phenylethyl, 1-methyl-1- (4-pyridyl) ethyl, phenyl, p- (phenylazo) benzyl, 2,4,6-tri-butylphenyl, 4- (trimethylammonium) benzyl, 2,4,6 -trimethylbenzyl); amides (N-formyl, N-acetyl, N-chloroacetyl, N-trichloroacetyl, N-trifluoroacetyl, N-phenylacetyl, N-3-phenylpropionyl, Npicolinoyl, N-3-pyridylcarboxamide, N-benzoylphenylalanyl, N-benzoyl, Np-phenylbenzoyl) ; Controlled cleavage amides (No-nitrophenylacetyl, No-nitrophenoxyacetyl, N-acetoacetyl, (N'-dithiobenzyloxycarbonylamino) acetyl, N-3- (p-hydroxyphenyl) propionyl, N-3- (o-nitrophenyl) propionyl, N-2 -methyl-2- (o-nitrophenoxy) propionyl, N-2-methyl-2- (o-phenylazophenoxy) propionyl, N-4-chlorobutyryl, N-3-methyl-3-nitrobutyryl, N-nitrocinnamoyl, N-acetylmethionine N-nitrobenzoyl, N - (benzoyloxymethyl) benzoyl, 4,5-diphenyl-3-oxazolin-2-one; cyclic imides and derivatives (N-phthalimide, N-dithiasuccinoyl, N-2,3-diphenylmaleoyl, N-2,5-dimethylpyrrolyl, N1,1,4,4-tetramethyldisilylazacyclopentane and addition product, 5-substituted, 1,3-dimethyl- 1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3-5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridonyl); N-alkyl and N-aryl amines (N-methyl, Nallyl, N- (2- (trimethylsilyl) ethoxy) methyl, N-3-acetoxypropyl, N- (1-isopropyl-4-nitro-2-oxo-3-pyrroline) 3-yl), quaternary ammonium salts, N-benzyl, N-di (4-methoxyphenyl) methyl, N-5-dibenzosuberyl, N-triphenylmethyl, N- (4-methoxyphenyl) diphenylmethyl, N-9-phenylfluorenyl, N- 2,7-dichloro-9-flurenylmethylene, N-ferrocenylmethyl, N-2-picolylamine Ν'-oxide), imine derivatives (N1,1-dimethylthiomethylene, N-benzylidene, Np-methoxybenzylidene, N-diphenylmethylene, N - ((2-pyridyl)) mesityl) methylene, N, (Ν ', Ν'-dimethylaminomethylene, Ν, Ν'-isopropylidene, Np-nitrobenzylidene, N-salicylidene, N-5-chlorosalicylidene, N- (5-chloro-2-hydroxyphenyl) phenylmethylene, N enamine derivatives (N- (5,5-dimethyl-3-oxo-1-cyclohexenyl)); N-metallic derivatives (N-borane derivatives, N-diphenylboronic acid derivatives, N- (phenyl (pentacarbonylchromo- or tungsten)) carbenyl, N-Cu or N-Zn chelate) NN derivatives (N-nitro, N-nitroso, N-oxide) NP derivatives (N-diphenylphosphinyl, N-dimethylthiophosphi) nyl, N-dialkyl phosphoryl, N-dibenzyl phosphoryl, N-diphenyl phosphoryl); N-Si derivatives; N-S derivatives; N-sulfenyl derivatives (N-benzenesulfenyl, N-o-nitrobenzenesulfenyl, N-2,4-dinitrobenzenesulfenyl, N-pentachlorobenzenesulfenyl, N-2-nitro-4-methoxybenzenesulfenyl, N-triphenylmethylsulfenyl, N-3-nitropyridinesulfenyl); and N-sulfonyl (N-toluenesulfonyl, N-benzenesulfonyl, N-2,3,6-trimethyl-4-methoxybenzenesulfonyl, N-2,4,6-trimethoxybenzenesulfonyl, N-2,6-dimethyl-4-methoxybenzenesulfonyl, N-pentamethylbenzenesulfonyl, N-2,3,5,6-tetramethyl-4-methoxybenzenesulfonyl, N-4-methoxybenzenesulfonyl, N-2,4,6-trimethylbenzenesulfonyl, N-2,6-dimethoxy-4-methylbenzene
-30CZ 297945 B6 sulfonyl, N-2,2,5,7,8-pentametylchrom-6-sulfonyl, N-metansulfonyl, Ν-β-trimetylsilyletansulfonyl, N-9-antracensulfonyl, N-4-(4',8'-dimetoxynaftylmetyl)benzensulfonyl, N-benzylsulfonyl, N-trifluorometylsulfonyl, N-fenacylsulfonyl).-30EN 297945 B6 sulfonyl, N-2,2,5,7,8-pentamethylchrom-6-sulfonyl, N-methanesulfonyl, β-trimethylsilylethanesulfonyl, N-9-anthracenesulfonyl, N-4- (4 ', 8' (dimethoxynaphthylmethyl) benzenesulfonyl, N-benzylsulfonyl, N-trifluoromethylsulfonyl, N-phenacylsulfonyl).
Mnohem obvyklejší je, že chráněné aminoskupiny zahrnují karbamáty a amidy, obvykle -NHC(O)Ri nebo -N=CRiN(Ri)2. Jiná ochranná skupina, která se rovněž používá jako prolék na místě Gi, zvláště pro amino nebo pro -NH(R5), je:More commonly, protected amino groups include carbamates and amides, usually -NHC (O) R 1 or -N = CR 1 N (R 1) 2 . Another protecting group that is also used as a prodrug at the G 1 site, especially for amino or -NH (R 5 ), is:
viz například Alexander, J.: a j.; J. Med. Chem. 1996, 39, 480—486.see, for example, Alexander, J .: et al .; J. Med. Chem. 1996, 39, 480-486.
Rfic je H nebo zbytek sloučeniny obsahující aminoskupiny, zvláště pak aminokyseliny, polypeptidy, ochranné skupiny, -NHSO2R4, NHC(O)R4, -N(R4)2, NH2 nebo -NH(R4)(H), přičemž například karboxylové skupiny nebo skupiny fosfoniové ve W) reagují s aminem a vytvářejí amid, například u -C(O)Réc, -P(O)(R6c)2 nebo -P(O)(R6C). Obecně má Rňc strukturu Ri7C(O)CH(Ri6)NH-, kde R17 je OH, OR6a, OR5, aminokyselina nebo polypeptidový zbytek.R fic is H or the remainder of a compound containing amino groups, especially amino acids, polypeptides, protecting groups, -NHSO 2 R 4, NHC (O) R 4, -N (R 4) 2 , NH 2 or -NH (R 4) (H), for example carboxyl groups or the phosphonium groups in W) react with an amine to form an amide, for example, -C (O) R 6c , -P (O) (R 6c ) 2, or -P (O) (R 6 C ). Generally, R c has the structure R 17 C (O) CH (R 16 ) NH-, wherein R 17 is OH, OR 6a , OR 5 , an amino acid or a polypeptide residue.
Aminokyseliny jsou sloučeniny s nízkou molekulární hmotností, řádově méně než asi 1000 m.hm., které obsahují minimálně 1 amino nebo imino skupinu a minimálně jednu karboxylovou skupinu. Obecně lze aminokyseliny nalézt v přírodě, tzn. lze je zjistit v biologickém materiálu jako jsou bakterie nebo jiné mikroby, rostliny, živočichové nebo člověk. Vhodné aminokyseliny jsou obvykle alfa aminokyseliny, tzn. sloučeniny, které jsou charakterizovány jedním amino nebo imino dusíkovým atomem odděleným od uhlíkového atomu jedné karboxylové skupiny jedním substituovaným nebo nesubstituovaným alfa uhlíkovým atomem. Zvláštní zájem je o hydrofóbní zbytky jako jsou mono- nebo di—alkyl nebo aryl aminokyselin, cykloalkylaminokyselin apod. Tyto zbytky přispívají k propustnosti buněk tím, že zvyšují u mateřského léku koeficient rozdělování mezi dvě fáze. Obvykle zbytek neobsahuje sulfhydrylový nebo guanidinový substituent.Amino acids are low molecular weight compounds, of the order of less than about 1000 m / m, containing at least 1 amino or imino group and at least one carboxyl group. In general, amino acids can be found in nature; they can be detected in biological material such as bacteria or other microbes, plants, animals or humans. Suitable amino acids are usually alpha amino acids, i. compounds which are characterized by one amino or imino nitrogen atom separated from the carbon atom of one carboxyl group by one substituted or unsubstituted alpha carbon atom. Of particular interest are hydrophobic residues such as mono- or di-alkyl or aryl amino acids, cycloalkylamino acids and the like. These residues contribute to cell permeability by increasing the coefficient of separation between the two phases of the parent drug. Usually the residue does not contain a sulfhydryl or guanidine substituent.
V přírodě se vyskytující zbytky aminokyselin jsou ty zbytky, které zjišťujeme v přírodě z rostlin, živočichů nebo mikrobů, zvláště jejich proteiny. Polypeptidy nejčastěji budou v podstatě složeny z těchto v přírodě se vyskytujících zbytků aminokyselin. Tyto aminokyseliny jsou glycin, alanin, valin, leucin, izoleucin, serin, threonin, cystein, methionin, kyselina glutamová, aspartová, lysin, hydroxylysin, arginin, histidin, fenylalanin, tyrosin, tryptofan, prolin, asparagin, glutamin a hydroxyprolin.Naturally occurring amino acid residues are those that are found in nature from plants, animals or microbes, especially their proteins. Polypeptides most often will essentially consist of these naturally occurring amino acid residues. These amino acids are glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, tryptophan, proline, asparagine, glutamine and hydroxyproline.
Jestliže jsou Rf,b a RéC jednoduché zbytky aminokyselin nebo polypeptidů, jsou obvykle substituovány na R3, Wů, Wi a/nebo W2, avšak obvykle pouze Wj nebo W2. Tyto konjugáty jsou produkovány vytvořením amidové vazby mezi karboxylovou skupinou aminokyseliny (nebo C-terminální aminokyselinou polypeptidu) a W2. Podobně, konjugáty se tvoří mezi Wi a aminovou skupinou aminokyseliny nebo polypeptidu. Obecně, pouze jedno ze všech míst mateřské molekuly se amiduje aminokyselinou tak, jak je zde popsáno, třebaže zůstává v rámci tohoto vynálezu uvádět aminokyseliny na více než jedno povolené místo. Obvykle je karboxylová skupina Wi amidována aminokyselinou. Všeobecně α-amino nebo α-karboxylová skupina aminokyseliny nebo koncová amino nebo karboxylová skupina polypeptidu se váží na mateřské funkce, to znamená, že karboxyl nebo aminoskupiny v postranním řetězci aminokyseliny se všeobecně neužívají k tomu, aby vytvářely amidové vazby s mateřskou sloučeninou (třebaže tyto skupiny mohou potřebovat ochranu během syntézy konjugátů tak, jak je dále popsáno).When R f, b and R c are simple amino acid or polypeptide residues, they are usually substituted on R 3 , W 6 , W 1 and / or W 2 , but usually only W 3 or W 2 . These conjugates are produced by forming an amide bond between the carboxyl group of the amino acid (or the C-terminal amino acid of the polypeptide) and W 2 . Similarly, conjugates are formed between the W 1 and the amino group of an amino acid or polypeptide. Generally, only one of all sites of the parent molecule is amidated with an amino acid as described herein, although it remains within the scope of this invention to introduce amino acids to more than one permitted site. Typically, the carboxyl group Wi is amidated by an amino acid. Generally, the α-amino or α-carboxyl group of an amino acid or the terminal amino or carboxyl group of a polypeptide binds to the parent functions, i.e., carboxyl or amino groups in the amino acid side chain are generally not used to form amide bonds with the parent compound ( groups may need protection during conjugate synthesis as described below).
-31 CZ 297945 B6-31 GB 297945 B6
S ohledem na karboxyl obsažený v postranních řetězcích aminokyselin nebo polypeptidů lze pochopit, že karboxylové skupina může být blokována např. Rňa, esterifíkována R5 nebo amidována R6c. Podobně postranní aminové řetězce R]6 mohou být blokovány R6b nebo substituovány R5. Tyto estery nebo amidové vazby s postranním řetězcem amino nebo karboxylových skupin, jako jsou estery nebo amidy s mateřskou molekulou, jsou hydrolyzovatelné in vivo nebo in vitro v kyselých (pH menší než 3) nebo bazických (Ph větší než 10) podmínkách. Alternativně, jsou podstatně stabilní v gastrointestinálním traktu člověka avšak jsou hydrolyzovány enzymaticky v krvi nebo v nitrobuněčném prostředí. Estery nebo aminokyselina nebo polypeptidové amidáty jsou rovněž užitečné jako meziprodukty pro přípravu mateřské molekuly, která obsahuje volné amino nebo karboxylové skupiny. Volná kyselina nebo zásada mateřské sloučeniny se například často vytváří z esterů nebo aminokyselin nebo polypeptidových konjugátů tohoto vynálezu konvenčními hydrolytickými postupy.With respect to the carboxyls contained in the side chains of amino acids or polypeptides, it can be understood that the carboxyl group can be blocked, eg, R 6 , esterified with R 5 or amidated with R 6c . Similarly, the side amino chains of R 16 may be blocked by R 6b or substituted by R 5 . These esters or amide bonds with side chain amino or carboxyl groups, such as esters or amides with the parent molecule, are hydrolyzable in vivo or in vitro under acidic (pH less than 3) or basic (Ph greater than 10) conditions. Alternatively, they are substantially stable in the human gastrointestinal tract but are hydrolyzed enzymatically in the blood or in the intracellular environment. Esters or amino acid or polypeptide amidates are also useful as intermediates for the preparation of a parent molecule that contains free amino or carboxyl groups. For example, the free acid or base of the parent compound is often formed from the esters or amino acids or polypeptide conjugates of the invention by conventional hydrolysis procedures.
Když zbytek aminokyseliny obsahuje jeden nebo více středů chirality, může se použít kterýkoliv D, L, mezo, threo nebo eiytro (podle vhodnosti) racemát, skalemát nebo jejich směsi. Obecně, jestliže se meziprodukty mají hydrolyzovat neenzymaticky (jak tomu může být tam, kde se amidy používají jako chemické meziprodukty pro volné kyseliny nebo volné aminy), jsou užitečné D izomery. Na druhé straně, L izomery jsou mnohem pružnější, protože mohou být citlivé jak vůči neenzymatické tak i enzymatické hydrolýze a jsou efektivněji transportovány aminokyselinou nebo dipeptidylovým dopravním systémem do gastrointestinálního traktu.When the amino acid residue contains one or more chiral centers, any of the D, L, meso, threo or eytytro (as appropriate) racemate, scalemate, or mixtures thereof may be used. In general, if the intermediates are to be hydrolyzed non-enzymatically (as can be the case where amides are used as chemical intermediates for free acids or free amines), the D isomers are useful. On the other hand, L isomers are much more flexible since they may be sensitive to both non-enzymatic and enzymatic hydrolysis and are more efficiently transported by the amino acid or dipeptidyl delivery system to the gastrointestinal tract.
Příklady vhodných aminokyselin, jejichž zbytky jsou představovány R6b a R6c zahrnují následující:Examples of suitable amino acids whose residues are represented by R 6 b and R 6c include the following:
glycin;glycine;
aminopolykarboxylové kyseliny např. kyselina aspartová, β-hydroxyaspartová kyselina, kyselina glutamová, kyselina β-hydroxyglutamová, kyselina β-metylaspartová, kyselina β-metylglutamová, kyselina β,β-dimetylaspartová, kyselina γ-hydroxyglutamová, kyselina, β,γ-hydroxyglutamová, kyselina β-fenylglutamová, kyselina γ-metylenglutamová, 3-aminoadipová kyselina, kyselina 2-aminopimelová, kyselina 2-aminosuberová a kyselina 2-aminosebaková;aminopolycarboxylic acids such as aspartic acid, β-hydroxyaspartic acid, glutamic acid, β-hydroxyglutamic acid, β-methylaspartic acid, β-methylglutamic acid, β, β-dimethylaspartic acid, γ-hydroxyglutamic acid, β, γ-hydroxyglutamic acid, β-phenylglutamic acid, γ-methylenglutamic acid, 3-aminoadipic acid, 2-aminopimelic acid, 2-aminosubric acid and 2-aminosebacic acid;
amidy aminokyselin jako je glutamin a asparagin;amino acid amides such as glutamine and asparagine;
polyamino- nebo polybazické monokarboxylové kyseliny jako je arginin, lysin, β-aminoalanin, γ-aminobutyrin, ornitin, cytrulin, homoarginin, homocitrulin, hydroxylysin, a kyselina diaminomáselná;polyamino- or polybasic monocarboxylic acids such as arginine, lysine, β-aminoalanine, γ-aminobutyrine, ornithine, cytrulin, homoarginine, homocitrulin, hydroxylysine, and diaminobutyric acid;
další bazické zbytky aminokyselin jako histidin;other basic amino acid residues such as histidine;
kyseliny diaminodikarboxylové jako je α,α'-diamino kyselina jantarová, α,α'-diaminoglutarová, α,α'-diaminoadipová, α,α'-diaminopimelová, a,ď-diamino^-hydroxypimelová, α,α'-diaminosuberová, α,α'-diaminoazelaová, a konečně α,α'-diaminosebaková kyselina;diaminodicarboxylic acids such as α, α'-diamino succinic acid, α, α'-diaminoglutaric acid, α, α'-diaminoadipic acid, α, α'-diaminopimelic acid, and, α-diamino-4-hydroxypimelic acid, α, α'-diaminosuberic acid, α, α'-diaminoazelaic, and finally α, α'-diaminosebacic acid;
imino kyseliny jako je prolin, hydroxyprolin, alohydroxyprolin, γ-metylprolin, pipekoliková kyselina, 5-hydroxypipekolinová kyselina a azetidin-2-karboxylová kyselina;imino acids such as proline, hydroxyproline, alohdroxyproline, γ-methylproline, pipecolic acid, 5-hydroxypipecolinic acid and azetidine-2-carboxylic acid;
mono- nebo di-alkyl (obvykle Ci-Cg rozvětvené nebo normální) aminokyseliny, jako je alanin, valin, leucin, alylglycin, butyrin, norvalin, norleucin, heptylin, α-metylserin, a-amino-a-metylγ-hydroxyvalerová kyselina, kyselina a-amino-cx-metyl-5-hydroxyvalerová, kyselina aamino-a-metyl-8-hydroxykapronová, izovalin, kyselina α-metylglutamová, kyselina oc-aminoizomáselná, kyselina oc-aminodietyloctová, kyselina α-aminodiizopropyloctová, kyselina aaminodi-n-propyloctová, kyselina a-aminodiizobutyloctová, kyselina a-aminodi-n-butyloctová, kyselina α-aminoetylizopropyloctová, kyselina α-amino-n-propyloctová, kyselina amono- or di-alkyl (usually C 1 -C 8 branched or normal) amino acids such as alanine, valine, leucine, allylglycine, butyrine, norvaline, norleucine, heptyline, α-methylserine, α-amino-α-methyl-hydroxyvaleric acid, α-amino-α-methyl-5-hydroxyvaleric acid, α-amino-α-methyl-8-hydroxycaproic acid, isovaline, α-methylglutamic acid, α-aminoisobutyric acid, α-aminodietylacetic acid, α-aminodiisopropylacetic acid, aaminodine -propylacetic acid, α-aminodiisobutylacetic acid, α-aminodi-n-butylacetic acid, α-aminoethylisopropylacetic acid, α-amino-n-propylacetic acid, and
-32CZ 297945 B6 aminodiizoamyloctová kyselina oc-metylaspartová, kyselina α-metylglutamová, kyselina 1aminocyklopropan-l-karboxylová, izoleucin, alloizoleucin, terc-leucin, β-metyltryptofan a kyselina a-amino-3-etyl-3-fenylpropionová;Α-Amino-diisoamylacetic acid α-methylaspartic acid, α-methylglutamic acid, 1-aminocyclopropane-1-carboxylic acid, isoleucine, alloisoleucine, tert-leucine, β-methyltryptophan and α-amino-3-ethyl-3-phenylpropionic acid;
β-fenylserinyl;β-phenylserinyl;
alifatické a-amino^-hydroxykyseliny jako je serin, β-hydroxyleucin, β-hydronorleucin, βhydroxynorvalin a a-amino-^-hydroxystearová kyselina;aliphatic .alpha.-amino-.beta.-hydroxy acids such as serine, .beta.-hydroxyleucine, .beta.-hydronorleucine, .beta.-hydroxynorvaline, and .alpha.-amino-.beta.-hydroxystearic acid;
zbytky α-amino, α-, γ-, ε- nebo ε-hydroxy kyselin jako homoserin, γ-hydroxynorvalin, δ-hydroxynorvalin a ε-hydroxynorleucin; kanavin a kanalin, γ-hydroxyomitin;α-amino, α-, γ-, ε- or ε-hydroxy acid residues such as homoserine, γ-hydroxynorvaline, δ-hydroxynorvaline and ε-hydroxynorleucine; cancan and canaline, γ-hydroxyomitin;
2-hexosaminové kyseliny jako je D-glukozaminová kyselina nebo D-galaktozaminová kyselina;2-hexosamine acids such as D-glucosaminic acid or D-galactosamic acid;
a-amino^-thioly jako penicilamin, β-thiolnorvalin nebo β-thiolbutyrin;α-amino-4-thiols such as penicillamine, β-thiolnorvaline or β-thiolbutyrine;
ostatní síru obsahující aminokyselinové zbytky zahrnují cystein; homocystin, β-fenylmethionin, methionin, S-allyl-L-cystein sulfoxid, 2-thiolhistidin, cystathionin, thiol estery cysteinu nebo homocysteinu;other sulfur-containing amino acid residues include cysteine; homocystine, β-phenylmethionine, methionine, S-allyl-L-cysteine sulfoxide, 2-thiolhistidine, cystathionine, thiol esters of cysteine or homocysteine;
fenylalanin, tryptofan a na kruhu substituované a amino kyseliny jako fenyl- nebo cyklohexyl aminokyseliny α-aminofenyloctová kyselina, α-aminocyklohexyloctová kyselina a kyselina aamino^-cyklohexylpropionová; fenylalaninové analogy a deriváty, které zahrnují aryl, nižší alkyl, hydroxy, guanidino, oxyalkyleter, nitro, síru nebo halogenem substituovaný fenyl (např. tyrosin, metyltyrosin a o-chloro-, ρ-chloro-, 3,4-dichloro, o-, m- nebo p-metyl, 2,4,6-trimetyl, 2-etoxy-5-nitro-, 2-hydroxy-5-nitro- a p-nitro-fenylalanin); furyl-, thienyl-, pyridyl-, pyrimidinyl-, purinyl- nebo naftyl- alaniny; tryptofanové analogy a deriváty zahrnující kynurenin, 3hydroxykynurenin, 2-hydroxytryptofan a 4-karboxytryptofan;phenylalanine, tryptophan and ring substituted a amino acids such as phenyl or cyclohexyl amino acids α-aminophenylacetic acid, α-aminocyclohexylacetic acid and amino-4-cyclohexylpropionic acid; phenylalanine analogs and derivatives that include aryl, lower alkyl, hydroxy, guanidino, oxyalkyl ether, nitro, sulfur or halogen substituted phenyl (e.g., tyrosine, methyltyrosine and o-chloro-, ρ-chloro-, 3,4-dichloro, o- , m- or p-methyl, 2,4,6-trimethyl, 2-ethoxy-5-nitro-, 2-hydroxy-5-nitro- and p-nitro-phenylalanine); furyl-, thienyl-, pyridyl-, pyrimidinyl-, purinyl- or naphthyl-alanines; tryptophan analogs and derivatives including kynurenine, 3-hydroxycynurenine, 2-hydroxytryptophan and 4-carboxytryptophan;
aminokyseliny substituované jako α-amino kyseliny včetně sarkosinu (N-metylglycin), Nbenzylglycin, N-metylalanin, N-benzylalanin, N-metylfenylalanin, N-benzylfenylalanin, Nmetylvalin a N-benzylvalin;amino acids substituted as α-amino acids including sarcosine (N-methylglycine), N-benzylglycine, N-methylalanine, N-benzylalanine, N-methylphenylalanine, N-benzylphenylalanine, N-methylvaline and N-benzylvaline;
α-hydroxy a substituované α-hydroxy aminokyseliny zahrnují serin, threonin, allothreonin, fosfoserin a fosfothreonin,α-hydroxy and substituted α-hydroxy amino acids include serine, threonine, allothreonine, phosphoserine and phosphothreonine,
Polypeptidy jsou polymery aminokyselin, ve kterých je karboxylová skupina jednoho monomeru aminokyseliny vázána na amino nebo imino skupinu dalšího monomeru aminokyseliny amidovou vazbou. Mezi polypeptidy patří dipeptidy, polypeptidy s nízkou molekulární hmotností (asi 1500-5000 m.hm.) a proteiny. Proteiny obvykle obsahují 3, 5, 10, 50, 75, 100 nebo více zbytků a je výhodné, že v podstatě jsou sekvenčně homologické s lidskými, zvířecími, rostlinnými nebo mikrobiálními proteiny. Zahrnují enzymy např. hydrogen peroxidázu stejně jako imunogeny jako je KLH, nebo protilátky proteinů jakéhokoli typu, proti kterému potřebujeme zvýšit imunitní reakci. Podstata a identita polypeptidů se může značně měnit.Polypeptides are amino acid polymers in which the carboxyl group of one amino acid monomer is bonded to the amino or imino group of another amino acid monomer by an amide bond. Polypeptides include dipeptides, low molecular weight (about 1500-5000 m / m) polypeptides, and proteins. Proteins typically contain 3, 5, 10, 50, 75, 100, or more residues, and are preferably substantially sequence-homologous to human, animal, plant, or microbial proteins. They include enzymes such as hydrogen peroxidase as well as immunogens such as KLH, or antibodies of proteins of any type against which we need to enhance the immune response. The nature and identity of polypeptides may vary considerably.
Polypeptidové amidáty jsou užitečné jako imunogeny při zvyšování množství protilátek proti buď polypeptidů (pokud není imunogenní u zvířat, kterým se podává) nebo proti epitopům na zbytku sloučeniny podle vynálezu.Polypeptide amidates are useful as immunogens in increasing the amount of antibodies against either a polypeptide (unless it is immunogenic in the animals to which it is administered) or against epitopes on the remainder of the compound of the invention.
Protilátky, které jsou schopny se vázat na mateřské nepeptidylové sloučeniny se používají na vydělování mateřské sloučeniny ze směsi, například při diagnóze nebo výrobě mateřské sloučeniny. Konjugáty mateřské sloučeniny a polypeptidů obvykle jsou více imunogenní než polypeptidy u blízko homologických živočichů a proto zvyšují imunogenitu polypeptidů a tak usnadňují tvorbu protilátek proti němu. V souladu s tím nemusí polypeptid nebo protein potřebovat, aby bylAntibodies that are capable of binding to the parent non-peptidyl compounds are used to separate the parent compound from the mixture, for example, in the diagnosis or manufacture of the parent compound. Conjugates of the parent compound and the polypeptides usually are more immunogenic than the polypeptides in closely homologous animals and therefore increase the immunogenicity of the polypeptides and thus facilitate the production of antibodies against it. Accordingly, the polypeptide or protein may not need to be
-33CZ 297945 B6 imunogenní u zvířat obvykle používaných pro zvyšování tvorby protilátek například u králíka, myši, koně, krysy, ale finální produkt konjugátu by měl být imunogenní minimálně v případě jednoho z těchto živočichů. Polypeptid může obsahovat místo pro štěpení peptidolytického enzymu na peptidové vazbě mezi prvním a druhým zbytkem přiléhajícím ke kyselému heteroatomu. 5 Takováto místa pro štěpení mají po stranách enzymatické struktury pro rozeznání enzymu například zvláštní sekvenci zbytků, které peptidolytický enzym rozeznává.However, the final conjugate product should be immunogenic in at least one of these animals. The polypeptide may comprise a peptidolytic enzyme cleavage site on the peptide bond between the first and second residues adjacent to the acidic heteroatom. Such cleavage sites have, for example, a special sequence of residues recognized by the peptidolytic enzyme on the sides of the enzyme recognition structure.
Peptidolytické enzymy pro štěpení polypeptidových konjugátů podle tohoto vynálezu jsou dobře známy a konkrétně se jedná o karboxypeptidázy. Karboxypeptidázy tráví polypeptidy tak, že 10 odstraňují koncové uhlíkové zbytky a jsou specifické v mnoha případech pro konkrétní konečné uhlíkové sekvence. Tyto enzymy a jejich substrátové požadavky jsou obecně dobře známy. Např. dipeptid (který má daný pár zbytků a volný karboxylový konec) je kovalentně vázán prostřednictvím své α-aminoskupiny na fosfor nebo na uhlík sloučeniny, o které se tu jedná. V částech, kde je Wj fosfonátem se očekává, že tento peptid bude štěpen příslušným peptidolytickým enzymem, 15 takže ponechá karboxyl nej bližšího zbytku aminokyseliny pro autokatalytické štěpení fosfonoamidátové vazby.Peptidolytic enzymes for cleavage of the polypeptide conjugates of this invention are well known and are particularly carboxypeptidases. Carboxypeptidases digest polypeptides such that 10 remove terminal carbon residues and are specific in many cases to particular terminal carbon sequences. These enzymes and their substrate requirements are generally well known. E.g. the dipeptide (which has a given pair of residues and a free carboxyl terminus) is covalently bonded via its α-amino group to the phosphorus or carbon of the compound in question. In the parts where W 1 is a phosphonate, it is expected that this peptide will be cleaved by the appropriate peptidolytic enzyme 15 so that it leaves the carboxyl of the nearest amino acid residue for autocatalytic cleavage of the phosphonoamidate linkage.
Vhodné dipeptidylové skupiny (označené písemným kódem) jsou:Suitable dipeptidyl groups (indicated by a written code) are:
AN, AD, AC, AE, AQ, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA,AN, AD, AC, AE, AQ, AH, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA,
RR, RN, RD, RC, RE, RQ, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV,RR, RN, RD, RC, RE, RQ, RG, RH, R, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV,
NA, NR, NN, ND, NC, NE, NQ, NG, NH, NI, NL, NK, NM, NF, NP. NS, NT, NW, NY,NA, NR, NN, ND, NC, N, NQ, NG, NH, NI, NL, NK, NM, NF, NP. NS, NT, NW, NY
NV, DA, DR, DN, DD, DC, DE, DQ, DG, DH, Dl, DL, DK, DM, DF, DP, DS, DT, DW,NV, DA, DR, DN, DD, DC, DE, DQ, DG, DH, D, DL, DK, DM, DF, DP, DS, DT, DW,
DY, DV, CA, CR, CN, CD, CC, CE, CQ, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, EA, ER, EN, ED, EC, EE, EQ, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, QA, QR, QN, QD, QC, QE, QQ, QG, QH, Ql, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, GA, GR, GN, GD, GC, GE, GQ, GG, GH, GI, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HE, HQ, HG, HH, Hl, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IE, IQ, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LE, LQ, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KE, KQ, KG, KH, Kl, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, ME, MQ, MG, MH, Ml,DY, DV, CA, CR, CN, CD, CC, CE, CQ, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, EA, ER, EN ED, EC, EW, EQ, EW, EW, EW, EW, EW, EW, EW, EW, EQ, EQ, EQ, EQ, EQ, EQ, EQ, EQ, QC, QE, QH, QL, QL, QK, QF, QW, QW, QW, QW, QV, GA, GV, GA, GR, GN, GD, GC, GH, GI, GL, GI, GL GF, GP, GS, GT, GW, GV, HA, HR, HN, HD, HC, HE, HQ, HG, HG, HH, Hl, HL IE, IE, IQ, IQ, IG, IH, II, IL, I, I, I, I, I, I, I, I, I, I, I, I, I, II LD, LC, LE, LQ, LG, LH, LI, LL, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KE, KQ, KG, KH, Kl, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, ME, MQ, MG, MH, Ml,
ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FE, FQ, FG,ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FE, FQ, FG,
FH, FI, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PE, PQ,FH, FI, FL, FK, FM, FF, FP, FS, FW, FY, FV, PA, PR, PN, PD, PC, PE, PQ,
PG, PH, Pl, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SE,PG, PH, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SE,
SQ, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC,SQ, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC,
TE, TQ, TG, TH, TI, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WE, WQ, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YE, YQ, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VE, VQ, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY W.TE, TQ, TG, TH, TI, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WE, WQ, WG, WH, Wl, WL, WK, WM, WF, WF, WP, WV, YA, YR, YN, YD, YC, YE, YC, YE, YQ, YL, YL, YK YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VE, VQ, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY W.
-34CZ 297945 B6-34GB 297945 B6
Tripeptidové zbytky jsou užitečné rovněž jako R(>b nebo Réc· Když je Wi fosfonát, sekvence-X4proX5- (kde X4 je jakýkoli zbytek aminokyseliny a X5 je zbytek aminokyseliny, karboxylový ester prolinu nebo vodík) bude štěpena luminální karboxypeptidázou, aby poskytla X4 s volným karboxylem, od kterého se zase očekává, že bude autokatalyticky štěpit fosfonoamidátovou vazbu. Karboxy skupina X5 může být esterifikována benzylem.Tripeptide residues are also useful as R (> b or R c) When W 1 is a phosphonate, the sequence-X 4 for X 5 - (where X 4 is any amino acid residue and X 5 is amino acid residue, carboxylic ester proline or hydrogen) will be cleaved by luminal carboxypeptidase to free carboxyl, which in turn is expected to autocatalytically cleave the phosphonoamidate linkage The carboxy group X5 can be esterified with benzyl.
Druhý dipeptidu nebo tripeptidu se dají zvolit na bázi známých transportních vlastností a/nebo citlivosti k peptidáze, což může ovlivnit dopravu do buněk střevní sliznice nebo jiných typů buněk. Dipeptidy a tripeptidy, které nemají α-aminoskupinu jsou dopravním substrátem pro dopravu peptidu, který byl nalezen na hraniční membráně buněk střevní sliznice (Bai, J. P. F., „Pharm. Res.“ 9:969-978 (1992). Peptidy schopné dopravy se takto mohou používat ke zvýšení biologické přístupnosti amidátových sloučenin. Di- nebo tripeptidy, které mají jednu nebo více aminokyselin v konfiguraci D jsou rovněž slučitelné s peptidovým transportem a dají se použít v amidátových sloučeninách tohoto vynálezu. Aminokyseliny, které mají konfiguraci D, se dají použít ke snížení citlivosti di- nebo tripeptidů k hydrolýze proteázami, které jsou běžné v tomto rozhraní jako aminopeptidáza N(EC 3.4.11.2). Navíc di- nebo tripeptidy se alternativně volí na bázi jejich relativní odolnosti vůči hydrolýze proteázami, které se nalézají ve střevním průchodu. Například tripeptidy nebo polypeptidy, které nemají asp (kyselina asparagová) a/nebo glu (kyselina glutaminová) jsou špatnými substráty pro aminopeptidázu A (EC 3.4.11.7), di- nebo tripeptidy, které nemají zbytky aminokyselin na N-koncové straně hydrofobních aminokyselin (leu, tyr, phe (fenylalaniri), val, trp (tryptofan)) jsou špatnými substráty pro endopeptidázu 24.11 (EC 3.4.24.11), a peptidy, kterým chybí pro zbytek pro karboxypeptidázu P (EC 3.4.17). Podobné úvahy se dají rovněž aplikovat na výběr peptidů, které jsou buď relativně odolné nebo relativně napadnutelné hydrolýzou cytózními, renálními, jatémími, sérovými a dalšími peptidázami. Takovéto špatně štěpitelné amidáty polypeptidů jsou imunogeny a nebo jsou užitečné pro vazbu proteinů při přípravě imunogenů.The second dipeptide or tripeptide may be selected based on known transport properties and / or peptidase sensitivity, which may affect delivery to intestinal mucosal cells or other cell types. Dipeptides and tripeptides lacking an α-amino group are a transport substrate for delivery of a peptide found on the border membrane of intestinal mucosal cells (Bai, JPF, "Pharm. Res." 9: 969-978 (1992). Di- or tripeptides having one or more amino acids in the D configuration are also compatible with peptide transport and can be used in the amidate compounds of the invention. reducing the susceptibility of di- or tripeptides to protease hydrolysis common in this interface as aminopeptidase N (EC 3.4.11.2) In addition, di- or tripeptides are alternatively selected based on their relative resistance to hydrolysis by proteases found in the intestinal passage. For example, tripeptides or polypeptides that do not have asp (aspartic acid ) and / or glu (glutamic acid) are poor substrates for aminopeptidase A (EC 3.4.11.7), di- or tripeptides that do not have amino acid residues on the N-terminal side of hydrophobic amino acids (leu, tyr, phe (phenylalaniri), val, trp (tryptophan)) are poor substrates for endopeptidase 24.11 (EC 3.4.24.11), and peptides lacking for the carboxypeptidase P residue (EC 3.4.17). Similar considerations can also be applied to the selection of peptides that are either relatively resistant or relatively vulnerable to hydrolysis by cytotic, renal, hepatic, serum and other peptidases. Such poorly cleavable amidates of polypeptides are immunogens or are useful for protein binding in the preparation of immunogens.
Sloučeniny podle vynálezu jsou obohacené nebo resolvované optické izomery na kterémkoli nebo všech asymetrických atomech. Například středy chirality, které jsou zřejmé z obrázků zde uvedených, jsou získávány jako chirální izomery nebo racemické směsi. Jak racemické tak i diastereomerické směsi stejně jako individuální optické izomery izolované nebo syntetizované, podstatně zbavené svých enantiomemích nebo diastereomemích partnerů, patří do rozsahu vynálezu. Racemické směsi se separují na své jednotlivé složky, v podstatě opticky čisté izomery prostřednictvím dobře známých postupů jako je například separace diastomemích solí tvořených s opticky aktivními adjunkty, například kyselinami nebo zásadami, po kterém následuje konverze zpět na opticky aktivní látky. Ve většině případů potřebný optický izomer se syntetizuje pomocí stereospecifických reakcí, počínaje příslušným stereoizomerem žádaného výchozího materiálu.The compounds of the invention are enriched or resolved optical isomers at any or all of the asymmetric atoms. For example, the centers of chirality that are apparent from the figures herein are obtained as chiral isomers or racemic mixtures. Both racemic and diastereomeric mixtures as well as individual optical isomers isolated or synthesized, substantially free of their enantiomeric or diastereomeric partners, are within the scope of the invention. Racemic mixtures are separated into their individual constituents, substantially optically pure isomers, by well known techniques such as, for example, separation of diastomeric salts formed with optically active adjuncts, for example acids or bases, followed by conversion back to optically active substances. In most cases, the required optical isomer is synthesized by stereospecific reactions, starting with the appropriate stereoisomer of the desired starting material.
Příklady stereochemie sloučenin tohoto vynálezu jsou uvedeny v následující tabulce C.Examples of stereochemistry of the compounds of this invention are shown in Table C below.
(0(0
-35CZ 297945 B6-35GB 297945 B6
Tabulka C vzorec (l)Table C formula (l)
Vzorec (I)Formula (I)
Sloučeniny podle vynálezu mohou v určitých případech také existovat jako tautomemí izomery. Například enaminové tautomery mohou existovat proimidazolové, guanidinové, amidinové a tetrazolové systémy a všechny jejich možné tautomemí formy spadají do rozsahu vynálezu.The compounds of the invention may also exist as tautomeric isomers in certain cases. For example, enamine tautomers may exist proimidazole, guanidine, amidine, and tetrazole systems, and all possible tautomeric forms thereof are within the scope of the invention.
Dále jsou v tabulce 6 uvedeny příklady sloučenin podle provedení vynálezu, aniž by to znamenalo nějaké omezení. Obecně, každá sloučenina je znázorněna jako substituované jádro, ve kterém je jádro označeno velkým písmenem a každý substituent je označen v pořadí podle malých písmen nebo čísel. Tabulky la a lb jsou seznamem jader, která se liší zásadně polohou nenasycených vazeb v kruhu a povahou substituentů kruhu. Každé jádro dostává abecední označení z tabulek la a lb a toto označení se v názvu každé sloučeniny objeví jako první. Podobně, tabulky 2a - av, 3a-b, 4a-c a 5a-d uvádějí vybrané substituenty Qb Q2, Q3 a Q4, opět podle písmen nebo čísel. V souladu s tím je každá uváděná sloučenina označena velkým písmenem, určujícím jádro z tabulky la—lb, za kterým následuje číslo, označující substituent Qi, dále malé písmeno označující substituent Q2, číslo označující substituent Q3 a malé písmeno nebo písmena, označující substituent Q4. V důsledku toho struktura 8, schéma 1, je prezentována jako A.49.a.4.i. Qi-Q4 je třeba chápat tak, že nepředstavují skupiny nebo atomy, že jsou prostými označeními konektivity.In the following, Table 6 gives examples of compounds according to embodiments of the invention without limiting it. Generally, each compound is depicted as a substituted nucleus in which the nucleus is capitalized and each substituent is designated in lowercase or numerical order. Tables 1a and 1b are a list of nuclei which differ essentially in the position of the unsaturated bonds in the ring and in the nature of the ring substituents. Each core receives an alphabetical designation from Tables 1a and 1b, and this designation appears first in the name of each compound. Similarly, Tables 2a - av, 3a-b, 4a-c and 5a-d show selected substituents Q b Q 2, Q 3 and Q 4, again by numbers or letters. Accordingly, each compound is identified by a capital letter identifying the core of Table 1a-1b, followed by a number denoting the substituent Q 1 , a lowercase denoting the substituent Q 2 , a number denoting the substituent Q 3 and a lowercase letter or letters denoting the substituent Q 4 . Consequently, structure 8, Scheme 1, is presented as A.49.a.4.i. Q-4 Q is to be understood, do not represent groups or atoms that are simple connectivity designations.
-36CZ 297945 B6-36GB 297945 B6
Tabulka 1aTable 1a
(C)(C)
(Q) (R)(R) (R)
-37CZ 297945 B6-37GB 297945 B6
Tabulka 1bTable 1b
01·.(S) (T) (U)01 ·. (S) (T) (U)
Ó3 (V)33 (A)
-38CZ 297945 B6-38GB 297945 B6
Tabulka ZaTable Za
H-Ch (1)H-Ch
H3C-Qi (2) (4) h3c (5) >-QiH 3 C-Q 1 (2) (4) h 3 c (5)> -Q 1
H3iH 3 i
Ml (6) (7)Ml (7) (7)
H3C h3CxJzUq.H 3 C h 3 C x J 2 U q .
(8) H3CY^Qi h3c(8) H 3 C Y 3 Q 3 h 3 c
H3Cv^QiH 3 Cl 2 Q 1
OO
OO
HsGxAq, (9) (10) (11) (12) (17) (21)HsGxAq, (9) (10) (11) (12) (17) (21)
hoy^ ho y ^
O (18)O (18)
OH (22) (15)Olympics (22) (15)
H3CH 3 C
(23)Italy (23)
Qi h3c (24)Qi h 3 c (23)
-39CZ 297945 B6-39GB 297945 B6
Tabulka 2bTable 2b
HO^Ý^Q, HO^Y°’ H3C Q (25) (26)HO ^ Ý ^ Q, HO ^ Y ° H3C Q (25) (26)
OHOH
(29) (30) (27)(29) (30)
H3CH 3 C
OO
HO'X^Q1 (28)HO ' X ^ Q 1
OO
HO^^Q, (31) (32)HO ^^ Q, (32)
nh2 (37) h2nxA^q1 h3cnh 2 (37) h 2 n x A ^ q 1 h 3 c
HgN''^01 HGN '^ 01
OO
(39) h’cAQ,(38) h ' c A Q ,
nh2 nh 2
(42)(42)
NH, ONH, O
(47)(47)
H2N/'X^Q1 (44)H 2 N / ' X ^ Q 1
O O HO^O.O O HO ^ O.
(AS) (46) (48)(48) (48)
-40CZ 297945 B6-40GB 297945 B6
Tabulka 2cTable 2c
(52)(52)
OO
(58) h2n'^ý^q1 nh2 (58) h 2 n ^ ý ^ q 1 nh 2
OH (56)Olympics (56)
OH O (59)OH O (58)
(62)(62)
OH OOH O
HaC^^^O,HaC ^^^ O,
nh2 nh 2
(64)(64)
(65)(65)
(66)(66)
-41 CZ 297945 B6-41 CZ 297945 B6
Tabulka 2dTable 2d
(67)(67)
(70)(70)
Ηο''χγχχα1 nh2 (73)Ηο 'χ γ χχ α 1 NH 2 (73)
(79)(79)
OH (74)Olympics (74)
NH2 NH 2
OHOH
(80)(80)
H2bk (83)H 2 BK (83)
(78)(78)
-42CZ 297945 B6-42EN 297945 B6
-43 CZ 297945 B6 labulka 2F-43 CZ 297945 B6 2F
Qv \^CH3 Ί3 ch3 Q in \ ^ CH 3 Ί 3 ch 3
ČH3 (103) (105)CH 3 (103) (105)
CH3 CH 3
QtQt
ch3. ch3 (109) ch3 ch 3 . ch 3 (108) ch 3
Ql'xX^xxCH3 (107) ch3 QiV^ch3 čh3 (110)Ql'xX ^ xx CH 3 (107) ch 3 Qi V ^ ch 3 ch 3 (110)
Qix ^ch3 Qix ^ ch 3
CH3 (108)CH 3 (108)
H3C. ch3 °Ά„3 (111)H 3 C. ch 3 ° Ά 3 (111)
(118) (119) (12O)(118) (119) (12)
-44CZ 297945 B6-44EN 297945 B6
Tabulka 2gTable 2g
H3CCH3 H 3 CCH 3
(125)(125)
(124)(124)
(127)(127)
(128 )(128)
(129) ch3 ch3 (130)(129) ch 3 ch 3
CH3 q’-XXch3 h3c ch3 (133)CH 3 q '-X X ch 3 h 3 c ch 3 (133)
CH3 (136)CH 3 (136)
H3C. ch3 H 3 C. ch 3
Qi\XxCH3 (137) h3g ch3 q>ch čh3 (132)Qi \ XxCH 3 (137) h 3 g ch 3 q > ch ch 3 (132)
(135)(135)
CH3 Q i ^3 ch3 (138)CH 3 Q i ^ 3 ch 3 (138)
-45CZ 297945 B6-45GB 297945 B6
Tabulka 2hTable 2h
ch3 (139)ch 3 (139)
CH3 CH 3
ch3 (144)ch 3 (144)
(146)(146)
(150)(150)
-46CZ 297945 B6-46GB 297945 B6
Tabulka 21 □iTable 21 □ i
CH3 >3 '3 Q1S^XX~CH3 h3c ch3 (154)CH 3 > 3 '3 Q 1S ^ XX ~ C H 3 h 3 c ch 3 (154)
Ql (155) ch3 o1v^ch3 ch3 (156) (157) (158) (159) ch3 ch3 (160)QL (155) CH 3 1V = CH 3 CH 3 (156) (157) ( 158) (159) CH 3 CH 3 (160)
(163) (162) ch3 čh3 (163) (162) CH 3 CH 3
QiQi
(165) rCH3 (165) r CH 3
QiQi
CH3 (167) (168) ch3 (166) ch3 ch3 (169)CH 3 (167) (168) ch 3 (166) ch 3 ch 3 (169)
-47CZ 297945 B6-47GB 297945 B6
Tabulka 2jTable 2j
(170)(170)
(172)(172)
(176)(176)
(174)(174)
ch3 (175)ch 3 (175)
θΐχχ\Ζ'^Η3 θΐχχ \ Ζ '^ Η 3
XtxXtx
Οι\χΧχΟΗ3 ΟΗι \ χΧχΟΗ 3
HgC^-CHgHgCl2 -CHg
-48CZ 297945 B6-48GB 297945 B6
Tabulka 2k h3cTable 2k h 3 c
QtQt
H3( (189)H 3 (189)
Q1 . Q1 .
ch3 (192) h3g /-ch3 Q1\z^\xCH3 (190) '3 ch3 h3ct ch3 (195)CH 3 (192), h 3 g / CH 3 Q 1 \ z ^ \ x C H 3 (190) @ 3 H CH 3 CH 3 3 ct (195)
(193)(193)
QiQi
ch3 ch3 (196) h3 ch 3 ch 3 (196) h 3
Qi CH3 ch3 ch3 (199)Qi CH 3 CH 3 CH 3 (199)
QH3 QH 3
QiQi
QiQi
-49CZ 297945 B6-49GB 297945 B6
Tabulka 21Table 21
-50CZ 297945 B6-50EN 297945 B6
ČH3CH3 (224)CH3CH3 (224)
(226)(226)
(225)(225)
CH3 (227)CH 3 (227)
HaC^CHá (229) wHaCl 2 CH 3 (229) w
ch3 (230)ch 3 (230)
(231)(231)
ch3 ch 3
(233) (232)(233)
CH3CH3 CH 3 CH 3
CH3CH3 (236)CH 3 CH 3 (236)
(237)(237)
(240)(240)
-51 CZ 297945 B6-51 CZ 297945 B6
Tabulka 2nTable 2n
(246)(246)
(249)(249)
H3C_CH3 ch3 (252)H 3 C_CH 3 ch 3 (252)
K3C (255) v^ch3 (258)K 3 C (255) in all 3 (258)
-52CZ 297945 B6-52EN 297945 B6
Tabulka 2oTable 2o
H3C uh3 (259) £H 3 C 3 (259)?
h3c^ch3 (260)h 3 c ^ ch 3 (260)
(262)(262)
(261)(261)
CH3CH3 í 'ch3 (264)CH 3 CH 3 í 3 (264)
(265)(265)
^CH3 (266)^ CH 3 (266)
(267)(267)
(265)(265)
(271)(271)
(272)(272)
(270)(270)
(274)(274)
-53CZ 297945 B6-53EN 297945 B6
Tabulka 2pTable 2p
(277)(277)
(281)(281)
(282)(282)
(284)(284)
(287)(287)
(290)(290)
(285)(285)
(288)(288)
(292) (293) (294)(292) (293) (294)
-54CZ 297945 B6 labulka 2q-54GB 297945 B6 Bulb 2q
HsCx* CHa (303)HSC CHa * x (303)
(304)(304)
(305)(305)
H3C“^CHfH3 (306)H 3 C "^ CHfH 3 (306)
(307)(307)
(308)(308)
(309)(309)
CH3 (311)CH 3 (311)
-55CZ 297945 B6-55GB 297945 B6
Tabulka 2rTable 2r
(319)(319)
(315)(315)
CH3 ch3 (318)CH 3 ch 3
CH3 ch3 CH 3 CH 3
ch3 ch3 ch3 (321)ch 3 ch 3 ch 3 (321)
(323)(323)
H3C ch3 (324)H 3 C ch 3 (324)
h3c ch-ph3 (325)h 3 c ch-ph 3 (325)
(327)(327)
(330)(330)
-56CZ 297945 B6-56GB 297945 B6
Tabulka 2sTable 2s
-57CZ 297945 B6-57GB 297945 B6
Tabulka 21Table 21
ch3 ch 3
CH, ch3 °1 .CH, CH 3 ° 1 .
ČH3 ch3 CH 3 ch 3
H CH C
Η3εψοΗ3 Qi'Yxch3 Q 3 εψοΗ 3 Qi 'Y x ch 3
CHg (350) (349)CHg (350)
Q1'YAch3 Q1 'Y A ch 3
CHg (352) CHg CH3 CH (352) CH 3 CH
QixAXcH3 QixAXcH 3
CHg (355) (353)CHg (355)
QHg CHgQHg CHg
CHgCHg
(364) (356)(364)
(359)(359)
(351)(351)
(363)(363)
(366) (365)(366)
-58CZ 297945 B6-58GB 297945 B6
Tabulka 2uTable 2u
(367)(367)
(369)(369)
-59CZ 297945 B6-59GB 297945 B6
Tabulka 2vTable 2v
(398) (399)(399)
-60CZ 297945 B6 labulku 2w-60EN 297945 B6 2w
(401)(401)
-61 CZ 297945 B6-61 CZ 297945 B6
Tabulka 2xTable 2x
(425)(425)
-62CZ 297945 B6-62EN 297945 B6
-63CZ 297945 B6 labulka 2z ch3 -63EN 297945 B6 labulka 2z ch 3
ch3 (465) (466)ch 3 (465)
Qrx/A..^>CH3 Qrx / A. .. CH 3
Q i ..*CH3 Q i .. * CH 3
QiQi
K3C CH3 K 3 C CH 3
°1 ch3 ch3 (471) (472) ^ch3 ° 1 ch 3 ch 3 (471) (472) ^ 3
(474)(474)
QH3 QH 3
CH3 (476)CH 3 (477)
Q,Q,
ch3 „*ch3 q^ch3 n3ch 3 '* ch 3 q ^ ch 3 n 3
Qi\r qh3 (480) Q i \ r qh 3
CHCH
(483)(483)
-64CZ 297945 B6-64GB 297945 B6
Tabulka 2aaTable 2aa
-65 CZ 297945 B6-65 GB 297945 B6
-66CZ 297945 B6-66EN 297945 B6
Tabulka ZacTable Zac
(543)(543)
(544)(544)
-67CZ 297945 B6-67EN 297945 B6
-68CZ 297945 B6-68EN 297945 B6
Tabulka 2aeTable 2ae
(570) (573)(570)
(575)(575)
-69CZ 297945 B6-69EN 297945 B6
Tabulka 2afTable 2af
-70CZ 297945 B6-70EN 297945 B6
Tabulka 2agTable 2ag
(619)(619)
(627)(627)
-71 CZ 297945 B6-71 GB 297945 B6
Tabulka 2ahTable 2ah
-72CZ 297945 B6-72GB 297945 B6
Tabulka ZaiTable Zai
-73CZ 297945 B6-73GB 297945 B6
Tabu 1ka 3aTable 1a 3a
I2 I 2
A”AND"
O q2 O q 2
T°'ch3 o (a) (c)T ° ch 3 o (a) (c)
O P v q2 zohOP vq 2 from oh
VIN
X'OH q2 X'OH q 2
Q2-S'OH (d)Q 2 -S 'OH (d)
O Ah q2 (e) (O (h)O Ah q 2 (e) (O (h))
O Ov >0 yOO at > 0 y
Q3 N CH3 Q 3 N CH 3
H vH v
XtrAcu * IXtrAcu * I
H o o oH o o o
AX q2 £ IAX q 2 £ I
H ch3 q2‘ (0 (i) (k) ch3 (I) (m) o-ch3 QA U2 O-CH3 ch3 °\χΟΗ r^OH Q2 (o) («0 °\ /O-ch3 H ch 3 q 2 '(0 (i) (k) ch 3 (I) (m) o-ch 3 Q A U 2 O-CH 3 ch 3 ° \ χ ΟΗ r ^ OH Q 2 (o) ° -O-ch 3
X o-ch3 q2 3 (r)X o-ch 3 q 2 3 (r)
-74CZ 297945 B6-74EN 297945 B6
Tabulka 5hTable 5h
(t)(t)
O o O (u)O o O
Q2 )^=O oQ 2 ) ^ = 0 o
L/CH’ (E) q2 >O O <^CH3 ch3 (F)L / CH '(E) q 2 > OO <^ CH 3 ch 3 (F)
-75CZ 297945 B6-75GB 297945 B6
Tabulka 4a '3Table 4a '3
H3C.H 3 C.
CH (18) (17)CH (17) (17)
NH (22) (23) (21)NH (22) (22) (21)
NHNH
H3CH 3 C
nh2 q3 nh 2 q 3
(24)(24)
-76CZ 297945 B6-76GB 297945 B6
OH 0 NH2 «3 * nh2 arY0H (27) q3'x'txnh2 0 OH NH 2 «* 3 NH 2 0H aryl- (27) q 3 'x' t, X is NH 2
OH (28)Olympics (28)
OHOH
NH2 nh2 NH 2 nh 2
Q3 *Q3 *
(32)(32)
(31)(31)
Q3~CNQ 3 ~ CN
NHNH
Q3^S^NH2 Q ^ S ^ 3 NH 2
-77CZ 297945 B6-77EN 297945 B6
Tabulka 4cTable 4c
HH
Qs^CHsQs ^ CHs
HH
Q3^NX/CH3 Q ^ N X 3 / CH 3
H iH i
(48) (46) (47)(47) (46) (47)
H3CH 3 C
(49) (50) (51)(50) (50)
q3 q 3
^ch3 ^ ch 3
Q3-^NXx-ch3 (52) (53)Q 3 - ^ N Xx- ch 3 (52)
-78CZ 297945 B6-78GB 297945 B6
Tabulka 5aTable 5a
-79CZ 297945 B6-79GB 297945 B6
Tabulka 5bTable 5b
(ad) (af) (ag)(ad) (af) (ag)
(ai)(ai)
(al)(al)
(am)(am)
-80CZ 297945 B6-80GB 297945 B6
Tabulka 5cTable 5c
-81 CZ 297945 B6-81 CZ 297945 B6
Tabulka 6 - Příklady sloučenin v číselném označeníTable 6 - Examples of numerical compounds
A.17.a.4.i; A.17.a.4.v; A.17.a.6.i; A.17.a.6.v; A.17.a.ll.i; A.17.a.ll.v; A.17.a.l4.i;A.17.a.4.i; A.17.a.4.v; A.17.a.6.i; A.17.a.6.v; A.17.a.ll.i; A.17.a.ll.v; A.17.a.l4.i;
A.17.a.l4.v; A.17.a.l5.i; A.17.a.l5.v; A.17.a.l8.i; A.17.a,18.v; A.17.a.25.i;A.17.a.l4.v; A.17.a.l5.i; A.17.a.l5.v; A.17.a.l8.i; A.17.a, 18.v; A.17.a.25.i;
A.17.a.25.v; A.17.e.4.i; A.17.e.4.v; A,17.e.6.i; A.17.e.6.v; A.17.e.ll.i; A.17.e.ll.v; A.17,e,14.i; A.17.e.l4.v; A.17.e.l5.i; A.I7.e.l5.v; A.17.e.l8.i; A.17.e.l8.v; A.17.e.25.i; A.17.e.25.v; A.17.g.4.i; A.17.g.4.v; A.17.g.6.i; A.17.g.6.v; A.17.g.U,i; A.17.g.ll.v; A.17.g.l4.i; A.17.g.l4.v; A.17.g.l5.i; A.17.g,15.v; A.17.g.l8.i; A.17.g.l8.v; A.17.g.25.i; A.17.g.25.v; A.17.1.4.Í; A.17.1.4.v; A.1716.Í; A.17.1.6.V; A.17.1.11.Í; A.17.1.11.v; A.17.1.14.Í; A.17.L14.V; A.17.1.15.Í; A.17.1.15.V; A.17.1.18.Í; A.17.1.18.V; A.17.I.25.Í; A.17.1.25.V; A.17.m.4.i; A.17.m.4.v; A.17.m.6.i; A.17.m.6.v; A.17.m.ll.i; A.17.m.ll.v; A.17.m.l4.i; A.17.m.l4.v; A.17.m.l5.i; A.17.m.l5,v; A.17.m.l8.i; A.17.m.l8.v; A.17.m.25.i; A.17.m.25.v; A.17.o.4.i; A.17.o.4.v; A.17.O.6.Í; A.17.o.6.v; A.17.0.1LÍ; A.17.o.ll.v; A.17.O.14.Í;A.17.a.25.v; A.17.e.4.i; A.17.e.4.v; A, 17.e.6.i; A.17.e.6.v; A.17.e.ll.i; A.17.e.ll.v; A.17, e, 14. A.17.e.l4.v; A.17.e.l5.i; A.I7.e.l5.v; A.17.e.l8.i; A.17.e.l8.v; A.17.e.25.i; A.17.e.25.v; A.17.g.4.i; A.17.g.4.v; A.17.g.6.i; A.17.g.6.v; A.17.g.U, i; A.17.g.ll.v; A.17.g.l4.i; A.17.g.l4.v; A.17.g.l5.i; A.17.g, 15.v; A.17.g.l8.i; A.17.g.l8.v; A.17.g.25.i; A.17.g.25.v; A.17.1.4.I; A.17.1.4.v; A.1716.Í; A.17.1.6.V; A.17.1.11.Í; A.17.1.11.v; A.17.1.14.Í; A.17.L14.V; A.17.1.15.Í; A.17.1.15.V; A.17.1.18.Í; A.17.1.18.V; A.17.I.25.Í; A.17.1.25.V; A.17.m.4.i; A.17.m.4.v; A.17.m.6.i; A.17.m.6.v; A.17.m.ll.i; A.17.m.ll.v; A.17.m.l4.i; A.17.m.l4.v; A.17.m.l5.i; A.17.m.15, v; A.17.m.l8.i; A.17.m.l8.v; A.17.m.25.i; A.17.m.25.v; A.17.o.4.i; A.17.o.4.v; A.17.O.6.Í; A.17.o.6.v; A.17.0.1LÍ; A.17.o.ll.v; A.17.O.14.Í;
A.17.0.14. v; A.17.O.15.Í; A.17.o.l5.v; A.17.o.l8.i; A.17.o.l8.v; A.17.o.25.i; A.17.o.25.v; A.33.a.4.i; A.33.a.4.v; A.33.a.6.i; A.33.a,6.v; A.33,a.ll.i; A.33.a.ll.v; A.33.a,14.i; A.33.a,14.v; A.33.a.l5.i; A.33.a.l5.v; A.33.a.l8.i; A.33.a.l8.v; A.33.a.25.i; A.33.a.25.v; A.33.e.4.i; A.33.e.4.v; A.33.e.6.i; A.33.e.6.v; A.33.e.ll.i; A.33.e.ll.v; A.33.e.l4.i; A.33.e.l4.v; A.33.e.l5.i; A.33.e.l5.v; A.33.ě.l8.i; A.33.e.l8.v; A.33.e.25.i; A.33.e.25.v; A.33.g.4.i; A.33.g.4.v; A.33.g.6.i; A.33.g.6.v; A.33.g.ll.i; A.33.g.ll.v; A.33.g.l4d; A.33.g.l4,v; A.33.g.l5.i; A.33.g.l5.v; A.33.g.l8.i; A.33.g.l8.v; A.33.g.25.i; A.33.g.25.v; A.33.1.4.Í; A.3314.V; Α.33.1.6.Ϊ; A.33.1.6.V; A.33.1.11.Í; A.33.1.U.v; A.33.1.14.Í; A.33.1.14.V; A.33.1.15.Í; A.33.1.15.V; A.33.U8.Í; A.33.1.18.v; A.33.1.25.Í; A.33.1.25.V; A.33.m.4.i; A,33.m.4.v; A.33.in.6.i; A.33.m.6.v; A.33.m.ll.i; A.33.m.ll.v; A.33.m.l4.i; A.33.m.l4.v; A.33.m.l5.i; A.33.m.l5.v; A.33.m.l8.i; A.33.m.l8.v; A.33.m.25.i; A.33.m.25.v; A.33.O.4.Í· A.33.o.4.v; A.33.O.6.Í; A.33.o.6.v; A.33.o.ll.i;A.33.o.ll.v; A.33.o.l4.i; A.33.O.14.V; A.33.o.l5.i; A.33.o,15.v; A.33.o.l8.i; Α.33.ο.18.ν; Α.33.Ο.25.Ϊ; A.33.O.25.V; A.49.a.4.i; A.49.a.4.v; A.49.a.6.i; A.49.a.6.v; A.49.a.ll.i; A.49.a.ll.v; A.49.a.l4.i; A.49.a,14.v; A.49.a.l5.i; A.49.a.l5.v; A.49.a.l8.i; A.49,a.l8.v; A.49.a.25.i; A.49.a.25.v; A.49.e.4.i; A.49.e.4.v; A.49.e.6.i; A.49.e.6.v; A.49.e.ll.i; A.49.e.ll.v; A.49.e.l4.i; A.49.e.l4.v; A.49.e.l5.i; A.49.e.l5.v; A.49.e.l8.i; A.49.e.l8.v; A.49.e.25.i; A.49.e.25.v; A.49.g.4.i; A.49.g.4.v; A.49.g.6.i; A.49.g.6.v; A.49.g.ll.i; A.49.g.ll.V; A.49.g.l4.i; A.49.g.l4.v; A.49.g.l5.i; A.49.g.l5.v; A.49.g.l8.i; A.49.g.l8.v; A.49.g.25.i; A.49.g.25.v; A.49.1.4.Í; A.49.1.4.V; A.49.1.6.Í; A.49.1.6.V; A.49.1.11.Í; A.49.1.11.v; A.49.L14.Í; A.49.1.14.v; A.49.L15.Í; A.49.1.15.v; A.49.1.18.Í; A.49.1.18.V; A.49.1.25.Í; A.49.1.25.v; A.49.m.4.i; A.49.m.4.v; A.49.m.6.i; A.49.m.6.v; A.49.m.ll.i; A.49.m.U.v; A.49.m.l4.i; A.49.m,14.v; A.49.m.l5.i; A.49.m.l5.v; A.49.m.l8.i; A.49.m,18.v; A.49.m.25.i; A.49.m.25.v; A.49.O.4.Í; A.49.o.4,v; A.49.o.6.i; A-49.o.6.v; A.49.O.11.Í; Α.49.ο.Π.ν; A.49.O.I4.Í; A.49.O.14.V; Α.49.Ο.15.Ϊ; A.49.o.l5.v; A.49.o.Í8.i; A.49.o.l8.v; A.49.O.25.Í;A.17.0.14. in; A.17.O.15.Í; A.17.o.l5.v; A.17.o.l8.i; A.17.o.l8.v; A.17.o.25.i; A.17.o.25.v; A.33.a.4.i; A.33.a.4.v; A.33.a.6.i; A.33.a, 6.v; A.33, a.ll.i; A.33.a.ll.v; A.33.a, 14.i; A.33.a, 14.v; A.33.a.l5.i; A.33.a.l5.v; A.33.a.l8.i; A.33.a.l8.v; A.33.a.25.i; A.33.a.25.v; A.33.e.4.i; A.33.e.4.v; A.33.e.6.i; A.33.e.6.v; A.33.e.ll.i; A.33.e.ll.v; A.33.e.l4.i; A.33.e.l4.v; A.33.e.l5.i; A.33.e.l5.v; A.33.ě.l8.i; A.33.e.l8.v; A.33.e.25.i; A.33.e.25.v; A.33.g.4.i; A.33.g.4.v; A.33.g.6.i; A.33.g.6.v; A.33.g.ll.i; A.33.g.ll.v; A.33.g.l4d; A.33.g.14, v; A.33.g.l5.i; A.33.g.l5.v; A.33.g.l8.i; A.33.g.l8.v; A.33.g.25.i; A.33.g.25.v; A.33.1.4.I; A.3314.V; Α.33.1.6.Ϊ; A.33.1.6.V; A.33.1.11.Í; A.33.1.U.v; A.33.1.14.Í; A.33.1.14.V; A.33.1.15.Í; A.33.1.15.V; A.33.U8.Í; A.33.1.18.v; A.33.1.25.Í; A.33.1.25.V; A.33.m.4.i; A, 33.m.4.v; A.33.in.6.i; A.33.m.6.v; A.33.m.ll.i; A.33.m.ll.v; A.33.m.l4.i; A.33.m.l4.v; A.33.m.l5.i; A.33.m.l5.v; A.33.m.l8.i; A.33.m.l8.v; A.33.m.25.i; A.33.m.25.v; A.33.O.4.I · A.33.o.4.v; A.33.O.6.Í; A.33.o.6.v; A.33.o.ll.i; A.33.o.ll.v; A.33.o.l4.i; A.33.O.14.V; A.33.o.l5.i; A.33.o, 15.v; A.33.o.l8.i; Α.33.ο.18.ν; Α.33.Ο.25.Ϊ; A.33.O.25.V; A.49.a.4.i; A.49.a.4.v; A.49.a.6.i; A.49.a.6.v; A.49.a.ll.i; A.49.a.ll.v; A.49.a.l4.i; A.49.a, 14.v; A.49.a.l5.i; A.49.a.l5.v; A.49.a.l8.i; A.49, a.188.v; A.49.a.25.i; A.49.a.25.v; A.49.e.4.i; A.49.e.4.v; A.49.e.6.i; A.49.e.6.v; A.49.e.ll.i; A.49.e.ll.v; A.49.e.l4.i; A.49.e.l4.v; A.49.e.l5.i; A.49.e.l5.v; A.49.e.l8.i; A.49.e.l8.v; A.49.e.25.i; A.49.e.25.v; A.49.g.4.i; A.49.g.4.v; A.49.g.6.i; A.49.g.6.v; A.49.g.ll.i; A.49.g.ll.V; A.49.g.l4.i; A.49.g.l4.v; A.49.g.l5.i; A.49.g.l5.v; A.49.g.l8.i; A.49.g.l8.v; A.49.g.25.i; A.49.g.25.v; A.49.1.4.I; A.49.1.4.V; A.49.1.6.I; A.49.1.6.V; A.49.1.11.Í; A.49.1.11.v; A.49.L14.Í; A.49.1.14.v; A.49.L15.Í; A.49.1.15.v; A.49.1.18.Í; A.49.1.18.V; A.49.1.25.Í; A.49.1.25.v; A.49.m.4.i; A.49.m.4.v; A.49.m.6.i; A.49.m.6.v; A.49.m.ll.i; A.49.m.U.v; A.49.m.l4.i; A.49.m, 14.v; A.49.m.l5.i; A.49.m.l5.v; A.49.m.l8.i; A.49.m, 18.v; A.49.m.25.i; A.49.m.25.v; A.49.O.4.Í; A.49.o.4, v; A.49.o.6.i; A-49o.6.v; A.49.O.11.Í; Α.49.ο.Π.ν; A.49.O.I4.Í; A.49.O.14.V; Α.49.Ο.15.Ϊ; A.49.o.l5.v; A.49.o.Í8.i; A.49.o.l8.v; A.49.O.25.Í;
A. 49.o.25.v; B.17.a.4.i; B.17.a.4.v; B.17.a.6.i; B.17.a.6.v; B.17.a.ll.i; B.17.a.ll.v;A. 49.o.25.v; B.17.a.4.i; B.17.a.4.v; B.17.a.6.i; B.17.a.6.v; B.17.a.ll.i; B.17.a.ll.v;
B. 17.a.l4.i; B.17.a.l4.v; B.17.a.l5.i; B.17.a.l5.y; B.17.a.l8.i; B.17.a,18.v; B.17.a.25.i;B. 17.a.l4.i; B.17.a.l4.v; B.17.a.l5.i; B.17.a.l5.y; B.17.a.l8.i; B.17.a, 18.v; B.17.a.25.i;
B.17.a.25.v; B.17.e.4.i; B.17.e.4.v; B.17.e.6.i; B.17.e.6.v; B.17.e.ll.i; B.17.e.ll.v;B.17.a.25.v; B.17.e.4.i; B.17.e.4.v; B.17.e.6.i; B.17.e.6.v; B.17.e.ll.i; B.17.e.ll.v;
B.17.e.l4.i; B.17.e.l4.v; B.17.e.l5.i; B.17.e.l5.v; B.17.e.l8.i; B.17.e.l8.v; B17.e.25.i; B.17.e.25.v; B.17.g.4.i; B.I7.g.4.v; B.l/.g.ó.i; B,17.g.6.v; B.17.g.ll.i; B.17.g.ll.v;B.17.e.l4.i; B.17.e.l4.v; B.17.e.l5.i; B.17.e.l5.v; B.17.e.l8.i; B.17.e.l8.v; B17.e.25.i; B.17.e.25.v; B.17.g.4.i; B.I7.g.4.v; B.l / g.o.i; B, 17.g.6.v; B.17.g.ll.i; B.17.g.ll.v;
-82CZ 297945 B6-82EN 297945 B6
B.17.g.l4.i; B.17.g.l4.v; B.17.g.l5.i; B.17.g.l5.v; B.17.g.l8.i; B.17.g.l8.v; B.17.g25.i; B.17.g.25.v; B.17.L4.Í; B.17.1.4.v; B.17.1.6.Í; B.17.1.6.v; B.17.I.11.Í; B.17X11.V; B.17.1.14.Í; B.17.1.14.V; B.17.1.15.Í; B.17.L18.Í; B.17.1.18.v; B.17.1.25.Í;B.17.g.l4.i; B.17.g.l4.v; B.17.g.l5.i; B.17.g.l5.v; B.17.g.l8.i; B.17.g.l8.v; B.17.g25.i; B.17.g.25.v; B.17.L4.Í; B.17.1.4.v; B.17.1.6.I; B.17.1.6.v; B.17.I.11.Í; B.17X11.V; B.17.1.14.Í; B.17.1.14.V; B.17.1.15.Í; B.17.L18.Í; B.17.1.18.v; B.17.1.25.Í;
B.17.1.25.v; B.17.m.4.i; B.17.m.4.v; B.17.m.6.v; B.17.m.ll.i;B.17.1.25.v; B.17.m.4.i; B.17.m.4.v; B.17.m.6.v; B.17.m.ll.i;
B.17.m.ll.v; B.17.m.l4.i; B.17.m,14.v; B.17.m.l5á; B.17.m.l5.v; B.17.m.l8.i; B.17.m.l8.v; B.17.m.25.i; B.17.m.25.v; B.17.O.4.Í; B.17.o.4.v; B.17.o.6.i; B.17.o.6.v; B.17.0.11.Í; B.17.0.11.V; B.17.o.l4.i; B.17.o.l4.v; B.17.O.15.Í; B.17.o.l5.v; B.17.O.18.Í; B.17.o.l8.v; B.17.o.25.i; B.17.o.25.v; B.33.a.4.i; B.33.a.4.v; B.33.a.6.i; B33.a.6.v; B.33.a.ll.i; B.33.a.ll.v; B.33.a.l4.i; B.33.a.l4.v; B.33.a.l5.i; B.33.a.l5.v; B.33.a.l8.i; B.33.a.l8.v; B.33.a.25.i; B.33.a.25.v; B,33.e.4.i; B.33.e.4.v; B.33.e.6.i; B.33.e.6.v; B.33.e.ll.i; B.33.e.ll.v; B.33.e.l4.i; B.33.e.l4.v; B.33.e.l5.i; B.33.e.l5.v; B.33.e.l8.i; B.33.e.l8.v; B.33.e.25.i; B.33.e.25.v; B.33.g.4.i; B.33.g.4.v; B.33.g.6.i; B.33.g.6.v; B.33.g,ll.x; B.33.g.ll.v; B.33.g.!4.Í; B.33.g.l4.v; B.33.g.l5.i; B.33.g.l5.v; B.33.g.l8.i; B.33.g.l8.v; B.33.g.25.i; B.33.g.25.v; B.33.1.4.Í; B.33.1.4.V; B.33.1.6.Í; B.33.1.6.v; B.33.1.11.Í; B.33.1.11.v; B.33.1.14.Í; B33.1.14.V; Β.33.1.15Λ; B.33.1.15.V; B.33.1.18.Í; B.33.I.18.v; B.33.1.25.Í; B.33.I.25.V; B.33.m.4.i; B.33.m.4.v; B.33.m.6.i; B.33.m.6.v; B.33.m.ll.i; B.33.m.lLv; B.33.m.l4.i; B.33.m.l4.v; B.33.m.l5.i; B.33.mT5.v; B.33.m.l8.i; B.33.m.l8.v; B.33.m.25.i; B.33.m.25.v; B.33.o.4.i; B.33.o.4.v; B.33.o.6.i; B.33.O.6.v; B.33.o.U.i; B.33.o.ll.v; B.33.O.14.Í; B.33.O.14.V; B.33.O.15.Í; B.33.o.l5.v; B.33.O.18.Í; Β.33.ο.18.ν; B.33.o.25.i; B.33.o.25.v; BA9.aA.i; B.49.a.4.v; B.49.a.6.i; B.49.a.6.v; B.49.a.U.í; B.49.a.ll.v; B.49.a.l4.i; B.49.a.l4.v; B.49.a.l5.i; B.49.a.l5.v; B.49.a.l8.i; B.49.a.l8.v; B.49.a.25.i; B.49.a25.v; B.49.e.4.i; B.49.e.4.v; B.49.e.6.i; B.49.e.6,v; B.49.e.ll.i; B.49,e.ll.v; B.49.e.l4.i; B.49.e.l4.v; B.49.e.l5.i; B.49.e.l5.v; B.49.e.l8.i; B.49.e.l8.v; B.49.e.25.í; B.49.e.25.v; B.49.g.4.i; B.49.g.4.v; B.49.g.6.i; B.49.g.6.v; B.49.g.ll.i; B.49.g.ll.v; B.49.g.l4.i; B.49.g.l4.v; B.49.g.lS.i; B.49.g.l5.v; B.49.g.l8.i; B.49.g.l8.v; B.49.g25.i; B.49.g.25.v; B.49.1.4.Í; B.49.1.4.V; B.49.1.6.Í; B.49.l.6.v; B.49.1.11.Í; B.49.I.11.V; B.49.1.14.Í; B.49.l,14.v; B.49.I.15.Í; B.49.1.15.V; B.49.1.18.Í; B.49.1.18.V· B.49.1.25.Í; B.49.1.25.v; B.49.m.4.i; B.49.m.4.v; B.49.m.6.i; B.49.m.6.v; B.49.m.ll.i; B.49.m.ll.v; B.49.m.l4.i; B.49.m.l4.V; B.49.m.l5.i; B.49.tn.l5.v; B.49.m.l8.i; B.49.m.I8.v; B.49.m.25.i; B.49.m.25.v; B.49.o.4.i; B49.o.4.v; B.49.o.6.i; B.49.o.6.v; B.49.o.ll.i; B.49.o.ll.v; B.49.O.14.Í; B.49.o.l4.v; B.49.o.l5.i; B.49.o.l5.v; B.49.o.l8.i; B.49.o.l8.v; B.49.O.25.Í; B.49.o.25.v; E.17.a.4.i; E.17.a.4.v; E.17.a.6.i; E.17.a.6.v; E.17.a.U.i; E.17.a.ll.v; E.17.a.l4.i; E.17.a.l4.v; E.17.a.I5.i; E.17.a.l5.v; E.17.a.i8.i; E.17.a.l8.v; E.17.a254; E.17.a.25.v; E.17.e.4.i; E.17.e.4.v; E.17.e.6.i; E.17.e.6.v; E.17.e.U.i; E.17.e.ll.v; E.17.e.l4.i; E.17.e.l4.v; E.17.e.l5.i; E.17.e.l5.v; E.17.e.18.i; E.17.e.l8.v; E.17.e.25.i; E.17.e.25.v; E.17.g.4.i; E.I7.g.4.v; E.17.g.6.i; E.17.g.6.v; E.17.g.ll.i; E.17.g.H.v; E.17.g.l4.i; E.17.g,14.v; E.17.g.l5.i; E.17,g.l5.v; E.17.g.l8.í: E.17.g.l8.v; E.17.g.25.i; E.17.g.25.v; E.I7.1.4.Í; E.17.1.4.v; E.I7.1.6.Í; E.17.1.6.v; E.17.I.11.Í; E.17.1.11.v; E.17.1.14.Í; E.17.1.14.V; E.17.1.15.Í; E.17.1.15.v; E.17.1.18.Í; E.17.I.18.V; E.17.1.25.Í; E.17.1.25.v; E.17.m.4.i; E.17.m.4.v; E.17.m.6.i; E.17.m.6.v; E.17.m.ll.i; E.17,m.ll.v; E.17.m.l4.i; E.17.m,14.v; E.17.m.l5.i; E.17.m.l5.v; E.17.m.l8.i; E.17.m.l8.v; E.17.m.25.i; E.17.m.25.v; E.17.o.4.i; E.17.o.4.v; E.17.O.6.Í; E.17.o.6.v; E.17.0.11.Í; E.17.o.ll.v; E.17.O.14.Í; E.17.o.l4.v; E.17.O.15.Í; E.17.o.l5.v; E.17.O.18.Í; Ε.17.ο·18.ν; E.17.o.25.i; E.17.o.25.v; E.33.a.4.i; E.33.a.4.v; E.33.a.6.í; E.33.a.6.v; E.33.a.ll.i; E.33.a.ll.v; E.33.a.l4.i; E.33,a.l4.v; E.33.a.l5.i; E.33.a.l5.v; E.33.a.l8.i; E.33.a.l8.v; E.33.a.25.i; E-33.a.25.v; E.33.e.4.i; E.33.e.4.v; E.33.e.6.i; E.33.e.6.v;B.17.m.ll.v; B.17.m.l4.i; B.17.m, 14.v; B.17.m.l5á; B.17.m.l5.v; B.17.m.l8.i; B.17.m.l8.v; B.17.m.25.i; B.17.m.25.v; B.17.O.4.Í; B.17.o.4.v; B.17.o.6.i; B.17.o.6.v; B.17.0.11.Í; B.17.0.11.V; B.17.o.l4.i; B.17.o.l4.v; B.17.O.15.Í; B.17.o.l5.v; B.17.O.18.Í; B.17.o.l8.v; B.17.o.25.i; B.17.o.25.v; B.33.a.4.i; B.33.a.4.v; B.33.a.6.i; B33.a.6.v; B.33.a.ll.i; B.33.a.ll.v; B.33.a.l4.i; B.33.a.l4.v; B.33.a.l5.i; B.33.a.l5.v; B.33.a.l8.i; B.33.a.l8.v; B.33.a.25.i; B.33.a.25.v; B, 33.e.4.i; B.33.e.4.v; B.33.e.6.i; B.33.e.6.v; B.33.e.ll.i; B.33.e.ll.v; B.33.e.l4.i; B.33.e.l4.v; B.33.e.l5.i; B.33.e.l5.v; B.33.e.l8.i; B.33.e.l8.v; B.33.e.25.i; B.33.e.25.v; B.33.g.4.i; B.33.g.4.v; B.33.g.6.i; B.33.g.6.v; B.33.g, II.x; B.33.g.ll.v; B.33.g.I.4; B.33.g.l4.v; B.33.g.l5.i; B.33.g.l5.v; B.33.g.l8.i; B.33.g.l8.v; B.33.g.25.i; B.33.g.25.v; B.33.1.4.I; B.33.1.4.V; B.33.1.6.I; B.33.1.6.v; B.33.1.11.Í; B.33.1.11.v; B.33.1.14.Í; B33.1.14.V; Β.33.1.15Λ; B.33.1.15.V; B.33.1.18.Í; B.33.I.18.v; B.33.1.25.Í; B.33.I.25.V; B.33.m.4.i; B.33.m.4.v; B.33.m.6.i; B.33.m.6.v; B.33.m.ll.i; B.33.m.lLv; B.33.m.l4.i; B.33.m.l4.v; B.33.m.l5.i; B.33.mT5.v; B.33.m.l8.i; B.33.m.l8.v; B.33.m.25.i; B.33.m.25.v; B.33.o.4.i; B.33.o.4.v; B.33.o.6.i; B.33.O.6.v; B.33.oUi; B.33.o.ll.v; B.33.O.14.Í; B.33.O.14.V; B.33.O.15.Í; B.33.o.l5.v; B.33.O.18.Í; Β.33.ο.18.ν; B.33.o.25.i; B.33.o.25.v; BA9.aA.i; B.49.a.4.v; B.49.a.6.i; B.49.a.6.v; B.49.aUí; B.49.a.ll.v; B.49.a.l4.i; B.49.a.l4.v; B.49.a.l5.i; B.49.a.l5.v; B.49.a.l8.i; B.49.a.l8.v; B.49.a.25.i; B.49.a25.v; B.49.e.4.i; B.49.e.4.v; B.49.e.6.i; B.49.e.6, v; B.49.e.ll.i; B.49, e.ll.v; B.49.e.l4.i; B.49.e.l4.v; B.49.e.l5.i; B.49.e.l5.v; B.49.e.l8.i; B.49.e.l8.v; B.49.e.25.í; B.49.e.25.v; B.49.g.4.i; B.49.g.4.v; B.49.g.6.i; B.49.g.6.v; B.49.g.ll.i; B.49.g.ll.v; B.49.g.l4.i; B.49.g.l4.v; B.49.g.lS.i; B.49.g.l5.v; B.49.g.l8.i; B.49.g.l8.v; B.49.g25.i; B.49.g.25.v; B.49.1.4.I; B.49.1.4.V; B.49.1.6.I; B.49.l.6.v; B.49.1.11.Í; B.49.I.11.V; B.49.1.14.Í; B.49.l, 14.v; B.49.I.15.Í; B.49.1.15.V; B.49.1.18.Í; B.49.1.18.V · B.49.1.25.Í; B.49.1.25.v; B.49.m.4.i; B.49.m.4.v; B.49.m.6.i; B.49.m.6.v; B.49.m.ll.i; B.49.m.ll.v; B.49.m.l4.i; B.49.m.l4.V; B.49.m.l5.i; B.49.tn.l5.v; B.49.m.l8.i; B.49.m.I8.v; B.49.m.25.i; B.49.m.25.v; B.49.o.4.i; B49.o.4.v; B.49.o.6.i; B.49.o.6.v; B.49.o.ll.i; B.49.o.ll.v; B.49.O.14.Í; B.49.o.l4.v; B.49.o.l5.i; B.49.o.l5.v; B.49.o.l8.i; B.49.o.l8.v; B.49.O.25.Í; B.49.o.25.v; E.17.a.4.i; E.17.a.4.v; E.17.a.6.i; E.17.a.6.v; E.17.aUi; E.17.a.ll.v; E.17.a.l4.i; E.17.a.l4.v; E.17.a.I5.i; E.17.a.l5.v; E.17.a.i8.i; E.17.a.l8.v; E.17.a254; E.17.a.25.v; E.17.e.4.i; E.17.e.4.v; E.17.e.6.i; E.17.e.6.v; E.17.eUi; E.17.e.ll.v; E.17.e.l4.i; E.17.e.l4.v; E.17.e.l5.i; E.17.e.l5.v; E.17. e .18.i; E.17.e.l8.v; E.17.e.25.i; E.17.e.25.v; E.17.g.4.i; E.I7.g.4.v; E.17.g.6.i; E.17.g.6.v; E.17.g.ll.i; E.17.gHv; E.17.g.l4.i; E.17.g, 14.v; E.17.g.l5.i; E.17, g.15.v; E.17.g.l8.i: E.17.g.l8.v; E.17.g.25.i; E.17.g.25.v; E.I7.1.4.I; E.17.1.4.v; E.I7.1.6.I; E.17.1.6.v; E.17.I.11.Í; E.17.1.11.v; E.17.1.14.Í; E.17.1.14.V; E.17.1.15.Í; E.17.1.15.v; E.17.1.18.Í; E.17.I.18.V; E.17.1.25.Í; E.17.1.25.v; E.17.m.4.i; E.17.m.4.v; E.17.m.6.i; E.17.m.6.v; E.17.m.ll.i; E.17, m.ll.v; E.17.m.l4.i; E.17.m, 14.v; E.17.m.l5.i; E.17.m.l5.v; E.17.m.l8.i; E.17.m.l8.v; E.17.m.25.i; E.17.m.25.v; E.17.o.4.i; E.17.o.4.v; E.17.O.6.Í; E.17.o.6.v; E.17.0.11.Í; E.17.o.ll.v; E.17.O.14.Í; E.17.o.l4.v; E.17.O.15.Í; E.17.o.l5.v; E.17.O.18.Í; Ε.18.ο · 18.ν; E.17.o.25.i; E.17.o.25.v; E.33.a.4.i; E.33.a.4.v; E.33.a.6.í; E.33.a.6.v; E.33.a.ll.i; E.33.a.ll.v; E.33.a.l4.i; E.33, a.l4.v; E.33.a.l5.i; E.33.a.l5.v; E.33.a.l8.i; E.33.a.l8.v; E.33.a.25.i; E-33.a.25.v; E.33.e.4.i; E.33.e.4.v; E.33.e.6.i; E.33.e.6.v;
-83CZ 297945 B6-83EN 297945 B6
E.33.e.ll.i; E.33.e.ll.v; E.33.e.l4.i; E.33.e.l4.v; E.33.e.l5.i; E.33.e.l5.v; E.33.e.l8.i; E.33.e.l8.v; E.33.e.25.i; E.33.e.25.v; E.33.g.4.i; E.33.g.4.v; E.33.g.6.i; E.33.g.6.v; E.33.g.ll.i; E33.g,ll.v; E.33.g.l4.i; E.33.g.l4.v; E33.g.l5.i; E.33.gJ5,v; E.33.g.l8.i; E.33.g.l8.v; E.33.g.25.i; E.33.g.25.v; E.33.L4.Í; E.33.I.4.V; E.33.1.6.Í; E.33.L6.v; E.33.1.11 .i; E.33.1.11.v; E.33.1.14.Í; E.33.1.14.v; E.33.1.15.Í; E.33.1.15.v; E.33.1.18.Í; E.33.L18.V; Ε.33.1.25.Ϊ; É.33.1.25.V; E.33.m.4.i; E.33.m.4.v; E.33.m.6.i; E.33.m.6.v; E.33.m.ll.i; E.33.m.ll.v; E.33.m.l4.i; E.33.m.l4.v; E-33.mA5.« E.33.m.l5.v; E.33.m,18.i; E.33.m.l8.v; E.33.m.25.i; E.33.m,25.v; E.33.O.4.Í; E.33.o.4,v; E.33.o.6.i; E33.o.6.v; E.33.O.11.Í; E.33.o.ll.v; E.33.O.14.Í; E.33.O.14.V; E.33.O.15.Í; E.33.o.l5.v; E.33.O.18.Í; E.33.o.l8.v; E.33.o.25.i; E.33.o.25.v; E.49.a.4.i; E.49.a.4.v; E.49.a.6.i; E.49.a,6.v; E.49.a.ll.i; E.49.a.ll.v; E.49.a.l4.i; E.49.a,14.v; E.49.a.l5.i; E.49.a.l5.v; E.49.a.l8.i; E.49.a.l8.v; E.49.a.25.i; E.49.a.25.v; E.49.e.4.i; E.49.e.4.v; E.49.e.6.i; E.49.e.6.v; E.49.e.ll.i; E.49.e.ll.v; E.49.e.l4.i; E.49.e.l4.v; E.49.e,15.i; E.49.e.l5.v; E.49.e.l8.i; E.49.e.l8.v; E.49.e,25.i; E.49.e.25.v; E.49.g.4.i; E.49.g.4.v; E.49.g.6.i; E.49.g.6.v; E.49.g.ll.i; E.49.g.ll.v; E.49.g.l4.i; E.49.g.l4.v; E.49.g.l5.i; E.49.g.l5.v; E.49.g.l8.i; E.49.g.l8.v; E.49.g.25.i; E.49.g.25.v; E.49.1.4.Í; E.49.1.4.V; Ε.49.1.6.Ϊ; E.49.1.6.V; E.49.1.11.Í; E.49.1.11.V; E.49.L14.Í; E.49.L14.v; E.49.L15.Í; E.49.1.15.v; E.49.1.18.Í; E.49.1.18.v; E.49.1.25.Í; E.49.1.25.v; E.49.m.4.i; E.49.m.4.v; E.49.m.6.i; E.49.m.6.v; E.49.m.ll.i; E.49.m.ll.v; E.49.m.l4.i; E.49.m.l4.v; E,49.m.l5.í; E.49.m.l5.v; E.49.m.l8.i; E.49.m.l8.v; E.49.m.25.i; E.49.m.25.v; E.49.o.4.i; E.49.O.4.V; E.49.o.6.i; E.49,o.6.v; E.49.o.ll.i; E.49.o.ll.v; E.49.O.14 i; E.49.o.l4.v; E.49.O.15.Í; E.49.o.l5.v; E.49.o.l8.i; E.49.o.l8.v; E.49.o.25.i; E.49.o.25.v; H.17.a.4.i;E.33.e.ll.i; E.33.e.ll.v; E.33.e.l4.i; E.33.e.l4.v; E.33.e.l5.i; E.33.e.l5.v; E.33.e.l8.i; E.33.e.l8.v; E.33.e.25.i; E.33.e.25.v; E.33.g.4.i; E.33.g.4.v; E.33.g.6.i; E.33.g.6.v; E.33.g.ll.i; E33.g, II.v; E.33.g.l4.i; E.33.g.l4.v; E33.g.l5.i; E.33.gJ5, v; E.33.g.l8.i; E.33.g.l8.v; E.33.g.25.i; E.33.g.25.v; E.33.L4.Í; E.33.I.4.V; E.33.1.6.I; E.33.L6.v; E.33.1.11 .i; E.33.1.11.v; E.33.1.14.Í; E.33.1.14.v; E.33.1.15.Í; E.33.1.15.v; E.33.1.18.Í; E.33.L18.V; Ε.33.1.25.Ϊ; É.33.1.25.V; E.33.m.4.i; E.33.m.4.v; E.33.m.6.i; E.33.m.6.v; E.33.m.ll.i; E.33.m.ll.v; E.33.m.l4.i; E.33.m.l4.v; E-33.mA5. E.33.m, 18. E.33.m.l8.v; E.33.m.25.i; E.33.m, 25.v; E.33.O.4.Í; E.33.o.4, v; E.33.o.6.i; E33.o.6.v; E.33.O.11.Í; E.33.o.ll.v; E.33.O.14.Í; E.33.O.14.V; E.33.O.15.Í; E.33.o.l5.v; E.33.O.18.Í; E.33.o.l8.v; E.33.o.25.i; E.33.o.25.v; E.49.a.4.i; E.49.a.4.v; E.49.a.6.i; E.49.a, 6.v; E.49.a.ll.i; E.49.a.ll.v; E.49.a.l4.i; E.49.a, 14.v; E.49.a.l5.i; E.49.a.l5.v; E.49.a.l8.i; E.49.a.l8.v; E.49.a.25.i; E.49.a.25.v; E.49.e.4.i; E.49.e.4.v; E.49.e.6.i; E.49.e.6.v; E.49.e.ll.i; E.49.e.ll.v; E.49.e.l4.i; E.49.e.l4.v; E.49.e, 15.i; E.49.e.l5.v; E.49.e.l8.i; E.49.e.l8.v; E.49.e, 25.i; E.49.e.25.v; E.49.g.4.i; E.49.g.4.v; E.49.g.6.i; E.49.g.6.v; E.49.g.ll.i; E.49.g.ll.v; E.49.g.l4.i; E.49.g.l4.v; E.49.g.l5.i; E.49.g.l5.v; E.49.g.l8.i; E.49.g.l8.v; E.49.g.25.i; E.49.g.25.v; E.49.1.4.I; E.49.1.4.V; Ε.49.1.6.Ϊ; E.49.1.6.V; E.49.1.11.Í; E.49.1.11.V; E.49.L14.Í; E.49.L14.v; E.49.L15.Í; E.49.1.15.v; E.49.1.18.Í; E.49.1.18.v; E.49.1.25.Í; E.49.1.25.v; E.49.m.4.i; E.49.m.4.v; E.49.m.6.i; E.49.m.6.v; E.49.m.ll.i; E.49.m.ll.v; E.49.m.l4.i; E.49.m.l4.v; E, 49.m.l5; E.49.m.l5.v; E.49.m.l8.i; E.49.m.l8.v; E.49.m.25.i; E.49.m.25.v; E.49.o.4.i; E.49.O.4.V; E.49.o.6.i; E.49, o.6.v; E.49.o.ll.i; E.49.o.ll.v; E.49.O.14 i; E.49.o.l4.v; E.49.O.15.Í; E.49.o.l5.v; E.49.o.l8.i; E.49.o.l8.v; E.49.o.25.i; E.49.o.25.v; H.17.a.4.i;
H.17.a.4.v; H.17.a.6.i; H.17.a.6.v; H,17.a.ll.i; H.17.a.U.v; H.17.a.l4.i; H.17.a.l4.v; H.17.a.l5.i; H.17.a.l5.v; H.17.a.l8.i; H.17.a.l8.v; H.17.a.25.i; H.17.a.25.v; H.17.e.4.i; H.17.e.4.v; H.17.e.6.i; H.17.e.6.v; H.17.e.ll.i; H.17.e.ll.v; H.17.e.l4.i; H.17.e.l4.v; H.17.e.l5.i; H.17.e.l5.v; H.17.e.l8.i; H.17.e,18.v; H.17.e.25.i; H.17.e.25.v; H.17.g.4.i; H.17.g.4.v; H.17.g.6.i; H.17.g.6.v; H.17.g.ll.i; H.17.g.ll.v; H.17.g.l4.i; H.17.g.l4.v; H.17.g.l5.i; H.17.g.l5.v; H.17.g.l8.i; H.17.g.l8.v; H.17.g.2S.i; H.17.g.25.v; H.17.1.4.Í; H.17.1.4.v; H.17.1.6.Í; H.17.1.6.v; H.17.1.11.Í; H.17.I.ll.v; H.I7.1.14.Í; H.17.L14.v; H.17.1.15.Í; H.17.1.15.v; H.17.1.18.Í; H.17.1.18.v; H.17.1.25.1; H.17.1.25.v; H.17.m.4.i; H.17.m.4.v; H.17.m.6.i; H.17,m.6.v; H.17.m.ll.i: H.17.m.ll.v; H.17.m.l4.i; H.17.m.l4.v; H.17.m.l5.i; H.17.m.l5.v; H.17.m.l8.i; H.17.m.l8.v; H.17,m.25.i; H.17.m.25.v; H.17.o.4.i; H.17.o.4.v; H.17.O.6.Í; H.17.o.6.v; H.17.o.U.i; H.17.o.ll.v; H.17.o.l4.i; H.17.o.l4.v; H.17.O.15.Í; H.17.o.l5.v; H.17.O.18.Í; H.17.o.l8.v; H.17.o.25.i; H.17.o.25.v; H.33.a.4.i; H.33.a.4.v; H.33.a.6.i; H.33.a.6.v; H.33.a.ll.i; H.33.a.ll.v; H.33.a.l4.i; H.33.a.l4.v; H.33.a.l5.i; H.33.a.l5.v; H.33.a.l8.i; H.33.a.l8.v; H.33-a.25.i; H.33.a.25.v; H.33.e.4.i; H.33.e.4.v; H.33.e.6.i; H.33.e.6.v; H.33.e.ll.i; H.33.e.ll.v; H.33.e.l4.i; H.33.e.l4.v; H.33.e.l5.i; H.33.e.l5.v; H.33.e.l8.i; H.33.e.l8.v; H.33.e.25.i; H.33.e.25.v; H.33.g.4.i; H.33.g.4.v; H.33.g.6.i; H.33.g.6.v; H.33.g.ll.i; H.33.g.ll.v; H.33.g.l4.i; H.33.g,14.v; H.33.g,15.i; H.33.g.l5.v; H.33.g.l8.i; H.33.g.l8.v: H.33.g.25.i; H.33.g.25.v; H.33.1.4.Í; H.3314.v; H.33.1.6.Í; H.33.1.6.v; H.33.1 ll.i; H.33111.v; Η.33.1.14.Ϊ; H.33d.l4,v; H,33.1.15.i; H.33.1.15.v; H.33.1.18.Í; H.33.1.18.v; H.33.1.25.1; H.33.1.25.v; H.33.m.4.i; H.33.m.4.v; H.33.m.6.i; H.33.m.6.v; H.33.m.ll.i; H.33.m.ll,v; H.33.m.l4.i; H.33,m.l4.v; H.33.m.l5.i; H.33.m.l5.v; H.33.m.l8.i; H.33.m.l8.v; H.33.m.25.i; H.33.m.25.v; H.33.o.4.i> H.33.o.4.v; H.33.O.6.Í; H.33.o.6.v; H.33.O.11.Í; H.33.o.ll.v; H.33.O.14.Í;H.17.a.4.v; H.17.a.6.i; H.17.a.6.v; H, 17.a.II.i; H.17.a.U.v; H.17.a.l4.i; H.17.a.l4.v; H.17.a.l5.i; H.17.a.l5.v; H.17.a.l8.i; H.17.a.l8.v; H.17.a.25.i; H.17.a.25.v; H.17.e.4.i; H.17.e.4.v; H.17.e.6.i; H.17.e.6.v; H.17.e.ll.i; H.17.e.ll.v; H.17.e.l4.i; H.17.e.l4.v; H.17.e.l5.i; H.17.e.l5.v; H.17.e.l8.i; H.17.e, 18.v; H.17.e.25.i; H.17.e.25.v; H.17.g.4.i; H.17.g.4.v; H.17.g.6.i; H.17.g.6.v; H.17.g.ll.i; H.17.g.ll.v; H.17.g.l4.i; H.17.g.l4.v; H.17.g.l5.i; H.17.g.l5.v; H.17.g.l8.i; H.17.g.l8.v; H.17.g.2S.i; H.17.g.25.v; H.17.1.4.I; H.17.1.4.v; H.17.1.6.I; H.17.1.6.v; H.17.1.11.Í; H.17.I.ll.v; H.I7.1.14.Í; H.17.L14.v; H.17.1.15.Í; H.17.1.15.v; H.17.1.18.Í; H.17.1.18.v; H.17.1.25.1; H.17.1.25.v; H.17.m.4.i; H.17.m.4.v; H.17.m.6.i; H.17, m.6.v; H.17.m.ll.i: H.17.m.ll.v; H.17.m.l4.i; H.17.m.l4.v; H.17.m.l5.i; H.17.m.l5.v; H.17.m.l8.i; H.17.m.l8.v; H.17, m.25i; H.17.m.25.v; H.17.o.4.i; H.17.o.4.v; H.17.O.6.Í; H.17.o.6.v; H.17.o.U.i; H.17.o.ll.v; H.17.o.l4.i; H.17.o.l4.v; H.17.O.15.Í; H.17.o.l5.v; H.17.O.18.Í; H.17.o.l8.v; H.17.o.25.i; H.17.o.25.v; H.33.a.4.i; H.33.a.4.v; H.33.a.6.i; H.33.a.6.v; H.33.a.ll.i; H.33.a.ll.v; H.33.a.l4.i; H.33.a.l4.v; H.33.a.l5.i; H.33.a.l5.v; H.33.a.l8.i; H.33.a.l8.v; H.33-a.25.i; H.33.a.25.v; H.33.e.4.i; H.33.e.4.v; H.33.e.6.i; H.33.e.6.v; H.33.e.ll.i; H.33.e.ll.v; H.33.e.l4.i; H.33.e.l4.v; H.33.e.l5.i; H.33.e.l5.v; H.33.e.l8.i; H.33.e.l8.v; H.33.e.25.i; H.33.e.25.v; H.33.g.4.i; H.33.g.4.v; H.33.g.6.i; H.33.g.6.v; H.33.g.ll.i; H.33.g.ll.v; H.33.g.l4.i; H.33.g, 14.v; H.33.g, 15.i; H.33.g.l5.v; H.33.g.l8.i; H.33.g.28.v: H.33.g.25.i; H.33.g.25.v; H.33.1.4.I; H.3314.v; H.33.1.6.I; H.33.1.6.v; H.33.1 ll.i; H.33111.v; Η.33.1.14.Ϊ; H.33d.14, v; H, 33.1.15.i; H.33.1.15.v; H.33.1.18.Í; H.33.1.18.v; H.33.1.25.1; H.33.1.25.v; H.33.m.4.i; H.33.m.4.v; H.33.m.6.i; H.33.m.6.v; H.33.m.ll.i; H.33.m.ll, v; H.33.m.l4.i; H.33, m.l4.v; H.33.m.l5.i; H.33.m.l5.v; H.33.m.l8.i; H.33.m.l8.v; H.33.m.25.i; H.33.m.25.v; H.33.o.4.i> H.33.o.4.v; H.33.O.6.I; H.33.o.6.v; H.33.O.11.Í; H.33.o.ll.v; H.33.O.14.Í;
-84CZ 297945 B6-84GB 297945 B6
H.33.o.l4.v; H.33.o.l5.i; H.33.o.l5.v; H.33.O.18.1; H.33.o.l8.v; H.33.O.25.1; H.33.O.25.V; H.49.a.4.i; H.49.a.4.v; H.49.a.6.i; H.49.a.6.v; H.49.a.ll.i; H.49.a.ll.v; H.49.a.l4.i; H.49.a.l4.v; H.49.a.l5.i; H.49.a.l5.v; H.49.a.l8.i; H.49.a.l8.v; H.49.aJ25.i; H.49.a.25.v; H.49.e.4.i; H.49.e.4.v; H.49.e.6.i; H.49.e.6.v; H.49.e.ll.i; H.49.e.ll.v; H.49.e.l4.i; H.49.e.l4.v; H.49.e.l5.i; H.49.e.l5.v; H.49.e.l8.i; H.49.e.l8.v; H.49.e.25.i; H.49.e.25.v; H.49.g.4.i; H.49.g.4.v; H.49.g.6.i; H.49.g.6.v; H.49.g.ll.i; H.49.g.ll.v; H.49.g.l4.i; H.49.g.l4.v; H.49.g.l5.i; H.49.g,15.v; H.49.g.l8.i; H.49.g.l8.v; H.49.g.25.i; H.49.g25.v; H.4914.1; H.49.1.4.V; H.49.1.6.1; H.49.1.6.V; H.49.1.11.Í; H.49.1.11.v; H.49.1.14.Í; H.49.1.14.V; H.49.1.15.1; H.49.1.15.V; H.49.1.18.Í; H.49.1.18.v; H.49.L25.Í; H.49.1.25.V; H.49.m.4.i; H.49.m.4.v; H.49.m.6.i; H.49 m.ó.v; H.49.m.ll.i; H,49.m.ll.v; H.49.m.l4.i; H.49.m.l4.v; H.49.m.l5.i; H.49.m.l5.v; H.49.m.l8.i; H-49.m.l8.v; H.49.m.25.i; H.49.m.25.v; H.49.O.4.Í; H.49.o.4.v; H.49.o.6.i; H.49.o.6.v; H.49.O.11.Í; H.49.o.ll.v; H.49.O.14.Í; H.49.O.14.V; H.49.O.15.Í; H.49.O.15.V; H.49.O.18.Í; H.49.o. 18.v; H.49.O.25.Í;H.33.o.l4.v; H.33.o.l5.i; H.33.o.l5.v; H.33.O.18.1; H.33.o.l8.v; H.33.O.25.1; H.33.O.25.V; H.49.a.4.i; H.49.a.4.v; H.49.a.6.i; H.49.a.6.v; H.49.a.ll.i; H.49.a.ll.v; H.49.a.l4.i; H.49.a.l4.v; H.49.a.l5.i; H.49.a.l5.v; H.49.a.l8.i; H.49.a.l8.v; H.49.aJ25.i; H.49.a.25.v; H.49.e.4.i; H.49.e.4.v; H.49.e.6.i; H.49.e.6.v; H.49.e.ll.i; H.49.e.ll.v; H.49.e.l4.i; H.49.e.l4.v; H.49.e.l5.i; H.49.e.l5.v; H.49.e.l8.i; H.49.e.l8.v; H.49.e.25.i; H.49.e.25.v; H.49.g.4.i; H.49.g.4.v; H.49.g.6.i; H.49.g.6.v; H.49.g.ll.i; H.49.g.ll.v; H.49.g.l4.i; H.49.g.l4.v; H.49.g.l5.i; H.49.g, 15.v; H.49.g.l8.i; H.49.g.l8.v; H.49.g.25.i; H.49.g25.v; H.4914.1; H.49.1.4.V; H.49.1.6.1; H.49.1.6.V; H.49.1.11.Í; H.49.1.11.v; H.49.1.14.Í; H.49.1.14.V; H.49.1.15.1; H.49.1.15.V; H.49.1.18.Í; H.49.1.18.v; H.49.L25.Í; H.49.1.25.V; H.49.m.4.i; H.49.m.4.v; H.49.m.6.i; H.49 m.o.v; H.49.m.ll.i; H, 49.m.ll.v; H.49.m.l4.i; H.49.m.l4.v; H.49.m.l5.i; H.49.m.l5.v; H.49.m.l8.i; H-49.m.l8v; H.49.m.25.i; H.49.m.25.v; H.49.O.4.Í; H.49.o.4.v; H.49.o.6.i; H.49.o.6.v; H.49.O.11.Í; H.49.o.ll.v; H.49.O.14.Í; H.49.O.14.V; H.49.O.15.Í; H.49.O.15.V; H.49.O.18.Í; H.49.o. 18.v; H.49.O.25.Í;
H. 49.0.25.v; I.17.a.4.i; I.17.a.4.v; I.17.a.6,i; I.17.a.6.v; I.17.a.ll.i; I.17.a.ll.v; 117.a.l4.i; I.17.a.l4.v; I.17.a.l5.i; L17.a.l5.v; I.17.a.l8.i; I.17.a.l8.v; I.17.a.25.i;H. 49.0.25.v; I.17.a.4.i; I.17.a.4.v; I.17.a.6, i; I.17.a.6.v; I.17.a.ll.i; I.17.a.ll.v; 117.a.l4.i; I.17.a.l4.v; I.17.a.l5.i; L17.a.l5.v; I.17.a.l8.i; I.17.a.l8.v; I.17.a.25.i;
I. 17.a.25.v; I.17.e.4.i; I.17.e.4.v; L17.e.6.i; I.17.e.6.v; I.17.e.ll.i; 1.17^.11.v;I. 17.a.25.v; I.17.e.4.i; I.17.e.4.v; L17.e.6.i; I.17.e.6.v; I.17.e.ll.i; 1.17 ^ .11.v;
1.17. e.l4.i; I.17.e.l4.v; I.17.e.l5.i; I.17.e.l5.v; I.17.e.l8.i; I.17^.18.v; I.17.e.25.i;1.17. e.l4.i; I.17.e.l4.v; I.17.e.l5.i; I.17.e.l5.v; I.17.e.l8.i; I.17 ^ .18.v; I.17.e.25.i;
1.17. e.25.v; I.17.g.4.i; I.17.g.4.v; U7.g.6.i; L17.g.6.v; 1.17.g.ll4; I.17.g.U.v; 117.g.l4.i; I.17.g.l4.v; I.17.g.l5.i; I.17.g.l5.v; I.17.g.l8.i; I.17.g;18.v; I.17.g.25.i;1.17. e.25.v; I.17.g.4.i; I.17.g.4.v; U7.g.6.i; L17.g.6.v; 1.17.g.ll4; I.17.g.U.v; 117.g.l4.i; I.17.g.l4.v; I.17.g.l5.i; I.17.g.l5.v; I.17.g.l8.i; I.17.g; 18.v; I.17.g.25.i;
1.17. g.25.v; I.17.1.4.Í; I.17.1.4.v; 117.16.1; 117.L6.V; 117.111.Í; L17.1.11.v; 1.17.1.144;1.17. g.25.v; I.17.1.4.I; I.17.1.4.v; 117.16.1; 117.L6.V; 117.111.Í; L17.1.11.v; 1.17.1.144;
1.17.1.14. V; 117.1.15.1; I.17.1.15.v; I.17.1.18.Í; I.17.1.18.v; I.17.1.25.Í; 117.1.25. v;1.17.1.14. IN; 117.1.15.1; I.17.1.15.v; I.17.1.18.Í; I.17.1.18.v; I.17.1.25.Í; 117.1.25. in;
1.17. m.4.i; L17,m.4.v; I.17.m.6.i; 1.17,m.ó.v; I.17.m.ll.i; I.17.m.ll.v; L17.m.l4.i;1.17. m.4.i; L17, m.4.v; I.17.m.6.i; 1.17; I.17.m.ll.i; I.17.m.ll.v; L17.m.l4.i;
1.17. m.l4.v; I.17.m.l5.i; I.17.m.l5.v; I.17.m.l8.i; I.17.m.l8.v; I.17.m.25.i;1.17. m.l4.v; I.17.m.l5.i; I.17.m.l5.v; I.17.m.l8.i; I.17.m.l8.v; I.17.m.25.i;
1.17. m.25.v; L17.O.4.Í; I.17.o.4.v; I.17.O.6.Í; I.17.o.6.v; I.17.o.ll.i; I.17.o.ll.v; 1.17.0.14.1; I.17.o.l4.v; 117.0.15.1; I.17.o.l5.v; I.17.O.18.Í; I.17.o.l8.v; 1.17.0.25.1; I.17.O.25.V; I.33.a.4.i; I.33.a.4.v; I.33.a.6.i; I.33.a,6.v; L33.a.ll.i; L33.a.ll.v;1.17. m.25.v; L17.O.4.I; I.17.o.4.v; I.17.O.6.Í; I.17.o.6.v; I.17.o.ll.i; I.17.o.ll.v; 1.17.0.14.1; I.17.o.l4.v; 117.0.15.1; I.17.o.l5.v; I.17.O.18.Í; I.17.o.l8.v; 1.17.0.25.1; I.17.O.25.V; I.33.a.4.i; I.33.a.4.v; I.33.a.6.i; I.33.a, 6.v; L33.a.ll.i; L33.a.ll.v;
1.33. a.l4.i; I.33.a.l4.v; I.33.a.l5.i; I.33.a.l5.v; I.33.a.l8.i; I.33.a.l8.v; I.33.a.25.i;1.33. a.l4.i; I.33.a.l4.v; I.33.a.l5.i; I.33.a.l5.v; I.33.a.l8.i; I.33.a.l8.v; I.33.a.25.i;
1.33. a.25.v; I.33.e.4.i; I.33.e.4.v; I.33.e.6.i; I.33.e.6.v; 1.33-e.ll.i; L33.e.ll.v;1.33. a.25.v; I.33.e.4.i; I.33.e.4.v; I.33.e.6.i; I.33.e.6.v; 1.33-e.ll.1; L33.e.ll.v;
1.33. e.l4.i; I.33.e.l4.v; I.33.e.l5.i; I.33.e.l5.v; 133.e.l8.i; I.33.e.l8.v; I.33.e.25.i;1.33. e.l4.i; I.33.e.l4.v; I.33.e.l5.i; I.33.e.l5.v; 133.e.l8.i; I.33.e.l8.v; I.33.e.25.i;
1.33. e.25.v; I.33.g.4.i; I.33.g.4.v; L33.g.6.i; I.33.g.6.v; 1.33.g. 11.i; I.33.g.ll.v;1.33. e.25.v; I.33.g.4.i; I.33.g.4.v; L33.g.6.i; I.33.g.6.v; 1.33.g. 11.i; I.33.g.ll.v;
1.33. g.l4.i; 1.33.g.l4.v; 1.33.g,15.i; I.33.g.l5.v; I.33.g.l8.i; L33.g.l8.v; I.33.g25.i; 133.g.25.v; 1.33.1.44; 133.1.4. v; 1.33.1.6.1; I.33.1.6.v; I.33.1.11.Í; I.33.1.11.v; 1.334.144; L33.1.14.V; I.33.1.15.Í; I.33.L15.v; 1.33.1.18.1; I.33.1.18.v; 1.33.1.254; 1.33.1.25.v;1.33. g.l4.i; 1.33.g.l4.v; 1.33.g, 15.i; I.33.g.l5.v; I.33.g.l8.i; L33.g.l8.v; I.33.g25.i; 133.g.25.v; 1.33.1.44; 133.1.4. in; 1.33.1.6.1; I.33.1.6.v; I.33.1.11.I; I.33.1.11.v; 1.334.144; L33.1.14.V; I.33.1.15.Í; I.33.L15.v; 1.33.1.18.1; I.33.1.18.v; 1.33.1.254; 1.33.1.25.v;
1.33. m.4.i; L33.m.4.v; 133m.6.i; I.33.m.6.v; I.33.m.ll.i; I.33.m.ll.v; L33.m.l4.i;1.33. m.4.i; L33.m.4.v; 133m.6.i; I.33.m.6.v; I.33.m.ll.i; I.33.m.ll.v; L33.m.l4.i;
1.33. m.l4.v; I.33.m.l5.i; I.33.m.l5.v; I.33.m.l8.i; I.33.m.l8.v; I.33.m.25.i;1.33. m.l4.v; I.33.m.l5.i; I.33.m.l5.v; I.33.m.l8.i; I.33.m.l8.v; I.33.m.25.i;
1.33. m.25.v; I.33.o.4.i; I.33.o.4.v; 1.33.0.6.i; 133.0.6.v; 133.0.11.i; 133.0.li.v; I.33.0.14.Í; 133.0.14.v; 133.0.15.1; I.33.o.l5.v; 133.O.18.Í; I.33.0.18.V; 133.O.25.Í; I.33.O.25.V; I.49.a.4.i; I.49.a.4.v; I.49.a.6.i; I.49.a.6.v; I.49.a.ll.i; I.49.a.ll.v;1.33. m.25.v; I.33.o.4.i; I.33.o.4.v; 1.33.0.6.i; 133.0.6.v; 133.0.11.i; 133.0.li.v; I.33.0.14.Í; 133.0.14.v; 133.0.15.1; I.33.o.l5.v; 133.O.18.Í; I.33.0.18.V; 133.O.25.Í; I.33.O.25.V; I.49.a.4.i; I.49.a.4.v; I.49.a.6.i; I.49.a.6.v; I.49.a.ll.i; I.49.a.ll.v;
1.49. a.l4.i; I.49.a.l4.v; I.49.a.l5.i; L49.a.l5.v; I.49.a.l8.i; 149.a.l8.v; I.49.a.25.i;1.49. a.l4.i; I.49.a.l4.v; I.49.a.l5.i; L49.a.l5.v; I.49.a.l8.i; 149.a.l8.v; I.49.a.25.i;
1.49. a.25.v; I.49.e.4.i; I.49.e.4.v; L49.e.6.i; I.49.e.6.v; I.49.e.ll.i; 149.e.ll«v;1.49. a.25.v; I.49.e.4.i; I.49.e.4.v; L49.e.6.i; I.49.e.6.v; I.49.e.ll.i; 149.e.ll «v;
1.49. e.l4.i; I.49.e.l4.v; I.49.e.l5.i; I.49.e.l5.v; I.49.e.lS.i; I.49.e.l8.v; I.49.e.25.i;1.49. e.l4.i; I.49.e.l4.v; I.49.e.l5.i; I.49.e.l5.v; I.49.e.lS.i; I.49.e.l8.v; I.49.e.25.i;
1.49. e.25.v; I.49.g.4.i: L49.g.4.v; I.49.g.6.i; I.49.g.6.v; I.49.g.ll.í; 149.g.ll.v;1.49. e.25.v; I.49.g.4.i: L49.g.4.v; I.49.g.6.i; I.49.g.6.v; I.49.g.ll.í; 149.g.ll.v;
1.49. g.l4.i; J.49.g.l4.v; I.49.g.l5.i; I.49.g.l5.v; I.49.g.l8.i; I.49.g.l8.v; I.49.g.25.i;1.49. g.l4.i; J.49.g.l4.v; I.49.g.l5.i; I.49.g.l5.v; I.49.g.l8.i; I.49.g.l8.v; I.49.g.25.i;
1.49. g.25.v; 1.49.1.4.1; I.49.1.4.v; 1.49.1.64; 1.49.1.6. v; 1.49.1.11.1; 149.1.11. v; 1.49.1.144;1.49. g.25.v; 1.49.1.4.1; I.49.1.4.v; 1.49.1.64; 1.49.1.6. in; 1.49.1.11.1; 149.1.11. in; 1.49.1.144;
1.49.1.14. V; 1.49.1.15.1; I.49.1.15.V; 1.49.1.18.1; I.49.L18.v; 1.49.1.254; I.49.L25.v;1.49.1.14. IN; 1.49.1.15.1; I.49.1.15.V; 1.49.1.18.1; I.49.L18.v; 1.49.1.254; I.49.L25.v;
1.49. m.4.i; I.49.m.4.v; 1.49.m.6.i; I.49.m.6.v; I.49.m.ll.i; I.49.m.ll.v; 149.m.l4.i;1.49. m.4.i; I.49.m.4.v; 1.49.m.6.i; I.49.m.6.v; I.49.m.ll.i; I.49.m.ll.v; 149.m.l4.i;
-85CZ 297945 B6-85GB 297945 B6
1.49. m.l4.v; I.49.m.l5.i; I.49.m.l5.v; I.49.m.l8.x; I.49.m.l8.v; I.49.m.25.i;1.49. m.l4.v; I.49.m.l5.i; I.49.m.l5.v; I.49.m.l8.x; I.49.m.l8.v; I.49.m.25.i;
1.49. m.25.v; I.49.O.4.Í; I.49.O.4.V; 1.49.0.6.x; I.49.o.6.v; 1.49.0.11 a; I.49.o.ll.v; I.49.O.14.Í; I.49.o.l4.v; I.49.o.l5.i; 1.49.0.15.v; I.49.o.l8.i; 1.49.0.18.v; I.49.o.25.i; I.49.o.25.v; L.17.a.4.i; L.17.a.4.v; L.17.a.6.i; L.17-a.6.v; L.17.a.U.i; L.17.a.ll.v; L.I7.a.l4.i; L.17.a,14.v; L.17.a.l5.i; L.17.a.l5.v; L.17.a.l8.i; L.17.a.l8.v; L.17.a.25.i; L.17.a.25.v; L.17.e.4.i; L.17.e.4.v; L.17.e.6.i; L.17.e.6.v; L.17.e.ll.i; L.17.e.ll.v; L.17.e.l4.i; L‘.17.e.l4.v; L.17.e.l54; L.17.e,15.v; L.17.e.l8.i; L.17.e.l8.v; L.17.e25.i; L.17.e.25.v; L.17.g.4.i; L.17.g.4.v; L.17.g.6.i; L.17.g.6.v; L.17.g.ll.i; L.17.g.ll.v; L.17.g.l4.x; L.17.g.l4.v; L.17.g.l5.i; L.17.g.l5.v; L.17.g.l8.i; L.17.g.l8.v; L.17.g25.i; L.17.g.25.v; L.17.1.4.X; L.17.1.4.v; L.17.1.6.Í; L17.1.6.V; L.17.1.11.X; L.17.1.11.v; L.17.1.14.Í; L.17.I.14.v; L.17.1.15.Í; L.17.1.15.v; L.17.1.18.Í; L.17.1.18.V; L.17.1.25.Í; L.17.1.25.V; L.17.m.4.i; L.17.m.4.v; L.17.m.6.i; L.17.m.6.v; L.17.m.ll.i; L.17.m.ll.v; L.17.m.l4.í; L.17.m.l4.v; L.17.m.l5.i; L.17.m.l5.v; L.17.m.l8.i; L.17.m.l8.v; L.17.xn.25.i; L.17.m.25.v; L.17.O.4.Í; L.17.o.4.v; L.17.o.6.i; L.17.o.6.v; L.17.0.11.Í; L.17.0.11.V; L.17.O.14.Í; L.17.o.l4.v; L.17.o.l5.x; L.17.o.l5.v; L.17.O.18.Í; L.17.O.18.V; L.17.o.25.i; L.17.o.25.v; L.33.a.4.x; L.33.a.4.v; L.33.a.6.i; L.33.a.6.v; L.33.a.ll.i; L.33.a.ll.v; L.33.a.l4.i; L.33.a.l4.v; L.33.a,15.x; L.33.a.l5.v; L.33.a.l8.i; L.33.a.l8.v; L.33.a.25.i; L.33.a.25,v; L.33.e.4.i; L.33.e.4.v; L.33.e.6.i; L.33.e.6.v; L.33.e.U.i; L.33.e.ll.v; L.33.e.l4.i; L.33.e.l4.v; L.33.e.l5.i; L.33.e.l5.v; L.33.e.l8,i; L..33.e.l8.v; L.33.e.25.i; L.33.e.25-v; L.33.g.4.i; L.33.g.4.v; L.33.g.6.i; L.33.g.6.v; L.33.g.ll.x; L.33.g.ll.v; L.33.g.l4.i; L.33.g.l4.v; L.33.g.l5.i; L.33.g.l5.v; L33.g.l8.x; L.33.g.l8.v; L.33.g.25.i; L.33.g.25.v; L.33.1.4.Í; L.33.1.4.v; L.33.1.6.Í; L.33.1.6.v; L.33.1.11.Í; L.33.1.11.V; L33.1.14.Í; L.33.1.14.v; L.33.1.15.Í; L33.1.15.v; L.33.1.18.Í; L.33.1.18.v; L.33.1.25.Í; L.33.1.25-v; L.33.m.4.i; L.33.m.4.v; L.33.m.6.i; L.33.m.6.v; L.33.m.ll.i; L.33.m.ll.v; L„33.m.l4.i; L.33.m..l4.v; L.33.xn.l5.i; L.33.m.l5.v;1.49. m.25.v; I.49.O.4.Í; I.49.O.4.V; 1.49.0.6.x; I.49.o.6.v; 1.49.0.11 a; I.49.o.ll.v; I.49.O.14.Í; I.49.o.l4.v; I.49.o.l5.i; 1.49.0.15.v; I.49.o.l8.i; 1.49.0.18.v; I.49.o.25.i; I.49.o.25.v; L.17.a.4.i; L.17.a.4.v; L.17.a.6.i; L.17-a.6.v; L.17.a.U.i; L.17.a.ll.v; L.I7.a.l4.i; L.17.a, 14.v; L.17.a.l5.i; L.17.a.l5.v; L.17.a.l8.i; L.17.a.l8.v; L.17.a.25.i; L.17.a.25.v; L.17.e.4.i; L.17.e.4.v; L.17.e.6.i; L.17.e.6.v; L.17.e.ll.i; L.17.e.ll.v; L.17.e.l4.i; L‘.17.e.l4.v; L.17.e.l54; L.17.e, 15.v; L.17.e.l8.i; L.17.e.l8.v; L.17.e25.i; L.17.e.25.v; L.17.g.4.i; L.17.g.4.v; L.17.g.6.i; L.17.g.6.v; L.17.g.ll.i; L.17.g.ll.v; L.17.g.l4.x; L.17.g.l4.v; L.17.g.l5.i; L.17.g.l5.v; L.17.g.l8.i; L.17.g.l8.v; L.17.g25.i; L.17.g.25.v; L.17.1.4.X; L.17.1.4.v; L.17.1.6.I; L17.1.6.V; L.17.1.11.X; L.17.1.11.v; L.17.1.14.Í; L.17.I.14.v; L.17.1.15.Í; L.17.1.15.v; L.17.1.18.Í; L.17.1.18.V; L.17.1.25.Í; L.17.1.25.V; L.17.m.4.i; L.17.m.4.v; L.17.m.6.i; L.17.m.6.v; L.17.m.ll.i; L.17.m.ll.v; L.17.m.l4.í; L.17.m.l4.v; L.17.m.l5.i; L.17.m.l5.v; L.17.m.l8.i; L.17.m.l8.v; L.17.xn.25.i; L.17.m.25.v; L.17.O.4.Í; L.17.o.4.v; L.17.o.6.i; L.17.o.6.v; L.17.0.11.Í; L.17.0.11.V; L.17.O.14.Í; L.17.o.l4.v; L.17.o.l5.x; L.17.o.l5.v; L.17.O.18.Í; L.17.O.18.V; L.17.o.25.i; L.17.o.25.v; L.33.a.4.x; L.33.a.4.v; L.33.a.6.i; L.33.a.6.v; L.33.a.ll.i; L.33.a.ll.v; L.33.a.l4.i; L.33.a.l4.v; L.33.a, 15.x; L.33.a.l5.v; L.33.a.l8.i; L.33.a.l8.v; L.33.a.25.i; L.33.a.25, v; L.33.e.4.i; L.33.e.4.v; L.33.e.6.i; L.33.e.6.v; L.33.e.U.i; L.33.e.ll.v; L.33.e.l4.i; L.33.e.l4.v; L.33.e.l5.i; L.33.e.l5.v; L.33.e.18, i; L..33.e.l8.v; L.33.e.25.i; L.33.e.25-v; L.33.g.4.i; L.33.g.4.v; L.33.g.6.i; L.33.g.6.v; L.33.g.ll.x; L.33.g.ll.v; L.33.g.l4.i; L.33.g.l4.v; L.33.g.l5.i; L.33.g.l5.v; L33.g.l8.x; L.33.g.l8.v; L.33.g.25.i; L.33.g.25.v; L.33.1.4.I; L.33.1.4.v; L.33.1.6.I; L.33.1.6.v; L.33.1.11.Í; L.33.1.11.V; L33.1.14.Í; L.33.1.14.v; L.33.1.15.Í; L33.1.15.v; L.33.1.18.Í; L.33.1.18.v; L.33.1.25.Í; L.33.1.25-v; L.33.m.4.i; L.33.m.4.v; L.33.m.6.i; L.33.m.6.v; L.33.m.ll.i; L.33.m.ll.v; L '33.m.l4.i; L.33.m..l4.v; L.33.xn.l5.i; L.33.m.l5.v;
L.33.m.l8.i; L.33.m.l8.v; L.33.m.25.x; L.33.m.25.v; L.33.o.4.i; L.33.o.4.v; L.33.o.6.i; L.33.O.6.V; L.33.o.ll.i; L.33.o.ll.v; L.33.O.14.Í; L.33.o.l4.v; L.33.O.15.Í; L.33.o.l5.v; L.33.0.18.1; L.33.o.l8.v; L.33.o.25.i; L.33.o.25.v; L.49.a.4.i; L.49.a.4.v; L.49.a.6.i; L.49.a.6.v; L.49.a.ll.i; L.49.a.ll.v; L.49.a.l4.i; L.49.a.l4.v; L.49.a.l5.i; L.49.a.l5.v; L.49.a.l8.i; L.49.a.l8.v· L.49.a.25.i; L.49.a.25.v; L.49.e.4.i; L.49.e.4.v; L.49.e.6.i; L49.e.6.v; L.49.e.U.i; L.49.e.ll.v; L.49.e.l4.i; L.49.e.l4.v; L.49.e.l5.i; L.49.e.l5.v; L.49.e.l8.i; L.49.e.l8.v; L.49.e.25.i; L.49.e.25.v; L.49.g.4.i; L.49.g.4.v; L.49.g,6.i; L.49.g.6.v; L.49.g.ll.i; L.49.g.ll.v; L49.g.l4.i; L.49.g.l4.v; L.49.g.l5.i; L.49.g.l5.v; L.49.g.l8.i; L.49.g,18.v; L49.g.25.x; L.49.g25.v; L.49.1.4.Í; L.49.1.4.V; L.49.1.6.Í; L.49.1.6.V; L.49.1.1í.i; L.49.1.11.v; L.49.1.14.Í; L.49.1.14.V; L.49.1.15.Í; L.49.1.15.V; L.49.L18.Í; L.49.1.18.V; L.49.1.25.Í; L.49.1.25.V; L.49.m.4.i; L.49.m.4.v; L.49.m.6.i; L.49.m.6.v; L.49.m.ll.i; L.49.m.ll.v; L.49.in.l4.i; L.49.m.l4.v; L.49.m.l5.i; L49.m-.15.v; L.49.m.l8.i; L.49.m.l8.v; L.49.m.25.i; L.49.m.25.v; L.49.o.4.i; L.49.O.4.V; L.49.o.6.i; L.49.o.6.v; L.49.o.U.i; L.49.o.ll.v; L.49.o.l4.i; L.49.o.l4.v; L.49.0.15.Í; L.49.o.l5.v; L.49.o.l8.i; L.49.O.18.V; L.49.0.25.Í; L.49.o.25.v; B.93.a.4.i; B.93.a.4.v; B.93.a.6.i; B.93.a.6.v; B.93.a.U.i; B.93.a.ll.v; B.93.a.l4.i; B.93.a.l4.v; B.93.a.l5.i; B.93.a.l5.v; B.93.a.l8.i; B,93.a.l8.v; B.93.a.25.i; B.93.a.25.v; B.93.e.4.i; B.93.e.4.v; B.93.e.6.i; B.93.e.6.v; B.93.e.ll.i; B.93.e.ll.v; B.93.e.l4.i; B.93.e.l4.v; B.93.e.l5.i; B.93.e.l5.v; B.93.e.l8.i; B.93.e.l8.v; B.93.e.25.i; B.93.e.25.v; B.93.g.4.i; B.93.g.4.v; B.93.g.6.i; B.93.g.6.v; B.93.g.ll.i; B.93.g.ll.v; B.93.g.l4.i; B.93.g.l4.v; B.93.g.l5.i; B.93.g.l5.v; B.93.g.l8.i; B.93.g.l8.v; B.93.g.25.i; B,93.g.25.v; B.93.1.4.Í; B.93.1.4.V; B.93.1.6.Í; B.93.1.6.V; B.93.1.11.Í; B.93111.V; B.93.1.14.Í; B.93.1.14.v;L.33.m.l8.i; L.33.m.l8.v; L.33.m.25.x; L.33.m.25.v; L.33.o.4.i; L.33.o.4.v; L.33.o.6.i; L.33.O.6.V; L.33.o.ll.i; L.33.o.ll.v; L.33.O.14.Í; L.33.o.l4.v; L.33.O.15.Í; L.33.o.l5.v; L.33.0.18.1; L.33.o.l8.v; L.33.o.25.i; L.33.o.25.v; L.49.a.4.i; L.49.a.4.v; L.49.a.6.i; L.49.a.6.v; L.49.a.ll.i; L.49.a.ll.v; L.49.a.l4.i; L.49.a.l4.v; L.49.a.l5.i; L.49.a.l5.v; L.49.a.l8.i; L.49.a.l8.v; L.49.a.25.i; L.49.a.25.v; L.49.e.4.i; L.49.e.4.v; L.49.e.6.i; L49.e.6.v; L.49.e.U.i; L.49.e.ll.v; L.49.e.l4.i; L.49.e.l4.v; L.49.e.l5.i; L.49.e.l5.v; L.49.e.l8.i; L.49.e.l8.v; L.49.e.25.i; L.49.e.25.v; L.49.g.4.i; L.49.g.4.v; L.49.g, 6.i; L.49.g.6.v; L.49.g.ll.i; L.49.g.ll.v; L49.g.l4.i; L.49.g.l4.v; L.49.g.l5.i; L.49.g.l5.v; L.49.g.l8.i; L.49.g, 18.v; L49.g.25.x; L.49.g25.v; L.49.1.4.I; L.49.1.4.V; L.49.1.6.I; L.49.1.6.V; L.49.1.1í.i; L.49.1.11.v; L.49.1.14.Í; L.49.1.14.V; L.49.1.15.Í; L.49.1.15.V; L.49.L18.Í; L.49.1.18.V; L.49.1.25.Í; L.49.1.25.V; L.49.m.4.i; L.49.m.4.v; L.49.m.6.i; L.49.m.6.v; L.49.m.ll.i; L.49.m.ll.v; L.49.in.l4.i; L.49.m.l4.v; L.49.m.l5.i; L49.m-.15.v; L.49.m.l8.i; L.49.m.l8.v; L.49.m.25.i; L.49.m.25.v; L.49.o.4.i; L.49.O.4.V; L.49.o.6.i; L.49.o.6.v; L.49.o.U.i; L.49.o.ll.v; L.49.o.l4.i; L.49.o.l4.v; L.49.0.15.Í; L.49.o.l5.v; L.49.o.l8.i; L.49.O.18.V; L.49.0.25.Í; L.49.o.25.v; B.93.a.4.i; B.93.a.4.v; B.93.a.6.i; B.93.a.6.v; B.93.a.U.i; B.93.a.ll.v; B.93.a.l4.i; B.93.a.l4.v; B.93.a.l5.i; B.93.a.l5.v; B.93.a.l8.i; B, 93.a.18.v; B.93.a.25.i; B.93.a.25.v; B.93.e.4.i; B.93.e.4.v; B.93.e.6.i; B.93.e.6.v; B.93.e.ll.i; B.93.e.ll.v; B.93.e.l4.i; B.93.e.l4.v; B.93.e.l5.i; B.93.e.l5.v; B.93.e.l8.i; B.93.e.l8.v; B.93.e.25.i; B.93.e.25.v; B.93.g.4.i; B.93.g.4.v; B.93.g.6.i; B.93.g.6.v; B.93.g.ll.i; B.93.g.ll.v; B.93.g.l4.i; B.93.g.l4.v; B.93.g.l5.i; B.93.g.l5.v; B.93.g.l8.i; B.93.g.l8.v; B.93.g.25.i; B, 93.g.25.v; B.93.1.4.I; B.93.1.4.V; B.93.1.6.I; B.93.1.6.V; B.93.1.11.Í; B.93111.V; B.93.1.14.Í; B.93.1.14.v;
-86CZ 297945 B6-86GB 297945 B6
B.93.1.15.Í; B.93.1.I5.V; B.93.1.18.Í; B.93.L18.V; B.93.1.25.Í; B.93.1.25.v; B.93.m.4.i; B.93.m.4.v; B.93.m.6.i; B,93.m.6.v; B.93.m.ll.i; B 93.m.ll.v; B.93.m.l4.i; B.93.m.l4.v; B.93.m.l5.i; B.93.m.l5.v; B.93.m.l8.i; B.93.m.l8.v; B.93.m.25.i; B.93.m.25.v; B.93.o.4.i; B.93.o.4.v; B.93.o.6.i; B.93.o.6.v; B.93.O.11.Í; B.93.o.ll.v; B.93.O.14.Í; Β.93.ο.14.ν; Β.93.Ο.15.Ϊ; B.93.O.15.V; B.93.o,18.i; B.93.o.l8.v; B.93.O.25.Í; B.93.o.25.v; B.94.a.4.i; B.94.a.4.v; B.94.a.6.i; B.94.a.6.v; B.94.a.ll.i; B.94.a.lLv; B.94.a.l4.i; B.94.a.l4.v; B.94.a.l5.i; B.94.a.l5.v; B.94.a.l8.i; B.94.a.l8.v; B.94.a.25.i; B.94.a.25.v; B.94.e.4.i; B.94.e.4.v; B.94.e.6.i; B.94.e.6.v; B.94.e.ll.i; B.94.e.ll.v; B.94.e.l4.i; B.94.e.l4.v; B.94.e.l5.i; B.94.e.l5.v; B.94.e.l8.i; B.94.e.l8.v; B.94.e.25.i; B.94.e.25.v; B.94.g.4.i; B.94.g.4.v; B.94.g.6.i; B.94.g.6.v; B.94.g.ll.i; B.94.g.ll.v; B.94.g.l4.i; B.94.g.l4.v; B.94.g.l5.i; B.94.g.l5.v; B.94.g.l8.i; B.94.g.l8.v; B.94.g.25.i; B.94.g.25.v; B.94.1.4.Í; B.94.1.4.v; B.94.1.6.Í; B.94.1.6.v; B.94.1.1I.Í; B.94.1.11.V; B.94.1.14.Í; B-94.1.14.V; B.94.1.15.X; B.94.1.15.v; B.94.1.18.Í; B.94.1.18.v; B.94.I.25.Í; B.94.L25.V; B.94.m.4.i; B.94.m.4.v; B.94.m.6.i; B.94.m.6.v; B.94.in.ll.i; B.94,m.ll.v; B.94.m.l4-i; B.94.m.l4.v; B.94.m.l5.i; B.94.m;i5.v; B.94.m.l8.i; B.94.m.l8.v; B.94.m.25.i; B.94.m.25 v; B.94.O.4.Í; B. 9 4. o. 4. v; B.94.O.6.Í; B.94.o.6.v; B.94.o.ll.i; B.94.o.ll.v; B.94.O.14.Í; B.94.o.l4.v; B.94.O.15.Í; B.94.o.l5.v; Β.94.ο.18.ί; B.94.o.l8;v; B.94.o.25.i; B,94.o.25.v; E.93.a.4.i; E.93.a.4.v; E.93.a.6.i; E.93.a.6.v; E.93.a.U.i; E.93.a.U.v; E.93.a,14.i; E.93.a.l4.v; E.93.a.l5.i; E.93.a.l5.v; E93.a.l8.i; E.93.a.I8.v; E.93.a.25.i; E.93.a.25.v; E.93.e.4.i; E.93.e.4.v; E.93.e.6.i; E.93.e.6.v; E93.e.ll.i; E.93.e.ll.v; E.93.e.l4.i; E.93.e.l4.v; E.93.e.l5.i; E.93.e.l5.v; E.93.e.l8.i; E93.e.l8.v; E.93.e.25.i; E.93.e.25.v; E.93.g.4.i; E.93.g.4.v; E.93.g.6.i; E.93.g.6.v; E.93.g.ll.i; E.93.g.ll.v; E.93.g.l4.i; E.93.g.l4.v; E93.g,15.i; E.93.g.l5.v; E.93.g.l8.i; E93.g.l8.v; E.93.g.25.í; E.93.g.25.v; E.93.1.4.Í; E.93.1.4.v; E93.1.6.Í; · E.93.L6.V; E.93.1.11.Í; EJ93.1.11.V; Ε.93.1.14.Ϊ; E.93.1.14.V; E.93.1.15.Í; E.93.1.15.V; E.93.1.18.Í; E.93.1.18.v; E.93.1.25.Í; E.93.1.25.v; E.93.m.4.i; E.93.m.4.v; E.93.m.6.i; E.93.m.6.v; E.93.m.ll.i; E.93.irull.v; E.93.m.l4.i; E.93.m.l4.V; E.93.m.l5.i; E.93.m.l5.v; E.93.m.l8.i; É,93.m.l8.v; E.93.m.25.i; E93.m.25.v; E.93.O.4.Í; E.93.O.4.V; E.93.O.6.Í; E.93.o.6.v; E.93.O.11.Í; E.93.o.U.v; E.93.o.l4.i; E.93.o.l4.v; E.93.O.15.Í; Ε.93.ο.15.ν; Ε.93.Ο.18.Ϊ; E.93.o.l8.v; E.93.O.25.Í; E.93.o.25.v; E.94.a.4.i; E.94.a.4.v; E.94.a.6.i; E.94.a.6.v; E.94.a.ll.i; E.94.a.ll.v; E.94.a.l4.í; E.94.a.l4.v; E.94.a.l5.i; E.94.a.l5.v; E.94.a.l8.i; E.94.a.l8.v; E.94.a.25.i; E.94.a.25.v; E.94.e.4.i; E.94.e.4.v; E.94.e.6.i; E.94.e.6.v; E.94.e.ll.í; E94.e.ll.v; E.94.e.l4.i; E.94.e.l4.v; E.94.e,15.i; E94.e.l5.v; E.94.e.l8.i; E.94.e.l8.v; E.94.e.25.i; E.94.e.25.v; E.94.g.4.i; E.94.g.4.v; E.94.g.6.i; E.94.g.6.v; E.94.g.ll.i; E.94.g.ll.v; E.94.g.l4.i; E.94.g.l4.v; E.94.g.l5.i; E.94.g,15.v; E.94.g.l8.i; E94.g.l8.v; E.94.g.25.i; E.94.g.25.v; E.94.1.4.Í; E.9414.V; E.94.1.6.Í; E.94.I.6.V; E.94.1.11.Í; E.94.1.11.v; E.94.1.14.Í; E94.1.14.V; E.94.1.I5.Í; E.94.1.15.v; E.94.1.18.Í; E.94.1.18.v; E.94.1.25.Í; E.94.1.25.V; E.94.m.4.i; E.94.m.4.v; E.94.m.6.i; E.94.m.6.v; E.94.m.ll.i; E.94.m.ll.v; E.94.m.l4.i; E.94.m.l4.v; E.94.m.l5.i; E.94.m.l5.v; E.94.m.l8.i; E.94.m.l8.v; E.94.m.25.i; E.94.m.25.v; E.94.G.4.Í; E.94.o.4.v; E.94,o.6.i; E.94.o.6.v; E.94.o.ll.i; E.94.o.ll.v; E.94.o,14,i; E.94.o.l4.v; E.94.O.15.Í; E.94.o.l5.v; E.94.O.18.Í; E.94.o.l8.v; E.94.o.25.i; E.94.O.25.V; I-93.a.4.i; I.93.a.4.v; I.93.a.6.i; I.93.a.6.v;,I.93.a.ll.i; I.93.a.ll.v;B.93.1.15.Í; B.93.1.I5.V; B.93.1.18.Í; B.93.L18.V; B.93.1.25.Í; B.93.1.25.v; B.93.m.4.i; B.93.m.4.v; B.93.m.6.i; B, 93.m.6.v; B.93.m.ll.i; B 93.m.ll.v; B.93.m.l4.i; B.93.m.l4.v; B.93.m.l5.i; B.93.m.l5.v; B.93.m.l8.i; B.93.m.l8.v; B.93.m.25.i; B.93.m.25.v; B.93.o.4.i; B.93.o.4.v; B.93.o.6.i; B.93.o.6.v; B.93.O.11.Í; B.93.o.ll.v; B.93.O.14.Í; Β.93.ο.14.ν; Β.93.Ο.15.Ϊ; B.93.O.15.V; B.93.o, 18.i; B.93.o.l8.v; B.93.O.25.Í; B.93.o.25.v; B.94.a.4.i; B.94.a.4.v; B.94.a.6.i; B.94.a.6.v; B.94.a.ll.i; B.94.a.lLv; B.94.a.l4.i; B.94.a.l4.v; B.94.a.l5.i; B.94.a.l5.v; B.94.a.l8.i; B.94.a.l8.v; B.94.a.25.i; B.94.a.25.v; B.94.e.4.i; B.94.e.4.v; B.94.e.6.i; B.94.e.6.v; B.94.e.ll.i; B.94.e.ll.v; B.94.e.l4.i; B.94.e.l4.v; B.94.e.l5.i; B.94.e.l5.v; B.94.e.l8.i; B.94.e.l8.v; B.94.e.25.i; B.94.e.25.v; B.94.g.4.i; B.94.g.4.v; B.94.g.6.i; B.94.g.6.v; B.94.g.ll.i; B.94.g.ll.v; B.94.g.l4.i; B.94.g.l4.v; B.94.g.l5.i; B.94.g.l5.v; B.94.g.l8.i; B.94.g.l8.v; B.94.g.25.i; B.94.g.25.v; B.94.1.4.I; B.94.1.4.v; B.94.1.6.I; B.94.1.6.v; B.94.1.1I.I; B.94.1.11.V; B.94.1.14.Í; B-94.1.14.V; B.94.1.15.X; B.94.1.15.v; B.94.1.18.Í; B.94.1.18.v; B.94.I.25.Í; B.94.L25.V; B.94.m.4.i; B.94.m.4.v; B.94.m.6.i; B.94.m.6.v; B.94.in.ll.i; B.94, m.ll.v; B.94.m.14-i; B.94.m.l4.v; B.94.m.l5.i; B.94.m; i5.v; B.94.m.l8.i; B.94.m.l8.v; B.94.m.25.i; B.94.m.25 v; B.94.O.4.Í; B. 9 4. o. 4. v; B.94.O.6.Í; B.94.o.6.v; B.94.o.ll.i; B.94.o.ll.v; B.94.O.14.Í; B.94.o.l4.v; B.94.O.15.Í; B.94.o.l5.v; Β.94.ο.18.ί; B.94.o.18; v; B.94.o.25.i; B, 94.o.25.v; E.93.a.4.i; E.93.a.4.v; E.93.a.6.i; E.93.a.6.v; E.93.a.U.i; E.93.a.U.v; E.93.a, 14.i; E.93.a.l4.v; E.93.a.l5.i; E.93.a.l5.v; E93.a.l8.i; E.93.a.I8.v; E.93.a.25.i; E.93.a.25.v; E.93.e.4.i; E.93.e.4.v; E.93.e.6.i; E.93.e.6.v; E93.e.ll.i; E.93.e.ll.v; E.93.e.l4.i; E.93.e.l4.v; E.93.e.l5.i; E.93.e.l5.v; E.93.e.l8.i; E93.e.l8.v; E.93.e.25.i; E.93.e.25.v; E.93.g.4.i; E.93.g.4.v; E.93.g.6.i; E.93.g.6.v; E.93.g.ll.i; E.93.g.ll.v; E.93.g.l4.i; E.93.g.l4.v; E93.g, 15.i; E.93.g.l5.v; E.93.g.l8.i; E93.g.l8.v; E.93.g.25.í; E.93.g.25.v; E.93.1.4.I; E.93.1.4.v; E93.1.6.I; · E.93.L6.V; E.93.1.11.Í; EJ93.1.11.V; Ε.93.1.14.Ϊ; E.93.1.14.V; E.93.1.15.Í; E.93.1.15.V; E.93.1.18.Í; E.93.1.18.v; E.93.1.25.Í; E.93.1.25.v; E.93.m.4.i; E.93.m.4.v; E.93.m.6.i; E.93.m.6.v; E.93.m.ll.i; E.93.irull.v; E.93.m.l4.i; E.93.m.l4.V; E.93.m.l5.i; E.93.m.l5.v; E.93.m.l8.i; E, 93.m.l8.v; E.93.m.25.i; E93.m.25.v; E.93.O.4.I; E.93.O.4.V; E.93.O.6.I; E.93.o.6.v; E.93.O.11.Í; E.93.o.U.v; E.93.o.l4.i; E.93.o.l4.v; E.93.O.15.Í; Ε.93.ο.15.ν; Ε.93.Ο.18.Ϊ; E.93.o.l8.v; E.93.O.25.Í; E.93.o.25.v; E.94.a.4.i; E.94.a.4.v; E.94.a.6.i; E.94.a.6.v; E.94.a.ll.i; E.94.a.ll.v; E.94.a.l4.í; E.94.a.l4.v; E.94.a.l5.i; E.94.a.l5.v; E.94.a.l8.i; E.94.a.l8.v; E.94.a.25.i; E.94.a.25.v; E.94.e.4.i; E.94.e.4.v; E.94.e.6.i; E.94.e.6.v; E.94.e.ll.í; E94.e.ll.v; E.94.e.l4.i; E.94.e.l4.v; E.94.e, 15.i; E94.e.l5.v; E.94.e.l8.i; E.94.e.l8.v; E.94.e.25.i; E.94.e.25.v; E.94.g.4.i; E.94.g.4.v; E.94.g.6.i; E.94.g.6.v; E.94.g.ll.i; E.94.g.ll.v; E.94.g.l4.i; E.94.g.l4.v; E.94.g.l5.i; E.94.g, 15.v; E.94.g.l8.i; E94.g.l8.v; E.94.g.25.i; E.94.g.25.v; E.94.1.4.I; E.9414.V; E.94.1.6.I; E.94.I.6.V; E.94.1.11.Í; E.94.1.11.v; E.94.1.14.Í; E94.1.14.V; E.94.1.I5.Í; E.94.1.15.v; E.94.1.18.Í; E.94.1.18.v; E.94.1.25.Í; E.94.1.25.V; E.94.m.4.i; E.94.m.4.v; E.94.m.6.i; E.94.m.6.v; E.94.m.ll.i; E.94.m.ll.v; E.94.m.l4.i; E.94.m.l4.v; E.94.m.l5.i; E.94.m.l5.v; E.94.m.l8.i; E.94.m.l8.v; E.94.m.25.i; E.94.m.25.v; E.94.G.4.Í; E.94.o.4.v; E.94, o.6.i; E.94.o.6.v; E.94.o.ll.i; E.94.o.ll.v; E.94.o, 14, i; E.94.o.l4.v; E.94.O.15.Í; E.94.o.l5.v; E.94.O.18.Í; E.94.o.l8.v; E.94.o.25.i; E.94.O.25.V; I-93.a.4.i; I.93.a.4.v; I.93.a.6.i; I.93.a.6.v; I.93.a.ll.i; I.93.a.ll.v;
1.93. a.l4.i; L93.a.l4.v; I.93.a.l5,i; 1.93.a.l5.v; I.93.a.l8.i; I.93.a.l8.v; I.93.a.25.i;1.93. a.l4.i; L93.a.l4.v; I.93.a.15, i; 1.93.a.l5.v; I.93.a.l8.i; I.93.a.l8.v; I.93.a.25.i;
1.93. a,25.v; I.93.e.4.i; I.93.e.4.v; I.93.e.6.i; I.93.e.6.v; L93.e.ll.i; I.93.e.ll.v;1.93. a, 25.v; I.93.e.4.i; I.93.e.4.v; I.93.e.6.i; I.93.e.6.v; L93.e.ll.i; I.93.e.ll.v;
1.93. e.l4.i; Ι.93^.14.ν; I.93.e.l5.i; I.93.e.l5.v; I.93.e.l8.i; I.93.e,18.v; I.93.e.25.i;1.93. e.l4.i; Ι.93 ^ .14.ν; I.93.e.l5.i; I.93.e.l5.v; I.93.e.l8.i; I.93.e, 18.v; I.93.e.25.i;
1.93. e.25.v; I.93.g.4.i; I.93.g.4.v; I.93.g.6.i; I.93.g.6.v; I.93.g.ll.i; I.93.g.ll.v;1.93. e.25.v; I.93.g.4.i; I.93.g.4.v; I.93.g.6.i; I.93.g.6.v; I.93.g.ll.i; I.93.g.ll.v;
-87CZ 297945 B6-87GB 297945 B6
1.93. g.l4.i; I.93.g.l4.v; I.93.g.l5.i; I.93.g.l5.v; I.93.g.l8.i; I.93.g.l8.v; I.93.g.2511.93. g.l4.i; I.93.g.l4.v; I.93.g.l5.i; I.93.g.l5.v; I.93.g.l8.i; I.93.g.l8.v; I.93.g.251
1.93. ^25. v; 193.1.4.1; I.93.1.4.V; 1.93161 I.93.1.6.v; 1.93.1.11,1; 1.93111.v; 193.114.x;1.93. ^ 25. in; 193.1.4.1; I.93.1.4.V; 1.93161 I.93.1.6.v; 1.93.1.11,1; 1.93111.v; 193.114.x;
1.93.1.14. v; 193.1.151 I.93.1.15.v; 1.93.1.184; I.93.1.18.v; 193.1.25.1; I.93.125.V; 193.m.4.i; I.93.m.4.v; L93.m.6.i; I.93.m.6.v; I.93.xn.ll.i; 1.93-m.ll.v; I.93.m.l4.i; 193.m.l4.v; I.93.m.l5.i; 193.m.l5.v; I.93.m.l8.i; I.93.m.l8.v; I.93.m.25.i;1.93.1.14. in; 193.1.151 I.93.1.15.v; 1.93.1.184; I.93.1.18.v; 193.1.25.1; I.93.125.V; 193.m.4.i; I.93.m.4.v; L93.m.6.i; I.93.m.6.v; I.93.xn.ll.i; 1.93-m.vll; I.93.m.l4.i; 193.m.l4.v; I.93.m.l5.i; 193.m.l5.v; I.93.m.l8.i; I.93.m.l8.v; I.93.m.25.i;
1.93. m25.v; 1.93.0.41I.93.o.4.v; 1.93.0.611.93.0.6. v; 193.0.111193.o.ll.v; 1.93.0.1411.93.0.14,v; 193.0.1511.93.o.l5.v; 193.0.1811.93.0.18.v; I.93.o25.i; I.93.o.25.v; I.94.a.4.i; I94.a.4.v; I.94.a.6.i; I.94.a.6.v; I.94.a.ll.i; I.94.a.ll.v;1.93. m25.v; 1.93.0.41I.93.o.4.v; 1.93.0.611.93.0.6. in; 193.0.111193.o.ll.v; 1.93.0.1411.93.0.14, v; 193.0.1511.93.o.l5.v; 193.0.1811.93.0.18.v; I.93.o25.i; I.93.o.25.v; I.94.a.4.i; I94.a.4.v; I.94.a.6.i; I.94.a.6.v; I.94.a.ll.i; I.94.a.ll.v;
1.94. a.l4.i; 194.a.l4.v; I.94.a.l5.i; I.94.a.l5.v; I.94.a.l8.i; I.94.a.l8.v; I.94.a25.i;1.94. a.l4.i; 194.a.l4.v; I.94.a.l5.i; I.94.a.l5.v; I.94.a.l8.i; I.94.a.l8.v; I.94.a25.i;
1.94. a,25.v; 194.e.41 I.94.e.4.v; I.94.e.6.i;1.94.e.6.v; I.94.e.ll.i; I.94.e.ll.v;1.94. a, 25.v; 194.e.41 I.94.e.4.v; I.94.e.6.i; 1.94.e.6.v; I.94.e.ll.i; I.94.e.ll.v;
1.94. e.l4.i; I.94.e.l4.v; I.94.e.l5.i; I,94.e.l5.v; 194.e.l8.i; I.94.e.l8.v;194.e.25.i;1.94. e.l4.i; I.94.e.l4.v; I.94.e.l5.i; I, 94.e.15.v; 194.e.l8.i; I.94.e.l8.v; 194.e.25.i;
1.94. e.25.v; I.94.g.4.i; I.94.g.4.v; I.94.g.6.i; I.94.g.6.v; I.94.g.ll.i; I.94.g.ll.v;1.94. e.25.v; I.94.g.4.i; I.94.g.4.v; I.94.g.6.i; I.94.g.6.v; I.94.g.ll.i; I.94.g.ll.v;
1.94. g.l4.i; I.94.g.l4.v; I.94.g.l5.i; I.94.g.l5.v; I.94.g.l8.i; I.94.g.l8.v; 194.g.25.i;1.94. g.l4.i; I.94.g.l4.v; I.94.g.l5.i; I.94.g.l5.v; I.94.g.l8.i; I.94.g.l8.v; 194.g.25.i;
1.94. g.25.v; 1.94141I.94.1.4.v; 1.94161194.1.6-V; 1.94.1.1111.94111.V; 1.94.1.1411.94. g.25.v; 1.94141I.94.1.4.v; 1.94161194.1.6-V; 1.94.1.1111.94111.V; 1.94.1.141
194.1.14. v; 1.9411511.94.1.15. v; 194.1.1811.94.1.18. v; 194.1.2511.94.1.25.v;194.1.14. in; 1.9411511.94.1.15. in; 194.1.1811.94.1.18. in; 194.1.2511.94.1.25.v;
1.94. m.41194.m.4.v; I.94.m.61I.94.m.6.v; 194jn.ll.i; I.94.m.ll.v; I.94.m.l4.i;1.94. m.41194.m.4.v; I.94.m.61I.94.m.6.v; 194jn.ll.i; I.94.m.ll.v; I.94.m.l4.i;
1.94. m.l4.v; I.94.m.l5.i; I.94.m.l5.v; I.94.m.l8.i; I.94.m.l8.v; I.94.m.25.i;1.94. m.l4.v; I.94.m.l5.i; I.94.m.l5.v; I.94.m.l8.i; I.94.m.l8.v; I.94.m.25.i;
1.94. m.25.v; 194.0.41I.94.o.4.v; 1.94.0.61I.94.o.6.v; 1.94.0.111I.94.o.U.v; 1.94.0.1411.94.0.14.v; 1.94.0.151 1.94.0.15. v; 1.94.0.1811.94.0.18.v; I.94.o.25.i; I.94.o.25.v; L93.a.4.i; L.93.a.4.v; L.93.a.61 L.93.a.6.v; L.93,a.ll.i; L.93.a.ll.v; L.93.a.l41 L.93.a.l4.v; L.93.a.l5.x; L.93.a.l5.v; L.93.a.l8.i; L.93.a.l8.v; L.93.a.25.i; L.93.a.25.v; L93.e.4.i; L.93.e.4.v; L.93.e.6.i; L.93.e.6.v; L.93.e.lll L93.e.ll.v; L.93.e.l4.i; L93.e.l4.v; L.93.e.l51 L.93.e.l5.v; L.93.e.l8.i; L.93.e.l8.v; L.93.e.251 L.93.e.25.v; L.93.g.41 L.93.g.4.v; L.93.g.6.i; 1.93.g.6.v; L.93.g.lll L.93.g.ll.v; L,93.g.l41 L.93.g.l4.v; L.93.g.l5.i; L.93.g.l5.v; L.93.g.l8.i; L.93.g.l8.v; L.93.g.25.i; L.93.g.25.v; L.93.1.41 L.93.1.4.V; 1.93.1.61 L93.1.6.V; L.93.1.1U 1.93.1.11.V; L93J.14.-x; L.93.1.14.v; L.93.1.15.Í; 1.93.1.15. v; L93J.18J; L.93.1.18.V; L.93.1.251 L.93.1.25.V; L.93.m.4.i; L.93.m.4.v; L.93.m.6.i; L.93.m.6.v; L93.m.lll L.93.m.ll.v; 1.93.m.l4.i; L.93.m.l4.v; L.93.m.l5.i; L.93.m.l'5.v; L.93.m.l8.i; L.93.m.l8.v; L.93.m.251 L.93.m.25.v; L.93.0.41 L.93.o.4.v; L.93.O.61 L.93.o.6.v; L.93.O.11.Í; L.93.o.ll.v; L.93.0.141 L.93.O.14.V; L.93.0.151-L93.o.l5.v; L.93.0.181 L.93.O.18.V; L.93.O.251 L.93.o.25.v; L.94.a.4.i; L.94.a.4.v; L94.a.6.i; L.94.a.6.v; L.94.a.ll.i; L.94.a.ll.v; L.94.a.l4.i; L.94.a.l4.v; L.94.a.l5.i; L.94.a.l5.v; L.94.a.l8.i; L.94.a.l8.v; L.94.a.251 L94.a.25.v; L.94.e.4.i; L.94.e.4.v; L.94.e.61 L.94.e.6.v; L.94.e.ll.i; L.94.e.lLv; L.94.e.l41 L.94.e.l4.v; L.94.e.l5.i; L.94.e.I5.v; L94.e.l81 L.94.e.l8.v; L.94.e.251 L.94.e.25.v; L94.g.4.i; L.94.g.4.v; L.94.g.6.i; L.94.g.6.v; L.94.g.ll.i; L94.g.ll.v; L.94.g.l4.i; L94.g,14.v; L.94.g.l5.i; L.94.g.l5.v; L.94.g.l8.i; L.94,g.l8.v; L.94.g.251 L.94.g.25.v; L.94.1.4.Í; L.94.1.4.v; 1.94.1.61 L.94.1.6.v; L.94.1.111 L94.1.11.V; L94.1.141 L94.1.14.V; L.94.1.151 L.94.1.15.V; L.94.1.181 L.94.1.18.v; L.94,1.251 L.94.1.25.v; L94.rn.41 L.94.m.4.v; L94.rn.61 L94.m.6.v; L94.xn.lll L.94.m.ll.v; L.94,m.l41 L.94.m.l4.v; L.94.m.l51 L.94.m.l5.v; L.94.m.l81 L.94.m.l8.v; L94.m.251 L94.m.25.v; L.94.o.4.i; L.94.o.4.v; L.94.0.61 L94.o.6.v; L.94.O.111 L.94.o.ll.v; L.94.O.141 L94.O..14.V; L.94.0.151 L94.O.15.V; L.94.O.181 L.94.O.18.V; 1.94.0.251 L.94.o,25.v; O.93.á.4.i; O.93.a.4.v; O.93.a.6.i; O.93.a.6.v; O.93.a.lll O.93.a.ll.v; Ó.93.a.l4.i; O.93.a,14.v; O.93.a.l5.i; O.93.a.l5.v; O.93.a.l8.i; 0.93 a-18.v; O.93.a.251 O.93.a.25.v; O.93.e.41O.93.e.4.v; O.93.e.61 O.93.e.6.v; O.93,e.lll O.93.e.ll.v; O.93.e.l4i O.93.e.l4.v; O.93.e.l511.94. m.25.v; 194.0.41I.94.o.4.v; 1.94.0.61I.94.o.6.v; 1.94.0.111I.94.o.U.v; 1.94.0.1411.94.0.14.v; 1.94.0.151 1.94.0.15. in; 1.94.0.1811.94.0.18.v; I.94.o.25.i; I.94.o.25.v; L93.a.4.i; L.93.a.4.v; L.93.a.61 L.93.a.6.v; L.93, a.ll.i; L.93.a.ll.v; L.93.a.l41 L.93.a.l4.v; L.93.a.l5.x; L.93.a.l5.v; L.93.a.l8.i; L.93.a.l8.v; L.93.a.25.i; L.93.a.25.v; L93.e.4.i; L.93.e.4.v; L.93.e.6.i; L.93.e.6.v; L.93.e.lll L93.e.ll.v; L.93.e.l4.i; L93.e.l4.v; L.93.e.l51 L.93.e.l5.v; L.93.e.l8.i; L.93.e.l8.v; L.93.e.251 L.93.e.25.v; L.93.g.41 L.93.g.4.v; L.93.g.6.i; 1.93.g.6.v; L.93.g.lll L.93.g.ll.v; L, 93.g.l41 L.93.g.l4.v; L.93.g.l5.i; L.93.g.l5.v; L.93.g.l8.i; L.93.g.l8.v; L.93.g.25.i; L.93.g.25.v; L.93.1.41 L.93.1.4.V; 1.93.1.61 L93.1.6.V; L.93.1.1U 1.93.1.11.V; L93J.14-x; L.93.1.14.v; L.93.1.15.Í; 1.93.1.15. in; L93J.18J; L.93.1.18.V; L.93.1.251 L.93.1.25.V; L.93.m.4.i; L.93.m.4.v; L.93.m.6.i; L.93.m.6.v; L93.m.lll L.93.m.ll.v; 1.93.m.l4.i; L.93.m.l4.v; L.93.m.l5.i; L.93.m.l'5.v; L.93.m.l8.i; L.93.m.l8.v; L.93.m.251 L.93.m.25.v; L.93.0.41 L.93.o.4.v; L.93.O.61 L.93.o.6.v; L.93.O.11.Í; L.93.o.ll.v; L.93.0.141 L.93.O.14.V; L.93.0.151-L93.o.15.v; L.93.0.181 L.93.O.18.V; L.93.O.251 L.93.o.25.v; L.94.a.4.i; L.94.a.4.v; L94.a.6.i; L.94.a.6.v; L.94.a.ll.i; L.94.a.ll.v; L.94.a.l4.i; L.94.a.l4.v; L.94.a.l5.i; L.94.a.l5.v; L.94.a.l8.i; L.94.a.l8.v; L.94.a.251 L94.a.25.v; L.94.e.4.i; L.94.e.4.v; L.94.e.61 L.94.e.6.v; L.94.e.ll.i; L.94.e.lLv; L.94.e.l41 L.94.e.l4.v; L.94.e.l5.i; L.94.e.I5.v; L94.e.l81 L.94.e.l8.v; L.94.e.251 L.94.e.25.v; L94.g.4.i; L.94.g.4.v; L.94.g.6.i; L.94.g.6.v; L.94.g.ll.i; L94.g.ll.v; L.94.g.l4.i; L94.g, 14.v; L.94.g.l5.i; L.94.g.l5.v; L.94.g.l8.i; L.94, g.188v; L.94.g.251 L.94.g.25.v; L.94.1.4.I; L.94.1.4.v; 1.94.1.61 L.94.1.6.v; L.94.1.111 L94.1.11.V; L94.1.141 L94.1.14.V; L.94.1.151 L.94.1.15.V; L.94.1.181 L.94.1.18.v; L.94,1.251 L.94.1.25.v; L94.rn.41 L.94.m.4.v; L94.rn.61 L94.m.6.v; L94.xn.lll L.94.m.ll.v; L.94, m.l41 L.94.m.l4.v; L.94.m.l51 L.94.m.l5.v; L.94.m.l81 L.94.m.l8.v; L94.m.251 L94.m.25.v; L.94.o.4.i; L.94.o.4.v; L.94.0.61 L94.o.6.v; L.94.O.111 L.94.o.ll.v; L.94.O.141 L94.O..14.V; L.94.0.151 L94.O.15.V; L.94.O.181 L.94.O.18.V; 1.94.0.251 L.94.o, 25.v; O.93.á.4.i; O.93.a.4.v; O.93.a.6.i; O.93.a.6.v; O.93.a.lll O.93.a.ll.v; Ó.93.a.l4.i; O.93.a, 14.v; O.93.a.l5.i; O.93.a.l5.v; O.93.a.l8.i; 0.93 a-18.v; O.93.a.251 O.93.a.25.v; O.93.e.41O.93.e.4.v; O.93.e.61 O.93.e.6.v; O.93, e.lll O.93.e.ll.v; O.93.e.l4i O.93.e.l4.v; O.93.e.l51
-88CZ 297945 B6-88GB 297945 B6
O.93.e.l5.v; O.93.e.l8.i; O.93.e.I8.v; O.93.e.25.i; O.93.e.25.v; O.93.g.4.i; O.93.g.4.v; O.93.g.6.i; O.93.g.6.v; O.93.g.U.i;O.93.g.ll.v; O.93.g.l4.i; O.93.g.l4.v; O.93.g.l5.i; 0.93. g. 15. v; O.93.g.l8.i; O.93.g.l8.v; O.93.g.25.i; O.93.g.25.v; 0.93.1.4.1; O.93.1.4.V; 0,93.1.64; O.93.1.6.v; 0.93.1.1 l.i; 0.93.1.11.v; 0.93.1.14.1; O.93.1.14.v; 0.93.1.154; O.93.1.15.v; 0.93.1.18.1; O.93.1.18.v; 0.93.1.254; O.93.1.25.v; O.93.m.4.i; O.93.m.4.v; O.93.m.6.i; O.93.m.6.v; O.93.m.ll.i; O.93.m.ll.v; O.93.m.l4.i; O.93.m.l4.v; O.93.m.l5.i; O.93.m.l5.v; O.93.m.l8.i; O.93.m.l8.v; O.93.m.25.i; 0.93.m.25.v; O.93.O.4.Í; O.93.o.4.v; O.93.O.6.Í; O.93.o.6.v; 0.93.0.11.1; O.93.o.ll.v; 0.93.0.144; O.93.o.l4.v; 0.93.0.154; O.93.o.l5.v; 0.93.0.184; O.93.o.l8.v; O.93.o.25.i; O.93.o.25.v; O.94.a.4.i; O.94.a.4.v; O.94.a.6.i; O.94.a.6.v; O.94.a.ll.i; O.94.a.ll.v; O.94.a,14.i; O.94.a.l4.v; O.94.a.l5.x; O.94.a,15.v; O.94.a.l8.i; O.94.a.l8.v; O.94.a.25.i; O.94.a.25.v; O.94.e.4.i; O.94.e.4.v; O.94.e.6.i; O.94.e.6.v; O.94.e.ll.i; O.94.e.ll.v; O.94.e.l4.i; O.94.e.l4.v; O.94.e.l5.i; O.94.e.l5.v; O.94.e.l84; O.94.e.l8.v; O.94.e.25.i; O.94.e.25.v; O.94.g.4.i; O.94.g.4.v; O.94.g.6.i; O.94.g.6.v; O.94.g.ll.i; O.94.g.ll.v; O.94.g.l44; O.94.g.l4.v; O.94.g.l5.i; O.94.g.l5.v; O.94.g.l8.i; O.94.g.l8.v; O.94.g.25.i; O.94.g.25.v; O.94.1.4.Í; O.9414.V; 0.94.1.64; 0.94.1.6.V; 0.94.1.114; O,94.1.11.v; 0.94.1.14.1; O.94.1.14.V; 0.94.1.154; O.94.1.15.V; 0.94.1.18.1; 0.94.1.18.v; 0.94.1.254; O.94.1.25.V; O,94.m.4.i; O.94.m.4.v; O.94.m.6.i; O.94.m.6.v; O.94.m.ll.i; O.94.m.ll.v; O.94.m.l4.i; O.94.m.l4.v; O.94.m.l5.i; O.94.m.l5.v; O.94.ňa.l8.1; O.94.m.l8.v; O.94.m.25.i; O.94.m.25.v; 0.94.0.4.1; O.94.o.4.v; O.94.O.6.Í; O.94.o.6.v; 0.94.0,114; O.94.o.ll.v; O.94.0.14.Í; O.94.o.l4.v;O.93.e.l5.v; O.93.e.l8.i; O.93.e.I8.v; O.93.e.25.i; O.93.e.25.v; O.93.g.4.i; O.93.g.4.v; O.93.g.6.i; O.93.g.6.v; O.93.g.U.i; O.93.g.ll.v; O.93.g.l4.i; O.93.g.l4.v; O.93.g.l5.i; 0.93. g. O.93.g.l8.i; O.93.g.l8.v; O.93.g.25.i; O.93.g.25.v; 0.93.1.4.1; O.93.1.4.V; 0,93.1.64; O.93.1.6.v; 0.93.1.1 l.i; 0.93.1.11.v; 0.93.1.14.1; O.93.1.14.v; 0.93.1.154; O.93.1.15.v; 0.93.1.18.1; O.93.1.18.v; 0.93.1.254; O.93.1.25.v; O.93.m.4.i; O.93.m.4.v; O.93.m.6.i; O.93.m.6.v; O.93.m.ll.i; O.93.m.ll.v; O.93.m.l4.i; O.93.m.l4.v; O.93.m.l5.i; O.93.m.l5.v; O.93.m.l8.i; O.93.m.l8.v; O.93.m.25.i; 0.93.m.25.v; O.93.O.4.Í; O.93.o.4.v; O.93.O.6.Í; O.93.o.6.v; 0.93.0.11.1; O.93.o.ll.v; 0.93.0.144; O.93.o.l4.v; 0.93.0.154; O.93.o.l5.v; 0.93.0.184; O.93.o.l8.v; O.93.o.25.i; O.93.o.25.v; O.94.a.4.i; O.94.a.4.v; O.94.a.6.i; O.94.a.6.v; O.94.a.ll.i; O.94.a.ll.v; O.94.a, 14.i; O.94.a.l4.v; O.94.a.l5.x; O.94.a, 15.v; O.94.a.l8.i; O.94.a.l8.v; O.94.a.25.i; O.94.a.25.v; O.94.e.4.i; O.94.e.4.v; O.94.e.6.i; O.94.e.6.v; O.94.e.ll.i; O.94.e.ll.v; O.94.e.l4.i; O.94.e.l4.v; O.94.e.l5.i; O.94.e.l5.v; O.94.e.l84; O.94.e.l8.v; O.94.e.25.i; O.94.e.25.v; O.94.g.4.i; O.94.g.4.v; O.94.g.6.i; O.94.g.6.v; O.94.g.ll.i; O.94.g.ll.v; O.94.g.l44; O.94.g.l4.v; O.94.g.l5.i; O.94.g.l5.v; O.94.g.l8.i; O.94.g.l8.v; O.94.g.25.i; O.94.g.25.v; O.94.1.4.Í; O.9414.V; 0.94.1.64; 0.94.1.6.V; 0.94.1.114; O, 94.1.11.v; 0.94.1.14.1; O.94.1.14.V; 0.94.1.154; O.94.1.15.V; 0.94.1.18.1; 0.94.1.18.v; 0.94.1.254; O.94.1.25.V; O, 94.m.4.i; O.94.m.4.v; O.94.m.6.i; O.94.m.6.v; O.94.m.ll.i; O.94.m.ll.v; O.94.m.l4.i; O.94.m.l4.v; O.94.m.l5.i; O.94.m.l5.v; O.94.ňa.l8.1; O.94.m.l8.v; O.94.m.25.i; O.94.m.25.v; 0.94.0.4.1; O.94.o.4.v; O.94.O.6.Í; O.94.o.6.v; 0.94.0,114; O.94.o.ll.v; O.94.0.14.Í; O.94.o.l4.v;
O. 94.0.154; O.94.o.l5.v; O.94.O.18.Í; O.94.o.l8.v; 0.94.0.254; O.94.o.25.v;O. 94.0.154; O.94.o.l5.v; O.94.O.18.Í; O.94.o.l8.v; 0.94.0.254; O.94.o.25.v;
P. 93.a.4.i; P.93.a.4.v; P.93.a.6.i; P.93.a.6.v; P.93.a.U.i; P.93.a.ll.v; P.93.a.l4.i; P.93.a,14.v; P.93.a.I54; P.93.a.l5.v; P.93.a.l8.i; P.93.a.l8.v; P.93.a.25.i; P.93.a.25.v; P.93.e.4.i; P.93.e.4.v; P.93.e.6.i; P.93.e.6.v; P.93.e.ll.i; P.93.e.ll.v; P.93.e.l44; P.93.e.l4.v; P.93.e.l5.1; P.93.e.l5.v; P.93.e.l8.i; P.93.e.l8.v; P.93.e.25.i; P.93.e.25.v; P.93.g.4.i; P.93.g.4.v; P.93.g.6.i; P.93.g.6.v; P.93.g.ll.i; P.93.g.ll.v; P.93.g.l44; P.93.g.l4.v; P.93.g.l5.i; P.93.g.l5.v; P.93.g.l8.i; P.93.g.l8.v; P.93.g.25.í; P.93.g.25.v; P.93.1.44; P.93.1.4.v; P.93.1.64; P.93.1.6.v; P.93.1.114; P.93.1.11.V; p-.93.L144; P.93.1.14.v; P.93.1.154; P.93.1.15.v; P.93.L184; P.93.L18.V; P.93.1.254; P.93.1.25.V; P.93.m.4.i; P.93.m.4.v; P.93.m.64; P.93.m.6.v; P.93.m.ll.i; P.93.m.U.v; P.93.m,14.í; P.93.m.l4.v; P.93.m.l5.i; P.93.m.,15.v; P.93.m.l8.i; P.93.m.l8.v; P.93.m.25.i; P.93.m.25.v; P.93.O.44; P.93.o.4.v; P.93.0.64; P.93.o.6.v; P.93.0.114; P.93.o.ll.v; P.93.o.l4.i; Ρ.93.ο.14.ν; P.93.O.15.1; Ρ.93.ο.15.ν; P.93.O.184; P.93.o.l8.v; P.93.O.25.Í; P.93.o.25.v; P.94.a.4.i; P.94.a.4.v; P.94.a.6.i; P.94.a.6.v; P.94.a.U.i; P.94.a.ll.v; P.94.a.l44; P.94.a.l4.v; P.94.a.l54; P.94.a.l5.v; P.94.a.l8.i; P.94.a.l8.v; P.94.a.25.i; P.94.a.25.v; P.94.e.4.i; P.94.e.4.v; P.94.e.6.i; P.94.e.6.v; P.94.e.ll.i; P.94.e.ll.v; P.94.e.l4.i; P.94.e.l4.v; P.94.e.l5.i; P.94.e.l5.v; P.94.e.l8.i; P.94.e.l8.v; P.94.e.25.i; P.94.e.25\v; P.94.g.4.i; P.94.g.4.v; P.94.g.6.i; P.94.g.6.v; P.94.g.ll.i; P.94.g.ll.v; P.94.g.l4.i; P.94.gl4.v; P.94.g.l5.i; P.94,g,15.v; P.94.g.l8.i; P.94.g.l8.v; P.94.g.25.x; P.94.g.25.v; P.94.1.44; P.94.1.4.V; P.94.1.6.1; P.94.1.6.V; P.94.1.11.Í; P.94.1.11.V; P.94.1.144; P.94.1.14.v; P.94.1.15.1; P.94.1.15.V; P.941184; P.94.1.18.v; P.94.1.254; P.94.1.25.v; P.94.m.4.i; P.94.m.4.v; P.94.m.6.i; P.94.m.6.v; P.94.m.ll.í; P.94.m.ll.v; P.94.m.l4.i; P.94.m.l4.v; P.94.m.l5.i; P.94.m.l5.v; P.94.m.l8.i; P.94.m.l8.v; P.94.m.25.i; P.94.m.25.v; P.94.O.4.Í; P.94.o.4.v; P.94.o.6.i; P.94.o.6.v; P.94.O.11.Í; P.94.O.11.V; P.94.0.14.1; P.94.O.14.V; P.94.0.154; P.94.o.l5.v; P.94.0.184; P.94.O.18.V; P.94.O.254; P.94.o.25.v; A.2.a.4.o; A.2.a.4.bh; A.2.a.4.bi; A.2.a.4.bj;P. 93.a.4.i; P.93.a.4.v; P.93.a.6.i; P.93.a.6.v; P.93.a.U.i; P.93.a.ll.v; P.93.a.l4.i; P.93.a, 14.v; P.93.a.I54; P.93.a.l5.v; P.93.a.l8.i; P.93.a.l8.v; P.93.a.25.i; P.93.a.25.v; P.93.e.4.i; P.93.e.4.v; P.93.e.6.i; P.93.e.6.v; P.93.e.ll.i; P.93.e.ll.v; P.93.e.l44; P.93.e.l4.v; P.93.e.l5.1; P.93.e.l5.v; P.93.e.l8.i; P.93.e.l8.v; P.93.e.25.i; P.93.e.25.v; P.93.g.4.i; P.93.g.4.v; P.93.g.6.i; P.93.g.6.v; P.93.g.ll.i; P.93.g.ll.v; P.93.g.l44; P.93.g.l4.v; P.93.g.l5.i; P.93.g.l5.v; P.93.g.l8.i; P.93.g.l8.v; P.93.g.25.í; P.93.g.25.v; P.93.1.44; P.93.1.4.v; P.93.1.64; P.93.1.6.v; P.93.1.114; P.93.1.11.V; p-.93.L144; P.93.1.14.v; P.93.1.154; P.93.1.15.v; P.93.L184; P.93.L18.V; P.93.1.254; P.93.1.25.V; P.93.m.4.i; P.93.m.4.v; P.93.m.64; P.93.m.6.v; P.93.m.ll.i; P.93.m.U.v; P.93.m, 14.i; P.93.m.l4.v; P.93.m.l5.i; P.93.m., 15.v; P.93.m.l8.i; P.93.m.l8.v; P.93.m.25.i; P.93.m.25.v; P.93.O.44; P.93.o.4.v; P.93.0.64; P.93.o.6.v; P.93.0.114; P.93.o.ll.v; P.93.o.l4.i; Ρ.93.ο.14.ν; P.93.O.15.1; Ρ.93.ο.15.ν; P.93.O.184; P.93.o.l8.v; P.93.O.25.Í; P.93.o.25.v; P.94.a.4.i; P.94.a.4.v; P.94.a.6.i; P.94.a.6.v; P.94.a.U.i; P.94.a.ll.v; P.94.a.l44; P.94.a.l4.v; P.94.a.l54; P.94.a.l5.v; P.94.a.l8.i; P.94.a.l8.v; P.94.a.25.i; P.94.a.25.v; P.94.e.4.i; P.94.e.4.v; P.94.e.6.i; P.94.e.6.v; P.94.e.ll.i; P.94.e.ll.v; P.94.e.l4.i; P.94.e.l4.v; P.94.e.l5.i; P.94.e.l5.v; P.94.e.l8.i; P.94.e.l8.v; P.94.e.25.i; P.94.e.25 \ v; P.94.g.4.i; P.94.g.4.v; P.94.g.6.i; P.94.g.6.v; P.94.g.ll.i; P.94.g.ll.v; P.94.g.l4.i; P.94.gl4.v; P.94.g.l5.i; P.94, g, 15.v; P.94.g.l8.i; P.94.g.l8.v; P.94.g.25.x; P.94.g.25.v; P.94.1.44; P.94.1.4.V; P.94.1.6.1; P.94.1.6.V; P.94.1.11.Í; P.94.1.11.V; P.94.1.144; P.94.1.14.v; P.94.1.15.1; P.94.1.15.V; P.941184; P.94.1.18.v; P.94.1.254; P.94.1.25.v; P.94.m.4.i; P.94.m.4.v; P.94.m.6.i; P.94.m.6.v; P.94.m.ll.í; P.94.m.ll.v; P.94.m.l4.i; P.94.m.l4.v; P.94.m.l5.i; P.94.m.l5.v; P.94.m.l8.i; P.94.m.l8.v; P.94.m.25.i; P.94.m.25.v; P.94.O.4.Í; P.94.o.4.v; P.94.o.6.i; P.94.o.6.v; P.94.O.11.Í; P.94.O.11.V; P.94.0.14.1; P.94.O.14.V; P.94.0.154; P.94.o.l5.v; P.94.0.184; P.94.O.18.V; P.94.O.254; P.94.o.25.v; A.2.a.4.o; A.2.a.4.bh; A.2.a.4.bi; A.2.a.4.bj;
-89CZ 297945 B6-89EN 297945 B6
A2.a.4.bk; A.2.a.ll.o; A.2.a.ll.bh; A.2.a.ll.bi; A2.a.ll.bj; A.2.a.ll.bk; A.2.a.l5.i; A.2.a.l5.o; A.2.a.l5.bh; A.2.a.l5.bi; A.2.a.l5.bj; A.2,a.l5.bk; A.2.a.37.i; A.2.a.37.o; A.2.a.37.bh; A.2.a.37.bi; A.2.a.37.bj; A.2.a37.bk; A.2.a.38.i; A.2.a.38.o; A.2.a.38.bh; A.2.a.38.bi; A.2.a.38.bj; A.2.a.38.bk; A.2.a.39.i; A.2.a.39.o; A.2.a.39.bh; A.2.a.39.bx; A.2.a.39.bj; A.2.a.39.bk; A.2.a.40.i; A.2.a.40.o; A.2.a.40.bh; A.2.a.40.bi; A.2.a.40.bj; A.2.a.40.bk; A2.a.41.i; A.2.a.41.o; A2-a.41.bh; A.2.a.41.bi; A.2.a.41.bj; A.2.a.41.bk; A.2.a.42.i; A.l.a.dZ.o; A.2.a.42.bh; A.2.a.42.bi; A.2.a.42.bj; A.2.a.42.bk; A2.a.43.i; A.2.a.43.o; A.2.a.43.bh; A.2.a.43.bi; A.2.a.43.bj; A.2.a.43.bk;A2.a.4.bk; A.2.a.ll.o; A.2.a.ll.bh; A.2.a.ll.bi; A2.a.ll.bj; A.2.a.ll.bk; A.2.a.l5.i; A.2.a.l5.o; A.2.a.l5.bh; A.2.a.l5.bi; A.2.a.l5.bj; A.2, a.l5.bk; A.2.a.37.i; A.2.a.37.o; A.2.a.37.bh; A.2.a.37.bi; A.2.a.37.bj; A.2.a37.bk; A.2.a.38.i; A.2.a.38.o; A.2.a.38.bh; A.2.a.38.bi; A.2.a.38.bj; A.2.a.38.bk; A.2.a.39.i; A.2.a.39.o; A.2.a.39.bh; A.2.a.39.bx; A.2.a.39.bj; A.2.a.39.bk; A.2.a.40.i; A.2.a.40.o; A.2.a.40.bh; A.2.a.40.bi; A.2.a.40.bj; A.2.a.40.bk; A2.a.41.i; A.2.a.41.o; A2-a.41.bh; A.2.a.41.bi; A.2.a.41.bj; A.2.a.41.bk; A.2.a.42.i; A.l.a.dZ.o; A.2.a.42.bh; A.2.a.42.bi; A.2.a.42.bj; A.2.a.42.bk; A2.a.43.i; A.2.a.43.o; A.2.a.43.bh; A.2.a.43.bi; A.2.a.43.bj; A.2.a.43.bk;
A.3.a.4.o; A.3.a.4.bh; A.3.a.4.bi; A.3.a.4.bj; A.3.a.4.bk; A.3.a.ll.o; A.3.a.U.bh;A.3.a.4.o; A.3.a.4.bh; A.3.a.4.bi; A.3.a.4.bj; A.3.a.4.bk; A.3.a.ll.o; A.3.a.U.bh;
A.3.a.U.bi; A.3.a.ll.bj; A.3.a.ll.bk; A.3.a.l5.i; A.3.a.l5.o; A.3.a.l5.bh; A.3.a,15.bi; A.3.a.l5.bj; A.3,a.l5.bk; A.3.a.37.i; A.3.a.37.o; A.3.a.37.bh; A-3.a.37.bi; A.3.a.37.bj; A.3.a.37.bk; A.3.a.38.i; A.3.a.38.o; A.3.a.38.bh; A.3.a.38.bi; A.3.a.38.bj; A.3.a.38.bk; A.3.a.39.i; A.3.a.39.o; A.3.a.39.bh; A.3.a.39.bi; A.3.a.39.bj; A.3.a.39.bk; A.3.a.40.i; A.3.a.40.o; A.3.a.40.bh; A.3.a.40.bi; A.3.a.40.bj; A.3.a.40.bk; A.3.a.41.i; A.3.a.41.o; A.3.a.41.bh; A.3.a.41.bi; A.3.a.41.bj; A.3.a.41,bk; A.3.a.42.i; A.3.a.42.o; A.3.a.42.bh; A3.a.42.bi; A.3.a.42.bj; A.3.a.42.bk; A.3.a.43.i; A.3.a.43.o; Á.3.a.43.bh; A.3.a.43.bi; A.3.a.43.bj; A.3.a.43.bk; A.4.a.4.o; A.4.a.4.bh; A.4.a.4.bi; A.4.a.4.bj; A.4.a.4.bk; A.4.a.ll.o; A.4.a.llbh; A.4.a.ll.bi; A.4.a.ll.bj; A.4.a.ll.bk; A.4.a.l5.i; A.4.a.l5.o; A.4.a.l5.bh; A.4.a.l5.bi; A.4.a.l5.bj; A.4.a.l5,bk; A.4.a.37.i; A.4.a.37.o; A.4.a.37.bh; A.4.a.37.bi; A.4.a.37.bj; A.4.a.37.bk; A.4.a.38.i; A.4.a.38.o; A.4.a.38.bh; A.4.a.38.bi; A.4.a.38.bj; A.4.a.38.bk; A.4.a.39.i; A.4.a.39.o; A.4.a.39.bh; A.4.a.39.bi; A.4.a.39.bj; A.4.a.39.bk; A.4.a.40.i; A.4,a.40.o; A.4.a.40.bh; A.4.a.40.bí; A.4.a.40.bj; A.4.a.40.bk; A.4.a.41.i; A.4.a.41.o; A.4.a.41.bh; A.4.a.41.bi; A.4.a.41.bj; A.4.a.41.bk; A.4.a.42.i; A.4.a.42.o; A.4.a.42.bh; A.4.a.42,bi; A.4.a.42.bj; A.4.a.42.bk; A.4.a.43.i; A.4.a.43.o; A.4.a.43.bh; A.4.a.43.bi; A.4.a.43.bj; A.4.a.43.bk; A.7.a.4.o; A.7.a.4.bh; A.7.a.4.bi; A.7.a.4.bj; A.7.a.4.bk; A.7.a.ll.o; A.7.a.ll.bh; A.7.a,ll.bi; A.7.a.ll.bj; A.7.a.ll.bk; A.7.a.l5.i; A.7.a.l5.o; A.7.a.l5.bh; A.7.a.l5.bi; A.7.a.l5.bj; A.7.a.lS.bk; A.7.a.37.i; A.7.a.37.o; A.7.a.37.bh; A.7.a.37.bi; A.7.a.37.bj; A.7.a.37.bk; A.7.a.38.i; A.7.a.38.o; A.7.a.38.bh; A.7.a.38.bi; A.7.a.38.bj; A.7.a.38.bk; A.7.a.39.i; A.7.a.39.o; A.7.a.39.bh; A.7.a.39,bi; A.7.a.39.bj; A.7.a.39.bk; A.7.a.40.i; A.7.a.40.o; A.7.a.40.bh; A.7.a.40.bi; A.7.a.40.bj; A.7.a.40.bk; A.7.a.41.i; A.7.a.41.o; A.7.a.41.bh; A.7.a.41.bi; A.7.a.41.bj; A.7.a.41.bk; A.7.a.42.i; A.7.a.42.o; A.7.a.42.bh; A.7.a.42.bi; A.7.a.42.bj; A.7.a.42.bk; A.7.a.43.i; A.7.a.43.o; A.7.a.43.bh; A.7.a.43.bi; A.7.a.43.bj; A.7.a.43.bk;A.3.a.U.bi; A.3.a.ll.bj; A.3.a.ll.bk; A.3.a.l5.i; A.3.a.l5.o; A.3.a.l5.bh; A.3.a, 15.bi; A.3.a.l5.bj; A.3, a.l5.bk; A.3.a.37.i; A.3.a.37.o; A.3.a.37.bh; A-3.a.37.bi; A.3.a.37.bj; A.3.a.37.bk; A.3.a.38.i; A.3.a.38.o; A.3.a.38.bh; A.3.a.38.bi; A.3.a.38.bj; A.3.a.38.bk; A.3.a.39.i; A.3.a.39.o; A.3.a.39.bh; A.3.a.39.bi; A.3.a.39.bj; A.3.a.39.bk; A.3.a.40.i; A.3.a.40.o; A.3.a.40.bh; A.3.a.40.bi; A.3.a.40.bj; A.3.a.40.bk; A.3.a.41.i; A.3.a.41.o; A.3.a.41.bh; A.3.a.41.bi; A.3.a.41.bj; A.3.a.41, bk; A.3.a.42.i; A.3.a.42.o; A.3.a.42.bh; A3.a.42.bi; A.3.a.42.bj; A.3.a.42.bk; A.3.a.43.i; A.3.a.43.o; Á.3.a.43.bh; A.3.a.43.bi; A.3.a.43.bj; A.3.a.43.bk; A.4.a.4.o; A.4.a.4.bh; A.4.a.4.bi; A.4.a.4.bj; A.4.a.4.bk; A.4.a.ll.o; A.4.a.llbh; A.4.a.ll.bi; A.4.a.ll.bj; A.4.a.ll.bk; A.4.a.l5.i; A.4.a.l5.o; A.4.a.l5.bh; A.4.a.l5.bi; A.4.a.l5.bj; A.4.a.15, bk; A.4.a.37.i; A.4.a.37.o; A.4.a.37.bh; A.4.a.37.bi; A.4.a.37.bj; A.4.a.37.bk; A.4.a.38.i; A.4.a.38.o; A.4.a.38.bh; A.4.a.38.bi; A.4.a.38.bj; A.4.a.38.bk; A.4.a.39.i; A.4.a.39.o; A.4.a.39.bh; A.4.a.39.bi; A.4.a.39.bj; A.4.a.39.bk; A.4.a.40.i; A.4, a.40.o; A.4.a.40.bh; A.4.a.40.bí; A.4.a.40.bj; A.4.a.40.bk; A.4.a.41.i; A.4.a.41.o; A.4.a.41.bh; A.4.a.41.bi; A.4.a.41.bj; A.4.a.41.bk; A.4.a.42.i; A.4.a.42.o; A.4.a.42.bh; A.4.a.42, bi; A.4.a.42.bj; A.4.a.42.bk; A.4.a.43.i; A.4.a.43.o; A.4.a.43.bh; A.4.a.43.bi; A.4.a.43.bj; A.4.a.43.bk; A.7.a.4.o; A.7.a.4.bh; A.7.a.4.bi; A.7.a.4.bj; A.7.a.4.bk; A.7.a.ll.o; A.7.a.ll.bh; A.7.a, II.bi; A.7.a.ll.bj; A.7.a.ll.bk; A.7.a.l5.i; A.7.a.l5.o; A.7.a.l5.bh; A.7.a.l5.bi; A.7.a.l5.bj; A.7.a.lS.bk; A.7.a.37.i; A.7.a.37.o; A.7.a.37.bh; A.7.a.37.bi; A.7.a.37.bj; A.7.a.37.bk; A.7.a.38.i; A.7.a.38.o; A.7.a.38.bh; A.7.a.38.bi; A.7.a.38.bj; A.7.a.38.bk; A.7.a.39.i; A.7.a.39.o; A.7.a.39.bh; A.7.a.39, bi; A.7.a.39.bj; A.7.a.39.bk; A.7.a.40.i; A.7.a.40.o; A.7.a.40.bh; A.7.a.40.bi; A.7.a.40.bj; A.7.a.40.bk; A.7.a.41.i; A.7.a.41.o; A.7.a.41.bh; A.7.a.41.bi; A.7.a.41.bj; A.7.a.41.bk; A.7.a.42.i; A.7.a.42.o; A.7.a.42.bh; A.7.a.42.bi; A.7.a.42.bj; A.7.a.42.bk; A.7.a.43.i; A.7.a.43.o; A.7.a.43.bh; A.7.a.43.bi; A.7.a.43.bj; A.7.a.43.bk;
A.17.a,4.i; A.17.a.4.o; A.17.a.4.bh; A.17.a.4.bi; A.17.a.4.bj; A.17.a.4.bk; A.17.a.ll.i; A.17.a.ll.o; A.17.a.ll,bh; A.17.a.ll.bi; A.17.a.ll.bj; A.17.a.ll.bk; A.17.a,15.i; A.17.a.l5.o; A.17.a.l5.bh; A.17.a.l5.bi; A.17.a.l5.bj; A.17.a.l5.bk; A.17.a.37.i; A.17.a.37.o; A.17.a.37.bh; A.17.a.37.bi; A.17.a.37.bj; A.17.a.37.bk; A.17,a.38.i; A.17.a.38.o; A.17.a.38.bh; A.17.a.38.bi; A.17.a.38.bj; A.17.a.38.bk; A.17.a.39.i; A.17.a.39.o; A.17.a.39.bh; A.17.a.39.bi; A.I7.a.39.bj; A.17.a.39.bk; A.17.a.40.i; A.17.a.40.o; A.17.a.40.bh; A.17.a.40.bi; A.I7.a.40.bj; A.17.a.40.bk; A.17.a.41.i; A.I7.a.41.o; A.17.a.41.bh; A.17.a.41.bi; A.17.a.41.bj; A.17.a.41.bk; A.17.a.42.i; A.17.a.42.o; A.17.a.42.bh; A.17.a.42.bi; A.17.a.42.bj; A.17.a.42.bk; A.17.a.43.i; A.17.a.43.o; A.17.a.43.bh; A.17.a.43.bi; A.17.a.43.bj; A.17.a.43.bk; A.18.a.4.i; A.18.a.4.o; A.18.a.4.bh; A.18.a.4.bi; A.18.a.4.bj; A.18.a.4.bk; A.18.a.ll.i;A.17.a, 4.i; A.17.a.4.o; A.17.a.4.bh; A.17.a.4.bi; A.17.a.4.bj; A.17.a.4.bk; A.17.a.ll.i; A.17.a.ll.o; A.17.a.ll, bh; A.17.a.ll.bi; A.17.a.ll.bj; A.17.a.ll.bk; A.17.a, 15.i; A.17.a.l5.o; A.17.a.l5.bh; A.17.a.l5.bi; A.17.a.l5.bj; A.17.a.l5.bk; A.17.a.37.i; A.17.a.37.o; A.17.a.37.bh; A.17.a.37.bi; A.17.a.37.bj; A.17.a.37.bk; A.17, a.38.i; A.17.a.38.o; A.17.a.38.bh; A.17.a.38.bi; A.17.a.38.bj; A.17.a.38.bk; A.17.a.39.i; A.17.a.39.o; A.17.a.39.bh; A.17.a.39.bi; A.I7.a.39.bj; A.17.a.39.bk; A.17.a.40.i; A.17.a.40.o; A.17.a.40.bh; A.17.a.40.bi; A.I7.a.40.bj; A.17.a.40.bk; A.17.a.41.i; A.I7.a.41.o; A.17.a.41.bh; A.17.a.41.bi; A.17.a.41.bj; A.17.a.41.bk; A.17.a.42.i; A.17.a.42.o; A.17.a.42.bh; A.17.a.42.bi; A.17.a.42.bj; A.17.a.42.bk; A.17.a.43.i; A.17.a.43.o; A.17.a.43.bh; A.17.a.43.bi; A.17.a.43.bj; A.17.a.43.bk; A.18.a.4.i; A.18.a.4.o; A.18.a.4.bh; A.18.a.4.bi; A.18.a.4.bj; A.18.a.4.bk; A.18.a.ll.i;
A.18.a.ll.o; A.18.a.ll.bh; A.18.a.ll.bi; A.18.a.ll.bj; A.18.a.U.bk; A.18.a.l5.i; A.18.a.l5.o; A.18.a.l5.bh; A.18.a.l5.bi; A.18.a.l5.bj; A.18.a.l5.bk; A.18.a.37.i; A.18.a.37.o; A.18.a.37.bh; A.18.a.37.bi; A.18.a.37,bj; A.18.a.37.bk; A.18.a.38.i;A.18.a.ll.o; A.18.a.ll.bh; A.18.a.ll.bi; A.18.a.ll.bj; A.18.a.U.bk; A.18.a.l5.i; A.18.a.l5.o; A.18.a.l5.bh; A.18.a.l5.bi; A.18.a.l5.bj; A.18.a.l5.bk; A.18.a.37.i; A.18.a.37.o; A.18.a.37.bh; A.18.a.37.bi; A.18.a.37, bj; A.18.a.37.bk; A.18.a.38.i;
-90CZ 297945 B6-90EN 297945 B6
A.18 a.38.o; A.18.a.38.bh; A.18.a.38.bi; A.18.a.38.bj; A.18.a.38.bk; A.18.a39.i; A.18.a.39.o; A.18.a.39.bh; A.18.a.39.bi; A.18.a.39.bj; A.18.a.39.bk; A.18.a.40.i; A.18.a.40.o; A.18.a.40.bh; A.18.a.40.bi; A.18.a.40.bj; A.18.a.40.bk; A.18.a.41.i; A.18.a.41.o; A.18.a.41.bh; A.18.a.4Lbx; A.18.a.41.bj; A.18.a.41.bk; A.18.a.42.i; A.18.a.42.o; A.18.a.42.bh; A.18.a.42.bi; A.18.a.42.bj; A.18.a,42.bk; A.18.a.43.i; A.18.a.43.o; A.18.a.43.bh; A.18.a.43.bi; A.18.a.43.bj; A.18.a.43.bk; A.19.a.4.i; A.19.a.4.o; A.19.a.4.bh; A.19.a.4.bi; A.19.a.4.bj; A.19.a.4.bk; A.19.a.ll.i; A.19.a.ll.o; A.19.a.ll.bh; A.19.a.ll.bi; A.19.a.ll.bj; A.19.a.ll.bk; A.19.a.l5.i; A.19.a,15.o; A.19.a.l5.bh; A.19-a.l5.bi; A.19.a,15.bj; A.19.a.l5.bk; A.19.a.37.i; A.19.a.37.o; A.19.a.37.bh; A.19.a.37.bi; A.19.a.37.bj; A.19.a37.bk; A.19.a.38.í; A.19.a.38.o; A.19.a.38.bh; A.19.a.38.bi; A.19.a.38.bj; A.19.a.38.bk; A.19.a.39.i; A.19.a.39.o; A.19.a.39.bh; A.19.a.39.bi; A.19.a.39.bj; A.19.a.39.bk; A.19.a.40.i; A.19.a.40.o; A.19.a.40.bh; A.19.a.40.bÍ; A.19.a.40.bj; A.19.a.40.bk; A.19.a.41.i; A.19.a.41.o; A.19.a.41.bh; A.19.a.41.bi; A.19.a.41.bj; A.19.a.41.bk; A.19.a.42.i; A.19.a.42.o; A.19.a.42.bh; A.19.a.42.bi; A.19.a.42.bj; A.19.a.42.bk; A.19.a.43.i; A.19.a.43.o; A.19.a.43.bh; A.19.a.43.bi; A.19.a.43.bj; A.19.a.43.bk; A.97.a.4.i; A.97.a.4.o; A.97.a.4.bh; A.97.a.4.bi; A.97.a.4.bj; A.97.a4.bk; A.97.a.ll.i; A.97.a.ll.o; A.97.a.U.bh; A.97.a.ll.bi; A.97.a.ll.bj; A.97.a.ll.bk; A.97.a.l5.i; A.97.a.l5.o; A.97.a.l5.bh; A.97.a.l5.bi; A.97.a.l5.bj; A.97.a.l5.bk; A.97.a.37.i; A.97.a.37.o; A.97.a.37.bh; A.97.a.37.bi; A.97.a.37.bj; A.97.a.37.bk; A.97.a.38.i; A.97.a.38.o; A.97.a.38.bh; A.97.a.38.bi; A.97.a.38.bj; A.97.a.38.bk; A.97.a.39.i; A.97.a.39.o; A.97.a.39.bh; A.97.a.39.bi; A.97.a.39.bj; A.97.a.39.bk; A.97.a.40.i; A.97.a.40.o; A.97.a.40.bh; A.97.a.40.bi; A.97.a.40.bj; A.97.a.40.bk; A.97.a.41.i; A.97.a.41.o; A.97.a.41.bh; A.97.a41.bi; A.97.a.4Lbj; A.97.a.41.bk; A.97.a.42.i; A.97.a42.o; A.97.a42.bh; A.97.a.42.bi; A.97.a.42.bj; A.97.a.42.bk; A.97.a.43.i; A.97.a.43.o; A.97.a.43.bh; A.97.a.43.bi; A.97.a.43.bj; A.97.a.43.bk; A.98.a.4.x; A.98.a.4.o; A.98.a.4.bh; A.98.a4.bx; A.98.a.4.bj; A.98.a.4.bk; A.98.a.ll.i; A.98.a.ll.o; A.98.a.ll.bh; A.98.a.ll.bi; A.98.a.ll.bj; A.98.a.ll.bk; A.98.a.l5.i; A.98.a.l5.o; A.98.a.l5.bh; A.98.a.l5.bx; A.98.a.l5.bj; A.98.a.l5.bk; A.98.a.37.i; A.98.a.37.o; A.98.a.37.bh; A.98.a.37.bi; A.98.a.37.bj; A.98.a.37.bk; A.98.a.38.í; A.98.a.38.o; A.98.a.38.bh; A.98.a.38.bi; A.98.a.38.bj; A.98.a.38.bk; A.98.a.39.i; A.98.a.39.o; A.98.a.39.bh; A.98.a.39.bi; A.98.a.39.bj; A.98.a.39.bk; A.98.a.40.i; A.98.a.40.o; A.98.a.40.bh; A.98.a40.bi; A.98.a.40.bj; A.98.a.40.bk; A.98.a.41.i; A.98.a.41.o; A.98.a.41.bh; A.98.a.41.bi; A.98.a.41.bj; A.98.a.41.bk; A.98.a.42.i; A.98.a42.o; A.98.a.42.bh; A.98.a.42.bi; A.98.a.42.bj; A.98.a.42.bk; A.98.a.43.i; A.98.a.43.o; A.98.a.43.bh; A.98.a.43.bi;A.98.a.43.bj; A.98.a.43.bk; A.2.a.4.x; A.3.a.4.i; A4.a.4.i; A.5.a.4.i; A.6.a.4.i; A.7.a.4.i; A.9.a4.i; A.10.a4.i; A.15.a.4.i; A.100.a.4.i; A.101.a.4.i; A.102.a.4.i; A.103.a.4.i; A.104.a.4.i; A.105.a.4.i; A.106.a.4.i; A.107.a.4.i; A.108.a.4.i; A.109.a.4.i; A.110.a.4.i; A.lll.a,4.i; A.112.a.4.i; A.113.a.4.i; A.114.a.4.i; A.115.a4.i; A.116.a.4.i; A.117.a.4.i; A,118.a.4.i; A.119.a.4.i; A.120.a.4.i; A.121.a.4.i; A.122.a.4.i; A.123.a.4.i; A.124.a.4.i; A.125.a.4.x; A.126.a.4.i; A.127.a.4.i; A.128.a4.i; A.129.a.4,i; A.130.a.4.i; A.131.a.4.i; A.132.a.4.i; A.133.a.4.i; A.134.a.4.i; A.135.a.4.x; A.136.a.4.i; Á.137.a.4.i; A.138.a.4.i; A.139.a.4.i; A.140.a.4.i; A.141.a.4.i; A.142.a.4.x; A.143.a.4.i; A.144.a.4.i; A.145.a.4.i; A.146.a.4.i; A.147.a.4.i; A.148.a.4.i; A.149.a.4.i; A.150.a.4.i; A.151,a.4.i; A.152.a.4.i;A.153.a.4.i; A.154.a.4.i; A.155.a.4.i; A.156.a.4.i; A.157.a.4 i; A.158.a.4.i; A.159.a4.j;A.160,a.4.i; A.161.a.4.x; A.162.a.4.i; A.163.a.4.i; A.164.a.4.i; A.165.a.4.i; A.166.a4.i; A.167.a.4.i; A.168.a.4.i; A.169.a.4.i;A.18 a.38.o; A.18.a.38.bh; A.18.a.38.bi; A.18.a.38.bj; A.18.a.38.bk; A.18.a39.i; A.18.a.39.o; A.18.a.39.bh; A.18.a.39.bi; A.18.a.39.bj; A.18.a.39.bk; A.18.a.40.i; A.18.a.40.o; A.18.a.40.bh; A.18.a.40.bi; A.18.a.40.bj; A.18.a.40.bk; A.18.a.41.i; A.18.a.41.o; A.18.a.41.bh; A.18.a.4Lbx; A.18.a.41.bj; A.18.a.41.bk; A.18.a.42.i; A.18.a.42.o; A.18.a.42.bh; A.18.a.42.bi; A.18.a.42.bj; A.18.a, 42.bk; A.18.a.43.i; A.18.a.43.o; A.18.a.43.bh; A.18.a.43.bi; A.18.a.43.bj; A.18.a.43.bk; A.19.a.4.i; A.19.a.4.o; A.19.a.4.bh; A.19.a.4.bi; A.19.a.4.bj; A.19.a.4.bk; A.19.a.ll.i; A.19.a.ll.o; A.19.a.ll.bh; A.19.a.ll.bi; A.19.a.ll.bj; A.19.a.ll.bk; A.19.a.l5.i; A.19.a, 15.o; A.19.a.l5.bh; A.19-a.l5.bi; A.19.a, 15.bj; A.19.a.l5.bk; A.19.a.37.i; A.19.a.37.o; A.19.a.37.bh; A.19.a.37.bi; A.19.a.37.bj; A.19.a37.bk; A.19.a.38.í; A.19.a.38.o; A.19.a.38.bh; A.19.a.38.bi; A.19.a.38.bj; A.19.a.38.bk; A.19.a.39.i; A.19.a.39.o; A.19.a.39.bh; A.19.a.39.bi; A.19.a.39.bj; A.19.a.39.bk; A.19.a.40.i; A.19.a.40.o; A.19.a.40.bh; A.19.a.40.bÍ; A.19.a.40.bj; A.19.a.40.bk; A.19.a.41.i; A.19.a.41.o; A.19.a.41.bh; A.19.a.41.bi; A.19.a.41.bj; A.19.a.41.bk; A.19.a.42.i; A.19.a.42.o; A.19.a.42.bh; A.19.a.42.bi; A.19.a.42.bj; A.19.a.42.bk; A.19.a.43.i; A.19.a.43.o; A.19.a.43.bh; A.19.a.43.bi; A.19.a.43.bj; A.19.a.43.bk; A.97.a.4.i; A.97.a.4.o; A.97.a.4.bh; A.97.a.4.bi; A.97.a.4.bj; A.97.a4.bk; A.97.a.ll.i; A.97.a.ll.o; A.97.a.U.bh; A.97.a.ll.bi; A.97.a.ll.bj; A.97.a.ll.bk; A.97.a.l5.i; A.97.a.l5.o; A.97.a.l5.bh; A.97.a.l5.bi; A.97.a.l5.bj; A.97.a.l5.bk; A.97.a.37.i; A.97.a.37.o; A.97.a.37.bh; A.97.a.37.bi; A.97.a.37.bj; A.97.a.37.bk; A.97.a.38.i; A.97.a.38.o; A.97.a.38.bh; A.97.a.38.bi; A.97.a.38.bj; A.97.a.38.bk; A.97.a.39.i; A.97.a.39.o; A.97.a.39.bh; A.97.a.39.bi; A.97.a.39.bj; A.97.a.39.bk; A.97.a.40.i; A.97.a.40.o; A.97.a.40.bh; A.97.a.40.bi; A.97.a.40.bj; A.97.a.40.bk; A.97.a.41.i; A.97.a.41.o; A.97.a.41.bh; A.97.a41.bi; A.97.a.4Lbj; A.97.a.41.bk; A.97.a.42.i; A.97.a42.o; A.97.a42.bh; A.97.a.42.bi; A.97.a.42.bj; A.97.a.42.bk; A.97.a.43.i; A.97.a.43.o; A.97.a.43.bh; A.97.a.43.bi; A.97.a.43.bj; A.97.a.43.bk; A.98.a.4.x; A.98.a.4.o; A.98.a.4.bh; A.98.a4.bx; A.98.a.4.bj; A.98.a.4.bk; A.98.a.ll.i; A.98.a.ll.o; A.98.a.ll.bh; A.98.a.ll.bi; A.98.a.ll.bj; A.98.a.ll.bk; A.98.a.l5.i; A.98.a.l5.o; A.98.a.l5.bh; A.98.a.l5.bx; A.98.a.l5.bj; A.98.a.l5.bk; A.98.a.37.i; A.98.a.37.o; A.98.a.37.bh; A.98.a.37.bi; A.98.a.37.bj; A.98.a.37.bk; A.98.a.38.í; A.98.a.38.o; A.98.a.38.bh; A.98.a.38.bi; A.98.a.38.bj; A.98.a.38.bk; A.98.a.39.i; A.98.a.39.o; A.98.a.39.bh; A.98.a.39.bi; A.98.a.39.bj; A.98.a.39.bk; A.98.a.40.i; A.98.a.40.o; A.98.a.40.bh; A.98.a40.bi; A.98.a.40.bj; A.98.a.40.bk; A.98.a.41.i; A.98.a.41.o; A.98.a.41.bh; A.98.a.41.bi; A.98.a.41.bj; A.98.a.41.bk; A.98.a.42.i; A.98.a42.o; A.98.a.42.bh; A.98.a.42.bi; A.98.a.42.bj; A.98.a.42.bk; A.98.a.43.i; A.98.a.43.o; A.98.a.43.bh; A.98.a.43.bi; A.98.a.43.bj; A.98.a.43.bk; A.2.a.4.x; A.3.a.4.i; A4.a.4.i; A.5.a.4.i; A.6.a.4.i; A.7.a.4.i; A.9.a4.i; A.10.a4.i; A.15.a.4.i; A.100.a.4.i; A.101.a.4.i; A.102.a.4.i; A.103.a.4.i; A.104.a.4.i; A.105.a.4.i; A.106.a.4.i; A.107.a.4.i; A.108.a.4.i; A.109.a.4.i; A.110.a.4.i; A.lll.a, 4.i; A.112.a.4.i; A.113.a.4.i; A.114.a.4.i; A.115.a4.i; A.116.a.4.i; A.117.a.4.i; A, 118.a.4.i; A.119.a.4.i; A.120.a.4.i; A.121.a.4.i; A.122.a.4.i; A.123.a.4.i; A.124.a.4.i; A.125.a.4.x; A.126.a.4.i; A.127.a.4.i; A.128.a4.i; A.129.a.4., I; A.130.a.4.i; A.131.a.4.i; A.132.a.4.i; A.133.a.4.i; A.134.a.4.i; A.135.a.4.x; A.136.a.4.i; Á.137.a.4.i; A.138.a.4.i; A.139.a.4.i; A.140.a.4.i; A.141.a.4.i; A.142.a.4.x; A.143.a.4.i; A.144.a.4.i; A.145.a.4.i; A.146.a.4.i; A.147.a.4.i; A.148.a.4.i; A.149.a.4.i; A.150.a.4.i; A.151, a.4.i; A.152.a.4.i; A.154.a.4.i; A.155.a.4.i; A.156.a.4.i; A.157.a.4 i; A.158.a.4.i; A.160, a.4.i; A.161.a.4.x; A.162.a.4.i; A.163.a.4.i; A.164.a.4.i; A.165.a.4.i; A.166.a4.i; A.167.a.4.i; A.168.a.4.i; A.169.a.4.i;
-91 CZ 297945 B6-91 GB 297945 B6
A.171.a.4.i; A.178.a.4.i; A.185.a.4.i; A.192.a.4.i; A.199.a.4.i; A.206.a.4.i; A213.a.4.i; A.220.a.4.i; A227.a.4.i; A.234.a.4.i; A.241.a.4.i; A.248.a.4.i; A255.a.4.i; A.262.a.4.i; A.269.a.4.i; A.276.a.4.i; A.283.a.4.i; A.290.a.4.i; A,297.a.4.i; A.304.a.4.j; A.311.a.4.x· A.318.a.4.i; A.326.a,4.i; A.333.a.4.i; A.340.a.4.i; A.347.a.4.i; A.354.a.4.i; A.361.a.4.i; A.368.a.4.i; A.375.a.4.i; A.382.a.4.i; A.389.a.4.i; A.396.a.4.i; A.403.a.4.i; A.410.a.4.i; A.417.a.4.i; A.424.a.4.i; A.431.a.4.i; A.438.a.4.i; A.445.a.4.i; A.452.a.4.i; A.459.a.4.i; A.466.a.4.i; A.473.a.4.i; A.480,a.4.í; A.487.a.4.i; A.494.a.4.i;A.171.a.4.i; A.178.a.4.i; A.185.a.4.i; A.192.a.4.i; A.199.a.4.i; A.206.a.4.i; A213.a.4.i; A.220.a.4.i; A227.a.4.i; A.234.a.4.i; A.241.a.4.i; A.248.a.4.i; A255.a.4.i; A.262.a.4.i; A.269.a.4.i; A.276.a.4.i; A.283.a.4.i; A.290.a.4.i; A, 297.a.4.i; A.304.a.4.j; A.311.a.4.x; A.318.a.4.i; A.326.a, 4.i; A.333.a.4.i; A.340.a.4.i; A.347.a.4.i; A.354.a.4.i; A.361.a.4.i; A.368.a.4.i; A.375.a.4.i; A.382.a.4.i; A.389.a.4.i; A.396.a.4.i; A.403.a.4.i; A.410.a.4.i; A.417.a.4.i; A.424.a.4.i; A.431.a.4.i; A.438.a.4.i; A.445.a.4.i; A.452.a.4.i; A.459.a.4.i; A.466.a.4.i; A.473.a.4.i; A.480, a.4.i; A.487.a.4.i; A.494.a.4.i;
A,172.a.4.i;A, 172.a.4.i;
A.179.a.4.i;A.179.a.4.i;
A.186.a.4.i;A.186.a.4.i;
A.193.a.4.i;A.193.a.4.i;
A.200.a.4.i;A.200.a.4.i;
A.207.a.4.i;A.207.a.4.i;
A.214.a.4,i;A.214.a.4., I;
A.221.a.4.i;A.221.a.4.i;
A.228.a.4.i;A.228.a.4.i;
A.235.a.4.i;A.235.a.4.i;
A,242.a.4.i;A, 242.a.4.i;
A.249.a.4.i;A.249.a.4.i;
A.256.a.4.i;A.256.a.4.i;
A.263.a.4.i;A.263.a.4.i;
A.270.a.4.i;A.270.a.4.i;
A.277.a.4.i;A.277.a.4.i;
A.284.a.4.i;A.284.a.4.i;
A.291.a.4.i;A.291.a.4.i;
A.298.a.4.i;A.298.a.4.i;
A.305.a.4.i;A.305.a.4.i;
A.312.a.4.í;A.312.a.4.í;
A.319.a.4.i;A.319.a.4.i;
A.327.a.4.i;A.327.a.4.i;
A.334.a.4.i;A.334.a.4.i;
A.341.a.4.i;A.341.a.4.i;
A.348.a.4.x;A.348.a.4.x;
A355.-a.44;A355.-a.44;
A.362.a.4.i;A.362.a.4.i;
A.369.a.4.i;A.369.a.4.i;
A.376.a.4.i;A.376.a.4.i;
A.383.a.4.i;A.383.a.4.i;
A.390.a.4.i;A.390.a.4.i;
A.397.a.4.i;A.397.a.4.i;
A.404.a.4.i;A.404.a.4.i;
A.411.a.4.i;A.411.a.4.i;
A.418.a.4.i;A.418.a.4.i;
A.425.a.4.i;A.425.a.4.i;
A.432.a.4.i;A.432.a.4.i;
A.439.a.4.i;A.439.a.4.i;
A.446.a.4.i;A.446.a.4.i;
A.453.a.4.i;A.453.a.4.i;
A.460.a.4.i;A.460.a.4.i;
A.467.a.4.i;A.467.a.4.i;
A.474.a,4.i;A.474.a, 4.i;
A.481.a.4.i;A.481.a.4.i;
A.488.a.4.i;A.488.a.4.i;
A.495.a.4.i;A.495.a.4.i;
A.170.a.4.i;A.170.a.4.i;
A.177.a.4.i;A.177.a.4.i;
A.184.a.4.i;A.184.a.4.i;
A.191.a.4.i;A.191.a.4.i;
A.198.a.4.i;A.198.a.4.i;
A.205.a.4.i;A.205.a.4.i;
A.212.a,4.i;A.212.a, 4.i;
A.219.a.4.i;A.219.a.4.i;
A.226.a.4.i;A.226.a.4.i;
A.233.a.4.i;A.233.a.4.i;
A.240.a.4.i;A.240.a.4.i;
A.247.a.4.i;A.247.a.4.i;
A.254.a.4.i;A.254.a.4.i;
A.261.a.4.i;A.261.a.4.i;
A.268.a.4.i;A.268.a.4.i;
A.275.a.4.i;A.275.a.4.i;
A.282.a.4.i;A.282.a.4.i;
A.289.a.4.i;A.289.a.4.i;
A.296.a.4.i;A.296.a.4.i;
A.303.a.4.i;A.303.a.4.i;
A.310.a.4.i;A.310.a.4.i;
A.317.a.4.i;A.317.a.4.i;
A.325.a.4.i;A.325.a.4.i;
A.332.a.4.i;A.332.a.4.i;
A.339.a.4.i;A.339.a.4.i;
A.346.a.4.i;A.346.a.4.i;
A.353.a.4.i;A.353.a.4.i;
A.360.a.4.i;A.360.a.4.i;
A.367.a.4.i;A.367.a.4.i;
A.374.a.4.i;A.374.a.4.i;
A.381.a.4.i;A.381.a.4.i;
A.388.a.4.i;A.388.a.4.i;
A.395.a.4.i;A.395.a.4.i;
A.402.a.4.i;A.402.a.4.i;
A.409.a.4.i;A.409.a.4.i;
A.416.a.4.i;A.416.a.4.i;
A.423.a.4.i;A.423.a.4.i;
A.430.a.4.i;A.430.a.4.i;
A.437.a.4.i;A.437.a.4.i;
A.444.a.4.i;A.444.a.4.i;
A.451.a.4.i;A.451.a.4.i;
A.458.a.4.i;A.458.a.4.i;
A.465.a.4.i;A.465.a.4.i;
A.472.a.4.i;A.472.a.4.i;
A.479.a.4.i;A.479.a.4.i;
A.486.a.4.i;A.486.a.4.i;
A.493.a.4.i;A.493.a.4.i;
A.173.a.4.i;A.173.a.4.i;
A.180.a.4.i,A.180.a.4.i,
A.187.a.4.i;A.187.a.4.i;
A.194.a.4.i;A.194.a.4.i;
A.201.a.4.i;A.201.a.4.i;
A.208.a.4.i;A.208.a.4.i;
A.215.a.4.i;A.215.a.4.i;
A.222.a.4.i;A.222.a.4.i;
A.229.a.4.i;A.229.a.4.i;
A.236.a.4.i;A.236.a.4.i;
A.243.a.4.i;A.243.a.4.i;
A.250.a.4.i;A.250.a.4.i;
A.257.a.4.i;A.257.a.4.i;
A264.a.4.i;A264.a.4.i;
A.271.a.4.i;A.271.a.4.i;
A.278.a.4.i;A.278.a.4.i;
A.285.a.4.i;A.285.a.4.i;
A.292.a.4.i;A.292.a.4.i;
A.299.a.4.i;A.299.a.4.i;
A.306.a.4.i;A.306.a.4.i;
A.313.a.4.i;A.313.a.4.i;
A.320.a.4.i;A.320.a.4.i;
A.328.a.4.i;A.328.a.4.i;
A.335.a.4.i;A.335.a.4.i;
A.342.a.4.i;A.342.a.4.i;
A.349.a.4.i;A.349.a.4.i;
A.356.a.4.i;A.356.a.4.i;
A.363.a.4.i;A.363.a.4.i;
A.370.a.4.i;A.370.a.4.i;
A.377.a.4.i;A.377.a.4.i;
A.384.a .4 .i;A.384.a .4 .i;
A.391.a.4.i;A.391.a.4.i;
A.398.a.4.i;A.398.a.4.i;
A.405.a.4.i;A.405.a.4.i;
A.412.a.4.i;A.412.a.4.i;
A.419.a.4.i;A.419.a.4.i;
A.426.a.4.i;A.426.a.4.i;
A.433.a.4.i;A.433.a.4.i;
A.440.a.4.i;A.440.a.4.i;
A.447.a.4.i;A.447.a.4.i;
A.454.a.4.i;A.454.a.4.i;
A.461.a.4.i;A.461.a.4.i;
A.468.a.4.i;A.468.a.4.i;
A.475.a.4.i;A.475.a.4.i;
A.482.a.4.i;A.482.a.4.i;
A.489.a.4.i;A.489.a.4.i;
A.496.a.4.i;A.496.a.4.i;
A.174.a.4.i;A.174.a.4.i;
A.181.a.4.i;A.181.a.4.i;
A.188.a.4.i;A.188.a.4.i;
A.195.a.4.i;A.195.a.4.i;
A.202.a.4.i;A.202.a.4.i;
A.209.a.4.i;A.209.a.4.i;
A.216.a.4.i;A.216.a.4.i;
A,223.a.4.i;A, 223.a.4.i;
A.230.a.4.i;A.230.a.4.i;
A.237.a.4.i;A.237.a.4.i;
A.244.a.4.i;A.244.a.4.i;
A.251.a.4.i;A.251.a.4.i;
A.258.a.4.i;A.258.a.4.i;
A.265.a.4.i;A.265.a.4.i;
A.272.a.4.i;A.272.a.4.i;
A.279.a.4.i;A.279.a.4.i;
A.286.a.4.i;A.286.a.4.i;
A.293.a.4.i;A.293.a.4.i;
A.300.a.4.i;A.300.a.4.i;
A.307.a.4.i;A.307.a.4.i;
A.314.a.4.i;A.314.a.4.i;
A.321.a.4.i;A.321.a.4.i;
A.329.a.4.i;A.329.a.4.i;
A.336.a.4.i;A.336.a.4.i;
A.343;a.4.i;A.343;
A.350.a.4.i;A.350.a.4.i;
A.357.a.4.i;A.357.a.4.i;
A.364.a.4.i;A.364.a.4.i;
A.371.a.4.i;A.371.a.4.i;
A.378.a.4.i;A.378.a.4.i;
A.385.a.4.i;A.385.a.4.i;
A.392.a.4.i;A.392.a.4.i;
A.399.a.4.i;A.399.a.4.i;
A.406.a.4.i;A.406.a.4.i;
A.413.a.4.i;A.413.a.4.i;
A.420.a.4.i;A.420.a.4.i;
A.427,a.4.i;A.427, a.4.i;
A.434.a.4.i:A.434.a.4.i:
A.441.a.4.i;A.441.a.4.i;
A.448.a.4.i;A.448.a.4.i;
A.455.a.4.i;A.455.a.4.i;
A.462.a.4.i;A.462.a.4.i;
A.469.a.4.x;A.469.a.4.x;
A.476.a.4.i;A.476.a.4.i;
A.483.a.4.i;A.483.a.4.i;
A.490.a.4.i;A.490.a.4.i;
A.497.a.4.i;A.497.a.4.i;
A.173.a.4.i;A.173.a.4.i;
A.182.a.4.i,A.182.a.4.i,
A.189.a.4.i;A.189.a.4.i;
A.196.a.4.i;A.196.a.4.i;
A.203.a.4.x;A.203.a.4.x;
A.210.a.4.i;A.210.a.4.i;
A217.a.4.i;A217.a.4.i;
A.224.a.4.i;A.224.a.4.i;
A.231.a.4.i;A.231.a.4.i;
A.238.a.4.i;A.238.a.4.i;
A.245.a.4.i;A.245.a.4.i;
A.252.a.4.i;A.252.a.4.i;
A.259.a.4.i;A.259.a.4.i;
A.266.a.4.i;A.266.a.4.i;
A.273.a.4.i;A.273.a.4.i;
A.280.a.4.i;A.280.a.4.i;
A.287.a.4.i;A.287.a.4.i;
A.294.a.4.i;A.294.a.4.i;
A.301.a.4.i;A.301.a.4.i;
A.308-a.4.i;A.308-a.4.i;
A.315.a.4.i;A.315.a.4.i;
A.323.a.4.i;A.323.a.4.i;
A.330.a.4.i;A.330.a.4.i;
A.337.a.4.i;A.337.a.4.i;
A.344.a.4.i;A.344.a.4.i;
A.351.a.4.i;A.351.a.4.i;
A.358.a.4.i;A.358.a.4.i;
A.365.a.4.i;A.365.a.4.i;
A.372.a.4.i;A.372.a.4.i;
A.379.a.4.i;A.379.a.4.i;
A.386.a.4.i;A.386.a.4.i;
A.393.a.4.i;A.393.a.4.i;
A.400.a.4.i;A.400.a.4.i;
A.407.a.4.i;A.407.a.4.i;
A.414.a.4.i;A.414.a.4.i;
A.421.a.4.i;A.421.a.4.i;
A.428.a.4.i;A.428.a.4.i;
A.435.a.4.i;A.435.a.4.i;
A.442.a.4,i;A.442.a.4, i;
A.449.a.4.i;A.449.a.4.i;
A.456.a.4.i;A.456.a.4.i;
A.463.a.4.i;A.463.a.4.i;
A.470.a.4.i;A.470.a.4.i;
A.477,a.4.i;A.477, a.4.i;
A.484.a.4.i;A.484.a.4.i;
A.491,a.4.i;A.491, a.4.i;
A.498,a.4.í;A.498, a.4.i;
A.176.a.4.i; A.183.a.4.i; A.190.a.4.i; A.197.a.4.i; A.204.a.4.i; A.211.a.4.i; A.218.a.4.i; A.225.a.4.i; A.232.a.4.i; A.239.a.4.i; A.246.a.4.i; A.253.a.4.i; A.260.a.4.i; A.267.a.4.i; A.274.a.4.i; A.28I.a.4.í; A.288.a.4.i; A.295.a.4.i; A.302.a.4.i; A.309.a.4.i; Á.316.a.4.i; A.324,a.4.i; A.331.a.4.i; A.338.a.4.i; A.345.a.4.i; A.352.a.4.i; A.359.a.4.i; A.366.a.4.i; A.373.a.4.i; A.380.a.4.i; A.387.a.4.i; A.394.a.4.i; A.401.a.4.í; A.408.a.4.i; A.415.a.4.i; A.422.a.4.i; A.429.a.4.i; A.436.a.4.i; A.443.a.4.i; A.450.a.4.i; A.457.a.4.i; A.464.a.4.i; A.471.a.4.i; A.478.a.4.i; A.485.a.4.i; A.492.a.4.i; A.499.a.4.i;A.176.a.4.i; A.183.a.4.i; A.190.a.4.i; A.197.a.4.i; A.204.a.4.i; A.211.a.4.i; A.218.a.4.i; A.225.a.4.i; A.232.a.4.i; A.239.a.4.i; A.246.a.4.i; A.253.a.4.i; A.260.a.4.i; A.267.a.4.i; A.274.a.4.i; A.28I.a.4.í; A.288.a.4.i; A.295.a.4.i; A.302.a.4.i; A.309.a.4.i; Á.316.a.4.i; A.324, a.4.i; A.331.a.4.i; A.338.a.4.i; A.345.a.4.i; A.352.a.4.i; A.359.a.4.i; A.366.a.4.i; A.373.a.4.i; A.380.a.4.i; A.387.a.4.i; A.394.a.4.i; A.401.a.4.í; A.408.a.4.i; A.415.a.4.i; A.422.a.4.i; A.429.a.4.i; A.436.a.4.i; A.443.a.4.i; A.450.a.4.i; A.457.a.4.i; A.464.a.4.i; A.471.a.4.i; A.478.a.4.i; A.485.a.4.i; A.492.a.4.i; A.499.a.4.i;
-92CZ 297945 B6-92EN 297945 B6
A.500.a.4.i; A.501.a.4.i; A.502.a.4.i; A.503.a.4.i; A.504.a.4.i; A.505.a.4.i; A.506.a.4.i; A.507.a.4.i; A.508.a.4.i; A.509.a.4.i; A.510.a.4.i; A.511.a.4.i; A.512.a.4.i; A.512.a.4.i; A.513.a.4.i; A.514.a4.í; A.515,a.4.i; A.516.a.4.i; A.517.a.4.i; A.518.a.4.i· A.519.a.4.i; A.520.a.4,i; A.521.a.4.i; A.522.a.4.i; A.523.a.4.i; A.524.a.4.i; A.525.a.4.i; A.526.a.4.i; A.527.a.4.i; A.528.a.4.i; A.529.a.4.i; A.530.a.4.í; A.531.a.4.i; A.532.a.4.i; A.533.a.4.i; A.534.a.4.i; A.535.a.4.í; A.536.a.4.i; A.537.a.4.i; A.538.a.4.i; A.539.a.4.i; A.540.a.4.i; A.541.a.4.i; A.542.a.4.i; A543.a.4.i; A.544.a.4.i; A.545.a.4.i; A.546.a.4.i; A.547.a4.i; A.548.a.4.i; A.549.a.4.i; A.550.a,4.i; A.551.a.4.i; A.552.a.4.í; A.553.a.4.i; A.554.a.4.i; A.555.a.4.i; A.556.a.4.i; A.557.a.4.i; A.558.a.4.i; A.559.a.4.i; A.560.a.4.i; A.561.a4.i; A.562.a.4.i; A.563.a.4.i; A.564.a.4ď; A.565.a.4.i; A.566.a.4.i; A.567.a.4.i; A.568.a.4.i; A.569.a.4.i; A.570.a.4.i; A.571.a.4.i; A.572.a.4.i; A.573.a.4.i; A.574.a.4.i; A.575.a.4.i; A.576.a.4.i; A.577.a.4.i; A.578.a.4.i; A.579.a.4.i; A.580.a.4.i; A.581.a.4.i; A.582.a.4.i; A.583.a.4.i; A.584.a.4.i; A.585.a,4.i; ,A.586»a.4.i; A.587.a.4d; A.588.a.4.i; A.589.a.4.i; A.590.a.4.i; A.591.a.4.i; A.592.a.4.i; A.593.a.4.i; A.594.a.4.i; A.595.a.4.i; A.596.a.4.i; A.597.a.4.i; A.598.a.4.i; A.599.a.4.i; A.600.a.4.i; A.601.a.4.i; A.602.a.4.i; A.603.a.4.i; A.604.a.4.i; A.605.a.4.i; A.606.a.4.i; A.607.a.4.i; A.608.a.4.i; A.609.a.4.i; A.610.a.4,i; A.611.a.4.i; A.612.a.4.i; A.613.a.4ď; A.614.a.4.i; A.615.a.4.í; A.616.a.4.i; A.617.a.4.i; A.618.a4.i; A.619.a4.i; A.620.a.4i; A.621.a.4.i; A.622.a.4.i; A.623.a.4.i; A.624.a.4.i; A.625.a.4.i; A.626.a.4.i; A.627.a.4.i; A.628.a.4.i; A.629.a.4.i; A.630.a.4.i; A,631.a.4.i; A.632.a.4.i; A.633.a4.i; A.634.a4.i; A.635.a.4.i; A.636.a.4.i; A.637.a.4.i; A.638.a.4.i; A.639.a.4,i; A.640.a.4.i; A.641.a.4.i; A.642.a.4.i; A.643.a.4.i; A.644.a.4.i; A.645.a.4.í; A.646.a.4.i; A.647.a.4.i; A,648.a.4.i; A.649.a.4.i; A.650.a.4.i; A.651.a.4.i; A.652.a.4.i; A.653.a.4.i; A.654.a.4.i; A.655.a.4.i; A.656.a.4.i; A.657.a.4.i; A.658.a.4.i; A.659.a.4.i; A.660.a.4.i; A.2.a.ll.i; A.S.a.ll.i; A.4.a.ll.i; A.S.a.ll.i; A.ó.a.ll.i; A.7.a.ll.i; A.9.a.ll.i; A.lO.a.lU; A.lS.a.ll.i; A.lOO.a.ll.i; A.lOl.a.ll.i; A.102.a.ll.i; A.103.a.ll.i; A.104.a.ll.i: A.lOS.a.U.i; A.106.a.ll.i; A.107.a.ll.i; A.108.a.ll.i; A.109.a.ll.i; A.llC.a.ll.i; A.lll.a.U.i; A.112.a.ll.i; A.113.a.ll.i; A.114.a.ll.i; A.llS.a.ll.i; A.lló.a.ll.i; A.117.a.ll.i; A.U8.a.ll.i; A.119.a.ll.i; A.120,a.ll.i; A.121.a.ll.i; A.122.a.ll.i; A.123,a.ll.i; A.124.a.ll.i; A.125.a.U.i; A.126.a.ll.i; A.127.a.ll.i; A.128.a.ll.i; A.129.a.ll.i; A.130.a.ll.i; A.131.a.ll.i; A.132.a.ll.i; A.133.a.ll.i; A.134.a.ll.i; A.135.a.ll.i; A.136.a.lLi; A.137.a.ll.i; A.138.a.ll.i; A,139.a.ll.i; A.14Cha.ll.i; A.141.a.lLi; A.142.a.ll.i; A.143.a.ll.i; A.144.a.lLi; A.145.a,ll.i; A.146.a.U.i; A.147.a.ll.i; A.148.a.ll.i; A.149.a.ll.j; A.150.a.ll.i; A.lSl.a.ll.i; A.152.a.ll.i; A.153.a.ll.i; A.154.a.ll.i; A.ISS.a.ll.i; A.156.a.ll.i; A.157.a.ll.i; A.158.a.ll.i; A.159.a.ll.i; A.lóO.a.ll.i; A.161.a.ll.i; A.162.a.ll.i; A.163.a.ll.i; A.164.a.ll.i; A.165.a.ll.i; A.166.a.ll.i; A.167.a.lU; A.168.a.ll.i; A.169.a.ll.i; A.170.a.ll.i; A.171.a.ll.i; A.172.a.ll.i; A.173.a.ll.i; A.174.a.ll.i; A.175.a.ll.i; A.176.a.ll.i; A.177.a.ll.i- A.178.a.ll.i; A.179.a.ll.i; A.180.a.ll.i; A.181.a.ll.i; A.182.a.ll.i; A.183.a.ll.i; A.184.a.ll.i; A.185.a.ll.i; A.186.a.ll.i; A.lS/.a.H.i; A.188,a.lU; A.189.a.ll.i; A.190.a.ll.i; A.191.a.ll.i; A.192.a.ll.i; A.193.a.n.i; A.194.a.ll.i; A.195.a.ll.i; A.196.a.ll.í; A.197.a.ll.i; A.198.a.ll.i; A.199.a.ll.i; A.ZOO.a.ll.i; A.201.a.ll.i; A.202.a.H.i; A.203.a.ll.i; A,204.a.ll.i; A.2O5.a.ll.i; A.2O6.a.ll.i; A.207.a.ll.i; A.208.a.ll.i;A.209.a.ll.i; A.210.a.ll.i; A.211.a.ll.i; A.212.a.ll.i; A.213.a.ll.i; A.214.a.ll.i; A.215.a.ll.i; A.216.a.U.i; A.217.a.ll.i; A.218.a.ll.i; A.219.a.ll.i; A.220.a.ll.i; A.221.a.ll.i; A.222.a.lU; A.223.a.ll.i; A.224.á.ll.i; A.225.a.ll.i; A.226.a.ll.i; A.227.a.ll.i; A.228.a.ll.i; A.229.a.ll.i; A.230.a.ll.i; A.231.a.n.i; A.232.a.ll.i; A.233.a.ll.i; A.234.a.ll.i;A.500.a.4.i; A.501.a.4.i; A.502.a.4.i; A.503.a.4.i; A.504.a.4.i; A.505.a.4.i; A.506.a.4.i; A.507.a.4.i; A.508.a.4.i; A.509.a.4.i; A.510.a.4.i; A.511.a.4.i; A.512.a.4.i; A.512.a.4.i; A.513.a.4.i; A.514.a4.í; A.515, a.4.i; A.516.a.4.i; A.517.a.4.i; A.518.a.4.i; A.520.a.4., I; A.521.a.4.i; A.522.a.4.i; A.523.a.4.i; A.524.a.4.i; A.525.a.4.i; A.526.a.4.i; A.527.a.4.i; A.528.a.4.i; A.529.a.4.i; A.530.a.4.í; A.531.a.4.i; A.532.a.4.i; A.533.a.4.i; A.534.a.4.i; A.535.a.4.í; A.536.a.4.i; A.537.a.4.i; A.538.a.4.i; A.539.a.4.i; A.540.a.4.i; A.541.a.4.i; A.542.a.4.i; A543.a.4.i; A.544.a.4.i; A.545.a.4.i; A.546.a.4.i; A.547.a4.i; A.548.a.4.i; A.549.a.4.i; A.550.a, 4.i; A.551.a.4.i; A.552.a.4.í; A.553.a.4.i; A.554.a.4.i; A.555.a.4.i; A.556.a.4.i; A.557.a.4.i; A.558.a.4.i; A.559.a.4.i; A.560.a.4.i; A.561.a4.i; A.562.a.4.i; A.563.a.4.i; A.564.a.4ď; A.565.a.4.i; A.566.a.4.i; A.567.a.4.i; A.568.a.4.i; A.569.a.4.i; A.570.a.4.i; A.571.a.4.i; A.572.a.4.i; A.573.a.4.i; A.574.a.4.i; A.575.a.4.i; A.576.a.4.i; A.577.a.4.i; A.578.a.4.i; A.579.a.4.i; A.580.a.4.i; A.581.a.4.i; A.582.a.4.i; A.583.a.4.i; A.584.a.4.i; A.585.a, 4.i; , A.586 »a.4.i; A.587.a.4d; A.588.a.4.i; A.589.a.4.i; A.590.a.4.i; A.591.a.4.i; A.592.a.4.i; A.593.a.4.i; A.594.a.4.i; A.595.a.4.i; A.596.a.4.i; A.597.a.4.i; A.598.a.4.i; A.599.a.4.i; A.600.a.4.i; A.601.a.4.i; A.602.a.4.i; A.603.a.4.i; A.604.a.4.i; A.605.a.4.i; A.606.a.4.i; A.607.a.4.i; A.608.a.4.i; A.609.a.4.i; A.610.a.4., I; A.611.a.4.i; A.612.a.4.i; A.613.a.4ď; A.614.a.4.i; A.615.a.4.í; A.616.a.4.i; A.617.a.4.i; A.618.a4.i; A.619.a4.i; A.620.a.4i; A.621.a.4.i; A.622.a.4.i; A.623.a.4.i; A.624.a.4.i; A.625.a.4.i; A.626.a.4.i; A.627.a.4.i; A.628.a.4.i; A.629.a.4.i; A.630.a.4.i; A, 631.a.4.i; A.632.a.4.i; A.633.a4.i; A.634.a4.i; A.635.a.4.i; A.636.a.4.i; A.637.a.4.i; A.638.a.4.i; A.639.a.4., I; A.640.a.4.i; A.641.a.4.i; A.642.a.4.i; A.643.a.4.i; A.644.a.4.i; A.645.a.4.í; A.646.a.4.i; A.647.a.4.i; A, 648.a.4.i; A.649.a.4.i; A.650.a.4.i; A.651.a.4.i; A.652.a.4.i; A.653.a.4.i; A.654.a.4.i; A.655.a.4.i; A.656.a.4.i; A.657.a.4.i; A.658.a.4.i; A.659.a.4.i; A.660.a.4.i; A.2.a.ll.i; A.S.a.ll.i; A.4.a.ll.i; A.S.a.ll.i; A.ó.a.ll.i; A.7.a.ll.i; A.9.a.ll.i; A.10.a.IIU; A.lS.a.ll.i; A.100.a.ll.i; A.I01.a.II.i; A.102.a.ll.i; A.103.a.ll.i; A.104.a.ll.i: A.lOS.a.U.i; A.106.a.ll.i; A.107.a.ll.i; A.108.a.ll.i; A.109.a.ll.i; A.llC.a.ll.i; A.lll.a.U.i; A.112.a.ll.i; A.113.a.ll.i; A.114.a.ll.i; A.llS.a.ll.i; A.lló.a.ll.i; A.117.a.ll.i; A.U8.a.ll.i; A.119.a.ll.i; A.120, a.111.i; A.121.a.ll.i; A.122.a.ll.i; A.123, a.ll.i; A.124.a.ll.i; A.125.a.U.i; A.126.a.ll.i; A.127.a.ll.i; A.128.a.ll.i; A.129.a.ll.i; A.130.a.ll.i; A.131.a.ll.i; A.132.a.ll.i; A.133.a.ll.i; A.134.a.ll.i; A.135.a.ll.i; A.136.a.lLi; A.137.a.ll.i; A.138.a.ll.i; A, 139.a.II.i; A.14Cha.ll.i; A.141.a.lLi; A.142.a.ll.i; A.143.a.ll.i; A.144.a.lLi; A.145.a, II.i; A.146.a.U.i; A.147.a.ll.i; A.148.a.ll.i; A.149.a.ll.j; A.150.a.ll.i; A.lSl.a.ll.i; A.152.a.ll.i; A.153.a.ll.i; A.154.a.ll.i; A.ISS.a.ll.i; A.156.a.ll.i; A.157.a.ll.i; A.158.a.ll.i; A.159.a.ll.i; A.10.0.a.ll.i; A.161.a.ll.i; A.162.a.ll.i; A.163.a.ll.i; A.164.a.ll.i; A.165.a.ll.i; A.166.a.ll.i; A.167.a.lU; A.168.a.ll.i; A.169.a.ll.i; A.170.a.ll.i; A.171.a.ll.i; A.172.a.ll.i; A.173.a.ll.i; A.174.a.ll.i; A.175.a.ll.i; A.176.a.ll.i; A.177.a.ll.i- A.178.a.ll.i; A.179.a.ll.i; A.180.a.ll.i; A.181.a.ll.i; A.182.a.ll.i; A.183.a.ll.i; A.184.a.ll.i; A.185.a.ll.i; A.186.a.ll.i; A.I./.a.H.i; A.188, a.1U; A.189.a.ll.i; A.190.a.ll.i; A.191.a.ll.i; A.192.a.ll.i; A.193.a.n.i; A.194.a.ll.i; A.195.a.ll.i; A.196.a.ll.í; A.197.a.ll.i; A.198.a.ll.i; A.199.a.ll.i; A.ZOO.a.ll.i; A.201.a.ll.i; A.202.a.H.i; A.203.a.ll.i; A, 204.a.II.i; A.2O5.a.ll.i; A.2O6.a.ll.i; A.207.a.ll.i; A.208.a.ll.i; A.209.a.ll.i; A.210.a.ll.i; A.211.a.ll.i; A.212.a.ll.i; A.213.a.ll.i; A.214.a.ll.i; A.215.a.ll.i; A.216.a.U.i; A.217.a.ll.i; A.218.a.ll.i; A.219.a.ll.i; A.220.a.ll.i; A.221.a.ll.i; A.222.a.lU; A.223.a.ll.i; A.224.á.ll.i; A.225.a.ll.i; A.226.a.ll.i; A.227.a.ll.i; A.228.a.ll.i; A.229.a.ll.i; A.230.a.ll.i; A.231.a.n.i; A.232.a.ll.i; A.233.a.ll.i; A.234.a.ll.i;
-93CZ 297945 B6-93EN 297945 B6
A.235.a.ll.i; A.236.a.ll.i; A.237.a.ll.i; A.241.a41.i; A.242.a.lLi; A.243.a.ll.i; A.247.a.ll.i; A.248.a.ll.i; A.249.a.U.i; A.253.a.ll4; A.254.a.ll.i; A.255.a.ll.i; A.259.a.ll.i; A.260.a.ll.i; A.26La.ll.Í; A.265.a.ll.i; A.266.a.ll.i; A.267.a.ll.i; A.271.a.ll.i; A.272.a.ll.i; A.273.a.ll.i; A377.a.ll.i; A278.a.llá; A.279.a.ll.i; A-283.a.ll.i; A.284.a.U.i; A.285.a.ll.i; A289.a.ll.i; A.290.a.ll.i; A.291.a.ll.i; A.295.a.ll.i; A.296.a.ll.i; A.297.a.ll.i; A.301.a.ll.i; A.302.a.ll.i; A.303.a.ll.i; A.307.a.ll.i; A.308.a.ll.i; A.309.a.ll.Í; A.313.a.ll.i; A314.a.ll.i; A.315.a.ll.i; A.319.a.ll.i; A.320.a.ll.i; A.321.a.ll.i; A.326.a.ll.i; A.327.a.ll.i; A.328.a.ll.í; A.332.a.ll.i; A.333.a.ll.i; A.334.a.ll.i; A338.a.ll.i; A.339.a.ll.i; A.34Q.a.ll.i; A.344.a.ll.i; A.345.a.ll.i; A.346.a.ll.i; A.350.a.ll.i; A.351,a.ll.i; A.352.a.ll.i; A.356.a.ll.i; A.357.a.ll.i; A.358.a.ll.i; A.362.a.ll.i; A.363.a.ll.i; A.364.a.ll.i; A368a.11.i; A.369.a.U.i; A.370.a.ll,i; A.374.a.ll.i; A.375.a.ll.i; A376.a.ll.i; A380.a.ll.i; A.381.a.ll.i; A.382.a.ll.i; A.386.a.Il.i; A.387.a.U.i; A.388.a.ll.i; A.392.a.ll.i; A.393.a.U.i; A.394.a.ll.i; A.398.a.ll.i; A.399.a.ll.i; A.400.a.lLi; A.404.a.ll.i; A.405.a.ll.i; A.406.a.ll.i; A.410.a.ll.i; A411a.11.í; A.412.a.ll.i; A.416.a.ll.i; A.417.a.ll.i; A.418.a.U.i; A.422.a.U.i; A.423.a.ll.i; A,424.a.ll.i; A.428.a.ll.i; A.429.a.U.i; A.430.a.ll.i; A.434.a.ll.i; A.435.a.ll.i; A.436.a.ll.i; A.440.a.ll.i; A.441.a.U.i; A.442.a.ll.i; A.446.a.ll.i; A.447.a.lLi; A.448.a.ll.i; A.452.a.ll.i; A.453.a.ll.i; A.454.a.ll.i; A.458.a.ll.i; A.459.a.ll.i; A.460.a.ll.i; A.464.a.ll.ij A.465.a.ll.i; A.466.a.ll.i; A.470.a.ll.i; A.471.a.ll.i; A.472.a.ll,i; A.476.a.ll.i; A.477.a.U.i; A.478.a.ll.i; A.482.a.ll.i; A.483.a.ll.i; A484a.11.i; A.488.a.ll.i; A.489.a.ll.i; A.490.a.U.i; A494.a.ll.i; A.495.a.ll.i; A.496.a.U.i; A.500.a.ll.i; A.501.a.ll.i; A.502.a.ll.i; A.506.a.ll.i; A.507.a.ll.i; A.508.a.ll.i; A.512.a.ll.i; A.512.a.ll.i; A.513.a.ll.i;A.235.a.ll.i; A.236.a.ll.i; A.237.a.ll.i; A.241.a41.i; A.242.a.lLi; A.243.a.ll.i; A.247.a.ll.i; A.248.a.ll.i; A.249.a.U.i; A.253.a.ll4; A.254.a.ll.i; A.255.a.ll.i; A.259.a.ll.i; A.260.a.ll.i; A.26La.ll.I; A.265.a.ll.i; A.266.a.ll.i; A.267.a.ll.i; A.271.a.ll.i; A.272.a.ll.i; A.273.a.ll.i; A377.a.ll.i; A278.a.llá; A.279.a.ll.i; A-283.a.II.i; A.284.a.U.i; A.285.a.ll.i; A289.a.ll.i; A.290.a.ll.i; A.291.a.ll.i; A.295.a.ll.i; A.296.a.ll.i; A.297.a.ll.i; A.301.a.ll.i; A.302.a.ll.i; A.303.a.ll.i; A.307.a.ll.i; A.308.a.ll.i; A.309.a.ll.I; A.313.a.ll.i; A314.a.ll.i; A.315.a.ll.i; A.319.a.ll.i; A.320.a.ll.i; A.321.a.ll.i; A.326.a.ll.i; A.327.a.ll.i; A.328.a.ll.í; A.332.a.ll.i; A.333.a.ll.i; A.334.a.ll.i; A338.a.ll.i; A.339.a.ll.i; A.34Q.a.ll.i; A.344.a.ll.i; A.345.a.ll.i; A.346.a.ll.i; A.350.a.ll.i; A.351, a.ll.i; A.352.a.ll.i; A.356.a.ll.i; A.357.a.ll.i; A.358.a.ll.i; A.362.a.ll.i; A.363.a.ll.i; A.364.a.ll.i; A368a.11.i; A.369.a.U.i; A.370.a.ll, i; A.374.a.ll.i; A.375.a.ll.i; A376.a.ll.i; A380.a.ll.i; A.381.a.ll.i; A.382.a.ll.i; A.386.a.Il.i; A.387.a.U.i; A.388.a.ll.i; A.392.a.ll.i; A.393.a.U.i; A.394.a.ll.i; A.398.a.ll.i; A.399.a.ll.i; A.400.a.lLi; A.404.a.ll.i; A.405.a.ll.i; A.406.a.ll.i; A.410.a.ll.i; A411a.11.í; A.412.a.ll.i; A.416.a.ll.i; A.417.a.ll.i; A.418.a.U.i; A.422.a.U.i; A.423.a.ll.i; A, 424.a.II.i; A.428.a.ll.i; A.429.a.U.i; A.430.a.ll.i; A.434.a.ll.i; A.435.a.ll.i; A.436.a.ll.i; A.440.a.ll.i; A.441.a.U.i; A.442.a.ll.i; A.446.a.ll.i; A.447.a.lLi; A.448.a.ll.i; A.452.a.ll.i; A.453.a.ll.i; A.454.a.ll.i; A.458.a.ll.i; A.459.a.ll.i; A.460.a.ll.i; A.464.a.ll.ij A.465.a.ll.i; A.466.a.ll.i; A.470.a.ll.i; A.471.a.ll.i; A.472.a.ll, i; A.476.a.ll.i; A.477.a.U.i; A.478.a.ll.i; A.482.a.ll.i; A.483.a.ll.i; A484a.11.i; A.488.a.ll.i; A.489.a.ll.i; A.490.a.U.i; A494.a.ll.i; A.495.a.ll.i; A.496.a.U.i; A.500.a.ll.i; A.501.a.ll.i; A.502.a.ll.i; A.506.a.ll.i; A.507.a.ll.i; A.508.a.ll.i; A.512.a.ll.i; A.512.a.ll.i; A.513.a.ll.i;
A.238.a.U.i; A.239.a.ll.i; A.240.a.ll.i; A.244.a.ll.i; A.245.a.ll.i; A.246.a.ll.i; A.250.a.ll.i; A.251.a.U.i; A.252.a.ll.i; A.256-a,ll.i; A.257.a.ll.i; A.258.a.ll.i; A262A.il.i; A.263.a.ll.i; A.264.a.ll.i; A.268.a.ll.i; A.269.a.ll.i; A.270.a.ll.i; A.274.a.ll.i; A.275.a.ll.i; A.276.a.ll.i; A.280.a.ll.i; A.281.a.ll.i; A.282.a.ll.i; A.286.a.ll.i; A-287.a.ll.i; A.288,a.ll.i; A.292.a.ll.i; A.293.a.ll.i; A.294.a.ll.i; A.298.a.ll.i; A.299.a.ll.i; A.300a.11.í; A.304.a.ll.i; A.305.a.ll.i; A.306.a.ll.i; A.310.a.ll.i; A.311.a.ll.i; A.312.a.ll.i; A316A.ll.ij A317a.11.i; A318.a.ll.i; A.323.a.ll.i; A324,a.ll.i; A.325.a.ll.Í; A.329.a.ll.i; A330.a.ll.i; A331a.11,.í; A.335.a.ll.i; A.336.a.ll.i; A337.a.ll.i; A341A.11.Í; A342.a.ll4í A.343.a.ll4; A.347.a.ll.i; A348.a.U4j A.349.a.ll.i; A.353.a.ll.i; A.354.a.ll.i; A.355.a.ll.i; A.359.a.ll.i; A.360.a.ll.i· A.361.a.ll4; A365.a.ll4; A366.a.ll.i; A367a.ll.ij A371a.ll.ij A.372a.ll4; A.373.a.U.i; A.377.a.ll.i; A378a.ll4j A.379.a.ll.i; A.383.a.ll.i; A384a.lLi; A385a.Il.ij A.389.a.ll.i; A.390.a.ll.i; A.391a.ll4; A395a.lld; A.396.a.ll.i; A.397.a.ll.i; A4Ola.ll.ij A.402.a.ll.i; A.403a.ll4; A.407.a.ll.i; A.408.a.ll.i; A.409.a.ll.i; A.413a.ll4; A.414.a.ll.i; A415A.114; A.419A.114; A420a.ll.i; A.421.a.ll.i; A.425.a.U.i; A.426a.ll.i; A.427.a.ll.i; A431a.114í A.432a.ll4; A.433.a.ll.i; A.437.a.ll.i; A.438.a.ll.i; A.439.a.ll.i; A.443.a.ll.i; A:444a.ll.i; A.445.a.ll.i; A.449.a.ll.i; A.450.a.ll.i; A451.a.ll4; A455a.ll4; A456a.ll.i; A.457a.ll4; A.461.a.ll.i; A.462a.ll.i; A.463.a.ll.i; A.467.a.ll.i; A.468.a.ll.i; A.469.a.ll.i; A473,a.ll4; A.474.a.ll.i; A.475a.ll.i; A.479.a.ll.i; A.480.a.ll4; A.481.a.ll.i; A.485.a.ll.i; A.486.a.ll.i; A.487.a.ll.i; A491a.ll.i; A.492.a.ll.i; A.493.a.ll.í; A497.a.ll4; A.498.a.ll.i; A.499a.ll.i; A.503.a.ll.i; A.504.a.ll.i; A.505a.ll4; A.509.a.ll.i; A.510.a.U.i; A.5Il.a.ll.i; A.514.a.ll.i; A.515a.ll4; A.SIÓ.a.ll.i;A.238.a.U.i; A.239.a.ll.i; A.240.a.ll.i; A.244.a.ll.i; A.245.a.ll.i; A.246.a.ll.i; A.250.a.ll.i; A.251.a.U.i; A.252.a.ll.i; A.256-a, II.1; A.257.a.ll.i; A.258.a.ll.i; A262A.il.i; A.263.a.ll.i; A.264.a.ll.i; A.268.a.ll.i; A.269.a.ll.i; A.270.a.ll.i; A.274.a.ll.i; A.275.a.ll.i; A.276.a.ll.i; A.280.a.ll.i; A.281.a.ll.i; A.282.a.ll.i; A.286.a.ll.i; A-287.a.II.i; A.288, a.ll.i; A.292.a.ll.i; A.293.a.ll.i; A.294.a.ll.i; A.298.a.ll.i; A.299.a.ll.i; A.300a.11.í; A.304.a.ll.i; A.305.a.ll.i; A.306.a.ll.i; A.310.a.ll.i; A.311.a.ll.i; A.312.a.ll.i; A316A.ll.ij A317a.11.i; A318.a.ll.i; A.323.a.ll.i; A324, a.1ll.1; A.325.a.ll.I; A.329.a.ll.i; A330.a.ll.i; A331a.11, .i; A.335.a.ll.i; A.336.a.ll.i; A337.a.ll.i; A341A.11.Í; A342.a.ll4i A.343.a.ll4; A.347.a.ll.i; A348.a.U4j A.349.a.ll.i; A.353.a.ll.i; A.354.a.ll.i; A.355.a.ll.i; A.359.a.ll.i; A.360.a.ll.i · A.361.a.ll4; A365.a.ll4; A366.a.ll.i; A367a.ll.ij A371a.ll.ij A.372a.ll4; A.373.a.U.i; A.377.a.ll.i; A378a.ll4j A.379.a.ll.i; A.383.a.ll.i; A384a.lLi; A385a.Il.ij A.389.a.ll.i; A.390.a.ll.i; A.391a.ll4; A395a.lld; A.396.a.ll.i; A.397.a.ll.i; A4Ola.ll.ij A.402.a.ll.i; A.403a.ll4; A.407.a.ll.i; A.408.a.ll.i; A.409.a.ll.i; A.413a.ll4; A.414.a.ll.i; A415A.114; A.419A.114; A420a.ll.i; A.421.a.ll.i; A.425.a.U.i; A.426a.ll.i; A.427.a.ll.i; A431a.114í A.432a.ll4; A.433.a.ll.i; A.437.a.ll.i; A.438.a.ll.i; A.439.a.ll.i; A.443.a.ll.i; A: 444a.II.i; A.445.a.ll.i; A.449.a.ll.i; A.450.a.ll.i; A451.a.ll4; A455a.ll4; A456a.ll.i; A.457a.ll4; A.461.a.ll.i; A.462a.ll.i; A.463.a.ll.i; A.467.a.ll.i; A.468.a.ll.i; A.469.a.ll.i; A473, a.114; A.474.a.ll.i; A.475a.ll.i; A.479.a.ll.i; A.480.a.ll4; A.481.a.ll.i; A.485.a.ll.i; A.486.a.ll.i; A.487.a.ll.i; A491a.ll.i; A.492.a.ll.i; A.493.a.ll.í; A497.a.ll4; A.498.a.ll.i; A.499a.ll.i; A.503.a.ll.i; A.504.a.ll.i; A.505a.ll4; A.509.a.ll.i; A.510.a.U.i; A.5Il.a.ll.i; A.514.a.ll.i; A.515a.ll4; A.SIÓ.a.ll.i;
-94CZ 297945 B6-94EN 297945 B6
A.517.a.ll.i; A.518.a.il.i; A.519.a.ll.i; A.520.a.ll.i; A.521,a.ll4; A.522.a.ll4; A.523.a.ll4; A.524.a,ll.x; A.525.a.ll.i; A.526.a.ll.i; A.527.a.ll.x; A.528.a.ll.i; A.529.a.ll4; A.530.a.ll.i; A-531.a.ll4; A.532.a.ll4; A.533.a.U.i; A.534.a.ll.i; A.535.a.U.i; A.536.a.ll.i; A.537.a,114; A.538.a.lLi; A.539.a.U.i; A.540.a.ll.i; A.541.a.ll.i; A 542.a.ll.i; A.543.a.ll.i; A.544.a.ll.x; A.545.a.ll.i; A.546.&.114; A 347.a.ll.i; A.548.a.lLi; A.549.a.ll.i; A.550.a.ll.i; A.551.a.ll4; A.552.a.ll.x; A.553.a.ll.i; A.554.a.ll.i; A.555.a.ll.i; A.556.a.ll.i; A,557.a.ll.x; A.558.a.ll.i; A.559.a.ll.i; A.560.a.ll4; A.561.a.ll4; A.562.a.ll.i; A.563.a.ll4; A.564.a.ll.i; A.565.a.U.i; A.566.a.ll.x; A.567.a.ll.i; A.568.a.ll.x; A.569.a.ll.i; A.570.a.ll.i; A.571.a.ll4; A.572.a.ll.i; A.573.a.ll.i; A.574.a.ll.i; A575.a.ll.i; A.576.a.ll.i; A.577.a.ll4; A.578.a.ll.i; A.579.a.ll.i; A.SSO.a.ll.i; A.581.a.ll.i; A.582.a.ll.i; A.583.a.U4; A.584.a.ll.i; A.585.a.ll.i; A586.a.ll.x; A.587.a.ll4; A.588.a.ll4; A.589.a.ll.i; A.590.a.ll4; A.591.a.ll.i; A.592.a.ll4; A.593.a.ll.i; A.594.a.lLi; A.595.a.ll4; A.596.a.ll.i; A.597.a.U.x; A.598.a.ll.x; A.599.a.ll.i; A.600.a.ll.i; A.601.a.ll.x; A.602.a.ll.í; A.603.a.ll.i; A.604.a.U.i; A.ÓOS.a.ll.i; A.óOó.a.ll.i; Α.607Λ.114; A^08.a,ll.i; A.609,a.ll.i; A.610.a.ll.x; A.óll.a.lLi; A.612.a.ll4; A.613.a.ll.i; A.614.a.ll.x; A.615.a.ll.i; A.616.a.ll.x; A.617.a.ll4; A.618.a.ll.i; A.619.a.ll.i; A.620.a.ll.i; A.621.a.ll.i; A.622.a.U.i; A.623.a.H.i; A.624.a.ll.i; A.625.a.ll.i; A.626.a.ll4; A.627.a.ll.i; A.628.a.ll.i; A.629.a,114; A.630.a.ll.i; A.631.a.ll4; A.632.a.ll.i; A.633.a.ll.i; A.634.a.ll4; A.635.a.ll.i; A.636.a.U.i; A.637.a.ll.x; A.638.a.ll.i; A.639.a.ll.i; A.640.a.lLi; A.641.a.ll4; A.642.a.ll.i; A.643.a.ll.i; A.644.a.U.i; A.645.a.ll.í; A.646.a.ll.i; A.647.a.ll.i; A.648.a.ll.i; A,649.a.ll4; A.óSO.a.ll.i; A.651.a.U.i; A.652.a.ll4; A.653.a.U4; A.654.a.ll.i; A.655.a.ll.i; A.656.a.ll.i; A.657.a.ll.i; A.658.a.ll.i; A.659.a.ll.i; A.660.a.ll.i; A.2.b,4.i; A.3.b.4.i; A.4.b.4.i; A.5.b.4.x; A.6.b.4.i; A.7.b.4.i; A.9.b.4.i; A.10.b.4.i; A.15.b.44; A.100.b.4.i; A.101.b.4.i; A.102.b.4.i; A.103.b.4.i; A.104.b.4.i; A.105.b.4d; A.106.b.4.i; A.107.b.4.i; A.108.b.44; A.109.b.4.x; A.110.b.4.i; A.lll.b.44; A.-112.b.44; A.113.b.4.i; A.114.b.4.í; A.115.b.4.i; A.116.b.4.i; A.U7.b.44; A.118.b.44; A.119.b.4.i; A.120.b.44; A.121.b.4.i; A.122.b.4.i; A.123.b.4.i; A.124.b.4.i; A.125.b.4.x; A.126.b.4.i; A.127.b.4.i; A.128.b.4.i; A.129.b.4.i; A.130.b.4 .i; A.131.b.44; A.132.b.4.i; A.133.b.4.i; A.134.b.4.i; A.135K44; A.136.b.4.i; A.137.b.4.i; A.138.b.4.i; A.139.b.4.i; A.140.b.4.i; A 141.b.44; A.142.b.4.i; A.143.b.4.i; A,144.b.4.i; A.145.b.4.i; A.146.b.4.i; A.147.b.4.i; A.148.b.4.i; A.149.b.4.i; A.150.b.4.i; A.151.b.44; A.152.b.4.i; A.153.b.4.i; A.154,b.4.i; A.155.b.44; A.156.b.4.i; A.157.b.4á; A.158K44; A.159.b.4.i; A.160.b.4.i; A.161.b.44; A.162.b.4.i; A.163.b.4.i; A.164.b.4.i; A.165.b.44; A.166.b.4.i; A.167.b.44; A.168.b.4.i; A.169.b.44; A.170.b.4.i; A.17Lb.44; A.172.b.44; A.173.b.4.i; A.174.b.4.x; A.175.b.44; A.176.b.44; A.177.b.4.i; A.178.b.4.i; A.179.b.44; A.180.b.44; A.181.b.44; A.182.b.4.i; A.183.b.44; A.184.b.4.i; A.185.b.4.i; A.186.b.44; A.187.b.44; A.188.b.4.i; A.189.b44; A.190.b.4.i; A.191.b,4.í; A.192.b.4.i; A.193.b.4.i; A.194.b.4.i; A.195.b.4.i; A.196.b.44; A.197.b.4.i; A.198.b.4.i; A.199.b.4.i; A200.b-.44; A201.b.4.i; A.202.b.4.x; A.203.b.4.i; A.204.b.4.i; A205.b.4.í; A.206.b.4.i; A207.b.4.i; A.208.b.4.i; A.209.b.4.i; A.210.b.4.i; A.211.b.4.i; A.212.b.4.i; A.213.b.4.i; A.214.b.4.i; A.215.b.44; A.216.b.4.i; A217.b.4.i; A.218.b.4.i; A.219.b.4.i; A.220.b.4.i; A.221.b.4.í; A.222.b.4.i; A.223.b.4.i; A.224.b.4.i; A.225.b.4.i; A226.b.4.i; A.227.b.4.i; A.228.b.4.i; A.229.b.4.i; A.230.b.4.i; A.231.b.4.i; A.232.b.4.i; A.233.b.4.i; A.234.b.4.i; A.235.b.4.i; A.236.b.4.i; A.237.b.4.i; A.238.b.4.i; A.239.b.4.i; A.240.b.4.i; A.241.b.4.i; A.242.b.4.i; A.243.b.4.i; A.244.b.4.i; A.245.b.4,i; A.246.b.4.i; A.247.b.4.i; A.248.b.44; A249.b.4.i; A.250.b.4.i; A.25-l.b.44; A.252.b.4.i;A.517.a.ll.i; A.518.a.il.i; A.519.a.ll.i; A.520.a.ll.i; A.521, a.114; A.522.a.ll4; A.523.a.ll4; A.524.a, II.x; A.525.a.ll.i; A.526.a.ll.i; A.527.a.ll.x; A.528.a.ll.i; A.529.a.ll4; A.530.a.ll.i; A-531.a.ll4; A.532.a.ll4; A.533.a.U.i; A.534.a.ll.i; A.535.a.U.i; A.536.a.ll.i; A.537.a, 114; A.538.a.lLi; A.539.a.U.i; A.540.a.ll.i; A.541.a.ll.i; A 542.a.ll.i; A.543.a.ll.i; A.544.a.ll.x; A.545.a.ll.i; A.546. &. 114; A 347.a.ll.i; A.548.a.lLi; A.549.a.ll.i; A.550.a.ll.i; A.551.a.ll4; A.552.a.ll.x; A.553.a.ll.i; A.554.a.ll.i; A.555.a.ll.i; A.556.a.ll.i; A, 557.a.ll.x; A.558.a.ll.i; A.559.a.ll.i; A.560.a.ll4; A.561.a.ll4; A.562.a.ll.i; A.563.a.ll4; A.564.a.ll.i; A.565.a.U.i; A.566.a.ll.x; A.567.a.ll.i; A.568.a.ll.x; A.569.a.ll.i; A.570.a.ll.i; A.571.a.ll4; A.572.a.ll.i; A.573.a.ll.i; A.574.a.ll.i; A575.a.ll.i; A.576.a.ll.i; A.577.a.ll4; A.578.a.ll.i; A.579.a.ll.i; A.SSO.a.ll.i; A.581.a.ll.i; A.582.a.ll.i; A.583.a.U4; A.584.a.ll.i; A.585.a.ll.i; A586.a.ll.x; A.587.a.ll4; A.588.a.ll4; A.589.a.ll.i; A.590.a.ll4; A.591.a.ll.i; A.592.a.ll4; A.593.a.ll.i; A.594.a.lLi; A.595.a.ll4; A.596.a.ll.i; A.597.a.U.x; A.598.a.ll.x; A.599.a.ll.i; A.600.a.ll.i; A.601.a.ll.x; A.602.a.ll.í; A.603.a.ll.i; A.604.a.U.i; A.ÓOS.a.ll.i; A.O10.a.ll.i; Α.607Λ.114; A ^ 08.a, II.i; A.609, a.ll.i; A.610.a.ll.x; A.óll.a.lLi; A.612.a.ll4; A.613.a.ll.i; A.614.a.ll.x; A.615.a.ll.i; A.616.a.ll.x; A.617.a.ll4; A.618.a.ll.i; A.619.a.ll.i; A.620.a.ll.i; A.621.a.ll.i; A.622.a.U.i; A.623.a.H.i; A.624.a.ll.i; A.625.a.ll.i; A.626.a.ll4; A.627.a.ll.i; A.628.a.ll.i; A.629.a, 114; A.630.a.ll.i; A.631.a.ll4; A.632.a.ll.i; A.633.a.ll.i; A.634.a.ll4; A.635.a.ll.i; A.636.a.U.i; A.637.a.ll.x; A.638.a.ll.i; A.639.a.ll.i; A.640.a.lLi; A.641.a.ll4; A.642.a.ll.i; A.643.a.ll.i; A.644.a.U.i; A.645.a.ll.í; A.646.a.ll.i; A.647.a.ll.i; A.648.a.ll.i; A, 649.a.l14; A.óSO.a.ll.i; A.651.a.U.i; A.652.a.ll4; A.653.a.U4; A.654.a.ll.i; A.655.a.ll.i; A.656.a.ll.i; A.657.a.ll.i; A.658.a.ll.i; A.659.a.ll.i; A.660.a.ll.i; A.2.b, 4.i; A.3.b.4.i; A.4.b.4.i; A.5.b.4.x; A.6.b.4.i; A.7.b.4.i; A.9.b.4.i; A.10.b.4.i; A.15.b.44; A.100.b.4.i; A.101.b.4.i; A.102.b.4.i; A.103.b.4.i; A.104.b.4.i; A.105.b.4d; A.106.b.4.i; A.107.b.4.i; A.108.b.44; A.109.b.4.x; A.110.b.4.i; A.lll.b.44; A.-112.b.44; A.113.b.4.i; A.114.b.4.í; A.115.b.4.i; A.116.b.4.i; A.U7.b.44; A.118.b.44; A.119.b.4.i; A.120.b.44; A.121.b.4.i; A.122.b.4.i; A.123.b.4.i; A.124.b.4.i; A.125.b.4.x; A.126.b.4.i; A.127.b.4.i; A.128.b.4.i; A.129.b.4.i; A.130.b.4 .i; A.131.b.44; A.132.b.4.i; A.133.b.4.i; A.134.b.4.i; A.135K44; A.136.b.4.i; A.137.b.4.i; A.138.b.4.i; A.139.b.4.i; A.140.b.4.i; A 141.b.44; A.142.b.4.i; A.143.b.4.i; A, 144.b.4.i; A.145.b.4.i; A.146.b.4.i; A.147.b.4.i; A.148.b.4.i; A.149.b.4.i; A.150.b.4.i; A.151.b.44; A.152.b.4.i; A.153.b.4.i; A.154, b.4.i; A.155.b.44; A.156.b.4.i; A.157.b.4á; A.158K44; A.159.b.4.i; A.160.b.4.i; A.161.b.44; A.162.b.4.i; A.163.b.4.i; A.164.b.4.i; A.165.b.44; A.166.b.4.i; A.167.b.44; A.168.b.4.i; A.169.b.44; A.170.b.4.i; A.17Lb.44; A.172.b.44; A.173.b.4.i; A.174.b.4.x; A.175.b.44; A.176.b.44; A.177.b.4.i; A.178.b.4.i; A.179.b.44; A.180.b.44; A.181.b.44; A.182.b.4.i; A.183.b.44; A.184.b.4.i; A.185.b.4.i; A.186.b.44; A.187.b.44; A.188.b.4.i; A.189.b44; A.190.b.4.i; A.191.b, 4.i; A.192.b.4.i; A.193.b.4.i; A.194.b.4.i; A.195.b.4.i; A.196.b.44; A.197.b.4.i; A.198.b.4.i; A.199.b.4.i; A200.b-.44; A201.b.4.i; A.202.b.4.x; A.203.b.4.i; A.204.b.4.i; A205.b.4.í; A.206.b.4.i; A207.b.4.i; A.208.b.4.i; A.209.b.4.i; A.210.b.4.i; A.211.b.4.i; A.212.b.4.i; A.213.b.4.i; A.214.b.4.i; A.215.b.44; A.216.b.4.i; A217.b.4.i; A.218.b.4.i; A.219.b.4.i; A.220.b.4.i; A.221.b.4.í; A.222.b.4.i; A.223.b.4.i; A.224.b.4.i; A.225.b.4.i; A226.b.4.i; A.227.b.4.i; A.228.b.4.i; A.229.b.4.i; A.230.b.4.i; A.231.b.4.i; A.232.b.4.i; A.233.b.4.i; A.234.b.4.i; A.235.b.4.i; A.236.b.4.i; A.237.b.4.i; A.238.b.4.i; A.239.b.4.i; A.240.b.4.i; A.241.b.4.i; A.242.b.4.i; A.243.b.4.i; A.244.b.4.i; A.245.b.4, i; A.246.b.4.i; A.247.b.4.i; A.248.b.44; A249.b.4.i; A.250.b.4.i; A.25-1.44; A.252.b.4.i;
-95CZ 297945 B6-95EN 297945 B6
A253.b.4.i; A.254.b.4.i; A.255.b.4.i; A.256.b.4.x; A.257.b.4.i; A.258.b.4.i; A.259.b.4.i; A.260.b.4.i; A^61.b.4.i; A.262.b.4.i; A.263.b.4.i; A.264.b.4.i; A.265.b.4.i; A.266.b.4.i; A267.b.4.i; A.268.b.4.i; A.269.b.4.i; A.270.b.4.i; A.271.b.4.i; A.272.b.4.i; A.273.b.4.i; A.274.b.4.i; A.275.b.4.i; A.276.b.4.i; A.277.b.4.i, A.278.b.4.i; A.279.b.4.i; A.280.b.4.i; A.281.b.4.i; A.282.b.4.i; A.283.b.4.i; A.284.b.4,i; A.285.b.4.i; A.286.b.4.i; A.287.b.4.i; A.288.b.4.x; A.289.b.4.i; A.290.b.4.i; A.291.b.4.i; A.292.b.4.i; A.293.b.4.i; A.294.b.4.i; A.295.b.4.i; A.296.b.4.i; A.297.b.4.i; A.298.b.4.i; A.299.b.4.i; A.300.b.4.i; A.301.b.4.i; A.302.b.4.i; A.303.b.4.i; A.304.b.4.i; A.305.b.4.i; A.306.b.4.i; A.307.b.4.i; A.308.b.4.i; A.309.b.4.i; A.310.b.4.x; A.311.b.4.i; A.312.b.4.i; A.313.b.4.i; A.314.b.4.i; A.315.b.4.i; A.316.b.4.i; A.317.b.4.i; A.318.b.4.i; A.319.b.4.i; A.320.b.4.i; A.321.b.4.i; A.323.b.4.i; A.324.b.4,i; A.325.b.4.i; A.326.b.4.í; A.327.b.4.i; A.328.b.4.i; A.329.b.4.i; A.330.b.4.i; A.331.b.4.i; A.332.b.4.i; A.333.b.4.x; A.334.b.4.i; A.335.b.4.i; A.336.b.4.i; A.337.b.4.i; A.338.b.4.i; A.339.b.4.i; A.340.b.4.x; A.341.b.4.i; A.342.b.4.i; A.343.b.4.i; A.344,b.4.i; A.345.b.4.i; A.346.b.4.i; A.347.b.4.i; A.348.b.4.i; A.349.b.4.i; A.350.b.4.i; A.351.b.4.i; A.352 b.4.i; A.353.b.4.i; A.354.b.4.i; A.355.b.4.i; A.356.b.4.i; A.357.b.4.i; A.358.b.4.i; A.359.b.4.i; A.360.b.4.i; A.361.b.4.i; A.362.b.4.i; A.363.b.4.i; A.364.b.4.i; A.365.b.4.i; A.366.b.4.i; A.367.b.4.i; A.368.b.4.í; A.369.b.4.i; A.370.b.4.i; A.371.b.4.i; A.372.b.4.i; A.373.b.4.i; A.374.b.4.i; A.375.b.4.i; A.376.b.4.i; A.377.b.4.i; A.378.b.4.x; A.379.b.4.i; A.380.b.4.i; A.381.b.4.i; A.382.b.4.i; A.383.b.4.i; A.384.b.4.i; A.385.b.4.i; A.386.b.4.i; A.387.b.4.Í; A.388.b.4.i; A.389.b.4.i; A.390.b.4.i; A.391.b.4.i; A.392.b.4.i;A.393.b.4.i; A.394.b.4.i; A.395.b.4.i; A.396.b.4.i; A.397.b.4.i; A.398.b.4.i; A.399.b.4.i; A.400.b.4.i; A.401.b.4.i; A.402.b.4.x; A.403.b.4.i; A.404.b.4.x; A.405.b.4.i; A.406.b.4.i; A.407.b.4.i; A.408.b.4.i; A.409.b.4.i; A.410.b.4.i; A.411.b.4.i; A.412.b.4.x; A.413.b.4.i; A.414.b.4.i; A.415.b.4.i; A.416.b.4.i; A.417.b.4.i; A.418.b.4.i; A.419.b.4.i; A.420.b.4.i; A.421.b.4.i; A.422.b.4.i; A.423.b.4.i; A.424.b.4.i; A.425.b.4.i; A.426.b.4.i; A.427.b.4.i; A.428.b.4.i; A.429.b.4.i; A.430.b.4.i; A.431.b.4.i; A.432.b.4.i; A.433.b.4.i; A.434.b.4.i; A.435K4.Í; A.436.b.4.x; A.437.b.4.i; A.438.b.4.i; A.439.b.4.i; A.440.b.4.i; A.441.b.4.i; A.442.b.4.i; A.443,b.4.i; A.444.b.4.i; A.445.b.4.i; A.446.b.4.i; A.447.b.4.i; A.448.b.4.i; A.449.b.4.i; A.450.b.4.i; A.451.b.4.i; A.452.b.4.i; A.453.b.4.i; A.454.b.4.i; A.455.b.4.i; A.456.b.4.i; A.457.b.4.i; A.458.b.4.i; A.459.b.4.i; A.460.b.4.i; A.461.b.4.i; A.462.b.4.i; A.463.b.4.í; A.464.b.4.i; A.465.b.4.i; A.466.b.4.i; A.467.b.4.i; A.468.b.4.i; A.469.b.4.i; A.470.b.4.i; A.471.b.4.i; A.472.b.4.i; A.473.b.4.i; A.474.b.4.i; A.475.b.4.i; A.476.b.4.i; A.477.b.4.i; A.478.b.4.i; A.479.b.4.i; A.480.b.4.i; A.481.b.4.x; A.482.b.4.i; A.483.b.4.i; A.484.b.4.i; A.485.b.4.i; A.486.b,4.i; A.487.b.4.i; A.488.b.4.i; A.489.b.4.i; A.490.b.4.i; A.491.b.4.x; A,492.b.4.i; A.493.b.4.i; A.494.b.4.i; A.495.b.4.i; A.496.b.4.i; A.497.b.4.i; A.498.b.4.i; A.499.b.4.i; A.500.b.4.i; A.501.b.4.i; A.502.b.4.i; A.503.b.4.i; A.504.b.4.i; A.505.b.4.i; A.506.b.4.i; A.507.b.4.i; A.508.b.4.i; A.509.b.4.i; A.510.b.4.Í; A.511.b.4.i; A.512.b.4.i; A.512.b.4.i; A.513.b.4.i; A.514.b.4.i; A.515.b.4.i; A.516.b.4.i; A.517.b.4.i; A.518.b.4.i; A.519.b.4.i; A.520.b.4.i; A.521.b.4.i; A.522.b.4.i; A.523.b.4.i; A.524.b.4.i; A.525.b.4.i; A.526.b.4.i; A.527.b.4.i; A.528.b.4.i; A.529.b.4.i; A.530.b.4.i; A.531.b.4.i; A.532.b.4.i; A.533.b.4.i; A.534.b.4.i; A.535.b.4.i; A.536.b.4.i; A.537.b.4.i; A.538.b.4.i; A.539.b.4.i; A.540.b.4.i; A.541.b.4.i; A.542.b.4.i; A.543.b.4.i; A.544.b.4.i; A.545.b.4.i; A.546.b.4.i; A.547.b.4.í; A.548.b.4.i; A.549.b.4.i; A.550.b.4.i; A.551.b.4.i; A.552.b.4.i; A.553.b.4.i; A.554.b.4.i; A.555.b.4.i; A.556.b.4.i; A.557.b.4.i; A.558.b.4.i; A.559.b.4.i; A.560.b.4.x; A.561.b.4.i; A.562.b.4.i; A.563.b.4.i; A.564.b.4.i; A.565.b.4.i; A.566.b.4.i; A.567.b.4.i; A.568.b.4.i; A.S69.b.4.i; A.570.b.4.i; A.571.b.4.i; A.572.b.4.i; A.573.b.4.i; A.574.b.4.i; A.575.b.4.i; A.576.b.4.i; A.577.b.4.i; A.578.b.4.i; A.579.b.4.i; A.580.b.4.i; A.581.b.4.i;A253.b.4.i; A.254.b.4.i; A.255.b.4.i; A.256.b.4.x; A.257.b.4.i; A.258.b.4.i; A.259.b.4.i; A.260.b.4.i; A ^ 61.b.4.i; A.262.b.4.i; A.263.b.4.i; A.264.b.4.i; A.265.b.4.i; A.266.b.4.i; A267.b.4.i; A.268.b.4.i; A.269.b.4.i; A.270.b.4.i; A.271.b.4.i; A.272.b.4.i; A.273.b.4.i; A.274.b.4.i; A.275.b.4.i; A.276.b.4.i; A.277.b.4.i, A.278.b.4.i; A.279.b.4.i; A.280.b.4.i; A.281.b.4.i; A.282.b.4.i; A.283.b.4.i; A.284.b.4, i; A.285.b.4.i; A.286.b.4.i; A.287.b.4.i; A.288.b.4.x; A.289.b.4.i; A.290.b.4.i; A.291.b.4.i; A.292.b.4.i; A.293.b.4.i; A.294.b.4.i; A.295.b.4.i; A.296.b.4.i; A.297.b.4.i; A.298.b.4.i; A.299.b.4.i; A.300.b.4.i; A.301.b.4.i; A.302.b.4.i; A.303.b.4.i; A.304.b.4.i; A.305.b.4.i; A.306.b.4.i; A.307.b.4.i; A.308.b.4.i; A.309.b.4.i; A.310.b.4.x; A.311.b.4.i; A.312.b.4.i; A.313.b.4.i; A.314.b.4.i; A.315.b.4.i; A.316.b.4.i; A.317.b.4.i; A.318.b.4.i; A.319.b.4.i; A.320.b.4.i; A.321.b.4.i; A.323.b.4.i; A.324.b.4, i; A.325.b.4.i; A.326.b.4.í; A.327.b.4.i; A.328.b.4.i; A.329.b.4.i; A.330.b.4.i; A.331.b.4.i; A.332.b.4.i; A.333.b.4.x; A.334.b.4.i; A.335.b.4.i; A.336.b.4.i; A.337.b.4.i; A.338.b.4.i; A.339.b.4.i; A.340.b.4.x; A.341.b.4.i; A.342.b.4.i; A.343.b.4.i; A.344, b.4.i; A.345.b.4.i; A.346.b.4.i; A.347.b.4.i; A.348.b.4.i; A.349.b.4.i; A.350.b.4.i; A.351.b.4.i; A.352 b.4.i; A.353.b.4.i; A.354.b.4.i; A.355.b.4.i; A.356.b.4.i; A.357.b.4.i; A.358.b.4.i; A.359.b.4.i; A.360.b.4.i; A.361.b.4.i; A.362.b.4.i; A.363.b.4.i; A.364.b.4.i; A.365.b.4.i; A.366.b.4.i; A.367.b.4.i; A.368.b.4.í; A.369.b.4.i; A.370.b.4.i; A.371.b.4.i; A.372.b.4.i; A.373.b.4.i; A.374.b.4.i; A.375.b.4.i; A.376.b.4.i; A.377.b.4.i; A.378.b.4.x; A.379.b.4.i; A.380.b.4.i; A.381.b.4.i; A.382.b.4.i; A.383.b.4.i; A.384.b.4.i; A.385.b.4.i; A.386.b.4.i; A.387.b.4.Í; A.388.b.4.i; A.389.b.4.i; A.390.b.4.i; A.391.b.4.i; A.392.b.4.i; A.393.b.4.i; A.394.b.4.i; A.395.b.4.i; A.396.b.4.i; A.397.b.4.i; A.398.b.4.i; A.399.b.4.i; A.400.b.4.i; A.401.b.4.i; A.402.b.4.x; A.403.b.4.i; A.404.b.4.x; A.405.b.4.i; A.406.b.4.i; A.407.b.4.i; A.408.b.4.i; A.409.b.4.i; A.410.b.4.i; A.411.b.4.i; A.412.b.4.x; A.413.b.4.i; A.414.b.4.i; A.415.b.4.i; A.416.b.4.i; A.417.b.4.i; A.418.b.4.i; A.419.b.4.i; A.420.b.4.i; A.421.b.4.i; A.422.b.4.i; A.423.b.4.i; A.424.b.4.i; A.425.b.4.i; A.426.b.4.i; A.427.b.4.i; A.428.b.4.i; A.429.b.4.i; A.430.b.4.i; A.431.b.4.i; A.432.b.4.i; A.433.b.4.i; A.434.b.4.i; A.435K4.Í; A.436.b.4.x; A.437.b.4.i; A.438.b.4.i; A.439.b.4.i; A.440.b.4.i; A.441.b.4.i; A.442.b.4.i; A.443, b.4.i; A.444.b.4.i; A.445.b.4.i; A.446.b.4.i; A.447.b.4.i; A.448.b.4.i; A.449.b.4.i; A.450.b.4.i; A.451.b.4.i; A.452.b.4.i; A.453.b.4.i; A.454.b.4.i; A.455.b.4.i; A.456.b.4.i; A.457.b.4.i; A.458.b.4.i; A.459.b.4.i; A.460.b.4.i; A.461.b.4.i; A.462.b.4.i; A.463.b.4.í; A.464.b.4.i; A.465.b.4.i; A.466.b.4.i; A.467.b.4.i; A.468.b.4.i; A.469.b.4.i; A.470.b.4.i; A.471.b.4.i; A.472.b.4.i; A.473.b.4.i; A.474.b.4.i; A.475.b.4.i; A.476.b.4.i; A.477.b.4.i; A.478.b.4.i; A.479.b.4.i; A.480.b.4.i; A.481.b.4.x; A.482.b.4.i; A.483.b.4.i; A.484.b.4.i; A.485.b.4.i; A.486.b.4i; A.487.b.4.i; A.488.b.4.i; A.489.b.4.i; A.490.b.4.i; A.491.b.4.x; A, 492.b.4.i; A.493.b.4.i; A.494.b.4.i; A.495.b.4.i; A.496.b.4.i; A.497.b.4.i; A.498.b.4.i; A.499.b.4.i; A.500.b.4.i; A.501.b.4.i; A.502.b.4.i; A.503.b.4.i; A.504.b.4.i; A.505.b.4.i; A.506.b.4.i; A.507.b.4.i; A.508.b.4.i; A.509.b.4.i; A.510.b.4.Í; A.511.b.4.i; A.512.b.4.i; A.512.b.4.i; A.513.b.4.i; A.514.b.4.i; A.515.b.4.i; A.516.b.4.i; A.517.b.4.i; A.518.b.4.i; A.519.b.4.i; A.520.b.4.i; A.521.b.4.i; A.522.b.4.i; A.523.b.4.i; A.524.b.4.i; A.525.b.4.i; A.526.b.4.i; A.527.b.4.i; A.528.b.4.i; A.529.b.4.i; A.530.b.4.i; A.531.b.4.i; A.532.b.4.i; A.533.b.4.i; A.534.b.4.i; A.535.b.4.i; A.536.b.4.i; A.537.b.4.i; A.538.b.4.i; A.539.b.4.i; A.540.b.4.i; A.541.b.4.i; A.542.b.4.i; A.543.b.4.i; A.544.b.4.i; A.545.b.4.i; A.546.b.4.i; A.547.b.4.í; A.548.b.4.i; A.549.b.4.i; A.550.b.4.i; A.551.b.4.i; A.552.b.4.i; A.553.b.4.i; A.554.b.4.i; A.555.b.4.i; A.556.b.4.i; A.557.b.4.i; A.558.b.4.i; A.559.b.4.i; A.560.b.4.x; A.561.b.4.i; A.562.b.4.i; A.563.b.4.i; A.564.b.4.i; A.565.b.4.i; A.566.b.4.i; A.567.b.4.i; A.568.b.4.i; A.S69.b.4.i; A.570.b.4.i; A.571.b.4.i; A.572.b.4.i; A.573.b.4.i; A.574.b.4.i; A.575.b.4.i; A.576.b.4.i; A.577.b.4.i; A.578.b.4.i; A.579.b.4.i; A.580.b.4.i; A.581.b.4.i;
-96CZ 297945 B6-96EN 297945 B6
A.582.b.4.i; A.583.b.4.i; A.584.b.4.i; A.585.b.4 j; A.586.b.4.i; A.587.b.4.i; A.588.b.4.i; A.589.b.4.i; A.590.b.4.i; A.591.b.4.i; A.592.b.4.i; A.593.b.4.i; A.594.b.4.i; A.595.b.4.i; A.596.b.4.i; A.597.b.4.i; A.598.b.4.i; A.599,b.4.i; A.600.b.4.i; A.601.b.4.i; A,602.b.4.i; A.603.b.4.i; A.604.b.4.i; A.605.b.4.i; A.606.b.4.i; A.607.b.4.i; A.608.b.4.i; A.609.b.4.i; A.610.b.4.i; A.611.b.4.i; A.612.b.4.i; A.613.b.4.i; A.614.b.4.i; A.615.b.4.i; A.616.b.4.i; A.61Zb.4.i; A.618.b.4.i; A.619.b.4.i; A.620.b.4.i; A.621.b.4.i; A.622.b.4.i; A.623.b.4.i; A.624.b.4.i; A.625.b.4.i; A.626.b.4.i; A.627.b.4.i; A.628.b.4.i; A.629.b.4.i; A.630.b.4.i; A.631.b.4.i; A.632.b.4.i; A.633.b.4.i; A.634.b.4.i; A.635.b.4.i; A.636.b.4.i; A.637.b.4.i; A.638.b.4.i; A.639.b.4.i; A.640.b.4.i; A.641.b.4.i; A.642. b.4. i; A.643.b.4.i; A.644.b.4.i; A.645.b.4.i; A.646.b.4.i; A.647.b.4.i; A.648.b.4.i; A.649.b.4.i; A.650.b.4.i; A.651.b.4.i; A-652.b.4.i; A.653.b.4.i; A.654.b.4.i; A.655.b.4.i; A.656.b.4.i; A.657.b.4.i; A.658.b.4.x; A.659.b.4.i; A.660.b.4.i; A.2.b.ll.i; A.3.b.U.i; A.4.b.ll.i; A.5.b-ll.i; A.6.b.ll.i; A.7-b.ll.i; A.9.b.ll.i; A.10,b.ll.i; A.15.b.ll.i; A.lOO.b.ll.i; A.101.b.ll.i; A.102.b.ll.i; A.108.b.ll.i;A.582.b.4.i; A.583.b.4.i; A.584.b.4.i; A.585.b.4 j; A.586.b.4.i; A.587.b.4.i; A.588.b.4.i; A.589.b.4.i; A.590.b.4.i; A.591.b.4.i; A.592.b.4.i; A.593.b.4.i; A.594.b.4.i; A.595.b.4.i; A.596.b.4.i; A.597.b.4.i; A.598.b.4.i; A.599, b.4.i; A.600.b.4.i; A.601.b.4.i; A, 602.b.4.i; A.603.b.4.i; A.604.b.4.i; A.605.b.4.i; A.606.b.4.i; A.607.b.4.i; A.608.b.4.i; A.609.b.4.i; A.610.b.4.i; A.611.b.4.i; A.612.b.4.i; A.613.b.4.i; A.614.b.4.i; A.615.b.4.i; A.616.b.4.i; A.61Zb.4.i; A.618.b.4.i; A.619.b.4.i; A.620.b.4.i; A.621.b.4.i; A.622.b.4.i; A.623.b.4.i; A.624.b.4.i; A.625.b.4.i; A.626.b.4.i; A.627.b.4.i; A.628.b.4.i; A.629.b.4.i; A.630.b.4.i; A.631.b.4.i; A.632.b.4.i; A.633.b.4.i; A.634.b.4.i; A.635.b.4.i; A.636.b.4.i; A.637.b.4.i; A.638.b.4.i; A.639.b.4.i; A.640.b.4.i; A.641.b.4.i; A.642. b.4. and; A.643.b.4.i; A.644.b.4.i; A.645.b.4.i; A.646.b.4.i; A.647.b.4.i; A.648.b.4.i; A.649.b.4.i; A.650.b.4.i; A.651.b.4.i; A-652.b.4.i .; A.653.b.4.i; A.654.b.4.i; A.655.b.4.i; A.656.b.4.i; A.657.b.4.i; A.658.b.4.x; A.659.b.4.i; A.660.b.4.i; A.2.b.ll.i; A.3.b.U.i; A.4.b.ll.i; A.5.b-II.i; A.6.b.ll.i; A.7-b.ll.1; A.9.b.ll.i; A.10, b.ll.1; A.15.b.ll.i; A.lOO.b.ll.i; A.101.b.ll.i; A.102.b.ll.i; A.108.b.ll.i;
A.114.b.ll.i; A.llS.b.ll.i; A.lló.b.ll.i; A.117.b.ll.i; A.118.b.ll.x; A.119.b.ll.x; A.120.b.ll.i;A.114.b.ll.i; A.llS.b.ll.i; A.lló.b.ll.i; A.117.b.ll.i; A.118.b.ll.x; A.119.b.ll.x; A.120.b.ll.i;
A-126.b.ll.i; A.132.b.ll.i; A.138.b.ll.i;A-126.b.II.i; A.132.b.ll.i; A.138.b.ll.i;
A.144.b.ll.i, A.150.b.ll.x; A.156.b.ll.i; A.162.b.ll.i; A.168.b,ll.i;A.144.b.ll.i, A.150.b.ll.x; A.156.b.ll.i; A.162.b.ll.i; A.168.b, II.i;
A.103.b.ll.i; A.104.b.ll.i; A.105.b.lLi; A.106.b.U.i; A.107.b.ll.x; i; A.109.b.ll.i; A.llO.b.ll.i; A.in.b.ll.i; A.112.b.ll.i; A.113.b.ll.i;A.103.b.ll.i; A.104.b.ll.i; A.105.b.lLi; A.106.b.U.i; A.107.b.ll.x; and; A.109.b.ll.i; A.llO.b.ll.i; A.in.b.ll.i; A.112.b.ll.i; A.113.b.ll.i;
A.240.b.ll.i;A.240.b.ll.i;
A.246.b.ll.i;A.246.b.ll.i;
A.252.b.ll.i;A.252.b.ll.i;
A.258.b.ll.i;A.258.b.ll.i;
A-264-b.ll.i;A-264-b.
A.121.b.ll,í; A.122.b.ll.i; A.123.b.ll.i; A.124.b.ll.i; A.125.b.ll.i;A.121.b.ll, i; A.122.b.ll.i; A.123.b.ll.i; A.124.b.ll.i; A.125.b.ll.i;
A.127.b.ll.i; A.128.b.ll.i; A.129.b.ll.i; A.130.b.lLi; A.131.b.ll.i;A.127.b.ll.i; A.128.b.ll.i; A.129.b.ll.i; A.130.b.lLi; A.131.b.ll.i;
A.133.b.ll.i; A.134.b.ll.i; A.135.b.ll.x; A.136.b.ll.i; A.137.b.ll.i;A.133.b.ll.i; A.134.b.ll.i; A.135.b.ll.x; A.136.b.ll.i; A.137.b.ll.i;
A.139.b.ll.i; A.140.b.ll.i; A.141.b.ll.i; A.142,b.ll.i; A.143.b.ll.i; ; A.145.b.ll.i; A.146.b.ll.i; A.147.b.ll.i; A.148.b.ll.i; A.149.b.ll.x;A.139.b.ll.i; A.140.b.ll.i; A.141.b.ll.i; A.142, b.ll.i; A.143.b.ll.i; ; A.145.b.ll.i; A.146.b.ll.i; A.147.b.ll.i; A.148.b.ll.i; A.149.b.ll.x;
A.151.b.ll.x; A.152.b.ll.i; A.153.b.ll.x; A.154.b.ll.i; A.155.b.lLi;A.151.b.ll.x; A.152.b.ll.i; A.153.b.ll.x; A.154.b.ll.i; A.155.b.lLi;
A.157.b.ll.i; A.158.b.ll.i; A.159.b.ll.i; A.160.b.ll.i; A.161.K11.Í;A.157.b.ll.i; A.158.b.ll.i; A.159.b.ll.i; A.160.b.ll.i; A.161.K11.I;
A.163.b.U.i; A.164.b.ll.i; A.165.b.lLi; A.166.b.ll.i; A.167.b.ll.x;A.163.b.U.i; A.164.b.ll.i; A.165.b.lLi; A.166.b.ll.i; A.167.b.ll.x;
A.169.b.ll.i; A.170.b.ll.i; A.171.b.ll.x; A.172.b.ll j; A.I73.b.ll.i;A.169.b.ll.i; A.170.b.ll.i; A.171.b.ll.x; A.172.b.ll j; A.I73.b.ll.i;
A.174.b.ll.i; A.175.b.ll.i; A.176.b.ll.i; A.177.b.ll.i; A.178.b.ll.i; A.179.b.ll.i;A.174.b.ll.i; A.175.b.ll.i; A.176.b.ll.i; A.177.b.ll.i; A.178.b.ll.i; A.179.b.ll.i;
A.180.b.ll.i; A.181.b.ll.i; A.182.b.U.i; A.183.b.U.i; A.184.b.ll.i; A.185.b.ll.x;A.180.b.ll.i; A.181.b.ll.i; A.182.b.U.i; A.183.b.U.i; A.184.b.ll.i; A.185.b.ll.x;
A.186.b.ll.i; A.187.b.ll.i; A.188.b.ll.i; A.189.b.ll.i; A.190.b.ll.i; A.191.b.ll.x;A.186.b.ll.i; A.187.b.ll.i; A.188.b.ll.i; A.189.b.ll.i; A.190.b.ll.i; A.191.b.ll.x;
A,192.b.ll.i; A.193.b.ll.i; A.194.b.ll.i; A.195.b.ll.x; A.196.b.U.i; A.197.b.U.i;A, 192.b.ll.i; A.193.b.ll.i; A.194.b.ll.i; A.195.b.ll.x; A.196.b.U.i; A.197.b.U.i;
A.198.b.ll.i; A.199b.ll.i; A.200.b.ll.i; A.201.b.ll.i; A.202.b.ll.i; A.203.b.ll.i;A.198.b.ll.i; A.199b.ll.i; A.200.b.ll.i; A.201.b.ll.i; A.202.b.ll.i; A.203.b.ll.i;
A.204.b.ll.i; A.205.b.ll.i; A.206.b.ll.i; A.207.b.ll.i; A.208.b.ll.i; A.209.b.U.i;A.204.b.ll.i; A.205.b.ll.i; A.206.b.ll.i; A.207.b.ll.i; A.208.b.ll.i; A.209.b.U.i;
A.210.b.ll.i; A.211.b.ll.i; A.212.b.U.i; A.213.b.ll.i; A.214.b.ll.i; A.215.b.ll.i;A.210.b.ll.i; A.211.b.ll.i; A.212.b.U.i; A.213.b.ll.i; A.214.b.ll.i; A.215.b.ll.i;
A.216.b.ll.i; A217.b.ll.i; A.218.b.ll.i; A.219.b.ll.i; A.220.b.ll.i; A.221.b.ll.i;A.216.b.ll.i; A217.b.ll.i; A.218.b.ll.i; A.219.b.ll.i; A.220.b.ll.i; A.221.b.ll.i;
A.222.b.ll.i; A223.b.ll.i; A.224.b.ll.i; A.225.b.ll.i; A.226.b.ll.i; A.227.b.ll.i;A.222.b.ll.i; A223.b.ll.i; A.224.b.ll.i; A.225.b.ll.i; A.226.b.ll.i; A.227.b.ll.i;
A.228.b,ll.x; A.229.b.ll.i; A.230.b.ll.i; A.231.b.ll.i; A.232.b.ll.i; A.233.b.lLi;A.228.b, II.x; A.229.b.ll.i; A.230.b.ll.i; A.231.b.ll.i; A.232.b.ll.i; A.233.b.lLi;
A.234.b.U.i; A.235.b.ll.i; A.236.b.ll.i; A.237.b.ll.i; A238.b.ll.i; A.239.b.U.i; : A.241.b.ll.i; A.242.b.ll.i; A.243.b.lLi; A.244.b.U.i; A.245.b.ll.i;A.234.b.U.i; A.235.b.ll.i; A.236.b.ll.i; A.237.b.ll.i; A238.b.ll.i; A.239.b.U.i; : A.241.b.ll.i; A.242.b.ll.i; A.243.b.lLi; A.244.b.U.i; A.245.b.ll.i;
A.247.b.ll.i; A.248.b.ll.i; A.249.b.ll.i; A.250.b.ll.i; A.25tb.ll.i;A.247.b.ll.i; A.248.b.ll.i; A.249.b.ll.i; A.250.b.ll.i; A.25tb.ll.i;
A.253.b.ll.i; A.254.b.U.i; A.255.b.ll.i; A.256.b.ll.i; A.257.b.ll.i;A.253.b.ll.i; A.254.b.U.i; A.255.b.ll.i; A.256.b.ll.i; A.257.b.ll.i;
A.259.b.ll.i; A.260.b.ll.i; A.261.b.ll.i; A.262.b.ll.x; A263.b.ll.i;A.259.b.ll.i; A.260.b.ll.i; A.261.b.ll.i; A.262.b.ll.x; A263.b.ll.i;
A.265.b.ll.i; A.266.b.lLi; A.267.b.ll.i; A.268.b.ll.i; A.269.b.ll.i;A.265.b.ll.i; A.266.b.lLi; A.267.b.ll.i; A.268.b.ll.i; A.269.b.ll.i;
A.271.b.ll.i; A.272.b.ll.i; A.273.b.ll.i· A.274.b.ll.i; A.275.b.lLi;A.271.b.ll.i; A.272.b.ll.i; A.273.b.ll.i · A.274.b.ll.i; A.275.b.lLi;
A.277.b.ll.i; A.278.b.ll.i; A.279.b.U.i; A.280.b.ll.i; A.281.b.ll.i;A.277.b.ll.i; A.278.b.ll.i; A.279.b.U.i; A.280.b.ll.i; A.281.b.ll.i;
A.270.b.ll.i;A.270.b.ll.i;
A.276.b.ll.i;A.276.b.ll.i;
A.282.b.il.i;A.282.b.il.i;
A.288.b.ll.i;A.288.b.ll.i;
A.294.b.ll.i;A.294.b.ll.i;
A.300.b.ll.i;A.300.b.ll.i;
A.283.b.ll.i; A.284.b.H.i; A.285.b.ll.i; A.286.b.ll.i; A.287.b.ll.i; A.289.b.ll.i; A.290.b.ll.i; A.291.b.ll.i; A.292.b.ll.i; A.293.b.ll.i; A.295.b.ll.í; A.296.b.ll.i; A.297.b.U.i; A.298.b.ll.i; A.299.b.ll.i; A.301.b.ll.i; A.302.b.ll.i; A.303.b.ll.i; A.304.b.U.i; A.305.b.ll.i;A.283.b.ll.i; A.284.b.H.i; A.285.b.ll.i; A.286.b.ll.i; A.287.b.ll.i; A.289.b.ll.i; A.290.b.ll.i; A.291.b.ll.i; A.292.b.ll.i; A.293.b.ll.i; A.295.b.ll.í; A.296.b.ll.i; A.297.b.U.i; A.298.b.ll.i; A.299.b.ll.i; A.301.b.ll.i; A.302.b.ll.i; A.303.b.ll.i; A.304.b.U.i; A.305.b.ll.i;
-97CZ 297945 B6-97EN 297945 B6
A.30ó.b.ll.í; A.307.b.ll.i; A.308.b.ll.i; A.309.b.ll.i; A.310.b.ll.i; A.311.b.ll.i; A.312.b.ll.i; A.313.b.lU; A.314.b.ll.i; A.315.b.ll.i; A.316.b.ll.i; A.317.b.ll.i; A.318.b.ll.i; A.319.b.ll.i; A.320.b.ll.i; A.32Lb.ll.i; A.323.b.ll.i; A.324.b.ll.i; A.325.b.ll.i; A.326.b.U.i; A.327.b.ll.i; A.328.b.ll.i; A.329.b.ll.i; A.330.b.ll.i; A.331.b.ll.i; A.332.b.ll.i; A.333.b.ll.i; A.334.b.ll.i; A.335.b.ll.i; A.336.b.ll.i; A.337.b.ll.i; A.338.b.ll.i; A.339.b.ll.i; A.340.b.ll.i; A.341.b.ll.i; A.342.b.ll.i; A.343.b.ll.i; A.344.b.U.i; A.345.b.U.i; A.346.b.ll.i; A.347.b.ll.i; A.348.b.U.i; A.349.b.ll.i; A.350.b.ll.i; A.351.b.ll.i; A352.b.ll.i; A.353.b.ll.i; A.354.b.ll.i; A.355.b.ll.i; A.356.b.ll.i; A.357.b.ll.i; A.358.b.ll.i; A.359.b.ll.i; A.360.b.ll.i; A.361.b.ll.i; A.362.b.U.i; A.363.b.ll.i; A.364.b.ll.i; A.365.b.ll.i; A.366.b.ll.i; A.367.b.ll.i; A.368.b.U.i; A.369.b.ll.i; A.370.b.ll.i; A.371.b.ll.i; A.372.b.ll.i; A.373.b.U.i; A.374.b.ll.i; A.375.b.ll.i; A376.b.ll.i; A.377.b.ll.i; A.378.b.ll.i; A.379.b.ll.i; A.380.b.ll.i; A.38Lb.lLi; A382.b.ll.i; A.383.b.ll.i; A.384.b.ll.i; A.385.b.ll.i; A.386.b.ll.i; A.387.b.ll.i; A.388.b.ll.i; A.389.b.ll.i; A.390.b.U.i; A.391.b.ll.i; A.392.b.ll.i; A.393.b.ll.i; A.394.b.ll.i; A.395.b.ll.i; A.396.b.ll.i; A.397.b.ll.i; A.398.b.ll.x; A.399.b.ll.i; A.400.b.ll.i; A.401.b.ll.i; A.402.b.ll.i; A.403.b.ll.i; A.404.b.ll.i; A.405.b.ll.i; A.406.b.ll.i; A.407.b.ll.i; A.408.b.ll.i; A.409.b.ll.i; A.410.b.ll.i; A.411.b.ll.i; A.4125.11.Í; A.413.b.ll.i; A.414.b.il.i; A.415.b.ll.i; A.416.b.ll.i; A.417.b.ll.i; A.418.b.ll.x; A.419.b,ll.i; A.420.b.ll.i; A.421.b.ll.i; A.422.b.ll.i; A.423.b.ll.i; A.424.b.lLi; A.425.b.ll.i; A.426.b.ll.i; A.427,b.ll.i; A.428.b.ll.i; A.429.b.ll.i; A.430.b.lki; A.431.b.ll.i; A.432.b.ll.i; A.433.b.ll.i; A.434.b.ll.i; A.435.b.U.i; A.436.b.ll.x; A.437.b.ll.i; A.438.b.ll.i; A.439.b.ll.i; A.440.b.ll.i; A.441.b.ll.i; A.442.b.ll.i; A.443.b.ll.i; A.444.b.ll.i; A.445.b.ll.i; A.446.b.ll.i; A.447.b.ll.i; A.448.b.ll.i; A.449.b.ll.i; A.450.b.lU; A.45Lb.lLi; A.452.b.ll.i; A.453.b.ll.x; A.454.b.ll.i; A.455.b.ll.i; A.456.b.l Li; A.457.b.ll.x; A.458.b.ll.i; A.459.b.ll.i; A.460.b.ll.i; A.461.b.ll.i; A.462.b.ll.i; A.463.b.ll.i; A.464.b.ll.x; A.465.b.ll.i; A.466.b.lLi; A.467.b.ll.í; A.468K11.i; A.469.b.ll.i; A.470.b.ll.i; A.471.b.H.i; A.472.b.ll.i; A.473.b.ll.i; A.474.b.ll.i; A.475.b.ll.i; A.476.b.ll.i; A.477.b.ll.i; A.478.b.lLi; A.479.b.ll.i; A.480.b.ll.i; A.481.b.lLi; A.482.b.ll.i; A.483.b.ll.i; A.484.b.lLi; A.485.b.U.i; A.486.b.U.i; A487.b.lLi; A.488.b.ll.i; A.489.b.ll.i; A.490.b.ll.i; A.491.b.ll.i; A492.b.ll.i; A.493.b.ll.i; A.494.b.ll.i; A.495.b.ll.i; A.496.b.ll.i; A.497.b.U.i; A.498.b.ll.i; A.499.b.ll.i; A.SOO.b.ll.i; A.501.b.ll.i; A.502.b.ll.i; A.503.b.ll.i; A.504.b.U.i; A.505.b.ll.i; A.506.b.U.i; A.507.b.Il.i; A.508±.ll.í; A.509.b.ll.i; A.510.b.ll.i; A.511.b.ll.i; A.512.b.ll.i; A.512.b.ll.i; A.513.b.ll.i; A.514.b.ll.i; A.515.b.ll.i; A.516.b.ll.i; A.5Í7.b.lLi; A.518.b.ll.i; A.519.b.Il.i; A.520.b.lLi; A.521.b.ll.i; A.522.b.ll.i; A.523.b.ll.i; A.524.b.ll.i; A.525.b.ll.i; A.526.b.lLi; A.527.b.ll.i; A.528.b.ll.i; A.529.b.ll.í; A.530.b.ll.i; A.53Lb.ll.i; A.532,b.ll.i; A.533.b.ll.i; A.534.b.ll.i; A.535.b.ll.i; A536.b.ll.i; A.537.b.ll.i; A.538.b.ll.x; A.539.b.ll.i; A.540.b.ll.i; A.541.b.ll.i; A.542.b.ll.i; A.543.b.ll.i; A.544.b.ll.i; A.545.b.ll.i; A.546.b.ll.i; A.547.b.ll.i; A.548.b.ll.x; A.549.b.lLi; A.550.b.U.i; A55Lb.llá; A.552.b.ll.í; A.553.b.ll.i; A.554,b.ll.i; A.555.b.ll.i; A.556.b.ll.i; A.557.b.ll.i; A.558.b.ll.i; A.559.b.ll.i; A.560.b.ll.i; A.561.b.ll.i; A.562.b.ll.i; A.563.b.ll.i; A.564.b.U.i; A.565.b.ll.i; A.566.b.U.i; A.567.b.lU; A.568.b.ll.i; A.569.b.ll.i; A.570.b.ll.i; A.571.b.ll.i; A.572.b.ll.i; A.573.b.ll.i; A.574.b.ll.i; A.575.b.ll.i; A.576.b.ll.í; A.577.b.ll.í: A.578.b.lLi; A.579.b.lLi; A.580.b.ll.i; A.581K11.Í; A.582.b.ll.i; A.583.b.ll.i; A.584.b.ll.í; A.585.b.llJ; A.586.b.ll.i; A.587.b.ll.i;A.30ó.b.ll.í; A.307.b.ll.i; A.308.b.ll.i; A.309.b.ll.i; A.310.b.ll.i; A.311.b.ll.i; A.312.b.ll.i; A.313.b.lU; A.314.b.ll.i; A.315.b.ll.i; A.316.b.ll.i; A.317.b.ll.i; A.318.b.ll.i; A.319.b.ll.i; A.320.b.ll.i; A.32Lb.ll.i; A.323.b.ll.i; A.324.b.ll.i; A.325.b.ll.i; A.326.b.U.i; A.327.b.ll.i; A.328.b.ll.i; A.329.b.ll.i; A.330.b.ll.i; A.331.b.ll.i; A.332.b.ll.i; A.333.b.ll.i; A.334.b.ll.i; A.335.b.ll.i; A.336.b.ll.i; A.337.b.ll.i; A.338.b.ll.i; A.339.b.ll.i; A.340.b.ll.i; A.341.b.ll.i; A.342.b.ll.i; A.343.b.ll.i; A.344.b.U.i; A.345.b.U.i; A.346.b.ll.i; A.347.b.ll.i; A.348.b.U.i; A.349.b.ll.i; A.350.b.ll.i; A.351.b.ll.i; A352.b.ll.i; A.353.b.ll.i; A.354.b.ll.i; A.355.b.ll.i; A.356.b.ll.i; A.357.b.ll.i; A.358.b.ll.i; A.359.b.ll.i; A.360.b.ll.i; A.361.b.ll.i; A.362.b.U.i; A.363.b.ll.i; A.364.b.ll.i; A.365.b.ll.i; A.366.b.ll.i; A.367.b.ll.i; A.368.b.U.i; A.369.b.ll.i; A.370.b.ll.i; A.371.b.ll.i; A.372.b.ll.i; A.373.b.U.i; A.374.b.ll.i; A.375.b.ll.i; A376.b.ll.i; A.377.b.ll.i; A.378.b.ll.i; A.379.b.ll.i; A.380.b.ll.i; A.38Lb.lLi; A382.b.ll.i; A.383.b.ll.i; A.384.b.ll.i; A.385.b.ll.i; A.386.b.ll.i; A.387.b.ll.i; A.388.b.ll.i; A.389.b.ll.i; A.390.b.U.i; A.391.b.ll.i; A.392.b.ll.i; A.393.b.ll.i; A.394.b.ll.i; A.395.b.ll.i; A.396.b.ll.i; A.397.b.ll.i; A.398.b.ll.x; A.399.b.ll.i; A.400.b.ll.i; A.401.b.ll.i; A.402.b.ll.i; A.403.b.ll.i; A.404.b.ll.i; A.405.b.ll.i; A.406.b.ll.i; A.407.b.ll.i; A.408.b.ll.i; A.409.b.ll.i; A.410.b.ll.i; A.411.b.ll.i; A.4125.11.Í; A.413.b.ll.i; A.414.b.il.i; A.415.b.ll.i; A.416.b.ll.i; A.417.b.ll.i; A.418.b.ll.x; A.419.b, II.i; A.420.b.ll.i; A.421.b.ll.i; A.422.b.ll.i; A.423.b.ll.i; A.424.b.lLi; A.425.b.ll.i; A.426.b.ll.i; A.427, b.ll.i; A.428.b.ll.i; A.429.b.ll.i; A.430.b.lki; A.431.b.ll.i; A.432.b.ll.i; A.433.b.ll.i; A.434.b.ll.i; A.435.b.U.i; A.436.b.ll.x; A.437.b.ll.i; A.438.b.ll.i; A.439.b.ll.i; A.440.b.ll.i; A.441.b.ll.i; A.442.b.ll.i; A.443.b.ll.i; A.444.b.ll.i; A.445.b.ll.i; A.446.b.ll.i; A.447.b.ll.i; A.448.b.ll.i; A.449.b.ll.i; A.450.b.lU; A.45Lb.lLi; A.452.b.ll.i; A.453.b.ll.x; A.454.b.ll.i; A.455.b.ll.i; A.456.b.l Li; A.457.b.ll.x; A.458.b.ll.i; A.459.b.ll.i; A.460.b.ll.i; A.461.b.ll.i; A.462.b.ll.i; A.463.b.ll.i; A.464.b.ll.x; A.465.b.ll.i; A.466.b.lLi; A.467.b.ll.í; A.468K11.i; A.469.b.ll.i; A.470.b.ll.i; A.471.b.H.i; A.472.b.ll.i; A.473.b.ll.i; A.474.b.ll.i; A.475.b.ll.i; A.476.b.ll.i; A.477.b.ll.i; A.478.b.lLi; A.479.b.ll.i; A.480.b.ll.i; A.481.b.lLi; A.482.b.ll.i; A.483.b.ll.i; A.484.b.lLi; A.485.b.U.i; A.486.b.U.i; A487.b.lLi; A.488.b.ll.i; A.489.b.ll.i; A.490.b.ll.i; A.491.b.ll.i; A492.b.ll.i; A.493.b.ll.i; A.494.b.ll.i; A.495.b.ll.i; A.496.b.ll.i; A.497.b.U.i; A.498.b.ll.i; A.499.b.ll.i; A.SOO.b.ll.i; A.501.b.ll.i; A.502.b.ll.i; A.503.b.ll.i; A.504.b.U.i; A.505.b.ll.i; A.506.b.U.i; A.507.b.Il.i; A.508 ± III; A.509.b.ll.i; A.510.b.ll.i; A.511.b.ll.i; A.512.b.ll.i; A.512.b.ll.i; A.513.b.ll.i; A.514.b.ll.i; A.515.b.ll.i; A.516.b.ll.i; A.5Í7.b.lLi; A.518.b.ll.i; A.519.b.Il.i; A.520.b.lLi; A.521.b.ll.i; A.522.b.ll.i; A.523.b.ll.i; A.524.b.ll.i; A.525.b.ll.i; A.526.b.lLi; A.527.b.ll.i; A.528.b.ll.i; A.529.b.ll.í; A.530.b.ll.i; A.53Lb.ll.i; A.532, b.ll.1; A.533.b.ll.i; A.534.b.ll.i; A.535.b.ll.i; A536.b.ll.i; A.537.b.ll.i; A.538.b.ll.x; A.539.b.ll.i; A.540.b.ll.i; A.541.b.ll.i; A.542.b.ll.i; A.543.b.ll.i; A.544.b.ll.i; A.545.b.ll.i; A.546.b.ll.i; A.547.b.ll.i; A.548.b.ll.x; A.549.b.lLi; A.550.b.U.i; A55Lb.llá; A.552.b.ll.í; A.553.b.ll.i; A.554, b.ll.i; A.555.b.ll.i; A.556.b.ll.i; A.557.b.ll.i; A.558.b.ll.i; A.559.b.ll.i; A.560.b.ll.i; A.561.b.ll.i; A.562.b.ll.i; A.563.b.ll.i; A.564.b.U.i; A.565.b.ll.i; A.566.b.U.i; A.567.b.lU; A.568.b.ll.i; A.569.b.ll.i; A.570.b.ll.i; A.571.b.ll.i; A.572.b.ll.i; A.573.b.ll.i; A.574.b.ll.i; A.575.b.ll.i; A.576.b.ll.í; A.577.b.ll.i: A.578.b.lli; A.579.b.lLi; A.580.b.ll.i; A.581K11.Í; A.582.b.ll.i; A.583.b.ll.i; A.584.b.ll.í; A.585.b.llJ; A.586.b.ll.i; A.587.b.ll.i;
-98CZ 297945 B6-98EN 297945 B6
A.588.b.ll.i; A.589.b.ll.i; Á.590.b.U.i; A.591.b.ll.i; A.592.b.lLi; A.593.b.ll.i; A.594.b.ll.i; A.595.b.ll.i; A.596.b.ll.i; A.597.b.ll.i; A.598.b.ll.i;A.599.b.ll.i; A.óOO.b.ll.i; A.óOl.b.ll.i; A.6Q2.b.ll.i; A.603.b.Xl.i; A.604.b.ll.i; A.605.b.ll.x; A.óOó.b.ll.i; A.607.b.ll.i; A.608.b.lLi; A.609.b.ll.i; A.610.b.ll.x; A.6Íl.b.ll.i; A.612.b.ll.i; A.613.b.ll.i; A.614.b.ll.i; A.615.b.ll.i; A.óló.b.lLi; A.617.b.ll.i; A.618.b.ll.i; A.619.b.ll.i; A.620.b.ll.i; A.621.b.lU; A.622.b.ll.i; A.623.b.ll.i; A.624.b.ll.i;'A.625.b.ll.i; A.626.b.ll.i; A.627.b.lli; A.628.b.ll.i; A.629.b.ll.i; A.630.b Jl.i; A.631.b.ll.i; A.632.b.ll.i; A.633.b.ll.i; A.634.b.ll.i; A.635.b.ll.i; A.636.b.ll.i; A.637.b.U.i; A.638.b.ll.i; A.639.b.ll.i; A.640.b.ll.i; A.641.b.ll.i; A.642.b.ll.i; A.643.b.ll.i; A.644.b.ll.i; A.645.b.ll.x; A.646.b.ll.i; A.647.b.llj; A.648.b.ll.i; A.649.b.ll.i; A.650.b.ll.i; A.651.b.ll.i; A.652.b.ll.i; A.653.b.ll.i; A.654.b.ll.i; A.655.b.ll.i; A.656.b.ll.i; A.657.b.ll.í; A.658.b.ll.i; A.659.b.ll.i; A.óóO.b.ll.i; A.2.x.4.i; A.3.x.4.i;A.4.x.4.i; A.5.x.4.i; A.6.x.4.i; A.7.x.4.x; A.9.x.4.i; A.10.X.4.Í; A.15.X.4.Í; A.100.X.4.Í; A.101.x.4.i; A.102.x.4.i; A.103.x.4.i; A.104.x.4.i; A.105.X.4.Í; A.106.x.4.i; A.107.x.4.i; Α.108.Χ.4.Ϊ; A.109.x.4.i; A.110.X.4.Í; A.lll.x.4.i; A.112.X.4.Í; A.113.x.4.i; A.114.x.4.i; A.115.x.4.i; A.116.x.4,i; A.117.x.4.i; A.118.X.4.Í; A.119.X.4.Í; A.120.x.4.i; A.121.X.4.Í; A.122.X.4.Í; A.123.x.4.i; A.124.x.4.i; A.125.X.4.Í; A.126.X.4.Í; A.127.X.4.Í; A.128.x.4.i; A.129.X.4.Í; A.130.x.4.i; A.131.X.4.Í; A.132.X.4.Í; A.133.X.4.Í; A.134.X.4.Í; A.135.X.4.i; A.136.x.4.i; A.137.x.4.i; A.138.X.4.i; A.139.X.4.Í; A.140.X.4.Í; A.141.x.4.i; A.142.x.4.i; A.143.x.4.i; A.144.X.4.Í; A.145.x.4.i; A.146.x.4.i; A.147.X.4.Í; A.148.x.4.i; A.149.X.4.Í; A.150.x.4.i; A.151.X.4.Í; A.152.X.4.Í; A.153.X.4.Í; A.154.X.4.Í; A.155.X.4.Í; A.156.x.4.i; A.157.x.4.i; A.158.x.4.í; A.159.x.4.i; A.160.x.4.i; A.161.X.4.Í; A.162.X.4.Í; A.163.x.4.i; A.164.x.4.i; A.165.X.4.Í; A.166jc.4.í; A.167.x.4.i; A.168.X.4.Í; A.169.x.4.i; A.170.x.4.i; A.171.x.4.i; A.172.X.4.Í; A.173.X.4.Í; A. 174.x.4.i; A.175.X.4.Í; A.176.x.4.i; A.177.x.4.i; A.178.x.4.i; A.179.x.4.i; A.180.x.4.i; A.181.X.4.Í; A.182.X.4.Í; A.183.x.4.i; A.184.x.4.i; A.185.x.4.i; A.186.x.4.i; A.187.x.4.i; A.188.X.4.Í; A.189.x.4.i; A.190.x.4.i; A.191.x.4.i; A.192.x.4.i; A.193.X.4.Í; A.194.x.4.i; Α.195.Χ.4.Ϊ; A.196.X.4.Í; A.197.x.4.i; A.198.x.4.i; A.199.x.4.i; A.200.x.4.i; A.201.x.4.i; A.202.x.4.i; A.203.X.4.Í; A.204.X.4.Í; A.205.X.4.Í; A.206.X.4.Í; A.207.X.4.Í; A.208.X.4.Í; A.209.x.4.i; A.210.X.4.Í; A.211.X.4.Í; A.212.X.4.Í; A.213.x.4.i; A.214.x.4.i; A.215.x.4.i; A.216.X.4.Í; A.217.X.4.Í; A.218.X.4.Í; A.219.x.4.i; A.220.x.4.i; A.221.x.4.i; A222o<.4.i; A.223.X.4.Í; A.224.x.4.i; A.225.x.4.i; A.226.x.4.i; A.227.x.4.i; A.228.x.4.i; A.229.x.4.i; A.230.x.4.i; A.231.X.4.Í; A.232.X.4.Í; A.233.X.4.Í; A.234.x.4.i; A.235.x.4.i; A.236.x.4.i; A.237.X.4.Í; A.238.X.4.Í; A.239.x.4.i; A.240.x.4.i; A24Lx.4.i; A242.X.4.Í; A.243.X.4.Í; A.244.X.4.Í; A.245.X.4.Í; A.246.x.4.i; A.247.x.4.i; A.248.x.4.i; A.249.x.4.i; A.250.x.4.i;A.251.x.4.i; A.252.X.4.Í; A.253.X.4.Í; A.254.x.4.i; A.255.x.4.i; A.256.X.4.Í; A.257.X.4a; A.258.X.4.Í; A.259.X.4.Í; A.260.x.4.i; A.261.x.4.i; A.262.x.4.i; A.263.x.4.i; A-264.x.4.i; A.265.x.4.x; A.266.X.4.Í; A.267.x.4.i; A-268.x.4.i; A,269.x.4.i; A.270.x.4.i; A.271.x.4.i; A.272.X.4.Í; A.273.x.4.i; A.274.X.4.Í; A.275.x.4.i; A.276.x.4.i; A.277.X.4.Í; A.278.x.4.i; A.279.X.4.X; A.280.X.4.Í; A.281.X.4.Í; A.282.X.4.Í; A.283.x.4.i; A.284.X.4.Í; A.285.x.4.i; A.286.X.4.Í; A.287.X.4.Í; A.288.x.4.i; A289.x.4.i; A.290.x.4.i; A.291.x.4.i; A.292.X.4.Í; A.293.X.4.Í; A.294.X.4.Í; A.295.x.4.i; A.296.x.4.i; A.297.X.4.Í; A.298.x.4.i; A.299.x.4.i; A.300.x.4.i; A.301.X.4.Í; A.302.X.4.Í; A.303.x.4.i; A.304.X.4.Í; A.305.X.4.Í; A.306.x.4.i; Α.307.Χ.4.Ϊ; A.308.X.4.Í; A.309.x.4.i; A.310.x.4.i; A.311.x.4.i; A.312.x.4.i; A.313.X.4.Í; A.314.x.4.i; A.315.X.4.Í; A.316.x.4.i; A.317.X.4.Í; A.318.X.4.Í; A.319.x.4.i; A.320.x.4.i; A.321.X.4.Í; A.323.X.4.Í; A.324.x.4.i; A.325.x.4.i; A.326.x.4.i; A.327.x.4.i; A.328.X.4.Í; A.329.X.4.Í; A.330.X.4.Í; A.331.x.4.i; A.332.x.4.i; A.333.x.4.i; A.334.x.4.i; A.335.x.4.i; Α.336.Χ.4.Ϊ;A.588.b.ll.i; A.589.b.ll.i; Á.590.b.U.i; A.591.b.ll.i; A.592.b.lLi; A.593.b.ll.i; A.594.b.ll.i; A.595.b.ll.i; A.596.b.ll.i; A.597.b.ll.i; A.598.b.ll.i; A.599.b.ll.i; A.óOO.b.ll.i; A.óOl.b.ll.i; A.6Q2.b.ll.i; A.603.b.Xl.i; A.604.b.ll.i; A.605.b.ll.x; A.óOó.b.ll.i; A.607.b.ll.i; A.608.b.lLi; A.609.b.ll.i; A.610.b.ll.x; A.6Íl.b.ll.i; A.612.b.ll.i; A.613.b.ll.i; A.614.b.ll.i; A.615.b.ll.i; A.óló.b.lLi; A.617.b.ll.i; A.618.b.ll.i; A.619.b.ll.i; A.620.b.ll.i; A.621.b.lU; A.622.b.ll.i; A.623.b.ll.i; A.624.b.ll.i; A.625.b.ll.i; A.626.b.ll.i; A.627.b.lli; A.628.b.ll.i; A.629.b.ll.i; A.630.b Jl.i; A.631.b.ll.i; A.632.b.ll.i; A.633.b.ll.i; A.634.b.ll.i; A.635.b.ll.i; A.636.b.ll.i; A.637.b.U.i; A.638.b.ll.i; A.639.b.ll.i; A.640.b.ll.i; A.641.b.ll.i; A.642.b.ll.i; A.643.b.ll.i; A.644.b.ll.i; A.645.b.ll.x; A.646.b.ll.i; A.647.b.llj; A.648.b.ll.i; A.649.b.ll.i; A.650.b.ll.i; A.651.b.ll.i; A.652.b.ll.i; A.653.b.ll.i; A.654.b.ll.i; A.655.b.ll.i; A.656.b.ll.i; A.657.b.ll.í; A.658.b.ll.i; A.659.b.ll.i; A.O6O.b.ll.i; A.2.x.4.i; A.3.x.4.i, A.4.x.4.i; A.5.x.4.i; A.6.x.4.i; A.7.x.4.x; A.9.x.4.i; A.10.X.4.Í; A.15.X.4.Í; A.100.X.4.Í; A.101.x.4.i; A.102.x.4.i; A.103.x.4.i; A.104.x.4.i; A.105.X.4.Í; A.106.x.4.i; A.107.x.4.i; Α.108.Χ.4.Ϊ; A.109.x.4.i; A.110.X.4.I; A.lll.x.4.i; A.112.X.4.Í; A.113.x.4.i; A.114.x.4.i; A.115.x.4.i; A.116.x.4, i; A.117.x.4.i; A.118.X.4.Í; A.119.X.4.Í; A.120.x.4.i; A.121.X.4.Í; A.122.X.4.Í; A.123.x.4.i; A.124.x.4.i; A.125.X.4.Í; A.126.X.4.Í; A.127.X.4.Í; A.128.x.4.i; A.129.X.4.Í; A.130.x.4.i; A.131.X.4.I; A.132.X.4.Í; A.133.X.4.Í; A.134.X.4.Í; A.135.X.4.i; A.136.x.4.i; A.137.x.4.i; A.138.X.4.i; A.139.X.4.Í; A.140.X.4.Í; A.141.x.4.i; A.142.x.4.i; A.143.x.4.i; A.144.X.4.Í; A.145.x.4.i; A.146.x.4.i; A.147.X.4.Í; A.148.x.4.i; A.149.X.4.Í; A.150.x.4.i; A.151.X.4.Í; A.152.X.4.Í; A.153.X.4.Í; A.154.X.4.Í; A.155.X.4.Í; A.156.x.4.i; A.157.x.4.i; A.158.x.4.í; A.159.x.4.i; A.160.x.4.i; A.161.X.4.Í; A.162.X.4.Í; A.163.x.4.i; A.164.x.4.i; A.165.X.4.Í; A.166jc.4.í; A.167.x.4.i; A.168.X.4.I; A.169.x.4.i; A.170.x.4.i; A.171.x.4.i; A.172.X.4.Í; A.173.X.4.I; A. 174.x.4.i; A.175.X.4.Í; A.176.x.4.i; A.177.x.4.i; A.178.x.4.i; A.179.x.4.i; A.180.x.4.i; A.181.X.4.Í; A.182.X.4.Í; A.183.x.4.i; A.184.x.4.i; A.185.x.4.i; A.186.x.4.i; A.187.x.4.i; A.188.X.4.Í; A.189.x.4.i; A.190.x.4.i; A.191.x.4.i; A.192.x.4.i; A.193.X.4.Í; A.194.x.4.i; Α.195.Χ.4.Ϊ; A.196.X.4.Í; A.197.x.4.i; A.198.x.4.i; A.199.x.4.i; A.200.x.4.i; A.201.x.4.i; A.202.x.4.i; A.203.X.4.Í; A.204.X.4.Í; A.205.X.4.Í; A.206.X.4.Í; A.207.X.4.Í; A.208.X.4.Í; A.209.x.4.i; A.210.X.4.Í; A.211.X.4.Í; A.212.X.4.Í; A.213.x.4.i; A.214.x.4.i; A.215.x.4.i; A.216.X.4.Í; A.217.X.4.Í; A.218.X.4.Í; A.219.x.4.i; A.220.x.4.i; A.221.x.4.i; A222o <.4i; A.223.X.4.Í; A.224.x.4.i; A.225.x.4.i; A.226.x.4.i; A.227.x.4.i; A.228.x.4.i; A.229.x.4.i; A.230.x.4.i; A.231.X.4.Í; A.232.X.4.Í; A.233.X.4.Í; A.234.x.4.i; A.235.x.4.i; A.236.x.4.i; A.237.X.4.Í; A.238.X.4.Í; A.239.x.4.i; A.240.x.4.i; A24Lx.4.i; A242.X.4.I; A.243.X.4.Í; A.244.X.4.Í; A.245.X.4.Í; A.246.x.4.i; A.247.x.4.i; A.248.x.4.i; A.249.x.4.i; A.250.x.4.i; A.251.x.4.i; A.252.X.4.Í; A.253.X.4.Í; A.254.x.4.i; A.255.x.4.i; A.256.X.4.Í; A.257.X.4a; A.258.X.4.Í; A.259.X.4.Í; A.260.x.4.i; A.261.x.4.i; A.262.x.4.i; A.263.x.4.i; A-264.x.4. A.265.x.4.x; A.266.X.4.Í; A.267.x.4.i; A-268.x.4. A, 269.x.4.i; A.270.x.4.i; A.271.x.4.i; A.272.X.4.Í; A.273.x.4.i; A.274.X.4.Í; A.275.x.4.i; A.276.x.4.i; A.277.X.4.Í; A.278.x.4.i; A.279.X.4.X; A.280.X.4.Í; A.281.X.4.Í; A.282.X.4.Í; A.283.x.4.i; A.284.X.4.Í; A.285.x.4.i; A.286.X.4.Í; A.287.X.4.Í; A.288.x.4.i; A289.x.4.i; A.290.x.4.i; A.291.x.4.i; A.292.X.4.Í; A.293.X.4.Í; A.294.X.4.Í; A.295.x.4.i; A.296.x.4.i; A.297.X.4.Í; A.298.x.4.i; A.299.x.4.i; A.300.x.4.i; A.301.X.4.Í; A.302.X.4.I; A.303.x.4.i; A.304.X.4.Í; A.305.X.4.Í; A.306.x.4.i; Α.307.Χ.4.Ϊ; A.308.X.4.Í; A.309.x.4.i; A.310.x.4.i; A.311.x.4.i; A.312.x.4.i; A.313.X.4.Í; A.314.x.4.i; A.315.X.4.Í; A.316.x.4.i; A.317.X.4.Í; A.318.X.4.Í; A.319.x.4.i; A.320.x.4.i; A.321.X.4.Í; A.323.X.4.Í; A.324.x.4.i; A.325.x.4.i; A.326.x.4.i; A.327.x.4.i; A.328.X.4.Í; A.329.X.4.Í; A.330.X.4.Í; A.331.x.4.i; A.332.x.4.i; A.333.x.4.i; A.334.x.4.i; A.335.x.4.i; Α.336.Χ.4.Ϊ;
-99CZ 297945 B6-99GB 297945 B6
A.337.X.4.Í; A.338.x.4.i; A.339.x.4.i; A.340.x.4.i; A.341.X.4.Í; A.342.x.4.i; A.343.x.4.i; A.344.X.4.Í; A.345.x.4.i; A.346.x.4.i; A.347.x.4.i; A.348.x.4.i; A.349.x.4.i; A.350.X.4.Í; A.351.x.4.i; A.352.x.4.i; A.353.x.4.i; A-354.x.4,i; A.355.X.4.Í; A.356.x.4.i; A357.X.4Ú; A.358.X.4.Í; A.359.x.4.i; A.360.x.4.i; A.361.x.4.i; A.362.x.4.i; A.363.x.4.i; A.364.x.4.i; A.365.X.4.Í; A,366.x.4.i; A.367.x.4.i; A.368.x.4.i; A.369.x.4.i; A.370.x.4.i; A.371.X.4.Í; Α.372.Χ.4.Ϊ; A.373.X.4.Í; A.374.x.4.i; A.375.x.4.i; A.376.x.4.i; Α.377.Χ.4.Ϊ; A.378.X.44; A.379.X-4.Í; A.380.X.4.Í; A.381.X.4.Í; A.382.x.4.i; A.383.x.4.i; A.384.x.4.i; A.385.x.4.i; A.386.X.4.Í; A.387.x.4.i; A.388.X.4.Í; A.389.x.4.i; A.390.x.4.i; A.391.x.4.i; A.392.x.4.i; Α.393.Χ.4.Ϊ; A.394.x.4.i; A.395.x.4.i; A.396.x.4.i; A.397.x.4.i; A.398.x.4.i; A.399.x,4.i; A.400.X.4.Í; A.401.x.4.i; A.402.x.4.i; A.403.X.4.Í; A.404.X.4.Í; A.405.x.4.i; Α.406.Χ.4.Ϊ; Α.407.Χ.4.Ϊ; A.408.X.4.Í; A.409.x.4.i; A.410.X.4.Í; A.411.X.4.Í; A.412.x.4.i; A.413.x.4.i; A.414.X.4.Í; A.415.x.4.i; A.416.x.4.i; Α.417.Χ.4Λ; A.418.x.4.i; Α.419.Χ.4.Ϊ; Α.420.Χ.4.Ϊ; A.421.X.4.Í; A.422.x.4.i; A.423.x.4.i; A.424.x.4.i; A.425.x.4.i; A.426.X.4.Í; A.427.x.4.i; A.428.X.4.Í; A.429.X.4.Í; A.430.x.4.i; A.431.x.4.i; A.432.X.4.Í; Α.433.Χ.4.Ϊ; A.434.X.4.Í; A.435.X.4.Í; A.436.X.4.Í; A.437.X.4.Í; A.438.x.4.x; A.439.X.4.Í; A.440.x.4.i; A.441.X.4.Í; A.442.X.4.Í; Α.443.Χ.4.Χ; A.444.x.4.i; A.445.x.4.i; A.446.x.4.i; A.447.x.4.i; A.448.x.4i; A.449.X.4.Í; A.450.x.4.i; A.451.x.4.i; A.452.x.4.i; A.453.x.4.i; A.454.x.4.i; A.455.X.4.Í; A.456.X.4.Í; A.457.x.4.i; A.458.x.4.i; A.459.x.4.i; A.460.X.4.Í; A.461.x.4.i; A.462.x.4.i; A.463.X.4.Í; A-464.x.4.i; A.465.x.4.i; A.466.x.4.i; A.467.x.4.i; A.468.x.4.i; A.469.x.4.i; A.470.X.4.Í; A.471.x.4.i; A.472.x.4.i; A.473.X.4.Í; A.474.x.4.i; A.475.x.4.i; A.476.x.4.i; Α.477.Χ.4.Ϊ; A.478.x.4.i; A.479,x.4.i; A.480.x.4.i; A.481.x.4.i; A.482.x.4.i; A.483.X.4.Í; A.484.X.4.Í; A.485.x.4.i; A.486.X.4.Í; A.487.x.4.i; A.488.x.4.i; A.489.X.4.Í; A.490.x.4.i; A.491.X.4.Í; A.492.X.4.Í; A.493,x.4.i; A-494.X.4.Í; A.495.x.4.i; A.496.x.4.i; A.497.X.4.Í; A.498.X.4.Í; A.499.x.4.i; A.500.x.4-i; A,501.x.4.i; A.502.x.4.i; A.503.x.4.i; A.504.x.4.i; A.505.x.4.i; A.506.x.4.i; A.507.X.4.Í; A.508.x.4.i; A.509.x.4.i; A.510,x.4.i; A.511.x.4.i; A.512.X.4.Í; A.512.x.4.i: A-513.x.4.i; A.514.x.4.i; A.515.x.4.i; A.516.x.4.i; A.517.x.4.i; Α.518.Χ.4.Ϊ; A.519.x.4,i; A-520.X.4.Í; A.521.X.4.Í; A.522.X.4.Í; A.523.x.4.i; A.524.x.4.i; A.525.x.4,i; A.526.x.4.i; A.527.x.4.i; A.528.X.4.Í; A.529.x.4.i; A.530.X.4.Í; A.531.X.4.Í; A.532.X.4.Í; A.533.X.4.Í; A.534.x.4.i; A.535.x.4.i; A.536.x.4.i; A.537.x.4.i; A.538.X.4.Í; A.539.X.4.Í; A.540.x.4.i; A.541.x.4.i; A.542.X.4-i; A.543.x.4.i; A.544.x.4.i; A.545.x.4.i; A.546.X.4.Í; A.547.x.4.i; A.548.x.4.i; A.549.x.4.i; A.550.x.4.i; A.551.x.4.i; A.552.x.4.i; A.553.X.4.X; A.554.x.4.i; A.555.x.4.i; A.556#x.4.i; A.557.x.4.i; A.558.x.4.i; A.559.X.4.Í; Α.560.Χ.4.Ϊ; A.561.x.4.i; A.562.x.4.i; A.563.X.4.Í; A.564.x.4.i; A.565.x.4.i; A.566.X.4.Í; A.567.X.4.Í; A.568.x.4.i; A.569.x.4.i; A.570,x.4.i; A.571.x.4.i; A-572.x.4.i; A.573.X.4.Í; A.574.X.4.Í; A.575.X.4.Í; A.576.x.4.i; A.577.x.4.i; A.578.x.4.i; A.579.x.4.i; A.580.X.4.Í; A.581.X.4.Í; A.582.x.4.i; A.583.x,4.i; A.584.X.4.X; A.585.x.4.x; A.586.x.4.i; A.587.x.4.i; A.588.X.4.Í; A.589.X.4.Í; A.590.x.4.i; A.591.x.4.i; A.592.X.4.Í; A.593.x.4.i; A.594.X.4.Í; A.595.X.4.Í; A.596.x.4.i; A.597.x.4.i; A.598.x.4.i; A.599.x.4.i; A.600.x.4.i; A.601.x.4.i; A.602.x.4.i; A.603,x.4.x; A.604.X.4.Í; A.605.x.4,i; A.606.x.4.i; A.607.X.4.Í; A.608.x.4.i; A.609.x.4a; A.610.x.4.i; A.611.x.4.i; A.612.x.4.i; A.613.x.4.i; A.614.x.4.i; A.615.X.4.Í; A.616.X.4.Í; Α.617.Χ.4.Ϊ; A-618.x.4.i; A.619.x.4.i; A.620.x.4.i; Α.621.Χ.4.Ϊ; A.622.X.4.Í; A.623.X.4.Í; A.624.x,4.i; A.625.x.4.i; A.626.X.4.Í; A.627.x.4.i; A.628.X.4.Í; A.629.X.4.Í; A.630.X.4.Í; A.631.x.4.i; A.632.x.4.i; A.633.x.4.i; A.634.X.4.Í; A.635.x.4.i; A.636.x.4.i; A.637.X.4.Í; A.638.X.4.Í; A.639.X.4.Í; A.640.x.4.i; A.641.x.4.i; A.642.x.4.i; A.643.X.4.Í; Α.644.Χ.4.Ϊ; A.645.x.4.i; A.646.x.4.i; A.647.X.4.Í; A.648.x.4.i; A.649.x.4.i; A.650.x.4.i; A.651.X.4.i; A.652.x.4.i; A.653.X.4.Í,· A.654.x.4.i; A.655.x.4.i; A.656.x.4.i; A.657.x.4.í; A.658.X.4.Í; A.659.x.4.i; Α·66Θ.χ.4.ϊ; A.2.x.ll.i; A.3.x.ll.i; A.4.x.ll.i; A.5.X.11.Í;A.337.X.4.Í; A.338.x.4.i; A.339.x.4.i; A.340.x.4.i; A.341.X.4.Í; A.342.x.4.i; A.343.x.4.i; A.344.X.4.Í; A.345.x.4.i; A.346.x.4.i; A.347.x.4.i; A.348.x.4.i; A.349.x.4.i; A.350.X.4.Í; A.351.x.4.i; A.352.x.4.i; A.353.x.4.i; A-354.x.4, i; A.355.X.4.Í; A.356.x.4.i; A357.X.4Ú; A.358.X.4.Í; A.359.x.4.i; A.360.x.4.i; A.361.x.4.i; A.362.x.4.i; A.363.x.4.i; A.364.x.4.i; A.365.X.4.Í; A, 366.x.4.i; A.367.x.4.i; A.368.x.4.i; A.369.x.4.i; A.370.x.4.i; A.371.X.4.Í; Α.372.Χ.4.Ϊ; A.373.X.4.Í; A.374.x.4.i; A.375.x.4.i; A.376.x.4.i; Α.377.Χ.4.Ϊ; A.378.X.44; A.379.X-4.I; A.380.X.4.Í; A.381.X.4.Í; A.382.x.4.i; A.383.x.4.i; A.384.x.4.i; A.385.x.4.i; A.386.X.4.Í; A.387.x.4.i; A.388.X.4.Í; A.389.x.4.i; A.390.x.4.i; A.391.x.4.i; A.392.x.4.i; Α.393.Χ.4.Ϊ; A.394.x.4.i; A.395.x.4.i; A.396.x.4.i; A.397.x.4.i; A.398.x.4.i; A.399.x, 4.i; A.400.X.4.Í; A.401.x.4.i; A.402.x.4.i; A.403.X.4.I; A.404.X.4.I; A.405.x.4.i; Α.406.Χ.4.Ϊ; Α.407.Χ.4.Ϊ; A.408.X.4.I; A.409.x.4.i; A.410.X.4.Í; A.411.X.4.Í; A.412.x.4.i; A.413.x.4.i; A.414.X.4.Í; A.415.x.4.i; A.416.x.4.i; Α.417.Χ.4Λ; A.418.x.4.i; Α.419.Χ.4.Ϊ; Α.420.Χ.4.Ϊ; A.421.X.4.Í; A.422.x.4.i; A.423.x.4.i; A.424.x.4.i; A.425.x.4.i; A.426.X.4.Í; A.427.x.4.i; A.428.X.4.Í; A.429.X.4.Í; A.430.x.4.i; A.431.x.4.i; A.432.X.4.Í; Α.433.Χ.4.Ϊ; A.434.X.4.Í; A.435.X.4.Í; A.436.X.4.Í; A.437.X.4.Í; A.438.x.4.x; A.439.X.4.Í; A.440.x.4.i; A.441.X.4.Í; A.442.X.4.Í; Α.443.Χ.4.Χ; A.444.x.4.i; A.445.x.4.i; A.446.x.4.i; A.447.x.4.i; A.448.x.4i; A.449.X.4.Í; A.450.x.4.i; A.451.x.4.i; A.452.x.4.i; A.453.x.4.i; A.454.x.4.i; A.455.X.4.Í; A.456.X.4.Í; A.457.x.4.i; A.458.x.4.i; A.459.x.4.i; A.460.X.4.Í; A.461.x.4.i; A.462.x.4.i; A.463.X.4.Í; A-464.x.4.i; A.465.x.4.i; A.466.x.4.i; A.467.x.4.i; A.468.x.4.i; A.469.x.4.i; A.470.X.4.Í; A.471.x.4.i; A.472.x.4.i; A.473.X.4.Í; A.474.x.4.i; A.475.x.4.i; A.476.x.4.i; Α.477.Χ.4.Ϊ; A.478.x.4.i; A.479, x.4.i; A.480.x.4.i; A.481.x.4.i; A.482.x.4.i; A.483.X.4.Í; A.484.X.4.Í; A.485.x.4.i; A.486.X.4.Í; A.487.x.4.i; A.488.x.4.i; A.489.X.4.Í; A.490.x.4.i; A.491.X.4.Í; A.492.X.4.Í; A.493, x.4.i; A-494.X.4. A.495.x.4.i; A.496.x.4.i; A.497.X.4.Í; A.498.X.4.Í; A.499.x.4.i; A.500.x.4-i; A, 501.x.4.i; A.502.x.4.i; A.503.x.4.i; A.504.x.4.i; A.505.x.4.i; A.506.x.4.i; A.507.X.4.I; A.508.x.4.i; A.509.x.4.i; A.510, x.4.i; A.511.x.4.i; A.512.X.4.Í; A.512.x.4.i. A.514.x.4.i; A.515.x.4.i; A.516.x.4.i; A.517.x.4.i; Α.518.Χ.4.Ϊ; A.519. X.4, i; A-520.X.4. A.521.X.4.Í; A.522.X.4.Í; A.523.x.4.i; A.524.x.4.i; A.525. X.4, i; A.526.x.4.i; A.527.x.4.i; A.528.X.4.Í; A.529.x.4.i; A.530.X.4.Í; A.531.X.4.Í; A.532.X.4.Í; A.533.X.4.Í; A.534.x.4.i; A.535.x.4.i; A.536.x.4.i; A.537.x.4.i; A.538.X.4.Í; A.539.X.4.Í; A.540.x.4.i; A.541.x.4.i; A.542. X.4-i; A.543.x.4.i; A.544.x.4.i; A.545.x.4.i; A.546.X.4.Í; A.547.x.4.i; A.548.x.4.i; A.549.x.4.i; A.550.x.4.i; A.551.x.4.i; A.552.x.4.i; A.553.X.4.X; A.554.x.4.i; A.555.x.4.i; A.555 # x.4.i; A.557.x.4.i; A.558.x.4.i; A.559.X.4.Í; Α.560.Χ.4.Ϊ; A.561.x.4.i; A.562.x.4.i; A.563.X.4.Í; A.564.x.4.i; A.565.x.4.i; A.566.X.4.Í; A.567.X.4.Í; A.568.x.4.i; A.569.x.4.i; A.570, x.4.i; A.571.x.4.i; A-572.x.4. A.573.X.4.Í; A.574.X.4.Í; A.575.X.4.Í; A.576.x.4.i; A.577.x.4.i; A.578.x.4.i; A.579.x.4.i; A.580.X.4.Í; A.581.X.4.Í; A.582.x.4.i; A.583.x, 4.i; A.584.X.4.X; A.585.x.4.x; A.586.x.4.i; A.587.x.4.i; A.588.X.4.Í; A.589.X.4.Í; A.590.x.4.i; A.591.x.4.i; A.592.X.4.Í; A.593.x.4.i; A.594.X.4.Í; A.595.X.4.Í; A.596.x.4.i; A.597.x.4.i; A.598.x.4.i; A.599.x.4.i; A.600.x.4.i; A.601.x.4.i; A.602.x.4.i; A.603, x.4.x; A.604.X.4.Í; A.605.x.4, i; A.606.x.4.i; A.607.X.4.Í; A.608.x.4.i; A.609.x.4a; A.610.x.4.i; A.611.x.4.i; A.612.x.4.i; A.613.x.4.i; A.614.x.4.i; A.615.X.4.Í; A.616.X.4.Í; Α.617.Χ.4.Ϊ; A-618.x.4.i; A.619.x.4.i; A.620.x.4.i; Α.621.Χ.4.Ϊ; A.622.X.4.Í; A.623.X.4.Í; A.624.x, 4.i; A.625.x.4.i; A.626.X.4.Í; A.627.x.4.i; A.628.X.4.Í; A.629.X.4.Í; A.630.X.4.Í; A.631.x.4.i; A.632.x.4.i; A.633.x.4.i; A.634.X.4.Í; A.635.x.4.i; A.636.x.4.i; A.637.X.4.Í; A.638.X.4.Í; A.639.X.4.Í; A.640.x.4.i; A.641.x.4.i; A.642.x.4.i; A.643.X.4.Í; Α.644.Χ.4.Ϊ; A.645.x.4.i; A.646.x.4.i; A.647.X.4.Í; A.648.x.4.i; A.649.x.4.i; A.650.x.4.i; A.651.X.4.i; A.652.x.4.i; A.653.X.4.I, · A.654.x.4.i; A.655.x.4.i; A.656.x.4.i; A.657.x.4.í; A.658.X.4.Í; A.659.x.4.i; Α · 66Θ.χ.4.ϊ; A.2.x.ll.i; A.3.x.ll.i; A.4.x.ll.i; A.5.X.11.Í;
- 100CZ 297945 B6- 100GB 297945 B6
A.6.X.11.Í; A.7.X.11.Í; A.9o.U.i; A.10.x.ll.i; A.15.x.ll.i; A.100.X.11.Í; A.lOl.x.114; i; Α.103.Χ.11.Ϊ; A.104.X.11.Í; A.105.X.11.Í; A.106.X.11.Í; A.107.x.ll.i; A.109.X.11.ÍA.6.X.11.Í; A.7.X.11.Í; A.9o.U.i; A.10.x.ll.i; A.15.x.ll.i; A.100.X.11.Í; A.lOl.x.114; and; Α.103.Χ.11.Ϊ; A.104.X.11.Í; A.105.X.11.Í; A.106.X.11.Í; A.107.x.ll.i; A.109.X.11.Í
A.115.X.11.Í;A.115.X.11.Í;
A.121.X.11.Í;A.121.X.11.Í;
A.127.X.11.Í,A.127.X.11.Í,
A.133.X.114,A.133.X.114,
A.139.X.11.ÍA.139.X.11.Í
A.145.X.11.Í,A.145.X.11.Í,
A.151.X.11.Í,A.151.X.11.Í,
A.157.X.11.Í,A.157.X.11.Í,
A.163.X.11.Í;A.163.X.11.Í;
A.169.X.1U;A.169.X.1U;
A.175.X.11.Í;A.175.X.11.Í;
A.181.X.11.Í;A.181.X.11.Í;
A.187.X.U.Í;A.187.X.U.I;
A.193.X.11.Í;A.193.X.11.Í;
Α.199.Χ.11.Ϊ;Α.199.Χ.11.Ϊ;
A.205.X.11.Í;A.205.X.11.Í;
A.211.X.11.Í;A.211.X.11.Í;
A.217.X.11.Í; A.218.X.11.Ě A219o.ll.i; A.220.X.11.Í; A22Lx.U.i; A.223.X.11.Í;A.217.X.11.Í; A.218.X.11.Ě A219o.ll.i; A.220.X.11.Í; A22Lx.U.i; A.223.X.11.Í;
A.229.X.11.Í;A.229.X.11.Í;
A235-x.il.i;A235-x.il.i;
A.241.X.11.Í;A.241.X.11.Í;
A.247.X.11.Í;A.247.X.11.Í;
A253.X.11.i;A253.X.11.i;
A.102.X.U.Í A.108.X.11.Í; A.U4.X.11.Í; A.120.x.ll.i; A.126.X.11.Í; A.132.x,lli; A.138.X.11.Í; A.144.X.11.Í; A.150.X.11.Í; A.156.X.11.Í; A.162.X.11.Í; A.168.X.11.Í; A.174.X.U.Í; A.180.X.11.Í; A.186.X.11.Í; A.192.X.11.Í; A.198.x.ll.i; A.204.X.11.Í; A.210.X.11.Í; A.216.X.11.Í; A.222.X.11.Í; A.228.X.11.Í; A.234.X.11.Í; A.240.X.11.Í; A.246.X.U.Í; A.252.X.11.Í; A.258.X.11.I; A.264.X.11.Í; A.270.X.11.1; A.276.X.11.Í; A.282.X.11.Í; A-288o.ll.i; A294o.ll i; A.300.x.ll.i; A.306.X.11.Í; A.312.X.11.Í; A318o.ll.i; A.325.x.ll.i;A.102.X.U.Í A.108.X.11.Í; A.U4.X.11.Í; A.120.x.ll.i; A.126.X.11.Í; A.132.x, lli; A.138.X.11.Í; A.144.X.11.Í; A.150.X.11.Í; A.156.X.11.Í; A.162.X.11.Í; A.168.X.11.Í; A.174.X.U.I; A.180.X.11.Í; A.186.X.11.Í; A.192.X.11.Í; A.198.x.ll.i; A.204.X.11.Í; A.210.X.11.Í; A.216.X.11.Í; A.222.X.11.Í; A.228.X.11.Í; A.234.X.11.Í; A.240.X.11.Í; A.246.X.U.I; A.252.X.11.Í; A.258.X.11.I; A.264.X.11.Í; A.270.X.11.1; A.276.X.11.Í; A.282.X.11.Í; A-288, III.i; A294o.11 i; A.300.x.ll.i; A.306.X.11.Í; A.312.X.11.Í; A318o.ll.i; A.325.x.ll.i;
A.331.X.11.ÍA.331.X.11.Í
A.337.X.11.ÍA.337.X.11.Í
A.343.x.ll.iA.343.x.ll.i
A.349.X.11.ÍA.349.X.11.Í
A.361.X.11.ÍA.361.X.11.Í
A.110.X.11.Í; A.111.X.11.Í; A.112.x.ll.i; A.113.X.114; A.116.X.114; A.117.x.ll.i; A.118.X.11.Í; A.119.x.ll.i; A.122.X.11.1; A.123.X.11.Í; A.124.x.ll.i; A.125.X.11.Í; A.128.X.11.Í; A.129.X.11.Í; A.130.X.114; A.131.X.11.Í; A.134.X.11.Í;. A.135.X.1U; A.136.X.11 .i; A-137a.ll j; , A.140.X.11.Í; A.141.X.11.Í; A.142.X.11.Í; A.143.X.11.Í;A.110.X.11.Í; A.111.X.11.Í; A.112.x.ll.i; A.113.X.114; A.116.X.114; A.117.x.ll.i; A.118.X.11.Í; A.119.x.ll.i; A.122.X.11.1; A.123.X.11.Í; A.124.x.ll.i; A.125.X.11.Í; A.128.X.11.Í; A.129.X.11.Í; A.130.X.114; A.131.X.11.Í; A.134.X.11.Í ;. A.135.X.1U; A.136.X.11 .i; A-137a.111; , A.140.X.11.I; A.141.X.11.Í; A.142.X.11.Í; A.143.X.11.Í;
A.146.X.U.Í; A.147.x.ll.i; A.148a.ll.i; A.149.x.ll.i; A.152.x.ll.i; A.153.X.11.Í; A.154.x.ll.i; Α.155.Χ.114;A.146.X.U.I; A.147.x.ll.i; A.148a.ll.i; A.149.x.ll.i; A.152.x.ll.i; A.153.X.11.Í; A.154.x.ll.i; Α.155.Χ.114;
: A.158.X.11.Í; Α.159.Χ.11 .i; A.lóO.x.ll.i; A.lól.x.ll.i; . A.164.X.11.Í; A.165.X.11.Í; A.166.x.ll.i; A.167.x.ll.i; A.170.X.11.Í; A.171.X.11.Í; A.172a.ll.i; A.173.x.ll.i; A.176.X.U.Í; A.177.X.11.Í; A.178.x.ll.i; A.179.X.11.Í; A.182.X.11.Í; A.183.x.ll.i; A.184.x.ll.i; A.185.x.ll.i; A.188.X.11.Í; A.189.x.ll.i; A.190.x.ll.i; A.191.X.11.Í; A.194.X.11.Í; A.195.x.U.i; A.196.X.11.Í; A.197.X.11 .i; A.200.X.11.Í; A.201.x.U.i; A.202.X.11.i; A.203.X.11.Í; A.206.X.11.Í; A.207.x.ll.i; A.208.x.ll.i; A.209.x.ll.i; A.212.X.11.Í; A213o.il .i; A.214.x.ll.i; A.215.x.ll.i;: A.158.X.11.Í; Α.159.Χ.11 .i; A.10.0.x.ll.i; A.lól.x.ll.i; . A.164.X.11.Í; A.165.X.11.Í; A.166.x.ll.i; A.167.x.ll.i; A.170.X.11.Í; A.171.X.11.Í; A.172a.ll.i; A.173.x.ll.i; A.176.X.U.I; A.177.X.11.Í; A.178.x.ll.i; A.179.X.11.Í; A.182.X.11.Í; A.183.x.ll.i; A.184.x.ll.i; A.185.x.ll.i; A.188.X.11.Í; A.189.x.ll.i; A.190.x.ll.i; A.191.X.11.Í; A.194.X.11.Í; A.195.x.U.i; A.196.X.11.Í; A.197.X.11 .i; A.200.X.11.Í; A.201.x.U.i; A.202.X.11.i; A.203.X.11.Í; A.206.X.11.Í; A.207.x.ll.i; A.208.x.ll.i; A.209.x.ll.i; A.212.X.11.Í; A213o.il .i; A.214.x.ll.i; A.215.x.ll.i;
A.259.X.11.Í;A.259.X.11.Í;
A.265.X.11.Í;A.265.X.11.Í;
A.271.x.ll.i;A.271.x.ll.i;
A.277.X.11.Í;A.277.X.11.Í;
Α.283.Χ.11.Ϊ;Α.283.Χ.11.Ϊ;
A.289.x.ll.i;A.289.x.ll.i;
A.295.X.11.Í;A.295.X.11.Í;
A.301.X.11.Í;A.301.X.11.Í;
A.307.X.11.Í;A.307.X.11.Í;
A.313.X.11.Í;A.313.X.11.Í;
A.319.X.11.Í;A.319.X.11.Í;
A.326.X.U.Í;A.326.X.U.I;
A.332.X.11.Í;A.332.X.11.Í;
A.338.X.11.Í;A.338.X.11.Í;
A.344.X.11.Í;A.344.X.11.Í;
A.350.X.11.Í;A.350.X.11.Í;
A.355.X.11.Í; A.356.x.ll.iA.355.X.11.Í; A.356.x.ll.i
A.224.X.U.Í; Α.225.Χ.11 .i; A.226.X.U.Í; A227.X.11.Í;A.224.X.U.I; Α.225.Χ.11 .i; A.226.X.U.I; A227.X.11.Í;
A.230.X.11.Í; A.231.X.11.Í; A.232.x.U.i; A.233.X.11.Í; A.236.X.11.Í; A.237.X.11.Í; A.238.X.11.Í; A.239.x.ll.i; A.242.X.11.Í; A.243.x.ll.i; A.244.X.11.Í; A245.X.11.Í;A.230.X.11.Í; A.231.X.11.Í; A.232.x.U.i; A.233.X.11.Í; A.236.X.11.Í; A.237.X.11.Í; A.238.X.11.Í; A.239.x.ll.i; A.242.X.11.Í; A.243.x.ll.i; A.244.X.11.Í; A245.X.11.Í;
A,248.x.ll.i; A.249.X.11.Í; A.250.x.ll.i; A.251.x.U.i;A, 248.x.II.i; A.249.X.11.Í; A.250.x.ll.i; A.251.x.U.i;
A.254.X.11.Í; A.255.X.1LÍ; Α.256.Χ.11.Ϊ; A.257.X.11.Í;A.254.X.11.Í; A.255.X.1LÍ; Α.256.Χ.11.Ϊ; A.257.X.11.Í;
A.260.X.11.Í; A.261.x.ll.i; A.262.X.1U; A.263.x.ll.i;A.260.X.11.Í; A.261.x.ll.i; A.262.X.1U; A.263.x.ll.i;
A.266.X.11.Í; A.267.X.11.Í; A.268.X.11.Í; A.269.x.ll.i;A.266.X.11.Í; A.267.X.11.Í; A.268.X.11.Í; A.269.x.ll.i;
A.272.X.11.Í; A373o.il.í; A.274.X.11.Í; A.275.X.11.Í;A.272.X.11.Í; A373o.il.í; A.274.X.11.Í; A.275.X.11.Í;
A.278.x.ll.i; A.279.x.ll.i; A.280.X.U.Í; A.281.X.11.Í;A.278.x.ll.i; A.279.x.ll.i; A.280.X.U.I; A.281.X.11.Í;
A.284.X.11.1; A.285.x.ll.i; A.286.x.ll,i; A.287.X.11.Í;A.284.X.11.1; A.285.x.ll.i; A.286.x.ll, i; A.287.X.11.Í;
A.290.X.11.Í; A.291.x.ll.i; A.292.x.ll.i; A.293.x.ll.i;A.290.X.11.Í; A.291.x.ll.i; A.292.x.ll.i; A.293.x.ll.i;
A.296.X.11.Í; A.297.x.ll.i; A.298.x.ll.i; A.299.X.1I.Í;A.296.X.11.Í; A.297.x.ll.i; A.298.x.ll.i; A.299.X.1I.I;
A.302.X.U.Í; A.303.X.11.Í; A.304.x.ll.i; A.305.x.ll.i;A.302.X.U.I; A.303.X.11.Í; A.304.x.ll.i; A.305.x.ll.i;
A.308.X.11.Í; A.309.x.ll.i; A.310.x.ll.i; A311a.ll.i;A.308.X.11.Í; A.309.x.ll.i; A.310.x.ll.i; A311a.ll.i;
A.314a41.i; A315.x.ll.i; A.316.X.11.Í; A.317.x.ll.i;A.314a41.i; A315.x.ll.i; A.316.X.11.Í; A.317.x.ll.i;
A.320.X.11.Í; A321.X.11.Í; A.323.X.11.Í; A.324.X.11.Í;A.320.X.11.Í; A321.X.11.Í; A.323.X.11.Í; A.324.X.11.Í;
A.327.X.11.Í; A.328.x.ll.i; A.329.X.11.Í;. A330.x,ll.i;A.327.X.11.Í; A.328.x.ll.i; A.329.X.11.Í ;. A330.x, II.i;
A.333.X.11.Í; A.334.X.11.Í; A.335.x.ll.i; A.336.x.ll.i;A.333.X.11.Í; A.334.X.11.Í; A.335.x.ll.i; A.336.x.ll.i;
A339.X.11.Í; A340.x.ll.i; A.341.X.11.Í; A.342.x.ll.i;A339.X.11.Í; A340.x.ll.i; A.341.X.11.Í; A.342.x.ll.i;
A.345.X.11.Í; A.346.x.ll.i; A.347.x,ll.i; A.348.X.11.Í;A.345.X.11.Í; A.346.x.ll.i; A.347.x, II.i; A.348.X.11.Í;
A.351.X.11.Í; A.352.X.11.Í; A.353.x.ll.i; A.354.x.ll.i; ; A.357.X.U.Í; A.358.x.ll,i; A.359.X.11 .i; A.360.x.ll.i;A.351.X.11.Í; A.352.X.11.Í; A.353.x.ll.i; A.354.x.ll.i; ; A.357.X.U.I; A.358.x.ll, i; A.359.X.11 .i; A.360.x.ll.i;
A.362.X.11.Í; A.363.x.llď: A364.x.ll.i; A.365.X.11.Í; A.366.x.ll.i;A.362.X.11.Í; A.363.x.IId: A364.x.ll.i; A.365.X.11.Í; A.366.x.ll.i;
A.369.X.U.Í; A.370.X.U.Í; A371.X.11.Í; A.372.x.ll.i;A.369.X.U.I; A.370.X.U.I; A371.X.11.Í; A.372.x.ll.i;
A.375.X.11.Í; A.376.x.ll.i; A377.X.11..Í; A.378.x.ll.i;A.375.X.11.Í; A.376.x.ll.i; A377.X.11..Í; A.378.x.ll.i;
A.367.X.11.Í; A.368.x.ll.iA.367.X.11.Í; A.368.x.ll.i
A.373.X.11.Í; A.374.x.ll.iA.373.X.11.Í; A.374.x.ll.i
-101 CZ 297945 B6-101 CZ 297945 B6
A.379.X.11.Í; A.380.X.1LÍ; A.381.x.ll.i; A.382.X.11.Í; A.383.X.1U; A.384.X.11.Í; A.385.X.11.Í; A.386.x.ll.i; A.387.x.ll.i; A.388.x.ll.i; A.389.x.ll.i; A390.X.11.Í; A.391.X.11.Í; A.392.x.ll.i; A.393.x.ll.i; A.394.X.11.Í; A.395.X.11.Í; A.396.x.ll.i; A.397,x.ll.i; A.398.x.ll.i; A.399.x.ll.i; A.400.x.U.i; A.401.x.U.i; A.402.x.ll.i; A.403.X.11.Í; A.404.x.ll.i; Α.405.Χ.11 .i; A.406.X.11.Í; A.407.x.ll.i; A.408.x.ll.i; A.409.X.11Ť; A4Í0.X.11.Í; A.41Lx.ll.i; Α.412.Χ.11 .i; A.413.x.ll.i; A.414.x.ll,i; A.415.X.11ÍÍ; A.416.x.ll.i; A.417.X.I1.Í; A.418.X.1LÍ; A.419.x.ll.i; A.420.x.U.i; A.421.X.11 .i; A.422.X.11.Í; A.423.x.ll.i; A,424.x.ll.i; A.425.x.ll.i; A.426.X.11.Í; A.427.X.11.Í; A.428.X.11.Í; A.429.x.U.i; A.430.X.U.Í; A.431.x.ll.i; A.432.X.11J; A.433.X.11.Í; A.434.x.ll.i; A.435.X.1U; A.436.x.ll.i; A.437.X.11.Í; A.438.x.ll.i; A.439.X.11.Í; A.440.X.11.Í; A.441.x.ll.i; A.442.X.11.Í; A.443.x.ll.i; A.444.x.ll.i; A.445.X.11.Í; A.446.x.ll.i; A.447,x.ll.i; A.448.x.ll,i; A.449.x.ll.i; A.450.X.11.Í; A.451.X.11.Í; A.452.x.ll.i; A.453.x.ll.i; A.454.x.ll.i; A.455.x.ll.i; A.456.x.ll.i; A.457.X.11.i; A.458.X.U.Í; A.459.x.ll.i; A.460.x.ll.i; A.461.x.ll.i; A.462.X.1U; Α.463.Χ.11.Ϊ; A.464.x.ll,i; A.465.x.ll.i; A.466.x.ll.i; A.467.x.ll.i; A.468.x.ll.i; A.469.X.11.Í; A.470.X.11.Í; A.471.x.ll.i; A.472.x.ll.i; A.473.x.U.i; A.474.x.U.i; A.475.X.11.Í; A.476.X.11.Í; A.477.x.ll.i; A.478.x.ll.i; A.479.X.1U; A.480.X.U.Í; A481.X.11.Í; A.482.x.ll.i; A,483.x.ll.i; A.484.x.ll.i; A,485.x.ll.i; A.486.x.U.i; A.487.X.11.Í; A.488.x.ll.i; A.489.x.ll.i; A.490.x.ll.i; A.491.x.ll.i; A.492.x.ll.i; A.493.X.11.Í; A.494.X.11.Í; A.495.x.ll.i; A.496.X.11.Í; A.497.x.ll.i; A.498.X.1U; A.499.X.11.Í; A.500.x.ll.i; A.SOLx.ll.i; A.502.x.ll.i; A.503.x.ll.i; A.504.x.ll.i; A.505.X.11.:; A.506.x.ll.i; A.507.x.ll.i; A.508.x.ll.i; A.509.x.ll.i; A.51G.x.ll.i; A.511.X.11.Í; A.512.x.ll.i; A.512.x.ll.i; A.513.x.ll.i; A.514.x.ll.i; A.515.x.ll.i; Α.516.Χ.11.Ϊ; A.517.x.ll.i; A.518.X.11.Í; A.519.x.lLi; A.520.x.ll.i; A.521.x.ll.i; A522.X.11.Í; A.523.X.11.Í; A.524.x.ll.i; A.525.x.ll.i; A.526.X.11.Í; A.527.X.114; A.528.X.11.Í; A.529.x.ll.i; A.530.x.ll.i; A.531.XJl.i; A.532.x.ll.i; A.533.X.11.Í; A.534.X.11.Í; A.535.x.ll.i; A.536.x.ll.i; A.537.x.ll.i; A.538.x.ll.i; A.539.x.ll.i; A.540.xAl-i; A.541.X.11.Í; A.542.x.ll.i; A.543.x.ll.i; A.544.x.U.i; A.545.x.ll.i; Α.546.Χ.11.Ϊ; A.547.x.ll.i; A.548.x.ll.i; A.549.x.ll.i; A.550.x.ll.i; A.551.x.ll.i; A.552.X.11.Í; A.553.x.ll.i; A.554.x.U.i; A.555.x.ll.i; A.556,x.ll.i; A.557.X.11.Í; A.558.X.11.Í; A.559.x.ll.i; A.560.x.ll.i; A.561.X.11.Í; A.562.x.Il.i; A.563.x.U.i; A.564.X.11.Í; A.565.x.ll.i; A.566.x.ll.i; A.567.x.ll.i; A.568.x.ll.i; A.569.x.ll.i; A.570.X.11.Í; A,571.x.ll.i; A.572.x.ll.i; A.573.x,ll.i; A.574.x.ll.i; A.575.x.ll.i; Α.576.Χ.11.Ϊ; A.577.x.ll.i; A.578.x.lLi; A.579.x.ll,i; A.580.x.ll.i; A.SSl.x.ll.i; A.582.X.11.Í; A.583.x.ll.i; A.584.X.11.Í; A.585.x.ll.i· A.586.X.11.Í; A.587.X.11.Í; Α.588.Χ.11.Ϊ; A*589.x.lLi; A.590.X.11.Í; A.591.x.ll.i; A.592.x.ll.i; A.593.x.ll.i; A.594.X.1U; A.595.X.11.Í; A.596.x.U.i; A.597.x.ll.i; A.598.x.lLi; A.599.x,ll.i; A.600.X.11.Í; A.ÓOl.x.ll.i; A.602.x.ll.i; A.603.x.ll.i; A.604.x.ll.i; A.ÓOS.x.ll.i; Α.606.Χ.11.Ϊ; A.607.X.11.Í; A.ÓOS.x.ll.i; A.609.X.11.Í; Α.610.Χ.11.Ϊ; A.611.x.ll.i; A.612.X.11.Í; A.613.x.ll.i; A.614.X.1U; A.615.x.ll.i; A.616.x.ll.i; A.617.x.ll.i; A.618.X.11.Í; A.619.X.11.Í; A.620.x.ll.i; A.621.x.ll.i; A.622.x.ll.i; A.623.X.11.Í; A.624.X.11.Í; Α.625.Χ.11.Ϊ; A.626.x.ll.i; A.627.x.ll.i; A.628.x.ll.i; A.629.x.ll.i; A.63O.X.11Í; A.631.x.ll.i; A.632.x.lLi; A.633.x.llď; A.634.x.ll.i; A.635.x.ll.i; A.636.X.11.Í; A.637.x.U.i; A.638.X.11.Í; A.639.x.ll.i; A.640.x.ll.i; A.641.X.11.Í; A.642.X.11.Í; A.643.x.ll.i; A.644.X.11.Í; A.645.x.ll.i; A.646.x.ll.i; A.647.x.ll,i; A.648.X.11.Í; A.649.x.ll.i; A.650.x.ll.i; A.651.x.ll.i; A.652.x.ll.i; A.653.x.ll.i; Α.654.Χ.11.Ϊ; A.655.x.ll.i; A.656.x.ll.i; A.657.x.U.i; A.658.x.ll.i; A.659.x.ll.i;A.379.X.11.Í; A.380.X.1LÍ; A.381.x.ll.i; A.382.X.11.Í; A.383.X.1U; A.384.X.11.Í; A.385.X.11.Í; A.386.x.ll.i; A.387.x.ll.i; A.388.x.ll.i; A.389.x.ll.i; A390.X.11.Í; A.391.X.11.Í; A.392.x.ll.i; A.393.x.ll.i; A.394.X.11.Í; A.395.X.11.Í; A.396.x.ll.i; A.397, x.ll.i; A.398.x.ll.i; A.399.x.ll.i; A.400.x.U.i; A.401.x.U.i; A.402.x.ll.i; A.403.X.11.Í; A.404.x.ll.i; Α.405.Χ.11 .i; A.406.X.11.Í; A.407.x.ll.i; A.408.x.ll.i; A.409.X.11Ť; A4Í0.X.11.Í; A.41Lx.ll.i; Α.412.Χ.11 .i; A.413.x.ll.i; A.414.x.ll, i; A.415.X.11ÍÍ; A.416.x.ll.i; A.417.X.I1.Í; A.418.X.1LÍ; A.419.x.ll.i; A.420.x.U.i; A.421.X.11 .i; A.422.X.11.Í; A.423.x.ll.i; A, 424.x.II.i; A.425.x.ll.i; A.426.X.11.Í; A.427.X.11.Í; A.428.X.11.Í; A.429.x.U.i; A.430.X.U.Í; A.431.x.ll.i; A.432.X.11J; A.433.X.11.Í; A.434.x.ll.i; A.435.X.1U; A.436.x.ll.i; A.437.X.11.Í; A.438.x.ll.i; A.439.X.11.Í; A.440.X.11.Í; A.441.x.ll.i; A.442.X.11.Í; A.443.x.ll.i; A.444.x.ll.i; A.445.X.11.Í; A.446.x.ll.i; A.447, x.ll.i; A.448.x.ll, i; A.449.x.ll.i; A.450.X.11.Í; A.451.X.11.Í; A.452.x.ll.i; A.453.x.ll.i; A.454.x.ll.i; A.455.x.ll.i; A.456.x.ll.i; A.457.X.11.i; A.458.X.U.I; A.459.x.ll.i; A.460.x.ll.i; A.461.x.ll.i; A.462.X.1U; Α.463.Χ.11.Ϊ; A.464.x.ll, i; A.465.x.ll.i; A.466.x.ll.i; A.467.x.ll.i; A.468.x.ll.i; A.469.X.11.Í; A.470.X.11.Í; A.471.x.ll.i; A.472.x.ll.i; A.473.x.U.i; A.474.x.U.i; A.475.X.11.Í; A.476.X.11.Í; A.477.x.ll.i; A.478.x.ll.i; A.479.X.1U; A.480.X.U.Í; A481.X.11.Í; A.482.x.ll.i; A, 483.x.II.i; A.484.x.ll.i; A, 485.x.II.i; A.486.x.U.i; A.487.X.11.Í; A.488.x.ll.i; A.489.x.ll.i; A.490.x.ll.i; A.491.x.ll.i; A.492.x.ll.i; A.493.X.11.Í; A.494.X.11.Í; A.495.x.ll.i; A.496.X.11.Í; A.497.x.ll.i; A.498.X.1U; A.499.X.11.Í; A.500.x.ll.i; A.SOLx.ll.i; A.502.x.ll.i; A.503.x.ll.i; A.504.x.ll.i; A.505.X.11. A.506.x.ll.i; A.507.x.ll.i; A.508.x.ll.i; A.509.x.ll.i; A.51G.x.ll.i; A.511.X.11.Í; A.512.x.ll.i; A.512.x.ll.i; A.513.x.ll.i; A.514.x.ll.i; A.515.x.ll.i; Α.516.Χ.11.Ϊ; A.517.x.ll.i; A.518.X.11.Í; A.519.x.lLi; A.520.x.ll.i; A.521.x.ll.i; A522.X.11.Í; A.523.X.11.Í; A.524.x.ll.i; A.525.x.ll.i; A.526.X.11.Í; A.527.X.114; A.528.X.11.Í; A.529.x.ll.i; A.530.x.ll.i; A.531.XJl.i; A.532.x.ll.i; A.533.X.11.Í; A.534.X.11.Í; A.535.x.ll.i; A.536.x.ll.i; A.537.x.ll.i; A.538.x.ll.i; A.539.x.ll.i; A.540.xA1-i; A.541.X.11.Í; A.542.x.ll.i; A.543.x.ll.i; A.544.x.U.i; A.545.x.ll.i; Α.546.Χ.11.Ϊ; A.547.x.ll.i; A.548.x.ll.i; A.549.x.ll.i; A.550.x.ll.i; A.551.x.ll.i; A.552.X.11.Í; A.553.x.ll.i; A.554.x.U.i; A.555.x.ll.i; A.556, x.ll.i; A.557.X.11.Í; A.558.X.11.Í; A.559.x.ll.i; A.560.x.ll.i; A.561.X.11.Í; A.562.x.Il.i; A.563.x.U.i; A.564.X.11.Í; A.565.x.ll.i; A.566.x.ll.i; A.567.x.ll.i; A.568.x.ll.i; A.569.x.ll.i; A.570.X.11.Í; A, 571.x.ll.i; A.572.x.ll.i; A.573.x, II.i; A.574.x.ll.i; A.575.x.ll.i; Α.576.Χ.11.Ϊ; A.577.x.ll.i; A.578.x.lLi; A.579.x.ll, i; A.580.x.ll.i; A.SSl.x.ll.i; A.582.X.11.Í; A.583.x.ll.i; A.584.X.11.Í; A.585.x.ll.i · A.586.X.11.I; A.587.X.11.Í; Α.588.Χ.11.Ϊ; A * 589.x.lLi; A.590.X.11.Í; A.591.x.ll.i; A.592.x.ll.i; A.593.x.ll.i; A.594.X.1U; A.595.X.11.Í; A.596.x.U.i; A.597.x.ll.i; A.598.x.lLi; A.599.x, II.i; A.600.X.11.Í; A.ÓOl.x.ll.i; A.602.x.ll.i; A.603.x.ll.i; A.604.x.ll.i; A.ÓOS.x.ll.i; Α.606.Χ.11.Ϊ; A.607.X.11.Í; A.ÓOS.x.ll.i; A.609.X.11.Í; Α.610.Χ.11.Ϊ; A.611.x.ll.i; A.612.X.11.Í; A.613.x.ll.i; A.614.X.1U; A.615.x.ll.i; A.616.x.ll.i; A.617.x.ll.i; A.618.X.11.Í; A.619.X.11.Í; A.620.x.ll.i; A.621.x.ll.i; A.622.x.ll.i; A.623.X.11.Í; A.624.X.11.Í; Α.625.Χ.11.Ϊ; A.626.x.ll.i; A.627.x.ll.i; A.628.x.ll.i; A.629.x.ll.i; A.63O.X.11Í; A.631.x.ll.i; A.632.x.lLi; A.633.x.llď; A.634.x.ll.i; A.635.x.ll.i; A.636.X.11.Í; A.637.x.U.i; A.638.X.11.Í; A.639.x.ll.i; A.640.x.ll.i; A.641.X.11.Í; A.642.X.11.Í; A.643.x.ll.i; A.644.X.11.Í; A.645.x.ll.i; A.646.x.ll.i; A.647.x.ll, i; A.648.X.11.Í; A.649.x.ll.i; A.650.x.ll.i; A.651.x.ll.i; A.652.x.ll.i; A.653.x.ll.i; Α.654.Χ.11.Ϊ; A.655.x.ll.i; A.656.x.ll.i; A.657.x.U.i; A.658.x.ll.i; A.659.x.ll.i;
-102CZ 297945 B6-102GB 297945 B6
A.660.X.11.Í; A.2.y.4.i; A.3.V.4.I; A.4.y.4.x; A.5.y.4.i; A.6.y.4.i; A.7.y.4.i; A.9.y.4.i; A.10.y.4.i; A.15.y'4.i; A.10Ó.y.4.i; A.Í01.y.4.i; A.102.y.4.i; A.103.y.4.i; A.104.y.4.i; A.105.y.4.i; A.106.y.4.i; A.107.y.4.i; A.108.y.4.i; A.109.y.4.i; A.110.y.4.i; A.lll.y.4.i; A.112.y.4.i; A.113.y.4.i; A.114.y.4.i; A.115.y.4.i; A.116.y.4.i; A.117.y.4.i; A.118.y.4.i; A.119.y.4.i; A.120.y.4.i; A.121.ý.4.i; A.122.V.4.Í; A.123.y.4.i; A.124.y.4.i; A.125.y.4.i; A.126.y.4.i; A.127.ý.4.i; A.128.y.4.i; A.129.ý.4.i; A.130.ý.4.i; A.131.y.4.i; A.132.y.4.i; A.133.y.4.i; Á.134.y.4.i; A.135.y.4.i; A.136.y.4.i; A.137.y.4.i; A.138.y.4.i; A.139.y.4.i; A.140.y.4.i; A.141,y.4.i; A.142.y.4.i; A.143.y.4.i; A.144.y.4.i; A.145.y.4.i; A.146.y.4.i; A.147.y.4.i; A.148.y.4.i; A.149.y.4.i; A.150.y.4.i; A.151.y.4.i; A.152.y.4.i; A.153.y.4.i; A.154.y.4.i; A.155.y.4.i; A.156.y.4.i; A.157.y.4.i; A.158.y.4.i; A.159.y.4.i; A.160.y.4.i; A.161.y.4.i; A.162.y.4.i; A.163.y.4.i; A.164.y.4.i; A.165.y.4.i; A.166.y.4-i; A.167.y.4.i; A.168.y.4.i; A.169.y.4.i; A.170.y.4.i; A.171.y.4.i; A.172.y.4.i; A.173.y.4.i; A.174.y.4.i; A.175.y.4.i; A.176.y.4.i; A.177.y.4.i; A.178.y.4.i; A.179.y.4.i; A,180.y.4.i; A.181.y.4.i; A.182.y.4.i; A.183.y.4.i; A.184.y.4.i; A.185.y.4.i; A.186.y.4.i; A.187.y.4.x; A.188.y.4.i; A.189.y.4.i; A.190.y.4.i; A,191.y.4.i; A.192.y.4.i; A.193.y.4.i; A.194.y.4.i; A.195.y.4.x; A.196.y.4.i; A.197.y.4.i; A.198.y.4.i; A.199.y.4.i; A.200.v .4. i; A.201.y.4.i; A.202.y.4.i; A203.y.4.i; A.204.V.4.Í; A.205.y.4.x; A.206.y.4.x; A.207.y.4.i; A.208.y.4.i; A.209.y.4.i; A.210.V.4.Í; A.211.y.4.i; A.212.y.4.i; A.213.y.4.i; A.214.y.4.i; A.215.y.4.i; A216.y.4.i; A.217.y.4.i; A.218.ý.4.i; A.2l9.y.4.i; A.220.V.4.Í; A.221.y.4.i; A.222.V.4.Í; A.223.V.4.Í; A.224.y.4.i; A.225.y.4.i; A226.ý.4.i; A.227.V.4.Í; A.228.v.4.i; A.229.y.4.i; A.230.y.4.i; A.231.y.4.i; A.232.y.4.i; A.233.y.4.i; A.234.y.4.í; A.235.ý.4.i; A.236.y.4.i; A.237.y.4.i; A238.y.4.i; A.239.y.4.i; A.240.y.4.i; A.241.y.4.i; A.242.y.4.i; A.243.y.4.i; A.244.y.4.i; A.245.y.4.i; A.246.y.4.i; A.247.V.4.Í; A.248.y.4.i; A.249.y.4.i; A.250.y.4.i; A.251.y.4.i; A.252.y.4.i; A.253.y.4.i; A.254.y.4.i; A.255.y.4.i; A.256.y.4.i;A-257.y.4.i; A.258.y.4.i; A.259.y.4.í; A.260.y.4.x; A.261.y.4.i; A.262.y.4.i; A.263.y.4.i; A264.y.4.i; A.265.y.4.i; A.266.y.4.i; A.267.y.4.i; A.268.y.4.i; A.269.y.4.i; A.270.y.4.i; A.271.y.4.i; A.272.y.4.i; A.273.V.4.Í; A.274.y.4.i; A.275.y.4.í; A276.y.4.i; A.277.y.4.í; A.278.y.4.i; A.279.y.4.i; A.280.V.4.Í; A.281.y.4.i; A.282.V.4.Í; A.283.y.4d; A.284.y.4.i; A285.y.4.i; A.286.y.4.i; A.287.y.4.i; A.288.y.4.i; A.289.y.4.i; A.290.y.4.i; A.291.y.4.i; A.292.y.4.i; A.293.y.4.i; A.294.y.4.i; A.295.y.4.i; A.296.ý.4.i; A.297.y.4.i; A.298.V.4.Í; A.299.y.4.i; A.300.y.4.i; A.301.y.4.i; A.302.y.4.x; A.303.y.4.i; A.304.y.4.i; A.305.y.4.i; A.306.y.4.i; A.307.y.4.i; A.308.y,4.x; A.309.y.4.i; A.310.V.4.Í; A.311.V.4.Í; A.312.v.4.i; A.313.y.4.i; A.314.y.4.i; A.315.y.4.i; A.316.y.4.i; A.317.y.4.i; A.318.y.4.i; A.319.y.4.i; A.320.y.4.i; A.321.y.4.i; A.323.y.4.i; A.324.y.4.i; A.325.y.4.x; A.326.y.4.x; A.327.y.4.i; A.328.y.4,i; A.329.y.4.i; A.330.y.4.i; A.331.y.4.i; A.332.y.4.i; A.333.y.4.i; A.334.y.4.i; A.335.y.4.i; A.336.y.4.i; A.337.y.4.i; A.338.y.4.i; A.339.y.4.i; A.340.y.4.i; A.341.y.4.i; A.342.y.4.i; A.343.y.4.i; A.344.y.4.i; A.345.y.4.i; A.346.v.4.i; A.347.y.4.i; A.348.v.4.i; A.349.y.4.i; A.350.y.4.i; A.351.y.4.i; A.352.y.4.i; A.353.ý.4.i; A.354.y.4.i; A.355.y.4.i; A.356.V.4.Í; A.357.y.4.x; A.358.V.4.Í; A.359.V.4.Í; A.360.y.4.i; A.361.y.4.i; A.362.y.4.i; A.363.ý.4.i; A.364.y.4.i; A.365.y.4.i; A.366.v.4.i; A.367.v.4.i; A.368.y.4.i; A.369.v.4.i; A.370.v.4.i; A.371.y.4.i; A.372.v.4a; A.373.ý.4.i; A.374.v.4.x; A.375.ý.4.x; A.376.Ý.4.Í; A.377.ý.4.x; A.378.y.4.i; A.379.V.4.Í; A.380.y.4.i; A.381.y.4.i; A.382.v.4.i; A.383.v.4.i; A.384.v.4.i; A.385.v.4.i; A.386.y.4.i; A.387.y.4.i; A.388.v.4.i; A.389.y.4.i· A.390.Ý.4.Í; A.391.ý.4.i; A.392.v.4.i; A.393.y.4.i; A.394.V.4.Í; A.395.V.4.Í; A.396.y.4.i; A.397.y.4.i; A.398.y.4.i; A.399.y.4.i; A.400.V.4.Í; A.401.y.4.i; A.402.V.4.Í; A.403.y.4.i; A.404.V.4.Í; A.405.y.4.i; A.406.V.4.Í; A.407.y.4.i; A.408.y.4.i; A.4Ó9.y.4.i; A.410.y.4.i; A.411.y.4.i; A.412.V.4.Í; A.413.V.4.Í; A.414.y.4.i; A.415.y.4.i; A.416.y.4.i; A.417.y.4á; A.418.y.4.i; A.419.y.4.i; A.420.y.4.i;A.660.X.11.Í; A.2.y.4.i; A.3.V.4.I; A.4.y.4.x; A.5.y.4.i; A.6.y.4.i; A.7.y.4.i; A.9.y.4.i; A.10.y.4.i; A.15.y'4.i; A.10Ó.y.4.i; A.Í01.y.4.i; A.102.y.4.i; A.103.y.4.i; A.104.y.4.i; A.105.y.4.i; A.106.y.4.i; A.107.y.4.i; A.108.y.4.i; A.109.y.4.i; A.110.y.4.i; A.lll.y.4.i; A.112.y.4.i; A.113.y.4.i; A.114.y.4.i; A.115.y.4.i; A.116.y.4.i; A.117.y.4.i; A.118.y.4.i; A.119.y.4.i; A.120.y.4.i; A.121.ý.4.i; A.122.V.4.Í; A.123.y.4.i; A.124.y.4.i; A.125.y.4.i; A.126.y.4.i; A.127.ý.4.i; A.128.y.4.i; A.129.ý.4.i; A.130.ý.4.i; A.131.y.4.i; A.132.y.4.i; A.133.y.4.i; Á.134.y.4.i; A.135.y.4.i; A.136.y.4.i; A.137.y.4.i; A.138.y.4.i; A.139.y.4.i; A.140.y.4.i; A.141, y.4.i; A.142.y.4.i; A.143.y.4.i; A.144.y.4.i; A.145.y.4.i; A.146.y.4.i; A.147.y.4.i; A.148.y.4.i; A.149.y.4.i; A.150.y.4.i; A.151.y.4.i; A.152.y.4.i; A.153.y.4.i; A.154.y.4.i; A.155.y.4.i; A.156.y.4.i; A.157.y.4.i; A.158.y.4.i; A.159.y.4.i; A.160.y.4.i; A.161.y.4.i; A.162.y.4.i; A.163.y.4.i; A.164.y.4.i; A.165.y.4.i; A.166.y.4-i; A.167.y.4.i; A.168.y.4.i; A.169.y.4.i; A.170.y.4.i; A.171.y.4.i; A.172.y.4.i; A.173.y.4.i; A.174.y.4.i; A.175.y.4.i; A.176.y.4.i; A.177.y.4.i; A.178.y.4.i; A.179.y.4.i; A, 180.y.4.i; A.181.y.4.i; A.182.y.4.i; A.183.y.4.i; A.184.y.4.i; A.185.y.4.i; A.186.y.4.i; A.187.y.4.x; A.188.y.4.i; A.189.y.4.i; A.190.y.4.i; A, 191.y.4.i; A.192.y.4.i; A.193.y.4.i; A.194.y.4.i; A.195.y.4.x; A.196.y.4.i; A.197.y.4.i; A.198.y.4.i; A.199.y.4.i; A.200.v .4. and; A.201.y.4.i; A.202.y.4.i; A203.y.4.i; A.204.V.4.Í; A.205.y.4.x; A.206.y.4.x; A.207.y.4.i; A.208.y.4.i; A.209.y.4.i; A.210.V.4.Í; A.211.y.4.i; A.212.y.4.i; A.213.y.4.i; A.214.y.4.i; A.215.y.4.i; A216.y.4.i; A.217.y.4.i; A.218.ý.4.i; A.2l9.y.4.i; A.220.V.4.Í; A.221.y.4.i; A.222.V.4.Í; A.223.V.4.Í; A.224.y.4.i; A.225.y.4.i; A226.ý.4.i; A.227.V.4.Í; A.228.v.4.i; A.229.y.4.i; A.230.y.4.i; A.231.y.4.i; A.232.y.4.i; A.233.y.4.i; A.234.y.4.í; A.235.ý.4.i; A.236.y.4.i; A.237.y.4.i; A238.y.4.i; A.239.y.4.i; A.240.y.4.i; A.241.y.4.i; A.242.y.4.i; A.243.y.4.i; A.244.y.4.i; A.245.y.4.i; A.246.y.4.i; A.247.V.4.Í; A.248.y.4.i; A.249.y.4.i; A.250.y.4.i; A.251.y.4.i; A.252.y.4.i; A.253.y.4.i; A.254.y.4.i; A.255.y.4.i; A.256.y.4.i; A-257.y.4.i; A.258.y.4.i; A.259.y.4.í; A.260.y.4.x; A.261.y.4.i; A.262.y.4.i; A.263.y.4.i; A264.y.4.i; A.265.y.4.i; A.266.y.4.i; A.267.y.4.i; A.268.y.4.i; A.269.y.4.i; A.270.y.4.i; A.271.y.4.i; A.272.y.4.i; A.273.V.4.Í; A.274.y.4.i; A.275.y.4.í; A276.y.4.i; A.277.y.4.í; A.278.y.4.i; A.279.y.4.i; A.280.V.4.Í; A.281.y.4.i; A.282.V.4.Í; A.283.y.4d; A.284.y.4.i; A285.y.4.i; A.286.y.4.i; A.287.y.4.i; A.288.y.4.i; A.289.y.4.i; A.290.y.4.i; A.291.y.4.i; A.292.y.4.i; A.293.y.4.i; A.294.y.4.i; A.295.y.4.i; A.296.ý.4.i; A.297.y.4.i; A.298.V.4.Í; A.299.y.4.i; A.300.y.4.i; A.301.y.4.i; A.302.y.4.x; A.303.y.4.i; A.304.y.4.i; A.305.y.4.i; A.306.y.4.i; A.307.y.4.i; A.308.y, 4.x; A.309.y.4.i; A.310.V.4.Í; A.311.V.4.Í; A.312.v.4.i; A.313.y.4.i; A.314.y.4.i; A.315.y.4.i; A.316.y.4.i; A.317.y.4.i; A.318.y.4.i; A.319.y.4.i; A.320.y.4.i; A.321.y.4.i; A.323.y.4.i; A.324.y.4.i; A.325.y.4.x; A.326.y.4.x; A.327.y.4.i; A.328.y.4, i; A.329.y.4.i; A.330.y.4.i; A.331.y.4.i; A.332.y.4.i; A.333.y.4.i; A.334.y.4.i; A.335.y.4.i; A.336.y.4.i; A.337.y.4.i; A.338.y.4.i; A.339.y.4.i; A.340.y.4.i; A.341.y.4.i; A.342.y.4.i; A.343.y.4.i; A.344.y.4.i; A.345.y.4.i; A.346.v.4.i; A.347.y.4.i; A.348.v.4.i; A.349.y.4.i; A.350.y.4.i; A.351.y.4.i; A.352.y.4.i; A.353.ý.4.i; A.354.y.4.i; A.355.y.4.i; A.356.V.4.Í; A.357.y.4.x; A.358.V.4.Í; A.359.V.4.Í; A.360.y.4.i; A.361.y.4.i; A.362.y.4.i; A.363.ý.4.i; A.364.y.4.i; A.365.y.4.i; A.366.v.4.i; A.367.v.4.i; A.368.y.4.i; A.369.v.4.i; A.370.v.4.i; A.371.y.4.i; A.372.v.4a; A.373.ý.4.i; A.374.v.4.x; A.375.ý.4.x; A.376.Ý.4.Í; A.377.ý.4.x; A.378.y.4.i; A.379.V.4.Í; A.380.y.4.i; A.381.y.4.i; A.382.v.4.i; A.383.v.4.i; A.384.v.4.i; A.385.v.4.i; A.386.y.4.i; A.387.y.4.i; A.388.v.4.i; A.389.y.4.i · A.390.Y.4.I; A.391.ý.4.i; A.392.v.4.i; A.393.y.4.i; A.394.V.4.Í; A.395.V.4.Í; A.396.y.4.i; A.397.y.4.i; A.398.y.4.i; A.399.y.4.i; A.400.V.4.Í; A.401.y.4.i; A.402.V.4.I; A.403.y.4.i; A.404.V.4.Í; A.405.y.4.i; A.406.V.4.Í; A.407.y.4.i; A.408.y.4.i; A.4Ó9.y.4.i; A.410.y.4.i; A.411.y.4.i; A.412.V.4.Í; A.413.V.4.Í; A.414.y.4.i; A.415.y.4.i; A.416.y.4.i; A.417.y.4á; A.418.y.4.i; A.419.y.4.i; A.420.y.4.i;
- 103CZ 297945 B6- 103GB 297945 B6
A.421.y.4.i; A.422.v.4.i; A.423.v.4.i: A.424.y.4.i; A.425.y.4.i; A.426.y.4.i; A.427.y.4.i; A.428.y.4.i; A.429.y.4.i; A.430.y.4.i; A.431.y.4.i; A.432.ý.4.i; A.433.y.4.i; A.434.y.4.i; A.435.y.4.i; A.436.y.4.i; A.437.y.4.i; A.438.y.4.i; A.439.y.4.i; A.440.y.4.i; A.441.y.4.i; A.442.y.4.i; A.443.y.4.i; A.444.y.4.i; A.445.y.4.i; A.446.y.4.i; A.447.y.4.i; A.448.y.4.i; A.449.y.4.i; A.450.y.4.i; A.451.V.4.Í; A.452.y.4.i; A.453.y.4.i; A.454.y.4.i; A.455.y.4.i; A.456.y.4.i;A.457.y.4.i; A.458.y.4.i; A.459.y.4.i; A.460.y.4.i; A.461.y.4.i; A.462.y.4.i; A.463.y.4.i; A.464.y.4.i; A.465.y.4.i; A.466.y.4.i; A.467.y.4.i; A.46S.V.4.Í; A.469.y.4.i; A.470.y.4.i; A.471.y.4.i; A.472.y.4.i; A.473.y.4.i; A.474.y.4.i; A.475.y.4.i; A.476.y.4.i; A.477.y.4.i; A.478.y.4.i; A.479.y.4.i; A.480.y.4.i; A.481.y.4.i; A.482.y.4.i; A.483.y.4.i; A.484.y.4.i; A.485.y.4.i; A.486.y.4.i; A.487.y.4.í; A.488.y.4.i; A.489.y.4.i; A.490.y.4.i; A.491.y.4.i; A.492.y.4.i; A.493.y.4.i; A.494.y.4.i; A.495.y.4.i; A.496.y.4.i; A.497.y.4.i; A.498.y.4.i; A.499.y.4.i; A.500.y.4.i; A.501.y.4.i; A.502.y.4.i; A.503.y.4.i; A.504.y.4.i; A.505.y.4.i; A.506.y.4,i; A.507.y.4.i; A.508.y.4.i; A.509,y.4.i; A.510.y.4.i; A.511.y.4ď; A.512.y.4.i; A.512.y.4.i; A.513.y.4.i; A.514.y.4.i; A.515.y.4.i; A.516.y.4.i; A.517.y.4.i; A.518.y.4.i; A.519.v.4.i; A.520.y.4.i; A.521.y.4.i; A.522.y.4.i; A.523.y.4.i; A.524.y.4.i; A.525.y.4.i; A.526.y.4.i; A.527.y.4.i; A.528.y.4.i; A.529.y.4.i; A.530.y.4.i; A.531.y.4.i; A-532.y.4.i; A.533.y.4.i; A.534.v.4.i; A.535.y.4.i; A.536.y.4,i; A.537.y.4.i; A.538.y.4.i; A.539.y.4.i; A.540.y.4.i; A.541.y.4.i; A.542.y.4.i; A.543.y.4.i; A.544.v.4.i; A.545.y.4.i; A.546.y.4.i; A.547.y.4.i; A.548.y.4.i; A.549.y.4.i; A.S50.y.4.i; A.551.y.4.i; A.552.y.4.i; A.553.y.4.i; A.554.y.4.i; A.555.y.4.i; A.556.y.4.i; A.557.y.4.i; A.558.y.4.i; A.559.y.4.i; A.560.y.4.i; A.561.y.4.i; A,562.y.4.i; A.563.y.4.i; A.564.y.4.i; A.565.y.4.i; A.566.y.4.i; A.567.y.4.i; A.568.y.4.i; A.569.y.4.i; A.570.y.4.i; A.571.y.4.i; A.572.y.4.i; A.573.y.4.i; A.574.y.4.i; Α.575^4.ί; A.576.y.4.i; A.577.y.4.i; A.578.y.4.i; A.579.y.4.i; A.580.y.4.i; A.581.y.4.i; A.582.y.4.i; A.583.y.4.i; A.584.y.4.i; A.585.y.4.i; A586.v.4.i; A.587.y.4.i; A.588.y.4.i; A.589.y.4.i; A,590.y.4.i; A.591.y.4.i; A.592.y.4.i; A.593.y.4.i; A.594.y.4.i; A.595.y.4.i; A.596.y.4.i; A.597.y.4.i; A.598.y.4.i; A.599.y.4.i; A.600.y.4.i; A.601.y.4.i; A.602.y.4.i; A.603.y.4.i; A.604.y.4.i; A.605.y.4.i; A.606.y.4.i; A.607.y.4.i; A.608,y,4.i; A.609.y.4.i; A.610.y.4.i; A.611.y.4.i; A.612.y.4.i; A.613.y.4.i; A.614.y.4.i; A.615.y.4.i; A.616.y.4.i; A.617.y.4.í; A.618.y.4.i; A.619.y.4.i; A.620.y.4.i; A.621.y 4.i; A.622.y.4.i; A.623.y.4.i; A.624.y.4.i; A.625.y.4.i; A.626.y.4.i; A.627.y.4.i; A.628.y.4.i; A.629.y.4.i; A.630.v.4.i; A.631.y.4.i; A.632.y.4.i; A.633.y.4.i; A.634.y.4.i; A.635.y.4.i; A.636.V.4.Í; A.637.y.4.i; A.638,y.4.i; A.639.y.4.i; A.640.y.4.i; A.641.y.4.i; A.642.y.4.i; A.643 y.4.i; A.644.y.4.i; A.645.y.4.i; A.646.y.4.i; A.647.y.4.i; A.648.y.4.i; A.649.y.4.i; A.650.y.4.i; A.651.y.4.i; A.652.y.4.i; A.653.y.4.i; A.654.y.4.i; A.655.y.4.Í; A.656.y.4.i; A.657.y.4.i; A.658.y.4.i; A.659.y.4.i; A.660.y.4.i; A.2.y.ll.i; A.3.y.ll.i; A.4.y.ll.i; A.S.v.ll.i; A.ó.y.ll.i; A.7.V.11.Í; A.9.y.U.i; A.lO.y.lU; A.15.y.ll.i; A.lOO.y.ll.i; A.ÍOl.y.lLi; A-102.y.ll.i; A403.y.ll.i; A.104.y.ll.i; A.105.y.ll.i; A.lOó.y.ll.i; A.107.y.ll.i; A.lOS.y.ll.i; A.109.v.ll.i; Α.Π0.ν.Π.ί; A.lll.y.n.i; A.112.v.ll.i; A.113-V.11.Í; A.114.V.11.Í; A.llS.v.ll.i; A.116.ý.ll.i; A.U7.y.ll.i; A.118.v.ll.i; A.119.v.ll.i; A.120.V.11.Í; A.121.y.ll.i; A.122.v.ll.i; A.123.y.ll.i; A.124.v.U.i; A.125.v.ll.x; A.126.V.11.Í; A.127.y.ll.i; A.128.v.ll.i; A.129.V.11.Í; A.130.V.U.Í; A.131.v.ll.i; A.132.y.ll.i; A.133.V.Í1.Í; A.134.v.ll.i; A.Í35.y.ll.i; A.136.v.ll.i; A.137.v.ll.i; A.138.y.ll.i; A.139.ý.ll.i; A.140.V.11.Í; A.141.y.ll.i; A.142.V.11.Í; A.143.V.1U; A.144.V.11.Í; A.145.y.ll.i; A.146.v.ll.i; A.147.v.ll.i; A.148.y.ll.i; A.149.v.U.i; A.150.V.11.Í; A.151.y.ll.i; A.152.v.ll.i; A.153.V.11.Í; A.154.V.U.Í; A.155.v.ll.i; A.156.ý.ll.i; A.157.y.ll.i; A.158.v.ll.i; A.159.y.ll.i; A.lÓO.y.ll.i; A.lól.v.ll.i; A.162.y.U.i; A.163.V.11.Í; A.164.V.1U; A.165.ý.U.i; A.166.V.11.Í; A.lóZv.ll.i;A.421.y.4.i; A.422.v.4.i; A.423.a.4.i: A.424.y.4.i; A.425.y.4.i; A.426.y.4.i; A.427.y.4.i; A.428.y.4.i; A.429.y.4.i; A.430.y.4.i; A.431.y.4.i; A.432.ý.4.i; A.433.y.4.i; A.434.y.4.i; A.435.y.4.i; A.436.y.4.i; A.437.y.4.i; A.438.y.4.i; A.439.y.4.i; A.440.y.4.i; A.441.y.4.i; A.442.y.4.i; A.443.y.4.i; A.444.y.4.i; A.445.y.4.i; A.446.y.4.i; A.447.y.4.i; A.448.y.4.i; A.449.y.4.i; A.450.y.4.i; A.451.V.4.Í; A.452.y.4.i; A.453.y.4.i; A.454.y.4.i; A.455.y.4.i; A.456.y.4.i; A.457.y.4.i; A.458.y.4.i; A.459.y.4.i; A.460.y.4.i; A.461.y.4.i; A.462.y.4.i; A.463.y.4.i; A.464.y.4.i; A.465.y.4.i; A.466.y.4.i; A.467.y.4.i; A.46S.V.4.I; A.469.y.4.i; A.470.y.4.i; A.471.y.4.i; A.472.y.4.i; A.473.y.4.i; A.474.y.4.i; A.475.y.4.i; A.476.y.4.i; A.477.y.4.i; A.478.y.4.i; A.479.y.4.i; A.480.y.4.i; A.481.y.4.i; A.482.y.4.i; A.483.y.4.i; A.484.y.4.i; A.485.y.4.i; A.486.y.4.i; A.487.y.4.í; A.488.y.4.i; A.489.y.4.i; A.490.y.4.i; A.491.y.4.i; A.492.y.4.i; A.493.y.4.i; A.494.y.4.i; A.495.y.4.i; A.496.y.4.i; A.497.y.4.i; A.498.y.4.i; A.499.y.4.i; A.500.y.4.i; A.501.y.4.i; A.502.y.4.i; A.503.y.4.i; A.504.y.4.i; A.505.y.4.i; A.506.y.4, i; A.507.y.4.i; A.508.y.4.i; A.509, y.4.i; A.510.y.4.i; A.511.y.4ď; A.512.y.4.i; A.512.y.4.i; A.513.y.4.i; A.514.y.4.i; A.515.y.4.i; A.516.y.4.i; A.517.y.4.i; A.518.y.4.i; A.519.v.4.i; A.520.y.4.i; A.521.y.4.i; A.522.y.4.i; A.523.y.4.i; A.524.y.4.i; A.525.y.4.i; A.526.y.4.i; A.527.y.4.i; A.528.y.4.i; A.529.y.4.i; A.530.y.4.i; A.531.y.4.i; A-532.y.4.i; A.533.y.4.i; A.534.v.4.i; A.535.y.4.i; A.536.y.4, i; A.537.y.4.i; A.538.y.4.i; A.539.y.4.i; A.540.y.4.i; A.541.y.4.i; A.542.y.4.i; A.543.y.4.i; A.544.v.4.i; A.545.y.4.i; A.546.y.4.i; A.547.y.4.i; A.548.y.4.i; A.549.y.4.i; A.S50.y.4.i; A.551.y.4.i; A.552.y.4.i; A.553.y.4.i; A.554.y.4.i; A.555.y.4.i; A.556.y.4.i; A.557.y.4.i; A.558.y.4.i; A.559.y.4.i; A.560.y.4.i; A.561.y.4.i; A, 562.y.4.i; A.563.y.4.i; A.564.y.4.i; A.565.y.4.i; A.566.y.4.i; A.567.y.4.i; A.568.y.4.i; A.569.y.4.i; A.570.y.4.i; A.571.y.4.i; A.572.y.4.i; A.573.y.4.i; A.574.y.4.i; Α.575 ^ 4.ί; A.576.y.4.i; A.577.y.4.i; A.578.y.4.i; A.579.y.4.i; A.580.y.4.i; A.581.y.4.i; A.582.y.4.i; A.583.y.4.i; A.584.y.4.i; A.585.y.4.i; A586.v.4.i; A.587.y.4.i; A.588.y.4.i; A.589.y.4.i; A, 590.y.4.i; A.591.y.4.i; A.592.y.4.i; A.593.y.4.i; A.594.y.4.i; A.595.y.4.i; A.596.y.4.i; A.597.y.4.i; A.598.y.4.i; A.599.y.4.i; A.600.y.4.i; A.601.y.4.i; A.602.y.4.i; A.603.y.4.i; A.604.y.4.i; A.605.y.4.i; A.606.y.4.i; A.607.y.4.i; A.608, y, 4.i; A.609.y.4.i; A.610.y.4.i; A.611.y.4.i; A.612.y.4.i; A.613.y.4.i; A.614.y.4.i; A.615.y.4.i; A.616.y.4.i; A.617.y.4.í; A.618.y.4.i; A.619.y.4.i; A.620.y.4.i; A.621.y 4.i; A.622.y.4.i; A.623.y.4.i; A.624.y.4.i; A.625.y.4.i; A.626.y.4.i; A.627.y.4.i; A.628.y.4.i; A.629.y.4.i; A.630.v.4.i; A.631.y.4.i; A.632.y.4.i; A.633.y.4.i; A.634.y.4.i; A.635.y.4.i; A.636.V.4.Í; A.637.y.4.i; A.638, y.4.i; A.639.y.4.i; A.640.y.4.i; A.641.y.4.i; A.642.y.4.i; A.643 y.4.i; A.644.y.4.i; A.645.y.4.i; A.646.y.4.i; A.647.y.4.i; A.648.y.4.i; A.649.y.4.i; A.650.y.4.i; A.651.y.4.i; A.652.y.4.i; A.653.y.4.i; A.654.y.4.i; A.655.y.4.I; A.656.y.4.i; A.657.y.4.i; A.658.y.4.i; A.659.y.4.i; A.660.y.4.i; A.2.y.ll.i; A.3.y.ll.i; A.4.y.ll.i; A.S.v.ll.i; A.ó.y.ll.i; A.7.V.11.Í; A.9.y.U.i; A.10.y.lU; A.15.y.ll.i; A.100.y.ll.i; A.ÍOl.y.lLi; A-102.y.ll.i; A403.y.ll.i; A.104.y.ll.i; A.105.y.ll.i; A.10O.y.ll.i; A.107.y.ll.i; A.lOS.y.ll.i; A.109.v.ll.i; Α.Π0.ν.Π.ί; A.lll.y.n.i; A.112.v.ll.i; A.113-V.11.I; A.114.V.11.Í; A.llS.v.ll.i; A.116.ý.ll.i; A.U7.y.ll.i; A.118.v.ll.i; A.119.v.ll.i; A.120.V.11.Í; A.121.y.ll.i; A.122.v.ll.i; A.123.y.ll.i; A.124.v.U.i; A.125.v.ll.x; A.126.V.11.Í; A.127.y.ll.i; A.128.v.ll.i; A.129.V.11.Í; A.130.V.U.I; A.131.v.ll.i; A.132.y.ll.i; A.133.V.Í1.Í; A.134.v.ll.i; A.I35.y.ll.i; A.136.v.ll.i; A.137.v.ll.i; A.138.y.ll.i; A.139.ý.ll.i; A.140.V.11.Í; A.141.y.ll.i; A.142.V.11.Í; A.143.V.1U; A.144.V.11.Í; A.145.y.ll.i; A.146.v.ll.i; A.147.v.ll.i; A.148.y.ll.i; A.149.v.U.i; A.150.V.11.Í; A.151.y.ll.i; A.152.v.ll.i; A.153.V.11.Í; A.154.V.U.I; A.155.v.ll.i; A.156.ý.ll.i; A.157.y.ll.i; A.158.v.ll.i; A.159.y.ll.i; A.lOOO.y.ll.i; A.ló.v.vll.i; A.162.y.U.i; A.163.V.11.Í; A.164.V.1U; A.165.ý.U.i; A.166.V.11.Í; A.lóZv.ll.i;
-104CZ 297945 B6-104GB 297945 B6
-A.168y.114; A.169.y.ll4; A.170y.ll4; A.171.V.114; A.172.v.ll.i; A.173.V.114; A.174.V.114; A.175y.ll4; A.176.y.ll4; A.177y,114; A.178.ý.ll.i; A.179.ý.ll.i; A.180.ý.ll4; A.181.y.ll.i; A.182.y.ll.i; A.183.y.ll4; A.184.V.114; A.185.y.ll.i; A.186.y.ll.i; A.187.V.114; A.188.y.ll4; A.189y.ll4; A.190.V.114; A.191.y.ll4; A.192y.U4; A.193.ý.U.i; A.194.y.ll4; A.495.V.114; A.196.y.ll.i; A.197.y.lLi; A.198.y,114; A.199.y.ll4; A.200.V.114; A.201.y.ll4; A.202.y.ll.i;A203.y.ll.i; A.204.y.ll.i; A205.y.U4; A.206.V.U4; A.207.y.ll.i; A.208.y.ll.i; A209.y.U4; A.210.y.ll.i; AJll.y.114; A.212.y.ll4; A.213.y.ll.i; A.214.y.ll4; AJ15.y.ll4; AJZló.y.ll.i; A.217.y.ll4; A.218y.ll.i; A.219.y.ll4; A.220.y.ll.i; AJ21.y.U4; A.222.V.114; A223.V.U4; A.224.y,114; AJ25.y.ll4; A226.y.ll4; AJ27y.ll 4; AJ28.ý.ll.i; A229.ý.ll.i; A.230.y.ll4; A.231.y.ll4; A.232.y.U4; A.233.y.ll.i; A234.y.ll4; AJ35y.ll.i; A.236.y.U.i; A.237.y.U.i; A.238.y.ll.i; A.239.y.ll.i; A240.y.ll4; A.241.y.ll.i; A.242.y.ll .i; A.243y.ll.i; A.244.y.ll4; A.245.y.ll.i; A.246.y.ll4; A.247.y.ll.i; A.248.y.ll4; A.249.y.ll.i; A.250.y.ll.i; A.251.y.ll4; A252.y.ll.i; AJ53.y.ll4; A.254y.ll4; AJSS.y.ll.i; A.256.y.ll.i; AJ57.y.ll.i; A258.y.ll4; A.259.y.ll.i; A.260y.ll.i; A.261.y.ll4; A.262.y.ll.i; A.263.y.ll.i; A.264.y.ll.i; A.265.y.ll.i; A.266.V.114; A.267.y.H4; A.268.V.114; A.269.y.ll.i; A.270.y.U4; A.271.y.ll.i; A.272.V.114; A.273.y.U4; AJ74.ý.ll.i; A.275.V.11 .i; A.276.y.ll.i; A.277y.U4; A.278.V.114; A.279y.U4; A.280.V.114; A.281.v.ll.i; A.282.y.ll4; A.283.y.ll4; A.284.y.U.i; A.285y.ll4; A.286.ý.ll.i; A.287.ý.ll4; A.288.y.ll4; A.289.V.114; A.290.V.114; A.291y.ll.i; A.292.ý.ll4; A.293.V.114; A.294.y.ll4; A.295.y.ll.i; A.296.y.ll4; A.297.y.U4; A.298y.ll4; A.299.V.114; A.300.y.ll4; A.301.y.ll.i; A.302.ý.ll4; A.303.y.ll4; ,A.304y.ll4; A.305.ý.ll4; A3G6.y.ll4; A.307.y.ll.i; A.308.y.ll4; A.309.y.ll,i; A.310.y.ll4; A.311.y.ll4; A.312,y.ll.i; A.313.y.li.i; A.314.y.ll4; A.315.y.U4; A.316.y.ll.i; A.317.y.ll4; A.318.y.ll4; A.319.y.U4; A.320.y.ll4; A.321y.ll4; A.323.y,ll.i; A.324.y.ll.i; A325y.ll.i; A.326y.ll4: A.327.y.ll4; A.328.y,114; A.329.y.U4; A.330.y.ll.í; A.331y.ll.i; A.332.y.ll.i; A.333.y.U.i; A.334y.ll4; -A.335y.114; A.336.V.114; A.337.y.U4; A.338.y.ll.i; A.339,y.U4; A.340.y.ll.i; A.341.y.ll4; -A.342.V.114; A.343.y.ll.i; A.344.y.ll.i; A.345.V.114; A.346.y.ll.i; A.347.y.ll4; A.348.V.114; A.349.V.114; A.350.V.114; A.351ý.U4; A.352.y.ll.i; A.353.V.114; A.354.V.114; A.355y.ll.i; A.35óý.ll4; A.357y.ll4; A.358.y.ll4; A.359.V.114; A.360.V.114; A.361 y.11 4; A.362.ý.l 1 4; A.363.ý.l 14; A.364.y. 114; A.365.ý. 114; A.366.V. 114; A.367.y.ll.i; A.368.V.114; A.369.y.ll.i; A.370.y.ll4; A.371.y.ll.i; A.372.V.114; A.373.y.ll4; A.374.ý.ll4; A.375.y.ll4; A.376.y.ll4; A.377.y.ll4; A.378.v.ll.i; A.379.y.ll.i; A.380.y,114; A.381.y.ll4; A.382.y.ll4; A.383.y.ll.i; A.384.V.114; A.385.y.ll.i; A.386.V.114; A.387.V.114; A.388.y.ll.i; A.389.V.114; A.390.V.114; A.391y.ll.i; A.392.y.ll4; A.393.y.ll4; A.394.y.ll4; A.395.ý.ll.i; A.396.V.114; A.397y.ll.i; A.398.y.ll4; A.399.V.114; A.400y.lÍ4; A.401.V.114; A.402.y.ll4; A.403.y.ll.i; A.404.y.ll4; A.405.V.114; A.406.V.114; A.407.V.114; A.408.v.ll.i; A.409y.ll.i; A.410.y,114; A.411,y.ll.i; A.412.V.114; A.413.ý.ll4; A.414.V.114; A.415.y.ll.i; A.416.V.114; A.417.V.114; A.418.y.ll4; A.419.V.114; A.420.V.114; A.421.V.114; A.422.V.114; A.423.V.U4; A.424.y.ll.i; A.425.ý.ll4> A.426.V.114; A.427.V.U4; A.428.y.ll.i; A.429.V.114; A.430.y.ll4; A.431y.ll4; A.432.V.U4; A.433.V.114; A.434.V.114; A.435.y.U4; A.436.V.114; A.437.y,114; A.438.V.114; A.439.y,U4; A.440.V.114; A.441.y.ll4; A.442.V.114; A.443.y.ll4; A.444.y.I14; A.445.V.114; A.446.V.114; A.447.V.114; A.448.y.ll.i; A.449.y.ll.i; A.45O;V.114;-A.168y.114; A.169.y.ll4; A.170y.ll4; A.171.V.114; A.172.v.ll.i; A.173.V.114; A.174.V.114; A.175y.ll4; A.176.y.ll4; A.177y, 114; A.178.ý.ll.i; A.179.ý.ll.i; A.180.ý.ll4; A.181.y.ll.i; A.182.y.ll.i; A.183.y.ll4; A.184.V.114; A.185.y.ll.i; A.186.y.ll.i; A.187.V.114; A.188.y.ll4; A.189y.ll4; A.190.V.114; A.191.y.ll4; A.192y.U4; A.193.ý.U.i; A.194.y.ll4; A.495.V.114; A.196.y.ll.i; A.197.y.lLi; A.198. Y, 114; A.199.y.ll4; A.200.V.114; A.201.y.ll4; A.202.y.ll.i; A203.y.ll.i; A.204.y.ll.i; A205.y.U4; A.206.V.U4; A.207.y.ll.i; A.208.y.ll.i; A209.y.U4; A.210.y.ll.i; AJll.y.114; A.212.y.ll4; A.213.y.ll.i; A.214.y.ll4; AJ15.y.ll4; AJZló.y.ll.i; A.217.y.ll4; A.218y.ll.i; A.219.y.ll4; A.220.y.ll.i; AJ21.y.U4; A.222.V.114; A223.V.U4; A.224.y, 114; AJ25.y.ll4; A226.y.ll4; AJ27y.ll 4; AJ28.ý.ll.i; A229.ý.ll.i; A.230.y.ll4; A.231.y.ll4; A.232.y.U4; A.233.y.ll.i; A234.y.ll4; AJ35y.ll.i; A.236.y.U.i; A.237.y.U.i; A.238.y.ll.i; A.239.y.ll.i; A240.y.ll4; A.241.y.ll.i; A.242.y.ll .i; A.243y.ll.i; A.244.y.ll4; A.245.y.ll.i; A.246.y.ll4; A.247.y.ll.i; A.248.y.ll4; A.249.y.ll.i; A.250.y.ll.i; A.251.y.ll4; A252.y.ll.i; AJ53.y.ll4; A.254y.ll4; AJSS.y.ll.i; A.256.y.ll.i; AJ57.y.ll.i; A258.y.ll4; A.259.y.ll.i; A.260y.ll.i; A.261.y.ll4; A.262.y.ll.i; A.263.y.ll.i; A.264.y.ll.i; A.265.y.ll.i; A.266.V.114; A.267.y.H4; A.268.V.114; A.269.y.ll.i; A.270.y.U4; A.271.y.ll.i; A.272.V.114; A.273.y.U4; AJ74.ý.ll.i; A.275.V.11 .i; A.276.y.ll.i; A.277y.U4; A.278.V.114; A.279y.U4; A.280.V.114; A.281.v.ll.i; A.282.y.ll4; A.283.y.ll4; A.284.y.U.i; A.285y.ll4; A.286.ý.ll.i; A.287.ý.ll4; A.288.y.ll4; A.289.V.114; A.290.V.114; A.291y.ll.i; A.292.ý.ll4; A.293.V.114; A.294.y.ll4; A.295.y.ll.i; A.296.y.ll4; A.297.y.U4; A.298y.ll4; A.299.V.114; A.300.y.ll4; A.301.y.ll.i; A.302.ý.ll4; A.303.y.ll4; , A.304y.ll4; A.305.ý.ll4; A3G6.y.ll4; A.307.y.ll.i; A.308.y.ll4; A.309.y.ll, i; A.310.y.ll4; A.311.y.ll4; A.312, y.ll.i; A.313.y.li.i; A.314.y.ll4; A.315.y.U4; A.316.y.ll.i; A.317.y.ll4; A.318.y.ll4; A.319.y.U4; A.320.y.ll4; A.321y.ll4; A.323.y, II.i; A.324.y.ll.i; A325y.ll.i; A.326y.ll4: A.327.y.ll4; A.328. Y, 114; A.329.y.U4; A.330.y.ll.í; A.331y.ll.i; A.332.y.ll.i; A.333.y.U.i; A.334y.ll4; -A.335y.114; A.336.V.114; A.337.y.U4; A.338.y.ll.i; A.339, y.U4; A.340.y.ll.i; A.341.y.ll4; -A.342.V.114; A.343.y.ll.i; A.344.y.ll.i; A.345.V.114; A.346.y.ll.i; A.347.y.ll4; A.348.V.114; A.349.V.114; A.350.V.114; A.351ý.U4; A.352.y.ll.i; A.353.V.114; A.354.V.114; A.355y.ll.i; A.35óý.ll4; A.357y.ll4; A.358.y.ll4; A.359.V.114; A.360.V.114; A.361 y.11 4; A.362.l.1 1 4; A.363.l.1 14; A.364.y. 114; A.365.ý. 114; A.366.V. 114; A.367.y.ll.i; A.368.V.114; A.369.y.ll.i; A.370.y.ll4; A.371.y.ll.i; A.372.V.114; A.373.y.ll4; A.374.ý.ll4; A.375.y.ll4; A.376.y.ll4; A.377.y.ll4; A.378.v.ll.i; A.379.y.ll.i; A.380.y, 114; A.381.y.ll4; A.382.y.ll4; A.383.y.ll.i; A.384.V.114; A.385.y.ll.i; A.386.V.114; A.387.V.114; A.388.y.ll.i; A.389.V.114; A.390.V.114; A.391y.ll.i; A.392.y.ll4; A.393.y.ll4; A.394.y.ll4; A.395.ý.ll.i; A.396.V.114; A.397y.ll.i; A.398.y.ll4; A.399.V.114; A.400y.lÍ4; A.401.V.114; A.402.y.ll4; A.403.y.ll.i; A.404.y.ll4; A.405.V.114; A.406.V.114; A.407.V.114; A.408.v.ll.i; A.409y.ll.i; A.410.y, 114; A.411, y.ll.i; A.412.V.114; A.413.ý.ll4; A.414.V.114; A.415.y.ll.i; A.416.V.114; A.417.V.114; A.418.y.ll4; A.419.V.114; A.420.V.114; A.421.V.114; A.422.V.114; A.423.V.U4; A.424.y.ll.i; A.425.ý.ll4> A.426.V.114; A.427.V.U4; A.428.y.ll.i; A.429.V.114; A.430.y.ll4; A.431y.ll4; A.432.V.U4; A.433.V.114; A.434.V.114; A.435.y.U4; A.436.V.114; A.437. Y, 114; A.438.V.114; A.439.y, U4; A.440.V.114; A.441.y.ll4; A.442.V.114; A.443.y.ll4; A.444.y.I14; A.445.V.114; A.446.V.114; A.447.V.114; A.448.y.ll.i; A.449.y.ll.i; A.45O, V.114;
-105CZ 297945 B6-105GB 297945 B6
A.451.y.ll.x; A452.y.ll.i; A.453.y.ll.i; A.454.y.ll.i; A455.y.ll.i; A.456.y.ll.i; A457.y.ll.i; A458.y.ll.i; A459.y.ll.i; A.460.y.ll.i; A.461.y.ll.i; A.462.y.H.i; A.463.y.ll.i; A.464.V.11.Í; A465.y.ll.i; Α466.γ.11.χ; A467.y.ll.i; A.468,y.ll.x; A469.y.ll.i; A470.ý.ll.i; A471.y.ll.x; A.472.ý.ll.i; A473.ý.ll.x; A474.v.ll.i; A475.y.ll.i; A476.y.ll.i; A477.y.ll.i; A478.y.ll.i; A479.y.ll.i; A480.ý.ll.i; A481.y.ll,i; A482.ý.ll.i; A483.y.ll.i; A.484.y.ll,i; A485.y.ll.i; A486.y.U.x; A.487.y.U.i; A488.y.ll.x; Α489.ν.Π.χ; A490.v.ll.i; A491.y.ll.i; A492.y-.lld; A493.y.lld; A494.y-.ll.i; A495.v.lld; A496.ý.ll.i; A497.y.ll.i; A498.y.ll.i; A499.y.lld; A.SOO.y.ll.i; A.501.V.11 .i; A.502.y.ll.i; A.503.y.ll.i; A.504.y.lld; A.505.y.ll.i; A.506.y.ll.i; A.507.y.ll.i; A.508.y.ll.i; A.5O9.y.lld; A.510.y.ll.i; A.511.y.lld; A.512.y.lld; A.512.y.ll.i; A.513.y.ll.í; A.514.y.ll.i; A.515.y.ll.i; A.516.y.ll.i; A.517.y.lld; A,518.y.ll.i; A.519.y.ll.i; A.520.y.lld; A.521.y.ll.i; A322.y.lld; A.523.y.ll.i; A.524.y.ll.i; A.525.y.ll.i; A.526.y.ll.i; A.527.y.ll.i; A.528.y.íl.i; A.529.y.ll.i; A.530.y.lld; A.531.y.lld; A.532.y.ll.i; A.533.y.ll.i; A.534.y.ll.i; A.535.y.ll.i; A.536.y.ll.i; A.537.y.ll.i; A.538.y.ll.i; A.539.y.ll.i; A.540.y.ll.i; A.541.y.ll.i; A.542.y.ll.i; A.543.y.ll.i; A.544.v.U.i; A.545.y.ll.i; A.546.y.ll.i; A.547.y.ll.i; A.548.y.ll.i; A.549.y.ll.i; AJSSO.ý.lld; A.551.y.ll.i; A.552.y.ll.i; A.553.y.ll.i; A-554.y.ll.i; AJ555.y.ll.i; A.556.y.ll.i; A.557.y.ll.i; A.558.y.lld; A.559.y.lld; A.560.v.ll.i; A.561.V.11.Í; A.562.y.ll.i; A.563.y.ll.i; A.564.y.ll.i; A.565.ý.ll.i; A.566 ý.lld; A.567.y.lld; A.568.y.U.i; A.569.y.ll.i; A,570.y.lld; A.571.y.ll.i; A.572.y.ll.i; A.573.y.ll.i; A.574.y.ll.i; A.575.y.ll.i; A.576.y.ll.x; A.577.y.ll.i; A.578.y.ll.i; A.579.y.ll.i; A.580.y.U.i; A.581.y.ll.x; A.582.y.lld; A.583.y.ll.i; A.584.y.ll.i; A.585.y.ll.i; A.586.y.ll.i; A.587.y.lld; A.588.y.ll.i; A.589.y.ll.i; A.590.y.ll.i; A.591.y.ll.x; A.592.y.ll.x; A.593.y.lld; A.594.y.ll.i; A.595.y.U.i; A.596.y.ll.i; A.597.y.ll.i; A.598.y.ll.i; A.599.V.11.Í; A.óOO.y.ll.i; A.óOl.y.lld; A.602.y.ll.i; A.603.y.ll.i; A.604.y.ll.i; A.óOS.y.lld; A.ÓOó.y.ll.i; A.607.y,ll.i; A.608.y.ll.x; A.609.y.ll.i; A.ólO.y.ll.i; A.611.y.ll.i; A.612.y.ll.i; A.613.y.ll.i; A.614.y.ll.i; A.615.y.ll.x; A.óló.y.ll.i; A.617.y.ll.i; A.618.y.lld; A.619.y.ll.i; A.620.y.íld; A.621.y.lLx; A.622.y.ll.i; A.623.y.ll.i; A.624.y.lld; A.625.v.ll.i; A.626.y.lld; A.627.y.lld; A.628.y.lld; A.629.y.ll.i; A.630.V.11.Í; A.63Lv.lLi; A.632.V.11.Í; A.633.y.ll.i; A.634.y.lld; A.635.V.1LÍ; A.636.y.ll,i; A.637.ý.ll,i; A.638.ý.U.i; A.639.V.11.Í; A.640.y.lld; A.641.y.ll.i; A.642.y.ll.i; A.643.y.ll.i; A.644.y.ll.i; A.645.y.lld; A.646.V.11 i; A.647.v.ll.i; A.648.y.ll.i; A.649.ý.lld; A.650.y.lld; A.651.y.lld; A.652.y.ll.x; A.653.y.ll.i; A.654.y.ll.i; A.655.y.U.i; A.656.v,lLi; A.657.y.ll.i; A.658.y.ll.i; A.659.v.ll.i; A.660.y.ll.i; A.2.z.4.i; A.3.z4d; Á4.z4.i; A.5.z4d; A.6.z4.i; A.7.z4.í; Á.9.z4.i; A.10.Z.4.Í; A.15.z4.i; A.100.z4d; A.101.z4.i; A.102.z4.i; A.103.z4.i; A.104.z4.i; A.105.z4d; A.106.z.4.i; A.107.z4.i; A.108.z4.i; A.109.z4.i; A.110.z4.i; A.lll.z4.i; A.112.Z.4.Í; A.113.z4.i; A.114.z4.i; A.115,z4.i; A.116.z.4d; A.117.z4.i; A.118.Z.4.Í; A.119.z4d; A.120.z4d; A.121.Z.4.Í; A.122.z4.i; A.123.z4d; A.124.z4.i; A.125.z4.i; A.126.Z4.Í; A.127.z4.i; A.128.z4.i; A.129.z4.i; A.130.z4.i; A.131.z4.Í; A.132.z4.i; A.133.z4.i; A.134.Z.4.Í; A.135.z4.i; A.136.z4.i; A.137.z4.i; A.138.z4.i; A.139.z4.i; A.140.z4.i; A.141.Z.4.Í; A.142.z4.i; A.143.z4.i; A.144.z4.i; A.145,z4.i; A.146.z4.i; A.147.z4.i; A.148.z4.i; A.149.z4.i; A.150.z4»i; A.151.z4.i; A.152.z4.i; A.153,z4.i; A.154.Z.4.Í; A.155.Z.4.Í; A.156.z4.i; A.157.z4.i; A.158.z4.i; A.159.z4.i; A.160.z4.i; A.161.z4.i; A.162.Z.4.Í; A.163.z.4.i; A.164.z 4.x; A.165.z4.i; A.166.z4.i; A.167.z 4.i; A.168.z4.i; A.169.z4.i; A.170.z4.i; A.171.z4.i; A.172.z4.i; A.173.z4.i; A.174.z4.x;A.451.y.ll.x; A452.y.ll.i; A.453.y.ll.i; A.454.y.ll.i; A455.y.ll.i; A.456.y.ll.i; A457.y.ll.i; A458.y.ll.i; A459.y.ll.i; A.460.y.ll.i; A.461.y.ll.i; A.462.y.H.i; A.463.y.ll.i; A.464.V.11.Í; A465.y.ll.i; Α466.γ.11.χ; A467.y.ll.i; A.468, y.ll.x; A469.y.ll.i; A470.ý.ll.i; A471.y.ll.x; A.472.ý.ll.i; A473.ý.ll.x; A474.v.ll.i; A475.y.ll.i; A476.y.ll.i; A477.y.ll.i; A478.y.ll.i; A479.y.ll.i; A480.ý.ll.i; A481.y.ll, i; A482.ý.ll.i; A483.y.ll.i; A.484.y.ll, i; A485.y.ll.i; A486.y.U.x; A.487.y.U.i; A488.y.ll.x; Α489.ν.Π.χ; A490.v.ll.i; A491.y.ll.i; A492.y-.ld; A493.y.lld; A494.y-III.i; A495.v.lld; A496.ý.ll.i; A497.y.ll.i; A498.y.ll.i; A499.y.lld; A.SOO.y.ll.i; A.501.V.11 .i; A.502.y.ll.i; A.503.y.ll.i; A.504.y.lld; A.505.y.ll.i; A.506.y.ll.i; A.507.y.ll.i; A.508.y.ll.i; A.5O9.y.lld; A.510.y.ll.i; A.511.y.lld; A.512.y.lld; A.512.y.ll.i; A.513.y.ll.í; A.514.y.ll.i; A.515.y.ll.i; A.516.y.ll.i; A.517.y.lld; A, 518.y.ll.i; A.519.y.ll.i; A.520.y.lld; A.521.y.ll.i; A322.y.lld; A.523.y.ll.i; A.524.y.ll.i; A.525.y.ll.i; A.526.y.ll.i; A.527.y.ll.i; A.528.y.íl.i; A.529.y.ll.i; A.530.y.lld; A.531.y.lld; A.532.y.ll.i; A.533.y.ll.i; A.534.y.ll.i; A.535.y.ll.i; A.536.y.ll.i; A.537.y.ll.i; A.538.y.ll.i; A.539.y.ll.i; A.540.y.ll.i; A.541.y.ll.i; A.542.y.ll.i; A.543.y.ll.i; A.544.v.U.i; A.545.y.ll.i; A.546.y.ll.i; A.547.y.ll.i; A.548.y.ll.i; A.549.y.ll.i; AJSSO.ý.lld; A.551.y.ll.i; A.552.y.ll.i; A.553.y.ll.i; A-554.y.ll.i; AJ555.y.ll.i; A.556.y.ll.i; A.557.y.ll.i; A.558.y.lld; A.559.y.lld; A.560.v.ll.i; A.561.V.11.Í; A.562.y.ll.i; A.563.y.ll.i; A.564.y.ll.i; A.565.ý.ll.i; A.566 ý.lld; A.567.y.lld; A.568.y.U.i; A.569.y.ll.i; A, 570.y.lld; A.571.y.ll.i; A.572.y.ll.i; A.573.y.ll.i; A.574.y.ll.i; A.575.y.ll.i; A.576.y.ll.x; A.577.y.ll.i; A.578.y.ll.i; A.579.y.ll.i; A.580.y.U.i; A.581.y.ll.x; A.582.y.lld; A.583.y.ll.i; A.584.y.ll.i; A.585.y.ll.i; A.586.y.ll.i; A.587.y.lld; A.588.y.ll.i; A.589.y.ll.i; A.590.y.ll.i; A.591.y.ll.x; A.592.y.ll.x; A.593.y.lld; A.594.y.ll.i; A.595.y.U.i; A.596.y.ll.i; A.597.y.ll.i; A.598.y.ll.i; A.599.V.11.Í; A.óOO.y.ll.i; A.óOl.y.lld; A.602.y.ll.i; A.603.y.ll.i; A.604.y.ll.i; A.óOS.y.lld; A.OOOO.y.ll.i; A.607.y, II.i; A.608.y.ll.x; A.609.y.ll.i; A.ólO.y.ll.i; A.611.y.ll.i; A.612.y.ll.i; A.613.y.ll.i; A.614.y.ll.i; A.615.y.ll.x; A.óló.y.ll.i; A.617.y.ll.i; A.618.y.lld; A.619.y.ll.i; A.620.y.íld; A.621.y.lLx; A.622.y.ll.i; A.623.y.ll.i; A.624.y.lld; A.625.v.ll.i; A.626.y.lld; A.627.y.lld; A.628.y.lld; A.629.y.ll.i; A.630.V.11.Í; A.63Lv.lLi; A.632.V.11.Í; A.633.y.ll.i; A.634.y.lld; A.635.V.1LÍ; A.636.y.ll, i; A.637, 11, i; A.638.ý.U.i; A.639.V.11.Í; A.640.y.lld; A.641.y.ll.i; A.642.y.ll.i; A.643.y.ll.i; A.644.y.ll.i; A.645.y.lld; A.646.V.11 i; A.647.v.ll.i; A.648.y.ll.i; A.649.ý.lld; A.650.y.lld; A.651.y.lld; A.652.y.ll.x; A.653.y.ll.i; A.654.y.ll.i; A.655.y.U.i; A.656.v, 11i; A.657.y.ll.i; A.658.y.ll.i; A.659.v.ll.i; A.660.y.ll.i; A.2.z.4.i; A.3.z4d; Á4.z4.i; A.5.z4d; A.6.z4.i; A.7.z4.í; Á.9.z4.i; A.10.Z.4.Í; A.15.z4.i; A.100.z4d; A.101.z4.i; A.102.z4.i; A.103.z4.i; A.104.z4.i; A.105.z4d; A.106.z.4.i; A.107.z4.i; A.108.z4.i; A.109.z4.i; A.110.z4.i; A.lll.z4.i; A.112.Z.4.Í; A.113.z4.i; A.114.z4.i; A.115, z4.i; A.116.z.4d; A.117.z4.i; A.118.Z.4.Í; A.119.z4d; A.120.z4d; A.121.Z.4.Í; A.122.z4.i; A.123.z4d; A.124.z4.i; A.125.z4.i; A.126.Z4.Í; A.127.z4.i; A.128.z4.i; A.129.z4.i; A.130.z4.i; A.131.z4.Í; A.132.z4.i; A.133.z4.i; A.134.Z.4.Í; A.135.z4.i; A.136.z4.i; A.137.z4.i; A.138.z4.i; A.139.z4.i; A.140.z4.i; A.141.Z.4.Í; A.142.z4.i; A.143.z4.i; A.144.z4.i; A.145, z4.i; A.146.z4.i; A.147.z4.i; A.148.z4.i; A.149.z4.i; A.150.z4 »i; A.151.z4.i; A.152.z4.i; A.153, z4.i; A.154.Z.4.Í; A.155.Z.4.Í; A.156.z4.i; A.157.z4.i; A.158.z4.i; A.159.z4.i; A.160.z4.i; A.161.z4.i; A.162.Z.4.Í; A.163.z.4.i; A.164.z 4.x; A.165.z4.i; A.166.z4.i; A.167.z 4.i; A.168.z4.i; A.169.z4.i; A.170.z4.i; A.171.z4.i; A.172.z4.i; A.173.z4.i; A.174.z4.x;
-106CZ 297945 B6-106GB 297945 B6
A.175.Z.4.Í; A.176.z.4.i; A.177.Z.4.Í; A.178.z.4.i; A.179.z.4.i; A.180.Z.4.Í; A.181.z.4.i; Α.182.Ζ.4.Ϊ; A.183.z.4.i; A.184.z.4.i; A.185.z.4.i; A.186.Z.4.Í; A-187.z.4.i; A.188.Z.4.Í; A.189.Z.4.Í; A.190.z.4.i; A.191.Z.4.Í; A.192.z.4.i; A.193.Z.4.Í; A.194.z.4.i; A.195.z.4.i; A496.Z.4.Í; A.197.z.4.i; A.198.Z.4.1; A.199.z.4.i; A.200.z.4.i; A.201.Z.4.i; A.202.z.4.x; A.203.Z.4.Í; Α.204.2.4.Ϊ; A.205.z.4.i; A.206.Z.4.Í; A.207.z.4.i; A.208.z.4.i; A.209.Z.4.Í; A.210.Z.4.Í; A211.z.4.i; A.212.z.4.i; A.213.Z.4.Í; A.214.z.4.i; A.215.Z.4.Í; A.216.z.4.i; A.217.Z.4.Í; A.218.Z.4.Í; A.219.z.4.i; A.220.Z.4.Í; A.221.Z.4.Í; Α.222.Ζ.4.Ϊ; A.223.Z.44; A.224.Z.4.Í; A.225.z.4.i; A.226.z.4.i; A.227.Z.4.Í; A.228.Z.4.Í; A.229.z.4.i; A.230.z.4.i; Α.231.Ζ.4.Ϊ; A.232.Z.4.Í; A.233.z.4.i; A.234.z.4.i; A.235.z.4.x; A.236.z.4.i; A.237.z.4.i; A.238.Z.4.Í; A.239.Z.4.Í; A.240.z.4.i; A.241.Z.4.Í; A.242.z.4.i; A.243.Z.4.Í; Α.244.Ζ.4.Ϊ; A.245.Z.4.Í; A.246.Z.4.Í; A.247.z.4.i; A.248.z.4.i; A.249.Z.4.Í; A.250.Z.4.Í; A.251.Z.4.Í; A.252.Z.4.Í; A.253.Z.4.Í; A.254.z.4.i; A.255.Z.4.Í; A.256.z.4.i; A257.z.4.i; A.258.z.4.i; A.259.Z.4.Í; A.260.Z.4.Í; A.261.z.4.i; A.262.Z.4.Í; A.263.z.4.i; A264.Z.4.Í; A.265.z.4.i; A.266.Z.4.Í; A.267.z.4.i; A.268.z.4.i; A.269.z.4.i; A.270.z.4.i; Α.271.Ζ.4.Ϊ; A.272.z.4á; A.273.Z.4.Í; A274.Z.4.Í; A.275.z.4.x; A.276.Z.4.Í; A.277.Z.4.Í; A.278.z.4.i; A.279.z.4.i; A.280.Z.4.Í; A281.z.4.i; A.282.Z.4.Í; Α-283-Ζ.4.Ϊ; A.284.Z.4.Í; AJ285.Z.4.Í; A.286.z.4.i; A.287.Z.4.Í; A.288.Z.4.Í; A.289.z.4.i; A.290.z.4.i; A.291.z.4.i; A.292.z.4.i; A.293.z.4.i; A.294.Z.4.Í; A.295.Z.4.Í; A.296.Z.4.Í; A.297.Z.4.Í; A.298.Z.4.Í; A.299.Z.4.Í; A.300.Z.4.Í; A.301.z.4.x; A.302.Z.4.Í; A.303.z.4.i; A.304.z.4.i; Α.305.Ζ.4.Ϊ; A.306.z.4.i; A.307.z.4.i; A.308.Z.4.Í; A.309.Z.4.Í; A.310.Z.4.Í; A.311.Z.4.Í; A.312.z.4.i; A.313.Z.4.Í; A.314.Z.4.Í; A.315.Z.4.Í; A.316.Z.4.Í; A.317.z.4.i; A.318.z.4.x; A.319.z.4.i; A.320.z.4.i; A.321.z.4.i; A.323.z.4.i; A.324.Z.4.Í; A.325.Z.4.i; A.326.z.4.i; A.327.z.4.i; A.328.z.4.i; A.329.z.4.i; A.330.Z.4.X; A.331.Z.4.Í; A.332.Z.4.Í; A.333.z.4.i; A.334.z.4.x; A.335.z.4.i; A.336.Z.4.Í; A.337.Z.4.Í; A.338.z.4.i; A.339.z.4.x; A.340.Z.4.i; A.341.z.4.i; A.342.z.4.i; A.343.z.4.i; A.344.Z.4.Í; A.345.z.4.i; A.346.Z.4.Í; A.347.Z.4.Í; A.348.z.4.i; Α.349.Ζ.4.Ϊ; A.350.Z.4.Í; A.351.Z.4.X; A.352.z.4.i; A.353.z.4.i; A.354.z.4.i; A.355.z.4.i; A.356.z.4.i; A.357.z.4.i; A.358.z.4,í; A.359.z.4.i; A.360.z.4.i; A.361.z.4.i; A.362.z.4.i; A.363.Z.4.Í; A.364.Z.4.1; A.365.Z.4.Í; A.366.Z.4.Í; A.367.z.4.i; A.368.Z.4.Í; A.369.z.4.i; A.370.Z.4.Í; A.371.Z.4.Í; A.372.Z.4.Í; A.373.z.4.i; A.374.z.4.i; A.375.z.4.x; A.376.z.4.x; A.377.z.4.i; A.378.z.4.i; A.379.Z.4.Í; A.380.Z.4.Í; A.381.z.4.i; A.382.Z.4.Í; A.383.Z.4.Í; A.384.z.4.i; A.385.z.4.i; A.386.Z.4.Í; A.387.Z.4.Í; A.388.z.4.x; A.389.z.4.i; A.390.z.4.i; A.391.z.4.i; A.392.z.4.i; A.393.z.4.i; A.394.z.4.i; A.395.z.4.i; A.396.Z.4.Í; A.397.Z.4.Í; A.398.z.4.i; A.399.z.4.i; A.400.Z.4.Í; A.401.Z.4.Í; A.402.Z.4.Í; A.403.Z.4.Í; A.404.z.4.i; A.405.Z.4.Í; A.406.z.4.i; A.407.Z.4.Í; A.408.Z.4.Í; A.409.z.4.i; Α.410.Ζ.4.Ϊ; A.411.Z.4.Í; A.412.z.4.i; Α.413.Ζ.4.Ϊ; A.414.Z.4.Í; A.415.Z.4.Í; A.416.Z.4.Í; A.417.z.4.i; A.418.Z.4.Í; A.419.z.4.i; A.420.Z.4.Í; A.421.Z.4.Í; A.422.Z.4.Í; A.423.z.4.i; A.424.z.4.i; A.425.z.4.i; A.426.z.4.i; A.427.z.4.i; A.428.Z.4.Í; A.429.z.4.i; A.430.z.4.i; A.431.z.4.i; A.432.Z.4.Í; A.433.Z.4.Í; A.434.Z.4.Í; Α.435.Ζ.4.Ϊ; A.436.z.4.i; A,437.z,4.i; A.438.z.4,i; A.439.z.4.i; A.440.Z.4.Í; A.441.z.4.i; A.442.Z.4.Í; A.443.Z.4.Í; A.444.z.4.i; Α.445.Ζ.4.Ϊ; A.446.z.4.i; A.447.z.4.i; A.448.z.4.i; A.449.Z.4.Í; A.450.z.4.i; A.451.z.4.i; A.452.z.4.i; A.453.Z.4.Í; A.454.z.4.i; A.455.Z.4.Í; A.456.Z.4.Í; A.457.z.4.i; A.458.Z.4.Í; A.459,z.4.i; A.460.Z.4.Í; A.461.z.4.i; A.462.Z.4.Í; A.463.Z.4.Í; A.464.z.4.i; A.465.z.4.i; A.466.z.4.i; A.467.z.4.i; A.468.Z.4.Í; A.469.Z.4.Í; A.470.Z.4.Í; A.471.z.4.i; A.472.z.4.i; A.473.z.4.i; A.474.z.4.i; A.475.Z.4.1; Α.476.Ζ.4Λ; A.477.Z.4.Í; A.478.Z.4.Í; A.479.z.4.i; A.480.Z.4.Í; Α.481.Ζ.4.Ϊ; A.482.Z.4.Í; A.483.Z.4.Í; A.484.Z.4.Í; A.485.z.4.i; A.486.z.4.i; A.487.Z.4.Í; A.488.z.4.i; A.489.z.4.i; A.490.z.4.i; A.491.z.4.i; A.492.z.4.i; A.493.Z.4.Í; A.494.z.4.i; A.495.z.4.i; A.496.Z.4.Í; A.497.z.4.i; A-498.Z.4.Í; A.499.z.4.i; A.500.z.4.i; A.501 .z.4.i; A.502.Z.4.Í; A.503.z.4.i; A.504.z.4.i;A.175.Z.4.Í; A.176.z.4.i; A.177.Z.4.Í; A.178.z.4.i; A.179.z.4.i; A.180.Z.4.Í; A.181.z.4.i; Α.182.Ζ.4.Ϊ; A.183.z.4.i; A.184.z.4.i; A.185.z.4.i; A.186.Z.4.Í; A-187.z.4.i; A.188.Z.4.Í; A.189.Z.4.Í; A.190.z.4.i; A.191.Z.4.Í; A.192.z.4.i; A.193.Z.4.Í; A.194.z.4.i; A.195.z.4.i; A496.Z.4.Í; A.197.z.4.i; A.198.Z.4.1; A.199.z.4.i; A.200.z.4.i; A.201.Z.4.i; A.202.z.4.x; A.203.Z.4.Í; Α.204.2.4.Ϊ; A.205.z.4.i; A.206.Z.4.Í; A.207.z.4.i; A.208.z.4.i; A.209.Z.4.Í; A.210.Z.4.Í; A211.z.4.i; A.212.z.4.i; A.213.Z.4.Í; A.214.z.4.i; A.215.Z.4.Í; A.216.z.4.i; A.217.Z.4.Í; A.218.Z.4.Í; A.219.z.4.i; A.220.Z.4.Í; A.221.Z.4.Í; Α.222.Ζ.4.Ϊ; A.223.Z.44; A.224.Z.4.Í; A.225.z.4.i; A.226.z.4.i; A.227.Z.4.Í; A.228.Z.4.Í; A.229.z.4.i; A.230.z.4.i; Α.231.Ζ.4.Ϊ; A.232.Z.4.Í; A.233.z.4.i; A.234.z.4.i; A.235.z.4.x; A.236.z.4.i; A.237.z.4.i; A.238.Z.4.Í; A.239.Z.4.Í; A.240.z.4.i; A.241.Z.4.Í; A.242.z.4.i; A.243.Z.4.Í; Α.244.Ζ.4.Ϊ; A.245.Z.4.Í; A.246.Z.4.Í; A.247.z.4.i; A.248.z.4.i; A.249.Z.4.Í; A.250.Z.4.Í; A.251.Z.4.Í; A.252.Z.4.Í; A.253.Z.4.Í; A.254.z.4.i; A.255.Z.4.Í; A.256.z.4.i; A257.z.4.i; A.258.z.4.i; A.259.Z.4.Í; A.260.Z.4.Í; A.261.z.4.i; A.262.Z.4.Í; A.263.z.4.i; A264.Z.4.Í; A.265.z.4.i; A.266.Z.4.Í; A.267.z.4.i; A.268.z.4.i; A.269.z.4.i; A.270.z.4.i; Α.271.Ζ.4.Ϊ; A.272.z.4á; A.273.Z.4.Í; A274.Z.4.Í; A.275.z.4.x; A.276.Z.4.Í; A.277.Z.4.Í; A.278.z.4.i; A.279.z.4.i; A.280.Z.4.Í; A281.z.4.i; A.282.Z.4.Í; Α-283-Ζ. A.284.Z.4.Í; AJ285.Z.4.Í; A.286.z.4.i; A.287.Z.4.Í; A.288.Z.4.Í; A.289.z.4.i; A.290.z.4.i; A.291.z.4.i; A.292.z.4.i; A.293.z.4.i; A.294.Z.4.Í; A.295.Z.4.Í; A.296.Z.4.Í; A.297.Z.4.Í; A.298.Z.4.Í; A.299.Z.4.Í; A.300.Z.4.Í; A.301.z.4.x; A.302.Z.4.Í; A.303.z.4.i; A.304.z.4.i; Α.305.Ζ.4.Ϊ; A.306.z.4.i; A.307.z.4.i; A.308.Z.4.Í; A.309.Z.4.Í; A.310.Z.4.Í; A.311.Z.4.Í; A.312.z.4.i; A.313.Z.4.Í; A.314.Z.4.Í; A.315.Z.4.Í; A.316.Z.4.Í; A.317.z.4.i; A.318.z.4.x; A.319.z.4.i; A.320.z.4.i; A.321.z.4.i; A.323.z.4.i; A.324.Z.4.Í; A.325.Z.4.i; A.326.z.4.i; A.327.z.4.i; A.328.z.4.i; A.329.z.4.i; A.330.Z.4.X; A.331.Z.4.Í; A.332.Z.4.Í; A.333.z.4.i; A.334.z.4.x; A.335.z.4.i; A.336.Z.4.Í; A.337.Z.4.Í; A.338.z.4.i; A.339.z.4.x; A.340.Z.4.i; A.341.z.4.i; A.342.z.4.i; A.343.z.4.i; A.344.Z.4.Í; A.345.z.4.i; A.346.Z.4.Í; A.347.Z.4.Í; A.348.z.4.i; Α.349.Ζ.4.Ϊ; A.350.Z.4.Í; A.351.Z.4.X; A.352.z.4.i; A.353.z.4.i; A.354.z.4.i; A.355.z.4.i; A.356.z.4.i; A.357.z.4.i; A.358.z.4, i; A.359.z.4.i; A.360.z.4.i; A.361.z.4.i; A.362.z.4.i; A.363.Z.4.Í; A.364.Z.4.1; A.365.Z.4.Í; A.366.Z.4.Í; A.367.z.4.i; A.368.Z.4.Í; A.369.z.4.i; A.370.Z.4.Í; A.371.Z.4.Í; A.372.Z.4.Í; A.373.z.4.i; A.374.z.4.i; A.375.z.4.x; A.376.z.4.x; A.377.z.4.i; A.378.z.4.i; A.379.Z.4.Í; A.380.Z.4.Í; A.381.z.4.i; A.382.Z.4.Í; A.383.Z.4.Í; A.384.z.4.i; A.385.z.4.i; A.386.Z.4.Í; A.387.Z.4.Í; A.388.z.4.x; A.389.z.4.i; A.390.z.4.i; A.391.z.4.i; A.392.z.4.i; A.393.z.4.i; A.394.z.4.i; A.395.z.4.i; A.396.Z.4.Í; A.397.Z.4.Í; A.398.z.4.i; A.399.z.4.i; A.400.Z.4.Í; A.401.Z.4.Í; A.402.Z.4.I; A.403.Z.4.Í; A.404.z.4.i; A.405.Z.4.Í; A.406.z.4.i; A.407.Z.4.Í; A.408.Z.4.Í; A.409.z.4.i; Α.410.Ζ.4.Ϊ; A.411.Z.4.Í; A.412.z.4.i; Α.413.Ζ.4.Ϊ; A.414.Z.4.Í; A.415.Z.4.Í; A.416.Z.4.Í; A.417.z.4.i; A.418.Z.4.Í; A.419.z.4.i; A.420.Z.4.Í; A.421.Z.4.Í; A.422.Z.4.Í; A.423.z.4.i; A.424.z.4.i; A.425.z.4.i; A.426.z.4.i; A.427.z.4.i; A.428.Z.4.Í; A.429.z.4.i; A.430.z.4.i; A.431.z.4.i; A.432.Z.4.Í; A.433.Z.4.Í; A.434.Z.4.Í; Α.435.Ζ.4.Ϊ; A.436.z.4.i; A, 437.f, 4.i; A.438.z.4, i; A.439.z.4.i; A.440.Z.4.Í; A.441.z.4.i; A.442.Z.4.Í; A.443.Z.4.Í; A.444.z.4.i; Α.445.Ζ.4.Ϊ; A.446.z.4.i; A.447.z.4.i; A.448.z.4.i; A.449.Z.4.Í; A.450.z.4.i; A.451.z.4.i; A.452.z.4.i; A.453.Z.4.Í; A.454.z.4.i; A.455.Z.4.Í; A.456.Z.4.Í; A.457.z.4.i; A.458.Z.4.Í; A.459, z.4.i; A.460.Z.4.Í; A.461.z.4.i; A.462.Z.4.Í; A.463.Z.4.Í; A.464.z.4.i; A.465.z.4.i; A.466.z.4.i; A.467.z.4.i; A.468.Z.4.Í; A.469.Z.4.Í; A.470.Z.4.Í; A.471.z.4.i; A.472.z.4.i; A.473.z.4.i; A.474.z.4.i; A.475.Z.4.1; Α.476.Ζ.4Λ; A.477.Z.4.Í; A.478.Z.4.Í; A.479.z.4.i; A.480.Z.4.Í; Α.481.Ζ.4.Ϊ; A.482.Z.4.Í; A.483.Z.4.Í; A.484.Z.4.Í; A.485.z.4.i; A.486.z.4.i; A.487.Z.4.Í; A.488.z.4.i; A.489.z.4.i; A.490.z.4.i; A.491.z.4.i; A.492.z.4.i; A.493.Z.4.Í; A.494.z.4.i; A.495.z.4.i; A.496.Z.4.Í; A.497.z.4.i; A-498.Z.4.I; A.499.z.4.i; A.500.z.4.i; A.501 .z.4.i; A.502.Z.4.I; A.503.z.4.i; A.504.z.4.i;
- 107CZ 297945 B6- 107GB 297945 B6
A.505.Z.4.Í; A.506.z.4.i; A.507.z.4.i; A.508.Z.4.Í; A.509.z.4.i; A.510.Z.4.Í; A.511.z.4.i; A.512.Z.4.Í; A.512.Z.4.Í; A.513.Z.41 A.514.z.4.i; A.515.z.4.i- A.516.Z.4.Í; A.517.z.4.i; A.518.Z.4.Í; A.519.z.4.i; A.520.z.4.i; A.521.z.4.i; A.522_z.4.i; A.523.Z.4.Í; A.524.z.4.i; A.525.Z.4.Í; A.526.Z.4.Í; A.527.z.4.i; A.528.z.4.i; A.529.z.4.i; A.530.z.4.i; A.531.Z.41 A.532.Z.4.Í; A.533.z.4.i; A.534,z.4.i; A.535.Z.4.Í; A.536.z.4.i; A.537.Z.41 A.538.z.4.i; A.539.Z.4.Í; A.540.z.4.i; A,541.z.4.i; A.542.z.4.i; A.543.z.4.i; A.544.Z.4.Í; A.545.z.4.i; Α.546.Ζ.4.Ϊ; A.547.z.4.i; A.548.z.4.i; A.549.Z.4.Í; A.550.Z.4.Í; A.55l.z.4.i; A.552.Z.4.Í; A.553.Z.4.Í; A.554.z.4.i; Α.555.Ζ.4.Ϊ; A.556.z.4.i; A.557.z.4.i; A.558.z.4.i; A.559.z.4.i; A.560.Z.4.Í; A.561.z.4.i; A.562.z.4.i; A.563.z.4.i; A.564.z.4.i; A.565.z.4.i; Α.566.Ζ.4.Ϊ; A.567.Z.4.Í; A.568.Z.4.Í; A.569.z.4.i; A.570.z.4.i; A.571.Z.4.1; A.572.z.4.i; A.573.z.4.i; A.574.Z.4.Í; A.575.z.4.i; A.576.z.4.i; A.577.z.4.i; A.578.z.4.i; A.579.z.4.i; Α.580.Ζ.4.Ϊ; A.581.Z.4.Í; A.582.z.4.i; A.583.z.4.i; A.584.Z.4.Í; A.585.z.4.i; A.586.z.4.i; A.587.z.4.i; A.588-Z.4.Í; A.589.z.4.i; A.590.z.4.i; A.591.z.4.i; A.592.z.4.i; A.593.z.4.i; A.594.z.4.i; A.595.z.4.i; A.596.z.4.i; A.597.z.4.i; A.598.z.4.i; A.599.Z.4.Í; A.600.z.4.i; A.601.z.4,i; A.602.Z.4.Í; A.603.z.4.i; A.604.z.4.i; A.605.Z.4.Í; A.606.z.4.i; A.607.z.4.i; A.608.z.4.i; A.609.Z.4.Í; A.610.z.4.i; A.611.z.4.i; A.612.z.4.i; A.613.z.4.i; A.614jz.4.í; A.615.Z.4.Í; A.616.Z.4.Í; A.617.z.4.i; A.618.z.4.i; A.619.Z.4.Í; A.620.Z.41 A.621.Z.4.Í; A.622.Z.4.Í; A.623.Z.4.Í; A.624.Z.4.Í; A.625.z.4.i; A.626.z.4.i; A.627.Z.4.Í; A.628.z.4.i; A.629.z.4.i; A.630.Z.4.Í; A.631.z.4.i; A.632.z.4.i; A.633.z.4.i; A.634.z.4.i; A.635.z.4.i; A.636.Z.4.Í; A.637.Z.4.Í; A.638.z.4.i; A.639.Z.4.Í; A.640.z.4.i; A.641.z.4.i; A.642.z.4.i; A.643.Z.4.1; A.644.Z.4.Í; A.645.Z.4.Í; A.646.z.4.í; A.647.z.4.i; A.648.Z.4.Í; Α.649.Ζ.4.Ϊ; A.650.z.4.i; A.651.Z.4.Í; A.652.z.4.i; A.653.Z.4.Í; A.654.z.4.i; A.655.z.4.i; A,656.z.4.i; A.657.Z.4.Í; A.658.Z.4.Í; A.659.Z.4.Í; A.660.Z.41 A.2.z.ll.i; A.3.z.ll.i; A.4.Z.11.Í; A.5.z.ll.i; A.6.Z.111 A.7.Z.11.Í; A.9.z.ll.i; A.lO.z.lLi; A.15.Z.111 A.lOO.z.111 A.101.z.ll.i; A.102.Z.11.Í; A.103.Z.11.Í; A.104.Z.11.Í; A.lOS.z.11 .i; A.106.Z.11.Í; A.107.z.ll.i; A.108.Z.11.Í; A.109.Z.11.Í; A.llO.z.ll.i; A.lll.z.ll.i; A.112.z.ll.i; A.113.Z.U.Í; A.114.Z.11.Í; A.115.Z.11.Í; A.lló.z.U.i; A.117.Z.11.Í; A.118.z.ll.i; A.119.z.ll.i; A.120.Z.11.Í; A.121.Z.11.Í; A.122.Z.U.Í; A.123.z.ll.i; A.124.Z.11.Í; A,125.z.U.i; A.126.Z.1H A.127.Z.111 A.128.Z.1LÍ; A.I29.Z.111 A.130.Z.U.Í; A.131.z.ll.i; A.132.Z.11.Í; A.133.z.ll.i; A.134.z.ll.i; A.135.z.ll.i; A.136.z.ll.i; A.137.Z.11.Í; A.138.Z.11.Í; A.139.Z.11.Í; A.140.Z.11.Í; A.141,z.ll.i; A.142.Z.111 A.143.z.ll.i; A.144.Z.11.Í; A.145.Z.U.Í; A.146.z.ll.i;: A.147,z.ll.i; A.148.Z.11.Í; A.149.Z.11.Í; A.150.Z.11.Í; A.lSl.z.ll.i; A.152.Z.U.Í; A.153.z.ll.i; A.154.Z.11.Í; A.155.z.ll.i; A.156.Z.11.Í; A.157.z.H.i; A.158.z.ll.i; A.159.z.U.i; A.160.Z.11.Í; A.161.z.ll.i; A.162.Z.11.Í; A.163.z.ll.i; A.164.z.ll.i; A.165.Z.11.Í; A.166.z.ll.i; A.167.z.ll.i; A.168.Z.11.Í; A.169.Z.11.Í; A.17O.Z.11.Í; A.171.Z.11.1; A.172.z.ll.i; Α.173.Ζ.111 A.174.Z.11.Í; A.175.z.ll.i; A.176.Z.11.Í; A.177.Z.11.Í; A.178.Z.11.Í; A.179.Z.11.Í; A.180.Z.11.Í; A.181.Z.11.Í; A.182.Z.11.Í; A.183.z.ll.i; A.184.z.ll.i; A.185.z.ll.i; A.186.Z.11.Í; Α.187.Ζ.11.Ϊ; A.188.Z.11.1; A.189.z.ll.i; A.19O.z.ll.i; A.191.z.ll.i; A.192.Z.111 A.193.Z.11.Í; A.194.Z.11.1; A.195.z.ll.i; A.196.Z.11.Í; A.197.z.ll.i; A.198.Z.11.Í; A.199.Z.11.Í; A.200.z.ll.i; A.201.Z.11.Í; A.202.Z.11.Í; A.203.Z.11.Í; A.204.Z.11.Í; A.205.z.U.i; A.206.z.ll.i; A.207.Z.11.Í; A.208.z.U.i; A.209.z.ll.i; A.210.Z.11.Í; A.2Il.z.ll.i; A.212.Z.1I.Í; A.213.z.ll.i; A.214.Z.U.Í; A.215.z.ll.i; A.216.Z.11.Í; A.217.z.U.i; A.218.Z.11.Í; A.219.Z.111 A.220.Z.11.Í; A.221.Z.11.1; A.222.Z.11.Í; A.223.Z.11.Í; A.224.z.ll.i; A.225.Z.111 A.226.z.ll.i; A.227.z.ll.i; A.228.Z.111 A.229.Z.U.Í; A.230.z.ll.i; A.231.Z.11.Í; A.232.z.ll.i; A.233.Z.11.Í; A.234.Z.11.Í; A.235.z.ll.i; A.236.z.H.i; A.237.Z.11.Í; A.238.Z.11.Í; A.239.Z.11.Í;A.505.Z.4.Í; A.506.z.4.i; A.507.z.4.i; A.508.Z.4.Í; A.509.z.4.i; A.510.Z.4.Í; A.511.z.4.i; A.512.Z.4.Í; A.512.Z.4.Í; A.513.Z.41 A.514.z.4.i; A.515.z.4.i- A.516.Z.4.I; A.517.z.4.i; A.518.Z.4.Í; A.519.z.4.i; A.520.z.4.i; A.521.z.4.i; A.522_z.4.i; A.523.Z.4.Í; A.524.z.4.i; A.525.Z.4.Í; A.526.Z.4.Í; A.527.z.4.i; A.528.z.4.i; A.529.z.4.i; A.530.z.4.i; A.531.Z.41 A.532.Z.4.I; A.533.z.4.i; A.534, z.4.i; A.535.Z.4.Í; A.536.z.4.i; A.537.Z.41 A.538.z.4.i; A.539.Z.4.Í; A.540.z.4.i; A, 541.z.4.i; A.542.z.4.i; A.543.z.4.i; A.544.Z.4.Í; A.545.z.4.i; Α.546.Ζ.4.Ϊ; A.547.z.4.i; A.548.z.4.i; A.549.Z.4.Í; A.550.Z.4.Í; A.55l.z.4.i; A.552.Z.4.Í; A.553.Z.4.Í; A.554.z.4.i; Α.555.Ζ.4.Ϊ; A.556.z.4.i; A.557.z.4.i; A.558.z.4.i; A.559.z.4.i; A.560.Z.4.Í; A.561.z.4.i; A.562.z.4.i; A.563.z.4.i; A.564.z.4.i; A.565.z.4.i; Α.566.Ζ.4.Ϊ; A.567.Z.4.Í; A.568.Z.4.Í; A.569.z.4.i; A.570.z.4.i; A.571.Z.4.1; A.572.z.4.i; A.573.z.4.i; A.574.Z.4.Í; A.575.z.4.i; A.576.z.4.i; A.577.z.4.i; A.578.z.4.i; A.579.z.4.i; Α.580.Ζ.4.Ϊ; A.581.Z.4.Í; A.582.z.4.i; A.583.z.4.i; A.584.Z.4.Í; A.585.z.4.i; A.586.z.4.i; A.587.z.4.i; A.588-Z.4.I; A.589.z.4.i; A.590.z.4.i; A.591.z.4.i; A.592.z.4.i; A.593.z.4.i; A.594.z.4.i; A.595.z.4.i; A.596.z.4.i; A.597.z.4.i; A.598.z.4.i; A.599.Z.4.Í; A.600.z.4.i; A.601.z.4, i; A.602.Z.4.Í; A.603.z.4.i; A.604.z.4.i; A.605.Z.4.Í; A.606.z.4.i; A.607.z.4.i; A.608.z.4.i; A.609.Z.4.Í; A.610.z.4.i; A.611.z.4.i; A.612.z.4.i; A.613.z.4.i; A.614jz.4.í; A.615.Z.4.Í; A.616.Z.4.Í; A.617.z.4.i; A.618.z.4.i; A.619.Z.4.Í; A.620.Z.41 A.621.Z.4.I; A.622.Z.4.Í; A.623.Z.4.Í; A.624.Z.4.Í; A.625.z.4.i; A.626.z.4.i; A.627.Z.4.Í; A.628.z.4.i; A.629.z.4.i; A.630.Z.4.Í; A.631.z.4.i; A.632.z.4.i; A.633.z.4.i; A.634.z.4.i; A.635.z.4.i; A.636.Z.4.Í; A.637.Z.4.Í; A.638.z.4.i; A.639.Z.4.Í; A.640.z.4.i; A.641.z.4.i; A.642.z.4.i; A.643.Z.4.1; A.644.Z.4.Í; A.645.Z.4.Í; A.646.z.4.í; A.647.z.4.i; A.648.Z.4.Í; Α.649.Ζ.4.Ϊ; A.650.z.4.i; A.651.Z.4.Í; A.652.z.4.i; A.653.Z.4.Í; A.654.z.4.i; A.655.z.4.i; A, 656.z.4.i; A.657.Z.4.Í; A.658.Z.4.Í; A.659.Z.4.Í; A.660.Z.41 A.2.z.ll.i; A.3.z.ll.i; A.4.Z.11.Í; A.5.z.ll.i; A.6.Z.111 A.7.Z.11.Í; A.9.z.ll.i; A.lO.z.lLi; A.15.Z.111 A.lOO.z.111 A.101.z.ll.i; A.102.Z.11.Í; A.103.Z.11.Í; A.104.Z.11.Í; A.lOS.z.11 .i; A.106.Z.11.Í; A.107.z.ll.i; A.108.Z.11.Í; A.109.Z.11.Í; A.ll0.z.ll.i; A.lll.z.ll.i; A.112.z.ll.i; A.113.Z.U.Í; A.114.Z.11.Í; A.115.Z.11.Í; A.lló.z.U.i; A.117.Z.11.Í; A.118.z.ll.i; A.119.z.ll.i; A.120.Z.11.Í; A.121.Z.11.Í; A.122.Z.U.Í; A.123.z.ll.i; A.124.Z.11.Í; A, 125.z.U.i; A.126.Z.1H A.127.Z.111 A.128.Z.1LI; A.I29.Z.111 A.130.Z.U.I; A.131.z.ll.i; A.132.Z.11.Í; A.133.z.ll.i; A.134.z.ll.i; A.135.z.ll.i; A.136.z.ll.i; A.137.Z.11.Í; A.138.Z.11.Í; A.139.Z.11.Í; A.140.Z.11.Í; A.141, z.ll.i; A.142.Z.111 A.143.z.ll.i; A.144.Z.11.Í; A.145.Z.U.Í; A.146, z.ll.i ;: A.147, z.ll.i; A.148.Z.11.Í; A.149.Z.11.Í; A.150.Z.11.Í; A.lSl.z.ll.i; A.152.Z.U.Í; A.153.z.ll.i; A.154.Z.11.Í; A.155.z.ll.i; A.156.Z.11.Í; A.157.z.H.i; A.158.z.ll.i; A.159.z.U.i; A.160.Z.11.Í; A.161.z.ll.i; A.162.Z.11.Í; A.163.z.ll.i; A.164.z.ll.i; A.165.Z.11.Í; A.166.z.ll.i; A.167.z.ll.i; A.168.Z.11.Í; A.169.Z.11.Í; A.17O.Z.11.Í; A.171.Z.11.1; A.172.z.ll.i; Α.173.Ζ.111 A.174.Z.11.Í; A.175.z.ll.i; A.176.Z.11.Í; A.177.Z.11.Í; A.178.Z.11.Í; A.179.Z.11.Í; A.180.Z.11.Í; A.181.Z.11.Í; A.182.Z.11.Í; A.183.z.ll.i; A.184.z.ll.i; A.185.z.ll.i; A.186.Z.11.Í; Α.187.Ζ.11.Ϊ; A.188.Z.11.1; A.189.z.ll.i; A.19O.z.ll.i; A.191.z.ll.i; A.192.Z.111 A.193.Z.11.I; A.194.Z.11.1; A.195.z.ll.i; A.196.Z.11.Í; A.197.z.ll.i; A.198.Z.11.Í; A.199.Z.11.Í; A.200.z.ll.i; A.201.Z.11.Í; A.202.Z.11.Í; A.203.Z.11.Í; A.204.Z.11.Í; A.205.z.U.i; A.206.z.ll.i; A.207.Z.11.Í; A.208.z.U.i; A.209.z.ll.i; A.210.Z.11.Í; A.2Il.z.ll.i; A.212.Z.1I.Í; A.213.z.ll.i; A.214.Z.U.Í; A.215.z.ll.i; A.216.Z.11.Í; A.217.z.U.i; A.218.Z.11.Í; A.219.Z.111 A.220.Z.11.I; A.221.Z.11.1; A.222.Z.11.Í; A.223.Z.11.Í; A.224.z.ll.i; A.225.Z.111 A.226.z.ll.i; A.227.z.ll.i; A.228.Z.111 A.229.Z.U.I; A.230.z.ll.i; A.231.Z.11.Í; A.232.z.ll.i; A.233.Z.11.Í; A.234.Z.11.Í; A.235.z.ll.i; A.236.z.H.i; A.237.Z.11.Í; A.238.Z.11.Í; A.239.Z.11.Í;
-108CZ 297945 B6-108GB 297945 B6
A.240.Z.114; A.241.Z.114; A.242.Z.114; A.243.Z.114; A.244.Z.1U; A.245.Z.I14; A.246.Z.114; A.247.Z.114; A.248.Z.114; A.249.Z.114; A.250.Z.114; A.251.Z.114; A.252.Z.11 .i; A253.Z.114; A254.Z.114; A255.Z.114; A.256.Z.114; A.257.z.ll.í; A.258.Z.114; A.259.Z.114; A.260.Z.114; A.261.Z.114; A.262.Z.114; A.263.Z.114; A.264.Z.114; A.265.Z.114; A.266.Z.114; A.267.Z.114; A.268.Z.114; A.269.Z.114; A.270.Z.114; A.271.Z.114; A.272.Z.114; A.273.Z.114; A.274.Z.114; A275.Z.114; A.276.Z.114; A.277.Z.114; A.278.Z.114; A.279.Z.114; A.280.Z.114; A.281.Z.114; A.282.Z.114; A.283.Z.114; A.284.Z.114; A.285.Z.114; A.286.Z.114; A.287.Z.114; A.288.Z.114; A.289.Z.114; A.290.Z.114; A291.Z.114; A292.Z.114; A.293.Z.114; A.294.Z.114; A.295.Z.114; A.296.Z.114; A.297.Z.114; A.298.Z.114; A.299.Z.114; A.300.Z.114; A.301.Z.114; A.302.Z.114; A.303.Z.114; A.304.Z.114; A.305.Z.114; A.306.Z.114; A.307.Z.114; A.308.Z.114; A.309.Z.114; A.310.Z.114; A.311.Z.114; A.312.Z.114; A.313.Z.114; A.314.Z.114; A.315.Z.114; A.316.Z.11 .i; A.317.Z.114; A.318.Z.114; A.319.Z.114; A.320.Z.114; A.321.Z.114; A.323.Z.114; A.324.Z.114; A.325.Z.114; A.326.Z.114; A.327.Z.114; A.328.Z.114; A.329.Z.114; A.330.Z.114; Α.331.Ζ.11.Ϊ; A.332.Z.114; A.333.Z.114; A.334.Z.114;A.335.Z.114; A.336.Z.114; A.337.Z.114; A.338.Z.114; A.339.Z.114; A.340.Z.1I4; A.341.Z.114; A.342.Z.114; A.343.Z.114; A.344.Z.114; A.345.Z.114; A.346.Z.114; A.347.Z.114; A.348.Z.114; A.349.Z.114; A.350.Z.114; A.351.Z.114; A.352.Z.114; A.353.Z.114; A.354.Z.114; A-355.Z.114; A.356.Z.114; A.357.Z.114; A.358.Z.114; A.359.Z.114; A.360.Z.114; A.361.Z.114; A.362.Z.114; A.363.Z.114; A.364.Z.114; A.365.Z.114; A.366.Z.114; A.367.Z.114; A.368.Z.114; A.369.Z.114; A.370.Z.114; A.371.Z.114; A.372.Z.114; A.373.Z.114; A.374.Z.114; A.375.Z.114; A.376.Z.114; A.377.Z.114; A.378.Z.114; A.379.Z.114; A.380.Z.114; A.381.Z.114; A.382.Z.114; A.383.Z.114; A.384.Z.114; A.385.Z.114; A.386.Z.114; A.387.Z.114; A.388.Z.114; A.389.Z.114; A.390.Z.114; A.391.Z.114; A.392.Z.114; A.393.Z.114; A.394.Z.114; Α.395.Ζ.Π4; A.396.Z.114; A.397.Z.114; A.398.Z.114; A.399.Z.114; A.400.Z.114; A.401.Z.114; A.402.Z.114; A.403.Z.114; A.404.Z.114; A.405.Z.114; A.406.Z.114; A.407.Z.114; A.408.Z.114; A.409.Z.114; A.410.Z.114; A.411.Z.114; A.412.Z.114; A.413.Z.114; A.414.Z.114; A.415.Z.114; A.416.Z.114; A.417.Z.114; A.418.Z.114; A.419.Z.114; A.420.Z.114; A.421.Z.1I4; A.422.Z.114; A.423.Z.114; A.424.Z.114; A.425.Z.114; A.426.Z.114; A.427.Z.114; A.428.Z.114; A.429.Z.114; A.430.Z.114; A.431.Z.114; A.432.Z.H4; A.433.Z.114; A.434.Z.114; A.435.Z.114; A.436.Z.114; A.437.Z.114; A.438.Z.114; A.439.Z.114; A.440.Z.114; A.441.Z.114; A.442.Z.114; A.443.Z.114; A.444.Z.114; A.445.Z.114; A.446.Z.114; A.447.Z.114; A.448.Z.114; A.449.Z.114; A.450.Z.114; A.451.Z.114; A.452.Z.114; A.453.Z.114; A.454.Z.114; A.455.Z.114; A.456.Z.114; A.457.Z.114; A.458.Z.114; A.459.Z.114; A.460.Z.114; A.461.Z.114; A.462.Z.114; A.463.Z.114; A.464.Z.114; A.465.Z.114; A.466.Z.114; A.467.Z.114; A.468.Z.114; A.469.Z.114; A.470.Z.114; A.471.Z.114; A.472.Z.114; A.473.Z.114; A.474.Z.114; A.475.Z.114; A.476.Z.114; A.477.Z.114; A.478.Z.114; A.479.Z.114; A.480.Z.114; A.481.Z.114; A.482.Z.114; A.483.Z.114; A.484.Z.114; A.485.Z.114; A.486.Z.114; A.487.Z.114; A.488.Z.114; A.489.Z.114; A.490.Z.114; A.491.Z.114; A.492.Z.114; A.493.Z.114; A.494.Z.114; A.495.Z.1I4; A.496.Z.114; A.497.Z.114; A.498.Z.114; A.499.Z.U4; A.500.Z.114; A.501.Z.114; A.502.Z.114; A.503.Z.114; A.504.Z.114; A.505.Z.114; A.506.Z.114; A.507.Z.114; A.508.Z.114; A.509.Z.114; A.510.Z.114; A.511.Z.114; A.512.Z.114; A.512.Z.114; A.513.Z.114; A.514.Z.114; Α.515.Ζ.Π4; A.516.Z.114; A.517.Z.114; A.518.Z.114; A.519.Z.114; A.520.Z.114; A.521.Z.114;A.240.Z.114; A.241.Z.114; A.242.Z.114; A.243.Z.114; A.244.Z.1U; A.245.Z.I14; A.246.Z.114; A.247.Z.114; A.248.Z.114; A.249.Z.114; A.250.Z.114; A.251.Z.114; A.252.Z.11 .i; A253.Z.114; A254.Z.114; A255.Z.114; A.256.Z.114; A.257.z.ll.í; A.258.Z.114; A.259.Z.114; A.260.Z.114; A.261.Z.114; A.262.Z.114; A.263.Z.114; A.264.Z.114; A.265.Z.114; A.266.Z.114; A.267.Z.114; A.268.Z.114; A.269.Z.114; A.270.Z.114; A.271.Z.114; A.272.Z.114; A.273.Z.114; A.274.Z.114; A275.Z.114; A.276.Z.114; A.277.Z.114; A.278.Z.114; A.279.Z.114; A.280.Z.114; A.281.Z.114; A.282.Z.114; A.283.Z.114; A.284.Z.114; A.285.Z.114; A.286.Z.114; A.287.Z.114; A.288.Z.114; A.289.Z.114; A.290.Z.114; A291.Z.114; A292.Z.114; A.293.Z.114; A.294.Z.114; A.295.Z.114; A.296.Z.114; A.297.Z.114; A.298.Z.114; A.299.Z.114; A.300.Z.114; A.301.Z.114; A.302.Z.114; A.303.Z.114; A.304.Z.114; A.305.Z.114; A.306.Z.114; A.307.Z.114; A.308.Z.114; A.309.Z.114; A.310.Z.114; A.311.Z.114; A.312.Z.114; A.313.Z.114; A.314.Z.114; A.315.Z.114; A.316.Z.11 .i; A.317.Z.114; A.318.Z.114; A.319.Z.114; A.320.Z.114; A.321.Z.114; A.323.Z.114; A.324.Z.114; A.325.Z.114; A.326.Z.114; A.327.Z.114; A.328.Z.114; A.329.Z.114; A.330.Z.114; Α.331.Ζ.11.Ϊ; A.332.Z.114; A.333.Z.114; A.334.Z.114; A.335.Z.114; A.336.Z.114; A.337.Z.114; A.338.Z.114; A.339.Z.114; A.340.Z.1I4; A.341.Z.114; A.342.Z.114; A.343.Z.114; A.344.Z.114; A.345.Z.114; A.346.Z.114; A.347.Z.114; A.348.Z.114; A.349.Z.114; A.350.Z.114; A.351.Z.114; A.352.Z.114; A.353.Z.114; A.354.Z.114; A-355.Z. A.356.Z.114; A.357.Z.114; A.358.Z.114; A.359.Z.114; A.360.Z.114; A.361.Z.114; A.362.Z.114; A.363.Z.114; A.364.Z.114; A.365.Z.114; A.366.Z.114; A.367.Z.114; A.368.Z.114; A.369.Z.114; A.370.Z.114; A.371.Z.114; A.372.Z.114; A.373.Z.114; A.374.Z.114; A.375.Z.114; A.376.Z.114; A.377.Z.114; A.378.Z.114; A.379.Z.114; A.380.Z.114; A.381.Z.114; A.382.Z.114; A.383.Z.114; A.384.Z.114; A.385.Z.114; A.386.Z.114; A.387.Z.114; A.388.Z.114; A.389.Z.114; A.390.Z.114; A.391.Z.114; A.392.Z.114; A.393.Z.114; A.394.Z.114; Α.395.Ζ.Π4; A.396.Z.114; A.397.Z.114; A.398.Z.114; A.399.Z.114; A.400.Z.114; A.401.Z.114; A.402.Z.114; A.403.Z.114; A.404.Z.114; A.405.Z.114; A.406.Z.114; A.407.Z.114; A.408.Z.114; A.409.Z.114; A.410.Z.114; A.411.Z.114; A.412.Z.114; A.413.Z.114; A.414.Z.114; A.415.Z.114; A.416.Z.114; A.417.Z.114; A.418.Z.114; A.419.Z.114; A.420.Z.114; A.421.Z.1I4; A.422.Z.114; A.423.Z.114; A.424.Z.114; A.425.Z.114; A.426.Z.114; A.427.Z.114; A.428.Z.114; A.429.Z.114; A.430.Z.114; A.431.Z.114; A.432.Z.H4; A.433.Z.114; A.434.Z.114; A.435.Z.114; A.436.Z.114; A.437.Z.114; A.438.Z.114; A.439.Z.114; A.440.Z.114; A.441.Z.114; A.442.Z.114; A.443.Z.114; A.444.Z.114; A.445.Z.114; A.446.Z.114; A.447.Z.114; A.448.Z.114; A.449.Z.114; A.450.Z.114; A.451.Z.114; A.452.Z.114; A.453.Z.114; A.454.Z.114; A.455.Z.114; A.456.Z.114; A.457.Z.114; A.458.Z.114; A.459.Z.114; A.460.Z.114; A.461.Z.114; A.462.Z.114; A.463.Z.114; A.464.Z.114; A.465.Z.114; A.466.Z.114; A.467.Z.114; A.468.Z.114; A.469.Z.114; A.470.Z.114; A.471.Z.114; A.472.Z.114; A.473.Z.114; A.474.Z.114; A.475.Z.114; A.476.Z.114; A.477.Z.114; A.478.Z.114; A.479.Z.114; A.480.Z.114; A.481.Z.114; A.482.Z.114; A.483.Z.114; A.484.Z.114; A.485.Z.114; A.486.Z.114; A.487.Z.114; A.488.Z.114; A.489.Z.114; A.490.Z.114; A.491.Z.114; A.492.Z.114; A.493.Z.114; A.494.Z.114; A.495.Z.1I4; A.496.Z.114; A.497.Z.114; A.498.Z.114; A.499.Z.U4; A.500.Z.114; A.501.Z.114; A.502.Z.114; A.503.Z.114; A.504.Z.114; A.505.Z.114; A.506.Z.114; A.507.Z.114; A.508.Z.114; A.509.Z.114; A.510.Z.114; A.511.Z.114; A.512.Z.114; A.512.Z.114; A.513.Z.114; A.514.Z.114; Α.515.Ζ.Π4; A.516.Z.114; A.517.Z.114; A.518.Z.114; A.519.Z.114; A.520.Z.114; A.521.Z.114;
-109CZ 297945 B6-109GB 297945 B6
A.522.Z.11.Í; A.523.Z.11.Í; A.524.Z.11.Í; A.525.Z.11.Í; A.526.Z.11.Í; A527.Z.11.Í; A.528.z.ll.i; A.529.Z.11.Í; A.530.z.ll.i; A.531.Z.11.Í; A.532,z.ll.i; A.533.Z.U.Í; A.534.Z.11.Í; A.535.z.ll.i; A.536.Z.11.Í; A.537.Z.11.Í; A.538.Z.11.Í; A.539.z.U.i; A.540.Z.11.Í; Α.541.Ζ.11Λ; A.542.Z.1U A.543.Z.11.Í; A.544.z.ll.i; A.545.Z.11.Í; A.546.Z.U.Í; A.547.Z.11.Í; A.548.Z.11.Í; A.549.Z.11.Í; A.550.z.ll.i; A.551.Z.11.Í; A.552.Z.11.Í; A.553.Z.11.Í; A.554.Z.11.Í; A.555.Z.1LÍ; A.556.Z.11.Í; A.557.Z.11.Í; A.558.Z.11J; A.559.z.ll.i; A.560.Z.1U; A.561.z.ll.i; A.562.Z.11.Í; A.563.Z.11.Í; A.564.Z.11.Í; A.565.z.ll.i; A.566.z.ll.i; A.567.Z.11.Í; A.568.Z.11.Í; A.569.Z.11.Í; A.570.Z.1U; A.571.z.ll.i; A.572.z.ll.i; A.573.Z.11.Í; A.574.Z.11.Í; A.575.Z.11.Í; A.576.Z.11.Í; A.577.z.ll.i; A.578.Z.11.Í; A.579.z.ll.i; A.580.z.ll.i; A.581.Z.11.Í; A.582.Z.11.Í; A.583.z.ll.i; A.584.z.ll.i; A585.z.ll.i; A.586.Z.11.Í; A.587.Z.11.Í; A.588.z.ll.i; A.589.z.U.i; A.590.z.ll.i; A.591.z.ll.i; A.592.Z.11.Í; A.593.Z.11.Í; A.594.Z.11 j; A.595.z.ll.i; A.596.Z.11.Í; A.597.Z.11.Í; A.598.Z.11.Í; A599.z.ll.i; A.600.Z.11.Í; A.601.Z.11.Í; A.602.z.ll.i; A.603.Z.1U; A.604.Z.11.Í; Α.605.Ζ.1Π; A.606.Z.11.Í; A.607.Z.11.Í; A.608.z.ll.i; A.609.Z.11.Í; A.610.z.ll.i; A.611.Z.11.Í; A.612.Z.11.Í; A.613.Z.11.Í; A.614.Z.11.Í; A.615.Z.11.Í; A.616.z.ll.i; A.617.z.ll.i; A.618.Z.11.Í; A.619.z.ll.i; A.620.Z.U.Í; A.621.Z.11.Í; A.622.Z.11.Í; A.623.Z.11.Í; A.624.z.ll.i; A.625.z.U.i; A.626.Z.1I.Í; A.627.Z.1U; A.628.z.ll.i; A.629.z.ll.i; A.630.Z.11.Í; A.631.z.ll.i; Α.632.Ζ.11.1; A.633.Z.U.Í; A.634.Z.11.Í; A.635.Z.11.Í; A.636.Z.11.Í; A.637.Z.11.Í; A.638.z.ll.i; A.639.Z.11.Í; A.640.Z.11.Í; A.641.Z.1Ú; A.642.Z.11.Í; A.643.z.ll.i; A.644.z.ll.i; A.645.z.ll.i; A.646.z.ll.i; A.647.z.ll.i; A.648.Z.11.Í; A.649.z.ll.i; A.650.z.ll.i; A.651.Z.11.Í; A.652.Z.11.Í; A.653.Z.114; A.654.Z.11.i; A.655.z.ll.i; Α.656.Ζ.11.Ϊ; A.657.z.ll.i; A.658.Z.11.Í; A.659.z.ll.i; A.660.Z.11.Í; A.2.A.4.Í; A.3.A.4.1; A.4.A.4.Í; A.5.A.4.Í; A.6.A.4.1; A.7.A.4.Í; A.9.A.4.Í; A.10.A.4.Í; A.15.A.4.Í; A.100.A.4.Í; A.101.A.4.Í; A.102.A.4.Í; A.103.A.4.Í; Α.104.Α.4.Ϊ; A.105.A.4.Í; A.106.A.4.Í; A.107.A.4.Í; A.108.A.4.Í; A.109.A.4.Í; A.110.A.4.Í; A.111.A.4.Í; A.112.A.4.Í; A.113.A.4.Í; A.114.A.4.Í; A.115.A.4.Í; A.116.A.4.Í; A.117.A.4.Í; A.118.A.4.Í; A.119.A.4.Í; A.120.A.4.Í; A.121.A.4.Í; A.122.A.4.Í; A.123.A.4.Í; A.124.A.4.Í; A.125.A.4.Í; A.126.A.4.Í; A.127.A.4.Í; A.128.A.4.Í; A.129.A.4.Í; A.130.A.4.Í; A.131.A.4.Í; A.132.A.4.Í; A.133.A.4.Í; A.134.A.4.i; A.135.A.4.Í; A.136.A.4.Í; A.137.A.4.Í; A.138.A.4.Í; A.139.A.4.Í; A.140.A.4.Í; A.141.A.4.Í; A.142.A.4.Í; A.143.A.4.Í; A.144.A.4.Í; Α.145.Α.4.Ϊ; A.146.A.4.Í; A.147.A.4.Í; A.148.A.4.Í; A.149.A.4.Í; A.150.A.4.Í; A.151.A.4.Í; A.152.A.4.Í; A.153.A.4.Í; A.154.A.4.Í; A.155.A.4.Í; A.156.A.4.Í; A.157.A.4.Í; A.158.A.4.Í; A.159.A.4.Í; A.160.A.4.Í; A.161.A.4.Í; A.162.A.4.Í; Α.163.Α.4.Ϊ; A.164.A.4.Í; A.165.A.4.Í; A.166.A.4.Í; A.167.A.4.Í; A.168.A.4.Í; A.169.A.4.Í; A.170.A.4.Í; A.171.A.4.i; A.172.A.4.Í; A.173.A.4.Í; A.174.A.4.Í; A.175.A.4.Í; A.176.A.4.Í; A.177.A.4.Í; A.178.A.4.Í; A.179.A.4.Í; A.180.A.4.Í; A.181.A.4.Í; A.182.A.4.Í; A.183.A.4.Í; Α.184.Α.4.Ϊ; A.185.A.4.Í; A.186.A.4.Í; A.187.A.4.Í; A.188.A.4.Í; A.189.A.4.Í; A.190.A.4.Í; A.191.A.4.Í; A.192.A.4.Í; A.193.A.4.Í; A.194.A.4.Í; A.195.A.4.Í; A.196.A.4.Í; A.197.A.4.Í; A.198.A.4.Í; Α.199.Α.4.Ϊ; A.200.A.4.Í; A.201.A.4.Í; A.202.A.4.Í; A.203.A.4.Í; A.204.A.4.Í; A.205.A.4.Í; A.206.A.4.1; A.207.A.4.Í; A.208.A.4.Í; A.209.A.4.Í; A.210.A.4.Í; Α.211.Α.4.Ϊ; A.212.A.4.Í; A.213.A.4.Í; A.214.A.4.Í; A.215.A.4.Í; A.216.A.4.Í; A.217.A.4.Í; A.218.A.4.Í; A.219.A.4.Í; A.220.A.4.Í; A.221.A.4.Í; A.222.A.4.Í; A.223.A.4.Í; A.224.A.4.Í; A.225.A.4.Í; A.226.A.4,i; A.227.A.4.Í; A.22S.A.4.Í; A.229.A.4.Í; A.230.A.4.Í; A.231.A.4.Í; A.232.A.4.Í; A.233.A.4.i; A.234.A.4.j;A.522.Z.11.Í; A.523.Z.11.Í; A.524.Z.11.Í; A.525.Z.11.Í; A.526.Z.11.Í; A527.Z.11.Í; A.528.z.ll.i; A.529.Z.11.Í; A.530.z.ll.i; A.531.Z.11.Í; A.532, z.111; A.533.Z.U.Í; A.534.Z.11.Í; A.535.z.ll.i; A.536.Z.11.Í; A.537.Z.11.Í; A.538.Z.11.Í; A.539.z.U.i; A.540.Z.11.Í; Α.541.Ζ.11Λ; A.542.Z.1U A.543.Z.11.I; A.544.z.ll.i; A.545.Z.11.Í; A.546.Z.U.Í; A.547.Z.11.Í; A.548.Z.11.Í; A.549.Z.11.Í; A.550.z.ll.i; A.551.Z.11.Í; A.552.Z.11.Í; A.553.Z.11.Í; A.554.Z.11.Í; A.555.Z.1LÍ; A.556.Z.11.Í; A.557.Z.11.Í; A.558.Z.11J; A.559.z.ll.i; A.560.Z.1U; A.561.z.ll.i; A.562.Z.11.Í; A.563.Z.11.Í; A.564.Z.11.Í; A.565.z.ll.i; A.566.z.ll.i; A.567.Z.11.Í; A.568.Z.11.Í; A.569.Z.11.Í; A.570.Z.1U; A.571.z.ll.i; A.572.z.ll.i; A.573.Z.11.Í; A.574.Z.11.Í; A.575.Z.11.Í; A.576.Z.11.Í; A.577.z.ll.i; A.578.Z.11.Í; A.579.z.ll.i; A.580.z.ll.i; A.581.Z.11.Í; A.582.Z.11.Í; A.583.z.ll.i; A.584.z.ll.i; A585.z.ll.i; A.586.Z.11.Í; A.587.Z.11.Í; A.588.z.ll.i; A.589.z.U.i; A.590.z.ll.i; A.591.z.ll.i; A.592.Z.11.Í; A.593.Z.11.Í; A.594.Z.11 j; A.595.z.ll.i; A.596.Z.11.Í; A.597.Z.11.Í; A.598.Z.11.Í; A599.z.ll.i; A.600.Z.11.Í; A.601.Z.11.Í; A.602.z.ll.i; A.603.Z.1U; A.604.Z.11.Í; Α.605.Ζ.1Π; A.606.Z.11.Í; A.607.Z.11.Í; A.608.z.ll.i; A.609.Z.11.Í; A.610.z.ll.i; A.611.Z.11.Í; A.612.Z.11.Í; A.613.Z.11.Í; A.614.Z.11.Í; A.615.Z.11.Í; A.616.z.ll.i; A.617.z.ll.i; A.618.Z.11.Í; A.619.z.ll.i; A.620.Z.U.Í; A.621.Z.11.Í; A.622.Z.11.Í; A.623.Z.11.Í; A.624.z.ll.i; A.625.z.U.i; A.626.Z.1I.Í; A.627.Z.1U; A.628.z.ll.i; A.629.z.ll.i; A.630.Z.11.Í; A.631.z.ll.i; Α.632.Ζ.11.1; A.633.Z.U.Í; A.634.Z.11.Í; A.635.Z.11.Í; A.636.Z.11.Í; A.637.Z.11.Í; A.638.z.ll.i; A.639.Z.11.Í; A.640.Z.11.Í; A.641.Z.1Ú; A.642.Z.11.Í; A.643.z.ll.i; A.644.z.ll.i; A.645.z.ll.i; A.646.z.ll.i; A.647.z.ll.i; A.648.Z.11.Í; A.649.z.ll.i; A.650.z.ll.i; A.651.Z.11.Í; A.652.Z.11.Í; A.653.Z.114; A.654.Z.11.i; A.655.z.ll.i; Α.656.Ζ.11.Ϊ; A.657.z.ll.i; A.658.Z.11.Í; A.659.z.ll.i; A.660.Z.11.Í; A.2.A.4.I; A.3.A.4.1; A.4.A.4.Í; A.5.A.4.I; A.6.A.4.1; A.7.A.4.I; A.9.A.4.I; A.10.A.4.Í; A.15.A.4.Í; A.100.A.4.I; A.101.A.4.I; A.102.A.4.Í; A.103.A.4.Í; Α.104.Α.4.Ϊ; A.105.A.4.Í; A.106.A.4.Í; A.107.A.4.Í; A.108.A.4.Í; A.109.A.4.Í; A.110.A.4.I; A.111.A.4.Í; A.112.A.4.I; A.113.A.4.Í; A.114.A.4.Í; A.115.A.4.Í; A.116.A.4.Í; A.117.A.4.Í; A.118.A.4.Í; A.119.A.4.Í; A.120.A.4.I; A.121.A.4.Í; A.122.A.4.Í; A.123.A.4.Í; A.124.A.4.Í; A.125.A.4.Í; A.126.A.4.Í; A.127.A.4.Í; A.128.A.4.Í; A.129.A.4.Í; A.130.A.4.I; A.131.A.4.I; A.132.A.4.I; A.133.A.4.I; A.134.A.4.i; A.135.A.4.I; A.136.A.4.Í; A.137.A.4.I; A.138.A.4.I; A.139.A.4.I; A.140.A.4.I; A.141.A.4.I; A.142.A.4.I; A.143.A.4.I; A.144.A.4.I; Α.145.Α.4.Ϊ; A.146.A.4.I; A.147.A.4.I; A.148.A.4.I; A.149.A.4.Í; A.150.A.4.I; A.151.A.4.I; A.152.A.4.Í; A.153.A.4.I; A.154.A.4.Í; A.155.A.4.I; A.156.A.4.I; A.157.A.4.Í; A.158.A.4.I; A.159.A.4.Í; A.160.A.4.Í; A.161.A.4.I; A.162.A.4.Í; Α.163.Α.4.Ϊ; A.164.A.4.Í; A.165.A.4.I; A.166.A.4.I; A.167.A.4.Í; A.168.A.4.I; A.169.A.4.Í; A.170.A.4.I; A.171.A.4.i; A.172.A.4.I; A.173.A.4.I; A.174.A.4.I; A.175.A.4.I; A.176.A.4.I; A.177.A.4.I; A.178.A.4.I; A.179.A.4.Í; A.180.A.4.Í; A.181.A.4.I; A.182.A.4.I; A.183.A.4.I; Α.184.Α.4.Ϊ; A.185.A.4.I; A.186.A.4.I; A.187.A.4.I; A.188.A.4.Í; A.189.A.4.Í; A.190.A.4.Í; A.191.A.4.Í; A.192.A.4.I; A.193.A.4.I; A.194.A.4.I; A.195.A.4.Í; A.196.A.4.Í; A.197.A.4.Í; A.198.A.4.Í; Α.199.Α.4.Ϊ; A.200.A.4.Í; A.201.A.4.Í; A.202.A.4.Í; A.203.A.4.Í; A.204.A.4.Í; A.205.A.4.Í; A.206.A.4.1; A.207.A.4.Í; A.208.A.4.Í; A.209.A.4.Í; A.210.A.4.I; Α.211.Α.4.Ϊ; A.212.A.4.I; A.213.A.4.I; A.214.A.4.I; A.215.A.4.I; A.216.A.4.Í; A.217.A.4.Í; A.218.A.4.I; A.219.A.4.Í; A.220.A.4.I; A.221.A.4.I; A.222.A.4.I; A.223.A.4.I; A.224.A.4.I; A.225.A.4.I; A.226.A.4., I; A.227.A.4.I; A.22S.A.4.I; A.229.A.4.I; A.230.A.4.I; A.231.A.4.I; A.232.A.4.I; A.233.A.4.i; A.234.A.4.j;
-110CZ 297945 B6-110GB 297945 B6
A235.A.4.Í; A.236.A.4.Í; Α.237.Α.4.Ϊ; A.241.A.4.Í; A.242.A.4.Í; A.243.A.4.Í; A.247.A.4.Í; A.248.A.4.1; A.249.A.4.Í; A253.A.4.Í; A.254.A.4.Í; A.255.A.4.Í; A259.A.4.Í; A.260.A.4.Í; A.261.A.4.Í; A.265.A.4.Í; Α.266.Α.4.Ϊ; A.267.A.4.Í; A.271.A.4.Í; A.272.A.4.Í; A.273.A.4.Í; A277.A.4.Í; A.278.A.4.Í; A.279.A.4.Í; A283.A.4.Í; A284.A.4.Í; A.285.A.4.Í; A289.A.4.Í; A290.A.4.Í; A.291.A.4.Í; Α295.Α.4.Ϊ; A.296.A.4.Í; A.297.A.4.Í; A.301.A.4.Í; A.302.A.4.Í; A.303.A.4.Í; A.307.A.4.Í; A.308.A.4.Í; A.309.A.4.Í; A.313.A.4.Í; A.314.A.4.Í; A.315.A.4.Í; A.319.A.4.i; A.320.A.4.Í; A.321.A.4.Í; A.326.A.4.Í; A.327.A.4.Í; A.328.A.4.Í; A.332.A.4.Í; A.333.A.4.Í; A.334.A.4.Í; A.338.A.4.Í; A.339.A.4.Í; A.340.A.4.Í; A.344.A.4.Í; Α.345.Α.4.Ϊ; A.346.A.4.i; A.350.A.4.Í; A.351.A.4.Í; A.352.A.4.Í; A.356.A.4.Í; A.357.A.4.Í; A.358.A.4.Í; A.362.A.4.Í; A.363.A.4.Í; A.364.A.4.Í; A.368.A.4.Í; A.369.A.4.Í; A.370.A.4.I; A.374.A.4.Í; A.375.A.4.Í; A.376.A.4.Í; A.380.A.4.Í; A.381.A.4.Í; A.382.A.4.Í; A.386.A.4.Í; A.387.A.4.Í; Α.388.Α.4.Ϊ; A.392.A.4J; A.393.A.4.Í; A.394.A.4.Í; A.398.A.4.Í; A.399.A.4.Í; A.400.A.4.Í; A.404.A.4.Í; A.405.A.4.Í; A.406.A.44; A.410.A.4.Í; A.411.A.4.Í; A.412.A.4.Í; A.416.A.4.Í; A.417.A.4.Í; A.418.A.4.Í; A.422.A.4.Í; A.423.A.4.1; A.424.A.4.Í; A.428.A.4.Í; A.429.A.4.Í; A.430.A.4.Í; A.434.A.4.Í; A.435.A.4.Í; A.436.A.4.Í; A.440.A.4.Í; Α.441.Α.4.Ϊ; A.442.A.4.Í; A.446.A.4.Í; A.447.A.4.Í; Α.448.Α.4.Ϊ; A.452.A.4.Í; A.453.A.4.Í; A.454.A.4.Í; A.45S.A.4.Í; A.459.A.4.Í; A.460.A.4.Í; A.464.A.4.Í; A.465.A.4.Í; A.466.A.4.Í; A.470.A.4.Í; A.471.A.4.1; A.472.A.4.Í; A.476.A.4.Í; A.477.A.4.i; A.478.A.4.Í; A.482.A.4.Í; A.483.A.4.Í; A.484.A.4.Í; A.488.A.4.Í; A.489.A.4.Í; Α.490.Α.4.Ϊ; A.494.A.4.Í; A.495.A.4.Í; A.496.A.4.Í; A.500.A.4.Í; A.501.A.4.1; A.502.A.4.Í; A.506.A.4.Í; A.507.A.4.Í; A.508.A.4.Í; A.512.A.4.Í; A.512.A.4.Í; A.513.A.4.Í;A235.A.4.I; A.236.A.4.Í; Α.237.Α.4.Ϊ; A.241.A.4.I; A.242.A.4.I; A.243.A.4.I; A.247.A.4.I; A.248.A.4.1; A.249.A.4.I; A253.A.4.I; A.254.A.4.Í; A.255.A.4.I; A259.A.4.Í; A.260.A.4.Í; A.261.A.4.I; A.265.A.4.I; Α.266.Α.4.Ϊ; A.267.A.4.Í; A.271.A.4.I; A.272.A.4.I; A.273.A.4.I; A277.A.4.I; A.278.A.4.I; A.279.A.4.I; A283.A.4.I; A284.A.4.Í; A.285.A.4.I; A289.A.4.Í; A290.A.4.I; A.291.A.4.Í; Α295.Α.4.Ϊ; A.296.A.4.I; A.297.A.4.Í; A.301.A.4.I; A.302.A.4.I; A.303.A.4.I; A.307.A.4.Í; A.308.A.4.Í; A.309.A.4.Í; A.313.A.4.Í; A.314.A.4.I; A.315.A.4.I; A.319.A.4.i; A.320.A.4.I; A.321.A.4.I; A.326.A.4.Í; A.327.A.4.Í; A.328.A.4.Í; A.332.A.4.I; A.333.A.4.Í; A.334.A.4.Í; A.338.A.4.Í; A.339.A.4.Í; A.340.A.4.Í; A.344.A.4.I; Α.345.Α.4.Ϊ; A.346.A.4.i; A.350.A.4.I; A.351.A.4.Í; A.352.A.4.Í; A.356.A.4.Í; A.357.A.4.Í; A.358.A.4.I; A.362.A.4.Í; A.363.A.4.Í; A.364.A.4.Í; A.368.A.4.I; A.369.A.4.Í; A.370.A.4.I; A.374.A.4.I; A.375.A.4.Í; A.376.A.4.Í; A.380.A.4.Í; A.381.A.4.Í; A.382.A.4.Í; A.386.A.4.I; A.387.A.4.Í; Α.388.Α.4.Ϊ; A.392.A.4J; A.393.A.4.I; A.394.A.4.Í; A.398.A.4.Í; A.399.A.4.Í; A.400.A.4.Í; A.404.A.4.I; A.405.A.4.Í; A.406.A.44; A.410.A.4.Í; A.411.A.4.Í; A.412.A.4.Í; A.416.A.4.Í; A.417.A.4.Í; A.418.A.4.Í; A.422.A.4.Í; A.423.A.4.1; A.424.A.4.Í; A.428.A.4.Í; A.429.A.4.Í; A.430.A.4.Í; A.434.A.4.Í; A.435.A.4.Í; A.436.A.4.Í; A.440.A.4.Í; Α.441.Α.4.Ϊ; A.442.A.4.Í; A.446.A.4.Í; A.447.A.4.Í; Α.448.Α.4.Ϊ; A.452.A.4.Í; A.453.A.4.Í; A.454.A.4.Í; A.45S.A.4.I; A.459.A.4.Í; A.460.A.4.Í; A.464.A.4.Í; A.465.A.4.Í; A.466.A.4.Í; A.470.A.4.Í; A.471.A.4.1; A.472.A.4.Í; A.476.A.4.Í; A.477.A.4.i; A.478.A.4.Í; A.482.A.4.Í; A.483.A.4.Í; A.484.A.4.Í; A.488.A.4.Í; A.489.A.4.Í; Α.490.Α.4.Ϊ; A.494.A.4.Í; A.495.A.4.Í; A.496.A.4.Í; A.500.A.4.I; A.501.A.4.1; A.502.A.4.I; A.506.A.4.I; A.507.A.4.I; A.508.A.4.I; A.512.A.4.I; A.512.A.4.I; A.513.A.4.I;
A.238.A.4.Í; A.239.A.4.Í; A.240.A.4.Í; A.244.A.4.Í; A.245.A.4.Í; A.246.A.4.Í; Α.250.Α.4.Ϊ; A251.A.4.Í; A.252.A.4.Í; A.256.A.4.Í; A.257.A.4.Í; A.258.A.4.Í; A.262.A.4.Í; A.263.A.4.Í; Α.264.Α.4.Ϊ; Α.268.Α.4.Ϊ; A.269.A.4.Í; A.270.A.4.Í; A274.A.4.Í; A275.A.4.Í; A.276.A.4.Í; A.280.A.4.Í; A.281.A.4.Í; A.282.A.4.Í; A.286.A.4.Í; A.287.A.4.Í; A.288.A.4.Í; A.292.A.4.Í; A.293.A.4.Í; A.294.A.4.Í; A.298.A.4.Í; A.299.A.4.Í; A.300.A.4.Í; A.304.A.4.Í; A.305.A.4.Í; A.306.A.4.Í; A.310.A.4Ť; A.311.A.4.Í; A.312.A.44; A.316.A.4.Í; A.317.A.4.Í; A.318.A.4.Í; A.323,A.4.i; A.324.A.4.Í; A.325.A.4.Í; A.329.A.4.Í; A.330.A.4.Í; A.331.A.4.Í; A.335.A.4.Í; A.336.A.4.Í; A.337.A.4.Í; A.341.A.4.Í; A.342.A.4.Í; A.343.A.4.Í; A.347.A.4.Í; A.348.A.4.Í; A.349.A.4.Í; A.353.A.4.Í; A.354.A.4.Í; A.355.A.4.Í; A.359.A.4.Í; A.360.A.4.Í; A.361.A.4.Í; A.365.A.4.i; A.366.A.4.Í; A.367.A.4.Í; A371.A.44; A.372.A.4.Í; A.373.A.4.Í; A.377.A.4.Í; A.378.A.4.Í; A.379.A.4.Í; A.383.A.4.Í; A.384.A.4.Í; A.385.A.4.Í; A.389.A.4.Í; A.390.A.4.Í; A.391.A.4.Í; A.395.A.4.Í; A.396.A.4.Í; A.397.A.4.Í; A.401.A.4.Í; A.402.A.4.Í; A.403.A.4.Í; A.407.A.4.Í; A.408.A.4.Í; A.409.A.4.Í; A.413.A.4.Í; A.414.A.4.Í; A.415.A.4.Í; A.419.A.4.Í; A.420.A.4.Í; A.421.A.4.Í; A.425.A.4.Í; A.426.A.4.Í; A.427.A.4.Í; A.431.A.4.Í; A.432.A.4.Í; A.433.A.4.Í; A.437.A.4.Í; A.438.A.4.Í; A.439.A.4.i; A.443.A.4.Í; A.444.A.4.Í; A.445.A.4.Í; A.449.A.4.Í; A.450.A.4.Í; A.451.A.4.Í; A.455.A.4.Í; A.456.A.4.Í; A.457.A.4.Í; A.461.A.4.Í; A.462.A.4.Í; A.463.A.4.Í; A.467.A.4.Í; A.468.A.4.Í; A.469.A.4.Í; A.473.A.4.Í; A.474.A.4.Í; A.475.A.4.Í; A.479.A.4.Í; A.480.A.4.Í; A.481.A.4.Í; A.485.A.4.Í; A.486.A.4.Í; A.487.A.4.Í; A.49LA.4.Í; A.492.A.4.Í; A.493.A.4.Í; A.497.A.4.Í; A.498.A.4.Í; Α.499.Α.4.Ϊ; A.503.A.4.Í; A.504.A.4.i; A.505.A.4.Í; A.509.A.4.Í; A.510.A.4.Í; A.511.A.4.Í; A.514.A.4.Í; A.515.A.44; A.516.A.4.Í;A.238.A.4.I; A.239.A.4.I; A.240.A.4.I; A.244.A.4.I; A.245.A.4.I; A.246.A.4.I; Α.250.Α.4.Ϊ; A251.A.4.Í; A.252.A.4.Í; A.256.A.4.I; A.257.A.4.Í; A.258.A.4.I; A.262.A.4.Í; A.263.A.4.I; Α.264.Α.4.Ϊ; Α.268.Α.4.Ϊ; A.269.A.4.Í; A.270.A.4.I; A274.A.4.I; A275.A.4.I; A.276.A.4.I; A.280.A.4.Í; A.281.A.4.I; A.282.A.4.Í; A.286.A.4.I; A.287.A.4.Í; A.288.A.4.I; A.292.A.4.I; A.293.A.4.I; A.294.A.4.I; A.298.A.4.Í; A.299.A.4.Í; A.300.A.4.I; A.304.A.4.I; A.305.A.4.Í; A.306.A.4.Í; A.310.A.4. A.311.A.4.I; A.312.A.44; A.316.A.4.Í; A.317.A.4.Í; A.318.A.4.Í; A.323, A.4.i; A.324.A.4.I; A.325.A.4.Í; A.329.A.4.I; A.330.A.4.I; A.331.A.4.I; A.335.A.4.Í; A.336.A.4.Í; A.337.A.4.Í; A.341.A.4.Í; A.342.A.4.I; A.343.A.4.I; A.347.A.4.Í; A.348.A.4.I; A.349.A.4.Í; A.353.A.4.Í; A.354.A.4.Í; A.355.A.4.I; A.359.A.4.Í; A.360.A.4.Í; A.361.A.4.Í; A.365.A.4.i; A.366.A.4.Í; A.367.A.4.Í; A371.A.44; A.372.A.4.I; A.373.A.4.I; A.377.A.4.Í; A.378.A.4.I; A.379.A.4.Í; A.383.A.4.Í; A.384.A.4.Í; A.385.A.4.Í; A.389.A.4.Í; A.390.A.4.Í; A.391.A.4.Í; A.395.A.4.Í; A.396.A.4.Í; A.397.A.4.Í; A.401.A.4.Í; A.402.A.4.I; A.403.A.4.I; A.407.A.4.I; A.408.A.4.I; A.409.A.4.I; A.413.A.4.Í; A.414.A.4.Í; A.415.A.4.Í; A.419.A.4.Í; A.420.A.4.Í; A.421.A.4.Í; A.425.A.4.Í; A.426.A.4.Í; A.427.A.4.Í; A.431.A.4.Í; A.432.A.4.Í; A.433.A.4.Í; A.437.A.4.Í; A.438.A.4.Í; A.439.A.4.i; A.443.A.4.Í; A.444.A.4.Í; A.445.A.4.Í; A.449.A.4.Í; A.450.A.4.Í; A.451.A.4.Í; A.455.A.4.Í; A.456.A.4.Í; A.457.A.4.Í; A.461.A.4.Í; A.462.A.4.Í; A.463.A.4.Í; A.467.A.4.Í; A.468.A.4.Í; A.469.A.4.Í; A.473.A.4.Í; A.474.A.4.Í; A.475.A.4.Í; A.479.A.4.Í; A.480.A.4.Í; A.481.A.4.Í; A.485.A.4.Í; A.486.A.4.Í; A.487.A.4.Í; A.49LA.4.Í; A.492.A.4.Í; A.493.A.4.Í; A.497.A.4.Í; A.498.A.4.Í; Α.499.Α.4.Ϊ; A.503.A.4.I; A.504.A.4.i; A.505.A.4.Í; A.509.A.4.Í; A.510.A.4.I; A.511.A.4.I; A.514.A.4.I; A.515.A.44; A.516.A.4.I;
-111 CZ 297945 B6-111 GB 297945 B6
A.517.A.4.Í; A.518.A.4.Í; A.519.A.4.Í; A.520.A.4.Í; A.521.A.4.Í; A.522.A.4.Í; A.523.A.4.i; A.524.A.4.Í; A.525.A.4.Í; A.526.A.4.Í; A.527.A.4.Í; A.528.A.4.Í; A.529.A.4.Í; A.530.A.4.Í; A.531.A.4J; A.532.A.4.Í; A.533. A.4. i; A.534.A.4.Í; A.535.A.4.i; A.536.A.4.Í; A.537.A.4.Í; A.538.A.4.Í; A.539.A.4.Í; A.540.A.4.Í; A.541.A.4.Í; A.542.A.4.Í; A.543.A.4.Í; A.544.A.4.Í; A.545.A.4.Í; A.546.A.4.Í; A.547.A.4.Í; A.548.A.4.Í; A.549.A.4.Í; A.550.A.4.1; A.551.A.4.Í; A.552.A.4.Í; Α-553.Α.4.Ϊ; A.554.A.4.Í; A.555.A.4.Í; A.556.A.4.Í; A.557.A.4.Í; A.558.A.4.Í; A-559.A.4.Í; A.560.A.4.Í; A.561.A.4.Í; A.562.A.4.Í; A.563.A.4.Í; A.564.A.4.Í; A.565.A.4.Í; A.566.A.4.Í; A.567.A.4.Í; A.568.A.4.Í; A.569.A.4.Í; A.570.A.4.Í; A571.A.4.Í; A.572.A.4.Í; A.573.A.4.Í; A.574.A.44; A.575.A.44; A.576.A.4.Í; AJ77.A.4.Í; A.578.A.4.Í; A.579.A.4.Í; A.580.A.4.Í; A.581.A.4.Í; A.582.A.4.Í; A.583.A.4.Í; A.584.A.4.Í; A.585.A.4.Í; A.586.A.4.Í; A.587.A.4.Í; A.588.A.4.Í; A.589.A.4.Í; A.590.A.4.i; A.591.A.4.Í; A.592.A.4.Í; A.593.A.4.Í; A.594.A.4.Í; A.595.A.4.Í; A.596.A.4.Í; A.597.A.4.Í; Α.598.Α.4.Ϊ; A.599.A.4.Í; A.600.A.4.Í; A.601.A.4.Í; A.602.A.4.Í; A.603.A.4.Í; A.604.A.4.Í; A.605.A.4J; A.606.A.4.Í; A.607.A.4.Í; A.608.A.4.Í; A.609.A.4.Í; A.610.A.4.Í; A.611.A.4.Í; A.612.A.4.Í; A.613.A.4.Í; A.614.A.4.Í; A.615.A.4.Í; A.616.A.4.Í; A.617.A.4.Í; A.618.A.4.Í; A.619.A.4.Í; A.620.A.4.Í; A.621.A.4.Í; Α.622.Α.4.Ϊ; A.623.A.4.Í; A.624.A.4.Í; A.625.A.4.:; A.626.A.4.Í; A.627.A.4.1; A.628.A.4.Í; A.629.A.4.Í; Α.630.Α.4.Ϊ; A.631.A.4.Í; A.632.A.4.Í; Α.633.Α.4.Ϊ; A.634.A.4.Í; A.635.A.4.Í; A.636.A.4.Í; A.637.A.4.Í; A.638.A.4.Í; A.639.A.4.1; A.640.A.4.Í; A.641.A.4.Í; A.642.A.4.Í; A.643.A.4.Í; A.644.A.4.Í; A.645.A.4.Í; Α.646.Α.4.Ϊ; A.647.A.4.Í; A.648.A.4.Í; A.649.A.4.Í; A.650.A.4.Í; A.651.A.4.Í; A.652.A.4.Í; A.653.A.4.Í; A.654.A.4.Í; A.655.A.4.Í; A.656.A.4.Í; A.657.A.4.Í; A.658.A.4.Í; A.659.A.4.Í; A.660.A.4.Í; A.2.A. 11.i; A.3.A.11.Í; A.4.A.11.Í; A.5.A.114; A.6.A.11.Í; A.7.A.11.Í; A.9.A.11.Í; A.10.A.11.Í; A.15.A.11.Í; A.100.A.11.Í; A.101.A.11.Í; A.102.A.11.Í; A.103.A.U.Í; A.104.A.11.Í; A.105.A.1LÍ; A.106.A.11.Í; A.107.A.11.Í; A.108.A.11.Í; A.109.A.114; A.110.A.11.Í; A.lll.A.ll.i; A.112.A.U.Í; A.113.A.11.Í; A.114.A.11.Í; A.115.A.11.Í; Α.116.Α.11.Ϊ; A.117.A.11.Í; A.118.A.11.Í; A.119.A.11.Í; A.120.A.11.Í; A.121.A.11.Í; A.122.A.11.Í; A.123.A.11.Í; A.124.A.114; A.125.A.11.Í; A.126.A.11 .i; A.127.A.11.Í; A.128.A.1LÍ; A.129.A.11.Í; A.130.A.114; A.131.A.11.Í; A.132.A.11.Í; A.133.A.11.Í; A.134.A.11.Í; A.135.A.11.Í; A.136.A.11.Í; A.137.A.11.Í; A.138.A.11.Í; A.139.A.11.Í; A.140.A.11.Í; Α.141.Α.Π.Ϊ; A.142.A.11.Í; A.143.A.11.Í; A.144.A.1U; A.145.A.114; A.146.A.11.Í; A.147.A.I1.Í; A.148.A.U.Í; A.149.A.11.Í; A.150.A.11.Í; A.151.A.11.Í; A.152.A.114; A.153.A.11.Í; A.154.A.1LÍ; A.155.A.11.Í; Α.156.Α.11.Ϊ; A.157.A.11.Í; A.158.A.11.Í; A.159.A.U.Í; A.160.A.U.Í; A.161.A.11.Í; A.162.A.11.Í; A.163.A.11.Í; A.164.A.11.Í; A.165.A.11.Í; A.166.A.U.Í; A.167.A.11.Í; A.168.A.11.Í; A.169.A.11.Í; A.170.A.11.Í; A.171.A.11.Í; A.172.A.11.Í; A.173.A.114; A.174.A.11.Í: A.175.A.11.Í; A.176.A.11.Í; Α.177.Α.11.Ϊ; A.178.A.11.Í; A.179.A.11.Í; A.180.A.11.Í; A.181.A.11.Í; A.182.A.11.Í; A.183.A.1L1; A.184.A.11.Í; Α.185.Α.11.Ϊ; A.186.A.11.Í; A.187.A.11.Í; A.188.A.11.Í; A.189.A.11.Í; A.190.A.11.Í; A.191.A.11.Í; A.192.A.U.Í; A.193.A.11.Í; A.194.A.11.Í; A.195.A.11.Í; A.196.A.1LÍ; A.197.A.11.Í; A.198.A.11.Í; A.199.A.11.Í; A.200.A.11.Í; A.201.A.11.Í; A.202.A.1U; A.203.A.11.Í; A.204.A.114; A.205.A.11.Í; A.206.A.11.Í; A.207.A.11.Í; Α.208.Α.11.Ϊ; A.209.A.11.Í; A.210.A.11.Í; A.211.A.11.Í; A.212.AAU; A.213.A.1U; A.214.A.11.Í; A.215.A.U.Í; A.216.A.11.Í; A.217.A.11.Í; A.218.A.U.Í; A.219.A.11.Í; A.220.A.11.Í; A.221.A.11.Í; A.222.A.11.Í; A.223.A.11.Í; A.224.A.11.Í; A.225.A.11.Í; Α.226.Α.11.Ϊ; A.227.A.11.Í; A.228.A.11.Í; A.229.A.11.Í;A.517.A.4.I; A.518.A.4.I; A.519.A.4.Í; A.520.A.4.I; A.521.A.4.I; A.522.A.4.I; A.523.A.4.i; A.524.A.4.I; A.525.A.4.I; A.526.A.4.I; A.527.A.4.I; A.528.A.4.I; A.529.A.4.I; A.530.A.4.I; A.531.A.4J; A.532.A.4.I; A.533. A.4. and; A.534.A.4.I; A.535.A.4.i; A.536.A.4.Í; A.537.A.4.I; A.538.A.4.I; A.539.A.4.I; A.540.A.4.I; A.541.A.4.I; A.542.A.4.I; A.543.A.4.I; A.544.A.4.I; A.545.A.4.I; A.546.A.4.I; A.547.A.4.I; A.548.A.4.I; A.549.A.4.I; A.550.A.4.1; A.551.A.4.I; A.552.A.4.I; Α-553.Α.4.Ϊ; A.554.A.4.Í; A.555.A.4.I; A.556.A.4.I; A.557.A.4.I; A.558.A.4.I; A-559.A.4.I; A.560.A.4.I; A.561.A.4.I; A.562.A.4.I; A.563.A.4.I; A.564.A.4.I; A.565.A.4.I; A.566.A.4.I; A.567.A.4.I; A.568.A.4.I; A.569.A.4.Í; A.570.A.4.I; A571.A.4.Í; A.572.A.4.I; A.573.A.4.I; A.574.A.44; A.575.A.44; A.576.A.4.I; AJ77.A.4.Í; A.578.A.4.I; A.579.A.4.I; A.580.A.4.I; A.581.A.4.I; A.582.A.4.I; A.583.A.4.I; A.584.A.4.I; A.585.A.4.I; A.586.A.4.I; A.587.A.4.Í; A.588.A.4.I; A.589.A.4.I; A.590.A.4.i; A.591.A.4.Í; A.592.A.4.I; A.593.A.4.I; A.594.A.4.I; A.595.A.4.I; A.596.A.4.I; A.597.A.4.Í; Α.598.Α.4.Ϊ; A.599.A.4.I; A.600.A.4.I; A.601.A.4.I; A.602.A.4.I; A.603.A.4.I; A.604.A.4.I; A.605.A.4J; A.606.A.4.Í; A.607.A.4.Í; A.608.A.4.Í; A.609.A.4.Í; A.610.A.4.I; A.611.A.4.I; A.612.A.4.I; A.613.A.4.I; A.614.A.4.I; A.615.A.4.I; A.616.A.4.I; A.617.A.4.I; A.618.A.4.I; A.619.A.4.Í; A.620.A.4.I; A.621.A.4.I; Α.622.Α.4.Ϊ; A.623.A.4.I; A.624.A.4.I; A.625.A.4. A.626.A.4.I; A.627.A.4.1; A.628.A.4.I; A.629.A.4.I; Α.630.Α.4.Ϊ; A.631.A.4.I; A.632.A.4.I; Α.633.Α.4.Ϊ; A.634.A.4.I; A.635.A.4.I; A.636.A.4.Í; A.637.A.4.I; A.638.A.4.I; A.639.A.4.1; A.640.A.4.I; A.641.A.4.I; A.642.A.4.I; A.643.A.4.I; A.644.A.4.I; A.645.A.4.I; Α.646.Α.4.Ϊ; A.647.A.4.I; A.648.A.4.I; A.649.A.4.I; A.650.A.4.I; A.651.A.4.I; A.652.A.4.I; A.653.A.4.Í; A.654.A.4.Í; A.655.A.4.I; A.656.A.4.I; A.657.A.4.Í; A.658.A.4.I; A.659.A.4.Í; A.660.A.4.I; A.2.A. 11.i; A.3.A.11.Í; A.4.A.11.Í; A.5.A.114; A.6.A.11.Í; A.7.A.11.Í; A.9.A.11.Í; A.10.A.11.Í; A.15.A.11.Í; A.100.A.11.Í; A.101.A.11.Í; A.102.A.11.Í; A.103.A.U.I; A.104.A.11.Í; A.105.A.1LÍ; A.106.A.11.Í; A.107.A.11.Í; A.108.A.11.Í; A.109.A.114; A.110.A.11.Í; A.lll.A.ll.i; A.112.A.U.I; A.113.A.11.Í; A.114.A.11.Í; A.115.A.11.Í; Α.116.Α.11.Ϊ; A.117.A.11.Í; A.118.A.11.Í; A.119.A.11.Í; A.120.A.11.Í; A.121.A.11.Í; A.122.A.11.Í; A.123.A.11.Í; A.124.A.114; A.125.A.11.Í; A.126.A.11 .i; A.127.A.11.Í; A.128.A.1LÍ; A.129.A.11.Í; A.130.A.114; A.131.A.11.Í; A.132.A.11.Í; A.133.A.11.Í; A.134.A.11.Í; A.135.A.11.Í; A.136.A.11.Í; A.137.A.11.Í; A.138.A.11.Í; A.139.A.11.Í; A.140.A.11.Í; Α.141.Α.Π.Ϊ; A.142.A.11.Í; A.143.A.11.Í; A.144.A.1U; A.145.A.114; A.146.A.11.Í; A.147.A.I1.Í; A.148.A.U.I; A.149.A.11.Í; A.150.A.11.Í; A.151.A.11.Í; A.152.A.114; A.153.A.11.Í; A.154.A.1LÍ; A.155.A.11.Í; Α.156.Α.11.Ϊ; A.157.A.11.Í; A.158.A.11.Í; A.159.A.U.I; A.160.A.U.I; A.161.A.11.Í; A.162.A.11.Í; A.163.A.11.Í; A.164.A.11.Í; A.165.A.11.Í; A.166.A.U.I; A.167.A.11.Í; A.168.A.11.Í; A.169.A.11.Í; A.170.A.11.Í; A.171.A.11.Í; A.172.A.11.Í; A.173.A.114; A.174.A.11.I: A.175.A.11.I; A.176.A.11.Í; Α.177.Α.11.Ϊ; A.178.A.11.Í; A.179.A.11.Í; A.180.A.11.Í; A.181.A.11.Í; A.182.A.11.Í; A.183.A.1L1; A.184.A.11.Í; Α.185.Α.11.Ϊ; A.186.A.11.Í; A.187.A.11.Í; A.188.A.11.Í; A.189.A.11.Í; A.190.A.11.Í; A.191.A.11.Í; A.192.A.U.I; A.193.A.11.Í; A.194.A.11.Í; A.195.A.11.Í; A.196.A.1LÍ; A.197.A.11.Í; A.198.A.11.Í; A.199.A.11.Í; A.200.A.11.Í; A.201.A.11.Í; A.202.A.1U; A.203.A.11.Í; A.204.A.114; A.205.A.11.Í; A.206.A.11.Í; A.207.A.11.Í; Α.208.Α.11.Ϊ; A.209.A.11.Í; A.210.A.11.Í; A.211.A.11.Í; A.212.AAU; A.213.A.1U; A.214.A.11.Í; A.215.A.U.I; A.216.A.11.Í; A.217.A.11.Í; A.218.A.U.I; A.219.A.11.Í; A.220.A.11.Í; A.221.A.11.Í; A.222.A.11.Í; A.223.A.11.Í; A.224.A.11.Í; A.225.A.11.Í; Α.226.Α.11.Ϊ; A.227.A.11.Í; A.228.A.11.Í; A.229.A.11.Í;
-112CZ 297945 B6-112GB 297945 B6
A.230.A.11.Í; A.231.A.11.Í; A.232.A.11.Í; A.233.A.U.Í; A.234.A.11.Í; A.235.A.11.Í; A.236.A.11.Í; A.237.A.11.Í; A.238.A.11.Í; A.239.A.11.Í; A.240.A.11.Í; Α.241.Α.11.ί; A.242.A.11.Í; A.243.A.11.Í; A.244.A.11.Í; A.245.A.11.Í; A246.A.11.Í; A.247.A.11.Í; A.248.A.11.Í; A.249.A.11.Í; A.250.A.11.Í; A.251.A.11.Í; A.252.A.11.Í; A.253.A.11.Í; A.254.A.11 .i; A.255.A.11.Í; A.256.A.11.Í; A.257.A.11.Í; A.258.A.11.Í; A.259.A.11.Í; A.260.A.11.Í; A.261.A.11.Í; A.262.A.11.Í; A.263.A.11.Í; A-264.A.11.Í; A265.A.11.Í; A.266.A.11.1; A.267. A.ll.i; A.268.A.11.Í; A.269.A.11.Í; A270.A.1LÍ; Α271.Α.11Λ; A.272.A.11.Í; A-273-A.ll.i; A.274.A.U.Í; A.275.A.11.Í; A.276.A.11.Í; A277.A.11.Í; A278.A.11.Í; A.279.A.11.Í; A.280. A.ll.i; A.281.A.1LÍ; A282.A.11.Í; A.283.A.11.Í; A284.A.11.Í; A.285.A.11.Í; A.286.A.11.Í; A.287.A.11.Í; A.288.A.11.Í; A.289.A.11.Í; A.290.A.11.Í; A.291 .A.ll.i; A.292.A.11.Í; A.293.A.11.i; A.294.A.11.Í; A.295.A.11.Í; A.296.A.11.Í; A.297.A.11.Í; A.298.A.11.Í; A.299.A.11.Í; A.300.A.1LÍ; A.301.A.11.Í; A.302.A.11.Í; A.303.A.1U; A.304.A.114; A.305.A.11.Í; A.306.A.11.Í; A.307.A.11.Í; A.308.A.11.Í; A.309.A.11.Í; A.310.A.114; A.3I1.A.11.Í; A.312.A.11.Í; A.313.A.11.Í; A.314-A.11.Í; A.315.A.11.Í; A.316.A.114; A.317.A.I1.Í; A.318.A.11.Í; A.319.A.11.Í; A.320.A.11.Í; A.321.A.11.Í; A.323.A.11.Í; A.324.A.1U; A.325.A.11.Í; A.326.A.11.Í; A.327.A.11.Í; A.328.A.11.Í; A.329.A.11.Í; A.330.A.ILÍ; A.331.A.11.Í; A.332.A.11.Í; A.333.A.11.Í; A.334.A.U.Í; A.335.A.U.Í; A.336.A.11.Í; A.337.A.11.Í; A.338.A.11.Í; A.339.A.11.Í; A.340.A.U.Í; A34LA.il4; A.342.A.11.Í; A.343.A.11.Í; A.344.A.U.Í; A.345.A.11.Í; A.346.A.11.Í; A.347.A.11.Í; A.348.A.11.Í; A.349.A.11.Í; A350.A.1LÍ; A.351.A.11.Í; A.352.A.11.Í; A353.A.11.Í; A.354.A.11.Í; A.355.A.11.i; A.356.A.ll.i; A357.A.11.Í; A.358.A.11.Í; A.359.A.11.Í; A.360.A.11.Í; A.361.A.11.Í; A.362.A.11.Í; A.363.A.11.Í; A.364.A.U.Í; A365.A.1U; A.366.A.11.Í; A367.A.1Í.Í; A.368.A.11.Í; A.369.A.11.Í; A370.A.11.Í; A.371.A.11.Í; A.372.A.11.Í; A.373.A.U.Í; A.374.A.11.Í; A.375.A.11.Í; A.376.A.ll.i; A.377.A.11.Í; A.378.A.11.Í; A.379.A.11.Í; A.380.A.11.Í; A.381.A.11.Í; A.382.A.11.Í; A.383.A.U.Í; A.384.A.1LÍ; A.385.A.11.Í; A.386.A.11.Í; A.387.A.11.Í; A.388.A.11.Í; A.389.A.11.Í; A390.A.11.Í; A39LA.11.X; A.392.A.11.Í; A393.A.11.Í; A.394.A.11.Í; A.395.A.11.Í; A.396.A.11.Í; A397.A.11.Í; A.398.A.11.Í; A.399.A.11.Í; A.400.A.11.Í; A.401.A.11.Í; A.402.A.11.Í; A.403.A.11.Í; A.404.A.U.Í; A.405.A.11.Í; A.406.A.11.Í; Α.407.Α.11.Ϊ; A.408.A.U.Í; A.409.A.U.Í; A.410.A.11.Í; A.411.A.11.Í; A.412.A.U.Í; A.413.A.11.Í; A.414A.ll.i; A.415.A.l 1 .i; A.416.A.ll.i; A.417.A.11.Í; A.418.A.11.Í; A.419.A.U.Í; A.420.A.11.Í; A.421.A.114; A.422.A.11.Í; A.423.A.11.Í; A.424-.A.11.Í; A.425.A.11.Í; A.426.A.11.Í; A.427.A.11.Í; A.428.A.11.Í; A.429.A.11.Í; A.430.A.11.Í; A.431.A.11.Í; A.432.A.114; A.433.A.11.Í; A.434.A.11.Í; A.435.A.11.Í; A.436.A.11.Í; A.437.A.11.Í; A.438.A.11.Í; A.439.A.11.Í; A.440.A.U.Í; A.441.A.11.Í; A.442.A.11.Í; A.443.A.11.Í; A.444.A.11.Í; A.445.A.11.Í; A.446.A.11.Í; A.447.A.11.Í; A.448.A.11.Í; A.449.A.11.Í; A.450.A.11.Í; A.451.A.11.Í; A.452.A.11.Í; A.453-A.11.Í; A.454.A.11.Í; A.455.A.11.Í; A.456.A.11.Í; A.457.A.11.Í; A.458.A.11.Í; A.459.A.11.Í; A.460.A.11.Í; A.461.A.11.Í; A.462.A.U.Í; A.463.A.U.Í; A.464.A.11.Í; A.465.A.11.Í; A.466.A.11.Í; A.467.A.11.Í; A.468.A.11.Í; A.469.A.11.Í; A.470.A.11.Í; A.471.A.11.Í'; A.472.A.11.Í; A.473.A.11.Í; A.474.A.11.Í; Α.475.Α.11.Ϊ; A.476.A.11.Í; A.477.A.11.Í; A.478.A.11.Í; A.479.A.ll.i; A.480.A.11.Í; A.481.A.11.Í; A.482.A.11.Í; A.483.A.1LÍ; A.484.A.11.Í; A.485.A.11.Í; A.486.A.11.Í; A.487.A.U.Í; A.488.A.11.Í; A.489.A.11 .i; A.490.A.11.Í; A.491.A.11.Í; A.492.A.11.Í; A.493.A.11.Í; A.494.A.11.Í; A.495.A.ll.i; A.496.A.ll.i; A.497.A.ll.i; A.498.A.11.Í; A.499.A.ll.i; A.500.A.11.Í; Α.501.Α.11.Ϊ; A.502.A.1I.Í; A.503.A.11.Í; A.504.A.11.Í; A.505.A.U.Í; A.506.A.11.Í; A.507.A.11.Í; A.508.A.11.Í; A.509.A.I1.Í; A.510.A.1LÍ; A.511.A.11.Í; A.512.A.U.Í;A.230.A.11.Í; A.231.A.11.Í; A.232.A.11.Í; A.233.A.U.I; A.234.A.11.Í; A.235.A.11.Í; A.236.A.11.Í; A.237.A.11.Í; A.238.A.11.Í; A.239.A.11.Í; A.240.A.11.Í; Α.241.Α.11.ί; A.242.A.11.Í; A.243.A.11.Í; A.244.A.11.Í; A.245.A.11.Í; A246.A.11.Í; A.247.A.11.Í; A.248.A.11.Í; A.249.A.11.Í; A.250.A.11.Í; A.251.A.11.Í; A.252.A.11.Í; A.253.A.11.Í; A.254.A.11 .i; A.255.A.11.Í; A.256.A.11.Í; A.257.A.11.Í; A.258.A.11.Í; A.259.A.11.Í; A.260.A.11.Í; A.261.A.11.Í; A.262.A.11.Í; A.263.A.11.Í; A-264.A.11.I; A265.A.11.Í; A.266.A.11.1; A.267. A.ll.i; A.268.A.11.Í; A.269.A.11.Í; A270.A.1LÍ; Α271.Α.11Λ; A.272.A.11.Í; A-273-A.II.1; A.274.A.U.I; A.275.A.11.Í; A.276.A.11.Í; A277.A.11.Í; A278.A.11.Í; A.279.A.11.Í; A.280. A.ll.i; A.281.A.1LÍ; A282.A.11.Í; A.283.A.11.Í; A284.A.11.Í; A.285.A.11.Í; A.286.A.11.Í; A.287.A.11.Í; A.288.A.11.Í; A.289.A.11.Í; A.290.A.11.Í; A.291 .A.ll.i; A.292.A.11.Í; A.293.A.11.i; A.294.A.11.Í; A.295.A.11.Í; A.296.A.11.Í; A.297.A.11.Í; A.298.A.11.Í; A.299.A.11.Í; A.300.A.1LÍ; A.301.A.11.Í; A.302.A.11.Í; A.303.A.1U; A.304.A.114; A.305.A.11.Í; A.306.A.11.Í; A.307.A.11.Í; A.308.A.11.Í; A.309.A.11.Í; A.310.A.114; A.3I1.A.11.Í; A.312.A.11.Í; A.313.A.11.Í; A.314-A.11.I; A.315.A.11.Í; A.316.A.114; A.317.A.I1.Í; A.318.A.11.Í; A.319.A.11.Í; A.320.A.11.Í; A.321.A.11.Í; A.323.A.11.Í; A.324.A.1U; A.325.A.11.Í; A.326.A.11.Í; A.327.A.11.Í; A.328.A.11.Í; A.329.A.11.Í; A.330.A.ILÍ; A.331.A.11.Í; A.332.A.11.Í; A.333.A.11.Í; A.334.A.U.I; A.335.A.U.I; A.336.A.11.Í; A.337.A.11.Í; A.338.A.11.Í; A.339.A.11.Í; A.340.A.U.I; A34LA.il4; A.342.A.11.Í; A.343.A.11.Í; A.344.A.U.I; A.345.A.11.Í; A.346.A.11.Í; A.347.A.11.Í; A.348.A.11.Í; A.349.A.11.Í; A350.A.1LÍ; A.351.A.11.Í; A.352.A.11.Í; A353.A.11.Í; A.354.A.11.Í; A.355.A.11.i; A.356.A.ll.i; A357.A.11.Í; A.358.A.11.Í; A.359.A.11.Í; A.360.A.11.Í; A.361.A.11.Í; A.362.A.11.Í; A.363.A.11.Í; A.364.A.U.I; A365.A.1U; A.366.A.11.Í; A367.A.1Í.Í; A.368.A.11.Í; A.369.A.11.Í; A370.A.11.Í; A.371.A.11.Í; A.372.A.11.Í; A.373.A.U.I; A.374.A.11.Í; A.375.A.11.Í; A.376.A.ll.i; A.377.A.11.Í; A.378.A.11.Í; A.379.A.11.Í; A.380.A.11.Í; A.381.A.11.Í; A.382.A.11.Í; A.383.A.U.I; A.384.A.1LÍ; A.385.A.11.Í; A.386.A.11.Í; A.387.A.11.Í; A.388.A.11.Í; A.389.A.11.Í; A390.A.11.Í; A39LA.11.X; A.392.A.11.Í; A393.A.11.Í; A.394.A.11.Í; A.395.A.11.Í; A.396.A.11.Í; A397.A.11.Í; A.398.A.11.Í; A.399.A.11.Í; A.400.A.11.Í; A.401.A.11.Í; A.402.A.11.I; A.403.A.11.Í; A.404.A.U.I; A.405.A.11.Í; A.406.A.11.Í; Α.407.Α.11.Ϊ; A.408.A.U.I; A.409.A.U.I; A.410.A.11.Í; A.411.A.11.Í; A.412.A.U.I; A.413.A.11.Í; A.414A.ll.i; A.415.A.1.1 .i; A.416.A.ll.i; A.417.A.11.Í; A.418.A.11.Í; A.419.A.U.I; A.420.A.11.Í; A.421.A.114; A.422.A.11.Í; A.423.A.11.Í; A.424-.A.11.I; A.425.A.11.Í; A.426.A.11.Í; A.427.A.11.Í; A.428.A.11.Í; A.429.A.11.Í; A.430.A.11.Í; A.431.A.11.Í; A.432.A.114; A.433.A.11.Í; A.434.A.11.Í; A.435.A.11.Í; A.436.A.11.Í; A.437.A.11.Í; A.438.A.11.Í; A.439.A.11.Í; A.440.A.U.I; A.441.A.11.Í; A.442.A.11.Í; A.443.A.11.Í; A.444.A.11.Í; A.445.A.11.Í; A.446.A.11.Í; A.447.A.11.Í; A.448.A.11.Í; A.449.A.11.Í; A.450.A.11.Í; A.451.A.11.Í; A.452.A.11.Í; A.453-A.11.I; A.454.A.11.Í; A.455.A.11.Í; A.456.A.11.Í; A.457.A.11.Í; A.458.A.11.Í; A.459.A.11.Í; A.460.A.11.Í; A.461.A.11.Í; A.462.A.U.I; A.463.A.U.I; A.464.A.11.Í; A.465.A.11.Í; A.466.A.11.Í; A.467.A.11.Í; A.468.A.11.Í; A.469.A.11.Í; A.470.A.11.Í; A.471.A.11.I '; A.472.A.11.Í; A.473.A.11.Í; A.474.A.11.Í; Α.475.Α.11.Ϊ; A.476.A.11.Í; A.477.A.11.Í; A.478.A.11.Í; A.479.A.ll.i; A.480.A.11.Í; A.481.A.11.Í; A.482.A.11.Í; A.483.A.1LÍ; A.484.A.11.Í; A.485.A.11.Í; A.486.A.11.Í; A.487.A.U.I; A.488.A.11.Í; A.489.A.11 .i; A.490.A.11.Í; A.491.A.11.Í; A.492.A.11.Í; A.493.A.11.Í; A.494.A.11.Í; A.495.A.ll.i; A.496.A.ll.i; A.497.A.ll.i; A.498.A.11.Í; A.499.A.ll.i; A.500.A.11.Í; Α.501.Α.11.Ϊ; A.502.A.1I.I; A.503.A.11.Í; A.504.A.11.Í; A.505.A.U.I; A.506.A.11.Í; A.507.A.11.Í; A.508.A.11.Í; A.509.A.I1.Í; A.510.A.1LÍ; A.511.A.11.Í; A.512.A.U.I;
-113CZ 297945 B6-113GB 297945 B6
A.512.A.U.Í; A.513.A.11.Í; A.514.A.11.Í; A.515.A.1U; A.516.A.11.Í; A.517.A.11.Í; A.518.A.11.Í; A.519.A.11.Í; A.520.A.11.Í; A.521.A.11.Í; A.522.A.11.Í; A.523.A.11.Í; A.524.A.11.Í; A.525.A.11.Í; A.526.A.114; A.527.A.11.Í; A.528.A.11.Í; Α-529.Α.Π4; A.530.A.11.Í; A.531.A.1M; A.532.A.11.Í; A.533.A.11.Í; A.534.A.11.Í; A.535.A.11.Í; A.536.A.11.Í; A.537.A.11.Í; A.538-A.1U; A.539.A.11.Í; A.540.A.11.Í; A.541.A.1Í.Í; A.542.A.11.Í; A.543.A.11Á; A.544.A.11.Í; A.545.A.11.i; A.546.A.11.Í; A.547.A.11.Í; A.548.A.11.Í; A.549.A.11.Í; A.550.A.11.Í; A.551.A.11.Í; A.552.A.11.Í; A.553.A.11.Í; A.554.A.11.Í; A.555.A.11.Í; A.556.A.11.Í; A.557.A.11.Í; A.558.A.11.Í; A.559.A.11.Í; Α.560.Α.11.Ϊ; A.561.A.11.Í; A.562.A.11.Í; Α.563.Α.11.Ϊ; A.564.A.11.Í; A.565.A.11.Í; A566.A.11.Í; A.567.A.11.Í; A.568.A.11.Í; A.569.A.11.Í; A.570.A.11.Í; A.571.A.11.Í; A.572.A.11.Í; A.573.A-U.Í; A.574.A.11.:; A.575.A.11.Í; A.576.A.11.Í; A.577.A.11.Í; A.578.A.11.Í; A.579.A.11.Í; A.580.A.11.Í; A.581.A.11.Í; A.582.A.U.Í; A.583.A.11.Í; A.584.A.11.Í; A.585.A.11.Í; A.586.A.11.Í; Α.587.Α.11.Ϊ; A.588.A.11.Í; A.589.A.11.Í; A590.A.11.Í; A.591 A.592.A11.Í; A.593.A-11.Í; A.594.A.11.Í; A.595.A.11.Í;A.512.A.U.I; A.513.A.11.Í; A.514.A.11.Í; A.515.A.1U; A.516.A.11.Í; A.517.A.11.Í; A.518.A.11.Í; A.519.A.11.Í; A.520.A.11.Í; A.521.A.11.Í; A.522.A.11.Í; A.523.A.11.Í; A.524.A.11.Í; A.525.A.11.Í; A.526.A.114; A.527.A.11.Í; A.528.A.11.Í; Α-529.Α.Π4; A.530.A.11.Í; A.531.A.1M; A.532.A.11.Í; A.533.A.11.Í; A.534.A.11.Í; A.535.A.11.Í; A.536.A.11.Í; A.537.A.11.Í; A.538-A.1U; A.539.A.11.Í; A.540.A.11.Í; A.541.A.1Í.Í; A.542.A.11.Í; A.543.A.11Á; A.544.A.11.Í; A.545.A.11.i; A.546.A.11.Í; A.547.A.11.Í; A.548.A.11.Í; A.549.A.11.Í; A.550.A.11.Í; A.551.A.11.Í; A.552.A.11.Í; A.553.A.11.Í; A.554.A.11.Í; A.555.A.11.Í; A.556.A.11.Í; A.557.A.11.Í; A.558.A.11.Í; A.559.A.11.Í; Α.560.Α.11.Ϊ; A.561.A.11.Í; A.562.A.11.Í; Α.563.Α.11.Ϊ; A.564.A.11.Í; A.565.A.11.Í; A566.A.11.Í; A.567.A.11.Í; A.568.A.11.Í; A.569.A.11.Í; A.570.A.11.Í; A.571.A.11.Í; A.572.A.11.Í; A.573.A-U.I; A.574.A.11. A.575.A.11.Í; A.576.A.11.Í; A.577.A.11.Í; A.578.A.11.Í; A.579.A.11.Í; A.580.A.11.Í; A.581.A.11.Í; A.582.A.U.I; A.583.A.11.Í; A.584.A.11.Í; A.585.A.11.Í; A.586.A.11.Í; Α.587.Α.11.Ϊ; A.588.A.11.Í; A.589.A.11.Í; A590.A.11.Í; A.591 A.592.A11.I; A.593.A-11.I; A.594.A.11.Í; A.595.A.11.Í;
Α.596.Α.Π.Ϊ; A.597.A.11.Í; A.598.A.11.Í; A.599.A.11.Í; A.600.A.11.Í; A.601.A.11.Í; A.602.A.11.Í; A.603.A.11.Í; A.604.A.11.Í; A.605.A.11.Í; A.606.A.11.Í; A.607.A.11.Í; A.608.A.11.Í; A.609.A.11.Í; A.610.A.11.Í; A.611.A.11.Í; A.612.A.11.Í; A.613.A.11.Í; A.614.A.1LÍ; A.615.A.11.Í; A.616.A.11.Í; Α.617.Α.11.Ϊ; A.618.A.11.Í; A.619.A.11.Í; Α.620.Α.11.Ϊ; A.621.A.11.Í; A.622.A.11.Í; A.623.A.11.Í; A.624.A.11.Í; A.625.A.11.Í; Α.626.Α.11.Ϊ; A.627.A.11.Í; A.628.A.1U; A.629.A.11.Í; A.630.A.IU; A.63LA.11.Í; A.632.A.11.Í; A.633.A.11.Í; A.634.A.11.Í; Α.635.Α.11.Ϊ; A.636.A.1U; A.637.A.U.Í; A.638.A.11.Í; Α.639.Α.11.Ϊ; A.640.A.1U; A.641.A.11.Í; A.642.A.11.Í; A.643.A.11.Í; A.644.A.11.Í; A.645.A.U.Í; A.646.A.11.Í; A.647.A.11.Í; A.648.A.U.Í; A.649.A.11.Í; A.650.A.11.Í; A.651.A.11.Í; Α.652.Α.11.Ϊ; A.653.A.11.Í; A.654.A.11.Í; A.655.A.11.Í; A.656.A.11.Í; A.657.A.11.Í; A.658.A.11.Í; Α.659.Α.11.Ϊ; A.660.A.11.Í; A.2.B.4.Í; Α.3.Β.4.Ϊ; A.4.B.4.Í; A.5.B.4.Í; A.6 B.4.Í; A.7.B.4Á; A.9.B.4.Í; A.10.B.4.Í; Α.15.Β.4Λ; A.100.B.4.Í; A.101.B.4.Í; A.102.B.4.Í; A.103.B.4.Í; A.104.B.4.Í; A.105.B.4.Í; A.106.B.4.Í; A.107.B.4.Í; A.108.B.4.Í; A.109.B.4.1; A.110.B.4.Í; Α.111.Β.4.Ϊ; A.112.B.4.Í; A.113.B.4.Í; A.114.B.4.Í; A.115.B.4.Í; A.116.B.44; A.117.B.4.Í; A.118.B.4.Í; A.119.B.44; A.120.B.44; A.121.B.44; A.122.B.44; A.123.B.44; A.124.B.44; A.125.B.44; A.126.B.44; A.127.B.44; A.128.B.44; A.129.B.44; A.130.B.44; A.131.B.44; A.132.B.44; A.133.B.44; A.134.B.44; A.135.B.44; A.136.B.44; A.137.B.44; A.138.B.4.1; A.139.B.4.Í; A.140.B.44; A.141.B.44; A.142.B.44; A.143.B.4.Í; A.144.B.4.Í; A.145.B.44; A.146.B.4.Í; A.147.B.44; A.148.B.4.Í; A.149.B.44; A.150.B.4.Í; A.151.B.4.Í; A.152.B.44; A.1S3.B.44; A.154.B.44; A.155.B.44; A.156.B.44; A.157.B.4J; A.158.B.44; A.159.B.44; A.160.B.4.Í; A.161.B.4.Í; A.162.B.4J; A.163.B.4.Í; A.164.B.4.Í; A.165.B.4.Í; ΑΛ66.Β.44; A.167.B.44; A.168.B.44; A.169.B.44; A.170.B.4.Í; A.171.B.44; A.172.B.44; A.173.B.4.Í; A.174.B.4.Í; A.175.B.4.Í; Α.176.Β.4.Ϊ; A.177.B.4.Í; A.178.B.44; A.179.B.44; A.180.B.44; A.181.B.44; A.182.B.44; A.183.B.44; Α.184·Β.4.ί; Α.185 B.4.Í; A.186.B.44; A.187.B.4.Í; A.188.B.4.Í; A.189.B.4.Í; A.190.B.44; A.191.B.44; A.192.B.4.Í; A.193.B.4.1; A.194.B.44; A.195.B.44; A.196.B.4.Í; A.197.B.4.Í; A.198.B.44; A.199.B.4.Í; A.200.B.44; A.201.B.4.Í; A.202.B.44; A.203.B.44; A.204.B.4.1; A.205.B.44; A.206.B.44; A.207.B.4.Í; A208.B.4.Í; A.209.B.4.Í; A.210.B.4.Í; A.211.B.4.Í; A.212.B.4.Í; A.213.B.4.Í; A.214.B.4.Í; A.215.B.4.Í; Α.216.Β.4.Ϊ; A.217.B.4.Í; A.218.B.4.Í; A.219.B.4.Í; A22O.B.4.Í; A.221.B.4.Í; A.222.B.4.Í; A.223.B.4 Í; A.224.B.4.Í; Α.225.Β.4.Ϊ;Α.596.Α.Π.Ϊ; A.597.A.11.Í; A.598.A.11.Í; A.599.A.11.Í; A.600.A.11.Í; A.601.A.11.Í; A.602.A.11.Í; A.603.A.11.Í; A.604.A.11.Í; A.605.A.11.Í; A.606.A.11.Í; A.607.A.11.Í; A.608.A.11.Í; A.609.A.11.Í; A.610.A.11.Í; A.611.A.11.Í; A.612.A.11.Í; A.613.A.11.Í; A.614.A.1LÍ; A.615.A.11.Í; A.616.A.11.Í; Α.617.Α.11.Ϊ; A.618.A.11.Í; A.619.A.11.Í; Α.620.Α.11.Ϊ; A.621.A.11.Í; A.622.A.11.Í; A.623.A.11.Í; A.624.A.11.Í; A.625.A.11.Í; Α.626.Α.11.Ϊ; A.627.A.11.Í; A.628.A.1U; A.629.A.11.Í; A.630.A.IU; A.63LA.11.Í; A.632.A.11.Í; A.633.A.11.Í; A.634.A.11.Í; Α.635.Α.11.Ϊ; A.636.A.1U; A.637.A.U.I; A.638.A.11.Í; Α.639.Α.11.Ϊ; A.640.A.1U; A.641.A.11.Í; A.642.A.11.Í; A.643.A.11.Í; A.644.A.11.Í; A.645.A.U.I; A.646.A.11.Í; A.647.A.11.Í; A.648.A.U.I; A.649.A.11.Í; A.650.A.11.Í; A.651.A.11.Í; Α.652.Α.11.Ϊ; A.653.A.11.Í; A.654.A.11.Í; A.655.A.11.Í; A.656.A.11.Í; A.657.A.11.Í; A.658.A.11.Í; Α.659.Α.11.Ϊ; A.660.A.11.Í; A.2.B.4.I; Α.3.Β.4.Ϊ; A.4.B.4.I; A.5.B.4.I; A.6 B.4.I; A.7.B.4A; A.9.B.4.I; A.10.B.4.I; Α.15.Β.4Λ; A.100.B.4.I; A.101.B.4.I; A.102.B.4.I; A.103.B.4.I; A.104.B.4.I; A.105.B.4.I; A.106.B.4.I; A.107.B.4.I; A.108.B.4.I; A.109.B.4.1; A.110.B.4.I; Α.111.Β.4.Ϊ; A.112.B.4.I; A.113.B.4.I; A.114.B.4.I; A.115.B.4.I; A.116.B.44; A.117.B.4.I; A.118.B.4.I; A.119.B.44; A.120.B.44; A.121.B.44; A.122.B.44; A.123.B.44; A.124.B.44; A.125.B.44; A.126.B.44; A.127.B.44; A.128.B.44; A.129.B.44; A.130.B.44; A.131.B.44; A.132.B.44; A.133.B.44; A.134.B.44; A.135.B.44; A.136.B.44; A.137.B.44; A.138.B.4.1; A.139.B.4.I; A.140.B.44; A.141.B.44; A.142.B.44; A.143.B.4.I; A.144.B.4.I; A.145.B.44; A.146.B.4.I; A.147.B.44; A.148.B.4.I; A.149.B.44; A.150.B.4.I; A.151.B.4.I; A.152.B.44; A.1S3.B.44; A.154.B.44; A.155.B.44; A.156.B.44; A.157.B.4J; A.158.B.44; A.159.B.44; A.160.B.4.I; A.161.B.4.I; A.162.B.4J; A.163.B.4.I; A.164.B.4.I; A.165.B.4.I; ΑΛ66.Β.44; A.167.B.44; A.168.B.44; A.169.B.44; A.170.B.4.I; A.171.B.44; A.172.B.44; A.173.B.4.I; A.174.B.4.I; A.175.B.4.I; Α.176.Β.4.Ϊ; A.177.B.4.I; A.178.B.44; A.179.B.44; A.180.B.44; A.181.B.44; A.182.B.44; A.183.B.44; Α.184 · Β.4.ί; Α.185 B.4.I; A.186.B.44; A.187.B.4.I; A.188.B.4.I; A.189.B.4.I; A.190.B.44; A.191.B.44; A.192.B.4.I; A.193.B.4.1; A.194.B.44; A.195.B.44; A.196.B.4.I; A.197.B.4.I; A.198.B.44; A.199.B.4.Í; A.200.B.44; A.201.B.4.Í; A.202.B.44; A.203.B.44; A.204.B.4.1; A.205.B.44; A.206.B.44; A.207.B.4.I; A208.B.4.I; A.209.B.4.Í; A.210.B.4.I; A.211.B.4.I; A.212.B.4.I; A.213.B.4.I; A.214.B.4.I; A.215.B.4.I; Α.216.Β.4.Ϊ; A.217.B.4.I; A.218.B.4.I; A.219.B.4.I; A22O.B.4.I; A.221.B.4.I; A.222.B.4.I; A.223.B.4 Í; A.224.B.4.I; Α.225.Β.4.Ϊ;
- 114CZ 297945 B6- 114GB 297945 B6
A.226.B.44; A.227.B.44; A228.B.44, A.232.B.4.Í; A.233.B.44; Α.234.Β.4 4. A.238.B.44; A.239.B.44; A.240.B.44; A.244.B.44; A.245.B.44; A.246.B.44; A.250.B.44; A.251.B.44; A.252.B.44; A.256.B.44; A.257.B.44; A.258.B.44; A.262.B.44; A.263.B.4.Í; A.264.B.44; A.268.B.44; A.269.B.44; A.270.B.44; A274.B.4.Í; A.275.B.4.1; A.276.B.44; A.280.B.44; A281.B.44; A.282.B.44; A.286.B.4.Í; A.287.B.44; A.288.B.44; A.292.B.44; A.293.B.4.Í; A.294.B.4.Í; A.298.B.44; A.299.B.44; A.300.B.44; A.304.B.44; A.305.B.44; A.306.B.44; A.310.B.44; A.311.B.44; A.312.B.44; A.316.B.44; A.317.B.44; A.318.B.44; A.323.B.44; A324.B.44; A.325.B.44; A.329.B.44; A.330.B.44; Α.331.ΒΛΪ; A.335.B.44; A.336.B.44; A.337.B.44; A.341.B.44; A.342.B.44; A343.B.44; A.347.B.44; A.348.B.44; A.349.B.44; A.353.B.44; A.354.B.44; A.355.B.4.Í; A.359.B.44; A.360.B.44; A361.B.44; A.365.B.44; A.366.B.4.Í; A.367.B.44; A.371.B.44; A.372.B.44; A.373.B.4.Í; A.377.B.44; A.378.B.4.Í; A.379.B.44; A.383.B.44; A.384.B.44; A.385.B.4.Í; A.389.B.44; A.390.B.44; A.391.B.44; A.395.B.44; A.396.B.44; A.397.B.44; A.401.B.44; A.402.B.4.1; A.403.B.44; Α.407.Β.4.Ϊ; A.408.B.4.Í; A.409.B.44; Α.413.Β.4.Ϊ; A.414.B.4.Í; A.415.B.44; A.419.B.44; A.420.B.44; A.421.B.44; A.425.B.44; A.426.B.44; A.427.B.44; A.431.B.44; A.432.B.4.Í; A.433.B.44; A.437.B.44; A.438B.44; A.439.B.44; A.443.B.44; A.444.B.44; A.445.B.44; A.449.B.44; A.450.B.44; A.451.B.44; A.455.B.44; A.456.B.44; A.457.B.44; A.46I.B.44; A.462.B.44; A.463.B.44; A.467B.44; A.468.B.44; Α.469.Β.4Λ; A.473.B.44; A.474.B.4.Í; A.475.B.44; A.479.B.4.Í; A.480.B.4.1; A.481.B.4.Í; A.485.B.44; A.486.B.44; A.487.B.44; A.491 .B.44; A.492.B.4.Í; A.493.B.44; A.497.B.44; A.498.B.4.Í; A.499.B.44; A.503.B.44; A.504.B.4.Í; A.505.B.44;A.226.B.44; A.227.B.44; A228.B.44, A.232.B.4.I; A.233.B.44; Α.234.Β.4 4. A.238.B.44; A.239.B.44; A.240.B.44; A.244.B.44; A.245.B.44; A.246.B.44; A.250.B.44; A.251.B.44; A.252.B.44; A.256.B.44; A.257.B.44; A.258.B.44; A.262.B.44; A.263.B.4.I; A.264.B.44; A.268.B.44; A.269.B.44; A.270.B.44; A274.B.4.I; A.275.B.4.1; A.276.B.44; A.280.B.44; A281.B.44; A.282.B.44; A.286.B.4.I; A.287.B.44; A.288.B.44; A.292.B.44; A.293.B.4.I; A.294.B.4.I; A.298.B.44; A.299.B.44; A.300.B.44; A.304.B.44; A.305.B.44; A.306.B.44; A.310.B.44; A.311.B.44; A.312.B.44; A.316.B.44; A.317.B.44; A.318.B.44; A.323.B.44; A324.B.44; A.325.B.44; A.329.B.44; A.330.B.44; Α.331.ΒΛΪ; A.335.B.44; A.336.B.44; A.337.B.44; A.341.B.44; A.342.B.44; A343.B.44; A.347.B.44; A.348.B.44; A.349.B.44; A.353.B.44; A.354.B.44; A.355.B.4.I; A.359.B.44; A.360.B.44; A361.B.44; A.365.B.44; A.366.B.4.I; A.367.B.44; A.371.B.44; A.372.B.44; A.373.B.4.I; A.377.B.44; A.378.B.4.I; A.379.B.44; A.383.B.44; A.384.B.44; A.385.B.4.I; A.389.B.44; A.390.B.44; A.391.B.44; A.395.B.44; A.396.B.44; A.397.B.44; A.401.B.44; A.402.B.4.1; A.403.B.44; Α.407.Β.4.Ϊ; A.408.B.4.I; A.409.B.44; Α.413.Β.4.Ϊ; A.414.B.4.I; A.415.B.44; A.419.B.44; A.420.B.44; A.421.B.44; A.425.B.44; A.426.B.44; A.427.B.44; A.431.B.44; A.432.B.4.I; A.433.B.44; A.437.B.44; A.438B.44; A.439.B.44; A.443.B.44; A.444.B.44; A.445.B.44; A.449.B.44; A.450.B.44; A.451.B.44; A.455.B.44; A.456.B.44; A.457.B.44; A.46I.B.44; A.462.B.44; A.463.B.44; A.467B.44; A.468.B.44; Α.469.Β.4Λ; A.473.B.44; A.474.B.4.I; A.475.B.44; A.479.B.4.I; A.480.B.4.1; A.481.B.4.I; A.485.B.44; A.486.B.44; A.487.B.44; A.491 .B.44; A.492.B.4.I; A.493.B.44; A.497.B.44; A.498.B.4.I; A.499.B.44; A.503.B.44; A.504.B.4.I; A.505.B.44;
A.229.B.4.Í; A.230.B.4.Í; A.231.B.44; A.235.B.44; A.236.B.44; A.237.B.4.i; A.241.B.44; A.242.B.44; A.243.B.44; A.247, B.4. i; A.248.B.44; A.249.B.4 i; A.253.B.44; A.254.B.44; A.255.B.44; A.259.B.44; A.260.B.44; A.261.B.44; A.265.B.4.Í; A.266.B.44; A.267.B.44; A.271.B.44; A.272.B.44; A.273.B.4.i; A.277.B.44; A.278.B.4.Í; A.279.B.44; A.283.B.44; A.284.B.44; A.285.B.44; A.289.B.44; A.290.B.4.Í; A.291.B.44; A.295.B.44; A296.B.44; A.297.B.44; A.301.B.44; A302.B.44; A.303.B.4.Í; A.307.B.44; A.308.B.44; A.309.B.4.Í; A.313.B.44; A314.B.44; A.315.B.44; A.319.B.4.Í; A320.B.44; A.321.B.44; A.326.B.44; A.327.B.44; A328.B.44; A.332.B.44; A.333.B.44; A.334.B.4J; A.338.B.44; A.339.B.44; A.340.B.44; A.344.B.44; A.345.B.44; A.346.B.44; A.350.B.44; A.351.B.44; A.352.B.44; A.356.B.44; A.357.B.44; A.358.B.44; A.362.B.44; A.363.B.4J; A.364.B.44; A.368.B.44; A.369.B.4.Í; A.370.B.44; A.374.B.44; A375.B.44; A.376.B.44; A.380.B.44; A38LB.44; A.382.B.44; A.386.B.4.Í; A387.B.44; A.388.B.44; A.392.B.44; A.393.B.44; A.394.B.44; A.398.B.44; A.399.B.44; A.400.B.44; A.404.B.44; A405.B.44; A.406.B.44; A.410.B.44; A.411.B.44; A.412.B.44; A.416.B.44; A.417.B.44; A.418.B.44; A.422.B.44; A423.B.44; A.424.B.44; A.428.B.44; A.429.B.44; A.430.B.4.1; A.434.B.44; A.435.B.44; A.436.B.44; A.440.B.44; A.441.B.44; A-442.B.44; A.446.B.44; A.447.B.44; A.448.B.44; A.452.B.44; A.453.B.44; A.454.B.44; A.458.B.44; A.459.B.44; A.460.B.44; A.464.B.4.Í; A.465.B.44; A.466.B.44; A.470.B.44; A.471.B.44; A.472.B.44; A.476.B.44; A.477.B.44; A.478.B.4.Í; A.482.B.44; A483.B.44; A.484.B.4J; A.488.B.44; A.489.B.44; A.490.B.44; A.494B.44; A.495.B.44; A.496.B.44; A.500.B.44; A501.B.44; A.502.B.44; A.506.B.44; A.507.B.44; A.508.B.44;A.229.B.4.I; A.230.B.4.I; A.231.B.44; A.235.B.44; A.236.B.44; A.237.B.4.i; A.241.B.44; A.242.B.44; A.243.B.44; B.2. and; A.248.B.44; A.249.B.4 i; A.253.B.44; A.254.B.44; A.255.B.44; A.259.B.44; A.260.B.44; A.261.B.44; A.265.B.4.I; A.266.B.44; A.267.B.44; A.271.B.44; A.272.B.44; A.273.B.4.i; A.277.B.44; A.278.B.4.I; A.279.B.44; A.283.B.44; A.284.B.44; A.285.B.44; A.289.B.44; A.290.B.4.I; A.291.B.44; A.295.B.44; A296.B.44; A.297.B.44; A.301.B.44; A302.B.44; A.303.B.4.I; A.307.B.44; A.308.B.44; A.309.B.4.I; A.313.B.44; A314.B.44; A.315.B.44; A.319.B.4.I; A320.B.44; A.321.B.44; A.326.B.44; A.327.B.44; A328.B.44; A.332.B.44; A.333.B.44; A.334.B.4J; A.338.B.44; A.339.B.44; A.340.B.44; A.344.B.44; A.345.B.44; A.346.B.44; A.350.B.44; A.351.B.44; A.352.B.44; A.356.B.44; A.357.B.44; A.358.B.44; A.362.B.44; A.363.B.4J; A.364.B.44; A.368.B.44; A.369.B.4.I; A.370.B.44; A.374.B.44; A375.B.44; A.376.B.44; A.380.B.44; A38LB.44; A.382.B.44; A.386.B.4.I; A387.B.44; A.388.B.44; A.392.B.44; A.393.B.44; A.394.B.44; A.398.B.44; A.399.B.44; A.400.B.44; A.404.B.44; A405.B.44; A.406.B.44; A.410.B.44; A.411.B.44; A.412.B.44; A.416.B.44; A.417.B.44; A.418.B.44; A.422.B.44; A423.B.44; A.424.B.44; A.428.B.44; A.429.B.44; A.430.B.4.1; A.434.B.44; A.435.B.44; A.436.B.44; A.440.B.44; A.441.B.44; A-442.B.44; A.446.B.44; A.447.B.44; A.448.B.44; A.452.B.44; A.453.B.44; A.454.B.44; A.458.B.44; A.459.B.44; A.460.B.44; A.464.B.4.I; A.465.B.44; A.466.B.44; A.470.B.44; A.471.B.44; A.472.B.44; A.476.B.44; A.477.B.44; A.478.B.4.I; A.482.B.44; A483.B.44; A.484.B.4J; A.488.B.44; A.489.B.44; A.490.B.44; A.494B.44; A.495.B.44; A.496.B.44; A.500.B.44; A501.B.44; A.502.B.44; A.506.B.44; A.507.B.44; A.508.B.44;
-115CZ 297945 B6-115GB 297945 B6
A.509.B.44; A.510.B.44; A.511.B.44; A.512.B.44; A.512.B.44; A.513.B.44; A.514.B.44; A.515.B.44; A.516.B.4.Í; A.517.B.4.Í; A.518.B.4.Í; A.519.B.44; A.520.B.44; A.521.B.44; A.522.B.44; A.523.B.44; A.524.B.44; A.525.B.44; A.526.B.44; A.527.B.44; A.528.Β.4.i; A.529.B.44; A.530.B.44; A.531.B.44; A.532.B.44; A.533.B.4.1; A.534.B.4.Í; A.535.B.4.Í; A.536.B.44; A.537.B.44; A.538.B.44; A.539.B.44; A.540.B.44; A.541.B.4.Í; A.542.B.44; A.543.B.4J; A.544.B.44; A.545.B.44; A.546.B.44; A.547.B.44; A.548.B.44; A.549.B.44; A.550.B.44; A.551.B.44; A.552.B.44; A.553.B.44; A.554.B.44; A.555.B.44; A.556.B.44; A.557.B.44; A.558.B.44; A.559.B.44; A.560.B.4.Í; A561.B.44; A.562.B.44; A.563.B.4.Í; A.564.B.44; A.565.B.44; A.566.B.44; A.567.B.44; A.568.B.44; A.569.B.4.Í; A.570.B.44; A.571.B.44; A.572.B.44; A.573.B.44; A.574.B.4.Í; A.575.B.4.Í; A.576.B.4.Í; A.577.B.4.Í; A.578.B.44; A.579.B.44; A.580.B.44; A.581.B.44; A.582.B.44; A.583.B.44; A.584.B.44; A.585.B.4.Í; A.586.B.4.Í; A.587.B.4.Í; A.588.B.4.1; A.589.B.44; A.590.B.4.Í; A.591.B.44; A.592.B.44; A.593.B.44; A.594.B.4.Í; A.595.B.44; A.596.B.44; A.597.B.44; A.598.B.44; A.599.B.4.Í; A.600.B.4.Í; A.601.B.44; A.602.B.44; A.603.B.44; A.604.B.44; A.605.B.44; A.606.B.44; A.607.B.44; A.608.B.44; A.609.B.4.1; A.610.B.44; A.611.B.44; A.612.B.44; A.613.B.44; A.614.B.4.Í; A.615.B.44; A.616.B.44; A.617.B.44; A.618.B.44; A.619.B.44; A.620.B.44; A.621.B.44; A.622.B.4.Í; A.623.B.4.Í;A.624.B.44; A.625.B.44; A.626.B.44; A.627.B.44; A.628.B.44; A.629.B.4.Í; A.630.B.44; A.631.B.4.Í; A.632.B.4.1; A.633.B.4.i; A634.B.44; A.635.B.44; A.636.B.4.Í; A.637.B.4.Í; A.638.B.44; A.639.B.4.Í; Α.640.Β.4.Ϊ; A.641.B.4.Í; A.642.B.4.Í; A.643.B.4.Í; A.644.B.4.Í; A.645.B.4.I; A.646.B.4.Í; A.647.B.4.Í; A.648.B.4.Í; A.649.B.4.Í; A.650.B.4.Í; A.651.B.4.Í; A.652.B.4.Í; A.653.B.4.Í; A.654.B.4.Í; A.655.B.4.Í; A.656>B.4.i; A.657.B.4.Í; A.658.B.4.Í; A.659.B.4.Í; A.660.B.4.Í; Α.2.Β.11.Ϊ; A.3.B.11.Í; A.4.B.11.Í; A.5.B.11 i; A.6.B.11.Í; A.7.B.U.Í; A.9.B.11.Í; A.10.B.11.Í; A.15.B.11.Í; A.1OO.B.11.Í; A.1O1.B.11.Í; A.102.B.11.Í; A-103.B.U.Í; A.104.B.11.Í; A.1O5.B.11.Í; A.106.B.11.Í; A.1O7.B.11.Í; A.1O8.B.11.Í; A.109.B.U.Í; A.110.B.U.Í; A.111.B.11.Í; A.112.B.U.Í; A.113.B.U.Í; A.114.B.11.Í; A.115.B.U.Í; A.116.B.U.Í; A.117.B.11.Í; A.118.B.11.Í; A.119.B.11.Í; A.120.B.11.Í; A.121.B.1U; A.122.B.11.Í; A.123.B.11.Í; Α.124.Β.11.Ϊ; A.125.B.11.Í; A.126.B.11.Í; A.127.B.11.Í; A.128.B.U.Í; A.129.B.11.Í; A.130.B.11.Í; A.131.B.11.Í; A.132.B.1U; A.133.B.U.Í; A.134.B.U.Í; A.135.B.11.Í; A.136.B.11.Í; A.137-B.11.Í; A.138.B.11.Í; A.139.B.11.Í; A.14O.B.11.Í; A.141.B.11.Í; A.142.B.11.Í; A.143.B.U.Í; A.144.B.11.Í; A.145.B.1U; A.146.B.11.Í; Α.147.ΒΛ1.Ϊ; A.148.B.11.Í; A.149.B.11.Í; A.150.B.11.Í; A.151.B.11.Í; A.152.B.U.Í; A.153.B.11.Í; A.154.B.11.Í; A.155.B.11J; Α.156.Β.1Ί4; A.157.B.11.Í; A.158.B.11.Í; Α.159.Β.1Π; A.lóO.B.ll.i; A.lól.B.ll.i; A.162.B.11.Í; A.163.B.11.Í; A.164.B.1U; A.165.B.IU; A.166.B.11.Í; A.167.B.Í1.Í; A.168.B.11.Í; A.I69.B.11.Í; A.170.B.U.Í; A.171.B.11.Í; A.172.B.11.Í; A.173.B.11.Í; A.174.B.1I.Í; A.175.B.11.Í; A.176.B.11.Í; A.177.B.11.Í; A.178.B.1LÍ; A.179.B.114; A.180.B.114; A-181.B. · l.i; A.182.B.114; A.183.B.11.Í; A.184.B.U4; A.185.B.11.Í; A.186.B.114; A.187.B.11.Í; A.188.B.114; A.1B9.B414; A.19O.B.114; A.191.B.11.Í; A.192.B.114; A.193.B.11.Í; A.194.B.11.Í; A.195.B.114; A.196.B.114; A.197.B.114; Α.198.Β.11.Ϊ; A.199.B.114; A.200.B.114; A.201.B.114; A.202.B.114; A.203.B.114; A.204.B.114; A.205.B.114; A.206.B.114; A.207.B.114; A.208.B.114; A.209.B.114; A.210.B.1U; Α.2Ι1.Β.11.Ϊ; A.212.B.114; A.213.B.11.Í; A.214.B.114; A.215.B.114; A.216.B.11.Í; A.217.B.U.Í; A.218.B.114; A.219.B.114; A.220.B.114;A.509.B.44; A.510.B.44; A.511.B.44; A.512.B.44; A.512.B.44; A.513.B.44; A.514.B.44; A.515.B.44; A.516.B.4.I; A.517.B.4.I; A.518.B.4.I; A.519.B.44; A.520.B.44; A.521.B.44; A.522.B.44; A.523.B.44; A.524.B.44; A.525.B.44; A.526.B.44; A.527.B.44; A.528.Β.4.i; A.529.B.44; A.530.B.44; A.531.B.44; A.532.B.44; A.533.B.4.1; A.534.B.4.I; A.535.B.4.I; A.536.B.44; A.537.B.44; A.538.B.44; A.539.B.44; A.540.B.44; A.541.B.4.I; A.542.B.44; A.543.B.4J; A.544.B.44; A.545.B.44; A.546.B.44; A.547.B.44; A.548.B.44; A.549.B.44; A.550.B.44; A.551.B.44; A.552.B.44; A.553.B.44; A.554.B.44; A.555.B.44; A.556.B.44; A.557.B.44; A.558.B.44; A.559.B.44; A.560.B.4.I; A561.B.44; A.562.B.44; A.563.B.4.I; A.564.B.44; A.565.B.44; A.566.B.44; A.567.B.44; A.568.B.44; A.569.B.4.I; A.570.B.44; A.571.B.44; A.572.B.44; A.573.B.44; A.574.B.4.I; A.575.B.4.I; A.576.B.4.I; A.577.B.4.I; A.578.B.44; A.579.B.44; A.580.B.44; A.581.B.44; A.582.B.44; A.583.B.44; A.584.B.44; A.585.B.4.I; A.586.B.4.I; A.587.B.4.I; A.588.B.4.1; A.589.B.44; A.590.B.4.I; A.591.B.44; A.592.B.44; A.593.B.44; A.594.B.4.I; A.595.B.44; A.596.B.44; A.597.B.44; A.598.B.44; A.599.B.4.I; A.600.B.4.I; A.601.B.44; A.602.B.44; A.603.B.44; A.604.B.44; A.605.B.44; A.606.B.44; A.607.B.44; A.608.B.44; A.609.B.4.1; A.610.B.44; A.611.B.44; A.612.B.44; A.613.B.44; A.614.B.4.I; A.615.B.44; A.616.B.44; A.617.B.44; A.618.B.44; A.619.B.44; A.620.B.44; A.621.B.44; A.622.B.4.I; A.624.B.4.I; A.624.B.44; A.625.B.44; A.626.B.44; A.627.B.44; A.628.B.44; A.629.B.4.I; A.630.B.44; A.631.B.4.I; A.632.B.4.1; A.633.B.4.i; A634.B.44; A.635.B.44; A.636.B.4.I; A.637.B.4.I; A.638.B.44; A.639.B.4.I; Α.640.Β.4.Ϊ; A.641.B.4.I; A.642.B.4.I; A.643.B.4.I; A.644.B.4.I; A.645.B.4.I; A.646.B.4.I; A.647.B.4.I; A.648.B.4.I; A.649.B.4.I; A.650.B.4.I; A.651.B.4.I; A.652.B.4.I; A.653.B.4.I; A.654.B.4.I; A.655.B.4.I; A.656> B.4.i; A.657.B.4.I; A.658.B.4.I; A.659.B.4.I; A.660.B.4.I; Α.2.Β.11.Ϊ; A.3.B.11.I; A.4.B.11.Í; A.5.B.11 i; A.6.B.11.I; A.7.B.U.I; A.9.B.11.I; A.10.B.11.Í; A.15.B.11.I; A.1OO.B.11.I; A.1O1.B.11.I; A.102.B.11.Í; A-103.B.U.I; A.104.B.11.Í; A.1O5.B.11.I; A.106.B.11.Í; A.1O7.B.11.I; A.1O8.B.11.I; A.109.B.U.I; A.110.B.U.I; A.111.B.11.Í; A.112.B.U.I; A.113.B.U.I; A.114.B.11.Í; A.115.B.U.I; A.116.B.U.I; A.117.B.11.Í; A.118.B.11.Í; A.119.B.11.Í; A.120.B.11.I; A.121.B.1U; A.122.B.11.Í; A.123.B.11.Í; Α.124.Β.11.Ϊ; A.125.B.11.Í; A.126.B.11.Í; A.127.B.11.Í; A.128.B.U.I; A.129.B.11.Í; A.130.B.11.Í; A.131.B.11.I; A.132.B.1U; A.133.B.U.I; A.134.B.U.I; A.135.B.11.I; A.136.B.11.Í; A.137-B.11.I; A.138.B.11.Í; A.139.B.11.Í; A.14O.B.11.Í; A.141.B.11.Í; A.142.B.11.I; A.143.B.U.I; A.144.B.11.Í; A.145.B.1U; A.146.B.11.Í; Α.147.ΒΛ1.Ϊ; A.148.B.11.Í; A.149.B.11.Í; A.150.B.11.Í; A.151.B.11.Í; A.152.B.U.I; A.153.B.11.Í; A.154.B.11.Í; A.155.B.11J; Α.156.Β.1Ί4; A.157.B.11.Í; A.158.B.11.Í; Α.159.Β.1Π; A.lOO.B.ll.i; A.lól.B.ll.i; A.162.B.11.Í; A.163.B.11.I; A.164.B.1U; A.165.B.IU; A.166.B.11.Í; A.167.B.I1.I; A.168.B.11.I; A.I69.B.11.I; A.170.B.U.I; A.171.B.11.I; A.172.B.11.Í; A.173.B.11.I; A.174.B.1I.I; A.175.B.11.Í; A.176.B.11.Í; A.177.B.11.Í; A.178.B.1LÍ; A.179.B.114; A.180.B.114; A-181.B. · L.i; A.182.B.114; A.183.B.11.I; A.184.B.U4; A.185.B.11.I; A.186.B.114; A.187.B.11.Í; A.188.B.114; A.1B9.B414; A.19O.B.114; A.191.B.11.Í; A.192.B.114; A.193.B.11.I; A.194.B.11.Í; A.195.B.114; A.196.B.114; A.197.B.114; Α.198.Β.11.Ϊ; A.199.B.114; A.200.B.114; A.201.B.114; A.202.B.114; A.203.B.114; A.204.B.114; A.205.B.114; A.206.B.114; A.207.B.114; A.208.B.114; A.209.B.114; A.210.B.1U; Α.2Ι1.Β.11.Ϊ; A.212.B.114; A.213.B.11.Í; A.214.B.114; A.215.B.114; A.216.B.11.Í; A.217.B.U.I; A.218.B.114; A.219.B.114; A.220.B.114;
-116CZ 297945 B6-116GB 297945 B6
Α221.Β.Ί1.χ; Α.222.Β.11.Ϊ; A.223.B.11.Í; A227.B.11.Í; A.228.B.11.Í; A.229.B.11.Í; A233.B.11J; A.234.B.11.Í; A.235.B.11.Í; A239.B.11.Í; A240.B.11.Í; A241.B.11.Í; A.245.B.U.Í; A246.B.1I.Í; A.247.B.11.Í; A251.B.11.Í; A.252.B.11.Í; A.253.B.11.Í; A257.B.11.Í; A.258.B.11.Í; A.259.B.11.Í; Α263.Β.11.Ϊ; Α264.Β.Π.Ϊ; A.265.B.11.Í; A269.B.11.Í; A270.B.11.Í; A.271.B.11.Í; A275.B.11.Í; A276.B.11.Í; A.277.B.11.Í; A281.B.11.Í; A282.B.Í1.Í; A283.B.11.Í; A287.B.11.Í; A288.B.U.Í; A289.B.11.Í; A293.B. 11 .i; Α294.Β.1Π; A295.B.11 .i; A299.B.11.Í; A.300.B-1U; A.301.B.11.Í; A.305.B.11.Í; Α.306.Β.11Λ; A.3Q7.B.1LÍ; A.311.B.11.Í; A.312.B.11.Í; A.313.B.11.Í; A.317.B.11.Í; A.318.B.11.Í; A.319.B.11.Í; A.324.B.U,i; A.325.B.1LÍ; Α.326.Β.1Π; A.330.B.11.Í; A.331.B.11.Í; A.332.B.11.Í; A.336.B.11.Í; A.337.B.11.Í; A.338.B.11.Í; Α.342.Β.11.Ϊ; A.343.B.I1.Í; A.344.B.11.Í; A.348.B.11.Í; A.349.B.11.Í; A.350.B.11.Í; A.354.B.11.Í; A.355.B.11.Í; A.356.B.11.Í; A.360.B.11.Í; A.361.B.1U; A.362.B.1U; A.366.B.11.Í; A.367.B.11.Í; A.368.B.11.Í; A.372.B.11.Í; A.373.B.11.Í; A.374.B.11.1; A.378.B.11.Í; A.379.B.1U; A.380.B.11.Í; A.384.B.11.Í; A.385.B.1U; A.386.B.U.Í; A.390.B.11.Í; A.391.B.11.Í; A392.B.11.Í; A.396.B.11.Í,· A.397.B.11.Í; A398.B.1U; A.402.B.11.Í; A.403.B.11.Í; A.404.B.Í1.Í; A.408.B.11.Í; A.409.B.U.Í; A.410.B.11.Í; A.414.B.11.Í; A.415.B.11.Í; Α.416.Β.1Π; A.420.B.U.Í; Α.421.Β.11.Ϊ; A.422.B.11.Í; Α.426.Β.11.Ϊ; A.427.B.11.Í; A.428.B.1U; A.432.B.11.Í; A.433.B.11.Í; A.434.B.11.Í; A.438.B..11.Í; A.439.B.11.Í; A.440.B.11.Í; A.444.B.11.Í; A.445.B.U.Í; A.446.B.11.Í; A.450.B.11.Í; A.451.B.11.Í; A.452.B.11.Í; A.456.B.11.Í; A.457.B.11.Í; A.458.B.11.Í; A.462.B.11.Í; A.463.B.U.Í; A.464.B.11.Í; A.468.B.1U; Á.469.B.11.Í; A.470.B.11.Í; A.474.B.11.Í; A.475.B.1U; A.476.B.11.Í; A.480.B.11.Í; A.481.B.U.Í; A.482.B.11.1; A.486.B.U.Í; A.487.B.11.Í: A.488.B.11.Í; A.492.B.11.Í; A.493.B.11.Í; A.494.B.11.Í; A.498.B.11.1; A.499.B.11.1; A.500.B.11.Í;Α221.Β.Ί1.χ; Α.222.Β.11.Ϊ; A.223.B.11.I; A227.B.11.I; A.228.B.11.Í; A.229.B.11.I; A233.B.11J; A.234.B.11.Í; A.235.B.11.Í; A239.B.11.I; A240.B.11.I; A241.B.11.I; A.245.B.U.I; A246.B.1I.I; A.247.B.11.Í; A251.B.11.I; A.252.B.11.Í; A.253.B.11.Í; A257.B.11.I; A.258.B.11.Í; A.259.B.11.Í; Α263.Β.11.Ϊ; Α264.Β.Π.Ϊ; A.265.B.11.Í; A269.B.11.I; A270.B.11.I; A.271.B.11.Í; A275.B.11.I; A276.B.11.I; A.277.B.11.Í; A281.B.11.I; A282.B.I1.I; A283.B.11.I; A287.B.11.I; A288.B.U.I; A289.B.11.I; A293.B. 11 .i; Α294.Β.1Π; A295.B.11 .i; A299.B.11.I; A.300.B-1U; A.301.B.11.Í; A.305.B.11.I; Α.306.Β.11Λ; A.3Q7.B.1LÍ; A.311.B.11.Í; A.312.B.11.Í; A.313.B.11.Í; A.317.B.11.Í; A.318.B.11.Í; A.319.B.11.Í; A.324.B.U, i; A.325.B.1LÍ; Α.326.Β.1Π; A.330.B.11.Í; A.331.B.11.Í; A.332.B.11.Í; A.336.B.11.Í; A.337.B.11.Í; A.338.B.11.Í; Α.342.Β.11.Ϊ; A.343.B.I1.I; A.344.B.11.Í; A.348.B.11.Í; A.349.B.11.Í; A.350.B.11.Í; A.354.B.11.Í; A.355.B.11.Í; A.356.B.11.Í; A.360.B.11.Í; A.361.B.1U; A.362.B.1U; A.366.B.11.Í; A.367.B.11.Í; A.368.B.11.I; A.372.B.11.Í; A.373.B.11.I; A.374.B.11.1; A.378.B.11.Í; A.379.B.1U; A.380.B.11.Í; A.384.B.11.Í; A.385.B.1U; A.386.B.U.I; A.390.B.11.Í; A.391.B.11.Í; A392.B.11.I; A.396.B.11.I, · A.397.B.11.I; A398.B.1U; A.402.B.11.I; A.403.B.11.I; A.404.B.I1.I; A.408.B.11.I; A.409.B.U.I; A.410.B.11.Í; A.414.B.11.Í; A.415.B.11.Í; Α.416.Β.1Π; A.420.B.U.I; Α.421.Β.11.Ϊ; A.422.B.11.Í; Α.426.Β.11.Ϊ; A.427.B.11.Í; A.428.B.1U; A.432.B.11.Í; A.433.B.11.Í; A.434.B.11.Í; A.438.B..11.I; A.439.B.11.Í; A.440.B.11.Í; A.444.B.11.Í; A.445.B.U.I; A.446.B.11.Í; A.450.B.11.Í; A.451.B.11.Í; A.452.B.11.Í; A.456.B.11.Í; A.457.B.11.Í; A.458.B.11.Í; A.462.B.11.Í; A.463.B.U.I; A.464.B.11.Í; A.468.B.1U; Á.469.B.11.Í; A.470.B.11.Í; A.474.B.11.Í; A.475.B.1U; A.476.B.11.Í; A.480.B.11.Í; A.481.B.U.I; A.482.B.11.1; A.486.B.U.I; A.487.B.11.I: A.488.B.11.I; A.492.B.11.Í; A.493.B.11.I; A.494.B.11.Í; A.498.B.11.1; A.499.B.11.1; A.500.B.11.Í;
A224.B.11.1; A.225.B.11.Í; A226.B.H.Í; A230.B.11.Í; A231.B.11.Í; A23ZB.il.i; A.236.B.11.Í; A.237.B.11.Í; A238.B.11.Í; A242.B.11.Í; A243.B.11.Í; A244.B.11.Í; A248.B.H.Í; A249.B.11.Í; A25O.B.11.Í; A.254.B.11.Í; A.255.B.11.Í; A256.B.1LÍ; A260.B.11.Í; A261.B.11.Í; A262.B.11.Í; A266.B.11.Í; A267.B.U.Í; A268.B.U.Í; A272.B.11.Í; A273.B.11.Í; A274.B.11.Í; A278.B.11.Í; A.279.B.11.Í; A28O3.11.Í; A284.B..1LÍ; A285.B.11.Í; A286.B.11.Í; A290.B.11.Í; A291.B.11.Í; A292.B.11.Í; A296.B.11.Í; A297.B.U.Í; A2983.11.Í; A.302.B.11.Í; A303.B.1U; A.304.B.11.Í; A.308.B.11.Í; A.309.B.11.Í; A.310.B.ll,i; A314.B.11.1; A.315.B.11.Í; A.316.B.11.Í; A.320.B.11.Í; A321.B.11.Í; A.323.B.1U; A.327.B.11.Í; A.328.B.11.Í; A329.B.11.Í; A.333.B.11.Í; Α.334.Β·11,χ; A.335.B.11.Í; A.339.B.11.Í; A.340.B.11.Í; A.341.B.11.Í; A.345.B.11.1; A.346.B.11.Í; A.347.B.11.Í; A.351.B.11.Í; A.352.B.11.Í; A353.B.ll.x; A.357.B.11.Í; A.358.B.11.Í; A359.B.11.Í; A.363.B.11.Í; A.364.B.11.Í; A.365.B.11.Í; A.369.B.11.Í; A370.B.11.Í; A371.B.11.Í; A375JB.11.Í; A.376.B.U.Í; A.377.B.11.Í; A.381.B.11.Í; A382.B.11.Í; A.383.B.11.Í; A.387.B.11.Í; A388.B.11.Í; A.389.B.11.Í; A393.B.11.Í; A394.B.11.Í; A.395.B.11.Í; A.399.B.11.Í; A.400.B.11.Í; A.401.B.1U; A.405.B.11.Í; A.406.B.11.Í; A.407.B.11.Í; A.411.B.U.Í; A.412.B.11.Í; A.413.B.1 l.i: A.417.B.11.Í; A.418.B.U.Í; A.419.B.11.Í; A.423.B.11.Í; A.424.B.11.Í; A.425.B.11.Í; A.429.B.11.Í; A.430.B.11.Í; A.431.B.11.Í; A.435.B.11.Í; A.436.B.11.Í; A.437.B.U.Í; A.441.B.11.Í; A.442.B.11.Í; A.443.B.11.Í; A.447.B.11.Í; A.448.B.1U; A.449.B.11.Í; A453.B.11.Í; A.454.B.11.Í; A.455.B.11.Í; A.459.B.11.1; A.460.B.11.Í; A.461.B.11.Í; A.465.B.11.Í; A.466.B.11.Í; A.467.B.11.Í; A.471.B.11.Í; A.472.B.11.Í; A.473.B.11.Í; A.477.B.11T; A.478.B.11.Í; A.479.B.11.Í; A.483.B.11.Í; A.484.B.11.Í; A.485.B.11.Í; A.489.B.11.I; A.490.B.11.Í; A.491.B.11.Í; A.495.B.11.Í; A.496.B.11.Í; A.497.B.11.Í; A.SOl.B.U.i; A.502.B.U.Í; A.503.B.11.Í;A224.B.11.1; A.225.B.11.Í; A226.B.H.I; A230.B.11.I; A231.B.11.I; A23ZB.il.i; A.236.B.11.Í; A.237.B.11.Í; A238.B.11.I; A242.B.11.I; A243.B.11.I; A244.B.11.I; A248.B.H.I; A249.B.11.I; A25O.B.11.I; A.254.B.11.Í; A.255.B.11.Í; A256.B.1LÍ; A260.B.11.I; A261.B.11.I; A262.B.11.I; A266.B.11.I; A267.B.U.I; A268.B.U.I; A272.B.11.I; A273.B.11.I; A274.B.11.I; A278.B.11.I; A.279.B.11.Í; A28O3.11.Í; A284.B..1LÍ; A285.B.11.I; A286.B.11.I; A290.B.11.I; A291.B.11.I; A292.B.11.I; A296.B.11.I; A297.B.U.I; A2983.11.Í; A.302.B.11.I; A303.B.1U; A.304.B.11.I; A.308.B.11.I; A.309.B.11.I; A.310.B.1, i; A314.B.11.1; A.315.B.11.Í; A.316.B.11.Í; A.320.B.11.Í; A321.B.11.I; A.323.B.1U; A.327.B.11.Í; A.328.B.11.Í; A329.B.11.I; A.333.B.11.Í; Α.334. · 11, χ; A.335.B.11.Í; A.339.B.11.Í; A.340.B.11.Í; A.341.B.11.Í; A.345.B.11.1; A.346.B.11.Í; A.347.B.11.Í; A.351.B.11.Í; A.352.B.11.Í; A353.B.ll.x; A.357.B.11.Í; A.358.B.11.Í; A359.B.11.I; A.363.B.11.Í; A.364.B.11.Í; A.365.B.11.Í; A.369.B.11.Í; A370.B.11.Í; A371.B.11.I; A375JB.11.Í; A.376.B.U.I; A.377.B.11.Í; A.381.B.11.Í; A382.B.11.I; A.383.B.11.Í; A.387.B.11.Í; A388.B.11.I; A.389.B.11.Í; A393.B.11.I; A394.B.11.I; A.395.B.11.Í; A.399.B.11.Í; A.400.B.11.Í; A.401.B.1U; A.405.B.11.I; A.406.B.11.I; A.407.B.11.I; A.411.B.U.I; A.412.B.11.Í; A.413.B.1 l.i: A.417.B.11.I; A.418.B.U.I; A.419.B.11.Í; A.423.B.11.Í; A.424.B.11.Í; A.425.B.11.Í; A.429.B.11.Í; A.430.B.11.Í; A.431.B.11.Í; A.435.B.11.Í; A.436.B.11.Í; A.437.B.U.I; A.441.B.11.Í; A.442.B.11.Í; A.443.B.11.Í; A.447.B.11.Í; A.448.B.1U; A.449.B.11.Í; A453.B.11.I; A.454.B.11.Í; A.455.B.11.Í; A.459.B.11.1; A.460.B.11.Í; A.461.B.11.Í; A.465.B.11.Í; A.466.B.11.Í; A.467.B.11.Í; A.471.B.11.Í; A.472.B.11.Í; A.473.B.11.Í; A.477.B.11T; A.478.B.11.Í; A.479.B.11.Í; A.483.B.11.Í; A.484.B.11.Í; A.485.B.11.Í; A.489.B.11.I; A.490.B.11.Í; A.491.B.11.Í; A.495.B.11.Í; A.496.B.11.Í; A.497.B.11.Í; A.SOl.B.U.i; A.502.B.U.I; A.503.B.11.I;
-117CZ 297945 B6-117GB 297945 B6
Α.504.Β.11.Ϊ; A.505.B.11.Í; A.506.B.11.Í; A.507.B.11.Í; A.508.B.11.Í; A.509.B.11.Í; A.510.B.11.Í; A.511.B.11.Í; A.512.B.11.Í; A.512.B.11.Í; A.513.B.11.Í; A.514.B.11.Í; A.515.B.11.Í; A.516.B.11.Í; A.517.B.11.Í; A.518.B.11.Í; A.519.B.11.Í; A.520.B.1U; A.521.B.11.Í; A322.B.U.Í; A.523.B.11.Í; A.524.B.11.Í; A525.B.11.Í; A.526.B.11.Í; A.527.B.11.Í; A528.B.1U; A.529.B.11.Í; A.530.B.11.Í; A.531.B.1LÍ; A.532.B.11.Í; A.533.B.11.Í; A.534.B.11.Í; A.535.B.11.Í; A.536.B.11.Í; A.537.B.11.Í; A.538.B.11.Í; A.539.B.11.Í; A.540.B.11.Í; A.541.B.11.Í; A.542.B.11.Í; A.543.B.11.Í; A.544.B.11.Í; A.545.B.11.Í; A.546.B.11.Í; A.547.B.U.Í; A.548.B.11.Í; A.549.B.11.Í; A.550.B.11.Í; A.551.B.11.Í; A.552.B.11 .i; A.553.B.11.Í; A.554.B.U.Í; A.555.B.11.Í; A.556.B.11J; A.557.B.11.Í; A.558.B.11.Í; A.559.B.11.Í; A.560.B.11.Í; A561.B.11.Í; A36ZB.il j; A.563.B.11.Í; A.564.B.11.Í; A.565.B.11.1; A.566.B.1U; A.567.B.11.Í; A.568.B.11.Í; A.569.B.11.1; A.570.B.11.Í; A.571.B.11.Í; A.572.B.11.Í; A.573.B.11.Í; A.574.B.11.Í; A.575.B.11.Í; A.576.B.11.Í; A.577.B.11.Í; A.578.B.11.Í; A.579.B.11.Í; A.580.B.11.Í; A381.B.11.Í; A3BZB.1U; A.583.B.11 .i; A.584.B.1U; A385.B.11.Í; A386.B.11.Í; Α.587.Β.11.Ϊ; A388.B.11.Í; A.589.B.11.Í; A.590.B.11.Í; A.591.B.11.Í; A392.B.11.Í; A393.B.11.Í; A.594.B.11.Í; A.595.B.11.Í; A.596.B.11.Í; A397.B.11.Í; A.598.B.11.Í; A399.B.U.Í; A.600.B.11.Í; A.601.B.11.Í; A.602.B.11.Í; A.603.B.1U; A.604.B.11.Í; A.605.B.11.Í; A.606.B.11.1; A.607.B.11.Í; A.608.B.11.Í; A.609.B.11.Í; A.6IO.B.H.1; A.611.B.11.Í; A.612.B.11.Í; A.613.B.11.Í; A.614.B.11.Í; A.615.B.11.Í; A.616.B.11.Í; A.617.B.11.Í; A.618.B.11.Í; A.619.B.11.Í; A.620.B.11J; A.621.B.U.Í; A.622.B.11.Í; A.623.B.11.Í; A.624.B.11.Í; A.625.B.11.Í; A.626.B.1U A.627.B.1U A.628.B.U.Í; Α.629.Β.11.Ϊ; A.630.B.11.Í; A.631.B.11.Í; A.632.B.11.Í; A.633.B.1U; A.634.B.11.Í; A.635.B.11.Í; A.636.B.11.Í; A.637.B.11.Í; A.638.B.11.Í; A.639.B.11.Í; A.640.B.11.Í; A.641.B.11.Í; A.642.B.11.Í; A.643.B.11.Í; A.644.B.11.Í; A.645.B.11.Í; A.646.B.11.Í; A.647.B.11.Í; A.648.B.11.Í; A.649.B.11.Í; A.650.B.11.Í; A.651.B.11.Í; A.652.B.11.Í; A.653.B.U.Í; A.654.B.ll.x; A.655.B.11.Í; A.656.B.1U; A.657.B.11.Í; A.658.B.11.Í; A.659.B.11.Í; A.660.B.11.Í; A.2.C.4.Í; A.3.Č.4.Í; A.4.C.4.Í; A.5.C.4.Í; A.6.C.4.Í; A.7.C.4.Í; A.9.C.4.Í; A.10.C.4.Í; A.15.C.4.Í; A.100.C.4.Í; A.101.C.4.Í; A.102.C.4.Í; A.103.C.4.Í; A.104.C.4.Í; A.105.C.4.Í; A.106.C.4.Í; A.107.C.4.Í; A.108.C.4.Í; A.109.C.4.Í; A.110.C.4.Í; A.111.C.4.Í; A.112.C.4.Í; A.I13.C.4.Í; A.114.C.4.Í; A.115.C.4.Í; A.116.C.4.Í; A.117.C.4.Í; A.118.C.4.Í; A.119G4.Í; A.120.C.4.Í; A.121.C.4.Í; A.122.C.4.Í; A.123.C.4.Í; A.124.C.4.Í; A.125.C.4.Í; A.126.C.4.Í; A.127.C.4.Í; Á.128.C4.Í; A.129.C.4.Í; A.130.C.4.Í; A.131.C.4.Í; A.132-C.4.Í; A.133.C.4.Í; A.134.C.4.Í; A.135.C.4.Í; A.136.C.4.X; A.137.C.4.Í; A.138.C.4.Í; A.139.C.4.Í; A.140.C.4.Í; A.141.C.4.Í; A.142.C.4.Í; A.143.C.4.Í; A.144.C.4.Í; A.145.C.4.Í; A.146.C.4.Í; A.147.C.4.Í; A.148.C.4.Í; A.149.C.4.Í; A.150.C.4.Í; A.151.C.4.Í; A.152.C.4.Í; A.153.C.4.Í; A.154.C.4.Í; A.155.C.4.1; A.156.C.4.1; A.157.C.4J; A.158.C.4.Í; A.159.C.4.Í; A.160.C.4.Í; A.161.C.4.Í; A.162.C.4.Í; A.163.C.44; A.164.C.4.Í; A.165.C4.Í; A.166.C.4.Í; A.167.C.4.Í; A.168.C.4.Í; A.169.C.4.:; A.170.C.4.Í; A.171.C.4.Í; A.172.C.4.Í; A.173.C.44; A.I74.C.4.Í; A.175.C.4.Í; A.176.C.4.Í; A.177.C.4.Í; A.178.C.4.Í; A.179.C.4.Í; A.180.C.4.Í; A.181.C.41; A.182.C.4.Í; A.183.C.4.Í; A.184.C.4.Í; A.185.C.4.Í; A.186.C.4.Í; A.187.C.4.Í: A.188.C.4.Í; A.189.C.4.Í; A.190.C.4.Í; A.191.C.4.Í; A.192.C.4.Í; A.193.C.4.Í; A.194.C.4.Í; A.195.C.4.Í; A.196.C.4.Í; A.197.C.4;i; A.198.C.4.Í; A.199.C.4.Í; A.200.C.4.Í; A.201.C4.Í; A.202.C4.Í; A.203.C.4.Í; A.204.C.4.Í; A205.C.4.Í; A.206.C.4.Í; A.207.C.4.Í; A.208.C.4.Í; A.209.C.4.Í; A.210.C.4.Í; A.211.C.4.Í; A.212.C4.Í; A.213.C.4.Í; A.214.C.4.Í; A.215.C.4.Í; A.216.C.4.Í;Α.504.Β.11.Ϊ; A.505.B.11.I; A.506.B.11.I; A.507.B.11.I; A.508.B.11.I; A.509.B.11.I; A.510.B.11.I; A.511.B.11.I; A.512.B.11.I; A.512.B.11.I; A.513.B.11.I; A.514.B.11.I; A.515.B.11.I; A.516.B.11.Í; A.517.B.11.I; A.518.B.11.I; A.519.B.11.Í; A.520.B.1U; A.521.B.11.I; A322.B.U.I; A.523.B.11.I; A.524.B.11.I; A525.B.11.Í; A.526.B.11.I; A.527.B.11.Í; A528.B.1U; A.529.B.11.I; A.530.B.11.Í; A.531.B.1LÍ; A.532.B.11.I; A.533.B.11.I; A.534.B.11.Í; A.535.B.11.I; A.536.B.11.Í; A.537.B.11.I; A.538.B.11.Í; A.539.B.11.I; A.540.B.11.Í; A.541.B.11.I; A.542.B.11.I; A.543.B.11.I; A.544.B.11.I; A.545.B.11.I; A.546.B.11.Í; A.547.B.U.I; A.548.B.11.Í; A.549.B.11.I; A.550.B.11.I; A.551.B.11.Í; A.552.B.11 .i; A.553.B.11.I; A.554.B.U.I; A.555.B.11.I; A.556.B.11J; A.557.B.11.I; A.558.B.11.I; A.559.B.11.Í; A.560.B.11.I; A561.B.11.I; A36ZB.il j; A.563.B.11.I; A.564.B.11.Í; A.565.B.11.1; A.566.B.1U; A.567.B.11.Í; A.568.B.11.I; A.569.B.11.1; A.570.B.11.Í; A.571.B.11.I; A.572.B.11.Í; A.573.B.11.I; A.574.B.11.Í; A.575.B.11.I; A.576.B.11.I; A.577.B.11.Í; A.578.B.11.Í; A.579.B.11.Í; A.580.B.11.Í; A381.B.11.I; A3BZB.1U; A.583.B.11 .i; A.584.B.1U; A385.B.11.I; A386.B.11.I; Α.587.Β.11.Ϊ; A388.B.11.I; A.589.B.11.Í; A.590.B.11.Í; A.591.B.11.Í; A392.B.11.I; A393.B.11.I; A.594.B.11.I; A.595.B.11.Í; A.596.B.11.Í; A397.B.11.I; A.598.B.11.Í; A399.B.U.I; A.600.B.11.Í; A.601.B.11.Í; A.602.B.11.I; A.603.B.1U; A.604.B.11.I; A.605.B.11.I; A.606.B.11.1; A.607.B.11.I; A.608.B.11.I; A.609.B.11.I; A.6IO.B.H.1; A.611.B.11.Í; A.612.B.11.Í; A.613.B.11.Í; A.614.B.11.Í; A.615.B.11.Í; A.616.B.11.Í; A.617.B.11.Í; A.618.B.11.Í; A.619.B.11.Í; A.620.B.11J; A.621.B.U.I; A.622.B.11.I; A.623.B.11.I; A.624.B.11.Í; A.625.B.11.Í; A.626.B.1U A.627.B.1U A.628.B.U.I; Α.629.Β.11.Ϊ; A.630.B.11.Í; A.631.B.11.Í; A.632.B.11.Í; A.633.B.1U; A.634.B.11.Í; A.635.B.11.Í; A.636.B.11.Í; A.637.B.11.Í; A.638.B.11.Í; A.639.B.11.Í; A.640.B.11.Í; A.641.B.11.Í; A.642.B.11.Í; A.643.B.11.Í; A.644.B.11.Í; A.645.B.11.Í; A.646.B.11.Í; A.647.B.11.Í; A.648.B.11.Í; A.649.B.11.Í; A.650.B.11.Í; A.651.B.11.Í; A.652.B.11.Í; A.653.B.U.I; A.654.B.ll.x; A.655.B.11.Í; A.656.B.1U; A.657.B.11.Í; A.658.B.11.Í; A.659.B.11.Í; A.660.B.11.Í; A.2.C.4.Í; A.3.Č.4.Í; A.4.C.4.Í; A.5.C.4.Í; A.6.C.4.Í; A.7.C.4.Í; A.9.C.4.Í; A.10.C.4.Í; A.15.C.4.Í; A.100.C.4.Í; A.101.C.4.Í; A.102.C.4.Í; A.103.C.4.Í; A.104.C.4.Í; A.105.C.4.Í; A.106.C.4.Í; A.107.C.4.Í; A.108.C.4.Í; A.109.C.4.Í; A.110.C.4.Í; A.111.C.4.Í; A.112.C.4.Í; A.I13.C.4.I; A.114.C.4.Í; A.115.C.4.Í; A.116.C.4.Í; A.117.C.4.Í; A.118.C.4.Í; A.119G4.Í; A.120.C.4.Í; A.121.C.4.Í; A.122.C.4.Í; A.123.C.4.Í; A.124.C.4.Í; A.125.C.4.Í; A.126.C.4.Í; A.127.C.4.Í; Á.128.C4.Í; A.129.C.4.Í; A.130.C.4.Í; A.131.C.4.Í; A.132-C.4.I; A.133.C.4.Í; A.134.C.4.Í; A.135.C.4.Í; A.136.C.4.X; A.137.C.4.Í; A.138.C.4.Í; A.139.C.4.Í; A.140.C.4.Í; A.141.C.4.Í; A.142.C.4.Í; A.143.C.4.Í; A.144.C.4.Í; A.145.C.4.Í; A.146.C.4.Í; A.147.C.4.Í; A.148.C.4.Í; A.149.C.4.Í; A.150.C.4.Í; A.151.C.4.Í; A.152.C.4.Í; A.153.C.4.Í; A.154.C.4.Í; A.155.C.4.1; A.156.C.4.1; A.157.C.4J; A.158.C.4.Í; A.159.C.4.Í; A.160.C.4.Í; A.161.C.4.Í; A.162.C.4.Í; A.163.C.44; A.164.C.4.Í; A.165.C4.Í; A.166.C.4.Í; A.167.C.4.Í; A.168.C.4.Í; A.169.C.4.:; A.170.C.4.Í; A.171.C.4.Í; A.172.C.4.Í; A.173.C.44; A.I74.C.4.I; A.175.C.4.Í; A.176.C.4.Í; A.177.C.4.Í; A.178.C.4.Í; A.179.C.4.Í; A.180.C.4.Í; A.181.C.41; A.182.C.4.Í; A.183.C.4.Í; A.184.C.4.Í; A.185.C.4.Í; A.186.C.4.Í; A.187.C.4.I: A.188.C.4.I; A.189.C.4.Í; A.190.C.4.Í; A.191.C.4.Í; A.192.C.4.Í; A.193.C.4.Í; A.194.C.4.Í; A.195.C.4.Í; A.196.C.4.Í; A.197.C.4; i; A.198.C.4.Í; A.199.C.4.Í; A.200.C.4.Í; A.201.C4.Í; A.202.C4.Í; A.203.C.4.Í; A.204.C.4.Í; A205.C.4.I; A.206.C.4.Í; A.207.C.4.Í; A.208.C.4.Í; A.209.C.4.Í; A.210.C.4.Í; A.211.C.4.Í; A.212.C4.Í; A.213.C.4.Í; A.214.C.4.Í; A.215.C.4.Í; A.216.C.4.Í;
-118CZ 297945 B6-118GB 297945 B6
A.217.C.44; A.218.C.4.Í; A.219.C.4.Í; A.220.C.4.Í; A.221.C.4.Í; A.222.C.4.Í; A.223.C.44; A224.C.44; A.225.C.4.Í; A.226.C.44; A.227.C.4.Í; A228.C.4.Í; A229.C.4.Í; A230.C.4.Í; A.231.C.44; A.232.C.4.Í; A.233.C.44; A.234.C.44; A.235.C.44; A.236.C.44; A.237.C.44; A238.C.44; A.239.C.44; A.240.C.4.Í; A.241.C.44; A.242.C.4.i; A.243.C.44; A.244.C.4i; A.245.C.44; A.246.C.44; A247.C.4.Í; A.248.C.4.Í; A.249.C.4.Í; A.250.C.4.Í; A.251.C.4.Í; A.252.C.4.Í; A.253.C.4.Í;A254.C.44; A.255.C.44; A.256.C.44; A.257.C.44; A258.C.4.Í; A259.C.44; A.260.C.44; A.261.C.4.Í; A.262.C.4.Í; A.263.C.44; A.264.C.4.Í; A265.C.4.Í; A.266.C.4.Í; A267.C.4.1; A.268.C.4.Í; A.269.C.44; A270.C.4.1; A271.C.44; A.272.C.44; A.273.C.44; A.274.C.44; A.275.C.4.Í; A276.C.4.Í; A.277.C.44; A.278.C.44; A.279.C.44; A.280.C.44; A.281.C.44; A.282.C.4.Í; A.283.C.44; A.284.C.4.Í; A.285.C.44; A.286.C.44; A.287.C.44; A.288.C.44; A.289.C.44; A.290.C.4.Í; A.291.C.4.Í; A.292.C.4.Í; A.293.C.44; A294.C.4.1; A.295.C.44; A.296.C.4.Í; A.297.C.4.1; A.298.C.4.1; A.299.C.44; A.300.C.4.Í; A.301.C.44; A.302.C.44; A.303.C.4.Í; A.304.C.44; A.305.C.44; A.306.C.44; A.307.C.44; A.308.C.44; A.309.C.4.1; A.310.C.44; A.311.C.44; A.312.C.44; A.313.C.4.Í; A.314.C.44; A.315.C.44; A.316.C.44; A.317.C.44; A.318.C.4.Í; A.319.C.44; A.320.C.44; A.321.C.4.Í; A.323.C.44; A.324.C.44; A.325.C.44; A.326.C.4.Í; A.327.C.4.Í; A.328.C.4.Í; A.329.C.44; A.330.C.4.Í; A.331.C.4.Í; A.332.C.4.Í; A.333.C.4.Í; A334.C.44; A.335.C.4.Í; A.336.C.4.1; A.337.C.4.Í; A.338.C.44; A.339.C.4.Í; A.340.C.4.Í; A.341.C.4.Í; A.342.C.44; A.343.C.4.Í; A.344.C.44; A.345.C.44; A.346.C.4.Í; A.347.C.44; A.348.C.4.Í; A.349.C.4.Í; A.350.C.44; A.351.C.44; A352.C.44; A.353.C.44; A.354.C.4.Í; A.355.C.44; A.356.C.44; A.357.C.44; A.358.C.4.Í; A.359.C44; A.360.C.4.Í; A.361.C.4.1; A.362.C.44; A.363.C.4.Í; A.364.C.4.Í; A.365.C.44; A.366.C.41; A.367.C.44; A.368.C.44; A.369.C.44; A.370.C.4.Í; A.371.C.4.Í; A.372.C.44; A.373.C.4.Í; A.374.C.44; A.375.C.44; A.376.C.44; A.377.C.4J; A.378.C.44; A.379.C.4.Í; A.380.C.44; A.381.C.44; A.382.C.44; A.383.C.44; A.384.C.44; A.385.C.44; A.386.C.44; A.387.C.44; A.388.C.44; A.389.C.44; A.390.C.44; A.391.C.4.Í; A.392.C.44; A.393.C.4.Í; A.394.C.4.Í; A.395.C.44; A.396.C.4.Í; A.397.C.4.Í; Á.398.G.44; A.399.C.4.Í; A.400.C.44; A.401.C.44; A.402.C.44; A.403.C.4.i; A.404.C.44; A.405.C.44; A.406.C.44; A.407.G44; A.408.C.44; A.409.C.4.Í; A.410.C.44; A.4U.C.44; A.412.C.44; A.413.C4J; A.414.C.44; A.415.C.44; A.416.C.44; A.417.C.44; A.418.C.44; A.419.C.44; A.420.C.44; A.421.C.44; A.422.C.44; A.423.C.44; A.424.C.44; A.425.C.44; A.426.C.44; A.427.C.44; A.428.C.44; A.429.C.44; A.430.C.4.Í; A.431.C.44; A.432.C.4.Í; A.433.Č44; A.434.C.44; A.435.C.44; A.436.C.4.Í; A.437.C.44; A.438.C.44; A.439.C.44; A.440.C.44; A.441.C.44; A.442.C.4.Í; A.443.C.44; A.444.C.44; A.445.C.4.Í; A.446.C.44; A.447.C.44; A.448.C.4.Í; A.449.C.44; A.450.C.44; A.451.C.4.Í; A.452.C.44; A.453.C.44; A.454.C.4.i; A.455.C.44; A.456.C.4.Í; A.457.C.4.Í; A.458.C.44; A.459C.44; A.460.C.44; A.461.C.44; A.462.C.44; A.463.C.4.Í; A.464.C.44; A.465.C.4.1; A.466.C.4.Í; A.467.C.4.Í; A.468.C.44; A.469.C.4.Í; A.47Ó.C44; A.471.C.44; A.472.C.4.Í; A.473.C.44; A.474-C.44; A.475.C.44; A.476.C.44; A.477.C.4.Í; A.478.C.4.Í; A.479.C.44; A.480.C.4.Í; A.481.C.4.Í; A.482.C.44; A.483.C.4.Í; A.484.C.4.Í; A.485.C.44; A.486.C.44; A.487.C.4.Í; A.488.C.44; A.489G44; A.490.C.4.Í; A.49LC.44; A.492.C.44; A.493.C.4.Í; A.494.C.44; A.495.C.44; A.496.C.4.Í; A.497.C.44; A.498.C.44; A499.C.44;A.217.C.44; A.218.C.4.Í; A.219.C.4.Í; A.220.C.4.Í; A.221.C.4.Í; A.222.C.4.Í; A.223.C.44; A224.C.44; A.225.C.4.Í; A.226.C.44; A.227.C.4.Í; A228.C.4.I; A229.C.4.I; A230.C.4.I; A.231.C.44; A.232.C.4.Í; A.233.C.44; A.234.C.44; A.235.C.44; A.236.C.44; A.237.C.44; A238.C.44; A.239.C.44; A.240.C.4.Í; A.241.C.44; A.242.C.4.i; A.243.C.44; A.244.C.4i; A.245.C.44; A.246.C.44; A247.C.4.I; A.248.C.4.Í; A.249.C.4.Í; A.250.C.4.Í; A.251.C.4.Í; A.252.C.4.Í; A254.C.44; A.255.C.44; A.256.C.44; A.257.C.44; A258.C.4.I; A259.C.44; A.260.C.44; A.261.C.4.Í; A.262.C.4.Í; A.263.C.44; A.264.C.4.Í; A265.C.4.I; A.266.C.4.Í; A267.C.4.1; A.268.C.4.Í; A.269.C.44; A270.C.4.1; A271.C.44; A.272.C.44; A.273.C.44; A.274.C.44; A.275.C.4.Í; A276.C.4.I; A.277.C.44; A.278.C.44; A.279.C.44; A.280.C.44; A.281.C.44; A.282.C.4.Í; A.283.C.44; A.284.C.4.Í; A.285.C.44; A.286.C.44; A.287.C.44; A.288.C.44; A.289.C.44; A.290.C.4.Í; A.291.C.4.Í; A.292.C.4.Í; A.293.C.44; A294.C.4.1; A.295.C.44; A.296.C.4.Í; A.297.C.4.1; A.298.C.4.1; A.299.C.44; A.300.C.4.Í; A.301.C.44; A.302.C.44; A.303.C.4.I; A.304.C.44; A.305.C.44; A.306.C.44; A.307.C.44; A.308.C.44; A.309.C.4.1; A.310.C.44; A.311.C.44; A.312.C.44; A.313.C.4.Í; A.314.C.44; A.315.C.44; A.316.C.44; A.317.C.44; A.318.C.4.Í; A.319.C.44; A.320.C.44; A.321.C.4.Í; A.323.C.44; A.324.C.44; A.325.C.44; A.326.C.4.Í; A.327.C.4.Í; A.328.C.4.Í; A.329.C.44; A.330.C.4.Í; A.331.C.4.Í; A.332.C.4.Í; A.333.C.4.Í; A334.C.44; A.335.C.4.Í; A.336.C.4.1; A.337.C.4.Í; A.338.C.44; A.339.C.4.Í; A.340.C.4.Í; A.341.C.4.Í; A.342.C.44; A.343.C.4.Í; A.344.C.44; A.345.C.44; A.346.C.4.Í; A.347.C.44; A.348.C.4.Í; A.349.C.4.Í; A.350.C.44; A.351.C.44; A352.C.44; A.353.C.44; A.354.C.4.Í; A.355.C.44; A.356.C.44; A.357.C.44; A.358.C.4.Í; A.359.C44; A.360.C.4.Í; A.361.C.4.1; A.362.C.44; A.363.C.4.Í; A.364.C.4.Í; A.365.C.44; A.366.C.41; A.367.C.44; A.368.C.44; A.369.C.44; A.370.C.4.Í; A.371.C.4.Í; A.372.C.44; A.373.C.4.Í; A.374.C.44; A.375.C.44; A.376.C.44; A.377.C.4J; A.378.C.44; A.379.C.4.Í; A.380.C.44; A.381.C.44; A.382.C.44; A.383.C.44; A.384.C.44; A.385.C.44; A.386.C.44; A.387.C.44; A.388.C.44; A.389.C.44; A.390.C.44; A.391.C.4.Í; A.392.C.44; A.393.C.4.Í; A.394.C.4.Í; A.395.C.44; A.396.C.4.Í; A.397.C.4.Í; Á.398.G.44; A.399.C.4.Í; A.400.C.44; A.401.C.44; A.402.C.44; A.403.C.4.i; A.404.C.44; A.405.C.44; A.406.C.44; A.407.G44; A.408.C.44; A.409.C.4.I; A.410.C.44; A.4U.C.44; A.412.C.44; A.413.C4J; A.414.C.44; A.415.C.44; A.416.C.44; A.417.C.44; A.418.C.44; A.419.C.44; A.420.C.44; A.421.C.44; A.422.C.44; A.423.C.44; A.424.C.44; A.425.C.44; A.426.C.44; A.427.C.44; A.428.C.44; A.429.C.44; A.430.C.4.Í; A.431.C.44; A.432.C.4.Í; A.433.Č44; A.434.C.44; A.435.C.44; A.436.C.4.Í; A.437.C.44; A.438.C.44; A.439.C.44; A.440.C.44; A.441.C.44; A.442.C.4.Í; A.443.C.44; A.444.C.44; A.445.C.4.Í; A.446.C.44; A.447.C.44; A.448.C.4.Í; A.449.C.44; A.450.C.44; A.451.C.4.Í; A.452.C.44; A.453.C.44; A.454.C.4.i; A.455.C.44; A.456.C.4.Í; A.457.C.4.Í; A.458.C.44; A.459C.44; A.460.C.44; A.461.C.44; A.462.C.44; A.463.C.4.Í; A.464.C.44; A.465.C.4.1; A.466.C.4.Í; A.467.C.4.Í; A.468.C.44; A.469.C.4.Í; A.47Ó.C44; A.471.C.44; A.472.C.4.Í; A.473.C.44; A.474-C.44; A.475.C.44; A.476.C.44; A.477.C.4.Í; A.478.C.4.Í; A.479.C.44; A.480.C.4.Í; A.481.C.4.Í; A.482.C.44; A.483.C.4.Í; A.484.C.4.Í; A.485.C.44; A.486.C.44; A.487.C.4.Í; A.488.C.44; A.489G44; A.490.C.4.Í; A.49LC.44; A.492.C.44; A.493.C.4.Í; A.494.C.44; A.495.C.44; A.496.C.4.Í; A.497.C.44; A.498.C.44; A499.C.44;
-119CZ 297945 B6-119GB 297945 B6
A.500.G4.Í; A.501.G4.Í; A-502.G4.ij A.503.C.4.1; A.504.G4.Í; A.505.G4.ij A.506.C.4j; A.507.C.4.Í; A.508.C.4.1; A.509.C.4.ij A.510.G4.Í; A.511.C.4.Í; A.512.C.4.Í; A.512.G4.Í; A.513.G4.Í; A.514.G4.Í; A.515.G4.Í; A.516.G4.Í; A.517.G4.Í; A.518.C.4.Í; A.519.C.4.Í; A.520.G4.Í; A.521.G4.Í; A.522.C.4.Í; A.523.C-4.ÍJ A.524.G4.Í; A-525.C.44; A.526G.4.Í; A.527.C.4.Í; A.528.C.4.Í; A.529.G4.Í; A.530.C.4.ij A.531.C.4.Í; A.532.C.4.Í; A.533.C.4.Í; A.534.G4.Í; A-535.G4.ij’ A.536.G4.1; A.537.C.4.Í; A.538.C.4.Í; A.539G.4.Í; A.540.G4.Í; A.541.C.4.Í; A.542.C4.Í; A.543.C.4.Í; A-.544.C4.ij A.545.C.4.ÍJ A.546.C.4.ij A.547.C.4.Í; A.548.C.4.Í; A.549C.4.ij A.550.C.4.Í; A.551.G4.Í; A352.C.4.1; A.553.C.4.Í; A.554.C4.Í; A.555.G4.Í; A.556.G4.Í; A.557.C.4.ij A.558.C.4.ij A.559.C4.Í; A.560.G4.Í; A.561.C4.Í; A.562.C.4.Í; A.563.C4.Í; A.564.C.4.Í; A.565.C.4.Í; A.566.C4.Í; A.567.C.4.Í; A.568.C.4.Í; A.569.C4.Í; A.570.C.4.Í; A.571.G4.Í; A.572.G4.Í; A.573.C.4.Í; A374.G4.ij A.575.C.4.Í; A.576.C4.Í; A.577.C.4.Í; A.578.C.4.ÍJ A.579.C.4.Í; A.580.C.4.Í; A.581.C4.Í; A.582.C4.ij A.583.C.4.Í; A.584.C.4.1; A.585.C4.1; A.586.C.4.Í; A.587.C.4.i; A.588.C.4.Í; A.589.C.4.Í; A.590.C.4.Í; A.591.C4.Í; A.592.G4.Í; A593.C4.ij A.594C.4.Í; A.595.C.4.Í; A.596.C.4.Í; A.597.C.4.Í; A598.G4.ij A-599.C4.i; A.600.C.4.Í; A.601.C.4.Í; A.602.C.4.Í; A.603.C.4.Í; A.604.C.4.Í; A.605.C.4.Í; A.606.C4.Í; A.607.C4.Í; A.608.G4.Í; A.609.G4.Í; A.610.G4.Í; A.611.C.4.:; A.612.G4-i; A.613.C.4.Í; A.614.C4.Í; A.615.G4.Í; A.616.C.4.Í; A.617.C.4.Í; A.618.C4.Í; A.619C.4.Í; A.620.C4.Í; A.621.C.4.Í; A.622.C.4.Í; A.623.C4.Í; A.624.C4.Í; A.625.G4.ij A.626.C.4.Í; A.627.C.4.Í; A.62S.C.4.Í; A.629.C.4.Í; A.630.C.4.Í; A-631.C4.ij A.632.C.4.Í; A.633.G4.Í; A-634.G4.ij A.635.C.4.Í; A.636.G4.Í; A.637.C.4.i; A.638.C4.Í; A.639.C.4.1; A.640.C.4.Í; A.641.G4.Í; A.642.C.4.Í; A.643.G4.Í; A.644.G4.Í; A.645.C4.Í; A.646.C44; A.647.G4.Í; A.648.G4.Í; A.649.C4.Í; A.650.C4.Í; A.651.C.4.Í; A.652.C.4.Í; A.653.C4.Í; A.654.C4.Í; A.655.G4.Í; A.656.C.4.Í; A.657.G4.Í; A.658.C4.Í; A.659.C4.ij A.660.G4.Í; A.2.C.11.Í; A3.Cll.ij A.4.C.11.Í; A5.Cll.ij A.6.G11.Í; A.7.C.11.Í; A.9.C.11.Í; A.lO.Gll.i; A.15.C.11.Í; A.lOO.Gll.i; A.lOLGll.i; A.102.G11.Í; A.103.C.11.Í; A.104.C.11 i; A.1O5.C.11.Í; A.106.C1U; A.107.C11.Í; A.108.C1U A.109.C11.Í; A.110.G11X A.lll.C.ll.i; A.112.GU.ÍJ A.113.C11.Í; A.114.C11.Í; A.115.G11.Í; A-ll6.Gll.ij A.117.C.11.Í; A.llS.C.ll.i; A.U9.G11.Í; A.120.C.11.Í; A.121.G11.Í; A.122.C.11.Í; A.123.C.11.Í; A.124.G.11.Í; A.125.GU.Í; A.126.G11.Í; A.127.G11.Í; A.128.C.11.Í; A.129.G11 .i; A.130.G11.Í; A.131.G11.Í; A.132.G11.Í; A.133.C.11 .i; A.134.G11.Í; A.135.C.11.Í; A.136.C.U.Í; A.137.G11.Í; A.138.G114; A.139.G11.Í; A.140.C.11.Í; A.141.C.11.Í; A.142.G11.Í; A.143.G11.Í; A.144.G11.Í; A.145.G11.Í; A.146.G11.Í; A.147.C.11.Í;.A. 148.C.11.i; A.149.G11.Í; A.150.G1U A.151.G114; A.152.G11.Í; A.153.G11.Í; A.154.C.11.Í; A.155.G11.Í; A.156.C.11.Í; A.157G.ll.ij A.158.C11.Í; A.159.G11.Í; A.160.GU.Í; A.161.G1U; A.162.Gll.ij A.163.C.11.ÍJ A.164.C.11.Í; A.165.C.11.Í; A.166.C11.Í; A.167.C.11.Í; A.168.G11.Í; A.169.G11.ÍJ A.170.C.11.ÍJ A.171.C.U.Í; A.172.G11.Í; A.173.Č.11.Í; A.174.C11.Í; A.175.C11.Í; A.176.G11.Í; A.177.C.11.Í; A.178.C11.ÍJ A.179.G11.Í; A.180.G11.Í; A.181.C.11.Í; A.182.C.11.Í; A.183.C.11.Í; A.184.C.11.Í; A.185.C.11.Í; A.186.G11.Í; A.187.G11.Í; A.188.G11.ÍJ A.189.C.11.Í; A-190.Gll.ij A.191.G1Í.Í; A.192.G11.Í; A-193.Gll.ij A.194.C.11.Í; A.195.G11.Í; A.196.G11.Í; A.197.G11.Í; A.198.C.11.Í; A.199.C.11.Í; A-200.GH.ij A.201.GU.Í; A.202.C.11.1; A.203.GH.Í; A.204.C.11.Í; A.205.C11.Í; A206.C.11.Í; A.207.C.11.Í; A.208.C.11.Í; A.209.C.11.Í; A.210.G11.Í; A.211.C11.Í;A.500.G4.Í; A.501.G4.Í; A-502.G4.ij A.503.C.4.1; A.504.G4.Í; A.505.G4.ij A.506.C.4j; A.507.C.4.I; A.508.C.4.1; A.509.C.4.ij A.510.G4.I; A.511.C.4.Í; A.512.C.4.Í; A.512.G4.Í; A.513.G4.Í; A.514.G4.Í; A.515.G4.Í; A.516.G4.Í; A.517.G4.Í; A.518.C.4.Í; A.519.C.4.Í; A.520.G4.Í; A.521.G4.Í; A.522.C.4.Í; A.523.C-4.IJ A.524.G4.I; A-525.C.44; A.526G.4.Í; A.527.C.4.Í; A.528.C.4.Í; A.529.G4.Í; A.530.C.4.ij A.531.C.4.I; A.532.C.4.Í; A.533.C.4.Í; A.534.G4.Í; A-535.G4.ij ´ A.536.G4.1; A.537.C.4.Í; A.538.C.4.Í; A.539G.4.Í; A.540.G4.Í; A.541.C.4.Í; A.542.C4.Í; A.543.C.4.Í; A.545.C.4.ij A.546.C.4.ij A.546.C.4.ij A.547.C.4.ij; A.548.C.4.Í; A.549C.4.ij A.550.C.4.I; A.551.G4.Í; A352.C.4.1; A.553.C.4.Í; A.554.C4.Í; A.555.G4.Í; A.556.G4.Í; A.557.C.4.ij A.558.C.4.ij A.559.C4.I; A.560.G4.Í; A.561.C4.Í; A.562.C.4.Í; A.563.C4.Í; A.564.C.4.Í; A.565.C.4.Í; A.566.C4.Í; A.567.C.4.Í; A.568.C.4.Í; A.569.C4.Í; A.570.C.4.Í; A.571.G4.Í; A.572.G4.Í; A.573.C.4.Í; A374.G4.ij A.575.C.4.I; A.576.C4.Í; A.577.C.4.Í; A.579.C.4.IJ A.579.C.4.I; A.580.C.4.Í; A.581.C4.Í; A.583.C4.ij A.583.C.4.I; A.584.C.4.1; A.585.C4.1; A.586.C.4.Í; A.587.C.4.i; A.588.C.4.Í; A.589.C.4.Í; A.590.C.4.Í; A.591.C4.Í; A.592.G4.Í; A593.C4.ij A.594C.4.I; A.595.C.4.Í; A.596.C.4.Í; A.597.C.4.Í; A598.G4.ij A-599.C4.i; A.600.C.4.Í; A.601.C.4.Í; A.602.C.4.I; A.603.C.4.I; A.604.C.4.I; A.605.C.4.I; A.606.C4.Í; A.607.C4.Í; A.608.G4.Í; A.609.G4.Í; A.610.G4.Í; A.611.C.4.:; A.612.G4-i; A.613.C.4.Í; A.614.C4.Í; A.615.G4.Í; A.616.C.4.Í; A.617.C.4.Í; A.618.C4.Í; A.619C.4.Í; A.620.C4.Í; A.621.C.4.Í; A.622.C.4.Í; A.623.C4.Í; A.624.C4.Í; A.625.CG.ij A.626.C.4.I; A.627.C.4.Í; A.62S.C.4.I; A.629.C.4.Í; A.630.C.4.Í; A-631.C4.ij A.632.C.4.I; A.633.G4.Í; A-634.CG.ij A.635.C.4.I; A.636.G4.Í; A.637.C.4.i; A.638.C4.Í; A.639.C.4.1; A.640.C.4.Í; A.641.G4.Í; A.642.C.4.Í; A.643.G4.Í; A.644.G4.Í; A.645.C4.Í; A.646.C44; A.647.G4.Í; A.648.G4.Í; A.649.C4.Í; A.650.C4.Í; A.651.C.4.Í; A.652.C.4.Í; A.653.C4.Í; A.654.C4.Í; A.655.G4.Í; A.656.C.4.Í; A.657.G4.Í; A.658.C4.Í; A.659.C4.ij A.660.G4.I; A.2.C.11.Í; A3.Cll.ij A.4.C.11.I; A5.Cll.ij A.6.G11.I; A.7.C.11.Í; A.9.C.11.Í; A.10.Gll.i; A.15.C.11.Í; A.100.Gll.i; A.IOLG11.i; A.102.G11.Í; A.103.C.11.Í; A.104.C.11 i; A.1O5.C.11.Í; A.106.C1U; A.107.C11.Í; A.108.C1U A.109.C11.I; A.110.G11X A.lll.C.ll.i; A.112.GU.IJ A.113.C11.I; A.114.C11.Í; A.115.G11.Í; A.117.C.11.I; A.llS.C.ll.i; A.U9.G11.Í; A.120.C.11.Í; A.121.G11.Í; A.122.C.11.Í; A.123.C.11.Í; A.124.G.11.Í; A.125.GU.Í; A.126.G11.Í; A.127.G11.Í; A.128.C.11.Í; A.129.G11 .i; A.130.G11.Í; A.131.G11.Í; A.132.G11.Í; A.133.C.11 .i; A.134.G11.Í; A.135.C.11.Í; A.136.C.U.I; A.137.G11.Í; A.138.G114; A.139.G11.Í; A.140.C.11.Í; A.141.C.11.Í; A.142.G11.Í; A.143.G11.Í; A.144.G11.Í; A.145.G11.Í; A.146.G11.Í; A.147.C.11.I; .A. 148.C.11.i; A.149.G11.Í; A.150.G1U A.151.G114; A.152.G11.Í; A.153.G11.Í; A.154.C.11.Í; A.155.G11.Í; A.156.C.11.Í; A.157G.ll.ij A.158.C11.I; A.159.G11.Í; A.160.GU.Í; A.161.G1U; A.162.CG.ij A.163.C.11.IJ A.164.C.11.I; A.165.C.11.Í; A.166.C11.Í; A.167.C.11.Í; A.168.G11.I; A.169.G11.IJ A.170.C.11.IJ A.171.C.U.I; A.172.G11.Í; A.173.Č.11.Í; A.174.C11.Í; A.175.C11.Í; A.176.G11.Í; A.177.C.11.Í; A.178.C11.IJ A.179.G11.I; A.180.G11.Í; A.181.C.11.Í; A.182.C.11.Í; A.183.C.11.Í; A.184.C.11.Í; A.185.C.11.Í; A.186.G11.Í; A.187.G11.Í; A.188.G11.IJ A.189.C.11.I; A-190.Gll.ij A.191.Gl.I; A.192.G11.Í; A-193.Gll.ij A.194.C.11.I; A.195.G11.Í; A.196.G11.Í; A.197.G11.Í; A.198.C.11.Í; A.199.C.11.Í; A-200.GH.ij A.201.GU.I; A.202.C.11.1; A.203.GH.Í; A.204.C.11.Í; A.205.C11.Í; A206.C.11.Í; A.207.C.11.Í; A.208.C.11.Í; A.209.C.11.Í; A.210.G11.Í; A.211.C11.Í;
-120CZ 297945 B6-120GB 297945 B6
A.213.C414; A.219.C414; A.225.C.114;A.213.C414; A.219.C414; A.225.C.114;
A.231.C.114;A.231.C.114;
A237.C414;A237.C414;
A.243.C414;A.243.C414;
A.249.C414;A.249.C414;
A255.C414;A255.C414;
A.261.C414;A.261.C414;
A267.C414;A267.C414;
A.273.C414;A.273.C414;
A.279.C.114;A.279.C.114;
A.285.C.114;A.285.C.114;
A291.C414;A291.C414;
A.297.C.114;A.297.C.114;
A.303.C414,·A.303.C414, ·
A.309.Č41.Í;A.309.Č41.Í;
A.315.C414;A.315.C414;
A.321.C.114;A.321.C.114;
A.328.C.114;A.328.C.114;
A.334.C.114;A.334.C.114;
A.340.C.114;A.340.C.114;
A.346C.114;A.346C.114;
A.352.C414;A.352.C414;
A.358.C.11.Í;A.358.C.11.Í;
A364.C.114;A364.C.114;
A.370.C414;A.370.C414;
A.376.C414;A.376.C414;
A.382.C.114;A.382.C.114;
A388.C.114;A388.C.114;
A.394.C414;A.394.C414;
A400.C414;A400.C414;
A.406.C414;A.406.C414;
A.412.C414;A.412.C414;
A.418.C414;A.418.C414;
A.424.C.114;A.424.C.114;
A.430.C41J;A.430.C41J;
A.436.C.114;A.436.C.114;
A.442.C414;A.442.C414;
A.448.C414;A.448.C414;
A.454.C.11.Í;A.454.C.11.Í;
A.460.C414;A.460.C414;
A.466.C414;A.466.C414;
A.472.C.114;A.472.C.114;
A.478.C414;A.478.C414;
A.484.C414;A.484.C414;
A.490.C.114;A.490.C.114;
A212.C41.Í; A.218.C.1U; A224.C41.Í; A.230.C.11.Í; A236.C11J; A.242.C.11.Í; A248.C41.Í; A254.C.11.Í; A360.C414 A.266.C.11.Í A272C.114 A.278.C.11.X A284C41.X A.290.C41.Í A.296.C41.Í A.302.C41.X A.308.C41.Í A.314.C.11.Í A.320.C41.Í A.327.C41.Í A333.C414 A339.C.11.Í A345.C.11.Í A.351.C41.Í A.357.C.11.Í A.363.C41.Í A.369.C.114 A375.C.11.Í A.381.C41.Í A.387.C.11.Í, A.393.C41.Í A.399.C41.Í A.405.C41.Í A.411.C.11.Í A.417.C41.Í A423.C.11.Í A.429.C.11.Í A.435.C41.Í A.441.C.11.Í A.447.C41.Í, A.453.C.11.Í A.459.C41.X A.465.C41.Í A.471.C41.Í A.477.C414 A.483.C414 A.489.C.114A212.C41.Í; A.218.C.1U; A224.C41.I; A.230.C.11.Í; A236.C11J; A.242.C.11.Í; A248.C41.I; A254.C.11.Í; A360.C414 A.266.C.11.I A272C.114 A.278.C.11.X A284C41.X A.290.C41.I A.296.C41.I A.302.C41.X A. 308.C41.I A.314.C.11.I A.320.C41.I A.327.C41.I A333.C414 A339.C.11.I A345.C.11.I A.351.C41 .I A.357.C.11.I A.363.C41.I A.369.C.114 A375.C.11.I A.381.C41.I A.387.C.11.I, A .393.C41.I A.399.C41.I A.405.C41.I A.411.C.11.I A.417.C41.I A423.C.11.I A.429.C.11 .I A.435.C41.I A.441.C.11.I A.447.C41.I, A.453.C.11.I A.459.C41.X A.465.C41.I A .471.C41.I A.477.C414 A.483.C414 A.489.C.114
A.214.C414; A.220.C.114; A.226.C414; A.232.C414; A.238.C414; A.244.C414; A250 C414; A.256.C.114; A.262.C414; A.268.C.114; A.274.C414; A.280.C.114; A.286.C414; A.292.C.114; A.298.C.114; A.304.C.114; A.310.C414; A.316.C414; A.323.C.114; A.329.C.114; A335.C414; A.341.C41.Í; A.347.C41.Í; A.353.C.114; A.359.C414; A.365.C414; A.371.C414; A.377.C414; A.383.C414; A.389.C.11.Í; A.395.C414; A.401.C414; A.407.C414; A.413.C414; A.419.C.11.Í; A.425.C414; A.431.C414; A.437.C414; A.443.C.114; A.449.C.114; A.455.C.11.Í; A.461.C414; A.467.C.11.Í; A.473.C.114; A.479.C.11.Í; A.485.C.11.Í; A.491.C41.Í;A.214.C414; A.220.C.114; A.226.C414; A.232.C414; A.238.C414; A.244.C414; A250 C414; A.256.C.114; A.262.C414; A.268.C.114; A.274.C414; A.280.C.114; A.286.C414; A.292.C.114; A.298.C.114; A.304.C.114; A.310.C414; A.316.C414; A.323.C.114; A.329.C.114; A335.C414; A.341.C41.Í; A.347.C41.Í; A.353.C.114; A.359.C414; A.365.C414; A.371.C414; A.377.C414; A.383.C414; A.389.C.11.Í; A.395.C414; A.401.C414; A.407.C414; A.413.C414; A.419.C.11.Í; A.425.C414; A.431.C414; A.437.C414; A.443.C.114; A.449.C.114; A.455.C.11.Í; A.461.C414; A.467.C.11.Í; A.473.C.114; A.479.C.11.Í; A.485.C.11.Í; A.491.C41.Í;
A215.C.114; A.221.C.114; A.227.C.114; A.233.C414; A.239.C414; A.245.C414; A251.C.114; A.257.C.114; A263.C.114; A.269.C.114; A.275.C.114; A.281.C.114; A.287.C414; A293.C414; A.299.C414; A.305.C.114; A.311.C.114; A.317.C414; A324.C41.ii' A.330.C414; A.336C414; A342.C414; A.348.C.114; A.354.C414; A.360.C.114; A366.C414; A.372.C414; A.378.C.114; A384.C.11.Í; A.390.C414; A.396.C414; A.402.C41 i; A.408.C.114; A.414.C414; A.420.C414; A.426.C414; A.432.C414; A.438.C414; A.444.C414; A.450.C41.Í; A.456.C.114; A.462.C414; A.468.C414; A.474.C414; A.480.C414; A.486.C414; A.492.C414;A215.C.114; A.221.C.114; A.227.C.114; A.233.C414; A.239.C414; A.245.C414; A251.C.114; A.257.C.114; A263.C.114; A.269.C.114; A.275.C.114; A.281.C.114; A.287.C414; A293.C414; A.299.C414; A.305.C.114; A.311.C.114; A.317.C414; A324.C41.ii 'A.330.C414; A.336C414; A342.C414; A.348.C.114; A.354.C414; A.360.C.114; A366.C414; A.372.C414; A.378.C.114; A384.C.11.Í; A.390.C414; A.396.C414; A.402.C41 i; A.408.C.114; A.414.C414; A.420.C414; A.426.C414; A.432.C414; A.438.C414; A.444.C414; A.450.C41.Í; A.456.C.114; A.462.C414; A.468.C414; A.474.C414; A.480.C414; A.486.C414; A.492.C414;
A216.C41.iJ A222.C414; A.228.C414; A.234.C.114; A.240.C414; A.246.C.114; A252.CJ.14i A.258.C.114; A.264.C.114; A.270.C414; A.276.C.114; A.282.C414; A288.C41.ij A.294.C.11.Í; A300.CJ14j A306.C414; A312.Gll.ij A.318.C.114; A325.G114-; A.331.C414; A337.C41.ij A.343.C.114; A.349.C414; A355.C414; A.361.G114j A.367.C.11.Í; A373.C414; A379.C414j A385C.ll.ij A391.C.114; A.397.G114; A.403.G114; A.409.C41.Í; A.415.G114; A.421.C414; A.427.G114; A.433.C.11.Í; A.439C414; A.445.G114; A.451.C,114; A.457.C414; A.463.C414; A.469.C.114; A.475.C41.Í; A.481.C414; A.487.G114; A.493.G114;A216.C41.iJ A222.C414; A.228.C414; A.234.C.114; A.240.C414; A.246.C.114; A252.CJ.14i A.258.C.114; A.264.C.114; A.270.C414; A.276.C.114; A.282.C414; A288.C41.ij A.294.C.11.I; A300.CJ14j A306.C414; A312.Gll.ij A.318.C.114; A325.G114-; A.331.C414; A337.C41.ij A.343.C.114; A.349.C414; A355.C414; A.367.C.11.I; A373.C414; A379.C414j A385C.ll.ij A391.C.114; A.397.G114; A.403.G114; A.409.C41.I; A.415.G114; A.421.C414; A.427.G114; A.433.C.11.Í; A.439C414; A.445.G114; A.451.C, 114; A.457.C414; A.463.C414; A.469.C.114; A.475.C41.Í; A.481.C414; A.487.G114; A.493.G114;
A.217.C41.Í; A.223.C414; A.229.C41.Í; A235.C.114; A241.C.114; A247.C414; A253.G114; A.259.C414; A.265.C.114; A.271.C.114; A-277.C41.Í; A.283C.114; A.289 C414; A295.CJ14; A.30LG114; A.307.C.114; A.313.C.114; A319.C114; A.326.C414; A332.Gll.ij A338.C41.ij A.344.C.114j A350.G114; A.356.C.114; A.362.C414; A.368.C414; A374.Gll.ij A.380.C.114; A.386.C.114; A.392.C.114; A.398.C414; A.404.C414; A.410.C41.Í; A.416.C.ll.ij A.422.C.114; A.428.C414; A.434.C.114; A.440.C41.Í; A446.C41.ii A.452.C.11.Í; A.458.C114; A.464.C.114; A.470.C.11.Í; A.476.C414; A.482.C41.Í; A.488.Č414; A.494.C114;A.217.C41.Í; A.223.C414; A.229.C41.Í; A235.C.114; A241.C.114; A247.C414; A253.G114; A.259.C414; A.265.C.114; A.271.C.114; A-277.C41.1; A.283C.114; A.289 C414; A295.CJ14; A.30LG114; A.307.C.114; A.313.C.114; A319.C114; A.326.C414; A332.Gll.ij A338.C41.ij A.344.C.114j A350.G114; A.356.C.114; A.362.C414; A.368.C414; A374.Gll.ij A.380.C.114; A.386.C.114; A.392.C.114; A.398.C414; A.404.C414; A.410.C41.Í; A.416.C.ll.ij A.422.C.114; A.428.C414; A.434.C.114; A.440.C41.Í; A446.C41.ii A.452.C.11.I; A.458.C114; A.464.C.114; A.470.C.11.Í; A.476.C414; A.482.C41.Í; A.488.Č414; A.494.C114;
-121 CZ 297945 B6-121 CZ 297945 B6
A.495.C.11.Í; A.496.C.11.Í; A.497.G1U; A.498.CU.Í; A.499.C11.Í; A.500.C11.Í; A.501.C.U.Í; A.502.C.11.Í; A.503.C.11.Í; A.504.G11.Í; A.505.C.11 .i; A.506.G11.Í; A.507.C1U; A.508.G11-i; A.509.C.11.Í; A.510.GU.Í; A5U.C11.Í; A.512.C.11.Í; A.512.C.11.Í; A513.Cll.ij A.514.C11.Í; A.515.G11.Í; A.516.C.11.Í; A.517.CU.Í; A.518.C.11.Í; A.519.C.11.Í; A520.Cll.ij A.521.C11.Í; A.522.G11.Í; A523.C.11.Í; A.524.G11.Í; A.525.C11.Í; A.526.C11.Í; A.527.C.11.Í; A.528.C.11.Í; A.529.C11.Í; A530.ClI.ij A.531.G11.Í; A.532.C11.Í; A.533C.11.Í; A.534.C.11.Í; A.535.C11.Í; A.536.GU.Í; A.537.C.11.Í; A.538.C11.Í; A539.GU.Í; A.540.C11 .i; A.541.C.11 ,i; A.542.C.11 .i; A.543.C.11.Í; A.544.C.11.Í; A.545.G11 .i; A.546.C11.Í; A.547.C.11.Í; A.548.G11.Í; A.549.C11.Í; A.550.C11.Í; A.551.C.11.Í; A.552.C.11.Í; A.553.G11.Í; A554.Gll.ij A.555.G11.Í; A.556.C11 .i; A.557.C11.Í; A558.Cll.ij A.559G11.Í; A.560.C.11.Í; A.561.C11.Í; A.562.C.11.Í; A.563.C11.Í; A.564.C11.Í; A.565.C11.Í; A.566.C.1U; A.567.G11.Í; A568.Cll.ij A569.C11.Í; A.570.C11.Í; A.571.C11.Í; A.572.G11.Í; A.573G11.Í; A.574.C11.Í; A575.C.11.Í; A.576C.11.Í; A.577.C11 j; A.578.C.11.Í; A.579C11.Í; A.580.C11 .i; A581C.ll.i; A.582G11.Í; A.583.C1I.i; A.584.C11.Í; A.585.G11.Í; A.586.C11 .i; A.587.C11.Í; A.588.C11.Í; A589.C.1U; A.590G.11.Í; A.591.G11.Í; A.592.G11.Í; A.593.CU.Í; A.594.C11.Í; A.595.CU.Í; A.596.C11.Í; A.597.C11.Í; A.598.C11.Í; A.599G11.Í; A.600.G11.Í; A.601.C11.Í; A.602.C11.Í; A.603G11.Í; A.604.G11.Í; A.605.C11.Í; A.606.C11.Í; A.607.C.11.Í; A.6O8.G11.Í; A609.Gll.ij A.610.C11.Í; A.611.CU.Í; A.612.C11.Í; A.613G11.Í; A.614.C.11.Í; A.615G11.Í; A.616.G11.Í; A.617.C11.Í; A.618.C11.Í; A.619.C11.Í; A.620.C.I1.Í; A621.Cll.ij A.622.G11.Í; A623.Cll.ij A.624.C11.Í; A.625.C.114;A.495.C.11.Í; A.496.C.11.Í; A.497.G1U; A.498.CU.Í; A.499.C11.Í; A.500.C11.Í; A.501.CUÍ; A.502.C.11.Í; A.503.C.11.Í; A.504.G11.I; A.505.C.11 .i; A.506.G11.I; A.507.C1U; A.508.G11-i; A.509.C.11.Í; A.510.GU.Í; A5U.C11.Í; A.512.C.11.Í; A.512.C.11.Í; A513.Cll.ij A.514.C11.I; A.515.G11.Í; A.516.C.11.Í; A.517.CU.Í; A.518.C.11.Í; A.519.C.11.Í; A520.Cll.ij A.521.C11.I; A.522.G11.Í; A523.C.11.Í; A.524.G11.Í; A.525.C11.Í; A.526.C11.Í; A.527.C.11.Í; A.528.C.11.Í; A.529.C11.Í; A530.ClI.ij A.531.G11.I; A.532.C11.Í; A.533C.11.Í; A.534.C.11.Í; A.535.C11.Í; A.536.GU.Í; A.537.C.11.Í; A.538.C11.Í; A539.GU.Í; A.540.C11 .i; A.541.C.11, i; A.542.C.11 .i; A.543.C.11.Í; A.544.C.11.Í; A.545.G11 .i; A.546.C11.Í; A.547.C.11.Í; A.548.G11.Í; A.549.C11.Í; A.550.C11.Í; A.551.C.11.Í; A.552.C.11.Í; A.553.G11.Í; A554.Gll.ij A.555.G11.I; A.556.C11 .i; A.557.C11.Í; A558.Cll.ij A.559G11.I; A.560.C.11.Í; A.561.C11.Í; A.562.C.11.Í; A.563.C11.Í; A.564.C11.Í; A.565.C11.Í; A.566.C.1U; A.567.G11.Í; A568.C11.ij A569.C11.I; A.570.C11.Í; A.571.C11.Í; A.572.G11.Í; A.573G11.Í; A.574.C11.Í; A575.C.11.Í; A.576C.11.Í; A.577.C11 j; A.578.C.11.Í; A.579C11.Í; A.580.C11 .i; A581C.ll.i ; A.582G11.Í; A.583.C1I.i; A.584.C11.Í; A.585.G11.Í; A.586.C11 .i; A.587.C11.Í; A.588.C11.Í; A589.C.1U; A.590G.11.Í; A.591.G11.Í; A.592.G11.Í; A.593.CU.Í; A.594.C11.Í; A.595.CU.Í; A.596.C11.Í; A.597.C11.Í; A.598.C11.Í; A.599G11.Í; A.600.G11.Í; A.601.C11.Í; A.602.C11.I; A.603G11.I; A.604.G11.I; A.605.C11.I; A.606.C11.I; A.607.C.11.Í; A.6O8.G11.Í; A609.Gll.ij A.610.C11.I; A.611.CU.Í; A.612.C11.Í; A.613G11.Í; A.614.C.11.Í; A.615G11.Í; A.616.G11.Í; A.617.C11.Í; A.618.C11.Í; A.619.C11.Í; A.620.C.I1.Í; A621.Cll.ij A.622.G11.I; A623.Cll.ij A.624.C11.I; A.625.C.114;
A.626.C.11.Í; A.627.G11 -i; A628.Cll.ij A.629.C.11.Í; A.630.C11.Í; A.631.C11.Í; A.632.C.11.Í; A.633.C11.Í; A.634.C11.Í; A.635.C11.Í; A.636.G11.Í; A.637.C.11X A638.Gll.ij A.639.G11.Í; A.640.C11.Í; A.641.C.11.Í; A642.Cll.ij A.643.C11.Í; A.644.C.11.Í; A.645.C11.Í; A646C.il.i; A.647.C.11.Í; A648.Cll.ij A.649.C.11.Í; A.650.C.11.Í; A.651.C11.Í; A.652.G11.Í; A.653.C.11.Í; A.654.G11.Í; A.655.C11.Í; A.656.C.11.Í; A.657.C.11.Í; A.658CU.Í; A.659.C.11.Í; A.660.CU.Í; A.2.D.4.Í; A.3.D.4.Í; A.4.D.4.Í; A.5.D.4.Í; A.6.D.4.Í; A.7.D.4.Í; A.9.D.4.Í; A.1O.D.4.Í; A.15.D.4.Í; A.100.D.4.Í; A.101.D.4.Í; A.102.D.4.Í; A.103.D.4.Í; A.104.D.4.Í; A.105.D.4.Í; A.106.D.4.Í; A.107.D.4.Í; A.108.D.4.Í; A.109.D.4.Í; A.110.D.4.Í; A.111.D.4.Í; A.112.D.4.Í; A.113.D.4.Í; A.1I4.D.4.Í; A.115.D.4.Í; A.116.D.4.Í; A.117.D.4.Í; A.118.D.4.Í; A.119.D.4.Í; A.120.D.4.Í; A.121.D.4.Í; A.122.D.4.Í; A.123.D.4.Í; A.124.D.4.Í; A.125.D.4.Í; A.126.D.4.Í; A.127.D.4.Í; A.128.D.4.Í; A.129.D.4.Í; A.130.D.4.Í; A.131.D.4.Í; A.132.D.4.Í; A.133.D.4.Í; A.134.D.4.Í; A.135.D.4.Í; A.136.D.4.Í; A.137.D.4.Í; A.138.D.4.Í; A.139.D.4.Í; A.140.D.4.Í; A.141.D.4.Í; A.142.D.4.Í; A.143.D.4.Í; A.144.D.4.Í; A.145.D.4.Í; A.146.D.4.Í; A.147.D.4.Í; A.148.0.44; A.149.D.4.Í; A.150.D.4.Í; A.151.D.4.Í; A.152.D.4.Í; A.153.D.4.Í; A.154.D.4.Í; A.155.D.4.Í; A.156.D.4.Í; A.157.D.4.Í; A.158.D.4.Í; A.159.D.4.Í; A.160.D.4.Í; A.161.D.4.Í; A162.D.4.Í; A.163.D.4.Í; A.164.D.4.Í; A.165.D.4.Í; A.166.D.4.Í; A.167.D.4.Í; A.168.D.4.Í; A.169.D.4.Í; A.170.D.4.Í; A.171.D.4.Í; A.Í72.D.4.Í; A.173.D.4.Í; A.174.D.4.Í; A.175.D.4.Í; A.176.D.4.Í; A.177.D.4.Í; A.178.D.4.Í; A.179.D.4.Í; A.180.D.4.Í; A.181.D.4.Í; A.182.D.4.Í; A.183.D.4.Í; A.184.D.4.Í; A.185.D.4.Í; A.186.D.4.Í; A.187.D.4.Í; A.188.D.4.Í; A.189.D.4.Í; A.190.D.4.Í; A.191.D.4.Í; A.192.D.4.Í; A.193.D.4.Í; A.194.D.4.Í; A.195.D.4.Í; A.196.D.4.Í; A.197.D.4.Í; A.198.D.4.Í; A.199.D.4J; A.200.D.4.Í; A.201.D.4.Í; A.202.D.44; A.203.D.4.Í; A.204.D.4.Í; A.205.D.4.Í; A.206.D.4.Í; A.207.D.4.Í;A.626.C.11.Í; A.627.G11 -i; A628.Cll.ij A.629.C.11.I; A.630.C11.Í; A.631.C11.Í; A.632.C.11.Í; A.633.C11.Í; A.634.C11.Í; A.635.C11.Í; A.636.G11.Í; A.637.C.11X A638.Gll.ij A.639.G11.I; A.640.C11.Í; A.641.C.11.Í; A642.C11.ij A.643.C11.I; A.644.C.11.Í; A.645.C11.Í; A646C.il.i; A.647.C.11.Í; A648.Cll.ij A.649.C.11.I; A.650.C.11.Í; A.651.C11.Í; A.652.G11.Í; A.653.C.11.Í; A.654.G11.Í; A.655.C11.Í; A.656.C.11.Í; A.657.C.11.Í; A.658CU.Í; A.659.C.11.Í; A.660.CU.Í; A.2.D.4.Í; A.3.D.4.Í; A.4.D.4.Í; A.5.D.4.Í; A.6.D.4.Í; A.7.D.4.Í; A.9.D.4.Í; A.1O.D.4.Í; A.15.D.4.Í; A.100.D.4.Í; A.101.D.4.Í; A.102.D.4.Í; A.103.D.4.Í; A.104.D.4.Í; A.105.D.4.Í; A.106.D.4.Í; A.107.D.4.Í; A.108.D.4.Í; A.109.D.4.Í; A.110.D.4.Í; A.111.D.4.Í; A.112.D.4.Í; A.113.D.4.Í; A.1I4.D.4.I; A.115.D.4.Í; A.116.D.4.Í; A.117.D.4.Í; A.118.D.4.Í; A.119.D.4.Í; A.120.D.4.Í; A.121.D.4.Í; A.122.D.4.Í; A.123.D.4.Í; A.124.D.4.Í; A.125.D.4.Í; A.126.D.4.Í; A.127.D.4.Í; A.128.D.4.Í; A.129.D.4.Í; A.130.D.4.Í; A.131.D.4.Í; A.132.D.4.Í; A.133.D.4.Í; A.134.D.4.Í; A.135.D.4.Í; A.136.D.4.Í; A.137.D.4.Í; A.138.D.4.Í; A.139.D.4.Í; A.140.D.4.Í; A.141.D.4.Í; A.142.D.4.Í; A.143.D.4.I; A.144.D.4.Í; A.145.D.4.Í; A.146.D.4.Í; A.147.D.4.Í; A.148.0.44; A.149.D.4.Í; A.150.D.4.Í; A.151.D.4.Í; A.152.D.4.Í; A.153.D.4.Í; A.154.D.4.Í; A.155.D.4.Í; A.156.D.4.Í; A.157.D.4.Í; A.158.D.4.Í; A.159.D.4.Í; A.160.D.4.Í; A.161.D.4.Í; A162.D.4.I; A.163.D.4.Í; A.164.D.4.Í; A.165.D.4.Í; A.166.D.4.Í; A.167.D.4.Í; A.168.D.4.Í; A.169.D.4.Í; A.170.D.4.Í; A.171.D.4.Í; A.I72.D.4.I; A.173.D.4.I; A.174.D.4.Í; A.175.D.4.Í; A.176.D.4.Í; A.177.D.4.Í; A.178.D.4.Í; A.179.D.4.Í; A.180.D.4.Í; A.181.D.4.Í; A.182.D.4.Í; A.183.D.4.Í; A.184.D.4.Í; A.185.D.4.Í; A.186.D.4.Í; A.187.D.4.Í; A.188.D.4.Í; A.189.D.4.Í; A.190.D.4.Í; A.191.D.4.Í; A.192.D.4.Í; A.193.D.4.I; A.194.D.4.Í; A.195.D.4.Í; A.196.D.4.Í; A.197.D.4.Í; A.198.D.4.Í; A.199.D.4J; A.200.D.4.Í; A.201.D.4.Í; A.202.D.44; A.203.D.4.Í; A.204.D.4.Í; A.205.D.4.Í; A.206.D.4.Í; A.207.D.4.Í;
- 122CZ 297945 B6- 122GB 297945 B6
A.208.D.4.Í; A209.D.4.Í; A.210.D4.Í; A.211.D4.Í; A.212.D.4.Í; A.213.D.4.Í; A.214.D.4.Í; A.215.D.4.Í; A.216.D.4.Í; A.217.D4.Í; A.218.D.4.Í; A.219.D.4.Í; A220.D4.ij A221.D.4.Í; A.222.D.4.Í; A.223.D.4.Í; A224.D4.ij A.225.D4.Í; A.226.D.4.1; A.227.D.4.U A-228.D4.ij A.229.D.4.Í; A.230.D.4.Í; A.231.D.4.Í; A.232.D4.Í; A.233.D.4.Í; A234.D4.ij. A.235.D.4.Í; A236.D4.ij A.237.D4.Í; A.238.D.4.Í; A.239.D.4.Í; A240.D4.ij A241.D4.ij A242.D4.ij A243.D4.ij A.244.D.4.Í; A.245.D4.Í; A.246.D.4.Í; A.247.D.4.Í; A.248.D.4.Í; A.249.D4.Í; A.250.D.4.Í; A.251.D.4.ij A.252.D.4.Í; A.253.D.4.Í; A254.D4.ij A.255.D4.Í; A.256.D.4.Í; A257.D4.ij A.258.D4.Í; A259.D4.ij A260.D4.ij A.261.D.4.Í; A262.D4.ij A263.D4.ij A.264.D.4.Í; A265.D.4.Í; A266.D4.ij A267.D4.ij A268.D4.ij A269.D4.ij A270.D4.ij A271.D4.ij A272.D4.ij A.273.D4.Í; A274.D4.ij A275.D4.Í; A.276.D.4.Í; A277.D4.ij A278.D4.ij A279.D4.ij A280.D4.ij A281.D4.ij A282.D4.ij A.283.D4.Í; A284.D4.ij A.285.D.4.Í; A286.D4.ij A287.D4.ij A.288.D.4.Í; A289.D4.Í; A290.D4.ij A291.D.4.Í; A292.D4.ij A293.D4.ij A294.D4.ij A295.D.4.i; A.296.D.4.Í; A297.D4.ij A298.D4.ij A299.D4.ij A.300.D4.Í; A301.D4.ij A.302.D4.Í; A303.D4.ij A304.D4.ij A.305.D.4.Í; A306.D4.ij A307.D4.ij A308.D4.ij A309.D4.ij A310.D4.ij A31Í.D4.Í; A312.D4.ij A313.D4.ij A314.D4.ij A315.D4.ij A316.D4.ij A317.D4.ij A318.D4.ij A.3I9.D4.Í; A320.D4.ij A321.D.4.Í; A323.D4.ij A324.D4.ij A325.D.4.Í; A326.D4.ij A327.D4.ij A328.D4.ij A329.D4.ij A.330.D.4.Í; A.331.D4.Í; A332.D4.ij A333.D.4.Í; A334.D4.ij A335.D4.ij A336.D4.ij A337.D4.ij A.338.D.4.:; A339.D4.ij A.340.D4.Í; A341.D4.ij A342.D4.ij A.343.D.4.Í; A.344.D.4.Í; A345.D4.ij A346.D4.ij A.347.D4.Í; A.348.D.4.1; A349.D4.ij A350.D4.ij A351.D4.ij A352.D4.ij A353.D4.ij A354.D.4.j; A355.D4.ij A356.D4.ij A357.D4.ij A358.D4.ij A359.D4.ij A360.D4.ij A361.D4.ij A362.D4.ij A363.D4.ij A364.D4.ij A365.D4.ij A366.D4.ij A367.D4.ij A368.D4.ij A369.D4.ij A370.D4.ij A.371.D.4.Í; A.372.D.4.Í; A373.D4.ij A374.D4.ij A375.D4.ij A376.D4.ij A377.D4.ij A378.D4.ij A379.D4.ij A380.D4.ij A.381.D.4.Í; A382.D4.ij A383.D4.ij A.384.D.4.Í; A385.D4.ij A386.D4.ij A387.D4.ij A388.D4.ij A389.D4.ij A390.D4.Í; A391.D4.ij A392.D4.ij A393.D4.ij A394.D.4.Í; A395.D4.ij A396.D4.ij A397.D4.ij A398.D4.ij A399.D4.ij A400.D4.ij A401.D4.ij A402.D4.ij A.403.D.4.Í; A404.D4.ij A405.D4.ij A406.D4.ij A407.D4.ij A408.D4.ij A.409.D.4.Í; A41O.D4.ij A.411.D.4.Í; A412.D4.ij A413.D4.ij A414.D4.ij A415.D4.ij A416.D.4.Í; A4I7.D4.ij A.418.D.4.Í; A419.D4.ij A420.D4.ij A421.D4.ij A.422.D.4.Í; A423.D4.ij A424.D4.ij A425.D4.ij A426.D4.ij A427.D4.ij A428.D4.ij A429.D4.ij A430.D4.ij A431.D4.ij A432.D4.ij A.433.D4.Í; A434.D4.Í; A435.D4.ij A436.D4.ij A437.D4.ij A438.D4.ij A.439.D.4.1; A.440.D.4.Í; A441.D4.ij A.442.D.4.Í; A443.D4.ij A444.D4.ij A.445.D4.Í; A.446.D.4.Í; A.447.D.4.Í; A.448.D4.Í; A449.D4.ij A.450.D.4.Í; A451.D4.ij A452.D4.ij A453.D4.ij A454.D4.ij A.455.D.4.Í; A456.D4.-i; A.457.D4.Í; A458.D4.ij A459.D4.ij A460.D4.ij -A461-.D4.ij A462.D4.ij A463.D4.ij A464.D4.ij A465.D4.ij A466.D4.ij A467.D4.ij A468.D4.ij A469.D4.ij A.470.D.4.Í; A.471.D.4.Í; A472.D4.ij A.473 D.4.1; A474.D 4.ij A475.D4.ij A476.D4.ij A.477.D.4.Í; A478.D4.ij A.479.D.4.1J A.480.D.4.1; A.481.D.4.Í; A482.D4.ij A483.D4.ij A484.D4.ij A485.D4.ij· A486.D.4.Í; A487.D4.ij A488.D4.ij A.489.D.4.Í; A490.D4.ijA.208.D.4.Í; A209.D.4.I; A.210.D4.Í; A.211.D4.Í; A.212.D.4.Í; A.213.D.4.Í; A.214.D.4.Í; A.215.D.4.Í; A.216.D.4.Í; A.217.D4.Í; A.218.D.4.Í; A.219.D.4.Í; A220.D4.ij A221.D.4.I; A.222.D.4.Í; A.223.D.4.Í; A224.D4.ij A.225.D4.I; A.226.D.4.1; A.227.D.4.U A-228.D4.ij A.229.D.4.I; A.230.D.4.Í; A.231.D.4.Í; A.232.D4.Í; A.233.D.4.Í; A234.D4.ij. A.235.D.4.Í; A236.D4.ij A.237.D4.I; A.238.D.4.Í; A.239.D.4.Í; A240.D4.ij A241.D4.ij A242.D4.ij A243.D4.ij A.244.D.4.I; A.245.D4.Í; A.246.D.4.Í; A.247.D.4.Í; A.248.D.4.Í; A.249.D4.Í; A.250.D.4.Í; A.251.D.4.ij A.252.D.4.I; A.253.D.4.Í; A254.D4.ij A.255.D4.I ; A.256.D.4.Í; A257.D4.ij A.258.D4.I; A259.D4.ij A260.D4.ij A.261.D.4.I; A262.D4.ij A263.D4.ij A.264.D.4.I; A265.D.4.I; A266.D4.ij A267.D4.ij A268.D4.ij A269.D4.ij A270.D4.ij A271.D4.ij A272.D4.ij A.273.D4.ij; A274.D4.ij A275.D4.I; A.276.D.4.Í; A277.D4.ij A278.D4.ij A279.D4.ij A280.D4.ij A281.D4.ij A282.D4.ij A.283.D4.ij; A284.D4.ij A.285.D.4.I; A286.D4.ij A287.D4.ij A.288.D.4.I; A289.D4.Í; A290.D4.ij A291.D.4.I; A292.D4.ij A293.D4.ij A294.D4.ij A295.D.4.i ; A.296.D.4.Í; A297.D4.ij A298.D4.ij A299.D4.ij A.300.D4.I; A301.D4.ij A.302.D4.I; A303.D4.ij A304.D4.ij A.305.D.4.I; A306.D4.ij A307.D4.ij A308.D4.ij A309.D4.ij A310.D4.ij A31I.D4.I; A312.D4.ij A313.D4.ij A314.D4.ij A315.D4.ij A316.D4.ij A317.D4.ij A318.D4.ij A.3I9.D4.I; A320.D4.ij A321.D.4.I; A323.D4.ij A324.D4.ij A325.D.4.I; A326.D4.ij A327.D4.ij A328.D4.ij A329.D4.ij A.330.D.4.I; A.331.D4.Í; A332.D4.ij A333.D.4.I; A334.D4.ij A335.D4.ij A336.D4.ij A337.D4.ij A.338.D.4.:; A339.D4.ij A.340.D4.I; A341.D4.ij A342.D4.ij A.343.D.4.I; A.344.D.4.Í; A345.D4.ij A346.D4.ij A.347.D4.I; A.348.D.4.1; A349.D4.ij A350.D4.ij A351.D4.ij A352.D4.ij A353.D4.ij A354.D.4.j; A355.D4.ij A356.D4.ij A357.D4.ij A358.D4.ij A359.D4.ij A360.D4.ij A361.D4.ij A362.D4.ij A363.D4.ij A364.D4.ij A365.D4.ij A366.D4.ij A367.D4.ij A368.D4.ij A369.D4.ij A370.D4.ij A.371.D.4.I; A.372.D.4.Í; A373.D4.ij A374.D4.ij A375.D4.ij A376.D4.ij A377.D4.ij A378.D4.ij A379.D4.ij A380.D4.ij A.381.D.4.I; A382.D4.ij A383.D4.ij A.384.D.4.I; A385.D4.ij A386.D4.ij A387.D4.ij A388.D4.ij A389.D4.ij A390.D4.I; A391.D4.ij A392.D4.ij A393.D4.ij A394.D.4.I; A395.D4.ij A396.D4.ij A397.D4.ij A398.D4.ij A399.D4.ij A400.D4.ij A401.D4.ij A402.D4.ij A.403.D.4.I; A404.D4.ij A405.D4.ij A406.D4.ij A407.D4.ij A408.D4.ij A.409.D.4.I; A41O.D4.ij A.411.D.4.I; A412.D4.ij A413.D4.ij A414.D4.ij A415.D4.ij A416.D.4.I; A4I7.D4.ij A.418.D.4.I; A419.D4.ij A420.D4.ij A421.D4.ij A.422.D.4.I; A423.D4.ij A424.D4.ij A425.D4.ij A426.D4.ij A427.D4.ij A428.D4.ij A429.D4.ij A430.D4.ij A431.D4.ij A432.D4.ij A.433.D4.Í; A434.D4.Í; A435.D4.ij A436.D4.ij A437.D4.ij A438.D4.ij A.439.D.4.1; A.440.D.4.Í; A441.D4.ij A.442.D.4.I; A443.D4.ij A444.D4.ij A.445.D4.I; A.446.D.4.Í; A.447.D.4.Í; A.448.D4.Í; A449.D4.ij A.450.D.4.I; A451.D4.ij A452.D4.ij A453.D4.ij A454.D4.ij A.455.D.4.I; A456.D4.-i; A.457.D4.Í; A458.D4.ij A459.D4.ij A460.D4.ij -A461-.D4.ij A462.D4.ij A463.D4.ij A464.D4.ij A465.D4.ij A466.D4.ij A467.D4 .ij A468.D4.ij A469.D4.ij A.470.D.4.I; A.471.D.4.Í; A472.D4.ij A.473 D.4.1; A474.D 4.ij A475.D4.ij A476.D4.ij A.477.D.4.I; A478.D4.ij A.479.D.4.1J A.480.D.4.1; A.481.D.4.Í; A482.D4.ij A483.D4.ij A484.D4.ij A485.D4.ij · A486.D.4.I; A487.D4.ij A488.D4.ij A.489.D.4.I; A490.D4.ij
- 123 CZ 297945 B6- 123 GB 297945 B6
A.491.D.4.Í; A.492.D.4.Í; A.493.D.4.Í; A.494.D.4.Í; A.495.D.4J; A.496.D.4.Í; A.497.D.4.Í; A.498.D.4.Í; A.499.D.4.Í; A.500.D.4.Í; A.501.D.4.Í; A.502.D.4.Í; A.503.D.4.Í; A,504.D,4.i; A.505.D.4.Í; A.506.D.4.Í; A.507.D.4.Í; A.508.D.4.Í; A 509.D.4.Í; A.510.D.4.Í; A.511.D.4.Í; A.512.D.4.Í; A.512.D.4.Í; A.513.D.4.Í; A.514.D.4.Í; A.515.D.4.1; A.516.D.4.Í; A.517.D.4.Í; A.518.D.4.Í; A.519.D.4.Í; A.520.D.4.Í; A.521.D.4.Í; A.522.D.4.Í; A.523.D.4.Í; A.524.D.4.Í; A.525.D.4.Í; A.526.D.4.Í; A.527.D.4.Í; A.528.D.4.Í; A.529.D.4.Í; A.530.D.4.Í; A.531.D.4.Í; A.532.D.4.Í; A.533.D.4.Í; A.534.D.4.Í; A.535.D.4.Í; A.536.D.4.Í; A.537.D.4.Í; A.538.D.4.Í; A.539.D.4.Í; A.540.D.4.Í; A.54LD.4.Í; A.542.D.4.Í; A.543.D.4.Í; A.544.D.4.Í; A.545.D.4.Í; A.546.D.4.Í; A.547.D.4.Í; A.548.D.4.Í; A.549.D.4.Í; A.550.D.4.Í; A.551.D.4.Í; A.552.D.4.Í; A.553.D.4.i; A.554.D.4.Í; A.555.D.4.Í; A.556.D.4.Í; A.557.D.4.Í; A.558.D.4.Í; A.559.D.4.Í; A.560.D.4.Í; A.56LD.4.Í; A.562.D.4.Í; A.563.D.4.Í; A.564.D.4.Í; A.565.D.4.1; A.566.D.4.Í; A367.D.4.Í; A.568.D.4.Í; A.569.D.4.Í; A.570.D.4.Í; A.571.D.4.Í; A.572.D.4.Í; A.573.D.4.Í; A.574.D.4.Í; A.575.D.4.Í; A.576.D.4.Í; A.577.D.4.Í; A.578.D.4.Í; A.579.D.4.Í; A.580.D.4.Í; A.581.D.4.Í; A.582.D.4.Í; A.583.D.4.Í; A.584.D.4.Í; A.585.D.4.Í; A.586.D.4.Í; A.587.D.4.Í; A.588.D.4.Í; A.589.D.4.Í; A.590,D.4.i; A.59LD.4.Í; A.592.D.4.Í; A.593.D.44; A.594.D.4.i; A.595.D.4.Í; A.596.D.4.Í; A.597.D.4.1; A.598.D.4.Í; A.599.D.4.Í; A.600.D.4.Í; A.601.D.4.Í; A.602.D.4.Í; A.603.D.4.Í; A.604.D.4.Í; A.605.D.4.Í; A.606.D.4.Í; A.607.D.4.Í; A.608.D.4.Í; A.609.D.4.Í; A.610.D.4.Í; A.611.D.44; A.612.D.4.Í; A.613.D.4.Í; A.614.D.4.Í; A.615.D.4.Í; A.616.D.4.Í; A.617.D.4.Í; A.618.D.4.Í; A.619.D.4.Í; A.620.D.4.Í; A.621.D.4J; A.622.D.4.Í; A.623.D.4.Í; A.624.D.4.Í; A.625.D.4.Í; A.626.D.4.Í; A.627.D.4.Í; A.628.D.4.Í; A.629.D.4.Í; A.630.D.4.Í; A.631.D.4.Í; A.632.D.4.Í; A.633.D.4.Í; A.634.D.4.Í; A.635.D.4.Í; A.636.D.4.Í; A.637.D.4.Í; A.638.D.4.Í; A.639.D.4.Í; A.640.D.4.Í; A.641.D.4.Í; A.642.D.4.Í; A.643.D.4.Í; A.644.D.4.Í; A.645.O.4.Í; A.646.D.4.Í; A.647.D.4.Í; A.648.D.4.Í; A.649.D.44; A.650.D.4.Í; A.651.D.4.Í; A.652.D.4.Í; A.653.D.4.Í; A.654.D.4.Í; A.655.D.4.Í; A.656.D.4.i; A.657.D.4.Í; A.658.D.4.Í; A.659.D.44; A.660.D.4.Í; A.2.D.11.Í; A.3.D.11.Í; A.4.D.11.Í; A.5.D.11.Í; A.ó.D.ll.i; A.7.D.11.Í; A.9.D.11.Í; A.lO.D.ll.i; A.15.D.11 .i; A.100.D.U.Í; A.lOl.D.ll.i; A.102.D.11.Í; A.103.D.11.Í; A.104.D.U.Í; A.1O5.D.11.Í; A.106.D.11.Í; A.107iD.ll.i; A.lOS.D.ll.i; A.109.D.U.Í; A.llO.D.U.i; A.111.D.11.Í; A.112.D.11.Í; A.113.D.11.Í; A.114.D.11.Í; A.115.D.11.Í; A.lló.D.U.i; A.117.D.11.Í; A.118.D.11.Í; A.119.D.11.Í; A.120.D.11.Í; A.121.D.11.Í; A.122.D.11.Í; A.123.D.11.Í; A.124.D.11.Í; A.125.D.11.Í; A.126.D.1 l.i; A.127.D.11.Í; A.128.D.11.Í; A.129.D.11.Í; A.130.D.11.Í; A.131.D.11.Í; A.132.D.11.Í; A.133.D.11.Í; A.134.D.11.Í; A.135.D.11.Í; A.136.D.11.Í; A.137.D.11.Í; A.138.D.11.Í; A.139.D.U.Í; A.140.D.U.Í; A.141.D.11.Í; A.142.D.11.Í; A.143.D.U.Í; A.144.D.1U A.145.D.11.Í; A.146.D.11.Í; A.147.D.U.Í; A.148.D.11.Í; A.149.D.11.Í; A.150.D.11.Í; A.151.D.11.Í; A.152.D.11.Í; A.153.D.11.Í; A.154.D.11.:; A.155.D.11.Í; A.156.D.1U; A.157.D.11.1; A.158.D.11 .i; A.159.D.11.Í; A.160.D.11.Í; A.161.D.11.Í; A.162.D.11.Í; A.163.D.11.Í; A.164.D.11.Í; A.165.D.11.1; A.166.D.11.Í; A.167.D.11.Í; A.168.D.11.Í; A.169.D.U.Í; A.170.D.11.Í; A.171.D.11.Í; A.172.D.11.Í; A.173.D.11.Í; A.174.D.11.Í; A.175.D.U.Í; A.176.D.11.Í; A.177.D.11.Í; A.178.D.11.Í; A.179.D.11.Í; A.180.D.11.Í; A.181.D.11.Í; A.182.D.U.Í; A.183.D.11.Í; A.184.D.11.Í; A.185.D.U.Í; A.186.D.U.Í; A.187.D.1LÍ; A.188.D.11.Í; A.189.D.U.Í; A.190.D.11.Í; A.191.D.11.Í; A.192.D.11.Í; A.193.D.ll.i; A.194.D.11.Í; A.195.D.11.Í; A.196.D.11.Í; A.197.D.11.Í; A.198.D.1U; A.199.D.11.Í; A.200.D.11.Í; A.201.D.11.Í; A.202.D.11.Í;A.491.D.4.Í; A.492.D.4.Í; A.493.D.4.Í; A.494.D.4.Í; A.495.D.4J; A.496.D.4.Í; A.497.D.4.Í; A.498.D.4.Í; A.499.D.4.Í; A.500.D.4.Í; A.501.D.4.Í; A.502.D.4.I; A.503.D.4.I; A, 504.D, 4.i; A.505.D.4.I; A.506.D.4.I; A.507.D.4.I; A.508.D.4.I; A 509.D.4.I; A.510.D.4.Í; A.511.D.4.Í; A.512.D.4.Í; A.512.D.4.Í; A.513.D.4.Í; A.514.D.4.Í; A.515.D.4.1; A.516.D.4.Í; A.517.D.4.Í; A.518.D.4.Í; A.519.D.4.Í; A.520.D.4.Í; A.521.D.4.Í; A.522.D.4.Í; A.523.D.4.Í; A.524.D.4.Í; A.525.D.4.Í; A.526.D.4.Í; A.527.D.4.Í; A.528.D.4.Í; A.529.D.4.Í; A.530.D.4.Í; A.531.D.4.Í; A.532.D.4.Í; A.533.D.4.Í; A.534.D.4.Í; A.535.D.4.Í; A.536.D.4.Í; A.537.D.4.Í; A.538.D.4.Í; A.539.D.4.Í; A.540.D.4.Í; A.54LD.4.Í; A.542.D.4.Í; A.543.D.4.Í; A.544.D.4.Í; A.545.D.4.Í; A.546.D.4.Í; A.547.D.4.Í; A.548.D.4.Í; A.549.D.4.Í; A.550.D.4.Í; A.551.D.4.Í; A.552.D.4.Í; A.553.D.4.i; A.554.D.4.Í; A.555.D.4.Í; A.556.D.4.Í; A.557.D.4.Í; A.558.D.4.Í; A.559.D.4.Í; A.560.D.4.Í; A.56LD.4.Í; A.562.D.4.Í; A.563.D.4.Í; A.564.D.4.Í; A.565.D.4.1; A.566.D.4.Í; A367.D.4.I; A.568.D.4.Í; A.569.D.4.Í; A.570.D.4.Í; A.571.D.4.Í; A.572.D.4.Í; A.573.D.4.I; A.574.D.4.Í; A.575.D.4.Í; A.576.D.4.Í; A.577.D.4.Í; A.578.D.4.Í; A.579.D.4.Í; A.580.D.4.Í; A.581.D.4.Í; A.582.D.4.Í; A.583.D.4.Í; A.584.D.4.Í; A.585.D.4.Í; A.586.D.4.Í; A.587.D.4.Í; A.588.D.4.Í; A.589.D.4.Í; A.590, D.4.i; A.59LD.4.Í; A.592.D.4.Í; A.593.D.44; A.594.D.4.i; A.595.D.4.Í; A.596.D.4.Í; A.597.D.4.1; A.598.D.4.Í; A.599.D.4.Í; A.600.D.4.Í; A.601.D.4.Í; A.602.D.4.I; A.603.D.4.I; A.604.D.4.I; A.605.D.4.I; A.606.D.4.I; A.607.D.4.I; A.608.D.4.I; A.609.D.4.I; A.610.D.4.Í; A.611.D.44; A.612.D.4.Í; A.613.D.4.Í; A.614.D.4.Í; A.615.D.4.Í; A.616.D.4.Í; A.617.D.4.Í; A.618.D.4.Í; A.619.D.4.Í; A.620.D.4.Í; A.621.D.4J; A.622.D.4.Í; A.623.D.4.Í; A.624.D.4.Í; A.625.D.4.Í; A.626.D.4.Í; A.627.D.4.Í; A.628.D.4.Í; A.629.D.4.Í; A.630.D.4.Í; A.631.D.4.Í; A.632.D.4.Í; A.633.D.4.Í; A.634.D.4.Í; A.635.D.4.Í; A.636.D.4.Í; A.637.D.4.Í; A.638.D.4.Í; A.639.D.4.Í; A.640.D.4.Í; A.641.D.4.Í; A.642.D.4.Í; A.643.D.4.Í; A.644.D.4.Í; A.645.O.4.Í; A.646.D.4.Í; A.647.D.4.Í; A.648.D.4.Í; A.649.D.44; A.650.D.4.Í; A.651.D.4.Í; A.652.D.4.Í; A.653.D.4.Í; A.654.D.4.Í; A.655.D.4.Í; A.656.D.4.i; A.657.D.4.Í; A.658.D.4.Í; A.659.D.44; A.660.D.4.Í; A.2.D.11.Í; A.3.D.11.Í; A.4.D.11.Í; A.5.D.11.Í; A.ó.D.ll.i; A.7.D.11.Í; A.9.D.11.Í; A.10.D.ll.i; A.15.D.11 .i; A.100.D.U.I; A.lOl.D.ll.i; A.102.D.11.Í; A.103.D.11.Í; A.104.D.U.I; A.1O5.D.11.Í; A.106.D.11.Í; A.107iD.ll.i; A.lOS.D.ll.i; A.109.D.U.Í; A.llO.D.U.i; A.111.D.11.Í; A.112.D.11.Í; A.113.D.11.Í; A.114.D.11.Í; A.115.D.11.Í; A.lló.D.U.i; A.117.D.11.Í; A.118.D.11.Í; A.119.D.11.Í; A.120.D.11.Í; A.121.D.11.Í; A.122.D.11.Í; A.123.D.11.Í; A.124.D.11.Í; A.125.D.11.Í; A.126.D.1 l.i; A.127.D.11.Í; A.128.D.11.Í; A.129.D.11.Í; A.130.D.11.Í; A.131.D.11.Í; A.132.D.11.Í; A.133.D.11.Í; A.134.D.11.Í; A.135.D.11.Í; A.136.D.11.Í; A.137.D.11.Í; A.138.D.11.Í; A.139.D.U.I; A.140.D.U.I; A.141.D.11.Í; A.142.D.11.Í; A.143.D.U.I; A.144.D.1U A.145.D.11.I; A.146.D.11.Í; A.147.D.U.I; A.148.D.11.Í; A.149.D.11.Í; A.150.D.11.Í; A.151.D.11.Í; A.152.D.11.Í; A.153.D.11.Í; A.154.D.11. A.155.D.11.Í; A.156.D.1U; A.157.D.11.1; A.158.D.11 .i; A.159.D.11.Í; A.160.D.11.Í; A.161.D.11.Í; A.162.D.11.Í; A.163.D.11.Í; A.164.D.11.Í; A.165.D.11.1; A.166.D.11.Í; A.167.D.11.Í; A.168.D.11.Í; A.169.D.U.I; A.170.D.11.Í; A.171.D.11.Í; A.172.D.11.Í; A.173.D.11.Í; A.174.D.11.Í; A.175.D.U.I; A.176.D.11.Í; A.177.D.11.Í; A.178.D.11.Í; A.179.D.11.Í; A.180.D.11.Í; A.181.D.11.Í; A.182.D.U.I; A.183.D.11.Í; A.184.D.11.Í; A.185.D.U.I; A.186.D.U.I; A.187.D.1LÍ; A.188.D.11.Í; A.189.D.U.I; A.190.D.11.Í; A.191.D.11.Í; A.192.D.11.Í; A.193.D.ll.i; A.194.D.11.Í; A.195.D.11.Í; A.196.D.11.Í; A.197.D.11.Í; A.198.D.1U; A.199.D.11.Í; A.200.D.11.Í; A.201.D.11.Í; A.202.D.11.Í;
-124CZ 297945 B6-124GB 297945 B6
A203.D.11.Í; A.204.D.11.Í; A.205.D.11.Í; A.206.D.11.Í; A.207.D.11J; A.208.D.U.Í; A.209.D.11.Í; A210.D.11.Í; AÍll.D.li.i; A.212.D.111 A.213.D.111 A214.D.11.Í; A215.D.11.Í; A.216.D.111 A.217.D.11.Í; A.218.D.11.1; A.219.D.11.Í; A220.D.U.Í; A.221.D.11.Í; A.222.D.11.Í; A.223.D.1LÍ; A.224.D.111 A.225.D.11.Í; A226.D.11.Í; A227.D.11.Í; A.228.D.11.Í; A.229.D.11.Í; A.230.D.11.Í; A.231.D.11.Í; A.232.D.11.Í; A.233.D.11.Í; A.234.D.11.Í; A.235.D.11.Í; A.236.D.111 A237.D.11.Í; A238.D.11.Í; A239.D.11Í A.240.D.114; A.241.D.U.Í; A242JD.il.i; A.243.D.U.Í; A.244.D.11.Í; A.245.D.11.Í; A.246.D.UJ; A.247.D.111 A.248.D.11.Í; A.249.D.11.Í; A.250.D.11.Í; A251.D.11J; A.252.D.111 A.253.D.11.Í; A.254.D.11.Í; A255.D.11.Í; A256.D.11.Í; A.257.D.11.Í; A.258.D.11.Í; A.259.D.11 .i; A.260.D.11.Í; A.261.D.11.Í; A262.D.11.Í; A263.D.11.Í; A.264.D.11.Í; A.265.D.11.Í; A.266.D.11.Í; A.267.D.111 A.268.D.U.Í; A.269.D.11.Í; A.270.D.11.Í; A.271.D.U.Í; A.272.D.1U; A.273.D.11.Í; A.274.D.11.Í; A.275.D.11.Í; A.276.D.11.Í; A.277.D.11.Í; A.278.D.11.Í; A.279.D.11.Í; A.280.D.11.Í; A281.D.111 A.282.D.11.Í; A.283.D.11.Í; A.284JD.11.Í; A.285.D.U.Í; A.286.D.11.Í; A287.D.11.Í; A.288.D.1U; A.289.D.11.Í; A.290.D.11.Í; A.291.D.11.Í; A292.D.U.Í; A293.D.11.Í; A.294.D.11.Í; A.295.D.11.Í; A.296.D.11.Í; A.297.D.11.Í; A.298.D.11.Í; A.299.D.11.Í; A.300.D.11.Í; A.301.D.11.Í; A.302.D.11.Í; A.303.D.11.Í; A.304.D.1LÍ; A.305.D.11.Í; A.306.D.11.Í; A.307.D.11.Í; A.308.D.11.Í; A.309.D.11.Í; A.310.D.11.Í; A.311.D.U.Í; Á.312.D.11.Í; A.313.D.U.Í; A.314.D.11.Í; A.315.D.1U; A.316.D.11.Í; A.317.D.11.Í; A.318.D.11.Í; A.319.D.11.Í; A.320.D.U.Í; A.321.D.11.Í; A.323.D.11.Í; A.324.D.11J; A.325.D.11.Í; A.326.D.11.Í; A.327.D.111 A.328.D.11.Í; A.329.D.11.Í; A.33Ó.D.11.Í· A.331.D.11.Í; A.332.D.11.Í; A.333.D.111 A.334.D.11.Í; A.335.D.11.Í; A.336.D.11.Í; A.337.D.11.Í; A.338.D.11.Í; A.339.D.11.Í; A.340.D.11.Í; A.341.D.11.Í; A.342.D.11.Í; A.343.D.11.Í; A.344.D.11.Í; A.345.D.11.Í; A.346.D.11.Í; A.347.D.11.Í; A.348.D.11.Í; A.349.D.1Ú; A.350.D.11.Í; A.35W.U.Í; A.352.D.11.Í; A.353.D.11.Í; A.354.D.11.Í; A.355.D.11.Í; A.356.D.U.Í; A.357.D.11.Í; A.358.D.11.Í; A.359.D.11.Í; A.360.D.11.Í; A.361.D.11.Í; A.362.D.11.Í; A.363.D.11.Í; A.364.D.1U; A.365.D.11.Í; A.366.D.11.Í; A.367.D.11.Í; A.368.D.11.Í; A.369.D.111 A.370.D.111 A.371.D.11.Í; A 372.D.11.Í; A.373.D.11.Í; A.374.D.11.Í; A.375.D.11.Í; A.376.D.11.Í; A.377.D.11.Í; A.378.D.11.Í; A.379.D.11.Í; A.380.Ď.111 A.381.D.U.Í; A.382.D.U.Í; A.383.D.11.Í; A.384.D.11.Í; A.385.D.U.Í; A.386.D.U.Í; A.387.D.111 A.388.D.U.Í; A.389.D.1U A.390.D.11.Í; A.391.D.11.Í; A.392.D.11.Í; A.393.D.11.Í; A.394.D.11.Í; A.395.D.111 A.396.D.11.Í; A.397.D.1U A.398.D.111 A.399.D.111 A.400.D.11.Í; A.401.D.11.Í; A.402.D.11.Í; A.403.D.11.Í; A.404.D.11.Í; A.405.D.11.Í; A.406.D.11.Í; A.407.D.11.Í; A.408.D.11.Í; A.409.D.11.Í; A.410.D.11.Í; A.411.D.11.Í; A.412.D.111 A.413.D.11.Í; A.414.D.111 A.415.D.111 A.416.D.11.Í; A.417.D.11.Í; A.418.D.11.Í; A.419.D.11.Í; A.420.D.111 A.421.D.11.Í; A.422.D.11.Í; A.423.D.11.Í; A.424.D.11.Í; A.425.D.11.Í; A.426.D.11.1; A.427.D.111 A.428.D.11.Í; A.429.D.11.Í; A.430.D.11.Í; A.431.D.11.Í; A.432.D.11J; A.433.D.1U; A.43W.111 A.435.D.U1 A.436.D.11.Í; A.437.D.11.Í; A.438.D.11.Í; A.439.D.11.Í; A.440.D.11.Í; A.441.D.11.Í; A.442.D.11.Í; A.443.D.11.Í; A.444.D.11.Í; A.445.D.11.Í; A.446.D.1LÍ; A.447.D.111 A.448.D.11.Í; A.449.D.11.Í; A.450.D.I11 A.451.D.11.Í; A.452.D.11.Í; A.453.D.U1 A.454.D.11.Í; A.455.D.11.Í; A.456.D.111 A.457.D.11.1; A.458.D.1U; A.459.D.U1 A.460.D.U.Í; A.461.D.11.Í; A.462.D.11.Í; A.463.D.111 A.464.D.11.Í; A.465.D.11.Í; A.466.D.11.Í; A.467.D.11.Í; A.468.D.11.Í; A.469.D.111 A.470.D.U.Í; A.471.D.111 A.472.D.11.Í; A.473.D.11.Í; A.474.D.11.Í; A.475.D.11.Í; A.476.D.U.Í; A.477.D.U.Í; A.478.D.U.Í; A.479.D.11.Í; A.480.D.11.Í; A.481.D.11.Í; A.482.D.11.Í; A.483.D.11.Í; A.484.D.111 A.485.D.11.Í;A203.D.11.Í; A.204.D.11.Í; A.205.D.11.Í; A.206.D.11.Í; A.207.D.11J; A.208.D.U.Í; A.209.D.11.Í; A210.D.11.Í; Alll.D.li.i; A.212.D.111 A.213.D.111 A214.D.11.I; A215.D.11.Í; A.216.D.111 A.217.D.11.I; A.218.D.11.1; A.219.D.11.Í; A220.D.U.I; A.221.D.11.Í; A.222.D.11.Í; A.223.D.1LÍ; A.224.D.111 A.225.D.11.I; A226.D.11.Í; A227.D.11.Í; A.228.D.11.Í; A.229.D.11.Í; A.230.D.11.Í; A.231.D.11.Í; A.232.D.11.Í; A.233.D.11.Í; A.234.D.11.Í; A.235.D.11.Í; A.236.D.111 A237.D.11.I; A238.D.11.Í; A239.D.11I A.240.D.114; A.241.D.U.I; A242JD.il.i; A.243.D.U.I; A.244.D.11.Í; A.245.D.11.Í; A.246.D.UJ; A.247.D.111 A.248.D.11.I; A.249.D.11.Í; A.250.D.11.Í; A251.D.11J; A.252.D.111 A.253.D.11.I; A.254.D.11.Í; A255.D.11.Í; A256.D.11.Í; A.257.D.11.Í; A.258.D.11.Í; A.259.D.11 .i; A.260.D.11.Í; A.261.D.11.Í; A262.D.11.Í; A263.D.11.Í; A.264.D.11.Í; A.265.D.11.Í; A.266.D.11.Í; A.267.D.111 A.268.D.U.I; A.269.D.11.Í; A.270.D.11.Í; A.271.D.U.I; A.272.D.1U; A.273.D.11.Í; A.274.D.11.Í; A.275.D.11.Í; A.276.D.11.Í; A.277.D.11.Í; A.278.D.11.Í; A.279.D.11.Í; A.280.D.11.Í; A281.D.111 A.282.D.11.I; A.283.D.11.Í; A.284JD.11.Í; A.285.D.U.I; A.286.D.11.Í; A287.D.11.Í; A.288.D.1U; A.289.D.11.Í; A.290.D.11.Í; A.291.D.11.Í; A292.D.U.I; A293.D.11.Í; A.294.D.11.Í; A.295.D.11.Í; A.296.D.11.Í; A.297.D.11.Í; A.298.D.11.Í; A.299.D.11.Í; A.300.D.11.Í; A.301.D.11.Í; A.302.D.11.Í; A.303.D.11.Í; A.304.D.1LÍ; A.305.D.11.Í; A.306.D.11.Í; A.307.D.11.Í; A.308.D.11.Í; A.309.D.11.Í; A.310.D.11.Í; A.311.D.U.I; Á.312.D.11.Í; A.313.D.U.I; A.314.D.11.Í; A.315.D.1U; A.316.D.11.Í; A.317.D.11.Í; A.318.D.11.Í; A.319.D.11.Í; A.320.D.U.I; A.321.D.11.Í; A.323.D.11.Í; A.324.D.11J; A.325.D.11.Í; A.326.D.11.Í; A.327.D.111 A.328.D.11.I; A.329.D.11.Í; A.33O.D.11.I · A.331.D.11.I; A.332.D.11.Í; A.333.D.111 A.334.D.11.I; A.335.D.11.Í; A.336.D.11.Í; A.337.D.11.Í; A.338.D.11.Í; A.339.D.11.Í; A.340.D.11.Í; A.341.D.11.Í; A.342.D.11.Í; A.343.D.11.Í; A.344.D.11.Í; A.345.D.11.Í; A.346.D.11.Í; A.347.D.11.Í; A.348.D.11.Í; A.349.D.1Ú; A.350.D.11.Í; A.35W.U.I; A.352.D.11.Í; A.353.D.11.Í; A.354.D.11.Í; A.355.D.11.Í; A.356.D.U.I; A.357.D.11.Í; A.358.D.11.Í; A.359.D.11.Í; A.360.D.11.Í; A.361.D.11.Í; A.362.D.11.Í; A.363.D.11.Í; A.364.D.1U; A.365.D.11.Í; A.366.D.11.Í; A.367.D.11.Í; A.368.D.11.Í; A.369.D.111 A.370.D.111 A.371.D.11.I; A 372.D.11.I; A.373.D.11.Í; A.374.D.11.Í; A.375.D.11.Í; A.376.D.11.Í; A.377.D.11.Í; A.378.D.11.Í; A.379.D.11.Í; A.380.Ď.111 A.381.D.U.I; A.382.D.U.I; A.383.D.11.Í; A.384.D.11.Í; A.385.D.U.I; A.386.D.U.I; A.387.D.111 A.388.D.U.I; A.389.D.1U A.390.D.11.I; A.391.D.11.Í; A.392.D.11.Í; A.393.D.11.Í; A.394.D.11.Í; A.395.D.111 A.396.D.11.I; A.397.D.1U A.398.D.111 A.399.D.111 A.400.D.11.I; A.401.D.11.Í; A.402.D.11.Í; A.403.D.11.Í; A.404.D.11.I; A.405.D.11.Í; A.406.D.11.Í; A.407.D.11.Í; A.408.D.11.Í; A.409.D.11.Í; A.410.D.11.Í; A.411.D.11.Í; A.412.D.111 A.413.D.11.I; A.414.D.111 A.415.D.111 A.416.D.11.I; A.417.D.11.Í; A.418.D.11.Í; A.419.D.11.Í; A.420.D.111 A.421.D.11.I; A.422.D.11.Í; A.423.D.11.Í; A.424.D.11.Í; A.425.D.11.Í; A.426.D.11.1; A.427.D.111 A.428.D.11.I; A.429.D.11.Í; A.430.D.11.Í; A.431.D.11.Í; A.432.D.11J; A.433.D.1U; A.435.D.U1 A.436.D.11.I; A.437.D.11.Í; A.438.D.11.Í; A.439.D.11.Í; A.440.D.11.Í; A.441.D.11.Í; A.442.D.11.Í; A.443.D.11.Í; A.444.D.11.Í; A.445.D.11.Í; A.446.D.1LÍ; A.447.D.111 A.448.D.11.I; A.449.D.11.Í; A.450.D.I11 A.451.D.11.I; A.452.D.11.Í; A.453.D.U1 A.454.D.11.I; A.455.D.11.Í; A.456.D.111 A.457.D.11.1; A.458.D.1U; A.459.D.U1 A.460.D.U.I; A.461.D.11.Í; A.462.D.11.Í; A.463.D.111 A.464.D.11.I; A.465.D.11.Í; A.466.D.11.Í; A.467.D.11.Í; A.468.D.11.Í; A.469.D.111 A.470.D.U.I; A.471.D.111 A.472.D.11.I; A.473.D.11.Í; A.474.D.11.Í; A.475.D.11.Í; A.476.D.U.I; A.477.D.U.I; A.478.D.U.I; A.479.D.11.Í; A.480.D.11.Í; A.481.D.11.Í; A.482.D.11.Í; A.483.D.11.Í; A.484.D.111 A.485.D.11.I;
- 125CZ 297945 B6- 125GB 297945 B6
A.486.D.11.Í; A.487.D.11.Í; A.488.D.11.Í; A.489.D.11.Í; A.490.D.1U; A.491.D.11.Í; A.492.D.11.Í; A.493.D.11.Í; A.494.D.11.Í; A.495.D.11.Í; A.496.D.11.Í; A.497.D.11.Í; A.498.D.11.Í; A.499.D.1LÍ; A.500.D.11.Í; A.501.D.11 .i; A.502.D.11.Í; A.503.D.11.Í; A.504.D.11.Í; A.505.D.U.Í; A.506.D.11.Í; A.507.D.11 .i; A.508.D.11.Í; A.509.D.11.Í; A.510.D.11.Í; A.511.D.11.Í; A.512.D.1LÍ; A.512.D.114; A.513.D.1LÍ; A.514.D.11.Í; A.515.D.11.Í; A.516.D.11.Í; A.517.D.11.1; A.518.D.11.Í; A.519.D.11.Í; A.520.D.U.Í; A.521.D.1U A.522.D.11.Í; A.523.D.U.Í; A.524.D.11.Í; A.525.D.U.Í; A526.D.1LÍ; A.527.D.11.Í; A.528.D.11.Í; A.529.D.11.Í; A.530.D.11.Í; A.531.D.11.Í; A.532.D.11.Í; A.533.D.11.Í; A.534.D.11.Í; A335.D.1Ú A.536.D.1LÍ; A,537.D.ll.i; A538.D.U.Í; A.539.D.11.Í; A.540.D.U.Í; A.541.D.11.Í; A.542.D.11.Í; A.543.D.11.Í; A.544.D.11.Í; A.545.D.11.Í; A.546.D.11.Í; A.547.D.U.I; A.548.D.11.Í; A.549.D.11.Í; A.550.D.11.Í; A.551.D.11 .i; A.552.D.11.Í; A.553.D.11.Í; A.554.D.U.Í; A.555.D.11.Í; A.556.D.U.Í; A.557.D.11.Í; A.558.D.11.Í; A.559.D4U; A.560.D.11.Í; A.561.DJ1.Í; A.562.D.1U; A.563.D.11.Í; A.564.D.11.Í; A.565.D.11.Í; A.566.D.11.Í; A.567.D.11 .i; A.568.D.11.Í; A.569.D.11.Í; A.570.D.11.Í; A.571.D.U.Í; A.572.D.11.Í; A.573.D.1LÍ; A.574.D.U.Í; A.575.D.11.Í; A.576.D.11.Í; A.577.D.11.Í; A.578.D.1LÍ; A.579.D.11.Í; A.580.D.11.Í; A.581.D.11.Í; A.582.D.U.Í; A.583.D.11.Í; A.584.D.1U; A.585.D.11.Í; A.586.D.11.Í; A.587.D.11.Í; A.588.D.11.Í; A.589.D.11.Í; A.590.D.11.Í; A.591.D.11.Í; A.592.D.1LÍ; A.593.D.11.1; A.594.D.11.Í; A.595.D.U.Í; A.596.D.11.Í; A.597.D.11 .i; A.598.D.11.Í; A.599.D.11.Í; A.ÓOO.D.ll.i; A.601.D.11.Í; A.602.D.11.Í; A.603.D.11 .i; A.604.D.11.Í; A.605.D.11.Í; A.606.D.11.Í; A.607.D.11.Í; A.608.D.11.Í; A.609.D.11.Í; A.610.D.11.Í; A.óll.D.ll.i; A.612.D.11.Í; A.613JD.11.Í; A.614.D.11.Í; A.615.D.11.Í; A.616.D.11.Í; A.617.D.11.Í; A.618.D.11.Í; A.619.D.1U; A.620.D.11.Í; A.621.D.11.Í; A.622.D.114; A.623.D.1I.Í; A.624.D.11.Í; A.625.D.11.Í; A.626.D.1LÍ; A.627.D.11.Í; A.628.D.1LÍ; A.629.D.11.Í; A.630.D.11.Í; A.631.D.U.Í; A.632.D.11.Í; A.633.D.11.Í; A.634.D.11.Í; A.635.D.11.Í; A.636.D.11.Í; A.637.D.11.Í; A.638.D.1U; A.639.D.U.Í; A.640.D.11.Í; A.641.D.11.Í; A.642.D.11.Í; A.643.D.11.Í; A.644.D.11.Í; A.645.D.11.Í; A.646.D.11.Í; A.647.D.11.Í; A.648.D.11.Í; A.649.D.11.Í; A.650.D.11.Í; A.651.D.11.Í; A.652.D.11.Í; A.653.D.11.Í; A.654.D.11.Í; A.655.D.11.Í; A.656.D.11.Í; A.657.D.U.Í; A.658.D.11.Í; A.659.D.11.Í; A.660.D.11.Í; A.2.E.4.Í; A.3.E.4.Í; A.4.E.4.Í; A.5.E.4.Í; A.6.E.4.Í; A.7.E.4.Í; A.9.E.4.Í; A.10.E.4.Í; A.15.E.4.Í; A.100.E.4.Í; A.101.E.4.Í; A.102.E.4.Í; A.103.E.4.Í; A.104.E.4.Í; A.105.E.4.Í; A.106.E.4.Í; A.107.E.4.Í; A.108.E.4.Í; A.109.E.4.Í; A.110.E.4.Í; A.111.E.4.Í; A.112.E.4.Í; ΑΛ13.Ε.44; A.114.E.4.Í; A.115.E.44; A.116.E.44; A.117.E.44; A.118.E.44; A.119.E.4.Í; A.120.E.44; A.121.E.44; Α.122.Ε.4.Ϊ; A.123.E.44; A.124.E.4.Í; Α.125Έ.44; A.126.E.44; A.127.E.44; A.128.E.44; A.129.E.44; A.130.E.44; A.131.E.44; A.132.E.4.Í; A.133.E.44; A.134.E.44; ΑΛ35.Ε.44; A.136.E.44; A.137.E.4.Í; A.138.E.4.Í; A.139.E.44; A.140.E.44; A.141.E.44; A.142.E.44; A.143.E.44; A.144.E.44; A.145.E.44; A.146.E.44; A.147.E.44; A.148.E.44; A.149.E.44; A.150.E.44; A.151.E.44; Λ.152.Ε.44; A.153.E.44· A.154.E.44; A.155.E.44; A.156.E.44; A.157.E.44; A458.E.44; A.159.E.44; A.160.E.44; A.161.E.44; A.162.E.44; A.163.E.44; A.164.E.44; A.165.E.44; A.166.E.44; A.167.E.44; A.168.E.44; A.169.E.44; Α.170.Ε.4.Ϊ; A.171.E.44; A.172.E.44; A.173.E.4.Í; A.174.E.4.Í; A.175.E.44; A.176.E.44; A.177.E.4.Í; A.178.E.44; A.179.E.44; A.180.E.44; A.181.E.44; A.182.E.4.Í; A.183.E.4.Í; ΑΛ84.Ε.44; A.185.E.44; A.186.E.4.Í; A.187.E.44; A.188.E.4.Í; A.189.E.4.Í; A.190.E.4.Í; A.191.E.44; A.192.E.4.Í; A.193.E.44; A.194.E.4.Í; A.195.E.44; A.196.E.44; Α.197.Ε.4Λ; A.198.E.44;A.486.D.11.Í; A.487.D.11.Í; A.488.D.11.Í; A.489.D.11.Í; A.490.D.1U; A.491.D.11.Í; A.492.D.11.Í; A.493.D.11.Í; A.494.D.11.Í; A.495.D.11.Í; A.496.D.11.Í; A.497.D.11.Í; A.498.D.11.Í; A.499.D.1LÍ; A.500.D.11.Í; A.501.D.11 .i; A.502.D.11.Í; A.503.D.11.Í; A.504.D.11.Í; A.505.D.U.I; A.506.D.11.Í; A.507.D.11 .i; A.508.D.11.Í; A.509.D.11.Í; A.510.D.11.Í; A.511.D.11.Í; A.512.D.1LÍ; A.512.D.114; A.513.D.1LÍ; A.514.D.11.Í; A.515.D.11.Í; A.516.D.11.Í; A.517.D.11.1; A.518.D.11.Í; A.519.D.11.Í; A.520.D.U.I; A.521.D.1U A.522.D.11.I; A.523.D.U.I; A.524.D.11.Í; A.525.D.U.I; A526.D.1LÍ; A.527.D.11.Í; A.528.D.11.Í; A.529.D.11.Í; A.530.D.11.Í; A.531.D.11.Í; A.532.D.11.Í; A.533.D.11.Í; A.534.D.11.Í; A335.D.1Ú A.536.D.1LÍ; A, 537.D.II.1; A538.D.U.I; A.539.D.11.Í; A.540.D.U.I; A.541.D.11.Í; A.542.D.11.Í; A.543.D.11.Í; A.544.D.11.Í; A.545.D.11.Í; A.546.D.11.Í; A.547.D.U.I; A.548.D.11.Í; A.549.D.11.Í; A.550.D.11.Í; A.551.D.11 .i; A.552.D.11.Í; A.553.D.11.Í; A.554.D.U.I; A.555.D.11.Í; A.556.D.U.I; A.557.D.11.Í; A.558.D.11.Í; A.559.D4U; A.560.D.11.Í; A.561.DJ1.Í; A.562.D.1U; A.563.D.11.Í; A.564.D.11.Í; A.565.D.11.Í; A.566.D.11.Í; A.567.D.11 .i; A.568.D.11.Í; A.569.D.11.Í; A.570.D.11.Í; A.571.D.U.I; A.572.D.11.Í; A.573.D.1LÍ; A.574.D.U.I; A.575.D.11.Í; A.576.D.11.Í; A.577.D.11.Í; A.578.D.1LÍ; A.579.D.11.Í; A.580.D.11.Í; A.581.D.11.Í; A.582.D.U.I; A.583.D.11.Í; A.584.D.1U; A.585.D.11.Í; A.586.D.11.Í; A.587.D.11.Í; A.588.D.11.Í; A.589.D.11.Í; A.590.D.11.Í; A.591.D.11.Í; A.592.D.1LÍ; A.593.D.11.1; A.594.D.11.Í; A.595.D.U.I; A.596.D.11.Í; A.597.D.11 .i; A.598.D.11.Í; A.599.D.11.Í; A.ÓOO.D.ll.i; A.601.D.11.Í; A.602.D.11.Í; A.603.D.11 .i; A.604.D.11.Í; A.605.D.11.Í; A.606.D.11.Í; A.607.D.11.Í; A.608.D.11.Í; A.609.D.11.Í; A.610.D.11.Í; A.óll.D.ll.i; A.612.D.11.Í; A.613JD.11.Í; A.614.D.11.Í; A.615.D.11.Í; A.616.D.11.Í; A.617.D.11.Í; A.618.D.11.Í; A.619.D.1U; A.620.D.11.Í; A.621.D.11.Í; A.622.D.114; A.623.D.1I.I; A.624.D.11.Í; A.625.D.11.Í; A.626.D.1LÍ; A.627.D.11.Í; A.628.D.1LÍ; A.629.D.11.Í; A.630.D.11.Í; A.631.D.U.I; A.632.D.11.Í; A.633.D.11.Í; A.634.D.11.Í; A.635.D.11.Í; A.636.D.11.Í; A.637.D.11.Í; A.638.D.1U; A.639.D.U.I; A.640.D.11.Í; A.641.D.11.Í; A.642.D.11.Í; A.643.D.11.Í; A.644.D.11.Í; A.645.D.11.Í; A.646.D.11.Í; A.647.D.11.Í; A.648.D.11.Í; A.649.D.11.Í; A.650.D.11.Í; A.651.D.11.Í; A.652.D.11.Í; A.653.D.11.Í; A.654.D.11.Í; A.655.D.11.Í; A.656.D.11.Í; A.657.D.U.I; A.658.D.11.Í; A.659.D.11.Í; A.660.D.11.Í; A.2.E.4.I; A.3.E.4.I; A.4.E.4.Í; A.5.E.4.I; A.6.E.4.I; A.7.E.4.I; A.9.E.4.I; A.10.E.4.Í; A.15.E.4.Í; A.100.E.4.I; A.101.E.4.I; A.102.E.4.Í; A.103.E.4.Í; A.104.E.4.Í; A.105.E.4.Í; A.106.E.4.Í; A.107.E.4.Í; A.108.E.4.Í; A.109.E.4.Í; A.110.E.4.I; A.111.E.4.Í; A.112.E.4.Í; ΑΛ13.Ε.44; A.114.E.4.Í; A.115.E.44; A.116.E.44; A.117.E.44; A.118.E.44; A.119.E.4.Í; A.120.E.44; A.121.E.44; Α.122.Ε.4.Ϊ; A.123.E.44; A.124.E.4.Í; Α.125Έ.44; A.126.E.44; A.127.E.44; A.128.E.44; A.129.E.44; A.130.E.44; A.131.E.44; A.132.E.4.Í; A.133.E.44; A.134.E.44; ΑΛ35.Ε.44; A.136.E.44; A.137.E.4.I; A.138.E.4.Í; A.139.E.44; A.140.E.44; A.141.E.44; A.142.E.44; A.143.E.44; A.144.E.44; A.145.E.44; A.146.E.44; A.147.E.44; A.148.E.44; A.149.E.44; A.150.E.44; A.151.E.44; Λ.152.Ε.44; A.153.E.44 · A.154.E.44; A.155.E.44; A.156.E.44; A.157.E.44; A458.E.44; A.159.E.44; A.160.E.44; A.161.E.44; A.162.E.44; A.163.E.44; A.164.E.44; A.165.E.44; A.166.E.44; A.167.E.44; A.168.E.44; A.169.E.44; Α.170.Ε.4.Ϊ; A.171.E.44; A.172.E.44; A.173.E.4.I; A.174.E.4.I; A.175.E.44; A.176.E.44; A.177.E.4.Í; A.178.E.44; A.179.E.44; A.180.E.44; A.181.E.44; A.182.E.4.I; A.183.E.4.I; ΑΛ84.Ε.44; A.185.E.44; A.186.E.4.I; A.187.E.44; A.188.E.4.Í; A.189.E.4.Í; A.190.E.4.Í; A.191.E.44; A.192.E.4.Í; A.193.E.44; A.194.E.4.Í; A.195.E.44; A.196.E.44; Α.197.Ε.4Λ; A.198.E.44;
-126CZ 297945 B6-126GB 297945 B6
A.199.E.44; A2Q0.E.4 j; Α201.Ε.4.Ϊ; A.2Q2.E4.Í; A203.E.4.Í; A.204.E.4.Í; A205.E.4.Í; A206.E.4.Í; A.207.E.4.Í; A.208.E.4.Í; A.209.E.4.Í; A210.E.4.Í; A211.E.44; A.212.E.4.Í; A.213.E4.Í; A.214.E.4.Í; A.215.E.4.Í; A216.E.4.Í; A.217.E.4.Í; A218.E.4Ť; A.219.E.4.Í; A.220.E.4.Í; A.221.E.4.Í; A.222.E.4.Í; A.223.E.4.Í; A224.E.44; A225.E.4.Í; A.226.E.4.Í; A.227.E.4.Í; A.228.E.4.Í; A.229.E.4.Í; A.230.E.4.Í; A.231.E.4.Í; A.232.E.4.Í; A.233.E.4.Í; A234.E.4.Í; A235.E.4.Í; A.236.E.4.Í; A237.E.4.Í; A.238.E.4.Í; A239.E.4.Í; A240.E.4.Í; A241.E.4.Í; A242.E.4.Í; A243.E4.Í; A244.E.4.Í; AJ45.E.4.i> A246.E.4.Í; A247.E.4.i; A248.E.4.Í; A249.E.4.Í; A250.E4.Í; A.251.E.4.Í; A252.E.4.Í; A253.E.4.Í; A.254.E.4.Í; A.255.E.4.Í; A256.E.4.Í; A.257.E.4.Í; A.258.E.4.Í; A.259.E.4.Í: A260.E.4.Í; A261.E.4.Í; A262.E.4.Í; A263.E4.Í; Α264.Ε.4.Ϊ; A.265.E.4.Í; A266.E44; A267.E.4.i; A268.E.4.Í; A269.E.4.i; A.270.E.4.Í; A271.E.4.Í; A272.E4.1; A273.E.4.1; A274.E.4.Í; A275.E.4.Í; A276.E.4.Í; A277.E.4.Í; A278.E.44; A279.E.4.Í; A280.E4.Í; Α.281.Ε4.Ϊ; A282.E4.Í; A283.E.4.Í; A284.E.4.Í; A285.E.4.Í; A286.E.4.Í; A287.E.4.Í; A288.E.4.Í; A289.E.4.Í; A290.E4.1; A291.E.4.Í; A292.E.4.Í; A293.E4.Í; A294.E.4.Í; A295.E.4.Í; A296.E.4.Í; A297.E.4.Í; A298.E.4.Í; A299.E.4.Í; A.300.E.44; A.301.E.4.Í; A.302.E.44; A.303.E.4.Í; A.304.E4.Í; A.305.E.4.Í; A.306.E.4.Í; A.307.E.4.Í; A.308.E.4.Í; A.309.E.4.Í; A.310.E.4.Í; A.311.E.4.i; A.312.E.4.Í; Α.313.Ε.4.Ϊ; A.314.E4.Í; A.315.E.4.Í; A.316.E.4.Í; A.317.E4.Í; A.318.E.4.Í; A.319.E.4.Í; A.320.E.4.Í; A.321.E.4.1; A.323.E.4.Í; A.324.E.4.Í; A.325.E.4.Í; A.326.E.4.Í; A.327.E.4.Í; A.328.E4.Í; A.329.E.4.Í; A.330.E.4.Í; A.331.E.4.i; A.332.E.4.Í; A.333.E.4.Í; A.334.E.4.Í; A.335.E4.Í; A.336.E.4.Í; A.337.E.44; A.338.E.4.1; A.339.E.4.Í; A.340E.4.Í; A.341.E4.Í; A.342.E.4.Í; A.343.E.44; A.344.E.4.Í; A.345.E.4.Í; A.346.E.4.Í; A.347.E4.Í; A.348.E.4.Í; A.349.E.4.Í; A.350.E.4.Í; A.351.E.4.Í; A.352E.4.Í; A.353.E4.Í; A.354.E.44; A.355.E.4.Í; A.356.E.4.Í; A.357.E.4.Í; A.358.E.4.Í; A.359.E.4.Í; A.360.E.4.i; A.361.E.4.Í; A.362.E.4.Í; A.363.E.4.Í; A.364.E.44; A.365.E4.Í; A.366.E.4.Í; A.367.E.4.Í; A.368.E.4.Í; A.369.E.4.Í; A.370.E.4.Í; A.371.E.4.Í; A.372.E.4.Í; A.373.E.4.Í; A 374.E.4.Í; A.375.E.4.Í; A.376.E.4.Í; A.377.E.4.Í; A.378.E4.Í; A.379.E.4.Í; A.380.E.4.Í; A.381.E.4.Í; A.382.E.4.Í; A.383.E4.Í; A.384.E.4.Í; A.385.E.4.Í; A.386E.4.Í; A.387.E.4.Í; A.388.E.4.Í; A.389.E.4.Í; A.390.E.4.Í; A.391.E.4.Í; A.392.E.4.Í; A.393.E.4.Í; A.394.E4.Í; A.395.E.4.Í; A.396.E.4.Í; A.397.E.4.Í; A.398.E.4.Í; A.399.E4.Í; A.400.E.4.Í; A.401.E.4.Í; A.402.E.4.Í; A.403.E.4.Í; A.404.E.4.Í; A.405.E.4.Í; A.406.E.4.Í; A.407.E.4.Í; A.408.E44; A.409.E.4.i; A.410.E.4.Í; A.411.E.4.Í; A.412.E.4.1; A.413.E.4.Í; A.414.E.4.Í; A.415.E.44; A.416.E.4.Í; A.417.E.4.i; A.418.E.4.Í; A.419.E.4.Í; A.420.E.4.Í; A.421.E.4.Í; Α.422.Ε.4.Ϊ; A.423.E.4.Í; A.424.E.4.Í; A.425.E4.Í; A.426.E.4Ť; A.427.E.4.Í; A.428.E.4.Í; A.429.E.4.Í; A.430.E.4.Í; A.431-.E.4.Í; A.432.E.4.Í; A.433.E.4.Í; Α.434.Ε.4.Ϊ; A.435.E.4.Í; A.436.E.4.Í; A.437.E.4.1; Α.438.Ε.4.Ϊ; A.439.E.4.Í; A.440.E.4.Í; A.441.E.4.Í; A.442.E.4.i; A.443.E.4.Í; A.444.E.4.Í; A.445.E.4.Í; A.446.E.44; A.447.E.4.Í; A.448.E.4.Í; A.449.E.4.Í; A,450.E.4.i; A.451.E.44; A.452.E.4.Í; A.453.E.4.Í; A.454.E.4.Í; A.455.E.4.Í; A.456.E4.Í; A.457.E.4.Í; A.458.E.4.Í; A.459.E.4.Í; A.460.E4.Í; A.461E.4.Í; A.462.E.4.Í; A.463.E,4.i; A.464.E.4.Í; A.465.E.4.Í; A.466.E.4.Í; A.467.E.4.Í; Α.468.Ε.4.Ϊ; A.469E.4.Í; Α.470.Ε4.Ϊ; A.471.E44; A.472.E.4.Í; A.473.E.4.Í; A.474.E.4.Í; A.475.E.4.Í; A.476.E.4.Í; A.477.E44; A.478.E.4.Í; A.479.E.4.Í; A.480.E4.Í; A.481.E.4.Í;A.199.E.44; A2Q0.E.4 j; Α201.Ε.4.Ϊ; A.2Q2.E4.Í; A203.E.4.I; A.204.E.4.Í; A205.E.4.Í; A206.E.4.Í; A.207.E.4.Í; A.208.E.4.Í; A.209.E.4.Í; A210.E.4.I; A211.E.44; A.212.E.4.Í; A.213.E4.Í; A.214.E.4.I; A.215.E.4.I; A216.E.4.I; A.217.E.4.Í; A218.E.4 «; A.219.E.4.Í; A.220.E.4.I; A.221.E.4.I; A.222.E.4.I; A.223.E.4.I; A224.E.44; A225.E.4.I; A.226.E.4.I; A.227.E.4.I; A.228.E.4.Í; A.229.E.4.I; A.230.E.4.Í; A.231.E.4.I; A.232.E.4.I; A.233.E.4.I; A234.E.4.I; A235.E.4.I; A.236.E.4.Í; A237.E.4.I; A.238.E.4.Í; A239.E.4.I; A240.E.4.I; A241.E.4.Í; A242.E.4.I; A243.E4.Í; A244.E.4.I; AJ45.E.4.i> A246.E.4.I; A247.E.4.i; A248.E.4.I; A249.E.4.I; A250.E4.I; A.251.E.4.I; A252.E.4.I; A253.E.4.Í; A.254.E.4.Í; A.255.E.4.I; A256.E.4.Í; A.257.E.4.Í; A.258.E.4.I; A.259.E.4.I: A260.E.4.I; A261.E.4.I; A262.E.4.I; A263.E4.I; Α264.Ε.4.Ϊ; A.265.E.4.Í; A266.E44; A267.E.4.i; A268.E.4.I; A269.E.4.i; A.270.E.4.Í; A271.E.4.I; A272.E4.1; A273.E.4.1; A274.E.4.I; A275.E.4.I; A276.E.4.I; A277.E.4.I; A278.E.44; A279.E.4.I; A280.E4.Í; Α.281.Ε4.Ϊ; A282.E4.Í; A283.E.4.I; A284.E.4.Í; A285.E.4.Í; A286.E.4.Í; A287.E.4.Í; A288.E.4.I; A289.E.4.Í; A290.E4.1; A291.E.4.I; A292.E.4.I; A293.E4.Í; A294.E.4.Í; A295.E.4.I; A296.E.4.I; A297.E.4.Í; A298.E.4.I; A299.E.4.I; A.300.E.44; A.301.E.4.Í; A.302.E.44; A.303.E.4.I; A.304.E4.Í; A.305.E.4.Í; A.306.E.4.Í; A.307.E.4.Í; A.308.E.4.Í; A.309.E.4.Í; A.310.E.4.Í; A.311.E.4.i; A.312.E.4.Í; Α.313.Ε.4.Ϊ; A.314.E4.Í; A.315.E.4.Í; A.316.E.4.Í; A.317.E4.Í; A.318.E.4.Í; A.319.E.4.Í; A.320.E.4.Í; A.321.E.4.1; A.323.E.4.Í; A.324.E.4.Í; A.325.E.4.Í; A.326.E.4.Í; A.327.E.4.Í; A.328.E4.Í; A.329.E.4.Í; A.330.E.4.Í; A.331.E.4.i; A.332.E.4.Í; A.333.E.4.Í; A.334.E.4.Í; A.335.E4.Í; A.336.E.4.Í; A.337.E.44; A.338.E.4.1; A.339.E.4.Í; A.340E.4.Í; A.341.E4.Í; A.342.E.4.Í; A.343.E.44; A.344.E.4.Í; A.345.E.4.Í; A.346.E.4.Í; A.347.E4.Í; A.348.E.4.Í; A.349.E.4.Í; A.350.E.4.Í; A.351.E.4.Í; A.352E.4.Í; A.353.E4.Í; A.354.E.44; A.355.E.4.Í; A.356.E.4.Í; A.357.E.4.Í; A.358.E.4.Í; A.359.E.4.Í; A.360.E.4.i; A.361.E.4.Í; A.362.E.4.Í; A.363.E.4.Í; A.364.E.44; A.365.E4.Í; A.366.E.4.Í; A.367.E.4.Í; A.368.E.4.Í; A.369.E.4.Í; A.370.E.4.Í; A.371.E.4.Í; A.372.E.4.Í; A.373.E.4.I; A 374.E.4.I; A.375.E.4.Í; A.376.E.4.Í; A.377.E.4.Í; A.378.E4.Í; A.379.E.4.Í; A.380.E.4.Í; A.381.E.4.Í; A.382.E.4.Í; A.383.E4.Í; A.384.E.4.Í; A.385.E.4.Í; A.386E.4.Í; A.387.E.4.Í; A.388.E.4.Í; A.389.E.4.Í; A.390.E.4.Í; A.391.E.4.Í; A.392.E.4.Í; A.393.E.4.I; A.394.E4.Í; A.395.E.4.Í; A.396.E.4.Í; A.397.E.4.Í; A.398.E.4.Í; A.399.E4.Í; A.400.E.4.Í; A.401.E.4.Í; A.402.E.4.I; A.403.E.4.I; A.404.E.4.I; A.405.E.4.Í; A.406.E.4.I; A.407.E.4.I; A.408.E44; A.409.E.4.i; A.410.E.4.Í; A.411.E.4.Í; A.412.E.4.1; A.413.E.4.Í; A.414.E.4.Í; A.415.E.44; A.416.E.4.Í; A.417.E.4.i; A.418.E.4.Í; A.419.E.4.Í; A.420.E.4.Í; A.421.E.4.Í; Α.422.Ε.4.Ϊ; A.423.E.4.Í; A.424.E.4.Í; A.425.E4.Í; A.426.E.4 «; A.427.E.4.Í; A.428.E.4.Í; A.429.E.4.Í; A.430.E.4.Í; A.431-.E.4.I; A.432.E.4.Í; A.433.E.4.Í; Α.434.Ε.4.Ϊ; A.435.E.4.Í; A.436.E.4.Í; A.437.E.4.1; Α.438.Ε.4.Ϊ; A.439.E.4.Í; A.440.E.4.Í; A.441.E.4.Í; A.442.E.4.i; A.443.E.4.Í; A.444.E.4.Í; A.445.E.4.Í; A.446.E.44; A.447.E.4.Í; A.448.E.4.Í; A.449.E.4.Í; A, 450.E.4.i; A.451.E.44; A.452.E.4.Í; A.453.E.4.Í; A.454.E.4.Í; A.455.E.4.Í; A.456.E4.Í; A.457.E.4.Í; A.458.E.4.Í; A.459.E.4.Í; A.460.E4.Í; A.461E.4.Í; A.462.E.4.Í; A.463.E, 4.i; A.464.E.4.Í; A.465.E.4.Í; A.466.E.4.Í; A.467.E.4.Í; Α.468.Ε.4.Ϊ; A.469E.4.Í; Α.470.Ε4.Ϊ; A.471.E44; A.472.E.4.Í; A.473.E.4.Í; A.474.E.4.Í; A.475.E.4.Í; A.476.E.4.Í; A.477.E44; A.478.E.4.Í; A.479.E.4.Í; A.480.E4.Í; A.481.E.4.Í;
-127CZ 297945 B6-127GB 297945 B6
Α.482.Ε.4.Ϊ; A.483.E.4.Í; Α.484.Ε.4.Ϊ; A.485.E.4.Í; A,486.E.4.i; A.487.E.4.Í; A.488.E.4 j; A.489.E.4.Í; A.490.E.4.Í; A.491.E.4.Í; A.492.E.4.Í; Α.493.Ε.4.Ϊ; A.494.E.4.Í· A.495.E.4.Í; A.496.E.4.Í; A.497.E.4.Í; A.498.E.4.Í; A.499.E.4.Í; A.500.E.4.Í; A.501.E.4.Í; A.502.E.4.Í; A.503.E.4.Í; A.504.E.4.Í; A.505.E.4.Í; A.506.E.4.Í; A.507.E.4.Í; Α.508.Ε.4.Ϊ; A.509.E.4.Í; A.510.E.4.Í; A.511.E.4.Í; A.512.E.4.Í; Α.512.Ε.4.Ϊ; A.513.E.4.Í; A.514.E.4.Í; A.515.E.4.Í; A.516.E.4.Í; A.517.E.4.Í; A.518.E.4.Í; A.5I9.E.4.Í; A.520.E.4.Í; A.521.E.4.Í; A.522.E.4.Í; A.523.E.4.Í; A.524.E.4.Í; A.525.E.4.Í; A.526.E.4.Í; A.527.E.4.Í; Α.528.Ε.4.Ϊ; A.529.E.4.Í; A.530.E.4.Í; A.531.E.4.Í; A.532.E.4.Í; A.533.E.4.1; A.534.E.4.Í; A.535.E.4.1; A.536.E.4.Í; A.537.E.4.Í; A.538.E.4.Í; A.539.E.4.Í; A.540.E.4.Í; A.54LE.4.Í; A.542.E.4.Í; A.543.E.4.Í; A.544.E.4.Í; A.545.E.4.Í; A.546.E.4.Í; Α.547.Ε.4.Ϊ; A.548.E.4.Í; A.549.E.4.Í; A.550.E.4.Í; A.551.E.44; Α.552.Ε.4.Ϊ; A.553.E.44; A.554.E.4.Í; A.555.E.4.Í; Α.556.Ε.4.Ϊ; Α.557.Ε.4.Ϊ; A.558.E.4.Í; A.559.E.4.Í; A.560.E.4.Í; A.561.E.4.Í; A.562.E.4.Í; A.563.E.4.Í; A.564.E.4.Í; Α.565.Ε.4.Ϊ; A.566.E.4.Í; A.567.E.4.Í; A.568.E.4.Í; A.569.E.4.Í; A.570.E.4.Í; A.571.E.4.Í; A.572.E.4.Í; A.573.E.4.Í; A.574.E.44; A.575.E.4.Í; A.576.E.4.Í; A.577.E.4.Í; A.578.E.4.Í; A.579.E.4.Í; A.580.E.4.Í; A.581.E.4.Í; A.582.E.4.Í; A.583.E.4.Í; A.584.E.4.1; A.585.E.4.Í; A.586.E.4.Í; A.587.E.4.Í; A.588.E.4.Í; A.589.E.4.Í; A.590.E.4.Í; A591.E.4.Í; A.592.E.4.Í; A.593.E.4.Í; A.594.E.4.Í; A.595.E.4.Í; A.596.E.4.Í; A.597.E.4.Í; A.598.E.4.Í; A.599.E.4.Í; A.600.E.4.Í; Α.601.Ε.4.Ϊ; A.602.E.4.Í; A.603.E.4.Í; A.604.E.4.Í; A.605.E.4.Í; A.606.E.4.Í; A.607.E.4.Í; A.608.E.4.Í; A.609.E.4.Í; Α.610.Ε.4.Ϊ; A.611.E.4.Í; A.612.E.4.Í; A.613.E.4.Í; A.614.E.4.Í; A.615.E.4.Í; A.616.E.4.Í; A.617.E.4.Í; A.618.E.4.Í; A.619.E.4.Í; A.620.E.4.Í; Α.621.Ε.4.Ϊ; A.622.E.4.Í; A.623.E.4.Í; A.624.E.4.Í; A.625.E.4.Í; A.626.E.4.Í; A.627.E.4.Í; A.628.E.4.Í; A.629.E.4.Í; A.630.E.4.Í; Α.631.Ε.4.Ϊ; A.632.E.4.Í; Α.633.Ε.4.Ϊ; A.634.E.4.1; A.635.E.4.1; A.636.E.4.Í; A.637.E.4.Í; A.638.E.4.Í; A.639.E.4.Í; A.640.E.4.Í; A.641.E.4.Í; A.642.E.4.Í; A.643.E.4.1; A.644.E.4.Í; A.645.E.4.Í; A.646.E.4.Í; A.647.E.4.Í; A.648.E.4.Í; Α.649.Ε.4.Ϊ; A.650.E.4.Í; A.651.E.4.Í; Α.652.Ε.4.Ϊ; A.653.E.4.Í; A.654.E.4.Í; A.655.E.4.Í; A.656.E.4.Í; A.657.E.4.Í; A.658.E.4.Í; A.659.E.4.Í; A.660.E.4.Í; A.2.E.11 .i; Α.3.Ε.Π.Ϊ; A.4.E.114; Α.5.Ε.11.Ϊ; A.6.E.11.Í; A.7.E.11.Í; A.9.E.11.Í; A.10.E.11.Í; A.15.E.H.Í; A.lOO.E.ll.i; A.lOl.E.ll.i; A.102.E.11.Í; A.103.E.11.Í; A.104.E.11.Í; A.105.E.11.Í; A.lOó.E.ll.i; A.107.E.11.1; A.1O8.E.11.Í; A.109.E.11.Í; A.110.E.11.Í; A.111.E.11.Í; A.112.E U.i; A.113.E.11.Í; A.114.E.11.Í; A.115-E.11.Í; A.116.E.11.Í; A.117.E.11.Í; A-118.E.11.Í; A.119.E.11.Í; A.120.E.11.1; A.121.E.11.Í; A.122.E.11.Í; A123.E.11.Í; A.124.E.11.Í; A.125.E.11.Í; A.126.E.11.Í; A.127.E.1U; A.128.E.11.Í; A.129.E.11.Í; A.130.E.11.Í; A.131.E.11.Í; A.132.E.11.Í; A.133.E.11.Í; A.134.E.11.Í; A.135.E.U.Í; ΑΛ36.Ε.Π.ί; A.137.E.1U; A.138.E.11.Í; A.139.E.11.Í; A.140.E.11.Í; A.141.E.11.Í; A.142.E.11.Í; A.143.E.11.Í; A.T44.E.11.Í; A.145.E.11.Í;A.146.E.11.1; A.147.E.H.Í; A.148.E.11.Í; A.149.E.11.Í; A.150.E.11.Í; A.151.E.11.Í; A.152.E.1U; A.153.E.11.Í; A.154.E.11.Í; A.155.E.11-i; A.156.E.11.Í; A.157.E.11.Í; A.158.E.H.Í; A.159.E.11.Í; A.160.E.11.Í; A.161.E.U.Í; A.162.E.11.Í; A.163.E.11.Í; Α.164.Ε.11.Ϊ; A.165.E.11J; A.166.E.11.Í; A.167.E11.1· A.168.E.11.Í; A.169.E.11.Í; A.170.E.U.Í; A.171.E.11.i; A.I72.E.11.Í; A.I73.E.114; A.174.E.11.Í; A.175.E.11.Í; A.176.E.11.Í; A.177.E.11.Í; A.178.E.11.Í; A.179.E.11.Í; A.180.E.11.Í; A.181.E.11.Í; A.182.E.11.Í; Α.183.Ε.Π.Ϊ; A.I84.E.11.Í; A.185.E.11.Í; A.186.E.11.Í; A.187.E.11.Í; A.188.E.11.Í; A.189.E.11.Í; A.190E.11.Í; A.191.E.1U; A.192.E.11 .i; A.193.E.11.Í: A.194.E.11.Í;Α.482.Ε.4.Ϊ; A.483.E.4.Í; Α.484.Ε.4.Ϊ; A.485.E.4.Í; A, 486.E.4.i; A.487.E.4.Í; A.488.E.4 j; A.489.E.4.Í; A.490.E.4.Í; A.491.E.4.Í; A.492.E.4.Í; Α.493.Ε.4.Ϊ; A.494.E.4.I · A.495.E.4.I; A.496.E.4.Í; A.497.E.4.Í; A.498.E.4.Í; A.499.E.4.Í; A.500.E.4.I; A.501.E.4.I; A.502.E.4.I; A.503.E.4.I; A.504.E.4.I; A.505.E.4.Í; A.506.E.4.I; A.507.E.4.I; Α.508.Ε.4.Ϊ; A.509.E.4.Í; A.510.E.4.I; A.511.E.4.I; A.512.E.4.I; Α.512.Ε.4.Ϊ; A.513.E.4.I; A.514.E.4.I; A.515.E.4.I; A.516.E.4.Í; A.517.E.4.I; A.518.E.4.I; A.5I9.E.4.Í; A.520.E.4.I; A.521.E.4.I; A.522.E.4.I; A.523.E.4.I; A.524.E.4.I; A.525.E.4.I; A.526.E.4.I; A.527.E.4.I; Α.528.Ε.4.Ϊ; A.529.E.4.I; A.530.E.4.I; A.531.E.4.I; A.532.E.4.I; A.533.E.4.1; A.534.E.4.Í; A.535.E.4.1; A.536.E.4.Í; A.537.E.4.I; A.538.E.4.I; A.539.E.4.I; A.540.E.4.I; A.54LE.4.Í; A.542.E.4.I; A.543.E.4.I; A.544.E.4.I; A.545.E.4.I; A.546.E.4.I; Α.547.Ε.4.Ϊ; A.548.E.4.I; A.549.E.4.I; A.550.E.4.I; A.551.E.44; Α.552.Ε.4.Ϊ; A.553.E.44; A.554.E.4.Í; A.555.E.4.I; Α.556.Ε.4.Ϊ; Α.557.Ε.4.Ϊ; A.558.E.4.I; A.559.E.4.Í; A.560.E.4.Í; A.561.E.4.I; A.562.E.4.Í; A.563.E.4.I; A.564.E.4.Í; Α.565.Ε.4.Ϊ; A.566.E.4.I; A.567.E.4.Í; A.568.E.4.I; A.569.E.4.Í; A.570.E.4.I; A.571.E.4.I; A.572.E.4.I; A.573.E.4.I; A.574.E.44; A.575.E.4.I; A.576.E.4.I; A.577.E.4.Í; A.578.E.4.I; A.579.E.4.I; A.580.E.4.Í; A.581.E.4.I; A.582.E.4.I; A.583.E.4.I; A.584.E.4.1; A.585.E.4.I; A.586.E.4.I; A.587.E.4.I; A.588.E.4.I; A.589.E.4.Í; A.590.E.4.I; A591.E.4.Í; A.592.E.4.I; A.593.E.4.I; A.594.E.4.I; A.595.E.4.I; A.596.E.4.I; A.597.E.4.Í; A.598.E.4.Í; A.599.E.4.I; A.600.E.4.Í; Α.601.Ε.4.Ϊ; A.602.E.4.I; A.603.E.4.I; A.604.E.4.Í; A.605.E.4.Í; A.606.E.4.Í; A.607.E.4.Í; A.608.E.4.Í; A.609.E.4.Í; Α.610.Ε.4.Ϊ; A.611.E.4.I; A.612.E.4.I; A.613.E.4.I; A.614.E.4.I; A.615.E.4.I; A.616.E.4.Í; A.617.E.4.Í; A.618.E.4.I; A.619.E.4.Í; A.620.E.4.I; Α.621.Ε.4.Ϊ; A.622.E.4.I; A.623.E.4.I; A.624.E.4.I; A.625.E.4.I; A.626.E.4.I; A.627.E.4.I; A.628.E.4.Í; A.629.E.4.I; A.630.E.4.Í; Α.631.Ε.4.Ϊ; A.632.E.4.I; Α.633.Ε.4.Ϊ; A.634.E.4.1; A.635.E.4.1; A.636.E.4.Í; A.637.E.4.I; A.638.E.4.Í; A.639.E.4.I; A.640.E.4.Í; A.641.E.4.I; A.642.E.4.I; A.643.E.4.1; A.644.E.4.I; A.645.E.4.I; A.646.E.4.Í; A.647.E.4.Í; A.648.E.4.Í; Α.649.Ε.4.Ϊ; A.650.E.4.I; A.651.E.4.Í; Α.652.Ε.4.Ϊ; A.653.E.4.Í; A.654.E.4.Í; A.655.E.4.I; A.656.E.4.I; A.657.E.4.Í; A.658.E.4.I; A.659.E.4.Í; A.660.E.4.Í; A.2.E.11 .i; Α.3.Ε.Π.Ϊ; A.4.E.114; Α.5.Ε.11.Ϊ; A.6.E.11.Í; A.7.E.11.Í; A.9.E.11.Í; A.10.E.11.Í; A.15.E.H.I; A.100.E.ll.i; A.lOl.E.ll.i; A.102.E.11.Í; A.103.E.11.Í; A.104.E.11.Í; A.105.E.11.Í; A.10O.E.ll.i; A.107.E.11.1; A.1O8.E.11.Í; A.109.E.11.Í; A.110.E.11.Í; A.111.E.11.Í; A.112.E U.i; A.113.E.11.Í; A.114.E.11.Í; A.115-E.11.I; A.116.E.11.Í; A.117.E.11.Í; A-118.E.11.I; A.119.E.11.Í; A.120.E.11.1; A.121.E.11.Í; A.122.E.11.Í; A123.E.11.Í; A.124.E.11.Í; A.125.E.11.Í; A.126.E.11.Í; A.127.E.1U; A.128.E.11.Í; A.129.E.11.Í; A.130.E.11.Í; A.131.E.11.Í; A.132.E.11.Í; A.133.E.11.Í; A.134.E.11.Í; A.135.E.U.I; ΑΛ36.Ε.Π.ί; A.137.E.1U; A.138.E.11.Í; A.139.E.11.Í; A.140.E.11.Í; A.141.E.11.Í; A.142.E.11.Í; A.143.E.11.Í; A.T44.E.11.Í; A.145.E.11.I; A.146.E.11.1; A.147.E.H.I; A.148.E.11.Í; A.149.E.11.Í; A.150.E.11.Í; A.151.E.11.Í; A.152.E.1U; A.153.E.11.Í; A.154.E.11.Í; A.155.E.11-i A.156.E.11.Í; A.157.E.11.Í; A.158.E.H.I; A.159.E.11.Í; A.160.E.11.Í; A.161.E.U.I; A.162.E.11.Í; A.163.E.11.Í; Α.164.Ε.11.Ϊ; A.165.E.11J; A.166.E.11.Í; A.167.E11.1 · A.168.E.11.I; A.169.E.11.Í; A.170.E.U.I; A.171.E.11.i; A.I72.E.11.Í; A.I73.E.114; A.174.E.11.Í; A.175.E.11.Í; A.176.E.11.Í; A.177.E.11.Í; A.178.E.11.Í; A.179.E.11.Í; A.180.E.11.Í; A.181.E.11.Í; A.182.E.11.Í; Α.183.Ε.Π.Ϊ; A.I84.E.11.Í; A.185.E.11.Í; A.186.E.11.Í; A.187.E.11.Í; A.188.E.11.Í; A.189.E.11.Í; A.190E.11.Í; A.191.E.1U; A.192.E.11 .i; A.193.E.11.I: A.194.E.11.I;
- 128CZ 297945 B6- 128GB 297945 B6
A.195.E.11.Í; A.196.E.11.Í; A.197.E.11.1; A.198.E.1U; A.199.E.11.Í; A.200.E.1I.Í; A.201.E.11.Í; A.202.E.11.Í; Α.203.Ε.11.Ϊ; A204.E.11.Í; A-205.E.11.1; A.206.E.11.Í; A.207.E.11.Í; Α.208.Ε.11.Ϊ; A.209.E.11.Í; A.210.E.11.Í; A2U.E.1LÍ; A212.E.11.Í; A.213.E.11.Í; A.214.E.U.Í; A.215.E.11.Í; A216.E11.Í; A.217.E.11.Í; A.218.E.11 .i; A.219.E.11.Í; A.220.E.11.Í; A221.E.11.Í; A222.E.U.Í; A.223.E.11.Í; A.224.E.11.Í; A.225.E.11.Í; A.226.E.11.Í; A.227.E.11.Í; A.228.E.U.Í; A.229.E.11.Í; A.230.E.11.Í; A.23LE.11.Í; A.232.E.11.Í; A.233.E.11.Í; A.234.E.1LÍ; A235.E.11.Í; A.236.E.11.Í; A237.E.11.Í; Α.238Έ.11.Ϊ; A.239.E.1U; A.240.E.11.Í; A.241.E.11.1; A.242.E.11 .i; A243.E.11.Í; A.244.E.11.Í; A.245.E1LÍ; A.246.E.11 .i; A247.E1LÍ; A.248.E.11.Í; A.249.E.11.Í; A.250.E.11.Í; A.251.E.11.Í; A.252.E.11.Í; A253.E.11.Í; A254.E.11.Í; A.255.E.11.Í; A.256.E.11.Í; Α.257.Ε.11.Ϊ; A.258.E.11.Í; A.259.E.11.Í; A260.E.11.Í; A261.E.11.Í; A.262.E.11.Í; A.263.E.11.Í; A.264.E.11.Í; A.265.E.11.Í; A.266.E.11.Í; A.267.E.11.Í; A.268.E.11.Í; A.269.E.11.Í; A.270.E.11.Í; A.271.E.11.Í; A.272.E.11.Í; A.273.E.11.Í; A.274.E.11.Í; A.275.E.11.Í; A.276.E.11.Í; A.277.E.11.Í; A.278.E.U.Í; A.279.E.11.Í; A.280.E.11.Í; A.281.E.U.Í; A.282.E.11 ,i; A.283.E.11.Í; A.284.E.11.Í; A.285.E.11.Í; A.286.E.11.Í; A.287.E.U.Í; A.288.E.11.Í; A.289.E.11.Í; A290.E.114; Α.291.Ε.11.Ϊ; A.292.E.11.Í; A.293.E.11.Í; A.294.E.11.Í; A.295.E.11.Í; A296.E.11.Í; A.297.E.11.Í; A.298.E.11.Í; A.299.E.11.Í; A.300.E.11.Í; A.301.EAU; A.302.E.11.Í; A.303.E.11.Í; A.304.E.11.Í; Α.305Έ.11.ί; A.306.E.11.Í; A.307.E.11.Í; A.308.E.11.Í; A.309.E.11.Í; A.310.E.11.Í; A.311.E.11.Í; A.312.E.11.Í; A.313.E.11J; A.314.E.114; A.315.E.11.Í; A.316.E.11.Í; A.317.E.11.Í; A.318.E.11.Í; A.319.E.11.Í; A.320.E.11.Í; A.321.E.11.Í; A.323.E.11.Í; A.324.E.11.Í; A.325.E.11.Í; A.326.E.11.Í; A.327.E.1U; A.328.E.11.Í; A.329.E.1U; Α.330.Ε.1Π; A.331.E.11.Í; A.332.E.11.Í; A.333.E.11.Í; A.334.E.11.Í; A.335.E.11.Í; A.336.E.11.Í; A.337.E.11.Í; A.338.E.11.Í; A.339.E.11.:; A.340.E.11.Í; A.341.E.11.Í; A.342.E.11.Í; A.343.E.11.Í; A.344.E.1LÍ; A.345.E.11.Í; A.346.E.11.Í; A.347.E.11.Í; A.348.E.1U; A.349.E.11.Í; A.350.E.11.Í; A.351.E.11.Í; A.352.E.114; A.353.E.11.Í; A.354.E.U.Í; A.355.E.11.Í; A.356.E.11.Í; A.357.E.11.Í; A.358.E.11.Í; Α.359.Ε.11.Ϊ; A.360,E.ll.i; A.361.E.11.Í; A.362.E.11.Í; A.363.E.11.Í; A.364.E.11.Í; A.365.E.11.Í; A.366.E.11.Í; A.367.E.11.Í; A.368.E.11.Í; A.369.E.1LÍ; A.370.E.11.Í; A.371.E.11.Í; Α.372Έ.11.Ϊ; A.373.E.11.Í; A.374.E.1U; A.375.E.11.Í; A.376.E.11.Í; A.377.E.11.Í; A.378.E.11.Í; A.379.E.U.Í; A.380.E.11.Í; A.381.E.11.Í; A.382.E.11.Í; A.383.E.U.Í; Α.384Έ.11.Ϊ; A.385.E.1U; A.386.E.11.Í; A.387.E.11.Í; A.388.E.11.Í; A.389.E.11.Í; A.390.E.11.Í; A.391.E.11.Í· A.392.E.U.Í; A.393.E.11.Í; A.394.E.11.Í; A.395.E.11.Í; A.396.E.11.Í; A.397.E.11.Í; A.398.E.11.Í; A.399.E.U.Í; A.400.E.11.Í; A.401.E.11.Í; A.402.E.11.Í; A.403.E.11.Í; A.404.E.11.Í; A.405.E.11.Í; A.406.E.11.Í; A.407.E.114; A.408.E.11.Í; A.409.E.U.Í; A.410.E.11 .i; A.4U.E.11.Í; A.412.E.11.Í; A.413.E.11.Í; A.414.E.11.Í; A.415.E.11.Í; A.416.E.11.Í; A.417.E.114; A.418.E.11.Í; A.419.E.11.Í; Α.420.Ε.1Π; A.421.E.11.Í; A.422.E.11.Í; A.423.E.11.1; A.424.E.11.Í; A.425.E.11.Í; A.426.E.11.Í; A.427.E.11.Í; A.428.E.11.Í; A.429.E.11.Í; A.430.E.11.Í; A.431.E.11.Ú A.432.E.11.Í; A.433.E.11.Í; A.434.E.11.Í; A.435.E.11.Í; A.436.E.11.Í; A.437.E.11.Í; A.438.E.11.Í; A.439.E.11.Í; A.440.E.11.Í; A.441.E.11.Í; Α.442.Ε.11.Ϊ; A.443.E.11.Í; A.444.E.11.Í; A.445.E1LÍ; A.446.E.11.Í; A.447.E.11.Í; A.448.E.11.Í; A.449.E.1LÍ; A.450.E.U.Í; A.451.E.11.Í; A.452.E.11.Í; A.453.E.11.Í; A.454.E.11.Í; A.455.E.11.Í; A.456.E.11.Í; A.457.E.11.Í; A.458.E.11.Í; A.459.E.ll,i; A.460.E.11.Í; A.461.E.11.Í; A.462.E.11.Í; A.463.E.11.Í; A.464.E.11.Í; A.465.E.11.Í; A.466.E.11 .i; A.467.E.11.1; A.468.E.11.Í; A.469.E.11.Í; A.470.E.11.Í; A.471.E.11.Í; A.472.E.11.Í; A.473.E.1U A.474.E.11.Í; A.475.E.11.Í; A.476.E.11.Í; A.477.E.H.Í;A.195.E.11.Í; A.196.E.11.Í; A.197.E.11.1; A.198.E.1U; A.199.E.11.Í; A.200.E.1I.Í; A.201.E.11.Í; A.202.E.11.Í; Α.203.Ε.11.Ϊ; A204.E.11.Í; A-205.E.11.1; A.206.E.11.Í; A.207.E.11.Í; Α.208.Ε.11.Ϊ; A.209.E.11.Í; A.210.E.11.Í; A2U.E.1LÍ; A212.E.11.Í; A.213.E.11.Í; A.214.E.U.I; A.215.E.11.Í; A216.E11.I; A.217.E.11.Í; A.218.E.11 .i; A.219.E.11.Í; A.220.E.11.Í; A221.E.11.Í; A222.E.U.I; A.223.E.11.Í; A.224.E.11.Í; A.225.E.11.Í; A.226.E.11.Í; A.227.E.11.Í; A.228.E.U.I; A.229.E.11.Í; A.230.E.11.Í; A.23LE.11.Í; A.232.E.11.Í; A.233.E.11.Í; A.234.E.1LÍ; A235.E.11.Í; A.236.E.11.Í; A237.E.11.Í; Α.238Έ.11.Ϊ; A.239.E.1U; A.240.E.11.Í; A.241.E.11.1; A.242.E.11 .i; A243.E.11.Í; A.244.E.11.Í; A.245.E1LÍ; A.246.E.11 .i; A247.E1LÍ; A.248.E.11.Í; A.249.E.11.Í; A.250.E.11.Í; A.251.E.11.Í; A.252.E.11.Í; A253.E.11.Í; A254.E.11.Í; A.255.E.11.Í; A.256.E.11.Í; Α.257.Ε.11.Ϊ; A.258.E.11.Í; A.259.E.11.Í; A260.E.11.Í; A261.E.11.Í; A.262.E.11.Í; A.263.E.11.Í; A.264.E.11.Í; A.265.E.11.Í; A.266.E.11.Í; A.267.E.11.Í; A.268.E.11.Í; A.269.E.11.Í; A.270.E.11.Í; A.271.E.11.Í; A.272.E.11.Í; A.273.E.11.Í; A.274.E.11.Í; A.275.E.11.Í; A.276.E.11.Í; A.277.E.11.Í; A.278.E.U.I; A.279.E.11.Í; A.280.E.11.Í; A.281.E.U.I; A.282. E.11, i; A.283.E.11.Í; A.284.E.11.Í; A.285.E.11.Í; A.286.E.11.Í; A.287.E.U.I; A.288.E.11.Í; A.289.E.11.Í; A290.E.114; Α.291.Ε.11.Ϊ; A.292.E.11.Í; A.293.E.11.Í; A.294.E.11.Í; A.295.E.11.Í; A296.E.11.Í; A.297.E.11.Í; A.298.E.11.Í; A.299.E.11.Í; A.300.E.11.Í; A.301.EAU; A.302.E.11.Í; A.303.E.11.Í; A.304.E.11.Í; Α.305Έ.11.ί; A.306.E.11.Í; A.307.E.11.Í; A.308.E.11.Í; A.309.E.11.Í; A.310.E.11.Í; A.311.E.11.Í; A.312.E.11.Í; A.313.E.11J; A.314.E.114; A.315.E.11.Í; A.316.E.11.Í; A.317.E.11.Í; A.318.E.11.Í; A.319.E.11.Í; A.320.E.11.Í; A.321.E.11.Í; A.323.E.11.Í; A.324.E.11.Í; A.325.E.11.Í; A.326.E.11.Í; A.327.E.1U; A.328.E.11.Í; A.329.E.1U; Α.330.Ε.1Π; A.331.E.11.Í; A.332.E.11.Í; A.333.E.11.Í; A.334.E.11.Í; A.335.E.11.Í; A.336.E.11.Í; A.337.E.11.Í; A.338.E.11.Í; A.339.E.11. A.340.E.11.Í; A.341.E.11.Í; A.342.E.11.Í; A.343.E.11.Í; A.344.E.1LÍ; A.345.E.11.Í; A.346.E.11.Í; A.347.E.11.Í; A.348.E.1U; A.349.E.11.Í; A.350.E.11.Í; A.351.E.11.Í; A.352.E.114; A.353.E.11.Í; A.354.E.U.I; A.355.E.11.Í; A.356.E.11.Í; A.357.E.11.Í; A.358.E.11.Í; Α.359.Ε.11.Ϊ; A.360, E.III.1; A.361.E.11.Í; A.362.E.11.Í; A.363.E.11.Í; A.364.E.11.Í; A.365.E.11.Í; A.366.E.11.Í; A.367.E.11.Í; A.368.E.11.Í; A.369.E.1LÍ; A.370.E.11.Í; A.371.E.11.Í; Α.372Έ.11.Ϊ; A.373.E.11.Í; A.374.E.1U; A.375.E.11.Í; A.376.E.11.Í; A.377.E.11.Í; A.378.E.11.Í; A.379.E.U.I; A.380.E.11.Í; A.381.E.11.Í; A.382.E.11.Í; A.383.E.U.I; Α.384Έ.11.Ϊ; A.385.E.1U; A.386.E.11.Í; A.387.E.11.Í; A.388.E.11.Í; A.389.E.11.Í; A.390.E.11.Í; A.391.E.11.I · A.392.E.U.I; A.393.E.11.Í; A.394.E.11.Í; A.395.E.11.Í; A.396.E.11.Í; A.397.E.11.Í; A.398.E.11.Í; A.399.E.U.I; A.400.E.11.Í; A.401.E.11.Í; A.402.E.11.Í; A.403.E.11.Í; A.404.E.11.Í; A.405.E.11.Í; A.406.E.11.Í; A.407.E.114; A.408.E.11.Í; A.409.E.U.I; A.410.E.11 .i; A.4U.E.11.Í; A.412.E.11.Í; A.413.E.11.Í; A.414.E.11.Í; A.415.E.11.Í; A.416.E.11.Í; A.417.E.114; A.418.E.11.Í; A.419.E.11.Í; Α.420.Ε.1Π; A.421.E.11.Í; A.422.E.11.Í; A.423.E.11.1; A.424.E.11.Í; A.425.E.11.Í; A.426.E.11.Í; A.427.E.11.Í; A.428.E.11.Í; A.429.E.11.Í; A.430.E.11.Í; A.431.E.11.Ú A.432.E.11.I; A.433.E.11.Í; A.434.E.11.Í; A.435.E.11.Í; A.436.E.11.Í; A.437.E.11.Í; A.438.E.11.Í; A.439.E.11.Í; A.440.E.11.Í; A.441.E.11.Í; Α.442.Ε.11.Ϊ; A.443.E.11.Í; A.444.E.11.Í; A.445.E1LÍ; A.446.E.11.Í; A.447.E.11.Í; A.448.E.11.Í; A.449.E.1LÍ; A.450.E.U.I; A.451.E.11.Í; A.452.E.11.Í; A.453.E.11.Í; A.454.E.11.Í; A.455.E.11.Í; A.456.E.11.Í; A.457.E.11.Í; A.458.E.11.Í; A.459.E.II, i; A.460.E.11.Í; A.461.E.11.Í; A.462.E.11.Í; A.463.E.11.Í; A.464.E.11.Í; A.465.E.11.Í; A.466.E.11 .i; A.467.E.11.1; A.468.E.11.Í; A.469.E.11.Í; A.470.E.11.Í; A.471.E.11.Í; A.472.E.11.Í; A.473.E.1U A.474.E.11.I; A.475.E.11.Í; A.476.E.11.Í; A.477.E.H.I;
-129CZ 297945 B6-129GB 297945 B6
A.478.E.11 .i; A.479.E.114; A.480.E.114; A.481.E.114; A.482.E.114; A.483.E.114; A.484.E.114; A.485.E.114; A.486.E.114; A.487.E.114; A.488.E.114; A.489.E.114; A.490.E.114; A.491.E.114; A.492.E.114; A.493.E.114; A.494.E.114; A.495.E.114; A.496.E.114; Α.497.Ε.Π4; A.498.E.114; A.499.E.114; A.500.E.114; A.50LE.114; A.502.E.114; A.503.E.114; A.504.E.114; A.505.E.114; A.506-E.114; A.507.E.114; A.508.E.114; Α.509Έ.114; A.510.E.114; A.511.E.114; A.512.E.114; A.512.E.114; A.513.E.114; A.514.E.114; A.515.E.114; A.516.E.114; A.517.E.114; A.518.E.114; A519.E.114; A.520.E.114; A.521.E.114; A.522.E.114; A.523.E.114; A.524.E.114; A.525.E.114; A.526.E.114; A.527.E.114; A.528.E.114; A.529.E.114; A.530.E.114; A.531.E.114; A.532.E.114; A.533.E.114; A.534.E.114; A.535.E.114; A.536.E.U4; A.537.E.114; A.538.E.114; A.539.E.114; A.540.E114; A.541.E.114; A.542.E.114; A.543.E.114; A.544.E.114; A.545.E.114; A.546.E.114; A.547.E.114; A.548.E.114; A.549.E.114; A.550.E.114; Α551Έ.114; A.552.E.114; A.553.E.114; Α.554.Ε.Π4; A.555.E.114; A.556.E.114; A.557.E114; A.558.E.114; A.559.E.114; A.560.E.114; A.561.E.114; A.562.E.114; A.563.E.114; A.564.E.114; A.565.E.114; A.566.E.114; A.567.E.114; A.568.E.114; A.569.E.114; A.570.E.114; A.571.E.114; A.572.E.114; A.573.E.114; A.574.E.114; A.575.E.114; A.576.E.114; Á.577.E.114; A.578.E.114; A.579.E.114; A.580.E114; A.581.E.114; A.582.E.114; A.583.E.114; A.584.E.114; A.585.E.114; A.586.E.114; A.587.E.114; A.588.E.114; Α.589Έ.114; Α.590.Ε.Π4; A.591.E.114; Α.592.Ε.Π4; A.593.E.114; A.594.E.114; A.595.E.U4; A.596.E.114; A.59EE.114; A.598.E.I14; A.599.E.114; A.600.E.114; A.601.E.114; A.602.E.114; A.603.E.114; A.604.E.114; A.605.E.114; A.606.E.114; A.607.E.114; A.608.E.114; A.609.E.114; A.610.E.114; A.611.E.114; A.612.E.114; A.613.E.114; A.614.E.114; A.615.E.114; A.616.E114; A.617.E.114; A.618.E.11 i; Α.619Έ.114; A.620.E.114; A.621.E.114; A.622.E.114; A.623.E.114; A.624.E.114; A.625.E.114; A.626.E.114; A.627.E.114; A.628.E.114; A.629.E.114; A.630.E.114; A.631.E.114; A.632.E.114; A.633.E.114; Α.634Έ.114; A.635.E.114; A.636.E.114; A.637.E.114; A.638.E.114; A.639.E.114; A.640.E.114; A.641.E.114; A.642.E.114; A.643.E.114; A.644.E.114; A.645.E.114; A.646.E.114; A.647.E.114; A.648.E.114; A.649.E.114; A.650.E.114; A.651.E.114; A.652.E.114; A.653.E.114; A.654.E.114; Α.655Έ.114; A.656.E.114; A.657.E.114; A.658.E.114; A.659.E.114; A.660.E.114; A.2.E44; A.3.F.4.Í; A.4.E44; A.5E.44; A.6E.44; A.7.E44; A.9.E44; A.10.R44; A.15E.44; A.100.E44; A.101E.44; A.102.E44; A.103.E44; A.104.E44; A.105.R44; A.106E.4.Í; A.I07E.44; A.108.E44; A.109E.44; A.110.E44; A.lll F.44; A.112.E44; A.113E.44; A. 114.F.44; A.115.E44; A.116.F.44; A.117.E44; Α.Π8.Ε44; A.U9.F.44; A.120.F.44; A.121.F.44; A.122.F.44; A.123.E44; A.124.F.44; A.125.F.44; A.126.F.44; A.127.R44; A.128.F.4.Í; A.129.E44; A.130.F.4.Í; A.131.E44; A.132.F.44; A.133.E44; A.134.F.4.Í; A.135.F.44; A.136.F.44; A.137.F.44; A.138.E4.Í; A.139.F.44; A.140.F.4.Í; A.141.F.4.Í; A.142.E44; A.143.F.44; A.144.E44; A.145.F.44; A.146.R44; A.147.R44; A.148.F.44; A.149E.44;’A.150.E44; A.151.F.44; A.152.F.44; A.153.F.44; A.154.E44; A.155.F.44; A.156E.44; A.157E.4.Í; A.158.F.44; A.159.F.44; A.160.F.4.Í; A.161.F.44; A.162.F.44; A.163.F.44; A.164.F.4.Í; A.165.F.44; A.166.E44; A.167.R44; A.168E.44; A.169.F.4.Í; A.170.F.44; A.171.F.44; A.172.F.4.Í; A.173.F.44; A.174.F.44; A.175.E44; A.176.F.44; A.177.F.44; A.178.E44; A.179.E44; A.180.F.44; A.181.E44; A.182.F.44; A.183.F.44; A.184.R44; A.185.R44; A.186.R44; A.187E.4.Í; A.188.F.44; A.189.R44; A.190.F.44;A.478.E.11 .i; A.479.E.114; A.480.E.114; A.481.E.114; A.482.E.114; A.483.E.114; A.484.E.114; A.485.E.114; A.486.E.114; A.487.E.114; A.488.E.114; A.489.E.114; A.490.E.114; A.491.E.114; A.492.E.114; A.493.E.114; A.494.E.114; A.495.E.114; A.496.E.114; Α.497.Ε.Π4; A.498.E.114; A.499.E.114; A.500.E.114; A.50LE.114; A.502.E.114; A.503.E.114; A.504.E.114; A.505.E.114; A.506-E.114; A.507.E.114; A.508.E.114; Α.509Έ.114; A.510.E.114; A.511.E.114; A.512.E.114; A.512.E.114; A.513.E.114; A.514.E.114; A.515.E.114; A.516.E.114; A.517.E.114; A.518.E.114; A519.E.114; A.520.E.114; A.521.E.114; A.522.E.114; A.523.E.114; A.524.E.114; A.525.E.114; A.526.E.114; A.527.E.114; A.528.E.114; A.529.E.114; A.530.E.114; A.531.E.114; A.532.E.114; A.533.E.114; A.534.E.114; A.535.E.114; A.536.E.U4; A.537.E.114; A.538.E.114; A.539.E.114; A.540.E114; A.541.E.114; A.542.E.114; A.543.E.114; A.544.E.114; A.545.E.114; A.546.E.114; A.547.E.114; A.548.E.114; A.549.E.114; A.550.E.114; Α551Έ.114; A.552.E.114; A.553.E.114; Α.554.Ε.Π4; A.555.E.114; A.556.E.114; A.557.E114; A.558.E.114; A.559.E.114; A.560.E.114; A.561.E.114; A.562.E.114; A.563.E.114; A.564.E.114; A.565.E.114; A.566.E.114; A.567.E.114; A.568.E.114; A.569.E.114; A.570.E.114; A.571.E.114; A.572.E.114; A.573.E.114; A.574.E.114; A.575.E.114; A.576.E.114; Á.577.E.114; A.578.E.114; A.579.E.114; A.580.E114; A.581.E.114; A.582.E.114; A.583.E.114; A.584.E.114; A.585.E.114; A.586.E.114; A.587.E.114; A.588.E.114; Α.589Έ.114; Α.590.Ε.Π4; A.591.E.114; Α.592.Ε.Π4; A.593.E.114; A.594.E.114; A.595.E.U4; A.596.E.114; A.59EE.114; A.598.E.I14; A.599.E.114; A.600.E.114; A.601.E.114; A.602.E.114; A.603.E.114; A.604.E.114; A.605.E.114; A.606.E.114; A.607.E.114; A.608.E.114; A.609.E.114; A.610.E.114; A.611.E.114; A.612.E.114; A.613.E.114; A.614.E.114; A.615.E.114; A.616.E114; A.617.E.114; A.618.E.11 i; Α.619Έ.114; A.620.E.114; A.621.E.114; A.622.E.114; A.623.E.114; A.624.E.114; A.625.E.114; A.626.E.114; A.627.E.114; A.628.E.114; A.629.E.114; A.630.E.114; A.631.E.114; A.632.E.114; A.633.E.114; Α.634Έ.114; A.635.E.114; A.636.E.114; A.637.E.114; A.638.E.114; A.639.E.114; A.640.E.114; A.641.E.114; A.642.E.114; A.643.E.114; A.644.E.114; A.645.E.114; A.646.E.114; A.647.E.114; A.648.E.114; A.649.E.114; A.650.E.114; A.651.E.114; A.652.E.114; A.653.E.114; A.654.E.114; Α.655Έ.114; A.656.E.114; A.657.E.114; A.658.E.114; A.659.E.114; A.660.E.114; A.2.E44; A.3.F.4.I; A.4.E44; A.5E.44; A.6E.44; A.7.E44; A.9.E44; A.10.R44; A.15E.44; A.100.E44; A.101E.44; A.102.E44; A.103.E44; A.104.E44; A.105.R44; A.106E.4.Í; A.I07E.44; A.108.E44; A.109E.44; A.110.E44; A.lll F.44; A.112.E44; A.113E.44; A. 114.F.44; A.115.E44; A.116.F.44; A.117.E44; Α.Π8.Ε44; A.U9.F.44; A.120.F.44; A.121.F.44; A.122.F.44; A.123.E44; A.124.F.44; A.125.F.44; A.126.F.44; A.127.R44; A.128.F.4.Í; A.129.E44; A.130.F.4.I; A.131.E44; A.132.F.44; A.133.E44; A.134.F.4.I; A.135.F.44; A.136.F.44; A.137.F.44; A.138.E4.Í; A.139.F.44; A.140.F.4.I; A.141.F.4.I; A.142.E44; A.143.F.44; A.144.E44; A.145.F.44; A.146.R44; A.147.R44; A.148.F.44; A.149E.44; ´ A.150.E44; A.151.F.44; A.152.F.44; A.153.F.44; A.154.E44; A.155.F.44; A.156E.44; A.157E.4.Í; A.158.F.44; A.159.F.44; A.160.F.4.I; A.161.F.44; A.162.F.44; A.163.F.44; A.164.F.4.I; A.165.F.44; A.166.E44; A.167.R44; A.168E.44; A.169.F.4.I; A.170.F.44; A.171.F.44; A.172.F.4.I; A.173.F.44; A.174.F.44; A.175.E44; A.176.F.44; A.177.F.44; A.178.E44; A.179.E44; A.180.F.44; A.181.E44; A.182.F.44; A.183.F.44; A.184.R44; A.185.R44; A.186.R44; A.187E.4.Í; A.188.F.44; A.189.R44; A.190.F.44;
-130CZ 297945 B6-130GB 297945 B6
A.191.E44; A192.E44; A.193.E44; A.197.E44; A.198.E44; A.199.F.44; A.203.F.44; A.204.F.4.1; A.205.E44; A.209.E44; A.210.E44; A.211.F.44; A.215.E44; A.216.E44; A.217.E44; A.221.F.44; A.222.F.44; A.223.F.44; A227E.44; A.228.F.44; A.229.F.44; A.233.E44; A.234.F.44; A.235.F.44; A.239.F.44; A.240.E44; A.241.E44; A.245. F.44; A.246.E44; A.247.F.44; A.251.E44; A.252.E44; A.253.E44; A.257.F.44; A.258.F.44; A.259.F.44; A.263.E44; A.264.E44; A.265.E44; A.269.F.44; A.270.E44; A.271.F.44; A.275.F.44; A276.E44; A.277.E44; A.281.E44; A.282.E44; A.283.E44; A.287.F.44; A.28S-F.44; A.289.F.44; A.293.F.44; A.294.E44; A.295.E44; A.299.E44; A.300.F.44; A.301.E44; A.305.E44; A.306.F.44: A.307.F.44; A.311.E44; A.312.E44; A.313.F.44; A.317.F.44; A.318.E44; A.319.E44; A.324.F.44; A.325.F.44; A.326.F.44; A.330.E44; A.331.E44; A.332.F.44; A.336.E44; A.337.E44; A.338.F.44; A.342.E44; A.343.F.44; A.344.E44; A.348.E44; A.349.E44; A.350.E44; A.354.E44; A.355.F.44; A.356.E44; A.360.E44; A.361.F.44; A.362.E44; A.366.E44; A.367.F.44; A.368.F.44; A.372.F.44; A.373.E44; A.374.E44; A.378.E44; A.379.F 44; A.380.E44; A.384.E44; A.385.E44; A.386.E44; A.390.E44; A.391.E44; A.392.E44; A.396.F.44; A.397.E44; A.398.E44; A.402.E44; A.403.E44; A.404.E44; A.408.F.44; A.409.E44; A.4W.F.44; A.414.E44; A.415.É44; A.416.E44; A.420.E44; A.421.E44; A.422.E44; A.426.E44; A.427.E44; A.428.F.44; A.432.E44; A.433.E44; A.434E.44; A.438.E44; A.439.F.4.1; A.440.E44; A.444E.44; A.445.F.44; A.446.F.4 i; A.450.E44; A.451.F.44; A.452.E44; A.456.E44; A.457.F.44; A.458.E44; A.462.F.44; A.463.E44; AA64.E44; A.468.E44; A.469.F.44; A.470.E44;A.191.E44; A192.E44; A.193.E44; A.197.E44; A.198.E44; A.199.F.44; A.203.F.44; A.204.F.4.1; A.205.E44; A.209.E44; A.210.E44; A.211.F.44; A.215.E44; A.216.E44; A.217.E44; A.221.F.44; A.222.F.44; A.223.F.44; A227E.44; A.228.F.44; A.229.F.44; A.233.E44; A.234.F.44; A.235.F.44; A.239.F.44; A.240.E44; A.241.E44; A.245. F.44; A.246.E44; A.247.F.44; A.251.E44; A.252.E44; A.253.E44; A.257.F.44; A.258.F.44; A.259.F.44; A.263.E44; A.264.E44; A.265.E44; A.269.F.44; A.270.E44; A.271.F.44; A.275.F.44; A276.E44; A.277.E44; A.281.E44; A.282.E44; A.283.E44; A.287.F.44; A.28S-F.44; A.289.F.44; A.293.F.44; A.294.E44; A.295.E44; A.299.E44; A.300.F.44; A.301.E44; A.305.E44; A.306.F.44: A.307.F.44; A.311.E44; A.312.E44; A.313.F.44; A.317.F.44; A.318.E44; A.319.E44; A.324.F.44; A.325.F.44; A.326.F.44; A.330.E44; A.331.E44; A.332.F.44; A.336.E44; A.337.E44; A.338.F.44; A.342.E44; A.343.F.44; A.344.E44; A.348.E44; A.349.E44; A.350.E44; A.354.E44; A.355.F.44; A.356.E44; A.360.E44; A.361.F.44; A.362.E44; A.366.E44; A.367.F.44; A.368.F.44; A.372.F.44; A.373.E44; A.374.E44; A.378.E44; A.379.F 44; A.380.E44; A.384.E44; A.385.E44; A.386.E44; A.390.E44; A.391.E44; A.392.E44; A.396.F.44; A.397.E44; A.398.E44; A.402.E44; A.403.E44; A.404.E44; A.408.F.44; A.409.E44; A.4W.F.44; A.414.E44; A.415.É44; A.416.E44; A.420.E44; A.421.E44; A.422.E44; A.426.E44; A.427.E44; A.428.F.44; A.432.E44; A.433.E44; A.434E.44; A.438.E44; A.439.F.4.1; A.440.E44; A.444E.44; A.445.F.44; A.446.F.4 i; A.450.E44; A.451.F.44; A.452.E44; A.456.E44; A.457.F.44; A.458.E44; A.462.F.44; A.463.E44; AA64.E44; A.468.E44; A.469.F.44; A.470.E44;
A.194.E44; A.195.E44; A.196.E44; A.200.E44; A.201.E44; A.202.E44; A.206.E44; AJ207.F.44; A.208.E44; A.212.F.44; A.213.E44; A.214.F.44; A.218.E44; A.219.F.44; A.220.E44; A.224.E44; A.225.E44; A.226.F.44; A.230.E44; A.231.E44; A.232.E44; A.236.F.44; A.237.F.44; A.238.F.44; A.242.E44; A.243.E44; A.244.E44; A.248.E44; A.249.E44; A.250.E44; A.254.E44; A.255E.44; A.256.E44; A.260.E44; A.261.E44; A262.E44; A.266.F.44; A267.F.44; A.268.E44; A.272.F.44; A.273.E44; A.274.F.44; A.278.E44; A.279.E44; A.280.E44; A.284.F.44; A.285.E44; A.286.E44; A.290.F.44; A.291.E44; A.292.E44; A.296.F.44; A.297.F.44; A.298.E44; A.302.E44; A.303.E44; A.304.F.44; A.308.E44; A.309.E44; A.310.E44; A.314.E44; A.315.E44; A.316.E44; A.320.F.44; A.321.E44; A.323.E44; A.327.F.44; A.328.E44; A.329.F.44; A.333.F.44; A.334.E44; A.335.E44; A.339.F.44; A.340.E44; Á.341.F.44; A.345.F.44; A.346.E44; A.347.E44; A.351.E44; A.352.E44; A.353.E44; A.357.F.44; A.358.E44; A.359.E44; A.363.E44; A.364.R44; A365.E44; A.369.E44; A.370.E44; A.371.E44; A.375.E44; A.376.E44; A.377.F.44; A.381.E44; A.382.E44; A.383.E44; A.387E.44; A.388.E44; A.389.E44; A.393.E44; A.394.E44; A.395.E44; A.399.F.44; A.400.E44; A.401.F.44; A.405.E44; A.406.E44; A.407.F.44; A.411.E44; A.412.E44; A.413.E44; A.417.E44; A.418.E44; A.419.E44; A.423E.44; A.424.F.44; A.425.E44; A.429.E44; A.430.E44; A.431.E44; A.435E.44; A.436.E44; A.437.E44; A.441.E44; A.442.F.44; A.443.F.44; A.447.F.44; A.448.F.44; A.449.E44; A.453.E44; A.454.E44; A.455.E44; A.459.E44; A.460.E44; A.461.F.44; A.465.E44; A.466.F.44; A.467.F.44; A.471.F.44; A.472.E44; A.473.F.44;A.194.E44; A.195.E44; A.196.E44; A.200.E44; A.201.E44; A.202.E44; A.206.E44; AJ207.F.44; A.208.E44; A.212.F.44; A.213.E44; A.214.F.44; A.218.E44; A.219.F.44; A.220.E44; A.224.E44; A.225.E44; A.226.F.44; A.230.E44; A.231.E44; A.232.E44; A.236.F.44; A.237.F.44; A.238.F.44; A.242.E44; A.243.E44; A.244.E44; A.248.E44; A.249.E44; A.250.E44; A.254.E44; A.255E.44; A.256.E44; A.260.E44; A.261.E44; A262.E44; A.266.F.44; A267.F.44; A.268.E44; A.272.F.44; A.273.E44; A.274.F.44; A.278.E44; A.279.E44; A.280.E44; A.284.F.44; A.285.E44; A.286.E44; A.290.F.44; A.291.E44; A.292.E44; A.296.F.44; A.297.F.44; A.298.E44; A.302.E44; A.303.E44; A.304.F.44; A.308.E44; A.309.E44; A.310.E44; A.314.E44; A.315.E44; A.316.E44; A.320.F.44; A.321.E44; A.323.E44; A.327.F.44; A.328.E44; A.329.F.44; A.333.F.44; A.334.E44; A.335.E44; A.339.F.44; A.340.E44; Á.341.F.44; A.345.F.44; A.346.E44; A.347.E44; A.351.E44; A.352.E44; A.353.E44; A.357.F.44; A.358.E44; A.359.E44; A.363.E44; A.364.R44; A365.E44; A.369.E44; A.370.E44; A.371.E44; A.375.E44; A.376.E44; A.377.F.44; A.381.E44; A.382.E44; A.383.E44; A.387E.44; A.388.E44; A.389.E44; A.393.E44; A.394.E44; A.395.E44; A.399.F.44; A.400.E44; A.401.F.44; A.405.E44; A.406.E44; A.407.F.44; A.411.E44; A.412.E44; A.413.E44; A.417.E44; A.418.E44; A.419.E44; A.423E.44; A.424.F.44; A.425.E44; A.429.E44; A.430.E44; A.431.E44; A.435E.44; A.436.E44; A.437.E44; A.441.E44; A.442.F.44; A.443.F.44; A.447.F.44; A.448.F.44; A.449.E44; A.453.E44; A.454.E44; A.455.E44; A.459.E44; A.460.E44; A.461.F.44; A.465.E44; A.466.F.44; A.467.F.44; A.471.F.44; A.472.E44; A.473.F.44;
-131 CZ 297945 B6-131 CZ 297945 B6
A.474.F.4.Í; A.475.F.4.Í; A.476.F.4.Í; A.477.E44; A.478.F.4.Í; A.479.F.44; A.480.F.44; A.481.E44; A.482.E44; A.483.F.4.Í; A.484.E44; A.485.F.4.Í; A.486.F.4.Í; A.487.E44; A.488.F.44; A.489.E44; A.490.E44; A.491.E44; A.492.F.4.Í; A.493.F.4.Í; A.494.F.4.Í; A.495.F.44; A.496.E44; A.497.F.44; A.498.F.4.Í; A.499.F.4.Í; A.500.F.4.Í; A.501.E4.Í; A.502.F.44; A.503.F.44; A.504.F.4.Í; A.505.E44; A.506.E4.Í; A.507.F.44; A.508.E44; A.509.F.44; A.510.E44; A.511.F.4.Í; A.512.F.44; A.512.E44; A.513.E44; A.514.E44; A.515.E4 i; A.516.F.4.Í; A.517.E44; A.518.R44; A.519.E44; A.520.F.4.Í; A.521.E44; A.522.É44; A.523.F.4.Í; A.524.E44; A.525.E44; A.526.E44; A.527.F.4.Í; A.528.E44; A.52RE44; A.530.E44; A.531.E44; A.532.F.44; Α.533.Ε4.Ϊ; Α.534.Ε4.Ϊ; A.535.E4.1; A.536.F.4.Í; A.537.F.44; A.538.F.4.Í; A.539.F.44; A.540.F.4.Í; A.541.E44; A.542.E44; A.543.F.44; A.544.E44; A.545E.44; A.546.E4.Í; A.547.E4.Í; A.548.R4.i; A.549.F.44; A.550.E44; A.551.E44; A.552.E4.Í; A.553.É44; A.554E.44; A.555.E44; A.556.E44; A.557.E44; A.558.F.4.Í; A.559.E44; A.560.E44; A.56LF.44; A.562.F.4.Í; AJ563.F.4.Í; A.564.E4.1; A.565.F.44; A.566.F.44; A.567.E44; A.568.E44; A.569.F.44; A.570.F.44; A.571.E44; A.572.F.44; A.573.E4J; A.574.E44; A.575.F.4.Í; A.576.E44; A.577.F.44; A.578.F.4.Í; A.579.E44; A.580.E44; A.581.F.4.Í; A.582.F.4.Í: A.583.E44; A.584E.44; A.585.E44; A.586.E44; A.587.E44; A.588.F.4.Í; A.589E.4.Í; A.590.E44; A.591.F.4.Í; A.592.F.4.Í; A.593.E44; A.594.F.4.Í; A.595.F.4.Í; A.596.F.44; A.597.F.4.Í; A.598E.44; A.599.F.44; A.600.E44; A.601.E44; A.602.F.4.Í; A.603.F.44; A.604.F.4.Í; A.605.F.4.Í; A.606.F.4.Í; A.607.E4T; A.608.E44; A.609.E44; A.610E.4.Í; A.611.E44; A.612.E44; A.613.F.44; A.614.F.4.Í; A.615.E44; A.616.E44; A.617.E44; A.618E.4.Í; A.619.F.44; A.620.E44; A.621.E44; A.62ZE4.Í; A.623.E44; A.624.F.44; A.625.F.4.Í; A.626.F.4.Í; A.627.F.44; A.628 F.4 i; A.629.E44; A.630.E4.Í; A.631E.44; A.632.F.44; A.633.E44; A.634.F.44; A.635.E44; A.636E.44; A.637.E44; A.638.E44; A.639.F.44; A.640.F.4.Í; A.64LE44; A.642.F.4.Í; A.643.E44; A.644.F.4.Í; A.645.E44; A.646E.44; A.647.F.44; A.648E.4.Í; A.649.F.4.Í; A.650.E44; A.651.F.4.Í; A.652.F.4.Í; A.653.E44; A.654.F.4.Í; A.655.E44; A.656.E4.Í; A.657.E44; A.658.E44; A.659.E44; A.660E.4.Í; A.2.F.11.Í; A.3.E1U; A.4.F.11.Í; A.5.F.11.Í; A.óEU.i; A.7.E114; A.9E.U.Í; A.lOE.ll.i; A.I5.F.U.Í; A.100.E114; A.1O1.F.11.Í; A.102.E114; A.103.F.11.Í; ΑΛ04.ΕΠ4; A.105.F.11.Í; A.106.E114; A.107.E114; A.108.F.11.Í; A.109E.114; A.llO.Ell.i; A.U1.E11.Í; A.112.E11.Í; A.113.F.11.Í; A.114.F.114; A.115.E114; A.1I6.E11.Í; ΑΛ17.Ε114; A.118.E114; A.119.E114; A.120E.114; A.121.E11.Í; A.122.E114; ΑΛ23.Ε114; A.124.E114; A.125.E114; A.126.E114; A.127.E114; A.128.F.11.Í; A.129.E114; A.13O.E114; A.131.E114; A.132.E114; A.133.E114; A.134.E114; A.I35.E114; A.136.E114; A.137.E114; A.138.E114; A-139.E11.Í; A.140E.114; A.14LE114; A.142.E114; A.143.E11.Í; A.144.E114; A.145.E114; A.146.E114; A.147.E114; A.148.E114; A.149.F.11.Í; A.150E.114; A.151E.114; A.152.E114; A.153.E114; A.154.E114; A.155.E114; A.156.E11.Í; A.157.R11.Í; A458.E11.Í; A.159.E11.Í; A.160.E114; A.lÓl.F.ll.i; A.162E.114; A.163.E114; A.164.E114; A.165.E114; A.166.E114; A.167.E114; A.168.F.114; A.169.E114; A.170.E1Í4; A.17LF.114; A.172.E114; A.173.E114; Α.174.ΕΠ4; A.175E.114; A.176.F.114; A.177.F.11.Í; Α.178.Ε11.Ϊ; A.179.E114; A.180.E114; A.18LE114; A.182.E114; A.183.E114; A.184.F.114; A.185.E114;A.474.F.4.Í; A.475.F.4.Í; A.476.F.4.Í; A.477.E44; A.478.F.4.Í; A.479.F.44; A.480.F.44; A.481.E44; A.482.E44; A.483.F.4.Í; A.484.E44; A.485.F.4.Í; A.486.F.4.Í; A.487.E44; A.488.F.44; A.489.E44; A.490.E44; A.491.E44; A.492.F.4.Í; A.493.F.4.Í; A.494.F.4.Í; A.495.F.44; A.496.E44; A.497.F.44; A.498.F.4.Í; A.499.F.4.Í; A.500.F.4.I; A.501.E4.Í; A.502.F.44; A.503.F.44; A.504.F.4.I; A.505.E44; A.506.E4.Í; A.507.F.44; A.508.E44; A.509.F.44; A.510.E44; A.511.F.4.I; A.512.F.44; A.512.E44; A.513.E44; A.514.E44; A.515.E4 i; A.516.F.4.Í; A.517.E44; A.518.R44; A.519.E44; A.520.F.4.I; A.521.E44; A.522.É44; A.523.F.4.I; A.524.E44; A.525.E44; A.526.E44; A.527.F.4.I; A.528.E44; A.52RE44; A.530.E44; A.531.E44; A.532.F.44; Α.533.Ε4.Ϊ; Α.534.Ε4.Ϊ; A.535.E4.1; A.536.F.4.Í; A.537.F.44; A.538.F.4.I; A.539.F.44; A.540.F.4.Í; A.541.E44; A.542.E44; A.543.F.44; A.544.E44; A.545E.44; A.546.E4.Í; A.547.E4.Í; A.548.R4.i; A.549.F.44; A.550.E44; A.551.E44; A.552.E4.Í; A.553.É44; A.554E.44; A.555.E44; A.556.E44; A.557.E44; A.558.F.4.I; A.559.E44; A.560.E44; A.56LF.44; A.562.F.4.I; AJ563.F.4.Í; A.564.E4.1; A.565.F.44; A.566.F.44; A.567.E44; A.568.E44; A.569.F.44; A.570.F.44; A.571.E44; A.572.F.44; A.573.E4J; A.574.E44; A.575.F.4.I; A.576.E44; A.577.F.44; A.578.F.4.I; A.579.E44; A.580.E44; A.581.F.4.I; A.582.F.4.I: A.583.E44; A.584E.44; A.585.E44; A.586.E44; A.587.E44; A.588.F.4.I; A.589E.4.Í; A.590.E44; A.591.F.4.Í; A.592.F.4.I; A.593.E44; A.594.F.4.I; A.595.F.4.I; A.596.F.44; A.597.F.4.Í; A.598E.44; A.599.F.44; A.600.E44; A.601.E44; A.602.F.4.I; A.603.F.44; A.604.F.4.I; A.605.F.4.Í; A.606.F.4.I; A.607.E4T; A.608.E44; A.609.E44; A.610E.4.Í; A.611.E44; A.612.E44; A.613.F.44; A.614.F.4.I; A.615.E44; A.616.E44; A.617.E44; A.618E.4.Í; A.619.F.44; A.620.E44; A.621.E44; A.62ZE4.Í; A.623.E44; A.624.F.44; A.625.F.4.I; A.626.F.4.I; A.627.F.44; A.628 F.4 i; A.629.E44; A.630.E4.Í; A.631E.44; A.632.F.44; A.633.E44; A.634.F.44; A.635.E44; A.636E.44; A.637.E44; A.638.E44; A.639.F.44; A.640.F.4.Í; A.64LE44; A.642.F.4.I; A.643.E44; A.644.F.4.I; A.645.E44; A.646E.44; A.647.F.44; A.648E.4.Í; A.649.F.4.I; A.650.E44; A.651.F.4.I; A.652.F.4.Í; A.653.E44; A.654.F.4.Í; A.655.E44; A.656.E4.Í; A.657.E44; A.658.E44; A.659.E44; A.660E.4.Í; A.2.F.11.Í; A.3.E1U; A.4.F.11.Í; A.5.F.11.Í; A.óEU.i; A.7.E114; A.9E.U.Í; A.10O.ll.i; A.I5.F.U.I; A.100.E114; A.1O1.F.11.Í; A.102.E114; A.103.F.11.Í; ΑΛ04.ΕΠ4; A.105.F.11.Í; A.106.E114; A.107.E114; A.108.F.11.Í; A.109E.114; A.ll0.Ell.i; A.U1.E11.Í; A.112.E11.Í; A.113.F.11.Í; A.114.F.114; A.115.E114; A.1I6.E11.Í; ΑΛ17.Ε114; A.118.E114; A.119.E114; A.120E.114; A.121.E11.Í; A.122.E114; ΑΛ23.Ε114; A.124.E114; A.125.E114; A.126.E114; A.127.E114; A.128.F.11.Í; A.129.E114; A.13O.E114; A.131.E114; A.132.E114; A.133.E114; A.134.E114; A.I35.E114; A.136.E114; A.137.E114; A.138.E114; A-139.E11.I; A.140E.114; A.14LE114; A.142.E114; A.143.E11.Í; A.144.E114; A.145.E114; A.146.E114; A.147.E114; A.148.E114; A.149.F.11.Í; A.150E.114; A.151E.114; A.152.E114; A.153.E114; A.154.E114; A.155.E114; A.156.E11.Í; A.157.R11.I; A458.E11.Í; A.159.E11.Í; A.160.E114; A.lÓl.F.ll.i; A.162E.114; A.163.E114; A.164.E114; A.165.E114; A.166.E114; A.167.E114; A.168.F.114; A.169.E114; A.170.E1I4; A.17LF.114; A.172.E114; A.173.E114; Α.174.ΕΠ4; A.175E.114; A.176.F.114; A.177.F.11.Í; Α.178.Ε11.Ϊ; A.179.E114; A.180.E114; A.18LE114; A.182.E114; A.183.E114; A.184.F.114; A.185.E114;
-132CZ 297945 B6-132GB 297945 B6
A.186.E114; A.187.E114; A.188.E114; A.189.E114; A.190.F.114; A.191.E114; A.192.E114; A.193.F.114; A.194.E114; A.195.E114; A.196.E114; A.197.E114; A.198E.114; A.199.F.114; A.200.E114; A.201.E114; A.202.E114; A.203.F.114; A.204.E114; A.205.F.114; A.206.EU4; A.207.F.114; A.208.F.114; A.209.F.U4; A.210.E114; A.211.E114; A.212.E114; A213.F.114; A.214.E114; A.215.E114; A.216.E114; A.217.F.U4; A.218.F.114; A219.F.114; A.220.E114; A.221.E114; A.222.E1LÍ; A.223.F.114; A.224.F.U4; A.225.E114; A.226.E114; A.227.E114; A.228.E114; Α229.Ε1Ϊ4; A.230.F.114; A.231.E114; A.232.E114; A.233.E114; A.234.E114; A235.F.114; A.236.F.114; A.237.E114; A.238.F.114; A.239.E114; A.240.E114; A.241.F.114; A.242.E114; A243.E114; A.244.E114; A.245.E114; A.246.E114; A.247.F.U4; A.248.E114; A.249.E114; A.250.E114; A.251.F.U4; A.252.E114; A.253.F.114; A.254.E114; A.255.E114; A.256.E114; A.257.E114; A.258.E114; A.259.E114; A.260.R114; A.261.E114; A.262.E114; A.263.F.114; A.264.F.114; A.265.E114; A.266.E114; A.267.F.114; A.268.F.114; A.269.E114; A.270.R114; A.271 .F.114; A.272.E114; A.273.E114; A.274.E114; A.275.E114; A.276.F.114; A.277.F.114; A.278.E114; A.279.E114; A.280.E114; A.281.E114; A.282.E114; A.283.F.U4; A.284.E114; A.285.E114; A.286.E114; Α.287.ΕΠ4; A.288.F.114; A.289 .F.114; A.290E.114; A.291.E114; A.292.E114; A.293.E114; A.294.E114; A.295.F.114; A.296.F.114; A.297.E114; A.298.E114; A.299.E114; A.300.E114; A.301.F.114; A.302.E114; A.303.E114; A.304.E114; A.305.F.114; A.306.F.114; A.307.F.114; A.308.E114; A.309.E114; A.310.E114; A.311.F.114; A.312.E114; A.313.E114; A.314.F.114; A.315.F.114; A.316.E114; A.317.E114; A.318.F.114; A.319.E114; A.320.E114; A.321.E114; A.323.E114; A.324.E114; A.325.F.114; A.326.F.114; A.327.E114; A.328.E114; A.329.E114; A.330.E114; A.331.E114; A.332.F.114; A.333.E114; A334.E114; A.335.E114; A.336.F.114; A.337.E114; A.338.F.114; A.339.E114; A.340.E114; A.341.F.114; A.342.F.114; A.343.F.114; A.344.E114; A.345.E114; A.346R114; A.347.F.114; A.348.F.114; A.349.E114; A.35Ó.E114; A.351 .F.114; A.352.E114; A.353.E114; A.354.E114; A.355.F.114; A.356.E114; A.357.E114; A.358.E114; A.359.E114; A.360.E114; A.361.F.114; A.362.E114; A.363.E114; A.364.E114; A.365.E114; A.366.E114; A.367.F.114; A.368.F.114; A.369.E114; A.370.E114; A.371.E114; A.372.E114; A.373.E114; A.374.EU4; A.375.E114; A.376.E114; A.377.E114; A.378.F.114; A.379.F.114; A.380.F.114; A.381.E1I4; A.382.E114; A.383.E114; A.384.E114; A.385.E114; A.386.F.114; A.387.F.114; A.388.E114; A.389.E114; A.390.E114; A.391.F.114; A.392.F.114; A.393.E114; A.394.F.114; A.395.E114; A.396.F.114; A.397.E114; A.398.F.114; A.399.E114; A.400.F.114; A.401.E114; A.402.E114; A.403.E114; A.404.F.114; A.405.E114; A.406.E114; A.407.E114; A.408.E114; A.409.E114; A.410.E114; A.411.F.114; A.412.E114; A.413.E114; A.414.E114; A.415.E114; A.416.F.114; A.417.F.114; A.418.E114; A.419.E114; A.420.E114; A.421.F.114; A.422.E114; A.423.E114; A.424.E114; A.425.F.114; A.426.F.114; A.427.F.114; A.428.F.114; A.429.E114; A.430.F.114; A.431.E114; A.432.F.114; A.433.E114; A.434.E114; A.435.E114; A.436.E114; A.437.E114; A.438.F.U4; A.439.F.114; A.440.F.114; A.441.F.114; A.442.F.U4; A.443.E114; A.444.E114; A.445.F.114; A.446.F.114; A.447.E114; A.448.F.114; A.449.F.U4; A.450.F.114; A.451.F.114; A.452.F.114; A.453.F.114; A.454.E114; A.455.E114; A.456.F.114; A.457,F.114; Α.458.ΕΠ4; A.459.F.U4; A.460.E114; A.461.F.114; A.462.E114; A.463.F.114; A.464.E114; A.465.F.114; A.466.E114; A.467.F.114; A.468.F.114;A.186.E114; A.187.E114; A.188.E114; A.189.E114; A.190.F.114; A.191.E114; A.192.E114; A.193.F.114; A.194.E114; A.195.E114; A.196.E114; A.197.E114; A.198E.114; A.199.F.114; A.200.E114; A.201.E114; A.202.E114; A.203.F.114; A.204.E114; A.205.F.114; A.206.EU4; A.207.F.114; A.208.F.114; A.209.F.U4; A.210.E114; A.211.E114; A.212.E114; A213.F.114; A.214.E114; A.215.E114; A.216.E114; A.217.F.U4; A.218.F.114; A219.F.114; A.220.E114; A.221.E114; A.222.E1LÍ; A.223.F.114; A.224.F.U4; A.225.E114; A.226.E114; A.227.E114; A.228.E114; Α229.Ε1Ϊ4; A.230.F.114; A.231.E114; A.232.E114; A.233.E114; A.234.E114; A235.F.114; A.236.F.114; A.237.E114; A.238.F.114; A.239.E114; A.240.E114; A.241.F.114; A.242.E114; A243.E114; A.244.E114; A.245.E114; A.246.E114; A.247.F.U4; A.248.E114; A.249.E114; A.250.E114; A.251.F.U4; A.252.E114; A.253.F.114; A.254.E114; A.255.E114; A.256.E114; A.257.E114; A.258.E114; A.259.E114; A.260.R114; A.261.E114; A.262.E114; A.263.F.114; A.264.F.114; A.265.E114; A.266.E114; A.267.F.114; A.268.F.114; A.269.E114; A.270.R114; A.271 .F.114; A.272.E114; A.273.E114; A.274.E114; A.275.E114; A.276.F.114; A.277.F.114; A.278.E114; A.279.E114; A.280.E114; A.281.E114; A.282.E114; A.283.F.U4; A.284.E114; A.285.E114; A.286.E114; Α.287.ΕΠ4; A.288.F.114; A.289 .F.114; A.290E.114; A.291.E114; A.292.E114; A.293.E114; A.294.E114; A.295.F.114; A.296.F.114; A.297.E114; A.298.E114; A.299.E114; A.300.E114; A.301.F.114; A.302.E114; A.303.E114; A.304.E114; A.305.F.114; A.306.F.114; A.307.F.114; A.308.E114; A.309.E114; A.310.E114; A.311.F.114; A.312.E114; A.313.E114; A.314.F.114; A.315.F.114; A.316.E114; A.317.E114; A.318.F.114; A.319.E114; A.320.E114; A.321.E114; A.323.E114; A.324.E114; A.325.F.114; A.326.F.114; A.327.E114; A.328.E114; A.329.E114; A.330.E114; A.331.E114; A.332.F.114; A.333.E114; A334.E114; A.335.E114; A.336.F.114; A.337.E114; A.338.F.114; A.339.E114; A.340.E114; A.341.F.114; A.342.F.114; A.343.F.114; A.344.E114; A.345.E114; A.346R114; A.347.F.114; A.348.F.114; A.349.E114; A.35Ó.E114; A.351 .F.114; A.352.E114; A.353.E114; A.354.E114; A.355.F.114; A.356.E114; A.357.E114; A.358.E114; A.359.E114; A.360.E114; A.361.F.114; A.362.E114; A.363.E114; A.364.E114; A.365.E114; A.366.E114; A.367.F.114; A.368.F.114; A.369.E114; A.370.E114; A.371.E114; A.372.E114; A.373.E114; A.374.EU4; A.375.E114; A.376.E114; A.377.E114; A.378.F.114; A.379.F.114; A.380.F.114; A.381.E1I4; A.382.E114; A.383.E114; A.384.E114; A.385.E114; A.386.F.114; A.387.F.114; A.388.E114; A.389.E114; A.390.E114; A.391.F.114; A.392.F.114; A.393.E114; A.394.F.114; A.395.E114; A.396.F.114; A.397.E114; A.398.F.114; A.399.E114; A.400.F.114; A.401.E114; A.402.E114; A.403.E114; A.404.F.114; A.405.E114; A.406.E114; A.407.E114; A.408.E114; A.409.E114; A.410.E114; A.411.F.114; A.412.E114; A.413.E114; A.414.E114; A.415.E114; A.416.F.114; A.417.F.114; A.418.E114; A.419.E114; A.420.E114; A.421.F.114; A.422.E114; A.423.E114; A.424.E114; A.425.F.114; A.426.F.114; A.427.F.114; A.428.F.114; A.429.E114; A.430.F.114; A.431.E114; A.432.F.114; A.433.E114; A.434.E114; A.435.E114; A.436.E114; A.437.E114; A.438.F.U4; A.439.F.114; A.440.F.114; A.441.F.114; A.442.F.U4; A.443.E114; A.444.E114; A.445.F.114; A.446.F.114; A.447.E114; A.448.F.114; A.449.F.U4; A.450.F.114; A.451.F.114; A.452.F.114; A.453.F.114; A.454.E114; A.455.E114; A.456.F.114; A.457, F.114; Α.458.ΕΠ4; A.459.F.U4; A.460.E114; A.461.F.114; A.462.E114; A.463.F.114; A.464.E114; A.465.F.114; A.466.E114; A.467.F.114; A.468.F.114;
-133 CZ 297945 B6-133 CZ 297945 B6
A.469.E114; A.470.E1U; A.47LF.114; A.472.F.11.Í; A.473.F.11.Í; A.474.F.11.Í; A.475.E114; A.476.E11.Í; A.477.F.11.Í; A.478.F.11.Í; A.479.E11.Í; A.480.F.11.Í; A.481.F.11.Í; A.482.E11.Í; A.483.E114; A.484.E114; A.485.E114; Α.486Ε.Π4; A.487.E11.Í; A.488.E11.Í; A.489.F.11.Í; A.490E.114; A.49LF.114; A.492.E114; A.493.F.11.Í; A.494.E114; A.495.E114; A.496E.114; A.497.E114; A.498.E114; A.499.E114; A.500.E11.Í; A.501.E114; A.502.E114; A.503E.114; A.504E.114; A.505E.11.Í; A.506E.11.1; A.507.E114; A.508.F.114; A.509.E114; A.510.E114; A.511.E114; A.512.E114; A.512.F.11.Í; A.513.E11.Í; A.514.E114; A.515E114; A.516E.114; A.517.E114; A.518.EI14; A.519.E114; A.520.E114; A.521.E11.Í; A.522.E114; A.523.E114; Α.524.Ε11.Ϊ; A.525.E114; A.526E.114; A2527E114; A.528.E11.Í; A.529.F.11.Í; A.530.F.U.Í; A.531.E114; A.532.E114; A.533E.114; A.534.F.114; A.535.E114; A.536.E114; A.537E.114; A.538.E114; A.539.EÚ4; A.540E.114; A.541.E114; A.542E114; A.543E.114; A.544.E114; Α.545.ΕΠ4; A.546.E114; Α.547.ΕΠ4; A.548.E114; A.549.E11.Í; A.550.E114; A.551E114; A.552.E114; A.553.F.114; A.554.E114; A.555.E114; A.556.E114; A.557E.114; A.558E.11.Í; A.559.E114; A.560T.114; Α.561.ΕΠ4; A.562.E114; A.563.E114; A.564.E114; A.565.E114; A.566.E11.1; A.567.E114; A.568.E114; A.569E114; A.570.E114; A.57LF.11.Í; Α.572.ΕΠ4; A.573.E114; A.574.E114; A.S75.E114; A.576.E114; A.S77.E114; Α.578Ε.11.Ϊ; A.579.E11.Í; A.580.E114; Α.581ΕΠ4; A.5S2.E11.Í; A.583.E114; A.584E11.Í; A.585.E114; A.586.E114; A.587.E114; A.588E.114; A.589.E114; A.590.F.11.Í; A.59LE114; A.592E.114; A.593E.114; Α.594Ε.11.Ϊ; Α.595.ΕΠ4; A-596.F.11.Í; Α.597.ΕΠ4; A.598.E114; A.599E11.1; A.ÓOOE.ll.i; A.601E.114; A.602.E114; A.603.E114; A.604.E114; A.605E114; A.606E.114; A.607.E114; A.608.E114; A.609E.114; A.610.F.114; A.611.E114; A.612.E114; A.613.E114; A.614.E114; A.615.E114; A.616.E114; Α.617ΕΠ4; A.618E.114; A.619.E114; Α.620.ΕΠ4; A.621E.11.1; A.622E.114; A.623.E114; A.624.E11J; A.625E11.1; A.626.E114; A.627E11.Í; A.628.EU4; A.629E.114; A.630.E114; A.631E.11.Í; A.632.E114; A.633.EU4; A.634.E114; A.635E.114; A.636.F.11.Í; A.637.E114; A.638.E114; A.639E.114; A.640.E114; A.641.E114; A.642E.11.Í; Α.643.ΕΠ4; A.644.E11.Í; A.645.F.1U; A.646.E114; A.647E.114; A.648E114; A.649.E114; A.650.E114; A.651.E114; A.652.E114; A.653E11.Í; A.654.F.11.Í; A.655.F.11.Í; A.656.F.1LÍ; A.657.F.11.Í; Α.658.ΕΠ4; A.659.E114; A.660.E114; A.2.a.44.i; A.3.a.44.i; A.4.a.444; A.5.a.44.i; A.9.a.44.i; A.100.a.444; A.101.a.44.i; A.102.a.44.i; A.103.a.44.i; A.104.a.44.i; A.105.a.44j; A.106.a.44.i; A.107.a.44.i; A.108.a.44.i; A.109.a.44.i; A.110.a.44.i; A.lll.a.44.i; A.U2.a.44.i; A.113.a.44.i; A.114.a.44.i; A.115.a.44.i; A.116.a.44.i; A.117.a.44.i; A.l]8.a.444; A.119.a.44.i; A.120.a.44.i; A.121.a.444; A.122.a.44.i; A.123.a.44.i; A.124.a,444; A.125.a.444; A.126.a.44.i; A-127.a.444; A.128.a.444; A.129.a.44.i; A.130.a.44.i; A.131.a.444; A.132.a,44.i; A.133.a.44.i; A. 134.a.444; A.135.a.444; A.136.a.44.i; A.137.a.44.i; A.138.a.44.i; A.139.a.444; A.140.a.44.i; A.141.a.44.i; A.142.a.44.i; A.143.a.44.i; A.144.a.44.i; A.145.a.44.i; A.146.a.44.i; A.147.a.444; A.148.a.44.i; A.149.a.44.i; A.150.a.44.i; A.151.a.44.í; A.152.a.44.i; A.153.a.44.i; A.154.a.44.i; A.155.a.444; A.156.a.44.i; A.157.a.44.i; A.158.a.44.i; A.159.a.44.i; A.160.a.44.i; A.161.a.44.i; A.162.a.44.i; A.163.a.44.i; A.164.a.44.i; A.165.a.44.i; A.166.a.44.i; A.167.a.44.i; A.168.a.44.i; A.169.a.44.i; A.170.a.44.i; A.171.a.44.i; A.172.a.44.i; A. 173.a.44. i; A.174.a.44.i; A.175.a.44.i; A.I76.a.44.i; A.177.a.44.i; A.178.a.444; A.179.a.44.i; A.180.a.44.i; A.181.a.44.i; A.182.a.44.i; A.183.a.44.i; A.184.a.44.i;A.469.E114; A.470.E1U; A.47LF.114; A.472.F.11.Í; A.473.F.11.Í; A.474.F.11.Í; A.475.E114; A.476.E11.Í; A.477.F.11.Í; A.478.F.11.Í; A.479.E11.Í; A.480.F.11.Í; A.481.F.11.Í; A.482.E11.Í; A.483.E114; A.484.E114; A.485.E114; Α.486Ε.Π4; A.487.E11.Í; A.488.E11.Í; A.489.F.11.Í; A.490E.114; A.49LF.114; A.492.E114; A.493.F.11.Í; A.494.E114; A.495.E114; A.496E.114; A.497.E114; A.498.E114; A.499.E114; A.500.E11.Í; A.501.E114; A.502.E114; A.503E.114; A.504E.114; A.505E.11.Í; A.506E.11.1; A.507.E114; A.508.F.114; A.509.E114; A.510.E114; A.511.E114; A.512.E114; A.512.F.11.Í; A.513.E11.Í; A.514.E114; A.515E114; A.516E.114; A.517.E114; A.518.EI14; A.519.E114; A.520.E114; A.521.E11.Í; A.522.E114; A.523.E114; Α.524.Ε11.Ϊ; A.525.E114; A.526E.114; A2527E114; A.528.E11.Í; A.529.F.11.Í; A.530.F.U.I; A.531.E114; A.532.E114; A.533E.114; A.534.F.114; A.535.E114; A.536.E114; A.537E.114; A.538.E114; A.539.EÚ4; A.540E.114; A.541.E114; A.542E114; A.543E.114; A.544.E114; Α.545.ΕΠ4; A.546.E114; Α.547.ΕΠ4; A.548.E114; A.549.E11.Í; A.550.E114; A.551E114; A.552.E114; A.553.F.114; A.554.E114; A.555.E114; A.556.E114; A.557E.114; A.558E.11.Í; A.559.E114; A.560T.114; Α.561.ΕΠ4; A.562.E114; A.563.E114; A.564.E114; A.565.E114; A.566.E11.1; A.567.E114; A.568.E114; A.569E114; A.570.E114; A.57LF.11.Í; Α.572.ΕΠ4; A.573.E114; A.574.E114; A.S75.E114; A.576.E114; A.S77.E114; Α.578Ε.11.Ϊ; A.579.E11.Í; A.580.E114; Α.581ΕΠ4; A.5S2.E11.I; A.583.E114; A.584E11.Í; A.585.E114; A.586.E114; A.587.E114; A.588E.114; A.589.E114; A.590.F.11.Í; A.59LE114; A.592E.114; A.593E.114; Α.594Ε.11.Ϊ; Α.595.ΕΠ4; A-596.F.11.I; Α.597.ΕΠ4; A.598.E114; A.599E11.1; A.ÓOOE.ll.i; A.601E.114; A.602.E114; A.603.E114; A.604.E114; A.605E114; A.606E.114; A.607.E114; A.608.E114; A.609E.114; A.610.F.114; A.611.E114; A.612.E114; A.613.E114; A.614.E114; A.615.E114; A.616.E114; Α.617ΕΠ4; A.618E.114; A.619.E114; Α.620.ΕΠ4; A.621E.11.1; A.622E.114; A.623.E114; A.624.E11J; A.625E11.1; A.626.E114; A.627E11.Í; A.628.EU4; A.629E.114; A.630.E114; A.631E.11.Í; A.632.E114; A.633.EU4; A.634.E114; A.635E.114; A.636.F.11.Í; A.637.E114; A.638.E114; A.639E.114; A.640.E114; A.641.E114; A.642E.11.Í; Α.643.ΕΠ4; A.644.E11.Í; A.645.F.1U; A.646.E114; A.647E.114; A.648E114; A.649.E114; A.650.E114; A.651.E114; A.652.E114; A.653E11.Í; A.654.F.11.Í; A.655.F.11.Í; A.656.F.1LÍ; A.657.F.11.Í; Α.658.ΕΠ4; A.659.E114; A.660.E114; A.2.a.44.i; A.3.a.44.i; A.4.a.444; A.5.a.44.i; A.9.a.44.i; A.100.a.444; A.101.a.44.i; A.102.a.44.i; A.103.a.44.i; A.104.a.44.i; A.105.a.44j; A.106.a.44.i; A.107.a.44.i; A.108.a.44.i; A.109.a.44.i; A.110.a.44.i; A.lll.a.44.i; A.U2.a.44.i; A.113.a.44.i; A.114.a.44.i; A.115.a.44.i; A.116.a.44.i; A.117.a.44.i; A.l] 8.a.444; A.119.a.44.i; A.120.a.44.i; A.121.a.444; A.122.a.44.i; A.123.a.44.i; A.124.a, 444; A.125.a.444; A.126.a.44.i; A-127.a.444. A.128.a.444; A.129.a.44.i; A.130.a.44.i; A.131.a.444; A.132.a, 44.i; A.133.a.44.i; A. 134.a.444; A.135.a.444; A.136.a.44.i; A.137.a.44.i; A.138.a.44.i; A.139.a.444; A.140.a.44.i; A.141.a.44.i; A.142.a.44.i; A.143.a.44.i; A.144.a.44.i; A.145.a.44.i; A.146.a.44.i; A.147.a.444; A.148.a.44.i; A.149.a.44.i; A.150.a.44.i; A.151.a.44.í; A.152.a.44.i; A.153.a.44.i; A.154.a.44.i; A.155.a.444; A.156.a.44.i; A.157.a.44.i; A.158.a.44.i; A.159.a.44.i; A.160.a.44.i; A.161.a.44.i; A.162.a.44.i; A.163.a.44.i; A.164.a.44.i; A.165.a.44.i; A.166.a.44.i; A.167.a.44.i; A.168.a.44.i; A.169.a.44.i; A.170.a.44.i; A.171.a.44.i; A.172.a.44.i; A. 173.a.44. and; A.174.a.44.i; A.175.a.44.i; A.I76.a.44.i; A.177.a.44.i; A.178.a.444; A.179.a.44.i; A.180.a.44.i; A.181.a.44.i; A.182.a.44.i; A.183.a.44.i; A.184.a.44.i;
-134CZ 297945 B6-134GB 297945 B6
A.185.a.44.i; A.186.a.44,i; A.187.a.44.i; A.188.a.44.i; A.189.a.44.i; A.190.a.44.i; A.191.a.44.í; A.192.a.44,i; A.193.a.44.í; A.194.a.44.i; A.195.a.44.i; A.196.a.44.i; A.197.a.44.i; A.198.a.44.i; A.199.a.44.i; A.200.a.44.i; A.201.a.44.i; A.202.a.44.i; A.203.a.44.i; A.204.a.44.i; A.205.a.44.i; A.206.a.44.i; A.207.a.44.i; A.208.a.44.i; A.209.a.44.i; A.210.a.44.i; A.211.a.44.i; A.212.a.44.i; A.213.a.44.i; A214.a.44.i; A.215.a.44.i; A.216.a.44.i; A.217.a.44.i; A.218.a.44.i; A219.a.44.i; A220.a.44.i; A.221.a.44.i; A.222.a.44.i; A.223.a.44.i; A.224.a.44.i; A.225.a.44.i; A.226.a.44.x; A227.a.44.i; A.228.a.44.i; A.229.a.44.i; A.230.a.44.i; A.231.a.44.i; A.232.a.44.i; A.233.a.44.i; A.234.a.44.i; A.235.a.44.i; A.236.a.44.i; A237.a.44.i; A.238.a.44.i; A.239.a,44.i; A.240.a.44.i; A.241.a.44.i; A.242.a.44.i; A.243.a.44.i; A.244.a.44.i; A.245.a.44.i; A.246.a.44.i; A.247.a.44.i; A.248.a.44.i; A.249.a.44.i; A.250.a.44.i; A.251.a.44.i; A.252.a.44.i; A.253.a.44.i; A.254.a.44.i; A.255.a.44.i; A.256.a.44.i; A.257.a.44.i; A.258.a.44.i; A.259.a.44.i; A.260.a.44.i; A.261.a.44.i; A.262.a.44.i; A.263. a. 44. i; A.264.a.44.i; A.265.a.44.i; A.266.a.44.i; A.267.a.44.i; A.268.a.44.x; A.269.a.44.i; A.270.a.44.i; A.271.a.44.i; A.272.a.44.i; A.273.a.44.i; A.274.a.44.i; A.275.a.44.i; A.276.a.44.i; A.277.a.44.i; A278.a.44.i; A.279.a.44.i; A.280.a.44.í; A.281.a.44.i; A.282.a.44.i; A.283.a.44.i; A.284.a.44.i; A.285.a.44.i; A.286.a.44.i; A.287.a.44.i; A.288.a.44.i; A.289.a.44.i; A.290.a.44.i; A.291.a.44.i; A.292.a.44.i; A.293.a.44.i; A.294.a.44.i; A.295.a.44.i; A.296.a.44.i; A.297.a.44.i; A.298.a.44.i; A.299.a.44.i; A.300.a.44.i; A.301.a.44.i; A.302.a.44.i; A.303.a.44.i; A.304.a.44.i; A.305.a.44.i; A.306.a.44.i; A.307.a.44.i; A.308.a.44.i; A.309.a.44.i; A.310.a.44.i; A,311.a.44.i; A.312.a.44.i; A.313.a.44.i; A.314.a.44.i; A.315.a.44.i; A.316.a.44.i; A.317.a.44.i; A.318.a.44.i; A.319.a.44.i; A.320.a.44.i; A.321.a.44.i; A322.a.44.i; A.323.a.44.i; A.324.a.44.i; A.325.a.44.i; A.326.a.44.i; A.327.a.44.i; A.328.a.44.i; A.329.a.44.i; A.330.a.44.i; A.331.a.44.i; A.332.a.44.i; A.333.a.44.i; A.334.a.44.i; A.335.a.44.i; A.336.a.44.i; A.337.a.44.í; A.338.a.44.i; A.339.a.44.i; A.340.a.44.i; A.341.a.44.i; A.342.a.44.i; A.343.a.44.i; A.344.a.44.i; A.345.a.44.i; A.346.a.44.i; A.347.a.44.i; A.348.a.44.i; A.349.a.44.i; A.350.a.44.i; A.351.a.44.i; A.352.a.44.i;A.185.a.44.i; A.186.a.44, i; A.187.a.44.i; A.188.a.44.i; A.189.a.44.i; A.190.a.44.i; A.191.a.44.í; A.192.a.44, i; A.193.a.44.í; A.194.a.44.i; A.195.a.44.i; A.196.a.44.i; A.197.a.44.i; A.198.a.44.i; A.199.a.44.i; A.200.a.44.i; A.201.a.44.i; A.202.a.44.i; A.203.a.44.i; A.204.a.44.i; A.205.a.44.i; A.206.a.44.i; A.207.a.44.i; A.208.a.44.i; A.209.a.44.i; A.210.a.44.i; A.211.a.44.i; A.212.a.44.i; A.213.a.44.i; A214.a.44.i; A.215.a.44.i; A.216.a.44.i; A.217.a.44.i; A.218.a.44.i; A219.a.44.i; A220.a.44.i; A.221.a.44.i; A.222.a.44.i; A.223.a.44.i; A.224.a.44.i; A.225.a.44.i; A.226.a.44.x; A227.a.44.i; A.228.a.44.i; A.229.a.44.i; A.230.a.44.i; A.231.a.44.i; A.232.a.44.i; A.233.a.44.i; A.234.a.44.i; A.235.a.44.i; A.236.a.44.i; A237.a.44.i; A.238.a.44.i; A.239.a, 44.i; A.240.a.44.i; A.241.a.44.i; A.242.a.44.i; A.243.a.44.i; A.244.a.44.i; A.245.a.44.i; A.246.a.44.i; A.247.a.44.i; A.248.a.44.i; A.249.a.44.i; A.250.a.44.i; A.251.a.44.i; A.252.a.44.i; A.253.a.44.i; A.254.a.44.i; A.255.a.44.i; A.256.a.44.i; A.257.a.44.i; A.258.a.44.i; A.259.a.44.i; A.260.a.44.i; A.261.a.44.i; A.262.a.44.i; A.263. a. 44. i; A.264.a.44.i; A.265.a.44.i; A.266.a.44.i; A.267.a.44.i; A.268.a.44.x; A.269.a.44.i; A.270.a.44.i; A.271.a.44.i; A.272.a.44.i; A.273.a.44.i; A.274.a.44.i; A.275.a.44.i; A.276.a.44.i; A.277.a.44.i; A278.a.44.i; A.279.a.44.i; A.280.a.44.í; A.281.a.44.i; A.282.a.44.i; A.283.a.44.i; A.284.a.44.i; A.285.a.44.i; A.286.a.44.i; A.287.a.44.i; A.288.a.44.i; A.289.a.44.i; A.290.a.44.i; A.291.a.44.i; A.292.a.44.i; A.293.a.44.i; A.294.a.44.i; A.295.a.44.i; A.296.a.44.i; A.297.a.44.i; A.298.a.44.i; A.299.a.44.i; A.300.a.44.i; A.301.a.44.i; A.302.a.44.i; A.303.a.44.i; A.304.a.44.i; A.305.a.44.i; A.306.a.44.i; A.307.a.44.i; A.308.a.44.i; A.309.a.44.i; A.310.a.44.i; A, 311.a.44.i; A.312.a.44.i; A.313.a.44.i; A.314.a.44.i; A.315.a.44.i; A.316.a.44.i; A.317.a.44.i; A.318.a.44.i; A.319.a.44.i; A.320.a.44.i; A.321.a.44.i; A322.a.44.i; A.323.a.44.i; A.324.a.44.i; A.325.a.44.i; A.326.a.44.i; A.327.a.44.i; A.328.a.44.i; A.329.a.44.i; A.330.a.44.i; A.331.a.44.i; A.332.a.44.i; A.333.a.44.i; A.334.a.44.i; A.335.a.44.i; A.336.a.44.i; A.337.a.44.í; A.338.a.44.i; A.339.a.44.i; A.340.a.44.i; A.341.a.44.i; A.342.a.44.i; A.343.a.44.i; A.344.a.44.i; A.345.a.44.i; A.346.a.44.i; A.347.a.44.i; A.348.a.44.i; A.349.a.44.i; A.350.a.44.i; A.351.a.44.i; A.352.a.44.i;
A. 353.a.44.i; A.354.a.44.i; A.355.a.44.i; A.356,a.44.Í; A.357.a.44.i; A.358.a.44.i;A. 353.a.44.i; A.354.a.44.i; A.355.a.44.i; A.356, a.44.I; A.357.a.44.i; A.358.a.44.i;
B. 2.a.44.i; B.3.a.44.i; B.4.a.44.i; B.5.a.44.i; B.9.a.44.i; B.100.a.44.i; B.101.a.44.i; B.102.a.44.i; B.103.a.44.i; B.104.a.44.i: B.105.a.44.i; B.106.a.44.i; B.107.a.44.i; B.108.a.44,i; B.109.a.44.i; B.110.a.44.i; B.lll.a.44.i; B.112.a.44.i; B.113.a.44.i; B.114.a.44.i; B.115.a.44.i; B.116.a.44.i; B.117.a.44.i; B.118.a.44.i; B.119.a.44.i; B.120.a.44.i; B.121.a.44.i; B.122.a.44.i; B.123.a.44.i; B.124.a.44.i; B.125.a.44.i; B.126.a.44.i; B.127.a.44.i; B.128.a.44.i; B.129.a.44.i; B.130.a.44.i; B.131.a.44.i; B.132.a.44.i; B.133.a.44.i; B.134.a.44.i; B.135.a.44.i; B.136.a.44.x; B.137.a.44.i; B.138.a.44.i; B.139.a.44.i; B.140.a.44.i; B.141.a.44.i; B.142.a.44.i; B.143.a.44.i; B.144.a.44.i; B.145.a.44.i; B.146.a.44.i; B.147.a.44.i; B.148.a.44.i; B.149.a.44.i; B.150-a.44.i; B.151.a.44.i; B.152.a.44.i; B.153.a.44.i; B.154.a.44.i; B.155.a.44.i; B.156.a.44.i; B.157.a.44.i; B.158.a.44.i; B.159.a.44.i; B.160.a.44.i: B.161.a.44.i; B.162.a.44.i; B.163.a.44.i; B.164.a.44.i; B.165.a.44.i; B.166.a,44.í; B.167.a.44.i; B.168.a.444; B.169.a.44.i; B.170.a.44.i; B.171.a.44.i; B.172.a.44.i; B.173.a.44.i; B.Í74.a.44.i; B.175.a.44.i; B.176.a.44.i; B.177.a.44.i; B.178.a.44.i; B.179.a.44.i; B.180.a.44.i; B.181.a.44.i; B.182.a.44.i; B.183.a.44.i; B.184.a.44.i; B.185.a.44.i; B.186.a.44.i; B.187.a.44.x; B.188.a.44.i; B.189.a.44.i; B.190.a.44.i; B.191.a.44.i; B.192.a.44.i; B,193.a.44.i; B.194.a.44.i; B-195.a.44.x; B.196.a.44.i; B.197.a.44.i; B.198.a.44.i; B.199.a.44.i; B.200.a.44.i; B.201.a.44.i; B.202.a.44.x; B.203.a.44.i;B. 2.a.44.i; B.3.a.44.i; B.4.a.44.i; B.5.a.44.i; B.9.a.44.i; B.100.a.44.i; B.101.a.44.i; B.102.a.44.i; B.103.a.44.i; B.104.a.44.i: B.105.a.44.i; B.106.a.44.i; B.107.a.44.i; B.108.a.44, i; B.109.a.44.i; B.110.a.44.i; B.lll.a.44.i; B.112.a.44.i; B.113.a.44.i; B.114.a.44.i; B.115.a.44.i; B.116.a.44.i; B.117.a.44.i; B.118.a.44.i; B.119.a.44.i; B.120.a.44.i; B.121.a.44.i; B.122.a.44.i; B.123.a.44.i; B.124.a.44.i; B.125.a.44.i; B.126.a.44.i; B.127.a.44.i; B.128.a.44.i; B.129.a.44.i; B.130.a.44.i; B.131.a.44.i; B.132.a.44.i; B.133.a.44.i; B.134.a.44.i; B.135.a.44.i; B.136.a.44.x; B.137.a.44.i; B.138.a.44.i; B.139.a.44.i; B.140.a.44.i; B.141.a.44.i; B.142.a.44.i; B.143.a.44.i; B.144.a.44.i; B.145.a.44.i; B.146.a.44.i; B.147.a.44.i; B.148.a.44.i; B.149.a.44.i; B.150-a.44.i; B.151.a.44.i; B.152.a.44.i; B.153.a.44.i; B.154.a.44.i; B.155.a.44.i; B.156.a.44.i; B.157.a.44.i; B.158.a.44.i; B.159.a.44.i; B.160.a.44.i: B.161.a.44.i; B.162.a.44.i; B.163.a.44.i; B.164.a.44.i; B.165.a.44.i; B.166.a, 44.i; B.167.a.44.i; B.168.a.444; B.169.a.44.i; B.170.a.44.i; B.171.a.44.i; B.172.a.44.i; B.173.a.44.i; B.I74.a.44.i; B.175.a.44.i; B.176.a.44.i; B.177.a.44.i; B.178.a.44.i; B.179.a.44.i; B.180.a.44.i; B.181.a.44.i; B.182.a.44.i; B.183.a.44.i; B.184.a.44.i; B.185.a.44.i; B.186.a.44.i; B.187.a.44.x; B.188.a.44.i; B.189.a.44.i; B.190.a.44.i; B.191.a.44.i; B.192.a.44.i; B, 193.a.44.i; B.194.a.44.i; B-195.a.44.x; B.196.a.44.i; B.197.a.44.i; B.198.a.44.i; B.199.a.44.i; B.200.a.44.i; B.201.a.44.i; B.202.a.44.x; B.203.a.44.i;
-135 CZ 297945 B6-135 CZ 297945 B6
B.206.a.44.i; B.207.a.44.i; B.208.a.44.i; B.209.a.44.i;B.206.a.44.i; B.207.a.44.i; B.208.a.44.i; B.209.a.44.i;
B.212.a.44.i; B.213.a.44.i; B.214.a.44.i; B.215.a.44.i;B.212.a.44.i; B.213.a.44.i; B.214.a.44.i; B.215.a.44.i;
B.218.a.44.i; B.219.a.44.i; B.220.a.44.i; B.221.a.44,i;B.218.a.44.i; B.219.a.44.i; B.220.a.44.i; B.221.a.44, i;
B.224.a.44.i; B.225.a.44.i; B.226.a.44.i; B.227.a.44.i;B.224.a.44.i; B.225.a.44.i; B.226.a.44.i; B.227.a.44.i;
B.230.a,44.i; B.231.a.44.i; B.232.a.44.i; B.233.a.44.i;B.230.a, 44.i; B.231.a.44.i; B.232.a.44.i; B.233.a.44.i;
B.236.a.44.i; B.237.a.44.i; B.238.a.44.i; B.239.a.44.i;B.236.a.44.i; B.237.a.44.i; B.238.a.44.i; B.239.a.44.i;
B.204.a.44.i; B.205.a.44.iB.204.a.44.i; B.205.a.44.i
B.210.a.44.i; B.211.a.44.i;B.210.a.44.i; B.211.a.44.i;
B.216.a.44.i; B.217.a.44.i;B.216.a.44.i; B.217.a.44.i;
B.222,a.44.i; B^23.a.44.i;B.222, a.44.i; B ^ 23.a.44.i;
B228.a.44.i; B.229.a.44ÁB228.a.44.i; B.229.a.44A
B234.a.44.i; B235.a.44.i;B234.a.44.i; B235.a.44.i;
B.240.a.44.i; B.241.a.44.i; B.242.a.44.i; B.243.a.44.i; B.244.a.44.i; B245.a.44.i;B.240.a.44.i; B.241.a.44.i; B.242.a.44.i; B.243.a.44.i; B.244.a.44.i; B245.a.44.i;
B246.a.44.i; B.247.a.44.í;B246.a.44.i; B.247.a.44.í;
B-252.a.44.i; B.253.a.44.i,B-252.a.44.i; B.253.a.44.i,
B.258.a.44.i; B.259.a.44.i;B.258.a.44.i; B.259.a.44.i;
B264.a.44.i; B.265.a.44.i;B264.a.44.i; B.265.a.44.i;
B.270.a.44.i; B.271.a.44.i;B.270.a.44.i; B.271.a.44.i;
B.276.a.44,i; B277.a.44.iB.276.a.44, i; B277.a.44.i
B.282.a.44.i; B.283.a.44.i;B.282.a.44.i; B.283.a.44.i;
B2288.a.44.i; B.289.a.44.i;B2288.a.44.i; B.289.a.44.i;
B.294.a.44.i; B.295.a.44.i;B.294.a.44.i; B.295.a.44.i;
B.300.a.44.i; B.301.a.44.iB.300.a.44.i; B.301.a.44.i
B.306.a.44.i; B.307.a.44.iB.306.a.44.i; B.307.a.44.i
B.312.a.44.i; B.313.a.44.iB.312.a.44.i; B.313.a.44.i
B.318.a.44.i; B.319,a.44.i,B.318.a.44.i; B.319, a.44.i,
B.324.a.44.i; B.325.a.44.i;B.324.a.44.i; B.325.a.44.i;
B.330.a.44.i; B.331.a.44.i;B.330.a.44.i; B.331.a.44.i;
B.336.a.44.i; B.337.a.44.i,B.336.a.44.i; B.337.a.44.i,
B.342.a.44.i; B343.a.44.iB.342.a.44.i; B343.a.44.i
B.34S.a.44.i; B.349X44'4,B.34S.a.44.i; B.349X44'4,
B.354.a.44.i; B.355.a.44.i;B.354.a.44.i; B.355.a.44.i;
E.4.a.44.i; E.5.a.44.i; E.9.E.4.a.44.i; E.5.a.44.i; E.9.
E.104.a.44.i; E.105.a.444E.104.a.44.i; E.105.a.444
E.110.a.444; E.lll.a.444E.110.a.444; E.lll.a.444
E.116.a.444; E.117.a.44.iE.116.a.444; E.117.a.44.i
E.122.a.444; E.123.a.44.iE.122.a.444; E.123.a.44.i
E.128.a.444; E.129.a.44.iE.128.a.444; E.129.a.44.i
E.134.a.44.i; E.135.a.44.iE.134.a.44.i; E.135.a.44.i
E.140.a,444; E.141.a.44.iE.140.a, 444; E.141.a.44.i
E.146.a.44.i; E.147.a,444E.146.a.44.i; E.147.a, 444
E.152.a.44.i; E.153.a.444E.152.a.44.i; E.153.a.444
E.158.a.444; E.159.a.44.iE.158.a.444; E.159.a.44.i
E.164.a.444; £.165x444E.164.a.444; £ .165x444
E.170.a,44.i; E.171.a.44.iE.170.a, 44.i; E.171.a.44.i
E.176.a.444; E.177.a.444E.176.a.444; E.177.a.444
E.182.a.44’4; E.183.a.444E.182.a.44’4; E.183.a.444
E.188.a.44.i; E.189.a.444E.188.a.44.i; E.189.a.444
E.194.a.44.i; E.195.a;444E.194.a.44.i; E.195.a; 444
E.200.a.444; E.201.a.44.iE.200.a.444; E.201.a.44.i
E.206.a.44.i; E.207.a.444E.206.a.44.i; E.207.a.444
E.212.a.44.i; E.213.a.444E.212.a.44.i; E.213.a.444
E.218.a.44.i; E.219X444E.218.a.44.i; E.219X444
B.248.a.44.i; B.249.a.44.i; B.250.a.44.i; B.251.a.44.i; B.254.a.44.i; B.255.a.44.i; B.256.a.44.i; B.257.a.44.i; B.260.a.44.i; B.261.a.44.i; B.262.a.44.i; B.263.a.44.i; B.266.a.44.i; B.267.a.44.i; B.268.a.44.i; B.269.a.44.i; B.272.a.44.i; B.273.a.44.i; B.274.a.44.i; B.275.a.44.i; B.278.a.44.i; B.279.a.44.i; B.280.a.44.i; B.281.a.44.i; B.284.a.44.i; B.285.a.44.i; B.286.a.44.i; B.287.a.44.i; B.290.a.44.i; B.291.a.44.i; B.292.a.44.i; B.293.a.44.i; B.296.a.44,i; B.297.a.44.i; B.298.a.44.i; B.299.a,44.i; B.302.a.44.i; B.3G3.a.44.i; B.304.a.44.i; B.305.a.44.i; B.308.a.44.i; B.309.a.44.i; B.310.a.44.i; B.311.a.44.i; B.314.a.44.i; B.315.a.44.i; B.316.a.44.i; B.317.a.44.i; B.320.a.44.i; B.32La.44.i; B.322.a.44.i; B.323.a.44.i; B.326.a.44.i; B.327.a.44.i; B.328.a.44.i; B.329.a.44.i; B.332.a.44.i; B.333.a.44.i; B.334.a.44.Í; B.335.a.44.i; B.338.a.44.i; B.339.a.44.i; B.340.a.44.i; B.34La.44.i; B.344.a.44.i; B.345.a.44.i; B.346.a.44.i; B347.a.44.i; B.350.a.44.i; B.351.a.44.i; B.352.a.44.i; B.353.a.44.i; B.356.a.44.í; B.357.a.44.i; B.358.a.44.i; E.2.a.44.i; E.3.a.44.i; a.44.i; E.100.a.44.i; E.101.a.44.i; E.102.a.44.i; E.103.a.44.i;B.248.a.44.i; B.249.a.44.i; B.250.a.44.i; B.251.a.44.i; B.254.a.44.i; B.255.a.44.i; B.256.a.44.i; B.257.a.44.i; B.260.a.44.i; B.261.a.44.i; B.262.a.44.i; B.263.a.44.i; B.266.a.44.i; B.267.a.44.i; B.268.a.44.i; B.269.a.44.i; B.272.a.44.i; B.273.a.44.i; B.274.a.44.i; B.275.a.44.i; B.278.a.44.i; B.279.a.44.i; B.280.a.44.i; B.281.a.44.i; B.284.a.44.i; B.285.a.44.i; B.286.a.44.i; B.287.a.44.i; B.290.a.44.i; B.291.a.44.i; B.292.a.44.i; B.293.a.44.i; B.296.a.44, i; B.297.a.44.i; B.298.a.44.i; B.299.a, 44.i; B.302.a.44.i; B.3G3.a.44.i; B.304.a.44.i; B.305.a.44.i; B.308.a.44.i; B.309.a.44.i; B.310.a.44.i; B.311.a.44.i; B.314.a.44.i; B.315.a.44.i; B.316.a.44.i; B.317.a.44.i; B.320.a.44.i; B.32La.44.i; B.322.a.44.i; B.323.a.44.i; B.326.a.44.i; B.327.a.44.i; B.328.a.44.i; B.329.a.44.i; B.332.a.44.i; B.333.a.44.i; B.334.a.44.Í; B.335.a.44.i; B.338.a.44.i; B.339.a.44.i; B.340.a.44.i; B.34La.44.i; B.344.a.44.i; B.345.a.44.i; B.346.a.44.i; B347.a.44.i; B.350.a.44.i; B.351.a.44.i; B.352.a.44.i; B.353.a.44.i; B.356.a.44.í; B.357.a.44.i; B.358.a.44.i; E.2.a.44.i; E.3.a.44.i; a.44.i; E.100.a.44.i; E.101.a.44.i; E.102.a.44.i; E.103.a.44.i;
E.106.a.44.i; E.107.a.44.i; E.108.a.44.i; E.109.a.44.i; E.112.a.44.i; E.113.a.44.i; E.114,a.44.i; E.115.a.44.i;E.106.a.44.i; E.107.a.44.i; E.108.a.44.i; E.109.a.44.i; E.112.a.44.i; E.113.a.44.i; E.114, a.44.i; E.115.a.44.i;
, E.118.a.44.i; E.119.a.44.i; E.120.a.44.i; E.121.a.44.i; E.124.a.44.i; E.125.a.44.i; E.126.a.44.i; E.127.a.44.i; E.130.a.44.i; E.131.a.44.i; E.132.a.44.i; E.133.a.44.i; E.136,a/4.i; E.137.a.44.i; E.138.a.44.i; E.139.a.44.i; E.142.a.44.i; E.143.a.44.i; E.144.a.44.i; E.145.a.44.i; E.148.a.44.i; E.149.a.44.i; E.150.a.44.i; E.151.a.44.i; E.154X44.Í; E.155.a.44.i; E.156.a.44.i; E.157.a.44.i; E.160.a.44.i; E.161.a.44.i; E.162.a.44.i; E.163.a.44.i; E.166.a.44.i; E.167.a.44.i; E.168.a.44.i; E.169.a.44.i; ír E.172.a.44.i; E.173.a.44.i; E.174.a.44.i; E.175.a.44.i; i; E.178.a.44.i; E.179.a.44.i; E180.a.44.i; E.181.a.44.i; E.184.a.44.i; E.185.a.44.i; E.186.a.44.i; E.187.a.44.i; E.190.a.44.i; E,191.a.44.i; E.192.a.44.i; E.193.a.44.i;, E.118.a.44.i; E.119.a.44.i; E.120.a.44.i; E.121.a.44.i; E.124.a.44.i; E.125.a.44.i; E.126.a.44.i; E.127.a.44.i; E.130.a.44.i; E.131.a.44.i; E.132.a.44.i; E.133.a.44.i; E.136, a / 4.i; E.137.a.44.i; E.138.a.44.i; E.139.a.44.i; E.142.a.44.i; E.143.a.44.i; E.144.a.44.i; E.145.a.44.i; E.148.a.44.i; E.149.a.44.i; E.150.a.44.i; E.151.a.44.i; E.154X44.Í; E.155.a.44.i; E.156.a.44.i; E.157.a.44.i; E.160.a.44.i; E.161.a.44.i; E.162.a.44.i; E.163.a.44.i; E.166.a.44.i; E.167.a.44.i; E.168.a.44.i; E.169.a.44.i; ir E.172.a.44.i; E.173.a.44.i; E.174.a.44.i; E.175.a.44.i; and; E.178.a.44.i; E.179.a.44.i; E180.a.44.i; E.181.a.44.i; E.184.a.44.i; E.185.a.44.i; E.186.a.44.i; E.187.a.44.i; E.190.a.44.i; E, 191.a.44.i; E.192.a.44.i; E.193.a.44.i;
; E.196.a 44-i; E.197.a.44.i; E.198.a.44.i; E.199,a.44.i;; E.196.a 44-i; E.197.a.44.i; E.198.a.44.i; E.199, a.44.i;
• E.202.a.44.i; E.203.a.44.i; E.204.a.44.i; E.205.a.44.i; E.208.a.44.i; E.209.a.44.i; E.210.a.44.i; E.211.a.44.i; E.214.a.44.i; E.215.a.44.i; E.216.a.44.i; E.217.a.44.i; E.220.a.44ď; E.221.a.44.i; E.222.a.44.i; E.223.a.44.i;• E.202.a.44.i; E.203.a.44.i; E.204.a.44.i; E.205.a.44.i; E.208.a.44.i; E.209.a.44.i; E.210.a.44.i; E.211.a.44.i; E.214.a.44.i; E.215.a.44.i; E.216.a.44.i; E.217.a.44.i; E.220.a.44ď; E.221.a.44.i; E.222.a.44.i; E.223.a.44.i;
-136CZ 297945 B6-136GB 297945 B6
E.224.a.44d; E.225.a.44.i; E.226.a.44.i; E227.a.44.i; E.228.a.44.i; E229.a.44.i; E230.a.44.i; E231.a.44.i; E.232.a.44.i; E233.a.44.i; E.234.a.44.i; E.235.a.44.i; E236.a.44.i; E.237.a.44.i; E.238.a.44.i; E.239.a.44.i; E.240.a.44.i; E241.a.44.i; E.242.a.44.i; E.243.a.44.i; E.244.a.44.i; E.245.a.44.i; E.246.a.44.i; E.247.a.44.i; E248.a.44.i; E.249.a.44.i; E.250.a.44.i; E251.a.44.í; E.252.a.44.i; EZ53.a.44.i; E.254.a.44.i; E255.a.44.i; E.256.a.44.i; E257.a.44.i; E.258.a.44.i; E259.a.44.i; E.260.a.44.i’; E261.a.44.i; E.262.a.44.i; E.263.a.44.x; E.264.a.44.i; E365.a.44.i; E.266.a.44.i; E.267.a.44.i; E.268.a.44.i; E269.a.44.i; E.270.a.44.i; E371.a.44.i; E372.a.44.x; E.273.a.44.x; E.274.a.44.i; E275.a.44.i; E.276.a.44.i; E277.a.44.i; E.278.a.44.i; E.279.a.44.x; E.280.a.44.i; E.28La.44.x; E.282.a.44.i; E283.a.44.i; E.284.a.44.i; E.285.a.44.i; E.286.a.44.i; E.287.a.44.i; E.288.a.44.i; E.289.a.44.i; E.290.a.44.i; E.291.a.44.i; E.292.a.44.i; E.293.a.44.i; E.294.a.44.i; E.295.a.44.i; E.296.a.44.i; E.297.a.44.i; E.298.a.44.i; E.299.a.44.x; E.300.a.44.i; E301.a.44.i; E.302.a.44.i; E.303.a.44.í; E.304.a44.i; E305.a.44.i; E.306.a.44.i; E.307.a.44.Í; E308.a.44.i; E.309.a.44.i; E.310,a.44.i; E.311.a.44.i; E.312.a.44.x; E313.a.44.i; E.314.a.44.i; E.315.a.44.i; E.316.a.44.i; E.317.a.44.i; E318.a.44.i; E319.a.44.i; E.320.a.44.i; E.321.a.44.i; E322.a.44.i; E323.a.44.i; E.324.a.44.i; E325.a.44.i; E326.a.44.i; E.327.a.44.i; E328.a.44.i; E.329.a.44.i; E.330.a.44.i; E.331.a.44.i; E332.a.44.i; E.333.a.44.i; E.334.a.44.x; E.335.a.44.i; E.336.a.44.i; E.337.a.44.i; E.338.a.44.i; E339.a.44.i; E.340.a.44.i; E.341.a.44.i; E.342.a.44.i; E.343.a.44.i; E.344.a.44.i; E.345.a.44.i; E.346.a.44.i; E.347.a.44.i; E.348.a.44.i; E349.a.44.i; E350.a.44,i; E351.a.44.i; E352.a.44.i; E353.a.44.i; E354.a.44.i; E355.a.44.i; E356.a.44.i; E357.a.44.i; E358.a.44.i; B.2.a.4.i; B3.a.4.i; B.4.a.4.i; B.5.a.4.i; B.9.a.4.i; B.100.a.4.i; B.101.a.4.i; B.102.a.4.i; B.103.a.4.i; B.104.a.4.i; B.105.a.4.i; B.106.a.4.i; B.107.a.4.i; B.108.a.4.i; B.109.a.4.i; B.110.a.4.i; B.lll.a.4.i; B.112.a.4.i; B.113.a.4.i; B.114.a.4.i; B.115.a.4.i; B.116.a.4.i; B.U7.a.4.i; B.118.a.4.i; B.119.a.4.í; B. 12O.a.4.i; B.121.a.4.i; B.122.a.4.i; B.123.a.4.i; B.124.a.4.i; B.125.a.4.i; B.126.a.4.i; B.127.a.4.i; B.128.a.4.i; B.129.a.4.i; B.130.a.4.i; B.131.a.4.i; B.132.a.4.i; B.133.a.4.i; B.134.a.4.i; B.135.a.4.x; B.136.a.4.i; B.137.a.4.i; B.138.a.4.i; B.139.a.4.i; B.140.a.4.i; B.141.a.4.i; B.142.a.4.i; B.143.a.4.i; B.144.a.4.x; B.145.a.4.i; B.146.a.4.i; B.147.a.4.i; B.148.a.4.i; B.149.a.4.i; B.150.a.4.í; B.151.a.4.i; B.152.a.4.i; B.153.a.4.x; B.154.a.4.i; B.155.a.4.i; B.156.a.4.i; B.157.a.4.i; B.158.a.4.i; B.159.a.4.i; B.160.a.4.i; B.161.a.4.i; B.162.a.4.i; B.163.a.4.i; B.164.a.4.i; B.165.a.4.i; B.166.a.4.i; B.167.a.4.i; B.168.a.4.i; B.169.a.4.i; B.170.a.4.i; B.171.a.4.i; B.172.a.4.i; B.173.a.4.i; B.174.a.4.i; B.175.a.4.i; B.176.a.4.i; B.177.a.4.x; B.178.a.4.i; B.179.a.4.i; B.180.a.4j; B.181.a.4.i; B.182.a.4.i; B.183.a.4.x; B.184.a.4.i; B.185.a.4.i; B.186.a.4.i; B.187.a.4.i; B.188.a.4.í; B.189.a.4.i; B.190.a.4.i; B.191.a.4.i; B.192.a.4.i; B.193.a.4.i; B.194.a.4.i; B495.a.4.i; B.196.a.4.i; B.197.a.4.i; B.198.a.4.i; B.199.a.4.i; B.200.a.4.i; B.201.a.4.i; B.202.a.4.i; B203.a.4.i; B.204.a.4.i; B.205.a.4.i; B.206.a.4.i; B.207.a.4.i; B.208.a.4.i; B.209.a.4.i; B.210.a.4.i; B.2U.a.4.i; B.212.a.4.i; B.213.a.4.i; B.214.a.4.i; B.215.a.4.i; B.216.a.4.i; B.217.a.4.i; B.218.a.4.i; B.219.a.4.i;· B.220.a.4.i; B.22La.4.i; B.222.a.4.i; B.223.a.4.i; B224.a.4.i; B.225.a.4.i; B.226.a.4.í; B.227.a.4.i; B.228.a.4.i; B.229.a.4.i; B,230.a.4.i; B.231.a.4.i; B.232.a.4.i; B.233.a.4.i; B.234.a.4.i; B.235.a.4.i; B.236.a.4.i; B.237.a.4.i; B.238.a.4.i; B.239.a.4.i; B.240.a.4.i; B.241.a.4.i; B.242.a.4.i; B.243.a.4.i; B.244.a.4.i; B.245.a.4.i; B.246.a.4.i;E.224.a.44d; E.225.a.44.i; E.226.a.44.i; E227.a.44.i; E.228.a.44.i; E229.a.44.i; E230.a.44.i; E231.a.44.i; E.232.a.44.i; E233.a.44.i; E.234.a.44.i; E.235.a.44.i; E236.a.44.i; E.237.a.44.i; E.238.a.44.i; E.239.a.44.i; E.240.a.44.i; E241.a.44.i; E.242.a.44.i; E.243.a.44.i; E.244.a.44.i; E.245.a.44.i; E.246.a.44.i; E.247.a.44.i; E248.a.44.i; E.249.a.44.i; E.250.a.44.i; E251.a.44.í; E.252.a.44.i; EZ53.a.44.i; E.254.a.44.i; E255.a.44.i; E.256.a.44.i; E257.a.44.i; E.258.a.44.i; E259.a.44.i; E.260.a.44.i ’; E261.a.44.i; E.262.a.44.i; E.263.a.44.x; E.264.a.44.i; E365.a.44.i; E.266.a.44.i; E.267.a.44.i; E.268.a.44.i; E269.a.44.i; E.270.a.44.i; E371.a.44.i; E372.a.44.x; E.273.a.44.x; E.274.a.44.i; E275.a.44.i; E.276.a.44.i; E277.a.44.i; E.278.a.44.i; E.279.a.44.x; E.280.a.44.i; E.28La.44.x; E.282.a.44.i; E283.a.44.i; E.284.a.44.i; E.285.a.44.i; E.286.a.44.i; E.287.a.44.i; E.288.a.44.i; E.289.a.44.i; E.290.a.44.i; E.291.a.44.i; E.292.a.44.i; E.293.a.44.i; E.294.a.44.i; E.295.a.44.i; E.296.a.44.i; E.297.a.44.i; E.298.a.44.i; E.299.a.44.x; E.300.a.44.i; E301.a.44.i; E.302.a.44.i; E.303.a.44.í; E.304.a44.i; E305.a.44.i; E.306.a.44.i; E.307.a.44.Í; E308.a.44.i; E.309.a.44.i; E.310, a.44.i; E.311.a.44.i; E.312.a.44.x; E313.a.44.i; E.314.a.44.i; E.315.a.44.i; E.316.a.44.i; E.317.a.44.i; E318.a.44.i; E319.a.44.i; E.320.a.44.i; E.321.a.44.i; E322.a.44.i; E323.a.44.i; E.324.a.44.i; E325.a.44.i; E326.a.44.i; E.327.a.44.i; E328.a.44.i; E.329.a.44.i; E.330.a.44.i; E.331.a.44.i; E332.a.44.i; E.333.a.44.i; E.334.a.44.x; E.335.a.44.i; E.336.a.44.i; E.337.a.44.i; E.338.a.44.i; E339.a.44.i; E.340.a.44.i; E.341.a.44.i; E.342.a.44.i; E.343.a.44.i; E.344.a.44.i; E.345.a.44.i; E.346.a.44.i; E.347.a.44.i; E.348.a.44.i; E349.a.44.i; E350.a.44, i; E351.a.44.i; E352.a.44.i; E353.a.44.i; E354.a.44.i; E355.a.44.i; E356.a.44.i; E357.a.44.i; E358.a.44.i; B.2.a.4.i; B3.a.4.i; B.4.a.4.i; B.5.a.4.i; B.9.a.4.i; B.100.a.4.i; B.101.a.4.i; B.102.a.4.i; B.103.a.4.i; B.104.a.4.i; B.105.a.4.i; B.106.a.4.i; B.107.a.4.i; B.108.a.4.i; B.109.a.4.i; B.110.a.4.i; B.lll.a.4.i; B.112.a.4.i; B.113.a.4.i; B.114.a.4.i; B.115.a.4.i; B.116.a.4.i; B.U7.a.4.i; B.118.a.4.i; B.119.a.4.í; B. 12O.a.4.i; B.121.a.4.i; B.122.a.4.i; B.123.a.4.i; B.124.a.4.i; B.125.a.4.i; B.126.a.4.i; B.127.a.4.i; B.128.a.4.i; B.129.a.4.i; B.130.a.4.i; B.131.a.4.i; B.132.a.4.i; B.133.a.4.i; B.134.a.4.i; B.135.a.4.x; B.136.a.4.i; B.137.a.4.i; B.138.a.4.i; B.139.a.4.i; B.140.a.4.i; B.141.a.4.i; B.142.a.4.i; B.143.a.4.i; B.144.a.4.x; B.145.a.4.i; B.146.a.4.i; B.147.a.4.i; B.148.a.4.i; B.149.a.4.i; B.150.a.4.í; B.151.a.4.i; B.152.a.4.i; B.153.a.4.x; B.154.a.4.i; B.155.a.4.i; B.156.a.4.i; B.157.a.4.i; B.158.a.4.i; B.159.a.4.i; B.160.a.4.i; B.161.a.4.i; B.162.a.4.i; B.163.a.4.i; B.164.a.4.i; B.165.a.4.i; B.166.a.4.i; B.167.a.4.i; B.168.a.4.i; B.169.a.4.i; B.170.a.4.i; B.171.a.4.i; B.172.a.4.i; B.173.a.4.i; B.174.a.4.i; B.175.a.4.i; B.176.a.4.i; B.177.a.4.x; B.178.a.4.i; B.179.a.4.i; B.180.a.4j; B.181.a.4.i; B.182.a.4.i; B.183.a.4.x; B.184.a.4.i; B.185.a.4.i; B.186.a.4.i; B.187.a.4.i; B.188.a.4.í; B.189.a.4.i; B.190.a.4.i; B.191.a.4.i; B.192.a.4.i; B.193.a.4.i; B.194.a.4.i; B495.a.4.i; B.196.a.4.i; B.197.a.4.i; B.198.a.4.i; B.199.a.4.i; B.200.a.4.i; B.201.a.4.i; B.202.a.4.i; B203.a.4.i; B.204.a.4.i; B.205.a.4.i; B.206.a.4.i; B.207.a.4.i; B.208.a.4.i; B.209.a.4.i; B.210.a.4.i; B.2U.a.4.i; B.212.a.4.i; B.213.a.4.i; B.214.a.4.i; B.215.a.4.i; B.216.a.4.i; B.217.a.4.i; B.218.a.4.i; B.219.a.4.i · B.220.a.4.i; B.22La.4.i; B.222.a.4.i; B.223.a.4.i; B224.a.4.i; B.225.a.4.i; B.226.a.4.í; B.227.a.4.i; B.228.a.4.i; B.229.a.4.i; B, 230.a.4.i; B.231.a.4.i; B.232.a.4.i; B.233.a.4.i; B.234.a.4.i; B.235.a.4.i; B.236.a.4.i; B.237.a.4.i; B.238.a.4.i; B.239.a.4.i; B.240.a.4.i; B.241.a.4.i; B.242.a.4.i; B.243.a.4.i; B.244.a.4.i; B.245.a.4.i; B.246.a.4.i;
B.247.a.4.i; B.248.a.4.í; B.249.a.4.i; B.250.a.4.i; B.251.a.4.i; B.252.a.4.i; B.253.a.4.i;B.247.a.4.i; B.248.a.4.í; B.249.a.4.i; B.250.a.4.i; B.251.a.4.i; B.252.a.4.i; B.253.a.4.i;
B.254.a.4.i; B.255.a.4.i; B.256.a.4.i; B.257.a.4.i; B.258.a.4.i; B.259.a.4.i; B.260.a.4.i;B.254.a.4.i; B.255.a.4.i; B.256.a.4.i; B.257.a.4.i; B.258.a.4.i; B.259.a.4.i; B.260.a.4.i;
B.261.a.4.i; B.262.a.4.i; Β.263.3.4.χ; B.264.a.4.i; B.265.a.4.i; B.266.a.4.i; B.267.a.4.i;B.261.a.4.i; B.262.a.4.i; Β.263.3.4.χ; B.264.a.4.i; B.265.a.4.i; B.266.a.4.i; B.267.a.4.i;
- 137CZ 297945 B6- 137GB 297945 B6
B.268,a.4.i; B.269.a.4.i; B.270.a.4.Í; B.271.a.4.i; B.272.a.4B.268, a.4.i; B.269.a.4.i; B.270.a.4.I; B.271.a.4.i; B.272.a.4
B.275.a.4.i; B.276.a.4.i; B.277.a.4.i; B.278.a.4.i; B.279.a.4B.275.a.4.i; B.276.a.4.i; B.277.a.4.i; B.278.a.4.i; B.279.a.4
B.282.a.4.i; B.283.a.4.i; B.284.a.4.i; B.285.a.4.i; B.286.a.4.i; B.287.a.4.i; B.288.a.4.i; B.289.a.4.i; B.290.a.4.i; B.291.a.4.i; B.292.a.4.i; B.293.a.4.i; B.294.a.4.i; B.295.a.4.i; B.296.a.4.i; B.297.a.4.i; B.298.a.4.i; B.299.a.4.i; B.300.a.4.i; B.301.a.4.i; B.302.a.4.i;B.282.a.4.i; B.283.a.4.i; B.284.a.4.i; B.285.a.4.i; B.286.a.4.i; B.287.a.4.i; B.288.a.4.i; B.289.a.4.i; B.290.a.4.i; B.291.a.4.i; B.292.a.4.i; B.293.a.4.i; B.294.a.4.i; B.295.a.4.i; B.296.a.4.i; B.297.a.4.i; B.298.a.4.i; B.299.a.4.i; B.300.a.4.i; B.301.a.4.i; B.302.a.4.i;
B.303.a.4.i; B.304.a.4.i; B.305.a.4.i; B.306.a.4.i; B.307.a.4.i; B.308.a.4.i; B.309.a.4.i; B.310.a.4.í; B.311.a.4.i; B.312.a.4.i; B.313.a.4.i; B.314.a.4.i; B.315.a.4.i; B.316.a.4.i; B.317.a.4.i; B.318.a.4.i; B.319.a.4.i; B.320.a.4.i; B.321.a.4.i; B.322.a.4.i; B.323.a.4.i; B.324.a.4.i; B.325.a.4.i; B.326.a.4.i; B.327.a.4.i; B.328.a.4.i; B.329.a.4.i; B.330.a.4.i; B.331.a.4.i; B.332.a.4.i; B.333.a.4.i; B.334.a.4.i; B.335.a.4.i; B.336.a.4.i; B.337.a.4.i; B.338.a.4.i; B.339.a.4.i; B.340.a.4.i; B.341.a.4.i; B.342.a.4.B.303.a.4.i; B.304.a.4.i; B.305.a.4.i; B.306.a.4.i; B.307.a.4.i; B.308.a.4.i; B.309.a.4.i; B.310.a.4.í; B.311.a.4.i; B.312.a.4.i; B.313.a.4.i; B.314.a.4.i; B.315.a.4.i; B.316.a.4.i; B.317.a.4.i; B.318.a.4.i; B.319.a.4.i; B.320.a.4.i; B.321.a.4.i; B.322.a.4.i; B.323.a.4.i; B.324.a.4.i; B.325.a.4.i; B.326.a.4.i; B.327.a.4.i; B.328.a.4.i; B.329.a.4.i; B.330.a.4.i; B.331.a.4.i; B.332.a.4.i; B.333.a.4.i; B.334.a.4.i; B.335.a.4.i; B.336.a.4.i; B.337.a.4.i; B.338.a.4.i; B.339.a.4.i; B.340.a.4.i; B.341.a.4.i; B.342.a.4.
B.345.a.4.i; B.346.a.4.i; B.347.a.4.i; B.348.a.4.i; B.349.a.4.i; B.350.a.4.i; B.351.a.4.i;B.345.a.4.i; B.346.a.4.i; B.347.a.4.i; B.348.a.4.i; B.349.a.4.i; B.350.a.4.i; B.351.a.4.i;
B.352.a.4.i; B.353.a.4.i; B.354.a.4.i; B.355.a.4.i; B.356.a.4.i; B.357.a.4.i; B.358.a.4.i; E.2.a.4.i; E.3.a.4.i; E.4.a.4.i; E.5.a.4.i; E.9.a.4.i; E.100.a.4.i;B.352.a.4.i; B.353.a.4.i; B.354.a.4.i; B.355.a.4.i; B.356.a.4.i; B.357.a.4.i; B.358.a.4.i; E.2.a.4.i; E.3.a.4.i; E.4.a.4.i; E.5.a.4.i; E.9.a.4.i; E.100.a.4.i;
E.103.a.4.i; E.104.a.4.i; E.105.a.4.i,E.103.a.4.i; E.104.a.4.i; E.105.a.4.i,
E.110.a.4.i; E.lll.a.4.i; E.112.a.4.i; E.113.a.4.i; E.114.a.4.i;E.110.a.4.i; E.lll.a.4.i; E.112.a.4.i; E.113.a.4.i; E.114.a.4.i;
i; Β273Λ,4ά; B.274.a.4.i; i; B.280.a.4.i; B.281.a.4.i;and; Λ273Λ, 4ά; B.274.a.4.i; and; B.280.a.4.i; B.281.a.4.i;
i; B.343.a.4.i; B.344.a.4.i;and; B.343.a.4.i; B.344.a.4.i;
E.106.a.4.i; E.107.a.4.i;E.106.a.4.i; E.107.a.4.i;
E.117.a.4.i; E.118.a.4.i; E.119.a.4.i; E.120.a.4.i; E.121.a.4.i;E.117.a.4.i; E.118.a.4.i; E.119.a.4.i; E.120.a.4.i; E.121.a.4.i;
E.124.a.4.i; E.125.a.4.i; E.126.a.4.i;E.124.a.4.i; E.125.a.4.i; E.126.a.4.i;
E.131.a.4.i; E.132.a.4.i; £.133.3.4.(E.131.a.4.i; E.132.a.4.i; £ .133.3.4. (
E.138.a.4.i; E.139.a.4.i; E.140.a.4.i;E.138.a.4.i; E.139.a.4.i; E.140.a.4.i;
E.145.a.4.i; E.146.a.4.i; E.147.a.4.i; E,148.a.4.i; E.149.a.4.iE.145.a.4.i; E.146.a.4.i; E.147.a.4.i; E, 148.a.4.i; E.149.a.4.i
E.152.a.4.i; E.153.a.4.i; E.154.a.4.i;E.152.a.4.i; E.153.a.4.i; E.154.a.4.i;
E.159.a.4.i; E.160.a.4.i; E.161.a.4.iE.159.a.4.i; E.160.a.4.i; E.161.a.4.i
E.166.a.4.i; E.167.a.4.i; E.168.a.4.i,E.166.a.4.i; E.167.a.4.i; E.168.a.4.i,
E.173.a.4.i; E.174.a.4.i; E.175.a.4.i;E.173.a.4.i; E.174.a.4.i; E.175.a.4.i;
E.180.a.4.i; E.181.a.4.i; E.182.a.4.i;E.180.a.4.i; E.181.a.4.i; E.182.a.4.i;
E.187.a.4.i; E.188.a.4.i; E.189.a.4.i; E.190.a.4.i; E.191.a.4.iE.187.a.4.i; E.188.a.4.i; E.189.a.4.i; E.190.a.4.i; E.191.a.4.i
E.194.a.4.i; E.195.a.4.i; E.196.a.4.i,E.194.a.4.i; E.195.a.4.i; E.196.a.4.i,
E.201.a.4.i; E.202.a.4.i; E.203.a.4.i;E.201.a.4.i; E.202.a.4.i; E.203.a.4.i;
E.208.a.4.i; E.209.a.4.i; E.210.a.4.i;E.208.a.4.i; E.209.a.4.i; E.210.a.4.i;
E.215.a.4.i; E.216.a.4.i; E.217.a.4.i;E.215.a.4.i; E.216.a.4.i; E.217.a.4.i;
E.222.a.4.i; E.223.a.4.i; E.224.a.4.i;E.222.a.4.i; E.223.a.4.i; E.224.a.4.i;
E.229.a.4.i; E.230.a.4.i; E.231.a.4.i; E.232.a.4.i; E.233.a.4.iE.229.a.4.i; E.230.a.4.i; E.231.a.4.i; E.232.a.4.i; E.233.a.4.i
E.236.a.4.i; E237.a.4.i; E.238.a.4.iE.236.a.4.i; E237.a.4.i; E.238.a.4.i
E.243.a.4.i; E.244.a.4.i; E.245.a.4.i;E.243.a.4.i; E.244.a.4.i; E.245.a.4.i;
E-250.a.4.i; E.251.a.4.i; E.252.a.4.i;E-250.a.4.i; E.251.a.4.i; E.252.a.4.i;
E257.a.4.i; E.258.a.4.i; E.259.a.4.i;E257.a.4.i; E.258.a.4.i; E.259.a.4.i;
E.264.a.4.i; E.265.a.4.i; E.266.a.4.iE.264.a.4.i; E.265.a.4.i; E.266.a.4.i
E.271.a.4.i; E.272.a.4.i; E.273.a.4.i;E.271.a.4.i; E.272.a.4.i; E.273.a.4.i;
E.278.a.4.i; E.279.a.4.i; E.280.a.4.i;E.278.a.4.i; E.279.a.4.i; E.280.a.4.i;
E.285.a.4.i; E.286.a.4.i; E.287.a.4.i;E.285.a.4.i; E.286.a.4.i; E.287.a.4.i;
E.292.a.4.i; E.293.a.4.i; E.294.a.4.iE.292.a.4.i; E.293.a.4.i; E.294.a.4.i
E.299.a.4.i; E.30Q.a.4.i; E.301.a.4.i;E.299.a.4.i; E.30Q.a.4.i; E.301.a.4.i;
E.306.a.4.i; E.307.a.4.i; E.308.a.4.i,E.306.a.4.i; E.307.a.4.i; E.308.a.4.i,
E.313.a.4.i; E.314.a.4.i; E.315.a.4.i;E.313.a.4.i; E.314.a.4.i; E.315.a.4.i;
E,320.a.4.i; E.321.a.4.i; E.322.a.4.iE, 320.a.4.i; E.321.a.4.i; E.322.a.4.i
E.327.a.4.i; E.328.a.4.i; E.329.a.4.i;E.327.a.4.i; E.328.a.4.i; E.329.a.4.i;
E.127.a.4.i; E.128.a.4.i;E.127.a.4.i; E.128.a.4.i;
E.134.a.4.i; E.135.a.4.i; ; E.141.a.4.i; E.142.a.4.i;E.134.a.4.i; E.135.a.4.i; ; E.141.a.4.i; E.142.a.4.i;
E.155.a.4.i; E.156.a.4.i; E.162.a.4.i; E.163.a.4.i; : E.169.a.4.i; E.170.a.4.i;E.155.a.4.i; E.156.a.4.i; E.162.a.4.i; E.163.a.4.i; : E.169.a.4.i; E.170.a.4.i;
E.176.a.4.i; E.177.a.4,i;E.176.a.4.i; E.177.a.4., I;
E.183.a.4.i; E.184.a.4.i,E.183.a.4.i; E.184.a.4.i,
E.101.a.4.i; E.102.a.4.i;E.101.a.4.i; E.102.a.4.i;
E.108.a.4.i; E.109.a.4.i;E.108.a.4.i; E.109.a.4.i;
E.115.a.4.i; E.116.a.4.i;E.115.a.4.i; E.116.a.4.i;
E.122.a.4.i; E.123.a.4.i;E.122.a.4.i; E.123.a.4.i;
E.129.a.4.i; E.130.a.4á;E.129.a.4.i; E.130.a.4á;
E.136.a.4.i; E.137.a.4.í;E.136.a.4.i; E.137.a.4.í;
E.143.a.4.i; E.144.a.4.i;E.143.a.4.i; E.144.a.4.i;
E.150.a.4 .i; E.151.a.4.i;E.150.a.4 .i; E.151.a.4.i;
E.157.a.4.i; E.158.a.4.i;E.157.a.4.i; E.158.a.4.i;
E.164.a.4.i; E.165.a.4.i;E.164.a.4.i; E.165.a.4.i;
E.171.a.4.i; E.172.a.4.i;E.171.a.4.i; E.172.a.4.i;
E.178.a.4.i; E.179.a.4.i;E.178.a.4.i; E.179.a.4.i;
E.185.a.4.i; E. 186. a.4.i;E.185.a.4.i; E. 186 a.4.i;
; E.197.a.4.i; E.198.a.4.i E.204.a.4.i; E.205.a.4.i, E211.a.4.i; E.212.a.4.i; E.218.a.4.i; E.219.a.4.i E.225.a.4.i; E.226.a.4.i; E.197.a.4.i; E.198.a.4.i E.204.a.4.i; E.205.a.4.i, E211.a.4.i; E.212.a.4.i; E.218.a.4.i; E.219.a.4.i E.225.a.4.i; E.226.a.4.i
E.192.a.4.i; E.193.a.4.i;E.192.a.4.i; E.193.a.4.i;
E.199.a.4.i; E.200.a.4.i;E.199.a.4.i; E.200.a.4.i;
E.206.a.4.i; E.207.a.4.i;E.206.a.4.i; E.207.a.4.i;
E-213.a.4.i; E.214.a.4.i;E-213.a.4.i; E.214.a.4.i;
E.220.a.4.i; E.221.a.4.i;E.220.a.4.i; E.221.a.4.i;
E.227.a.4.i; E.228.a.4.i;E.227.a.4.i; E.228.a.4.i;
; E.239.a.4.i; E.240.a.4.i ; E.246.a.4.i; E.247.a.4.i; E.239.a.4.i; E.240.a.4.i; E.246.a.4.i; E.247.a.4.i
E.253.a.4.i; E254.a.4.iE.253.a.4.i; E254.a.4.i
E.260.a.4.i; E.261.a.4.i ; E.267.a.4.i; E.268.a.4.iE.260.a.4.i; E.261.a.4.i; E.267.a.4.i; E.268.a.4.i
E.274.a.4.i; E.275.a.4.iE.274.a.4.i; E.275.a.4.i
E.281.a.4.i; E.282.a.4.iE.281.a.4.i; E.282.a.4.i
E.288.a.4.i; E.289.a.4.íE.288.a.4.i; E.289.a.4.í
E.295.a.4.i; E.296.a.4.iE.295.a.4.i; E.296.a.4.i
E.302.a.4.i; E.303.a.4.iE.302.a.4.i; E.303.a.4.i
E.309.a.4.i; E.310.a.4.iE.309.a.4.i; E.310.a.4.i
E.316.a,4.i; E.317.a.4.iE.316.a, 4.i; E.317.a.4.i
E.323.a.4.i; E.324.a.4.iE.323.a.4.i; E.324.a.4.i
E.330.a.4.i; E.331.a.4.iE.330.a.4.i; E.331.a.4.i
E.234.a.4.i; E.235.a.4.i;E.234.a.4.i; E.235.a.4.i;
E.241.a.4.i; E.242.a.4,i;E.241.a.4.i; E.242.a.4., I;
E.248.a.4.i; E.249.a.4.i;E.248.a.4.i; E.249.a.4.i;
E.255.a.4.i; E.256.a.4.i;E.255.a.4.i; E.256.a.4.i;
E.262.a.4.i; E.263.a.4.i;E.262.a.4.i; E.263.a.4.i;
E.269.a.4.i; E.270.a.4.i;E.269.a.4.i; E.270.a.4.i;
E.276.a.4.i; E.277.a.4.i;E.276.a.4.i; E.277.a.4.i;
E.283.a.4.i; E.284.a.4.i;E.283.a.4.i; E.284.a.4.i;
E.290.a.4.i; E.291.a.4.i;E.290.a.4.i; E.291.a.4.i;
E.297.a.4.i; E.298.a.4.i;E.297.a.4.i; E.298.a.4.i;
E.304.a.4.i; E.305.a.4.i;E.304.a.4.i; E.305.a.4.i;
E.311.a.4.i; E.312.a.4.i;E.311.a.4.i; E.312.a.4.i;
E.318.a.4.i; E.319.a.4.i;E.318.a.4.i; E.319.a.4.i;
E.325.a.4.i; E.326.a.4.i;E.325.a.4.i; E.326.a.4.i;
E.332,a.4.i; E.333.a.4.i;E.332, a.4.i; E.333.a.4.i;
- 138CZ 297945 B6- 138GB 297945 B6
E.334.a.4.i; E.335.a.4.i; E.336.a.4.i; E.337.a.4.i; E.338.a.4.i; E,339.a.4.i; E.340.a.4.i; E.341.a.4.i; E.342.a.4.i; E.343.a.4.i; E.344.a.4.i; E.345.a.4.i; E.346.a.4.i; E347.a.4.i; E.348.a.4.i; E.349.a.4.i; E.350.a.4á; E.351.á.4.i; E.352.a.4.i; E.353.a.4.i; E354.a.4.i; E.355.a.4.i; E.356.a.4.i; E.357.a.4.i; E.358.a.4.i; B.2.a.ll.x; B.3.a.ll.i; B.4.a.ll.i; B.5.a.ll.i; B.9.a.ll.i; B.lOO.a.ll.i; B.lOl.a.ll.i; B.102.a.ll.i; B.lOS.a.ll.i;E.334.a.4.i; E.335.a.4.i; E.336.a.4.i; E.337.a.4.i; E.338.a.4.i; E, 339.a.4.i; E.340.a.4.i; E.341.a.4.i; E.342.a.4.i; E.343.a.4.i; E.344.a.4.i; E.345.a.4.i; E.346.a.4.i; E347.a.4.i; E.348.a.4.i; E.349.a.4.i; E.350.a.4á; E.351.á.4.i; E.352.a.4.i; E.353.a.4.i; E354.a.4.i; E.355.a.4.i; E.356.a.4.i; E.357.a.4.i; E.358.a.4.i; B.2.a.ll.x; B.3.a.ll.i; B.4.a.ll.i; B.5.a.ll.i; B.9.a.ll.i; B.100.a.ll.i; B.10.a.ll.i; B.102.a.ll.i; B.lOS.a.ll.i;
B.104.a.11.i; B.lOS.a.ll.i; B.llO.a.ll.i; B.lll.a.ll.i; B.lló.a.ll.i; B.117.a.U.i; B.122.a.ll.i; B.123.a.ll.i; B.128.a.ll.i; B.129.a.ll.i; B.134.a.ll.i; B.135.a.ll.i; B.140.a.ll.i; B.141.a.ll.i; B.146.a.ll.i; B.147.a.ll.i; B.152.a.ll.x; B.153.a.ll.i; B.158.a.ll.i; B.159.a.ll.i; B.164.a.ll.i; B.165.a.ll.i; B.170.a.ll.i; B.171.a.ll.i; B.176.a.ll.i; B.177.a.ll.i; B.182.a.ll.i; B.183.a.ll.í; B.188.a.ll.i; B.189.a.ll.i; B.194.a.ll.i; B.195.a.ll.í; B.200.a.ll.i; B.201.a.ll.í; B.206.a.ll.i; B.207.a.ll.i; B212.a.ll.i; B.213.a.ll.i; B.218.a.ll.i; B.219.a. 11.i; B224.a.ll.i; B.225.a.ll.i; B.230.a.U.i; B.231.a.ll.i; B.236.a.ll.i; B.237.a.ll.x; B.242.a.ll.i; B.243.a.ll.i; B.248.a.ll.i; B.249.a.ll.i; B.254.a.ll.i; B.255.a.ll,i; B.260.a.ll.i; B.261.a.ll.i; B.266.a.H.i; B.267.a.ll.i; B.272.a.ll.x; B.273.a.ll.i; B.278.a.ll.i; B.279.a.ll.i; B.284.a.ll i; B.285.a.ll.i; B.290.a.ll.i; B.291.a.U.i; B.296.a.ll.x; B.297.a.ll.i; B.3O2.a.ll.i; B.303.a.ll.i; B.308.a.ll.i; B.3O9.a.ll.i; B.314.a.ll.i; B.315.a.ll.i; B.320.a.H.i; B.321.a.ll,i; B.326.a.ll.i; B.327.a.ll.x; B.332.a.ll.i; B.333,a.U.i; B.338.a.ll.i; B.339.a.ll.i; B.344.a.ll.i; B.345.a.ll.i; B.350.a.ll.i; B.351.a.ll.i;B.104.a.11.i; B.lOS.a.ll.i; B.ll0.a.ll.i; B.lll.a.ll.i; B.lló.a.ll.i; B.117.a.U.i; B.122.a.ll.i; B.123.a.ll.i; B.128.a.ll.i; B.129.a.ll.i; B.134.a.ll.i; B.135.a.ll.i; B.140.a.ll.i; B.141.a.ll.i; B.146.a.ll.i; B.147.a.ll.i; B.152.a.ll.x; B.153.a.ll.i; B.158.a.ll.i; B.159.a.ll.i; B.164.a.ll.i; B.165.a.ll.i; B.170.a.ll.i; B.171.a.ll.i; B.176.a.ll.i; B.177.a.ll.i; B.182.a.ll.i; B.183.a.ll.í; B.188.a.ll.i; B.189.a.ll.i; B.194.a.ll.i; B.195.a.ll.í; B.200.a.ll.i; B.201.a.ll.í; B.206.a.ll.i; B.207.a.ll.i; B212.a.ll.i; B.213.a.ll.i; B.218.a.ll.i; B.219.a. 11.i; B224.a.ll.i; B.225.a.ll.i; B.230.a.U.i; B.231.a.ll.i; B.236.a.ll.i; B.237.a.ll.x; B.242.a.ll.i; B.243.a.ll.i; B.248.a.ll.i; B.249.a.ll.i; B.254.a.ll.i; B.255.a.ll, i; B.260.a.ll.i; B.261.a.ll.i; B.266.a.H.i; B.267.a.ll.i; B.272.a.ll.x; B.273.a.ll.i; B.278.a.ll.i; B.279.a.ll.i; B.284.a.ll i; B.285.a.ll.i; B.290.a.ll.i; B.291.a.U.i; B.296.a.ll.x; B.297.a.ll.i; B.3O2.a.ll.i; B.303.a.ll.i; B.308.a.ll.i; B.3O9.a.ll.i; B.314.a.ll.i; B.315.a.ll.i; B.320.a.H.i; B.321.a.II, i; B.326.a.ll.i; B.327.a.ll.x; B.332.a.ll.i; B.333, a.U.i; B.338.a.ll.i; B.339.a.ll.i; B.344.a.ll.i; B.345.a.ll.i; B.350.a.ll.i; B.351.a.ll.i;
B.lOó.a.ll.x; B.lOZa.ll.i;B.10.a.ll.x; B.lOZa.ll.i;
B,112.a.ll.i; B.113.a.ll.i;B, 112.a.II.i; B.113.a.ll.i;
B.118.a.ll.i; B.119.3.11.Í;B.118.a.ll.i; B.119.3.11.Í;
B.124.a.ll.i; B.125,a.ll.i;B.124.a.ll.i; B.125, a.ll.i;
B.130.a.ll.i; B.131.a.ll.í;B.130.a.ll.i; B.131.a.ll.í;
B.136.a.ll.i; B.137.a.ll.i;B.136.a.ll.i; B.137.a.ll.i;
B.142.a.ll.i; B.143.a.ll.x;B.142.a.ll.i; B.143.a.ll.x;
B.148.a.ll.i; B.149.a.ll.i;B.148.a.ll.i; B.149.a.ll.i;
B.154.3.11.Í; B.155.a.ll.i;B.154.3.11.Í; B.155.a.ll.i;
B.lóO.a.ll.i; B.lól.a.lU;B.10.a.ll.i; B.lól.a.lU;
B.166.a.ll.i; B.167.a.ll.i;B.166.a.ll.i; B.167.a.ll.i;
B.172.a.ll.i; B.173.a.ll.x;B.172.a.ll.i; B.173.a.ll.x;
B.178.a.ll.i; B.179.a.ll.i;B.178.a.ll.i; B.179.a.ll.i;
B.184.a.ll.i; B.185.a.ll.i;B.184.a.ll.i; B.185.a.ll.i;
B.190.3.11.Í; B.191.a.ll.i;B.190.3.11.Í; B.191.a.ll.i;
B.196.3.11.Í; B.197.a.ll.i;B.196.3.11.Í; B.197.a.ll.i;
B.202.a.ll.i; B.203.a.U.i;B.202.a.ll.i; B.203.a.U.i;
B.208.3.11.1; B.209.a.ll.i;B.208.3.11.1; B.209.a.ll.i;
B.214.a.ll.i; B.215.a.ll.i;B.214.a.ll.i; B.215.a.ll.i;
B.220.a.ll.i; B.221.a.ll.i;B.220.a.ll.i; B.221.a.ll.i;
B.226.a.ll.i; B.227.a.ll.x;B.226.a.ll.i; B.227.a.ll.x;
B.232.a.ll.i; B.233.a.ll.i;B.232.a.ll.i; B.233.a.ll.i;
B.238.a.ll.i; B.239.a.ll.x;B.238.a.ll.i; B.239.a.ll.x;
B.244.a.ll.i; B.245.a.ll.i;B.244.a.ll.i; B.245.a.ll.i;
B.250.a.ll.i; B.251.a.ll.x;B.250.a.ll.i; B.251.a.ll.x;
B.256.a.U.x; B.257.a.ll.i;B.256.a.U.x; B.257.a.ll.i;
B.262.a.ll.i; B.263.a.ll.x;B.262.a.ll.i; B.263.a.ll.x;
B.268.a.ll.i; B.269.a.ll.i;B.268.a.ll.i; B.269.a.ll.i;
B.274.a.ll.i; B.275.a.ll.i;B.274.a.ll.i; B.275.a.ll.i;
B.280.a.ll.i; B.281.a.ll.i;B.280.a.ll.i; B.281.a.ll.i;
B.286.a.ll.i; B.287.a.U.i;B.286.a.ll.i; B.287.a.U.i;
B.292.a.ll.i; B.293.a.ll.i;B.292.a.ll.i; B.293.a.ll.i;
B.298,a.ll.i; B.299.a.ll.i;B.298, a.ll.i; B.299.a.ll.i;
B.304.a.U.x; B.305.a.U.i;B.304.a.U.x; B.305.a.U.i;
B.310.a.ll.i; B.3U.a.ll.i;B.310.a.ll.i; B.3U.a.ll.i;
B.31 ó.a.ll.i; B.317.a.ll.x;B.31 ó.a.ll.i; B.317.a.ll.x;
B,322.a.ll.i; B.323.a.ll.i;B, 322.a.II.i; B.323.a.ll.i;
B.328.a.ll.i; B.329.a.ll.i;B.328.a.ll.i; B.329.a.ll.i;
B.334.a.ll.i; B.335.a.ll.i;B.334.a.ll.i; B.335.a.ll.i;
B.340.a.ll.i; B.341.a.ll.i;B.340.a.ll.i; B.341.a.ll.i;
B.346.a.ll.i; B.347.a,ll.i;B.346.a.ll.i; B.347.a, II.i;
B.352.a.ll.i; B.353.a.ll.i;B.352.a.ll.i; B.353.a.ll.i;
B.108.a.ll.i; B.109.a.ll.i; B.114.a.ll.i; B.llS.a.ll.i; B.120.a.ll.i; B.121.a.ll.i; B.126.a.ll.i; B.127.a.ll.i; B.132.a.ll.i; B.133.a.ll.i; B.138.a.ll.i; B.139.a.ll.i; B.144.a.ll.i; B.145.a.ll.i; B.150.a.ll.i; B.lSl.a.ll.i; B.156.a.ll.i; B.157.a.ll.i; B.162.a.ll.i; B.163.a.ll.i; B.168.a.ll.i; B.169.a.ll.i; B.174.a.U.i; B.175.a.ll.i; B.180.a.ll.i; B.181.a.ll.i; B.186.a.ll.x; B.187.a.ll.i; B.192.a.ll.i; B.193.a.ll.i; B.198.a.ll.i; B.199.a.ll.i; B.204.a.ll.i; B.205.a.ll.x; B.210.a.ll.i; B.211.a.ll.i; B.216.a.ll.i; B.217.a.ll.i; B.222.a.ll.i; B.223.a.ll.i; B.228.a.ll.í; B.229.a.ll.i; B.234.a.ll.x; B.235.a.ll.i; B.240.a.ll.i; B.241.a.ll.i; B.246.a.ll.i; B.247.a.ll.x; B.252.a.ll.i; B253.a.ll.i; B.258.á.ll.i; B.259.a.ll.i; B.264.a.ll.i; B.265.a.ll.i; B.270.a.ll.i; B.271.a.ll.x; B.276.a.ll.i; B.277.a.U.i; B.282.a.ll.i; B.283.a.ll.i; B.288.a.ll.i; B.289.a.ll.i; B.294.a.ll.i; B.295.a.ll.x; B.300.a.ll.i; B.301.a.U.x; B.306.a.ll.i; B.307.a.ll.i; B.312.a.ll.i; B.313.a.ll.i; B.318.a.ll.i; B.319.a.ll.i; B.324.a.ll.i; B.325.a.ll.i; B.330.a.ll.i; B.331.a.ll.i; B.336.a.ll.i; B.337.a.ll.i; B.342.a.ll.i; B.343.a.ll.i; B.348.a.ll.i; B.349.a.U.i; B.354.a.ll.i; B.355.a.ll.i;B.108.a.ll.i; B.109.a.ll.i; B.114.a.ll.i; B.llS.a.ll.i; B.120.a.ll.i; B.121.a.ll.i; B.126.a.ll.i; B.127.a.ll.i; B.132.a.ll.i; B.133.a.ll.i; B.138.a.ll.i; B.139.a.ll.i; B.144.a.ll.i; B.145.a.ll.i; B.150.a.ll.i; B.I.Sl.a.II.i; B.156.a.ll.i; B.157.a.ll.i; B.162.a.ll.i; B.163.a.ll.i; B.168.a.ll.i; B.169.a.ll.i; B.174.a.U.i; B.175.a.ll.i; B.180.a.ll.i; B.181.a.ll.i; B.186.a.ll.x; B.187.a.ll.i; B.192.a.ll.i; B.193.a.ll.i; B.198.a.ll.i; B.199.a.ll.i; B.204.a.ll.i; B.205.a.ll.x; B.210.a.ll.i; B.211.a.ll.i; B.216.a.ll.i; B.217.a.ll.i; B.222.a.ll.i; B.223.a.ll.i; B.228.a.ll.í; B.229.a.ll.i; B.234.a.ll.x; B.235.a.ll.i; B.240.a.ll.i; B.241.a.ll.i; B.246.a.ll.i; B.247.a.ll.x; B.252.a.ll.i; B253.a.ll.i; B.258.á.ll.i; B.259.a.ll.i; B.264.a.ll.i; B.265.a.ll.i; B.270.a.ll.i; B.271.a.ll.x; B.276.a.ll.i; B.277.a.U.i; B.282.a.ll.i; B.283.a.ll.i; B.288.a.ll.i; B.289.a.ll.i; B.294.a.ll.i; B.295.a.ll.x; B.300.a.ll.i; B.301.a.U.x; B.306.a.ll.i; B.307.a.ll.i; B.312.a.ll.i; B.313.a.ll.i; B.318.a.ll.i; B.319.a.ll.i; B.324.a.ll.i; B.325.a.ll.i; B.330.a.ll.i; B.331.a.ll.i; B.336.a.ll.i; B.337.a.ll.i; B.342.a.ll.i; B.343.a.ll.i; B.348.a.ll.i; B.349.a.U.i; B.354.a.ll.i; B.355.a.ll.i;
-139CZ 297945 B6-139GB 297945 B6
B. 356.a.ll.i; B.357,a.H4; B.358.a.ll.i; E.2.a.ll.i; E.3.a.ll4; E.4.a.ll.i; E.5.a.ll.i; E.9.a.ll4; E100.a.ll4; E.101.a.ll.i; E.102.a.U4; E.103.a.U4; E.104.a.ll.i; E105.a.ll.i; E106.a.ll.i; E107.a.ll4; E108.a.ll.i; E.109.a.ll4; E.llO.a.114; Elll.a.114; E.112.a.ll.i; E.113.a.ll4; E.U4.a.ll4; E115.a.ll4; E116.a.U4; E.117.a.ll.i; E118.a.ll4; E119.a.ll.i; E.120.a.ll.i; E121.a.ll4; E.122.a.ll4; E123.a.ll.i; E.124.a,il4; E125.a.U.i; E126-a.il4; E.127.a.ll4; E.128.a.U.i; E129.a.ll4; E130.a.ll.i; E131.a.ll.i; E132.a.ll4; E.133.a.ll4; E134.a.ll4; E.135.a.ll4; E136.a.ll4; E137.a.ll4; E.138.a.ll4; E.139.a.ll4; E.140.a.Il.i; E.141.3.114; E.142.a.ll4; E.143.a.ll4; E144.a.ll4; E145.a.ll.i; E146.a.ll.i; E147.a.ll4; E.148.a.ll4; E149.a.ll.i; E150.a.ll4; E151.a.ll4; E152.a.ll4; E153.a.ll4; E.154.a.ll4; E155.a.ll4; E156.a.ll4; E157.a,114; E158.a.ll4; E159.a.ll.i; E.160.a.ll4; E161.a.U4; E162.a.U4; E.163.a.ll4; E.164.a.ll.i; E.165.a.ll.í; E.166.a.Il.i; E167.a.ll.i; E168.a.U4; E.169.a.ll4;E.170.a.ll4; E.171.a.ll.i; E.172.a.U4; E.173.a.ll.i; E474.a.ll4; E.175.a.ll4; E.176.a.ll.i; E.177.a.ll4; E.178.a.ll4;E179.a.ll4; E180.a.ll4; E.181.a.ll4; E182.a.U4; E.183.a.U4; E184.a.ll4; E.185.a.ll4; E186.a.ll4; E.187.a.ll4;E188,a.U4; E189.a.lI4; E190.a.ll4; E.191.a.ll4; E192.a.ll4; E.193.a.U4; E194.a.H4; E.195.a.ll4; E.196.a.U4; E.197.a.ll.i; E.198.a.ll4; E.199.a.ll4; E.200.a.U4; E201.a.ll4; E.202.a.U4; E.203.a.ll4; E204.a.ll4; E.205.a.U4; E.206.a.ll4; E.207.a.U4; E.208.a.ll4;E.209.a.ll4; E.210.a.ll4; E211.a.ll4; E.212.a.ll4; E213.a.ll.i; E214.a.ll4; E215.a.ll4; E.216.a.lU; E217.a.ll4; E218.a.U4; E219.a.ll4; E.220.a.U4; E.221.a.ll4; E222.a.ll4; E.223.a.ll.i; E.224.a.ll.i; E225.a.U4; E226.a.ll4; E227.a.ll4; E228.a.ll.i; E229.a.ll4; E.230.a.ll4; E231.a.ll.i; E.232.a.U4; E.233.a.ll4; E.234.a.ll.i; E235.a.ll.i; E236.a.ll4; E237.a.ll.i; E.238.a.ll.i; E239.a.ll4; E.240.a.ll4; E241.a.ll4; E242.a.ll.i; E.243.a.ll4; E244.a.ll4; E.245.a.ll4; E246.a,114;E.247.a.ll4; E248.a.U4; E.249.a.ll4; E250.a,114; E251.a.ll4; E.252.a.ll4; E253.a.U.i; E254.a.ll 4; E.255.a.U4; E.256.a.ll.i; E257.a.H4; E.258.a,114; E.259.a.ll4; E260.a.U4; E.261.a.ll.i; E.262.a.ll4; E.263.a.ll.i;E264.a.ll.i; E265.a.ll.i; E266.a.ll.i; E267.a.ll4; E268.a,114; E269.a.ll.i; E.270.a.ll4; E271.a.ll4; E272.a.U4; E.273.a.U.i; E274.a.ll4; E275.a.ll4; E.276.a.ll4; E277.a.ll4; E278.a.ll4; E279.a.ll.i; E280.a.ll4; E.281.a.ll4; E282.a.ll.i; E283.a.ll4; E284.a.ll4; E285.a.ll4; E286.a.ll4; E287.a.I14; E288.a.ll4; E289.a.H4; E.290.a.ll4; E291.a.ll4; E292.a.ll4; E293.a.ll4; E294.a.ll4; E295.a.ll4; E.296.a.ll.i; E.297.a.ll4; E298.a.ll4; E299.a.ll4; E.300.a.ll4; E.301.a.ll4; E.302.a.ll.i; E.3O3.a.ll4; E.304.a.ll4; E305.a.ll.i; E.306.a.ll4; E.307.a.ll4; E.308.a.U4; E.309.a.U.i; E.310.a.U4; E.3U.a.ll.i; E.312.a.ll4; E.313.a.ll4; E314.a.U4; E.315.a.ll4; E.316.a.ll4; E.317.a.ll4; E.318.a.ll4;E319.a.ll4; E.320.a.ll4; E.321.a.ll4; E.322.a.lU; E.323.a.ll.i; E324.a.ll4; E.325.a.ll4; E.326.a.U4; Ε327ΧΠ4; E328.a.ll4; E329.a.ll4; E.330.a.ll4; E.331.a.ll4; E.332.a,114; E.333.a.ll4; E.334.a.lU; E.335.a.ll.i; E.336.a.ll.i; E.337.a.ll4; E.338.a.U4; E.339.a.ll4; E.340.a.ll4; E.341.a.ll4; E.342.a.ll4; E.343.a.ll.i; E.344.a.ll4; E.345.a.ll.i; E.346.a.ll4; E347.a.H4; E.348.a.ll4; E.349.a.U4; E.35O.a.ll4; E.351.a.U4; E352.a.ll4; E.353.a.ll4; E.354.a.ll4; E.355.a.ll4; E356.a.ll4; E.357.a.ll.i; E358.a.ll4; A.661.a.44; A.662.a.44; A.663.a.44; A.664.a.44;B. 356.a.ll.i; B.357, a.H4; B.358.a.ll.i; E.2.a.ll.i; E.3.a.ll4; E.4.a.ll.i; E.5.a.ll.i; E.9.a.ll4; E100.a.ll4; E.101.a.ll.i; E.102.a.U4; E.103.a.U4; E.104.a.ll.i; E105.a.ll.i; E106.a.ll.i; E107.a.ll4; E108.a.ll.i; E.109.a.ll4; E.ll0.a.114; Elll.a.114; E.112.a.ll.i; E.113.a.ll4; E.U4.a.ll4; E115.a.ll4; E116.a.U4; E.117.a.ll.i; E118.a.ll4; E119.a.ll.i; E.120.a.ll.i; E121.a.ll4; E.122.a.ll4; E123.a.ll.i; E.124.a, il4; E125.a.U.i; E126-a.114; E.127.a.ll4; E.128.a.U.i; E129.a.ll4; E130.a.ll.i; E131.a.ll.i; E132.a.ll4; E.133.a.ll4; E134.a.ll4; E.135.a.ll4; E136.a.ll4; E137.a.ll4; E.138.a.ll4; E.139.a.ll4; E.140.a.Il.i; E.141.3.114; E.142.a.ll4; E.143.a.ll4; E144.a.ll4; E145.a.ll.i; E146.a.ll.i; E147.a.ll4; E.148.a.ll4; E149.a.ll.i; E150.a.ll4; E151.a.ll4; E152.a.ll4; E153.a.ll4; E.154.a.ll4; E155.a.ll4; E156.a.ll4; E157.a, 114; E158.a.ll4; E159.a.ll.i; E.160.a.ll4; E161.a.U4; E162.a.U4; E.163.a.ll4; E.164.a.ll.i; E.165.a.ll.í; E.166.a.Il.i; E167.a.ll.i; E168.a.U4; E.169.a.ll4; E.170.a.ll4; E.171.a.ll.i; E.172.a.U4; E.173.a.ll.i; E474.a.ll4; E.175.a.ll4; E.176.a.ll.i; E.177.a.ll4; E.178.a.ll4; E179.a.ll4; E180.a.ll4; E.181.a.ll4; E182.a.U4; E.183.a.U4; E184.a.ll4; E.185.a.ll4; E186.a.ll4; E.187.a.II4; E188, a.U4; E189.a.lI4; E190.a.ll4; E.191.a.ll4; E192.a.ll4; E.193.a.U4; E194.a.H4; E.195.a.ll4; E.196.a.U4; E.197.a.ll.i; E.198.a.ll4; E.199.a.ll4; E.200.a.U4; E201.a.ll4; E.202.a.U4; E.203.a.ll4; E204.a.ll4; E.205.a.U4; E.206.a.ll4; E.207.a.U4; E.208.a.ll4; E.209.a.ll4; E.210.a.ll4; E211.a.ll4; E.212.a.ll4; E213.a.ll.i; E214.a.ll4; E215.a.ll4; E.216.a.lU; E217.a.ll4; E218.a.U4; E219.a.ll4; E.220.a.U4; E.221.a.ll4; E222.a.ll4; E.223.a.ll.i; E.224.a.ll.i; E225.a.U4; E226.a.ll4; E227.a.ll4; E228.a.ll.i; E229.a.ll4; E.230.a.ll4; E231.a.ll.i; E.232.a.U4; E.233.a.ll4; E.234.a.ll.i; E235.a.ll.i; E236.a.ll4; E237.a.ll.i; E.238.a.ll.i; E239.a.ll4; E.240.a.ll4; E241.a.ll4; E242.a.ll.i; E.243.a.ll4; E244.a.ll4; E.245.a.ll4; E246.a, 114; E.247.a.II4; E248.a.U4; E.249.a.ll4; E250.a, 114; E251.a.ll4; E.252.a.ll4; E253.a.U.i; E254.a.ll 4; E.255.a.U4; E.256.a.ll.i; E257.a.H4; E.258.a, 114; E.259.a.ll4; E260.a.U4; E.261.a.ll.i; E.262.a.ll4; E.263.a.ll.i; E264.a.ll.i; E265.a.ll.i; E266.a.ll.i; E267.a.ll4; E268.a, 114; E269.a.ll.i; E.270.a.ll4; E271.a.ll4; E272.a.U4; E.273.a.U.i; E274.a.ll4; E275.a.ll4; E.276.a.ll4; E277.a.ll4; E278.a.ll4; E279.a.ll.i; E280.a.ll4; E.281.a.ll4; E282.a.ll.i; E283.a.ll4; E284.a.ll4; E285.a.ll4; E286.a.ll4; E287.a.I14; E288.a.ll4; E289.a.H4; E.290.a.ll4; E291.a.ll4; E292.a.ll4; E293.a.ll4; E294.a.ll4; E295.a.ll4; E.296.a.ll.i; E.297.a.ll4; E298.a.ll4; E299.a.ll4; E.300.a.ll4; E.301.a.ll4; E.302.a.ll.i; E.3O3.a.ll4; E.304.a.ll4; E305.a.ll.i; E.306.a.ll4; E.307.a.ll4; E.308.a.U4; E.309.a.U.i; E.310.a.U4; E.3U.a.ll.i; E.312.a.ll4; E.313.a.ll4; E314.a.U4; E.315.a.ll4; E.316.a.ll4; E.317.a.ll4; E.318.a.ll4; E319.a.ll4; E.320.a.ll4; E.321.a.ll4; E.322.a.lU; E.323.a.ll.i; E324.a.ll4; E.325.a.ll4; E.326.a.U4; Ε327ΧΠ4; E328.a.ll4; E329.a.ll4; E.330.a.ll4; E.331.a.ll4; E.332.a, 114; E.333.a.ll4; E.334.a.lU; E.335.a.ll.i; E.336.a.ll.i; E.337.a.ll4; E.338.a.U4; E.339.a.ll4; E.340.a.ll4; E.341.a.ll4; E.342.a.ll4; E.343.a.ll.i; E.344.a.ll4; E.345.a.ll.i; E.346.a.ll4; E347.a.H4; E.348.a.ll4; E.349.a.U4; E.35O.a.ll4; E.351.a.U4; E352.a.ll4; E.353.a.ll4; E.354.a.ll4; E.355.a.ll4; E356.a.ll4; E.357.a.ll.i; E358.a.ll4; A.661.a.44; A.662.a.44; A.663.a.44; A.664.a.44;
A.665.a.44; B.661.a.44; B.662.a.44; B.663.a.44; B.664.a.44; B.665.a.44; C,.661.a.44;A.665.a.44; B.661.a.44; B.662.a.44; B.663.a.44; B.664.a.44; B.665.a.44; C, .661.a.44;
C. 662.a,44; C.663.a.4.i; C-664.a.4.i; C.665.a.4.i; A.661.a.lí.i; A.662.a.ll4;C. 662.a, 44; C.663.a.4.i; C-664.a.4.i .; C.665.a.4.i; A.661.a.lí.i; A.662.a.ll4;
-140CZ 297945 B6-140GB 297945 B6
A. 663.a.ll.i; A.664.a.ll.i; A.665.a.ll.i; B.661.a.ll.i; B.662.a.ll.i; B.663.a.ll.i;A. 663.a.ll.i; A.664.a.ll.i; A.665.a.ll.i; B.661.a.ll.i; B.662.a.ll.i; B.663.a.ll.i;
B. 664.a.ll.i; B.665.a.lU; C.661.a.ll.i; C.662.a.ll.i; C.663.a.ll.i; C.664.a.ll.i;B. 664.a.ll.i; B.665.a.lU; C.661.a.ll.i; C.662.a.ll.i; C.663.a.ll.i; C.664.a.ll.i;
C. 665.a.ll.i; A.661.a.44.i; A.662.a.44.i; A.663.a.44.i; A.664.a.44.i; A.665.a.44.i;C. 665.a.ll.i; A.661.a.44.i; A.662.a.44.i; A.663.a.44.i; A.664.a.44.i; A.665.a.44.i;
B. 661.a.44.i; B.662.a.44.i; B.663.a.44.i; B.664.a.44.i; B.665.a.44.i; C.661.a.44.i;B. 661.a.44.i; B.662.a.44.i; B.663.a.44.i; B.664.a.44.i; B.665.a.44.i; C.661.a.44.i;
C. 662.a.44.i; C.663.a.44J; C.664.a.44.i; C.665.a.44.i; A.666.a.4.i; A.666.a.ll.i; A.666.a.44.i; A.666.b.4.i; A.666.b.ll.i; A.666.b.44.i; A.666.x.4.i; A.666.x.ll.i; A.666.X.44.Í; A.666.y.4.i; A.666.y.ll.i; A.666.y.44.i; A.666.Z.4.Í; A.666.Z.11.Í; A.666.Z.44.Í; A.666.A.4.Í; A.666.A.11.Í; A.666.A.44.Í; A.666.B.4.Í; A.666.B.11.Í; A.666.B.44.Í; A.666.C.4.Í; A.666.C.1LÍ; A.666.C.44.Í; A.666.D.4.Í; A.666.D.11.Í; A.666.D.44.Í; A.666.E.4.Í; A.666.E.11.Í; Α.666Έ.44.Ϊ; A.666.F.4.Í; A.666.F.11.Í;C. 662.a.44.i; C.663.a.44J; C.664.a.44.i; C.665.a.44.i; A.666.a.4.i; A.666.a.ll.i; A.666.a.44.i; A.666.b.4.i; A.666.b.ll.i; A.666.b.44.i; A.666.x.4.i; A.666.x.ll.i; A.666.X.44.Í; A.666.y.4.i; A.666.y.ll.i; A.666.y.44.i; A.666.Z.4.Í; A.666.Z.11.Í; A.666.Z.44.Í; A.666.A.4.I; A.666.A.11.Í; A.666.A.44.Í; A.666.B.4.I; A.666.B.11.Í; A.666.B.44.Í; A.666.C.4.Í; A.666.C.1LÍ; A.666.C.44.Í; A.666.D.4.Í; A.666.D.11.Í; A.666.D.44.Í; A.666.E.4.I; A.666.E.11.Í; Α.666Έ.44.Ϊ; A.666.F.4.I; A.666.F.11.Í;
A. 666.F.44.Í; B.666.a.4,i; B.666.a.ll.i; B.666.a.44.i; B.666.b.4.i; B.666.b.ll.i;A. 666.F.44.Í; B.666.a.4., I; B.666.a.ll.i; B.666.a.44.i; B.666.b.4.i; B.666.b.ll.i;
B. 666.b.44ď; B.666.x.4.x; B.666.X.11 .i; B.666.x.44.i; B.666.y.4,i; B.666.y.ll.i; B.666.y.44.i; B.666.z.4.i; B.666.z.ll.i; B.666.z.44.x; B.666.B.4.Í; Β.666.Β.11.Ϊ; B.666.B.44.Í; B.666.B.4.Í; B.666.B.11.Í; B.666.B.44.Í; B.666.C.4.Í; B.666.C.11.Í; B.666.C.44.Í; B.666.D.4.Í; B.666.D.H.Í; B.666.D.44.Í; B.666.E.4.Í; B.666.E.U.Í; B.666.E.44.Í; B.666.F.4.Í; B.666.F.11.Í; B.666.F.44.Í; E.666.a.4.i; E.666.a.ll.i; E.666.a.44.i; E.666.b.4.i; E.666.b.ll.i; E.666.b.44.i; E.666.x.4.i; E.666.x.ll.i; E.666.X.44.Í; E.666.v.4.i; E.666.V.1LÍ; E.666.y.44.i; E.666.z.4.x; E.666.z.ll.i;B. 666.b.44ď; B.666.x.4.x; B.666.X.11 .i; B.666.x.44.i; B.666.y.4, i; B.666.y.ll.i; B.666.y.44.i; B.666.z.4.i; B.666.z.ll.i; B.666.z.44.x; B.666.B.4.I; Β.666.Β.11.Ϊ; B.666.B.44.Í; B.666.B.4.I; B.666.B.11.Í; B.666.B.44.Í; B.666.C.4.Í; B.666.C.11.Í; B.666.C.44.Í; B.666.D.4.Í; B.666.D.H.I; B.666.D.44.Í; B.666.E.4.I; B.666.E.U.I; B.666.E.44.Í; B.666.F.4.I; B.666.F.11.Í; B.666.F.44.Í; E.666.a.4.i; E.666.a.ll.i; E.666.a.44.i; E.666.b.4.i; E.666.b.ll.i; E.666.b.44.i; E.666.x.4.i; E.666.x.ll.i; E.666.X.44.Í; E.666.v.4.i; E.666.V.1LÍ; E.666.y.44.i; E.666.z.4.x; E.666.z.ll.i;
E 666.Z.44.Í; E.666.E.4.Í; E.666.E.11.Í; E.666.E.44.Í; E.666.B.4.Í; E.666.B.11.Í; E.666.B.44.Í; E.666.C.4.Í; E.666.C.11.Í; E.666.C.44.Í; E,666.D.4.i; E.666.D.U.Í; E.666.D.44.Í; E.666.E.4.Í; E.666.E.11.Í; E.666.E.44.Í; E.666.F.4.Í; E.666.F.11.Í; E.666.F.44.Í;E 666.Z.44.Í; E.666.E.4.I; E.666.E.11.Í; E.666.E.44.Í; E.666.B.4.I; E.666.B.11.I; E.666.B.44.Í; E.666.C.4.Í; E.666.C.11.Í; E.666.C.44.Í; E, 666.D.4.i; E.666.D.U.I; E.666.D.44.Í; E.666.E.4.I; E.666.E.11.Í; E.666.E.44.Í; E.666.F.4.I; E.666.F.11.Í; E.666.F.44.Í;
A.2.a.46.i; A.3.a.46.i; A.4.a.46.i; A.5.a.46.i; A.7.a.46.i; A.9.a.46.i; A.100.a.46.i; A.101.a.46.i; A.102.a.46.i; A.103.a.46.i; A.104.a.46.i; A.105.a.46.i; A.106.a.46.i; A.107.a.46.i; A.108.a.46.i; A.109.a.46.i; A.110.a.46.i; A.lll.a.46.i; A.112.a.46.i; A.113.a.46.i; A.114.a.46.i; A.115.a.46.i; A.116,a.46.i; A.117.a.46.i; A.118.a.46.i; A.119.a.46.i; A.120.a.46.i; A.121.a.46.i; A.122.a.46.i; A.123.a.46.i; A.124.a.46.i; A.125.a.46.i; A.126.a.46.i; A.127.a.46.i; A.128.a.46.i; A.129.a.46.i; A.130.a.46.i; A.131.a.46.x; A.132.a.46.i; A.133.a.46.i; A.134.a.46_i; A.135.a.46.i; A.136.a.46.i; A.137.a.46.x; A.138.a.46.i; A.139.a.46.i; A.140.a.46.i; A.141,a.46.i; A.2.a.47.i; A.3.a.47.x; A.4.a.47.i; A.5.a.47.i; A.7.a.47.i; A.9.a.47.i; A.100.a.47.i; A.101.a.47.i; A.102.a.47.i; A.103.a.47.i; A.104.a.47.i; A.105.a.47.i; A.106.a.47.i; A.107.a.47.i; A.108.a.47.i; A.109.a.47.i; A.110.a.47.i; A.lll.a.47.i; A.112.a.47.i; A.113.a.47.i; A.114.a.47.i; A.115.a.47.i; A.116.a.47.i; A.117.a.47.i; A.118.a.47.i; A.U9.a.47.i; A.120.a.47.i; A.121.a.47.i; A.I22.a.47.i; A.123,a.47.i; A.124.a.47.i; A.125.a.47.i; A.126.a.47.i; A.127.a.47.i; A.128.a.47.i; A.129.a.47.i; A.130.a.47.i; A.131.a.47.i; A.132.a.47.i; A.133.a.47.i; A.134.a.47.i; A.135.a.47.i; A.136.a.47.i; A.137.a.47.i; A.138.a.47.i; A.139.a.47.i; A,140.a.47.x; A.l 41.a.47. i; A.2.a.48.i; A.3.a.48.i; A.4.a.48.i; A.5.a.48.i; A.7.a.48.i; A.9.a.48.i; A.100.a.48.i; A.101.a.48.i; A.102.a.48.i; A.103.a.48.i; A.104.a.48,i; A.105.a.48.i; A.106.a.48.i; A,107.a.48.i; A.108.a.48.i; A.109.a.48.í; A.110.a.48.i; A.lll.a.48.x; A.112.a.48.i; A.113.a.48.i; A.114.a.48.i; A.115.a.48.i; A.116.a.48.i; A.117.a.48.i; A.118.a.48.i; A.119.a.48.i; A.120.a.48.i; A.121.a.48.i; A.122.a.48.i; A.123.a.48.i; A.124.a.48.i; A.125,a.48.i; A.126.a.48.i; A.127.a.48.í; A.128.a.48.i: A.129.a.48.i; A.130.a.48.i; A.131.a.48.i; A.132.a.48.i; A.133.a.48.i; A.134.a.48.i; A.135.a.48.i; A.136.a.48.i; A.137.a.48.i; A.138.a.48.i; A.139.a.48.i; A.140.a.48.i; A.141.a.48.i; A.2.a.49.i; A.3.a.49.i; A.4.a.49.i; A.5.a.49.x; A.7.a.49.i; A.9.a.49.i; A.100.a.49.i; A.101.a.49.i; A.102.a.49.i; A.103.a.49.i;A.2.a.46.i; A.3.a.46.i; A.4.a.46.i; A.5.a.46.i; A.7.a.46.i; A.9.a.46.i; A.100.a.46.i; A.101.a.46.i; A.102.a.46.i; A.103.a.46.i; A.104.a.46.i; A.105.a.46.i; A.106.a.46.i; A.107.a.46.i; A.108.a.46.i; A.109.a.46.i; A.110.a.46.i; A.lll.a.46.i; A.112.a.46.i; A.113.a.46.i; A.114.a.46.i; A.115.a.46.i; A.116, a.46.i; A.117.a.46.i; A.118.a.46.i; A.119.a.46.i; A.120.a.46.i; A.121.a.46.i; A.122.a.46.i; A.123.a.46.i; A.124.a.46.i; A.125.a.46.i; A.126.a.46.i; A.127.a.46.i; A.128.a.46.i; A.129.a.46.i; A.130.a.46.i; A.131.a.46.x; A.132.a.46.i; A.133.a.46.i; A.134.a.46_i; A.135.a.46.i; A.136.a.46.i; A.137.a.46.x; A.138.a.46.i; A.139.a.46.i; A.140.a.46.i; A.141, a.46.i; A.2.a.47.i; A.3.a.47.x; A.4.a.47.i; A.5.a.47.i; A.7.a.47.i; A.9.a.47.i; A.100.a.47.i; A.101.a.47.i; A.102.a.47.i; A.103.a.47.i; A.104.a.47.i; A.105.a.47.i; A.106.a.47.i; A.107.a.47.i; A.108.a.47.i; A.109.a.47.i; A.110.a.47.i; A.lll.a.47.i; A.112.a.47.i; A.113.a.47.i; A.114.a.47.i; A.115.a.47.i; A.116.a.47.i; A.117.a.47.i; A.118.a.47.i; A.U9.a.47.i; A.120.a.47.i; A.121.a.47.i; A.I22.a.47.i; A.123, a.47.i; A.124.a.47.i; A.125.a.47.i; A.126.a.47.i; A.127.a.47.i; A.128.a.47.i; A.129.a.47.i; A.130.a.47.i; A.131.a.47.i; A.132.a.47.i; A.133.a.47.i; A.134.a.47.i; A.135.a.47.i; A.136.a.47.i; A.137.a.47.i; A.138.a.47.i; A.139.a.47.i; A, 140.a.47.x; A.l 41.a.47. and; A.2.a.48.i; A.3.a.48.i; A.4.a.48.i; A.5.a.48.i; A.7.a.48.i; A.9.a.48.i; A.100.a.48.i; A.101.a.48.i; A.102.a.48.i; A.103.a.48.i; A.104.a.48, i; A.105.a.48.i; A.106.a.48.i; A, 107.a.48.i; A.108.a.48.i; A.109.a.48.í; A.110.a.48.i; A.lll.a.48.x; A.112.a.48.i; A.113.a.48.i; A.114.a.48.i; A.115.a.48.i; A.116.a.48.i; A.117.a.48.i; A.118.a.48.i; A.119.a.48.i; A.120.a.48.i; A.121.a.48.i; A.122.a.48.i; A.123.a.48.i; A.124.a.48.i; A.125, a.48.i; A.126.a.48.i; A.127.a.48.í; A.128.a.48.i: A.129.a.48.i; A.130.a.48.i; A.131.a.48.i; A.132.a.48.i; A.133.a.48.i; A.134.a.48.i; A.135.a.48.i; A.136.a.48.i; A.137.a.48.i; A.138.a.48.i; A.139.a.48.i; A.140.a.48.i; A.141.a.48.i; A.2.a.49.i; A.3.a.49.i; A.4.a.49.i; A.5.a.49.x; A.7.a.49.i; A.9.a.49.i; A.100.a.49.i; A.101.a.49.i; A.102.a.49.i; A.103.a.49.i;
-141 CZ 297945 B6-141 CZ 297945 B6
A,104.a.49.i; A.105.a,49.i; A.X06.a.49.i; A.XQ7.a.49.i; A.108.a.49.i; A.X09.a.49.i; A.XX0.a.49.i; A.XXX.a.49.i; A.XX2.a.49.i; A.XI3.a.49.i; A.IX4,a.49.i; A.115.a.49.i; A,XX6.a.49.i; A.117.a.49.i; A.118.a.49.i; A.119.a.49.i; A.120.a.49.i; A.121.a.49.i; A.122.a.49.i; A.X23.a.49.i; A.124.a.49.i; A.125.a.49.i; A.X26.a.49.i; A.X27.a.49.i; A.X28.a.49.i; A.129.a.49.i; A.130.a.49.i; A.X3X.a.49.i; A.132,a.49.i; A.X33.a.49.i; A.X34.a.49.i; A.135.a.49.i; A.X36.a.49.i; A.X37.a.49.i; A.138.a.49.i; A.139.a.49.i; A.140.a.49.i; A.141.a.49.i; A.2,a.50.i; A.3.a.50.i; A.4.a.50.i; A.5.a.50.i; A.7.a.50.i; A.9.a.50.i; A.100.a.50.i; A.X0X.a.50.i; A.X02.a.50.i; A.X03.a.50.i; A.104.a.50.i; A.105.aJ50.i; A.106.a.50.i; A.107.a.50,i; A.108.a.50d; A.109.a.50.i; A.llO.aóOá; A.XXX.a.50.i; A.112.a.50.i; A.XX3.a.50.i; A.XX4.a.5O.i; A.XX5.a.50.i; A.XX6.a.50.i; A.117.a.50.i; A.118.a.50.i; A.119.a.50.i; A.120.a.50,i; A.121.a.50-i; A.122.a.50.i; A.123.a.50.i; A,124.a.50.i; A.125.a.50.i; A.X26.a.50.i; A.127.a.50.i; A.128.a.50.i; A.X29.a.50.i; A.130.a.50.i; A.131.a.50.i; A.132.a.50J; A.X33.a5O.i; A.X34.a.50.i; A.X35.a.50.i; A.X36.a.50.i; A.X37.a.50.i; A.138.a.50.i; A.X39.a.50.i; A.140.a.50.i; A.X4X.a.5O.i; A.2.a.5X.i; A.3.a.5X.i; A.4.a.51.i; A.5.a.5X.i; A.7.a.51.i; A.9.a.Sl.i; A.X00.a.5X.i; A.X0X.a.5X.i; A.X02.a.5X.i; A.X03.a.5Xd; A.X04.a.5X.i; A.X05.a.5X.i; A.106.a.51.i; A.107.a.51.i; A.108.a.51.i; A.X09.a.5X.i; A.XX0.a.5X.i; A.XXX.a.5I.x; A.112.a.51.i; A.113.a.51.i; A.114.a.51.i; A.115.a.51.i; A.116.a.51.i; A.XX7.a5X.i; A.U8.a.51.i; A.XX9.a.5X.i; A.X2O.a.5X.i; A.121.a.51.i; A.122.a.51.i; A.123.a.51.i; A.124.a.5Li; A.125.a.51.i; A.X26.a.5X.i; A.127.a.51.i; A.128.a.51.i; A.129.a.514; A.X30.a.51.i; A.X3X.a.5X.i; A.X32.a.5I.i; A.X33.a.5X.i; A.X34.a.5X.i; A.135.a.51.i; A.X36.a.5X.i; A.137.a.51.i; Α.138.3.51.χ; A.139.a.51.i; A.140.a.51.i; A.X4X.a.5X.i; A.2.b.46.i; A.3.b.46.i; A.4.b.46.i; A.5.b.46.i; A.7.b.46.i; A.9.b.46.i; A.100.b.46.i; A.101.b.46.i; A.XO2.b.46.i; A.103.b.46.i; A.104.b.46.i; A.105.b.46.i; A.106.b.46.i; A.107.b.46.i; A.108.b.46.i; A.109.b.46.i; A.110.b.46.i; A.XXX.b.46.i; A.U2.b.46.i; A.X13.b.46.i; A.XX4.b.46.i; A.115.b.46.i; A.U6.b.46.i; A.117.b.46.i; A.XX8.b.46.i; A.119.b.46.i; A.120.b.46.i; A.121.b.46.i; A.122.b.46.i; A.123.b.46.i; A.124.b.46.i; A.125;b.46.i; A.X26.b.46.i; A.127.b.46.i; A.X28.b.46.i; A.X29.b.46.i; A.130.b.46.i; A.X3I.b.46.i; A.132.b.46.i; A.133.b.46.i; A.134.b.46.i; A.135.b.46.i; A.X36.b.46.i; A 137.b.46.i; A.138.b.46.i; A.139.b.46,i; A.X40.b.46.i; A.141.b.46.i; A.2.b.47.i; A.3.b.47.i; A.4.b.47.i; A.5.b.47.i; A.7.b.47.i; A.9.b.47.i; A.100.b.47.i; A.101.b.47.i; A.XO2.b.47.i; A.103.b.47.1; A.104.b.47.Í; A.105.b.47.i; A.106.b.47.i; A.107.b.47.i; A.108.b.47.i; A.IO9.b.47.i; A.110.b.47.i; A.lll.b.47.i; A.112.b.47.i; A.113.b47.í; A.114.b.47.i; A.115.b.47.i; A.116.b.47.x; A.117.b.47.i; A.XX8.b.47.i; A.119.b.47.i; A.120.b.47.i; A.121.b.47.i; A.122.b.47.i; A.123.b.47.i; A.124.b.47.i; A.125.b.47.i; A.X26.b.47.i; A.127.b.47.i; A.128.b.47.i; A.129.b.47.i; A.130.b.47.i; A.131.b.47.i; A.X32.b.47.i; A.X33.b.47.i; A.X34.b.47.i; A.I35.b.47.i; A.136.b.47.i; A.X37.b.47.i; A.138.b.47.i; A.139.b.47á; A.140.b.47.i; A.14X.b.47.i; A.2.b.48.i; A.3.b.48.i; A.4.b.48.i; A.5.b.48.i; A.7.b.48.i; A.9.b.48.i; A.100.b.48.i; A.1O1 .b.48.i; A.X02.b.48.i; A.103.b.48.i; A.104.b.48.i; A.X05.b.48.i; A.106.b.48.i; A.107.b.48.i; A.X08.b.48.i; A.XO9.b.48.i; A.XX0.b.48.i; A.lll.b.48á; A.lX2.b.48.i; A.X13.b.48.i; A.114.b.48.i; A.XX5.b.48.i; A.XX6.b.48.i; A.117.b.48.i; A.X18.b.48.i; A.XX9.b.48.i; A.120,b.48.i; A.X2X.b.48.i; A.X22.b.48.i; A.X23.b.48.i; A.X24.b.48.i; A.125.b.48.i; A.X26.b.48.i; A.X27.b.48.i; A.X28.b.48.i; A.X29.b.48.i; A.X30.b.48.i; A.X3X.b.48.i; A.132.b.48.i; A.X33.b.48.i; A.134.b.48.i; A.X35.b.48.i; A.X36.b.48.i; A.X37.b.48.i; A.X38.b.48.i; A.X39.b,48.i; A.X40.b.48.i; A.X4X.b.48.i; A.2.b.49.i; A.3.b.49.i; A.4.b.49.i; A.5.b.49.i; A.7.b.49.i; A.9.b.49.i; A.X00.b.49.i; A.XOX,b.49.i; A.XQ2.b.49.i; A.103.b.49.i;A, 104.a.49.i; A.105.a, 49.i; A.X06.a.49.i; A.XQ7.a.49.i; A.108.a.49.i; A.X09.a.49.i; A.XX0.a.49.i; A.XXX.a.49.i; A.XX2.a.49.i; A.XI3.a.49.i; A.IX4, a.49.i; A.115.a.49.i; A, XX6.a.49.i; A.117.a.49.i; A.118.a.49.i; A.119.a.49.i; A.120.a.49.i; A.121.a.49.i; A.122.a.49.i; A.X23.a.49.i; A.124.a.49.i; A.125.a.49.i; A.X26.a.49.i; A.X27.a.49.i; A.X28.a.49.i; A.129.a.49.i; A.130.a.49.i; A.X3X.a.49.i; A.132, a.49.i; A.X33.a.49.i; A.X34.a.49.i; A.135.a.49.i; A.X36.a.49.i; A.X37.a.49.i; A.138.a.49.i; A.139.a.49.i; A.140.a.49.i; A.141.a.49.i; A.2, a.50.i; A.3.a.50.i; A.4.a.50.i; A.5.a.50.i; A.7.a.50.i; A.9.a.50.i; A.100.a.50.i; A.X0X.a.50.i; A.X02.a.50.i; A.X03.a.50.i; A.104.a.50.i; A.105.aJ50.i; A.106.a.50.i; A.107.a.50, i; A.108.a.50d; A.109.a.50.i; A.ll0.aóOá; A.XXX.a.50.i; A.112.a.50.i; A.XX3.a.50.i; A.XX4.a.5O.i; A.XX5.a.50.i; A.XX6.a.50.i; A.117.a.50.i; A.118.a.50.i; A.119.a.50.i; A.120.a.50, i; A.121.a.50-i; A.122.a.50.i; A.123.a.50.i; A, 124.a.50.i; A.125.a.50.i; A.X26.a.50.i; A.127.a.50.i; A.128.a.50.i; A.X29.a.50.i; A.130.a.50.i; A.131.a.50.i; A.132.a.50J; A.X33.a5O.i; A.X34.a.50.i; A.X35.a.50.i; A.X36.a.50.i; A.X37.a.50.i; A.138.a.50.i; A.X39.a.50.i; A.140.a.50.i; A.X4X.a.5O.i; A.2.a.5X.i; A.3.a.5X.i; A.4.a.51.i; A.5.a.5X.i; A.7.a.51.i; A.9.a.Sl.i; A.X00.a.5X.i; A.X0X.a.5X.i; A.X02.a.5X.i; A.X03.a.5Xd; A.X04.a.5X.i; A.X05.a.5X.i; A.106.a.51.i; A.107.a.51.i; A.108.a.51.i; A.X09.a.5X.i; A.XX0.a.5X.i; A.XXX.a.5I.x; A.112.a.51.i; A.113.a.51.i; A.114.a.51.i; A.115.a.51.i; A.116.a.51.i; A.XX7.a5X.i; A.U8.a.51.i; A.XX9.a.5X.i; A.X2O.a.5X.i; A.121.a.51.i; A.122.a.51.i; A.123.a.51.i; A.124.a.5Li; A.125.a.51.i; A.X26.a.5X.i; A.127.a.51.i; A.128.a.51.i; A.129.a.514; A.X30.a.51.i; A.X3X.a.5X.i; A.X32.a.5I.i; A.X33.a.5X.i; A.X34.a.5X.i; A.135.a.51.i; A.X36.a.5X.i; A.137.a.51.i; Α.138.3.51.χ; A.139.a.51.i; A.140.a.51.i; A.X4X.a.5X.i; A.2.b.46.i; A.3.b.46.i; A.4.b.46.i; A.5.b.46.i; A.7.b.46.i; A.9.b.46.i; A.100.b.46.i; A.101.b.46.i; A.XO2.b.46.i; A.103.b.46.i; A.104.b.46.i; A.105.b.46.i; A.106.b.46.i; A.107.b.46.i; A.108.b.46.i; A.109.b.46.i; A.110.b.46.i; A.XXX.b.46.i; A.U2.b.46.i; A.X13.b.46.i; A.XX4.b.46.i; A.115.b.46.i; A.U6.b.46.i; A.117.b.46.i; A.XX8.b.46.i; A.119.b.46.i; A.120.b.46.i; A.121.b.46.i; A.122.b.46.i; A.123.b.46.i; A.124.b.46.i; A.125, b.46.i; A.X26.b.46.i; A.127.b.46.i; A.X28.b.46.i; A.X29.b.46.i; A.130.b.46.i; A.X3I.b.46.i; A.132.b.46.i; A.133.b.46.i; A.134.b.46.i; A.135.b.46.i; A.X36.b.46.i; A 137.b.46.i; A.138.b.46.i; A.139.b.46, i; A.X40.b.46.i; A.141.b.46.i; A.2.b.47.i; A.3.b.47.i; A.4.b.47.i; A.5.b.47.i; A.7.b.47.i; A.9.b.47.i; A.100.b.47.i; A.101.b.47.i; A.XO2.b.47.i; A.103.b.47.1; A.104.b.47.Í; A.105.b.47.i; A.106.b.47.i; A.107.b.47.i; A.108.b.47.i; A.IO9.b.47.i; A.110.b.47.i; A.lll.b.47.i; A.112.b.47.i; A.113.b47.í; A.114.b.47.i; A.115.b.47.i; A.116.b.47.x; A.117.b.47.i; A.XX8.b.47.i; A.119.b.47.i; A.120.b.47.i; A.121.b.47.i; A.122.b.47.i; A.123.b.47.i; A.124.b.47.i; A.125.b.47.i; A.X26.b.47.i; A.127.b.47.i; A.128.b.47.i; A.129.b.47.i; A.130.b.47.i; A.131.b.47.i; A.X32.b.47.i; A.X33.b.47.i; A.X34.b.47.i; A.I35.b.47.i; A.136.b.47.i; A.X37.b.47.i; A.138.b.47.i; A.139.b.47á; A.140.b.47.i; A.14X.b.47.i; A.2.b.48.i; A.3.b.48.i; A.4.b.48.i; A.5.b.48.i; A.7.b.48.i; A.9.b.48.i; A.100.b.48.i; A.1O1 .b.48.i; A.X02.b.48.i; A.103.b.48.i; A.104.b.48.i; A.X05.b.48.i; A.106.b.48.i; A.107.b.48.i; A.X08.b.48.i; A.XO9.b.48.i; A.XX0.b.48.i; A.lll.b.48á; A.lX2.b.48.i; A.X13.b.48.i; A.114.b.48.i; A.XX5.b.48.i; A.XX6.b.48.i; A.117.b.48.i; A.X18.b.48.i; A.XX9.b.48.i; A.120, b.48.i; A.X2X.b.48.i; A.X22.b.48.i; A.X23.b.48.i; A.X24.b.48.i; A.125.b.48.i; A.X26.b.48.i; A.X27.b.48.i; A.X28.b.48.i; A.X29.b.48.i; A.X30.b.48.i; A.X3X.b.48.i; A.132.b.48.i; A.X33.b.48.i; A.134.b.48.i; A.X35.b.48.i; A.X36.b.48.i; A.X37.b.48.i; A.X38.b.48.i; A.X39.b, 48. A.X40.b.48.i; A.X4X.b.48.i; A.2.b.49.i; A.3.b.49.i; A.4.b.49.i; A.5.b.49.i; A.7.b.49.i; A.9.b.49.i; A.X00.b.49.i; A.XOX, b.49.i; A.XQ2.b.49.i; A.103.b.49.i;
- 142CZ 297945 B6- 142GB 297945 B6
A.104.b.49.i; A.105.b.49.i; A106.b.494; A.107.b.49.i; A.108.b.49.i; A.109.b.49.i; A.110.b.49.i; A.lll.b.49.i; A.112.b.49.i; A.113.b.494; A.114.b.49.i; A.115.E494; A.116.b.49.i; A.117.b.49.i; A.118.b.49.i; A.119.b.49.i; A.120.b.494; A.121.b.494; A.122.b.49.i; A.123.b.494; A.124.b.49.i; A.125.b.49.i; A.126.b.49.i; A.127.b.494; A.128.b.49.i; A.129.b,494; A.130.b.494; A.131.b,494; A.132.b.494; A.133.b.49.i; A.134.b.49.i; A.135.b.49.i; A.136.b.49.i; A.137.b.494; A.138.b.49.i; A.139.b.49.i; A.140.b.49.i; A.141.b.49.i; A.2.b.5O4; A.3.b.50.i; A.4.b.5O4; A.5.b.5O4; A.7.b.50.i; A.9.b.50.i; A.100.b.50.i; A101.b.50.i; A.102.b.50.i; A.103.b.50.i; A.104.b.50.i; A.105.b,504; A.106.b.50.i;A.107.b.50.i; A.108>b.504; A.109.b.50.i; A.110.b.504; A.lU.b.50.i; A.112.b.5O4; A.113.b.5O4; A.114.b.5O4; A.115.b.50.i; A.116.b.50.i; A-117.b.5O4; A.118.b.5Q4;A.119.b.50.i; A.120.b.50.i; A.121.b.50.i; A.122.b.50.i; A.123.b.50.i; A.124.b.5O4; A.125.b.50.i; A.126.b.5O4; A.127.b.50.i; A.128.b.50.i; A.129.b.50.i; A.130.b.50 4; A.131.b.50.i; A.132.b.5O4; A.133.b.50.i; A.134.b.5O4; A.135.b.5O4; A.136.b.5O4; A.137.b.5O4; A.138.b.5O.i; A.139.b.5O4; A.14O.b.5O4; A.141.b.5O4; A.2.b.51.i; A.3.b.51.i; A.4.b.51.i; A.5.b.51.i; A.7.b.51.i; A.9.b.514; A.100.b.51.i; A.101.b.51.i; A.102.b.51.i; A.103.b.51.i; A.104.b.51.i; A.105.b.514; A.106.b.51.i; A.107.b.51.i; A.108.b.51.i; A,109.b.51.i; A.llO.b.514; A.lll.b.514; A.112.b.51.i; A.113.b.514; A.114.b.51.i; A.115.b.514; A.116.b.51.i; A.117.b.51.i; A.118.b.51.i; A.119.b.51.i; A.120.b.514; A.121.b.51.i; A.122.b.51.i; A.123.b.51.i; A.124.b.51.i; A.125.b.51.i; A.126.b.51.i; A.127.b.51.i; A.128.b.51.i; A.129.b.51.i; A.130.b.514; A.131.b.51.i; A.132.b.51.i; A.133.b.514; A.134.b.51.i; A.135.b.51.i; A.136.b.51.i; A.137.b.51.i; A.138.b.51.i; A.139.b.51.i; A.140.b.51.i; A.141.b.51.i; A.2.X.464; A.3.X.464; A.4.X.464; A.5.X.464; A.7.X.464; A.9.X.464; A.lOO.x.464; A.lOl.x.464; A.102.X.464; A.103.X.464; A.104.X.464; A.105.X.464; A.106.X.464; A.107.X.464; A.108.X.464; A.109.X.464; A.llO.x.464; A.lll.x.464; A.112.X.464; A.113.X.464; A.114.X.464; A.115.X.464; A.lló.x.464; A.117.X.464; A.118.X.464; A.119.X.464; A.120.X.464; A.121.X.464; A.122.X.464; A.123.X.464; A.124.X.464; A.125.X.464; A.126.X.464; A.127.X.464; A.128.X.464; A.129.X.464; A.130.X.464; A.131.X.464; A.132.X.464; A.133.X.464; A.134.X.464; A.135.X.464; A.136.X.464; A.137.X.464; A.138.X.464; A.139.X.464; A.140.X.464; A.141.X.464; A.2.X.474; A.3.X.474; A.4.X.474; A.5.X.474; A.7.X.47.Í; A.9.X.474; A.lOO.x.474; A.lOl.x.474; A.102.X.474; A.103.X.474; Α104.Χ.474; A.105.X.474; A.106.X.474; A.107.X.474; A.108.X.474; A.109.X.474; A.llO.x.474; A.lll.x.474; A.112.X.474; A.113.X.474; A.114.X.474; A.115.X.474; A.116.x.47.i; A.117.X.474; A.118;x.47.i; A.119.X.474; A.120.X.474; A.121.X.474; A.122.X.474; A.123.X.474; A.124.X.474; A.125.X.474; A.126.X.474; A.127.X.474; A.128.X.474; A.129.X.474; A.130.X.474; A.131.X.474; A.132.X.474; A.133.X.474; A.134.X.474· A.135.x.47.i; A.136.X.474; A.137.X.474; A.138.X.474; A.139.X.474; A.140.X.474; A.141.X.474; A.2.X.484; A.3.X.484;A.104.b.49.i; A.105.b.49.i; A106.b.494; A.107.b.49.i; A.108.b.49.i; A.109.b.49.i; A.110.b.49.i; A.lll.b.49.i; A.112.b.49.i; A.113.b.494; A.114.b.49.i; A.115.E494; A.116.b.49.i; A.117.b.49.i; A.118.b.49.i; A.119.b.49.i; A.120.b.494; A.121.b.494; A.122.b.49.i; A.123.b.494; A.124.b.49.i; A.125.b.49.i; A.126.b.49.i; A.127.b.494; A.128.b.49.i; A.129.b, 494; A.130.b.494; A.131.b, 494; A.132.b.494; A.133.b.49.i; A.134.b.49.i; A.135.b.49.i; A.136.b.49.i; A.137.b.494; A.138.b.49.i; A.139.b.49.i; A.140.b.49.i; A.141.b.49.i; A.2.b.5O4; A.3.b.50.i; A.4.b.5O4; A.5.b.5O4; A.7.b.50.i; A.9.b.50.i; A.100.b.50.i; A101.b.50.i; A.102.b.50.i; A.103.b.50.i; A.104.b.50.i; A.105.b, 504; A.106.b.50.i; A.107.b.50.i; A.108> b.504; A.109.b.50.i; A.110.b.504; A.lU.b.50.i; A.112.b.5O4; A.113.b.5O4; A.114.b.5O4; A.115.b.50.i; A.116.b.50.i; A-117.b.5O4; A.118.b.5Q4; A.119.b.50.i; A.120.b.50.i; A.121.b.50.i; A.122.b.50.i; A.123.b.50.i; A.124.b.5O4; A.125.b.50.i; A.126.b.5O4; A.127.b.50.i; A.128.b.50.i; A.129.b.50.i; A.130.b.50 4; A.131.b.50.i; A.132.b.5O4; A.133.b.50.i; A.134.b.5O4; A.135.b.5O4; A.136.b.5O4; A.137.b.5O4; A.138.b.5O.i; A.139.b.5O4; A.14O.b.5O4; A.141.b.5O4; A.2.b.51.i; A.3.b.51.i; A.4.b.51.i; A.5.b.51.i; A.7.b.51.i; A.9.b.514; A.100.b.51.i; A.101.b.51.i; A.102.b.51.i; A.103.b.51.i; A.104.b.51.i; A.105.b.514; A.106.b.51.i; A.107.b.51.i; A.108.b.51.i; A, 109.b.51.i; A.llO.b.514; A.lll.b.514; A.112.b.51.i; A.113.b.514; A.114.b.51.i; A.115.b.514; A.116.b.51.i; A.117.b.51.i; A.118.b.51.i; A.119.b.51.i; A.120.b.514; A.121.b.51.i; A.122.b.51.i; A.123.b.51.i; A.124.b.51.i; A.125.b.51.i; A.126.b.51.i; A.127.b.51.i; A.128.b.51.i; A.129.b.51.i; A.130.b.514; A.131.b.51.i; A.132.b.51.i; A.133.b.514; A.134.b.51.i; A.135.b.51.i; A.136.b.51.i; A.137.b.51.i; A.138.b.51.i; A.139.b.51.i; A.140.b.51.i; A.141.b.51.i; A.2.X.464; A.3.X.464; A.4.X.464; A.5.X.464; A.7.X.464; A.9.X.464; A.100.x.464; A.lOl.x.464; A.102.X.464; A.103.X.464; A.104.X.464; A.105.X.464; A.106.X.464; A.107.X.464; A.108.X.464; A.109.X.464; A.llO.x.464; A.lll.x.464; A.112.X.464; A.113.X.464; A.114.X.464; A.115.X.464; A.lló.x.464; A.117.X.464; A.118.X.464; A.119.X.464; A.120.X.464; A.121.X.464; A.122.X.464; A.123.X.464; A.124.X.464; A.125.X.464; A.126.X.464; A.127.X.464; A.128.X.464; A.129.X.464; A.130.X.464; A.131.X.464; A.132.X.464; A.133.X.464; A.134.X.464; A.135.X.464; A.136.X.464; A.137.X.464; A.138.X.464; A.139.X.464; A.140.X.464; A.141.X.464; A.2.X.474; A.3.X.474; A.4.X.474; A.5.X.474; A.7.X.47.Í; A.9.X.474; A.100.x.474; A.lOl.x.474; A.102.X.474; A.103.X.474; Α104.Χ.474; A.105.X.474; A.106.X.474; A.107.X.474; A.108.X.474; A.109.X.474; A.llO.x.474; A.lll.x.474; A.112.X.474; A.113.X.474; A.114.X.474; A.115.X.474; A.116.x.47.i; A.117.X.474; A.118; A.119.X.474; A.120.X.474; A.121.X.474; A.122.X.474; A.123.X.474; A.124.X.474; A.125.X.474; A.126.X.474; A.127.X.474; A.128.X.474; A.129.X.474; A.130.X.474; A.131.X.474; A.132.X.474; A.133.X.474; A.134.X.474 · A.135.x.47.i; A.136.X.474; A.137.X.474; A.138.X.474; A.139.X.474; A.140.X.474; A.141.X.474; A.2.X.484; A.3.X.484;
A.4.X.484; A.S.x.484; A.7.X.484; A.9.X.484; A.lOO.x.484; A.lOl.x.484; A.102.X.484; A.103.X.484; A.104.X.484; A.105.X.48.Í; A.lOó.x.484· A.107.X.484; A.108.X.484; A.109.X.48.Í; A.UO.x.484; A.lll.x.484; A.112.X.484; A.113.X.484; A.114.X.484; A.115.X.484; A.116.X.484; A.117.X.484; A.118.X.484; A.119.X.484; A.120.X.484; A.121.X.484; A.122.X.484; A.123.X.48.Í; A.124.X.484; A.125.X.484; A.126.X.484; A.127.X.484; A.128.X.484; A.129.X.484; A.130.X.484; A.131.X.484; A.132.X.484; A.133.X.484; A.134.X.484; A.135.X.484; A.136.X.484; A.137.X.484; A.138.X.484; A.139.X.484; A.140.X.484; A.141.X.484; A.2.X.494; A.3.X.494; A.4.X.494; A.5.X.494; A.7.X.494; A.9.X.494; A.lOO.x.494; A.101.X.494; A.102.X.494; A.103.X.494;A.4.X.484; A.S.x.484; A.7.X.484; A.9.X.484; A.100.x.484; A.lOl.x.484; A.102.X.484; A.103.X.484; A.104.X.484; A.105.X.48.Í; A.107.X.484; A.108.X.484; A.109.X.48.Í; A.UO.x.484; A.lll.x.484; A.112.X.484; A.113.X.484; A.114.X.484; A.115.X.484; A.116.X.484; A.117.X.484; A.118.X.484; A.119.X.484; A.120.X.484; A.121.X.484; A.122.X.484; A.123.X.48.Í; A.124.X.484; A.125.X.484; A.126.X.484; A.127.X.484; A.128.X.484; A.129.X.484; A.130.X.484; A.131.X.484; A.132.X.484; A.133.X.484; A.134.X.484; A.135.X.484; A.136.X.484; A.137.X.484; A.138.X.484; A.139.X.484; A.140.X.484; A.141.X.484; A.2.X.494; A.3.X.494; A.4.X.494; A.5.X.494; A.7.X.494; A.9.X.494; A.100.x.494; A.101.X.494; A.102.X.494; A.103.X.494;
-143 CZ 297945 B6-143 CZ 297945 B6
A.104.X.49.Í; A.105.x.49.i; A.106.x.49.i; A.107.x.49.i; A.108.x.49.i; A.109.x.49.i; A.110.X.49.Í; A.lll.x.494; A.112.X.49.Í; A.113.x.49.i; A.114.X.49-i; A.115.X.49.Í; A.116.x.49.i; A.117.x.49.i; A.118.X.49.Í; A.119.X.49.Í; A.120.x.49.i; A.121.x.49.i; A.122.X.49.Í; A.123.x.49.i; A.124.X.49.Í; A.125.x.49.i; A.126.x.49.i; A.127,x.49.i; A.128.X.49.Í; A.129.x.49.i; A.130.x.49.i; A.131.x.49.i; A.132.x.49.i; A.133.x.49.i; A.134.X.49.Í; A.135.X.49.Í; A.136.x.49.i; A.137.x.49.i; A.138.X.49.Í; A.139.x.49.i; A.140.X.49.Í; A.141.x.49.i; A.2.X.50.Í; Α.3.Χ.50.Ϊ; A.4.X.50.Í; A.5.X.50.Í; A.7.x.50.i; A.9.x.50,i; A.100.X.50.Í; A.101.x.50.i; A.102.x.50.i; A.103.x.50.i; A.104.X.50.Í; A.105.X.50.Í; A.106.x.50.i; A.107.x.50.i; A.108.x.50.i; A.109.x50.i; A.110.X.50.Í; Α.111.Χ.50.Ϊ; A.112.x.50.i; A.113.X.504; Α.114.Χ.50.Ϊ; A.115.X-50.Í; A.116.x.50.i; A.117.X.5D.Í; A.118.X.50.Í; A.119.x,50.i; A.120.x.50.i; A.121.x.50.i; A.122.X.50.Í; Α.123.Χ.50.Ϊ; A.124.x.50.i; A.125.x.50.i; A.I26.X.50.1; A.127.x.50.i; A.128.x.50.i; A.129.X.50.Í; A.130.X.50.Í; A.131.x.50.i; A.132.X.50.Í; A.133.X.50.Í; A.134.X.50.Í; A.135.X.50.Í; A.136,x.50.i; A.137.x.50.i; A.138.x.50.i; A.139.x.50.i; A.140.x.50.i; A.141.X.50.Í; A.2.x.51.i; Α.3.Χ.51.Ϊ; A.4.x,51.i; A.5.X.51.Í; A.7.x.51.i; A.9.x.51.i; A.100.X.51.Í; A.101.X.51.Í; A.102.x.51.i; A.103.x.51.i; A.104.x.51.i; A.105.X.5U; A.106.X.51.Í; A.107.x.51.i; A.108.X.514; A.109.X.514; A.llO.x.514; A.lll.x.514; A.112.X.514; Α.Π3.Χ.514; A.114.X.514; A.115.X.514; A.116.X.514; A.117.X.514; A.118.X.514; A419.X.514; A.120.X.514; A.121.X.514; A.122.X.514; A.123.X.514; A-124.X.514; A.125.X.514; A.126.X.514; A.127.X.514; A.128.X.514; A.129.X.514; A.130.X.514; A.131.X.514; A.132.X.514; A.133.X.514; A.134.X.514; A.135.X.514; A-136.X.514; A.137.X.514; A.138.X.514; A.139.X.514; A.140.X.514; A.141.X.514; A.2.V.464; A.3.y.46.i; A.4.y.46.i; A.5.y.46.i; A.7.y.464; A.9.y.464; A.100.y.464;A.104.X.49.Í; A.105.x.49.i; A.106.x.49.i; A.107.x.49.i; A.108.x.49.i; A.109.x.49.i; A.110.X.49.Í; A.lll.x.494; A.112.X.49.Í; A.113.x.49.i; A.114.X.49-i; A.115.X.49.Í; A.116.x.49.i; A.117.x.49.i; A.118.X.49.Í; A.119.X.49.Í; A.120.x.49.i; A.121.x.49.i; A.122.X.49.Í; A.123.x.49.i; A.124.X.49.Í; A.125.x.49.i; A.126.x.49.i; A.127, x.49.i; A.128.X.49.Í; A.129.x.49.i; A.130.x.49.i; A.131.x.49.i; A.132.x.49.i; A.133.x.49.i; A.134.X.49.Í; A.135.X.49.Í; A.136.x.49.i; A.137.x.49.i; A.138.X.49.Í; A.139.x.49.i; A.140.X.49.Í; A.141.x.49.i; A.2.X.50.I; Α.3.Χ.50.Ϊ; A.4.X.50.I; A.5.X.50.I; A.7.x.50.i; A.9.x.50, i; A.100.X.50.I; A.101.x.50.i; A.102.x.50.i; A.103.x.50.i; A.104.X.50.Í; A.105.X.50.Í; A.106.x.50.i; A.107.x.50.i; A.108.x.50.i; A.109.x50.i; A.110.X.50.I; Α.111.Χ.50.Ϊ; A.112.x.50.i; A.113.X.504; Α.114.Χ.50.Ϊ; A.115.X-50I; A.116.x.50.i; A.117.X.5D.I; A.118.X.50.Í; A.119.x, 50.i; A.120.x.50.i; A.121.x.50.i; A.122.X.50.I; Α.123.Χ.50.Ϊ; A.124.x.50.i; A.125.x.50.i; A.I26.X.50.1; A.127.x.50.i; A.128.x.50.i; A.129.X.50.Í; A.130.X.50.I; A.131.x.50.i; A.132.X.50.I; A.133.X.50.I; A.134.X.50.I; A.135.X.50.I; A.136, x.50.i; A.137.x.50.i; A.138.x.50.i; A.139.x.50.i; A.140.x.50.i; A.141.X.50.I; A.2.x.51.i; Α.3.Χ.51.Ϊ; A.4.x, 51.i; A.5.X.51.Í; A.7.x.51.i; A.9.x.51.i; A.100.X.51.Í; A.101.X.51.Í; A.102.x.51.i; A.103.x.51.i; A.104.x.51.i; A.105.X.5U; A.106.X.51.Í; A.107.x.51.i; A.108.X.514; A.109.X.514; A.llO.x.514; A.lll.x.514; A.112.X.514; Α.Π3.Χ.514; A.114.X.514; A.115.X.514; A.116.X.514; A.117.X.514; A.118.X.514; A419.X.514; A.120.X.514; A.121.X.514; A.122.X.514; A.123.X.514; A-124.X.514; A.125.X.514; A.126.X.514; A.127.X.514; A.128.X.514; A.129.X.514; A.130.X.514; A.131.X.514; A.132.X.514; A.133.X.514; A.134.X.514; A.135.X.514; A-136.X.514; A.137.X.514; A.138.X.514; A.139.X.514; A.140.X.514; A.141.X.514; A.2.V.464; A.3.y.46.i; A.4.y.46.i; A.5.y.46.i; A.7.y.464; A.9.y.464; A.100.y.464;
A.ldl.y.464; A.102.y.464; A.103.y.464; A.104.y.464; A.105.y.464; A.106.v.46.i; A.107.y.464; A.108.y.464; A.109.V.464; A.110.y.464; A.lll.y.464; A.112.y.464; A.113.y.464; A.114.V.464; A.U5.ý.464; A.116.y,464; A.117.y.464; A.118.y.46.i; A.119.y.46.i; A.120.y.464; A.121.y.464; A.122.y.464; A.123.y.464; A.124.y.464; A.125.y.46.i; A.126.V.464; A.127.y.464; A.128.y.464; A.129.y.46.i; A.130.y.464; A.131.y.464; A.132.ý.46 i; A.133.V.464; A.134.y.46.i; A.135.y.46.i; A.136.y.46.i; A.137.y.46.i; A.138.V.464; A.139.V.464; A.140.y.464; A.141.y.464; A.2.y,474; A.3.y.474; A.4.y.47,i; A.S.y.474; A.7.V.474; A.9.y.474; A.lOÓ.y.474; A.ÍOl.y.474; A.lÓ2.y.474; A.103.v.47.i; A.104.V-474; A.105.V.474; A.lOó.y.474; A.107.y.474; A.108.y.474; A.109.V.474; A.llO.y.474; A.lll.ý.474; A.112.V.474; A.113.y.474; A.114.y.474; A.115.y.474; A.116.V.474; A.117.y.47.i; A.118.y.474; A.119.y.47.i; A.120.y.47.i; A.121.V.474; A.122.v.47.i; A.123.y.47.i; A.124.y.47.i; A.125.y.47.i; A.126.y.47.i; A.127.ý.47.i; A.128.y.47.i; A.129.y.47.i; A.130.y.47.i; A.131.y.47.i; A.132.y.47.i; A.133.v.47.i; A.134.V.47.Í; A.135.y.47.i; A.136.v»47.i; A.137.v.47.i; A.138.y.47.i; A.139.y,47.i; A.140.y.47.i; A.141.y.47.i; A.2.y.48.i; A.3.y.48.i; A.4.V.48.Í; A.5.v.48,i; A.7.V.48.Í; Á.9.y.48.i; A.Í00.y.48.i; Á.101.y.48.i; A.102.V.48.Í; A.1Ó3.V.48.Í; a'104.v.48.í; A.105.y.48.i; A.106.y.48.i; A.107.v.48.i; A.108.V.48.Í; A.109.V.48.Í; A.110.v.48.i; A.111.V.48.Í; A.112.v.48.i; A.113.V.48.Í; A.114.y.48.i; A.115.V.48.Í; A.U6.v.48.i; A.117.y.48.i; A.118.V.48.Í; A.119.V.48.Í; A.120.y.48.i; A.121.V.48.Í; A.122.V.48.Í; A.123.v.48.i; A.124.v.48.i; A.125.V.48.Í; A.126.V.48.Í; A.127.V.48.Í; A.128.v.48.i; A.129.v.48.i; A.130.v.48.i; A.131.v.48.i; A.132.v.48.i; A.133.y.48.i; A.134.V.48.Í; A.135.y.48.i; A.136.V.48.Í; A.137.y.48.i; A.138.ý.48.i;A.ldl.y.464; A.102.y.464; A.103.y.464; A.104.y.464; A.105.y.464; A.106.v.46.i; A.107.y.464; A.108.y.464; A.109.V.464; A.110.y.464; A.lll.y.464; A.112.y.464; A.113.y.464; A.114.V.464; A.U5.ý.464; A.116.y, 464; A.117.y.464; A.118.y.46.i; A.119.y.46.i; A.120.y.464; A.121.y.464; A.122.y.464; A.123.y.464; A.124.y.464; A.125.y.46.i; A.126.V.464; A.127.y.464; A.128.y.464; A.129.y.46.i; A.130.y.464; A.131.y.464; A.132.ý.46 i; A.133.V.464; A.134.y.46.i; A.135.y.46.i; A.136.y.46.i; A.137.y.46.i; A.138.V.464; A.139.V.464; A.140.y.464; A.141.y.464; A.2.y, 474; A.3.y.474; A.4.y.47, i; A.S.y.474; A.7.V.474; A.9.y.474; A.10O6.y.474; A.ÍOl.y.474; A.lÓ2.y.474; A.103.v.47.i; A.104.V-474; A.105.V.474; A.106.y.474; A.107.y.474; A.108.y.474; A.109.V.474; A.ll0.y.474; A.lll.ý.474; A.112.V.474; A.113.y.474; A.114.y.474; A.115.y.474; A.116.V.474; A.117.y.47.i; A.118.y.474; A.119.y.47.i; A.120.y.47.i; A.121.V.474; A.122.v.47.i; A.123.y.47.i; A.124.y.47.i; A.125.y.47.i; A.126.y.47.i; A.127.ý.47.i; A.128.y.47.i; A.129.y.47.i; A.130.y.47.i; A.131.y.47.i; A.132.y.47.i; A.133.v.47.i; A.134.V.47.Í; A.135.y.47.i; A.136.v »47.i; A.137.v.47.i; A.138.y.47.i; A.139.y, 47.i; A.140.y.47.i; A.141.y.47.i; A.2.y.48.i; A.3.y.48.i; A.4.V.48.Í; A.5.v.48, i; A.7.V.48.Í; Á.9.y.48.i; A.Í00.y.48.i; Á.101.y.48.i; A.102.V.48.Í; A.1Ó3.V.48.Í; a'104.v.48.í; A.105.y.48.i; A.106.y.48.i; A.107.v.48.i; A.108.V.48.Í; A.109.V.48.Í; A.110.v.48.i; A.111.V.48.Í; A.112.v.48.i; A.113.V.48.Í; A.114.y.48.i; A.115.V.48.Í; A.U6.v.48.i; A.117.y.48.i; A.118.V.48.Í; A.119.V.48.Í; A.120.y.48.i; A.121.V.48.Í; A.122.V.48.Í; A.123.v.48.i; A.124.v.48.i; A.125.V.48.Í; A.126.V.48.Í; A.127.V.48.Í; A.128.v.48.i; A.129.v.48.i; A.130.v.48.i; A.131.v.48.i; A.132.v.48.i; A.133.y.48.i; A.134.V.48.Í; A.135.y.48.i; A.136.V.48.Í; A.137.y.48.i; A.138.ý.48.i;
A.139.y.48.i; A.140.v.48.i; A.141.y.48.i; A.2.y.49.i; A.3.y.49.i; A.4.v.49.i; Á.5.v.49.i; A.7.y.49.i; A.9.y.49.i; A.100,y.49.i; A.101.V.49.Í; A.102.y.49.i; A.lÓ3.v.49.i;A.139.y.48.i; A.140.v.48.i; A.141.y.48.i; A.2.y.49.i; A.3.y.49.i; A.4.v.49.i; Á.5.v.49.i; A.7.y.49.i; A.9.y.49.i; A.100, y.49.i; A.101.V.49.Í; A.102.y.49.i; A.lÓ3.v.49.i;
- 144CZ 297945 B6- 144GB 297945 B6
A.104.y.49.i; A.105.v.49.i; Á.106.V.49.Í; A.107.V.49 j; A.108y.49d; A.109.y.49.i; A.110.V.49.Í; A.lll.v.49.i; A.1I2.V.49.Í; A.113.ý.49.i; A.114.y.49.i; A.115.y.49.i; A.116.ý.49.i; A.117.y.49.i; A.118.ý.49.i; A.119,v,49.i; A.120.y.49.i; A.121.y.49.i; A.122.y.49.i; A.123.V.49.Í; A.124.y.49.i; A.125.v.49.i; A.126.v.49.i; A.127.y.49.i; A.128.y.49.i; A.129.V.49.Í; A.130.v.49.i; A.131.ý.49.i; A.132.V.49.Í; A.133.y.49.i; A.134.y.49.i; A.135.V.49.Í; A.136.v.49.i; A.137.y.49.i; A.138.y.49.i; A.139.y.49.i; A.140.y.49.i; A.141.V.49.Í; A.2.y.50.i; A.3.y.50.i; AAy.SO.i; A.5.y.50.i; A,7.y.50.i; A.9.y.50.i; A.100.V.50.Í; A.lOl.v.SO.i; A.102.v.50.i; A.103.v.50.i; A.104.y.50.i; A.105.y.50.i; A.lÓ6.v.50.i; A.W7.y.50.i; A.108.y.50.i; A.lÓ9.y.50.i; A.110.y.50.i; A.lll.y.50.i; A.112.'y.50.i; A.113.y.50.i; A.114.y.50.i; A.115.y.50.i; A.116.y.50.i; A.117.y.50.i; A.llS.y.SO.i; A.119,y.50.i; A.120.y.50.i; A.121.y.50.i; A.122.y.50.i; A.123.y.50.i; A.124.y.50.i; A.125.y.50.i; A.126.y.50.i; A.127.y.50.i; A.128.y.50.i; A.129.y.50.i; A.130.v.50.i; A.131.y.50.i; A.132.y.50.i; A.133.y.50.i; A.134.y,50.i; A.135.y.50.i; A.I36.y.50.i; A.137.y.50.i; A.138.y.50.i; A.139.y.50.i; A.140.y.50.i; A.141.y.50.i; A.2.y.51.i; A.3.y.51.i; A.4.y.51.i; A.5.y.51.i; A.7.y.51,i; A.9.y.51.i; A.lOO.y.Sl.i; A.lÓl.y.51.i; A.102.y.51.i; A.103.y.51.i; A.104.y.51.i; A.105.y.51.i; A.106.V.51.Í; A.107.y.51i; A.108.y.51.i; A.109.y.51.i; A.llO.y.51 .i; A.lll.y.51.i; A.1I2.V.51.Í; A.113.v.51.i; A.114.v.51.i; A.115.v.51.i; A.116.v.51.i; A.117.v.51.i; A.118.y.51.i; A.U9.ý.5I.i; A.120.y.51.i; A.121.ý.51.i; A.122.y.5Li; A.123.y.51.i; A.124.y.51.í; A.I25.y.5I.i; A.126.y.51.i; A.127.y.51.i; A.128.y.51.i; A.129.y.51.i; A.130.y.51.i; A.131.v.51.i; A.132.y.51.i; A.133.y.51.i; A.134.v.51.i; A.135.y.51.i; A.136.y.51.i; A.137.y.51.i; A.138.y.51.i; A.139.y.51.i; A.140.y.51.i; A.14Ly.51.i; A.2.Z.46.Í; Α.3.Ζ.46.Ϊ; A.4.Z.46.Í; Á.5.Z.46.Í; A.7.z.46.i; A.9.z.46,i; A.100.z.46.i; Α.101.Ζ.46.Ϊ; A.1Q2.Z.46.Í; A.103.z.46.i; A.104.z.46.i; A.105.z.46.i; A.106.Z.46.Í; A.107.Z.46.Í; A.108.z.46.i; A.109.z.46.i; A.110.Z.46.Í; A.llLz.46.i; A.112.z.46.i; A.113.Z.46.Í; A.114.Z.46.Í; A.115.z.46.i; A.116.Z.46.Í; A.117.Z.46.Í; A.118.Z.46.Í; A.U9.Z.46.Í; A.120.Z.46.Í; A.121.Z.46.1; A.Í22.z.46.i; A.123.z.46.i; A.124.z.46.i; A.125.Z.46.Í; A.126.Z.46.Í; A.127.z.46.i; A.128.z.46.i; A.129.z.46.i; A.130.z,46.i; A.131.Z.46.Í; A.132.Z.46.Í; A.133.z.46.i; Α.134.Ζ.46.Ϊ; A.I35.z.4ó.i;A.136.z.46.i; A.137.Z.46.Í; A.138.Z.46.Í; A.139.z.46.i; A.140.Z.46.Í; A.141.z.46.i; A.2.Z.47.Í; A.3.Z.47.Í; A.4.Z.47.Í; A.5.z.47.i; A.7.z.47.i; A.9.z.47.i; A.100.z.47.i; A.101.z.47.i; A.102.Z.47.Í; A.103.z.47.i; A.104.Z.47.Í; A.105.Z.47.1; A.106.Z.47.Í; A.107.z.47.i; A.108.Z.47.Í; A.109.z.47.i; A.lW.z.47.i; A.111.Z.47.Í; A.112.z.47.i; A.113.Z.47.Í; A.114.Z.47.Í; A.115.Z.47.Í; A.116.z.47.i; A.117.Z.47.Í; A.118.Z.47.Í; A.119.z.47.i; A.120.Z.47.Í; A.12Lz.47.i; A.122.Z.47.Í; A.123.Z.47.Í; A.124.Z.47.Í; A.125.Z.47.Í; A.126.Z.47.Í; A.127.Z.47.Í; A.128.Z.47.Í; A.129.Z.47.Í; A.130.Z.47.Í; A.131.Z.47.Í; A.132.Z.47.Í; A.I33.Z.47.Í; A.134.Z.47.Í; A.135.Z.47.Í; A.136.Z.47.Í; A.137.z.47.i; A.138.Z.47.Í; A.139.z.47.i; A.140.z.47.i; A.141.Z.47.Í; A.2.z.48.i; A.3.z.48.i;A.104.y.49.i; A.105.v.49.i; Á.106.V.49.Í; A.107.V.49 j; A.108y.49d; A.109.y.49.i; A.110.V.49.Í; A.lll.v.49.i; A.1I2.V.49.Í; A.113.ý.49.i; A.114.y.49.i; A.115.y.49.i; A.116.ý.49.i; A.117.y.49.i; A.118.ý.49.i; A.119, v, 49.i; A.120.y.49.i; A.121.y.49.i; A.122.y.49.i; A.123.V.49.Í; A.124.y.49.i; A.125.v.49.i; A.126.v.49.i; A.127.y.49.i; A.128.y.49.i; A.129.V.49.Í; A.130.v.49.i; A.131.ý.49.i; A.132.V.49.Í; A.133.y.49.i; A.134.y.49.i; A.135.V.49.Í; A.136.v.49.i; A.137.y.49.i; A.138.y.49.i; A.139.y.49.i; A.140.y.49.i; A.141.V.49.Í; A.2.y.50.i; A.3.y.50.i; AAy.SO.i; A.5.y.50.i; A, 7.y.50.i; A.9.y.50.i; A.100.V.50.I; A.lOl.v.SO.i; A.102.v.50.i; A.103.v.50.i; A.104.y.50.i; A.105.y.50.i; A.lÓ6.v.50.i; A.W7.y.50.i; A.108.y.50.i; A.lÓ9.y.50.i; A.110.y.50.i; A.lll.y.50.i; A.112.'y.50.i; A.113.y.50.i; A.114.y.50.i; A.115.y.50.i; A.116.y.50.i; A.117.y.50.i; A.llS.y.SO.i; A.119, y.50.i; A.120.y.50.i; A.121.y.50.i; A.122.y.50.i; A.123.y.50.i; A.124.y.50.i; A.125.y.50.i; A.126.y.50.i; A.127.y.50.i; A.128.y.50.i; A.129.y.50.i; A.130.v.50.i; A.131.y.50.i; A.132.y.50.i; A.133.y.50.i; A.134.y, 50.i; A.135.y.50.i; A.I36.y.50.i; A.137.y.50.i; A.138.y.50.i; A.139.y.50.i; A.140.y.50.i; A.141.y.50.i; A.2.y.51.i; A.3.y.51.i; A.4.y.51.i; A.5.y.51.i; A.7.y.51, i; A.9.y.51.i; A.100.y.Sl.i; A.lÓl.y.51.i; A.102.y.51.i; A.103.y.51.i; A.104.y.51.i; A.105.y.51.i; A.106.V.51.Í; A.107.y.51i; A.108.y.51.i; A.109.y.51.i; A.ll0.y.51 .i; A.lll.y.51.i; A.1I2.V.51.Í; A.113.v.51.i; A.114.v.51.i; A.115.v.51.i; A.116.v.51.i; A.117.v.51.i; A.118.y.51.i; A.U9.ý.5I.i; A.120.y.51.i; A.121.ý.51.i; A.122.y.5Li; A.123.y.51.i; A.124.y.51.í; A.I25.y.5I.i; A.126.y.51.i; A.127.y.51.i; A.128.y.51.i; A.129.y.51.i; A.130.y.51.i; A.131.v.51.i; A.132.y.51.i; A.133.y.51.i; A.134.v.51.i; A.135.y.51.i; A.136.y.51.i; A.137.y.51.i; A.138.y.51.i; A.139.y.51.i; A.140.y.51.i; A.14Ly.51.i; A.2.Z.46.Í; Α.3.Ζ.46.Ϊ; A.4.Z.46.Í; Á.5.Z.46.Í; A.7.z.46.i; A.9.z.46, i; A.100.z.46.i; Α.101.Ζ.46.Ϊ; A.1Q2.Z.46.Í; A.103.z.46.i; A.104.z.46.i; A.105.z.46.i; A.106.Z.46.Í; A.107.Z.46.Í; A.108.z.46.i; A.109.z.46.i; A.110.Z.46.Í; A.llLz.46.i; A.112.z.46.i; A.113.Z.46.Í; A.114.Z.46.Í; A.115.z.46.i; A.116.Z.46.Í; A.117.Z.46.Í; A.118.Z.46.Í; A.U9.Z.46.Í; A.120.Z.46.Í; A.121.Z.46.1; A.Í22.z.46.i; A.123.z.46.i; A.124.z.46.i; A.125.Z.46.Í; A.126.Z.46.Í; A.127.z.46.i; A.128.z.46.i; A.129.z.46.i; A.130.z, 46.i; A.131.Z.46.Í; A.132.Z.46.Í; A.133.z.46.i; Α.134.Ζ.46.Ϊ; A.I35.z.46.i; A.136.z.46.i; A.137.Z.46.Í; A.138.Z.46.Í; A.139.z.46.i; A.140.Z.46.Í; A.141.z.46.i; A.2.Z.47.Í; A.3.Z.47.Í; A.4.Z.47.Í; A.5.z.47.i; A.7.z.47.i; A.9.z.47.i; A.100.z.47.i; A.101.z.47.i; A.102.Z.47.Í; A.103.z.47.i; A.104.Z.47.Í; A.105.Z.47.1; A.106.Z.47.Í; A.107.z.47.i; A.108.Z.47.Í; A.109.z.47.i; A.lW.z.47.i; A.111.Z.47.Í; A.112.z.47.i; A.113.Z.47.Í; A.114.Z.47.Í; A.115.Z.47.Í; A.116.z.47.i; A.117.Z.47.Í; A.118.Z.47.Í; A.119.z.47.i; A.120.Z.47.Í; A.12Lz.47.i; A.122.Z.47.Í; A.123.Z.47.Í; A.124.Z.47.Í; A.125.Z.47.Í; A.126.Z.47.Í; A.127.Z.47.Í; A.128.Z.47.Í; A.129.Z.47.Í; A.130.Z.47.Í; A.131.Z.47.Í; A.132.Z.47.Í; A.I33.Z.47.Í; A.134.Z.47.Í; A.135.Z.47.Í; A.136.Z.47.Í; A.137.z.47.i; A.138.Z.47.Í; A.139.z.47.i; A.140.z.47.i; A.141.Z.47.Í; A.2.z.48.i; A.3.z.48.i;
A.4.Z.48.Í; A.5.z.48.i; A.7.z,48.i; A.9.z.48.i; A.100.z.48.i; A.lOl.z.48.:; A.102.z.48.i; A.103.Z.48.Í; A.104.z.48.i; A.105.z.48.i; A.I06.z.48.i; A.107.z.48.i; A.108.z.48.i; A.109.Z.48.Í; A.110.z.48.i; A.lll.z.48.i; A.112,z.48.i; A.113.z.48.i; A.114.z.48.i; A.115.Z.48.Í; A.116.z.48.i; A.117.z.48.i; A.118.z.48.i; A.119.z.48.i; A.120.z.48.i; A.121.Z.48.Í; A,122.z.48.i; A.123.z.48.i; A.124.z.48.i; A.125.z.48.i; A.126.Z.48.Í; A.127.z.48,i; A.128.Z.48.Í; A.129.z.48.i; A.130.Z.48.Í; A.131.z.48.i; A.132.z.48.i; A.133.Z.48.Í; A.134.Z.48.Í; A.135.z.48.i; A.136.z.48.i; A.137.z.48.i; A.138.z.48.i;A.4.Z.48.Í; A.5.z.48.i; A.7.z, 48.i; A.9.z.48.i; A.100.z.48.i; A.lOl.z.48.:; A.102.z.48.i; A.103.Z.48.Í; A.104.z.48.i; A.105.z.48.i; A.I06.z.48.i; A.107.z.48.i; A.108.z.48.i; A.109.Z.48.Í; A.110.z.48.i; A.lll.z.48.i; A.112, z.48.i; A.113.z.48.i; A.114.z.48.i; A.115.Z.48.Í; A.116.z.48.i; A.117.z.48.i; A.118.z.48.i; A.119.z.48.i; A.120.z.48.i; A.121.Z.48.Í; A, 122.z.48.i; A.123.z.48.i; A.124.z.48.i; A.125.z.48.i; A.126.Z.48.Í; A.127.z.48, i; A.128.Z.48.Í; A.129.z.48.i; A.130.Z.48.Í; A.131.z.48.i; A.132.z.48.i; A.133.Z.48.Í; A.134.Z.48.Í; A.135.z.48.i; A.136.z.48.i; A.137.z.48.i; A.138.z.48.i;
A.139.Z.48J; A.140.z.48.i; A.141.Z.48.Í; A.2.Z.49.Í; A.3.z.49.i; A.4.Z.49.Í; A.5.z.49.i; A.7.Z.49.Í; A.9.z.49.i; Α.100.Ζ.49.Ϊ; A.101.Z.49.Í; A.102.Z.49.Í; A.103.z.49.i;A.139.Z.48J; A.140.z.48.i; A.141.Z.48.Í; A.2.Z.49.Í; A.3.z.49.i; A.4.Z.49.Í; A.5.z.49.i; A.7.Z.49.Í; A.9.z.49.i; Α.100.Ζ.49.Ϊ; A.101.Z.49.Í; A.102.Z.49.Í; A.103.z.49.i;
- 145 CZ 297945 B6- 145 GB 297945 B6
A.104.Z.49.Í; A.105.Z.49.Í; A.106.z.49.i; A.107.z.49.i; A.108.z.49.i; A.109.z.49.i; A.110.Z.49.Í; A.111.Z.49.Í; Α.1Ι2.Ζ.49.Ϊ; A.113.z.49j; A.114.z.49.i; A.115.z.49.i; A.116.z.49.i; A.117.Z.49.Í; A.118.Z.49.Í; A.119.z.49.i; A.120.Z.49.Í; A.121.Z.49.Í; Α.122.Ζ.49.Ϊ; A.123.Z.494; A.124.z.49.i; A.125.Z.49.Í; A.126.Z.49.Í; A.127.Z.494; A.128.Z.49.Í; A.129.Z.49.Í; A.130.Z.49.Í; A.131.Z.49.Í; A.132.z.49.i; A.133.Z.49.Í; A.134.Z.49.Í; A.135.z.49.i; A.136.Z.49.Í; A.137.z.49.i; A.138.z.49.i; A.139.z.49.i; A.140.z.49.i; A.141.z.49.i; A.2.z.50.i; Α.3.Ζ.50.Ϊ; A.4.Z.50.Í; A.5.z.50.i; A.7.z.50.i; A.9.Z.504; A.100.Z.50.Í; A.101.z.50.i; A.102.z.50.i; A.103.Z.50.Í; A.104.z.50.i; A.105.Z.50.Í; A.106.Z.50.Í; A.107.Z.50.Í; A.108.Z.50.Í; A.109.z.50.i; A.110.z30.i; A.111.Z.50.Í; A.112jz.50.í; A.113.Z.50.Í; A.U4.z.50.i; A.115.z.50.i; A.116.z.50.i; A.117.Z.50.Í; A.118.z.50.i; A.119.Z.50.Í; A.T20.z.50.i; Α.121.Ζ.50.Ϊ; A.122^.50.i; A.123.Z.50.Í; A.124.z.50.i; A.125.z.50.i; A.126.z.50.i; A.127.Z.50.Í; A.128.Z.50.Í; A.129.Z.50.Í; A.130.z.50.i; A.131.z.50.i; A.132.z.50.i; A.133.Z.50.Í; A.134.Z.5O.i; A.135.Z.50.Í; A.136.Z.50.1; A.137.z.50.i; A.138.z.50.i; A.139.Z.50.Í; A.140.z.50.i; A.141.Z.50.Í; A.2.z.51.i; A.3.z.51.i; A.4.Z.51.Í; A.5.z.51.i; A.7.Z.51.Í; A.9.z.51.i; A.100.Z.51.Í; A.101.z.51.i; A.102.z.51.i; A.103.z.51.i; A.104.Z.51.Í; A.105.z.51.i; Α.106.Ζ.51.Ϊ; A.107.z.51.i; A.1O8.Z.51.Í; A.109.Z.51.Í; A.110.Z.51.Í; A.lll.z.51.i; A.112.Z.51.Í; A.113.Z.5Í.Í; A.114.z.51.i; A.115.z.51.i; A.116.z.51.i; A.117.z.51.i; A.118.Z.51.Í; A.1I9.Z.51.Í; A.120.z.51.i; A.121,z.51.i; A.122.Z.51.Í; A.123.z.51.i; A.124.Z.51.Í; A.125.z.51.i; A.126.Z.51.Í; A.127.z.51.i; A.128.z.51.i; A.129.z.51.i; A.130.Z.51.Í; A.131.Z.51.Í; A.132.z.51.i; A.133.z.51.i; A.134.z.51.i; A.135,z.51.i; Α.136.Ζ.51.Ϊ; A.137.z.51.i; A.138.Z.51.Í; A.139.z.51.i; A.140.Z.51.Í; A.141.z.51.i; A.2.A.46.Í; Α.3.Α.46.Ϊ; A.4.A.46.Í; A.5.A.46.Í; A.7.A.46.Í; A.9.A.46.Í; A.100.A.46.Í; A.101.A.46.Í; A.102.A.46.Í; A.103.A.46.Í; A.104.A.46.Í; A.105.A.46.Í; A.106.A.46.Í; A.107.A.46.Í; A.108.A.46.Í; Α.1Ό9.Α.46.Ϊ; A.110.A.46.Í; A.11LA.46.Í; A.112.A.46.Í; Α.113.Α.46.Ϊ; A.114.A.46.Í; A.U5.A.46.Í; Α.116.Α.46.Ϊ; A.117.A.46.Í; A.118.A.46.Í; Α.Π9.Α.46.ί; A.120.A.46.Í; A.121.A.46.Í; A.122.A.46.Í; A.123.A.46.Í; A.124.A.46.Í; A.125.A.46.1; A.126.A.464; A.127.A.46.Í; A.128.A.46.Í; A.129.A.46.Í; Α.130.Α.46.Ϊ; A.131.A.46.Í; A.132.A.46.Í; A.133.A.46.Í; A.134.A.46.Í; A.135.A.46.Í; A.136.A.46.Í; A.137.A.46.Í; A.138.A.46.Í; A.139.A.46.Í; A.140.A.46.Í; A.I41.A.46.Í; A.2.A.47.Í; A.3.A.47.Í; A.4.A.47.Í; A.5.Á.47.Í; A.7.A.47.Í; A.9.A.47.Í; A.100.A.47.Í;A.104.Z.49.Í; A.105.Z.49.Í; A.106.z.49.i; A.107.z.49.i; A.108.z.49.i; A.109.z.49.i; A.110.Z.49.Í; A.111.Z.49.Í; Α.1Ι2.Ζ.49.Ϊ; A.113.z.49j; A.114.z.49.i; A.115.z.49.i; A.116.z.49.i; A.117.Z.49.Í; A.118.Z.49.Í; A.119.z.49.i; A.120.Z.49.Í; A.121.Z.49.Í; Α.122.Ζ.49.Ϊ; A.123.Z.494; A.124.z.49.i; A.125.Z.49.Í; A.126.Z.49.Í; A.127.Z.494; A.128.Z.49.Í; A.129.Z.49.Í; A.130.Z.49.Í; A.131.Z.49.Í; A.132.z.49.i; A.133.Z.49.Í; A.134.Z.49.Í; A.135.z.49.i; A.136.Z.49.Í; A.137.z.49.i; A.138.z.49.i; A.139.z.49.i; A.140.z.49.i; A.141.z.49.i; A.2.z.50.i; Α.3.Ζ.50.Ϊ; A.4.Z.50.I; A.5.z.50.i; A.7.z.50.i; A.9.Z.504; A.100.Z.50.I; A.101.z.50.i; A.102.z.50.i; A.103.Z.50.Í; A.104.z.50.i; A.105.Z.50.Í; A.106.Z.50.Í; A.107.Z.50.Í; A.108.Z.50.Í; A.109.z.50.i; A.110.z30.i; A.111.Z.50.Í; A.112jz.50.í; A.113.Z.50.Í; A.U4.z.50.i; A.115.z.50.i; A.116.z.50.i; A.117.Z.50.Í; A.118.z.50.i; A.119.Z.50.Í; A.T20.z.50.i; Α.121.Ζ.50.Ϊ; A.122 ^ .50.i; A.123.Z.50.Í; A.124.z.50.i; A.125.z.50.i; A.126.z.50.i; A.127.Z.50.Í; A.128.Z.50.Í; A.129.Z.50.Í; A.130.z.50.i; A.131.z.50.i; A.132.z.50.i; A.133.Z.50.I; A.134.Z.5O.i; A.135.Z.50.I; A.136.Z.50.1; A.137.z.50.i; A.138.z.50.i; A.139.Z.50.I; A.140.z.50.i; A.141.Z.50.I; A.2.z.51.i; A.3.z.51.i; A.4.Z.51.Í; A.5.z.51.i; A.7.Z.51.Í; A.9.z.51.i; A.100.Z.51.Í; A.101.z.51.i; A.102.z.51.i; A.103.z.51.i; A.104.Z.51.Í; A.105.z.51.i; Α.106.Ζ.51.Ϊ; A.107.z.51.i; A.1O8.Z.51.Í; A.109.Z.51.Í; A.110.Z.51.Í; A.lll.z.51.i; A.112.Z.51.Í; A.113.Z.5Í.Í; A.114.z.51.i; A.115.z.51.i; A.116.z.51.i; A.117.z.51.i; A.118.Z.51.Í; A.1I9.Z.51.Í; A.120.z.51.i; A.121, z.51.i; A.122.Z.51.Í; A.123.z.51.i; A.124.Z.51.Í; A.125.z.51.i; A.126.Z.51.Í; A.127.z.51.i; A.128.z.51.i; A.129.z.51.i; A.130.Z.51.Í; A.131.Z.51.Í; A.132.z.51.i; A.133.z.51.i; A.134.z.51.i; A.135, z.51.i; Α.136.Ζ.51.Ϊ; A.137.z.51.i; A.138.Z.51.Í; A.139.z.51.i; A.140.Z.51.Í; A.141.z.51.i; A.2.A.46.Í; Α.3.Α.46.Ϊ; A.4.A.46.Í; A.5.A.46.Í; A.7.A.46.Í; A.9.A.46.Í; A.100.A.46.Í; A.101.A.46.Í; A.102.A.46.Í; A.103.A.46.Í; A.104.A.46.Í; A.105.A.46.Í; A.106.A.46.Í; A.107.A.46.Í; A.108.A.46.Í; Α.1Ό9.Α.46.Ϊ; A.110.A.46.Í; A.11LA.46.Í; A.112.A.46.Í; Α.113.Α.46.Ϊ; A.114.A.46.Í; A.U5.A.46.Í; Α.116.Α.46.Ϊ; A.117.A.46.Í; A.118.A.46.Í; Α.Π9.Α.46.ί; A.120.A.46.Í; A.121.A.46.Í; A.122.A.46.Í; A.123.A.46.Í; A.124.A.46.Í; A.125.A.46.1; A.126.A.464; A.127.A.46.Í; A.128.A.46.Í; A.129.A.46.Í; Α.130.Α.46.Ϊ; A.131.A.46.Í; A.132.A.46.Í; A.133.A.46.Í; A.134.A.46.Í; A.135.A.46.Í; A.136.A.46.Í; A.137.A.46.Í; A.138.A.46.Í; A.139.A.46.Í; A.140.A.46.Í; A.I41.A.46.Í; A.2.A.47.Í; A.3.A.47.Í; A.4.A.47.Í; A.5.Á.47.Í; A.7.A.47.Í; A.9.A.47.Í; A.100.A.47.Í;
A.101.A.47.Í; A.102.A.47.Í; A.103.A.47.Í; A.104.A.47.Í; A.105.A.47.Í; A.106.A.47.Í; A.107.A.47.Í; A.108.A.47.Í; A.109.A.47.Í; A.U0.A.47.Í; A.111.A.47.Í; A.1I2.A.47.Í; Α.113.Α.47.Ϊ; A.114.A.47.Í; A.115.A.47.Í; A.116.A.47.Í; A.117.A.47.Í; A.118.A.47.Í; A.119.A.47.Í; Α.Ι20.Α.47.Ϊ; A.121.A.47.Í; A.122.A.47.Í; A.123.A.47.Í; A.124.A.47.Í; A.125.A.47.Í; A.126.A.47.Í; A.127.A.47.Í; A.128.A.47.Í; A.129.A.47.Í; A.130.A.47.Í; A.131.A.47.Í; A.132.A.47.Í; A.133.A.47.Í; A.134.A.47.Í; A.135.A.47.Í: A.136.A.47.Í; A.137.A.47.Í; A.138.A.47.Í; A.139.A.474; A.140.A.47.Í; A.141.A.47.Í; A.2.A.48.Í; A.3.A.48.Í; A.4.A.48.Í; A.5.A.48.Í; A.7.A.48.Í; A.9.A.48.Í; A.100.A.48.Í;A.101.A.47.Í; A.102.A.47.Í; A.103.A.47.Í; A.104.A.47.Í; A.105.A.47.Í; A.106.A.47.Í; A.107.A.47.Í; A.108.A.47.Í; A.109.A.47.Í; A.U0.A.47.Í; A.111.A.47.Í; A.1I2.A.47.Í; Α.113.Α.47.Ϊ; A.114.A.47.Í; A.115.A.47.Í; A.116.A.47.Í; A.117.A.47.Í; A.118.A.47.Í; A.119.A.47.Í; Α.Ι20.Α.47.Ϊ; A.121.A.47.Í; A.122.A.47.Í; A.123.A.47.Í; A.124.A.47.Í; A.125.A.47.Í; A.126.A.47.Í; A.127.A.47.Í; A.128.A.47.Í; A.129.A.47.Í; A.130.A.47.Í; A.131.A.47.Í; A.132.A.47.Í; A.133.A.47.Í; A.134.A.47.Í; A.135.A.47.I: A.136.A.47.I; A.137.A.47.Í; A.138.A.47.Í; A.139.A.474; A.140.A.47.Í; A.141.A.47.Í; A.2.A.48.Í; A.3.A.48.Í; A.4.A.48.Í; A.5.A.48.Í; A.7.A.48.Í; A.9.A.48.Í; A.100.A.48.Í;
A.101.A.48.Í; A.102.A.48.Í; A.103.A.48.Í; A.104.A.48.Í; A.105.A.48.Í; Α.106.Α.48.Ϊ; A.107.A.48.Í; A.1Ó8.A.48.Í; Α.109.Α.48.Ϊ; A.110.A.48.Í; A.111.A.484; Α.112.Α.48.Ϊ; A.113.A.48.Í; A.114.A.48.Í; A.U5.A.48.Í; A.116.A.48.Í; A.117.A.48.Í; A.118.A.48.Í; A.119A.48.Í; A.120.A.48.Í; A.121.A.48.Í; A.122.A.48.1; A.123.A.484; A.124.A.48.Í; A.125.A.48.Í; A.126.A.48.Í; A.127.A.48.Í; A.128.A.48.Í; A.129.A.48.Í; A.130.A.48.Í; A.131 .A.48.Í; A.132.A.48.Í; A.133.A.48.Í; Α.134.Α.48.Ϊ; A.135.A.48.Í; A.136.A.48.Í; A.137.A.48.Í; A.138.A.48.Í; A.139.A.48.Í; A.140.A.48.Í; A.141.A.484; A.2.A.494; A.3.A.494; A.4.A.494; A.5.A.494; A.7.A.494; A.9.A.494; AJ00.A.494;A.101.A.48.Í; A.102.A.48.Í; A.103.A.48.Í; A.104.A.48.Í; A.105.A.48.Í; Α.106.Α.48.Ϊ; A.107.A.48.Í; A.1Ó8.A.48.Í; Α.109.Α.48.Ϊ; A.110.A.48.Í; A.111.A.484; Α.112.Α.48.Ϊ; A.113.A.48.Í; A.114.A.48.Í; A.U5.A.48.Í; A.116.A.48.Í; A.117.A.48.Í; A.118.A.48.Í; A.119A.48.Í; A.120.A.48.Í; A.121.A.48.Í; A.122.A.48.1; A.123.A.484; A.124.A.48.Í; A.125.A.48.Í; A.126.A.48.Í; A.127.A.48.Í; A.128.A.48.Í; A.129.A.48.Í; A.130.A.48.Í; A.131 .A.48.Í; A.132.A.48.Í; A.133.A.48.Í; Α.134.Α.48.Ϊ; A.135.A.48.Í; A.136.A.48.Í; A.137.A.48.Í; A.138.A.48.Í; A.139.A.48.Í; A.140.A.48.Í; A.141.A.484; A.2.A.494; A.3.A.494; A.4.A.494; A.5.A.494; A.7.A.494; A.9.A.494; AJ00.A.494;
-146CZ 297945 B6-146GB 297945 B6
A.101.A.49.Í; A.102.A.49.Í; A.103.A.49.Í; A.104.A.49.Í; A.105.A.49.Í; A.106.A.49.Í; A.107.A.49.Í; A.108.A.49.Í; A.109.A.49.Í; Α.110.Α.49.Ϊ; A.111.A.49.Í; A.112.A.49.Í; Α.Π3.Α.49.Ϊ; Α.114.Α.49.Ϊ; A.115.A.49.Í; A.116.A.49.Í; A.117.A.49.Í; A.118.A.49.Í; A.119.A.49.Í; A.120.A.49.Í; A.121.A.49.Í; A.122.A.49.Í; A.123.A.49.Í; A.124.A.49.Í; A.125.A.49.Í; A.126.A.49.Í; A.127.A.49.Í; A.128.A.49.Í; A.129.A.49.Í; A.130.A.49.Í; A.131.A.49.Í; A.132.A.49.Í; A.133.A.49.Í; A.134.A.49.Í; A.135.A.49.Í; A.136.A.49.Í; Α.137.Α.49.Ϊ; A.138.A.49.Í; Α.139.Α.49.Ϊ; A.140.A.49.Í; A.141.A.49.Í; A.2.A.50.Í; A.3.A.50.Í; A.4.A.50.Í; A.5.A.50.Í; A.7.A.504; A.9.A.50.Í; A.100.A.50.Í;A.101.A.49.Í; A.102.A.49.Í; A.103.A.49.Í; A.104.A.49.Í; A.105.A.49.Í; A.106.A.49.Í; A.107.A.49.Í; A.108.A.49.Í; A.109.A.49.Í; Α.110.Α.49.Ϊ; A.111.A.49.Í; A.112.A.49.Í; Α.Π3.Α.49.Ϊ; Α.114.Α.49.Ϊ; A.115.A.49.Í; A.116.A.49.Í; A.117.A.49.Í; A.118.A.49.Í; A.119.A.49.Í; A.120.A.49.Í; A.121.A.49.Í; A.122.A.49.Í; A.123.A.49.Í; A.124.A.49.Í; A.125.A.49.Í; A.126.A.49.Í; A.127.A.49.Í; A.128.A.49.Í; A.129.A.49.Í; A.130.A.49.Í; A.131.A.49.Í; A.132.A.49.Í; A.133.A.49.Í; A.134.A.49.Í; A.135.A.49.Í; A.136.A.49.Í; Α.137.Α.49.Ϊ; A.138.A.49.Í; Α.139.Α.49.Ϊ; A.140.A.49.Í; A.141.A.49.Í; A.2.A.50.I; A.3.A.50.I; A.4.A.50.I; A.5.A.50.I; A.7.A.504; A.9.A.50.I; A.100.A.50.I;
A.101.A.50.Í; A.102.A.50.Í; A.103.A.50.1; A.104.A.50.Í; A.105.A.50.Í; A.106.A.50.Í; Α.107.Α.50.Ϊ; A.108.A.50.Í; A.109.A.50.Í; A.110.A.50.Í; A.111.A.50.Í; A.112.A.50.Í; A.113.A.50.1; A.114.A.50.Í; A.115.A.50.Í; A.116.A.50.Í; A.117.A.50.Í; A.118.A.50.Í; A.119.A50.Í; A.120.A.504; A.121.A.504; A.122.A.504; A.123.A.504; A.124.A.504; A.125.A.504; AA26.A.50.i; A.127.A.504; A.128.A.504; A.129.A.504; A.130.A.504; A.131.A.504; A.132.A.504; A.133.A504; A.134.A.504; Α.135.Α.50Λ; A.136.A.504; A.137.A.504; A.138.A.504; A.139.A.504; A.140.A.50.Í; A.141.A.504; A.2.A.514; A.3.A.514; A.4.A.514; A.5.A.514; Α.7.Α.51.Ϊ; A.9.A.51.Í; A.100.A.514;A.101.A.50.I; A.102.A.50.I; A.103.A.50.1; A.104.A.50.I; A.105.A.50.Í; A.106.A.50.I; Α.107.Α.50.Ϊ; A.108.A.50.I; A.109.A.50.I; A.110.A.50.I; A.111.A.50.I; A.112.A.50.I; A.113.A.50.1; A.114.A.50.I; A.115.A.50.Í; A.116.A.50.I; A.117.A.50.I; A.118.A.50.I; A.119.A50.Í; A.120.A.504; A.121.A.504; A.122.A.504; A.123.A.504; A.124.A.504; A.125.A.504; AA26.A.50.i; A.127.A.504; A.128.A.504; A.129.A.504; A.130.A.504; A.131.A.504; A.132.A.504; A.133.A504; A.134.A.504; Α.135.Α.50Λ; A.136.A.504; A.137.A.504; A.138.A.504; A.139.A.504; A.140.A.50.I; A.141.A.504; A.2.A.514; A.3.A.514; A.4.A.514; A.5.A.514; Α.7.Α.51.Ϊ; A.9.A.51.Í; A.100.A.514;
A.101.A.514; A.102.A.514; A.103.A.514; A.104.A.514; A.105.A.514; A.106.A.514; A.107.A.514; A.108.A.514; A.109.A.51.Í; A.110.A.514; A.111.A.514; A.112.A.514; A.113.A.514; A.114.A.51.Í; A.115.A.51.Í; A.116.A.514; A.117.A.514; A.118.A.514; A.119.A.514; A.120.A.514; A.121.A.51.Í; A.122.A.514; A.123.A.514; A.124.A.514; A.125.A.514; A.I26.A.514; A.127.A.51.Í; A.128.A.514; A.129.A.514; A.130.A.51.Í; A.131.A.514; A.132.A.514; A.133.A.514; A.134.A.514; A.135.A.514; A.136.A.514; A.137.A.514; A.138.A.514; A.139.A.51.Í; A.140.A.514; A.141.A.514; A.2.B.464; A.3.B.46.Í; A.4.B.464; A.5.B.464; A.7.B.464; A.9.B.464; A.100.B.464; A.101.B.464; A.102.B.464; A.103.B.464; A.104.B.464; A.105.B.464; A.106.B.464; A.107.B.464; A.108.B.46.Í; A.109.B.464; A.110.B.464; A.111.B.464; A.112.B.464; Α.Π3.Β.464; A.114.B.464; A.115.B.464; A.116.B.464; A.117.B.464; A.118.B.46.Í; A.119.B.464; A.120.B.464; ΑΛ21.Β.464; A.122.B.464; A.123.B.464; A.124.B.464; A.125.B.464; A.126.B.46.Í; A.127.B.464; A.128.B.464; A.129.B.46.Í; A.130.B.46.Í; A.131.B.46.Í; Α.132.Β.46.Ϊ; A.133.B.464; A.134.B.464; A.135.B.46.Í; A.136.B.464; A.137.B.464; A.138.B.464; A.139.B.464; A.140.B.464; A.141.B.46.Í; A.2.B.474; A.3.B.474; A.4.B.474; A.5.B.474; A.7.B.474; A.9.B.47.Í; A.100.B.474; A.1Q1.B.474;A.101.A.514; A.102.A.514; A.103.A.514; A.104.A.514; A.105.A.514; A.106.A.514; A.107.A.514; A.108.A.514; A.109.A.51.Í; A.110.A.514; A.111.A.514; A.112.A.514; A.113.A.514; A.114.A.51.Í; A.115.A.51.Í; A.116.A.514; A.117.A.514; A.118.A.514; A.119.A.514; A.120.A.514; A.121.A.51.Í; A.122.A.514; A.123.A.514; A.124.A.514; A.125.A.514; A.I26.A.514; A.127.A.51.Í; A.128.A.514; A.129.A.514; A.130.A.51.Í; A.131.A.514; A.132.A.514; A.133.A.514; A.134.A.514; A.135.A.514; A.136.A.514; A.137.A.514; A.138.A.514; A.139.A.51.Í; A.140.A.514; A.141.A.514; A.2.B.464; A.3.B.46.Í; A.4.B.464; A.5.B.464; A.7.B.464; A.9.B.464; A.100.B.464; A.101.B.464; A.102.B.464; A.103.B.464; A.104.B.464; A.105.B.464; A.106.B.464; A.107.B.464; A.108.B.46.Í; A.109.B.464; A.110.B.464; A.111.B.464; A.112.B.464; Α.Π3.Β.464; A.114.B.464; A.115.B.464; A.116.B.464; A.117.B.464; A.118.B.46.Í; A.119.B.464; A.120.B.464; ΑΛ21.Β.464; A.122.B.464; A.123.B.464; A.124.B.464; A.125.B.464; A.126.B.46.Í; A.127.B.464; A.128.B.464; A.129.B.46.Í; A.130.B.46.Í; A.131.B.46.Í; Α.132.Β.46.Ϊ; A.133.B.464; A.134.B.464; A.135.B.46.Í; A.136.B.464; A.137.B.464; A.138.B.464; A.139.B.464; A.140.B.464; A.141.B.46.Í; A.2.B.474; A.3.B.474; A.4.B.474; A.5.B.474; A.7.B.474; A.9.B.47.Í; A.100.B.474; A.1Q1.B.474;
A.102.B.474; A.103.B.474; A.104.B.474; A.105.B.474; A.106.B.47.Í; A.107.B.474; A.108.B.474; A.109.B.474; A.110.B.474; A.111.B.474; A.112.B.474; A.113.B.474; A.114.B.474; A.U5.B.474; A.116.B.47.Í; A.117.B.47.Í; A.118.B.47.Í; A.119.B.47J; A.I20.B.474; A.121.B.474; A.122.B.474; A.123.B.474; A.124.B.474; A.125.B.474; A.126.B.474; A.127.B47.Í; A.128.B.474; A.129.B.47.Í; A.130.B.47.Í; A.131.B.47.Í; A.132.B.47.Í; A.133.B.47.Í; A.134.B.47.Í; A.135.B.474; A.136.B.47.Í; Α.137.Β.47.Ϊ; A.138.B.47.Í; Α.139.Β.47.Ϊ; A.140.B.47.Í; A.141.B.47.Í; A.2.B.48.Í; A.3.B.48.Í; A.4.B.48.Í; A.5.B.484; A.7.B.48.Í; A.9.B.48.Í; A.100.B.48.Í; A.101.B.48.Í;A.102.B.474; A.103.B.474; A.104.B.474; A.105.B.474; A.106.B.47.Í; A.107.B.474; A.108.B.474; A.109.B.474; A.110.B.474; A.111.B.474; A.112.B.474; A.113.B.474; A.114.B.474; A.U5.B.474; A.116.B.47.Í; A.117.B.47.Í; A.118.B.47.Í; A.119.B.47J; A.I20.B.474; A.121.B.474; A.122.B.474; A.123.B.474; A.124.B.474; A.125.B.474; A.126.B.474; A.127.B47.Í; A.128.B.474; A.129.B.47.Í; A.130.B.47.Í; A.131.B.47.Í; A.132.B.47.Í; A.133.B.47.Í; A.134.B.47.Í; A.135.B.474; A.136.B.47.Í; Α.137.Β.47.Ϊ; A.138.B.47.Í; Α.139.Β.47.Ϊ; A.140.B.47.Í; A.141.B.47.Í; A.2.B.48.Í; A.3.B.48.Í; A.4.B.48.Í; A.5.B.484; A.7.B.48.Í; A.9.B.48.Í; A.100.B.48.Í; A.101.B.48.Í;
A.102.B.48.Í; A.103.B.48.Í; A.104.B.48.Í; A.105.B.48.Í; A.106.B.48.Í; A.107.B.48.Í; A.108.B.48.Í; A.109.B.48.Í; A.110.B.48.Í; A.111.B.48.Í; A.112.B.48.Í; A.113.B.48.Í; A.114.B.48.Í; A.115.B.48.Í; A.1I6.B.48.Í; A.117.B.48.Í; A.118.B.48.Í; A.119.B.48.Í; A.120.B.48.Í; A.121.B.48.1; A.122.B.48.Í; A.123.B.48.Í; A.124.B.48.Í; A.125.B.48.Í; A.126.B.48.Í; A.127.B.48.Í; A.128.B.48.Í; A.129.B.48.Í; A.130.B.48.Í; A.131.B.48.Í; A.132 B.48.Í; A.133.B.48.Í; A.134.B.48.Í; A.135.B.48.Í; A.136.B.48.Í; A.137.B.48 A.138.B.48.Í; A.139.B.48.Í; A.140.B.48.Í; A.141.B.48.Í; A.2.B.49.Í; A.3.B.49.Í;A.102.B.48.Í; A.103.B.48.Í; A.104.B.48.Í; A.105.B.48.Í; A.106.B.48.Í; A.107.B.48.Í; A.108.B.48.Í; A.109.B.48.Í; A.110.B.48.Í; A.111.B.48.Í; A.112.B.48.Í; A.113.B.48.Í; A.114.B.48.Í; A.115.B.48.Í; A.1I6.B.48.Í; A.117.B.48.Í; A.118.B.48.Í; A.119.B.48.Í; A.120.B.48.Í; A.121.B.48.1; A.122.B.48.Í; A.123.B.48.Í; A.124.B.48.Í; A.125.B.48.Í; A.126.B.48.Í; A.127.B.48.Í; A.128.B.48.Í; A.129.B.48.Í; A.130.B.48.Í; A.131.B.48.Í; A.132 B.48.Í; A.133.B.48.Í; A.134.B.48.Í; A.135.B.48.Í; A.136.B.48.Í; A.137.B.48 A.138.B.48.I; A.139.B.48.Í; A.140.B.48.Í; A.141.B.48.Í; A.2.B.49.Í; A.3.B.49.Í;
- 147CZ 297945 B6- 147GB 297945 B6
A.4.B.49.Í; A.5.B.49.Í; A.7.B.494; A.9.B.49.Í; A.100.B.49.Í; A.101.B.49.Í;A.4.B.49.Í; A.5.B.49.Í; A.7.B.494; A.9.B.49.Í; A.100.B.49.Í; A.101.B.49.Í;
A.102.B.494; A.103.B.49.Í; A.104.B.494; A.105.B.49.1; A.106.B.494; A.107.B.494; A.108.B.494; A.109.B.494; A.110.B.494; A.111.B.494; A.112.B.494; A.113.B.494; A.114.B.494; A.115.B.494; A.Í16.B.494; A.117.B494; A.118.B.494; A.119.B.494; A.120.B.494; A.12LB.49.Í; A.122.B.494; A.123.B.49.Í; A.124.B.494; A.125.B.49.Í; A.126.B.49.Í; A.127.B.49.Í; A.128.B.494; A.129.B.494; A.130.B.49.Í; A.131.B.494; A.132.B.494; A.133.B.494; A.134.B.494; A.135.B.49.Í; A.136.B.494; A.137.B.494; A.138.B.49.Í; A.139.B.494; A.140.B.494; A.141.B.49.Í; A.2.B50.Í; A.3.B.50.Í; A.4.B.504; A.5.B.504; A.7.B.504; A.9.B.504; A.100.B.5Ó4; A.101.B.50.Í;A.102.B.494; A.103.B.49.Í; A.104.B.494; A.105.B.49.1; A.106.B.494; A.107.B.494; A.108.B.494; A.109.B.494; A.110.B.494; A.111.B.494; A.112.B.494; A.113.B.494; A.114.B.494; A.115.B.494; A.I16.B.494; A.117.B494; A.118.B.494; A.119.B.494; A.120.B.494; A.12LB.49.Í; A.122.B.494; A.123.B.49.Í; A.124.B.494; A.125.B.49.Í; A.126.B.49.Í; A.127.B.49.Í; A.128.B.494; A.129.B.494; A.130.B.49.Í; A.131.B.494; A.132.B.494; A.133.B.494; A.134.B.494; A.135.B.49.Í; A.136.B.494; A.137.B.494; A.138.B.49.Í; A.139.B.494; A.140.B.494; A.141.B.49.Í; A.2.B50.I; A.3.B.50.I; A.4.B.504; A.5.B.504; A.7.B.504; A.9.B.504; A.100.B.5Ó4; A.101.B.50.I;
A.102.B.504; A.103.B.504; A.104.B.504; A.105.B.504; A.106.B.50.Í; A.107.B.504; A.108.B.50.Í; A.109.B.504; A.110.B.50.Í; A.111.B.504; A.112.B.504; A.113.B.50.Í; A.114.B.504; A.115.B.504; A.116.B.5O4; A.117.B.504; A.118.B.504; A.119.B.504; A.120.B.504; A.121.B.504; A.122.B.504; A.123.B.504; A.124.B.504; A.125.B.504; A.126.B.504; A.127.B.504; A.128.B.50.Í; A.129.B.504; A.130.B.504; A.131.B.504; A.132.B.504; A.133.B.504; A.134.B.504; A.135.B.504; A.136.B.50.Í; A.137.B.504; A.138.B.50.Í; A.139.B.504; A.140.B.50.Í; A.141.B.50.Í; Α.2.Β.51Λ; A.3.B.51.Í; A.4.B.514; A.5.B514; A.7.B.51.Í; A.9.B.514; A.100.B.51.Í; A.101.B.51.Í;A.102.B.504; A.103.B.504; A.104.B.504; A.105.B.504; A.106.B.50.I; A.107.B.504; A.108.B.50.I; A.109.B.504; A.110.B.50.I; A.111.B.504; A.112.B.504; A.113.B.50.I; A.114.B.504; A.115.B.504; A.116.B.5O4; A.117.B.504; A.118.B.504; A.119.B.504; A.120.B.504; A.121.B.504; A.122.B.504; A.123.B.504; A.124.B.504; A.125.B.504; A.126.B.504; A.127.B.504; A.128.B.50.I; A.129.B.504; A.130.B.504; A.131.B.504; A.132.B.504; A.133.B.504; A.134.B.504; A.135.B.504; A.136.B.50.I; A.137.B.504; A.138.B.50.I; A.139.B.504; A.140.B.50.I; A.141.B.50.I; Α.2.Β.51Λ; A.3.B.51.Í; A.4.B.514; A.5.B514; A.7.B.51.Í; A.9.B.514; A.100.B.51.Í; A.101.B.51.Í;
A.102.B.514; A.103.B.514; A.104.B.51.Í; A.105.B.51.Í; A.106.B.51.Í; A.107.B.514; A.108.B.51.1; A.109.B.51.Í; A.110.B.51.Í; A.111.B.51.Í; A.112.B.51.Í; A.113.B.514; A.114.B.514; A.115.B.514; A.116.B.514; A.117.B.51.Í; Α.Π8.Β.514; A.119.B.514; A.120.B.51.Í; A.121.B.514; A.122.B.514; A.123.B.514; A.124.B.51.Í; A.125.B.514; A.126.B.514; A.127.B.51.Í; A.128.B.514; A.129.B.51.Í; A.130.B.51.Í; A.131.B.514; A.132.B.514; A.133.B.514; A.134.B.514; A.135.B.514; A.136.B.51.Í; A.137.B.514; A 138.B.514; A.139.B.51.Í; A.140.B514; A.141.B.514; A.2.C.464; A.3.C.46.Í; A.4.C.464; A.5.C.46.Í; A.7.C.464; A.9.C.464; A.100.C.464; A.101.C.46.Í;A.102.B.514; A.103.B.514; A.104.B.51.Í; A.105.B.51.Í; A.106.B.51.Í; A.107.B.514; A.108.B.51.1; A.109.B.51.Í; A.110.B.51.Í; A.111.B.51.Í; A.112.B.51.Í; A.113.B.514; A.114.B.514; A.115.B.514; A.116.B.514; A.117.B.51.Í; Α.Π8.Β.514; A.119.B.514; A.120.B.51.Í; A.121.B.514; A.122.B.514; A.123.B.514; A.124.B.51.Í; A.125.B.514; A.126.B.514; A.127.B.51.Í; A.128.B.514; A.129.B.51.Í; A.130.B.51.Í; A.131.B.514; A.132.B.514; A.133.B.514; A.134.B.514; A.135.B.514; A.136.B.51.Í; A.137.B.514; A 138.B.514; A.139.B.51.Í; A.140.B514; A.141.B.514; A.2.C.464; A.3.C.46.Í; A.4.C.464; A.5.C.46.Í; A.7.C.464; A.9.C.464; A.100.C.464; A.101.C.46.Í;
A.102.C.464; A.1Q3.C.46.Í; A.104.C.464; A.105.C.464; A.106.C.46.Í; A.107.C.464; A.108.C.46.Í; A.109.C.46.Í; A.110.C.46.Í; A.H1.C.46.Í; A.112.C.464; A.113.C.464; A.114.C.464; A.115.C.46.Í; A.U6.C.464; A.117.C.46.Í; A.118.C.464; A.119.C.464; A.120.C.46.Í; A.121.C.464; A.122.C.46.Í; A.123.C464; A.124.C.46.Í; A.125.C.464; A.126.C.464; A.127.C.464; A.I28.C.464; A.129.C.464; A.130.C.46.Í; A.131.C.464; A.132.C.464; A.133.C.464; A.134.C.46.Í; A.135.C.464; A.136.C.46.Í; A.137.C.464; A.138.Č.464; A.139.C.46.Í; A.140.C.46.Í; A.141.C.464; A.2.C.47.Í; A.3.C.47.Í; A.4.C.474; A.5.C.47.Í; A.7.C.474; A.9.C.474; A.100.C.47.Í; A.101.C.474;A.102.C.464; A.1Q3.C.46.Í; A.104.C.464; A.105.C.464; A.106.C.46.Í; A.107.C.464; A.108.C.46.Í; A.109.C.46.Í; A.110.C.46.Í; A.H1.C.46.Í; A.112.C.464; A.113.C.464; A.114.C.464; A.115.C.46.Í; A.U6.C.464; A.117.C.46.Í; A.118.C.464; A.119.C.464; A.120.C.46.Í; A.121.C.464; A.122.C.46.Í; A.123.C464; A.124.C.46.Í; A.125.C.464; A.126.C.464; A.127.C.464; A.I28.C.464; A.129.C.464; A.130.C.46.Í; A.131.C.464; A.132.C.464; A.133.C.464; A.134.C.46.Í; A.135.C.464; A.136.C.46.Í; A.137.C.464; A.138.Č.464; A.139.C.46.Í; A.140.C.46.Í; A.141.C.464; A.2.C.47.Í; A.3.C.47.Í; A.4.C.474; A.5.C.47.Í; A.7.C.474; A.9.C.474; A.100.C.47.Í; A.101.C.474;
A.102.C.474; A.103.C.47.Í; A.104.C.47.Í; A.105.C.474; A.106.C.47.Í; A.1Ó7.C.474; A.108.C.474; A.109.C.47.Í; A.110.C.47.Í; A.111.C.47.Í; A.112.C.47.Í; A.113.C.47.Í; A.114.C.474; A.115.C.47.Í; A.116.C.474; A.117.C.474; A.118.C.474; A.119.C.474; A.120.C.474; A.121.C.47.Í; A.122.C.47.Í; A.123.C.47.Í; A.124.C.474; A.125.C.474; A.126.C.474; A.127.C.47.Í; A.128.C.474; A.129.C.474; A.130.C47.Í; A.131.C.474; A.132.C.474; A.133.C.47.Í; A.134.C.47.Í; A.135.C.47.Í; A.136.C.474; A.137.C.474; A.138.C.474; A.139.C.47.Í; A.14Ú.C.47.Í; A.141.C.474; A.2.C.48.Í; A.3.C.48.Í; A.4.C.484; Á.5.C.48.Í; A.7.C.484; A.9.C.484; A.100.C.484; A.101.C.48.Í;A.102.C.474; A.103.C.47.Í; A.104.C.47.Í; A.105.C.474; A.106.C.47.Í; A.1Ó7.C.474; A.108.C.474; A.109.C.47.Í; A.110.C.47.Í; A.111.C.47.Í; A.112.C.47.Í; A.113.C.47.Í; A.114.C.474; A.115.C.47.Í; A.116.C.474; A.117.C.474; A.118.C.474; A.119.C.474; A.120.C.474; A.121.C.47.Í; A.122.C.47.Í; A.123.C.47.Í; A.124.C.474; A.125.C.474; A.126.C.474; A.127.C.47.Í; A.128.C.474; A.129.C.474; A.130.C47.Í; A.131.C.474; A.132.C.474; A.133.C.47.Í; A.134.C.47.Í; A.135.C.47.Í; A.136.C.474; A.137.C.474; A.138.C.474; A.139.C.47.Í; A.14Ú.C.47.Í; A.141.C.474; A.2.C.48.Í; A.3.C.48.Í; A.4.C.484; Á.5.C.48.Í; A.7.C.484; A.9.C.484; A.100.C.484; A.101.C.48.Í;
A.102.C.484; A.1O3.C.48.Í; A.1O4.C.48.Í; A.105.C.48.Í; A.106.C.48.Í; A.107.C.48.Í; A.108.C.48.Í; A.109.C.484; A.110.C484; A.111.C.484; A.112.C.48.Í; A.113.C.48.Í; A.114-C.484; A.115.C.48.Í; A.116.C.48.Í; A.117.C.48.Í; A.118.C.48.Í; A.119.C.48.Í; A.120.C.48.Í; AT21.C.48.Í; A.122.C.48.Í; A.123.C.48.Í; A.124.C.48.Í; A.125.C.48.Í; A.126.C.48.Í; A.127.C.48.1; A.128.C.48.Í; A.129.C.48.Í; A.130.C.48.Í; A.131.C.48.Í; A.132.C.48.Í; A.133.C.48.Í; A.I34.C.48.Í; A.135.C.48.Í; A.136.C.48.Í; A.137.C.48.Í;A.102.C.484; A.1O3.C.48.Í; A.1O4.C.48.Í; A.105.C.48.Í; A.106.C.48.Í; A.107.C.48.Í; A.108.C.48.Í; A.109.C.484; A.110.C484; A.111.C.484; A.112.C.48.Í; A.113.C.48.Í; A.114-C.484; A.115.C.48.Í; A.116.C.48.Í; A.117.C.48.Í; A.118.C.48.Í; A.119.C.48.Í; A.120.C.48.Í; AT21.C.48.Í; A.122.C.48.Í; A.123.C.48.Í; A.124.C.48.Í; A.125.C.48.Í; A.126.C.48.Í; A.127.C.48.1; A.128.C.48.Í; A.129.C.48.Í; A.130.C.48.Í; A.131.C.48.Í; A.132.C.48.Í; A.133.C.48.Í; A.I34.C.48.Í; A.135.C.48.Í; A.136.C.48.Í; A.137.C.48.Í;
-148CZ 297945 B6-148GB 297945 B6
A.138.C.484; A.139.C.484; A.140.C.484; A.141.C.48.Í; A2.C.494; A.3.C.49.Í; A.4.C.494; A.5.C.494; A.7.C.494; A.9.C.49.Í; A.100.C.494; A.101.C494;A.138.C.484; A.139.C.484; A.140.C.484; A.141.C.48.Í; A2.C.494; A.3.C.49.Í; A.4.C.494; A.5.C.494; A.7.C.494; A.9.C.49.Í; A.100.C.494; A.101.C494;
A.102.C.494; A.103.C.494; A.104.C.494;.Á.105.C.494; A.106.C.494; A.107.C.494; A.108.C.49.Í; A.109.C.494; A.110.C.494; A.111.C.494; A.112.C.494; A.113.C.494; A.114.G494; A.115.C.494; A.116.C.494; A.117.C.494; A.118.C.494; A.119.C.49.Í; A.120.C.494; A.121.C494; A.122.C.49.Í; A.123.C.494; A.124.C.494; A.125.C.494; A.126.C.49.1; A.127.C.494; A.128.C.494; A.129.C.494; A.130.C494; A.131.C.494; A.132.C.494; A.133.C494; A.134.C.494; A.135.C.494; A.136.C.494; A.137.C.494; A.138.C.494; A.139.C.494; A.140.C.494; A.141.C.494; A.2.C.50.Í; A.3.C-504; A.4.C.504; A5.C.504; A.7.C.504; A.9.C504; A.100.C.504; A.101.C504;A.102.C.494; A.103.C.494; A.104.C.494; .A.105.C.494; A.106.C.494; A.107.C.494; A.108.C.49.Í; A.109.C.494; A.110.C.494; A.111.C.494; A.112.C.494; A.113.C.494; A.114.G494; A.115.C.494; A.116.C.494; A.117.C.494; A.118.C.494; A.119.C.49.Í; A.120.C.494; A.121.C494; A.122.C.49.Í; A.123.C.494; A.124.C.494; A.125.C.494; A.126.C.49.1; A.127.C.494; A.128.C.494; A.129.C.494; A.130.C494; A.131.C.494; A.132.C.494; A.133.C494; A.134.C.494; A.135.C.494; A.136.C.494; A.137.C.494; A.138.C.494; A.139.C.494; A.140.C.494; A.141.C.494; A.2.C.50.I; A.3.C-504; A.4.C.504; A5.C.504; A.7.C.504; A.9.C504; A.100.C.504; A.101.C504;
A.102.C504; A.103.C.504; A.1O4.C504; A.105.C.504; A.106.C.504; A.107.C.504; A.108.Č504; A.109.Č.50.Í; A.110.C.504; A.111.C.504; A.112.C504; A.113.C.504; A.114.C.504; A.115.C.504; A.116.C50.Í; A.117.C.504; A,U8.C504; A.119.C504; A.120.C504; A.121.C504; A.122.C504; A.123.C.504; A.124.C504; A.125.C.504; A.126.C504; A.127.C.504; A.I28.C.504; A.129.C.504; A.130.C.504; A.131.C504; A.132.C504; A.133.C504; A.134.C504; A.135.CS04; A.136.C504; A.137.C504; A.138.C.504; A.139.C504; A.140.C.504; A.141.C504; A.2.C.51.Í; A.3.C514; A.4.C514; A5.C.514; A.7.C.514; · A.9.C514; A.100.C.514; A.101.C514;A.102.C504; A.103.C.504; A.1O4.C504; A.105.C.504; A.106.C.504; A.107.C.504; A.108.Č504; A.109.Č.50.Í; A.110.C.504; A.111.C.504; A.112.C504; A.113.C.504; A.114.C.504; A.115.C.504; A.116.C50.Í; A.117.C.504; A, U8.C504; A.119.C504; A.120.C504; A.121.C504; A.122.C504; A.123.C.504; A.124.C504; A.125.C.504; A.126.C504; A.127.C.504; A.I28.C.504; A.129.C.504; A.130.C.504; A.131.C504; A.132.C504; A.133.C504; A.134.C504; A.135.CS04; A.136.C504; A.137.C504; A.138.C.504; A.139.C504; A.140.C.504; A.141.C504; A.2.C.51.Í; A.3.C514; A.4.C514; A5.C.514; A.7.C.514; · A.9.C514; A.100.C.514; A.101.C514;
A.102.C.514; A.103.C.514; A.104.C514; A.105.C514; A.106.C314; A.107.C.514; A.108.C.514; A.109.C.514; A.110.C514; A.111.C514; A.112.C514; A.113.C514; A.114.C514; A.115.C.514; A.116.Č.51.Í; A.117.C514; A.118.C514; A.119.C514; A.120.C514; A.121.G514; A.122.C.51.Í; A.123.C514; A.124.C514; A.125.C514; A.126.C.514; A.127.C.514; A.128.C514; A.129.C514; A.130.C514; A.131.C514; A.132.C.514; A.133.C514; A.134.C514; A.135.C.514; A.136.C.514; A.137.C.514; A.138.C.514; A.139.C514; A.140.C514; A.141.C.514; A.2.D.464; A.3.D.46.Í; A.4.D.464; A.5.D.46.Í; A.7.D.464; A.9.D.464; A.100.D.464; A.101.D.464;A.102.C.514; A.103.C.514; A.104.C514; A.105.C514; A.106.C314; A.107.C.514; A.108.C.514; A.109.C.514; A.110.C514; A.111.C514; A.112.C514; A.113.C514; A.114.C514; A.115.C.514; A.116.Č.51.Í; A.117.C514; A.118.C514; A.119.C514; A.120.C514; A.121.G514; A.122.C.51.Í; A.123.C514; A.124.C514; A.125.C514; A.126.C.514; A.127.C.514; A.128.C514; A.129.C514; A.130.C514; A.131.C514; A.132.C.514; A.133.C514; A.134.C514; A.135.C.514; A.136.C.514; A.137.C.514; A.138.C.514; A.139.C514; A.140.C514; A.141.C.514; A.2.D.464; A.3.D.46.Í; A.4.D.464; A.5.D.46.Í; A.7.D.464; A.9.D.464; A.100.D.464; A.101.D.464;
A.102.D.464; A.103.D.464; A.104.D.464; A.105.D.464; A.106.D.464; A.107.D.46.Í; A.108.D.46.Í; A.109.D.464; A.110.D.464; A.U1.D.464; A.112.D.464; A.113.D.464; A.114.D.464; A.U5.D.464; A.116.D.464; A.U7.D.464; A.118.D.464; A.119.D.46.Í; A12D.D.464; A.121.D.464; A.122.D.464; A.123.D.464; A.124.D.464; A.125.D.46.Í; A.126.D.464; A.127.D.464; A.128.D.464; A.129.D.464; A.130.D.46.Í; A.131.D.464; A.132.D.464; A.133.D.46.Í; A.134.D.464; A.135.D.46.Í; A.136.D.464; A.137.D.464; A.138.D.46.Í; A.139.D.464; A.140.D.464; A.141.D.464; A.2.D.474; A.3.D.474; A.4.D.474; A.5.D.47.Í; A7.D.474; A.9.D.47.Í; A.100.D.474; A.101.D.474;A.102.D.464; A.103.D.464; A.104.D.464; A.105.D.464; A.106.D.464; A.107.D.46.Í; A.108.D.46.Í; A.109.D.464; A.110.D.464; A.U1.D.464; A.112.D.464; A.113.D.464; A.114.D.464; A.U5.D.464; A.116.D.464; A.U7.D.464; A.118.D.464; A.119.D.46.Í; A12D.D.464; A.121.D.464; A.122.D.464; A.123.D.464; A.124.D.464; A.125.D.46.Í; A.126.D.464; A.127.D.464; A.128.D.464; A.129.D.464; A.130.D.46.Í; A.131.D.464; A.132.D.464; A.133.D.46.Í; A.134.D.464; A.135.D.46.Í; A.136.D.464; A.137.D.464; A.138.D.46.Í; A.139.D.464; A.140.D.464; A.141.D.464; A.2.D.474; A.3.D.474; A.4.D.474; A.5.D.47.Í; A7.D.474; A.9.D.47.Í; A.100.D.474; A.101.D.474;
A.102.D.474; A.103.D.474; A.104.D.474; A.105.D.474; A.106.D.47.Í; A.107.D.474; A.108.D.474; A.109.D.474; A.110.D.474; A.U1.D.474; A.112.D.474; A.113.D.474; A.114.D.47.Í; A.115.D.474; A.116.D.474; A.117.D.474; A.118.D.474; A.119.D.474; A.120.D.474; A.121.D.474; A.122JX474; A.123.D.474; A.124.D.47.Í; A.125.D.474; A.126.D.474; A.127.D.474; A.128.D.474; A.129.D.474; A.130.D.474; A.131.D.474; A.132.D.474; A.133.D.474; A.134.D.474; A.Í35.D.474; A.136.D.474; A.137.D.474; A.138.D.47.Í; A.139.D.47.Í; A.140.D.474; A.141.D.474; A.2.D.484; A.3.D.484; A.4.Ď.484; A5.D.484; A.7.D.484; A.9.D48 i; A.100.D.48.Í; A.101.D.484;A.102.D.474; A.103.D.474; A.104.D.474; A.105.D.474; A.106.D.47.Í; A.107.D.474; A.108.D.474; A.109.D.474; A.110.D.474; A.U1.D.474; A.112.D.474; A.113.D.474; A.114.D.47.Í; A.115.D.474; A.116.D.474; A.117.D.474; A.118.D.474; A.119.D.474; A.120.D.474; A.121.D.474; A.122JX474; A.123.D.474; A.124.D.47.Í; A.125.D.474; A.126.D.474; A.127.D.474; A.128.D.474; A.129.D.474; A.130.D.474; A.131.D.474; A.132.D.474; A.133.D.474; A.134.D.474; A.Í35.D.474; A.136.D.474; A.137.D.474; A.138.D.47.Í; A.139.D.47.Í; A.140.D.474; A.141.D.474; A.2.D.484; A.3.D.484; A.4.Ď.484; A5.D.484; A.7.D.484; A.9.D48 i; A.100.D.48.Í; A.101.D.484;
A.102.D.484; A403.D.484; A.104.D.484; A.105.D.484; A.106.D.48.Í; A.107.D.48.Í; A.108.D.48.Í; A.109.D.48.Í; A.110.D.484; A.I11.D.48.Í; A.112.D.484; A.113.D.48.Í; A.114.D.484; A.115.D.48.Í; A.116.D.484; A.117.D.484; A.118.D.48.Í; A.U9.D.484; A.120.D.484; A.12LD.484; A.122.D.484; A.123.D.484; A.124.D.484; A.125.D.484; A.126.D.484; A.127.D.484; A.128.D.484; A.129.D.484; A.130.D.484; A.131.D.48.Í;A.102.D.484; A403.D.484; A.104.D.484; A.105.D.484; A.106.D.48.Í; A.107.D.48.Í; A.108.D.48.Í; A.109.D.48.Í; A.110.D.484; A.I11.D.48.Í; A.112.D.484; A.113.D.48.Í; A.114.D.484; A.115.D.48.Í; A.116.D.484; A.117.D.484; A.118.D.48.Í; A.U9.D.484; A.120.D.484; A.12LD.484; A.122.D.484; A.123.D.484; A.124.D.484; A.125.D.484; A.126.D.484; A.127.D.484; A.128.D.484; A.129.D.484; A.130.D.484; A.131.D.48.Í;
- 149CZ 297945 B6- 149GB 297945 B6
A.132.D.48.Í; A.133.D.481 A.134.D.481 A.135.D.481 A.136.D.481 A.137.D.48.Í; A.138.D.481 A.139.D.481 A.140.D.481 A.141.D.481 A.2.D.49.1; A.3.D.49.Í; A.4.D.49.Í; A.5.D.49.Í; A.7.D.49.Í; A.9.D.491 A.100.D.491 A.101.D.491 A.102.D.49.Í; A.103JD.491 A.104.D.49.Í; A.105.D.49.Í; A.106.D.49.Í; A.107.D.491 A.108.D.49.Í; A.109.D.491 A.110.D.49.Í; A.111.D.491 A.112.D.49.Í; A.113.D.491 A.114.D.491 A.115.D.491 A.116.D.491 A.117.D.491 A.118.D.491 A.119.D.491 A.120.D.49.1; A.121.D.49.Í; A.122.D.491 A.123.D.49.Í; A.124.D.49.Í; A.125.D.49.Í; A.126.D.49.Í; A.127.D.49.Í; A.128.D.491 A.129.D.49.Í; A.130.D.49.Í; A.131.D.491 A.132.D.491 A.133.D.491 A.134.D.491 A.135.D.491 A.136.D.491 A.137.D.49.Í; A.138.D.491 A.139.D.49.Í; A.140.D.49.Í; A.141.D.491 A2.D.501 A.3.D.501 A.4.D.50.Í; A.5.D.50.Í; A.7.D.501 A.9.D.501 A.100.D.50.Í; A.101.D.501 A.1.02.D.501 A.103.D.501 A.104.D.501 A.105.D.50.Í; A.106.D.50.Í; A.107.D.50.Í; A.108.D.50.Í; A.109.D.501 A.110.D.501 A.111.D.501 A.112.D.501 A.113.D.50.Í; A.114.D.5O.Í; A.115.D.50.Í; A.116.D.501 A.117.D.501 A.U8.D.501 A.119.D.5O.Í; A.120.D.501 A.121.D.501 A.122.D.501 A.123.D.501 A.124.D.501 A.125.D.50.Í; A.126.D.50.Í; A.127.D.501 A.128.D.501 A.129.D.501 A.130.D.50.Í; A.131.D.501 A.132.D.501 A.133.D.501 A.134.D.501 A.135.D.501 A.136.D.501 A.137.D.50.Í; A.138.D.501 A.139.D.501 A.140.D.501 A.141.D.501 A.2.D.511 A.3.D.511 A.4.D.511 A.5.D.511 A.7.D.511 A.9.D.511 A.100.D.511 A.101.D.511 A.102.D.511 A.1G3.D.511 A.104.D.511 A.105.D.511 A.106.D.511 A.107.D.511 A.108.D.511 A.109.D.511 A.110.D.5U A.111.D.511 A.112.D.5U A.113.D.511 A.114.D.511 A.115.D.511 A.116.D.511 A.117.D.511 A.118.D.511 A.119.D.51.Í; A.120.D.51.Í; A.121.D.511 A.122.D.51.Í; A.123.D.5U A.124.D.511 A.125.D.511 A.126.D.511 A.127.D.511 A.128.D.511 A.129.D.511 A.130.D.511 A.131.D.511 A.132.D.511 A.133.D.511 A.134.D.511 A.135.D.511 A.136.D.511 A.137.D.511 A.138.D.511 A.139.D.511 A.140.D.511 A.141.D.511 A.2.E.461 A.3.E.461 A.4.E.461 A.5.E.461 A.7.E.461 A.9.E.461 A.100.E.461 A.1Ó1.E.461 A.102.E.461 A.103.E.461 A.104.E.461 A.105.E.461 A.106.E.461 A.107.E.461 A.108.E.461 A.109.E.461 A.110.E.461 A.111.E.461 A.112.E.461 A.113.E.461 A.114.E.461 A.115.E.461 A.116.E.461 A.117.E.461 A.118.E.461 A.119.E.461 A.120.E.461 A.121.E.461 A.122.E.461 A.123.E.461 A.124.E.461 A.125.E.461 A.126.E.461 A.127.E.461 A.128.E.461 A.129.E.461 A.130.E.461 A.131.E.461 A.132.E.461 A.133.E.461 A.134.É.46.Í; A.135.E.461 A.136.E.461 A.137.E.461 A.138.E.461 A.139.E.461 A.140.E.461 A.141.E.461 A.2.E.47.Í; A.3.E.471 A.4.E.471 A.5.E.471 A.7.E.471 A.9.E.471 A.100.E.47.Í; A.10LE.471 A.102.E.471 A.103.E.471 A.104.E.471 A.105.E.471 A.106.E.471 A.107.E.471 A.108.E.471 A.109.E.47.Í; Α.Π0.Ε.471 A.111.E.471 A.112.E.471 A.113.E.471 A.114.E.471 A.115.E.471 Α.Π6.Ε.471 A.117.E.47.Í; A.118.E.471 ΑΛ19.Ε.471 A.120.E.47.Í; A.121.E.47.Í; A.122.E.47.Í; A.123.E.471 A.124.E.471 A.125.E.471 A.126.E.47.Í; A.127.E.471 A.128.E.471 A.129.E.471 A.130.E.471 A.131.E.471 A.132.E.471 A.133.E.471 A.134.E.471 A.135.E.471 A.136.E.471 A.137.E.471 A.138.E.471 A.139.E.47.Í; A.140.E.471 A.141.E.471 A.2.E.481 A.3.E.481 A.4.E.481 A.5.E.481 A.7.E.481 A.9.E.481 A.100.E.481 A.101.E.481 A.102.E.481 A.103.E.481 A.104.E.481 A.105.E.481 A.106.E.481 A.107.E.481 Α.108Έ.481 A.109.E.481 A.110.E.481 A.U1.E.481 A.112.E.481 A.113.E.481 A.114.E.481 A.115.E.481 A.116.E.481 A.117.E.481 A.118.E.481 A.119.E.481 A.120.E.481 A.121.E.481 A.122.E.481 A.123.E.481 A.124.E.481 A.125.E.481 A.126.E.481 A.127.E.481 A.128.E.481A.132.D.48.Í; A.133.D.481 A.134.D.481 A.135.D.481 A.136.D.481 A.137.D.48.I; A.138.D.481 A.139.D.481 A.140.D.481 A.141.D.481 A.2.D.49.1; A.3.D.49.Í; A.4.D.49.Í; A.5.D.49.Í; A.7.D.49.Í; A.9.D.491 A.100.D.491 A.101.D.491 A.102.D.49.I; A.103JD.491 A.104.D.49.Í; A.105.D.49.Í; A.106.D.49.Í; A.107.D.491 A.108.D.49.Í; A.109.D.491 A.110.D.49.Í; A.111.D.491 A.112.D.49.Í; A.113.D.491 A.114.D.491 A.115.D.491 A.116.D.491 A.117.D.491 A.118.D.491 A.119.D.491 A .120.D.49.1; A.121.D.49.Í; A.122.D.491 A.123.D.49.Í; A.124.D.49.Í; A.125.D.49.Í; A.126.D.49.Í; A.127.D.49.Í; A.128.D.491 A.129.D.49.Í; A.130.D.49.Í; A.131.D.491 A.132.D.491 A.133.D.491 A.134.D.491 A.135.D.491 A.136.D.491 A.137.D.49. AND; A.138.D.491 A.139.D.49.I; A.140.D.49.Í; A.141.D.491 A2.D.501 A.3.D.501 A.4.D.50.I; A.5.D.50.I; A.7.D.501 A.9.D.501 A.100.D.50.I; A.101.D.501 A.1.02.D.501 A.103.D.501 A.104.D.501 A.105.D.50.I; A.106.D.50.I; A.107.D.50.I; A.108.D.50.I; A.109.D.501 A.110.D.501 A.111.D.501 A.112.D.501 A.113.D.50.I; A.114.D.5O.Í; A.115.D.50.I; A.116.D.501 A.117.D.501 A.U8.D.501 A.119.D.5O.I; A.120.D.501 A.121.D.501 A.122.D.501 A.123.D.501 A.124.D.501 A.125.D.50.I; A.126.D.50.I; A.127.D.501 A.128.D.501 A.129.D.501 A.130.D.50.I; A.131.D.501 A.132.D.501 A.133.D.501 A.134.D.501 A.135.D.501 A.136.D.501 A.137.D.50. AND; A.138.D.501 A.139.D.501 A.140.D.501 A.141.D.501 A.2.D.511 A.3.D.511 A.4.D.511 A .5.D.511 A.7.D.511 A.9.D.511 A.100.D.511 A.101.D.511 A.102.D.511 A.1G3.D.511 A. 104.D.511 A.105.D.511 A.106.D.511 A.107.D.511 A.108.D.511 A.109.D.511 A.110.D.5U A.111 .D.511 A.112.D.5U A.113.D.511 A.114.D.511 A.115.D.511 A.116.D.511 A.117.D.511 A.118. D.511 A.119.D.51.I; A.120.D.51.Í; A.121.D.511 A.122.D.51.I; A.123.D.5U A.124.D.511 A.125.D.511 A.126.D.511 A.127.D.511 A.128.D.511 A.129.D.511 A .130.D.511 A.131.D.511 A.132.D.511 A.133.D.511 A.134.D.511 A.135.D.511 A.136.D.511 A. 137.D.511 A.138.D.511 A.139.D.511 A.140.D.511 A.141.D.511 A.2.E.461 A.3.E.461 A.4 .E.461 A.5.E.461 A.7.E.461 A.9.E.461 A.100.E.461 A.1O1.E.461 A.102.E.461 A.103. E.461 A.104.E.461 A.105.E.461 A.106.E.461 A.107.E.461 A.108.E.461 A.109.E.461 A.110.E .461 A.111.E.461 A.112.E.461 A.113.E.461 A.114.E.461 A.115.E.461 A.116.E.461 A.117.E. 461 A.118.E.461 A.119.E.461 A.120.E.461 A.121.E.461 A.122.E.461 A.123.E.461 A.124.E.461 A.125.E.461 A.126.E.461 A.127.E.461 A.126.E.461 .132.E.461 A.133.E.461 A.134.É.46.Í; A.135.E.461 A.136.E.461 A.137.E.461 A.138.E.461 A.139.E.461 A.140.E.461 A.141.E.461 A .2.E.47.Í; A.3.E.471 A.4.E.471 A.5.E.471 A.7.E.471 A.9.E.471 A.100.E.47.I; A.10LE.E.471 A.103.E.471 A.104.E.471 A.105.E.471 A.106.E.471 A.107.E.471 A.108 .E.471 A.109.E.47.Í; Α.Π0.Ε.471 A.111.E.471 A.112.E.471 A.113.E.471 A.114.E.471 A.115.E.471 Α.Π6.Ε.471 A .117.E.47.Í; A.118.E.471 ΑΛ19.Ε.471 A.120.E.47.Í; A.121.E.47.Í; A.122.E.47.Í; A.123.E.471 A.124.E.471 A.125.E.471 A.126.E.47.I; A.127.E.471 A.130.E.471 A.131.E.471 A.132.E.471 A.133.E.471 A .134.E.471 A.135.E.471 A.136.E.471 A.137.E.471 A.138.E.471 A.139.E.47.I; A.140.E.471 A.141.E.471 A.2.E.481 A.3.E.481 A.4.E.481 A.5.E.481 A.7.E.481 A .9.E.481 A.100.E.481 A.101.E.481 A.102.E.481 A.103.E.481 A.104.E.481 A.105.E.481 A. 106.E.481 A.107.E.481 Α.108Έ.481 A.109.E.481 A.110.E.481 A.U1.E.481 A.112.E.481 A.113.E .481 A.114.E.481 A.115.E.481 A.116.E.481 A.117.E.481 A.118.E.481 A.119.E.481 A.120.E. 481 A.121.E.481 A.122.E.481 A.123.E.481 A.124.E.481 A.125.E.481 A.126.E.481 A.127.E.481 A.128.E.481
- 150CZ 297945 B6- 150GB 297945 B6
A.129.E.48.Í; A.130.E.48.Í; A.131.E.48.Í; A.132.E.48.Í; A.133.E.48.Í; A.134.E.48.Í; A.135.E.484; A.136.E.484; A.137.E.48.Í; A.138.E.48.Í; A.139.E.48.Í; A.140.E.48.Í; A.141.E.484; A.2.E.494; A.3.E.494; A.4.E.49.Í; A3.E.494; A.7.E.49.Í; A.9.E.494; A.100.E.494; A.101.E.494; A.102.E.49.Í; A.103.E.494; A.104.E.494; A.105.E.494; A.106.E.49.Í; A.107.E.494; A.108.E.49.Í; A.109.E.494; A.110.E.49.Í; A.111.E.49.Í; A.112.E.49.Í; Α.Ί13.Ε.494; A.I14.E.494; A.115.E.49.Í; Α.116Έ.494; A.117.E.49.Í; A.118.E.494; A.119.E.494; A.120.E.494; A.121.E.494; A.122.E.494; A.123.E.49.Í; A.124.E.494; A.125.E.494; A.126.E.494;· A.127.E.494; A.128.E.49.Í; Α.129Έ.494; A.130.E.494; A.131.E.494; A.132.E.494; A.133.E.494; Α.Ί34.Ε.494; Α.135Έ.494; Α.136Έ.494; A.137.E.49.Í; A.138.E.494; A.139.E.49.Í; A.140.E.494; A.141.E.49.Í; A.2.E.50.Í; A.3.E.50.Í· A.4.E.50.Í; A.5.E.504; A.7.E.504; A.9.E.50.Í; A.100.E.50.Í; A.101.E.504; A.102.E.504; A.103.E304; A.104.E.504; A.105.E.504; A.106.E304; A.107.E.504; Α.108.Ε.50Λ; A.109.E.50.Í; A.110.E.50.Í; A.111.E.50.Í; A.112.E.50.Í; A.113.E.50.Í; A.114.E.50.Í; A.115.E.504; A.116.E.50.Í; A.117.ES04; A.118.E.504; A.119.E.50.Í; A.120.E.50.Í; A.121.E.504; A.122.E.50.Í; A.123.E.50.Í; A.124.E.504; A.125.E.50.Í; A.126.E.50.Í; A.127.E.504; A.128.E.50.Í; A.129.E504; A.130.E.504; A.131.E.50.Í; A.132.E.504; A.133.E.504; A.134.E.504; A.135.E.50.Í; A.136.E.50.Í; A.137.E.504; A.138.E.50A; A.139.E304; Α.Ι40.Ε50Λ; A.141.E.50.Í; A.2.E.514; A.3.E.514; A.4.E.51.Í; A.5.E.51.Í; A.7.E.514; Α.9Έ.51.Ϊ; A.100.E.514; A.101.E.5I4; A.102.E.51.Í; A.103.E.51.Í; A.104.E.514; A.105.E.51.Í; A.106.E.514; A.107.E.514; A.108.E.51J; A.109.E.51.Í; A.110.E.51.Í; A.111.E.51.Í; A.112.E514; A.113.E.51.Í; A.114.E.51.Í; A.115.E.5U; A.116.E.51.Í; A.117.E.51.Í; A.118.E314; A.119.E314; A.120.E.51A; A.121.E.514; A.122.E.514; A.123.E514; A.124.E31.Í; A.125.E314; A.126.E514; A.127.E514; A.128.E.51.Í; A.129.E.51.Í; A.130.E51.Í; A.131.E.514; A.132.E.51.Í; A.133.E.514; A.134.E.514; A.135.E.51.Í; A.136.E51.Í; A.137.E314; A.138.E.51.Í; A.139.E.514; A.140.E.514; A.141.E.51.Í; A.2.F.46.Í; A.3.F.46.Í; A.4.F.464; A.5.F.464; A.7.F.46.Í; A.9.F.464; A.100.F.46.Í; A.101.F.46.Í; A.102.F.46J; A.103.F.46.Í; A.104.F.46.Í; A.105.F.46.Í; A.106.F.46.Í; A.107.F.464; A.108.F.46.Í; A.109.F.46J; A.110.F.46.Í; A.111.F.46.Í; A.112.F.46.Í; A.113.F.46.Í; A.114.F.46.Í; A.115.F.46.Í; A.116.F.46.Í; A.117.F.46.Í; A.118.F.464;· A.119J.464;' A.120.F.46.Í; A.121.F.46.Í; A.122.F.464; A.123.F.46.Í; A.124.F46.Í; A.125.F.46.Í; A.126.F.46.Í; A.127.F.46.Í; A.128.F.46.Í; A.129.F.46.Í; A.130.F.46.Í; A.131.F.46.Í; A.132.F.464; A.I33.F.46.Í; A.134.F.464; A.135.F.46.Í; A.136.F46.Í; A.137.F.464; A.138.F.464;A.129.E.48.Í; A.130.E.48.Í; A.131.E.48.Í; A.132.E.48.Í; A.133.E.48.Í; A.134.E.48.Í; A.135.E.484; A.136.E.484; A.137.E.48.Í; A.138.E.48.Í; A.139.E.48.Í; A.140.E.48.Í; A.141.E.484; A.2.E.494; A.3.E.494; A.4.E.49.Í; A3.E.494; A.7.E.49.Í; A.9.E.494; A.100.E.494; A.101.E.494; A.102.E.49.Í; A.103.E.494; A.104.E.494; A.105.E.494; A.106.E.49.Í; A.107.E.494; A.108.E.49.Í; A.109.E.494; A.110.E.49.Í; A.111.E.49.Í; A.112.E.49.Í; Α.Ί13.Ε.494; A.I14.E.494; A.115.E.49.Í; Α.116Έ.494; A.117.E.49.Í; A.118.E.494; A.119.E.494; A.120.E.494; A.121.E.494; A.122.E.494; A.123.E.49.Í; A.124.E.494; A.125.E.494; A.127.E.494; A.128.E.49.Í; Α.129Έ.494; A.130.E.494; A.131.E.494; A.132.E.494; A.133.E.494; Α.Ί34.Ε.494; Α.135Έ.494; Α.136Έ.494; A.137.E.49.Í; A.138.E.494; A.139.E.49.Í; A.140.E.494; A.141.E.49.Í; A.2.E.50.I; A.3.E.50.I · A.4.E.50.I; A.5.E.504; A.7.E.504; A.9.E.50.I; A.100.E.50.I; A.101.E.504; A.102.E.504; A.103.E304; A.104.E.504; A.105.E.504; A.106.E304; A.107.E.504; Α.108.Ε.50Λ; A.109.E.50.Í; A.110.E.50.I; A.111.E.50.Í; A.112.E.50.I; A.113.E.50.I; A.114.E.50.Í; A.115.E.504; A.116.E.50.Í; A.117.ES04; A.118.E.504; A.119.E.50.Í; A.120.E.50.I; A.121.E.504; A.122.E.50.I; A.123.E.50.I; A.124.E.504; A.125.E.50.Í; A.126.E.50.Í; A.127.E.504; A.128.E.50.Í; A.129.E504; A.130.E.504; A.131.E.50.I; A.132.E.504; A.133.E.504; A.134.E.504; A.135.E.50.I; A.136.E.50.I; A.137.E.504; A.138.E.50A; A.139.E304; Α.Ι40.Ε50Λ; A.141.E.50.I; A.2.E.514; A.3.E.514; A.4.E.51.Í; A.5.E.51.Í; A.7.E.514; Α.9Έ.51.Ϊ; A.100.E.514; A.101.E.5I4; A.102.E.51.Í; A.103.E.51.Í; A.104.E.514; A.105.E.51.Í; A.106.E.514; A.107.E.514; A.108.E.51J; A.109.E.51.Í; A.110.E.51.Í; A.111.E.51.Í; A.112.E514; A.113.E.51.Í; A.114.E.51.Í; A.115.E.5U; A.116.E.51.Í; A.117.E.51.Í; A.118.E314; A.119.E314; A.120.E.51A; A.121.E.514; A.122.E.514; A.123.E514; A.124.E31.Í; A.125.E314; A.126.E514; A.127.E514; A.128.E.51.Í; A.129.E.51.Í; A.130.E51.Í; A.131.E.514; A.132.E.51.Í; A.133.E.514; A.134.E.514; A.135.E.51.Í; A.136.E51.Í; A.137.E314; A.138.E.51.Í; A.139.E.514; A.140.E.514; A.141.E.51.Í; A.2.F.46.Í; A.3.F.46.Í; A.4.F.464; A.5.F.464; A.7.F.46.Í; A.9.F.464; A.100.F.46.Í; A.101.F.46.Í; A.102.F.46J; A.103.F.46.Í; A.104.F.46.Í; A.105.F.46.Í; A.106.F.46.Í; A.107.F.464; A.108.F.46.Í; A.109.F.46J; A.110.F.46.Í; A.111.F.46.Í; A.112.F.46.Í; A.113.F.46.Í; A.114.F.46.Í; A.115.F.46.Í; A.116.F.46.Í; A.117.F.46.Í; A.118F.464; · A.119J.464; ' A.120.F.46.Í; A.121.F.46.Í; A.122.F.464; A.123.F.46.Í; A.124.F46.Í; A.125.F.46.Í; A.126.F.46.Í; A.127.F.46.Í; A.128.F.46.Í; A.129.F.46.Í; A.130.F.46.Í; A.131.F.46.Í; A.132.F.464; A.I33.F.46.Í; A.134.F.464; A.135.F.46.Í; A.136.F46.Í; A.137.F.464; A.138.F.464;
A.139.F.46.Í; A.140.F.464; A.141.F.46.Í; A.2.F.47.Í; A.3.F.47.Í; A.43.474; A.5.F.47.Í; A.7.F.47.Í; A.9.F.47.Í; A.100.F.47.Í; A.1Q1.F.474; A.102.F.47.Í; A.103.F.47.Í;A.139.F.46.Í; A.140.F.464; A.141.F.46.Í; A.2.F.47.Í; A.3.F.47.Í; A.43.474; A.5.F.47.Í; A.7.F.47.Í; A.9.F.47.Í; A.100.F.47.Í; A.1Q1.F.474; A.102.F.47.Í; A.103.F.47.Í;
A.104.F.47.Í; A.105.F.47.Í; A.106.F.47.Í; A.107.F.47.Í; A.108.F.47.Í; A.109.F.47.Í; A.110.F.47.Í; A.1U.F.47.Í; A.112.F.47.Í; A.113.F.474; A.114.F.47.Í; A.1153.474; A.116.F.47.Í; A.117.F.47.Í; A.118.F.47.Í; A.l193.474; A.1203.474; A.1213.474; A.122.F.47.Í; A.123.F.47.Í; A.124.F.47.Í; A.125.F.47.Í; A.126.F.474; A.1273.474; A.128.F.47.Í; A.1293.474; A.1303.47.Í; A.1313.474; A.132.F.47.Í; A.133.F.47.Í; A.134.F.47.Í; A.135.F.47.Í; A.136.F.47.Í; A.137.F.47.Í; A.138.F.474; A.139.F.474; A.140.F.47.Í; A.141.F.47.Í; A.2.F.48.Í;A.3.F.484; A.4.F.48.Í; AS.F.484; A.7.F.48.Í; A.9.F.48.Í; A.100.F.48.Í; A.1013.48.Í; A.102.F.48.Í; A.1033.48.Í; A.1043.484; A.105.F.48.Í; A.1063.48.1; A.107.F.48.Í; Α.1083.48Λ; A.1093.48.Í; A.110.F.484; A.111.F.48.Í; A.112.F.484; A.113.F.48.Í; A.1143.484; A.115.F.484; A.1163.484; A.117.F.48.Í; A.118.E484; A.l 193.484; A.120.F.484; A.121.F.484; A.1223.484; A.123.F48.1; A.124.F.48.Í; A.125.F.48.Í; A.126.F.48.Í; A.127.F.48.Í; A.128.F.48.Í;A.104.F.47.Í; A.105.F.47.Í; A.106.F.47.Í; A.107.F.47.Í; A.108.F.47.Í; A.109.F.47.Í; A.110.F.47.Í; A.1U.F.47.Í; A.112.F.47.Í; A.113.F.474; A.114.F.47.Í; A.1153.474; A.116.F.47.Í; A.117.F.47.Í; A.118.F.47.Í; A.l193.474; A.1203.474; A.1213.474; A.122.F.47.Í; A.123.F.47.Í; A.124.F.47.Í; A.125.F.47.Í; A.126.F.474; A.1273.474; A.128.F.47.Í; A.1293.474; A.1303.47.Í; A.1313.474; A.132.F.47.Í; A.133.F.47.Í; A.134.F.47.Í; A.135.F.47.Í; A.136.F.47.Í; A.137.F.47.Í; A.138.F.474; A.139.F.474; A.140.F.47.Í; A.141.F.47.Í; A.2.F.48.I; A.3.F.484; A.4.F.48.Í; AS.F.484; A.7.F.48.Í; A.9.F.48.Í; A.100.F.48.Í; A.1013.48.Í; A.102.F.48.Í; A.1033.48.Í; A.1043.484; A.105.F.48.Í; A.1063.48.1; A.107.F.48.Í; Α.1083.48Λ; A.1093.48.Í; A.110.F.484; A.111.F.48.Í; A.112.F.484; A.113.F.48.Í; A.1143.484; A.115.F.484; A.1163.484; A.117.F.48.Í; A.118.E484; A.l 193.484; A.120.F.484; A.121.F.484; A.1223.484; A.123.F48.1; A.124.F.48.Í; A.125.F.48.Í; A.126.F.48.Í; A.127.F.48.Í; A.128.F.48.Í;
-151 CZ 297945 B6-151 CZ 297945 B6
A.129.F.484; A.13O.E484; A.131.E484; A.132.E484; A.133.F.48.Í; A.134.E484; A.135.E484; A.136.E484; A.137.E484; A.138.F.484; A.139.F.48.Í; A.140.E484; A.141.F.484; A.2.F.494; A.3.E494; A.4.E494; A.5.E494; A.7.E494; A.9.E494; A.100.E494; A.101.F.494; A.102.E494; A.103.F.494; A.104.E494; A.105.E494; A.106.E494; A.107.E494; A.108.E494; A.109.F.494; A.110.F.49.Í; A.I11.F.494; A.112.F.494; A.U3.E494; A.I14.E494; A.115.E494; A.116.E494; A.117.E494; A.118.F.494; A.119.E494; A.120.F.494; A.121.F.494; A.122.F.494; A.I23.E494; A.124.E494; A.125.E494; A.126.E494; A.127.F.494; A.128.F.494; A.129.F.494; A.130.F.494; A.131.E494; A.132.F.494; A.133.E494; A.134.E494; A.135.F.494; A.136.F.494; A.137.E494; A.138.E494; A.139.E494; A.140.E494; A.141.E494; A.2.E504; A.3.E504; A.4.F.504; A.5.F.504; A.7.E504; A.9.E504; A.100.F.504; A.101.F.504; A.102.E504; A.103.E504; A.104.E504; A.105.E504; A.106.E504; A.107.E504; A.108.E504; A.109.F.504; A.110.E504; A.111.E504; A.112.E504; A.113.F.504; A.114.E504; A.115.E504; A.116.E504; A.117.E504; A.118.E504; A.119.F.504; A.120.F.504; A.121.E504; A.122.E504; A.123.F.504; A.124.F.504; A.125.E504; A.126.F.504; A.127.E504; A.128.E504; A.129.E504; A.130.F.504; A.131.F.50.Í; A.132.E504; A.133.E504; A.134.E504; A.135.E504; A.136.E504; A.137.E504; A.138.E504; A.139.E504; A.140.E504; ΑΛ41.Ε504; A.2.E514; A.3.F.514; A.4.E514; A.5.F514; A.7.F.514; A.9.F.514; A.100.F.514; A.101.E514; A.102.F.514; A.103.E514; A.104.E514; A.105.E514; A.106.F.514; A.107.E514; A.108.E514; A.109.E514; A.110.F.514; A.U1.F.514; A.112.E514; A.113.F.514; A.114.F.514; A.115.F.514; A.116.E514; A.117.F.514; A.U8.F.514; ΑΛ19.Ε514; A.120.F.514; A.121.E514; A.I22.E514; A.123.E514; A.124.E514; A.125.F.514; A.126.E514; A.127.E514; A.128.E514; A.129.E514; A.130.E514; A.131.E514; A.132.E514; A.133.F.514; A.134.E514; A.135.E514; A.136.E514; A.137.F.514; A.138.E514; A.139.F.514; A.140.E514; A.141.E514;A.129.F.484; A.13O.E484; A.131.E484; A.132.E484; A.133.F.48.Í; A.134.E484; A.135.E484; A.136.E484; A.137.E484; A.138.F.484; A.139.F.48.Í; A.140.E484; A.141.F.484; A.2.F.494; A.3.E494; A.4.E494; A.5.E494; A.7.E494; A.9.E494; A.100.E494; A.101.F.494; A.102.E494; A.103.F.494; A.104.E494; A.105.E494; A.106.E494; A.107.E494; A.108.E494; A.109.F.494; A.110.F.49.Í; A.I11.F.494; A.112.F.494; A.U3.E494; A.I14.E494; A.115.E494; A.116.E494; A.117.E494; A.118.F.494; A.119.E494; A.120.F.494; A.121.F.494; A.122.F.494; A.I23.E494; A.124.E494; A.125.E494; A.126.E494; A.127.F.494; A.128.F.494; A.129.F.494; A.130.F.494; A.131.E494; A.132.F.494; A.133.E494; A.134.E494; A.135.F.494; A.136.F.494; A.137.E494; A.138.E494; A.139.E494; A.140.E494; A.141.E494; A.2.E504; A.3.E504; A.4.F.504; A.5.F.504; A.7.E504; A.9.E504; A.100.F.504; A.101.F.504; A.102.E504; A.103.E504; A.104.E504; A.105.E504; A.106.E504; A.107.E504; A.108.E504; A.109.F.504; A.110.E504; A.111.E504; A.112.E504; A.113.F.504; A.114.E504; A.115.E504; A.116.E504; A.117.E504; A.118.E504; A.119.F.504; A.120.F.504; A.121.E504; A.122.E504; A.123.F.504; A.124.F.504; A.125.E504; A.126.F.504; A.127.E504; A.128.E504; A.129.E504; A.130.F.504; A.131.F.50.I; A.132.E504; A.133.E504; A.134.E504; A.135.E504; A.136.E504; A.137.E504; A.138.E504; A.139.E504; A.140.E504; ΑΛ41.Ε504; A.2.E514; A.3.F.514; A.4.E514; A.5.F514; A.7.F.514; A.9.F.514; A.100.F.514; A.101.E514; A.102.F.514; A.103.E514; A.104.E514; A.105.E514; A.106.F.514; A.107.E514; A.108.E514; A.109.E514; A.110.F.514; A.U1.F.514; A.112.E514; A.113.F.514; A.114.F.514; A.115.F.514; A.116.E514; A.117.F.514; A.U8.F.514; ΑΛ19.Ε514; A.120.F.514; A.121.E514; A.I22.E514; A.123.E514; A.124.E514; A.125.F.514; A.126.E514; A.127.E514; A.128.E514; A.129.E514; A.130.E514; A.131.E514; A.132.E514; A.133.F.514; A.134.E514; A.135.E514; A.136.E514; A.137.F.514; A.138.E514; A.139.F.514; A.140.E514; A.141.E514;
Vynález také zahrnují soli sloučenin podle vynálezu, zejména farmaceuticky přijatelné netoxické soli obsahující například Na+, Li+, Ca++ a Mg++. Takovéto soli zahrnují také soli odvozené kombinaci příslušného kationtů jako iontu alkalického kovu nebo kovu alkalických zemin nebo amoniový a kvartémí aminový ion s aniontem kyseliny, typická Wi karboxylová skupina. Monovalentní soli jsou preferované v případě, zeje žádaná ve vodě rozpustná sůl.The invention also includes salts of the compounds of the invention, especially pharmaceutically acceptable non-toxic salts containing, for example, Na + , Li + , Ca ++ and Mg ++ . Such salts also include salts derived from the combination of the corresponding cations such as an alkali metal or alkaline earth metal ion or ammonium and quaternary amine ion with an acid anion, a typical W 1 carboxyl group. Monovalent salts are preferred when a water-soluble salt is desired.
Typické kovové soli se připravují reakci hydroxidu kovu se sloučeninou podle vynálezu. Příkladem kovových solí připravených touto cestou jsou soli obsahující Li+, Na+ a K+. Méně rozpustné kovové soli se mohou připravit vysrážením z roztoku více rozpustné soli přidáváním vhodné sloučeniny kovu.Typical metal salts are prepared by reacting a metal hydroxide with a compound of the invention. Examples of metal salts prepared in this way are those containing Li + , Na + and K + . Less soluble metal salts can be prepared by precipitation from a more soluble salt solution by adding a suitable metal compound.
Dále je možné vytvořit soli přidáním určité organické nebo anorganické kyseliny například HC1, HBr, H2SO4 nebo organických sulfonových kyselin, do zásaditých center, typických amino skupin Gi nebo kyselých skupin jako E].It is also possible to form salts by adding certain organic or inorganic acids for example, HC1, HBr, H 2 SO 4 or organic sulfonic acids, to basic centers, typically an amino group Gi or acidic groups such as E].
Konečně je třeba chápat, že zde uváděné formulace zahrnují sloučeniny podle vynálezu v jejich neionizované i obojetně ionizované formě a kombinace se stechiometrickým množstvím vody jako v hydrátech.Finally, it is to be understood that the formulations disclosed herein include the compounds of the invention in both their unionized and zwitterionized form and in combination with a stoichiometric amount of water as in hydrates.
Rovněž jsou do rozsahu tohoto vynálezu zahrnuty soli mateřských sloučenin s jednou nebo více aminokyselinami. Každá z aminokyselin popsaných výše je vhodná, zvláště pak v přírodě se objevující aminokyseliny, které nalézáme jako komponenty proteinů, třebaže aminokyseliny jsou obvykle ty, které mají postranní řetězec s bazickou nebo acidickou skupinou, např. lysin, arginin nebo kyselinou glutamovou nebo neutrální skupinu jako je glycin, serin, threnonin, alanin, izoleucin nebo leucin.Also included within the scope of this invention are salts of parent compounds with one or more amino acids. Each of the amino acids described above is suitable, especially the naturally occurring amino acids that we find as protein components, although the amino acids are usually those having a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid or a neutral group such as is glycine, serine, threnonine, alanine, isoleucine or leucine.
-152CZ 297945 B6-152GB 297945 B6
Vynález rovněž zahrnuje metody inhibice aktivity neuraminidázy zahrnující působení na vzorek podezřelý z obsahu neuraminidázy sloučeninou podle vynálezu.The invention also includes methods of inhibiting neuraminidase activity comprising treating a sample suspected of containing neuraminidase with a compound of the invention.
Kompozice podle vynálezu působí jako inhibitory neuraminidázy, jako meziprodukty těchto inhibitorů a nebo mají jiné užitečné vlastnosti, jež jsou popsány dále. Inhibitory se budou vázat na místa na povrchu nebo v dutinách neuraminidázy, které mají tvar, který je pro neuraminidázu jedinečný. Formulace vázající neuraminidázu se mohou vázat s různým stupněm reverzibility. Ty sloučeniny, které se v podstatě váží nereverzibilně, jsou ideálními kandidáty pro použití v této metodě podle vynálezu. Jednou označené, v podstatě nereverzibilně nevázané sloučeniny jsou užitečné jako testy pro detekci neuraminidázy. V souladu s tím se vynález vztahuje k metodám detekce neuraminidázy na vzorku, podezřelém z obsahu neuraminidázy zahrnující působení kompozice obsahující sloučeninu podle vynálezu vzorek podezřelý z obsahu neuraminidázy, vázaným na označenou sloučeninu; a pozorovat účinek vzorku na aktivitu označení. Vhodná označení jsou v diagnostickém oboru dobře známa a zahrnují stabilní volné radikály, fluorofory, radioizotopy, enzymy, chemiluminiscenční skupiny a chromogeny. Sloučeniny zde obsažené jsou označovány běžným způsobem za použití funkčních skupin jako jsou hydroxyl nebo aminoskupiny.The compositions of the invention act as neuraminidase inhibitors, as intermediates of these inhibitors, or have other useful properties as described below. Inhibitors will bind to sites on the surface or cavities of neuraminidase having a shape that is unique to neuraminidase. Neuraminidase binding formulations may bind with varying degrees of reversibility. Those compounds that bind substantially irreversibly are ideal candidates for use in this method of the invention. Once labeled, substantially irreversibly unbound compounds are useful as assays for detecting neuraminidase. Accordingly, the invention relates to methods for detecting a neuraminidase on a sample suspected of containing neuraminidase comprising treating a sample suspected of containing neuraminidase with a labeled compound; and observe the effect of the sample on label activity. Suitable labels are well known in the diagnostic art and include stable free radicals, fluorophores, radioisotopes, enzymes, chemiluminescent groups, and chromogens. The compounds contained herein are labeled in conventional manner using functional groups such as hydroxyl or amino groups.
V rámci vynálezu vzorky podezřelé z obsahu neuraminidázy tvoří přírodní nebo umělé materiály, jako jsou žijící organizmy; tkáně nebo buněčné kultury; biologické vzorky jako jsou těchto vzorky těchto materiálů (krev, sérum, moč, cerebrospinální kapalina, slzy, sputum, sliny, vzorky tkání apod.); laboratorní vzorky; potrava, voda nebo vzorky vzduchu; vzorky biologických produktů jako jsou výtažky buněk, zvláště pak rekombinantní buňky syntetizující požadovaný glykoprotein; apod. Obvykle budou vzorky podezřelé z obsahu organizmu, který produkuje neuraminidázu, běžně jde o patogenní organizmus jako je virus. Vzorky mohou být obsaženy v jakémkoliv médiu včetně vody a organických směsí rozpouštědlo/voda. Vzorky zahrnují živé organizmy jako jsou lidé a umělé materiály, jako jsou buněčné kultury.Within the scope of the invention, samples suspected of containing neuraminidase comprise natural or artificial materials such as living organisms; tissue or cell culture; biological samples such as these samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, etc.); laboratory samples; food, water or air samples; samples of biological products such as cell extracts, particularly recombinant cells synthesizing the desired glycoprotein; etc. Typically, samples will be suspected of containing a neuraminidase producing organism, typically a pathogenic organism such as a virus. The samples may be contained in any medium including water and organic solvent / water mixtures. Samples include living organisms such as humans and artificial materials such as cell cultures.
Působení podle vynálezu zahrnuje přidání sloučeniny podle vynálezu ke vzorku nebo zahrnuje přidání prekurzoru sloučeniny do vzorku. Krok přidávání zahrnuje každou metodu podávání tak, jak byla popsána výše.The treatment of the invention involves adding a compound of the invention to the sample or comprising adding a precursor of the compound to the sample. The addition step includes each administration method as described above.
Je-li to žádoucí, pak se aktivita neuraminidázy po aplikaci sloučeniny dá pozorovat každou metodou zahrnující přímé a nepřímé metody detekce aktivity neuraminidázy. Hodí se kvantitativní, kvalitativní i semikvantitativní metody určování aktivity neuraminidázy. Obvykle se používá jedna zvýše popsaných metod zjišťování (screening), ovšem všechny ostatní metody jako je pozorování fyziologických vlastností žijícího organizmu se dají použít rovněž.If desired, neuraminidase activity after administration of the compound can be observed by any method including direct and indirect methods for detecting neuraminidase activity. Quantitative, qualitative and semiquantitative methods of determining neuraminidase activity are suitable. Usually one of the screening methods described above is used, but all other methods such as observing the physiological properties of a living organism can also be used.
Organizmy, které obsahují neuraminidázu jsou bakterie (Vibrio cholerae, Clostridium perfringens, Streptococcus pneumoniae a Arthobacter sialofílus) a viry (zvláště ortomyxoviry nebo paramyxoviry jako je chřipkový virus A a B, virus parachřipky, virus příušnic, virus Newcastleovy choroby, virus drůbežího moru a virus sendai). Inhibice aktivity neuraminidázy získaná nebo nalezená v těchto organizmech je právě předmětem vynálezu. Virologie chřipkových virů je popsána v práci „Fundamental Virology“ (Raven Press, New York, 1986), kapitola 24. Sloučeniny podle vynálezu jsou užitečné při léčení nebo profylaxi těchto infekcí u živočichů např. u kachen, hlodavců nebo prasat nebo u člověka.Organisms that contain neuraminidase are bacteria (Vibrio cholerae, Clostridium perfringens, Streptococcus pneumoniae and Arthobacter sialophilia) and viruses (particularly orthomyxoviruses or paramyxoviruses such as influenza A and B virus, paravirus virus, mumps virus, Newcastle disease virus, and poultry virus virus). sendai). The inhibition of neuraminidase activity obtained or found in these organisms is the object of the invention. Influenza virus virology is described in Fundamental Virology (Raven Press, New York, 1986), Chapter 24. The compounds of the invention are useful in the treatment or prophylaxis of these infections in animals, e.g., ducks, rodents or pigs, or in humans.
Ovšem v případě sloučenin pro screening, které jsou schopné inhibice chřipkových virů, je třeba mít na paměti, že výsledky enzymových zkoušek nemusí korelovat se zkouškami buněčných kultur, jak je ukázáno v tabulce 1 v práci Chandlera aj., výše. V důsledku toho zkoušky snížení nákazy by měly být primárním nástrojem screeningu.However, in the case of screening compounds capable of inhibiting influenza viruses, it should be remembered that the results of enzyme assays may not correlate with cell culture assays, as shown in Table 1 of Chandler et al., Supra. Consequently, disease reduction tests should be the primary screening tool.
-153 CZ 297945 B6-153 GB 297945 B6
Třídění inhibitorů neuramínídázyClassification of neuraminidase inhibitors
Sloučeniny podle vynálezu se třídí z hlediska inhibiční aktivity vůči neuraminidáze kteroukoli běžných technik pro vyhodnocování aktivity enzymu. V kontextu vynálezu jsou obvyklé formulace nejdříve tříděny z hlediska inhibice neuraminidázy in vitro a ty formulace, které vykazují inhibiční aktivitu se potom třídí z hlediska aktivity in vivo.The compounds of the invention are screened for neuraminidase inhibitory activity by any of the conventional techniques for evaluating enzyme activity. In the context of the invention, conventional formulations are first screened for neuraminidase inhibition in vitro and those formulations that exhibit inhibitory activity are then screened for in vivo activity.
Sloučeniny, které mají inhibiční konstanty in vitro Ki nižší než zhruba 5X106 M, obvykle méně než asi 1X10“7 M a s výhodou méně než asi 5X10“8 M jsou potom vhodné především pro použití in vivo.Compounds having in vitro inhibitory constants of Ki of less than about 5X10 6 M, usually less than about 1X10 -7 M and preferably less than about 5X10 -8 M, are particularly suitable for in vivo use.
Metody třídění in vitro byly podrobně popsány a nebudou zde dále uváděny. Ovšem, von Itzstein M. a j. v „Nátuře“, 363 (6428): 418-423 (1993) zvláště pak na str. 420 ve sloupci 2, celý odstavec 3 na str. 421, sloupec 2, první odstavec, popisuje vhodné zkoušky in vitro, které prováděl Potier M. a j.: „Anylt. Biochem“, 94:287-296 (1979), jak je modifikoval Chong, A. K. J. aj. v „Biochem. Biofys. Acta“, 1077:65-71 (1991) a Colman P. M.; a j. v Intemational Publication č. WO 92/06691 (Int. App. č. PCT/AU90/00501, datum publikace 30. dubna 1992) strana 34, řádek 13 až po str. 35 řádek 16, použije jiné užitečné třídění in vitro.In vitro screening methods have been described in detail and will not be discussed further herein. However, von Itzstein M. et al. In "Nature", 363 (6428): 418-423 (1993) especially on page 420 in column 2, the entire paragraph 3 on page 421, column 2, first paragraph, describes appropriate in vitro assays performed by Potier M. et al., "Anylt. Biochem., 94: 287-296 (1979) as modified by Chong, A. K. J. et al. In "Biochem. Biophys. Acta, 1077: 65-71 (1991) and Colman P.M .; and j. in Intemational Publication No. WO 92/06691 (Int. App. No. PCT / AU90 / 00501, date of publication 30 April 1992) page 34, line 13 to page 35, line 16, uses another useful classification in in vitro.
Třídění in vivo bylo rovněž popisováno podrobně viz von Itzstein, M. a j., cit. dílo, zvláště pak na str. 421, sloupec 2, první celý odstavec až na stranu 423 sloupec 2, část prvního odstavce a Colman, P. M. a j. cit. dílo str. 36, řádky 1-38, kde jsou popsána vhodná třídění in vivo.In vivo screening has also been described in detail by von Itzstein, M. et al. 421, column 2, first full paragraph except page 423, column 2, part of the first paragraph, and Colman, P.M. et al. 36, lines 1-38, which describe suitable in vivo screenings.
Farmaceutické přípravky a způsoby podáváníPharmaceutical compositions and methods of administration
Sloučeniny podle vynálezu tvoří farmaceutické přípravky za pomoci konvenčních nosičů a vehikul, které se budou vybírat v souladu s běžnou praxí. Tabletky budou obsahovat vehikula, přípravky umožňující klouzání, plnidla, pojidla a pod. Vhodné přípravky jsou připravovány ve sterilní formě a když jsou zamýšleny pro podávání jinou cestou než orálně, obvykle půjde o izotonické roztoky. Veškeré kompozice budou podle výběru obsahovat excipienty, jako jsou ty, které jsou uváděny v „Handbook of Pharmaceutical Excipient“ (1986). Vehikula zahrnují kyselinu askorbovou a další antioxidanty, chelatizační činidla jako je EDTA, uhlovodany jako je dextrin, hydroxyalkylcelulóza, hydroxyalkylmetylcelulóza, kyselina stearová a pod. pH kompozic se pohybuje od 3 do 11, avšak běžně bývá 7 až 10.The compounds of the invention form pharmaceutical compositions using conventional carriers and vehicles, which will be selected in accordance with conventional practice. The tablets will contain vehicles, glidants, fillers, binders and the like. Suitable formulations are prepared in sterile form and, if intended to be administered by a route other than orally, will usually be isotonic solutions. All compositions will optionally contain excipients such as those disclosed in the Handbook of Pharmaceutical Excipient (1986). Vehicles include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH of the compositions ranges from 3 to 11, but is typically 7 to 10.
Cestou vhodnou pro podmínky léčení se podává jedna nebo více sloučenin vynálezu, (o kterých se zde mluví jako o aktivních ingredientech). Vhodné způsoby zahrnují: orální, rektální, nasální, topické (včetně lícních a podjazykových), vaginální a parenterální (včetně podkožních, nitrosvalových, nitrožilních, nitrokožních, intratekálních a epidurálních) apod. Je vhodné, aby cesta podávání se lišila podle stavu příjemce. Výhodou sloučenin podle vynálezu je, že jsou orálně biologicky přístupné a mohou být dávkovány ústy; není nezbytné je podávat cestou intrapulmonámí nebo intranasální. Je překvapující, že protichřipkové sloučeniny VO 91/16320, WO 92/06691 a US patent 5360,817 jsou úspěšně podávány orálně nebo cestou intraperitoneální. Viz příklad 161 níže.One or more compounds of the invention (referred to herein as active ingredients) are administered by a route appropriate to the conditions of treatment. Suitable methods include: oral, rectal, nasal, topical (including facial and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), etc. It is desirable that the route of administration vary according to the condition of the recipient. An advantage of the compounds of the invention is that they are orally bioavailable and can be dosed orally; it is not necessary to administer them by intrapulmonary or intranasal route. It is surprising that the anti-influenza compounds WO 91/16320, WO 92/06691 and US Patent 5,360,817 are successfully administered orally or via the intraperitoneal route. See example 161 below.
Třebaže je možné aby byly aktivní ingredienty podávány samostatně, je vhodné je předkládat jako farmaceutické kompozice. Přípravky podle vynálezu, jak pro veterinární tak pro humánní použití, obsahují minimálně jednu aktivní složku tak jak je definována výše, společně s jedním nebo více přijatelnými nosiči a podle možnosti i jiné terapeutické složky. Nosič (nosiče) musí být „přijatelný“ ve smyslu kompatibility s ostatními složkami kompozice a fyziologicky nezávadné pro jejich příjemce.While it is possible for the active ingredients to be administered alone, it is desirable to present them as pharmaceutical compositions. The compositions of the invention, for both veterinary and human use, comprise at least one active ingredient as defined above, together with one or more acceptable carriers, and preferably other therapeutic ingredients. The carrier (s) must be "acceptable" in the sense of being compatible with the other ingredients of the composition and physiologically acceptable to the recipient thereof.
Farmaceutické přípravky zahrnují ty, které jsou vhodné pro předcházející cesty podávání. Přípravky však mohou být výhodně předkládány v jednotné dávkovači formě a mohou být připraveny kteroukoliv z metod dobře známých ve farmacii. Techniky a formulace se obecně naleznouPharmaceutical compositions include those suitable for prior routes of administration. The formulations, however, may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations are generally found
- 154CZ 297945 B6 v Remingtonově Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Tyto metody zahrnují krok sdružování aktivní složky s nosičem, který tvoří jedna nebo více přístupných složek. Obecně jsou kompozice připravovány rovnoměrným a těsným spojením aktivní složky s kapalnými nosiči nebo jemně rozdělenými pevnými nosiči nebo obojím a potom, jestliže je to nezbytné, i tvarováním výrobku.- 154GB 297945 B6 in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). These methods include the step of associating the active ingredient with a carrier which constitutes one or more accessible ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers, or both, and then, if necessary, shaping the article.
Farmaceutické přípravky podle vynálezu, vhodné pro orální podávání se připravují jako oddělené jednotky jako jsou kapsle, sáčky nebo tablety, z nichž každý obsahuje předem stanovené množství aktivní složky; jako prášek nebo granule; jako roztok nebo suspenze ve vodné kapalině nebo nevodné kapalině; nebo jako kapalné emulze oleje ve vodě nebo emulze vody v oleji. Aktivní složka může být přítomna jako velká pilulka, lektvar nebo pasta.Pharmaceutical compositions of the invention suitable for oral administration are prepared as discrete units such as capsules, sachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous liquid or a non-aqueous liquid; or as liquid oil-in-water emulsions or water-in-oil emulsions. The active ingredient may be present as a large pill, potion or paste.
Tabletka se vyrábí stlačováním nebo lisováním, podle možnosti s jednou nebo více složkami. Komprimované tablety se dají připravovat stlačováním ve vhodném stroji, kde se aktivní složka ve volně tekoucí formě jako je prášek nebo granule vhodně míchá s pojivém, mazivem, vnitřním rozpouštědlem, ochranným činidlem, povrchově aktivním nebo dispergačním prostředkem. Lisované tablety se dají vyrábět lisováním vhodné směsi práškové aktivní složky zvlhčené inertním kapalným rozpouštědlem ve vhodném stroji. Tablety se mohou případně povlékat nebo rýhovat a podle možnosti upravovat složení tak, aby umožňovalo pomalé nebo regulované uvolňování aktivní složky.The tablet is made by compression or compression, preferably with one or more ingredients. Compressed tablets can be made by compression in a suitable machine, wherein the active ingredient in a free-flowing form such as a powder or granules is suitably mixed with a binder, lubricant, internal solvent, preservative, surfactant or dispersant. Compressed tablets may be made by molding in a suitable machine a suitable mixture of the powdered active ingredient moistened with an inert liquid solvent. The tablets may optionally be coated or scored and, if possible, formulated to permit slow or controlled release of the active ingredient.
Pro infekci očí a jiných vnějších tkání například úst a pokožky, se receptury převážně aplikují jako povrchové masti nebo krém obsahující aktivní složku (složky) v množství např. 0,075 až 20 % hmotnosti (včetně aktivní složky) v rozsahu mezi 0,1 až 20 % po skocích 0,1 % hmotnostních jako 0,6 % hm, 0,7 % hm atd. (nejlépe 0,2 až 15 % hm a nejlépe 0,5 až 10 % hm). Při formulaci jako masti může být aktivní složka uložena buď do parafínové nebo s vodou mísitelné olejové báze. Alternativně, mohou být aktivní složky formulovány jako krém s krémovou bází oleje ve vodě.For infection of eyes and other external tissues such as the mouth and skin, the formulations are predominantly applied as an ointment or cream containing the active ingredient (s) in an amount of, for example, 0.075 to 20% by weight (including the active ingredient) in the range in steps of 0.1% by weight such as 0.6% by weight, 0.7% by weight, etc. (preferably 0.2 to 15% by weight and most preferably 0.5 to 10% by weight). When formulated as an ointment, the active ingredient may be incorporated into either a paraffinic or a water-miscible oil base. Alternatively, the active ingredients may be formulated as a cream with an oil-in-water cream base.
Je-li to žádoucí, pak vodná fáze krémové báze může zahrnovat například minimálně 30 % hm. polyhydrického alkoholu, tzn. alkoholu, který má dvě nebo více hydroxylových skupin jako je propylenglykol, butan 1,3-diol, manitol, sorbitol, glycerol a polyetylén glykol (včetně PEG 400) a jejich směsi. Topické receptury mohou zahrnovat i sloučeninu, která zvyšuje absorpci nebo penetraci aktivní složky pokožkou nebo jinou napadenou oblastí. Příklady takových podpůrných prostředků kožní (dermální) penetrace obsahují například dimetyl sulfoxid a příbuzné analogy.If desired, the aqueous phase of the cream base may comprise, for example, at least 30 wt. polyhydric alcohol; an alcohol having two or more hydroxyl groups such as propylene glycol, 1,3-diol butane, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. Topical formulations may also include a compound that enhances absorption or penetration of the active ingredient through the skin or other contaminated area. Examples of such dermal penetration enhancers include, for example, dimethyl sulfoxide and related analogs.
Olejová fáze emulze v přípravku podle vynálezu může být tvořena ze známých složek známým způsobem. Třebaže fáze může obsahovat pouze emulzifíkátor (jinak známý jako emulgační činidlo), je vhodné, aby obsahovala směs minimálně jedno emulgační činidlo s tukem nebo olejem, a to jak pro použití stukem tak i olejem. Je vhodnější, aby byl zahrnut i hydrofilní emulgátor s lipofílním emulgátorem, který působí jako stabilizátor. Je také vhodnější použít jak oleje tak i tuku. Celkem vzato, emulgační činidlo (činidla) se stabilizátorem (stabilizátory) vytváří tzv. emulgační vosk a vosk společně s olejem a tukem vytvářejí tak zvanou emulzifíkační bázi mazání, která vytváří olejovou dispergovanou bázi krémových receptur.The oily phase of the emulsion in the composition of the invention may be formed from known ingredients in a known manner. Although the phase may contain only an emulsifier (otherwise known as an emulsifying agent), it is desirable to include a mixture of at least one emulsifying agent with a fat or an oil, both for use as a stucco and an oil. It is preferable to include a hydrophilic emulsifier with a lipophilic emulsifier which acts as a stabilizer. It is also preferable to use both oils and fat. All in all, the emulsifying agent (s) with the stabilizer (s) form so-called emulsifying wax and the wax together with the oil and fat form a so-called emulsifying lubricating base which forms an oil dispersed base of cream recipes.
Emulgátory a stabilizátory emulze, které se hodí pro použití v kompozicích podle vynálezu, zahrnuj í Tween® 60, Spán® 80, cetostearyl alkohol, benzyl alkohol, myristyl alkohol, glycerol monostearát a lauryl sulfát sodný.Emulsifiers and emulsion stabilizers suitable for use in the compositions of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glycerol monostearate and sodium lauryl sulfate.
Výběr vhodných olejů nebo tuků pro receptury se zakládá na dosažení žádaných kosmetických vlastností. Krém by měl v první řadě být nemastivý, neměl by dělat skvrny a mělo by jít o výrobek, který lze umýt a který bude mít vhodnou konzistenci, aby se zabránilo jeho vytékání z tubiček nebo jiných kontejnerů. Lze také používat mono nebo dibazické alkylestery s rovným nebo rozvětveným řetězcem jako je di-izoadipát, izocetyl stearát, propylen glykol diester mastných kyselin kokosu, izopropyl myristát, decyl oleát, izopropyl palmitát, butyl stearát, 2-etylhexylThe choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. First of all, the cream should be non-greasy, non-staining, and should be a washable product of suitable consistency to prevent it from leaking out of tubes or other containers. Straight or branched chain mono or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, coconut propylene glycol diester, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl can also be used
- 155CZ 297945 B6 palmitát nebo směs esterů s rozvětveným řetězcem známou jako Crodamol CAP, přičemž poslední tři jsou estery, kterým lze dávat přednost. Tyto mohou být používány samostatně nebo v kombinaci v závislosti na požadovaných vlastnostech. Alternativně, se používají i lipidy s vysokým bodem tání jako je bílý měkký parafín a/nebo tekutý parafín nebo jiné minerální oleje.Palmitate or a mixture of branched chain esters known as Crodamol CAP, the last three being preferred esters. These can be used alone or in combination depending on the desired properties. Alternatively, high melting point lipids such as white soft paraffin and / or liquid paraffin or other mineral oils are also used.
Receptury, které se hodí pro topické podáván do očí také tvoří oční kapky, kde je aktivní složka rozpuštěna nebo suspendována ve vhodném nosiči, zvláště ve vodném rozpouštědle pro aktivní složku. Aktivní složka je nejlépe přítomna v těchto recepturách v koncentraci 0,5 až 20 %, obvykle 0,5 až 10 % a zvláště pak někdy 1,5 % hm. Receptury, které se hodí pro topické podávání v ústech jsou pastilky obsahující aktivní složku na ochucené bázi, obvykle sacharózy a arabské klovatiny; pastilky obsahující aktivní složku na inertní bázi jako je želatina a glycerin nebo sacharóza a klovatina; a dále ústní vody obsahující aktivní složka ve vhodném kapalném nosiči.Formulations suitable for topical administration to the eye also form eye drops where the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in these formulations at a concentration of 0.5 to 20%, usually 0.5 to 10%, and especially sometimes 1.5% by weight. Formulations suitable for topical administration in the mouth are lozenges containing the active ingredient on a flavored basis, usually sucrose and acacia; pastilles comprising an active ingredient on an inert basis such as gelatin and glycerin or sucrose and acacia; and mouthwashes containing the active ingredient in a suitable liquid carrier.
Recepty pro rektální podávání mohou být formulovány jako čípky s vhodnou bází obsahující například kakaové máslo nebo salicylát.Recipes for rectal administration may be formulated as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
Receptury vhodné pro intrapulmonární nebo nasální podávání mají velikost částic, např. v rozsahu 0,1 až 500 mikronů (včetně částic o velikosti 0,1 a 500 mikronů rozdělených po krocích 0,5, 1, 30 mikronů, 35 mikronů atd.), které se podávají rychlým vdechnutím nosními průchody nebo vdechováním ústy tak, aby se dosáhlo až alveolámích sklípků. Vhodné receptury obsahují vodný nebo olejový roztok aktivní složky. Formulace, které se hodí pro aerosol nebo podávání prášku se dají připravit běžnými metodami a mohou se podávat s ostatními léčivými činidly jako jsou sloučeniny používané při léčení nebo profylaxi chřipky A nebo B tak, jak je popsáno níže.Formulations suitable for intrapulmonary or nasal administration have a particle size of, e.g., in the range of 0.1 to 500 microns (including 0.1 and 500 micron particles separated in steps of 0.5, 1, 30 microns, 35 microns, etc.), which are administered by rapid inhalation through the nasal passages or by inhalation to reach alveolar alveoli. Suitable formulations contain an aqueous or oily solution of the active ingredient. Formulations suitable for aerosol or powder administration can be prepared by conventional methods and can be administered with other therapeutic agents such as compounds used in the treatment or prophylaxis of influenza A or B as described below.
Receptury vhodné pro vaginální podávání se mohou formulovat jako pesary, tampony, krémy, gely, pasty, pěny nebo spreje obsahující vedle aktivní složky takové nosiče, jaké jsou vhodné pro tento druh aplikace.Formulations suitable for vaginal administration may be formulated as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are appropriate for this type of application.
Receptury vhodné pro parenterální podávání zahrnují vodné a nevodné sterilní injekční roztoky, které mohou obsahovat antioxidanty, pufry, bakteriostatika a rozpuštěné látky, které dávají receptu izotonické vlastnosti vhodné pro krev příslušného příjemce a dále vodné a nevodné sterilní suspenze, které mohou obsahovat suspenzační činidla nebo zahušťovadla.Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injectable solutions which may contain antioxidants, buffers, bacteriostats and solutes which give the recipe isotonic properties suitable for the recipient's blood, and aqueous and non-aqueous sterile suspensions which may contain suspending agents or thickeners. .
Receptury se poskytují v jednotné dávce nebo v kontejnerech s více dávkami, např. v hermetizovaných ampulkách a lahvičkách a mohou být skladovány v lyofílizovaných podmínkách (sušených mrazem), kdy se vyžaduje pouze přidání sterilního kapalného nosiče, např. vody pro injekce těsně před použitím. Injekční roztoky a suspenze připravované v okamžiku potřeby se připravují ze sterilních prášků, granulí a tablet druhu, jaký byl již popsán. Receptury, dávkování obsahují ty, které se podávají jako denní dávka nebo denní dílčí dávka, tak jak již bylo uvedeno nebo jako jejich příslušná část s aktivní složkou.The formulations are provided in a single dose or in multi-dose containers, e.g., in hermetized ampoules and vials, and can be stored under freeze-dried (freeze-dried) conditions, requiring only the addition of a sterile liquid carrier, such as water for injection just prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Dosage formulations include those which are administered as a daily dose or daily sub-dose, as mentioned above, or as an appropriate portion thereof with the active ingredient.
Je třeba pochopit, že vedle složek konkrétně již uvedených, receptury podle tohoto vynálezu mohou obsahovat ještě i další činidla, která jsou konvenční pro příslušný typ receptury, např. ty, které jsou vhodné pro orální podávání, mohou obsahovat ochucovací činidla.It will be understood that in addition to the ingredients specifically mentioned above, the formulations of the present invention may also contain other agents that are conventional for the particular type of formulation, eg those that are suitable for oral administration may contain flavoring agents.
Vynález dále zahrnuje i veterinární receptury skládající se minimálně z jedné aktivní složky tak jako výše a definované společně s potřebným veterinárním nosičem.The invention further encompasses veterinary formulations consisting of at least one active ingredient as above and defined together with the necessary veterinary carrier.
Veterinární nosiče jsou materiály užívané pro účely podávání receptury a mohou být pevné, kapalné nebo plynné, které jsou buď inertní nebo přijatelné ve veterinárním použití a jsou slučitelné s aktivní složkou. Tyto veterinární receptury se mohou podávat orálně, parenterálně a nebo jiným požadovaným způsobem.Veterinary carriers are materials used for the purpose of administering the recipe and can be solid, liquid or gaseous, which are either inert or acceptable in veterinary use and are compatible with the active ingredient. These veterinary formulations may be administered orally, parenterally, or by any other desired route.
Sloučenin podle vynálezu se používá pro zajištění regulovaného uvolňování farmaceutických receptur obsahujících jako aktivní složku jedno nebo více sloučenin vynálezu („receptury reguloThe compounds of the invention are used to provide controlled release of pharmaceutical formulations containing, as an active ingredient, one or more compounds of the invention ("
-156CZ 297945 B6 váného uvolňování“), ve kterých se uvolnění aktivní složky reguluje a kontroluje tak, aby umožňovalo méně časté dávkování nebo aby to zlepšovalo farmakokinetiku nebo toxicitní profil příslušné aktivní složky.-156E 297945 B6 ') in which the release of the active ingredient is controlled and controlled so as to allow less frequent dosing or to improve the pharmacokinetics or toxicity profile of the active ingredient concerned.
Účinná dávka aktivní složky závisí minimálně na povaze stavu, který se léčí, na toxicitě, zda se sloučenina používá profylakticky (nižší dávky) nebo již proti aktivní chřipkové infekci, podle metody podání a farmaceutické receptury a bude určována také lékařem, který použije konvenční studie zvyšování dávky. Lze očekávat, že půjde od 0,001 až po 100 mg/kg tělesné váhy denně. Obvykle, od asi 0,01 do asi 10 mg/kg tělesné váhy denně. Ještě častější od 0,01 do asi 5 mg/kg tělesné váhy denně. Ještě obvyklejší je od 0,05 do 0,5 mg/kg tělesné váhy denně. Například pro inhalaci se bude denní dávka u dospělého člověka s hmotností přibližně 70 kg pohybovat od 1 mg do 1000 mg, nejvýhodněji mezi 5 mg a 500 mg, a může mít formu jedné nebo několikanásobné dávky.The effective dose of the active ingredient depends at least on the nature of the condition being treated, the toxicity of the compound being used prophylactically (lower doses) or already against active influenza infection, according to the administration method and pharmaceutical formulation, and will also be determined by a physician using conventional elevation studies. benefits. It can be expected to go from 0.001 to 100 mg / kg body weight per day. Usually, from about 0.01 to about 10 mg / kg body weight per day. Even more frequent from 0.01 to about 5 mg / kg body weight per day. Even more common is from 0.05 to 0.5 mg / kg body weight per day. For example, for inhalation, the daily dose in an adult human weighing about 70 kg will range from 1 mg to 1000 mg, most preferably between 5 mg and 500 mg, and may take the form of a single or multiple dose.
Aktivní složky vynálezu se rovněž používají v kombinaci s ostatními aktivními složkami. Tyto kombinace se vybírají na bázi stavu, který se léčí, na vzájemné reaktivitě složek a farmako-kinetických vlastnostech kombinace. Například, při léčbě virové infekce dýchacího systému, konkrétně chřipkové infekce, kompozice podle vynálezu se kombinují s látkami, které působí antivirovně (jako je amantidin, rimantadin a ribavirin), mukolytiky, expektoranty, bronchodilatancii, antibiotiky, antipyretiky nebo analgetiky. Spolu se sloučeninami podle tohoto vynálezu se běžně podávají antibiotika, antipyretika a analgetika.The active ingredients of the invention are also used in combination with other active ingredients. These combinations are selected based on the condition being treated, the mutual reactivity of the components, and the pharmacokinetic properties of the combination. For example, in the treatment of viral respiratory tract infections, particularly influenza infections, the compositions of the invention are combined with agents that act antivirally (such as amantidine, rimantadine and ribavirin), mucolytics, expectorants, bronchodilators, antibiotics, antipyretics or analgesics. Antibiotics, antipyretics and analgesics are commonly administered with the compounds of this invention.
Metabolity sloučenin dle vynálezuMetabolites of the compounds of the invention
Do rozsahu tohoto vynálezu patří také metabolické produkty sloučenin zde popisovaných, které se objevují in vivo, do rozsahu, do jakého jsou tyto produkty nezvyklé a nové proti předchozím způsobům. Tyto produkty mohou vznikat například z oxidace, redukce, hydrolýzy, amidace, esterifikace a podobně podávaných sloučenin, především v důsledků enzymatických procesů. V souladu s tím vynález zahrnuje nové a nezvyklé sloučeniny produkované procesem, který představuje kontaktování sloučeniny podle tohoto vynálezu se žlázami po dobu postačující k poskytnutí jejich metabolického produktu. Tyto produkty se obvykle identifikují tak, že se sloučenina podle vynálezu připraví tak, že je radioaktivně označena (například C14 nebo H3) a podá se parenterálně v dávce, kterou lze zjistit (např. větší než asi 0,5 mg/kg) takovým živočichům jako jsou krysy, myši, morčata, opice nebo člověku a umožní se dostatečná doba proběhnutí metabolizmu (obvykle asi 30 sekund - 30 hodin) a potom se izolují konverzní produkty z moči, krve nebo jiných biologických vzorků. Tyto produkty se snadno izolují, protože jsou označené (ostatní jsou izolovány použitím antilátek, schopných vázat epitopy přežívající v metabolitu). Struktury metabolitu se určují běžným způsobem, např. analýzou MS nebo NMR. Obecně, analýza metabolitů se provádí stejným způsobem, tak jak je známo v běžných studiích metabolizmu léčiv, alespoň těm, znalým v oboru. Produkty konverze, dokud nejsou jinak nalezeny in vivo, jsou užitečné v diagnostických zkouškách pro terapeutické dávkování sloučenin podle vynálezu, a to i tehdy, jestliže vlastní inhibiční aktivitu neuraminidázy.Also included within the scope of this invention are metabolic products of the compounds described herein that appear in vivo to the extent that these products are unusual and novel over the prior art. These products may arise, for example, from oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compounds, particularly as a result of enzymatic processes. Accordingly, the invention encompasses novel and unusual compounds produced by a process comprising contacting a compound of the invention with glands for a time sufficient to provide their metabolic product. These products are typically identified by preparing a compound of the invention by radiolabeling (e.g., C 14 or H 3 ) and administering parenterally at a detectable dose (eg, greater than about 0.5 mg / kg) such animals as rats, mice, guinea pigs, monkeys or humans and allow sufficient metabolic time (usually about 30 seconds - 30 hours) and then convert the conversion products from urine, blood or other biological samples. These products are readily isolated because they are labeled (others are isolated using antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in a conventional manner, for example by MS or NMR analysis. In general, metabolite analysis is performed in the same manner as is known in conventional drug metabolism studies, at least to those skilled in the art. Conversion products, unless otherwise found in vivo, are useful in diagnostic assays for therapeutic dosages of compounds of the invention, even if they possess neuraminidase inhibitory activity.
Další použití sloučenin tohoto vynálezuOther uses of the compounds of the invention
Sloučeniny podle tohoto vynálezu nebo biologicky aktivní látky produkované z těchto sloučenin hydrolýzou nebo metabolismem in vivo, se používají jako imunogeny nebo pro konjugaci na proteiny, čímž slouží jako složky imunogenetické kompozice pro přípravu antilátek, schopných vázat se konkrétně na protein, na sloučeniny nebo jejich metabolické produkty, které si udrží imunologicky rozeznatelné epitopy (místa vázání protilátek). Imunogenní formulace jsou proto užitečné jako meziprodukty při přípravě protilátek pro použití v diagnostice, kontrole kvality nebo podobně, u různých metod nebo zkoušek sloučenin nebo jejich nových a nezvyklých metabolických produktů. Sloučeniny jsou užitečné pro tvorbu protilátek proti jinak neimunogenním polypeptidům, vtom smyslu, že sloučeniny slouží jako místa kzachycení stimulující imunitní reakce, která vzájemně reaguje s nemodifikovaným konjugovaným proteinem.The compounds of the invention or biologically active substances produced from these compounds by hydrolysis or metabolism in vivo are used as immunogens or for conjugation to proteins, thereby serving as components of an immunogenetic composition for the preparation of antibodies specifically capable of binding to a protein, compounds or metabolic thereof products that retain immunologically recognizable epitopes (antibody binding sites). Immunogenic formulations are therefore useful as intermediates in the preparation of antibodies for use in diagnosis, quality control or the like, in various methods or assays of compounds or novel and unusual metabolic products thereof. The compounds are useful for generating antibodies against otherwise non-immunogenic polypeptides, in the sense that the compounds serve as capture sites for a stimulating immune response that interacts with the unmodified conjugated protein.
-157CZ 297945 B6-157GB 297945 B6
Produkty hydro lýzy, které nás zajímají, zahrnují produkty hydrolýzy chráněných acidických a bazických skupin, o kterých již byla řeč. Jak bylo uvedeno výše, acidické nebo bazické amidy zahrnující imunogenní polypeptidy jako je albumin nebo hemokyanin se obvykle používají jako imunogeny. Metabolické produkty popsané výše si mohou udržet podstatný stupeň imunologické reaktivity se sloučeninami podle vynálezu. V důsledku toho protilátky tohoto vynálezu budou schopné se vázat na nechráněné sloučeniny podle vynálezu bez vazby na chráněné sloučeniny; alternativně metabolické produkty budou schopny se vázat na chráněné sloučeniny a/nebo metabolické produkty bez vazby na chráněné sloučeniny podle vynálezu, nebo budou schopné se vázat konkrétně na jednu nebo všechny tři. Protilátky by neměly v podstatě reagovat na materiály, které se vyskytují v přírodě. Podstatná vzájemná reaktivita je reaktivita při specifických zkušebních podmínkách pro účely specifických analýz, které jsou schopné ovlivňovat výsledky zkoušky.The hydrolysis products of interest include the hydrolysis products of the protected acidic and basic groups mentioned above. As mentioned above, acidic or basic amides comprising immunogenic polypeptides such as albumin or hemocyanine are usually used as immunogens. The metabolic products described above can maintain a substantial degree of immunological reactivity with the compounds of the invention. As a result, the antibodies of the invention will be able to bind to the unprotected compounds of the invention without binding to the protected compounds; alternatively, the metabolic products will be able to bind to the protected compounds and / or metabolic products without binding to the protected compounds of the invention, or will be able to bind specifically to one or all three. In principle, antibodies should not respond to materials that occur in nature. Substantial mutual reactivity is reactivity under specific test conditions for the purpose of specific analyzes that are capable of influencing the test results.
Imunogeny podle tohoto vynálezu obsahují sloučeniny tohoto vynálezu, které mají žádaný epitop ve spojení s imunogenní substancí. V rámci předloženého vynálezu toto sdružení představuje kovalentní vazbu k vytvoření imunogenního konjugátu (kde přichází v úvahu) nebo směsi nekovalentně vázaných materiálů nebo jejich kombinace. Imunogenní látky zahrnují adjuvanty jako je Freundův adjuvant, imunogenní proteiny jako jsou virové, bakteriální, kvasinkové, rostlinné a živočišné polypeptidy, konkrétně pak hemokyanin, sérový albumin, dobytčí thyroglobulin nebo trypsinový inhibitor sojových bobů a imunogenní póly sacharidy. Obvykle je sloučenina, která má strukturu požadovaného epitopu, kovalentně svázána s imunogenním polypeptidem nebo polysacharidem za použití polyfunkčního (obvykle bifunkčního) síťovacího činidla. Metody používané pro výrobu hapto imunogenů jsou konvenční per se a všechny tyto metody proto používané pro konjugování hapténů na imunogenní polypeptidy nebo podobně se vhodně využívají rovněž, přičemž se berou v úvahu funkční skupiny prekurzorů nebo hydrolytických produktů, které jsou k dispozici pro síťování a pravděpodobnost tvorby protilátek, specifických pro epitop, o který se jedná, jako protiklad imunogenní substance.The immunogens of the invention comprise compounds of the invention having the desired epitope in association with an immunogenic substance. Within the scope of the present invention, this association constitutes a covalent bond to form an immunogenic conjugate (where applicable) or a mixture of non-covalently bound materials or combinations thereof. Immunogenic agents include adjuvants such as Freund's adjuvant, immunogenic proteins such as viral, bacterial, yeast, plant and animal polypeptides, particularly hemocyanine, serum albumin, cattle thyroglobulin or trypsin inhibitor soybeans, and immunogenic poles carbohydrates. Typically, a compound having the structure of the desired epitope is covalently bound to an immunogenic polypeptide or polysaccharide using a polyfunctional (usually bifunctional) crosslinking agent. The methods used to produce hapto immunogens are conventional per se, and all these methods, therefore, used to conjugate hapten to immunogenic polypeptides or the like are also conveniently used, taking into account the functional groups of precursors or hydrolytic products available for cross-linking and the likelihood of formation. antibodies specific for the epitope in question as opposed to an immunogenic substance.
Obvykle je polypeptid konjugovaný na místě sloučeniny podle vynálezu, vzdáleném od epitopu, který se má rozeznat.Typically, the polypeptide is conjugated at a site of a compound of the invention remote from the epitope to be recognized.
Konjugáty se připravují běžným způsobem. Například, síťovací činidlo N-hydroxysukcinimid, anhydrid kyseliny sukcinové nebo alkN=C=Nalk, to jsou látky vhodné pro přípravu konjugátů podle tohoto vynálezu. Konjugáty zahrnují sloučeninu podle vynálezu připojenou vazbou nebo vázací skupinou 1 až 100, obvykle 1 až 25 a ještě častěji 1 až 10 uhlíkových atomů na imunogenní látku. Konjugáty se separují od výchozích materiálů a vedlejších produktů za použití chromatografie nebo podobně a potom se sterilně filtrují a ukládají ke skladování v lahvičkách.Conjugates are prepared in conventional manner. For example, the crosslinking agent N-hydroxysuccinimide, succinic anhydride or alkN = C = Nalk are those suitable for preparing the conjugates of the invention. The conjugates include a compound of the invention attached by a bond or linking group of 1 to 100, usually 1 to 25 and more often 1 to 10 carbon atoms per immunogenic agent. The conjugates are separated from the starting materials and by-products using chromatography or the like and then sterile filtered and stored for storage in vials.
Sloučeniny podle tohoto vynálezu jsou zesíťovány například prostřednictvím jednoho nebo jedné nebo více z následujících skupin: hydroxylová skupina Uj; karboxylová skupina Εβ uhlíkový atom U], Ei, G] nebo Ti jako substituce H; a aminová skupina Gp Mezi tyto sloučeniny jsou zahrnuty amidy polypeptidů, kde polypeptidy slouží jako výše popsané skupiny R.6C nebo RebZvířata jsou obvykle imunizována proti imunogenním konjugátům nebo derivátům a antisérům nebo monoklonálním protilátkám, připraveným běžným způsobem.The compounds of the invention are crosslinked, for example, through one or more of the following groups: hydroxyl group Uj; carboxyl group Εβ carbon atom U], Ei, G] or Ti as a substitution for H; and amino group Gβ Included among these compounds are amides of polypeptides, wherein the polypeptides serve as the R 6 C or Reb groups described above . The animals are typically immunized against immunogenic conjugates or derivatives and antisera or monoclonal antibodies prepared in a conventional manner.
Sloučeniny podle vynálezu jsou užitečné pro udržování strukturální integrity glykoproteinů v rekombinantní kultuře buňky, to znamená, že se přidávají do fermentací, ve kterých se produkují glykoproteiny pro obnovu tak, aby bránily štěpení potřebných glykoproteinů katalyzovanému neuraminidázou. Toto má zvláštní hodnotu v rekombinantní syntéze proteinů u heterologních hostitelských buněk, které mohou nevhodně degradovat podíl cukrů a proteinů, který se má syntetizovat.The compounds of the invention are useful for maintaining the structural integrity of glycoproteins in recombinant cell culture, i.e., they are added to fermentations in which glycoproteins are produced for recovery to prevent neuraminidase catalyzed cleavage of the necessary glycoproteins. This has a particular value in recombinant protein synthesis in heterologous host cells, which may inappropriately degrade the proportion of sugars and proteins to be synthesized.
-158CZ 297945 B6-158GB 297945 B6
Sloučeniny podle vynálezu jsou polyfunkční. Jako takové představují jedinečnou třídu monomerů pro syntézu polymerů. Jako příklad, nikoliv však výhradně, polymery připravené ze sloučenin tohoto vynálezu zahrnují polyamidy a polyestery.The compounds of the invention are polyfunctional. As such, they represent a unique class of monomers for the synthesis of polymers. By way of example, but not exclusively, polymers prepared from the compounds of this invention include polyamides and polyesters.
Tyto sloučeniny se používají jako monomery, aby se tak poskytl přístup k polymerům, které mají jedinečné visící funkcionality. Sloučeniny podle tohoto vynálezu jsou užitečné pro homopolymery nebo jako komonomery s monomery, které nespadají do rozsahu vynálezu. Homopolymery sloučenin podle tohoto vynálezu budou užitečné jako činidla pro výměnu kationtů (polyestery nebo polyamidy), při přípravě molekulárních sít (polyamidy), tkaniny, vlákna, filmy, tvarované výrobky a pod., kde kyselá funkčnost E] je esterifikována například na hydroxylovou skupinu v Ub přičemž visící bazická skupina Gi je schopná vázat kyselou funkci, jaká se nachází u polypeptidů, jejichž čištění se má provést. Polyamidy jsou připravovány síťováním Ej a Gi s Ui a přilehlou částí kruhu, která zbývá volná k tomu, aby fungovala jako hydrofilní nebo hydrofobní skupina, v závislosti na výběru skupiny Ub Příprava těchto polymerů ze sloučenin podle vynálezu je samo o sobě konvenční.These compounds are used as monomers to provide access to polymers that have unique hanging functionality. The compounds of this invention are useful for homopolymers or as comonomers with monomers not within the scope of the invention. Homopolymers of the compounds of this invention will be useful as cation exchange agents (polyesters or polyamides), in the preparation of molecular sieves (polyamides), fabrics, fibers, films, shaped articles, and the like, wherein the acid functionality of E 1 is esterified to, for example, In b, the hanging base group G 1 is capable of binding an acidic function as found in the polypeptides to be purified. The polyamides are prepared by crosslinking E 1 and G 1 with U 1 and the adjacent ring moiety left to function as a hydrophilic or hydrophobic group, depending on the choice of group U b The preparation of these polymers from the compounds of the invention is itself conventional.
Sloučeniny podle vynálezu jsou také užitečné jako jedinečná třída polyfunkčních povrchových činidel. Konkrétně tam, kde Uj neobsahuje hydrofilní substituent a je například alkylem nebo alkoxylem, sloučeniny mají vlastnosti bifunkčních surfaktantů. Jako takové mají užitečné vlastnosti povrchově aktivní, povrchově krycí, emulzifikačně upravující, dále upravují reologii a smáčení povrchu potřebných látek.The compounds of the invention are also useful as a unique class of polyfunctional surfactants. In particular, where U 1 does not contain a hydrophilic substituent and is, for example, alkyl or alkoxy, the compounds have the properties of bifunctional surfactants. As such, they have useful surface-active, surface-covering, emulsifying-modifying properties, and further regulate the rheology and surface wetting of the required substances.
Jako polyfunkční sloučeniny s definovanou geometrií, které nesou současně polární a nepolární podíly, sloučeniny podle vynálezu jsou užitečné jako jedinečná třída činidel pro transfer fáze. Jako příklad, nikoliv však výhradně, sloučeniny vynálezu jsou užitečné při katalýze transferu fáze a extrakci iontů na bázi kapalina/kapalina (LIX).As polyfunctional compounds with defined geometry that carry both polar and non-polar moieties, the compounds of the invention are useful as a unique class of phase transfer agents. By way of example, but not exclusively, the compounds of the invention are useful in catalysing phase transfer and liquid / liquid ion extraction (LIX).
Sloučeniny vynálezu mohou obsahovat asymetrické uhlíkové atomy ve skupinách Ub Eb Gi a Tb Jako takové, tvoří jedinečnou třídu pomocných prostředků pro použití v syntéze nebo tvorbě jiných opticky aktivních materiálů. Tak například racemická směs karboxylových kyselin se dá rozložit na složky enantiomerů: 1) vytvořením směsi diastereomemích esterů nebo amidů se sloučeninou vynálezu, kde Ui je asymetrickým hydroxyalkanem nebo aminoalkanovou skupinou; 2) oddělením diastereomerů; 3) hydrolyzací esterové struktury. Racemické alkoholy se oddělují tvorbou esterů s acidickou skupinou Eb Dále, tato metoda se dá použít pro rozlišení sloučenin vynálezu samých, jestliže se použijí opticky aktivní kyseliny nebo alkoholy místo racemického výchozího materiálu.The compounds of the invention may contain asymmetric carbon atoms in the groups U b E b Gi and T b As such, they form a unique class of excipients for use in the synthesis or formation of other optically active materials. For example, a racemic mixture of carboxylic acids can be decomposed into enantiomer components by: 1) forming a mixture of diastereomeric esters or amides with a compound of the invention wherein U 1 is an asymmetric hydroxyalkane or aminoalkane group; 2) separation of diastereomers; 3) hydrolyzing the ester structure. Racemic alcohols are separated by ester formation with an acid group E b Furthermore, this method can be used to distinguish the compounds of the invention themselves if optically active acids or alcohols instead of racemic starting material.
Sloučeniny tohoto vynálezu jsou užitečné jako vazební a nebo rozmísťovací (spacery) při přípravě matric pro afinitní absorpci, imobilizovaných enzymů pro proces regulace nebo jako činidla pro imunologické zkoušky. Sloučeniny zde obsažené mají řadu funkčních skupin, které se hodí jako místa pro síťování s požadovaným substancemi. Například, je běžné spojovat afinitní reagenty jako jsou hormony, peptidy, protilátky, léky a podobné s nerozpustnými substráty. Tato nerozpustná činidla se používají známým způsobem pro absorbování vazebních partnerů pro afínitní činidla za vyráběných přípravků, diagnostických vzorků nebo jiných nečistých směsí. Podobně, imobilizované enzymy se používají k provádění katalytických konverzí při snadném zpětném získání enzymu. Bifunkční sloučeniny se běžně používají pro vázání při analýze označených skupin při přípravě diagnostických činidel.The compounds of the invention are useful as binding and / or spacers in the preparation of affinity absorption matrices, immobilized enzymes for the regulatory process, or as immunoassay reagents. The compounds contained herein have a number of functional groups that are useful as sites for crosslinking with the desired substances. For example, it is common to associate affinity reagents such as hormones, peptides, antibodies, drugs, and the like with insoluble substrates. These insoluble reagents are used in a known manner to absorb binding partners for affinity reagents from manufactured preparations, diagnostic samples or other impure compositions. Similarly, immobilized enzymes are used to perform catalytic conversions to readily recover the enzyme. Bifunctional compounds are commonly used for binding in the analysis of labeled groups in the preparation of diagnostic agents.
Mnohé funkční skupiny ve sloučeninách podle tohoto vynálezu se hodí pro použití při síťování. Například karboxylová nebo fosfoniová kyselina skupiny Ej se používá pro vytváření esterů s alkoholy nebo amidy s aminy reagentu, který se má sesíťovat. Místa Gb která jsou substituována OH, NHRb SH, azido (která je redukována na amino jestliže se to požaduje před zesíťováním), CN, NO2, amino, guanidino, halogen a podobné, jsou výhodná místa. Vhodná ochrana reaktivních skupin se používá tam, kde je to nezbytné při spojování sesíťovacího činidla, aby se zabránilo polymerizací bifunkční sloučeniny podle tohoto vynálezu. Obecně se sloučeniny zdeMany of the functional groups in the compounds of this invention are suitable for use in crosslinking. For example, the carboxylic or phosphonic acid of group Ej is used to form esters with alcohols or amides with amines of the reagent to be crosslinked. G b sites which are substituted with OH, NHR b SH, azido (which is reduced to amino if required prior to crosslinking), CN, NO 2 , amino, guanidino, halogen and the like are preferred sites. Appropriate protection of the reactive groups is used where necessary in coupling the crosslinking agent to prevent polymerization of the bifunctional compound of the invention. Generally, the compounds here
- 159CZ 297945 B6 používají tak, že se spojují prostřednictvím karboxylových nebo fosfoniových kyselin na hydroxyly nebo aminoskupiny prvního vázaného partnera, potom se kovalentně váží na druhého vázacího partnera prostřednictvím skupiny Ti nebo Gp Například první vázaný partner, jako je steroidní hormon se esterifikuje na kyselinu karboxylovou sloučeniny podle vynálezu a potom se konjuguje sesíťováním prostřednictvím Gi hydroxylu na kyanogenním bromidem aktivovanou sefarózou, přičemž se imobilizuje steroid, který se takto získá. Další chemické vlastnosti při konjugaci jsou dobře známy. Viz např. Maggio „Enzyme-Immunoassay“ (CRC, 1988, pp 71135) a tam citované odkazy.They are used by linking via carboxylic or phosphonic acids to hydroxyls or amino groups of the first bound partner, then covalently bonding to the second binding partner via the Ti or Gp group. For example, the first bound partner, such as a steroid hormone, is esterified to carboxylic acid. of the compound of the invention and then conjugated by crosslinking via Gi hydroxyl to cyanogenic bromide-activated sepharose, immobilizing the steroid thus obtained. Other chemical properties in conjugation are well known. See, eg, Maggio "Enzyme-Immunoassay" (CRC, 1988, pp 71135) and references cited therein.
Jak již bylo poznamenáno, terapeuticky užitečné sloučeniny podle tohoto vynálezu, kde jsou chráněny skupiny Wb nebo Gi karboxyl, hydroxyl nebo amino skupiny, jsou užitečné jako orální nebo prolongovaná forma uvolňování. V těchto případech použití se ochranná skupina odstraňuje in vivo například se hydrolyzuje nebo oxiduje, takže poskytuje volný karboxyl, amino nebo hydroxyl. Vhodné estery nebo amidy pro toto použití jsou vybírány podle specifičnosti esteráz substrátu a/nebo cyklopeptidáz, které očekáváme, že najdeme v buňkách, kde je žádoucí hydrolýza prekurzoru. Do toho rozsahu, do jakého specifičnost těchto enzymů není známa, lze třídit pluralitu sloučenin podle tohoto vynálezu až do doby, kdy se nalezne specifičnost žádaného substrátu. Tato se objeví na základě toho, že se objeví také volná sloučenina nebo antivirová aktivita. Obecně lze vybírat amidy nebo estery sloučenin vynálezu které (I) nejsou hydrolyzovány nebo relativně pomalu se hydrolyzují v horním střevě (II) jsou propustné ve střevem a buňkami (III) hydrolyzované v buněčné cytoplazmě a/nebo systémové cirkulaci. Třídicí zkoušky s výhodou používají buňky z konkrétních tkání, které jsou náchylné k chřipkové infekci, to znamená mukózní membrány bronchopulmonámího traktu. Zkoušky, které jsou známy, se hodí i pro určování biologické přístupnosti in vivo, včetně intestinální stability průchodu, buněčné propustnosti, jaterní stability a zkoušek stability plazmy. Ovšem i když ester, amid nebo jiné chráněné deriváty nejsou konvertovány in vivo na volné karboxyly, amino nebo hydroxylové skupiny, zůstávají nadále užitečné jako chemické meziprodukty.As noted above, therapeutically useful compounds of the invention wherein W b or G 1 groups are protected by carboxyl, hydroxyl or amino groups are useful as an oral or prolonged release form. In these cases of use, the protecting group is removed in vivo, for example, hydrolysed or oxidized to provide free carboxyl, amino, or hydroxyl. Suitable esters or amides for this use are selected according to the specificity of the substrate esterases and / or cyclopeptidases which we expect to find in cells where hydrolysis of the precursor is desired. To the extent that the specificity of these enzymes is unknown, a plurality of the compounds of the invention can be sorted until the specificity of the desired substrate is found. This occurs because free compound or antiviral activity also appears. In general, amides or esters of the compounds of the invention which (I) are not hydrolyzed or relatively slowly hydrolyzed in the upper intestine (II) are permeable to the intestine and cells (III) hydrolyzed in the cell cytoplasm and / or systemic circulation may be selected. Preferably, screening assays use cells from particular tissues that are susceptible to influenza infection, i.e., mucous membranes of the bronchopulmonary tract. The assays known are also suitable for determining in vivo bioavailability, including intestinal passage stability, cell permeability, liver stability, and plasma stability assays. However, although the ester, amide or other protected derivatives are not converted in vivo to free carboxy, amino or hydroxyl groups, they remain useful as chemical intermediates.
Příklady způsobů přípravy sloučenin podle vynálezůExamples of methods for preparing compounds of the invention
Vynález se rovněž vztahuje k způsobům přípravy sloučenin podle vynálezu. Tyto sloučeniny se připravují každou aplikovatelnou technikou organické syntézy. Mnohé z těchto technik jsou dobře známy. Ovšem, mnohé ze známých technik byly podrobně zpracovány a uvedeny v „Compendium of Organic Synthetic Metods“ (John Wiley & Sons, New York), svazek 1, IanT. Harrison a Shuyen Harrison, 1971; svazek 2, lan T. Harrison a Shuyen Harrison, 1974; svazek 3, Louis S. Hegedus a Leroy Wade, 1977; svazek 4, Leroy G. Wade, junior, 1980; svazek 5, Leroy G. Wade, junior, 1984; a svazek 6 Michael B. Smith; stejně tak jako March, J., „Advanced Organic Chemistry, 3. vydání“, (John Wiley & Sons, New York, 1985), „Comprehensive Organic Synthesis. Selectivity, Stratégy & Effíciency in Modem Organic Chemistry. V 9 svazcích“, Barry M. Trošt, šéfredaktor (Pergamon Press, New York, výtisk 1993).The invention also relates to processes for preparing the compounds of the invention. These compounds are prepared by any applicable organic synthesis technique. Many of these techniques are well known. However, many of the known techniques have been elaborated and reported in "Compendium of Organic Synthetic Methods" (John Wiley & Sons, New York), Volume 1, IanT. Harrison and Shuyen Harrison, 1971; Volume 2, Lan T. Harrison and Shuyen Harrison, 1974; Volume 3, Louis S. Hegedus and Leroy Wade, 1977; Volume 4, Leroy G. Wade, junior, 1980; Volume 5, Leroy G. Wade, junior, 1984; and Volume 6 of Michael B. Smith; as well as March, J., "Advanced Organic Chemistry, 3rd Edition," (John Wiley & Sons, New York, 1985), "Comprehensive Organic Synthesis. Selectivity, Strategies & Efficiency in Modem Organic Chemistry. In 9 volumes ”, Barry M. Trošt, editor-in-chief (Pergamon Press, New York, copy 1993).
Řada příkladů způsobů pro přípravu sloučenin podle vynálezu je uvedena dále. Tyto způsoby jsou zamýšleny k tomu, aby ilustrovaly povahu těchto přípravků a nejsou zamýšleny k tomu, aby omezovaly rozsah aplikovatelných způsobů.Numerous examples of methods for preparing compounds of the invention are set forth below. These methods are intended to illustrate the nature of the compositions and are not intended to limit the scope of the applicable methods.
Obecně, reakční podmínky jako je teplota, reakční doba, rozpouštědla, postupy úpravy a podobně budou ty, které jsou běžné pro konkrétní reakci, která se má provádět. Citovaný referenční materiál společně s materiálem zde citovaným, obsahuje podrobný popis těchto podmínek. Obvykle se teploty pohybují od - 100 do 200 °C, rozpouštědla budou aprotická nebo protická a reakční doba bude 10 sekund až 10 dní. Úprava se obvykle skládá z rychlého ochlazení všech nezreagovaných činidel, po kterém následuje dělení mezi systémem vrstev voda/organická vrstva (extrakce) a oddělování vrstvy, která obsahuje výrobek.In general, reaction conditions such as temperature, reaction time, solvents, treatment procedures and the like will be those common to the particular reaction to be performed. The cited reference material together with the material cited herein contains a detailed description of these conditions. Typically, temperatures range from -100 to 200 ° C, the solvents will be aprotic or protic and the reaction time will be 10 seconds to 10 days. The treatment usually consists of rapidly cooling all unreacted reagents, followed by separation between a water / organic layer system (extraction) and separation of the layer containing the product.
Oxidace a redukce se obvykle provádějí při teplotách blízkých teplotě místnosti (asi 20 °C), třebaže pro redukce kovovými hydridy se běžně teplota snižuje na 0 až -100 °C, rozpouštědla jsouOxidation and reductions are usually carried out at temperatures close to room temperature (about 20 ° C), although for metal hydride reductions the temperature is normally reduced to 0 to -100 ° C, the solvents are
-160CZ 297945 B6 obvykle aprotická pro redukci a mohou být buď protická nebo aprotická pro oxidace. Reakční doba se upravuje tak, aby se dosáhlo požadovaných konverzí.Usually aprotic for reduction and may be either protic or aprotic for oxidation. The reaction time is adjusted to achieve the desired conversions.
Kondenzační reakce se obvykle provádějí za teplot blízkých teplotě místnosti, třebaže pro nerov5 novážné, kineticky regulované kondenzace se teploty snižují (0 až -100 °C), což je rovněž běžné.The condensation reactions are usually carried out at temperatures close to room temperature, although for uneven, kinetically controlled condensations the temperatures decrease (0 to -100 ° C), which is also common.
Rozpouštědla mohou být buď protická (běžné v rovnovážných reakcích) nebo aprotická (běžné v kineticky regulovaných reakcích).Solvents can be either protic (common in equilibrium reactions) or aprotic (common in kinetically controlled reactions).
Při tomto způsobu jsou běžné standardní syntetické techniky, jako je azeotropní odstraňování io reakčních vedlejších produktů a použití bezvodých podmínek reakce (např. inertní plyn) a aplikuje se tam, kde je to vhodné.Standard synthetic techniques such as azeotropic removal of reaction by-products and the use of anhydrous reaction conditions (e.g., inert gas) are common in this process and are applied where appropriate.
Jeden příkladný způsob přípravy sloučeniny podle vynálezu je uveden na schématu níže. Podrobný popis způsobů metod je uveden v experimentální části uvedené dále.One exemplary method of preparing a compound of the invention is shown in the scheme below. A detailed description of the methods is provided in the experimental section below.
-161 CZ 297945 B6-161 GB 297945 B6
Schéma 1Scheme 1
OHOH
Kyselina šikimováShikimic acid
(3)(3)
ch3 (5)ch 3 (4)
H3iH 3 i
(6)(6)
-162CZ 297945 B6-162GB 297945 B6
Modifikace schématu pro vytvoření dalších provedení vynálezu je uvedena na schématech 2-4.A modification of the scheme to create other embodiments of the invention is shown in Schemes 2-4.
Schéma 2Scheme 2
Schéma 2Scheme 2
Aziridin 5 se konvertuje na aminonitril 9 pomocí Yb(CN)3 přídavkem katalyzujícího TMSCN podle postupu Utimota a jeho spolupracovníků v „Tetrahedron Lett.“, 31:6379 (1990).Aziridine 5 is converted to aminonitrile 9 by Yb (CN) 3 by addition of TMSCN catalysing according to the procedure of Utimoto and co-workers in "Tetrahedron Lett.", 31: 6379 (1990).
Konverze nitrilu 9 na odpovídající amidin 10 se provádí s použitím tří standardních kroků: I) H2S; II) CH3I; III) NH4OAc. Typickou konverzi nalezneme v J. Med. Chem.“, 36:1811 (1993).The conversion of the nitrile 9 to the corresponding amidine 10 is carried out using three standard steps: I) H 2 S; II) CH 3 I; Iii) NH 4 OAc. A typical conversion is found in J. Med. Chem., 36: 1811 (1993).
Nitril 9 se konvertuje na aminometyl sloučeninu 11 redukcí za použití kterékoli přístupné metody jakou nalezneme v „Modem Synthetic Reactions“ 2. vydání H. O. House, Benjamin/Cummings Publishing Co., 1972.Nitrile 9 is converted to aminomethyl compound 11 by reduction using any accessible method found in "Modem Synthetic Reactions" 2nd Edition by H.O. House, Benjamin / Cummings Publishing Co., 1972.
Aminometylovaná sloučenina 11 se konvertuje na bis-Boc chráněnou guanidino sloučeninu 12 tím, že se na 11 působí N,N'-bis-Boc-l 1-pyrazol-l-karboxamidin podle metody, kterou nalezneme v „Tetrahedron Lett.“, 36:299 (1995).The aminomethylated compound 11 is converted to the bis-Boc protected guanidino compound 12 by treating 11 with N, N'-bis-Boc-11-pyrazole-1-carboxamidine according to the method found in "Tetrahedron Lett.", 36 299 (1995).
-163CZ 297945 B6-163GB 297945 B6
Schéma 3Scheme 3
O2MeO 2 Me
AcHN iAcHN i
NCZ^CO2tBuNC Z 2 CO 2 tBu
(13)(13)
AcHNAcHN
NHBocNHBoc
BocN (16)BocN (15)
COzMe (17)CO from Me (17)
X^NHX = NH
NHZ NH Z
Schéma 3Scheme 3
Aziridin 5 se otevře t-butyl esterem alfa-kyano octovou kyseliny, aby poskytl sloučeninu 13. Aziridinové otevření tohoto typu nalezneme opět v „Tetrahedron Lett.“ 23:5021 (1982). Selektivní hydrolýza části t-butyl esteru v kyselých podmínkách je následována dekarboxylací, za které vznikne nitril 14.Aziridine 5 is opened with alpha-cyano acetic acid t-butyl ester to give compound 13. Aziridine opening of this type is again found in "Tetrahedron Lett." 23: 5021 (1982). Selective hydrolysis of a portion of the t-butyl ester under acidic conditions is followed by decarboxylation to give the nitrile 14.
Redukce 14 na aminoetyl derivát 15 se provádí stejným způsobem jako konverze 9 na 11. Amin 15 je potom konvertován na guanidino deriváty 16 s N,N'-bis-Boc-lH-pyrazol-l-karboxamidin podle metody nalezené v „Tetrahedron Lett.“, 36:299 (1995).The reduction of 14 to the aminoethyl derivative 15 is carried out in the same manner as the conversion of 9 to 11. The amine 15 is then converted to the guanidino derivatives 16 with N, N'-bis-Boc-1H-pyrazole-1-carboxamidine according to the method found in Tetrahedron Lett. , 36: 299 (1995).
Nitril 14 se konvertuje na odpovídající amidin 17 za použití stejného postupu popsaného výše pro konverzi 9 na 10.The nitrile 14 is converted to the corresponding amidine 17 using the same procedure described above for the conversion of 9 to 10.
-164CZ 297945 B6-164GB 297945 B6
Schéma 4Scheme 4
CO3M eCO 3 M e
N3 (20)N 3 (20)
PGOPGO
AcHNAcHN
Schéma 4Scheme 4
Epoxy alkohol 1 je chráně (PG=ochranná skupina) například MOMC1. Typické podmínky se naleznou v „Protective Groups in Organic Synthesis“ druhé vydání T.W. Greene a P.G.M. Wuts, John Wiley & Sons, New York, NY, 1991.Epoxy alcohol 1 is protected (PG = protecting group) for example MOMC1. Typical conditions are found in "Protective Groups in Organic Synthesis" second edition T.W. Greene and P.G.M. Wuts, John Wiley & Sons, New York, NY, 1991.
Epoxid 19 se otevírá pomocí NaN3/NH4Cl na aminoalkohol 20 podle postupu Sharplesse a spolupracovníků „J. Org. Chem.“, 50:1557 (1985).The epoxide 19 is opened with NaN 3 / NH 4 Cl to the aminoalcohol 20 according to the procedure of Sharpless and colleagues "J. Org. Chem., 50: 1557 (1985).
Redukce 20 na N-acetyl aziridin 21 se provádí třístupňovým postupem: 1) MsCl/trietyl amin; 2) H2Pd; 3) AcCl/pyridin. Tato transformace se dá najít v „Agnew. Chem. Int. Ed. Engl.“, 33:599 15 (1994).The reduction of 20 to N-acetyl aziridine 21 is carried out in a three-step procedure: 1) MsCl / triethylamine; 2) H 2 Pd; 3) AcCl / pyridine. This transformation can be found in “Agnew. Chem. Int. Ed. Engl., 33: 599 15 (1994).
-165 CZ 297945 B6-165 CZ 297945 B6
Azírídín 21 se převádí na azido amin 22 otevřením pomocí NáN3/NH4Cl v DMF při 65 °C je popsáno v „J. Chem. Soc. Perkin Trans I“, 801 (1976).Aziridine 21 is converted to azido amine 22 by opening with Na 3 / NH 4 Cl in DMF at 65 ° C as described in "J. Chem. Soc. Perkin Trans I, 801 (1976).
Odstranění ochranné skupiny 22 MOM se provádí za použití metod popsaných v „Protective Groups in Organic Synthesis“ 2. vydání T.W. Greene a P.G.M. Wuts, John Wiley & Sons, New York, NY, 1991. Vznikající alkohol se konvertuje přímo na aziridin 24 pomocí TsCl v pyridinu. Tyto transformace se najdou v „Agnew. Chem. Int. Ed. Engl.“, 33:599 (1994).Removal of protecting group 22 MOM is performed using the methods described in "Protective Groups in Organic Synthesis" 2nd edition T.W. Greene and P.G.M. Wuts, John Wiley & Sons, New York, NY, 1991. The resulting alcohol is converted directly to aziridine 24 by TsCl in pyridine. These transformations can be found in “Agnew. Chem. Int. Ed. Engl., 33: 599 (1994).
Aziridin 24 potom reaguje s ROH, RNH2m RSH nebo organokovem (metal-R), aby poskytl odpovídající deriváty s otevřeným kruhem 25, 26, 27 a 27,1. Aziridinová otevření tohoto typu lze nalézt v „Tetrahedron Lett.“ 23:5021 (1982) a „Angew. Chem. Int. Ed. Engl.“, 33:599 (1994).Aziridine 24 is then reacted with ROH, RNH 2m RSH or organometallic (metal-R) to provide the corresponding ring-opened derivatives 25, 26, 27 and 27.1. Aziridine openings of this type can be found in "Tetrahedron Lett." 23: 5021 (1982) and "Angew. Chem. Int. Ed. Engl., 33: 599 (1994).
Schéma 5Scheme 5
Jinou třídu sloučenin vynálezu můžeme připravit způsobem podle schémat 5a a 5b. Kyselina chinová se konvertuje na 28 metodou Shing., T.K.M. aj.; „Tetrahedron“, 47(26):4571 (1991). Mesylace pomocí MsCl na TEA/CH2C12 poskytne 29, který reaguje s NaN3 v DMF a poskytne 30. Reakce 30 sTFA v CH2C12 vede k 31, kteiý je mesylován pomocí MsCl vTEA/CH2Cl2 a poskytuje 32. Reakce s trifenylfosfinem ve vodě poskytne 33, který se převádí na 35 postupnou aplikací, 1) CH3C(O)C1 v pyridinu, 2) NaN3 v DMF, 3) NaH v THF. Alkylace 35 se širokou možností použití nukleofilů běžných v tomto druhu postupu poskytne řadu sloučenin takových, jako je 36. Způsoby zpracování sloučenin jako je 36 na další provedení podle vynálezu budou podobné těm které již byly popsány výše.Another class of compounds of the invention can be prepared by the method of Schemes 5a and 5b. Quinic acid is converted to 28 by Shing., TKM, etc .; Tetrahedron, 47 (26): 4571 (1991). Mesylation with MsCl to TEA / CH 2 Cl 2 gives 29, which reacts with NaN 3 in DMF to give 30. Reaction of 30 sTFA in CH 2 Cl 2 leads to 31 which is mesylated with MsCl in TEA / CH 2 Cl 2 and provides 32 Reaction with triphenylphosphine in water yields 33, which is converted to 35 by sequential application, 1) CH 3 C (O) Cl in pyridine, 2) NaN 3 in DMF, 3) NaH in THF. Alkylation 35 with the wide variety of nucleophiles conventional in this type of process will provide a variety of compounds such as 36. Methods for treating compounds such as 36 for further embodiments of the invention will be similar to those already described above.
-166CZ 297945 B6-166GB 297945 B6
Schetna 5aSchetna 5a
kyselina chinováquinic acid
(30)(30)
(33)United Kingdom (33)
-167CZ 297945 B6-167GB 297945 B6
Schéma 5bScheme 5b
Ň3 (34) 3 (34)
(36)(36)
(37)(37)
-168CZ 297945 B6-168GB 297945 B6
Schéma 6Scheme 6
(22) co2ch3 (22) 2 ch 3
Schéma 6Scheme 6
Další třída sloučenin vynálezu se připravuje způsobem podle schématu 6. Chráněný alkohol 22 (PG=metoxymetyl éter) je zbaven ochrany za standardních podmínek popsaných v „Protective Groups in Organic Synthesis“ 2 vydání, T.W. Greene a P.G.M. Wuts, John Wiley & Sons, NewYork, NY, 1991. Alkohol 51 se konvertuje na acetát 52 acetanhydridem a pyridinem za standardních podmínek. Acetát 52 je potom vystaven působení TMSOTf nebo BF3. OEt aby poskytl oxazolin 53. Tyto transformace jsou popsány v „Liebigs Ann. Chem.“, 129/1991) a „Carbohydrate Research“, 181 (1993). Alternativně se alkohol 51 transformuje na oxazolin 53 konverzí na odpovídající mesylát nebo tosylát 23 a následně se cyklizuje na oxazolin za standardních podmínek, jak je popsáno v „J. Org. Chem.“, 50:1126 (1985) a „J. Chem. Soc.“, 1385 (1970). Oxazolin 53 reaguje s ROH, RR'NH nebo RSH (kde R a R' jsou vybrány tak, aby byly v souladu s definicí W7) uvedenou výše) takže poskytne odpovídající deriváty s otevřeným kruhem 54, 55 a 56. Tyto transformace jsou popsány v „J. Org. Chem.“, 49:4889 (1984) a „Chem. Rev“, 71:483 (1971).Another class of compounds of the invention is prepared according to Scheme 6. Protected Alcohol 22 (PG = methoxymethyl ether) is deprotected under the standard conditions described in "Protective Groups in Organic Synthesis" 2 Edition, TW Greene and PGM Wuts, John Wiley & Sons, NewYork , NY, 1991. Alcohol 51 is converted to acetate 52 by acetic anhydride and pyridine under standard conditions. The acetate 52 is then exposed to TMSOTf or BF 3 . OEt to give oxazoline 53. These transformations are described in "Liebigs Ann. Chem. ", 129/1991) and" Carbohydrate Research ", 181 (1993). Alternatively, alcohol 51 is transformed into oxazoline 53 by conversion to the corresponding mesylate or tosylate 23 and subsequently cyclized to oxazoline under standard conditions as described in "J. Org. Chem. ", 50: 1126 (1985) and" J. Chem. Soc., 1385 (1970). Oxazoline 53 reacts with ROH, RR'NH or RSH (where R and R 'are selected to be in accordance with the definition of W 7) above) to provide the corresponding ring-opened derivatives 54, 55 and 56. These transformations are described in 'J. Org. Chem., 49: 4889 (1984) and "Chem. Rev., 71: 483 (1971).
Schémata 7-35Schemes 7-35
Další příklady způsobů přípravy sloučenin podle vynálezu jsou znázorněny na schématech 7-35. Podrobný popis způsobů přípravy je uveden v příkladové části.Further examples of methods for preparing compounds of the invention are illustrated in Schemes 7-35. A detailed description of the preparation methods is given in the Examples section.
-169CZ 297945 B6-169GB 297945 B6
Kyselina chinováQuinic acid
(63)(63)
Rt = R2 = OR t = R 2 = O
Rrs= OH, R2 - HR R = OH, R 2 - H
R = HR = H
R = PivR = Piv
R1=R2 = H R1 = R2 = H
R1+R2 = -S(O)- 170CZ 297945 B6R 1 + R 2 = -S (O) - 170E 297945 B6
SchemoTbSchemoTb
(69)Italy (69)
n3 (70) R = H (71) R = Msn 3 (70) R = H (71) R = Ms
(74) R = N3 (75) R = NH2 (74) R = N 3 (75) R = NH 2
- 171 CZ 297945 B6- 171 GB 297945 B6
Schéma 7cScheme 7c
(78) R»N3 (79) R = NH2 (78) R N 3 (79) R = NH 2
(80) (81) R = N3 (82) R « NH2 (80) (81) R = N 3 (82) R = NH 2
-172CZ 297945 B6-172GB 297945 B6
Schéma 8Scheme 8
H3CO nh2 H 3 CO nh 2
AcHNAcHN
BocHNBocHN
Schéma 9 (93) (94)Scheme 9 (93) (94)
co2ch3 co 2 ch 3
(102)(102)
(103)(103)
-173 CZ 297945 B6-173 GB 297945 B6
Schéma 10Scheme 10
Schéma 11Scheme 11
(124)(124)
-174CZ 297945 B6-174GB 297945 B6
Schéma 12 /Scheme 12 /
Schéma 13Scheme 13
(130) (131)(130)
(1)(1)
AcHN £ AcHN £
Ň3 Ň 3
AcHNAcHN
NH2 co2h •HCI (151)NH 2 co 2 h • HCl (151)
- 175CZ 297945 B6- 175GB 297945 B6
Schéma 14Scheme 14
CO2CH3 CO 2 CH 3
(152)(152)
(153)(153)
- 176CZ 297945 B6- 176GB 297945 B6
Schéma 15aScheme 15a
Schéma 15bScheme 15b
OHOH
N3 N 3
164164
(163)(163)
002Μβ00 2 Μβ
AcHNAcHN
NH2 NH 2
-177CZ 297945 B6-177GB 297945 B6
Schéma 16Scheme 16
COgMsCOgMs
PG=MOM (19)PG = MOM
(22)Italy (22)
(114)(114)
-178CZ 297945 B6-178GB 297945 B6
Schéma 17Scheme 17
OHOH
OH (180)Olympics (180)
(D(D
,co2ch3 what 2 ch 3
N3 (184)N3 (184)
(183)(183)
-179CZ 297945 B6-179GB 297945 B6
(201)(201)
(203)(203)
-180CZ 297945 B6-180GB 297945 B6
Schéma 20Scheme 20
co2hco 2 h
CO2Na ηνύη CO 2 Na ην ύ η
NHNH
Schéma 21 (102)Scheme 21 (102)
- 181 CZ 297945 B6- 181 GB 297945 B6
Schéma 22 ✓'XAScheme 22 ✓'XA
N3 (209)N 3 (209)
(211)(211)
Schéma 23Scheme 23
NHBocNHBoc
NHBoc (213)NHBoc (212)
-1S2CZ 297945 B6-1S2EN 297945 B6
Schéma 24Scheme 24
(216) (217)(217)
Schéma 25Scheme 25
AcHNAcHN
(200)(200)
NBocNBoc
NBoc INBoc I
NBocNBoc
CH3 CH 3
I ch3 I ch 3
-183CZ 297945 B6-183EN 297945 B6
Schéma 26Scheme 26
(223)(223)
Schéma 27Scheme 27
(226)(226)
-184 CZ 297945 B6-184 GB 297945 B6
Schéma 28Scheme 28
(183)(183)
CO2CH3 CO 2 CH 3
(228) (229)(228)
Schéma 29Scheme 29
(232)(232)
- 185CZ 297945 B6- 185GB 297945 B6
Schéma 30Scheme 30
(233)(233)
(235)(235)
Schéma 31Scheme 31
OH (Quinie Acid )OH (Quinie Acid)
(241)(241)
OTs (243)OTs (243)
VíShe knows
(D(D
- 186CZ 297945 B6- 186GB 297945 B6
Schéma 32Scheme 32
(4) (244)(244)
(102)(102)
187CZ 297945 B6187GB 297945 B6
Schéma 33Scheme 33
(251) (228)(228)
NH ·ΟΓ3ΟΟ2Η (252)NH · ΟΓ 3 ΟΟ 2 252 (252)
-188CZ 297945 B6-188GB 297945 B6
Schéma 34Scheme 34
(227) (260)(227)
(261) (262)(262)
Schéma 35Scheme 35
NHBocNHBoc
NBoc (263)NBoc (263)
-189CZ 297945 B6-189EN 297945 B6
Schéma 36Scheme 36
Kyselina šikimováShikimic acid
(270) (270)(270)
(271) (271)(271)
or52 (272)or 52 (272)
(273)(273)
-190CZ 297945 B6-190EN 297945 B6
Schéma 37Scheme 37
(275)(275)
(276)(276)
(272)(272)
- 191 CZ 297945 B6- 191 GB 297945 B6
Schéma 38Scheme 38
(277)(277)
(278)(278)
(279)(279)
(280)(280)
(281)(281)
-192CZ 297945 B6-192EN 297945 B6
Schéma 39Scheme 39
Schéma 40Scheme 40
(281) (282)(281)
(285)(285)
(285)(285)
-193 CZ 297945 B6-193 GB 297945 B6
Schéma 40.1Scheme 40.1
(290) ---- (291)(290) ----
Další provedení způsobu přípravy a užití sloučenin podle vynálezu jsou zakresleny ve schéma5 těch 36-40.1. Jedním aspektem vynálezu je, že je zaměřen na způsob přípravy sloučenin podle vynález, které zahrnují procesy A, B, C, D, E, F, G, Η, I, J, K, L, Μ, N, O, P, Q, R, S, T, U, V nebo W ve schématech 36-40.1, buď samotně nebo ve vzájemné kombinaci. Tabulka 27 popiFurther embodiments of the process for the preparation and use of the compounds of the invention are illustrated in Flow Diagram 36-40.1. One aspect of the invention is that it is directed to a process for preparing compounds of the invention which include processes A, B, C, D, E, F, G, Η, I, J, K, L, Μ, N, O, P, Q, R, S, T, U, V, or W in Schemes 36-40.1, either alone or in combination with each other. Table 27 pop
-194CZ 297945 B6 suje příklady provedení procesů A-W. Každé provedení je individuálním způsobem používajícím jednotné procesy A-W samotné nebo v kombinaci. Každá metoda, jak je uvedena v tab. 27, je oddělena, Jestliže provedení je jedno písmeno, potom odpovídá jednomu z procesů A-Q. Jestliže jde o více než jedno písmeno, potom odpovídá každému procesu, který byl prováděn postupně v naznačeném pořadí.-194GB 297945 B6 provides examples of A-W processes. Each embodiment is an individual method using uniform A-W processes alone or in combination. Each method as shown in Tab. 27, is separated. If the embodiment is a single letter, then it corresponds to one of the processes A-Q. If it is more than one letter, it corresponds to each process that was carried out in the order indicated.
Další aspekty vynálezu jsou zaměřeny na metody používání kyseliny šikimové na přípravu sloučeniny 270 jak je uvedeno jako A na schématu 36, dále metody používání sloučenin 270 pro přípravu sloučeniny 271 uvedené jako B na schématu 36, metod používajících sloučeninu 271 pro přípravu sloučenin 272 uváděnou jako C na schématu 36, metody použití sloučeniny 272 pro přípravu sloučeniny 273 uváděnou jako D na schématu 36, metody používání kyseliny chinové pro přípravu sloučeniny 274 uváděné jako E ve schématu 37, metody použití sloučeniny 274 pro přípravu sloučeniny 275 uváděné jako F ve schématu 37, metody použití sloučeniny 275 pro přípravu sloučeniny 276 uváděné jako G ve schématu 37, metody používání sloučeniny 276 pro přípravu sloučeniny 272 uváděné jako H ve schématu 37, metody použití sloučeniny 273 pro přípravu sloučeniny 277 uváděné jako I ve schématu 38, metody použití sloučeniny 277 pro přípravu sloučeniny 278 uváděné jako J ve schématu 38, metody použití sloučeniny 278 pro přípravu sloučeniny 279 uvedené jako Kve schématu 38, metody použití sloučeniny 279 pro přípravu sloučeniny 280 uvedené jako L ve schématu 38, metody použití sloučeniny 280 pro přípravu sloučeniny 281 uvedené jako M ve schématu 38, metody použití sloučeniny 281 pro přípravu sloučeniny 282 uvedené jako N ve schématu 39, metody použití sloučeniny 282 pro přípravu sloučeniny 283 uvedené jako O ve schématu 39, metody použití sloučeniny 283 pro přípravu sloučeniny 284 uvedené jako P ve schématu 39, metody použití sloučeniny 283 pro přípravu sloučeniny 285 uvedené jako Q ve schématu 40, metody použité sloučeniny 285 pro přípravu sloučeniny 286 uvedené jako R ve schématu 40, metody použití sloučeniny 287 pro přípravu sloučeniny 288 uvedené jako S ve schématu 40.1, metody použití sloučeniny 288 pro přípravu sloučeniny 289 uváděné jako T ve schématu 40.1, metody použití sloučeniny 289 pro přípravu sloučeniny 290 uváděné jako U ve schématu 40.1, metody použití sloučeniny 290 pro přípravu sloučeniny 291 uváděné jako ve schématu 40.1, a metody použití sloučeniny 291 pro přípravu sloučeniny 292 uváděné jako W ve schématu 40.1Other aspects of the invention are directed to methods of using shikimic acid to prepare compound 270 as shown as A in Scheme 36, methods of using compounds 270 to prepare compound 271 listed as B in Scheme 36, methods using compound 271 to prepare compounds 272 referred to as C in Scheme 36, methods of using compound 272 to prepare Compound 273 referred to as D in Scheme 36, methods of using quinic acid to prepare Compound 274 reported as E in Scheme 37, methods of using Compound 274 to prepare Compound 275 reported as F in Scheme 37, methods use of compound 275 for the preparation of compound 276 reported as G in Scheme 37, methods of using compound 276 for the preparation of compound 272 reported as H in Scheme 37, methods of using compound 273 for the preparation of compound 277 reported as I in Scheme 38 77 for the preparation of Compound 278 reported as J in Scheme 38, methods of using Compound 278 for the preparation of Compound 279 listed as K in Scheme 38, methods of using Compound 279 for the preparation of Compound 280 listed as L in Scheme 38 as M in Scheme 38, methods of using compound 281 to prepare compound 282 listed as N in Scheme 39, methods of using compound 282 to prepare compound 283 listed as O in Scheme 39, methods of using compound 283 to prepare compound 284 listed as P in Scheme 39 , methods of using compound 283 to prepare compound 285 shown as Q in Scheme 40, methods of using compound 285 to prepare compound 286 shown as R in Scheme 40, methods of using compound 287 to prepare compound 288 listed as S in Scheme 40.1, methods of using compound 288 to prepare the merge ny 289 reported as T in Scheme 40.1, methods of using compound 289 to prepare Compound 290 referred to as U in Scheme 40.1, methods of using compound 290 to prepare Compound 291 presented as in Scheme 40.1, and methods of using compound 291 to prepare Compound 292 referred to as W in diagram 40.1
Obecné aspekty těchto příkladných způsobů jsou popsány níže a také v příkladech. Každý z produktů následujících procesů se podle možnosti separuje, izoluje a/nebo čistí před svým použitím v následných procesech.The general aspects of these exemplary methods are described below and also in the examples. Each of the products of the following processes is preferably separated, isolated and / or purified prior to its use in subsequent processes.
Termín „působený“, „působení“, „působí se“, „úprava“ „reakce“, „reaguje“ a podobné znamenají kontaktování, míchání, reakci, umožnění reakce, uvedení do kontaktu a další termíny, které jsou běžně v praxi pro naznačení toho, že jedna nebo více chemických jednotek je manipulována takovým způsobem, aby se konvertovala do jedné nebo více jiných chemických jednotek. To znamená, že „úprava sloučeniny 1 sloučeninou 2“ nebo „působení sloučeninou 2 na sloučeninu 1“ je synonymické s „umožnění sloučenině 1 reagovat se sloučeninou 2“, „kontaktování sloučeniny 1 sloučeninou 2“, „reakce sloučeniny 1 se sloučeninou 2“ a dalšími výrazy, které jsou běžné v praxi organické syntézy pro účelné naznačení, že sloučenina 1 byla „upravena“, „reagovala“, „dovolilo sejí reagovat“, atd. se sloučeninou 2.The terms "acting", "acting", "acting", "modifying" "reaction", "reacting" and the like mean contacting, stirring, reacting, allowing reaction, contacting and other terms that are commonly used in practice to indicate that one or more chemical units are manipulated in such a way as to be converted into one or more other chemical units. That is, "compound 1 treatment of compound 1" or "compound 1 treatment of compound 2" is synonymous with "allowing compound 1 to react with compound 2", "contacting compound 1 with compound 2", "reacting compound 1 with compound 2" and other terms that are common in the practice of organic synthesis to effectively indicate that Compound 1 has been "treated", "reacted", "allowed to react", etc. with Compound 2.
„Působení či úprava nebo reakce“ naznačuje účelný a obvyklý způsob, jakým se umožňuje organickým chemikáliím, aby reagovaly. Jde o běžné koncentrace (0,01M až 10M, obvykle 0,lM až 1M), teploty (-100 až 250 °C, obvykle -78 až 150 °C, ještě častěji -78 až 100 °C, a ještě častěji pak 0 až 100 °C), reakční nádoby (obvykle sklo, plastické hmoty, kov), rozpouštědla, tlaky, atmosféry (obvykle vzduchu místo kyslíku a vody bez ohledu na reakce dusíku nebo argonu místo kyslíku nebo vody tam, kde by to vadilo) atd., pokud není jinak uvedeno, znalost podobných reakcí známých v praxi organické syntézy se používá při výběru podmínek a přístrojů pro „působení“ v daném procesu. Zvláště, jedna z běžných dovedností v praxi organické syntézy volí podmínky a přístroje, od kterých se rozumně očekává, že na nich bude úspěšně provedena chemická reakce popisovaných procesů na bázi znalosti v oboru."Treatment or treatment or reaction" indicates an expedient and usual way in which organic chemicals are allowed to react. These are common concentrations (0.01M to 10M, usually 0.1M to 1M), temperatures (-100 to 250 ° C, usually -78 to 150 ° C, more often -78 to 100 ° C, and even more often 0 to 100 ° C), reaction vessels (usually glass, plastics, metal), solvents, pressures, atmospheres (usually air instead of oxygen and water regardless of nitrogen or argon reactions instead of oxygen or water where this would interfere) etc. unless otherwise stated, knowledge of similar reactions known in the art of organic synthesis is used to select conditions and instruments for "acting" in the process. In particular, one of the common skills in organic synthesis practice selects conditions and devices that are reasonably expected to be successfully chemically reacted with the described processes based on the knowledge in the art.
-195CZ 297945 B6-195GB 297945 B6
Proces A. Schéma 36Process A. Scheme 36
Kyselina šikimová se používá pro přípravu sloučenin 270 následujícím postupem.Shikimic acid is used to prepare compounds 270 by the following procedure.
Cis-4,5-diol funkce šikimové kyseliny je diferencována od karboxylové kyseliny na uhlíku 1 selektivní ochrannou těchto dvou funkčních míst. Obvykle cis-4,5-diol funkce je chráněna jako cyklický ketal a karboxylová funkce kyseliny je chráněna jako ester.The cis-4,5-diol function of shikimic acid is differentiated from carboxylic acid on carbon 1 by selective protection of these two functional sites. Usually the cis-4,5-diol function is protected as a cyclic ketal and the carboxylic acid function is protected as an ester.
R-50 je 1,2—diol ochranná skupina nestálé kyseliny jako ty, které se popisují ve výše citované práci Greeneové, obvykle cyklický ketal nebo acetal, ještě častěji ketal cyklohexanonu nebo acetonu. R51 je stabilní karboxylová kyselina s ochrannou skupinou jako jsou ty, které jsou popisovány ve výše uváděné práci Greeneové, obvykle lineární, rozvětvený nebo cyklický alkyl, alkenyl nebo alkinyl s jedním nebo 12 uhlíkovými atomy, jako jsou ty, které jsou uvedeny jako skupiny 2-7, 9-10, 15 nebo 100 - 660 v tabulce 2, častěji však lineární nebo rozvětvený alkyl o 1-8 uhlíkových atomech jako jsou ty, které jsou uváděny jako skupiny 2-5, 9 nebo 100-358 na tabulce 2, přesto však ještě obvykleji lineární nebo rozvětvený alkyl s 1-6 uhlíkovými atomy jako ty, které jsou uváděny jako skupiny 2-5, 9 nebo 100-141 tabulky 2, nejčastěji však R51 je metyl, etyl, npropyl, i-propyl, n-butyl, sec-butyl, i-butyl nebo t-butyl.R-50 is a 1,2-diol volatile acid protecting group such as those described in Greene, cited above, usually a cyclic ketal or acetal, more often a cyclohexanone or acetone ketal. R51 is a stable carboxylic acid with a protecting group such as that described in the Greene work cited above, usually a linear, branched or cyclic alkyl, alkenyl or alkynyl having one or 12 carbon atoms, such as those listed as groups 2- 7, 9-10, 15 or 100 - 660 in Table 2, but more often linear or branched alkyl of 1-8 carbon atoms such as those listed as groups 2-5, 9 or 100-358 in Table 2, yet however, more usually linear or branched alkyl having 1-6 carbon atoms such as those listed as groups 2-5, 9 or 100-141 of Table 2, but most often R51 is methyl, ethyl, n-propyl, i-propyl, n-butyl , sec-butyl, i-butyl or t-butyl.
Kyselina šikimová reaguje tak, aby chránila karboxylovou kyselinu skupinou R51 a cis-4,5-diol skupinou R50. Obvykle se na kyselinu šikimovou působí alkoholem jako je metanol, etanol, npropanol nebo i-propanol a kyselým katalyzátorem, jako je minerální kyselina nebo sulfonová kyselina jako je metan- benzen, nebo toluensulfonová kyselina, načež následuje dialkyl ketal nebo acetal ketonu nebo aldehydu, jako 2,2-dimetoxy-propan nebo 1,1-dimetoxy-cyklohexan za přítomnosti odpovídajícího ketonu nebo aldehydu jako je aceton nebo cyklohexanon. Je možné také, aby produkt katalytického působení alkoholu a kyseliny se separoval, izoloval a/nebo čistil před působením dialkyl ketalem nebo acetalem. Alternativně se na kyselinu šikimovou působí CH2N2.Shikimic acid reacts to protect the carboxylic acid with R51 and cis-4,5-diol with R50. Usually, shikimic acid is treated with an alcohol such as methanol, ethanol, npropanol or i-propanol and an acid catalyst such as a mineral acid or a sulfonic acid such as methanes-benzene or toluenesulfonic acid followed by a dialkyl ketal or acetal of a ketone or aldehyde such as 2,2-dimethoxy-propane or 1,1-dimethoxy-cyclohexane in the presence of the corresponding ketone or aldehyde such as acetone or cyclohexanone. It is also possible for the catalytic action of the alcohol and acid to be separated, isolated and / or purified prior to treatment with a dialkyl ketal or acetal. Alternatively, shikimic acid is treated with CH 2 N 2 .
Obvykle, tento pochod zahrnuje působení na kyselinu šikimovou alkanolem a kyselinou sulfonovou; po kterém následuje působení geminálním dialkoxyalkanem nebo geminálním dialkoxycykloalkanem a akanonem nebo cykloalkanonem, aby vznikla sloučenina 270. Častěji proces zahrnuje působení na kyselinu šikimovou akanolem a kyselinou sulfonovou; po odpaření přebytečného alkanolu se na zbytek působí geminálním dialkoxyalkanem nebo geminálním dialkoxycykloalkanem a alkanonem nebo cykloalkanonem, aby se vytvořila sloučenina 270. Častěji pak proces zahrnuje působení na kyselinu šikimovou metanolem a paratoluensulfonovou kyselinou; odpařením přebytečného metanolu se získá zbytek; na zbytek se působí 2,2-dimetoxypropanem a acetonem, aby tak vznikla sloučenina 270.Usually, this process involves treating the shikimic acid with an alkanol and a sulfonic acid; followed by treatment with geminal dialkoxyalkane or geminal dialkoxycycloalkane and akanone or cycloalkanone to give compound 270. More often, the process involves treating shikimic acid with ethanol and sulfonic acid; after evaporation of the excess alkanol, the residue is treated with geminal dialkoxyalkane or geminal dialkoxycycloalkane and an alkanone or cycloalkanone to form compound 270. More often, the process involves treating shikimic acid with methanol and paratoluenesulfonic acid; evaporation of the excess methanol yields a residue; the residue was treated with 2,2-dimethoxypropane and acetone to give compound 270.
Příkladným výsledkem tohoto procesuje Příklad 55 uvedený v dalším textu.An exemplary result of this process is Example 55 below.
Proces B. Schéma 36Process B. Scheme 36
Na přípravu sloučeniny 271 se používá sloučenina 270 při následujícím procesu.To prepare compound 271, compound 270 is used in the following process.
Hydroxy skupina v poloze 3 se aktivuje, obvykle odstraňovacími reakcemi, ještě obvykleji pak je aktivována směrem k vytvoření epoxidového kruhu alkoholem na poloze 4.The hydroxyl group at the 3-position is activated, usually by removal reactions, and more usually it is activated towards the formation of the epoxy ring by the alcohol at the 4-position.
R52 je alkoholová aktivační skupina, obvykle aktivační skupina vedoucí k nahrazovací reakci, častěji aktivační skupina vedoucí k náhradě epoxidového kruhu alkoholem v poloze 4. Tyto skupiny zahrnují ty, které jsou typické pro praxi, jako je estery kyseliny sulfonové, ještě obvykleji metan-, benzen- nebo toluen-, ester kyseliny sulfonové. Jako jeden výsledek je R52 společně s O (např. -OR52), je odchozí skupinou jako jsou ty, které jsou v praxi běžné. Obvykle proto zahrnujeR 52 is an alcohol activating group, usually an activating group leading to a replacement reaction, more often an activating group leading to the substitution of the epoxy ring with an alcohol at the 4-position. These groups include those typical of practice, such as sulfonic acid esters, more usually methane, benzene or toluene, sulfonic acid ester. As one result, R 52, together with O (eg, -OR 52), is an outgoing group such as those common in the art. Usually therefore includes
-196CZ 297945 B6 působení na sloučeninu 270 halogenidem kyseliny, aby se vytvořila sloučenina 271. Ještě obvykleji proces zahrnuje působení na sloučenin 270 halogenidem sulfonové kyseliny ve vhodném rozpouštědle za účelem vytvoření sloučeniny 271. Ještě obvyklejší pak je, že proces obsahuje působení na sloučeninu 270 halidem kyseliny sulfonové ve vhodném rozpouštědle jako je amin, aleje možné i za přítomnosti spolurozpouštědla, jako je halogenický alkan, aby se vytvořila opět sloučenina 271. Stejně tak možné je, aby proces zahrnoval působení metalsulfonylchloridu a trietylaminu/dichlorometanu na sloučeninu 270, aby vznikla sloučenina 271.More commonly, the process comprises treating compound 270 with a sulfonic acid halide in a suitable solvent to form compound 271. More typically, the process comprises treating compound 270 with a halide. sulfonic acid in a suitable solvent such as an amine, but it is also possible in the presence of a cosolvent such as a halo alkane to recreate compound 271. It is equally possible for the process to include compound 270 to treat compound 270 to form compound 271 .
Příkladem výsledku tohoto procesuje to, co uvádíme jako příklad 56 dalšího textu.An example of the result of this process is what we present as example 56 of the following text.
Proces C. Schéma 36Process C. Scheme 36
Sloučenina 271 se zde používá k přípravě sloučeniny 272 následujícím postupem.Compound 271 is used herein to prepare compound 272 as follows.
Ochranná skupina nestálé kyseliny (R50) pro hydroxy skupiny na poloze 4 a 5 se odstraní. Obvykle se R5o odstraní bez toho, že by se podstatně odstranily ochranné skupiny labilní karboxylové kyseliny (např. R5i) nebo aktivační skupiny hydroxy (např. R52). Ještě obvykleji je, že R50 se štěpí v kyselém prostředí.The volatile acid protecting group (R 50 ) for the hydroxy groups at positions 4 and 5 is removed. Typically, R 5 a is removed without that substantially deprotected labile carboxylic acid (e.g. R i 5) or activation of hydroxy (e.g. R 52). More usually, R 50 is cleaved in an acidic medium.
Obvykle proces zahrnuje působení na sloučenin 271 protickým rozpouštědlem, mnohem obvykleji pak za přítomnosti kyselého katalyzátoru jak popsáno výše. Ještě obvyklejší je, že proces zahrnuje úpravu sloučeniny 271 alkanolem, jak je popsáno výše a kyselým katalyzátorem, jak bylo rovněž popsáno. Přesto však ještě obvyklejší je, že proces zahrnuje působení na sloučeninu 271 metanolem a kyselinou para-toluen-sulfonovou, aby tak vznikla sloučenina 272.Typically, the process involves treating compounds 271 with a protic solvent, more usually in the presence of an acid catalyst as described above. More typically, the process comprises treating Compound 271 with an alkanol as described above and an acid catalyst as also described. However, it is even more common that the process involves treating compound 271 with methanol and para-toluenesulfonic acid to produce compound 272.
Z příkladu 57 je vidět příkladné provedení tohoto procesu.Example 57 shows an exemplary embodiment of this process.
Proces D. Schéma 36Process D. Scheme 36
Zde se používá sloučenina 272 pro přípravu sloučeniny 273 následovně.Here, compound 272 is used to prepare compound 273 as follows.
Aktivovaná hydroxy skupina v poloze 3 sloučeniny 272 se nahradí hydroxy skupinou na poloze 4 sloučeniny 272 tak, aby vznikla epoxydová sloučenina 273. Obvykle je náhrada katalyzována vhodnou zásadou, ještě obvykleji aminovou zásadou, jako DBU nebo DBN.The activated hydroxy group at the 3-position of compound 272 is replaced with the hydroxy group at the 4-position of compound 272 to form the epoxy compound 273. Usually, the replacement is catalyzed by a suitable base, more usually an amine base such as DBU or DBN.
Typický proces zahrnuje působení na sloučeninu 272 bazickým katalyzátorem podle možnosti za přítomnosti vhodného rozpouštědla. Ještě obvyklejší je, že proces zahrnuje úpravu sloučeniny 272 aminovanou zásadou s polárním neprotickém rozpouštědle jako je dietyl eter nebo THF. Ještě obvyklejší je, že proces zahrnuje úpravu sloučeniny 272 pomocí DBU v THF, aby tak vznikla sloučeniny 273. Příkladný výsledek tohoto procesuje uveden v dalším textu jako příklad 58.A typical process involves treating compound 272 with a basic catalyst, preferably in the presence of a suitable solvent. More typically, the process involves treating Compound 272 with an aminated base with a polar non-protic solvent such as diethyl ether or THF. More typically, the process involves treating Compound 272 with DBU in THF to give Compound 273. An exemplary result of this process is shown below as Example 58.
Proces E. Schéma 37Process E. Scheme 37
Pro přípravu sloučeniny 274 se používá se kyselina chinová a to následujícím postupem.To prepare Compound 274, quinic acid was used as follows.
Cis-4,5-diolová funkce kyseliny chinové se diferencuje od karboxylové kyseliny na uhlíku 1 selektivní ochranou těchto dvou funkcí. Obvykle cis-4,5-diolová funkce je chráněna cyklickým ketalem a karboxylová funkce je chráněna jako lakton na hydroxy skupinou na poloze 3.The cis-4,5-diol function of quinic acid differentiates from carboxylic acid on carbon 1 by selective protection of these two functions. Usually the cis-4,5-diol function is protected by a cyclic ketal and the carboxyl function is protected as a lactone at the hydroxy group at the 3-position.
Rso byl popsán výše.R 50 has been described above.
-197CZ 297945 B6-197GB 297945 B6
Je obvyklé, že proces zahrnuje působení na kyselinu chinovou s geminaldialkoxyalkanem nebo geminálním dialkoxycykloakanem tak, jak bylo popsáno výše a alkanonem nebo cykloalkanonem, jak popsáno výše, podle možnosti za přítomnosti kyselého katalyzátoru, jak bylo rovněž opsáno výše, aby vznikla sloučenina 274. Je obvyklejší, že proces zahrnuje působení na kyselinu chinovou, geminal-dialkoxyalkanem nebo geminal-dialkoxycykloalkanem, nebo alkanonem nebo cykloalkanonem a kyselým katalyzátorem, aby vznikla sloučenina 270. Ještě obvyklejší je, že proces zahrnuje úpravu kyseliny chinové pomocí 2,2-dimetoxypropanu, acetonu a kyseliny para-toluensulfonové tak, aby vznikla sloučenina 274.Typically, the process comprises treating quinic acid with geminaldialkoxyalkane or geminal dialkoxycycloacane as described above, and an alkanone or cycloalkanone as described above, preferably in the presence of an acid catalyst as described above to form compound 274. It is more common that the process comprises treating quinic acid, geminal-dialkoxyalkane or geminal-dialkoxycycloalkane, or an alkanone or cycloalkanone and an acid catalyst to form compound 270. More typically, the process comprises treating quinic acid with 2,2-dimethoxypropane, acetone and acid. para-toluenesulfone to give compound 274.
Klasický příklad výsledku tohoto procesuje uveden jako příklad 101 v dalším textu.A classic example of the result of this process is given as Example 101 below.
Proces F. Schéma 37Process F. Scheme 37
Sloučenina 274 se používá pro přípravu sloučeniny 275 následujícím postupem.Compound 274 is used to prepare compound 275 as follows.
Lakton se otevře tak, aby vytvořil sloučeninu 275. Obvykle se lakton otevře tak, aby produkoval chráněnou karboxylovou kyselinu v poloze 1 a volný hydroxyl na poloze 3. Ještě obvyklejší je, že lakton se otevírá v zásaditém prostředí, aby vznikl R5i chráněná karboxylová kyselina na poloze 1 a volná hydroxylová skupina na poloze 3.The lactone is opened to form compound 275. Usually, the lactone is opened to produce the protected carboxylic acid at the 1-position and the free hydroxyl at the 3-position. More typically, the lactone opens in a basic environment to give the R 5i protected carboxylic acid. at position 1 and the free hydroxyl group at position 3.
R51 byl již popsán výše.R51 has already been described above.
Obvykle je sloučenina 274 upravována vhodnou zásadou ve vhodném protickém rozpouštědle. Obvykleji sloučenina 275 je vystavena působení kovové alkoxydové zásady jako je sodný, draselný nebo litiový alkoxid v alkanolu, tak jak bylo popsáno. Ještě obvyklejší je, že sloučenina 274 se upravuje NaOMe v MeOH tak, aby vznikla sloučenina 275.Typically, compound 274 is treated with a suitable base in a suitable protic solvent. More usually, compound 275 is exposed to a metal alkoxy base such as sodium, potassium or lithium alkoxide in an alkanol as described. More typically, compound 274 is treated with NaOMe in MeOH to give compound 275.
Příkladem výsledku tohoto procesuje to, co je uvedeno jako příklad 102 v dalším textu.An example of the result of this process is what is shown as Example 102 below.
Proces G. Schéma 37Process G. Scheme 37
Zde se používá sloučenina 275 pro přípravu sloučeniny 276 následujícím postupem.Here, compound 275 is used to prepare compound 276 by the following procedure.
Hydroxylová skupina v poloze 3 se aktivuje, obvykle se aktivuje směrem k nahrazovacím reakcím, ještě obvykleji je aktivována k náhradě tvorby epoxydového kruhu s alkoholem na poloze 4.The hydroxyl group at the 3-position is activated, usually activated towards the replacement reactions, more usually it is activated to replace the formation of the epoxy ring with the alcohol at the 4-position.
R52 je aktivační skupina alkoholu, obvykle aktivační skupina směrem k vytěsňovacím reakcí, častěji aktivační skupina k vytěsnění a tvorbě epoxydového kruhu alkoholem na pozici 4. Tyto skupiny zahrnují ty, které jsou typické v praxi jako jsou esteiy, kyseliny sulfonové, častěji metan- benzen- nebo toluen ester kyseliny sulfonové. V jednom případě R52 společně s O (tzn. -OR52), je vytěsňovanou skupinou jako je tomu běžně v praxi.R52 is an alcohol activating group, usually an activating group towards displacement reactions, more often an activating group for displacing and forming an epoxy ring with an alcohol at position 4. These groups include those typical in practice such as esters, sulfonic acids, more often methane-benzene- or toluene sulfonic acid ester. In one instance, R 52 together with O (i.e., -OR 52 ) is a displaced group as is common practice.
Obvykle proces zahrnuje působení na sloučeninu 275 halogenidem kyseliny, aby se vytvořila sloučenina 276. Obvykle proces zahrnuje postup, při kterém se na sloučeninu 275 působí hydrogenem kyseliny sulfonové ve vhodném rozpouštědle tak, aby se vytvořila sloučenina 276. Znamená to, že se tedy na sloučeninu 275 působí halogenidem kyseliny sulfonové ve vhodném rozpouštědle jako je amin, podle možnosti za přítomnosti dalšího rozpouštědla jako je halogenalkan, aby se vytvořila sloučenina 276. Ještě konkrétněji, proces zahrnuje působení na sloučeninu 275 p-toluen sulfonyl chloridem pyridinu dichlorometanu tak, aby se vytvořila sloučenina 276.Typically, the process comprises treating compound 275 with an acid halide to form compound 276. Typically, the process comprises treating a compound 275 with sulfonic acid hydrogen in a suitable solvent to form compound 276. Thus, the compound 275 is treated with a sulfonic acid halide in a suitable solvent such as an amine, preferably in the presence of another solvent such as a haloalkane to form compound 276. More specifically, the process comprises treating compound 275 with p-toluene sulfonyl chloride pyridine dichloromethane to form a compound. 276.
Typická provedení tohoto procesuje uvedeno jako příklad 103 v dalším textu.Typical embodiments of this process are exemplified by Example 103 below.
-198CZ 297945 B6-198GB 297945 B6
Proces H. Schéma 37Process H. Scheme 37
Sloučenina 276 se používá pro přípravu sloučeniny 272 následujícím postupem.Compound 276 is used to prepare Compound 272 as follows.
Hydroxy skupina v poloze 1 se eliminuje a cis-4,5-diol ochranná skupina se odstraní. Hydroxy skupina v poloze 1 je eliminována tak, aby se vytvořila olefínická vazba mezi polohou 1 a 6 a cis-4,5-diol ochranná skupina se odstraní tak, aby se znovu regeneroval cis-4,5-dio.The hydroxyl group at the 1-position is eliminated and the cis-4,5-diol protecting group is removed. The hydroxyl group at position 1 is eliminated to form an olefinic bond between positions 1 and 6 and the cis-4,5-diol protecting group is removed to regenerate the cis-4,5-dio.
V tomto procesuje na sloučeninu 276 působeno vhodným dehydratačním činidlem jako je minerální kyselina (HC1, H2SO4) nebo SO2CI2. Ještě konkrétněji sloučenina 276 je vystavena účinku SO2C12, po kterém následuje alkanol, pokud možno za přítomnosti kyselého katalyzátoru. Ještě konkrétněji, se na sloučeninu 276 působí SO2C12 ve vhodném polárním, aprotickém rozpouštědle, jako je amin, aby se vytvořil oleím. Na olefín se působí alkanolem jako je popsáno výše a za přítomnosti kyselého katalyzátoru, jak je rovněž popsáno výše, aby vznikla sloučenina 272. Sloučenina 275 je vystavena účinku SO2Cl2 v pyridinu/CH2Cl při teplotách -100 až 0 °C obvykle -100 až -10 °C a nejěastěji -78 °C, aby se vytvořil olefín; olefín je potom vystaven účinku metanolu a para-toluen sulfonové kyseliny tak, aby se z něj vytvořila sloučenina 272.In this process, compound 276 is treated with a suitable dehydrating agent such as mineral acid (HCl, H2SO4) or SO2Cl2. More particularly, compound 276 is exposed to SO 2 Cl 2 , followed by an alkanol, preferably in the presence of an acid catalyst. More particularly, compound 276 is treated with SO 2 Cl 2 in a suitable polar, aprotic solvent such as an amine to form oils. The olefin is treated with an alkanol as described above and in the presence of an acid catalyst as described above to give compound 272. Compound 275 is exposed to SO 2 Cl 2 in pyridine / CH 2 Cl at temperatures from -100 to 0 ° C usually -100 to -10 ° C and most often -78 ° C to form an olefin; the olefin is then exposed to methanol and para-toluene sulfonic acid to form compound 272.
Typický příklad tohoto procesuje uveden jako příklad 104 v dalším textu.A typical example of this process is given as Example 104 below.
Proces I. Schéma 38Process I. Scheme 38
Sloučenina 273 se používá pro přípravu sloučeniny 277 následujícím postupem.Compound 273 is used to prepare compound 277 by the following procedure.
Hydroxy skupina na poloze 5 je chráněná. Obvykl je chráněná skupina pod ochranou hydroxidu labilní kyseliny. Ještě obvykleji ochranná skupina brání transferu na sousední hydroxy skupiny.The hydroxy group at position 5 is protected. Usually, the protected group is protected by labile acid hydroxide. More usually, the protecting group prevents transfer to adjacent hydroxy groups.
R53 je ochranná skupina labilní hydroxy kyselina tak, jak je popsáno výše v citované práci Greeneové. Ještě přesněji R53 je štěpitelný éter kyseliny přesněji R53 je metoxymetyl (MOM, CH3-O-CH2-).R53 is a labile hydroxy acid protecting group as described in Greene, cited above. More precisely, R 53 is a cleavable ether of acid more precisely R 53 is methoxymethyl (MOM, CH 3 -O-CH 2 -).
Obvykle tento proces zahrnuje působení na sloučeninu 273 činidlem ochranné hydroxy skupiny, jak popisuje Greeneová. Přesněji proces zahrnuje to, že na sloučeninu 273 se působí substituovaným nebo nesubstituovaným halogen alkanem nebo alkenem jako je metoxymetyl chlorid (MOM chlorid, CH3-O-CH2-C1), ve vhodném rozpouštědle jako je polární, aprotické rozpouštědlo. Přesněji, proces zahrnuje působení na sloučeninu 273 chloridem MOM v aminovém rozpouštědle. Tento proces zahrnuje úpravu sloučeniny 273 chloridem MOM v diizopropyl etyl aminu.Typically, this process involves treating compound 273 with a hydroxy protecting agent as described by Greene. More specifically, the process comprises treating compound 273 with a substituted or unsubstituted halo alkane or alkene such as methoxymethyl chloride (MOM chloride, CH 3 -O-CH 2 -C 1 ), in a suitable solvent such as a polar, aprotic solvent. More specifically, the process comprises treating compound 273 with MOM chloride in an amine solvent. This process involves treating compound 273 with MOM chloride in diisopropyl ethyl amine.
Příklad provedení tohoto procesuje uveden jako příklad 59 v dalším textu.An exemplary embodiment of this process is given as Example 59 below.
Proces J. Schéma 38J. Scheme Process 38
Sloučeniny 277 se používá pro přípravu sloučeniny 278 následujícím procesem.Compound 277 is used to prepare compound 278 by the following process.
Epoxid v poloze 3 a 4 se otevře, aby vytvořil azid. Ještě přesněji epoxid v poloze 3 a 4 je otevírán tak, aby vytvořil 3-azido-4-hydroxy sloučeninu 278.The epoxide at positions 3 and 4 opens to form the azide. More specifically, the epoxide at positions 3 and 4 is opened to form the 3-azido-4-hydroxy compound 278.
Obvykle tento proces zahrnuje působení azidové soli ve vhodném rozpouštědle na sloučeninu 277. Přesněji, proces zahrnuje působení azidu sodíku a mírné zásady na sloučeninu 277, jako je např. halogenid čpavku, v polárním protickém rozpouštědle, jak je alkanol nebo voda, ještě přesněji proces zahrnuje působení azidu sodíku a chloridu amonného ve vodném/metanolovém roztoku na sloučenin 277, aby vznikla sloučenina 278.Typically, the process involves treating compound 277 with an azide salt in a suitable solvent. More specifically, the process comprises treating sodium 277, such as ammonia halide, in a polar protic solvent, such as an alkanol or water, with a sodium base and a mild base. treatment of compound 277 with sodium azide and ammonium chloride in aqueous / methanol solution to give compound 278.
-199CZ 297945 B6-199GB 297945 B6
Typické provedení tohoto procesuje uvedeno jako příklad 60 v dalším textu.A typical embodiment of this process is exemplified by Example 60 below.
Proces K. Schéma 38K. Process 38
Pro přípravu sloučeniny 279 se použije sloučenina 278 následujícím postupem.To prepare compound 279, compound 278 was used as follows.
Hydroxy skupina v poloze 4 sloučeniny 278 se nahradí 3-azido skupinou, aby se vytvořila aziridinová sloučenina 279.The hydroxy group at the 4-position of compound 278 is replaced with a 3-azido group to form the aziridine compound 279.
Tento proces zahrnuje to, že se působí na sloučeninu 278 hydroxyaktivační skupinou jak popsáno výše, organofosfinem a zásadou. Přesněji proces se týká úpravy sloučeniny 278 halogenidem kyseliny sulfonové, jak popsáno výše, aby se vytvořila aktivovaná hydroxy sloučenina, aktivovaná hydroxy sloučenina je potom vystavena působení trialkyl nebo triarylfosfinu, jako je trifenylfosfín, aby tak vznikla fosfoniová sůl a fosfoniová sůl je vystavena působení zásady jak oje amin, aby tak vznikla sloučenina 279. Konkrétněji proces znamená, že na sloučeninu 278 se působí mesyl chloridem, aby se vytvořila aktivovaná hydroxy sloučenina a aktivovaná hydroxy sloučenina se trifenylfosfínem převede na fosfoniovou sůl a fosfoniová sůl potom trietylaminem a H2O na sloučenin 279.This process involves treating compound 278 with a hydroxyactivating group as described above, with organophosphine and a base. More specifically, the process relates to treating compound 278 with a sulfonic acid halide as described above to form an activated hydroxy compound, the activated hydroxy compound is then exposed to a trialkyl or triarylphosphine such as triphenylphosphine to form a phosphonium salt and the phosphonium salt is exposed to both More particularly, the process means treating compound 278 with mesyl chloride to form an activated hydroxy compound and converting the activated hydroxy compound to triphenylphosphine to a phosphonium salt and then phosphonium salt to triethylamine and H 2 O to compound 279. .
Typické provedení tohoto procesuje uvedeno jako příklad 61 a 62 v dalším textu.A typical embodiment of this process is exemplified by Examples 61 and 62 below.
Proces L. Schéma 38Process L. Scheme 38
Sloučenina 279 se používá pro přípravu sloučeniny 280 následujícím postupem.Compound 279 is used to prepare compound 280 as follows.
Aziridinová sloučenina 279 se otevře azidem, aby se vytvořil azido amin 280.Aziridine Compound 279 is opened with azide to form azido amine 280.
Obvykle proces zahrnuje působení azidovou solí ve vhodném rozpouštědle na sloučeninu 279. Přesněji, proces zahrnuje úpravu sloučeniny 279 azidem sodíku a mírnou zásadou, jako je halogenid čpavku v polárním, aprotickém rozpouštědle jako je éter, amin nebo amid. Konkrétněji pak proces zahrnuje úpravu sloučeniny 279 působením azidu sodíku a chloridu amonného v roztoku DMF, aby vznikla sloučenina 280.Typically, the process comprises treating the compound 279 with an azide salt in a suitable solvent. More specifically, the process comprises treating compound 279 with sodium azide and a mild base such as an ammonia halide in a polar, aprotic solvent such as an ether, amine or amide. More specifically, the process comprises treating compound 279 with sodium azide and ammonium chloride in a DMF solution to form compound 280.
Typické provedení tohoto procesuje uvedeno jako příklad 63 v dalším textu.A typical embodiment of this process is exemplified by Example 63 below.
Proces M. Schéma 38M. Scheme Process 38
Pro přípravu sloučeniny 281 se používá sloučenina 280 následujícím postupem.To prepare compound 281, compound 280 was used as follows.
Chráněná hydroxy skupina v poloze 5 je nahražena aminem v poloze 4, aby se vytvořil azidin 281. Obvykle je aziridin 281 substituován labilní acidickou skupinou, přesněji pak aziridinovou aktivační skupinou.The protected hydroxy group at the 5-position is replaced with an amine at the 4-position to form azidine 281. Usually, aziridine 281 is substituted with a labile acidic group, more specifically an aziridine activating group.
R54 je labilní kyselá skupina, obvykle je to ochranná skupina labilního kyselého aminu jako ta, která je popisována ve výše uvedené práci Greeneové. Ještě přesněji R54 je aktivační skupina aziridinu, přesněji skupina schopná aktivovat aziridin směrem k otevření kruhu katalýzo váném kyselinou. Typické skupiny R54 zahrnují jako příklad nikoliv však výhradně, lineární nebo rozvětvenou 1-oxo-alk-l-yl skupinu o 1 až 12 uhlících, kde alkylová část je 1-11 uhlíkový lineární nebo rozvětvený řetězec alkylové skupiny (takové, jako je CH3(CH2)ZC(O)-, kde z je celé číslo od 0 do 10, např. acetyl CH3C(O)~, atd.), substituovaný metyl (např. trifenylmetyl, Ph3C-, trityl, Tr), nebo karbamát jako je BOC nebo Cbz nebo sulfonát (např. alkyl sulfonáty jako jsou metylR54 is a labile acidic group, usually a labile acidic amine protecting group such as that described in Greene, supra. More specifically, R 54 is an aziridine activating group, more specifically a group capable of activating aziridine towards an acid-catalyzed ring opening. Typical R 54 groups include, but are not limited to, a linear or branched 1-oxo-alk-1-yl group of 1 to 12 carbons, wherein the alkyl moiety is a 1-11 carbon linear or branched chain alkyl group (such as CH 3 (CH 2 ) Z C (O) -, wherein z is an integer from 0 to 10, eg acetyl CH 3 C (O) -, etc.), substituted methyl (eg triphenylmethyl, Ph 3 C-, trityl , Tr), or a carbamate such as BOC or Cbz or a sulfonate (e.g., alkyl sulfonates such as methyl
-200CZ 297945 B6 sulfonáty). Přesněji R54 skupiny zahrnují trifenylmetyl a 1-oxo-alk-l-yl skupiny, které mají 18, ale častěji 1,2,3,4,5, nebo 6 uhlíkových atomů, ale častěji to bývají 2 nebo 3.-200EN 297945 B6 sulfonates). More specifically, R 54 groups include triphenylmethyl and 1-oxo-alk-1-yl groups having 18, but more often 1,2,3,4,5, or 6 carbon atoms, but more often being 2 or 3.
Obvykle tento proces zahrnuje v sobě to, že se na sloučeninu 280 působí činidlem likvidujícím ochranu, aby se odstranila skupina R53. Je to činidlo produkující R54jako jsou ta, která popisuje Greeneová (halogenid R54, jako je acetylchlorid nebo Tr-Cl, nebo R54-O-R54, jako je anhydrid kyseliny octové) a hydroxy aktivační skupina taková jako jsou ty, které jsou popsány v procesu B, schéma 36. Konkrétněji se jedná o tomto procesu o působení na sloučeninu 280 s polárním protickým rozpouštědlem, podle možnosti za přítomnosti kyselého katalyzátoru jak popsáno výše, aby se vytvořil první meziprodukt; působení na první meziprodukt Tr-Cl v polárním, aprotickém rozpouštědle, jako je amin, aby se vytvořil druhý meziprodukt; a působením na druhý meziprodukt halogenidem kyseliny sulfonové jako je mesylchlorid nebo paratoluen sulfonychlorid v polárním aprotickém rozpouštědle, jak oje amin, aby vznikla sloučenina 281. Ještě podrobněji tento proces zahrnuje jen to, že se na sloučeninu 280 působí metanolem a kyselinou solnou, aby se vytvořil první meziprodukt. První meziprodukt je vystaven působení Tr-Cl a trietylaminu, aby se vytvořil druhý meziprodukt; na druhý meziprodukt se potom působí mesyl chloridem a trietylaminem, aby vznikla sloučenina 281.Typically, the process involves treating Compound 280 with a deprotecting agent to remove the R 53 group. It is an R 54 producing agent such as that described by Greene (R 54 halide such as acetyl chloride or Tr-Cl, or R 54 -OR 54 such as acetic anhydride) and a hydroxy activating group such as those which are described in Process B, Scheme 36. More specifically, this process involves treating Compound 280 with a polar protic solvent, preferably in the presence of an acid catalyst as described above to form a first intermediate; treating the first Tr-Cl intermediate in a polar, aprotic solvent such as an amine to form a second intermediate; and treating the second intermediate with a sulfonic acid halide such as mesyl chloride or paratoluene sulfonyl chloride in a polar aprotic solvent such as an amine to form compound 281. More particularly, this process involves only treating compound 280 with methanol and hydrochloric acid to form first intermediate. The first intermediate is treated with Tr-Cl and triethylamine to form a second intermediate; the second intermediate is then treated with mesyl chloride and triethylamine to give compound 281.
Typické provedení tohoto procesuje uvedeno jako příklad 64 v dalším textu.A typical embodiment of this process is exemplified by Example 64 below.
Proces N. Schéma 39Process N. Scheme 39
Pro přípravu sloučeniny 282 se použije sloučenina 281 následujícím postupem.To prepare Compound 282, Compound 281 was used as follows.
Aziridin 281 je otevřený a výsledný amin je substituován skupinou R55, aby se vytvořila sloučenina 282. Konkrétně aziridin 281 je otevřen kyselinou, katalyzující otevření kruhu a výsledný amin se acyluje.Aziridine 281 is open and the resulting amine is substituted with R 55 to form compound 282. Specifically, aziridine 281 is opened with a ring-catalyzing acid and the resulting amine is acylated.
R55 je W3 jak definován výše. Obvykle je R55 -C(O)R5. Konkrétněji jde o R55 který je -C(O)Ri. Detailněji pak R55 je -C(O)CH3.R 55 is W 3 as defined above. Typically, R 55 is -C (O) R 5 . More specifically, it is R 55 which is -C (O) R 1. More specifically, R 55 is -C (O) CH 3 .
R56 je Ui jak popsán výše. Obvykle je R56 W6-O-, W6-S-, nebo W6-N(H)-. Ještě přesněji R56 je R5-O-, R5-S-, nebo Rs-N(H)-, a ještě konkrétněji R56 je R5-O-, konkrétně pak může být R56 je Ri-O-.R 56 is U 1 as described above. Typically, R 56 is W 6 -O-, W 6 -S-, or W 6 -N (H) -. Even more specifically, R 56 is R 5 -O-, R 5 -S-, or R 5 -N (H) -, and even more specifically R 56 is R 5 -O-, in particular R 56 is R 1 -O-.
Obvykle tento proces znamená, že na sloučeninu 281 se působí kyselým katalyzátorem a sloučeninou o vzorci Wř-Xi-H, kde X3 je, jak definováno výše, aby se vytvořil aminový poloprodukt. Aminový poloprodukt je potom vystaven působení sloučeniny o vzorci W3-Xj-W3, W3-Xio, kde X10 je vytěsňovací skupina, aby se vytvořila sloučenina 282. Kyselý katalyzátor je obvykle Lewiesů kyselý katalyzátor běžný v praxi jako je BF3. Et2O, TiCl3, TMSOTf, Sml2(THF)2, LiClO4, Mg(ClO4)2, Ln(OTf)3 (kde Ln=Yb, Gd, Nd), Ti(Oi-Pr)4, A1C13, AlBr3, BeCl2, CdCl2, ZnCl2, BF3, BC13, BBr3, GaC13, GaBr3, TiCl4, TiBr4, ZrCl4, SnCl4, SnBr4, SbCl5, SbCl3, BiCl3, FeCl3, UC14, ScCl3, YC13 LaCl3, CeCl3, PrCl3, NdCl3, SmCl3, EuCl3, GdCl3, TbCl3, LuCl3, DyCl3 HoC13, ErCl3, TmCl3, YbCl3, Znl2, Al(OPr‘)3, Al(acac)3, ZnBr2 místo SnCl4. Xi je obvykle -O-, -S-, nebo -N(H)-. X10 je obvykle halogenidem jako je chlór, bróm nebo jód,. Ještě konkrétněji proces zahrnuje postup, při kterém se na sloučeninu 281 působí sloučeninou o vzorci R5-OH, R5-SH, nebo R5-SH, nebo R5NH2, a BF3. Et2O, aby se vytvořil poloprodukt; na tento poloprodukt se potom působí anhydridem alkanové kyseliny, aby vznikla sloučenina 282. Obvykle tento proces zahrnuje postup, při kterém se na sloučeninu 281 působí sloučeninou o vzorci R5- OH a BF3.Et2O, aby vznikl poloprodukt; na tento poloprodukt se potom působí substituovaným nebo nesubstituovaným anhydridem kyseliny octové, aby vznikla sloučenina 282. Jako příklad je sloučenina o vzorci R5-OH uvedena v tabulce 2 skupiny 2-7, 9-10, 15 a 100-660, kde Qi je -OH. Další sloučeniny jako příklad vzorce R5-OH zahrnují ty, které jsou uvedeny v tabulce 25 v dalším textu (společně s jejich registračními čísly servisu Chemical Abstracts) a ty,Typically, this process means that compound 281 is treated with an acid catalyst and a compound of formula W 1 -X 1 -H, where X 3 is as defined above to form an amine intermediate. The amine intermediate is then exposed to a compound of formula W 3 -X 1 -W 3 , W 3 -X 10, where X 10 is a displacement group to form compound 282. The acid catalyst is usually a Lewies acid catalyst common in the practice of BF 3 . Et 2 O, TiCl 3 , TMSOTf, Sml 2 (THF) 2 , LiClO 4 , Mg (ClO 4 ) 2 , Ln (OTf) 3 (where Ln = Yb, Gd, Nd), Ti (Oi-Pr) 4 , A1C1 3, AlBr 3, beclomethasone 2 CDCl 2, ZnCl 2, BF 3, BC1 3, BBr 3, GaC13, gabbros 3, TiCl 4, TiBr 4, ZrCl 4, SnCl 4, CNBr 4, SbCl 5, SbCl 3, BiCl 3, FeCl 3, UC1 4 SCCL 3 YC1 3 lacI 3, CeCl 3, PrCl 3, NdCl 3, SmCl 3, Eucla 3, GdCl 3, TbCl 3, LuCl 3, DyCl 3 HoC1 3, ErCl 3, TMCL 3 , YbCl 3 , Zn 12 , Al (OPr ') 3 , Al (acac) 3 , ZnBr 2 instead of SnCl 4 . X 1 is usually -O-, -S-, or -N (H) -. X10 is typically a halide such as chlorine, bromine or iodine. More particularly, the process comprises a process wherein Compound 281 is treated with a compound of the formula R 5 -OH, R 5 -SH, or R 5 -SH, or R 5 NH 2 , and BF 3 . Et 2 O to form a semi-product; the intermediate is then treated with alkanoic anhydride to give compound 282. Typically, this process involves a process of treating compound 281 with a compound of formula R 5 -OH and BF 3 .Et 2 O to form a intermediate; this intermediate is then treated with substituted or unsubstituted acetic anhydride to give compound 282. By way of example, the compound of formula R 5 -OH is shown in Table 2 of groups 2-7, 9-10, 15 and 100-660, where Q 1 is -OH. Other compounds exemplified by the formula R 5 -OH include those listed in Table 25 below (together with their Chemical Abstracts registration numbers) and
-201 CZ 297945 B6 které jsou uvedeny v tabulce 26 v dalším textu (společně s jejich registračními čísly servisu Chemical Abstracts a výrobními čísly Aldrich Chemical Company). Konkrétněji pak jako příklad můžeme uvést, že sloučeniny vzorce R5-OH jsou ty, které jsou popisovány v tabulce 2, skupiny 2-5, 9 a 100-141, kde Q! je-OH.Which are listed in Table 26 below (together with their Chemical Abstracts Service Registration Numbers and Aldrich Chemical Company serial numbers). More specifically, by way of example, the compounds of formula R 5 -OH are those described in Table 2, Groups 2-5, 9, and 100-141, wherein Q 1 is R 1 -OH. is -OH.
V jiném provedení procesu N, schéma 39, je R55 H.In another embodiment of Process N, Scheme 39, R 55 is H.
Obvykle provedení tohoto procesu zahrnuje to, že na sloučeninu 281 se působí kyselým katalyzátorem a sloučeninou vzorci R56-Xi-H, kde Xi je definováno výše tak, aby se vytvořil aminový poloprodukt pro tvorbu sloučeniny 282. Kyselý katalyzátor a Xi jsou stejné jak bylo popsáno. Blíže pak proces zahrnuje to, že na sloučeninu 281 se působí sloučeninou o vzorci R5-SH, R5-SH nebo R5-NH2 a BF3.Et2O, aby se vytvořila sloučenina 282. Ještě typičtější je, že proces zahrnuje to, že na sloučeninu 281 se působí sloučeninou o vzorci R5-OH a BF3.Et2O aby vznikla sloučenina 282. Typické sloučeniny vzorce R5-OH, byly popsány výše.Typically, an embodiment of this process involves treating compound 281 with an acid catalyst and a compound of formula R 56 -X 1 -H, where X 1 is as defined above to form an amine intermediate to form compound 282. The acid catalyst and X 1 are the same as previously described. described. More specifically, the process comprises treating compound 281 with a compound of formula R 5 -SH, R 5 -SH, or R 5 -NH 2 and BF 3 .Et 2 O to form compound 282. More typically, the process comprises: Compound 281 is treated with a compound of formula R 5 -OH and BF 3 .Et 2 O to give compound 282. Typical compounds of formula R 5 -OH have been described above.
Příklady provedení tohoto procesu jsou uvedeny jako příklad 65, 86, 92 a 95 v dalším textu.Examples of this process are given as examples 65, 86, 92, and 95 below.
Proces O. Schéma 39Process O. Scheme 39
Sloučenina 282 se zde používá pro přípravu sloučenin 283 následujícím postupem.Compound 282 is used herein to prepare compounds 283 by the following procedure.
Azid sloučeniny 282 se redukuje tak, aby se vytvořila aminosloučenina 283.The azide of compound 282 is reduced to form the amino compound 283.
Konkrétně tento proces zahrnuje to, že na sloučeninu 282 se působí redukčním činidlem, aby se vytvořila sloučenina 283. Ještě blíže pak proces zahrnuje to, že na sloučeninu 282 se působí plynným vodíkem a katalyzátorem, jako je platina na uhlíku nebo Lindlarův katalyzátor nebo redukčním činidlem (jako je trialkyl nebo triaryl fosfin jak popsáno výše). Mnohem přesněji ještě pak proces zahrnuje působení na sloučeninu 282 trifenylfosfinem ve vodě/THF, aby vznikla sloučenina 283.Specifically, the process comprises treating compound 282 with a reducing agent to form compound 283. More particularly, the process comprises treating compound 282 with a hydrogen gas and a catalyst such as platinum on carbon or a Lindlar catalyst or reducing agent. (such as trialkyl or triaryl phosphine as described above). More specifically, the process involves treating compound 282 with triphenylphosphine in water / THF to provide compound 283.
Typické příklady provedení tohoto procesu jsou uvedeny jako příklady 87, 93 a 96 v dalším textu.Typical embodiments of this process are set forth as Examples 87, 93 and 96 below.
Proces P. Schéma 39P. Scheme Process 39
Pro přípravu sloučeniny 284 se používá sloučenina 283 následujícím postupem.To prepare Compound 284, Compound 283 was used as follows.
Odstraní se ochranná skupina karboxylové kyseliny.The carboxylic acid protecting group is removed.
Typické je, že při tomto procesu se na sloučeninu 283 působí zásadou. Konkrétněji pak proces znamená, že na sloučení 283 se působí kovovým hydroxidem ve vhodném rozpouštědle jako je aprotické, polární rozpouštědlo. Přesněji pak se jedná o to, že při procesu se působí na sloučeninu 283 vhodným roztokem hydroxidu draselného v THF a tak, aby se vytvořila sloučenina 284.Typically, in this process, compound 283 is treated with a base. More specifically, the process means that compound 283 is treated with a metal hydroxide in a suitable solvent such as an aprotic, polar solvent. More specifically, the process is treated with Compound 283 with a suitable solution of potassium hydroxide in THF to form Compound 284.
Provedení tohoto procesu jsou uvedena jako příklady 88, 94 a 97 v dalším textu.Embodiments of this process are exemplified by Examples 88, 94 and 97 below.
Proces O. Schéma 40Process O. Scheme 40
Sloučenina 283 se používá pro přípravu sloučeniny 285 následujícím postupem.Compound 283 is used to prepare compound 285 as follows.
Amin se převede na chráněný guanidin.The amine is converted to protected guanidine.
-202CZ 297945 B6-202GB 297945 B6
R57 je ochranná skupina guanidinu, která je běžná v praxi, jako je BOC nebo Me.R57 is a guanidine protecting group that is conventional in the art, such as BOC or Me.
Konkrétně pak tento proces znamená, že na sloučeninu 283 se působí guanidylačním činidlem, jaká jsou běžná v praxi. Příklady činidel zahrnují Bis-BOC Thio-močovinu aminoiminometansulfonovou kyselinu (Kim; aj.; „Tet. Lett.“ 29(26):3183-3186 (1988) a 1-guanylpyrazoly (Bernatowicz; aj.;“Tet. Lett.“ 34(21):3389-3392 (1993). Ještě přesněji pak proces zahrnuje to, že na sloučeninu 283 se působí kyselinou Bis-BOC thiomočovina. Konkrétněji proces zahrnuje to, že na sloučeninu 283 se působí kyselinou Bis-BOC-thio-močoviny a HgCl2, aby vznikla sloučenina 285.In particular, this process means that Compound 283 is treated with a guanidylating agent as is conventional in the art. Examples of reagents include Bis-BOC Thiourea aminoiminomethanesulfonic acid (Kim; et al., "Tet. Lett." 29 (26): 3183-3186 (1988) and 1-guanylpyrazoles (Bernatowicz et al.; "Tet. Lett."). 34 (21): 3389-3392 (1993) More specifically, the process comprises treating compound 283 with Bis-BOC thiourea, and more specifically the process comprising treating compound 283 with Bis-BOC-thiourea. and HgCl 2 to give compound 285.
Příklad provedení tohoto procesuje uveden jako příklad 67 v dalším textu.An exemplary embodiment of this process is given as Example 67 below.
Proces R. Schéma 40The R. Scheme Process 40
Sloučenina 285 se používá pro přípravu sloučeniny 286 následujícím postupem.Compound 285 is used to prepare compound 286 as follows.
Odstraní se karboxylová kyselina a ochranné guanidinové skupiny.The carboxylic acid and guanidino protecting groups are removed.
Obvykle tento proces zahrnuje to, že na sloučeninu 285 se působí zásadou, poté následuje působení kyselinou, jako popsáno výše. Konkrétněji tento proces znamená, že na sloučeninu 285 se působí kovovou hydroxydovou zásadou, jak popsáno výše, aby vznikl poloprodukt. Tento poloprodukt je vystaven působení kyseliny, aby vznikla sloučenina 286. Ještě obvykleji tento proces zahrnuje to, že na sloučeninu 285 se působí vodným roztokem hydroxidu draselného a THF, aby vznikl poloprodukt a na vzniklý poloprodukt se působí TFA, aby se vytvořila sloučenina 286.Typically, this process involves treating compound 285 with a base, followed by treatment with an acid as described above. More specifically, this process means that compound 285 is treated with a metal hydroxyde base, as described above, to form a semi-product. This intermediate is treated with acid to give compound 286. More typically, the process comprises treating compound 285 with an aqueous solution of potassium hydroxide and THF to form the intermediate and treating the resulting intermediate with TFA to form compound 286.
Proces S. Schéma 40.1Process S. Scheme 40.1
Sloučenina 287 se používá pro přípravu sloučeniny 288 následujícím postupem.Compound 287 is used to prepare compound 288 as follows.
Ei, Ji a J2 sloučenin 287 a 288 jsou stejné jak popsáno výše. Obvykle Ei je -CO2R5i jak již popsáno. Rovněž obvykle Ji je H, F, nebo metyl, nejčastěji H. Obvykle J2 je H nebo lineární nebo rozvětvený alkyl o 1 až 6 uhlíkových atomech, nej častěji H, metyl, etyl, n-propyl, nebo i-propyl, nejčastěji H.E 1, J 1 and J 2 of compounds 287 and 288 are the same as described above. Usually E 1 is -CO 2 R 5 i as already described. Also usually J 1 is H, F, or methyl, most commonly H. Usually J 2 is H or a linear or branched alkyl of 1 to 6 carbon atoms, most often H, methyl, ethyl, n-propyl, or i-propyl, most commonly H .
Rf,o a Réi jsou skupiny, které jsou schopny reagovat tak, aby vytvořily R63 (definováno dále) substituovaný aziridinový kruh sloučeniny 288. Obvykle jeden z R60 nebo R6I je primárním nebo sekundárním aminem nebo skupinou, která je schopná konverze na primární nebo sekundární amin. Tyto skupiny, které přicházejí v úvahu pro R60 a pro R<,i zahrnují jako příklad nikoliv však výhradně -NH2, -N(H)(R6b), -N(Reb)2, -N(H)(Ri), -N(Ri)(R6b), a -N3. Ostatní R60 a R6i jsou obvykle skupiny, schopné své náhrady primárním nebo sekundárním aminem tak, aby se vytvořil aziridin. Tyto skupiny zahrnují například, nikoliv však výhradně -OH, -OR6a, Br, Cl, a I. Obvykle jsou Rbo a R6] v transkonfiguraci. Konkrétněji Rbo je primární nebo sekundární amin, nebo skupina, která je schopna konverze na primární či sekundární amin a R6 i je skupina schopná vytěsnění primárním nebo sekundárním aminem za tvorby aziridinu. Nejčastěji Róo je β-azido nebo β-ΝΗ2, a Réi je α-Oh, a-OMesyl, nebo a-OTosyl.R, oa REI are groups capable of reacting to form R63 (defined below) substituted aziridine ring of compound 288. Typically, one of R 60 or R 6I is a primary or secondary amine or a group which is capable of conversion to a primary or secondary amine. These groups which may be considered for R 60 and R 6 include, but are not limited to, -NH 2 , -N (H) (R 6b ), -N (Re b ) 2, -N (H) ( R 1), -N (R 1) (R 6b ), and -N 3 . Other R 60 and R 6i are usually groups capable of substituting their primary or secondary amine so as to form an aziridine. These groups include, but are not limited to, -OH, -OR 6a , Br, Cl, and I. Typically, R b and R 6] are in the trans configuration. More specifically, R b0 is a primary or secondary amine, or a group capable of conversion to a primary or secondary amine, and R 6i is a group capable of being displaced by a primary or secondary amine to form aziridine. Most commonly, R 6 is β-azido or β-ΝΗ 2 , and R 6 is α-Oh, α-OMesyl, or α-OTosyl.
Rez je popsaný níže v procesu U, schéma 40.1.The section is described below in Process U, Scheme 40.1.
Proces zahrnuje to, že na sloučeninu 287 se působí tak, aby vznikla sloučenina 288. To se obvykle provádí tím, že na sloučeninu 288 se působí tak, aby Rbi se nahradil Reo- Ještě konkrétněji, sloučenina 287 je vystavena působení takovému, které aktivuje R^i pro náhradu R6o. Konkrétně pak sloučenina 287 je vystavena působení, aby se aktivoval Rf,i pro náhradu R6o a R6o se aktivuje směrem k náhradě R^. Jestliže jsou Rbo a Rei aktivovány, pak aktivace mohou být prováděnyThe process involves treating compound 287 to form compound 288. This is usually done by treating compound 288 to replace R b i with more specifically, Compound 287 is exposed to one that activates R for compensation of R 6. Specifically, compound 287 is exposed to activating Rf, and for replacing R o and R 6 a 6 activates toward replacing the R ^. If R b and R e are activated, then activations can be performed
-203 CZ 297945 B6 současně nebo postupně. Jestliže aktivace jsou prováděny postupně, mohou být prováděny v jakémkoli pořadí, obvykle aktivace R6| předchází aktivaci R^oAktivace Rei tak, aby nahradila R6« se obvykle provádí tak, že na sloučeninu 287 se působí hydroxyaktivačním činidlem jako je mesyl nebo tosyl chlorid. Aktivace Re0, tak aby nahradila Réi je prováděna tak, že na sloučeninu 287 se působí, aby vytvořila primární nebo sekundární amin a na tento amin se působí zásadou. Jako příklad a nikoliv výhradně, se na sloučeninu 287 působí redukčním činidlem, které je schopno redukovat azid na amin a potom zásadou.Simultaneously or sequentially. If the activations are carried out sequentially, they can be performed in any order, usually R 6 activation prevents activation of R 6. Activation of R 16 to replace R 6 'is usually accomplished by treating compound 287 with a hydroxyactivating agent such as mesyl or tosyl chloride. Activation of Re 0 to replace R 6 is accomplished by treating compound 287 to form a primary or secondary amine and treating the amine with a base. By way of example and not exclusively, compound 287 is treated with a reducing agent capable of reducing azide to an amine and then a base.
V jednom provedení tohoto procesu se na sloučeninu 287 působí aktivačním činidlem R6i a aktivačním činidlem R^o, aby vznikla sloučenina 288. Při jiném postupu se na sloučeninu 287 působí ve vhodném rozpouštědle aktivačním činidlem R6i a aktivačním činidlem R()o, aby vznikla sloučenina 288. Při jiném postupu na sloučeninu 287 se působí aktivačním činidlem R61 a aktivačním činidlem Reo a zásadou, aby vznikla sloučenina 288. Při dalším jiném postupuje na sloučeninuIn one embodiment of this process, compound 287 is treated with an activating agent R 6i and the activating agent of R, to produce compound 288. In another process, compound 287 is treated in a suitable solvent with an activating agent R 6 IA activating reagent R () of that Compound 287 was formed in another procedure. Compound 287 was treated with R 61 and Reo activating agent and a base to form Compound 288. In another other step, Compound 287 was formed.
287 působeno ve vhodném rozpouštědle aktivačním činidlem Rfii a aktivačním činidlem R60 a potom zásadou, aby vznikla sloučenina 288. Při dalším případu se na sloučeninu 287, kde R^o je azid, působí aktivačním činidlem R^j a redukčním činidlem azidu, aby vznikla sloučenina 288. Při jiném postupuje sloučenina 287, kde R60 je azid, vystavena působením vhodného rozpouštědla s aktivačním činidlem Rbi redukčním činidlem azidu aby vznikla sloučenina 288. Další postup je, že na sloučeninu 287, kde R&) je azid se působí aktivačním činidlem Rbb redukčním činidlem azidu a zásadou, aby vznikla sloučenina 288. Další možnost představuje, že na sloučeninu 287, kde Réo je azid, se působí ve vhodném rozpouštědle aktivačním činidlem Reb redukčním činidlem azidu a zásadou, aby vznikla sloučenina 288. Další postup umožňuje, aby se sloučeninu 287, kde Reo je azid a Rei je hydroxyl, se působilo aktivačním činidlem hydroxylu a redukčním činidlem azidu, aby tak vznikla sloučenina 288. Jinou možnost představuje, když na sloučeninu 287, kde Reo je azid a Rei je hydroxid, se působí ve vhodném rozpouštědle aktivačním činidlem hydroxylu a redukčním činidlem azidu aby vznikla sloučenina 288. Jiná možnost je, když na sloučeninu 287, kde Reo je azid a Réi je hydroxyl, se působí aktivačním činidlem hydroxylu, redukčním činidlem a zásadou, aby vznikla sloučenina 288. Další možnost je, že na sloučeninu 287, kde Reo je azid a R6i je hydroxyl se působí ve vhodném rozpouštědle aktivačním činidlem hydroxylu, redukčním činidlem azidu a zásadou za vzniku sloučeniny 288.287 treated in a suitable solvent with an activating agent fi R i and R 60 activating reagent and a base to produce compound 288. In another case, compound 287 wherein R is the azide acts activator R ja azide reducing reagent to produce compound 288. In another step, a compound 287 wherein R60 is an azide is exposed to the action of an appropriate solvent with an activating agent R b and an azide reducing reagent to produce compound 288. Another technique is to compound 287 where R &) is an azide is treated with an activating Rb b with an azide reducing agent and a base to form compound 288. Another possibility is that compound 287 wherein R 6 is an azide is treated in a suitable solvent with an activating agent Re b with an azide reducing agent and a base to form compound 288. Next procedure allows Compound 287, wherein Reo is azide and Rei is hydroxyl, to be treated with the activating agent hyd Another possibility is when compound 287, wherein Reo is azide and Rei is hydroxide, is treated in a suitable solvent with a hydroxyl activator and an azide reducing agent to form compound 288. Another possibility is when the compound 287 is an azide where Reo and REI is hydroxy is treated with a hydroxy activating reagent, reducing agent and a base to produce compound 288. Another possibility is that the compound 287 wherein Reo is an azide and R 6 is hydroxyl and is treated in a suitable solvent with a hydroxyl activating agent, an azide reducing agent, and a base to form compound 288.
Příklady provedení tohoto procesu jsou uvedeny jako proces K, schéma 38, výše.Examples of this process are given as Process K, Scheme 38, above.
Proces T. Schéma 40.1Process T. Scheme 40.1
Sloučenina 288 se zde používá pro přípravu sloučenin 289 následujícím postupem.Compound 288 is used herein to prepare compounds 289 by the following procedure.
R64 je obvykle H, Reb nebo skupina, která je schopná konverze na H nebo R6b. Obvykle Re4 je H. R65 je obvykle Gj nebo skupina, která je schopna konverze na Gb Ještě obvykleji Res je -N3, -CN, nebo -(CRbRi)miW2. Ještě obvykleji R65 je -N3, -NH2, -N(H)(Reb), -(RebK -CH2N3 nebo -ch2cn.R 64 is typically H, Reb or a group capable of conversion to H or R 6b . Usually Re 4 is H. R 65 is usually G 1 or a group that is capable of converting to G b More usually Res is -N 3 , -CN, or - (CR b R 1) m i W 2 . More usually, R 65 is -N 3 , -NH 2 , -N (H) (Re b ), - (Reb K -CH 2 N 3, or -ch 2 cn.
V zásadě se na sloučeninu 288 působí tak, aby vytvořila amin 289. Konkrétně se to provádí tak, že na sloučeninu 288 se působí nukleofilním, typicky nitrogen nukleofílním činidlem jako je Re5, kationickou solí Res nebo protoninovaným analogem R65, jako je např. nikoliv však výhradně NH3, sůl azidu (jako NaN3, KN3 nebo pod.), HCN, kyanidovou solí (jako NaCN, KCN nebo pod.), nebo solí kyanoalkylu (např. CH2CN)_) (jako je NaCH2CN, KCH2CN nebo podobně). Ještě konkrétněji se pak na sloučeninu 288 působí azidovou solí. Je možné také použít zásady, obvykle mírné zásady jako je chlorid amonný a rozpouštědla, obvykle polárního aprotického rozpouštědla, jako je éter, amin nebo amid.In principle, compound 288 is treated to form the amine 289. Specifically, compound 288 is treated with a nucleophilic, typically nitrogen nucleophilic agent such as Re 5 , a cationic salt of Res, or a protonated analog of R6 5 , such as e.g. but not exclusively NH 3 , an azide salt (such as NaN 3 , KN 3 or the like), HCN, a cyanide salt (such as NaCN, KCN or the like), or a cyanoalkyl salt (e.g. CH 2 CN) _) (such as NaCH 2 CN, KCH 2 CN or the like). More particularly, compound 288 is then treated with an azide salt. It is also possible to use bases, usually mild bases such as ammonium chloride and solvents, usually polar aprotic solvents such as ether, amine or amide.
Při jednom průběhu se na sloučeninu 288 působí nukleofílem. V jiném postupu se na sloučeninuIn one course, compound 288 is treated with a nucleophile. In another method, the compound is reacted
288 působí nukleofílem ve vhodném rozpouštědle, aby vznikla sloučenina 289. Při jiném postupu288 was treated with nucleophile in a suitable solvent to give compound 289. In another procedure
-204CZ 297945 B6 je sloučenina 288 vystavena působení nukleofilu a zásady, aby vznikla sloučenina 289. V jiném postupu se na sloučeninu působí nukleofílem a zásadou ve vhodném rozpouštědle, aby vznikla sloučenina 289. Při dalším postupu se na sloučeninu 288 působí dusíkatým nukleofílem, aby vznikla sloučenina 289. Při jiném postupu se na sloučeninu 288 působí dusíkatým nukleofílem ve vhodném rozpouštědle za vzniku sloučeniny 289. Při jiném postupu se na sloučeninu 288 působí dusíkatým nukleofílem a zásadou, aby vznikla sloučenina 289. V jiném postupu je sloučeninaCompound 288 is exposed to nucleophile and a base to form compound 289. In another method, the compound is treated with a nucleophile and a base in a suitable solvent to form compound 289. In another method, compound 288 is treated with a nitrogen nucleophile to form compound 289. In another method, compound 288 is treated with nitrogen nucleophile in a suitable solvent to form compound 289. In another method, compound 288 is treated with nitrogen nucleophile and a base to form compound 289. In another method, the compound is
288 vystavena působení dusíkatého nukleofilu a zásady ve vhodném rozpouštědle za vzniku sloučeniny 289. V dalším postupuje sloučenina 288 vystavena působení soli azidu, aby vznikla sloučenina 289. V jiném postupu se na sloučeninu 288 působí solí azidu ve vhodném rozpouštědle, aby vznikla sloučenina 289. V dalším postupu je sloučenina 288 vystavena působení soli azidu a zásady, aby vznikla sloučenina 289. V dalším postupu je sloučenina 288 vystavena působení soli azidu a zásady ve vhodném rozpouštědle za vzniku sloučeniny 289.288 is treated with a nitrogen nucleophile and a base in a suitable solvent to form compound 289. Subsequently, compound 288 is treated with an azide salt to form compound 289. In another method, compound 288 is treated with an azide salt in a suitable solvent to form compound 289. in another method, compound 288 is treated with an azide salt and a base to form compound 289. In another method, compound 288 is exposed to an azide salt and a base in a suitable solvent to form compound 289.
Příklad průběhu tohoto procesuje uveden jako proces L, schéma 38, výše.An example of this process is shown as Process L, Scheme 38, above.
Proces U.Schéma 40.1Process U.Scheme 40.1
Sloučenina 289 se používá k přípravě sloučeniny 290 následujícím postupem.Compound 289 is used to prepare compound 290 as follows.
R<52 je skupina která je schopná reakce s aminem, aby vznikla Ré6 (jak je definována dále) substituovaný aziridinový kruh sloučeniny 290. Obvykle ΙΥ je skupina schopná své náhrady primárním nebo sekundárním aminem, aby vznikl aziridin. Tyto skupiny zahrnují jako příklad nikoli jako omezení -OR53, -OH, -OR6a, Br, Cl a I. Obvykle R62 je v transkonfíguraci ve vztahu k dusíku na poloze 4. Bývá také, že R^ je častěji -OR53.R <52 is a group capable of reacting with an amine to form a R 6 (as defined below) substituted aziridine ring of compound 290. Usually, the group is capable of being replaced with a primary or secondary amine to form aziridine. These groups include, by way of example, not limitation -OR 53, -OH, -OR 6a , Br, Cl, and I. Typically, R 62 is in trans-configuration relative to the nitrogen at position 4. Also, R 6 is more often -OR 53.
R64 je H nebo Rób, obvykle ochranná skupina labilní kyseliny jako je R54.R 64 is H or R a, usually a labile acid protecting group such as R 54 .
R66 je H, Réb nebo R54.R 66 is H, R e or R 54 .
Tento proces zahrnuje působení na sloučeninu 289 tak, aby vznikla sloučenina 290. To se obvykle provádí tím, že na sloučeninu 289 se působí, aby se R62 nahradil aminem na poloze 4. Ještě obvykleji se n a sloučeninu 289 působí tak, aby se aktivoval amin v poloze 4 ve smyslu náhrady Rň2· Ještě více symbolicky lze říci, že sloučenina 289 podléhá působení, které aktivuje amin v poloze 4 směrem k náhradě R62 a R^ je aktivován směrem k náhradě aminem v poloze 4. Jak R62 tak i amin v poloze 4 jsou aktivovány, aktivace se může provést současně nebo postupně. Jestliže se aktivace provádějí postupně, mohou být provedeny v kterémkoliv pořadí, obvykle aktivace Rf,2 předchází aktivaci aminů v poloze 4.This process involves treating Compound 289 to form Compound 290. This is usually done by treating Compound 289 to replace R 62 with an amine at the 4-position. More usually, Compound 289 is treated to activate the amine at position 4 in the sense of compensation RN 2 · even more symbolically we can say that compound 289 is subject to the action which activates the amine at position 4 toward R 62 to substitute, and R ^ is activated towards compensation amine at position 4. as R 62 and The amines at the 4-position are activated, the activation can be performed simultaneously or sequentially. If the activations are carried out sequentially, they may be performed in any order, typically the activation of Rf, 2 precedes the activation of the amines at the 4-position.
Aktivace Re2 směrem k náhradě aminů na poloze 4 se obvykle provádí tak, že na sloučeninu 289 se působí činidlem aktivujícím hydroxyl, jako jsou ta, která jsou popsána v procesu B, schéma 36. Je také možné, že R62 se zbaví ochrany před aktivací. Aktivace aminů v poloze 4 směrem k náhradě Ró2 se obvykle provádí tak, že na sloučeninu 289 se působí, aby vytvořila primární nebo sekundární amin a na amin se pak působí kyselým katalyzátorem jako jsou ty, které jsou popsány v procesu N, schéma 39, výše.Activation of Re 2 towards the substitution of the amines at the 4-position is typically accomplished by treating compound 289 with a hydroxyl activating agent such as that described in Process B, Scheme 36. It is also possible that R 62 is deprotected activation. Activation of the amines at the 4-position towards the R 2 substitution is usually accomplished by treating compound 289 to form a primary or secondary amine and then treating the amine with an acid catalyst such as those described in Process N, Scheme 39, above.
Obvykle, jestliže R62 je -OR53 a Reó je R5ó, pak proces zahrnuje působení na sloučeninu 289 činidlem, zbavujícím ochrany tak, aby se odstranila skupina R53 činidlem produkujícím R54 jako jsou ta, která jsou popsána v Greeneové (halogenidy R54, jako je acetylchlorid nebo Tr-Cl, nebo R54-O-R54, jako je anhydrid kyseliny octové) a hydroxy aktivační skupina, jako jsou ty, které jsou popsány v procesu B, schéma 36. Ještě obvykleji proces zahrnuje působení na sloučeninuTypically when R 62 is -OR 53 and R Reo O 5, the process comprises treating compound 289 agent zbavujícím protection to remove group R 53 R 54 producing reagent such as those described in Greene (halides R 54 such as acetyl chloride or Tr-Cl, or R 54 -O-R 54 such as acetic anhydride) and a hydroxy activating group such as those described in Process B, Scheme 36. Even more commonly, the process involves treating the compound
289 polárním, protickým rozpouštědlem, opačně za přítomnosti kyselého katalyzátoru, jak je popsáno výše, aby se vytvořil první meziprodukt; potom se na první meziprodukt působí Tr-Cl v polárním a protickém rozpouštědle jako je amin, aby vznikl druhý meziprodukt, potom se na druhý meziprodukt působí halogenidem kyseliny sulfonové jako je metylchlorid nebo paratoluen289 with a polar, protic solvent, in the presence of an acid catalyst as described above, to form the first intermediate; then treating the first intermediate with Tr-Cl in a polar and protic solvent such as an amine to form the second intermediate, then treating the second intermediate with a sulfonic acid halide such as methyl chloride or paratoluene
-205 CZ 297945 B6 sulfonyl chlorid v polárním aprotickém rozpouštědle, jako je amin, aby vznikla sloučenina 280. Stejně obvykle je, že proces zahrnuje působení na sloučeninu 289 metanolem a HC1, aby vznikl první meziprodukt; dále působení na první meziprodukt pomocí Tr-Cl a trietylaminem, aby vznikl druhý meziprodukt; a konečně působení na druhý meziprodukt mesyl chloridem a trietylaminem, aby vznikla sloučenina 290.Sulfonyl chloride in a polar aprotic solvent, such as an amine, to form compound 280. Equally usually, the process involves treating compound 289 with methanol and HCl to form the first intermediate; further treating the first intermediate with Tr-Cl and triethylamine to form a second intermediate; and finally treating the second intermediate with mesyl chloride and triethylamine to give compound 290.
V jednom případě se na sloučeninu 289 působí kyselým katalyzátorem, aby vznikla sloučenina 290. V jiném případě se na sloučeninu 289 působí kyselým katalyzátorem ve vhodném rozpouštědle, aby vznikla sloučenina 290. V jiném případě se na sloučeninu 289 působí činidlem, aktivujícím hydroxid a kyselým katalyzátorem, aby vznikla sloučenina 290. V jiném případě se na sloučeninu 289 působí činidlem, aktivujícím hydroxyl a kyselým katalyzátorem ve vhodném rozpouštědle aby vznikla sloučenina 290. V jiném případě pak se na sloučeninu 289 působí činidlem, zbavujícím ochrany hydroxyl činidle zbavujícím hydroxyl a kyselým katalyzátorem, aby vznikla sloučenina 290. V jiném případě se na sloučeninu 289 působí činidlem aktivujícím hydroxyl a kyselým katalyzátorem ve vhodném rozpouštědle, aby vznikla sloučenina 290.In one case, compound 289 is treated with an acid catalyst to form compound 290. In another case, compound 289 is treated with an acid catalyst in a suitable solvent to form compound 290. In another case, compound 289 is treated with a hydroxide activating agent and an acid catalyst to form compound 290. Alternatively, compound 289 is treated with a hydroxyl activating agent and an acid catalyst in a suitable solvent to form compound 290. Alternatively, compound 289 is treated with a hydroxyl deprotecting agent and an acidic catalyst, Alternatively, compound 289 is treated with a hydroxyl activating agent and an acid catalyst in a suitable solvent to form compound 290.
Příklad provedení tohoto procesuje uveden jako proces M, schéma 38, výše.An exemplary embodiment of this process is shown as Process M, Scheme 38, above.
Proces V. Schéma 40.1Process V. Scheme 40.1
Sloučenina 290 se používá pro přípravu sloučenina 291 následujícím postupem.Compound 290 is used to prepare Compound 291 as follows.
Na aziridin 290 se působí, aby vznikla sloučenina 291. Obvykle se aziridin 290 otevře otevřením kruhu katalyzovaném kyselinou a výsledný amin se potom acyluje.Aziridine 290 is treated to give compound 291. Typically, aziridine 290 is opened by acid-catalyzed ring opening and the resulting amine is then acylated.
R6S je nezávisle H, Réb, Ri nebo R55 jak definováno výše. Obvykle R55 je - C(O)R5. Obvykle jeden R^s je H nebo Rbb a ostatní je W3.R 6S is independently H, R 6b, R 1 or R 55 as defined above. Typically R 55 is - C (O) R 5 . Usually one R 6 is H or R b b and the other is W 3 .
Ré7 je Ui, jak je popsáno výše. Obvykle R67 je W6-O-, W6-S- nebo W6-N(H). Ještě obvyklejší je, že R67 je R5-Ó- R5-S- nebo R5-N(H)_.R 7 is U 1 as described above. Typically R 67 is W 6 -O-, W 6 -S- or W 6 -N (H). More usually, R 67 is R 5 -O- R 5 -S- or R 5 -N (H) -.
Obvykle proces zahrnuje postup, při kterém se na sloučeninu 290 působí kyselým katalyzátorem a sloučeninou o vzorci Wř-Xi-H, kde Xi je, jak definováno, výše, aby vznikl amin meziproduktu; potom se na amin meziproduktu působí sloučeninou o vzorci W3-Xi-W3 nebo W3-X10, kde X10 je odstupující skupina, aby vznikla sloučenina 291. Působení sloučeniny o vzorci W6-X|-H a kyselým katalyzátorem může být provedeno dříve nebo současně s působením sloučeninou o vzorci W3-X]-W3 nebo W3-X10.Typically, the process comprises a process of treating compound 290 with an acid catalyst and a compound of formula W 1 -X 1 -H, wherein X 1 is as defined above to form an amine intermediate; then the amine of the intermediate is treated with a compound of formula W 3 -X 1 -W 3 or W 3 -X 10 , where X 10 is a leaving group to form compound 291. Treatment of a compound of formula W 6 -X 1 -H with an acid catalyst can be performed earlier or simultaneously with treatment with a compound of formula W 3 -X 1 -W 3 or W 3 -X 10 .
Kyselý katalyzátor je obvykle jeden z těch, které jsou popsány v procesu N, schéma 39, výše. Častěji, proto zahrnuje působení na sloučeninu 290 sloučeninou o vzorci R5-OI1, R5-SH nebo R5-NH2 a kyselým katalyzátorem; potom následuje působení na meziprodukt anhydrídem alkanolické kyseliny, aby vznikla sloučenina 291.The acid catalyst is usually one of those described in Process N, Scheme 39, above. More often, therefore, treatment of Compound 290 includes a compound of the formula R 5 -Ol, R 5 -SH or R 5-NH 2 and an acid catalyst; followed by treatment of the intermediate with an alkanolic anhydride to give compound 291.
Jednou provedení zahrnuje působení na sloučeninu 290 sloučeninou o vzorci W6-Xi-H a kyselým katalyzátorem, aby vznikla sloučenina 291. Jiné provedení zahrnuje působení na sloučeninu 290 sloučeninou o vzorci W6-Xi-H, a kyselým katalyzátorem ve vhodném rozpouštědle aby vznikla sloučenina 191. Jiné provedení zahrnuje působení sloučeniny o vzorci W6-X1-H, kyselého katalyzátoru a sloučeniny o vzorci W3-X1-W3 nebo W3-X!o na sloučeninu 290 tak, aby vznikla sloučenina 291. Jiný příklad zahrnuje působení na sloučeninu 290 sloučeninou o vzorci Wé-Xi-H, kyselým katalyzátorem a sloučeninou o vzorci W3-Xi-W3-Xio ve vhodném rozpouštědle, aby vznikla sloučenina 291.One embodiment comprises treating Compound 290 with a compound of Formula W 6 -X 1 -H and an acid catalyst to form Compound 291. Another embodiment involves treating Compound 290 with a compound of Formula W 6 -X 1 -H, and an acid catalyst in a suitable solvent to form compound 191. Another embodiment comprises treating a compound of the formula W6-X1-H and an acid catalyst a compound of the formula W3-X1-W3 or W3 -X pyrazolo compound 290 so as to produce compound 291. Another embodiment comprises treating compound 290 with a compound of formula We-Xi-H, an acid catalyst, and a compound of formula W 3 -X 1 -W 3 -X 10 in a suitable solvent to give compound 291.
Příklad provedení tohoto procesu a další jsou uvedeny jako proces N, schéma 39, výše.An exemplary embodiment of this process and others are shown as Process N, Scheme 39, above.
-206CZ 297945 B6-206GB 297945 B6
Proces W. Schéma 40.1The W. Process 40.1
Sloučenina 291 se používá pro přípravu sloučeniny 292 následujícím postupem.Compound 291 is used to prepare compound 292 as follows.
Na sloučeninu 291 se působí tak, aby vznikla sloučenina 292. Obvykle se Rb5 konvertuje na formu Gi, Ui je Rfi7 a Ti je formou -N(R68)2 připravených v procesu, V, schéma 40.1, výše.Compound 291 is treated to give compound 292. Typically, R b 5 is converted to form G 1, U 1 is R f 17 and Ti is the form of -N (R 68 ) 2 prepared in process, V, scheme 40.1, supra.
V jednom postupuje R^ zbaven ochrany, alkylován, guanidylován, oxidován a redukován tak, aby vznikl Gb Lze provést jakýkoliv počet těchto působení, je-li Rb5 azido, pak nám příklady tohoto procesu zahrnují procesy O, OQ, OQR, OP. Typická alkylační činidla jsou ta, která jsou běžná v praxi včetně jako příklad, nikoliv však výhradně halogenidů alkylu jako je metyl jodid, metyl bromid, etyl jodid, etyl bromid, n-propyl, n-propyl bromid, i-propyl jodid, i-propyl bromid; a olefínový oxid jako je etylen oxid nebo propylen oxid. Zásaditý katalyzátor je takový, jak je zde popsán na může být při alkylačním postupu použit podle vhodnosti.In one process, R 1 is deprotected, alkylated, guanidyllated, oxidized and reduced to form G b. Any number of these actions can be performed when R b is 5 azido, then examples of this process include processes O, OQ, OQR, OP . Typical alkylating agents are those which are common in practice including, but not limited to, alkyl halides such as methyl iodide, methyl bromide, ethyl iodide, ethyl bromide, n-propyl, n-propyl bromide, i-propyl iodide, i- propyl bromide; and an olefin oxide such as ethylene oxide or propylene oxide. The basic catalyst is as described herein and may be used as appropriate in the alkylation process.
Jedním příkladem tohoto procesu je působení na sloučeninu 291, kde R65 je azido redukčním činidlem, aby vznikla sloučenina 292. Jiný příklad zahrnuje působení na sloučeninu 291, kde Rbs je azido s redukčním činidlem, aby vznikla sloučenina 292 ve vhodném rozpouštědle. Dalším příkladem je působení na sloučeninu 291, kde Rós je amino s alkylačním činidlem, aby vznikla sloučenina 292. Jiný příklad postupu zahrnuje působení na sloučeninu 291, kde Res je amino alkylačním činidlem aby vznikla sloučenina 292 ve vhodném rozpouštědle. Jiný příklad provedení zahrnuje působení na sloučeninu 291, kde R<,5 je azido, redukčním činidlem, alkylačním činidlem, aby vznikla sloučenina 292. Další příklad zahrnuje působení na sloučeninu 291, kde R65 je azido redukčním činidlem a alkylačním činidlem za vzniku sloučeniny 292 ve vhodném rozpouštědle. Jiné provedení zahrnuje působení na sloučeninu 291, kde R65 je amino alkylačním činidlem a zásaditým katalyzátorem, aby vznikla sloučenina 292. Jiný příklad provedení zahrnuje působení na sloučeninu 291, kde Ró5 je amino, alkylačním činidlem a zásaditým katalyzátorem za vzniku sloučeniny 292 ve vhodném rozpouštědle. Jiný příklad provedení zahrnuje působení na sloučeninu 291, kde Růs je azido, redukčním činidlem, alkylačním činidlem a zásaditým katalyzátorem, aby vznikla sloučenina 292. Jiný příklad provedení zahrnuje působení na sloučeninu 291, kde Rď5 je azido redukčním činidlem, alkylačním činidlem a zásaditým katalyzátorem za vzniku sloučeniny 292 ve vhodném rozpouštědle.One example of this process is treatment of Compound 291 wherein R 65 is an azido reducing agent to form Compound 292. Another example involves treating Compound 291 wherein R b s is an azido reducing agent to form Compound 292 in a suitable solvent. Another example is treatment of Compound 291 wherein R 6 is amino with an alkylating agent to form Compound 292. Another example of the procedure involves treating Compound 291 wherein Res is an amino alkylating agent to form Compound 292 in a suitable solvent. Another exemplary embodiment comprises treating Compound 291 wherein R <5 is azido, a reducing agent, an alkylating agent to form Compound 292. Another example includes treating Compound 291 wherein R 65 is an azido reducing agent, and an alkylating agent to form Compound 292 in a suitable solvent. Another embodiment includes treating Compound 291 wherein R 65 is an amino alkylating agent and a basic catalyst to form Compound 292. Another exemplary embodiment includes treating Compound 291 wherein R 5 is amino, an alkylating agent and a basic catalyst to form Compound 292 in a suitable solvent . Another exemplary embodiment includes treating Compound 291 wherein R 6 is azido, a reducing agent, an alkylating agent, and a basic catalyst to form Compound 292. Another exemplary embodiment includes treating Compound 291 wherein R 5 is an azido reducing agent, an alkylating agent, and a basic catalyst behind. forming Compound 292 in a suitable solvent.
Příklady provedení tohoto procesu jsou uvedena jako proces O, schéma 39 výše.Examples of this process are given as Process 0, Scheme 39 above.
Příklady provedení tohoto procesu jsou uvedeny jako příklady 68 a 69 v dalším textu.Examples of this process are given as Examples 68 and 69 below.
-207CZ 297945 B6-207EN 297945 B6
Tabulka 25: Příklady sloučenin obecného vzorce R5-OH (Registrační číslo OAS)Table 25: Examples of compounds of formula R 5 -OH (OAS Registration Number)
C4 fluoralkoholv (R ,R*)-(±)-3-fluor-2-butanol (139755-61-6)C4 fluoroalcohol (R, R *) - (±) -3-fluoro-2-butanol (139755-61-6)
1- fluor-2-butanol (124536-12-5) (R)-3-fluor-1-butanol (120406-57-7)1-fluoro-2-butanol (124536-12-5) (R) -3-fluoro-1-butanol (120406-57-7)
3- fluor-1 -butanol (19808-95-8)3-Fluoro-1-butanol (19808-95-8)
4- fluor-2-butanol (18804-31 -4) (R,S’)-3-fluor-2-butanol (6228-94-0) (R*,R‘)-3-fluor-2-butanol (6133-82-0)4-fluoro-2-butanol (18804-31 -4) (R, S ') - 3-fluoro-2-butanol (6228-94-0) (R *, R') - 3-fluoro-2-butanol (6133-82-0)
2- fluor-1-butanol (4459-24-9)2-fluoro-1-butanol (4459-24-9)
2- fluor-2-methyl-1 -propanol (3109-99-7)2-Fluoro-2-methyl-1-propanol (3109-99-7)
3- fluor-2-butanol (1813-13-4)3-fluoro-2-butanol (1813-13-4)
4- fluor-1-butanol (372-93-0)4-fluoro-1-butanol (372-93-0)
1- fluor-2-methyl-2-propanol (353-80-0)1-Fluoro-2-methyl-2-propanol (353-80-0)
C5 fluoralkoholvC5 fluoroalkoholv
2- fluor-úpentanol (123650-81 -7) (R) -2-fluor-3-methyl-1 -butanol (113943-11 -6) (S) -2-fluor-3-methyl-1 -butanol (113942-98-6)2-fluoro-pentanol (123650-81-7) (R) -2-fluoro-3-methyl-1-butanol (113943-11 -6) (S) -2-fluoro-3-methyl-1-butanol ( 113942-98-6)
4-fluor-3-methyl-1 -butanol (104715-25-5)4-fluoro-3-methyl-1-butanol (104715-25-5)
1- fluor-3-pentanol (30390-84 2)1-Fluoro-3-pentanol (30390-84 2)
4- fluor-2-pentanol (19808-94-7)4-fluoro-2-pentanol (19808-94-7)
5- fluoro-2-pentanol (18804-35-8)5-fluoro-2-pentanol (18804-35-8)
3- fluor-2-methyl-2-butanol (7284-96-0)3-Fluoro-2-methyl-2-butanol (7284-96-0)
2- fluor-2-methyl-1-butanol (4456-02-4)2-fluoro-2-methyl-1-butanol (4456-02-4)
3- fluor-3-methyl-2-butanol (1998-77-2)3-Fluoro-3-methyl-2-butanol (1998-77-2)
5-flu or-1 -pentanol (592-80-3)5-Fluoro-1-pentanol (592-80-3)
C6 fluoralkoholv (R-(R ,S‘))-2-fluor-3-methyl-1-pentanol (168749-88-0)C6 fluoroalkoholv (R- (R, S‘)) - 2-fluoro-3-methyl-1-pentanol (168749-88-0)
1- fluor-2,3-dimethyl-2-butanol (161082-90-2)1-Fluoro-2,3-dimethyl-2-butanol (161082-90-2)
2- fluor-2)3-dimethyl-1-butanol(161082-89-9) (R) -2;flupr-4-methyl-1-pehtanol (157988-30-2) (S-(R\R*))-2-fluor-3-methyl-1 -pentanol (151717-18-9) (R*,S‘)-2-fluor-3-methyl-1-pentanol (151657-14-6) (S) -2-fluor-3,3-dimethyl-1-butanol (141022-94-8) (M)-2-fluor-2-methyl-1-pentanol (137505-57-8) (S)-2-fluor-1 -hexanol (127608-47-3)2-fluoro-2 ) 3-dimethyl-1-butanol (161082-89-9) (R) -2; flupr-4-methyl-1-panol (157988-30-2) (S- (R \ R *) 2-Fluoro-3-methyl-1-pentanol (151717-18-9) (R *, S ') - 2-fluoro-3-methyl-1-pentanol (151657-14-6) (S) -2-fluoro-3,3-dimethyl-1-butanol (141022-94-8) (M) -2-fluoro-2-methyl-1-pentanol (137505-57-8) (S) -2-fluoro -1-hexanol (127608-47-3)
3- fluor-3-methyl-1-pentanol (112754-22-0)3-Fluoro-3-methyl-1-pentanol (112754-22-0)
3- fluor-2-methyl-2-pentano1 (69429-54-5)3-Fluoro-2-methyl-2-pentano1 (69429-54-5)
2-fluor-2-methyl-3-pentanol (69429-53-4)2-Fluoro-2-methyl-3-pentanol (69429-53-4)
1- fluor-3-hexanol (30390-85-3)1-Fluoro-3-hexanol (30390-85-3)
5-fluor-2-methyl-2-pentanol (21871-78-3)5-Fluoro-2-methyl-2-pentanol (21871-78-3)
5-fluor-3-hexanol (19808-92-5)5-Fluoro-3-hexanol (19808-92-5)
4- fluor-3-methyl-2-pentanol (19808-90-3)4-Fluoro-3-methyl-2-pentanol (19808-90-3)
4-fluor-4-methyl-2-pentanol (19031-69-7)4-Fluoro-4-methyl-2-pentanol (19031-69-7)
-fluor-3,3-dimethyl-2-butanol (4604-66-4)-fluoro-3,3-dimethyl-2-butanol (4604-66-4)
2- fluor-2-methyl-1 -pentanol (4456-03-5)2-Fluoro-2-methyl-1-pentanol (4456-03-5)
2-fluor-4-methyl-1 -pentanol (4455-95-2)2-Fluoro-4-methyl-1-pentanol (4455-95-2)
-208CZ 297945 B6-208EN 297945 B6
2- fluor-1 -hexanol (1786-48-7)2-fluoro-1-hexanol (1786-48-7)
3- fluor-2,3-dimethyl-2-butanol (661 -63-2)3-fluoro-2,3-dimethyl-2-butanol (661-63-2)
6- fluor-1 -hexanol (373-32-0)6-fluoro-1-hexanol (373-32-0)
C7 fluoralkoholyC7 fluoroalcohols
5- fluor-5-methyl-1 -hexanol (168268-63-1) (R) -1-fluor-2-methyl-2-hexanol (153683-63-7) (S) -3-fluor-1-heptanol (141716-56-5) (S)-2-fluor-2-methyl-1-hexanol (132354-09-7) (R) -3-fluor-1 -heptanol (120406-54-4) (S) -2-fluor-1 -heptanol (110500-31-7)5-fluoro-5-methyl-1-hexanol (168268-63-1) (R) -1-fluoro-2-methyl-2-hexanol (153683-63-7) (S) -3-fluoro-1- heptanol (141716-56-5) (S) -2-fluoro-2-methyl-1-hexanol (132354-09-7) (R) -3-fluoro-1-heptanol (120406-54-4) (S) ) -2-fluoro-1-heptanol (110500-31-7)
-fluor-3-heptanol (30390-86-4)-fluoro-3-heptanol (30390-86-4)
7- fluor-2-heptanol (18804-38-1)7-Fluoro-2-heptanol (18804-38-1)
2-ethyl 2-(fluormethyl)-1 -butanol (14800-35-2)2-ethyl 2- (fluoromethyl) -1-butanol (14800-35-2)
2-(fluormethyl)-2-methyl-1 -pentanol (13674-80-1)2- (fluoromethyl) -2-methyl-1-pentanol (13674-80-1)
2-fluor-5-methyl-1-hexanol (4455-97-4)2-Fluoro-5-methyl-1-hexanol (4455-97-4)
2-fluor-1-heptanol (1786-49-8)2-fluoro-1-heptanol (1786-49-8)
Ί fluor-1-heptanol (408-16-2)Ί Fluoro-1-heptanol (408-16-2)
C8 fluoralkoholy (M)-2-fluor-2-methyl-1-heptanol (137505-55-6)C8 fluoroalcohols (M) -2-fluoro-2-methyl-1-heptanol (137505-55-6)
6- fluor-6-methyl-1 -heptanol (135124-57-1)6-Fluoro-6-methyl-1-heptanol (135124-57-1)
1- fluor-2-oktanol (127296-11-1) (R) -2-fluoř-1-oktanol (118205-91-7) (±)-2-fluor-2-methyl-1 -heptanol (117169-40-1) (S) -2-fluor-1-oktanol (110500-32-8) (S)-1 -fluor-2-oktanol (110270-44-5) (R) -1-fluor-2-oktanol (110270-42-3) (±)-1 -fluor-2-oktanol (110229-70-4)1-fluoro-2-octanol (127296-11-1) (R) -2-fluoro-1-octanol (118205-91-7) (±) -2-fluoro-2-methyl-1-heptanol (117169- 40-1) (S) -2-fluoro-1-octanol (110500-32-8) (S) -1-fluoro-2-octanol (110270-44-5) (R) -1-fluoro-2- Octanol (110270-42-3) (±) -1-Fluoro-2-octanol (110229-70-4)
2- fluor-4-methyl-3-heptanol (87777-41 -1)2-Fluoro-4-methyl-3-heptanol (87777-41 -1)
2-fluor-6-methyl-1 -heptanol (4455-99-6)2-Fluoro-6-methyl-1-heptanol (4455-99-6)
2- fluor-1-oktanol (4455-93-0)2-fluoro-1-octanol (4455-93-0)
8- fluor-1 -oktanol (408-27-5)8-Fluoro-1-octanol (408-27-5)
C9 fluoralkoholyC9 fluoroalcohols
6-fluor-2,6-dimethyl-2-heptanol (160981-64-6) (S) -3-fIuor-1 -nonanol (160706-24-1) (R-(R*,R'))-3-fluor-2-nonanol (137909-46-7) (R-(R*,S*))-3-fluor-2-nonanol (137909-45-6)6-fluoro-2,6-dimethyl-2-heptanol (160981-64-6) (S) -3-fluoro-1-nonanol (160706-24-1) (R- (R *, R ')) - 3-fluoro-2-nonanol (137909-46-7) (R- (R *, S *)) - 3-fluoro-2-nonanol (137909-45-6)
3- fluqr-2-nonanol (137639-20-4) (S-(R',R’))-3-fluor-2-nonanol (137639-19-1) (S-(R’řS))-3-fluor-2-nohanol (137639-18-0) (±)-3-fIuor-1 -nonanol (134056-76-1) 2-fluor-1 -nonanol (123650-79-3) 2-fluor-2-methyl-1 -oktanol (120400-89-7) (R) -2-fluor-1-nonanol (118243-18-8) (S) -1-fluor-2-nonanol (111423-41-7) (S)-2-fluor-1-nonanol (110500-33-9)3- fluqr-2-nonanol (137639-20-4) (S- (R *, R *)) - 3-fluoro-2-nonanol (137639-19-1) (S- (R * R)) -3-fluoro-2-hexanol (137639-18-0) (±) -3-fluoro-1-nonanol (134056-76-1) 2-fluoro-1-nonanol (123650-79-3) 2-fluoro -2-methyl-1-octanol (120400-89-7) (R) -2-fluoro-1-nonanol (118243-18-8) (S) -1-fluoro-2-nonanol (111423-41-7) (S) -2-fluoro-1-nonanol (110500-33-9)
-fluor-3-nonanol (30390-87-5) 2-fluor-2,6-dimethyl-3-heptanol (684-74-2)-fluoro-3-nonanol (30390-87-5) 2-fluoro-2,6-dimethyl-3-heptanol (684-74-2)
-209CZ 297945 B6-209EN 297945 B6
9- fIuor-1 -nonanol (463-24-1)9-Fluoro-1-nonanol (463-24-1)
C W fluoralkoholyC W fluoroalcohols
4-fluoM -dekanol (167686-45-5) (P)-10-fluor-3-dekanol (145438-91-1) (R-(R*,R))-3-fluor-5-methyl-1-nonanol (144088-79-9) (P)-10-fluor-2-dekanol (139750-57-5)4-fluoro-decanol (167686-45-5) (P) -10-fluoro-3-decanol (145438-91-1) (R- (R *, R)) - 3-fluoro-5-methyl-1 -nonanol (144088-79-9) (P) -10-fluoro-2-decanol (139750-57-5)
-fluor-2-dekanol (130876-22-1) (S)-2-f!uor-1-dekanol (127608-48-4) (R) -1 -fluor-2-dekanol (119105-16-7) (S) -1 fluor-2-dekanol (119105-15-6)-fluoro-2-decanol (130876-22-1) (S) -2-fluoro-1-decanol (127608-48-4) (R) -1-fluoro-2-decanol (119105-16-7 (S) -1 Fluoro-2-decanol (119105-15-6)
2-fiuor-1-dekanol (110500-35-1)2-Fluoro-1-decanol (110500-35-1)
-fluor-5 dekanol (106533-31-7)-fluoro-5 decanol (106533-31-7)
4-fIuor-2,2,5,5-tetramethyl-3- hexanol (24212-87-1)4-Fluoro-2,2,5,5-tetramethyl-3-hexanol (24212-87-1)
I G-fiuor-1 -dekanol (334-64-5)I G-fluoro-1-decanol (334-64-5)
C11 fluoralkoholyC11 fluoroalcohols
10- fluor-2-methyl-1 -dekanol (139750-53-1)10-Fluoro-2-methyl-1-decanol (139750-53-1)
2-fluor-1-undekanol (110500-34-0)2-fluoro-1-undecanol (110500-34-0)
8-fluor-5.8-dimethyl-5-nonanol (110318-90-6)8-Fluoro-5,8-dimethyl-5-nonanol (110318-90-6)
11- fluor-2-undekanol (101803-63-8)11-Fluoro-2-undecanol (101803-63-8)
II -fluor- 1-undekanol (463-36-5)II-Fluoro-1-undecanol (463-36-5)
C12 fluoralkoholyC12 fluoroalcohols
11- fluor-2-methyl-1-undekanol (139750-52-0)11-Fluoro-2-methyl-1-undecanol (139750-52-0)
1- fluor-2-dodekanol (132547-33-2) (R\S’)-7-fluor-6-dodekanol (130888-52-7) (R R )-7 fluor-6-dodekanol (130876-18-5) (S)-2-fli.or-1-codekanol (127608-49-5)1-fluoro-2-dodecanol (132547-33-2) (R \ S ') -7-fluoro-6-dodecanol (130888-52-7) (RR) -7 fluoro-6-dodecanol (130876-18- (5) (S) -2-fluoro-1-codecanol (127608-49-5)
12- fluor-2-oentyl-heptanol (120400-91-1) (R ,S )-(±)-7-fluor-6-dodekanol (119174-39-9) (R'.R)-(±)-7-fluor-6-dodekanoi (119174-38-8)12-fluoro-2-oentyl-heptanol (120400-91-1) (R, S) - (±) -7-fluoro-6-dodecanol (119174-39-9) (R'.R) - (±) -7-fluoro-6-dodecanoe (119174-38-8)
2- fluor-1dodekanol (110500-36-2)2-fluoro-1-dodecanol (110500-36-2)
-fluor 2-methyl-2-undekanol (101803-67-2) fiuor-1 -dodekanoi (100278-87-3)-fluoro-2-methyl-2-undecanol (101803-67-2) fluoro-1-dodecanoe (100278-87-3)
12-fluor-1 -dodekanoi (353-31 -1)12-Fluoro-1-dodecanoi (353-31 -1)
C4 nitroalkoholy (R) -4-nitro-2-butanol (129520-34-9) (S) -4-nitro-2-butanol (120293-74-5)C4 nitroalcohols (R) -4-nitro-2-butanol (129520-34-9) (S) -4-nitro-2-butanol (120293-74-5)
4-nitro-1-butanol radikálový ion (1-) (83051-13-2) (R ,S')-3-nitro-2-butanoI (82978-02-7) (R*,RA)-3-nitra-2-butanol (82978-01-6)4-nitro-1-butanol radical ion (1-) (83051-13-2) (R, S ') - 3-nitro-2-butanol (82978-02-7) (R *, R A ) -3 -nitra-2-butanol (82978-01-6)
4-nitro-1 -butanol (75694-90-5) (±)-4 nitro-2-butanol (72959-86-5)4-nitro-1-butanol (75694-90-5) (±) -4 nitro-2-butanol (72959-86-5)
4-nitro-2-butánol (55265-82-2)4-nitro-2-butanol (55265-82-2)
1-hydroxynitroryl-2-butanol (22916-75-2) hydroxynitroryi-2-butanol (22916-74-1) methyl 3-nitro-1 -propanol (21527-52-6)1-hydroxynitroryl-2-butanol (22916-75-2) hydroxynitroryl-2-butanol (22916-74-1) methyl 3-nitro-1-propanol (21527-52-6)
3- nitro-2-butánol (6270-16-2)3-nitro-2-butanol (6270-16-2)
-210CZ 297945 B6-210GB 297945 B6
2-methyl-1-nitro-2-propanol (5447-98-3) 2-hydroxynitroryl-1-butanol (4167-97-9) 1 -nitro-2-butandl (3156-74-9) 2-nitro-l-butanol (609-31-4)2-methyl-1-nitro-2-propanol (5447-98-3) 2-hydroxynitroryl-1-butanol (4167-97-9) 1-nitro-2-butanedl (3156-74-9) 2-nitro- 1-butanol (609-31-4)
2- methyl-2-nitro-1 -propanol (76-39-1)2-Methyl-2-nitro-1-propanol (76-39-1)
C5 nitroalkoholv (R) -3-methyl-3-nitro-2-butanol (154278-27-0)C5 Nitroalcohol (R) -3-methyl-3-nitro-2-butanol (154278-27-0)
3- methyl-1 -nitro-1 -butanol (153977-20-9) (±)-1-nitro-3-pentanol (144179-64-6) (S) -1-nítro-3-pentanol (144139-35-5) (R)-1-nitro-3-pentanol (144139-34-4) (R)-3-methy I-1 -nitro-2-butanol (141434-98-2) (+)-3-methyl-1 -nitro-2-butanol (141377-55-1) (R”,R‘)-3-nitro-2-pentanol (138751-72-1) (R‘,S*)-3-nitro-2-pentanol (138751 -71 -0) (R*,R*)-2-nitro-3-pentanol (138668-26-5) (R,S')-2-nitro-3-pentanol (138668-19-6)3-Methyl-1-nitro-1-butanol (153977-20-9) (±) -1-nitro-3-pentanol (144179-64-6) (S) -1-nitro-3-pentanol (144139- 35-5) (R) -1-nitro-3-pentanol (144139-34-4) (R) -3-methyl-1-nitro-2-butanol (141434-98-2) (+) - 3 -methyl-1-nitro-2-butanol (141377-55-1) (R ', R') - 3-nitro-2-pentanol (138751-72-1) (R ', S *) - 3-nitro -2-pentanol (138751 -71-O) (R *, R *) - 2-nitro-3-pentanol (138668-26-5) (R, S ') - 2-nitro-3-pentanol (138668- 19-6)
3- nitro-1-pentanol (135462-98-5) (R) -5-nitro-2-pentanol (129520-35-0) (S) -5-nitro-2-pentanol (120293-75-6)3-nitro-1-pentanol (135462-98-5) (R) -5-nitro-2-pentanol (129520-35-0) (S) -5-nitro-2-pentanol (120293-75-6)
4- nitro-1-pentanol (116435-64-4) (±)-3-methyl-3-nitro-2-butanol (114613-30-8) (S)-3-nAethyl-3-nitro-2-butanol (109849-50-5)4-nitro-1-pentanol (116435-64-4) (±) -3-methyl-3-nitro-2-butanol (114613-30-8) (S) -3-methyl-3-nitro-2- butanol (109849-50-5)
3-methyl-4-nitro-2-butanol (96597-30-7) (±)-5-nitro-2-pentanol (78174-81-9)3-Methyl-4-nitro-2-butanol (96597-30-7) (±) -5-nitro-2-pentanol (78174-81-9)
2- methyl-2-nitro-1 -butanol (77392-55-3)2-Methyl-2-nitro-1-butanol (77392-55-3)
3- methyl-2-nitro-1 -butanol (77392-54-2)3-Methyl-2-nitro-1-butanol (77392-54-2)
3-methyl-4-nitro-1 -butanol (75694-89-2)3-Methyl-4-nitro-1-butanol (75694-89-2)
2- methyl-4-nitro-2-butanol (72183-50-7)2-Methyl-4-nitro-2-butanol (72183-50-7)
3- methyl-3-nitro-1 -butanol (65102-50-3)3-Methyl-3-nitro-1-butanol (65102-50-3)
5- nitro-2-pentanol (54045-33-9) 2-methyl-3-hydroxynitrory!-2-butanol (22916-79-6) 2-methyl-1 -hydroxynitroryl-2-butanol (22916-78-5) 2-methyl-3-nÍtro-2-butanol (22916-77-4) 2-methyl-1 -nitro-2-butanol (22916-76-3)5-nitro-2-pentanol (54045-33-9) 2-methyl-3-hydroxynitroryl-2-butanol (22916-79-6) 2-methyl-1-hydroxynitroryl-2-butanol (22916-78-5 ) 2-methyl-3-nitro-2-butanol (22916-77-4) 2-methyl-1-nitro-2-butanol (22916-76-3)
5-nitro-1-pentanol (21823-27-8) 2-methyl-3-nitro-1 -butanol(21527-53-7)5-nitro-1-pentanol (21823-27-8) 2-methyl-3-nitro-1-butanol (21527-53-7)
2- nitro-3-pentanol (20575-40-0)2-Nitro-3-pentanol (20575-40-0)
3- methyl-3-nitro-2-butanol (20575-38-6) 3-nitro-2-pentanol (5447-99-4)3-Methyl-3-nitro-2-butanol (20575-38-6) 3-nitro-2-pentanol (5447-99-4)
2- nitro-1 -pentanol (2899-90-3)2-Nitro-1-pentanol (2899-90-3)
3- methyl-1 -nitro-2-butanol (2224-38-6) 1 -nitro-2-pentanol (2224-37-5) nitroalkoholv (-)-4-methyl-1 -nitro-2-pentanol (158072-33-4) 3-(nitromethyl)-3-pentanol (156544-56-8) (R ,R*)-3-methyl-2-nitro-3-pentanol (148319-17-9) (R*,S )-3-methyl-2-nitro-3-pentanol (148319-16-8)3-methyl-1-nitro-2-butanol (2224-38-6) 1-nitro-2-pentanol (2224-37-5) nitroalcohol (-) - 4-methyl-1-nitro-2-pentanol (158072 -33-4) 3- (nitromethyl) -3-pentanol (156544-56-8) (R, R *) - 3-methyl-2-nitro-3-pentanol (148319-17-9) (R *, S) -3-Methyl-2-nitro-3-pentanol (148319-16-8)
-211 CZ 297945 B6-211 CZ 297945 B6
6-nítro-2-hexanol (146353-95-9) (±)-6-nitro-3-hexanol (144179-63-5) (S)-6-nitro-3-hexanol (144139-33-3) (R)-6-nitro-3-hexanol (144139-32-2)6-Nitro-2-hexanol (146353-95-9) (±) -6-nitro-3-hexanol (144179-63-5) (S) -6-nitro-3-hexanol (144139-33-3) (R) -6-Nitro-3-Hexanol (144139-32-2)
3- nitro-2-hexanol (127143-52-6)3-Nitro-2-hexanol (127143-52-6)
5- nÍtro-2-hexanol (110364-37-9)5-Nitro-2-hexanol (110364-37-9)
4- methyl-1 -nitro-2-pentanol (102014-44-8) (R*.S*)-2-methyl-4-nitro-3-pentanol (82945-29-7) (R‘,R*)-2-methyl-4-nitro-3-pentanol (82945-20-8) 2-methyl-5-nitro-2-pentanol (79928-61-3)4-Methyl-1-nitro-2-pentanol (102014-44-8) (R * .S *) - 2-methyl-4-nitro-3-pentanol (82945-29-7) (R ', R * ) -2-Methyl-4-nitro-3-pentanol (82945-20-8) 2-Methyl-5-nitro-2-pentanol (79928-61-3)
2.3- dimethyl-1-nitro-2-butanol (68454-59-1) 2-methyl-3-nitro-2-pentanol (59906-62-6)2,3-Dimethyl-1-nitro-2-butanol (68454-59-1) 2-methyl-3-nitro-2-pentanol (59906-62-6)
3.3- dimethyl-Í -nitro-2-butanol (58054-88-9)3,3-dimethyl-1-nitro-2-butanol (58054-88-9)
2.3- dimethyl-3-nitro-2-butanol (51483-61-5) 2-methyM -nitro-2-pentanoi (49746-26-1)2,3-dimethyl-3-nitro-2-butanol (51483-61-5) 2-methyl-4-nitro-2-pentano (49746-26-1)
3.3- dimethyl-2-nitro-1 -butanol (37477-66-0)3.3-Dimethyl-2-nitro-1-butanol (37477-66-0)
6- nitro-1-hexanol (31968-54-4) 2-methyJ-3-nitro-1 -pentanol (21527-55-9)6-nitro-1-hexanol (31968-54-4) 2-methyl-3-nitro-1-pentanol (21527-55-9)
2.3- dimethyl-3-nitro-1 -butanol (21527-54-8) 2-methyl-4-nitro-3-pentanol (20570-70-1) 2-methyl-2-nitro-3-pentanol (20570-67-6)2,3-dimethyl-3-nitro-1-butanol (21527-54-8) 2-methyl-4-nitro-3-pentanol (20570-70-1) 2-methyl-2-nitro-3-pentanol (20570- 67-6)
2- nitro-3-hexanol (5448-00-0)2-Nitro-3-hexanol (5448-00-0)
4-nitro-3-hexanol (5342-71-2)4-Nitro-3-hexanol (5342-71-2)
4- methyl-4-nitro-1 -pentanol (5215-92-9)4-Methyl-4-nitro-1-pentanol (5215-92-9)
-nitro-2-hexanol (2224-40-0)-nitro-2-hexanol (2224-40-0)
C7 nitroalkoholyC7 nitroalcohols
-nitro-4-heptanoi (167696-66-4) (R)-1-nitro-2-heptanol (146608-19-7)-nitro-4-heptanol (167696-66-4) (R) -1-nitro-2-heptanol (146608-19-7)
7- nitro-1 -heptanol (133088-94-5) (R*,S*)-3-nitro-2-heptanol (127143-73-1) (R‘?R‘)-3-nitro-2-heptanol (127143-72-0) (R*,S )-2-nitro-3-heptanoí (127143-71 -9) (R*,R*)-2-nitro-3-heptanol (127143-70-8) (R’,S)-2-methyl-5-nitro-3-hexanol (103077-95-8) (R*,R*)-2-methyl-5-nitro-3-hexanol (103077-87-8)7-nitro-1-heptanol (133088-94-5) (R *, S *) - 3-nitro-2-heptanol (127143-73-1) (R? R ') - 3-nitro-2- heptanol (127143-72-0) (R *, S) -2-nitro-3-heptanol (127143-71-9) (R *, R *) - 2-nitro-3-heptanol (127143-70-8) (R ', S) -2-methyl-5-nitro-3-hexanol (103077-95-8) (R *, R *) -2-methyl-5-nitro-3-hexanol (103077-87-) 8)
3- ethyl-4-nitro-1 -pentanol (92454-38-1) 3-ethyl-2-n itro-3-pentan ol (77922-54-4) 2-nitro-3-heptanol (61097-77-6) 2-methyl-1 -nitro-3-hexanol (35469-17-1) 2-methyl-4-nitro-3-hexanol (20570-71 -2)3-ethyl-4-nitro-1-pentanol (92454-38-1) 3-ethyl-2-nitro-3-pentanol (77922-54-4) 2-nitro-3-heptanol (61097-77- 6) 2-Methyl-1-nitro-3-hexanol (35469-17-1) 2-Methyl-4-nitro-3-hexanol (20570-71 -2)
2- methyl-2-nitro-3-hexanol (20570-69-8)2-Methyl-2-nitro-3-hexanol (20570-69-8)
5- methyl-5-nitro-2-hexanol (7251 -87-8) 1-nitro-2-heptanol (6302-74-5)5-Methyl-5-nitro-2-hexanol (7251-87-8) 1-nitro-2-heptanol (6302-74-5)
3- nitro-4-heptanol (5462-04-4)3-Nitro-4-heptanol (5462-04-4)
4- nitro-3-heptanol (5342-70-1)4-Nitro-3-heptanol (5342-70-1)
C8 nitroalkoholy (±)-1 -nitro-3-oktanol (141956-93-6) i -nitro-4-oktánol (167642-45-7)C8 nitroalcohols (±) -1-nitro-3-octanol (141956-93-6) i -nitro-4-octanol (167642-45-7)
-212CZ 297945 B6 (S)-1-nitro-4-oktanol (167642-18-4)-212EN 297945 B6 (S) -1-Nitro-4-octanol (167642-18-4)
6-methyl-6-nitro-2-heptanol (142991-77-3) (R*,S*)-2-nitro-3-oktanol (135764-74-8) (R ,R*)-2-nitro-3-oktanol (135764-73-7)6-Methyl-6-nitro-2-heptanol (142991-77-3) (R *, S *) - 2-nitro-3-octanol (135764-74-8) (R, R *) - 2-nitro -3-Octanol (135764-73-7)
5-nitro-4-oktanol (132272-46-9) (R*,R*)-3-nitro-4-oktanol (130711-79-4) (R*,S*)-3-nitro-4-oktanol (130711-78-3)5-nitro-4-octanol (132272-46-9) (R *, R *) - 3-nitro-4-octanol (130711-79-4) (R *, S *) - 3-nitro-4- octanol (130711-78-3)
4-ethyl-2-nitro-3-hexanol (126939-74-0)4-Ethyl-2-nitro-3-hexanol (126939-74-0)
2- nitro-3-oktanol (126939-73-9) 1 -nitro-3-oktanol (126495-48-5) (R*,R*)-(±)-3-nitro-4-oktanol (118869-22-0) (R*,S*)-(±)-3-nitro-4-oktanol (118869-21-9)2-nitro-3-octanol (126939-73-9) 1-nitro-3-octanol (126495-48-5) (R *, R *) - (±) -3-nitro-4-octanol (118869- 22-0) (R *, S *) - (±) -3-nitro-4-octanol (118869-21-9)
3- nitrp-2-oktanol (127143-53-7) (R*,S*)-2-methyl-5-nitro-3-heptanol (103078-03-1) (R*.R*)-2-methyl-5-nitro-3-heptanol (103077-90-3)3-nitrp-2-octanol (127143-53-7) (R *, S *) -2-methyl-5-nitro-3-heptanol (103078-03-1) (R * .R *) -2- Methyl-5-nitro-3-heptanol (103077-90-3)
8- nitro-1 -oktanol (101972-90-1) (±)-2-nitro-1 -oktanol (96039-95-1)8-Nitro-1-octanol (101972-90-1) (±) -2-Nitro-1-octanol (96039-95-1)
3.4- dimethyl-1-nitro-2-hexanol (64592-02-5)3,4-Dimethyl-1-nitro-2-hexanol (64592-02-5)
3- (nitromethyl)-4-heptanol (35469-20-6)3- (Nitromethyl) -4-heptanol (35469-20-6)
2.5- dimethyl-1 -nitro-3-hexanol (35469-19-3) 2-methyl-1 -nitro-3-heptanol (35469-18-2) 2l4>4-trimethyl-1-nÍtro-2-pentanol (35223-67-7)2.5- dimethyl-1-nitro-3-hexanol (35469-19-3) 2-methyl-1-nitro-3-heptanol (35469-18-2), 2 l of 4> 4-trimethyl-1-nitro-2- pentanol (35223-67-7)
2.5- dimethyl-4-nitro-3-hexanol (22482-65-1) 2-nitro-1-oktanol (2882-67-9)2,5-Dimethyl-4-nitro-3-hexanol (22482-65-1) 2-Nitro-1-octanol (2882-67-9)
-nitro-2-oktanol (2224-39-7)-nitro-2-octanol (2224-39-7)
C9 nitroalkoholyC9 nitroalcohols
4- nitro-3-nonanol (160487-89-8) (R*,R’)-3-ethyi-2-nitro-3-heptanol (148319-18-0)4-nitro-3-nonanol (160487-89-8) (R *, R ') - 3-ethyl-2-nitro-3-heptanol (148319-18-0)
2.6- dimethyl-6-nitro-2-heptanol (117030-50-9) (R’,S')-2-nitro-4-nonanol (103077-93-6) (R*,R*)-2-nitro-4-nonanol (103077-85-6) 2-nitro-3-nonanol (99706-65-7)2,6-Dimethyl-6-nitro-2-heptanol (117030-50-9) (R ', S') - 2-nitro-4-nonanol (103077-93-6) (R *, R *) - 2- nitro-4-nonanol (103077-85-6) 2-nitro-3-nonanol (99706-65-7)
9- nitro-1-nonanol (81541-84-6) 2-methyl-1 -nitro-3-oktanol (53711 -06-1)9-Nitro-1-nonanol (81541-84-6) 2-methyl-1-nitro-3-octanol (53711 -06-1)
4- nitro-5-nonanol (34566-13-7) 2-rnethyl-3-(nitromethyi)-3-hepténol (5582-88-7) 1 -nitro-2-nonanol (4013-87-0)4-nitro-5-nonanol (34566-13-7) 2-methyl-3- (nitromethyl) -3-heptenol (5582-88-7) 1-nitro-2-nonanol (4013-87-0)
C10 nitroalkoholyC10 nitroalcohols
2- nitro-4-dekanol (141956-94-7) (R*,S*)-3-nitro-4-dekanol (135764-76-0) (R’,R')-3-nitro-4-dekanol (135764-75-9) 5,5-dimethyl-4-(2-nitroethyl)-1 -hexanol (133088-96-7) (R. R*)-(±)-3-nitro-4-dekanol (118869-20-8) (R‘,S>(±)-3-nitro^-dekanol (118869-19-5)2-nitro-4-decanol (141956-94-7) (R *, S *) - 3-nitro-4-decanol (135764-76-0) (R ', R') - 3-nitro-4- Decanol (135764-75-9) 5,5-dimethyl-4- (2-nitroethyl) -1-hexanol (133088-96-7) (R. R *) - (±) -3-nitro-4-decanol (118869-20-8) (R ', S> (±) -3-nitro-4-decanol (118869-19-5)
5- nitro-2-dekanol (112882-29-8)5-Nitro-2-decanol (112882-29-8)
3- nitro-4-dekanol (93297-82-6)3-Nitro-4-decanol (93297-82-6)
4.6.6- trimethyl-l -nitro-2-heptanol (85996-72-1) 2-methyl-2-nitro-3-nonanol (80379-17-5)4.6.6-Trimethyl-1-nitro-2-heptanol (85996-72-1) 2-methyl-2-nitro-3-nonanol (80379-17-5)
-213 CZ 297945 B6-213 CZ 297945 B6
-nitro-2-dekanol (65299-35-6)-nitro-2-decanol (65299-35-6)
2,2^4-tetramethyl-3-(nitromethyl)-3-pentar»ol (58293-26-8)2,2,4-tetramethyl-3- (nitromethyl) -3-pentaroline (58293-26-8)
C11 nitroalkoholyC11 nitroalcohols
1l-nitro-5-undekanol (167696-69-7) (R*,Rj-2-nitro-3-undekanol (144434-56-0) (R’,S)-2-nitro-3-undekanol (144434-55-9) 2-nítro-3-undekanol (143464-92-0) 2,2-dimethyl-4-nitro-3-nonanol (126939-76-2) 4,8-dimethyl-2-nitro-1 -nonanol (118304-30-6)11-Nitro-5-undecanol (167696-69-7) (R *, Rj-2-nitro-3-undecanol (144434-56-0) (R ', S) -2-nitro-3-undecanol (144434 -55-9) 2-nitro-3-undecanol (143464-92-0) 2,2-dimethyl-4-nitro-3-nonanol (126939-76-2) 4,8-dimethyl-2-nitro-1 -nonanol (118304-30-6)
11- nitro-1-undekanol (81541-83-5)11-Nitro-1-undecanol (81541-83-5)
C12 nitroalkoholyC12 nitroalcohols
2-methyl-2-nitro-3-undekanol (126939-75-1)2-Methyl-2-nitro-3-undecanol (126939-75-1)
2-nitro-1 -dodekanol (62322-32-1)2-Nitro-1-dodecanol (62322-32-1)
1- nitro-2-dodekanol (62322-31-0)1-nitro-2-dodecanol (62322-31-0)
2- nitro-3-dodekanol (82981 -40-6)2-Nitro-3-dodecanol (82981 -40-6)
12- n itro-1-dodekanol (81541-78-8)12-nitro-1-dodecanol (81541-78-8)
Tabulka 26: Příklady sloučenin obecného vzorce R5-OH (registrační číslo OAS, číslo Aldrich)Table 26: Examples of compounds of formula R 5 -OH (OAS Registration Number, Aldrich Number)
-214CZ 297945 B6-214GB 297945 B6
-215CZ 297945 B6-215GB 297945 B6
-216CZ 297945 B6-216GB 297945 B6
Tabulka 27: Příklady uspořádáni procesů A-RTable 27: Examples of A-R process layouts
A; B; C; O; I; J; K; L; Μ; N; O; P; Q; R; E; F; G; Η; AB; BC; CD; Dl; IJ; JK; KL; LM; MN; NO; OP; OQ; QR; EF; FG; GH; Hl; ABC; BCD; CDI; DIJ; UK; JKL; KLM; LMN; MNO; NOPjNOQ; OQR; EFG; FGH; GHI; HIJ; ABDC; BCDI; CDU; DUK; IJKL; JKLM; KLMN; LMNO; MNOP; MNOQ; NOQR; EFHG; FGHI; GH1J; HIJK; ABCDI; BCDIJ; CDIJK; DIJKL; IJKLM; JKLMN; KLMNO; LMNOP; LMNOQ; MNOQR; EFGHI; FGHIJ; GHIJK; HUKL; ABCDU; BCDIJK; CDUKL; CDIJKL; DIJKLM; UKLMN; JKLMNO; KLMNOP; KLMNOQ; LMNOQR; EFGHIJ; FGHIJK; GHIJKL; HIJKLM; ABCDIJK; BCDIJKL; CDIJKLM; DIJKLMN; IJKLMNO; JKLMNOP; JKLMNOQ; KLMNOQR; EFGHIJK; FGHIJKL; GHIJKLM; HIJKLMN; ABCDIJKL; BCDIJKLM; CDIJKLMN; DIJKLMNO; IJKLMNOP; UKLMNOQ; JKLMNOQR; EFGHIJKL; FGHIJKLM; GHIJKLMN; HIJKLMNO; ABCDUKLM; BCDUKLMN; CDIJKLMNO; DIJKLMNOP; D1JKLMNOQ; UKLMNOQR; EFGHIJKLM; FGHUKLMN; GHIJKLMNO; HIJKLMNOP; HIJKLMNOQ; ABCDUKLMN; BCDUKLMNO; CDIJKLMNOP; CDIJKLMNOQ; DIJKLMNOQR; EFGHIJKLMN; FGHIJKLMNO; GHUKLMNOP; GHUKLMNOQ; HIJKLMNOQR; ABCDIJKLMNO; BCDIJKLMNOP; BCDIJKLMNOQ; CDIJKLMNOQR: EFGHIJKLMNO; FGHIJKLMNOP; FGHIJKLMNOQ; GHIJKLMNOQR; ABCDUKLMNOP; ABCDIJKLMNOQ; BCDIJKLMNOQR; EFGHUKLMNOP; EFGHUKLMNOQ; FGHIJKLMNOQR; ABCDUKLMNOQR; EFGHIJKLMNOQR; S; T; LI; V; W; ST; TU; UV; VW; STU; TUV; UWV; STUV; TUVW; STUVWAND; B; C; O; AND; J; TO; L; Μ; N; O; P; Q; R; E; F; G; Η; AB; BC; CD; Dl; IJ; JK; KL; LM; MN; NO; OP; OQ; QR; EF; FG; GH; Hl; ABC; BCD; CDI; DIJ; UK; JKL; KLM; LMN; MNO; NOPjNOQ; OQR; EFG; FGH; GHI; HIJ; ABDC; BCDI; CDU; DUK; IJKL; JKLM; KLMN; LMNO; MNOP; MNOQ; NOQR; EFHG; FGHI; GH1J; HIJK; ABCDI; BCDIJ; CDIJK; DIJKL; IJKLM; JKLMN; KLMNO; LMNOP; LMNOQ; MNOQR; EFGHI; FGHIJ; GHIJK; HUKL; ABCDU; BCDIJK; CDUKL; CDIJKL; DIJKLM; UKLMN; JKLMNO; KLMNOP; KLMNOQ; LMNOQR; EFGHIJ; FGHIJK; GHIJKL; HIJKLM; ABCDIJK; BCDIJKL; CDIJKLM; DIJKLMN; IJKLMNO; JKLMNOP; JKLMNOQ; KLMNOQR; EFGHIJK; FGHIJKL; GHIJKLM; HIJKLMN; ABCDIJKL; BCDIJKLM; CDIJKLMN; DIJKLMNO; IJKLMNOP; UKLMNOQ; JKLMNOQR; EFGHIJKL; FGHIJKLM; GHIJKLMN; HIJKLMNO; ABCDUKLM; BCDUKLMN; CDIJKLMNO; DIJKLMNOP; D1JKLMNOQ; UKLMNOQR; EFGHIJKLM; FGHUKLMN; GHIJKLMNO; HIJKLMNOP; HIJKLMNOQ; ABCDUKLMN; BCDUKLMNO; CDIJKLMNOP; CDIJKLMNOQ; DIJKLMNOQR; EFGHIJKLMN; FGHIJKLMNO; GHUKLMNOP; GHUKLMNOQ; HIJKLMNOQR; ABCDIJKLMNO; BCDIJKLMNOP; BCDIJKLMNOQ; CDIJKLMNOQR: EFGHIJKLMNO; FGHIJKLMNOP; FGHIJKLMNOQ; GHIJKLMNOQR; ABCDUKLMNOP; ABCDIJKLMNOQ; BCDIJKLMNOQR; EFGHUKLMNOP; EFGHUKLMNOQ; FGHIJKLMNOQR; ABCDUKLMNOQR; EFGHIJKLMNOQR; WITH; T; IF; IN; W; ST; HERE; UV; VW; STU; TUV; UWV; STUV; TUVW; STUVW
-217CZ 297945 B6-217GB 297945 B6
Schéma 41Scheme 41
(300) (301)(300)
(304) (305) (306)(304) (305)
(307) (308) (309)(307) (308)
(310) (311) (312)(310) (312) (312)
-218CZ 297945 B6-218GB 297945 B6
Schéma 41Scheme 41
Amino 300 (meziprodukt v příkladu 52, podle možnosti čištěný před použitím) je upravován s hydridem BOC, aby vznikl chráněný amin mono Boc 301. Tuto transformaci lze nalézt u Greeneové. T. W. „Protective Groups in Organics Synthesi“ 2. vydání (John Wiley & Sons, New York, 1991) str. 327-328.Amino 300 (intermediate in Example 52, preferably purified before use) is treated with BOC hydride to provide the protected mono Boc 301 amine. This transformation can be found in Greene. T. W. "Protective Groups in Organics Synthesi" 2nd Edition (John Wiley & Sons, New York, 1991) pp. 327-328.
Metyl ester 301 se redukuje na odpovídající primární allylický alkohol 302 pomocí DIBAL za nízké teploty. Tuto konverzi popisuje Gamer, P a Park, J. M. „J. Org. Chem.“, 52:2361 (1987).The methyl ester 301 is reduced to the corresponding primary allylic alcohol 302 with DIBAL at low temperature. This conversion is described by Gamer, P and Park, J.M. Org. Chem., 52: 2361 (1987).
Primární alkohol 302 je chráněn svým derivátem p-metoxybenzyleter 303 působením 4-metoxybenzyl chloridem v zásaditém prostředí. Tato konverze je popisována K. Horitou aj., „Tetrahedron“, 42:3021 (1986).The primary alcohol 302 is protected by its p-methoxybenzyl ether 303 derivative by treatment with 4-methoxybenzyl chloride in an alkaline medium. This conversion is described by K. Horita et al., "Tetrahedron", 42: 3021 (1986).
Ochranné skupiny 303 MON a BOC se odstraní působením TFA/CH2C12, aby vznikl amino alkohol 304. Tyto transformace lze nalézt u Greeneové T.W. „Protective Groups in Organic Synthesis“, 2. vydání (John Wiley & Sons, New York, 1991).The protective groups 303 MON and BOC are removed by treatment with TFA / CH 2 Cl 2 to give amino alcohol 304. These transformations can be found in Greene's TW "Protective Groups in Organic Synthesis", 2nd edition (John Wiley & Sons, New York, 1991) ).
Konverze 304 na odpovídající aziridin 305 chráněný tritylem je prováděna reakcí v jedné aparatuře (one poť) po dvou krocích: 1. TrCl/TEA, 2. MsCl/TEA. Tyto transformace již byly popsány.The conversion of 304 to the corresponding trityl protected aziridine 305 is accomplished by one step reaction in two steps: 1. TrCl / TEA, 2. MsCl / TEA. These transformations have already been described.
Aziridin 305 se pak konvertuje odpovídajícím derivátem 307 chráněným Boc tím, že se nejdříve odstraní tritylová skupina HCl/aceton, aby vznikl 306. Tato transformace je opsána u Hanson, R.W. a Law. H.D. „J. Chem. Soc.“, 7285 (1965). Aziridin 306 se potom převádí na odpovídající derivát 307 Boc tím, že se na něj působí anhydridem Boc. Tato konverze je popisována v práci Fitremanna, J„ aj. „Tetrahedron Lett.“ 35:1201 (1994).Aziridine 305 is then converted with the corresponding Boc protected derivative 307 by first removing the trityl HCl / acetone group to give 306. This transformation is described by Hanson, R.W. and Law. H.D. 'J. Chem. Soc., 7285 (1965). Aziridine 306 is then converted to the corresponding Boc derivative 307 by treatment with Boc anhydride. This conversion is described in Fitremann, J. "et al.," Tetrahedron Lett. "35: 1201 (1994).
Allylický aziridin 307 se otevírá selektivně na pozici allylu a to nukleofílním uhlíkem, který se dodává organokuprátem vyššího řádu za přítomnosti BF3-Et2O, za nízké teploty, aby tak vznikl otevřený produkt adice 308. Toto otevření popisuje Hudlicky, T. aj. „Synlett.“ 1125 (1995).The allylic aziridine 307 opens selectively at the allyl position by nucleophilic carbon, which is supplied by a higher order organohydrate in the presence of BF 3 -Et 2 O, at low temperature to provide an open addition product 308. This opening is described by Hudlicky, T. et al. Synlett. 1125 (1995).
Amin 308 chráněný Boc se konvertuje na Ν-acetyl derivát 309 ve dvou stupních: 1) TFA/CH2C12; 2) Ac2O/pyridin. Tyto transformace můžeme nalézt u Greeneové, T.W., „Protective Groups in Organic Synthesis“, 2. vydání (John Wiley & Sons, New York, 1991) strany 327-328 a 351-352.The Boc-protected amine 308 is converted to the acet-acetyl derivative 309 in two steps: 1) TFA / CH 2 Cl 2 ; 2) Ac 2 O / pyridine. These transformations can be found in Greene, TW, "Protective Groups in Organic Synthesis," 2nd Edition (John Wiley & Sons, New York, 1991) pages 327-328 and 351-352.
Benzyl eter 309 se zbaví ochrany DDQ za pokojové teploty, aby vznikl primární allylový alkohol 310. Tato transformace je popsána Horita, K„ aj. „Tetrahedron“ 42:3021 (1986).Benzyl ether 309 is deprotected at room temperature to provide primary allylic alcohol 310. This transformation is described by Horita, K., et al., Tetrahedron 42: 3021 (1986).
Alkohol 310 se oxiduje a převádí reakcí v jedné aparatuře (one pot) na metyl ester 311 prostřednictvím Coreyho oxidace za použití MnO2/AcOH/MeOH/NaCN. Tuto transformaci lze nalézt v práci Corey, E.J., aj. „J. Am. Chem. Soc.“, 90:5616 (1968).The alcohol 310 is oxidized and converted by one pot reaction to the methyl ester 311 via Corey oxidation using MnO 2 / AcOH / MeOH / NaCN. This transformation can be found in Corey, EJ, etc. "J. Am. Chem. Soc., 90: 5616 (1968).
Azido ester 311 se konvertuje na aminokyselinu 312 dvoustupňovým postupem 1) Ph3P/H2O/THF; 2) KOH/THF. Tato konverze již byla dříve popsána.Azido ester 311 is converted to amino acid 312 by a two step procedure 1) Ph 3 P / H 2 O / THF; 2) KOH / THF. This conversion has been previously described.
-219CZ 297945 B6-219GB 297945 B6
Schéma 42Scheme 42
HO'*HIM'*
HO/«.HIM/".
OMsOMs
(323) (322)(323)
(326)(326)
-220CZ 297945 B6-220GB 297945 B6
Schéma 42Scheme 42
Známý fluoroacetát 320 (Sutherland, J. K., aj. „J Chem. Soc. Chem. Commun.“ 464 (1993) je zbaven ochrany na volný alkohol a potom konvertován na odpovídající mesylát 321 dvěma kroky“ 1) NaOMe; 2) MsCl/TEA. Tyto transformace jsou popsány u Greeneové, T.W., „Protective Groups in Organic Synthesis“, 2. vydání (John Wiley & Sons, New York, 1991).The known fluoroacetate 320 (Sutherland, J.K., et al., "J Chem. Soc. Chem. Commun." 464 (1993) is deprotected to the free alcohol and then converted to the corresponding mesylate 321 in two steps "1) NaOMe; 2) MsCl / TEA. These transformations are described by Greene, T. W., "Protective Groups in Organic Synthesis," 2nd Edition (John Wiley & Sons, New York, 1991).
Zbavení ochrany 321 v kyselých podmínkách poskytne diol 322, který se cyklizuje na epoxy alkohol 323 v zásaditém prostředí. Tato konverze již byla dříve popsána.Deprotection 321 under acidic conditions affords diol 322, which is cyclized to epoxy alcohol 323 under basic conditions. This conversion has been previously described.
Konverze 323 na N-trityl chráněný aziridin 324 se provádí následujícím postupem: 1) MOC1/TEA, 2) NaNj/NHtCl; 3) MsCl/TEA; 4) PPh3/TEA/H2O; 5) NaNs/NHjCl; 6) HCl/MeOH; 7) i)TrCl, ii) MsCl/TEA. Tento postup již byl dříve popsán.The conversion of 323 to N-trityl protected aziridine 324 is carried out as follows: 1) MOCl / TEA, 2) NaNj / NHtCl; 3) MsCl / TEA; 4) PPh 3 / TEA / H 2 O; 5) NaN 5 / NH 3 Cl; 6) HCl / MeOH; 7) i) TrCl, ii) MsCl / TEA. This procedure has been previously described.
Aziridin 324 se potom otevře příslušným alkoholem za kyselých podmínek podle Lewise a potom se na něj působí Ac2O/pyridinem, aby vznikl acetylovaný produkt 325. Tato transformace již byla dříve popsána.Aziridine 324 is then opened with the appropriate alcohol under Lewis acidic conditions and then treated with Ac 2 O / pyridine to give the acetylated product 325. This transformation has been previously described.
Ester 325 se konvertuje na odpovídající aminokyselinu 326 ve dvou stupních: 1) PPh3/H2O/THF; 2) KOH/THF. Tato transformace již byla dříve popsána.Ester 325 is converted to the corresponding amino acid 326 in two steps: 1) PPh 3 / H 2 O / THF; 2) KOH / THF. This transformation has been previously described.
Patent US 5,214,165 a zvláště pak „Popisy a příklady; ve sloupci 9, řádka 61 až sloupec 18, řádka 26 popisují přípravu 6a a 6β fluoro šikimové kyselin. Tyto fluorosloučeniny jsou vhodným výchozím materiálem pro výrobu sloučenin vynálezu, které používají kyselinu šikimovou.U.S. Patent 5,214,165, and in particular "Descriptions and Examples;" in column 9, line 61 through column 18, line 26 describe the preparation of 6a and 6β fluoro shikimic acids. These fluoro compounds are a suitable starting material for the preparation of compounds of the invention which use shikimic acid.
-221 CZ 297945 B6-221 CZ 297945 B6
Schéma 43Scheme 43
OAc (331)OAc (334)
OAcOAc
(333)(333)
(335)(335)
(337)(337)
-222CZ 297945 B6-222EN 297945 B6
Schéma 43Scheme 43
Nenasycený ester 330 (který lze získat standardními acetylačními metodami z acetonidového alkoholu jak popisuje Campbell, M.: aj. „Synthesis“ 179 (1993)) reaguje s příslušným organokuprátem, kde R' je ligandem, který se má převést z organokuprátu. Výsledný meziprodukt se potom zachytí PhSeCl, aby poskytl 331, na který se potom působí 30% H2O2, aby vznikl α,βnenasycený ester 332. Tato transformace se dá nalézt u Hayashi, Y., aj. „J. Org. Chem.“ 47:3428 (1982).The unsaturated ester 330 (obtainable by standard acetylation methods from acetonide alcohol as described by Campbell, M., et al., "Synthesis" 179 (1993)) reacts with the appropriate organohydrate, where R 'is the ligand to be converted from the organohydrate. The resulting intermediate is then captured with PhSeCl to give 331, which is then treated with 30% H 2 O 2 to form α, β unsaturated ester 332. This transformation can be found in Hayashi, Y., et al. "J. Org. Chem., 47: 3428 (1982).
Acetát 332 se potom převádí na o odpovídající mesylát 333 ve dvou krocích: 1) NaOMe/MeOH; 2) MsCl/TEA. Tato transformace již byla dříve popsána a může být rovněž nalezena v práci Greeneové, T. W., „Protective Groups in Organic Synthesis“, 2. vydání (John Wiley & Sons, NewYork, 1991).The acetate 332 is then converted to the corresponding mesylate 333 in two steps: 1) NaOMe / MeOH; 2) MsCl / TEA. This transformation has been previously described and can also be found in Greene, T. W., "Protective Groups in Organic Synthesis," 2nd Edition (John Wiley & Sons, NewYork, 1991).
Acetonid 333 se potom převádí na epoxy alkohol 334 dvěma kroky. 1) p-TsOH/MeOH/Δ; 2) DBU/THF. Tato transformace již byla dříve popsána.Acetone 333 is then converted to epoxy alcohol 334 in two steps. 1) p-TsOH / MeOH / Δ; 2) DBU / THF. This transformation has been previously described.
Konverze epoxydu 334 na N-trityl aziridin 335 se provádí následujícím postupem: 1) M0MC1/TEA; 2) NaN3/NH4Cl; 3) MsCl/TEA; 4) PPh3/TEA/H2O; 5) NaN3/NH4Cl; 6) HCl/MeOH; 7) i) TrCl, ii) MsCl/TEA. Takový postup již byl dříve popsán.The conversion of epoxy 334 to N-trityl aziridine 335 is carried out by the following procedure: 1) MoCl / TEA; 2) NaN 3 / NH 4 Cl; 3) MsCl / TEA; 4) PPh 3 / TEA / H 2 O; 5) NaN 3 / NH 4 Cl; 6) HCl / MeOH; 7) i) TrCl, ii) MsCl / TEA. Such a procedure has been previously described.
Aziridin 335 se potom otevře příslušným alkoholem za kyselých podmínek pro Lewíse a potom se na něj působí Ac2O/pyridinem, aby poskytl acetylovaný produkt velký 336. Tato transformace již byla dříve popsána.Aziridine 335 is then opened with the appropriate alcohol under acidic conditions for Lewis and then treated with Ac 2 O / pyridine to give the acetylated product 336. This transformation has been previously described.
Azido ester 336 se převádí na odpovídající aminokyselinu 337 dvěma kroky: 1) PPh3/H2O/THF; 2) KOH/THF. Tato transformace již byla dříve popsána.The azido ester 336 is converted to the corresponding amino acid 337 by two steps: 1) PPh 3 / H 2 O / THF; 2) KOH / THF. This transformation has been previously described.
Schémata 44 a 45 jsou uváděna mezi příklady.Schemes 44 and 45 are exemplified.
-223 CZ 297945 B6-223 CZ 297945 B6
Schéma 44Scheme 44
(340)(340)
Schéma 45Scheme 45
Modifikace příkladných výchozích materiálů tak, aby vznikly různé skupiny Ei již byly podrobně popsány a nebudou zde dále uváděny. Viz Fleet, G.W. J. aj.; „J. Chem. Soc. Perkin Trans. I“, 5 905-908 (1984), Fleet, G.W.J. aj.; „J. Chem. Soc., Chem. Commun.“, 849-850 (1983). Yee,Modifications of exemplary starting materials to form different E 1 groups have already been described in detail and will not be discussed further herein. See Fleet, G.W. J. aj .; 'J. Chem. Soc. Perkin Trans. I, 5,905-908 (1984), Fleet, G.W.J. aj .; 'J. Chem. Soc., Chem. Commun., 849-850 (1983). Yee,
Ying K. Aj.; „J. Med. Chem.“, 33:2347-2451 (1990); Olson, R.E. aj.; „Bioorganic & MedicinalYing K. Aj .; 'J. Copper. Chem., 33: 2347-2451 (1990); Olson, R.E. aj .; Bioorganic & Medicinal
Chemistry Letters“, 4(18):2229-2234 (1994); Santella, J.B.III aj.; „Biorganic & MedicinalChemistry Letters, 4 (18): 2229-2234 (1994); Santella, J.B.III et al .; 'Biorganic & Medicinal
-224CZ 297945 B6-224GB 297945 B6
Chemistry Letters“, 4(18)2235-2240 (1994); Judd, D.B. aj.; „J. Med. Chem.“ 37:3108-3120 (1994) a Lombaert, S. De aj.; „Bioorganic & Medicinal Chemistry Letters“, 5(2):151-154 (1994).Chemistry Letters, 4 (18) 2235-2240 (1994); Judd, D.B. aj .; 'J. Copper. Chem., 37: 3108-3120 (1994) and Lombaert, S. De et al .; Bioorganic & Medicinal Chemistry Letters, 5 (2): 151-154 (1994).
Ei sírové analogy sloučenin karboxylových kyselin vynálezu se připravují kteroukoliv ze standardních technik. Jako příklad, nikoliv však výhradně, se karboxylové kyseliny redukují na alkoholy standardními metodami. Alkoholy se převádějí na halogenidy nebo estery sulfonové kyseliny standardními metodami a výsledné sloučeniny reagují s NaSH tak, aby vznikl sulfidový produkt. Tyto reakce jsou popsány u Patai, „The Chemistry of the Thiol Groups“ (John Wiley, New York, 1974), část 2 a zvláště na stránkách 721-735.The E 1 sulfur analogs of the carboxylic acid compounds of the invention are prepared by any of the standard techniques. By way of example, but not exclusively, carboxylic acids are reduced to alcohols by standard methods. Alcohols are converted to halides or sulfonic acid esters by standard methods, and the resulting compounds are reacted with NaSH to form a sulfide product. These reactions are described in Patai, "The Chemistry of the Thiol Groups" (John Wiley, New York, 1974), Part 2, and in particular pages 721-735.
Modifikace každého z výše uvedených schémat vede k různým analogům konkrétních exemplárních materiálů, produkovaných výše. Výše uváděné citace popisují vhodné metody organické syntézy platí i pro tyto modifikace.Modifications to each of the above schemes result in different analogs of the particular exemplary materials produced above. The above citations describe suitable methods of organic synthesis also apply to these modifications.
Může být výhodné u každého výše uvedeného příkladného schématu oddělovat reakční výrobky od sebe navzájem a/nebo od výchozích materiálů. Žádané produkty každého kroku nebo řady kroků se oddělují nebo čistí a poté oddělují (na potřebný stupeň homogenity) technikami, které jsou v praxi běžné. Obvykle tyto separace zahrnují multifázovou reakci, krystalizací z rozpouštědla nebo směsi rozpouštědel, destilaci, sublimaci nebo chromatografií. Chromatografie může zahrnovat jakýkoliv počet metod včetně např. vylučovací chromatografie podle velikosti částic nebo iontoměničová chromatografie, kapalné chromatografie ve vysokém, středním nebo nízkém tlaku, chromatografie v malém měřítku a separativní chromatografie v tenké nebo silné vrstvě, kde stejně tak jako techniky malého měřítka v tenké vrstvě a mžiková (flash) chromatografie.It may be advantageous to separate the reaction products from each other and / or from the starting materials for each of the above exemplary schemes. The desired products of each step or series of steps are separated or purified and then separated (to the necessary degree of homogeneity) by techniques that are conventional in practice. Typically, these separations include a multi-phase reaction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography may include any number of methods including, for example, particle size exclusion chromatography or ion exchange chromatography, high, medium or low pressure liquid chromatography, small-scale and thin-layer separative chromatography, as well as small-scale thin-layer techniques. and flash chromatography.
Jinou třídu separačních metod představuje působení na směs činidlem, které je vybráno tak, aby vázalo nebo aby poskytovalo jiným způsobem oddělitelný, žádoucí produkt, nezreagovaný výchozí materiál, reakční vedlejší produkt nebo pod. Tato činidla zahrnují akcerbenty nebo absorbenty, jako je aktivní uhlí, molekulová síta, iontoměniče nebo podobně. Alternativně činidla mohou být kyseliny v případě bazických materiálů, zásady v případě kyselých materiálů, vázací činidla jako jsou protilátky, vázací proteiny, selektivní chelátory jako jsou korunové étery, činidla, iontové extrakce, kapalina/kapalina (LIX) nebo podobně.Another class of separation methods involves treating the mixture with an agent that is selected to bind, or otherwise provide, a separable, desirable product, unreacted starting material, reaction by-product or the like. These agents include accelerators or absorbents such as activated carbon, molecular sieves, ion exchangers, or the like. Alternatively, the agents may be acids for basic materials, bases for acidic materials, binding agents such as antibodies, binding proteins, selective chelators such as crown ethers, reagents, ion extraction, liquid / liquid (LIX) or the like.
Výběr příslušných metod separace závisí na povaze materiálu, který se používá. Například jde o bod varu, molekulární hmotnost při destilaci a sublimaci, přítomnost nebo nepřítomnost polárních funkčních skupin v chromatografií, stabilitě materiálů v acidickém a bazickém prostředí ve vícefázové extrakci a podobně. Odborník v této oblasti bude aplikovat techniky, které nejpravděpodobněji dosáhnou požadované separace.The selection of appropriate separation methods depends on the nature of the material being used. For example, boiling point, molecular weight in distillation and sublimation, presence or absence of polar functional groups in chromatography, stability of materials in acidic and basic media in multiphase extraction and the like. One skilled in the art will apply techniques that are most likely to achieve the desired separation.
U veškeré použité literatury a citací patentů jsou na místě citací uvedeny odkazy. Přesně citované části nebo stránky výše citovaných prací jsou uvedeny s přesným odkazem. Vynález je popsán dostatečně detailně, aby odborník mohl použít podstatu následujících nároků. Je zřejmé, že je možno v rámci rozsahu a duchu vynálezu provést určité modifikace metod a sloučenin podle nároků.For all literature and patent references, references are incorporated herein by reference. Exactly cited parts or pages of the above cited works are listed with exact reference. The invention is described in sufficient detail to enable one skilled in the art to make use of the spirit of the following claims. It will be understood that certain modifications to the methods and compounds of the claims may be made within the scope and spirit of the invention.
Vynález je dále objasněn na příkladech aniž se jimi omezuje. Následující příklady se vztahují ke schématům. Některé příklady byly provedeny několikrát. V opakovaných příkladech byly podmínky reakce, jako čas, teplota, koncentrace apod., a výtěžky v normálu experimentu. Při opakovaných příkladech, kde byly provedeny významné modifikace, byly tyto zaznamenány tam, kde se výsledky významně lišily od výsledků popsaných. V příkladech, kde byly použity odlišné výchozí materiály, jsou rovněž zaznamenány. Tam, kde se opakovaném příklady vztahují ke „korespondujícímu“ analogu sloučeniny, jako „korespondují etylester“, to znamená, že jinak přítomná skupina, v tomto případě metylester, se považuje za tutéž skupinu, modifikovanou uvedeným způsobem. Například, „odpovídající etylester sloučeniny 1“ jeThe invention is further illustrated by the following examples without being limited thereto. The following examples relate to the diagrams. Some examples were performed several times. In repeated examples, reaction conditions such as time, temperature, concentration, and the like, and yields were normal to the experiment. In repeated examples where significant modifications were made, these were noted where the results differed significantly from those described. In the examples where different starting materials were used, they are also noted. Where repeated examples relate to a "corresponding" analog of a compound, such as "correspond to an ethyl ester", this means that the otherwise present group, in this case the methyl ester, is considered to be the same group modified as described above. For example, "the corresponding ethyl ester of compound 1" is
-225 CZ 297945 B6-225 CZ 297945 B6
(500)(500)
Příklady provedení vynálezuDETAILED DESCRIPTION OF THE INVENTION
Příklad 1Example 1
Epoxyalkohol 1: Připravený z kyseliny šikimové, postup McGowan 30 and Berchtold, J. Org. Chem.“, 46:2381 (1981).Epoxyalcohol 1: Prepared from Shikimic Acid, Procedure McGowan 30 and Berchtold, J. Org. Chem., 46: 2381 (1981).
Příklad 2Example 2
Epoxyalyléter 2: Do roztoku epoxyalkoholu 1 (2,37 g, 5 14,08 mmol) v bezvodém benzenu (50 ml) byl přidán v jedné dávce thallium(I)ethoxid (1,01 ml). Po 2 hodinách byla reakce koncentrována in vacuo a zbytek rozpuštěn v acetonitrilu. Po přidání alyljodidu (3,0 ml) se směs 16 hodin míchala ve tmě. Pevné částice byly přefiltrovány přes celitový list a promyty chloroformem. Koncentrace in vacuo a mžiková chromatografíe (40% EtOAc v hexanu) dala 1,24 g (42%) ze 2 jako světlý viskózní 10 olej. 'HNMR (300 MHz, CDC13): delta 6,75 (1H, m); 6,10-5,90 (1H, m, -CH=, alyl); 5,40-5,15 (2H, m, =CH2, alyl); 4,47-4,43 (1H, m); 4,30-4,15 (2H, mCH2-, alyl); 3,73 (3H, s); 3,55-3,50 (1H, m); 3,45-3,40 (1H, m); 3,15-3,00 (1H, dm, J =Epoxyalylether 2: To a solution of epoxyalcohol 1 (2.37 g, δ 14.08 mmol) in anhydrous benzene (50 mL) was added in one portion thallium (I) ethoxide (1.01 mL). After 2 hours, the reaction was concentrated in vacuo and the residue dissolved in acetonitrile. After addition of allyl iodide (3.0 mL), the mixture was stirred in the dark for 16 hours. The solids were filtered through a pad of celite and washed with chloroform. Concentration in vacuo and flash chromatography (40% EtOAc in hexane) gave 1.24 g (42%) of 2 as a light viscous 10 oil. 1 H NMR (300 MHz, CDCl 3 ): δ 6.75 (1H, m); 6.10-5.90 (1 H, m, -CH =, allyl); 5.40 to 5.15 (2H, m, = CH2, allyl); 4.47-4.43 (1 H, m); 4.30-4.15 (2H, mCH 2 -, allyl); 3.73 (3 H, s); 3.55-3.50 (1 H, m); 3.45-3.40 (1 H, m); 3.15-3.00 (1 H, dm, J =
19,5 Hz), 2,50-2,35 (1H, dm, J= 2,7, 19,5 Hz).19.5 Hz), 2.50-2.35 (1H, dm, J = 2.7, 19.5 Hz).
Příklad 3Example 3
Azidoalkohol 3: Epoxid 2 (1,17 g, 5,57 mmol), azid sodný (1,82 g) a chlorid amonný (658 mg) byly refluxovány v MeOH/H2O (8:1) (35 ml) po dobu 18 hodin. Reakce byla pak koncentrována in vacuo a zbytek rozdělen mezi etyléter a vodu. Organická vrstva byla promyta solankou a vysušena. Koncentrace in vacuo dala 3 jako světlý olej 1,3 g (92%), který byl použit bez dalšího čištění. *HNMR (300 MHz, CDC13): delta 6,95-6,85 (1H, m); 6,00-5,85 (1H, m, -CH=, allyl); 5,355,25 (2H, m, =CH2, alyl); 4,25-4,10 (2H, m, -CH2- alyl); 4,12 (1H, bt, J= 4,2 Hz); 3,95-3,75 (2H, m); 3,77 (3H, s); 2,85 (1H, dd, ./= 5,3, 18,3 Hz), 2,71 (1H, bs); 2,26 (1H, dd, J= 7,2,Azidoalcohol 3: Epoxy 2 (1.17 g, 5.57 mmol), sodium azide (1.82 g) and ammonium chloride (658 mg) were refluxed in MeOH / H 2 O (8: 1) (35 mL) after for 18 hours. The reaction was then concentrated in vacuo and the residue partitioned between ethyl ether and water. The organic layer was washed with brine and dried. Concentration in vacuo gave 3 as a light oil 1.3 g (92%), which was used without further purification. 1 H NMR (300 MHz, CDCl 3 ): δ 6.95-6.85 (1H, m); 6.00-5.85 (1 H, m, -CH =, allyl); 5355.25 (2H, m, = CH2, allyl); 4.25-4.10 (2H, m, -CH 2 - allyl); 4.12 (1H, bt, J = 4.2Hz); 3.95-3.75 (2 H, m); 3.77 (3 H, s); 2.85 (1H, dd, J = 5.3, 18.3 Hz), 2.71 (1H, bs); 2.26 (1 H, dd, J = 7.2,
18,3 Hz).18.3 Hz).
Příklad 4Example 4
Aziridin 4: Do roztoku alkoholu 3 (637 mg, 2,52 mmol) v CH2C12 (20 ml) ochlazeného na 0 °C byl přidán DMAP (několik krystalů) a trietylamin (442 μΐ). Dále byl přidán MsCl (287 μΐ) a reakce míchána při 0 °C po dobu 2 hodin. Byly odvedeny těkavé látky a zbytek rozdělen mezi etyléter a vodu.Aziridine 4: To a solution of alcohol 3 (637 mg, 2.52 mmol) in CH 2 Cl 2 (20 mL) cooled to 0 ° C was added DMAP (several crystals) and triethylamine (442 μ °). MsCl (287 μΐ) was added and the reaction stirred at 0 ° C for 2 hours. Volatiles were removed and the residue partitioned between ethyl ether and water.
Organická vrstva byla promyta nasyceným hydrogenuhličitanem, solankou a poté vysušena. Koncentrace in vacuo dala 881 mg surového mesylátu. 'Η NMR (300 MHz, CDC13): delta 6,876,84 (1H, s); 6,00-5,85 (1H, m, -CH=, alyl); 5,40-5,25 (2H, m=CH2, alyl); 4,72 (1H, dd, J= 3,9,The organic layer was washed with saturated bicarbonate, brine and then dried. Concentration in vacuo gave 881 mg of crude mesylate. 1 H NMR (300 MHz, CDCl 3 ): δ 6.876.84 (1H, s); 6.00-5.85 (1 H, m, -CH =, allyl); 5.40-5.25 (2H, m = CH2, allyl); 4.72 (1H, dd, J = 3.9,
-226CZ 297945 B6-226EN 297945 B6
8,5 Hz); 4,32 (1H, bt, J= 3,9 Hz); 4,30-4,15 (2H, m, -CH2- alyl); 3,77 (3H, s); 2,95 (1H, dd, J= 5,7,18,6 Hz); 2,38 (1H, dd, J= 6,7, 18,6 Hz).8.5 Hz); 4.32 (1H, bt, J = 3.9Hz); 4.30-4.15 (2H, m, -CH 2 - allyl); 3.77 (3 H, s); 2.95 (1H, dd, J = 5.7, 18.6 Hz); 2.38 (1H, dd, J = 6.7, 18.6 Hz).
Surový mesylát byl rozpuštěn v suchém THF (20 ml) a vystaven účinku Ph3P (727 mg). Po míchání při teplotě místnosti po dobu 3 hodin byla přidána voda (15 ml) a pevný NaHCO3 (1,35 g) a směs byla míchána přes noc při teplotě místnosti. Reakce pak byla koncentrována in vacuo a zbytek rozdělen mezi EtOAc, nasycený hydrogenuhliěitan a solanku. Organická vrstva byla oddělena a vysušena pomocí MgSO4. Koncentrace in vacuo a mžiková chromatografíe zbytku dala aziridin 4 170 mg (33 %) jako světle žlutý olej. H NMR (300 MHz, CDC13): delta 6,826,80 (1H, m); 6,04-5,85 (1H, m, -CH=, allyl); 5,35-5,20 (2H, m, =CH2, alyl); 4,39 (1H bd, 7=2,4 Hz); 4,20-4,05 (2H, m, -CH2-alyl); 3,73 (3H, s); 2,90-2,80 (1H, bd, 7=18,9 Hz); 2,65-2,40 (2H, m).The crude mesylate was dissolved in dry THF (20 mL) and exposed to Ph 3 P (727 mg). After stirring at room temperature for 3 hours, water (15 mL) and solid NaHCO 3 (1.35 g) were added and the mixture was stirred overnight at room temperature. The reaction was then concentrated in vacuo and the residue partitioned between EtOAc, saturated bicarbonate and brine. The organic layer was separated and dried over MgSO 4 . Concentration in vacuo and flash chromatography of the residue gave aziridine 4170 mg (33%) as a pale yellow oil. 1 H NMR (300 MHz, CDCl 3 ): δ 6.826.80 (1H, m); 6.04-5.85 (1 H, m, -CH =, allyl); 5.35 to 5.20 (2H, m, = CH2, allyl); 4.39 (1H bd, J = 2.4 Hz); 4.20-4.05 (2H, m, -CH 2 -alyl); 3.73 (3 H, s); 2.90-2.80 (1H, bd, J = 18.9 Hz); 2.65-2.40 (2 H, m).
Příklad 5Example 5
N-acetylaziridin 5: Aziridin 4 (170 mg, 0,814 mmol) byl rozpuštěn v CH2C12 (2 ml) a pyridinu (4 ml) a ochlazen na 0 °C. Poté byl přidán acetylchlorid (87 μΐ) a reakce míchána při 0 °C po dobu 1 hodiny. Těkavé látky byly odstraněny in vacuo a zbytek rozdělen mezi etyléter, nasycený hydrouhličitan a solanku. Organická vrstva byla oddělena a vysušena pomocí MgSO4. Koncentrace dala surové 196 mg (96%), které byl použit bez dalšího čištění. 'HNMR (300 MHz, CDC13): delta 6,88-6,86 (1H, 20 m); 6,00-5,85 (1H, m, -CH=, alyl); 5,40-5,20 (2H, m, =CH2, alyl); 4,45-4,40 (1H, m); 4,16 (2H, d, 7=6,0 Hz, -CH2- alyl); 3,76 (3H, s); 3,00-2,95 (2H, m), 2,65 (1H, bd, 7=18,5 Hz); 2,14 (3H, s).N-Acetylaziridine 5: Aziridine 4 (170 mg, 0.814 mmol) was dissolved in CH 2 Cl 2 (2 mL) and pyridine (4 mL) and cooled to 0 ° C. Acetyl chloride (87 μΐ) was then added and the reaction stirred at 0 ° C for 1 hour. The volatiles were removed in vacuo and the residue partitioned between ethyl ether, saturated bicarbonate and brine. The organic layer was separated and dried over MgSO 4 . Concentration gave crude 196 mg (96%) which was used without further purification. 1 H NMR (300 MHz, CDCl 3 ): δ 6.88-6.86 (1H, 20 m); 6.00-5.85 (1 H, m, -CH =, allyl); 5.40-5.20 (2H, m, = CH2, allyl); 4.45-4.40 (1 H, m); 4.16 (2H, d, 7 = 6.0 Hz, -CH 2 - allyl); 3.76 (3 H, s); 3.00-2.95 (2H, m), 2.65 (1H, bd, J = 18.5 Hz); 2.14 (3 H, s).
Příklad 6Example 6
Azidoalyléter 6: Aziridin 5 (219 mg, 0,873 mmol), azid sodný (426 mg) a chlorid amonný (444 mg) v suchém DMF (7 ml) se přes noc zahřívaly při 65 °C pod argonem. Reakce byla nalita do nasyceného hydrouhličitanu/solanky a několikrát extrahována etyléterem. Sloučené éterové vrstvy byly promyty solankou a vysušeny. Koncentrace a po ní mžiková chromatografíe (pouze EtOAc) daly azidoamin 77 mg (35%), který byl rozpuštěn vCH2C12 (1 ml) a pyridinu (1 ml) a ochlazen na 0 °C. Byl přidán acetylchlorid (38 μΐ) a po 45 minutách byl přidán pevný NaHCO3 a těkavé látky odstraněny při vakuu. Zbytek byl rozdělen mezi EtOAc a solanku. Organická vrstva byla vysušena pomocí MgSO4 a koncentrována in vacuo. Mžiková chromatografíe (pouze EtOAc) dala 690 mg (99 %). Ή NMR (500 MHz, CDC13): delta 6,86 (1H, bt, 7=2,2 Hz); 5,955,82 (1H, m, CH=, alyl); 5,68 (1H, bd, 7=7,3 Hz); 5,35-5,20 (2H, m, =CH2, alyl); 4,58^1,52 (1H, m); 4,22-4,10 (2H, m); 4,04 (1H, dd, 7=5,9, 11,5 Hz); 3,77 (3H, s); 3,54-3,52 (1H, m); 2,89 (1H, dd, 7=5,9, 17,6 Hz); 2,32-2,22 (1H, m); 2,06 (3H, s).Azidoalylether 6: Aziridine 5 (219 mg, 0.873 mmol), sodium azide (426 mg) and ammonium chloride (444 mg) in dry DMF (7 mL) were heated at 65 ° C under argon overnight. The reaction was poured into saturated bicarbonate / brine and extracted several times with ethyl ether. The combined ether layers were washed with brine and dried. Concentration followed by flash chromatography (EtOAc only) gave azidoamine 77 mg (35%) which was dissolved in CH 2 Cl 2 (1 mL) and pyridine (1 mL) and cooled to 0 ° C. Acetyl chloride (38 μΐ) was added and after 45 minutes solid NaHCO 3 was added and the volatiles removed under vacuum. The residue was partitioned between EtOAc and brine. The organic layer was dried over MgSO 4 and concentrated in vacuo. Flash chromatography (EtOAc only) gave 690 mg (99%). Ή NMR (500 MHz, CDCl 3 ): δ 6.86 (1H, bt, J = 2.2 Hz); 5,955.82 (1H, m, CH = allyl); 5.68 (1H, bd, J = 7.3 Hz); 5.35 to 5.20 (2H, m, = CH2, allyl); 4.58- 1.52 (1H, m); 4.22-4.10 (2 H, m); 4.04 (1H, dd, J = 5.9, 11.5 Hz); 3.77 (3 H, s); 3.54-3.52 (1 H, m); 2.89 (1H, dd, J = 5.9, 17.6 Hz); 2.32-2.22 (1 H, m); 2.06 (3 H, s).
Příklad 7Example 7
Azidodiol 7: Do roztoku olefinů 6 (90 mg, 0,306 mmol) v acetonu (3 ml) a vodě (258 μΐ) byl přidán N-metylmorfolin-N-oxid (39 mg) a OsO4 (73 μΐ 2,5% v/v v /-butanolu). Reakce se pak míchala 3 dny při teplotě místnosti. Byl přidán pevný hydrosiřičitan a po 20 minutách míchání byla reakce přefiltrována přes celitový list a promyta značným množstvím acetonu. Koncentrace in vacuo a poté mžiková chromatografíe (10% MeOH v CH2C12) dala diol 7 50 mg (50%). ’HNMR (300 MHz, CD3CN): delta 6,80-6,70 (1H, m); 4,20-4,15 (1H, bm); 3,95-3,80 (1H, m); 3,80-3,25 (6H, m); 3,70 (3H, s); 3,10 (1H, bs), 2,85 (1H, bs), 2,85-2,75 (1H, m); 2,30-2,15 (1H, m); 2,16 (1H, bs); 1,92 (3H, s).Azidodiol 7: To a solution of olefins 6 (90 mg, 0.306 mmol) in acetone (3 mL) and water (258 μΐ) was added N-methylmorpholine N-oxide (39 mg) and OsO 4 (73 μΐ 2.5% v). (vv) -butanol). The reaction was then stirred at room temperature for 3 days. Solid bisulfite was added and after stirring for 20 minutes, the reaction was filtered through a pad of celite and washed with a considerable amount of acetone. Concentration in vacuo followed by flash chromatography (10% MeOH in CH 2 Cl 2 ) gave diol 7 50 mg (50%). 1 H NMR (300 MHz, CD 3 CN): δ 6.80-6.70 (1H, m); 4.20-4.15 (1 H, bm); 3.95-3.80 (1 H, m); 3.80-3.25 (6 H, m); 3.70 (3 H, s); 3.10 (1H, bs), 2.85 (1H, bs), 2.85-2.75 (1H, m); 2.30-2.15 (1 H, m); 2.16 (1 H, bs); 1.92 (3 H, s).
-227CZ 297945 B6-227EN 297945 B6
Příklad 8Example 8
Diol aminokyseliny 8: Roztok diolu 7 (23 mg, 0,07 mmol) v THF (1 ml) byl vystaven vod. KOH (223 μΐ, z roztoku 0,40 M) při teplotě místnosti. Po míchání po dobu 1,5 hod byla reakce acidifikována na pH=4 pomocí iontoměničové pryskyřice Alberlite IR-120 (plus). Pryskyřice byla filtrována a promyta MeOH. Koncentrace in vacuo dala surovou kyselinu karboxylovou, která byla rozpuštěna v etanolu (1,5 ml). Do tohoto roztoku byl přidán Lindlarův katalyzátor (20 mg) a reakce byla míchána přes vodíkovou atmosféru (1 tm přes baňku) po dobu 20 hodin. Reakční směs byla filtrována přes celitový list a vymyta horkým etanolem a vodou. Etanol byla odstraněn při vakuu a výsledná vodná vrstva lyofilizována tak, že vznikla směs požadované aminokyseliny 8 a výchozího azidu 7 jako bílý prášek. Sloučenina 8: 'H NMR (500 MHz, D2O): delta 6,5 (1H, s); 4,24-4,30 (2H, m); 4,25-4,18 (1H, m); 3,90-3,55 (5H, komplexní m); 2,96-2,90 (1H, m); 2,58-2,50 (1H, komplexní m); 2,12 (3H, s).Amino Acid Diol 8: A solution of diol 7 (23 mg, 0.07 mmol) in THF (1 mL) was treated with aq. KOH (223 μΐ, from 0,40 M solution) at room temperature. After stirring for 1.5 hours, the reaction was acidified to pH = 4 with Alberlite IR-120 (plus) ion exchange resin. The resin was filtered and washed with MeOH. Concentration in vacuo gave the crude carboxylic acid, which was dissolved in ethanol (1.5 mL). To this solution was added Lindlar's catalyst (20 mg) and the reaction was stirred under a hydrogen atmosphere (1 µm through a flask) for 20 hours. The reaction mixture was filtered through a celite pad and washed with hot ethanol and water. The ethanol was removed in vacuo and the resulting aqueous layer lyophilized to give a mixture of the desired amino acid 8 and the starting azide 7 as a white powder. Compound 8: 1 H NMR (500 MHz, D 2 O): δ 6.5 (1H, s); 4.24-4.30 (2 H, m); 4.25-4.18 (1 H, m); 3.90-3.55 (5H, complex m); 2.96-2.90 (1 H, m); 2.58-2.50 (1H, complex m); 2.12 (3 H, s).
Příklad 9Example 9
Sloučenina 62: Suspenze chinové kyseliny (60 g), cyklohexanonu (160 ml) a kyseliny toluensulfonové (600 mg) v benzenu (450 ml) byla refluxována Dean-Starkovým efektem po dobu 14 hodin. Reakční směs byla ochlazena na teplotu místnosti a nalita do nasyceného roztoku NaHCO3 (150 ml). Vodná vrstva byla extrahována pomocí CH2C12 (3x). Spojené organické vrstvy byly promývány vodou (2x), solankou (lx) a vysušeny přes Na2SO4. Koncentrace dala bílenou pevnou látku, která byla rekrystalizována z éteru (75 g, 95%): ’H NMR (CDC13) delta 4,T3 (dd, J = 6,1, 2,5 Hz, 1H), 4,74 (ddd, J = 7,0, 7,0, 3,0 Hz, 1H), 4,30 (ddd, J = 5,4, 2,6, 1,4 Hz, 1H), 2,96 (s, 1H), 2,66 (d, J = 11,7 Hz, 1H), 2,40-2,15 (m, 3H), 1,72-1,40 (m, 10 H).Compound 62: A suspension of quinic acid (60 g), cyclohexanone (160 mL) and toluenesulfonic acid (600 mg) in benzene (450 mL) was refluxed with Dean-Stark effect for 14 hours. The reaction mixture was cooled to room temperature and poured into saturated NaHCO 3 solution (150 mL). The aqueous layer was extracted with CH 2 Cl 2 (3x). The combined organic layers were washed with water (2x), brine (1x) and dried over Na 2 SO 4 . Concentration gave a white solid which was recrystallized from ether (75 g, 95%): 1 H NMR (CDCl 3 ) δ4, T3 (dd, J = 6.1, 2.5 Hz, 1H), 4.74 (ddd, J = 7.0, 7.0, 3.0 Hz, 1H), 4.30 (ddd, J = 5.4, 2.6, 1.4 Hz, 1H), 2.96 (s 1 H, 2.66 (d, J = 11.7 Hz, 1 H), 2.40-2.15 (m, 3H), 1.72-1.40 (m, 10 H).
Příklad 10Example 10
Sloučenina 63: Do roztoku laktonu 62 (12,7 g, 50 mmol) v metanolu (300 ml) byl přidán metoxid sodný (2,7 g, 50 mmol) v jedné dávce. Směs byla míchána při teplotě místnosti po dobu 3 hodin, a rychle zchlazena kyselinou octovou (3 ml) a míchána 10 minut. Směs byla nalita do nasyceného roztoku NH4C1 (300 ml) a extrahována CH2C12 (3x). Složená organická fáze byla promyta solankou (lx) a vysušena přes MgSO4. Čištění mžikovou sloupcovou chromatografií (hexan/EtOAc = 1/1 k 1/2) dala diol (11,5 g, 80%) a výchozí materiál (1,2 g, 10%): Ή NMR (CDC13) delta 4,47 (ddd, J = 7,4, 5,8 3,5 Hz, 1H), 4,11 (m, 1H), 3,98 (m, 1H), 15 3,81 (s, 3H), 3,45 (s, 1H), 2,47 (d, J = 3,3 Hz, 1H), 2,27 (m, 2H), 2,10 (dd, J = 11,8, 4,3 Hz, 1H), 1,92-1,26 (m, 10H).Compound 63: To a solution of lactone 62 (12.7 g, 50 mmol) in methanol (300 mL) was added sodium methoxide (2.7 g, 50 mmol) in one portion. The mixture was stirred at room temperature for 3 hours, and quenched with acetic acid (3 mL) and stirred for 10 minutes. The mixture was poured into saturated NH 4 Cl solution (300 mL) and extracted with CH 2 Cl 2 (3x). The combined organic phase was washed with brine (1x) and dried over MgSO 4 . Purification by flash column chromatography (hexane / EtOAc = 1/1 to 1/2) gave the diol (11.5 g, 80%) and the starting material (1.2 g, 10%): Ή NMR (CDCl 3 ) δ 4, 47 (ddd, J = 7.4, 5.8 3.5 Hz, 1H), 4.11 (m, 1H), 3.98 (m, 1H), 15 3.81 (s, 3H), 3 .45 (s, 1H), 2.47 (d, J = 3.3 Hz, 1H), 2.27 (m, 2H), 2.10 (dd, J = 11.8, 4.3 Hz, 1H), 1.92-1.26 (m, 10H).
Příklad 11Example 11
Sloučenina 64: Do směsi diolu 63 (1,100 g, 3,9 mmol), molekulových sít (3 A, 2,2 g) a pyridinu (1,1 g) v CH2C12 (15 ml) byl přidán PCC (3,3 g, 15,6 mmol) v jedné dávce. Směs byla míchána při teplotě místnosti po dobu 26 hodin, a naředěna éterem (30 ml). Suspenze byla filtrována celitovým listem a vymývána éterem (2x20 ml). Sloučený éter byl vymýván solankou (2x) a vysušen přes MgSO4. Koncentrace a čištění bylo mžikovou sloupcovou chromatografií (hexan/EtOAc = 3/1) a vznikl keton (0,690 g, 67%): ’H NMR (CDC13) delta 6,84 (d, J = 2,8 Hz, 1H), 4,69 (ddd, J = 6,4, 4,9, 1,6 Hz, 1 H), 4,30 (d, J = 5,0 Hz, 1H), 3,86 (s, 3H), 3,45 (d, J = 22,3 Hz, 1H), 2,86 (m, 1H), 1,69-1,34 (m, 10H).Compound 64: To a mixture of diol 63 (1.100 g, 3.9 mmol), molecular sieves (3 A, 2.2 g) and pyridine (1.1 g) in CH 2 Cl 2 (15 mL) was added PCC (3 mL). (3 g, 15.6 mmol) in one portion. The mixture was stirred at room temperature for 26 hours, and diluted with ether (30 mL). The suspension was filtered through a celite pad and eluted with ether (2 x 20 mL). The combined ether was washed with brine (2x) and dried over MgSO 4 . Concentration and purification was by flash column chromatography (hexane / EtOAc = 3/1) to give the ketone (0.690 g, 67%): 1 H NMR (CDCl 3 ) δ 6.84 (d, J = 2.8 Hz, 1H) 4.69 (ddd, J = 6.4, 4.9, 1.6 Hz, 1H), 4.30 (d, J = 5.0 Hz, 1H), 3.86 (s, 3H) 3.45 (d, J = 22.3 Hz, 1 H), 2.86 (m, 1 H), 1.69-1.34 (m, 10 H).
Příklad 12Example 12
Sloučenina 28: Do roztoku ketonu 64 (0,630 g, 2,4 mmol) v MeOH (12 ml) při teplotě 0 °C byl přidán NaBH4 ve 30 minutách. Směs byla míchána další 1,5 hodiny při 0 °C a rychle zchlazenaCompound 28: To a solution of ketone 64 (0.630 g, 2.4 mmol) in MeOH (12 mL) at 0 ° C was added NaBH 4 over 30 minutes. The mixture was stirred for an additional 1.5 hours at 0 ° C and quenched rapidly
-228CZ 297945 B6 ml nasyceného roztoku NH4CI. Roztok byl extrahován CH2CI2 (3x) a složený organický extrakt byl vysušen přes MgSO4. Čištěním mžikovou sloupcovou chromatografií (hexan/EtOAc = 2/1) vznikl alkohol (0,614 g, 97%): Ή NMR (CDC13) delta 6,94 (d, J = 0,5 Hz, IH), 4,64 (ddd, J = 9,8, 6,7, 3,2 Hz, IH), 4,55 (dd, J = 7,1, 4,2 Hz, IH), 4,06 (m, IH), 3,77 (s, 3H), 3,04 (dd, J =B28 mL of saturated NH 4 Cl solution. The solution was extracted with CH 2 Cl 2 (3x) and the combined organic extract was dried over MgSO 4 . Purification by flash column chromatography (hexane / EtOAc = 2/1) gave the alcohol (0.614 g, 97%): Ή NMR (CDCl 3 ) δ 6.94 (d, J = 0.5 Hz, 1H), 4.64 ( ddd, J = 9.8, 6.7, 3.2 Hz, 1H), 4.55 (dd, J = 7.1, 4.2 Hz, IH), 4.06 (m, 1H), 3 77 (s, 3H), 3.04 (dd, J =
16,5 Hz, IH), 2,73 (d, J = 10,2 Hz, IH), 1,94 (m, IH), 1,65-1,29 (m, 10H).16.5 Hz, 1H), 2.73 (d, J = 10.2 Hz, 1H), 1.94 (m, 1H), 1.65-1.29 (m, 10H).
Příklad 13Example 13
Sloučenina 66: Alkohol 28 (2,93 g, 10,9 mmol) a kyselina toluensulfonová (1,5 g) byly rozpuštěny v acetonu (75 ml) a směs byla míchána při teplotě místnosti po dobu 15 hodin. Tato reakce byla rychle zchlazena vodou (30 ml) a bazifíkována koncentrovaným NH3H2O až k dosažení pH = 9. Aceton byl odstraněn pod sníženým tlakem, extrakty byly vymývány solankou (lx) a vysušeny přes Na2SO4. Koncentrace přinesla požadovaný produkt: 'H NMR (CDC13) delta 7,01 (m, IH), 4,73 (m, IH), 4,42 (m, IH), 3,97 (m, IH), 3,76 (s, 3H), 2,71-2,27 (m, 2H), 2,02 (s, 3H), 1,98 (s,3H).Compound 66: Alcohol 28 (2.93 g, 10.9 mmol) and toluenesulfonic acid (1.5 g) were dissolved in acetone (75 mL) and the mixture was stirred at room temperature for 15 hours. This reaction was quenched with water (30 mL) and basified with concentrated NH 3 H 2 O until pH = 9. Acetone was removed under reduced pressure, the extracts were washed with brine (1x) and dried over Na 2 SO 4 . Concentration yielded the desired product: 1 H NMR (CDCl 3 ) δ 7.01 (m, 1H), 4.73 (m, 1H), 4.42 (m, 1H), 3.97 (m, 1H), 3 76 (s, 3H), 2.71-2.27 (m, 2H), 2.02 (s, 3H), 1.98 (s, 3H).
Příklad 14Example 14
Sloučenina 67: Do roztoku alkoholu 66 (10,9 mmol) v CH2C12 (60 ml) při teplotě 0°C byl přidán pyridin (4,4 ml, 54,5 mmol) a poté přidán trimetylacetylchlorid (2,7 ml, 21,8 mmol). Směs byla zahřáta na teplotu místnosti a míchána po dobu 14 hodin. Směs byla naředěna CH2C12, a vymývána vodou (2x), solankou (lx) a vysušena přes MgSO4. Čištění mžikovou sloupcovou chromatografií (hexan/EtOAc = 9/1) dalo diester (2,320 g, 68%): 'H NMR (CDC13) delta 6,72 (m, IH), 5,04 (m, IH), 4,76 (m, IH), 4,40 (m, IH), 3,77 (s, 3H), 2,72-2,49 (m, 2H), 1,37 (sm, 3H), 1,35 (s, 3H), 1,23 (s, 9H).Compound 67: To a solution of alcohol 66 (10.9 mmol) in CH 2 Cl 2 (60 mL) at 0 ° C was added pyridine (4.4 mL, 54.5 mmol) then trimethylacetyl chloride (2.7 mL). , 21.8 mmol). The mixture was warmed to room temperature and stirred for 14 hours. The mixture was diluted with CH 2 Cl 2 , and eluted with water (2x), brine (1x) and dried over MgSO 4 . Purification by flash column chromatography (hexane / EtOAc = 9/1) gave the diester (2.320 g, 68%): 1 H NMR (CDCl 3 ) δ 6.72 (m, 1H), 5.04 (m, IH), 4 76 (m, 1H); 4.40 (m, 1H); 3.77 (s, 3H); 2.72-2.49 (m, 2H); 1.37 (sm, 3H); 35 (s, 3H), 1.23 (s, 9H).
Příklad 15Example 15
Sloučenina 68: Diester 67 (2,32 g, 2,3 mmol) byl rozpuštěn v acetonu/H2O (1/1, 100 ml) a zahříván při 55 °C po dobu 16 hodin. Ředidla byla odstraněna, přidána voda (2 x 50 ml) a odpařována. Koncentrace s toluenem (2 x 50 ml) dala diol, který byl použit bez dalšího čištění: ’H NMR (CDC13) delta 6,83 (m, IH), 5,06 (m, IH), 4,42 (m, IH), 4,09 (m, IH), 3,77 (s, 3H), 2,68-2,41 (m, 2H), 1,22 (s, 9H).Compound 68: Diester 67 (2.32 g, 2.3 mmol) was dissolved in acetone / H 2 O (1/1, 100 mL) and heated at 55 ° C for 16 hours. The diluents were removed, water (2 x 50 mL) was added and evaporated. Concentration with toluene (2 x 50 mL) gave the diol which was used without further purification: 1 H NMR (CDCl 3 ) δ 6.83 (m, 1H), 5.06 (m, 1H), 4.42 (m 1 H, 4.09 (m, 1H), 3.77 (s, 3H), 2.68-2.41 (m, 2H), 1.22 (s, 9H).
Příklad 16Example 16
Sloučenina 69: Do roztoku diolu 68 (0,410 g, 1,5 mmol) v THF (8 ml) při 0 °C byl přidán trietylamin (0,83 ml, 6,0 mmol), následovalo pomalé přidávání thionylchloridu (0,33 ml, 4,5 mmol). Směs byla zahřáta na teplotu místnosti a míchána po dobu 3 hodin. Směs byla naředěna CHC13 apromývána vodou (3x), solankou (lx), a vysušena přes MgSO4. Čištění mžikovou sloupcovou chromatografií (hexaby/EtOAc = 5/1) dalo exo/endo směs (0,430 g, 90%): *HNMR (CDC13) delta 6,89-6,85 (m, 1 H), 5,48-4,48 (m, 3 H), 3,80, 3,78 (s, 3 H), 2,90-2,60 (m, 2 H), 1,25, 1,19 (s,9H).Compound 69: To a solution of diol 68 (0.410 g, 1.5 mmol) in THF (8 mL) at 0 ° C was added triethylamine (0.83 mL, 6.0 mmol), followed by slow addition of thionyl chloride (0.33 mL) , 4.5 mmol). The mixture was warmed to room temperature and stirred for 3 hours. The mixture was diluted with CHCl 3 and washed with water (3x), brine (1x), and dried over MgSO 4 . Purification by flash column chromatography (hexaby / EtOAc = 5/1) gave an exo / endo mixture (0.430 g, 90%): 1 H NMR (CDCl 3 ) δ 6.89-6.85 (m, 1H), 5.48 -4.48 (m, 3H), 3.80, 3.78 (s, 3H), 2.90-2.60 (m, 2H), 1.25, 1.19 (s, 9H) ).
Příklad 17Example 17
Sloučenina 70: Směs sulfonu 69 (0,400 g, 1,3 mmol) a azidu sodného (0,410 g, 6,29 mmol) v DMF (10 ml) byla míchána po dobu 20 hodin. Reakční směs byla pak naředěna etylacetátem, vymyta nasyceným roztokem NH4CI, vodou, solankou, a vysušena přes MgSO4. KoncentraceCompound 70: A mixture of sulfone 69 (0.400 g, 1.3 mmol) and sodium azide (0.410 g, 6.29 mmol) in DMF (10 mL) was stirred for 20 hours. The reaction mixture was then diluted with ethyl acetate, washed with saturated NH 4 Cl solution, water, brine, and dried over MgSO 4 . Concentration
-229CZ 297945 B6 dala azid (0,338 g, 90%): ‘HNMR (CDC13) delta 6,78 (m, 1H), 5,32 (m, 1H), 5,32 (m, 1H), 4,20 (m, 1H), 3,89 (m, 1H), 3,78 (s, 3 H), 3,00-2,60 (m, 2 H), 1,21 (s, 9 H).-229EN 297945 B6 gave azide (0.338 g, 90%): 1 H NMR (CDCl 3 ) δ 6.78 (m, 1H), 5.32 (m, 1H), 5.32 (m, 1H), 4, 20 (m, 1H), 3.89 (m, 1H), 3.78 (s, 3H), 3.00-2.60 (m, 2H), 1.21 (s, 9H).
Příklad 18Example 18
Sloučenina 71: K roztoku alkoholu 70 (0,338 g, 1,1 mmol) v CH2C12 (11 ml) při 0 °C byl přidán trietylamin (0,4 ml, 2,9 mmol), poté pomalu přidáván chlorid metylsulfonový (0,18 ml,Compound 71: To a solution of alcohol 70 (0.338 g, 1.1 mmol) in CH 2 Cl 2 (11 mL) at 0 ° C was added triethylamine (0.4 mL, 2.9 mmol) then slowly added methylsulfonic chloride ( 0,18 ml,
2.3 mmol). Směs byla míchána při teplotě 0 °C po dobu 30 minut, a naředěna CH2C12. Organická vrstva byla promývána vodou (2x), solankou, a vysušena přes MgSO4. Čištění mžikovou sloupcovou chromatografíi (hexan(EtOAc = 3/1) dalo požadovanou sloučeninu (0,380 g, 82%): ]H NMR (CDC13) delta 6,82 (m, 1H), 5,44 (Μ, 1H), 4,76 (dd, J = 7,3, 1,4 Hz, 1H), 4,48 (m, 1H), 3,80 (s, 20 3 H), 3,1 (s, 3 H), 2,82-2,61 (m, 2H), 1,21 (s, 9 H).2.3 mmol). The mixture was stirred at 0 ° C for 30 minutes, and diluted with CH 2 Cl 2 . The organic layer was washed with water (2x), brine, and dried over MgSO 4 . Purification by flash column chromatography (hexane (EtOAc = 3/1) gave the desired compound (0.380 g, 82%): 1 H NMR (CDCl 3 ) δ 6.82 (m, 1H), 5.44 (Μ, 1H), 4.76 (dd, J = 7.3, 1.4 Hz, 1H), 4.48 (m, 1H), 3.80 (s, 20H), 3.1 (s, 3H), 2.82-2.61 (m, 2H), 1.21 (s, 9H).
Příklad 19Example 19
Sloučenina 72: Směs azidu 71 (0,380 g, 0,94 mmol) a trifenylfosfínu (0,271 g, 1,04 mmol) v THF (19 ml) byla míchána po dobu 2 hodin. Reakce byla rychle zchlazena vodou (1,9 ml) atrietylaminem (0,39 ml, 2,82 mmol), a směs byla míchána po dobu 14 hodin. Rozpouštědla byla odstraněna pod sníženým tlakem, a směs byla použita pro další krok. Do roztoku výše uvedené směsi v CH2C12 (20 ml) při teplotě 0 °C byl přidán pyridin (0,68 ml, 8,4 mmol), poté pomalu přidáván acetylchlorid (0,30 ml, 4,2 mmol). Směs byla míchána při teplotě 0 °C po dobu 5 minut a naředěna etylacetátem. Směs byla promývána vodou (2x), solankou (lx), vysušena přes MgSO4. Čištění mřížkovou sloupcovou chromatografíi (hexany/EtOAc = 3/1) dalo aziridin (0,205 g, 83%): 'H NMR (CDC13) delta 7,19 (m, 1 H), 5,59 (m, 1H), 3,77 (s, 3 H), 3,14 (m, 2 H), 2,85 (dd, J = 7,0, 1,6 Hz, 1 H), 2,34 (m, 1 H), 2,16 (s, 3 H), 1,14 (s, 9 H).Compound 72: A mixture of azide 71 (0.380 g, 0.94 mmol) and triphenylphosphine (0.271 g, 1.04 mmol) in THF (19 mL) was stirred for 2 hours. The reaction was quenched with water (1.9 mL) atrietylamine (0.39 mL, 2.82 mmol), and the mixture was stirred for 14 hours. The solvents were removed under reduced pressure, and the mixture was used for the next step. To a solution of the above mixture in CH 2 Cl 2 (20 mL) at 0 ° C was added pyridine (0.68 mL, 8.4 mmol), then acetyl chloride (0.30 mL, 4.2 mmol) was added slowly. The mixture was stirred at 0 ° C for 5 minutes and diluted with ethyl acetate. The mixture was washed with water (2x), brine (1x), dried over MgSO 4 . Purification by column chromatography (hexanes / EtOAc = 3/1) gave aziridine (0.205 g, 83%): 1 H NMR (CDCl 3 ) δ 7.19 (m, 1H), 5.59 (m, 1H), 3.77 (s, 3H), 3.14 (m, 2H), 2.85 (dd, J = 7.0, 1.6 Hz, 1H), 2.34 (m, 1H) , 2.16 (s, 3H), 1.14 (s, 9H).
Příklad 20Example 20
Sloučenina 73: Směs aziridinu 72 (0,200 g, 0,68 mmol), azidu sodného (0,221 g, 3,4 mmol) a chloridu amonného (0,146 g, 2,7 5 mmol) v DMF (10 ml) byla míchána při teplotě místnosti po dobu 14 hodin. Pak byla směs naředěna etylacetátem a vymývána vodou (5x), solankou (lx), a vysušena přes MgSO4. Čištění mžikovou sloupcovou chromatografíi (hexany/EtOAc = 2/1) dalo požadovaný produkt a deacetylamin (0,139 g). Směs byla rozpuštěna v acetanhydridu (2 ml), a míchána po dobu 2 hodin. Přebytečný anhydrid byl odstraněn pod sníženým tlakem a vznikl požadovaný produkt (149 mg): 'HNMR (CDC13) delta 6,76 (m, 1 H), 5,53 (d, J =Compound 73: A mixture of aziridine 72 (0.200 g, 0.68 mmol), sodium azide (0.221 g, 3.4 mmol) and ammonium chloride (0.146 g, 2.7 5 mmol) in DMF (10 mL) was stirred at temperature room for 14 hours. Then the mixture was diluted with ethyl acetate and washed with water (5x), brine (1x), and dried over MgSO 4 . Purification by flash column chromatography (hexanes / EtOAc = 2/1) gave the desired product and deacetylamine (0.139 g). The mixture was dissolved in acetic anhydride (2 mL), and stirred for 2 hours. Excess anhydride was removed under reduced pressure to give the desired product (149 mg): 1 H NMR (CDCl 3 ) δ 6.76 (m, 1H), 5.53 (d, J =
8,5 Hz, 1 H), 5,05 (m, 1 H), 4,31 (m, 1 H), 4,08 (m, 1H), 3,79 (s, 3 H), 2,91 (m, 1 H), 2,51 (m, 1 H), 1,99 (s, 3 H), 1,20 (s, 9 H).8.5 Hz, 1H), 5.05 (m, 1H), 4.31 (m, 1H), 4.08 (m, 1H), 3.79 (s, 3H), 2, 91 (m, 1H), 2.51 (m, 1H), 1.99 (s, 3H), 1.20 (s, 9H).
Příklad 21Example 21
Sloučenina 74: Roztok hydroxidu draselného v MeOH/H2O (0,5 M, 4,4 ml, 2,2 mmol) byl přidán k esteru 73 (149 mg, 0,44 mmol) a směs byla míchána při teplotě místnosti po 3 hodiny. Směs byla ochlazena na 0 °C, a okyselena Amberlitem (kyselý) na pH = 3-4. Směs byla přefiltrována a vymyta MeOH. Koncentrace dala kyselinu karboxylovou jako bílou pevnou látku (73 mg, 69%): ’HNMR (CD3OD) δ 6,62 (m, 1 H), 4,15 (m, 1 H), 3,95-3,72 (m, 2 H), 2,84 (dd, J = 6,7,Compound 74: A solution of potassium hydroxide in MeOH / H 2 O (0.5 M, 4.4 mL, 2.2 mmol) was added to ester 73 (149 mg, 0.44 mmol) and the mixture was stirred at room temperature for 3 hours. The mixture was cooled to 0 ° C, and acidified with Amberlite (acidic) to pH = 3-4. The mixture was filtered and washed with MeOH. Concentration gave the carboxylic acid as a white solid (73 mg, 69%): 1 H NMR (CD 3 OD) δ 6.62 (m, 1H), 4.15 (m, 1H), 3.95-3, 72 (m, 2H), 2.84 (dd, J = 6.7,
1.4 Hz, 1H), 2,23 (m, 1 H), 1,99 (s, 3 H).1.4 Hz, 1H), 2.23 (m, 1H), 1.99 (s, 3H).
-230CZ 297945 B6-230GB 297945 B6
Příklad 22Example 22
Sloučenina 75: Směs azidu 74 (8 mg, a Pd-C (Lindlar) (15 mg) v etanolu (2 ml) byla míchána pod vodíkem po dobu 16 hodin. Směs byla přefiltrována přes celit, vymyta horkým MeOH-H2O (1/1) Koncentrace dala pevnou látku. Pevná látka byla rozpuštěna ve vodě a prohnána krátkou kolonou C-8, a promyta vodou. Koncentrace dala bílou pevnou látku (6 mg): ]H NMR (D2O) δ 6,28 (m, 1H), 4,06-3,85 (m, 3H), 2,83 (dd, J = 17,7, 5,4 Hz, 1 H), 2,35 (m, 1 H), 2,06 (s, 3H).Compound 75: A mixture of azide 74 (8 mg, and Pd-C (Lindlar) (15 mg) in ethanol (2 mL) was stirred under hydrogen for 16 h.) The mixture was filtered through celite, washed with hot MeOH-H 2 O ( 1/1) Concentration gave a solid The solid was dissolved in water and passed through a short column of C-8, and washed with water The concentration gave a white solid (6 mg): 1 H NMR (D 2 O) δ 6.28 ( m, 1H), 4.06-3.85 (m, 3H), 2.83 (dd, J = 17.7, 5.4 Hz, 1H), 2.35 (m, 1H), 2 06 (s, 3H).
Příklad 23Example 23
Sloučenina 76: kyselina karboxylová 74 (68 mg, 0,28 mmol) a difenyldiazometan (61 mg, 0,31 mmol) byly rozpuštěny v etanolu (12 ml), a míchány po dobu 16 hodin. Reakce byla rychle zchlazena kyselinou octovou (0,5 ml) a směs byla míchána po dobu 10 minut. Rozpouštědla byla odstraněna při sníženém tlaku. Čištění mžikovou sloupcovou chromatografií (EtOAc) dalo ester (56 mg, 50%): *H NMR (CDC13OD) δ 7,36-7,23 (m, 10 H), 6,88 (s, 1H), 6,76 (s, 1 H), 4,21 (m, 1H), 3,93-3,79 (m, 2 H), 2,89 (dd, J = 17,7, 5,0 Hz, 1 H), 2,34 (m, 1 H), 2,00 (s, 3 H).Compound 76: carboxylic acid 74 (68 mg, 0.28 mmol) and diphenyldiazomethane (61 mg, 0.31 mmol) were dissolved in ethanol (12 mL), and stirred for 16 hours. The reaction was quenched with acetic acid (0.5 mL) and stirred for 10 minutes. The solvents were removed under reduced pressure. Purification by flash column chromatography (EtOAc) gave the ester (56 mg, 50%): 1 H NMR (CDCl 3 OD) δ 7.36-7.23 (m, 10H), 6.88 (s, 1H), 6 76 (s, 1H), 4.21 (m, 1H), 3.93-3.79 (m, 2H), 2.89 (dd, J = 17.7, 5.0 Hz, 1 H, 2.34 (m, 1H), 2.00 (s, 3H).
Příklad 24Example 24
Sloučenina 77: K roztoku alkoholu 76 (20 mg, 0,05 mmol) v CH2C12 (1 ml) byl přidán pyridin (40 μΐ, 0,5 mmol), poté byl přidán acetanhydrid (24 μΐ, 0,25 mmol). Směs byla míchána po dobu 24 hodin, a rozpouštědla a reagencie byly odstraněny za sníženého tlaku. Čištění mžikovou sloupcovou chromatografií )hexan/EtOAc = 1/2) dalo diester (20 mg, 91%): 'HNMR (CDC13) delta 7,40-7,27 (m, 10 H), 6,95 (s, 1 H), 6,87 (m, 1 H), 5,60 (m, 1 H) 5,12 (ddd, J = 16,4, 10,2, 5,9 Hz, 1 H), 4,28 (dd, J = 20,0, 9,4 Hz, 1 H), 4,15 (m, 1 H), 2,93 (dd, J = 17,8, 5,2 Hz, 1 H), 2,57 (m, 1H), 2,09 (s, 3 H), 2,01 (s, 3 H).Compound 77: To a solution of alcohol 76 (20 mg, 0.05 mmol) in CH 2 Cl 2 (1 mL) was added pyridine (40 µΐ, 0.5 mmol) then acetic anhydride (24 µΐ, 0.25 mmol) was added. ). The mixture was stirred for 24 hours, and the solvents and reagents were removed under reduced pressure. Purification by flash column chromatography (hexane / EtOAc = 1/2) gave the diester (20 mg, 91%): 1 H NMR (CDCl 3 ) δ 7.40-7.27 (m, 10 H), 6.95 (s, 1 H), 6.87 (m, 1H), 5.60 (m, 1H) 5.12 (ddd, J = 16.4, 10.2, 5.9 Hz, 1H), 4, 28 (dd, J = 20.0, 9.4 Hz, 1H), 4.15 (m, 1H), 2.93 (dd, J = 17.8, 5.2 Hz, 1H), 2.57 (m, 1H), 2.09 (s, 3H), 2.01 (s, 3H).
Příklad 25Example 25
Sloučenina 78: Směs diesteru 77 (20 mg, 0,045 mmol), anisolu (50 μΐ, 0,45 mmol), a TFA (1 ml), v CH2C12 (1 ml) byla míchána po dobu 20 minut. Rozpouštědla a reagencie byly odstraněny za sníženého tlaku. Čištění mžikovou sloupcovou chromatografií (EtOAc až EtOAc/AcOH = 100/1) dalo kyselinu karboxylovou (6 mg): ’H NMR (CDC13) delta 6,85 (m, 1H), 5,54 (m, 1 H), 5,54 (m, 1 H), 5,12 (m, 1 H), 4,31-4,03 (m, 2H), 2,89 (m, 1 H), 2,60-2,41 (m, 1 H), 2,11 (s, 3 H), 2,03 (s, 3 H).Compound 78: A mixture of diester 77 (20 mg, 0.045 mmol), anisole (50 µΐ, 0.45 mmol), and TFA (1 mL) in CH 2 Cl 2 (1 mL) was stirred for 20 minutes. Solvents and reagents were removed under reduced pressure. Purification by flash column chromatography (EtOAc to EtOAc / AcOH = 100/1) gave the carboxylic acid (6 mg): 1 H NMR (CDCl 3 ) δ 6.85 (m, 1H), 5.54 (m, 1H), 5.54 (m, 1H), 5.12 (m, 1H), 4.31-4.03 (m, 2H), 2.89 (m, 1H), 2.60-2.41 (m, 1H), 2.11 (s, 3H), 2.03 (s, 3H).
Příklad 26Example 26
Sloučenina 79: Směs azidu 78 (6 mg, 0,02 mmol) a Pd-C (Lindlar) (15 mg) v EtOH/H2O (2,2 ml, 10/1) byla míchána pod vodíkem po dobu 3 hodin. Směs byla přefiltrována přes celitový list, vymyta horkým MeOH/H2O (1/1) Po odpaření vznikla bílá pevná látka. Pevná látka byla rozpuštěna ve vodě, a prohnána kolonou C-8. Po odpaření vody vzniklý bílý prášek (3 mg): ’H NMR (D2O) delta 6,32 (m, 1 H), 5,06 (m, 1 H), 4,06 (t, J = 10,4 Hz, 1 H), 3,84 (m, 1H), 2,83 (m, 1 H), 2,42 (m, 1H), 2,06 (s, 3 H), 2,00 (s, 3 H).Compound 79: A mixture of azide 78 (6 mg, 0.02 mmol) and Pd-C (Lindlar) (15 mg) in EtOH / H 2 O (2.2 mL, 10/1) was stirred under hydrogen for 3 hours . The mixture was filtered through a celite pad, washed with hot MeOH / H 2 O (1/1). Evaporation gave a white solid. The solid was dissolved in water, and passed through a C-8 column. Evaporation of water gave a white powder (3 mg): 1 H NMR (D 2 O) δ 6.32 (m, 1H), 5.06 (m, 1H), 4.06 (t, J = 10, 4 Hz, 1H), 3.84 (m, 1H), 2.83 (m, 1H), 2.42 (m, 1H), 2.06 (s, 3H), 2.00 (s 3 H).
Příklad 27Example 27
Sloučenina 80: K roztoku alkoholu 76 (35 mg, 0,086 mmol), Boc-glycinu (30 mg, 0,172 mmol), a katalytického množství DMAP v CH2C12 (1 ml) byl přidán DCC (35 mg, 0,172 mmol). Směs byla míchána po dobu 30 minut, a fdtrována a promyta CHC13. Roztok CHC13 byl vymyt vodouCompound 80: To a solution of alcohol 76 (35 mg, 0.086 mmol), Boc-glycine (30 mg, 0.172 mmol), and a catalytic amount of DMAP in CH 2 Cl 2 (1 mL) was added DCC (35 mg, 0.172 mmol). The mixture was stirred for 30 minutes, and filtered and washed with CHCl 3 . CHC1 3 solution was washed with water
-231 CZ 297945 B6 (2x). Koncentrace byla bílou pevnou látkou. Čištění mžikovou sloupcovou chromatografií (hexan/EtOAc = 1(2) dalo produkt (30 mg): 'H NMR (CDC13) delta 7,39-7,26 (m, 10 H), 6,95 (s, 1 H), 6,86 (m, 1 H), 5,77 (m, 1 H), 5,27 (m, 1 H), 4,99 (m, 1 H), 4,18-4,01 (m, 2 H), 3,943,84 (m, 2 H), 2,96 (dd, J = 7,8, 5,9 Hz, 1 H), 2,57 (m, 1 H), 2,02 (s, 3 H), 1,45 (s, 9 H).(2x). Concentration was a white solid. Purification by flash column chromatography (hexane / EtOAc = 1 (2) gave the product (30 mg): 1 H NMR (CDCl 3 ) δ 7.39-7.26 (m, 10 H), 6.95 (s, 1 H) ), 6.86 (m, 1H), 5.77 (m, 1H), 5.27 (m, 1H), 4.99 (m, 1H), 4.18-4.01 ( m, 2H), 3,943.84 (m, 2H), 2.96 (dd, J = 7.8, 5.9 Hz, 1H), 2.57 (m, 1H), 2.02 (s, 3H), 1.45 (s, 9H).
Příklad 28Example 28
Sloučenina 81: Směs diesteru 80 (30 mg, 0,05 mmol), anisolu (150 μΐ) a TFA (1 ml) v CH2CI2 (1 ml) byla míchána po dobu 3 hodin. Rozpouštědla a reagencie byla odpařena. Směs byla rozpuštěna ve vodě a vymývána CHCI3 (3x) Vodní fáze byla odpařena a vzniklá bílá pevná látka (15 mg): 'H NMR (CD3OD) delta 6,73 (m, 1 H), 5,25-5,15 (m, 1 H), 4,35 (m, IH), 4,17 10 (m, 1 H), 3,82 (m, 2 H), 2,93 (dd, J = 17,7, 5,6 Hz, 1 H), 2,42 (m, 1 H), 1,97 (s, 3 H).Compound 81: A mixture of diester 80 (30 mg, 0.05 mmol), anisole (150 μΐ) and TFA (1 mL) in CH 2 Cl 2 (1 mL) was stirred for 3 hours. The solvents and reagent were evaporated. The mixture was dissolved in water and eluted with CHCl 3 (3x) The aqueous phase was evaporated to give a white solid (15 mg): 1 H NMR (CD 3 OD) δ 6.73 (m, 1H), 5.25-5.15 ( m, 1H), 4.35 (m, 1H), 4.1710 (m, 1H), 3.82 (m, 2H), 2.93 (dd, J = 17.7, 5, 6 Hz, 1H), 2.42 (m, 1H), 1.97 (s, 3H).
Příklad 29Example 29
Sloučenina 82: Směs azidu 81 (15 mg, 0,05 mmol) a Pd-C (Lindlar) (30 mg) v EtOH/H2O (4 ml, 1/1) byla míchána po dobu 3 hodin. Směs byla přefiltrována přes celitový list a vymyta horkým MeOH/H2O (1/1). Koncentrace dala pevnou sklovitou látku. Pevná látka byla rozpuštěna ve vodě a prohnána kolonou C-8. Odpařením vody vznikla aminokyselina: 'H NMR (D2O) delta 6,68 (m, IH), 5,28 (m, IH), 4,29 (m, IH), 4,08-3,79 (m, 3 H), 2,85 (m, 1 H), 2,41 (m, IH), 2,04 (s, 3 H).Compound 82: A mixture of azide 81 (15 mg, 0.05 mmol) and Pd-C (Lindlar) (30 mg) in EtOH / H 2 O (4 mL, 1/1) was stirred for 3 hours. The mixture was filtered through celite and washed with hot MeOH / H 2 O (1/1). Concentration gave a solid glassy substance. The solid was dissolved in water and passed through a C-8 column. Evaporation of water gave the amino acid: 1 H NMR (D 2 O) δ 6.68 (m, 1H), 5.28 (m, IH), 4.29 (m, IH), 4.08-3.79 (m 3H), 2.85 (m, 1H), 2.41 (m, 1H), 2.04 (s, 3H).
Příklad 30 bis-Boc guanidinylmetylester 92: Působení podle Kim and Qian, „Tetrahedron Lett.“ 34:7677 (1993). Do roztoku aminu 91 (42 mg, 0,154 mmol), bis-Boc thiomočoviny (43 mg, 0,155 mmol) a trietylaminu (72 μΐ) v suchém DMF (310 μΐ), ochlazeném na 0 °C byl přidán chlorid rtuťný (46 mg, 0,170 mmol) v jedné dávce. Po 30 minutách byla reakce zahřáta na teplotu místnosti a míchána další 2,5 hodiny. Reakční směs byla pak přefiltrována přes celitový list, koncentrována a čištěna mžikovou sloupcovou chromatografíi (100% etylacetát) a vzniklo 70 mg (89%) 92 jako bezbarvá pěna. Ή NMR (CDC13, 300 MHz): delta 11,37 (s, IH); 8,60 d, IH, J= 7,8 Hz); 6,83 (t, IH, J= 2,1 Hz); 6,63 (d, IH, J= 8,4 Hz); 4,76 (d, IH, J= 7,0 Hz); 4,71 (d, IH, J= 7,0 Hz); 4,45-4,10 (komplex m, 2H); 3,76 (s, 3H); 3,39 (s, 3H); 2,84 (IH, J= 5,4, 17,4 Hz); 2,45-2,30 (m, IH); 1,92 (s, 3H); 1,49 (s, 18H).Example 30 bis-Boc guanidinyl methyl ester 92: Treatment according to Kim and Qian, "Tetrahedron Lett." 34: 7677 (1993). To a solution of amine 91 (42 mg, 0.154 mmol), bis-Boc thiourea (43 mg, 0.155 mmol) and triethylamine (72 μΐ) in dry DMF (310 μΐ) cooled to 0 ° C was added mercuric chloride (46 mg, 0.170 mmol) in one portion. After 30 minutes, the reaction was warmed to room temperature and stirred for an additional 2.5 hours. The reaction mixture was then filtered through celite, concentrated, and purified by flash column chromatography (100% ethyl acetate) to give 70 mg (89%) 92 as a colorless foam. Ή NMR (CDCl 3 , 300 MHz): δ 11.37 (s, 1H); 8.60 d, 1H, J = 7.8 Hz); 6.83 (t, 1H, J = 2.1 Hz); 6.63 (d, 1H, J = 8.4 Hz); 4.76 (d, 1H, J = 7.0 Hz); 4.71 (d, 1H, J = 7.0 Hz); 4.45-4.10 (complex m, 2H); 3.76 (s, 3H); 3.39 (s, 3H); 2.84 (1H, J = 5.4, 17.4 Hz); 2.45-2.30 (m, 1H); 1.92 (s, 3H); 1.49 (s, 18H).
Příklad 31 bis-Boc guanidinylkarboxylová kyselina 93: Do roztoku esteru 92 (70 mg, 0,1365 mmol) v THF (3 ml), ochlazeného na 0 °C byl přidán vodný KOH (350 μΐ z 0,476 M roztoku). Reakce byla poté zahřáta na teplotu místnosti a míchána po dobu 2 hodin. Reakce byla poté acidifíkována na pH = 4,5 pomocí kyselé pryskyřice Amberlite IR-120 (plus). Pryskyřice byla pak přefiltrována a promyta etanolem a H2O. Koncentrace in vacuo dala 66 mg (97%) kyseliny karboxylové 93 jako bílou pevnou látku. *H NMR (CDC13, 300 MHz): delta 11,40 (br s, IH); 8,67 (d, IH, J= 7,8 Hz); 6,89 (s, IH); 6,69 (br d, IH, 8,4 Hz); 4,77 (d, IH, J= 7,2 Hz); 4,70 (d, IH, J= 7,2 Hz); 4,40-4,15 (m, 2H), 3,39 (s, 3H), 2,84 (dd, IH, J= 4,8, 17,1 Hz); 2,45-2,30 (m, IH), 1,95 (s, 3H); 1,49 (s, 9H); 1,48 (s, 9H).Example 31 bis-Boc guanidinylcarboxylic acid 93: To a solution of ester 92 (70 mg, 0.1365 mmol) in THF (3 mL) cooled to 0 ° C was added aqueous KOH (350 μ 350 of 0.476 M solution). The reaction was then warmed to room temperature and stirred for 2 hours. The reaction was then acidified to pH = 4.5 with Amberlite IR-120 (plus) acid resin. The resin was then filtered and washed with ethanol and H 2 O. Concentration in vacuo gave 66 mg (97%) of carboxylic acid 93 as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ 11.40 (br s, 1H); 8.67 (d, 1H, J = 7.8 Hz); 6.89 (s, 1H); 6.69 (br d, 1H, 8.4 Hz); 4.77 (d, 1H, J = 7.2 Hz); 4.70 (d, 1H, J = 7.2 Hz); 4.40-4.15 (m, 2H), 3.39 (s, 3H), 2.84 (dd, 1H, J = 4.8, 17.1 Hz); 2.45-2.30 (m, 1H); 1.95 (s, 3H); 1.49 (s, 9H); 1.48 (s, 9H).
-232CZ 297945 B6-232GB 297945 B6
Příklad 32Example 32
TFA sůl 94 guanidinkarboxylové kyseliny: Do roztoku bis-Boc guanidinylkarboxylové kyseliny 93 (23 mg, 0,046 mmol) v CH2C12 (1 ml), ochlazeného na 0 °C byla přidána čistá kyselina trifluoroctová (500 μΐ). Po 30 minutách byla reakce zahřáta na teplotu místnosti a míchána další 1,25 hodiny. Těkavé látky byly odstraněny za vakua a zbytek společně odpařen s několika díly H2O, čímž vznikla bledě oranžová pevná látka, zbytek byl čištěn chromatografii s obrácenou fází Cig za použití H2O jako eluent. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány, tak že vzniklo 15 mg 93 jako bílý prášek. 'H NMR (D2O, 500 MHz): delta 6,82 (t, IH, J= 2,0 Hz), 4,51-4,74 (m, IH); 3,93 (dd, IH, J = 9,0, 11,2 Hz), 3,87-3,80 (zřejmé ddd, IH); 2,88 (m, IH); 2,48-2,45 (komplexní m); 2,07 (s, 3H). 13C NMR (D2O): delta 176,1; 170,0; 157,1; 139,2; 129,5; 69,4; 56,2; 50,9; 30,3; 22,2.Guanidinecarboxylic Acid TFA Salt 94: To a solution of bis-Boc guanidinylcarboxylic acid 93 (23 mg, 0.046 mmol) in CH 2 Cl 2 (1 mL) cooled to 0 ° C was added pure trifluoroacetic acid (500 μΐ). After 30 minutes, the reaction was warmed to room temperature and stirred for an additional 1.25 hours. The volatiles were removed in vacuo and the residue co-evaporated with a few portions of H 2 O to give a pale orange solid, the residue was purified by C 18 reverse phase chromatography using H 2 O as eluent. Fractions containing the desired product were combined and lyophilized to give 15 mg of 93 as a white powder. 1 H NMR (D 2 O, 500 MHz): δ 6.82 (t, 1H, J = 2.0 Hz), 4.51-4.74 (m, 1H); 3.93 (dd, 1H, J = 9.0, 11.2 Hz), 3.87-3.80 (apparent ddd, 1H); 2.88 (m, 1H); 2.48-2.45 (complex m); 2.07 (s, 3H). 13 C NMR (D 2 O): δ 176.1; 170.0; 157.1; 139.2; 129.5; 69.4; 56.2; 50.9; 30.3; 22.2.
Příklad 33Example 33
Syntéza 102: Roztok azidoalyléteru 6 (24 mg, 0,082 mmol) vetanolu (1 ml) byl vystaven naSynthesis 102: A solution of azidoalylether 6 (24 mg, 0.082 mmol) in ethanol (1 mL) was exposed to
I, 5 hodiny plynného vodíku (1 atm) přes Lindlarův katalyzátor (30 mg). Reakční směs byla přefiltrována celitovým listem a promyta horkým etanolem. Koncentrace in vacuo dala bledou pevnou látku, která byla rozpuštěna v THF (1,5 ml) a reagovala s vodným KOH (246 μΐ 0,50 M roztoku). Po 2 hodinách míchání při teplotě místnosti byla reakce acidifikována na pH = 4,0 pomocí acidické pryskyřice Amberlite IR-120 (plus) filtrována a promyta etanolem a H2O. Koncentrace in vacuo dala oranžovou pevnou látku, která byla čištěna sloupcovou chromatografii Cig elutovaná H2O. Frakce obsahující produkt, byly spojeny a lyofilizovány tak, že vznikla směs 102 2 ku 1 a plně nasycená sloučenina 103 jako bílý prášek. Data 'H NMR pro sloučeninu 102: !H NMR (D2O, 500 MHz): delta: 7,85 (s, IH); 4,29 (br d, IH, J= 9,2 Hz); 4,16 (dd, 35 IH, J= 11,6,1.5 hours hydrogen gas (1 atm) through Lindlar catalyst (30 mg). The reaction mixture was filtered through a celite pad and washed with hot ethanol. Concentration in vacuo afforded a pale solid which was dissolved in THF (1.5 mL) and treated with aqueous KOH (246 μΐ 0.50 M solution). After stirring at room temperature for 2 hours, the reaction was acidified to pH = 4.0 with Amberlite IR-120 (plus) acidic resin filtered and washed with ethanol and H 2 O. Concentration in vacuo gave an orange solid which was purified by column chromatography C 18 eluted H 2 O. the product containing fractions were pooled and lyophilized to give a mixture of 2 to 1 102 and the fully saturated compound 103 as a white powder. Data 'H NMR for Compound 102:! 1 H NMR (D 2 O, 500 MHz): δ 7.85 (s, 1H); 4.29 (br d, 1H, J = 9.2 Hz); 4.16 (dd, 35 IH, J = 11.6,
II, 6 Hz); 3,78-3,72 (m, 2H), 3,62 (zřejmé ddd, IH); 2,95 (zřejmé dd, IH); 2,58 -2,52 (m, IH); 2,11 (s, 3H); 1,58 (q, 2H,J= 7,3 Hz); 0,91 (t, 3H,J= 7,3 Hz).II, 6 Hz); 3.78-3.72 (m, 2H), 3.62 (apparent ddd, 1H); 2.95 (apparent dd, 1H); 2.58 - 2.52 (m, 1H); 2.11 (s, 3H); 1.58 (q, 2H, J = 7.3Hz); 0.91 (t, 3H, J = 7.3Hz).
Příklad 34Example 34
Syntéza 115: Roztok aminokyseliny 114 (10,7 mg, 0,38 mmol) ve vodě (1,3 ml), ochlazený na 0 °C byl upraven na pH = 9,0 pomocí 1,0 M NaOH. Poté byl přidán benzylformimidathydrochlorid (26 mg, 0,153 mmol) v jedné dávce a reakce míchána mezi 0 až 5 °C po dobu 3 hodin, při udržování pH mezi 8,5-9,0 pomocí 1,0 M NaOH. Reakce byla poté koncentrována in vacuo a zbytek aplikován do kolony Cig a elutován vodou. Frakce, obsahující produkt, byly spojeny a lyofilizovány, tak že vznikla formamidindarboxylová kyselina 115 (10 mg) jako bílý prášek. 10 ’HNMR (D2O, 300 MHz, izomeiy směsi): delta 7,83 (s, IH); [6,46(s)& 6,43 (s); IH celkem]; 4,83 (d, IH, J= 7,3 Hz), 4,73 (d, IH, 7 = 7,3 Hz); 4,50-4,35 (m, IH); 4,10-4,05 (m, IH); [4,033,95 (m) & 3,80-3,65 (m), 1 H celkem]; 3,39 (s, 3H); 2,90-2,75 (m, IH); 2,55-2,30 (m, IH); [2,03 (s) & 2,01 (s), 3H celkem].Synthesis 115: A solution of amino acid 114 (10.7 mg, 0.38 mmol) in water (1.3 mL) cooled to 0 ° C was adjusted to pH = 9.0 with 1.0 M NaOH. Benzylformimidate hydrochloride (26 mg, 0.153 mmol) was then added in one portion and the reaction stirred between 0-5 ° C for 3 hours, maintaining the pH between 8.5-9.0 with 1.0 M NaOH. The reaction was then concentrated in vacuo and the residue applied to a C 18 column and eluted with water. Product containing fractions were combined and lyophilized to give formamideindarboxylic acid 115 (10 mg) as a white powder. 10 1 HNMR (D 2 O, 300 MHz, isomer mixtures): δ 7.83 (s, 1H); [6.46 (s) & 6.43 (s); IH total]; 4.83 (d, 1H, J = 7.3 Hz), 4.73 (d, 1H, J = 7.3 Hz); 4.50-4.35 (m, 1H); 4.10-4.05 (m, 1H); [4,033.95 (m) & 3.80-3.65 (m), 1 H total]; 3.39 (s, 3H); 2.90-2.75 (m, 1H); 2.55-2.30 (m, 1H); [2.03 (s) & 2.01 (s), 3H total].
Příklad 35Example 35
Sloučenina 123: Do roztoku alkoholu 63 (5,842 g, 20,5 mmol) a DMAP (200 mg) v pyridinu (40 ml) byl přidán tosylchlorid (4,3 g, 22,6 mmol). Směs byla míchána po dobu 40 hodin při teplotě místnosti, a pyridin byl odstraněn pod sníženým tlakem. Reakce byla rychle zchlazena vodou a extrahována pomocí EtOAc (3x). Spojené organické extrakty byly promyty vodou, solankou a vysušeny přes MgSO4. Čištění mžikovou sloupcovou chromatografii (hexany/EtOAc = 2/1) daly tosylat (8,04 g, 89%): ’HNMR (CDC13 delta 7,84 (d, J = 8,3 Hz, 2H), 7,33 (d, J = 8,1 Hz, 2 H), 4,78 (m, IH), 4,43 (m, 1 H), 4,06 (m, 1 H), 3,79 (s, 3 H), 2,44 (s, 3 H), 2,43-1,92 (m, 4 H), 1,61-1,22 (m, 10 H).Compound 123: To a solution of alcohol 63 (5.842 g, 20.5 mmol) and DMAP (200 mg) in pyridine (40 mL) was added tosyl chloride (4.3 g, 22.6 mmol). The mixture was stirred for 40 hours at room temperature, and pyridine was removed under reduced pressure. The reaction was quenched with water and extracted with EtOAc (3x). The combined organic extracts were washed with water, brine and dried over MgSO 4 . Purification by flash column chromatography (hexanes / EtOAc = 2/1) gave tosylate (8.04 g, 89%): 1 H NMR (CDCl 3, δ 7.84 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.78 (m, 1H), 4.43 (m, 1H), 4.06 (m, 1H), 3.79 (s, 3 H), 2.44 (s, 3H), 2.43-1.92 (m, 4H), 1.61-1.22 (m, 10H).
-233 CZ 297945 B6-233 CZ 297945 B6
Příklad 36Example 36
Sloučenina 124: Do roztoku alkoholu 123 (440 mg, 100 mmol) v pyridinu (3 ml) byl přidán POC13 (100 μΐ, 1,1 mmol). Směs byla míchána při teplotě místnosti po dobu 12 hodin, a rychle zchlazena nasyceným roztokem NH4CI. Vodní fáze byla extrahována éterem (3x). Spojené éterové vrstvy byly promývány vodou (2x), roztokem 2 N HC1 (2x) solankou a vysušeny přes MgSO4. Čištění mžikovou sloupcovou chromatografií (hexan/EtOAc = 2/1) dalo směs požadovaného produktu 124 a určité nečistoty (350 mg, 83 %, 2/1).Compound 124: To a solution of alcohol 123 (440 mg, 100 mmol) in pyridine (3 mL) was added POCl 3 (100 μΐ, 1.1 mmol). The mixture was stirred at room temperature for 12 hours, and quenched with saturated NH 4 Cl solution. The aqueous phase was extracted with ether (3x). The combined ether layers were washed with water (2X), 2 N HCl solution (2X) brine and dried over MgSO 4 . Purification by flash column chromatography (hexane / EtOAc = 2/1) gave a mixture of the desired product 124 and some impurities (350 mg, 83%, 2/1).
Příklad 37Example 37
Sloučenina 1: Do roztoku známého acetonidu metylšikimatu (877 mg, 3,85 mmol, „Tetrahedron Lett.“, 26:21 (1985)) v dichlormetanu (15 ml) při teplotě -10 °C byl přidán metansulfonychlorid (330 μΐ, 4,23 mmol), poté po kapkách přidán trietylamin (640 μΐ, 4,62 mmol). Roztok byl míchán při -10 °C po dobu 1 hodiny, pak při teplotě 0 °C po dobu 2 hodin, a v této době byl přidán metansulfonylchlorid (30 μΐ), trietylamin (64 μΐ). Po 1 hodině byla přidána studená voda, organická fáze byla odloučena, promyta vodou, vysušena (MgSO4) a odpařena. Surový produkt byl chromatografován na silikagelu (1/1-hexan/etylacetát), čímž vznikl mesylát 130 (1,1 g, 93%), jako olej. Mesylát 130 (990 mg, 3,2 mmol) byl rozpuštěn v tetrahydrofuranu (5 ml) a vystaven účinku 1M HC1 (5 ml). Roztok byl míchán při teplotě místnosti po dobu 19 hodin, rozředěn vodu (5 ml) a míchán dalších 7 hodin. Odpařováním organického rozpouštědla se vysrážel olejovitý zbytek, který byl extrahován na etylacetát. Spojené organické extrakty byly promyty solankou, vysušeny (MgSO4) a odpařeny. Přidáním CH2C12 do surového zbytku se vysrážela bílá pevná látka, která byla filtrována a promyta CH2CI2, což dalo diol 131 (323 mg, 38%). Do částečně suspenze diolu 131 (260 mg, 0,98 mmol) v THF (5 ml) při teplotě 0 °C byl přidán DBU (154 μΐ, 1,03 mmol). Roztok byl míchán při teplotě 0 °C po dobu 3 hodin, a pak zahříván na teplotu místnosti za míchání po dobu 5 hodin. Rozpouštědlo se odpařilo a surový zbytek byl rozdělen mezi etylacetát (40 ml) a 5% kyselinu citrónovou (20 ml). Organická fáze byla promyta solankou. Vodné fáze byly zpětně extrahovány etylacetátem (15 ml) a spojené organické extrakty byly vysušeny (MgSO4) a odpařeny, takže vznikl epoxid (117 mg, 70%) jako bílá pevná látka, která měla spektrum 'H NMR shodné se strukturou 1, připravenou metodou podle literatury.Compound 1: To a solution of the known methylshikimate acetonide (877 mg, 3.85 mmol, "Tetrahedron Lett.", 26:21 (1985)) in dichloromethane (15 mL) at -10 ° C was added methanesulfonyl chloride (330 μΐ, 4 , 23 mmol), then triethylamine (640 μΐ, 4.62 mmol) was added dropwise. The solution was stirred at -10 ° C for 1 hour, then at 0 ° C for 2 hours, at which time methanesulfonyl chloride (30 μΐ), triethylamine (64 μΐ) was added. After 1 hour cold water was added, the organic phase was separated, washed with water, dried (MgSO 4 ) and evaporated. The crude product was chromatographed on silica gel (1/1-hexane / ethyl acetate) to give mesylate 130 (1.1 g, 93%) as an oil. The mesylate 130 (990 mg, 3.2 mmol) was dissolved in tetrahydrofuran (5 mL) and treated with 1M HCl (5 mL). The solution was stirred at room temperature for 19 hours, diluted with water (5 mL) and stirred for an additional 7 hours. Evaporation of the organic solvent precipitated an oily residue which was extracted into ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO 4 ) and evaporated. Addition of CH 2 Cl 2 to the crude residue precipitated a white solid, which was filtered and washed with CH 2 Cl 2 to give diol 131 (323 mg, 38%). To a partial suspension of diol 131 (260 mg, 0.98 mmol) in THF (5 mL) at 0 ° C was added DBU (154 µΐ, 1.03 mmol). The solution was stirred at 0 ° C for 3 hours, and then warmed to room temperature with stirring for 5 hours. The solvent was evaporated and the crude residue was partitioned between ethyl acetate (40 mL) and 5% citric acid (20 mL). The organic phase was washed with brine. The aqueous phases were back extracted with ethyl acetate (15 mL) and the combined organic extracts were dried (MgSO 4 ) and evaporated to give the epoxide (117 mg, 70%) as a white solid, which had a 1 H NMR spectrum consistent with structure 1, prepared method according to literature.
Příklad 38Example 38
Alkohol 51: Do roztoku chráněného alkoholu (PG = metoxymetyl) (342 mg, 1,15 mmol) v CH2C12 (10 ml) při teplotě 0 °C byla přidána kyselina trifluoroctová (8 ml). Po 5 minutách při 0 °C byl roztok míchán 1 hodinu při teplotě místnosti a odpařen. Surový produkt byl vyčištěn na silikagelu (etylacetát), čímž vznikl alkohol 51 (237 mg, 82%) jako olej: *H NMR (300 MHz, CDCI3) delta 2,11 (s, 3H), 2,45 (m, 1H), 2,97 (dd, 1H, J= 3,8, 18,8), 3,66 (m, 2H), 3,78 (s, 3H), 4,40 (br s, 1H), 5,22 (br s, 1H), 6,19 (br s, 1H), 6,82 (m, 1H).Alcohol 51: To a solution of protected alcohol (PG = methoxymethyl) (342 mg, 1.15 mmol) in CH 2 Cl 2 (10 mL) at 0 ° C was added trifluoroacetic acid (8 mL). After 5 minutes at 0 ° C, the solution was stirred for 1 hour at room temperature and evaporated. The crude product was purified on silica gel (ethyl acetate) to give alcohol 51 (237 mg, 82%) as an oil: 1 H NMR (300 MHz, CDCl 3) δ 2.11 (s, 3H), 2.45 (m, 1H) 2.97 (dd, 1H, J = 3.8, 18.8), 3.66 (m, 2H), 3.78 (s, 3H), 4.40 (br s, 1H), 5 22 (br s, 1H), 6.19 (br s, 1H), 6.82 (m, 1H).
Příklad 39Example 39
Metyléter 150: Do roztoku alkoholu 1 (46 mg, 0,18 mmol) a metyljodidu (56 μΐ, 0,90 mmol) v THF (0,7 ml) při teplotě 0 °C byl přidán NaH jako 60% disperze minerálního oleje (8 mg, 0,20 mmol). Roztok byl míchán při teplotě 0 °C po dobu 2,5 hodiny, a byl přidán druhý díl NaH (2 mg). Po další 1 hodině při teplotě 0 °C a 4 hodinách při teplotě místnosti byl roztok ochlazen na 0 °C a byla přidána 5% kyselina citrónová (0,5 ml). Směs byla extrahována etylacetátem (4x2 ml) a spojené organické extrakty byly vysušeny (MgSO4) a odpařeny. Čištění surového zbytku na silikagelu (etylacetátu) dalo metyléter 150 (12 mg, 25%) jako pevnou látku: ’HNMRMethyl ether 150: To a solution of alcohol 1 (46 mg, 0.18 mmol) and methyl iodide (56 μΐ, 0.90 mmol) in THF (0.7 mL) at 0 ° C was added NaH as a 60% mineral oil dispersion ( 8 mg, 0.20 mmol). The solution was stirred at 0 ° C for 2.5 hours, and a second portion of NaH (2 mg) was added. After an additional 1 hour at 0 ° C and 4 hours at room temperature, the solution was cooled to 0 ° C and 5% citric acid (0.5 ml) was added. The mixture was extracted with ethyl acetate (4 x 2 mL) and the combined organic extracts were dried (MgSO 4 ) and evaporated. Purification of the crude residue on silica gel (ethyl acetate) gave methyl ether 150 (12 mg, 25%) as a solid: 1 HNMR
-234CZ 297945 B6 (300 MHz, CDC13) delta 2,07 (s, 3H), 2,23-2,34 (m, 1H), 2,89 (zř. ddd, 1H), 3,43 (s, 3H), 3,58 (m, 1H), 3,78 (s, 3H), 4,13 (m, 1H), 4,40 (m, 1H), 5,73 (d, 1H, J = 7,6), 6,89 (m, 1H).-234E 297945 B6 (300 MHz, CDCl 3 ) δ 2.07 (s, 3H), 2.23-2.34 (m, 1H), 2.89 (broad ddd, 1H), 3.43 (s (3H), 3.58 (m, 1 H), 3.78 (s, 3 H), 4.13 (m, 1 H), 4.40 (m, 1 H), 5.73 (d, 1 H, J = 7.6), 6.89 (m, 1H).
Příklad 40Example 40
Aminokyselina 151: Do roztoku metyléteru 150 (12 mg, 0,45 mmol) v THF (1 ml)/voda (100 μΐ) byl přidám polymemí nosič Ph3P (75 mg, 3 mmol P/g pryskyřice). Směs byla míchána při teplotě místnosti po dobu 19 hodin. Pryskyřice byla přefiltrována, několikrát promyta THF a spojený filtrát a výplach byly odpařeny, čímž vzniklo 8 mg surového zbytku. Zbytek byl rozpouštěn v THF (0,5 ml) a byl přidán 0,5 M KOH (132 pl)/voda (250 μΐ). Roztok byl míchán při teplotě místnosti po dobu 1,25 hodiny a pH bylo upraveno na 3-4 pomocí iontoměničové pryskyřice IR 120. Pryskyřice byla filtrována a míchána s 1M HC1. Po filtraci byla pryskyřice vystavena stejnému působení s 1M HC1, dokud acidický výplach nevykazoval pozitivní výsledky na amin s ninhydrinem. Spojený výplach pryskyřice byl odpařen a zbytek vyčištěn na silikagelu C-18 v obrácené fázi, eluováno vodou, čímž po lyofílizaci vznikla aminokyselina 151 (1,8 mg, 15%) jako bílá pevná látka: !H NMR (300 MHz, D2O) delta 2,09 (s, 3H), 2,48-2,59 (zř. qt, 1H), 2,94 (DD, 1H, J= 5,7, 17,4), 3,61 (m, 1H), 4,14-4,26 (m, 2H), 6,86 (br s, 1H).Amino acid 151: To a solution of methyl ether 150 (12 mg, 0.45 mmol) in THF (1 mL) / water (100 μΐ) was added polymeric carrier Ph 3 P (75 mg, 3 mmol P / g resin). The mixture was stirred at room temperature for 19 hours. The resin was filtered, washed several times with THF, and the combined filtrate and washings were evaporated to give 8 mg of crude residue. The residue was dissolved in THF (0.5 mL) and 0.5 M KOH (132 µL) / water (250 µΐ) was added. The solution was stirred at room temperature for 1.25 hours and the pH was adjusted to 3-4 with an IR 120 ion exchange resin. The resin was filtered and stirred with 1M HCl. After filtration, the resin was treated with 1M HCl until acidic wash showed positive results for the amine with ninhydrin. The combined resin wash was evaporated and the residue purified on reversed phase C-18 silica gel, eluting with water to afford, after lyophilization, amino acid 151 (1.8 mg, 15%) as a white solid . 1 H NMR (300 MHz, D 2 O) δ 2.09 (s, 3H), 2.48-2.59 (broad qt, 1H), 2.94 (DD, 1H, J = 5.7, 17) 4), 3.61 (m, 1H), 4.14-4.26 (m, 2H), 6.86 (br s, 1H).
Příklad 41Example 41
Allyléter aminokyseliny 153: Do roztoku azidu 6(16 mg, 0,054 mmol) v THF (0,50 ml) a H2O (35 μΐ) byl přidán polystyrénem nasycený PPh3 (50 mg). Reakční směs byla míchána při teplotě místnosti po dobu 24 hodin, filtrována nálevkou ze slinutého skla a promyta horkým metanolem. Koncentrace in vacuo dala surový aminoester, který byl rozpuštěn v THF (1,0 ml) a reagoval s vodným KOH (220 μΐ z roztoku 0,5 M). Po míchání při teplotě místnosti po dobu 2 hodin byla přidána acidická pryskyřice Amberlite IR-120 (plus), dokud roztok nedosáhl pH = 4,5. Pryskyřice byla přefiltrována a promyta etanolem a H2O. Koncentrace in vacuo dala bledě oranžovou pevnou látku, která byla čištěna chromatografií Ci8 se zpětnou fází při použití H2O jako eluent. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány, čímž vznikla aminokyselina jako bílý prášek. !HNMR (D2O, 300 MHz): delta 6,51 (br t, 1H); 6,05-5,80 (m, 1H, -CH=, allyl); 5,36-5,24 (m, 2H, =CH2, allyl); 4,35—4,25 (m, 1H); 4,25-4,05 (m, 2H, -CH2- allyl); 4,02-3,95 (m, 1H); 3,81-3,70 (m, 1H); 2,86-2,77 (zřejmé dd, 1H); 2,35-2,24 (komplexní m, 1H); 2,09 (s, 3H).Allyl ether 153: To a solution of azide 6 (16 mg, 0.054 mmol) in THF (0.50 mL) and H 2 O (35 μΐ) was added polystyrene saturated PPh 3 (50 mg). The reaction mixture was stirred at room temperature for 24 hours, filtered through a sintered glass funnel and washed with hot methanol. Concentration in vacuo gave the crude aminoester, which was dissolved in THF (1.0 mL) and treated with aqueous KOH (220 μΐ of 0.5 M solution). After stirring at room temperature for 2 hours, Amberlite IR-120 (plus) acidic resin was added until the solution reached pH = 4.5. The resin was filtered and washed with ethanol and H 2 O. Concentration in vacuo gave a pale orange solid which was purified by C 18 reverse phase chromatography using H 2 O as eluent. Fractions containing the desired product were combined and lyophilized to give the amino acid as a white powder. ! 1 HNMR (D 2 O, 300 MHz): δ 6.51 (br t, 1H); 6.05-5.80 (m, 1H, -CH = allyl); 5.36 to 5.24 (m, 2H, = CH2, allyl); 4.35-4.25 (m, 1H); 4.25 to 4.05 (m, 2H, -CH 2 -, allyl); 4.02-3.95 (m, IH); 3.81-3.70 (m, IH); 2.86-2.77 (apparent dd, 1H); 2.35-2.24 (complex m, 1H); 2.09 (s, 3H).
Příklad 42Example 42
Epoxid 161: MCPBA (690 mg) byl přidán k roztoku olefinu 160 (532 mg, 1,61 mmol, připravenému podle příkladu 14, surový mesylát byl filtrován přes silikagel při použití 30% EtOAc/hexany před použitím) v dichlormetanu (15 ml), ochlazenému na 0 °C. Směs byla zahřáta na pokojovou teplotu a přes noc míchána. Většina rozpouštědla byla odstraněna za vakua a směs naředěna etylacetátem. Organická vrstva byla promyta vodným natriumbisulfitem, nasyceným hydrogenuhličitanem sodným, solankou a vysušena přes MgSO4. Koncentrace in vacuo, poté mžiková sloupcové chromatografie zbytku (30% hexany v etylacetátu) daly 437 mg (78%) 161 jako světlý olej. *H NMR (CDC13, 300 MHz): [1:1 směs diastereoizomerů] delta [4,75 (dd, J= 3,9, 8,2 Hz), & 4,71 (dd, J= 3,9, 84 Hz), 1H celkem]; 4,37 (m, 1H); 4,25^1,00 (m, 2H); 3,78 (s, 3H); [3,68 (dd, J= 5,7 11,7 Hz) & 3,51 (dd, J = 6,6, 11,7 Hz), 1H celkem]; [3,17 (s) & 25 3,16 (s), 3H celkem]; [2,99 (m) & 2,93 (m), 1H celkem]; [2,83 (t, J= 4,1 Hz) & 2,82 (t, J= 4,5 Hz), 1H celkem]; 2,70-2,60 (m, 1H); 2,45-2,30 (m, 1H).Epoxy 161: MCPBA (690 mg) was added to a solution of olefin 160 (532 mg, 1.61 mmol, prepared according to Example 14, the crude mesylate was filtered through silica gel using 30% EtOAc / hexanes before use) in dichloromethane (15 mL) , cooled to 0 ° C. The mixture was warmed to room temperature and stirred overnight. Most of the solvent was removed in vacuo and the mixture diluted with ethyl acetate. The organic layer was washed with aqueous sodium bisulfite, saturated sodium bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo, then flash column chromatography of the residue (30% hexanes in ethyl acetate) gave 437 mg (78%) 161 as a light oil. 1 H NMR (CDCl 3 , 300 MHz): [1: 1 mixture of diastereoisomers] delta [4.75 (dd, J = 3.9, 8.2 Hz), δ 4.71 (dd, J = 3.9) , 84 Hz), 1H total]; 4.37 (m, IH); 4.25? 1.00 (m, 2H); 3.78 (s, 3H); [3.68 (dd, J = 5.7, 11.7 Hz) & 3.51 (dd, J = 6.6, 11.7 Hz), 1H total]; [3.17 (s) & 25 3.16 (s), 3H total]; [2.99 (m) & 2.93 (m), 1H total]; [2.83 (t, J = 4.1 Hz) & 2.82 (t, J = 4.5 Hz), 1H total]; 2.70-2.60 (m, IH); 2.45-2.30 (m, IH).
-235 CZ 297945 B6-235 CZ 297945 B6
Příklad 43Example 43
Diol 162: Epoxid 161 (437 mg, 1,23 mmol) byl jemně refluxován po dobu 1 hodiny v THF (20 ml) a H2O (10 ml) s obsahem 5 kapek 70% HCIO4. Byl přidán pevný NaHCO3 a směs koncentrována in vacuo. Zbytek byl rozpuštěn v EtOAc, vymyt solankou a vysušen. Koncentrace in vacuo dala surový diol 162 jako světlý olej v kvantitativním výtěžku. Použit bez jakéhokoliv čištění pro další reakci.Diol 162: Epoxy 161 (437 mg, 1.23 mmol) was gently refluxed for 1 hour in THF (20 mL) and H 2 O (10 mL) containing 5 drops of 70% HClO 4. Solid NaHCO 3 was added and the mixture concentrated in vacuo. The residue was dissolved in EtOAc, washed with brine and dried. Concentration in vacuo gave crude diol 162 as a light oil in quantitative yield. Used without further purification for the next reaction.
Příklad 44Example 44
Aldehyd 163: Byla provedena oxidace diolu 162 podle postupu Vo-Quang et al., „Synthesis“, 68 (1988). Do řídké suspenze silikagelu (4,3 g) v dichlormetanu (30 ml) byl přidán roztok NaIO4 (4,4 ml 0,65 M vodného roztoku). Do této řídké suspenze byl přidán roztok surového diolu 162 (520 mg) v EtOAc (5 ml) a dichlormetanu (15 ml). Po 1 hodině byly pevné částice přefiltrovány a promyty 20% hexany/EtOAc. Koncentrace dala olejovitý zbytek, který byl rozpuštěn v EtPAc a vysušen přes MgSO4. Koncentrace in vacuo dala aldehyd 163 jako světlý olej, který byl ihned použit pro další reakci. 'H NMR (CDC13, 300 MHz); delta 9,69 (s, 1H); 6,98 (m, 1H); 4,72 (dd, 1H, J= 3,7 9,1 Hz); 4,53 (d, 1H, J = 18,3 Hz); 4,45 (d, 1H, J= 18,3 Hz); 4,31 (m, 1H); 4,26-4,18 (m, 1H); 3,79 (s, 3H); 3,19 (s, 3H); 3,05 (dd, 1H, J= 5,7, 18,6 Hz); 2,20-2,45 m, 1H).Aldehyde 163: The diol 162 was oxidized according to the procedure of Vo-Quang et al., "Synthesis", 68 (1988). To a thin suspension of silica gel (4.3 g) in dichloromethane (30 mL) was added a solution of NaIO 4 (4.4 mL of a 0.65 M aqueous solution). To this slurry was added a solution of crude diol 162 (520 mg) in EtOAc (5 mL) and dichloromethane (15 mL). After 1 hour, the solids were filtered and washed with 20% hexanes / EtOAc. Concentration gave an oily residue which was dissolved in EtPAc and dried over MgSO 4 . Concentration in vacuo gave aldehyde 163 as a light oil, which was used immediately for the next reaction. 1 H NMR (CDCl 3 , 300 MHz); δ 9.69 (s, 1H); 6.98 (m, IH); 4.72 (dd, 1H, J = 3.7, 9.1 Hz); 4.53 (d, 1H, J = 18.3Hz); 4.45 (d, 1H, J = 18.3Hz); 4.31 (m, IH); 4.26-4.18 (m, IH); 3.79 (s, 3H); 3.19 (s. 3H); 3.05 (dd, 1H, J = 5.7, 18.6 Hz); 2.20-2.45 m, 1H).
Příklad 45Example 45
Alkohol 164: Surový aldehyd 163 reagoval sNaCNBH3 podle postupu Borch et al., „J. Amer. Chem. Soc.“, 93:2897 (1971), a vzniklo 269 mg (65%) alkoholu 164 po mžikové chromatografii (40% hexanů v etylacetátu). *H NMR (CDC13, 300 MHz): delta 6,91 (m, 1H); 4,75 (dd, 1H, J= 3,9, 8,7 Hz); 4,34 (br t, 1H, J= 4,1 Hz); 4,25^1,15 (m, 1H); 3,85-3,70 (m, 4H); 3,77 (s, 3H); 3,16 (s,3H), 2,95 (dd, 1H, .7=5,7, 18,6 Hz); 2,37 (dd, 1H, .7=7,1, 18,6 Hz); 2,26 (br s, 1H).Alcohol 164: Crude aldehyde 163 was reacted with NaCNBH 3 according to the procedure of Borch et al., "J. Amer. Chem. Soc., 93: 2897 (1971), to give 269 mg (65%) of alcohol 164 after flash chromatography (40% hexanes in ethyl acetate). 1 H NMR (CDCl 3 , 300 MHz): δ 6.91 (m, 1H); 4.75 (dd, 1H, J = 3.9, 8.7 Hz); 4.34 (br t, 1H, J = 4.1Hz); 4.25- 1.15 (m, 1H); 3.85-3.70 (m, 4H); 3.77 (s, 3H); 3.16 (s, 3H), 2.95 (dd, 1H, J = 5.7, 18.6 Hz); 2.37 (dd, 1H, J = 7.1, 18.6 Hz); 2.26 (brs, 1H).
Příklad 46Example 46
Aziridin 165: Alkohol 164 (208 mg, 0,62 mmol) byl acetylován obvyklým způsobme (AcCl, pyridin, dichlormetan, kat. DMAP), tak vznikl acetát (241 mg, 100%). Surový acetát (202 mg, 0,54 mmol) reagoval v pokojové teplotě s Ph3P (155 mg) v THF (12 ml) po dobu 2 hodin. Poté byla přidána H2O (1,1 ml) vtrietylamin (224 μΐ) a roztok přes noc míchán. Reakční směs byla koncentrována a zbytek rozdělen mezi etylacetát a nasycený hydrogenuhličitan/solanku. Organická vrstva byla vysušena, koncentrována in vacuo a vyčištěna mžikovou chromatografii (10% MeOH v EtOAc), tak vzniklo 125 mg (90%) aziridinu 165 jako bílá pevná látka. 'H NMR (CDC13, 300 MHz): delta 6,80 (m, 1H); 4,44 (br s, 1H); 4,23 (t, 2H, J = 4,8 Hz); 3,82-3,65 (m, 2H); 3,74 (s, 3H); 2,85 (br d, 1H, J= 19,2 Hz); 2,65-2,40 (m, 3H); 2,09 35 (s, 3H); 1,25 (br s, 1H).Aziridine 165: Alcohol 164 (208 mg, 0.62 mmol) was acetylated in the usual manner (AcCl, pyridine, dichloromethane, cat. DMAP) to give acetate (241 mg, 100%). The crude acetate (202 mg, 0.54 mmol) was treated at room temperature with Ph 3 P (155 mg) in THF (12 mL) for 2 hours. H 2 O (1.1 mL) in triethylamine (224 µΐ) was then added and the solution stirred overnight. The reaction mixture was concentrated and the residue partitioned between ethyl acetate and saturated bicarbonate / brine. The organic layer was dried, concentrated in vacuo and purified by flash chromatography (10% MeOH in EtOAc) to give 125 mg (90%) of aziridine 165 as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ 6.80 (m, 1H); 4.44 (brs, 1H); 4.23 (t, 2H, J = 4.8Hz); 3.82-3.65 (m, 2 H); 3.74 (s, 3H); 2.85 (br d, 1H, J = 19.2Hz); 2.65-2.40 (m, 3H); 2.09 35 (s, 3H); 1.25 (brs, 1H).
Příklad 47Example 47
N-Boc aziridin 166: Boc anhydrid (113 mg, 0,52 mmol) byl přidán do roztoku aziridinu 165 (125 mg, 0,49 mmol), trietylaminu (70 μΐ), DMAP (kat. množství) v dichlormetanu (7 ml). Po 1 hodině byla reakce koncentrována a zbytek vystaven mžikovou chromatografii (40% EtOAc v hexanech), tak vzniklo 154 mg (88%) N Boc aziridinu 166 jako světlý olej. 'H NMR (CDC13, 300 MHz): delta 6,82 (m, 1H); 4,47 (br m, 1H); 4,23 (t, 2H, J= 4,7 Hz); 3,81 (t, 2H, J= 4,7 Hz); 3,75 (s, 3H); 3,00 (br d, 1H, J= 18,0 Hz); 2,90-2,85 (m, 2H); 2,65-2,55 (m, 1H); 2,10 (s, 3H); 1,44 (s, 9H).N-Boc aziridine 166: Boc anhydride (113 mg, 0.52 mmol) was added to a solution of aziridine 165 (125 mg, 0.49 mmol), triethylamine (70 μΐ), DMAP (cat. Amount) in dichloromethane (7 mL) ). After 1 hour the reaction was concentrated and the residue subjected to flash chromatography (40% EtOAc in hexanes) to give 154 mg (88%) of N Boc aziridine 166 as a light oil. 1 H NMR (CDCl 3 , 300 MHz): δ 6.82 (m, 1H); 4.47 (br m, IH); 4.23 (t, 2H, J = 4.7Hz); 3.81 (t, 2H, J = 4.7Hz); 3.75 (s, 3H); 3.00 (br d, 1H, J = 18.0 Hz); 2.90-2.85 (m, 2 H); 2.65-2.55 (m, IH); 2.10 (s. 3H); 1.44 (s, 9H).
-236CZ 297945 B6-236GB 297945 B6
Příklad 48Example 48
Azidoester 167: Aziridin 166 (154 mg, 0,43 mmol), azid sodný (216 mg), a chlorid amonný (223 mg) byly zahřívány při teplotě 100°C v DMF (5 ml) po dobu 18 hodin. Ochlazená reakční směs byla oddělena mezi etyléter a solanku. Éterová vrstva byla promyta H2O, solankou a vysušena přes MgSO4. Koncentrace dala surový zbytek, který reagoval se 40% TFA v dichlormetanu při teplotě místnosti. Po 2 hodinách byla rekce koncentrována in vacuo, a vznikl světlý olej, který byl prohnán krátkou kolonou silikagelu s eluentem EtOAc. Produkt byl poté acylován obvyklým způsobem (AcCI, pyridin, dichlormetan, kat. DMA) a vznikl azidoester 167 jako bledě žlutý olej 16 mg (11% pro 3 kroky) po mžikové chromatografíi (5% MeOh v chloroformu). *HNMR (CDC13, 300 MHz): delta 6,85 (m, 1H); 5,80 (br, d, 1H, 7,8 Hz); 4,55 (m, 1H);Azidoester 167: Aziridine 166 (154 mg, 0.43 mmol), sodium azide (216 mg), and ammonium chloride (223 mg) were heated at 100 ° C in DMF (5 mL) for 18 hours. The cooled reaction mixture was partitioned between ethyl ether and brine. The ether layer was washed with H 2 O, brine and dried over MgSO 4 . Concentration gave the crude residue which was treated with 40% TFA in dichloromethane at room temperature. After 2 hours, the reaction was concentrated in vacuo to give a light oil which was passed through a short column of silica gel with EtOAc eluent. The product was then acylated in the usual manner (AcCl, pyridine, dichloromethane, cat. DMA) to give the azidoester 167 as a pale yellow oil of 16 mg (11% for 3 steps) after flash chromatography (5% MeOh in chloroform). 1 H NMR (CDCl 3 , 300 MHz): δ 6.85 (m, 1H); 5.80 (br. D, 1H, 7.8 Hz); 4.55 (m, IH);
4,25-4,10 (m, 3H); 3,90-3,85 (m, 2H); 3,78 (s, 3H); 3,55 (m, 1H); 2,90 (dd, 1H, J= 5,4, 17,0 Hz); 2,45-2,25 (m, 1H); 2,10 (s, 3H); 2,05 (s, 3H).4.25-4.10 (m, 3H); 3.90-3.85 (m, 2 H); 3.78 (s, 3H); 3.55 (m, IH); 2.90 (dd, 1H, J = 5.4, 17.0 Hz); 2.45-2.25 (m, IH); 2.10 (s. 3H); 2.05 (s, 3H).
Příklad 49Example 49
Aminokyselina 168. Do roztoku esteru 167 (16 mg, 0,047 mmol) v THF (1 ml), ochlazeného na 0 °C byl přidán vod. KOH (208 μΐ z roztoku 0,476 M). Reakce byla poté zahřáta na teplotu místnosti a míchána po dobu 2 hodin. Reakce byla poté acidifikována na pH = 4,0 pomocí acidické pryskyřice Amberlite IR-120 (plus). Pryskyřice byla pak filtrována a promyta etanolem a H2O. Koncentrace in vacuo dala 14 mg (100%) azidokarboxylové kyseliny jako bílé pevné látky. Azidokyselina byla rozpuštěna vetanolu (2 ml) a reagovala s vodíkovým plynem (1 atm) při Lindlarově katalyzátoru (15 mg) po 16 hodin podle postupu Corey et al., „Synthesis“, 590 (1975). Reakční směs byla filtrována přes celitový list a vymývána horkým etanolem a H2O. Koncentrace in vacuo dala bledě oranžovou pevnou látku, která byla čištěna sloupcovou chromatografií Cis eluovanou H2O. Frakce, obsahující produkt, byly spojeny a lyofilizovány tak, že vzniklo 9,8 mg, 168 jako bílý prášek. *H NMR (D2O, 500 MHz): delta: 6,53 (br s, 1H); 4,28 (br m, 1H); 4,08 (dd, 1H, J = 11,0, 11,0 Hz); 3,80-3,65 (komplexní m, 4H); 3,44 (m, 1H); 2,84 (zřejmé dd, 1H); 2,46-2,39 (komplexní m, 1H); 2,08 (s, 3H).Amino acid 168. To a solution of ester 167 (16 mg, 0.047 mmol) in THF (1 mL) cooled to 0 ° C was added aq. KOH (208 μΐ of 0,476 M solution). The reaction was then warmed to room temperature and stirred for 2 hours. The reaction was then acidified to pH = 4.0 with Amberlite IR-120 (plus). The resin was then filtered and washed with ethanol and H 2 O. Concentration in vacuo gave 14 mg (100%) of the azidocarboxylic acid as a white solid. The azido acid was dissolved in ethanol (2 mL) and treated with hydrogen gas (1 atm) at Lindlar catalyst (15 mg) for 16 hours according to the procedure of Corey et al., "Synthesis", 590 (1975). The reaction mixture was filtered through a celite pad and eluted with hot ethanol and H 2 O. Concentration in vacuo gave a pale orange solid which was purified by column chromatography C 18 eluted with H 2 O. The fractions containing the product were combined and lyophilized to give a 9% yield. , 8 mg, 168 as a white powder. * H NMR (D 2 O, 500 MHz) delta: 6.53 (br s, 1H); 4.28 (br m, IH); 4.08 (dd, 1H, J = 11.0, 11.0 Hz); 3.80-3.65 (complex m, 4H); 3.44 (m, IH); 2.84 (apparent dd, 1H); 2.46-2.39 (complex m, 1H); 2.08 (s, 3H).
Příklad 50Example 50
MOM epoxyéter 19 (PG=metoxymetyl): Připravený v 74% z epoxyalkoholu 1 podle postupu Mordini et al., „J. Org. Chem.“, 49:4784 (1994). rH NMR (CDC13, 300 MHz): delta 6,73 (m, 1H); 4,87 (s, 2H); 4,59 (t, 1H, J= 2,4 Hz); 3,76 (s, 3H), 3,57 (m, 1H); 3,50-3,40 (m, 1H); 3,48 (s, 3H); 3,10 (d, J= 19,5 Hz); 2,45 (m, 1H).MOM epoxy ether 19 (PG = methoxymethyl): Prepared in 74% of epoxyalcohol 1 according to the procedure of Mordini et al., "J. Org. Chem., 49: 4784 (1994). 1 H NMR (CDCl 3 , 300 MHz): δ 6.73 (m, 1H); 4.87 (s, 2 H); 4.59 (t, 1H, J = 2.4Hz); 3.76 (s, 3H); 3.57 (m, 1H); 3.50-3.40 (m, IH); 3.48 (s, 3H); 3.10 (d, J = 19.5 Hz); 2.45 (m, IH).
Příklad 51Example 51
Aziridin 170: Připraven ve výsledných 77% z epoxidu 19 (PG=metoxymetyl) podle obecného produktu, popsaného v příkladech 3 a 4: 'H NMR (CDC13, 300 MHz): delta 6,85 (m, 1H); 4,78 (s, 2H); 4,54 (m, 1H); 3,73 (s, 3H); 3,41 (s, 3H); 2,87 (d, 1H, J= 18,9 Hz); 2,70-2,45 (m, 3H).Aziridine 170: Prepared in a resultant 77% of epoxide 19 (PG = methoxymethyl) according to the general product described in Examples 3 and 4: 1 H NMR (CDCl 3 , 300 MHz): δ 6.85 (m, 1H); 4.78 (s, 2 H); 4.54 (m, IH); 3.73 (s, 3H); 3.41 (s, 3H); 2.87 (d, 1H, J = 18.9Hz); 2.70-2.45 (m, 3H).
Příklad 52Example 52
Azidoester 22 (PG=Metoxymetyl): Aziridin 170 (329 mg, 1,54 mmol), NaN3 (446 mg) a NH4C1 (151 mg) byly zahřívány při teplotě 65 °C v DMF (20 ml) po dobu 18 hodin. Ochlazená reakční směs byla rozdělena mezi etyléter a solanku. Éterová vrstva byla promyta H2O, solankou a vysušena přes MgSO4. Koncentrace in vacuo dala surový azidoamin jako světlý olej, který byl jímán do CH2C12 (15 ml) a reagoval s pyridinem (4 ml) a AcCI (150 μΐ). Po zpracování vodou následoAzidoester 22 (PG = Methoxymethyl): Aziridine 170 (329 mg, 1.54 mmol), NaN 3 (446 mg), and NH 4 Cl (151 mg) were heated at 65 ° C in DMF (20 mL) for 18 hours. hours. The cooled reaction mixture was partitioned between ethyl ether and brine. The ether layer was washed with H 2 O, brine and dried over MgSO 4 . Concentration in vacuo gave the crude azidoamin as a pale oil which was taken up in CH 2 C1 2 (15 mL) and treated with pyridine (4 mL) and AcCl (150 μΐ). After water treatment follow
-237CZ 297945 B6 vala mžiková chromatografíe zbytku, která dala 350 mg (76%) azidoesteru 22 (PG=metoxymetyl) jako světlý olej. !H NMR (CDC13, 300 MHz): delta 6,78 (s, 1H); 6,39 (br d, 1H, J = 7,8 Hz); 4,72 (d, 1H, J= 6,9 Hz); 4,66 (d, 1H, J= 6,9 Hz); 4,53 (br d, 1H, J= 8,4 30 Hz); 4,00-3,90 (m 1H); 3,80-3,65 (m, 1H); 3,75 (s, 3H); 3,37 (s, 3H); 2,85 (dd, 1H, J= 5,4, 17,7 Hz); 2,35-2,20 (m, 1H); 2,04 (s, 3H).Flash chromatography of the residue gave 350 mg (76%) of azidoester 22 (PG = methoxymethyl) as a light oil. ! 1 H NMR (CDCl 3 , 300 MHz): δ 6.78 (s, 1H); 6.39 (br d, 1H, J = 7.8Hz); 4.72 (d, 1H, J = 6.9Hz); 4.66 (d, 1H, J = 6.9Hz); 4.53 (br d, 1H, J = 8.4, 30 Hz); 4.00-3.90 (m, 1H); 3.80-3.65 (m, IH); 3.75 (s, 3H); 3.37 (s, 3H); 2.85 (dd, 1H, J = 5.4, 17.7 Hz); 2.35-2.20 (m, IH); 2.04 (s, 3H).
Příklad 53Example 53
Aminokyselina 114: Azid 22 (PG=metoxymetyl) (39 mg, 0,131 mmol) reagovala s vodíkovým plynem při 1 atmosféře při Lindlarově katalyzátoru (39 mg) v etanolu po dobu 2,5 hodiny podle postupu Corey et al., „Synthesis“, 590 (1975). Reakční směs byla filtrována celitovým listem, promyta horkým etanolem a koncentrována tak, že vznikl surový amin 33 mg (92%) jako světlá pěna. Amin v THF (1 ml) reagoval s vod. KOH (380 μΐ z 0,476 M roztoku). Po 1 hodině byla reakce acidifíkována na pH 5 = 4,0 pomocí acidické pryskyřice Amberlite IR-120 (plus). Pryskyřice byla poté filtrována, promyta H2O a koncentrována tak, že vznikla světlá pevná látka, která byla čištěna sloupcovou chromatografii C18, eluovanou H2O. Frakce, obsahující produkt, byly spojeny a lyofilizovány tak, že vzniklo 20mg 114 jako bílý prášek. 'HNMR (D2O, 300 MHz): delta 6,65 (s, 1H); 4,87 (d, 1H, J= 7,5 Hz); 4,76 (d, 1H, J= 10 7,5 Hz); 4,47 (br d, 1H, «7= 8,7 Hz); 4,16 (dd, 1H, J= 11,4, 11,4 Hz); 3,70-3,55 (m, 1H); 3,43 (s, 3H); 2,95 (dd, 1H, J= 5,7, 17,4 Hz); 2,60-2,45 (m, 1H); 2,11 (s, 3H).Amino acid 114: Azide 22 (PG = methoxymethyl) (39 mg, 0.131 mmol) was reacted with hydrogen gas at 1 atmosphere at Lindlar catalyst (39 mg) in ethanol for 2.5 hours according to the procedure of Corey et al., "Synthesis", 590 (1975). The reaction mixture was filtered through a celite pad, washed with hot ethanol and concentrated to give the crude amine 33 mg (92%) as a light foam. The amine in THF (1 mL) was treated with aq. KOH (380 μΐ of 0,476 M solution). After 1 hour, the reaction was acidified to pH 5 = 4.0 with Amberlite IR-120 (plus). The resin was then filtered, washed with H 2 O and concentrated to give a light solid which was purified by C 18 column chromatography, eluting with H 2 O. The fractions containing the product were combined and lyophilized to give 20mg of 114 as a white powder . 1 H NMR (D 2 O, 300 MHz): δ 6.65 (s, 1H); 4.87 (d, 1H, J = 7.5Hz); 4.76 (d, 1H, J = 10, 7.5 Hz); 4.47 (br d, 1H, J = 8.7 Hz); 4.16 (dd, 1H, J = 11.4, 11.4 Hz); 3.70-3.55 (m, IH); 3.43 (s, 3H); 2.95 (dd, 1H, J = 5.7, 17.4 Hz); 2.60-2.45 (m, IH); 2.11 (s, 3H).
Příklad 54Example 54
Aminokyselina 171: K pevné aminokyselině 114 (4 mg, 0,015 mmol) byl přidán 40% TFA vCH2C12 (1 ml, ochlazený na 0 °C před přidáním). Po míchání při teplotě místnosti po dobu 1,5 hodiny byla reakční směs koncentrována, až vzniklá bílá pěna. Po několikerém společném odpařování zH2O a následné lyofilizaci vzniklá bílá pevná látka, 5,5 mg 117, jako sůl TFA. ’HNMR (D2O, 300 MHz): delta 6,85 (m, 1H); 4,45 (m, 1H); 4,05 (dd, 1H, J= 11,4, 11,4 Hz); 3,65-3,55 (m, 1H); 3,00-2,90 (m, 1H); 2,60-2,45 (m, 1H); 2,09 (s, 3H).Amino acid 171: To solid amino acid 114 (4 mg, 0.015 mmol) was added 40% TFA in CH 2 Cl 2 (1 mL, cooled to 0 ° C before addition). After stirring at room temperature for 1.5 hours, the reaction mixture was concentrated until a white foam formed. After several common evaporation from H 2 O and subsequent lyophilization, a white solid formed, 5.5 mg of 117 as a TFA salt. 1 H NMR (D 2 O, 300 MHz): δ 6.85 (m, 1H); 4.45 (m, IH); 4.05 (dd, 1H, J = 11.4, 11.4 Hz); 3.65-3.55 (m, IH); 3.00-2.90 (m, IH); 2.60-2.45 (m, IH); 2.09 (s, 3H).
Příklad 55Example 55
Acetonid 180: Do suspenze šikimové kyseliny (25 g, 114 mmol, Aldrich) v metanolu (300 ml) byla přidána /2-toluensulfonová kyselina (274 mg, 1,44 mmol, 1 mol%) a směs byla pro reflux zahřívána po dobu 2 hodin. Po přidání další p-toluensulfonové kyseliny (1 mol%) byla reakce po dobu 26 hodin refluxována a odpařována. Surový metylester (28,17 g) byl suspendován v acetonu (300 ml) a reagoval s dimetoxypropanem (35 ml, 288 mmol) a byl míchán při teplotě místnosti po dobu 6 hodin a poté odpařován. Surový produkt byl rozpouštěn v etylacetátu (400 ml) apromýván nasyceným NaHCO3 (3x125 ml) a nasyceným NaCI. Organická fáze byla vysušena (MgSO4), filtrována a odpařována, takže vznikl surový acetonid 180 (~29,4 g), který byl přímo použit. 'H NMR (CDC13) delta 6,91 (t, 1H, J= 1,1), 4,74 (t, 1H, J= 4,8), 4,11 (t, 1H, J= 6,9), 3,90 (m, 1H), 2,79 (dd, 1H, J= 4,5, 17,4), 2,25 (m, 2H), 1,44 (s, 3H), 1,40 (s, 3H).Acetone 180: To a suspension of shikimic acid (25 g, 114 mmol, Aldrich) in methanol (300 mL) was added [2-toluenesulfonic acid (274 mg, 1.44 mmol, 1 mol%) and the mixture was heated at reflux for 2 hours. After addition of additional p-toluenesulfonic acid (1 mol%), the reaction was refluxed for 26 hours and evaporated. The crude methyl ester (28.17 g) was suspended in acetone (300 mL) and treated with dimethoxypropane (35 mL, 288 mmol) and stirred at room temperature for 6 hours and then evaporated. The crude product was dissolved in ethyl acetate (400 mL) and washed with saturated NaHCO 3 (3x125 mL) and saturated NaCl. The organic phase was dried (MgSO 4 ), filtered and evaporated to give crude acetonide 180 (~ 29.4 g) which was used directly. 1 H NMR (CDCl 3 ) δ 6.91 (t, 1H, J = 1.1), 4.74 (t, 1H, J = 4.8), 4.11 (t, 1H, J = 6, 9), 3.90 (m, 1H), 2.79 (dd, 1H, J = 4.5, 17.4), 2.25 (m, 2H), 1.44 (s, 3H), 1 40 (s, 3H).
Příklad 56Example 56
Mesylát 130: Do roztoku acetonidu 180 (29,4 g, 141 mmol) v CH2C12 (250 ml) při teplotě 0 °C byl přidán trietylamin 5 (29,5 ml, 212 mmol), poté byl během 10 minut přidán metansulfonylchlorid (13,6 ml, 176 mmol). Reakce byla míchána při teplotě 0 °C po dobu 1 hodiny a byla přidána ledově studená voda (250 ml). Po přenosu do zvláštní nálevky byly organická fáze promývána vodou, 5% kyselinou citrónovou (300 ml), nasyceným NaHCO3 (300 ml) a vysušena (MgSO4), filtrována a odpařována. Surový produkt byl přefiltrován krátkým kuželem silikageluMesylate 130: To a solution of acetonide 180 (29.4 g, 141 mmol) in CH 2 Cl 2 (250 mL) at 0 ° C was added triethylamine 5 (29.5 mL, 212 mmol) then added over 10 minutes methanesulfonyl chloride (13.6 mL, 176 mmol). The reaction was stirred at 0 ° C for 1 hour and ice-cold water (250 mL) was added. After transfer to a separate funnel, the organic phase was washed with water, 5% citric acid (300 mL), saturated NaHCO 3 (300 mL) and dried (MgSO 4 ), filtered and evaporated. The crude product was filtered through a short silica gel cone
-238 CZ 297945 B6 na skloněné fritové nálevce, eluované etylacetátem. Filtrát byl odpařen tak, že vznikl mesylát 130 (39,5 g, 91%) jako viskózní olej, který byl přímo použit v dalším kroku: ]H NMR (CDC13) delta 6,96 (m, 1H), 4,80 (m, 2H), 4,28 (dd, 1H, 7 = 6,6, 7,5), 3,79 (s, 3H), 3,12 (s, 3H), 3,01 (dd, 1H, 7=5, 17,7), 2,56-2,46 (m, 1H).On an inclined fritted funnel, eluted with ethyl acetate. The filtrate was evaporated to give mesylate 130 (39.5 g, 91%) as a viscous oil which was used directly in the next step: 1 H NMR (CDCl 3 ) δ 6.96 (m, 1H), 4.80 (m, 2H), 4.28 (dd, 1H, J = 6.6, 7.5), 3.79 (s, 3H), 3.12 (s, 3H), 3.01 (dd, 1H) .Delta. = 5, 17.7), 2.56-2.46 (m, 1H).
Příklad 57Example 57
Diol 131: Do roztoku mesylátu 130 (35,85 g, 117 mmol) v metanolu (500 ml) byla přidána ptoluensulfonová kyselina (1,11 g, 5,85 mol, 5 mol%) a roztok byl refluxován po dobu 1,5 hodiny a odpařován. Zbytek byl znovu rozpuštěn v metanolu (500 ml) a byl refluxován další 4 hodiny. Rozpouštědlo bylo odpařeno a surový olej byl triturován dietyléterem (250 ml). Po dokončení krystalizace přes noc při teplotě 0 °C byla pevná látka přefiltrována a vymyta studeným dietyléterem a usušena tak, aby vznikl diol 131 (24,76 g) jako bílá pevná látka. Odpařováním filtrátu a krystalizací zbytku z metanolu/dietyléteru vznikl další 1,55 g. Získáno 26,3 g (85%) diolu 131: 'H NMR (CD3OD) delta 6,83 (m, 1H), 4,86 (m, 1H), 4,37 (t, 1H, J= 4,2), 3,87 (dd, 1H, J= 4,2, 8,4), 3,75 (s, 3H), 3,13 (s, 3H), 2,98-2,90 (m, 1H), 2,53-2,43 (m, 1H).Diol 131: To a solution of mesylate 130 (35.85 g, 117 mmol) in methanol (500 mL) was added ptoluenesulfonic acid (1.11 g, 5.85 mol, 5 mol%) and the solution was refluxed for 1.5 hours and evaporated. The residue was redissolved in methanol (500 mL) and refluxed for an additional 4 hours. The solvent was evaporated and the crude oil was triturated with diethyl ether (250 mL). After crystallization was completed overnight at 0 ° C, the solid was filtered and washed with cold diethyl ether and dried to give diol 131 (24.76 g) as a white solid. Evaporation of the filtrate and crystallization of the residue from methanol / diethyl ether gave an additional 1.55 g. 26.3 g (85%) of diol 131 were obtained: 1 H NMR (CD 3 OD) δ 6.83 (m, 1H), 4.86 ( m, 1H), 4.37 (t, 1H, J = 4.2), 3.87 (dd, 1H, J = 4.2, 8.4), 3.75 (s, 3H), 3, 13 (s, 3H), 2.98-2.90 (m, 1H), 2.53-2.43 (m, 1H).
Příklad 58Example 58
Epoxyalkohol 1: Suspenze diolu 131 (20,78 g, 78 mmol) v tetrahydrofuranu (400 ml) při teplotě 0 °C reagovala s l,8-diazabicyklo[5,4,0]undec-7-enem (11,7 ml, 78 mmol) a byla míchána při teplotě místnosti po dobu 9 hodin, kdy byla reakce dokončena. Reakční směs byla odpařována a surový zbytek byl rozpuštěn v CH2CÍ2 (200 ml) a byl vymyt nasyceným NaCl (300 ml). Vodná fáze byla extrahována pomocí CH2C12 (2X200 ml). Kombinované organické extrakty byly vysušeny (MgSO4), filtrovány a odpařovány. Surový produkt byl vyčištěn na silikagelu (etylacetát), aby vznikl epoxyalkohol 1 (12 g, 90%) jako bílá pevná látka, jehož spektrum 1H NMR bylo shodné se spektrem, uváděným v literatuře: McGowan, D.A.; Berchtold, G.A., „J. Org. Chem.“, 46:2381 (1981).Epoxyalcohol 1: A suspension of diol 131 (20.78 g, 78 mmol) in tetrahydrofuran (400 mL) at 0 ° C was treated with 1,8-diazabicyclo [5.4.0] undec-7-ene (11.7 mL, 78 mmol) and stirred at room temperature for 9 hours when the reaction was complete. The reaction mixture was evaporated and the crude residue was dissolved in CH 2 CI 2 (200 mL) and was washed with saturated NaCl (300 mL). The aqueous phase was extracted with CH 2 Cl 2 (2X200 mL). The combined organic extracts were dried (MgSO 4 ), filtered and evaporated. The crude product was purified on silica gel (ethyl acetate) to give epoxyalcohol 1 (12 g, 90%) as a white solid whose 1 H NMR spectrum was consistent with that reported in the literature: McGowan, DA; Berchtold, GA, "J. Org. Chem., 46: 2381 (1981).
Příklad 59Example 59
Metoxymetyléter 22 (PG=metoxymetyl): Do roztoku epoxyalkoholu 1 (4 g, 23,5 mmol) v CH2C12 (100 ml) byl přidán N,N'-diizopropyletylamin (12,3 ml, 70,5 mmol), poté chlormetyl metyléter (3,6 ml, 47 mmol, destilovaný z těch, kvality). Roztok byl refluxován po dobu 3,5 hodiny a rozpouštědlo bylo odpařeno. Zbytek byl rozdělen mezi etylacetát (200 ml) a vodu (200 ml). Vodná fáze byla extrahována etylacetátem (100 ml). Kombinované organické extrakty byly vymyty nasyceným NaCl (100 ml), vysušeny (MgSO4), filtrovány a odpařeny tak, že vznikly 4,9 g pevného zbytku, který měl vhodnou čistotu, takže byl přímo použít v dalším kroku: mp 62-65° (surová); mp 64-66 °C (dietyléter/hexan); 'H NMR (CDC13) delta 6,73 (m, 1H), 4,87 (s, 2H), 4,59 (m, 1H);, 3,75 (s, 3H), 3,57 (m, 1H), 3,48 (m přesahující s 4H), 3,07 (dd, 1H), J= 1,2, 19,8), 2,47 (dq, 1H, 7=2,7, 19,5).Methoxymethyl ether 22 (PG = methoxymethyl): To a solution of epoxy alcohol 1 (4 g, 23.5 mmol) in CH 2 C1 2 (100 mL) was added N, N'-diisopropylethylamine (12.3 mL, 70.5 mmol) then chloromethyl methyl ether (3.6 mL, 47 mmol, distilled from those of quality). The solution was refluxed for 3.5 hours and the solvent was evaporated. The residue was partitioned between ethyl acetate (200 mL) and water (200 mL). The aqueous phase was extracted with ethyl acetate (100 mL). The combined organic extracts were washed with saturated NaCl (100 mL), dried (MgSO 4 ), filtered and evaporated to give 4.9 g of a solid residue of suitable purity, so it was directly used in the next step: mp 62-65 ° (crude); mp 64-66 ° C (diethyl ether / hexane); 1 H NMR (CDCl 3 ) δ 6.73 (m, 1H), 4.87 (s, 2H), 4.59 (m, 1H); 3.75 (s, 3H), 3.57 (m (1H), 3.48 (m exceeding 4H), 3.07 (dd, 1H), J = 1.2, 19.8), 2.47 (dq, 1H, J = 2.7, 19, 5).
Analog etylesteru sloučeniny 22:Ethyl ester analog of compound 22:
Do roztoku odpovídajícího etylesteru sloučeniny 1 (12,0 g, 0,065 mmol) v CH2C12 (277 ml) při teplotě místnosti byl přidán diizopropyletylamin (34,0 ml, 0,13 mol), poté chlormetyl metyléter (10,0 ml, 0,19 mol). Reakční směs pak byla po dobu 2 hodin jemně refluxována, ochlazena, koncentrována in vacuo a rozdělena mezi EtOAc a vodu. Organická vrstva byla oddělena a následně promyta zřed. HC1, nasyceným hydrogenuhličitanem, solankou a vysušena přes MgSO4. Po koncentraci in vacuo následovala mžiková chromatografíe na silikagelu (50% hexanů v EtOAc), kdy vzniklo 13,3 g (90%) odpovídajícího etylesteru sloučeniny 22 jako bezbarvá kapalina. Ή NMR (300 MHz, CDC13) delta 6,73-6,71 (m, 1H); 4,87 (s, 2H); 4,61^1,57 (m, 1H); 4,21To a solution of the corresponding ethyl ester of compound 1 (12.0 g, 0.065 mmol) in CH 2 Cl 2 (277 mL) at room temperature was added diisopropylethylamine (34.0 mL, 0.13 mol) followed by chloromethyl methyl ether (10.0 mL). , 0.19 mol). The reaction mixture was then gently refluxed for 2 hours, cooled, concentrated in vacuo and partitioned between EtOAc and water. The organic layer was separated and then washed with dilute. HCl, saturated bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo was followed by flash chromatography on silica gel (50% hexanes in EtOAc) to give 13.3 g (90%) of the corresponding ethyl ester of compound 22 as a colorless liquid. 1 H NMR (300 MHz, CDCl 3 ) δ 6.73-6.71 (m, 1H); 4.87 (s, 2 H); 4.61 - 1.57 (m, 1H); 4.21
-239 CZ 297945 B6 (q, 2H, J= 7,2 Hz); 3,60-3,55 (m, 1H); 3,50-3,45 (m, 1H); 3,48 (s, 3H); 3,12-3,05 (m, 1H); 2,52-2,42 (m, 1H); 1,29 (t, 3H, J= 7,2 Hz).(Q, 2H, J = 7.2Hz); 3.60-3.55 (m, IH); 3.50-3.45 (m, IH); 3.48 (s, 3H); 3.12-3.05 (m, IH); 2.52-2.42 (m, IH); 1.29 (t, 3H, J = 7.2Hz).
Příklad 60Example 60
Alkohol 181: Do roztoku metoxymetyléteru 22 (PG=metoxymetyl) (4,9 g, 22,9 mmol) v 8/1MeOH/H2O (175 ml, v/v) byl přidán azid sodný (7,44 g, 114,5 mmol) a chlorid amonný (2,69 g,Alcohol 181: To a solution of methoxymethyl ether 22 (PG = methoxymethyl) (4.9 g, 22.9 mmol) in 8/1 MeOH / H 2 O (175 mL, v / v) was added sodium azide (7.44 g, 114 mL). , 5 mmol) and ammonium chloride (2.69 g,
50,4 mmol) a směs byla refluxována po dobu 15 hodin. Reakce byla naředěna vodou (75 ml), aby se rozpustily vysrážené soli a roztok byl koncentrován, aby se odstranil metanol. Výsledná vodná fáze, obsahující vysrážený olejovitý zbytek byla naředěna na objem 200 ml vodou a byla extrahována etylacetátem (3X100 ml). Kombinované organické extrakty byly promyty nasyceným NaCl (100 ml), vysušeny (MgSO4), filtrovány a odpařovány. Surový produkt byl čištěn na silikagelu (1/1-hexan/etylacetát) tak, že vznikl alkohol 181 (5,09 g, 86%) jako bledě žlutý olej. Po následné přípravě alkoholu 181 vznikl materiál, který byl dostatečně čistý, aby mohl být použit v dalším kroku bez dalšího čištění: 'H NMR (CDC13) delta 6,86 (m, 1H), 4,79 (s, 2H), 4,31 (br t, 1H, J= 4,2), 3,90-3,75, 3,77 (m překrývající s, 5H), 3,43 (s, 3H), 2,92 (d, 1H, J- 6,6), 2,87 (dd, 1H, J= 5,4, 18,6), 2,21-2,30 (m, 1H).50.4 mmol) and the mixture was refluxed for 15 hours. The reaction was diluted with water (75 mL) to dissolve the precipitated salts and the solution was concentrated to remove methanol. The resulting aqueous phase containing the precipitated oily residue was diluted to 200 mL with water and extracted with ethyl acetate (3X100 mL). The combined organic extracts were washed with saturated NaCl (100 mL), dried (MgSO 4 ), filtered and evaporated. The crude product was purified on silica gel (1/1-hexane / ethyl acetate) to give alcohol 181 (5.09 g, 86%) as a pale yellow oil. Subsequent preparation of alcohol 181 gave a material that was sufficiently pure to be used in the next step without further purification: 1 H NMR (CDCl 3 ) δ 6.86 (m, 1H), 4.79 (s, 2H), 4.31 (br t, 1H, J = 4.2), 3.90-3.75, 3.77 (m overlapping with, 5H), 3.43 (s, 3H), 2.92 (d, 1H, J = 6.6), 2.87 (dd, 1H, J = 5.4, 18.6), 2.21-2.30 (m, 1H).
Příklad 61Example 61
Mesylát 184: Do roztoku alkoholu 181 (6,47 g, 25,2 mmol) v CH2C12 (100 ml) při teplotě 0 °C byl přidán nejdříve trietylamin (4,4 ml, 31,5 mmol), pak metansulfonylchlorid (2,14 ml, 27,7 mmol). Reakce byla míchána při teplotě 0 °C po dobu 45 minut, poté zahřívána na teplotu místnosti, míchána po dobu 15 minut. Reakce byla odpařena a zbytek byl rozdělen mezi etylacetát (200 ml) a vodu (100 ml). Organická fáze byla promyta vodou (100 ml), nasyceným NaHCO3 (100 ml), nasyceným NaCl (100 ml). Výplach vody byl extrahován jedinou dávkou etylacetátu, který byl promyt stejnými roztoky NaHCO3/NaCl. Kombinované organické extrakty byly vysušeny (MgSO4), filtrovány a odpařeny. Surový produkt měl vhodnou čistotu, aby mohl být použit přímo v následujícím kroku: Ή BNR (CDC13) delta 6,85 (m, 1H), 4,82 (d, 1H, J = 6,9), 4,73 (d, 1H, J= 6,9), 25 4,67 (dd, 1H, J= 3,9, 9,0), 4,53 (br, t, 1H, J= 4,2), 3,78 (s, 3H), 3,41 (s, 3H), 3,15 (s, 3H), 2,98 (dd, 1H, J= 6,0, 18,6), 2,37 (m, 1H); ,3C NMR (CDC13) delta 165,6, 14,3, 129,6, 96,5, 78,4. 69,6, 55,8, 55,7, 52,1, 3,2, 29,1.Mesylate 184: To a solution of alcohol 181 (6.47 g, 25.2 mmol) in CH 2 Cl 2 (100 mL) at 0 ° C was added first triethylamine (4.4 mL, 31.5 mmol) then methanesulfonyl chloride. (2.14 mL, 27.7 mmol). The reaction was stirred at 0 ° C for 45 minutes, then warmed to room temperature, stirred for 15 minutes. The reaction was evaporated and the residue was partitioned between ethyl acetate (200 mL) and water (100 mL). The organic phase was washed with water (100 mL), saturated NaHCO 3 (100 mL), saturated NaCl (100 mL). The water wash was extracted with a single portion of ethyl acetate, which was washed with the same NaHCO 3 / NaCl solutions. The combined organic extracts were dried (MgSO 4 ), filtered and evaporated. The crude product was of suitable purity to be used directly in the following step: Ή BNR (CDCl 3 ) δ 6.85 (m, 1H), 4.82 (d, 1H, J = 6.9), 4.73 ( d, 1H, J = 6.9), 25 4.67 (dd, 1H, J = 3.9, 9.0), 4.53 (br, t, 1H, J = 4.2), 3, 78 (s, 3H), 3.41 (s, 3H), 3.15 (s, 3H), 2.98 (dd, 1H, J = 6.0, 18.6), 2.37 (m, 1H); 13 C NMR (CDCl 3 ) δ 165.6, 14.3, 129.6, 96.5, 78.4. 69.6, 55.8, 55.7, 52.1, 3.2, 29.1.
Příklad 62Example 62
Aziridin 170: Do roztoku mesylátu 184 (8,56 g, 25 mmol) v THF (150 ml) při teplotě 0 °C byl přidán Ph3P (8,2 g, 31 mmol), zpočátku přidána třetina množství při chlazení, a poté, po odstranění ledové lázně přidán zbytek Ph3P za dobu 10 až 15 minut. Po přidání celého množství Ph3P byla reakce míchána při teplotě místnosti po dobu 3 hodiny s vytvořením bílé sraženiny. Do této suspenze byl přidán trietylamin (5,2 ml, 37,5 mmol) a voda (10 ml) a směs byla míchána při pokojové teplotě po dobu 12 hodin. Reakce byla koncentrována pro odstranění THF a zbytek byl rozdělen mezi CH2C12 (200 ml a nasycený NaCl (200 ml). Vodná fáze byla extrahována několika díly CH2C12 a kombinované organické extrakty byly vysušeny (Na2SO4), filtrovány a odpařovány tak, aby ze surového produktu, který byl vyčištěn na silikagelu (10% MeOH/EtOAc), aby vznikl aziridin 170 (4,18 g, 78%) jako olej, který typicky obsahoval stopová množství nečistoty trifenylfosfinoxidu: *H NMR (CDC13) delta 6,81 (m, 1H), 4,78 (s, 2H), 4,54 (m, 1H), 3,73 (s, 3H), 3,41 (s, 3H), 2,87 (zřej. dd, 1H), 2,64 (br s, 1H), 2,56-2,47 (m, 2H), NH signál nebyl zřejmý; 13C NMR(CDC13) delta 166,9, 132,5, 128,0, 95,9, 69,5, 55,2, 51,6, 31,1, 27,7, 24,1.Aziridine 170: To a solution of mesylate 184 (8.56 g, 25 mmol) in THF (150 mL) at 0 ° C was added Ph 3 P (8.2 g, 31 mmol), initially added a third of the amount while cooling, and then, after removing the ice bath, the remainder of Ph 3 P is added over a period of 10 to 15 minutes. After addition of the entire amount of Ph 3 P, the reaction was stirred at room temperature for 3 hours to form a white precipitate. To this suspension was added triethylamine (5.2 mL, 37.5 mmol) and water (10 mL) and the mixture was stirred at room temperature for 12 hours. The reaction was concentrated to remove THF and the residue was partitioned between CH 2 Cl 2 (200 mL and saturated NaCl (200 mL). The aqueous phase was extracted with several portions of CH 2 Cl 2 and the combined organic extracts were dried (Na 2 SO 4 ), filtered and evaporated to a crude product that was purified on silica gel (10% MeOH / EtOAc) to give aziridine 170 (4.18 g, 78%) as an oil typically containing trace amounts of triphenylphosphine oxide impurity: 1 H NMR ( CDCl 3 ) δ 6.81 (m, 1H), 4.78 (s, 2H), 4.54 (m, 1H), 3.73 (s, 3H), 3.41 (s, 3H), 2 87 (app. Dd, 1H), 2.64 (br s, 1H), 2.56-2.47 (m, 2H), NH signal not apparent; 13 C NMR (CDCl 3 ) δ 166.9, 132.5, 128.0, 95.9, 69.5, 55.2, 51.6, 31.1, 27.7, 24.1.
-240CZ 297945 B6-240GB 297945 B6
Příklad 63Example 63
Amin 182: Do roztoku aziridinu 170 (3,2 g, 15 mmol) v DMF (30 ml) bylo po několik minut aplikováno vakuum na rotačním odpařovací (40 °C) na odplynění roztoku. Do roztoku byl přidán azid sodný (4,9 g, 75 mmol) a chlorid amonný (1,6 g, 30 mmol) a směs byla zahřívána po dobu 21 hodin při teplotě 65 až 70 °C. Reakční směs byla ochlazena na teplotu místnosti, naředěna etylacetátem (~100 ml) a byla filtrována. Filtrát byl odpařen a zbytek byl rozdělen mezi dietyléter (100 ml) a nasycený NaCl (100 ml). Organická fáze byla znovu promyta nasyceným NaCl 20 (100 ml), vysušena (MgSO4), filtrována a byla odpařena. Další surový produkt byl získán z vodných výplachů extrakcí pomocí etylacetátu a reakce byla stejná, jako je popsána výše. Surový produkt byl čištěn na silikagelu (5%MeOH/CH2Cl2), aby vznikl amin 182 (2,95 g) jako olej, který obsahoval malé množství 25 nečistoty trifenylfosfinoxidu z předchozího kroku: 'HNMR (CDC13) delta 6,82 (t, 1H, J=2,3), 4,81 (ed, 1H, J= 7,2), 4,77 (d, 1H, J= 6,9), 4,09-4,04 (m, 1H), 3,76 (s, 3H), 3,47 a 3,44 (m přesahující s, 4H), 2,94-2,86 (m, 2H), 2,36-2,24 (m, 1H); I3C NMR (CDCls) delta 165,9, 137,3, 128,2, 96,5, 79,3,61,5,55,7, 55,6,51,9, 29,5.Amine 182: To a solution of aziridine 170 (3.2 g, 15 mmol) in DMF (30 mL) was applied a rotavap (40 ° C) vacuum for several minutes to degass the solution. Sodium azide (4.9 g, 75 mmol) and ammonium chloride (1.6 g, 30 mmol) were added to the solution, and the mixture was heated at 65-70 ° C for 21 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (~ 100 mL) and filtered. The filtrate was evaporated and the residue was partitioned between diethyl ether (100 mL) and saturated NaCl (100 mL). The organic phase was washed again with saturated NaCl 20 (100 mL), dried (MgSO 4 ), filtered and evaporated. Additional crude product was obtained from aqueous washes by extraction with ethyl acetate and the reaction was as described above. The crude product was purified on silica gel (5% MeOH / CH 2 Cl 2 ) to give amine 182 (2.95 g) as an oil containing a small amount of the 25 triphenylphosphine oxide impurity from the previous step: 1 H NMR (CDCl 3 ) δ 6, 82 (t, 1H, J = 2.3), 4.81 (ed, 1H, J = 7.2), 4.77 (d, 1H, J = 6.9), 4.09-4.04 (m, 1H), 3.76 (s, 3H), 3.47 and 3.44 (m in excess of, 4H), 2.94-2.86 (m, 2H), 2.36-2.24 (m, 1 H); I3 C NMR (CDCl) d 165.9, 137.3, 128.2, 96.5, 79,3,61,5,55,7, 55,6,51,9, 29.5.
Příklad 64Example 64
N-tritylaziridin 183: Amin 182 (2,59 g, 10,2 mmol) byl rozpuštěn v 5% HCl/MeOH (30 ml) a roztok byl míchán po dobu 3 hodin při teplotě místnosti. Přidáno bylo dalších 5% HCl/MeOH (10 ml) při míchání po dobu 1 hodiny a rozpouštědlo bylo odpařeno tak, že po vysokém vakuu vznikly 2,52 g, soli HC1 jako činící pevná látka. Do roztoku soli HC1 v CH2CL2 (50 ml) při teplotě 0 °C byl přidán trietylamin (3,55 ml, 25,5 mmol), poté byl přidán pevný tritylchlorid (5,55 g, 12,8 mmol) v jedné dávce. Směs byla míchána při teplotě 0 °C po dobu 1 hodiny, a pak byla zahřáta na teplotu místnosti za míchání po dobu 2 hodin. Reakce byla ochlazena na 0 °C, byl přidán trietylamin (3,6 ml, 25,5 mmol) a metansulfonylchlorid (0,97 ml, 12,5 mmol) za míchání výsledné směsi po dobu 1 hodiny při teplotě 0 °C a po dobu 22 hodin při teplotě místnosti. Reakce byla odpařena a zbytek byl rozdělen mezi dietyléter (200 ml) a vodu (200 ml). Organická fáze byla promyta vodou (200 ml) a spojené vodné fáze byly extrahovány dietyléterem (200 ml). Spojené organické extrakty byly promyty vodou (100 ml), nasyceným NaCl (200 ml) a byly vysušeny (Na2SO4), filtrovány a odpařeny. Surový produkt byl čištěn na silikagelu (1/1-hexan/CH2C12) tak, aby vnikl N-tritylaziridin 183 (3,84 g, 86%) jako bílá pěna: 1H NMR (CDC13) delta 7,4-7,23 (m, 16H), 4,32 (m, 1H), 3,81 (s, 3H), 3,06 (dt, 1H, J= 1,8, 17,1), 2,94-2,86 (m, 1H), 2,12 (m, 1H), 1,85 (t, 1H, J= 5,0).N-tritylaziridine 183: The amine 182 (2.59 g, 10.2 mmol) was dissolved in 5% HCl / MeOH (30 mL) and the solution was stirred for 3 hours at room temperature. An additional 5% HCl / MeOH (10 mL) was added with stirring for 1 hour and the solvent was evaporated to give 2.52 g of the HCl salt as a tanning solid under high vacuum. To a solution of the HCl salt in CH 2 Cl 2 (50 mL) at 0 ° C was added triethylamine (3.55 mL, 25.5 mmol) then solid trityl chloride (5.55 g, 12.8 mmol) was added in single dose. The mixture was stirred at 0 ° C for 1 hour, and then warmed to room temperature with stirring for 2 hours. The reaction was cooled to 0 ° C, triethylamine (3.6 mL, 25.5 mmol) and methanesulfonyl chloride (0.97 mL, 12.5 mmol) were added while stirring the resulting mixture for 1 hour at 0 ° C and after for 22 hours at room temperature. The reaction was evaporated and the residue was partitioned between diethyl ether (200 mL) and water (200 mL). The organic phase was washed with water (200 mL) and the combined aqueous phases were extracted with diethyl ether (200 mL). The combined organic extracts were washed with water (100 mL), saturated NaCl (200 mL) and dried (Na 2 SO 4 ), filtered and evaporated. The crude product was purified on silica gel (1/1-hexane / CH 2 Cl 2 ) to give N-tritylaziridine 183 (3.84 g, 86%) as a white foam: 1 H NMR (CDCl 3 ) δ 7.4 -7.23 (m, 16H), 4.32 (m, 1H), 3.81 (s, 3H), 3.06 (dt, 1H, J = 1.8, 17.1), 2.94 -2.86 (m, 1H), 2.12 (m, 1H), 1.85 (t, 1H, J = 5.0).
Příklad 65Example 65
Sloučenina 190: Roztok N-tritylaziridinu 183 (100 mg, 0,23 mmol), cyklohexanolu (2 ml) a trifluoridéteru boritého (42 μΐ, 0,35 mmol) byl zahříván při teplotě 70 °C po dobu 1,25 hodiny a byl odpařován. Zbytek byl rozpuštěn v pyridinu (2 ml) a reagoval s acetanhydridem (110 μΐ, 1,15 mmol) a katalytickým DMPA. Po míchání po dobu 3 hodin při pokojové teplotě byla reakce odpařována. Zbytek byl rozdělen mezi etylacetát a 5% kyselinu citrónovou. Vodná fáze byla extrahována pomocí etylacetátu a spojené organické extrakty byly promývány nasyceným NaHCO3 a nasyceným NaCl. Organická fáze byla vysušena (MgSO4), filtrována a odpařována. Surový produkt byl čištěn na silikagelu (1/1-hexan/etylacetát), což umožnilo vznik sloučeniny 190 (53 mg, 69%) jako pevné látky: mp 105-107 °C (etylacetát/hexan); 'HNMR (CDC13) delta 6,78 (m, 1H), 6,11 (d, 1H), J = Ί,4), 4,61 (m, 1H), 4,32-4,23 (m, 1H), 3,76 (s, 3H), 2,44-3,28 (m, 2H), 2,85 (dd, 1H, J= 5,7, 17,6), 2,28-2,17 (m, 1H), 2,04 (s, 3H), 1,88-1,19 (m, 10H).Compound 190: A solution of N-tritylaziridine 183 (100 mg, 0.23 mmol), cyclohexanol (2 mL), and boron trifluoride ether (42 μΐ, 0.35 mmol) was heated at 70 ° C for 1.25 hours and was evaporated. The residue was dissolved in pyridine (2 mL) and treated with acetic anhydride (110 µΐ, 1.15 mmol) and catalytic DMPA. After stirring for 3 hours at room temperature, the reaction was evaporated. The residue was partitioned between ethyl acetate and 5% citric acid. The aqueous phase was extracted with ethyl acetate and the combined organic extracts were washed with saturated NaHCO 3 and saturated NaCl. The organic phase was dried (MgSO 4 ), filtered and evaporated. The crude product was purified on silica gel (1/1 hexane / ethyl acetate) to afford compound 190 (53 mg, 69%) as a solid: mp 105-107 ° C (ethyl acetate / hexane); 1 H NMR (CDCl 3 ) δ 6.78 (m, 1H), 6.11 (d, 1H), J = =, 4), 4.61 (m, 1H), 4.32-4.23 (m 1 H, 3.76 (s, 3H), 2.44-3.28 (m, 2H), 2.85 (dd, 1H, J = 5.7, 17.6), 2.28-2 17 (m, 1H); 2.04 (s, 3H); 1.88-1.19 (m, 10H).
-241 CZ 297945 B6-241 GB 297945 B6
Příklad 66Example 66
Sloučenina 191: Do roztoku sloučeniny 190 (49 mg, 0,15 mmol) v THF byl přidán trifenylfosfín (57 mg, 0,22 mmol) a voda (270 μΐ) a roztok byl zahříván při teplotě 50 °C po dobu 10 hodin. Reakce byla odpařena a zbytek byl rozpuštěn v etylacetátu, vysušen (Na2SO4), filtrován a odpařen. Surový produkt byl čištěn na silikagelu (1/1-metanol/etylacetát), čímž vznikl amin (46 mg) jako bledě žlutá pevná látka. Do roztoku aminu v THF (1,5 ml) byl přidán roztok l,039N KOH (217 μΐ) a voda (200 μΐ). Směs byla míchána při pokojové teplotě po dobu 1 hodiny a poté byla ochlazena na 0 °C a acidifíkována na pH 6-6,5 pomocí iontoměničové pryskyřice IR 120. Pryskyřice byla přefiltrována, promyta metanolem a filtrát byl odpařen. Pevný zbytek byl rozpuštěn ve vodě a byl prohnán kolonou (4X1 cm) 1-18 se silikagelem s reverzní fází, elutovanou vodou, a poté 2,5% acetonitrilem/vodou. Frakce produktu byla spojena a odpařeny a zbytek byl rozpuštěn ve vodě a lyofilizován tak, že vznikla aminokyselina 191 (28 mg) jako bílá pevná látka: 'H NMR (C2O) delta 6,47 (br s, IH), 4,80 (br d, IH), 4,00 (dd, IH, 7= 8,9, 11,6), 3,59-3,50 (m, 2H), 2,87 (dd, IH, J = 5,5, 17,2), 2,06 (s, 3H), 1,90-1,15 (série m, 10H); Analýza pro Ci5H24N2O4.H2O: Vypočteno: C 57,31; H, 8,34; N, 8,91: zjištěno: C, 57,38; H, 8,09; N, 8,77.Compound 191: To a solution of compound 190 (49 mg, 0.15 mmol) in THF was added triphenylphosphine (57 mg, 0.22 mmol) and water (270 μΐ) and the solution was heated at 50 ° C for 10 hours. The reaction was evaporated and the residue was dissolved in ethyl acetate, dried (Na 2 SO 4 ), filtered and evaporated. The crude product was purified on silica gel (1/1-methanol / ethyl acetate) to give the amine (46 mg) as a pale yellow solid. To a solution of the amine in THF (1.5 mL) was added a solution of 1.039N KOH (217 μΐ) and water (200 μΐ). The mixture was stirred at room temperature for 1 hour and then cooled to 0 ° C and acidified to pH 6-6.5 with IR 120 ion exchange resin. The resin was filtered, washed with methanol and the filtrate was evaporated. The solid residue was dissolved in water and passed through a 1-18 column of reverse phase silica gel eluted with water, followed by 2.5% acetonitrile / water. The product fractions were combined and evaporated and the residue was dissolved in water and lyophilized to give amino acid 191 (28 mg) as a white solid: 1 H NMR (C 2 O) δ 6.47 (br s, 1H), 4, 80 (br d, 1H), 4.00 (dd, 1H, J = 8.9, 11.6), 3.59-3.50 (m, 2H), 2.87 (dd, 1H, J 5.5, 17.2), 2.06 (s, 3H), 1.90-1.15 (m series, 10H); Analysis for C 15 H 24 N 2 O 4 .H 2 O: Calculated: C 57.31; H, 8.34; N, 8.91. Found: C, 57.38; H, 8.09; N, 8.77.
Příklad 67 bis-BOc quanidinoester 201: Reakce podle postupu Kim and 15 Qian, „Tetrahedron Lett.“, 34:7677 (1993). Do roztoku aminu 200 (529 mg, 1,97 mmol, připraveného metodou Příkladu 109, bis-Boc thiomočovina (561 mg, 2,02 mmol) a Et3N (930 μΐ) v suchém DMF (5,0 ml), ochlazeného na 0 °C, byl přidán HgCl2 (593 mg, 2,18 mmol) v jedné dávce. Heterogenní reakční směs byla míchána po dobu 45 minut při teplotě 0 °C, pak při teplotě místnosti po dobu 15 minut, poté byla reakce naředěna EtOAc a filtrována přes celitový list. Po koncentraci in vacuo následovala mžiková chromatografie zbytku na silikagelu (10% hexany v etylacetátu), vzniklo 904 mg (90%) 201 jako světlý olej. 'H NMR (CDC13, 300 MHz): delta 11,39 (s, IH); 8,63 (d, IH, J= 7,8 Hz), 6,89 (t, IH, J= 2,4 Hz), 6,46 (d IH, J= 8,7 Hz); 4,43^1,32 (m, IH); 4,27-4,17 (m, IH); 4,134,06 (m, IH); 3,77 (s, 3H); 3,67-3,59 (m, IH); 2,83 (dd, IH, J = 5,1, 17,7 Hz); 2,45-2,33 (m, IH); 1,95 (s, 3H); 1,65-1,50 (m, 2H); 1,45 (s, 18H); 0,90 (t, 3H, J= 7,5 Hz).Example 67 bis-BOc quanidinoester 201: Reaction according to Kim and 15 Qian, "Tetrahedron Lett.", 34: 7677 (1993). To a solution of amine 200 (529 mg, 1.97 mmol, prepared by the method of Example 109), bis-Boc thiourea (561 mg, 2.02 mmol) and Et 3 N (930 μΐ) in dry DMF (5.0 mL), cooled to 0 ° C, HgCl 2 (593 mg, 2.18 mmol) was added in one portion The heterogeneous reaction mixture was stirred for 45 minutes at 0 ° C, then at room temperature for 15 minutes, then the reaction was diluted EtOAc and filtered through a pad of celite followed by concentration in vacuo followed by flash chromatography of the residue on silica gel (10% hexanes in ethyl acetate) to give 904 mg (90%) of 201 as a light oil. 1 H NMR (CDCl 3 , 300 MHz): δ 11 39 (s, 1H); 8.63 (d, 1H, J = 7.8 Hz); 6.89 (t, 1H, J = 2.4 Hz); 6.46 (d IH, J = 8 Hz); 7 Hz), 4.43-4.32 (m, 1H); 4.27-4.17 (m, 1H); 4.134.06 (m, 1H); 3.77 (s, 3H); 67-3.59 (m, 1H); 2.83 (dd, 1H, J = 5.1, 17.7 Hz); 2.45-2.33 (m, 1H); 1.95 (s) 1.65-1.50 (m, 2H), 1.45 (s, 18H), 0.90 (t, 3H, J = 7.5 Hz).
Příklad 68Example 68
Kyselina karboxylová 202: Do roztoku metylesteru 201 (904 mg, 30 1,77 mmol) v THF (10 ml) byl přidán vodný KOH (3,45 ml z roztoku 1,039 N). Reakční směs byla míchána při teplotě místnosti po dobu 17 hodin, ochlazena na 0 °C a acidifíkována na pH 4,0 pomocí acidické piyskyřice Amberlite IR-120 (H ' j. Pryskyřice byla filtrována a promyta vodou a metanolem. Koncentrací in vacuo vznikla volná kyselina jako světlá pěna, která byla použita bez dalšího čištění v další reakci.Carboxylic acid 202: To a solution of methyl ester 201 (904 mg, 30 1.77 mmol) in THF (10 mL) was added aqueous KOH (3.45 mL of 1.039 N solution). The reaction mixture was stirred at room temperature for 17 hours, cooled to 0 ° C and acidified to pH 4.0 with Amberlite IR-120 (H 1 J) acidic resin. The resin was filtered and washed with water and methanol. an acid as a light foam which was used in the next reaction without further purification.
Příklad 69Example 69
Guanidinkarboxylová kyselina 203: Do roztoku bis-Boc guanidnylové kyseliny 202 (surová z předchozí reakce) v CH2C12 (40 ml), ochlazeného na 0 °C, byla přidána čistá trifluorooctová kyselina (25 ml). Reakční směs byla míchána při teplotě 0 °C po dobu 1 hodiny, a poté při teplotě místnosti po dobu 2 hodin. Koncentrací in vacuo vznikla světle oranžová pevná látka, která byla čištěna chromatografií Cu se zpětnou fází, eluovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány tak, že vzniklo 495 mg (68%, 2 kroky) guanidinkarboxylové kyseliny 203 jako sůl trifluorooctové kyseliny. 'H NMR (D2O, 300 MHz): delta 6,66 (s, IH); 4,29 (bd, 1, J= 9,0 Hz); 4,01 (dd, IH, J= 10,8, 10,8 Hz); 3,87-3,79 (m, IH); 3,76-3,67 (m, IH); 3,60-3,50 (m, IH), 2,83 (dd, IH, J= 5,1, 17,4 Hz); 2,47-2,36 (m, IH); 2,06 (s, 3H); 1,65-1,50Guanidine acid 203: To a solution of bis-Boc guanidnyl acid 202 (crude from previous reaction) in CH 2 C1 2 (40 mL), cooled to 0 ° C was added neat trifluoroacetic acid (25 mL). The reaction mixture was stirred at 0 ° C for 1 hour, and then at room temperature for 2 hours. Concentration in vacuo gave a light orange solid, which was purified by reverse phase Cu chromatography eluting with water. Fractions containing the desired product were combined and lyophilized to give 495 mg (68%, 2 steps) of guanidine carboxylic acid 203 as the trifluoroacetic acid salt. 1 H NMR (D 2 O, 300 MHz): δ 6.66 (s, 1H); 4.29 (bd, J, 9.0 Hz); 4.01 (dd, 1H, J = 10.8, 10.8 Hz); 3.87-3.79 (m, 1H); 3.76-3.67 (m, 1H); 3.60-3.50 (m, 1H), 2.83 (dd, 1H, J = 5.1, 17.4 Hz); 2.47-2.36 (m, 1H); 2.06 (s. 3H); 1,65-1,50
-242CZ 297945 B6 (m, 2H); 0,90 (t, 3H, J = 7,2 Hz). Anal. vypočteno pro C15H23O6N4F3: C, 43,69; H, 5,62; N, 13,59. Zjištěno: C, 43,29; H, 5,90; N, 13,78.-242E 297945 B6 (m, 2H); 0.90 (t, 3H, J = 7.2Hz). Anal. Calcd. for C 15 H 23 O 6 N 4 F 3: C, 43.69; H, 5.62; N, 13.59. Found: C, 43.29; H, 5.90; N, 13.78.
Příklad 70Example 70
Formamidinkarboxylová kyseliny 204: Roztok aminokyseliny 102 (25 mg, 0,10 mmol, připraveném metodou Příkladu 110) ve vodě (500 μΐ) při teplotě 0-5 °C byl upraven na pH 8,5 pomocí 1,0 N NaOH. V jedné dávce byl přidán benzylformimidathydrochlorid (45 mg, 0,26 mmol) a reakční směs byla míchána po dobu 3 hodiny při této teplotě a pH udržováno na 8,5-9,0 pomocí 1,0 N NaOH. Reakce byla poté koncentrována in vacuo a čištěna chromatografíi Cu se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány tak, že vznikly 4,0 mg (13%) formamidinkarboxylové kyseliny 204. 'HNMR (C2O, 300 MHz): delta 7,85 (s, 1H); 6,53 (bd, 1H, J = 7,8 Hz); 4,32-^1,25 (bm, 1H); 4,10-3,97 (m, 1H); 5 3,76-3,67 (m, 2H); 3,57-3,49 (m, 1H); 2,86-2,81 (m, 1H); 2,55-2,40 (m, 1H); 2,04 (s, 3H); 1,65-1,50 (m, 2H); 0,90 (t, 3H, 7,4 Hz).Formamidine carboxylic acid 204: A solution of amino acid 102 (25 mg, 0.10 mmol, prepared by the method of Example 110) in water (500 μΐ) at 0-5 ° C was adjusted to pH 8.5 with 1.0 N NaOH. Benzylformimidate hydrochloride (45 mg, 0.26 mmol) was added in one portion and the reaction mixture was stirred for 3 hours at this temperature and the pH was maintained at 8.5-9.0 with 1.0 N NaOH. The reaction was then concentrated in vacuo and purified by reverse phase Cu chromatography, eluted with water. Fractions containing the desired product were combined and lyophilized to give 4.0 mg (13%) of formamidine carboxylic acid 204. 1 H NMR (C 2 O, 300 MHz): δ 7.85 (s, 1H); 6.53 (bd, 1H, J = 7.8Hz); 4.32 - 1.25 (bm, 1H); 4.10-3.97 (m, IH); Δ 3.76-3.67 (m, 2H); 3.57-3.49 (m, IH); 2.86-2.81 (m, IH); 2.55-2.40 (m, 1 H); 2.04 (s. 3H); 1.65-1.50 (m, 2 H); 0.90 (t, 3H, 7.4 Hz).
Příklad 71Example 71
Aminokyselina 206: Do roztoku aminometylesteru 205 (84 mg, 0,331 mmol, připraveného podle Příkladu 107) v THF (1,0 ml) byl přidán vodný KOH (481 μΐ z 1,039 N roztoku). Reakční směs byla míchána při teplotě místnosti po dobu 2,5 hodin a acidifíkována na pH 6,5 pomocí acidické pryskyřice Amberlite IR-120 (H+). Pryskyřice byla filtrována a vymyta vodou a metanolem. Koncentraci in vacuo vznikla aminokyselina jako bílá pevná látka, která byla čištěna chromatografíí Cis se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofílizovány tak, že vzniklo 59 mg (74 %) aminokyseliny 206. 1H NMR (CD3OD, 300 MHz): delta 6,60 (bd, 1H, J= 1,8 Hz); 4,01-3,95 (m, 1H); 3,71-3,60 (m, 2H); 3,50-3,42 (m, 1H); 3,05-2,85 (m, 2H); 2,39-2,28 (m, 1H); 1,70-1,55 (m, 2H); 0,95 (t, 3H, J= 7,05 Hz).Amino acid 206: To a solution of the aminomethyl ester 205 (84 mg, 0.331 mmol, prepared according to Example 107) in THF (1.0 mL) was added aqueous KOH (481 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 2.5 hours and acidified to pH 6.5 with Amberlite IR-120 (H + ) acidic resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a white solid, which was purified by C 18 reverse phase chromatography eluted with water. Fractions containing the desired product were combined and lyophilized to give 59 mg (74%) of amino acid 206. 1 H NMR (CD 3 OD, 300 MHz): δ 6.60 (bd, 1H, J = 1.8 Hz) ); 4.01-3.95 (m, IH); 3.71-3.60 (m, 2 H); 3.50-3.42 (m, IH); 3.05-2.85 (m, 2 H); 2.39-2.28 (m, IH); 1.70-1.55 (m, 2H); 0.95 (t, 3H, J = 7.05 Hz).
Příklad 72Example 72
Trifluoroacetamid 207: Do odplyněného roztoku aminokyseliny 206 (59 mg, 0,246 mmol) v suchém metanolu (1,0 ml) pod argonem byl přidán Et3N (35 μΐ), poté metyltrifluoroacetát (35 μΐ). Reakce byla míchána po dobu jednoho týdne při teplotě místnosti a koncentrována. Analýza pomocí 'H NMR ukázala, že reakce byla 40% kompletní. Surový produkt reakce byl znovu rozpouštěn v suchém metanolu (1,0 ml), metyltrifluoroacetátu (1,0 ml) a Et3N (0,5 ml) a míchán při teplotě místnosti po dobu 5 dní. Reakce byla pak koncentrována in vacuo a rozpuštěna v 50% vodném THF (2,0 ml), acidifíkována na pH 4 pomocí acidické pryskyřice Amberlite IR-120 (H+) a filtrována. Koncentrací vznikla surová kyselina trifluoroacetamidkarboxylová, která byla použita bez dalšího čištění pro další reakci.Trifluoroacetamide 207: To a degassed solution of amino acid 206 (59 mg, 0.246 mmol) in dry methanol (1.0 mL) under argon was added Et 3 N (35 μΐ) followed by methyltrifluoroacetate (35 μΐ). The reaction was stirred for one week at room temperature and concentrated. 1 H NMR analysis showed that the reaction was 40% complete. The crude reaction product was redissolved in dry methanol (1.0 mL), methyltrifluoroacetate (1.0 mL) and Et 3 N (0.5 mL) and stirred at room temperature for 5 days. The reaction was then concentrated in vacuo and dissolved in 50% aqueous THF (2.0 mL), acidified to pH 4 with Amberlite IR-120 (H + ) acidic resin and filtered. Concentration gave crude trifluoroacetamide carboxylic acid, which was used without further purification for the next reaction.
Příklad 73Example 73
Aminokyselina 208: Roztok azidu 207 (surový z předchozí reakce) v THF (2,0 ml) a vodě (160 μΐ) reagoval při teplotě místnosti s trifenylfosfmem (225 mg) s polymerovým nosičem. Po míchání po dobu 20 hodin byl polymer filtrován a vymyt metanolem. Koncentrací in vacuo vznikla bledá pevná látka, která byla čištěna chromatografíi C)g se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofílizovány tak, že vzniklo 6,5 mg (9%) trifluoroacetamidové aminokyseliny 208. 'H NMR (D2O, 300 MHz): delta 6,59 (bs, 1H); 4,40^1,30 (m, 1H); 4,26 (t, 1H, J= 10,1 Hz); 3,80-3,66 (m, 2H); 3,56-3,47 (m, 1H); 2,96 (bdd, 1H, J= 5,4 17,7 Hz); 2,58-2,45 (m, 1H); 1,62-1,50 (m, 2H); 0,89 (t, 3H, 7,5 Hz).Amino Acid 208: A solution of azide 207 (crude from the previous reaction) in THF (2.0 mL) and water (160 μΐ) was treated at room temperature with triphenylphosphine (225 mg) with a polymer carrier. After stirring for 20 hours, the polymer was filtered and washed with methanol. Concentration in vacuo afforded a pale solid which was purified by reverse phase chromatography with eluted water. Fractions containing the desired product were combined and lyophilized to give 6.5 mg (9%) of the trifluoroacetamide amino acid 208. 1 H NMR (D 2 O, 300 MHz): δ 6.59 (bs, 1H); 4.40-1.30 (m, 1H); 4.26 (t, 1H, J = 10.1Hz); 3.80-3.66 (m, 2 H); 3.56-3.47 (m, IH); 2.96 (bdd, 1H, J = 5.4, 17.7 Hz); 2.58-2.45 (m, IH); 1.62-1.50 (m, 2 H); 0.89 (t, 3H, 7.5 Hz).
-243 CZ 297945 B6-243 GB 297945 B6
Příklad 74Example 74
Metylsulfonamidmetylester 209: Metansulfonylchlorid (19 μΐ) byl přidán do roztoku aminu 205 (58 mg, 0,23 mmol, připraveného podle příkladu 107), Et3N (97 μΐ) a katalytického množství DMAP (několik krystalů) v CH2C12 (1,0 ml) při teplotě 0 °C. Po 30 minutách byla reakční směs zahřívána na teplotu místnosti a míchána po další 1 hodinu. Koncentrací in vacuo a následnou mžikovou chromatografií zbytku na silikagelu (50 % hexanů v etylacetátu) vzniklo 61 mg (79%) sulfonamidu 209. 'H NMR (CDC13, 300 MHz): delta 6,87 (t, 1H, J= 2,3 Hz); 5,08 (d, 1H, J =Methylsulfonamide methyl ester 209: Methanesulfonyl chloride (19 μΐ) was added to a solution of amine 205 (58 mg, 0.23 mmol, prepared according to Example 107), Et 3 N (97 μΐ) and a catalytic amount of DMAP (several crystals) in CH 2 Cl 2 ( 1.0 mL) at 0 ° C. After 30 minutes, the reaction mixture was warmed to room temperature and stirred for an additional 1 hour. Concentration in vacuo followed by flash chromatography of the residue on silica gel (50% hexanes in ethyl acetate) gave 61 mg (79%) of sulfonamide 209. 1 H NMR (CDCl 3 , 300 MHz): δ 6.87 (t, 1H, J = 2) , 3 Hz); 5.08 (d, 1 H, J =
7.5 Hz); 4,03-3,90 (m, 1H); 3,78 (s, 3H); 3,75-3,45 (m, 4H); 3,14 (s, 3H); 2,95 (dd, 1H; J= 5,2, 17,3 Hz); 2,42-2,30 (m, 1H); 1,75-1,55 (m, 2H); 0,95 (t, 3H, J= 7,5 Hz).7.5 Hz); 4.03-3.90 (m, IH); 3.78 (s, 3H); 3.75-3.45 (m, 4H); 3.14 (s, 3H); 2.95 (dd, 1H; J = 5.2, 17.3 Hz); 2.42-2.30 (m, 1 H); 1.75-1.55 (m, 2 H); 0.95 (t, 3H, J = 7.5Hz).
Příklad 75Example 75
Aminoester 210: Roztok azidu 209 (61 mg, 0,183 mmol) v THF (2,0 ml) a vodě (118 μΐ) reagoval s trifenylfosfinem (170 mg) s polymemím nosičem při teplotě místnosti. Po míchání po dobuAminoester 210: A solution of azide 209 (61 mg, 0.183 mmol) in THF (2.0 mL) and water (118 μΐ) was treated with triphenylphosphine (170 mg) with a polymeric carrier at room temperature. After stirring for
17.5 hodiny byl polymer filtrován a vymyt metanolem. Koncentrací in vacuo a následnou mžikovou chromatografií zbytku krátkým sloupcem silikagelu (100% metanol) vzniklo 45 mg (80%) aminoesteru 210 jako světlá pěna. Ή NMR (CDC13, 300 MHz): delta 6,85 (s, 1H); 3,94 (bd, 1H, .7 = 7,8 Hz); 3,77 (s, 3H); 3,74-3,60 (m, 2H); 3,55-3,45 (m, 1H); 3,25-3,15 (m, 1H); 3,11 (s, 3H); 2,94-2,85 (m, 1H); 2,85 (bs, 2H); 2,22-2,10 (m, 1H); 1,70-1,56 (m, 2H); 0,94 (t, 3H, J =The polymer was filtered and washed with methanol for 17.5 hours. Concentration in vacuo followed by flash chromatography of the residue with a short column of silica gel (100% methanol) afforded 45 mg (80%) of aminoester 210 as a light foam. 1 H NMR (CDCl 3 , 300 MHz): δ 6.85 (s, 1H); 3.94 (bd, 1H, J = 7.8 Hz); 3.77 (s, 3H); 3.74-3.60 (m, 2 H); 3.55-3.45 (m, IH); 3.25-3.15 (m, IH); 3.11 (s, 3H); 2.94-2.85 (m, IH); 2.85 (bs, 2 H); 2.22-2.10 (m, IH); 1.70-1.56 (m, 2 H); 0.94 (t, 3 H, J =
7.5 Hz).7.5 Hz).
Příklad 76Example 76
Aminokyselina 211: Roztok mety testeru 210 (21 mg, 0,069 mmol) v THF (200 μΐ) reagoval s vodným KOH (135 μΐ z 1,039 N roztoku). Reakční směs byla míchána při teplotě místnosti po dobu 40 minut a neutralizována na pH 7,0 pomocí acidické piyskyřice Amberlite IR-120 (H+). Pryskyřice byla filtrována a vymyta vodou a metanolem. Koncentrací in vacuo vznikla aminokyselina jako světlá pevná látka, která byla čištěna chromatografií C]g se zpětnou fází, elutovanou vodu. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány a vznikl 3,5 mg (17%) aminokyseliny 211. *H NMR (D2O, 300 MHz): delta 6,60 (d, 1H, J= 1,8 Hz); 4,30-4,20 (m, 1H); 3,84-3,75 (m, 1H); 3,68-3,58 (m, 1H); 3,60-3,40 (m, 2H); 3,20 (s, 3H); 2,96-2,88 (m, 1H); 2,55-2,45 (m, 1H); 1,72-1,59 (m, 2H); 0,93 (t, 3H, J= 7,4 Hz).Amino acid 211: A solution of methyl tester 210 (21 mg, 0.069 mmol) in THF (200 μΐ) was treated with aqueous KOH (135 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 40 minutes and neutralized to pH 7.0 with Amberlite IR-120 (H + ) acidic resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a pale solid, which was purified by reverse phase C18 g eluting with water. Fractions containing the desired product were combined and lyophilized to give 3.5 mg (17%) of amino acid 211. 1 H NMR (D 2 O, 300 MHz): δ 6.60 (d, 1H, J = 1.8 Hz) ); 4.30-4.20 (m, IH); 3.84-3.75 (m, IH); 3.68-3.58 (m, IH); 3.60-3.40 (m, 2 H); 3.20 (s, 3H); 2.96-2.88 (m, 1 H); 2.55-2.45 (m, IH); 1.72-1.59 (m, 2 H); 0.93 (t, 3H, J = 7.4Hz).
Příklad 77Example 77
Bis-BoC guanidinoester 212: Reakce podle postupu Kim and Qian, „Tetrahedron Lett.“ 34:7677 (1993). Do roztoku aminu 210 (31 mg, 0,101 mmol), bis-Boc thiomočoviny (28,5 mg, 0,103 mmol) vEt3N (47 μΐ) v suchém DMF (203 μΐ), ochlazeném na 0 °C, byl přidán HgCl2 (30 mg, 0,11 mmol) v jedné dávce. Heterogenní reakční směs byla míchána po dobu 30 minut při teplotě 0 °C, a poté při teplotě místnosti po dobu 30 minut, načež byla reakce naředěna EtOAc a filtrována přes celitový list. Koncentrací in vacuo a následnou mžikovou chromatografií zbytku na silikagelu (40% hexanů v etylacetátu) vzniklo 49 mg (89%) 212 jako světlý olej. *HNMR (CDC13, 300 MHz): delta 11,47 (s, 1H); 7,66 (d, 1H, J= 8,4 Hz); 6,87 (s 1H); 6,01 (bs, 1H); 4,50-4,35 (m, 1H); 4,04 (bd, 1H, J = 8,4 Hz); 3,76 (s, 3H); 3,70-3,60 (m, 1H); 3,53-3,45 (m, 2H); 3,02 (s, 3H); 2,85 (dd, 1H, J= 5,3, 17,3 Hz); 2,42-2,30 (m, 1H); 1,66-1,55 (m, 2H); 1,49 (s, 9H); 1,48 (s, 9H); 0,93 (t, 3H, J= 7,3 Hz).Bis-BoC guanidinoester 212: Kim and Qian reaction, "Tetrahedron Lett." 34: 7677 (1993). To a solution of amine 210 (31 mg, 0.101 mmol), bis-Boc thiourea (28.5 mg, 0.103 mmol) in Et 3 N (47 μΐ) in dry DMF (203 μΐ) cooled to 0 ° C was added HgCl 2 (30 mg, 0.11 mmol) per dose. The heterogeneous reaction mixture was stirred for 30 minutes at 0 ° C and then at room temperature for 30 minutes, then the reaction was diluted with EtOAc and filtered through a celite pad. Concentration in vacuo followed by flash chromatography of the residue on silica gel (40% hexanes in ethyl acetate) gave 49 mg (89%) 212 as a light oil. 1 HNMR (CDCl 3 , 300 MHz): δ 11.47 (s, 1H); 7.66 (d, 1H, J = 8.4Hz); 6.87 (s 1H); 6.01 (bs, 1 H); 4.50-4.35 (m, IH); 4.04 (bd, 1H, J = 8.4Hz); 3.76 (s, 3H); 3.70-3.60 (m, IH); 3.53-3.45 (m, 2 H); 3.02 (s, 3H); 2.85 (dd, 1H, J = 5.3, 17.3 Hz); 2.42-2.30 (m, 1 H); 1.66-1.55 (m, 2 H); 1.49 (s, 9H); 1.48 (s, 9H); 0.93 (t, 3H, J = 7.3Hz).
-244CZ 297945 B6-244GB 297945 B6
Příklad 78Example 78
Kyselina karboxylová 213: Do roztoku metylesteru 212 (49 mg, 0,090 mmol) v THF (1,0 ml) byl přidán vodný KOH (260 μΐ z 1,039 N roztoku). Reakční směs byla míchána v pokojové teplotě po dobu 16 hodin, ochlazena na 0 °C a acidifíkována na pH 4,0 a acidickou pryskyřicí Amberlite IR-120 (H+). Pryskyřice byla filtrována a vymyta vodou a metanolem. Koncentrací in vacuo vznikla volná kyselina jako světlá pěna, která byla použita bez dalšího čištění v další reakci.Carboxylic acid 213: To a solution of methyl ester 212 (49 mg, 0.090 mmol) in THF (1.0 mL) was added aqueous KOH (260 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 16 hours, cooled to 0 ° C and acidified to pH 4.0 with Amberlite IR-120 (H + ) acid resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the free acid as a light foam, which was used without further purification in the next reaction.
Příklad 79Example 79
Guanidinkarboxylová kyselina 214: Do roztoku bis-Boc guanidnylové kyseliny 213 (surové z předchozí reakce) v CH2C12 (2,0 ml), ochlazenému na 0 °C, byla přidána čistá trifluoroctová kyselina (2,0 ml). Reakční směs byla míchána při teplotě 0 °C po dobu 1 hodiny, a pak při teplotě místnosti po dobu 1 hodiny. Koncentrací in vacuo vznikla světle oranžová pevná látka, která byla čištěna chromatografii Cig se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány tak, že vzniklo 10 mg (25%, 2 kroky) kyseliny guanidinkarboxylové kyseliny 214. 'HNMR (D2O, 300 MHz: delta 6,60 (bs, 1H); 4,22 (bd, 1H, J = 9,0 Hz); 3,82-3,66 (m, 2H); 3,65-3,54 (m, 1H); 3,43 (bt, 1H, J= 9,9 Hz); 3,15 (s, 3H); 2,82 (dd, 1H, J= 50, 17,5 Hz); 2,48-2,30 (m, 1H); 1,71-1,58 (m, 2H); 0,93 (t, 3H, .7= 7,4 Hz).Guanidine carboxylic acid 214: To a solution of bis-Boc guanidnylic acid 213 (crude from the previous reaction) in CH 2 Cl 2 (2.0 mL) cooled to 0 ° C was added pure trifluoroacetic acid (2.0 mL). The reaction mixture was stirred at 0 ° C for 1 hour, and then at room temperature for 1 hour. Concentration in vacuo afforded a pale orange solid, which was purified by reverse phase C 18 chromatography eluted with water. Fractions containing the desired product were combined and lyophilized to give 10 mg (25%, 2 steps) of guanidinecarboxylic acid 214. 1 H NMR (D 2 O, 300 MHz: δ 6.60 (bs, 1H); 22 (bd, 1H, J = 9.0 Hz) 3.82-3.66 (m, 2H) 3.65-3.54 (m, 1H) 3.43 (bt, 1H, J = 9.9 Hz); 3.15 (s, 3H); 2.82 (dd, 1H, J = 50, 17.5 Hz); 2.48-2.30 (m, 1H); 1.58 (m, 2H), 0.93 (t, 3H, J = 7.4 Hz).
Příklad 80Example 80
Propionamidmetylester 215: Propionylchlorid (96 μΐ, 1,1 mol) byl přidán do roztoku amino 205 (179 mg, 0,70 mmol, připraveného podle příkladu 107) a pyridinu (1,5 ml) vCH2Cl2 (2,0 ml), ochlazeného na 0 °C. Po 30 minutách při 0°C byla reakce koncentrována a rozdělena mezi etylacetát a solanku. Organická vrstva byla oddělena a postupně promyta nasyceným natriumhydrogenuhličitanem, solankou a vysušen přes MgSO4. Koncentrací in vacuo a následně mžikovou chromatografii zbytku na silikagelu (40% hexanů v etylacetátu) vzniklo 186 mg (86%) propionamidmetylesteru 215 jako bledě žlutá pevná látka. *H NMR (CDC13, 300 MHz): delta 6,86 (t, 1H, J= 2,3 Hz); 5,72 (bd, 1H, J = 7,8 Hz); 4,52-4,49 (m, 1H); 4,25^1,15 (m, 1H); 3,77 (s, 3H); 3,65-3,37 (komplexní m, 3H); 2,87 (dd, 1H, J= 5,7, 17,7 Hz); 2,28 (q, 2H, J= 7,5 Hz); 2,25-2,20 (m, 1H); 1,65-1,50 (m, 2H); 1,19 (t, 3H, J= 7,5 Hz); 0,92 (t, 3H, J= 7,5 Hz).Propionamide methyl ester 215: Propionyl chloride (96 μΐ, 1.1 mol) was added to a solution of amino 205 (179 mg, 0.70 mmol, prepared according to Example 107) and pyridine (1.5 mL) in CH 2 Cl 2 (2.0 mL). ) cooled to 0 ° C. After 30 minutes at 0 ° C, the reaction was concentrated and partitioned between ethyl acetate and brine. The organic layer was separated and washed successively with saturated sodium bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo followed by flash chromatography of the residue on silica gel (40% hexanes in ethyl acetate) gave 186 mg (86%) of propionamide methyl ester 215 as a pale yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ 6.86 (t, 1H, J = 2.3 Hz); 5.72 (bd, 1H, J = 7.8Hz); 4.52-4.49 (m, IH); 4.25- 1.15 (m, 1H); 3.77 (s, 3H); 3.65-3.37 (complex m, 3H); 2.87 (dd, 1H, J = 5.7, 17.7 Hz); 2.28 (q, 2H, J = 7.5Hz); 2.25-2.20 (m, IH); 1.65-1.50 (m, 2 H); 1.19 (t, 3H, J = 7.5Hz); 0.92 (t, 3H, J = 7.5Hz).
Příklad 81Example 81
Aminometylester 216: Roztok azidu 215 (186 mg, 0,60 mmol) v THF (5,0 ml) ve vodě (400 μΐ) reagoval s trifenylfosfinem (560 mg) na polymemím nosiči při teplotě místnosti. Po míchání po dobu 21 hodin byl polymer filtrován a vymyt metanolem. Koncentrací in vacuo vznikl surový aminoester 216, který byl použit bez jakéhokoliv dalšího čištění pro další krok.Aminomethyl ester 216: A solution of azide 215 (186 mg, 0.60 mmol) in THF (5.0 mL) in water (400 μΐ) was treated with triphenylphosphine (560 mg) on a polymeric support at room temperature. After stirring for 21 hours, the polymer was filtered and washed with methanol. Concentration in vacuo gave the crude aminoester 216, which was used without further purification for the next step.
Příklad 82Example 82
Aminokyselina 217: Roztok metylesteru 216 (surový z předchozí reakce) v THF (500 μΐ) reagoval s vodným KOH (866 μΐ z 1,039 N roztoku). Reakční směs byla míchána při teplotě místnosti po dobu 3 hodin a neutralizována na pH 7,0 pomocí acidické pryskyřice Amberlite IR-120 (H+). Pryskyřice byla filtrována a vymyta vodou a metanolem. Koncentrací in vacuo vznikla aminokyselina jako světlá pevná látka, která byla čištěna chromatografii C]8 se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány, čímž vzniklo 49 mg (31% 2 kroky) aminokyseliny 217. Ή NMR (D2O, 300 MHz): delta 6,54 (s, 1H); 4,25 (bd, 1H, J= 8,7 Hz); 4,13 (dd, 1H, J= 9,0, 11,3 Hz), 3,74-3,60 (m, 1H); 3,61-3,40 (m, 2H); 2,85 (dd, 1H,Amino acid 217: A solution of methyl ester 216 (crude from the previous reaction) in THF (500 μΐ) was treated with aqueous KOH (866 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 3 hours and neutralized to pH 7.0 with Amberlite IR-120 (H + ) acidic resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a pale solid which was purified by C] 8 reverse phase chromatography eluting with water. Fractions containing the desired product were combined and lyophilized to give 49 mg (31% 2 steps) of amino acid 217. 1 H NMR (D 2 O, 300 MHz): δ 6.54 (s, 1H); 4.25 (bd, 1H, J = 8.7Hz); 4.13 (dd, 1H, J = 9.0, 11.3 Hz), 3.74-3.60 (m, 1H); 3.61-3.40 (m, 2 H); 2.85 (dd, 1 H,
-245CZ 297945 B6-245GB 297945 B6
J= 5,9, 17,1 Hz); 2,55-2,40 (m, 1H); 2,35 (q, 2H, J= 7,5 Hz); 1,65-1,45 (m, 2H); 1,13 (t„ 3H,J = 5.9, 17.1 Hz); 2.55-2.40 (m, 1 H); 2.35 (q, 2H, J = 7.5Hz); 1.65-1.45 (m, 2 H); 1.13 (t, 3H,
7,5 Hz); 0,88 (t, 3H, J= 7,5 Hz);7.5 Hz); 0.88 (t, 3H, J = 7.5Hz);
Příklad 83 (monometyl)bis-Boc guanidinoester 218: Do roztoku aminu 200 (51 mg, 0,19 mmol) a monometyl-bis-Boc thiomočoviny (36 mg, 0,19 mmol) v suchém DMF (1,0 ml) byl přidán l-(3dimetylaminopropyl)-3-etylkarbodiimidhydrochlorid (38 mg) a Et3N (56 μΐ) při teplotě místnosti. Po 1,5 hodině byl v jedné dávce při teplotě místnosti přidán HgCL2 (~75 mg, nadbytek). Heterogenní reakční směs byla míchána po dobu 45 minut, naředěna etylacetátem a filtrována celkovým listem. Filtrát byl naředěn dalším etylacetátem a promyt zředěným HC1, nasyceným natrium-hydrouhličitanem, solankou a vysušen přes MgSO4. Koncentrací in vacuo a následnou mžikovou chromatografií zbytku na silikagelu (10% metanol v etylacetátu) vzniklo 13 mg (16%) (monometyl) bis-Boc guanidinoesteru 218 jako bezbarvá pěna. ’H NMR (CDC13, 300 MHz): delta 6,84 (s, 1H); 6,20 (bd, 1H, 5,1 Hz); 5,45 (bs, 1H); 4,25-4,40 (bm, 1H); 4,20-4,05 (bm,Example 83 (monomethyl) bis-Boc guanidinoester 218: To a solution of amine 200 (51 mg, 0.19 mmol) and monomethyl-bis-Boc thiourea (36 mg, 0.19 mmol) in dry DMF (1.0 mL) was added added 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (38 mg) and Et 3 N (56 μΐ) at room temperature. After 1.5 hours, HgCL 2 (~ 75 mg, excess) was added in one portion at room temperature. The heterogeneous reaction mixture was stirred for 45 minutes, diluted with ethyl acetate and filtered with a complete sheet. The filtrate was diluted with additional ethyl acetate and washed with dilute HCl, saturated sodium bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo followed by flash chromatography of the residue on silica gel (10% methanol in ethyl acetate) gave 13 mg (16%) of (monomethyl) bis-Boc guanidinoester 218 as a colorless foam. 1 H NMR (CDCl 3 , 300 MHz): δ 6.84 (s, 1H); 6.20 (bd, 1H, 5.1 Hz); 5.45 (bs, 1 H); 4.25-4.40 (bm, IH); 4.20-4.05 (bm,
2H); 3,76 (s, 3H); 3,60-3,50 (m, 1H); 3,43-3,30 (m, 1H); 1,90 (dd, 1H, J= 5,4, 17,7 Hz), 2,77 (d, 3H, J= 4,8 Hz); 2,35-2,25 (m, 1H); 1,69 (s, 3H); 1,60-1,50 (m, 2H); 1,47 (s, 9H); 0,91 (t, 3H, J= 7,2 Hz).2H); 3.76 (s, 3H); 3.60-3.50 (m, IH); 3.43-3.30 (m, IH); 1.90 (dd, 1H, J = 5.4, 17.7 Hz), 2.77 (d, 3H, J = 4.8 Hz); 2.35-2.25 (m, IH); 1.69 (s, 3H); 1.60-1.50 (m, 2 H); 1.47 (s, 9H); 0.91 (t, 3H, J = 7.2Hz).
Příklad 84Example 84
Kyselina (monometyl)bis-Boc guanidinová 219: Do roztoku metylesteru 218 (13 mg, 0,031 mmol) v THF (500 μΐ) byl přidán vodný KOH (60 μΐ z 1,039 N roztoku). Reakční směs byla míchána při teplotě místnosti po dobu 1 hodiny a poté jemně refluxována po dobu 1 hodiny. Reakce byla ochlazena na 0 °C a acidifikována na pH 6,0 pomocí acidické pryskyřice Amberlite IR-120 (H+). Pryskyřice byla filtrována a promyta vodou a metanolem. Koncentrací in vacuo vznikla volná kyselina 219, která byla použita bez dalšího čištění v další reakci.(Monomethyl) bis-Boc guanidine acid 219: To a solution of methyl ester 218 (13 mg, 0.031 mmol) in THF (500 μΐ) was added aqueous KOH (60 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 1 hour and then gently refluxed for 1 hour. The reaction was cooled to 0 ° C and acidified to pH 6.0 with Amberlite IR-120 (H + ) acidic resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the free acid 219 which was used without further purification in the next reaction.
Příklad 85Example 85
Kyselina (monometyl)guanidinoaminová 220: Do roztoku kyseliny (monometyl)bis-Boc guanidnylové 219 (surové z předchozí reakce) v CH2CI2 (1,0 ml), ochlazeném na 0 °C byla přidána čistá trifluorooctová (1,0 ml). Reakční směs byla míchána při teplotě 0 °C po dobu 1 hodiny, a pak při teplotě místnosti po dobu 1 hodiny. Koncentrací in vacuo vznikla bledá pevná látka, která byla čištěna chromatografií C18 se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány tak, že vznikly 4,4 mg (33%, 2 kroky) kyseliny guanidinkarboxylové 220. *HNMR (D2O, 300 MHz): delta 6,52 (bs, 1H); 4,27 (bd, 1H, J= 8,4 Hz); 4,01 (dd, 1H, J= 9,2, 10,3 Hz); 3,86-3,75 (m, 1H); 3,75-3,67 (m, 1H); 3,60-3,49 (m, 1H); 2,85 (s, 3H); 2,80 (dd, 1H, J= 5,1, 17,7 Hz); 2,47-2,37 (m, 1H); 2,04 (s, 3H); 1,64-1,50 (m, 2H); 0,90 (t, 3H, J= 7,2 Hz).(Monomethyl) guanidinoaminic acid 220: To a solution of (monomethyl) bis-Boc guanidnylic acid 219 (crude from the previous reaction) in CH 2 Cl 2 (1.0 mL) cooled to 0 ° C was added pure trifluoroacetic acid (1.0 mL). The reaction mixture was stirred at 0 ° C for 1 hour, and then at room temperature for 1 hour. Concentration in vacuo gave a pale solid which was purified by C 18 reverse phase chromatography eluting with water. Fractions containing the desired product were combined and lyophilized to give 4.4 mg (33%, 2 steps) of guanidinecarboxylic acid 220. 1 H NMR (D 2 O, 300 MHz): δ 6.52 (bs, 1H); 4.27 (bd, 1H, J = 8.4Hz); 4.01 (dd, 1H, J = 9.2, 10.3 Hz); 3.86-3.75 (m, IH); 3.75-3.67 (m, IH); 3.60-3.49 (m, IH); 2.85 (s, 3H); 2.80 (dd, 1H, J = 5.1, 17.7 Hz); 2.47-2.37 (m, IH); 2.04 (s. 3H); 1.64-1.50 (m, 2 H); 0.90 (t, 3H, J = 7.2Hz).
Příklad 86 (R)-metylpropylester 221: BF3Et2O (63 μΐ, 0,51 mmol) byl přidán do roztoku N-tritylaziridinu 183 (150 mg, 0,341 mmol) v (R)-(-)-2-butanolu (1,2 ml) pod argonem při míchání při teplotě místnosti. Bledý roztok byl zahříván při 70 °C po dobu 2 hodin, a poté koncentrován in vacuo, čímž vznikl hnědý zbytek, který byl rozpuštěn v suchém pyridinu (2,0 ml) a reagoval s acetahydridem (225 μΐ) a katalytickým množstvím DMAP (několik krystalů) při teplotě 0 °C. Reakce se nechala zahřát na pokojovou teplotu a byla míchána po dobu 2 hodin, koncentrována in vacuo a rozdělena mezi etylacetát a solankou. Organická vrstva byla oddělena a následně promyta zředěným HC1, nasyceným natrium-hydrouhličitanem, solankou a vysušena přes MgSO4. KoncentExample 86 (R) -Methylpropyl ester 221: BF 3 Et 2 O (63 µΐ, 0.51 mmol) was added to a solution of N-tritylaziridine 183 (150 mg, 0.341 mmol) in (R) - (-) - 2-butanol (1.2 mL) under argon with stirring at room temperature. The pale solution was heated at 70 ° C for 2 hours and then concentrated in vacuo to give a brown residue which was dissolved in dry pyridine (2.0 mL) and treated with acetahydride (225 μΐ) and a catalytic amount of DMAP (several crystals) at 0 ° C. The reaction was allowed to warm to room temperature and was stirred for 2 hours, concentrated in vacuo and partitioned between ethyl acetate and brine. The organic layer was separated and then washed with dilute HCl, saturated sodium bicarbonate, brine and dried over MgSO 4 . Concent
-246CZ 297945 B6 raci in vacuo a následnou mžikovou chromatografií zbytku na silikagelu (50% hexanů v etylacetátu) vzniklo 75 mg (72%) (R)-metylpropylesteru 221 jako bledá pevná látka. *HNMR (CDC13, 300 MHz): delta 6,79 (t, IH, J= 2,2 Hz); 6,14 (d, IH, J= 7,3 Hz); 4,55 (bd, IH, J =Chromatography of the residue on silica gel (50% hexanes in ethyl acetate) afforded 75 mg (72%) of (R) -methyl propyl ester 221 as a pale solid. * 1H NMR (CDCl3, 300 MHz) delta 6.79 (t, IH, J = 2.2 Hz); 6.14 (d, 1H, J = 7.3 Hz); 4.55 (bd, 1H, J =
8.7 Hz); 4,33-4,23 (m, IH); 3,77 (s, 3H); 3,56-3,45 (m, IH); 3,40-3,27 (m, IH); 2,86 (dd, IH, J= 5,5, 17,5 Hz); 2,30-2,15 (m, IH); 2,04 (s, 3H); 1,5901,40 (m, 2H); 1,10 (d, 3H, J= 6,0 Hz); 0,91 (t, 3H, J= 7,4 Hz).8.7 Hz); 4.33-4.23 (m, 1H); 3.77 (s, 3H); 3.56-3.45 (m, 1H); 3.40-3.27 (m, 1H); 2.86 (dd, 1H, J = 5.5, 17.5 Hz); 2.30-2.15 (m, 1H); 2.04 (s. 3H); 1.5901.40 (m, 2 H); 1.10 (d, 3H, J = 6.0 Hz); 0.91 (t, 3H, J = 7.4Hz).
Příklad 87 (R)-metylpropylaminoester 222: Ph3P (95 mg, 0,36 mmol) byl přidán v jedné dávce do roztoku azidu 221 (75 mg, 0,24 mmol) a vody (432 μΐ) v THF (3,0 ml). Bledě žlutý roztok byl poté zahříván při teplotě 50 °C po dobu 10 hodin, ochlazen a koncentrován in vacuo, čímž vznikla světlá pevná látka. Čištěním mžikovou chromatografií na silikagelu (50% metanol v etylacetátu) vzniklo 66 mg (97%) aminoesteru 222 jako světlá pevná látka.Example 87 (R) -Methylpropylaminoester 222: Ph 3 P (95 mg, 0.36 mmol) was added in one portion to a solution of azide 221 (75 mg, 0.24 mmol) and water (432 μΐ) in THF (3, 0 ml). The pale yellow solution was then heated at 50 ° C for 10 hours, cooled and concentrated in vacuo to give a light solid. Purification by silica gel flash chromatography (50% methanol in ethyl acetate) afforded 66 mg (97%) of aminoester 222 as a light solid.
Příklad 88Example 88
Aminokyselina 223. Roztok metylesteru 222 (34 mg, 0,12 mmol) v THF (1,0 ml) reagoval s vodným KOH (175 μΐ z 2,039 N roztoku). Reakční směs byla míchána při teplotě místnosti po dobu 3 hodin a acidifikována na pH 6,0 acidickou pryskyřicí Amberlite IR-120 (H+). Piyskyřice byla filtrována a vymývána vodou a metanolem. Koncentrací in vacuo vznikla aminokyselina jako světlá pevná látka, která byla čištěna chromatografií C]g se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány tak, že vzniklo 11,5 mg (36%) aminokyseliny 223.!H NMR (D2O, 300 MHz): delta 6,52 (bs, IH); 4,28 (bd, IH, J = 8,7 Hz); 4,04 (dd, IH, J= 8,8, 11,5 Hz); 3,74-3,65 (m, IH); 3,50-3,60 (m, IH); 2,90 (dd, IH, J= 5,5, 17,2 Hz); 2,50-2,40 (m, 1H0; 2,10 (s, 3H); 1,60-1,45 (m, 2H); 1,14 (d, 3H, J= 6,2 Hz); 0,91 (t, 3H, J = 7,4 Hz).Amino acid 223. A solution of methyl ester 222 (34 mg, 0.12 mmol) in THF (1.0 mL) was treated with aqueous KOH (175 μΐ of 2.039 N solution). The reaction mixture was stirred at room temperature for 3 hours and acidified to pH 6.0 with Amberlite IR-120 (H + ) acidic resin. The resin was filtered and eluted with water and methanol. Concentration in vacuo gave the amino acid as a pale solid, which was purified by reverse phase C18 chromatography eluting with water. The fractions containing the desired product were pooled and lyophilized to give 11.5 mg (36%) of amino acid 223 . 1 H NMR (D 2 O, 300 MHz): δ 6.52 (bs, 1H); 4.28 (bd, 1H, J = 8.7 Hz); 4.04 (dd, 1H, J = 8.8, 11.5 Hz); 3.74-3.65 (m, 1H); 3.50-3.60 (m, 1H); 2.90 (dd, 1H, J = 5.5, 17.2 Hz); 2.50-2.40 (m, 1H, 2.10 (s, 3H), 1.60-1.45 (m, 2H), 1.14 (d, 3H, J = 6.2 Hz); 0.91 (t, 3H, J = 7.4Hz).
Příklad 89 bis-Boc guanidinoester 224: Postup podle Kim and Quian, „Tetrahedron Lett.“. 34:7677 (1993): Do roztoku k aminu 222 (32 mg, 0,113 mmol), bis-Boc thiomočoviny (32 mg, 0,115 mmol) a Et3N (53 μΐ) v suchém DMF (350 μΐ), ochlazeného na 0 °C byl přidán HgCl2 (34 mg, 0,125 mmol) v jedné dávce. Heterogenní reakční směs byla míchána po dobu 45 minut při teplotě 0 °C, a pak při teplotě místnosti po dobu 1 hodiny, poté byla reakce naředěna EtOAc a filtrována přes celitový list. Koncentrací in vacuo a poté mžikovou chromatografií zbytku na silikagelu (20% hexany v etylacetátu) vzniklo 57 mg (96%) 224 jako bezbarvá pěna. !H NMR (CDCI3, 300 MHz): delta 11,40 (s, IH); 8,65 (d, IH, J= 7,8 Hz); 6,82 (s, IH); 6,36 (d, IH, J= 8,7 Hz); 4,46-4,34 (m, IH); 4,20-4,10 (m, IH); 4,10-3,95 (m, IH); 3,76 (s, 3H); 2,79 (dd, IH, 5,4,Example 89 bis-Boc guanidinoester 224: The procedure of Kim and Quian, "Tetrahedron Lett." 34: 7677 (1993): To a solution of amine 222 (32 mg, 0.113 mmol), bis-Boc thiourea (32 mg, 0.115 mmol) and Et 3 N (53 μΐ) in dry DMF (350 μΐ) cooled to 0 HgCl 2 (34 mg, 0.125 mmol) was added in one portion at 0 ° C. The heterogeneous reaction mixture was stirred for 45 minutes at 0 ° C and then at room temperature for 1 hour, then the reaction was diluted with EtOAc and filtered through a celite pad. Concentration in vacuo and then flash chromatography of the residue on silica gel (20% hexanes in ethyl acetate) gave 57 mg (96%) of 224 as a colorless foam. ! 1 H NMR (CDCl 3, 300 MHz): δ 11.40 (s, 1H); 8.65 (d, 1H, J = 7.8 Hz); 6.82 (s, 1H); 6.36 (d, 1H, J = 8.7 Hz); 4.46-4.34 (m, 1H); 4.20-4.10 (m, 1H); 4.10-3.95 (m, 1H); 3.76 (s, 3H); 2.79 (dd, 1H, 5.4,
17.7 Hz); 2,47-2,35 (m, IH); 1,93 (s, 3H); 1,60-1,45 (m, 2H); 1,49 (s, 18H); 1,13 (d, 3H, J = 6,0 Hz); 0,91 (t, 3H, J= 7,5 Hz).17.7 Hz); 2.47-2.35 (m, 1H); 1.93 (s, 3H); 1.60-1.45 (m, 2 H); 1.49 (s, 18H); 1.13 (d, 3H, J = 6.0 Hz); 0.91 (t, 3H, J = 7.5Hz).
Příklad 90Example 90
Kyselina karboxylová 225. Do roztoku metylesteru 224 (57 mg, 0,11 mmol) v THF (1,5 ml) byl přidán vodný KOH (212 μΐ z 1,039 N roztoku). Reakční směs byla míchána při pokojové teplotě po dobu 16 hodin, ochlazena na 0 °C a acidifikována na pH 4,0 acidickou pryskyřicí Amberlite IR-120 (H+). Pryskyřice byla filtrována a promyta vodou a metanolem. Koncentrace in vacuo vznikla volná kyselina jako světlá pěna, která byla použita bez dalšího čištění v další reakci.Carboxylic acid 225. To a solution of methyl ester 224 (57 mg, 0.11 mmol) in THF (1.5 mL) was added aqueous KOH (212 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 16 hours, cooled to 0 ° C and acidified to pH 4.0 with Amberlite IR-120 (H + ) acid resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the free acid as a light foam, which was used without further purification in the next reaction.
-247CZ 297945 B6-247EN 297945 B6
Příklad 91Example 91
Kyselina guanidinkarboxylová 226: Do roztoku bis-Boc guanidnylové kyseliny 225 (surové z předchozí reakce) v CH2C12 (4,0 ml), ochlazeného na 0 °C, byla přidána čistá trifluoroctová kyselina (4,0 ml). Reakční směs byla míchána při teplotě 0 °C po dobu 1 hodiny, a pak při teplotě místnosti po dobu 2 hodin. Koncentrací in vacuo vznikla bledě oranžová pevná látka, která byla čištěna chromatografií Cu se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány tak, že vzniklo 18,4 mg (40% 2 kroky) guanidinkarboxylové kyseliny 226. *HNMR (D2O, 300 MHz): delta 6,4Ί (s, 1H); 4,28 (bd, 1H, J= 8,4 Hz); 3,933,74 (m, 2H); 3,72-3,63 (m, 1H);, 2,78 (dd, 1H, 4,8, 17,4 Hz); 2,43-2,32 (m, 2H); 1,58-1,45 (m, 2H); 1,13 (d, 3H, J= 6,0 Hz); 0,90 (t, 3H, J= 7,4 Hz).Acid guanidine 226: To a solution of bis-Boc guanidnyl acid 225 (crude from previous reaction) in CH 2 C1 2 (4.0 mL), cooled to 0 ° C was added neat trifluoroacetic acid (4.0 mL). The reaction mixture was stirred at 0 ° C for 1 hour, and then at room temperature for 2 hours. Concentration in vacuo gave a pale orange solid, which was purified by reverse phase Cu chromatography eluted with water. Fractions containing the desired product were combined and lyophilized to give 18.4 mg (40% 2 steps) of guanidine carboxylic acid 226. * 1 H NMR (D 2 O, 300 MHz): δ 6.4: (s, 1H); 4.28 (bd, 1H, J = 8.4Hz); 3.933.74 (m, 2H); 3.72-3.63 (m, 1H); 2.78 (dd, 1H, 4.8, 17.4 Hz); 2.43-2.32 (m, 2 H); 1.58-1.45 (m, 2 H); 1.13 (d, 3H, J = 6.0 Hz); 0.90 (t, 3H, J = 7.4Hz).
Příklad 92 (Dietyl)metyléterester 227: BF3Et2O (6,27 ml, 51 mmol) byl přidán do roztoku N-tritylaziridinu 183 (15 g, 34 mmol) ve 3-pentanolu (230 ml) po argonem za míchání při teplotě místnosti. Světlý roztok byl zahříván při teplotě 70 až 75 °C po dobu 1,75 hodiny, a poté koncentrován in vacuo, čímž vznikl hnědý zbytek, který byl rozpuštěn v suchém pyridinu (2,0 ml) a reagoval s acetanhydridem (16 ml, 170 mmol) a katalytickým množstvím DMAP 200 mg. Reakce byla míchána při teplotě místnosti po dobu 18 hodin, koncentrována in vacuo a rozdělena mezi etylacetát a 1M HC1. Organická vrstva byla oddělena a následně promývána nasyceným natriumhydrogenuhličitanem, solankou a vysušena přes MgSO4. Koncentrací in vacuo a následnou mžikovou chromatografií zbytku na silikagelu (50% hexanů v etylacetátu) vzniklo 7,66 g (dietyl)metyléteresteru, který byl rekrystalizován etylacetátem/hexanem, tak, že vzniklo 227 (7,25 g, 66%) jako bezbarvé jehličky: ’H NMR (CDC13, 300 MHz): delta 6,79 (t, 1H, J- 2,1 Hz); 5,92 (d, 1H, J= 7,5 Hz); 4,58 (bd, 1H, J= 8,7 Hz); 4,35-4,25 (m, 1H); 3,77 (s, 3H); 3,36-3,25 (m, 2H); 2,85 (dd, 1H, J= 5,7, 17,4 Hz); 2,29-2,18 (m, 1H); 2,04 (s, 3H); 1,60-1,45 (m, 4H); 0,91 (t, 3H, J= 3,7 Hz); 0,90 (t, 3H, J= 7,3 Hz).Example 92 (Diethyl) methyl ether 227: BF 3 Et 2 O (6.27 mL, 51 mmol) was added to a solution of N-tritylaziridine 183 (15 g, 34 mmol) in 3-pentanol (230 mL) after argon with stirring at room temperature. The light solution was heated at 70-75 ° C for 1.75 hours and then concentrated in vacuo to give a brown residue which was dissolved in dry pyridine (2.0 mL) and treated with acetic anhydride (16 mL, 170 mL). mmol) and a catalytic amount of DMAP of 200 mg. The reaction was stirred at room temperature for 18 hours, concentrated in vacuo and partitioned between ethyl acetate and 1M HCl. The organic layer was separated and then washed with saturated sodium bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo followed by flash chromatography of the residue on silica gel (50% hexanes in ethyl acetate) gave 7.66 g of (diethyl) methyl ether which was recrystallized with ethyl acetate / hexane to give 227 (7.25 g, 66%) as colorless. needles: 1 H NMR (CDCl 3 , 300 MHz): δ 6.79 (t, 1H, J = 2.1 Hz); 5.92 (d, 1H, J = 7.5Hz); 4.58 (bd, 1H, J = 8.7Hz); 4.35-4.25 (m, IH); 3.77 (s, 3H); 3.36-3.25 (m, 2 H); 2.85 (dd, 1H, J = 5.7, 17.4 Hz); 2.29-2.18 (m, IH); 2.04 (s. 3H); 1.60-1.45 (m, 4H); 0.91 (t, 3H, J = 3.7Hz); 0.90 (t, 3H, J = 7.3Hz).
Příklad 93 (Dietyl)metyléteraminoester 228: Ph3P (1,21 g, 4,6 mmol) byl přidán v jedné dávce do roztoku azidu 227 (1 g, 3,1 mmol) a vody (5,6 ml) v THF (30 ml). Bledě žlutý roztok byl pak zahříván při teplotě 50 °C po dobu 10 hodin, ochlazen a koncentrován in vacuo. Vodný olejovitý zbytek byl rozdělen mezi EtOAc a nasycený NaCl. Organická fáze byla vysušena (MgSO4), filtrována a odpařována. Čištěn mžikovou chromatografií na silikagelu (50% metanolu v etylacetátu) vzniklo 830 mg (90%) aminoesteru 228 jako světle bílá pevná látka. 'H NMR (CDC13, 300 MHz): delta 6,78 (t, 1H, J= 2,1 Hz); 5,68 (bd, 1H, J= 7,8 Hz); 4,21-4,18 (m, 1H); 3,75 (s, 3H); 3,543,45 (m, 1H); 3,37-3,15 (m, 2H); 2,74 (dd, 1H, J= 5,1, 17,7 Hz); 2,20-2,07 (m, 1H); 2,03 (s, 3H); 2,69 (bs, 2H); -NH2); 1,57-1,44 (m, 4H); 0,90 (t, 3H, J= 7,5 Hz); 0,89 (t, 3H, J= 7,5 Hz).Example 93 (Diethyl) methyl ether amino ester 228: Ph 3 P (1.21 g, 4.6 mmol) was added in one portion to a solution of azide 227 (1 g, 3.1 mmol) and water (5.6 mL) in THF (30 mL). The pale yellow solution was then heated at 50 ° C for 10 hours, cooled and concentrated in vacuo. The aqueous oily residue was partitioned between EtOAc and saturated NaCl. The organic phase was dried (MgSO 4 ), filtered and evaporated. Purification by flash chromatography on silica gel (50% methanol in ethyl acetate) gave 830 mg (90%) of aminoester 228 as a light white solid. 1 H NMR (CDCl 3 , 300 MHz): δ 6.78 (t, 1H, J = 2.1 Hz); 5.68 (bd, 1H, J = 7.8Hz); 4.21-4.18 (m, IH); 3.75 (s, 3H); 3.543.45 (m, IH); 3.37-3.15 (m, 2 H); 2.74 (dd, 1H, J = 5.1, 17.7 Hz); 2.20-2.07 (m, IH); 2.03 (s, 3H); 2.69 (bs, 2 H); -NH 2 ); 1.57-1.44 (m, 4H); 0.90 (t, 3H, J = 7.5Hz); 0.89 (t, 3H, J = 7.5Hz).
Příklad 94Example 94
Aminokyselina 229: Roztok metylesteru 228 (830 mg, 2,8 mmol) v THF (15 ml) reagoval s vodným KOH (4 ml z 1,039 N roztoku). Reakční směs byla míchána při pokojové teplotě po dobu 40 minut a acidifikována na pH 5,5-6,0 acidickou pryskyřicí Dowex 50WX8. Pryskyřice byla filtrována a vymývána vodou a metanolem. Koncentrací in vacuo vznikla aminokyselina jako světlá pevná látka, která byla čištěna chromatografií C18 se zpětnou fází, eluovanou vodou, a poté 5% CH3CN/vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány tak, že vzniklo 600 mg (75%) aminokyseliny 229. 'H NMR (D2O, 300 MHz): delta 6,50 (t, 1H, J= 2,1 Hz); 4,30-4,26 (m, 1H); 4,03 (dd, 1H, J= 9,0, 11,7 Hz); 3,58-3,48 (m, 2H); 2,88 (dd, 1H, J =Amino Acid 229: A solution of methyl ester 228 (830 mg, 2.8 mmol) in THF (15 mL) was treated with aqueous KOH (4 mL of 1.039 N solution). The reaction mixture was stirred at room temperature for 40 minutes and acidified to pH 5.5-6.0 with Dowex 50WX8 acid resin. The resin was filtered and eluted with water and methanol. Concentration in vacuo gave the amino acid as a pale solid, which was purified by C 18 reverse phase chromatography, eluting with water, then with 5% CH 3 CN / water. Fractions containing the desired product were combined and lyophilized to give 600 mg (75%) of amino acid 229. 1 H NMR (D 2 O, 300 MHz): δ 6.50 (t, 1H, J = 2.1 Hz) ); 4.30-4.26 (m, IH); 4.03 (dd, 1H, J = 9.0, 11.7 Hz); 3.58-3.48 (m, 2 H); 2.88 (dd, 1 H, J =
-248CZ 297945 B6-248GB 297945 B6
5,4, 16,8 Hz); 2,53-2,41 (m, 1H); 1,62-1,40 (m, 4H); 0,90 (t, 3H, J= 7,5 Hz); 0,85 (t, 3H, J =5.4, 16.8 Hz); 2.53-2.41 (m, IH); 1.62-1.40 (m, 4H); 0.90 (t, 3H, J = 7.5Hz); 0.85 (t, 3 H, J =
7.5 Hz).7.5 Hz).
Příklad 95Example 95
Z-amyléterester 230: BF3.Et2O (43 μΐ, 0,35 mmol) byl přidán do roztoku N-tritylaziridinu 183 (104 mg, 0,24 mmol) v ř-amylalkoholu (2,5 ml) pod argonem při míchání při teplotě místnosti. Světlý roztok byl zahříván při teplotě 75 °C po dobu 3 hodin, a poté koncentrován in vacuo tak, že vznikl hnědý zbytek, který byl rozpuštěn v suchém pyridinu (2,0 ml) a reagovat s acetanhydridem (250 μΐ) a katalytickým množstvím DMAP (několik krystalů). Reakce byla míchána při pokojové teplotě po dobu 1,5 hodiny, koncentrována in vacuo a rozdělena mezi etylacetát a solanku. Organická vrstva byla oddělena a promývána následně ředěným HC1, nasyceným natrium-hydrogenuhličitanem, solankou a vysušena přes MgSO4. Koncentrací in vacuo, poté mžikovou chromatografií zbytku na silikagelu (50% hexany v etylacetátu) vzniklo 27 mg (35%) Z-amyléteresteru 230 jako světle oranžový olej. *HNMR (CDC13, 300 MHz); delta 6,72 (t, 1H, J= 2,1 Hz); 5,83 (d, 1H, J= 7,2 Hz); 4,71 (bd, 1H, J= 5,7, 17,4 Hz); 4,45-4,35 (m, 1H); 3,75 (s, 3H); 3,27-3,17 (m, 1H); 2,84 (dd, 1H, 5,7, 17,4 Hz); 2,27-2,15 (m, 1H); 2,05 (s, 3H);Z-Amyl Ether Ester 230: BF 3 .Et 2 O (43 µΐ, 0.35 mmol) was added to a solution of N-tritylaziridine 183 (104 mg, 0.24 mmol) in β-amyl alcohol (2.5 mL) under argon at stirring at room temperature. The light solution was heated at 75 ° C for 3 hours, and then concentrated in vacuo to give a brown residue which was dissolved in dry pyridine (2.0 mL) and treated with acetic anhydride (250 μΐ) and a catalytic amount of DMAP (several crystals). The reaction was stirred at room temperature for 1.5 hours, concentrated in vacuo and partitioned between ethyl acetate and brine. The organic layer was separated and washed successively with dilute HCl, saturated sodium bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo, then flash chromatography of the residue on silica gel (50% hexanes in ethyl acetate) gave 27 mg (35%) of Z-amyl ether ester 230 as a pale orange oil. * 1H NMR (CDCl3, 300 MHz); δ 6.72 (t, 1H, J = 2.1 Hz); 5.83 (d, 1H, J = 7.2Hz); 4.71 (bd, 1H, J = 5.7, 17.4 Hz); 4.45-4.35 (m, IH); 3.75 (s, 3H); 3.27-3.17 (m, IH); 2.84 (dd, 1H, 5.7, 17.4 Hz); 2.27-2.15 (m, IH); 2.05 (s. 3H);
I, 57-1,47 (m, 2H); 2,19 (s, 3H); 1,15 (s, 3H); 0,90 (t, 3H, J= 7,5 Hz).1.57-1.47 (m, 2H); 2.19 (s. 3H); 1.15 (s. 3H); 0.90 (t, 3H, J = 7.5Hz).
Příklad 96Example 96
Z-amyléteraminoester 231: Ph3P (35 mg, 0,133 mmol) byl přidán v jedné dávce do roztoku azidu 230 (27 mg, 0,083 mmol) a vody (160 μΐ) v THF (1,5 ml). Světle oranžový roztok byl pak zahříván při teplotě 50 °C po dobu 10 hodin, ochlazena a koncentrován in vacuo tak, že vznikla světlá pevná látka. Čištěním mžikovou chromatografií na silikagelu (50% metanolu v etylacetátu) vzniklo 20 mg (82%) aminoesteru 231 jako světlý olej.Z-Amyletheraminoester 231: Ph 3 P (35 mg, 0.133 mmol) was added in one portion to a solution of azide 230 (27 mg, 0.083 mmol) and water (160 µΐ) in THF (1.5 mL). The light orange solution was then heated at 50 ° C for 10 hours, cooled and concentrated in vacuo to give a light solid. Purification by flash chromatography on silica gel (50% methanol in ethyl acetate) gave 20 mg (82%) of aminoester 231 as a light oil.
Příklad 97Example 97
Aminokyselina 232: Roztok metylesteru 231 (20 mg, 0,068 mmol) v THF (1,0 ml) reagoval vodným KOH (131 μΐ z 1,039 N roztoku). Reakční směs byla míchána při pokojové teplotě po dobuAmino acid 232: A solution of methyl ester 231 (20 mg, 0.068 mmol) in THF (1.0 mL) was treated with aqueous KOH (131 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for
2.5 hodiny a acidifikována na pH 5,0 acidickou pryskyřicí Amberlite IR-120 (H ). Pryskyřice byla filtrována a promývána vodou a metanolem. Koncentrací in vacuo vznikla aminokyselina jako světlá pevná látka, která byla čištěna chromatografií C]8 se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány tak, že vzniklo 8,6 mg (45%) aminokyseliny 232. 'H NMR (D2O, 300 MHz): delta 6,47 (bs, 1H); 3,97 (dd, 1H, J= 8,4,2.5 hours and acidified to pH 5.0 with Amberlite IR-120 (H) acid resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a pale solid which was purified by C] 8 reverse phase chromatography eluting with water. Fractions containing the desired product were combined and lyophilized to give 8.6 mg (45%) of amino acid 232. 1 H NMR (D 2 O, 300 MHz): δ 6.47 (bs, 1H); 3.97 (dd, 1H, J = 8.4,
II, 4 Hz); 3,65-3,54 (m, 1H); 2,88 (dd, 1H, J= 5,5, 17,3 Hz); 2,51-2,39 (m, 1H); 2,08 (s, 3H); 1,61-1,46 (m, 2H); 1,23 (s, 3H); 1,18 (s, 3H), 0,86 (t, 3H, J= 7,5 Hz).II, 4 Hz); 3.65-3.54 (m, IH); 2.88 (dd, 1H, J = 5.5, 17.3 Hz); 2.51-2.39 (m, IH); 2.08 (s, 3H); 1.61-1.46 (m, 2 H); 1.23 (s. 3H); 1.18 (s, 3H), 0.86 (t, 3H, J = 7.5 Hz).
Příklad 98 n-propylthioéterester 233: BF3Et2O (130 μΐ, 1,06 mmol) byl přidán do roztoku N-tritylaziridin 183 (300 mg, 0,68 mmol) v 1-propanethiolu (8,0 ml) pod argonem při míchání při teplotě místnosti. Světlý roztok byl poté zahříván při teplotě 65 °C po dobu 45 minut, koncentrován a rozdělen mezi etylacetát a solanku. Organická vrstva byla oddělena a vymývána nasyceným natriumhydrogenuhličitanem, solankou a vysušena přes MgSO4. Koncentrací in vacuo, poté mžikovou chromatografií zbytku na silikagelu (30% hexany v etylacetátu) vzniklo 134 mg (73%) «-propylthioéteresteru 233 jako světlý olej. 'H NMR (CDC13, 300 MHz): delta 6,87 (t, 1H, J= 2,4 Hz); 3,77 (s, 3H); 3,48-3,38 (m, 1H); 3,22-2,18 (m, 1H), 2,93 (dd, 1H, J= 5,4, 17,4 Hz); 2,80 (t, 1H, J = 9,9 Hz); 2,51 (t, 2H, J= 7,2 Hz); 2,32 - 2,20 (m, 1H); 1,96 (bs, 2H, -NH2), 1,69 - 1,56 (m, 2H); 1,00 (t, 3H, J=7,2 Hz).Example 98 n-Propylthioetherester 233: BF 3 Et 2 O (130 µΐ, 1.06 mmol) was added to a solution of N-tritylaziridine 183 (300 mg, 0.68 mmol) in 1-propanethiol (8.0 mL) under argon. with stirring at room temperature. The light solution was then heated at 65 ° C for 45 minutes, concentrated and partitioned between ethyl acetate and brine. The organic layer was separated and washed with saturated sodium bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo, then flash chromatography of the residue on silica gel (30% hexanes in ethyl acetate) gave 134 mg (73%) of n-propylthioetherester 233 as a light oil. 1 H NMR (CDCl 3 , 300 MHz): δ 6.87 (t, 1H, J = 2.4 Hz); 3.77 (s, 3H); 3.48-3.38 (m, IH); 3.22-2.18 (m, 1H), 2.93 (dd, 1H, J = 5.4, 17.4 Hz); 2.80 (t, 1H, J = 9.9Hz); 2.51 (t, 2H, J = 7.2Hz); 2.32 - 2.20 (m, 1H); 1.96 (bs, 2H, -NH 2 ), 1.69-1.56 (m, 2H); 1.00 (t, 3H, J = 7.2Hz).
-249CZ 297945 B6-249GB 297945 B6
Příklad 99Example 99
M-propylthioéterazidoester 234: Do roztoku aminu 233 (134 mg, 0,50 mmol) v pyridinu (1,5 ml), ochlazeném na 0 °C byl přidán čistý acetylchlorid (60 μΐ, 0,84 mmol). Po míchání po dobu 1 hodiny byla reakční směs zahřáta na teplotu místnosti a míchána po dobu dalších 15 minut. Reakce byla koncentrovaná a rozdělená mezi etylacetát a solankou a vymývána následně ředěným HC1, vodou, nasyceným natrium-hydrogenuhličitanem, solankou a sušena přes MgSO4. Koncentraci in vacuo a následnou mžikovou chromatografií zbytku na silikagelu (30% hexany v etylacetátu) vzniklo 162 mg (100%) w-propylthioéterazidoesteru 234 jako světle žlutá pevná látka. !H NMR (CDC13, 300 MHz): delta 6,90 (t, 1H, J= 2,7 Hz); 5,87 (bd, 1H, J= 7,8 Hz); 4,07 - 3,98 (m, 1H); 3,77 (s, 3H); 3,65-3,55 (m, 1H); 2,95-2,85 (m, 1H); 2,60-2,45 (m, 2H); 2,30-2,18 (m, 1H); 2,08 (s, 3H); 1,65 - 1,53 (m, 2H); 0,98 (t, 3H, J= 7,2 Hz).M-propylthioetherazidoester 234: To a solution of amine 233 (134 mg, 0.50 mmol) in pyridine (1.5 mL) cooled to 0 ° C was added pure acetyl chloride (60 µΐ, 0.84 mmol). After stirring for 1 hour, the reaction mixture was warmed to room temperature and stirred for an additional 15 minutes. The reaction was concentrated and partitioned between ethyl acetate and brine and eluted subsequently with dilute HCl, water, saturated sodium bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo followed by flash chromatography of the residue on silica gel (30% hexanes in ethyl acetate) gave 162 mg (100%) of n-propylthioetherazidoester 234 as a pale yellow solid. ! 1 H NMR (CDCl 3 , 300 MHz): δ 6.90 (t, 1H, J = 2.7 Hz); 5.87 (bd, 1H, J = 7.8Hz); 4.07-3.98 (m, 1H); 3.77 (s, 3H); 3.65-3.55 (m, IH); 2.95-2.85 (m, IH); 2.60-2.45 (m. 2H); 2.30-2.18 (m, IH); 2.08 (s, 3H); 1.65-1.53 (m, 2H); 0.98 (t, 3H, J = 7.2Hz).
Příklad 100 w-propylthioéteraminoester 235: Azid 234 (130 mg, 0,416 mmol) v etylacetátu (10 ml) byl hydrogenován (1 atmosféra) přes Lindlarův katalyzátor (150 mg) po dobu 18 hodin při teplotě místnosti. Katalyzátor byl pak filtrován celitovým listem a vymýván horkým etylacetátem a metanolem. Koncentrací in vacuo s následnou mžikovou chromatografií oranžového zbytku vzniklo 62 mg (53%) fl-propylthioéteraminoesteru 235. H NMR (CDC13, 300 MHz): delta 6,88 (t, 1H, J= 2,7 Hz); 5,67 (bd, 1H, J= 8,7 Hz); 3,76 (s, 3H); 3,75 - 3,65 (m, 1H); 3,45 - 3,35 (bm, 1H); 3,05 - 2,95 (m, 1H); 2,87 - 2,78 (m, 1H); 2,56 - 2,40 (m, 2H); 2,18 - 2,05 (m, 1H); 2,09 (s, 3H); 1,65 - 1,50 (m, 2H); 1,53 (bs, 2H, -NH2); 0,98 (t, 3H, J= 7,2 Hz).Example 100 n-Propylthioetheramine Ester 235: Azide 234 (130 mg, 0.416 mmol) in ethyl acetate (10 mL) was hydrogenated (1 atmosphere) over Lindlar catalyst (150 mg) for 18 hours at room temperature. The catalyst was then filtered through a celite pad and eluted with hot ethyl acetate and methanol. Concentration in vacuo followed by flash chromatography of the orange residue afforded 62 mg (53%) of β-propylthioetheramino ester 235. 1 H NMR (CDCl 3 , 300 MHz): δ 6.88 (t, 1H, J = 2.7 Hz); 5.67 (bd, 1H, J = 8.7 Hz); 3.76 (s, 3H); 3.75 - 3.65 (m, 1H); 3.45-3.35 (bm, 1H); 3.05-2.95 (m, 1H); 2.87-2.78 (m, 1H); 2.56 - 2.40 (m, 2H); 2.18-2.05 (m, 1H); 2.09 (s. 3H); 1.65-1.50 (m, 2H); 1.53 (bs, 2H, -NH 2 ); 0.98 (t, 3H, J = 7.2Hz).
Příklad 101Example 101
Sloučenina 240: Suspenze chinové kyseliny (103 g), 2,2-dimetoxypropanu (200 ml) a toluensulfonové kyseliny (850 mg) v acetonu (700 ml) byla míchána při teplotě místnosti po dobu 4 dní. Rozpouštědla a přebytečné reagencie byly odstraněny pod sníženým tlakem. Čištěním mžikovou sloupcovou chromatografií (hexany/EtOAc = 2/1 - 1,5/1) vznikl lakton 240 (84 g, 73%): 'H NMR (CDC13) delta 4,72 (dd, J = 2,4, 6,1 Hz, 1 H), 4,50 (m, 1 H), 4,31 (m, 1 H), 2,67 (m, 2 H), 2,4 - 2,2 (m, 3 H), 1,52 (s, 3 H), 1,33 (s, 3 H). Vzhledem k provádění reakce při refluxových teplotách po dobu 4 hodin, vznikl lakton 240 ve výtěžku 71 % po vodném zpracování (etylacetát/vodní podíl) a rekrystalizaci surového produktu z etylacetátu/hexanu.Compound 240: A suspension of quinic acid (103 g), 2,2-dimethoxypropane (200 mL) and toluenesulfonic acid (850 mg) in acetone (700 mL) was stirred at room temperature for 4 days. Solvents and excess reagents were removed under reduced pressure. Purification by flash column chromatography (hexanes / EtOAc = 2/1 - 1.5 / 1) gave lactone 240 (84 g, 73%): 1 H NMR (CDCl 3 ) δ 4.72 (dd, J = 2.4, 6.1 Hz, 1H), 4.50 (m, 1H), 4.31 (m, 1H), 2.67 (m, 2H), 2.4-2.2 (m, 3H) H), 1.52 (s, 3H), 1.33 (s, 3H). By conducting the reaction at reflux temperatures for 4 hours, lactone 240 was formed in 71% yield after aqueous work-up (ethyl acetate / aqueous fraction) and recrystallization of the crude product from ethyl acetate / hexane.
Příklad 102Example 102
Sloučenina 241: Do roztoku laktonu 240 (43,5 g, 203 mmol) v metanolu (1200 ml) byl přidán metoxid sodný (4,37 M, 46,5 ml, 203 mmol) v jedné dávce. Směs byla míchána při teplotě místnosti po dobu 3 hodin, a rychle zchlazena kyselinou octovou (11,62 ml). Metanol byl odstraněn při sníženém tlaku. Směs byla naředěna vodou a extrahována pomocí EtOAc (3x). Složená organická fáze byla promyta vodou (lx) a solankou (lx) a vysušena přes MgSO4. Čištěním mžikovou chromatografií (hexany/EtOAc = 1/1 až 1/4) vznikl diol (43,4 g, 87%): *HNMR (CDC13) delta 4,48 (m, 1 H), 4,13 (m, 1H), 3,99 (t, J = 6,4 Hz, 1 H), 3,82 (s, 3 H), 3,34 (s, 3 H), 2,26 (d, J = 3,8 Hz, 2 H), 2,08 (m, 1 H), 1,91 (m, 1 H), 1,65 (s, 3 H), 1,38 (s, 3 H). Nebo, při reakci laktonu 240 s katalytickým etoxidem sodným (1 mol%) v etanolu vznikl odpovídající etylester v 67% po kiystalizaci surového produktu z etylacetátu/hexanu. Zbytek získaný z matečného louhu (tvořeného výchozím materiálem a produktem) byl opět vystaven podmínkám stejné reakce, čímž po rekrystalizaci vznikl další produkt. Celkový výtěžek byl 83%.Compound 241: To a solution of lactone 240 (43.5 g, 203 mmol) in methanol (1200 mL) was added sodium methoxide (4.37 M, 46.5 mL, 203 mmol) in one portion. The mixture was stirred at room temperature for 3 hours, and quenched with acetic acid (11.62 mL). The methanol was removed under reduced pressure. The mixture was diluted with water and extracted with EtOAc (3x). The combined organic phase was washed with water (1x) and brine (1x) and dried over MgSO 4 . Purification by flash chromatography (hexanes / EtOAc = 1/1 to 1/4) gave diol (43.4 g, 87%): 1H NMR (CDCl3) delta 4.48 (m, 1H), 4.13 (m 1 H, 3.99 (t, J = 6.4 Hz, 1 H), 3.82 (s, 3 H), 3.34 (s, 3 H), 2.26 (d, J = 3) 8 Hz, 2 H), 2.08 (m, 1H), 1.91 (m, 1H), 1.65 (s, 3H), 1.38 (s, 3H). Or, the reaction of lactone 240 with catalytic sodium ethoxide (1 mol%) in ethanol gave the corresponding ethyl ester in 67% after crystallization of the crude product from ethyl acetate / hexane. The residue obtained from the mother liquor (consisting of the starting material and the product) was again subjected to the same reaction conditions, whereby another product was formed after recrystallization. The overall yield was 83%.
-250CZ 297945 B6-250GB 297945 B6
Příklad 103Example 103
Sloučenina 242: Do roztoku diolu 241 (29,8 g, 121 mmol) a 4-(N,N-dimetylamino)pyridinu (500 mg) v pyridinu (230 ml) byl přidán tosylchlorid (27,7 g, 145 mmol). Směs byla míchána při pokojové teplotě po dobu 3 dnů a pyridin byl odstraněn za sníženého tlaku. Směs byla naředěna vodou a extrahována EtOAc (3x). Složená organická fáze byla promývána vodou (2x) a solankou (lx) a vysušena přes MgSO4. Koncentrací a čištěním mžikovou sloupcovou chromatografii (hexany/EtOAc = 2/1 - 1/1) vznikl tosylát 242 (44,6 g, 92%): 'HNMR (CDC13) delta 7,84 (d, J = 8,4 Hz, 2 H), 7,33 (d, J = 8,1 Hz, 2 H), 4,76 (m, 1 H), 4,42 (m, 1 H), 4,05 (dd, J = 5,5, 7,5 Hz, 1 H), 3,80 (s, 3 H), 2,44 (s, 3 H), 2,24 (m, 2 H), 1,96 (m, 1 H), 1,26 (s, 3 H), 1,13 (s, 3 H). Odpovídající etylester sloučeniny 241 reagoval s metansulfonylchloridem a trietylaminem v CH2C12 při teplotě 0 °C a vznikl derivát mesylátu v kvantitativním výtěžku po vodném zpracování. Mesylát byl použit přímo bez jakéhokoliv dalšího čištění.Compound 242: To a solution of diol 241 (29.8 g, 121 mmol) and 4- (N, N-dimethylamino) pyridine (500 mg) in pyridine (230 mL) was added tosyl chloride (27.7 g, 145 mmol). The mixture was stirred at room temperature for 3 days and pyridine was removed under reduced pressure. The mixture was diluted with water and extracted with EtOAc (3x). The combined organic phase was washed with water (2x) and brine (1x) and dried over MgSO 4 . Concentration and purification by flash column chromatography (hexanes / EtOAc = 2/1 - 1/1) gave tosylate 242 (44.6 g, 92%): 1 H NMR (CDCl 3 ) δ 7.84 (d, J = 8.4) Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.76 (m, 1H), 4.42 (m, 1H), 4.05 (dd, J) = 5.5, 7.5 Hz, 1 H), 3.80 (s, 3 H), 2.44 (s, 3 H), 2.24 (m, 2 H), 1.96 (m, 1 H), 1.26 (s, 3 H), 1.13 (s, 3 H). The corresponding ethyl ester of compound 241 was reacted with methanesulfonyl chloride and triethylamine in CH 2 Cl 2 at 0 ° C to give the mesylate derivative in quantitative yield after aqueous work-up. The mesylate was used directly without any further purification.
Příklad 104Example 104
Sloučenina 243: Do roztoku tosylátu 242 (44,6 g, 111,5 mmol) vCH2C12 (450 ml) při teplotě -78 °C byl přidán pyridin (89 ml), poté pomalu přidáván SO2C12 (26,7 ml, 335 mmol). Směs byla míchána při teplotě -78 °C po dobu 5 hodin a po kapkách byl přidáván metanol (45 ml). Směs byla zahřívána na teplotu místnosti a míchána po dobu 12 hodin. Byl přidán etyléter a směs byla promývána vodou (3x) a solankou (lx) a vysušena přes MgSO4. Koncentrací vznikl meziprodukt jako olej (44,8 g). Do roztoku meziproduktu (44,8 g, 111,5 mmol) v MeOH (500 ml) byl přidán TsOH (1,06 g, 5,6 mmol). Směs byla refluxována po dobu 4 hodin. Reakční směs byla ochlazena na teplotu místnosti a metanol byl odstraněn při sníženém tlaku. Byl přidán čerstvý metanol (500 ml) a celá směs byla refluxována další 4 hodiny. Reakční směs byla ochlazena na teplotu místnosti a metanol byl odstraněn za sníženého tlaku. Čištěním mžikovou sloupcovou chromatografií (hexany/EtOAc = 3/1 - 1/3) vznikla směs dvou izomerů (26,8 g). Rekrystalizací z EtOAc/hexanů vznikl čistý požadovaný produkt 243 (20,5 g, 54%): 1H NMR (CDC13) delta 7,82 (d, J = 8,3 Hz, 2 H), 7,37 (d, J = 8,3 Hz, 2 H), 6,84 (m, 1 H), 4,82 (dd, J = 5,8, 7,4 Hz, 1 H), 4,50 (m, 1 H), 3,90 (dd, J = 4,4, 8,1 Hz, 1 H), 3,74 (s, 3 H), 2,79 (dd, J = 5,5, 18,2 Hz, 1 H), 2,42 (dd, J = 6,6, 18,2 Hz, 1 H). Odpovídající mesylát-etylester derivát sloučeniny 242 reagoval stejným způsobem, jako bylo popsáno. Acetonidová ochranná skupina byla odstraněna kyselinou octovou v refluxujícím etanolu tak, že vznikl diol v 39% výtěžku přímým vysrážením s éterem ze surové reakční směsi.Compound 243: To a solution of tosylate 242 (44.6 g, 111.5 mmol) in CH 2 Cl 2 (450 mL) at -78 ° C was added pyridine (89 mL), then slowly added SO 2 Cl 2 (26, 7 mL, 335 mmol). The mixture was stirred at -78 ° C for 5 hours, and methanol (45 mL) was added dropwise. The mixture was warmed to room temperature and stirred for 12 hours. Ethyl ether was added and the mixture was washed with water (3x) and brine (1x) and dried over MgSO 4 . Concentration gave the intermediate as an oil (44.8 g). To a solution of intermediate (44.8 g, 111.5 mmol) in MeOH (500 mL) was added TsOH (1.06 g, 5.6 mmol). The mixture was refluxed for 4 hours. The reaction mixture was cooled to room temperature and the methanol was removed under reduced pressure. Fresh methanol (500 mL) was added and the whole was refluxed for another 4 hours. The reaction mixture was cooled to room temperature and the methanol was removed under reduced pressure. Purification by flash column chromatography (hexanes / EtOAc = 3/1 - 1/3) gave a mixture of two isomers (26.8 g). Recrystallization from EtOAc / hexanes gave pure desired product 243 (20.5 g, 54%): 1 H NMR (CDCl 3 ) δ 7.82 (d, J = 8.3 Hz, 2 H), 7.37 (d J = 8.3 Hz, 2H), 6.84 (m, 1H), 4.82 (dd, J = 5.8, 7.4 Hz, 1H), 4.50 (m, 1H) H), 3.90 (dd, J = 4.4, 8.1 Hz, 1H), 3.74 (s, 3 H), 2.79 (dd, J = 5.5, 18.2 Hz) 1 H), 2.42 (dd, J = 6.6, 18.2 Hz, 1 H). The corresponding mesylate-ethyl ester derivative of compound 242 was reacted in the same manner as described above. The acetone protecting group was removed with acetic acid in refluxing ethanol to give the diol in 39% yield by direct precipitation with ether from the crude reaction mixture.
Příklad 105Example 105
Sloučenina 1: Do roztoku diolu 243 (20,0 g, 58,5 mmol) v THF (300 ml) při teplotě 0 °C byl přidán DBU (8,75 ml, 58,5 mmol). Reakční směs byla zahřívána na teplotu místnosti a míchána po dobu 12 hodin. Rozpouštědlo (THF) bylo odstraněno při sníženém tlaku. Čištěním mžikovou sloupcovou chromatografii (hexany/EtOAc = 1/3) vznikl epoxid 1 (9,72 g, 100%). 'HNMR (CDC13) delta 6,72 (m, 1 H), 4,56 (td, J = 2,6, 10,7 Hz, 1 H), 3,76 (s, 3 H), 3,56 (m, 2 H), 3,0 (d, J = 21 Hz, 1 H), 2,50 (d, J = 20 Ηζ,Ι H ), 2,11 (d, 10,9 Hz, 1 H). Odpovídající mesylát-etylester derivát sloučeniny 243 reagoval stejným způsobem, jako bylo popsáno, čímž vznikl epoxid v téměř kvantitativním výtěžku.Compound 1: To a solution of diol 243 (20.0 g, 58.5 mmol) in THF (300 mL) at 0 ° C was added DBU (8.75 mL, 58.5 mmol). The reaction mixture was warmed to room temperature and stirred for 12 hours. The solvent (THF) was removed under reduced pressure. Purification by flash column chromatography (hexanes / EtOAc = 1/3) gave epoxide 1 (9.72 g, 100%). 1 H NMR (CDCl 3 ) δ 6.72 (m, 1H), 4.56 (td, J = 2.6, 10.7 Hz, 1H), 3.76 (s, 3H), 3, 56 (m, 2H), 3.0 (d, J = 21Hz, 1H), 2.50 (d, J = 20Hz, 1H), 2.11 (d, 10.9Hz, 1H) H). The corresponding mesylate-ethyl ester derivative of compound 243 was reacted in the same manner as described to give the epoxide in almost quantitative yield.
Příklad 106Example 106
Aziridin 244: Roztok alyléteru 4 (223 ml, 1,07 mmol) a Lindlarova katalyzátoru (200 mg) v absolutním etanolu (8,0 ml) reagoval s vodíkovým plynem (1 atmosféra) při teplotě místnosti po dobu 50 minut. Katalyzátor byl poté přefiltrován přes celitový list a vymyt horkým metanoAziridine 244: A solution of allyl ether 4 (223 mL, 1.07 mmol) and Lindlar catalyst (200 mg) in absolute ethanol (8.0 mL) was treated with hydrogen gas (1 atmosphere) at room temperature for 50 minutes. The catalyst was then filtered through a pad of celite and washed with hot methane
-251 CZ 297945 B6 lem. Koncentrací in vacuo vzniklo ~230 mg 244 jako světle žlutý olej, který byl použit pro další reakci bez jakéhokoliv dalšího čištění.-251 CZ 297945 B6 hem. Concentration in vacuo afforded ~ 230 mg of 244 as a pale yellow oil which was used for the next reaction without any further purification.
Příklad 107Example 107
Azidoamin 205: Surový aziridin 244 (230 mg), azid sodný (309 mg, 4,75 mmol) a chlorid amonný (105 mg, 1,96 mmol) v suchém DMF (10 ml) byly zahřívány při teplotě 70 °C po dobu 16 hodin v argonové atmosféře. Reakce byla zchlazena, filtrována přes nálevku z fritového skla, aby se odstranily pevné látky, a rozdělena mezi etylacetát a solanku. Organická vrstva byla oddělena a vysušena přes MgSO4. Koncentrací in vacuo a následnou mžikovou chromatografii zbytku na silikagelu (10% hexany v etylacetátu) vzniklo 154 mg (57%, 2 kroky) 205 jako žlutý viskózní olej dostatečně čistý pro další reakci.Azidoamine 205: Crude aziridine 244 (230 mg), sodium azide (309 mg, 4.75 mmol) and ammonium chloride (105 mg, 1.96 mmol) in dry DMF (10 mL) were heated at 70 ° C for 16 hours in argon atmosphere. The reaction was cooled, filtered through a sintered glass funnel to remove solids, and partitioned between ethyl acetate and brine. The organic layer was separated and dried over MgSO 4 . Concentration in vacuo followed by flash chromatography of the residue on silica gel (10% hexanes in ethyl acetate) gave 154 mg (57%, 2 steps) 205 as a yellow viscous oil sufficiently pure for the next reaction.
Příklad 108Example 108
N-acetylazid 245. Acetylchlorid (70 μΐ, 0,98 mmol) byl přidán do roztoku aminu 205 (154 mg, 0,61 mmol) a pyridinu (1,3 ml) v CH2CI2 (4,0 ml), ochlazeného na 0 °C. Po 1,5 hodině při 0 °C byla reakce koncentrována a rozdělena mezi etylacetát a solanku. Organická vrstva byla oddělena a následně promývána nasyceným natrium-hydrogenuhličitanem, solankou a vysušena přes MgSO4. Koncentrací in vacuo a následnou mžikovou chromatografii zbytku na silikagelu (etylacetát) vzniklo 167 mg (93%) 245 jako světle žlutá pevná látka.N-Acetylazide 245. Acetyl chloride (70 μΐ, 0.98 mmol) was added to a solution of amine 205 (154 mg, 0.61 mmol) and pyridine (1.3 mL) in CH 2 Cl 2 (4.0 mL) cooled to 0. Noc: 2 ° C. After 1.5 h at 0 ° C, the reaction was concentrated and partitioned between ethyl acetate and brine. The organic layer was separated and then washed with saturated sodium bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo followed by flash chromatography of the residue on silica gel (ethyl acetate) afforded 167 mg (93%) of 245 as a pale yellow solid.
Příklad 109Example 109
Aminoester 200: Trifenylfosfin (1,7 g, 6,48 mmol) byl přidán po několika částech do roztoku 245 (1,78 g, 6,01 mmol) v THF (40 ml) a vody (1,5 ml). Reakce byla pak míchána při teplotě místnosti po dobu 42,5 hodin. Těkavé látky byly odstraněny ve vakuu a surová pevná látka absorbována na silikagelu a čištěna mžikovou chromatografii na silikagelu (100% etylacetát, pak 100% metanol) a vznikl 1,24 g (77%) 200 jako světlá pevná látka.Aminoester 200: Triphenylphosphine (1.7 g, 6.48 mmol) was added in portions to a solution of 245 (1.78 g, 6.01 mmol) in THF (40 mL) and water (1.5 mL). The reaction was then stirred at room temperature for 42.5 hours. The volatiles were removed in vacuo and the crude solid absorbed on silica gel and purified by silica gel flash chromatography (100% ethyl acetate then 100% methanol) to give 1.24 g (77%) 200 as a light solid.
Příklad 110Example 110
Aminokyselina 102: Do roztoku metylesteru 200 (368 mg, 1,37 mmol) v THF (4,0 ml), ochlazeného na 0 °C byl přidán vodný NaOH (1,37 ml z 1,0 N roztoku). Reakční směs byla míchána při 0 °C po dobu 10 minut, při teplotě místnosti po dobu 1,5 hodiny, a poté acidifíkována na pH 7,0 - 7,5 acidickou pryskyřicí Amberlite IR-120 (H). Pryskyřice byla filtrována a promyta vodou a metanolem. Koncentrací in vacuo vznikla aminokyselina jako bílá pevná látka, která byla čištěna chromatografii Cig se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofilizovány, vzniklo 290 mg (83%) aminokyseliny 102.Amino acid 102: To a solution of methyl ester 200 (368 mg, 1.37 mmol) in THF (4.0 mL) cooled to 0 ° C was added aqueous NaOH (1.37 mL of 1.0 N solution). The reaction mixture was stirred at 0 ° C for 10 minutes, at room temperature for 1.5 hours, and then acidified to pH 7.0 - 7.5 with Amberlite IR-120 (H) acid resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a white solid, which was purified by reverse phase C 18 chromatography eluted with water. Fractions containing the desired product were pooled and lyophilized to give 290 mg (83%) of amino acid 102.
Příklad 111Example 111
Aminhydrochlorid 250: Amin 228 (15,6 mg, 0,05 mmol) reagoval s 0,1 N HC1 a byl odpařen. Zbytek byl rozpuštěn ve vodě a byl filtrován malým sloupcem silikagelu Cig se zpětnou fází. Sůl hydrochloridu 250 (12 mg) byla získána jako pevná látka po lyofilizaci: *HNMR (D2O) delta 6,86 (s, IH), 4,35 (brd, J= 9,0), 4,06 (dd, IH, J= 9,0, 11,6), 3,79 (s, 3H), 3,65 - 3,52 (m, 2H), 2,97 (dd, IH, J = 5,5, 17,2), 2,58-2,47 (m, IH), 2,08 (s, 3H), 1,61 - 1,41 (m, 4H), 0,88 (t, 3H, 7=7,4), 0,84 (t, 3H,J=7,4).Amine hydrochloride 250: Amine 228 (15.6 mg, 0.05 mmol) was treated with 0.1 N HCl and evaporated. The residue was dissolved in water and was filtered through a small column of C18 reverse phase silica gel. The hydrochloride salt 250 (12 mg) was obtained as a solid after lyophilization: * H NMR (D 2 O) d 6.86 (s, IH), 4.35 (brd, J = 9.0), 4.06 (dd 1H, J = 9.0, 11.6), 3.79 (s, 3H), 3.65-3.52 (m, 2H), 2.97 (dd, 1H, J = 5.5, 17.2), 2.58-2.47 (m, 1H), 2.08 (s, 3H), 1.61-1.41 (m, 4H), 0.88 (t, 3H, 7 = 7.4), 0.84 (t, 3H, J = 7.4).
-252CZ 297945 B6-252EN 297945 B6
Příklad 112Example 112
Bis-Boc-Guanidin 251: Do roztoku aminu 228 (126 mg, 0,42 mmol), N,N'-bis-fór/-butoxykarbonylthiomočoviny (127 mg, 0,46 mmol) a trietylaminu (123 μΐ, 0,88 mmol) v DMF (4 ml) při teplotě 0 °C byl přidán HgCl2 (125 mg, 0,46 mmol). Směs byla míchána při teplotě 0 °C po dobu 30 minut a při teplotě místnosti po dobu 1,5 hodiny. Reakce byla naředěna etylacetátem a filtrována přes celit. Rozpouštědlo bylo odpařeno a zbytek byl rozdělen mezi etylacetát a vodu. Organická fáze byla promyta nasyceným NaCl, vysušena (MgSO4), filtrována a rozpouštědlo bylo odpařeno. Surový produkt byl čištěn na silikagelu (2/1, 1/1-hexan/etylacetát) a vznikl bis— Boc-guanidin 251 (155 mg, 69%) jako pevná látka: *HNMR (CDC13) delta 11,40 (s, 1H), 8,66 (d, 1H, J= 7,9), 6,8 (s, 1H), 6,22 (d, 1H, J= 8,9), 4,43 - 4,34 (m, 1H), 4,19 - 4,08 (m, 1H), 4,03 (m, 1H), 3,76 (s, 3H), 3,35 (m, 1H), 2,79 (dd, 1H, J= 5,4, 17,7), 2,47-2,36 (m, 1H), 1,92 (s, 3H), 1,50, 1,49 (2s, 18H), 0,89 (m, 6H).Bis-Boc-Guanidine 251: To a solution of amine 228 (126 mg, 0.42 mmol), N, N'-bis-tert-butoxycarbonylthiourea (127 mg, 0.46 mmol) and triethylamine (123 μΐ, 0.88 mmol) in DMF (4 mL) at 0 ° C was added HgCl 2 (125 mg, 0.46 mmol). The mixture was stirred at 0 ° C for 30 minutes and at room temperature for 1.5 hours. The reaction was diluted with ethyl acetate and filtered through celite. The solvent was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with saturated NaCl, dried (MgSO 4 ), filtered and the solvent was evaporated. The crude product was purified on silica gel (2/1, 1/1-hexane / ethyl acetate) to give bis-Boc-guanidine 251 (155 mg, 69%) as a solid: 1 H NMR (CDCl 3 ) δ 11.40 (s (1H), 8.66 (d, 1H, J = 7.9), 6.8 (s, 1H), 6.22 (d, 1H, J = 8.9), 4.43-4.44 (m, 1H), 4.19-4.08 (m, 1H), 4.03 (m, 1H), 3.76 (s, 3H), 3.35 (m, 1H), 2.79 (s) dd, 1H, J = 5.4, 17.7), 2.47-2.36 (m, 1H), 1.92 (s, 3H), 1.50, 1.49 (2s, 18H), 0.89 (m, 6 H).
Příklad 113Example 113
Kyselina guanidinová 252: Do roztoku bis-Boc-guanidinu 251 (150 mg, 0,28 mmol) v THF (3 ml) byl přidán roztok l,039N KOH (337 μΐ) a vody (674 μΐ). Směs byla míchána po dobu 3 hodin, byl přidán další roztok l,039N KOH (67 μΐ) a míchání pokračovalo po dobu 2 hodin. Reakce byla filtrována, aby se odstranilo malé množství tmavé sraženiny. Filtrát byl ochlazen na 0 °C a acidifikován iontoměničovou pryskyřicí IR 120 na pH 4,5 - 5,0. Pryskyřice byla filtrována a vymyta metanolem.Filtrát byl odpařen na zbytek, který byl rozpuštěn v CH2C12 (3 ml), ochlazen na 0 °C a reagoval s trifluorooctovou kyselinou (3 ml). Po míchání po dobu 10 minut při 0 °C byla reakce míchána při teplotě místnosti po dobu 2,5 hodiny. Rozpouštědla byla odpařena a zbytek byl rozpuštěn ve vodě a chromatografován v krátkém sloupci (3x1,5 cm) silikagelu C18 se zpětnou fází, elutovaném zpočátku vodou, a pak 5% acetonitrilem/vodou. Frakce produktu byly spojeny a odpařeny. Zbytek byl rozpuštěn ve vodě a lyofilizován tak, že vznikla kyselina guanidinová 252 (97 mg, 79%) jako bílá pevná látka.Guanidine acid 252: To a solution of bis-Boc-guanidine 251 (150 mg, 0.28 mmol) in THF (3 mL) was added a solution of 1.039N KOH (337 μΐ) and water (674 μΐ). The mixture was stirred for 3 hours, an additional solution of 1.039N KOH (67 μΐ) was added and stirring was continued for 2 hours. The reaction was filtered to remove a small amount of dark precipitate. The filtrate was cooled to 0 ° C and acidified with an IR 120 resin to pH 4.5-5.0. The resin was filtered and washed with methanol. The filtrate was evaporated to a residue which was dissolved in CH 2 Cl 2 (3 mL), cooled to 0 ° C and treated with trifluoroacetic acid (3 mL). After stirring for 10 minutes at 0 ° C, the reaction was stirred at room temperature for 2.5 hours. The solvents were evaporated and the residue was dissolved in water and chromatographed on a short column (3 x 1.5 cm) of reverse phase C18 silica gel, eluted initially with water and then with 5% acetonitrile / water. The product fractions were combined and evaporated. The residue was dissolved in water and lyophilized to give guanidine acid 252 (97 mg, 79%) as a white solid.
Příklad 114Example 114
Kyselina azidová 260: Do roztoku metylesteru 227 (268 mg, 0,83 mmol) v THF (7,0 ml) byl přidán vodný KOH (1,60 ml z 1,039 N roztoku) při teplotě místnosti. Po míchání po dobu 19 hodin při teplotě místnosti byla reakce acidifikována na pH 4,0 acidickou pryskyřicí Amberlite IR-120 (H+). Pryskyřice byla filtrována a vymyta vodou a etanolem. Koncentrací in vacuo vznikla surová kyselina azidová 260 jako světle oranžová pěna, která byla použita pro další reakci bez jakéhokoliv dalšího čištění.Azidic Acid 260: To a solution of methyl ester 227 (268 mg, 0.83 mmol) in THF (7.0 mL) was added aqueous KOH (1.60 mL of 1.039 N solution) at room temperature. After stirring for 19 hours at room temperature, the reaction was acidified to pH 4.0 with Amberlite IR-120 (H + ) resin. The resin was filtered and washed with water and ethanol. Concentration in vacuo afforded the crude azide acid 260 as a pale orange foam, which was used for the next reaction without any further purification.
Příklad 115Example 115
Azidoetylester 261: Do roztoku kyseliny karboxylové 260 (surové z předchozí reakce, předpokládejme 0,83 mmol), etylalkoholu (150 μΐ) a katalytického DMAP v CH2C12 (6,0 ml) byl přidán DCC (172 mg, 0,83 mmol) v jedné dávce při teplotě místnosti. Po několika minutách se vytvořila sraženina a po další 1 hodině míchání byla reakce filtrována a vymyta CH2C12. Koncentrací in vacuo vznikla světlá pevná látka, která byla čištěna mžikovou chromatografií na silikagelu (50% hexany v etylacetátu) a vzniklo 272 mg (96%, přítomno malé množství nečistoty DCU) 261 jako bílá pevná látka. Když byl DCC nahrazen diizopropylkarbodiimidem, pak byl výtěžek 261 93%, ale chromatografické čištění eliminovalo nečistoty močoviny, které byly přítomny při použití DCC.Azidoethyl ester 261: To a solution of carboxylic acid 260 (crude from the previous reaction, suppose 0.83 mmol), ethyl alcohol (150 μΐ) and catalytic DMAP in CH 2 Cl 2 (6.0 mL) was added DCC (172 mg, 0.83) mmol) in one portion at room temperature. After a few minutes, a precipitate formed and after an additional 1 hour of stirring, the reaction was filtered and washed with CH 2 Cl 2 . Concentration in vacuo gave a light solid which was purified by silica gel flash chromatography (50% hexanes in ethyl acetate) to give 272 mg (96%, a small amount of DCU impurity present) 261 as a white solid. When DCC was replaced with diisopropylcarbodiimide, the yield was 261 93%, but chromatographic purification eliminated the urea impurities that were present using DCC.
-253 CZ 297945 B6-253 GB 297945 B6
Příklad 116Example 116
Aminoetylester 262: Trifenylfosfín (342 mg, 1,30 mmol) byl přidán v jedné dávce do roztoku 261 (272 g, 0,80 mmol) v THF (17 ml) a vody (1,6 ml). Reakce byla poté zahřívána na 50 °C po dobu 10 hodin, ochlazena a koncentrována in vacuo, a vznikla bledě bílá pevná látka. Čištěním surové pevné látky mžikovou chromatografíí na silikagelu (50% metanol v etylacetátu) vzniklo 242 mg (96%) aminoetylesteru 262 jako světlá pevná látka. Aminoetylester se rozpustil v 3N HC1 a byl lyofílizován tak, že vznikla odpovídající forma soli HC1 rozpustná ve vodě. ’HNMR (D2O, 300 MHz): delta 6,84 (s, 1H); 4,36 - 4,30 (br m, 1H); 4,24 (q, 2H, J= 7,2 Hz); 4,05 (dd, 1H, J= 9,0, 11,7 Hz); 3,63 - 3,50 (tn, 2H); 2,95 (dd, 1H, J= 5,7, 17,1 Hz); 2,57 - 2,45 (m, 1H); 1,60 - 1,39 (M, 4H); 1,27 (t, 3H, J= 7,2 Hz); 0,89 - 0,80 (m, 6H).Aminoethyl ester 262: Triphenylphosphine (342 mg, 1.30 mmol) was added in one portion to a solution of 261 (272 g, 0.80 mmol) in THF (17 mL) and water (1.6 mL). The reaction was then heated to 50 ° C for 10 hours, cooled and concentrated in vacuo to give a pale white solid. Purification of the crude solid by flash chromatography on silica gel (50% methanol in ethyl acetate) gave 242 mg (96%) of aminoethyl ester 262 as a pale solid. The aminoethyl ester was dissolved in 3N HCl and lyophilized to give the corresponding water-soluble HCl salt form. 1 H NMR (D 2 O, 300 MHz): δ 6.84 (s, 1H); 4.36-4.30 (br m, 1H); 4.24 (q, 2H, J = 7.2Hz); 4.05 (dd, 1H, J = 9.0, 11.7 Hz); 3.63 - 3.50 (tn, 2H); 2.95 (dd, 1H, J = 5.7, 17.1 Hz); 2.57 - 2.45 (m, 1H); 1.60-1.39 (M, 4H); 1.27 (t, 3H, J = 7.2Hz); 0.89-0.80 (m, 6H).
Příklad 117 bis-Boc guanidinoetylester 263: Reakce podle postupu Kim and Qian, „Tetrahedron Lett.“ 34:7677 (1993). Do roztoku aminu 262 (72 mg, 0,23 mmol), bis-Boc thiomočoviny (66 mg, 0,24 mmol) a Et3N (108 μΐ) v suchém DMF (600 μΐ), ochlazeného na 0 °C byl přidán HgCl2 (69 mg, 0,25 mmol) v jedné dávce. Heterogenní reakční směs byla míchána po dobu 1 hodiny při teplotě 0 °C, pak při teplotě místnosti po dobu 15 minut, a poté byla reakce naředěna EtOAc a filtrována celitovým listem. Koncentrací in vacuo a následnou mžikovou chromatografíí zbytku na silikagelu (20% hexanů v etylacetátu) vzniklo 113 mg (89%) 263 jako bezbarvá pěna. 'HNMR (CDC13, 300 MHz) delta 11,41 (s, 1H); 8,65 (d, 1H, J= 8,1 Hz); 6,83 (s, 1H); 6,22 (d, 1H, J= 9,0 Hz); 4,46 - 4,34 (m, 1H); 4,21 (q, 2H, J= 6,9 Hz); 4,22 - 4,10 (m, 1H); 4,04 4,00 (m, 1H); 3,36 (kvintet, 1H, J= 5,7 Hz); 2,78 (dd, 1H, J= 5,4, 17,7 Hz); 2,46 - 2,35 (m, 1H); 1,94 (s, 3H); 1,60 - 1,40 (m, 4H); 1,49 (s, 9H); 1,50 (s, 9H); 1,30 (t, 3H, J= 6,9 Hz); 0,93 - 0,84 (m, 6H).Example 117 bis-Boc guanidinoethyl ester 263: Reaction according to the Kim and Qian procedure, "Tetrahedron Lett." 34: 7677 (1993). To a solution of amine 262 (72 mg, 0.23 mmol), bis-Boc thiourea (66 mg, 0.24 mmol) and Et 3 N (108 μΐ) in dry DMF (600 μΐ) cooled to 0 ° C was added HgCl 2 (69 mg, 0.25 mmol) per dose. The heterogeneous reaction mixture was stirred for 1 hour at 0 ° C, then at room temperature for 15 minutes, and then the reaction was diluted with EtOAc and filtered through a celite pad. Concentration in vacuo followed by flash chromatography of the residue on silica gel (20% hexanes in ethyl acetate) afforded 113 mg (89%) 263 as a colorless foam. 1 H NMR (CDCl 3 , 300 MHz) δ 11.41 (s, 1H); 8.65 (d, 1H, J = 8.1Hz); 6.83 (s, 1 H); 6.22 (d, 1H, J = 9.0Hz); 4.46 - 4.34 (m, 1H); 4.21 (q, 2H, J = 6.9Hz); 4.22-4.10 (m, 1H); 4.04 4.00 (m, IH); 3.36 (quintet, 1H, J = 5.7 Hz); 2.78 (dd, 1H, J = 5.4, 17.7 Hz); 2.46 - 2.35 (m, 1H); 1.94 (s, 3H); 1.60-1.40 (m, 4H); 1.49 (s, 9H); 1.50 (s, 9H); 1.30 (t, 3H, J = 6.9Hz); 0.93 - 0.84 (m, 6H).
Příklad 118Example 118
Guanidinoetylester 264. Do roztoku bis-Boc guanidinyletylesteru 263 (113 mg, 0,20 mmol) v CH2C12 (5,0 ml), ochlazeného na 0 °C byla přidána čistá trifluoroctová kyselina (5,0 ml). Reakční směs byla míchána při teplotě 0 °C po dobu 30 minut, a poté při teplotě místnosti po dobu 1,5 hodiny. Reakce byla pak koncentrována in vacuo, vznikla bledě oranžová pevná látka, která byla čištěna chromatografíí C18 se zpětnou fází, elutovanou vodou. Frakce, obsahující požadovaný produkt, byly spojeny a lyofílizovány tak, že vzniklo 63 g (66%) guanidinetylesteru 264 jako bílá pevná látka. 'HNMR (D2O, 300 MHz) delta 6,82 (s, 1H); 4,35 - 4,31 (m, 1H); 4,24 (q, 2H, J= 7,1 Hz); 3,95 - 3,87 (m, 1H); 3,85 - 3,76 (m, 1H); 3,57 -3,49 (m, 1H); 2,87 (dd, 1H, J=5,l, 17,7 Hz); 2,46- 2,34 (m, 1H); 2,20 (s, 3H); 1,60- 1,38 9M, 4H); 1,28 (t, 3H, J= 7,1 Hz); 0,90-0,80 (m, 6H).Guanidinoetylester 264. To a solution of bis-Boc guanidinyletylesteru 263 (113 mg, 0.20 mmol) in CH 2 C1 2 (5.0 mL) cooled to 0 ° C was added neat trifluoroacetic acid (5.0 mL). The reaction mixture was stirred at 0 ° C for 30 minutes, and then at room temperature for 1.5 hours. The reaction was then concentrated in vacuo to give a pale orange solid which was purified by C 18 reverse phase chromatography eluted with water. The fractions containing the desired product were combined and lyophilized to give 63 g (66%) of guanidine ethyl ester 264 as a white solid. 1 H NMR (D 2 O, 300 MHz) δ 6.82 (s, 1H); 4.35 - 4.31 (m, 1H); 4.24 (q, 2H, J = 7.1Hz); 3.95 - 3.87 (m, 1H); 3.85 - 3.76 (m, 1H); 3.57-3.49 (m, IH); 2.87 (dd, 1H, J = 5.1, 17.7 Hz); 2.46-2.34 (m, 1 H); 2.20 (s, 3H); 1.60-1.38 (9M, 4H); 1.28 (t, 3H, J = 7.1Hz); 0.90-0.80 (m, 6H).
-254CZ 297945 B6-254GB 297945 B6
Příklad 119Example 119
Enzymatická inhibice: Při použití metod screeningu aktivity in vitro, jak je popsáno výše, byly zjištěny tyto aktivity (+ 10-100 pm, + + 1-10 pm, + + + < 1,0 pm):Enzymatic Inhibition: The following activities (+ 10-100 pm, + + 1-10 pm, + + + <1.0 pm) were observed using in vitro activity screening methods as described above:
Příklad 120Example 120
Sloučeniny A. 113,b.4.i a A.113.X.4.Í byly samostatně inkubovány v pufru při kvantitativním stanovení enzymů a testovány na aktivitu, jak je popsáno v Příkladu 119. Aktivita pro obě byla > 100 pm. Když byla každá sloučenina samostatně inkubována v krysí plazmě před testováním, jak je popsáno v Příkladu 119, aktivita obou byla podobná sloučenina A.l 13.a.4.i.Compounds A. 113, b.4.i and A.113.X.4.I were separately incubated in buffer for quantitative enzyme assays and assayed for activity as described in Example 119. The activity for both was> 100 µm. When each compound was separately incubated in rat plasma prior to testing, as described in Example 119, the activity of both was similar to Compound A.l 13.a.4.i.
Příklad 121Example 121
Pod dohledem Dr. Roberta Sidwella byla v Institutu pro antivirový výzkum Státní univerzity Utahu prováděny studie pro určení komparativní aktivity proti chřipce A sloučenin 203 (příklad 69), GG167 a ribavirinu in vivo u myší podáváním intraperitoneálním (i.p.) nebo perorálním (p.o.). GG167 a ribavirin jsou známé sloučeniny, působící proti chřipkovému viru.Under the supervision of Dr. Robert Sidwell at the Utah State University Antivirus Research Institute conducted studies to determine comparative activity against influenza A of Compound 203 (Example 69), GG167, and ribavirin in vivo in mice by intraperitoneal (i.p.) or oral (p.o.) administration. GG167 and ribavirin are known compounds against the influenza virus.
-255 CZ 297945 B6-255 CZ 297945 B6
(AC)(H)N (GG167)(G) N (GG167)
Myši: Ze Simonsen Laboratories (Gilroy, Kalifornie) byly získány samice myší BALB/c bez specifického patogenu. Byly v karanténě po 24 hodin před použitím a živeny Wayne Lab Blox a užitkovou vodou. Když byly infikovány, pitná voda obsahovala 0,006% oxytetracyklinu (Pfizer, New York, New York) pro kontrolu možných sekundárních bakteriálních infekcí.Mice: Female pathogen-free BALB / c mice were obtained from Simonsen Laboratories (Gilroy, California). They were quarantined for 24 hours before use and nourished with Wayne Lab Blox and process water. When infected, the drinking water contained 0.006% oxytetracycline (Pfizer, New York, New York) to control possible secondary bacterial infections.
Virus: Chřipka A/NWS/33 (H1N1) byla získána od K. W. Cochrana, z Univerzity Michiganu (Ann Arbor, Michigan). Virová hotovost byla připravena nainfikováním souvislých monovrstev Madin Darby buněk ledvin psa (MDCK), které byly inkubovány při teplotě 37 °C v 5% CO2 a sklízeny po 3 až 5 dnech, kdy cytopatický účinek viru byl 90 až 100%. Zásobní virus byl uchován v ampulích při teplotě -80 °C až do doby použití.Virus: Influenza A / NWS / 33 (H1N1) was obtained from KW Cochran, University of Michigan (Ann Arbor, Michigan). Viral cash was prepared by infecting continuous monolayers of Madin Darby dog kidney cells (MDCK), which were incubated at 37 ° C in 5% CO 2 and harvested after 3-5 days when the cytopathic effect of the virus was 90-100%. The stock virus was stored in ampoules at -80 ° C until use.
Sloučeniny: Sloučeniny 203 a GG167 byly pro tuto studii rozpuštěny ve sterilním fyziologickém biologickém roztoku.Compounds: Compounds 203 and GG167 were dissolved in sterile saline for this study.
Stanovení arteriální nasycenosti kyslíkem (SaOýy. SaO2 byl stanoven při použití pulzního oximetru Ohmeda Biox 3740 (Ohmeda, Louisville, Ohio). Bylo použito uchycení ušní sondy, sonda byla připevněna na stehno zvířete a zvolen byl pomalý režim nástroje. Odčítání se provádělo po 30 sekundách stabilizačního času u každého zvířete. Použití tohoto přístroje pro měření účinků chřipkového viru na arteriální nasycenost kyslíkem popsal Sidwell et al., Antimicrob. Agents Chemother. 36:473-^176 (1992).Determination of arterial oxygen saturation (SaOýy. SaO 2 was determined using a pulse oximeter Ohmeda Biox 3740 (Ohmeda, Louisville, Ohio). Was used mounting ear probes, a probe was attached to the thigh of the animal and the chosen was slow tool mode. Subtraction is carried out for 30 The use of this instrument to measure the effects of influenza virus on arterial oxygen saturation has been described by Sidwell et al., Antimicrob. Agents Chemother. 36: 473-176 (1992).
Návrh experimentu pro studii při orálním podávání. Skupiny jedenácti myší, které byly intranazálně infikovány přibližně 95% smrtelnou dávkou viru, která jim byla podána v každé dávce testovací sloučeniny. Dávky 203 i GG167 byly 50, 10, 2 a 0,5 mg/kg/den. Léčba byla i.p. dvakrát denně po dobu 5 dní počínaje 4 hodiny před vystavením viru. U osmi infikovaných, léčených myší u každé dávky a 16 infikovaných kontrolních myší, léčených fyziologickým roztokem, byly stanovovány hladiny SaO2 dne 3 až 10; úmrtí byla u těchto zvířat zaznamenávána denně po dobu 21 dní. Zbývající tři zvířata v každé skupině, stejně jako šest kontrolních myší, léčených fyziologickým roztokem, byla usmrcena 6. den ajejich plíce byly vyjmuty, zváženy, byly jim přiděleny konsolidační skóry na základě zbarvení plic (0=normální, 4=100% plic postiženo). Protože při dávkování 203 po 300 mg/kg/den nebyla zjištěna žádná toxicita a v literatuře se uvádí, že GG167 je podobně netoxická, kontroly toxicity nebyly do této studie zahrnuty.Design of experiment for oral administration study. Groups of eleven mice that were intranasally infected with approximately 95% of the lethal dose of virus given to them at each dose of test compound. Both 203 and GG167 doses were 50, 10, 2 and 0.5 mg / kg / day. Treatment was ip twice daily for 5 days starting 4 hours before exposure to the virus. In eight infected, treated mice at each dose, and 16 infected saline-treated control mice, SaO 2 levels were determined on days 3 to 10; deaths in these animals were recorded daily for 21 days. The remaining three animals in each group, as well as the six saline-treated control mice, were sacrificed on day 6 and their lungs were removed, weighed, and given consolidation scores based on lung coloring (0 = normal, 4 = 100% lung affected) . Since no toxicity was found at a dose of 203 at 300 mg / kg / day and GG167 is reported to be similarly non-toxic in the literature, toxicity controls were not included in this study.
Návrh experimentu pro studii intraperitoneálního podávání: Skupiny 11 myší byly intranazálně infikovány přibližně 95% smrtelnou dávkou viru a léčeny 250, 50 nebo 10 mg/kg/den 203 nebo GG167 nebo 100, 32 nebo 10 mg/kg/den ribavirinu. Léčba byla prováděna orální žaludeční sondou (p.o.) dvakrát denně po dobu 5 dní počínaje 4 hodiny před vystavením viru. Osm zvířat v každé skupině bylo udrženo po dobu 21 dní, s denním zaznamenáváním úmrtí a určování hladin SaO2 dne 3-10. Zbývající 3 infikované myši v každé skupině byly usmrceny dne 6 ajejich plíce vyjmuty, zváženy, byly jim přiděleny konsolidační skóry 0 (normální) až 4 (100% plic postiženo). Patnáct infikovaných myší bylo léčeno pouze fyziologickým roztokem a udržováno 21 dníExperimental design for intraperitoneal administration study: Groups of 11 mice were intranasally infected with approximately 95% lethal dose of virus and treated with 250, 50 or 10 mg / kg / day 203 or GG167 or 100, 32 or 10 mg / kg / day ribavirin. Treatment was performed by oral gavage (po) twice daily for 5 days starting 4 hours prior to virus exposure. Eight animals in each group were maintained for 21 days, with daily death records and determination of SaO 2 levels on 3-10. The remaining 3 infected mice in each group were sacrificed on 6 and their lungs removed, weighed, and given a consolidation score of 0 (normal) to 4 (100% lung affected). Fifteen infected mice were treated with saline only and maintained for 21 days
-256CZ 297945 B6 s určováním SaO2 tak, jak je uvedeno výše, a 6 dalších infikovaných myší, léčených fyziologickým roztokem, bylo usmrceno dne 6 na testování plic. Tři normální kontroly byly prováděny 21 dní, SaO2 určováno současně s výše uvedenými, a další 3 normální zvířata byla usmrcena dne 6 pro zvážení a skórování plic.-256GB 297945 B6 with SaO 2 determination as above, and 6 other infected saline-treated mice were sacrificed on day 6 for lung testing. Three normal controls were performed for 21 days, SaO 2 was determined concurrently with the above, and another 3 normal animals were sacrificed on day 6 for weighing and scoring the lungs.
Návrh experimentu pro studii orálního podávání nízkých dávek. Skupiny 8 myší, infikovaných intranazálně přibližně 90% smrtelnou koncentrací viru, podané v každé dávce sloučeniny. Dávky každé sloučeniny byly 10, 1 a 0,1 mg/kg/den. Léčba byla p.o. dvakrát denně po dobu 5 dní počínaje 4 hodiny před vystavením viru. Osm infikovaných, léčených myší u každého dávkování a 16 infikovaných kontrolních myší, léčených fyziologickým roztokem, bylo kontrolováno na hladinu SaO2 dne 3 až 11; úmrtí byla u těchto zvířat zaznamenávána denně po dobu 21 dní.Design of experiment for study of oral administration of low doses. Groups of 8 mice infected intranasally with approximately 90% lethal virus concentration administered at each dose of compound. Doses of each compound were 10, 1 and 0.1 mg / kg / day. Treatment was twice daily for 5 days starting 4 hours before exposure to the virus. Eight infected, treated mice at each dose and 16 infected saline-treated control mice were checked for SaO 2 levels on days 3 to 11; deaths in these animals were recorded daily for 21 days.
Statistické hodnocení: Zvýšení počtu myší, které přežily, bylo hodnoceno pomocí analýzy chi-kvadrát s korekcí dle Yatese. Zvýšení průměrné doby přežití a rozdíly v SaO2, váze plic aplicních titrech viru byly analyzovány pomocí t-testu. Rozdíly skóru plic byly hodnoceny pomocí analýzy součtové řady. Ve všech případech byly studovány rozdíly mezi zvířaty léčenými léky a kontrolními zvířaty léčenými fyziologickým roztokem.Statistical evaluation: The increase in the number of surviving mice was evaluated by chi-square analysis with Yates correction. The increase in mean survival time and differences in SaO 2 , lung weight and lung virus titers were analyzed by t-test. Differences in lung scores were evaluated by sum series analysis. In all cases, differences between drug-treated animals and saline-treated animals were studied.
Výsledky experimentu i.p. dávkování jsou shrnuty v Tabulce I a na obr. 1 a 2. Zatímco u tohoto modelu byly obě sloučeniny značně inhibitující ve vysoké dávce, která byla použita, výsledkem léčby pomocí 203 byl také značný počet přeživších zvířat při dávce 10 mg/kg/den. Pokles SaO2 byl částečně inhibován u obou sloučenin při dávce 50 mg/kg/den, a opět se ukázalo, že GG167 rovněž brání tomuto poklesu při 10 a dokonce 2 mg/kg/den. Údaje o plicním skóru jak se zdá vykazují stejný trend u GG167, která je účinná při více než jedné dávce. Určitá nepravidelnost byla vidět ve váze plic, kdy plíce, vyjmuté myším, které dostávaly nej vyšší dávku GG167, měly větší průměrnou váhu, než u kontrolních myší, léčených fyziologickým roztokem.The results of the ip dosing experiment are summarized in Table I and Figures 1 and 2. While in this model both compounds were highly inhibitory at the high dose that was used, treatment with 203 also resulted in a significant number of surviving animals at a dose of 10 mg / kg. /day. The decrease in SaO 2 was partially inhibited for both compounds at a dose of 50 mg / kg / day, and again it was shown that GG167 also prevented this decrease at 10 and even 2 mg / kg / day. Pulmonary score data appears to show the same trend for GG167, which is effective at more than one dose. Some irregularity was seen in lung weight, with the lungs removed from mice receiving the highest dose of GG167 having a greater average weight than saline-treated control mice.
Studie p.o. dávkování je shrnuta v Tabulce II, denní hodnoty SaO2 jsou na obr. 3-5. Orální léčba u všech tří léčiv v tomto modelu byla značně inhibující pro virovou infekci chřipky, bránila úmrtí, snižovala plicní skóry a váhy plic, související s infekcí, a inhibovala obvyklý pokles SaO2.The post-dosing study is summarized in Table II, with daily SaO 2 values in Fig. 3-5. Oral treatment in all three drugs in this model was greatly inhibiting for viral influenza infection, prevented death, reduced lung scores and lung weights associated with infection, and inhibited the usual decrease in SaO 2 .
Výsledky studie nízkých p.o. dávek jsou shrnuty v Tabulce III a na obr. 6-8. V tomto experimentu byla infekce smrtelná pro 14 až 16 zvířat léčených fyziologickým roztokem, průměrná doba přežití byla v této skupině 9,6 dne. Zatímco všechny tři sloučeniny vykazovaly určitý stupeň inhibujícího účinku na virovou infekci, 262 (prodroga etylester) byla nejúčinnější u každé dávky, jak dokazuje počet zvířat, která přežila, průměrná doba přežití a zamezení poklesu SaO2.The results of the low dose study are summarized in Table III and Figure 6-8. In this experiment, the infection was lethal for 14-16 saline-treated animals, with a mean survival time of 9.6 days in this group. While all three compounds showed some degree of inhibitory effect on viral infection, 262 (prodrug ethyl ester) was most effective at each dose, as evidenced by the number of survivors, the average survival time, and the avoidance of SaO 2 decline.
Tabulka III uvádí průměrné SaO2% pro všechny doby hodnocení společně. Denní hodnoty pro každou sloučeninu jsou vyjádřeny graficky na obr. 6 až 8. Obr. 6 uvádí data SaO2 pro nej vyšší koncentrace u každé sloučeniny; obr. 7 ukazuje hodnoty u středních dávek každé sloučeniny a hodnoty SaO2 pro nej nižší dávky každé sloučeniny jsou porovnány na obr. 8.Table III shows the average SaO of 2 % for all evaluation periods taken together. The daily values for each compound are shown graphically in Figures 6 to 8. 6 shows the SaO 2 data for the highest concentrations for each compound; Figure 7 shows the mean doses of each compound and the SaO 2 values for the lower doses of each compound are compared in Figure 8.
Tabulka III a obr. 6-8 naznačují, že i když všechny tři sloučeniny byly aktivní orálně proti experimentálně indukované virové infekci chřipky A (H1N1), 262 byla považována za nejúčinnější. Nebylo stanoveno, zda lepší antivirová schopnost 262 nebyla doprovázena souběžným zvýšením toxicity u zvířat, aleje to nepravděpodobné, protože se očekává, že její větší účinnost je důsledkem její zvýšené orální biologické dostupnosti.Table III and Figures 6-8 indicate that although all three compounds were active orally against experimentally induced influenza A (H1N1) viral infection, 262 was considered to be most effective. It has not been established whether the improved antiviral ability 262 was accompanied by a concomitant increase in toxicity in animals, but this is unlikely because its greater efficacy is expected to be due to its increased oral bioavailability.
-257CZ 297945 B6-257EN 297945 B6
Tabulka I. Srovnání účinku 203 a GG167, podávaných i.p.a myším infikovaným virem chřipky A (H1N1)Table I. Comparison of the effect of 203 and GG167 administered ip and mice infected with influenza A virus (H1N1)
Infikované, léčenéInfected, treated
Průměrné parametry plic^Mean lung parameters ^
Slou- Dávkování Přež./ Prům.přež. Prům.SaO2c VáhaDosing / Surv. / Avg. Avg.SaO2 c Weight
-258CZ 297945 B6-258EN 297945 B6
Tabulka II. Srovnání účinku orálně podávanýcha203, GG167 a Ribavirinu na virovou infekci chřipky A (H1N1) u myší.Table II. Comparison of the effect of orally administered and 203, GG167 and Ribavirin on viral infection influenza A (H1N1) in mice.
Infikované, léčenéInfected, treated
Průměrné parametry plic^Mean lung parameters ^
Slou- Dávkování Přež./ Prům.přež.b Prům.SaO2c VáhaDosage Slou- Prez. / Prům.přež.b Prům.SaO2 c Weight
-259CZ 297945 B6-259EN 297945 B6
Tabulka III. Srovnání účinku orálně podávanýcha260, 262 a GG167 na virovou infekci chřipky A (H1N1) u myší.Table III. Comparison of the effect of orally administered and 260, 262 and GG167 on influenza A (H1N1) virus infection in mice.
Slou- Dávkování Přež./ % Průmpřež. Prům.SaO2c čenina (mg/kg/den) celk. přež. Dobab(dny) %Dosage Overdose /% Dia. Avg.SaO2 c Chinese (mg / kg / day) total surviv. Time b (days)%
Poznámky k Tabulkám I—III:Notes to Tables I-III:
“Pokus x 5 počínaje 4 hodiny před vystavením viru.“Experiment x 5 starting 4 hours before exposure to virus.
bZvířata zemřela dne 21 nebo před ním. b Animals died on or before 21.
cPrůměmé hodnoty určeny dne 3-10. c Averages determined on 3-10.
dUrčeno dne 6. d Determined on 6.
P<0,05, P<0,01, P<0,001 ve srovnání s kontrolními zvířaty léčenými fyziologickým roztokemP <0.05, P <0.01, P <0.001 compared to saline-treated animals
Výše uvedené kupodivu demonstruje, že v tomto modelu bylo orální nebo i.p. podávání GG167 efektivní v praktických terapeutických dávkách při snižování úmrtnosti myší infikovaných chřipkou, přes závěr Ryan et al. Antimicrob. Agents Chemother., 38(10):2270-2275) [1994], že ,je pravděpodobné, že relativně chabá aktivita in vivo, kterou vidíme u GG167 u myší po intraperitoneálním podávání, nehledě na dobrou biologickou dostupnost, je způsobena jeho rychlým odstraňováním z plazmy, což umožňuje chabé pronikání do respiračních sekrecí, spolu s jeho neschopností pronikat a přetrvávat uvnitř buněk. Podobně, chabá účinnost po orálním dávkování je pravděpodobně důsledkem chabé orální biologické dostupnosti kromě těchto dalších faktorů.“ (str. 2274). Tato pozorování jsou shodná s Von Izstein et al., WO 91/16320, WO 92/06691 a patentem USA 5,360,817, které pokrývají nebo jsou zaměřeny specificky na GG167. TytoSurprisingly, the above demonstrates that in this model it was oral or i.p. administration of GG167 effective at practical therapeutic doses in reducing mortality in influenza-infected mice, despite Ryan et al. Antimicrob. Agents Chemother., 38 (10): 2270-2275) [1994] that, it is likely that the relatively poor in vivo activity seen in GG167 in mice after intraperitoneal administration, despite good bioavailability, is due to its rapid clearance. from plasma, allowing poor penetration into respiratory secretions, along with its inability to penetrate and persist within cells. Similarly, poor efficacy after oral dosing is likely due to poor oral bioavailability in addition to these other factors. ”(P. 2274). These observations are consistent with Von Izstein et al., WO 91/16320, WO 92/06691 and US Patent 5,360,817, which cover or are directed specifically to GG167. These
-260CZ 297945 B6 patentové dokumenty postrádají jakékoliv učení nebo návrhy na podávání GG167 jiným způsobem, než intranazálně. Avšak o intranazálním podávání panuje názor, že je za některých okolností nepohodlné a nákladné. Bylo by výhodnější, kdyby bylo možno použít snadnější způsoby podávání pro GG167 a jeho příbuzné sloučeniny, uvedené v WO 91/16320, WO 92/006691 a patentu USA 5,360,817.The patent documents lack any teaching or suggestion for administering GG167 other than intranasally. However, intranasal administration is believed to be inconvenient and costly in some circumstances. It would be preferable to use easier routes of administration for GG167 and its related compounds, as disclosed in WO 91/16320, WO 92/006691 and US Patent 5,360,817.
Vynález tedy zahrnuje metodu léčby nebo prevence virové infekce chřipky v hostiteli, zahrnující podávání hostiteli jiným způsobem než konkrétně do respirační soustavy, terapeuticky účinnou dávku antivirově aktivní sloučeniny vzorce (x) nebo (y)Thus, the invention encompasses a method of treating or preventing a viral influenza infection in a host, comprising administering to the host by means other than specifically the respiratory tract, a therapeutically effective dose of an antiviral active compound of formula (x) or (y)
RL^yR1 RL ^ yR 1
R2 R 2
R3 R3' (y) kde v obecném vzorci (x) A představuje kyslík, uhlík nebo síru a v obecném vzorci (y) A představuje dusík nebo uhlík;R 3 R 3 '(y) wherein in formula (x), A is oxygen, carbon or sulfur, and in formula (y), A is nitrogen or carbon;
R1 označuje COOH, P(O)(OH)2, NO2, SOOH, SO3H, tetrazol, CH2CHO, CHO nebo CH(CHO)2,R 1 denotes COOH, P (O) (OH) 2 , NO 2 , SOOH, SO 3 H, tetrazole, CH 2 CHO, CHO or CH (CHO) 2 ,
R2 označuje H, OR6, F, Cl, Br, CN, NHR6, SR6, nebo CH2X, kde X je NHR6, halogen nebo OR6 aR 2 denotes H, OR 6 , F, Cl, Br, CN, NHR 6 , SR 6 , or CH 2 X, wherein X is NHR 6 , halogen or OR 6, and
R6 je vodík; acylová skupina, která obsahuje 1 až 4 atomy uhlíku; lineární nebo cyklická alkylová skupina, která obsahuje 1 až 6 atomů uhlíku, nebo její analog substituovaný halogenem; alylová skupina nebo nesubstituovaná arylová skupina nebo aryl substituovaná halogenem, skupina OH, skupina NO2, skupina NH2 nebo skupina COOH.R 6 is hydrogen; acyl having 1 to 4 carbon atoms; a linear or cyclic alkyl group having 1 to 6 carbon atoms, or a halogen substituted analog thereof; allyl or unsubstituted aryl or halogen substituted aryl, OH, NO 2 , NH 2 or COOH.
R3 a R3' jsou stejné nebo odlišné, a každý označuje vodík, CN, NHR6, N3, SR6, =N.OR6, OR6, guanidino,R 3 and R 3 'are the same or different, and each denotes hydrogen, CN, NHR 6, N 3, SR 6, = N.OR 6, OR 6, guanidino,
N-R6 NR6 · N-—O ' — NHN-R6 NR 6 NR 6 · N-O-NHN-R 6
OR6 r6 Ř6 Ř6 OR 6 r6 Ø 6 Ø 6
R4 označuje NHR6, SR6, OR6, COOR6, NO2, C(R6)3, CH2COOR6, CH2NO2 nebo CH2NHR6,R 4 denotes NHR 6 , SR 6 , OR 6 , COOR 6 , NO 2, C (R 6 ) 3, CH 2 COOR 6 , CH 2 NO 2 or CH 2 NHR 6 ,
R5 označuje CH2YR6, CHYR6CH2YR6 nebo CHYR6CHYR6CH2YR6, kde Y je O, S, NH neboR 5 denotes CH2YR 6 6 Chyra CH2YR 6 or 6 Chyra Chyra 6 CH 2 YR 6, wherein Y is O, S, NH, or
H, a následné části Y ve skupině R5 jsou stejné nebo odlišné, a jejich farmaceuticky přijatelné soli nebo deriváty, za předpokladu, že v obecném vzorci (x),H, and the subsequent Y moieties in R 5 are the same or different, and their pharmaceutically acceptable salts or derivatives, provided that in formula (x),
-261 CZ 297945 B6 (i) kde R3 nebo R3' je OR6 nebo vodík a A je kyslík nebo síra, pak zmíněná sloučenina nemůže mít obojí (a) R2, která je vodík a (b) R4, které je NH-acyl, a (ii) (i) (ii)(I) where R 3 or R 3 'is OR 6 or hydrogen and A is oxygen or sulfur, then said compound cannot have both (a) R 2 which is hydrogen and (b) R 4 which is NH-acyl, and (ii) (i) (ii)
R6 představuje kovalentní vazbu, kde Y je vodík, a že v obecném vzorci (y), kde R3 nebo R3', je OR6 nebo vodík, a A je dusík, pak zmíněná sloučenina nemůže mít obojí (a) R2, které je vodík, a (b) R4, které je NH-acyl, aR 6 represents a covalent bond wherein Y is hydrogen and that in the general formula (s) where R 3 or R 3 'is OR 6 or hydrogen, and A is nitrogen, then said compound cannot have both (a) R 2 which is hydrogen, and (b) R 4 which is NH-acyl, and
R6 představuje kovalentní vazbu, kde Y je vodík.R 6 represents a covalent bond wherein Y is hydrogen.
Sloučeniny podle vzorců x ay jsou podrobněji popsány v WO 91/16320, strana Ί, řádka 1, WO 92/06691 a v patentu USA 5,360,817, x a y jsou zde popsány jako „Γ a„Ia“.Compounds of formulas x and y are described in more detail in WO 91/16320, page řád, line 1, WO 92/06691 and in U.S. Patent 5,360,817, x and y are described herein as "Γ and" Ia ".
na straně 3, řádka 23 až '64on page 3, lines 23 to '64
Pro naše účely podávání způsobem Jiným, než konkrétně do respiračního traktu“ nevylučuje podávání sloučeniny cestou bukální nebo sublingvální a nevylučuje doprovodné vstřebávání sloučeniny v jícnu během orálního, bukálního nebo sublingválního podávání, avšak za předpokladu, že takové bukální, orální, sublingvální nebo jícnové vstřebávání nei plic nebo nosních cest inhalátory nebo podobně. Obvykle se sloučenina forma, suspenze nebo roztok.For our purposes, other than specifically to the respiratory tract, administration does not preclude administration of the compound via the buccal or sublingual route and does not preclude concomitant absorption of the compound in the esophagus during oral, buccal or sublingual administration, provided such buccal, oral, sublingual or pulmonary or nasal passages by inhalers or the like. Usually, the compound form, suspension or solution.
doprovází podávání do podává jako tvarovanáaccompanies the administration to the served as shaped
Při typickém provedení podle tohoto vynálezu je sloučeninou GG167, hostitelem je jiné zvíře než myši (jako fretky nebo lidé), způsob podávání je orální a cílem léčby a prevence je snížení úmrtnosti. Případně se použije prodroga sloučeniny vzorce (x) nebo (y), přestože, jak je uvedeno výše, toho není třeba pro dosažení antivirového účinku orálním podáváním. Jako prodroga GG167 a jeho společně objevených sloučenin, jakékoliv estery, amidy nebo jiné prodrogy, popsané zde na jiných místech pro sloučeniny tohoto vynálezu, jsou vhodné pro použití sanalogickými skupinami sloučenin vzorce (x) a (y), například karboxylestery nebo amidy.In a typical embodiment of the invention, the compound is GG167, the host is an animal other than mice (such as ferrets or humans), the route of administration is oral, and the goal of treatment and prevention is to reduce mortality. Optionally, a prodrug of a compound of formula (x) or (y) is used, although, as mentioned above, this is not required to achieve an antiviral effect by oral administration. As the prodrug of GG167 and its co-discovered compounds, any esters, amides or other prodrugs described elsewhere herein for the compounds of this invention are suitable for use by sanalogical groups of compounds of formula (x) and (y), for example, carboxy esters or amides.
Terapeuticky účinnou dávku GG167 a jeho příbuzných sloučenin při podání orálním nebo jinými nenosními cestami podání určí běžně zkušený klinický lékař ve světle úva h, uvedených v souvislosti s dávkováním sloučenin podle tohoto vynálezu. Z větší části se hlavně uvažuje o způsobech podání a druhu hostitele. Obecně, větší dávky budou potřeba, když postupujeme od intravenózního k podkožnímu nebo orálnímu způsobu podávání, a v souladu s kom kými principy měření, když přecházíme ke větším zvířatům. Stanovení dávek je docela dobře v rámci běžných zkušeností v oboru, ale obecně budou dávky v podstatně stejné, jako dávky použité pro sloučeniny podle tohoto vynálezu.The therapeutically effective dose of GG167 and its related compounds when administered by the oral or other non-carrier routes of administration will be determined by the ordinarily skilled clinician in light of the considerations presented in connection with dosing of the compounds of this invention. For the most part, the route of administration and the host species are mainly considered. In general, larger dosages will be needed when proceeding from the intravenous to the subcutaneous or oral route of administration, and in accordance with the measurement principles when moving to larger animals. Dose determination is well within the ordinary skill in the art, but generally the doses will be substantially the same as those used for the compounds of the invention.
enčními farmakologicterapeuticky aktivníchactive pharmacologically therapeutically active
Příklad 122Example 122
Každá z reakcí uvedených v Tabulce 50 byla provedena podle Schématu 50. Provedené reakce jsou označeny ,7“. Pokud není jinak uvedeno v Tabulce 50, kroky AA, AB a AC byly provedeny podle Příkladů 92, 93 a 94 a krok AD byl proveden podle kombinace Příkladů 112 a 113.Each of the reactions listed in Table 50 was performed according to Scheme 50. The reactions performed are indicated by 7 '. Unless otherwise indicated in Table 50, steps AA, AB and AC were performed according to Examples 92, 93 and 94 and step AD was performed according to a combination of Examples 112 and 113.
-262CZ 297945 B6-262GB 297945 B6
CO2CH3 CO 2 CH 3
Schéma 50Scheme 50
ABAB
NH ·ΟΡ3ΟΟ2Η (404)NH · ΟΡ 3 ΟΟ 2 404 (404)
-263 CZ 297945 B6-263 CZ 297945 B6
Tabulka 50Table 50
-264CZ 297945 B6-264EN 297945 B6
Tabulka 50 (pokračování)Table 50 (continued)
Tabulka 50 (poznámky)Table 50 (notes)
a) hydrolýza esteru před redukcí azidua) ester hydrolysis prior to azide reduction
b) redukce azidu při použití Ph3P při teplotě místnostib) azide reduction using Ph 3 P at room temperature
c) hydrolýza esteru při použití vodného KOH/MeOHc) ester hydrolysis using aqueous KOH / MeOH
d) redukce azidu při použití polymemího nosiče Ph3P při teplotě místnostid) azide reduction using a polymeric carrier Ph 3 P at room temperature
-265 CZ 297945 B6-265 CZ 297945 B6
e) izolováno jako sůl HC1e) isolated as the HCl salt
f) redukce azidu při použití Ph3P v MeOH/THF/H2Of) azide reduction using Ph 3 P in MeOH / THF / H 2 O
g) diastereoizomerická směs, označen hlavní diastereoizomerg) a diastereoisomeric mixture, denoted by the principal diastereoisomer
h) redukce azidu rovněž provedena s Me3Ph) azide reduction also performed with Me 3 P
i) otevření aziridinu provedeno při teplotě 55 °C(i) the opening of aziridine is carried out at a temperature of 55 ° C
j) byly izolovány C-alkylované produktyj) C-alkylated products were isolated
(405) (406)(405)
Příklad 123Example 123
Trifluoroacetamid 340: Do roztoku aminu 228 (100 mg, 0,34 mmol) v CH2C12 (3,5 ml) při teplotě 0 °C byl přidán pyridin (41 μΐ, 0,51 mmol) a trifluoroacetylanhydrid (TFAA) (52 μΐ, 0,37 mmol) a roztok byl míchán po dobu 45 minut, a v této době byl přidán další TFAA (ekv. 0,5). Po 15 minutách byla reakce odpařována za sníženého tlaku a zbytek byl rozdělen mezi etylacetát a 1M HC1. Organická fáze byla promyta nasyceným NaHCO3, nasyceným NaCl, a byla vysušena (MgSO4), filtrována a odpařena. Zbytek byl chromatografován na silikagelu (2/1-hexan/etylacetát), vznikl trifluoroacetamid 340 (105 mg, 78%): 'ílNMR (CDC13) delta 8,64 (d, 1H, J= 7,7), 6,81 (s, 1H), 6,48 (d, 1H, J= 8,2), 4,25 - 4,07 (m, 3H), 3,75 (s, 3H), 3,37 (m, 1H), 2,76 (dd, 1H, J= 4,5, 18,7), 2,54 (m, 1H), 1,93 (s, 3H), 1,48 (m, 4H), 0,86 (m, 6H).Trifluoroacetamide 340: To a solution of amine 228 (100 mg, 0.34 mmol) in CH 2 Cl 2 (3.5 mL) at 0 ° C was added pyridine (41 µΐ, 0.51 mmol) and trifluoroacetyl anhydride (TFAA) ( 52 μΐ, 0.37 mmol) and the solution was stirred for 45 minutes, at which time additional TFAA (eq. 0.5) was added. After 15 minutes, the reaction was evaporated under reduced pressure and the residue was partitioned between ethyl acetate and 1M HCl. The organic phase was washed with saturated NaHCO 3 , saturated NaCl, and was dried (MgSO 4 ), filtered and evaporated. The residue was chromatographed on silica gel (2/1-hexane / ethyl acetate) to give trifluoroacetamide 340 (105 mg, 78%): 1 H NMR (CDCl 3 ) δ 8.64 (d, 1H, J = 7.7), 81 (s, 1H), 6.48 (d, 1H, J = 8.2), 4.25-4.07 (m, 3H), 3.75 (s, 3H), 3.37 (m, 1H), 2.76 (dd, 1H, J = 4.5, 18.7), 2.54 (m, 1H), 1.93 (s, 3H), 1.48 (m, 4H), 0 86 (m, 6H).
Příklad 124Example 124
N-metyltrifluoroacetamid 341: Do roztoku trifluoroacetamidu 340 (90 mg, 0,23 mmol) v DMF (2 ml) při teplotě 0 °C byl přidán hydrid sodný (10 mg, 60% disperze v minerálním oleji, 0,25 mmol). Po 15 minutách při teplotě 0 °C byl přidán metyljodid (71 μΐ, 1,15 mmol) a reakce byla míchána po dobu 2 hodin při teplotě 0 °C a po dobu 1 hodiny při teplotě místnosti. Byla přidána kyselina octová (28 μΐ) a roztok byl odpařen. Zbytek byl rozdělen mezi etylacetát a vodu. Organická fáze byla promyta nasycenými NaCl, vysušena (MgSO4), filtrována a odpařena. Zbytek byl chromatografován na silikagelu (1/1-hexan/etylacetát), vznikl N-metyltrifluoroacetamid 341 (81 mg, 87%) jako bezbarvé sklo: ’H NMR (CDC13) delta 6,80 (s, 1H), 6,26 (d, 1H, J= 9,9), 4,67 (m, 1H), 4,32 (m, 1H), 4,11 (m, 1H), 3,78 (s, 3H), 3,32 (m, 1H), 3,07 (br s, 3H), 2,60 (m, 2H), 1,91 (s, 3H), 1,48 (m, 4H), 0,87 (m, 6H).N-methyltrifluoroacetamide 341: To a solution of trifluoroacetamide 340 (90 mg, 0.23 mmol) in DMF (2 mL) at 0 ° C was added sodium hydride (10 mg, 60% dispersion in mineral oil, 0.25 mmol). After 15 minutes at 0 ° C, methyl iodide (71 µΐ, 1.15 mmol) was added and the reaction was stirred for 2 hours at 0 ° C and for 1 hour at room temperature. Acetic acid (28 μΐ) was added and the solution was evaporated. The residue was partitioned between ethyl acetate and water. The organic phase was washed with saturated NaCl, dried (MgSO 4 ), filtered and evaporated. The residue was chromatographed on silica gel (1/1-hexane / ethyl acetate) to give N-methyltrifluoroacetamide 341 (81 mg, 87%) as a colorless glass: 1 H NMR (CDCl 3 ) δ 6.80 (s, 1H), 6, 26 (d, 1H, J = 9.9), 4.67 (m, 1H), 4.32 (m, 1H), 4.11 (m, 1H), 3.78 (s, 3H), 3 32 (m, 1H), 3.07 (br s, 3H), 2.60 (m, 2H), 1.91 (s, 3H), 1.48 (m, 4H), 0.87 (m , 6H).
-266CZ 297945 B6-266EN 297945 B6
Příklad 125Example 125
N-metylamin 342: Do roztoku N-metyltrifluoroacetamidu 341 (81 mg, 0,20 mmol) v THF (3 ml) byl přidán 1,04 N KOH (480 μΐ, 0,50 mmol) a směs byla míchána při pokojové teplotě po dobu 14 hodin. Reakce byla acidifíkována iontoměničovou pryskyřicí IR 120 na pH-4. Pryskyřice byla zfiltrována, vymyta THF a filtrát byl odpařen. Zbytek byl rozpuštěn v 10% TFA/voda (5 ml) a byl odpařen. Zbytek byl prohnán kolonou (1,5x2,5 cm) silikagelu C-18 se zpětnou fází, elutované vodou. Frakce produktu byly spojeny a lyofilizovány tak, že vznikl N-metylamin 342 (46 mg, 56%) jako bílá pevná látka: *H NMR (D2O) delta 6,80 (s, IH), 4,31 (br d, IH, J= 8,8), 4,09 (dd, IH, J= 8,9, 11,6), 3,53 (m, 2H), 2,98 (dd, IH, J= 5,4, 16,9), 2,73 (s, 3H), 2,52-2,41 (m, IH), 2,07 (s, 3H), 1,61-1,39 (m, 4H), 0,84 (m, 6H).N-methylamine 342: To a solution of N-methyltrifluoroacetamide 341 (81 mg, 0.20 mmol) in THF (3 mL) was added 1.04 N KOH (480 μΐ, 0.50 mmol) and the mixture was stirred at room temperature for for 14 hours. The reaction was acidified with IR 120 ion-exchange resin to pH-4. The resin was filtered, washed with THF and the filtrate was evaporated. The residue was dissolved in 10% TFA / water (5 mL) and evaporated. The residue was passed through a column (1.5x2.5 cm) of reverse-phase C-18 silica gel eluted with water. The product fractions were combined and lyophilized to give N-methylamine 342 (46 mg, 56%) as a white solid: 1 H NMR (D 2 O) δ 6.80 (s, 1H), 4.31 (br d) 1 H, J = 8.8), 4.09 (dd, 1H, J = 8.9, 11.6), 3.53 (m, 2H), 2.98 (dd, 1H, J = 5, 4, 16.9), 2.73 (s, 3H), 2.52-2.41 (m, 1H), 2.07 (s, 3H), 1.61-1.39 (m, 4H) 0.84 (m, 6H).
Příklad 126Example 126
Sloučenina 346: Do roztoku epoxidu 345 (13,32 g, 58,4 mmol) v 8/l-MeOH/H2O (440 ml, v/v) byl přidán azid sodný (19,0 g, 292,0 mmol) a chlorid amonný (2,69 g, 129,3 mmol) a směs byla refluxována po dobu 15 hodin. Reakce byla ochlazena, koncentrována při sníženém tlaku a rozdělena mezi EtOAc a H2O. Organická vrstva byla promyta postupně nasyceným hydrogenuhličitanem, solankou a vysušena přes MgSO4. Koncentraci in vacuo a následnou mžikovou chromatografíí na silikagelu (30% EtOAc v hexanech) vzniklo 11,81 g (75%) azidoalkoholu 346 jako viskózní olej. ‘HNMR (300 MHz, CDC13) delta 6,90 - 6,86 (m, IH); 4,80 (s, 2H); 4,32 (bt, IH, J= 4,2 Hz); 4,22 (q, 2H, J= 7,2 Hz); 3,90 - 3,74 (přesahující m, 2H); 3,44 (s, 3H); 2,90 (d, IH, J= 6,9 Hz); 2,94 - 2,82 (m, IH); 2,35 - 2,21 (m, IH); 1,30 (t, 3H, J= 7,2 Hz).Compound 346: To a solution of epoxide 345 (13.32 g, 58.4 mmol) in 8/1-MeOH / H 2 O (440 mL, v / v) was added sodium azide (19.0 g, 292.0 mmol) ) and ammonium chloride (2.69 g, 129.3 mmol) and the mixture was refluxed for 15 hours. The reaction was cooled, concentrated under reduced pressure and partitioned between EtOAc and H 2 O. The organic layer was washed successively with saturated bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo followed by flash chromatography on silica gel (30% EtOAc in hexanes) gave 11.81 g (75%) of azidoalcohol 346 as a viscous oil. 1 H NMR (300 MHz, CDCl 3 ) δ 6.90-6.86 (m, 1H); 4.80 (s, 2 H); 4.32 (bt, 1H, J = 4.2 Hz); 4.22 (q, 2H, J = 7.2Hz); 3.90 - 3.74 (exceeding m, 2H); 3.44 (s, 3H); 2.90 (d, 1H, J = 6.9 Hz); 2.94 - 2.82 (m, 1H); 2.35-2.21 (m, 1H); 1.30 (t, 3H, J = 7.2Hz).
Příklad 127Example 127
Sloučenina 347: Do roztoku etylesteru 346 (420 mg, 1,55 mmol) v suchém THF (8,0 ml), ochlazeném na -78 °C, byl přidán DIBAL (5,1 ml z 1,0 M roztoku v toluenu) po kapkách injekční stříkačkou. Světle žlutá reakční směs byla míchána při teplotě -78 °C po dobu 1,25 hodiny, a poté pomalu hydrolyzována pomalým přidáváním MeOH (1,2 ml). Těkavé látky byly odstraněny při sníženém tlaku a zbytek rozdělen mezi EtOAc a studený zředěný HC1. Organická vrstva byla oddělena a vodná vrstva zpětně extrahována pomocí EtOAc. Organické vrstvy byly spojeny a promývány postupně nasyceným hydrogenuhličitanem, solankou a sušeny přes MgSO4. Koncentrací in vacuo a následnou mžikovou chromatografii na silikagelu (20% hexanů v EtOAc) vzniklo 127 mg (36%) diolu 347 jako bezbarvý viskózní olej. 'H NMR (300 MHz, CDC13) delta 5,83 - 5,82 (m, IH); 4,78 (s, 3H); 4,21 (bt, IH, J= 4,4 Hz); 4,06 (bs, 2H); 3,85 - 3,65 (přesahující m, 2H); 3,43 (s, 3H); 3,18 (d, IH, J= 8,1 Hz); 2,51 (dd, IH, J= 5,5, 17,7 Hz); 2,07 - 1,90 (m, IH); 1,92 (bs, IH).Compound 347: To a solution of ethyl ester 346 (420 mg, 1.55 mmol) in dry THF (8.0 mL) cooled to -78 ° C was added DIBAL (5.1 mL of 1.0 M solution in toluene) drop by syringe. The light yellow reaction mixture was stirred at -78 ° C for 1.25 hours, and then slowly hydrolyzed by the slow addition of MeOH (1.2 mL). The volatiles were removed under reduced pressure and the residue partitioned between EtOAc and cold dilute HCl. The organic layer was separated and the aqueous layer back extracted with EtOAc. The organic layers were combined and washed successively with saturated bicarbonate, brine and dried over MgSO 4 . Concentration in vacuo followed by flash chromatography on silica gel (20% hexanes in EtOAc) gave 127 mg (36%) of diol 347 as a colorless viscous oil. 1 H NMR (300 MHz, CDCl 3 ) δ 5.83-5.82 (m, 1H); 4.78 (s, 3H); 4.21 (bt, 1H, J = 4.4 Hz); 4.06 (bs, 2H); 3.85 - 3.65 (exceeding m, 2H); 3.43 (s, 3H); 3.18 (d, 1H, J = 8.1 Hz); 2.51 (dd, 1H, J = 5.5, 17.7 Hz); 2.07-1.90 (m, 1H); 1.92 (bs, 1H).
-267CZ 297945 B6-267EN 297945 B6
PATENTOVÉ NÁROKYPATENT CLAIMS
Claims (2)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39524595A | 1995-02-27 | 1995-02-27 | |
US08/476,946 US5866601A (en) | 1995-02-27 | 1995-06-06 | Carbocyclic compounds |
US58056795A | 1995-12-29 | 1995-12-29 | |
PCT/US1996/002882 WO1996026933A1 (en) | 1995-02-27 | 1996-02-26 | Novel selective inhibitors of viral or bacterial neuraminidases |
Publications (2)
Publication Number | Publication Date |
---|---|
CZ269097A3 CZ269097A3 (en) | 1997-11-12 |
CZ297945B6 true CZ297945B6 (en) | 2007-05-02 |
Family
ID=27410155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CZ0269097A CZ297945B6 (en) | 1995-02-27 | 1996-02-26 | Novel selective inhibitors of viral and bacterial neuraminidases, pharmaceutical compositions in which said inhibitors are comprised and the use of the inhibitors |
Country Status (27)
Country | Link |
---|---|
US (3) | US5952375A (en) |
EP (1) | EP0759917B1 (en) |
JP (3) | JP3300365B2 (en) |
KR (1) | KR100447096B1 (en) |
CN (2) | CN100409844C (en) |
AT (2) | ATE305453T1 (en) |
AU (1) | AU720933B2 (en) |
BR (2) | BR9607098A (en) |
CZ (1) | CZ297945B6 (en) |
DE (4) | DE10299052I1 (en) |
DK (1) | DK0759917T3 (en) |
ES (2) | ES2118674T3 (en) |
GR (1) | GR3033914T3 (en) |
HK (1) | HK1026893A1 (en) |
HU (1) | HU228450B1 (en) |
LU (1) | LU90991I2 (en) |
MX (1) | MX9706496A (en) |
NL (1) | NL300105I2 (en) |
NO (1) | NO318455B1 (en) |
NZ (1) | NZ306625A (en) |
PL (1) | PL194173B1 (en) |
PT (1) | PT759917E (en) |
RU (1) | RU2181357C2 (en) |
SG (1) | SG45864A1 (en) |
SI (1) | SI9620042A (en) |
UA (1) | UA56128C2 (en) |
WO (1) | WO1996026933A1 (en) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996026933A1 (en) | 1995-02-27 | 1996-09-06 | Gilead Sciences, Inc. | Novel selective inhibitors of viral or bacterial neuraminidases |
US5714509A (en) * | 1995-05-03 | 1998-02-03 | The University Of Alabama | Inhibitors of bacterial sialidase and methods of making and using the same |
US5763483A (en) * | 1995-12-29 | 1998-06-09 | Gilead Sciences, Inc. | Carbocyclic compounds |
US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
US6518438B2 (en) | 1996-08-23 | 2003-02-11 | Gilead Sciences, Inc. | Preparation of cyclohexene carboxylate derivatives |
EP0920410B1 (en) * | 1996-08-23 | 2002-03-27 | Gilead Sciences, Inc. | Preparation of cyclohexene carboxylate derivatives |
US5859284A (en) * | 1996-08-23 | 1999-01-12 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
AU743333B2 (en) * | 1996-10-21 | 2002-01-24 | Gilead Sciences, Inc. | Piperidine compounds |
US5994377A (en) * | 1996-10-21 | 1999-11-30 | Gilead Sciences, Inc. | Piperidine compounds |
TR199901081T2 (en) * | 1996-11-14 | 1999-08-23 | Biota Scientific Management Pty.Ltd. | The method and new compounds used in this method. |
WO1999006369A1 (en) * | 1997-08-01 | 1999-02-11 | University Of Florida | Neuraminidase inhibitors |
US5886213A (en) * | 1997-08-22 | 1999-03-23 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
US20040053999A1 (en) * | 1997-09-17 | 2004-03-18 | Bischofberger Norbert W. | Novel compounds and methods for synthesis and therapy |
AU747702B2 (en) * | 1997-09-17 | 2002-05-16 | Gilead Sciences, Inc. | Compounds containing six-membered rings, processes for their preparation, and their use as medicaments |
TW480247B (en) * | 1997-12-12 | 2002-03-21 | Gilead Sciences Inc | Novel compounds useful as neuraminidase inhibitors and pharmaceutical compositions containing same |
SK8712000A3 (en) * | 1997-12-17 | 2000-11-07 | Biocryst Pharm Inc | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
US6455571B1 (en) | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
AU3554599A (en) * | 1998-04-23 | 1999-11-08 | Abbott Laboratories | Pyrrolidines as inhibitors of neuraminidases |
US6518305B1 (en) | 1998-04-23 | 2003-02-11 | Abbott Laboratories | Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases |
EP0957078B1 (en) * | 1998-05-13 | 2001-11-28 | F. Hoffmann-La Roche Ag | Process for the preparation of shikimic acid and its derivatives |
WO2000029385A1 (en) * | 1998-11-13 | 2000-05-25 | Gilead Sciences, Inc. | 1,4,5,6-tetrahydro-pyridazine derivatives, their preparation and their use as neuraminidase inhibitors |
AUPP913999A0 (en) * | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
DE60002949T2 (en) | 1999-06-11 | 2004-05-19 | F. Hoffmann-La Roche Ag | Process for the preparation of the neuraminidase inhibitor ro-64-0796 |
DE19930177B4 (en) | 1999-06-30 | 2007-02-08 | Nikolai Vladimirovich Bovin | Intermolecular associating compounds and their use |
WO2001028981A1 (en) * | 1999-10-19 | 2001-04-26 | Abbott Laboratories | 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors |
US6593314B1 (en) | 1999-10-19 | 2003-07-15 | Abbott Laboratories | Neuraminidase inhibitors |
US6627396B1 (en) * | 1999-10-28 | 2003-09-30 | The Regents Of The University Of California | Influenza sensor |
JP2001131144A (en) | 1999-11-02 | 2001-05-15 | Sagami Chem Res Center | Method for producing 7-azabicyclo[4.1.0]hept-3-ene-3- carboxylate compounds |
US6462226B1 (en) * | 1999-12-03 | 2002-10-08 | Hoffmann-La Roche Inc. | Process for the preparation of 4,5-diamino shikimic acid derivatives |
EP1245569A1 (en) * | 1999-12-27 | 2002-10-02 | Sagami Chemical Research Center | Process for the production of 5-oxy-7-oxabicyclo- 4.1.0]hept-3-e ne-3-carboxylic acid esters |
US8642051B2 (en) * | 2000-03-21 | 2014-02-04 | Suzanne Jaffe Stillman | Method of hydration; infusion packet system(s), support member(s), delivery system(s), and method(s); with business model(s) and Method(s) |
WO2001080892A1 (en) * | 2000-04-25 | 2001-11-01 | Sankyo Company, Limited | Preventives for influenza |
GB0015324D0 (en) * | 2000-06-22 | 2000-08-16 | Biota Scient Management | Medicaments |
JP4149803B2 (en) | 2000-06-27 | 2008-09-17 | エフ.ホフマン−ラ ロシュ アーゲー | Method for preparing the composition |
AUPR001000A0 (en) | 2000-09-08 | 2000-10-05 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
WO2002092555A1 (en) * | 2001-05-11 | 2002-11-21 | Sankyo Company, Limited | Sialic acid derivatives |
US6964784B2 (en) | 2002-03-07 | 2005-11-15 | Optigenex, Inc. | Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals |
US7807174B2 (en) * | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
US7122684B2 (en) | 2003-03-13 | 2006-10-17 | Roche Colorado Corporation | Process for preparing 1,2-diamino compounds |
WO2004111064A1 (en) * | 2003-06-16 | 2004-12-23 | Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic | Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs |
WO2007053792A2 (en) * | 2005-11-05 | 2007-05-10 | Amplyx Pharmaceuticals, Inc. | Improving the pharmacokinetics of protease inhibitors and other drugs |
PL1951654T3 (en) * | 2005-11-25 | 2011-11-30 | Hetero Drugs Ltd | Improved process for oseltamivir phosphate |
KR100819759B1 (en) | 2005-12-01 | 2008-04-07 | (주)파인켐 | Synthetic process of 1,2-diamino compounds without any explosion of azide compounds |
EP2178819A2 (en) * | 2005-12-28 | 2010-04-28 | F.Hoffmann-La Roche Ag | Epoxide intermediate in the tamiflu synthesis |
CN101389323B (en) | 2006-02-20 | 2013-08-21 | 中外制药株式会社 | Pharmaceutical composition comprising oseltamivir phosphate |
US20080063722A1 (en) * | 2006-09-08 | 2008-03-13 | Advanced Inhalation Research, Inc. | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) |
US20080306098A1 (en) * | 2006-11-06 | 2008-12-11 | Mutz Mitchell W | Pharmacokinetics of protease inhibitors and other drugs |
AU2008208865B2 (en) | 2007-01-23 | 2013-01-24 | Therapicon Srl | Antiviral compounds |
US20080194801A1 (en) * | 2007-02-14 | 2008-08-14 | Swanson Basil I | Robust multidentate ligands for diagnosis and anti-viral drugs for influenza and related viruses |
EP2145010A1 (en) | 2007-04-13 | 2010-01-20 | Monsanto Technology, LLC | Use of glyphosate to produce shikimic acid in microorganisms |
US20090054334A1 (en) * | 2007-05-23 | 2009-02-26 | Mutz Mitchell W | Combinatorial improvement of bifunctional drug properties |
AU2008292859C1 (en) * | 2007-08-31 | 2014-03-06 | Academia Sinica | Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity |
EP2201123B1 (en) * | 2007-10-16 | 2012-01-18 | Monsanto Technology, LLC | Processes for recovering shikimic acid |
WO2009055042A1 (en) * | 2007-10-24 | 2009-04-30 | Amplyx Pharmaceuticals, Inc. | Enhancing the efficacy of anti-infective therapeutics |
US8304553B2 (en) * | 2007-12-19 | 2012-11-06 | Nanyang Technological University | Method of forming oseltamivir and derivatives thereof |
US8334319B2 (en) * | 2008-01-04 | 2012-12-18 | Roche Palo Alto Llc | Polymorphic forms of oseltamivir phosphate |
US20100081713A1 (en) * | 2008-03-19 | 2010-04-01 | CombinatoRx, (Singapore) Pte. Ltd. | Compositions and methods for treating viral infections |
EP2276479B1 (en) | 2008-04-15 | 2014-07-02 | SineVir Therapeutics LLC | Prodrugs of neuraminidase inhibitors |
TWI491416B (en) | 2008-12-24 | 2015-07-11 | Daiichi Sankyo Co Ltd | A dry powder pharmaceutical composition for inhalation |
CN101486664B (en) * | 2008-12-31 | 2013-09-04 | 北京大学深圳研究生院 | Polysubstituted five membered ring small molecular compound used as influenza virus neuraminidase inhibitor |
US8877945B2 (en) | 2009-05-15 | 2014-11-04 | Redx Pharma Limited | Redox drug derivatives |
WO2011021223A2 (en) * | 2009-08-19 | 2011-02-24 | Msn Laboratories Limited | Novel salts of ethyl (3r, 4s, 5r)-4,5-imino-3-(l-ethylpropoxy)-1- cvclohexene-1-carboxylate and its use |
JP5837502B2 (en) * | 2009-11-11 | 2015-12-24 | スリーエム イノベイティブ プロパティズ カンパニー | POLYMER COMPOSITION, PROCESS FOR PRODUCING THE SAME, AND ARTICLE |
IT1396620B1 (en) | 2009-11-25 | 2012-12-14 | Therapicon Srl | CHEMICAL ANALOGUES |
US20130131126A1 (en) | 2010-07-16 | 2013-05-23 | Jsc Grindeks | Derivatives of 1,4-dihydropyridine possessing antiviral efficacy |
AT510585B1 (en) | 2010-11-18 | 2012-05-15 | Apeptico Forschung & Entwicklung Gmbh | COMPOSITION COMPRISING A PEPTIDE AND AN INHIBITOR OF VIRAL NEURAMINIDASE |
KR101369584B1 (en) | 2011-04-19 | 2014-03-06 | 일양약품주식회사 | Phenyl-isoxazol derivatives and preparation process thereof |
EP2578218A1 (en) | 2011-10-06 | 2013-04-10 | Grindeks, A Joint Stock Company | Antiviral efficacy of disodium 2,6-dimethyl-1,4-dihydropyridine-3,5-bis(carbonyloxyacetate) and its derivatives |
DE102011117128A1 (en) | 2011-10-28 | 2013-05-02 | Christian-Albrechts-Universität Zu Kiel | Compounds for the treatment of influenza |
RU2469020C1 (en) * | 2011-11-08 | 2012-12-10 | Александр Васильевич Иващенко | (3r,4r,5s)-4-acylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acids, their esters and method for using |
RU2489422C1 (en) * | 2012-05-12 | 2013-08-10 | Александр Васильевич Иващенко | Fluorine-substituted (3r,4r,5s)-5-guanidino-4-acylamino-3-(pentan-3-yloxy)cyclohexene-1-carboxylic acids, esters thereof and method of application |
RU2521593C1 (en) * | 2013-02-27 | 2014-06-27 | Общество с ограниченной ответственностью "Интеллектуальный Диалог" | Mono and difluorosubstituted ethyl (3r,4r,5s)-5-azido-4-acetylamino-3-(1-ethylpropoxy)-cyclohexene-1-carboxylates, method of obtaining and application |
JP6453050B2 (en) * | 2013-11-15 | 2019-01-16 | 国立大学法人富山大学 | 2-deoxy-2,3-didehydrosialic acid derivative and method for producing the same |
CN103819357B (en) * | 2014-01-28 | 2016-03-16 | 浙江大学 | The preparation method of (-)-effective mould alcohol nitrine tetraacetate |
CA2939491A1 (en) | 2014-02-14 | 2015-08-20 | Toa Eiyo Ltd. | Cyclic hydrocarbon compound |
US20170100385A1 (en) | 2014-05-12 | 2017-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
US9392814B2 (en) | 2014-06-06 | 2016-07-19 | Nicholas J. Singer | Delivery system for drinks |
GB2532178A (en) * | 2014-06-09 | 2016-05-18 | Redx Pharma Plc | Antiviral compounds |
EP3939985B1 (en) | 2014-12-26 | 2024-05-08 | Emory University | Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections |
USD773313S1 (en) | 2015-06-23 | 2016-12-06 | Nicholas J. Singer | Package |
WO2017106820A1 (en) * | 2015-12-17 | 2017-06-22 | Thomas Jefferson University | Antiviral agents for drug-resistant influenza a |
KR102339817B1 (en) | 2016-06-30 | 2021-12-16 | 한미약품 주식회사 | An oral solid formulation containing oseltamivir and a process for the preparation thereof |
PE20190662A1 (en) * | 2016-08-10 | 2019-05-08 | Shionogi & Co | PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES OF PIRIDONA SUBSTITUTED POLICIES AND PROFARMACY OF THE SAME |
KR102626210B1 (en) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
KR20200106607A (en) | 2019-03-05 | 2020-09-15 | 주식회사 코아팜바이오 | A pharmaceutical composition comprising oseltamivir |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016320A1 (en) * | 1990-04-24 | 1991-10-31 | Biota Scientific Management Pty Ltd | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
WO1992006691A1 (en) * | 1990-10-19 | 1992-04-30 | Biota Scientific Management Pty. Ltd. | Anti-viral compounds that bind the active site of influenza neuramidase and display in vivo activity against orthomyxovirus and paramyxovirus |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
US5206400A (en) * | 1986-07-07 | 1993-04-27 | Ohio State University | Diastereomeric mono- and di-substituted diamino cyclohexane compounds and the method of preparation thereof |
US5175273A (en) * | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US5270340A (en) * | 1988-12-27 | 1993-12-14 | Bayer Aktiengesellschaft | Substituted 2-cyclohexen-1-yl-amine fungicidal and herbicidal agents |
DE4033415A1 (en) * | 1990-10-20 | 1992-04-23 | Bayer Ag | ANTIMICROBIAL AGENTS AND SUBSTITUTED 2-CYCLOHEXAN-1-YL-AMINE DERIVATIVES AND THE PRODUCTION THEREOF |
DE4131311A1 (en) * | 1991-09-20 | 1993-04-01 | Basf Ag | DIHYDROPYRENE DERIVATIVES AND ITS PLANT PROTECTION AGENTS |
CA2081068C (en) * | 1991-10-23 | 2005-11-29 | Laurence Mark Von Itzstein | Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of .alpha.-d-neuraminic acid |
GB9126725D0 (en) * | 1991-12-17 | 1992-02-12 | Glaxo Group Ltd | Process |
FR2687674B1 (en) * | 1992-02-07 | 1995-05-19 | Roussel Uclaf | NEW PYRIDONE DERIVATIVES, THEIR PREPARATION PROCESS, THE NEW INTERMEDIATES OBTAINED, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5292938A (en) * | 1992-04-13 | 1994-03-08 | Associated Universities, Inc. | Synthesis of 4-substituted-trans-1, 2-diaminocyclohexyl polyaminocarboxylate metal chelating agents for the preparation of stable radiometal antibody immunoconjugates for therapy and spect and pet imaging |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
GB9220327D0 (en) * | 1992-09-25 | 1992-11-11 | Glaxo Group Ltd | Process |
GB9220241D0 (en) * | 1992-09-25 | 1992-11-11 | Glaxo Group Ltd | Process |
US5639786A (en) * | 1992-12-04 | 1997-06-17 | Biota Scientific Management, Pty., Ltd. | Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of α-D-neuraninic acid |
US5514798A (en) * | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
US5819730A (en) * | 1993-06-09 | 1998-10-13 | Glaxo Wellcome Australia Ltd. | Device for administering pharmaceutical substances |
GB9311873D0 (en) * | 1993-06-09 | 1993-07-28 | Glaxo Group Ltd | Process |
GB9312531D0 (en) * | 1993-06-17 | 1993-08-04 | Glaxo Group Ltd | Process |
GB9325841D0 (en) * | 1993-12-17 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
GB9400206D0 (en) * | 1994-01-07 | 1994-03-02 | Glaxo Group Ltd | Chemical compound |
AUPM354694A0 (en) * | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
US5985859A (en) * | 1994-04-14 | 1999-11-16 | The University Of Alabama | Methods of inhibiting bacterial sialidase |
GB9410817D0 (en) * | 1994-05-28 | 1994-07-20 | Glaxo Group Ltd | Medicaments |
AUPM725794A0 (en) * | 1994-08-03 | 1994-08-25 | Biota Scientific Management Pty Ltd | Chemical compounds |
US5556963A (en) * | 1994-08-05 | 1996-09-17 | Oklahoma Medical Research Foundation | Synthesis of 4-alkoxy-N-acetylneuraminic acid |
US5512596A (en) * | 1994-09-02 | 1996-04-30 | Gilead Sciences, Inc. | Aromatic compounds |
CA2203570A1 (en) | 1994-11-04 | 1996-05-17 | Lawrence R. Mcgee | Thiepane compounds inhibiting and detecting hiv protease |
WO1996026933A1 (en) * | 1995-02-27 | 1996-09-06 | Gilead Sciences, Inc. | Novel selective inhibitors of viral or bacterial neuraminidases |
US5866601A (en) * | 1995-02-27 | 1999-02-02 | Gilead Sciences, Inc. | Carbocyclic compounds |
US5602277A (en) * | 1995-03-30 | 1997-02-11 | Biocryst Pharmaceuticals, Inc. | Substituted benzene derivatives useful as neuraminidase inhibitors |
US5714509A (en) * | 1995-05-03 | 1998-02-03 | The University Of Alabama | Inhibitors of bacterial sialidase and methods of making and using the same |
GB9525389D0 (en) | 1995-12-12 | 1996-02-14 | Biota Scient Management Ltd | Chemical compounds |
GB9510141D0 (en) | 1995-05-19 | 1995-07-12 | Biota Scient Management | Chemical compounds |
EP0833825B1 (en) * | 1995-05-19 | 2001-09-26 | Biota Scientific Management Pty. Ltd. | 6-carboxamido dihydropyran derivatives |
GB9516276D0 (en) * | 1995-08-08 | 1995-10-11 | Biota Scient Management | Chemical compounds |
US5763483A (en) * | 1995-12-29 | 1998-06-09 | Gilead Sciences, Inc. | Carbocyclic compounds |
US5859284A (en) | 1996-08-23 | 1999-01-12 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
EP0920410B1 (en) | 1996-08-23 | 2002-03-27 | Gilead Sciences, Inc. | Preparation of cyclohexene carboxylate derivatives |
WO1998011083A1 (en) * | 1996-09-10 | 1998-03-19 | Daikin Industries, Ltd. | 4-substituted-2,7-dideoxy-7-fluoro-2,3-didehydrosialic acids |
US5886213A (en) | 1997-08-22 | 1999-03-23 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
-
1996
- 1996-02-26 WO PCT/US1996/002882 patent/WO1996026933A1/en active IP Right Grant
- 1996-02-26 NZ NZ306625A patent/NZ306625A/en not_active IP Right Cessation
- 1996-02-26 CN CNB011247142A patent/CN100409844C/en not_active Expired - Lifetime
- 1996-02-26 SG SG1997004840A patent/SG45864A1/en unknown
- 1996-02-26 CZ CZ0269097A patent/CZ297945B6/en not_active IP Right Cessation
- 1996-02-26 BR BR9607098A patent/BR9607098A/en not_active IP Right Cessation
- 1996-02-26 DE DE2002199052 patent/DE10299052I1/en active Pending
- 1996-02-26 JP JP52644296A patent/JP3300365B2/en not_active Expired - Lifetime
- 1996-02-26 MX MX9706496A patent/MX9706496A/en unknown
- 1996-02-26 SI SI9620042A patent/SI9620042A/en not_active IP Right Cessation
- 1996-02-26 DE DE69607704T patent/DE69607704T2/en not_active Expired - Lifetime
- 1996-02-26 DE DE0759917T patent/DE759917T1/en active Pending
- 1996-02-26 ES ES96912404T patent/ES2118674T3/en not_active Expired - Lifetime
- 1996-02-26 AT AT99117934T patent/ATE305453T1/en active
- 1996-02-26 PT PT96912404T patent/PT759917E/en unknown
- 1996-02-26 HU HU9800026A patent/HU228450B1/en unknown
- 1996-02-26 KR KR1019970705932A patent/KR100447096B1/en not_active IP Right Cessation
- 1996-02-26 AT AT96912404T patent/ATE191711T1/en active
- 1996-02-26 DK DK96912404T patent/DK0759917T3/en active
- 1996-02-26 ES ES99117934T patent/ES2249863T3/en not_active Expired - Lifetime
- 1996-02-26 BR BRPI9607098-6B8D patent/BR9607098B8/en unknown
- 1996-02-26 US US08/606,624 patent/US5952375A/en not_active Expired - Lifetime
- 1996-02-26 CN CNB961901330A patent/CN1185223C/en not_active Expired - Lifetime
- 1996-02-26 UA UA97094796A patent/UA56128C2/en unknown
- 1996-02-26 AU AU53571/96A patent/AU720933B2/en not_active Expired
- 1996-02-26 EP EP96912404A patent/EP0759917B1/en not_active Expired - Lifetime
- 1996-02-26 PL PL96322000A patent/PL194173B1/en unknown
- 1996-02-26 DE DE69635231T patent/DE69635231T2/en not_active Expired - Lifetime
- 1996-02-26 RU RU97116714/04A patent/RU2181357C2/en active
- 1996-05-24 US US08/653,034 patent/US20050176758A1/en not_active Abandoned
-
1997
- 1997-08-26 NO NO19973908A patent/NO318455B1/en not_active IP Right Cessation
-
1999
- 1999-04-08 US US09/288,091 patent/US6225341B1/en not_active Expired - Lifetime
-
2000
- 2000-07-07 GR GR20000401599T patent/GR3033914T3/en unknown
- 2000-08-02 HK HK00104830A patent/HK1026893A1/en not_active IP Right Cessation
-
2001
- 2001-08-24 JP JP2001255372A patent/JP4234917B2/en not_active Expired - Lifetime
-
2002
- 2002-10-29 NL NL300105C patent/NL300105I2/en unknown
- 2002-12-11 LU LU90991C patent/LU90991I2/en unknown
-
2005
- 2005-07-15 JP JP2005207906A patent/JP2006036770A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016320A1 (en) * | 1990-04-24 | 1991-10-31 | Biota Scientific Management Pty Ltd | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
WO1992006691A1 (en) * | 1990-10-19 | 1992-04-30 | Biota Scientific Management Pty. Ltd. | Anti-viral compounds that bind the active site of influenza neuramidase and display in vivo activity against orthomyxovirus and paramyxovirus |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CZ297945B6 (en) | Novel selective inhibitors of viral and bacterial neuraminidases, pharmaceutical compositions in which said inhibitors are comprised and the use of the inhibitors | |
US5763483A (en) | Carbocyclic compounds | |
EP1015417A1 (en) | Compounds containing six-membered rings, processes for their preparation, and their use as medicaments | |
WO1996026933A9 (en) | Novel selective inhibitors of viral or bacterial neuraminidases | |
US5866601A (en) | Carbocyclic compounds | |
JP2008273948A (en) | New selective inhibitor of viral or bacterial neuraminidase | |
KR20000052702A (en) | Piperidine compounds | |
US20040053999A1 (en) | Novel compounds and methods for synthesis and therapy | |
AU2003204079B2 (en) | Novel compounds and methods for synthesis and therapy | |
TW426663B (en) | Novel compounds and methods for synthesis and therapy | |
MXPA99003626A (en) | Piperidine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD00 | Pending as of 2000-06-30 in czech republic | ||
MK4A | Patent expired |
Effective date: 20160226 |